FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Lee, KW
   Lee, S
   Oh, DK
   Na, BG
   Choi, JY
   Cho, W
   Lee, S
   Kim, JM
   Choi, G
   Kwon, CHD
   Joh, JW
   Lee, SK
AF Lee, Kyo Won
   Lee, Sanghoon
   Oh, Dong Kyu
   Na, Byung Gon
   Choi, Jin Yong
   Cho, Wontae
   Lee, Seunghwan
   Kim, Jong Man
   Choi, Gyuseong
   Kwon, Choon Hyuck David
   Joh, Jae-Won
   Lee, Suk-Koo
TI Outcome of partial reconstruction of multiple hepatic arteries in
   pediatric living donor liver transplantation using left liver grafts
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE bile duct complication; hepatic artery complication; multiple artery;
   pediatric liver transplantation
ID SINGLE-CENTER EXPERIENCE; RIGHT LOBE; ADULT; COMPLICATIONS; LIGATION;
   STUMPS; KOREA
AB Partial liver grafts used in living donor liver transplantation (LDLT) may have multiple hepatic artery (HA) stumps. This study was designed to validate the safety of partial reconstruction of multiple HAs in pediatric LDLT cases. From January 2000 to June 2014, 136 pediatric LDLT recipients were categorized into three groups: single HA group (Group 1, n = 74), multiple HAs with total reconstruction group (Group 2, n = 23), and multiple HAs with partial reconstruction group (Group 3, n = 39). Partial reconstruction was performed only when there was pulsatile back-bleeding after larger HA reconstruction and sufficient intrahepatic arterial flow was confirmed by Doppler ultrasound (DUS). There was no significant difference in biliary complication rate, artery complication rate, patient survival, and graft survival among these groups. Risk factor analysis revealed that the presence of multiple HAs and partial reconstruction of multiple HAs were not risk factors of biliary anastomosis stricture. In conclusion, partial reconstruction of HAs during pediatric LDLT using a left liver graft with multiple HA stumps does not increase the risk of biliary anastomosis stricture or affect graft survival when intrahepatic arterial communication is confirmed by pulsatile back-bleeding and DUS.
C1 [Lee, Kyo Won; Lee, Sanghoon; Oh, Dong Kyu; Na, Byung Gon; Choi, Jin Yong; Cho, Wontae; Lee, Seunghwan; Kim, Jong Man; Choi, Gyuseong; Kwon, Choon Hyuck David; Joh, Jae-Won; Lee, Suk-Koo] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea.
RP Lee, SK (reprint author), Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea.
EM sukkoo.lee@samsung.com
CR Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   D'Alessandro AM, 2007, PEDIATR TRANSPLANT, V11, P661, DOI 10.1111/j.1399-3046.2007.00737.x
   Douard R, 2002, TRANSPLANTATION, V73, P993, DOI 10.1097/00007890-200203270-00029
   Haberal M, 2008, PEDIATR TRANSPLANT, V12, P407, DOI 10.1111/j.1399-3046.2008.00888.x
   Ikegami T, 1996, SURGERY, V119, P431, DOI 10.1016/S0039-6060(96)80144-9
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Julka KD, 2014, PEDIATR SURG INT, V30, P39, DOI 10.1007/s00383-013-3436-z
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kim JM, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000084
   Kim JM, 2013, J KOREAN MED SCI, V28, P42, DOI 10.3346/jkms.2013.28.1.42
   Kim SJ, 2011, CLIN TRANSPLANT, V25, P929, DOI 10.1111/j.1399-0012.2010.01385.x
   KOEHLER RE, 1975, RADIOLOGY, V117, P49
   Lee S, 2014, LIVER TRANSPLANT, V20, pS207
   Marcos A, 2003, LIVER TRANSPLANT, V9, P570, DOI 10.1053/jlts.2003.50093
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   PLENGVAN.U, 1972, ANN SURG, V175, P105
   REDMAN HC, 1970, RADIOLOGY, V94, P575
   Rodriguez-Davalos MI, 2014, JAMA SURG, V149, P63, DOI 10.1001/jamasurg.2013.3384
   Song S, 2015, TRANSPL P, V47, P1905, DOI 10.1016/j.transproceed.2015.06.014
   Suehiro T, 2002, LIVER TRANSPLANT, V8, P495, DOI 10.1053/jlts.2002.32986
   Sugawara Y, 2011, SURGERY, V149, P841, DOI 10.1016/j.surg.2010.11.016
   Takatsuki M, 2006, SURGERY, V140, P824, DOI 10.1016/j.surg.2006.02.021
   Uchiyama H, 2010, SURGERY, V147, P878, DOI 10.1016/j.surg.2009.06.028
   Yang Y, 2014, WORLD J GASTROENTERO, V20, P10545, DOI 10.3748/wjg.v20.i30.10545
NR 25
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0934-0874
EI 1432-2277
J9 TRANSPL INT
JI Transpl. Int.
PD AUG
PY 2016
VL 29
IS 8
BP 890
EP 896
DI 10.1111/tri.12787
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA DS8ZB
UT WOS:000381070400007
PM 27112373
ER

PT J
AU Ogura, Y
   Imai, H
   Kamei, H
   Hori, T
   Kurata, N
   Onishi, Y
AF Ogura, Yasuhiro
   Imai, Hisashi
   Kamei, Hideya
   Hori, Tomohide
   Kurata, Nobuhiko
   Onishi, Yasuharu
TI Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release
   Tacrolimus in Liver Transplantation: A Single-Center Experience
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE Immunosuppression; Liver Transplantation; Tacrolimus
ID ONCE-DAILY TACROLIMUS; RECIPIENTS
AB Background: Prolonged-release tacrolimus (Tac QD) is widely used in organ transplantation. However, the conversion from twice-daily tacrolimus (Tac BID) to Tac QD in Japan is usually done in stable patients months or years after liver transplantation. The aim of this study was to assess the early conversion of Tac QD during liver transplant hospital stay.
   Material/Methods: Eighteen liver transplants (excluding pediatric) were performed during 2014-2015. All cases except 2 early-expired patients were enrolled. Our standard immunosuppression is oral Tac BID and steroid taper, and we add mycophenolate mofetil if indicated. Conversion criteria from Tac BID to Tac QD were:1) relatively stable liver function with stable trough level by oral Tac BID, and 2) good general condition (no or well-controlled complications). We did not fix the exact conversion date because each patient's recovery was different. Dose conversion rate from Tac BID to Tac QD was set at 1:1.
   Results: The median number of conversion days after liver transplant was 27 days. Sixty-two percent of patients were converted within 4 weeks after liver transplant, and 56% were discharged from the hospital within 2 weeks after conversion. The comparison of the last week of Tac BID and the first week of Tac QD revealed that the mean tacrolimus trough level declined by 30.4%, resulting in the 26.2% tacrolimus dose increase during the first 2 weeks after conversion. Adverse events after conversion were limited, and all patients show normal liver function to date.
   Conclusions: Early Tac QD conversion is safe and feasible, but its long-term effects need further investigation.
C1 [Ogura, Yasuhiro; Imai, Hisashi; Kamei, Hideya; Hori, Tomohide; Kurata, Nobuhiko; Onishi, Yasuharu] Nagoya Univ Hosp, Dept Transplantat Surg, Nagoya, Aichi, Japan.
RP Ogura, Y (reprint author), Nagoya Univ Hosp, Dept Transplantat Surg, Nagoya, Aichi, Japan.
EM oguchan@med.nagoya-u.ac.jp
CR Adam R, 2015, AM J TRANSPLANT, V15, P1267, DOI 10.1111/ajt.13171
   Burra P, 2011, LIVER TRANSPLANT, V17, P760, DOI 10.1002/lt.22294
   Fischer L, 2011, LIVER TRANSPLANT, V17, P167, DOI 10.1002/lt.22211
   Lieber SR, 2013, DIGEST DIS SCI, V58, P824, DOI 10.1007/s10620-012-2412-0
   O'Carroll RE, 2006, LIVER TRANSPLANT, V12, P1862, DOI 10.1002/it.20828
   Sugawara Y, 2011, BIOSCI TRENDS, V5, P156, DOI 10.5582/bst.2011.v5.4.156
   Thorat A, 2014, BIOMED RES INT, V2014
   Trunecka P, 2010, AM J TRANSPLANT, V10, P2313, DOI 10.1111/j.1600-6143.2010.03255.x
   Trunecka P, 2015, AM J TRANSPLANT, V15, P1843, DOI 10.1111/ajt.13182
   Uemoto S, 2014, TRANSPL P, V46, P749, DOI 10.1016/j.transproceed.2013.11.071
   Valente G, 2013, TRANSPL P, V45, P1273, DOI 10.1016/j.transproceed.2013.02.021
   Wu Yi-Ju, 2016, Ann Transplant, V21, P30
NR 12
TC 0
Z9 0
U1 1
U2 1
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD JUL 19
PY 2016
VL 21
DI 10.12659/AOT.898604
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA DR6ZL
UT WOS:000380049700001
ER

PT J
AU Salvalaggio, PR
   Neto, JS
   Alves, JA
   Fonseca, EA
   de Albuquerque, LC
   Andraus, W
   Massarollo, PB
   Garcia, VD
   Maurette, RJ
   Ruf, AE
   Pacheco-Moreira, LF
   Rusca, LAC
   Osorio, VB
   Matamoros, MA
   Varela-Fascinetto, G
   Jarufe, NP
AF Salvalaggio, Paolo R.
   Neto, Joao Seda
   Alves, Jefferson Andre
   Fonseca, Eduardo A.
   de Albuquerque, Luiz Carneiro
   Andraus, Wellington
   Massarollo, Paulo B.
   Garcia, Valter Duro
   Maurette, Rafael J.
   Ruf, Andres E.
   Pacheco-Moreira, Lucio F.
   Caicedo Rusca, Luis A.
   Botero Osorio, Veronica
   Amalia Matamoros, Maria
   Varela-Fascinetto, Gustavo
   Jarufe, Nicolas P.
TI Consensus, Dilemmas, and Challenges in Living Donor Liver
   Transplantation in Latin America
SO TRANSPLANTATION
LA English
DT Article
ID HEPATECTOMIES; COMPLICATIONS
AB We reviewed the history, volume, outcomes, uniqueness, and challenges of living donor liver transplantation (LDLT) in Latin America. We used the data from the Latin American and Caribbean Transplant Society, local transplant societies, and opinions from local transplant experts. There are more than 160 active liver transplant teams in Latin America, but only 30 centers have used LDLT in the past 2 years. In 2014, 226 LDLTs were done in the region (8.5% of liver transplant activities). Living donor liver transplantation is mainly restricted to pediatric patients. Adult-to-adult LDLT activities decreased after the implementation of the model for end-stage liver disease score and a concomitant increase on the rate of deceased donors per million population. Posttransplant outcome analysis is notmandatory, transparent or regulated in most countries. More experienced teams have outcomes comparable to international expert centers, but donor and recipient morbidity might be underreported. Latin America lags behind in terms of the number of adult LDLT and the rate of living donor utilization in comparison with other continents with similar donation rates. Local alliances and collaborations with major transplant centers in the developed world will contribute to the development of LDLT in Latin America.
C1 [Salvalaggio, Paolo R.; Alves, Jefferson Andre] Hosp Israelita Albert Einstein, Liver Transplant Ctr, Av Albert Einstein 627,Bldg A,2SS, BR-05652900 Sao Paulo, SP, Brazil.
   [Neto, Joao Seda; Fonseca, Eduardo A.] Hosp Sirio Libanes, Liver Transplant Ctr, Sao Paulo, Brazil.
   [Neto, Joao Seda; Fonseca, Eduardo A.] AC Camargo Canc Ctr, Liver Transplant Ctr, Sao Paulo, Brazil.
   [de Albuquerque, Luiz Carneiro; Andraus, Wellington; Massarollo, Paulo B.] Univ Sao Paulo, Dept Surg, Sao Paulo, Brazil.
   [Massarollo, Paulo B.] Santa Casa de Misericordia Sao Paulo, Dept Surg, Sao Paulo, Brazil.
   [Garcia, Valter Duro] Santa Casa de Misericordia Porto Alegre, Div Renal Transplantat, Porto Alegre, RS, Brazil.
   [Maurette, Rafael J.; Ruf, Andres E.] Hosp Britan, Liver Transplant Ctr, Buenos Aires, DF, Argentina.
   [Pacheco-Moreira, Lucio F.] Ctr Estadual Transplante, Liver Transplant Ctr, Rio De Janeiro, Brazil.
   [Caicedo Rusca, Luis A.; Botero Osorio, Veronica] Fdn Vale de Lilli, Liver Transplant Ctr, Cali, Colombia.
   [Amalia Matamoros, Maria] Hosp Mexico, Ctr CCSS, Liver Transplant Ctr, San Jose, Costa Rica.
   [Varela-Fascinetto, Gustavo] Hosp Infantil Mexico Dr Federico Gomez, Liver Transplant Ctr, Mexico City, DF, Mexico.
   [Jarufe, Nicolas P.] Univ Catolica Chile, Dept Surg, Santiago, Chile.
RP Salvalaggio, PR (reprint author), Hosp Israelita Albert Einstein, Av Albert Einstein 627,Bldg A,2SS, BR-05652900 Sao Paulo, SP, Brazil.
EM salvalaggio@einstein.br
CR Ates M, 2015, TRANSPL P, V47, P1319, DOI 10.1016/j.transproceed.2015.04.038
   Chen CL, 2013, NAT REV GASTRO HEPAT, V10, P746, DOI 10.1038/nrgastro.2013.194
   Dar FS, 2015, LIVER TRANSPLANT, V21, P982, DOI 10.1002/lt.24151
   de Santibanes E, 2000, LIVER TRANSPLANT, P108
   Fernandes R, 2010, TRANSPL P, V42, P421, DOI 10.1016/j.transproceed.2010.01.012
   Massarollo PCB, 2004, TRANSPLANT P, V36, P964, DOI 10.1016/j.transproceed.2004.03.120
   RAIA S, 1989, LANCET, V2, P497
   Salvalaggio PR, 2014, TRANSPLANTATION, V98, P241, DOI 10.1097/TP.0000000000000198
   Neto JS, 2010, LIVER TRANSPLANT, V16, P426, DOI 10.1002/lt.22000
   Wiederkehr JC, 2005, TRANSPLANT P, V37, P1079, DOI 10.1016/j.transproceed.2004.12.221
NR 10
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUN
PY 2016
VL 100
IS 6
BP 1161
EP 1164
DI 10.1097/TP.0000000000001180
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DN5QZ
UT WOS:000377126600001
PM 27203583
ER

PT J
AU Kawano, Y
   Mizuta, K
   Sanada, Y
   Urahashi, T
   Ihara, Y
   Okada, N
   Yamada, N
   Sasanuma, H
   Sakuma, Y
   Taniai, N
   Yoshida, H
   Kawarasaki, H
   Yasuda, Y
   Uchida, E
AF Kawano, Y.
   Mizuta, K.
   Sanada, Y.
   Urahashi, T.
   Ihara, Y.
   Okada, N.
   Yamada, N.
   Sasanuma, H.
   Sakuma, Y.
   Taniai, N.
   Yoshida, H.
   Kawarasaki, H.
   Yasuda, Y.
   Uchida, E.
TI Complementary Indicators for Diagnosis of Hepatic Vein Stenosis After
   Pediatric Living-donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 14th Congress of the Asian-Society-of-Transplantation
CY AUG 23-26, 2015
CL Singapore, SINGAPORE
SP Asian Soc Transplantat
ID BUDD-CHIARI-SYNDROME; VASCULAR COMPLICATIONS; OBSTRUCTION; EXPERIENCE;
   CHILDREN; VOLUME
AB Introduction. Although hepatic vein stenosis after liver transplantation is a rare complication, the complication rate of 1% to 6% is higher in pediatric living-donor liver transplantation than that in other liver transplantation cases. Diagnosis is very important because this complication can cause hepatic congestion that develops to liver cirrhosis, graft loss, and patient loss. However, this is unlikely in cases where there are no ascites or hypo albuminemia.
   Objectives. Eleven of 167 patients who had undergone pediatric living-donor liver transplantation were identified in the outpatient clinic at Jichi Medical University as having suffered from hepatic vein stenosis, and were enrolled in the study.
   Methods. We conducted a retrospective study in which we reviewed historical patient records to investigate the parameters for diagnosis and examine treatment methods and outcomes.
   Results. The 11 patients were treated with 16 episodes of balloon dilatation. Three among these received retransplantation and another 2 cases required the placement of a metallic stent at the stenosis. Histological examination revealed severe fibrosis in four of nine patients who had a liver biopsy, with mild fibrosis revealed in the other five grafts. Furthermore, hepatomegaly and splenomegaly diagnosed by computed tomography, elevated levels of hyarulonic acid, and/or a decrease in calcineurin inhibitor clearance were found to be pathognomonic at diagnosis, and tended to improve after treatment.
   Conclusions. Diagnosis of hepatic vein stenosis after liver transplantation can be difficult, so careful observation is crucial to avoid the risk of acute liver dysfunction. Comprehensive assessment using volumetry of the liver and spleen and monitoring of hyarulonic acid levels and/or calcineurin inhibitor clearance, in addition to some form of imaging examination, is important for diagnosis and evaluation of the effectiveness of therapy.
C1 [Kawano, Y.; Taniai, N.; Yoshida, H.; Uchida, E.] Nippon Med Sch, Dept Surg, 1-1-5 Sendagi, Tokyo 113, Japan.
   [Mizuta, K.; Sanada, Y.; Urahashi, T.; Ihara, Y.; Okada, N.; Yamada, N.; Kawarasaki, H.; Yasuda, Y.] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi, Japan.
   [Sasanuma, H.; Sakuma, Y.] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan.
RP Kawano, Y (reprint author), Nippon Med Sch, Dept Surg, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.
EM y-kawano@nms.ac.jp
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 2004, LIVER TRANSPLANT, V10, P248, DOI 10.1002/lt.20055
   Darcy Michael D, 2007, Tech Vasc Interv Radiol, V10, P240, DOI 10.1053/j.tvir.2007.09.018
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   Kathuria R, 2014, EUR J GASTROEN HEPAT, V26, P1030, DOI 10.1097/MEG.0000000000000144
   Kawano Y, 2007, HEPATO-GASTROENTEROL, V54, P1821
   Nanashima A, 2001, J GASTROEN HEPATOL, V16, P1158, DOI 10.1046/j.1440-1746.2001.02599.x
   SCHLESINGER AE, 1993, AM J ROENTGENOL, V160, P1107
   Singh V, 2000, J GASTROEN HEPATOL, V15, P550, DOI 10.1046/j.1440-1746.2000.02157.x
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Sugimoto K, 2003, THER DRUG MONIT, V25, P294, DOI 10.1097/00007691-200306000-00007
   Totsuka E, 2004, TRANSPLANT P, V36, P2252, DOI 10.1016/j.transproceed.2004.08.066
   Urahashi T, 2012, EXP CLIN TRANSPLANT, V10, P350, DOI 10.6002/ect.2012.0075
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5
   Valla D, 1997, HEPATOLOGY, V25, P814, DOI 10.1002/hep.510250405
   Wang SL, 2005, RADIOLOGY, V236, P352, DOI 10.1148/radiol.2361040327
   WESTRA SJ, 1993, RADIOGRAPHICS, V13, P1081
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
   ZAJKO AB, 1989, RADIOLOGY, V170, P763
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2016
VL 48
IS 4
BP 1156
EP 1161
DI 10.1016/j.transproceed.2015.12.114
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DP8PP
UT WOS:000378760400038
PM 27320577
ER

PT J
AU Hsu, HW
   Huang, TL
   Cheng, YF
   Chen, TY
   Tsang, LL
   Ou, HY
   Yu, CY
   Concejero, AM
   Chen, CL
AF Hsu, H. -W.
   Huang, T. -L.
   Cheng, Y. -F.
   Chen, T. -Y.
   Tsang, L. L.
   Ou, H. -Y.
   Yu, C. -Y.
   Concejero, A. M.
   Chen, C. -L.
TI Sonographic Evaluation of Post-transplantation Portal Vein Stenosis in
   Pediatric Living-donor Liver Transplant Recipients With Left-liver
   Grafts
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 14th Congress of the Asian-Society-of-Transplantation
CY AUG 23-26, 2015
CL Singapore, SINGAPORE
SP Asian Soc Transplantat
ID DOPPLER ULTRASOUND; COMPLICATIONS
AB Introduction. Portal vein (PV) stenosis is not uncommon in post-transplantation pediatric living-donor liver transplant (PLDLT) recipients. The purpose of this study was to identify specific ultrasound criteria that may be used to detect PV stenosis in PLDLT with left-liver grafts.
   Patients and Methods. From January 2010 to October 2014, 87 pediatric recipients underwent PLDLT with left lobes or left lateral segments at our hospital. All patients underwent routine liver Doppler ultrasound (DUS) as follow-up protocol. The morphologic narrowing and mean time averaged velocity (TAV) at the PV anastomotic site, change in anastomotic/pre-anastomotic TAV (Delta TAV), and the umbilical portal width were evaluated and analyzed. Ultrasound findings were correlated with computed tomography angiography where PV stenosis was suspected.
   Results. In the liver graft follow-up study, 80.4% (70 of 87 patients) of PV anastomosis was well visualized and measured by Doppler ultrasound. The optimal threshold values for TAV and Delta TAV were 49.6 cm/s and 30 cm/s, respectively, for significant PV anastomosis stenosis. In the other 19.5% (17/87), the PV anastomosis could not be identified properly. The PV anastomosis was not always visible with ultrasound; however, the optimal dilated umbilical portion of the PV indicating possible PV anastomosis narrowing threshold was umbilical portal width >1.5 cm.
   Conclusions. Increased anastomotic TAV and Delta TAV are useful features for diagnosing PV stenosis. The identification of a dilated umbilical portion of the left PV helps in detection of PV stenosis in PLDLT recipients especially when the anastomotic narrowed region cannot be visualized.
C1 [Hsu, H. -W.; Huang, T. -L.; Cheng, Y. -F.; Chen, T. -Y.; Tsang, L. L.; Ou, H. -Y.; Yu, C. -Y.] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Diagnost Radiol, Kaohsiung, Taiwan.
   [Concejero, A. M.; Chen, C. -L.] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Dept Surg, Kaohsiung, Taiwan.
RP Cheng, YF (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, 123 Ta Pei Rd, Kaohsiung 83305, Taiwan.
EM cheng.yufan@msa.hinet.net
CR Cheng YF, 2006, AM J TRANSPLANT, V6, P2994, DOI 10.1111/j.1600-6143.2006.01562.x
   Cheng YF, 2010, AM J TRANSPLANT, V10, P1276, DOI 10.1111/j.1600-6143.2010.03076.x
   Cheng YF, 2009, AM J TRANSPLANT, V9, P1382, DOI 10.1111/j.1600-6143.2009.02626.x
   Chong WK, 2007, AM J ROENTGENOL, V188, pW515, DOI 10.2214/AJR.06.1262
   DEGAETANO AM, 1995, AM J ROENTGENOL, V165, P1151
   Fan ST, 2000, ANN SURG, V231, P126, DOI 10.1097/00000658-200001000-00018
   Hosten N, 2003, MED RAD DIA IMG, P191
   Huang TL, 2012, TRANSPL P, V44, P481, DOI 10.1016/j.transproceed.2012.01.047
   Huang TL, 2010, TRANSPL P, V42, P879, DOI 10.1016/j.transproceed.2010.02.036
   Iida T, 2014, CLIN TRANSPLANT, V28, P1025, DOI 10.1111/ctr.12412
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Moon JI, 2010, TRANSPL P, V42, P871, DOI 10.1016/j.transproceed.2010.02.059
   Mullan CP, 2010, AM J ROENTGENOL, V195, P1438, DOI 10.2214/AJR.10.4636
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2016
VL 48
IS 4
BP 1162
EP 1165
DI 10.1016/j.transproceed.2015.12.061
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DP8PP
UT WOS:000378760400039
PM 27320578
ER

PT J
AU Miyagi, S
   Kawagishi, N
   Kashiwadate, T
   Fujio, A
   Tokodai, K
   Hara, Y
   Nakanishi, C
   Kamei, T
   Ohuchi, N
   Satomi, S
AF Miyagi, S.
   Kawagishi, N.
   Kashiwadate, T.
   Fujio, A.
   Tokodai, K.
   Hara, Y.
   Nakanishi, C.
   Kamei, T.
   Ohuchi, N.
   Satomi, S.
TI Relationship Between Bile Duct Reconstruction and Complications in
   Living Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 14th Congress of the Asian-Society-of-Transplantation
CY AUG 23-26, 2015
CL Singapore, SINGAPORE
SP Asian Soc Transplantat
ID BILIARY COMPLICATIONS; RECIPIENT MORBIDITY; COHORT
AB Objectives. In living donor liver transplantation (LDLT), the recipient bile duct is thin and short. Bile duct complications often occur in LDLT, with persistent long-term adverse effects. Recently, we began to perform microsurgical reconstruction of the bile duct. The purpose of this study was to investigate the relationship between bile duct reconstruction methods and complications in LDLT.
   Methods. From 1991 to 2014, we performed 161 LDLTs (pediatric:adult = 90:71; left lobe:right lobe = 95:66). In this study, we retrospectively investigated the initial bile duct complications in LDLT and performed univariate and multivariate analyses to identify the independent risk factors for complications.
   Results. The most frequent complication was biliary stricture (9.9%), followed by biliary leakage (6.8%). On univariate and multiple logistic regression analysis, the independent risk factors for biliary stricture were bile leakage (P = .0103) and recurrent cholangitis (P = .0077). However, there were no risk factors for biliary leakage on univariate analysis in our study. The reconstruction methods (hepaticojejunostomy or duct-to-duct anastomosis) and reconstruction technique (with or without microsurgery) were not risk factors for biliary stricture and leakage.
   Conclusion. In this study, the most frequent complication of LDLT was biliary stricture. The independent risk factors for biliary stricture were biliary leakage and recurrent cholangitis. Duct-to-duct anastomosis and microsurgical reconstruction of the bile duct were not risk factors for biliary stricture and leakage.
C1 [Miyagi, S.; Kawagishi, N.; Kashiwadate, T.; Fujio, A.; Tokodai, K.; Hara, Y.; Nakanishi, C.; Kamei, T.; Ohuchi, N.; Satomi, S.] Tohoku Univ, Div Transplantat Upper Digest & Vasc Surg, Sendai, Miyagi 980, Japan.
RP Miyagi, S (reprint author), Tohoku Univ, Div Transplantat Upper Digest & Vasc Surg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
EM msmsmiyagi@yahoo.co.jp
CR Akamatsu Nobuhisa, 2014, World J Hepatol, V6, P626, DOI 10.4254/wjh.v6.i9.626
   Davidson BR, 1999, BRIT J SURG, V86, P447
   Duailibi DF, 2010, TRANSPL P, V42, P517, DOI 10.1016/j.transproceed.2010.01.017
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   Julka KD, 2014, PEDIATR SURG INT, V30, P39, DOI 10.1007/s00383-013-3436-z
   Li C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027366
   Lin TS, 2009, LIVER TRANSPLANT, V15, P1766, DOI 10.1002/lt.21947
   Pascher A, 2006, J HEPATO-BILIARY-PAN, V13, P487, DOI 10.1007/s00534-005-1083-z
   Reichman TW, 2013, TRANSPL INT, V26, P780, DOI 10.1111/tri.12127
   Saha Anupam, 2012, Med J Armed Forces India, V68, P110, DOI 10.1016/S0377-1237(12)60018-5
   Zimmerman MA, 2013, LIVER TRANSPLANT, V19, P259, DOI 10.1002/lt.23595
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2016
VL 48
IS 4
BP 1166
EP 1169
DI 10.1016/j.transproceed.2015.10.073
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DP8PP
UT WOS:000378760400040
PM 27320579
ER

PT J
AU Seda-Neto, J
   da Fonseca, EA
   Pugliese, R
   Candido, HL
   Benavides, MR
   Afonso, RC
   Neiva, R
   Porta, G
   Miura, IK
   Teng, HW
   Iwase, FC
   Rodrigues, ML
   de Albuquerque, LAC
   Kondo, M
   Chapchap, P
AF Seda-Neto, Joao
   da Fonseca, Eduardo Antunes
   Pugliese, Renata
   Candido, Helry L.
   Benavides, Marcel R.
   Afonso, Rogerio Carballo
   Neiva, Romerito
   Porta, Gilda
   Miura, Irene K.
   Teng, Hsiang W.
   Iwase, Fernanda C.
   Rodrigues, Monica L.
   Carneiro de Albuquerque, Luis Augusto
   Kondo, Mario
   Chapchap, Paulo
TI Twenty Years of Experience in Pediatric Living Donor Liver
   Transplantation: Focus on Hepatic Artery Reconstruction, Complications,
   and Outcomes
SO TRANSPLANTATION
LA English
DT Article
ID URGENT REVASCULARIZATION; VASCULAR COMPLICATIONS; PORTAL-VEIN;
   THROMBOSIS; IMPACT; GRAFT; MICROSCOPE; SURVIVAL; EVENT
AB Background. Hepatic artery thrombosis (HAT) increases morbidity and mortality after liver transplantation (LT). The identification of risk factors for HAT may aid transplant teams in the development of strategies aimed at reducing HAT. This article describes the risk factors for HAT and outcomes after LT. Methods. This report describes a retrospective study (1995 to 2015) of primary pediatric living donor LT (LDLT). Pretransplant and technical variables were included in the study. Binary logistic regression was used for data analysis. Results. This study included 656 primary LDLT. The median age, body weight, and pediatric end-stage liver disease score at the time of transplant were 13 months, 8.4 kg and 15, respectively. Twenty-one (3.2%) patients developed HAT. Intraoperative HAT (odds ratio, 62.63; 95% confidence interval, 12.64-310.19; P < 0.001) and the use of liver grafts with a graft-to-recipient weight ratio less than 1.1% (odds ratio, 24.46; 95% confidence interval, 4.55-131.56; P < 0.001) retained statistical significance in the multivariate model. Patient and graft survivals were significantly worse in cases with HAT. The overtime trend analysis revealed a decrease in the incidence of HAT (P = 0.008) and an increase in the use of 2-arterial anastomosis (P < 0.001). Conclusions. A graft-to-recipient weight ratio of 1.1% or less and intraoperative HAT were independently associated with HAT. Trend analysis further revealed a significant reduction in the incidence of HAT over time, as well as the increased use of 2 hepatic arteries for anastomosis during graft implantation. The double artery anastomosis may represent an extra protection to pediatric recipients undergoing LDLT.
C1 [Seda-Neto, Joao; da Fonseca, Eduardo Antunes; Pugliese, Renata; Candido, Helry L.; Benavides, Marcel R.; Afonso, Rogerio Carballo; Neiva, Romerito; Porta, Gilda; Miura, Irene K.; Teng, Hsiang W.; Iwase, Fernanda C.; Rodrigues, Monica L.; Kondo, Mario; Chapchap, Paulo] Hosp Siriolibanes, Hepatol & Liver Transplantat, Sao Paulo, SP, Brazil.
   [Seda-Neto, Joao; da Fonseca, Eduardo Antunes; Pugliese, Renata; Candido, Helry L.; Benavides, Marcel R.; Afonso, Rogerio Carballo; Neiva, Romerito; Porta, Gilda; Miura, Irene K.; Teng, Hsiang W.; Iwase, Fernanda C.; Rodrigues, Monica L.; Kondo, Mario] AC Camargo Canc Ctr, Hepatol & Liver Transplantat, Sao Paulo, SP, Brazil.
   [Carneiro de Albuquerque, Luis Augusto] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver Transplant Serv, Sao Paulo, Brazil.
RP Seda-Neto, J (reprint author), Hosp AC Camargo Fund Antonio Prudente, Hosp Siriolibanes, Rua Barata Ribeiro 414,Cj 65, BR-01308000 Sao Paulo, Brazil.
EM joaoseda@gmail.com
CR Ackermann O, 2012, AM J TRANSPLANT, V12, P1496, DOI 10.1111/j.1600-6143.2011.03984.x
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   BUCKELS JAC, 1989, TRANSPLANT P, V21, P2460
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Gallo A, 2014, LIVER TRANSPLANT, V20, P512, DOI 10.1002/lt.23886
   Guarrera JV, 2004, TRANSPLANT INT, V17, P585, DOI 10.1007/s00147-004-0782-8
   Gunsar F, 2003, LIVER TRANSPLANT, V9, P605, DOI 10.1053/jlts.2003.50057
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   Ikegami T, 2006, J HEPATO-BILIARY-PAN, V13, P105, DOI 10.1007/s00534-005-1015-y
   Ikegami T, 1996, SURGERY, V119, P431, DOI 10.1016/S0039-6060(96)80144-9
   Ito T, 2003, TRANSPLANTATION, V75, P1313, DOI 10.1097/01.TP.0000063707.90525.10
   Julka KD, 2014, PEDIATR SURG INT, V30, P39, DOI 10.1007/s00383-013-3436-z
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   LALLIER M, 1995, J PEDIATR SURG, V30, P1122, DOI 10.1016/0022-3468(95)90002-0
   LANGNAS AN, 1991, TRANSPLANTATION, V51, P86, DOI 10.1097/00007890-199101000-00013
   Madalosso C, 1998, TRANSPLANTATION, V66, P294, DOI 10.1097/00007890-199808150-00003
   Markmann JF, 1997, ANN SURG, V226, P408, DOI 10.1097/00000658-199710000-00002
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   MOR E, 1993, TRANSPLANTATION, V56, P1399, DOI 10.1097/00007890-199312000-00024
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   SAMUEL D, 1989, TRANSPLANT P, V21, P2225
   Sanchez SE, 2012, J PEDIATR SURG, V47, P1255, DOI 10.1016/j.jpedsurg.2012.03.035
   Neto JS, 2014, LIVER TRANSPLANT, V20, P1157, DOI 10.1002/lt.23934
   Neto JS, 2012, LIVER TRANSPLANT, V18, P577, DOI 10.1002/lt.23393
   Seda-Neto J, 2008, TRANSPLANTATION, V86, P697, DOI 10.1097/TP.0b013e318183ed22
   Shackleton CR, 1997, AM J SURG, V173, P431, DOI 10.1016/S0002-9610(97)00066-4
   Smyrniotis V, 2002, TRANSPLANT INT, V15, P355, DOI 10.1007/s00147-002-0425-x
   Tiao Gregory M, 2006, Semin Pediatr Surg, V15, P218, DOI 10.1053/j.sempedsurg.2006.03.008
   Uchida Y, 2009, CLIN TRANSPLANT, V23, P392, DOI 10.1111/j.1399-0012.2008.00924.x
   Warnaar N, 2010, LIVER TRANSPLANT, V16, P847, DOI 10.1002/lt.22063
   YAMAOKA Y, 1991, TRANSPLANTATION, V52, P157, DOI 10.1097/00007890-199107000-00035
   YANAGA K, 1989, TRANSPLANT P, V21, P3511
NR 32
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAY
PY 2016
VL 100
IS 5
BP 1066
EP 1072
DI 10.1097/TP.0000000000001135
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DN5QU
UT WOS:000377126000021
PM 27014791
ER

PT J
AU Kanda, S
   Morisada, N
   Kaneko, N
   Yabuuchi, T
   Nawashiro, Y
   Tada, N
   Nishiyama, K
   Miyai, T
   Sugawara, N
   Ishizuka, K
   Chikamoto, H
   Akioka, Y
   Iijima, K
   Hattori, M
AF Kanda, Shoichiro
   Morisada, Naoya
   Kaneko, Naoto
   Yabuuchi, Tomoo
   Nawashiro, Yuri
   Tada, Norimasa
   Nishiyama, Kei
   Miyai, Takayuki
   Sugawara, Noriko
   Ishizuka, Kiyonobu
   Chikamoto, Hiroko
   Akioka, Yuko
   Iijima, Kazumoto
   Hattori, Motoshi
TI New-onset diabetes after renal transplantation in a patient with a novel
   HNF1B mutation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric kidney transplantation; complications; NODAT; HNF1B
ID KIDNEY-TRANSPLANT; RISK-FACTORS; CHILDREN; GENE; MORPHOGENESIS; DISEASE
AB CAKUT are the most frequent causes of ESRD in children. Mutations in the gene encoding HNF1B, a transcription factor involved in organ development and maintenance, cause a multisystem disorder that includes CAKUT, diabetes, and liver dysfunction. Here, we describe the case of a patient with renal hypodysplasia who developed NODAT presenting with liver dysfunction. The NODAT was initially thought to be steroid and FK related. However, based on the patient's clinical features, including renal hypodysplasia and recurrent elevations of transaminase, screening for an HNF1B mutation was performed. Direct sequencing identified a novel splicing mutation of HNF1B, designated c.344 + 2T>C. Because CAKUT is the leading cause of ESRD in children and HNF1B mutations can cause both renal hypodysplasia and diabetes, HNF1B mutations may account for a portion of the cases of NODAT in pediatric patients who have undergone kidney transplantation. NODAT is a serious and major complication of solid organ transplantation and is associated with reduced graft survival. Therefore, for the appropriate management of kidney transplantation, screening for HNF1B mutations should be considered in pediatric patients with transplants caused by CAKUT who develop NODAT and show extra-renal symptoms.
C1 [Kanda, Shoichiro; Kaneko, Naoto; Yabuuchi, Tomoo; Nawashiro, Yuri; Tada, Norimasa; Nishiyama, Kei; Miyai, Takayuki; Sugawara, Noriko; Ishizuka, Kiyonobu; Chikamoto, Hiroko; Akioka, Yuko; Hattori, Motoshi] Tokyo Womens Med Univ, Sch Med, Dept Pediat Nephrol, 8-1 Kawadacho, Tokyo 1628666, Japan.
   [Morisada, Naoya; Iijima, Kazumoto] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 657, Japan.
RP Hattori, M (reprint author), Tokyo Womens Med Univ, Sch Med, Dept Pediat Nephrol, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.
EM hattori@kc.twmu.ac.jp
CR Chen YZ, 2010, CHINESE MED J-PEKING, V123, P3326, DOI 10.3760/cma.j.issn.0366-6999.2010.22.029
   Clissold RL, 2015, NAT REV NEPHROL, V11, P102, DOI 10.1038/nrneph.2014.232
   Coffinier C, 2002, DEVELOPMENT, V129, P1829
   De Vas MG, 2015, DEVELOPMENT, V142, P871, DOI 10.1242/dev.110759
   Faguer S, 2014, KIDNEY INT, V86, P1007, DOI 10.1038/ki.2014.202
   Garro R, 2015, PEDIATR NEPHROL, V30, P405, DOI 10.1007/s00467-014-2830-7
   Haldorsen IS, 2008, DIABETIC MED, V25, P782, DOI 10.1111/j.1464-5491.2008.02460.x
   Harambat J, 2012, PEDIATR NEPHROL, V27, P363, DOI 10.1007/s00467-011-1939-1
   Hattori M, 2015, CLIN EXP NEPHROL, V19, P933, DOI 10.1007/s10157-014-1077-8
   Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384
   McCaughan JA, 2014, J AM SOC NEPHROL, V25, P1037, DOI 10.1681/ASN.2013040383
   Nakayama M, 2010, PEDIATR NEPHROL, V25, P1073, DOI 10.1007/s00467-010-1454-9
   Sharif A, 2010, NAT REV NEPHROL, V6, P415, DOI 10.1038/nrneph.2010.66
   Thomas R, 2011, PEDIATR NEPHROL, V26, P897, DOI 10.1007/s00467-011-1826-9
   Tudorache E, 2012, PEDIATR DIABETES, V13, pe35, DOI 10.1111/j.1399-5448.2011.00842.x
   Ulinski T, 2006, J AM SOC NEPHROL, V17, P497, DOI 10.1681/ASN.2005101040
   Waller SC, 2002, AM J KIDNEY DIS, V40, P1325, DOI 10.1053/ajkd.2002.36915
   Weber S, 2006, J AM SOC NEPHROL, V17, P2864, DOI 10.1681/ASN.2006030277
   Wilkinson A, 2005, CLIN TRANSPLANT, V19, P291, DOI 10.1111/j.1399-0012.2005.00359.x
   Yang J, 2011, TRANSPLANTATION, V91, P1114, DOI 10.1097/TP.0b013e31821620f9
   Zuber J, 2009, NAT REV NEPHROL, V5, P480, DOI 10.1038/nrneph.2009.98
NR 21
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2016
VL 20
IS 3
BP 467
EP 471
DI 10.1111/petr.12690
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DI7IO
UT WOS:000373673100020
PM 26899772
ER

PT J
AU Cramm, SL
   Waits, SA
   Englesbe, MJ
   Bucuvalas, JC
   Horslen, SP
   Mazariegos, GV
   Soltys, KA
   Anand, R
   Magee, JC
AF Cramm, Shannon L.
   Waits, Seth A.
   Englesbe, Michael J.
   Bucuvalas, John C.
   Horslen, Simon P.
   Mazariegos, George V.
   Soltys, Kyle A.
   Anand, Ravinder
   Magee, John C.
TI Failure to Rescue as a Quality Improvement Approach in Transplantation:
   A First Effort to Evaluate This Tool in Pediatric Liver Transplantation
SO TRANSPLANTATION
LA English
DT Article
ID HOSPITAL VOLUME; SURGERY; COMPLICATIONS; MORTALITY
AB Background. Significant intercenter variation exists inmortality and death-censored graft loss (DCGL) after transplantation. Failure to rescue (FTR, death after a major complication) is an emerging tool in quality improvement and may underlie this variation. This study is the first effort to investigate the relationship between FTR and outcomes in transplantation to assess its utility in care improvement. Methods. Using the Studies of Pediatric Liver Transplantation database, we identified 2330 children undergoing primary liver transplants at 21 centers. Centers were ranked by risk-adjusted mortality and sorted into tertiles. We then compared mortality, complications, and FTR across tertiles. Results. Overall mortality was 4.9%, ranging from 1.4% to 8.1% in the low and highmortality tertiles (P < 0.01). The low mortality tertile had significantly lower rates of complications (30.9% vs 38.5% and 40.4%, P < 0.01) as well as FTR (4.6% vs 9.9% and 14.3%, P < 0.01). A similar trend was seen in the DCGL analysis. Conclusions. Our results demonstrate that although centers with higher mortality and DCGL have more frequent major complications, they exhibit 3-fold the rate of FTR. Efforts to standardize perioperative care, and thus minimize FTR, will have value to pediatric liver transplantation recipients. This preliminary study indicates that FTR may provide a useful quality improvement tool for the field of transplantation and warrants further investigation.
C1 [Cramm, Shannon L.; Waits, Seth A.; Englesbe, Michael J.; Magee, John C.] Univ Michigan, Dept Surg, Sect Transplantat, Ann Arbor, MI 48109 USA.
   [Bucuvalas, John C.] Cincinnati Childrens Hosp, Pediat Liver Care Ctr, Cincinnati, OH USA.
   [Horslen, Simon P.] Seattle Childrens Hosp, Div Gastroenterol, Seattle, WA USA.
   [Mazariegos, George V.; Soltys, Kyle A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
   [Anand, Ravinder] EMMES Corp, Rockville, MD USA.
RP Magee, JC (reprint author), 2924 Taubman Hlth Care Ctr, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM mageej@med.umich.edu
FU American Society of Transplant Surgeons Presidential Student Mentorship
   Grant
FX These data were provided by the Studies of Pediatric Liver
   Transplantation group. Funding for this project was in part from the
   American Society of Transplant Surgeons Presidential Student Mentorship
   Grant.
CR Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337
   Englesbe MJ, 2012, AM J TRANSPLANT, V12, P2301, DOI 10.1111/j.1600-6143.2012.04204.x
   Forum NQ, 2012, FAIL RESC 30 DAY MOR
   Ghaferi AA, 2009, ANN SURG, V250, P1029, DOI 10.1097/SLA.0b013e3181bef697
   Ghaferi AA, 2011, MED CARE, V49, P1076, DOI 10.1097/MLR.0b013e3182329b97
   Indicators AfHRaQ, PAT SAF IND TECHN SP
   Magee JC, 2008, AM J TRANSPLANT, V8, P935, DOI 10.1111/j.1600-6143.2008.02172.x
   McDiarmid S V, 2003, Clin Transpl, P119
   McDiarmid SV, 2011, ANN SURG, V254, P145, DOI 10.1097/SLA.0b013e31821ad86a
   Pasquali SK, 2012, ANN THORAC SURG, V94, P573, DOI 10.1016/j.athoracsur.2012.03.065
   Pasquali SK, 2012, ANN THORAC SURG, V94, P579
   Reddy HG, 2013, ANN THORAC SURG, V95, P1976, DOI 10.1016/j.athoracsur.2013.03.027
   Silber JH, 2009, ARCH SURG-CHICAGO, V144, P113, DOI 10.1001/archsurg.2008.569
   SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
NR 15
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD APR
PY 2016
VL 100
IS 4
BP 801
EP 807
DI 10.1097/TP.0000000000001121
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DN5QR
UT WOS:000377125700024
PM 26910329
ER

PT J
AU Ramisch, D
   Rumbo, C
   Echevarria, C
   Moulin, L
   Niveyro, S
   Orce, G
   Crivelli, A
   Martinez, MI
   Chavez, L
   Paez, MA
   Trentadue, J
   Klein, F
   Fernandez, A
   Solar, H
   Gondolesi, GE
AF Ramisch, D.
   Rumbo, C.
   Echevarria, C.
   Moulin, L.
   Niveyro, S.
   Orce, G.
   Crivelli, A.
   Martinez, M. I.
   Chavez, L.
   Paez, M. A.
   Trentadue, J.
   Klein, F.
   Fernandez, A.
   Solar, H.
   Gondolesi, G. E.
TI Long-Term Outcomes of Intestinal and Multivisceral Transplantation at a
   Single Center in Argentina
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 14th International Small Bowel Transplant Symposium (ISBTS)
CY JUN 10-13, 2015
CL Univ Catolica Argentina, Buenos Aires, ARGENTINA
SP The Transplantat Soc, Intestinal Transplant Assoc, Argentinean Transplant Soc
HO Univ Catolica Argentina
ID SMALL-BOWEL TRANSPLANTATION; QUALITY-OF-LIFE; UNITED-STATES; LIVER;
   CANDIDATES; ALLOGRAFTS; REJECTION; ALLOCATION; RECIPIENTS; NUTRITION
AB Background. Intestinal failure (IF) patients received parenteral nutrition (PN) as the only available therapy until intestinal transplantation (ITx) evolved as an accepted treatment. The aim of this article is to report the long-term outcomes of a series of ITx performed in pediatric and adult patients at a single center 9 years after its creation.
   Patients and Methods. This is a retrospective analysis of the ITx performed between May 2006 and January 2015. Diagnoses, pre-ITx mean time on PN, indications for ITx, time on the waiting list for types of ITx, mean total ischemia time, and warm ischemia time, time until PN discontinuation, incidence of acute and chronic rejection, and 5-year actuarial patient survival are reported.
   Results. A total of 42 patients received ITx; 80% had short gut syndrome (SG); the mean time on PN was 1620 days. The main indication for ITx was lack of central venous access followed by intestinal failure associated liver disease (IFALD) and catheter-related infectious complications. The mean time on the waiting list was 188 days (standard deviation, +/- 183 days). ITx were performed in 26 children and 14 adults. In all, 32 procedures were isolated ITx (IITX); 10 were multiorgan Tx (MOT; 3 combined, 7 multivisceral Tx (MVTx), 1 modified MVTx and 2 with kidney); 2 (4.7 %) were retransplantations: 1 IITx, 1 MVTx, and 5 including the right colon. Thirteen patients (31%) received abdominal rectus fascia. All procedures were performed by the same surgical team. Total ischemia time was 7:53 +/- 2:04 hours, and warm ischemia time was 40.2 +/- 10.5 minutes. The mean length of implanted intestine was 325 63 cm. Bishop-Koop ileostomy was performed in 67% of cases. In all, 16 of 42 Tx required early reoperations. The overall mean follow-up time was 41 +/- 35.6 months. The mean time to PN discontinuation after Tx was 68 days (P = .001). The total number of acute cellular rejection (ACR) episodes until the last follow-up was 83; the total number of grafts lost due to ACR was 4; and the total graft lost due to chronic rejection was 3. At the time of writing, the overall 5-year patient survival is 55% (65% for IITx vs 22% for MOT; P = .0001); 60% for pediatric recipients vs 47% for adults (P = NS); 64% when the indication for ITx was SG vs 25% for non-SG (P = .002).
   Conclusions. At this center, candidates with SG, in the absence of IFALD requiring IITx, showed the best long-term outcomes, independent of recipient age. A multidisciplinary approach is mandatory for the care of intestinal failure patients, to sustain a rehabilitation and transplantation program over time.
C1 [Ramisch, D.; Rumbo, C.; Echevarria, C.; Moulin, L.; Crivelli, A.; Martinez, M. I.; Chavez, L.; Paez, M. A.; Fernandez, A.; Solar, H.; Gondolesi, G. E.] Univ Hosp, Fdn Favaloro, Inst Trasplante Multiorgan, Unidad Insuficiencia Intestinal Rehabil & Traspla, Av Belgrano 1782,7mo Piso, RA-1093 Caba, Bs As, Argentina.
   [Niveyro, S.; Orce, G.] Univ Hosp, Fdn Favaloro, Dept Anesthesia, Av Belgrano 1782,7mo Piso, RA-1093 Caba, Bs As, Argentina.
   [Trentadue, J.] Univ Hosp, Fdn Favaloro, Pediat Intens Care Unit, Av Belgrano 1782,7mo Piso, RA-1093 Caba, Bs As, Argentina.
   [Klein, F.] Univ Hosp, Fdn Favaloro, Adult Intens Care Unit, Av Belgrano 1782,7mo Piso, RA-1093 Caba, Bs As, Argentina.
RP Gondolesi, GE (reprint author), Univ Hosp, Fdn Favaloro, Inst Trasplante Multiorgan, Unidad Insuficiencia Intestinal Rehabil & Traspla, Av Belgrano 1782,7mo Piso, RA-1093 Caba, Bs As, Argentina.
EM ggondolesi@ffavaloro.org
CR Abu-Elmagd KM, 2009, ANN SURG, V250, P567, DOI 10.1097/SLA.0b013e3181b67725
   Abu-Elmagd KM, 2009, TRANSPL INT, V22, P96, DOI 10.1111/j.1432-2277.2008.00785.x
   Abu-Elmagd KM, 2012, ANN SURG, V256, P494, DOI 10.1097/SLA.0b013e318265f310
   Abu-Elmagd K, 2008, INTESTINAL FAILURE D, P245
   Avitzur Y, 2010, PEDIATR CLIN N AM, V57, P415, DOI 10.1016/j.pcl.2010.01.019
   Cheng E, 2012, AM J TRANSPLANT, V12, P3047
   da Silva RF, 2008, TRANSPL P, V40, P827, DOI 10.1016/j.transproceed.2008.02.067
   Desschans B, 2008, ACTA CHIR BELG, V108, P31
   Fishbein TM, 2009, NEW ENGL J MED, V361, P998, DOI 10.1056/NEJMra0804605
   Fishbein TM, 2002, TRANSPLANTATION, V73, P1538, DOI 10.1097/00007890-200205270-00004
   Fishbein TM, 2003, GASTROENTEROLOGY, V124, P1615, DOI 10.1016/S0016-5085(03)00375-5
   Freeman RB, 2008, AM J TRANSPLANT, V8, P958, DOI 10.1111/j.1600-6143.2008.02174.x
   Fryer J, 2003, LIVER TRANSPLANT, V9, P748, DOI 10.1053/jlts.2003.50151
   Gondolesi G, 2014, AM J TRANSPLANT S, P217
   Gondolesi G, 2006, AM J TRANSPLANT, V6, P2786, DOI 10.1111/j.1600-6143.2006.01513.x
   Gondolesi G, 2009, TRANSPLANTATION, V27, P1884
   Gondolesi G, 2006, TRANSPLANTATION, V81, P1743, DOI 10.1097/01.tp.0000226078.94635.76
   Gondolesi Gabriel E, 2009, Acta Gastroenterol Latinoam, V39, P63
   Gondolesi GE, 2012, MT SINAI J MED, P246
   Grant D, 2015, AM J TRANSPLANT, V15, P210, DOI 10.1111/ajt.12979
   Horslen S, 2004, LIVER TRANSPLANT, V10, pS86, DOI 10.1002/lt.20257
   Iyer KR, 2002, J PEDIATR SURG, V37, P151, DOI 10.1053/jpsu.2002.30240
   Kato T, 2008, TRANSPLANTATION, V86, P293, DOI 10.1097/TP.0b013e31817ef01c
   Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x
   Kaufman SS, 2001, CURR OPIN PEDIATR, V13, P425, DOI 10.1097/00008480-200110000-00007
   KIRKMAN RL, 1984, TRANSPLANTATION, V37, P429, DOI 10.1097/00007890-198405000-00001
   Langnas A, 2008, INTESTINAL FAILURE D, P245
   Levi DM, 2003, LANCET, V361, P2173, DOI 10.1016/S0140-6736(03)13769-5
   Mangus RS, 2013, J GASTROINTEST SURG, V17, P179, DOI 10.1007/s11605-012-2047-7
   Matarese LE, 2007, NUTR CLIN PRACT, V22, P474, DOI 10.1177/0115426507022005474
   Mazariegos GV, 2010, AM J TRANSPLANT, V10, P1020, DOI 10.1111/j.1600-6143.2010.03044.x
   Mazariegos George V, 2009, Curr Gastroenterol Rep, V11, P226
   Mazariegos GV, 2008, TRANSPLANTATION, V86, P1777, DOI 10.1097/TP.0b013e3181910f51
   Minneci Peter C, 2014, Pathophysiology, V21, P119, DOI 10.1016/j.pathophys.2013.11.014
   O'Keefe SJD, 2007, AM J GASTROENTEROL, V102, P1093, DOI 10.1111/j.1572-0241.2007.01125.x
   Reyes JD, 2014, J PEDIATR SURG, V49, P13, DOI 10.1016/j.jpedsurg.2013.09.022
   Ruiz P, 2004, TRANSPLANT P, V36, P335, DOI 10.1016/j.transproceed.2004.01.079
   Ruiz P, 2014, CURR OPIN ORGAN TRAN, V19, P293, DOI 10.1097/MOT.0000000000000075
   Shiffman ML, 2006, AM J TRANSPLANT, V6, P1170, DOI 10.1111/j.1600-6143.2006.01273.x
   Smith JM, 2013, AM J TRANSPLANT, V13, P103, DOI 10.1111/ajt.12022
   STARZL TE, 1962, AM J SURG, V103, P219, DOI 10.1016/0002-9610(62)90491-9
   Trentadue J, 2011, ARCH ARGENT PEDIATR, V109, P135, DOI 10.1590/S0325-00752011000200008
   Vianna RM, 2009, CURR OPIN CLIN NUTR, V12, P281, DOI 10.1097/MCO.0b013e32832a2215
   Zanfi C, 2010, TRANSPL P, V42, P35, DOI 10.1016/j.transproceed.2009.12.019
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2016
VL 48
IS 2
BP 457
EP 462
DI 10.1016/j.transproceed.2015.12.066
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DK9HA
UT WOS:000375240300041
PM 27109978
ER

PT J
AU Chapman, B
   De Cruz, P
   Jones, R
   Hardikar, W
   Testro, A
AF Chapman, B.
   De Cruz, P.
   Jones, R.
   Hardikar, W.
   Testro, A.
TI Intestinal Failure and Transplant: The Australian Experience (2009 to
   2014)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 14th International Small Bowel Transplant Symposium (ISBTS)
CY JUN 10-13, 2015
CL Univ Catolica Argentina, Buenos Aires, ARGENTINA
SP The Transplantat Soc, Intestinal Transplant Assoc, Argentinean Transplant Soc
HO Univ Catolica Argentina
ID REHABILITATION
AB Background. A joint adult and pediatric intestinal transplant (ITx) program for Australia was developed in 2009 to provide life-saving ITx to patients with irreversible intestinal failure (IF). We aimed to analyze the outcomes of patients treated by our service over the past 5 years.
   Methods. A retrospective medical record review was conducted on all IF patients referred to our service. Patient demographics, underlying disease, nutrition support, TPN complications, and current transplant program status were evaluated.
   Results. Fifty-seven patients (35 adults, 40.4 +/- 12.4 years; 22 children, 6.3 +/- 4.3 years) throughout Australia and New Zealand have been referred. Leading causes of IF were short bowel syndrome followed by pseudo-obstruction. Forty patients (70%) exhibited at least 1 life-threatening complication of PN at referral: liver failure, impending loss of venous access, and/or recurrent line sepsis. Three patients have undergone ITx with 100% survival (median follow-up, 1161 days). Four patients (8%) are listed for transplant, 6 patients (12%) are awaiting transplant assessment, and 4 patients (8%) have died (2 while awaiting transplantation, 2 during assessment period). Causes of death included sepsis and intracranial bleed. Two-thirds of all referred patients (n = 40) were deferred or rejected from wait-listing.
   Conclusions. After 5 years of establishing the first dedicated ITx program in Australia and New Zealand, early results indicate that ITx is an available and life-saving option for IF patients in these countries. Current barriers to ITx in Australia include a shortage of appropriate donors and a high rate of donor-specific antibodies among potential recipients. Growing awareness of the service and early referral to assist appropriate patient selection will aid in the program's success.
C1 [Chapman, B.] Austin Hlth, Dept Nutr & Dietet, Melbourne, Vic, Australia.
   [De Cruz, P.; Jones, R.; Testro, A.] Austin Hlth, Liver & Intestinal Transplant Unit, Melbourne, Vic, Australia.
   [Hardikar, W.] Royal Childrens Hosp, Liver & Intestinal Transplant Unit, Melbourne, Vic, Australia.
RP Chapman, B (reprint author), Austin Hlth, Studley Rd, Heidelberg, Vic 3084, Australia.
EM brooke.chapman@austin.org.au
CR Abu-Elmagd K, 2015, NAT REV GASTRO HEPAT, V12, P108, DOI 10.1038/nrgastro.2014.216
   Avitzur Y, 2015, J PEDIATR GASTR NUTR, V61, P18, DOI 10.1097/MPG.0000000000000735
   Beath S, 2008, TRANSPLANTATION, V85, P1378, DOI 10.1097/TP.0b013e31816dd513
   Commonwealth of Australia, AUSTR ORG TISS DON T
   Gomez M P, 2014, Transplant Proc, V46, P1044, DOI 10.1016/j.transproceed.2013.11.138
   Grant D, 2015, AM J TRANSPLANT, V15, P210, DOI 10.1111/ajt.12979
   IRODAT, 2010, ORG TISSUE CELLS, V13, P147
   Matarese LE, 2007, NUTR CLIN PRACT, V22, P474, DOI 10.1177/0115426507022005474
   Matarese LE, 2014, JPEN S1, V28, p60S
   Tappenden KA, 2014, JPEN S1, V28, p14S
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2016
VL 48
IS 2
BP 463
EP 467
DI 10.1016/j.transproceed.2015.09.071
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DK9HA
UT WOS:000375240300042
PM 27109979
ER

PT J
AU Giraldi, E
   Provenzi, M
   Conter, V
   Colledan, M
   Bolognini, S
   Foglia, C
   Sebastiani, R
   Fiocchi, R
   Gianatti, A
   D'Antiga, L
   Rambaldi, A
AF Giraldi, Eugenia
   Provenzi, Massimo
   Conter, Valentino
   Colledan, Michele
   Bolognini, Stefania
   Foglia, Carlo
   Sebastiani, Roberta
   Fiocchi, Roberto
   Gianatti, Andrea
   D'Antiga, Lorenzo
   Rambaldi, Alessandro
TI Risk-adapted Treatment for Severe B-Lineage Posttransplant
   Lymphoproliferative Disease After Solid Organ Transplantation in
   Children
SO TRANSPLANTATION
LA English
DT Article
ID PEDIATRIC LIVER-TRANSPLANTATION; LOW-DOSE CHEMOTHERAPY;
   PROGNOSTIC-FACTORS; ANTI-CD20 ANTIBODY; TUMOR REGISTRY; ONCOLOGY-GROUP;
   SINGLE-CENTER; DISORDERS; RITUXIMAB; RECIPIENTS
AB Background. Optimal management of posttransplant lymphoproliferative disease (PTLD) remains to be defined due to heterogeneity of this condition and lack of predictors of the outcome. Here we report our experience with pediatric PTLD nonresponsive to immunosuppression (IS) withdrawal, managed after stratification into high and low risk according to the presenting features. Methods. This is a single-center retrospective review of prospectively enrolled patients. From 2001 to 2011, 17 children were diagnosed with severe B-lineage, CD20+, PTLD after a median of 37 months (range, 5-93) from liver (12), heart (4), or multiorgan (1) transplantation. Treatment was tailored on 2 risk groups: (1) standard-risk (SR) patients received IS reduction and rituximab; (2) high-risk (HR) patients received IS discontinuation, rituximab and polychemotherapy. Results. The cumulative incidence of rejection at 1 and 5 years after the diagnosis of PTLD was 35% (95% confidence interval [95% CI], 18-69%) and 53% (33-85%), respectively, whereas the disease-free survival at 1 and 5 years was 94%(95% CI, 65-99%) and 75%(45-90%), respectively. Three children died, PTLD-free, from different transplant-related complications: primary nonfunction after retransplantation (liver), cytomegalovirus disease 21 months after PTLD treatment (liver), graft dysfunction 25 months after PTLD (heart). Conclusions. Severe B-lineage PTLD after solid organ transplantation may be classified as SR or HR and treated accordingly with a tailored protocol obtaining a satisfactory long-term outcome. This approach accomplishes the control of lymphoproliferation in severe forms as well as the minimization of toxicity in milder PTLDs.
C1 [Giraldi, Eugenia; Provenzi, Massimo; Conter, Valentino; Bolognini, Stefania; Foglia, Carlo; D'Antiga, Lorenzo] Hosp Papa Giovanni XXIII, Dept Pediat, Piazza OMS 1, I-24127 Bergamo, Italy.
   [Colledan, Michele] Hosp Papa Giovanni XXIII, Dept Transplant Surg, Bergamo, Italy.
   [Sebastiani, Roberta; Fiocchi, Roberto] Hosp Papa Giovanni XXIII, Dept Cardiac Surg, Bergamo, Italy.
   [Gianatti, Andrea] Hosp Papa Giovanni XXIII, Dept Pathol, Bergamo, Italy.
   [Rambaldi, Alessandro] Hosp Papa Giovanni XXIII, Dept Hematol, Bergamo, Italy.
RP D'Antiga, L (reprint author), Hosp Papa Giovanni XXIII, Dept Pediat, Piazza OMS 1, I-24127 Bergamo, Italy.
EM ldantiga@hpg23.it
CR Aull MJ, 2004, TRANSPLANTATION, V78, P1676, DOI 10.1097/01.TP.0000144333.19106.58
   Buell JF, 2005, TRANSPLANT P, V37, P956, DOI 10.1016/j.transproceed.2004.12.124
   Choquet S, 2006, BLOOD, V107, P3053, DOI 10.1182/blood-2005-01-0377
   Choquet S, 2007, HAEMATOL-HEMATOL J, V92, P273, DOI 10.3324/haematol.10595
   Choquet Sylvain, 2002, Recent Results Cancer Res, V159, P67
   Choquet S, 2007, ANN HEMATOL, V86, P599, DOI 10.1007/s00277-007-0298-2
   D'Antiga L, 2007, LIVER TRANSPLANT, V13, P343, DOI 10.1002/lt.20958
   Dharnidharka VR, 2011, AM J TRANSPLANT, V11, P751, DOI 10.1111/j.1600-6143.2011.03470.x
   Dotti G, 2001, HAEMATOLOGICA, V86, P618
   Dotti G, 2000, TRANSPLANTATION, V69, P827
   Dotti G, 2002, TRANSPLANTATION, V74, P1095, DOI 10.1097/00007890-200210270-00007
   Elstrom RL, 2006, AM J TRANSPLANT, V6, P569, DOI 10.1111/j.1600-6143.2005.01211.x
   Evens AM, 2010, J CLIN ONCOL, V28, P1038, DOI 10.1200/JCO.2009.25.4961
   Evens AM, 2010, CURR ONCOL REP, V12, P383, DOI 10.1007/s11912-010-0132-1
   Gallego S, 2010, PEDIATR TRANSPLANT, V14, P61, DOI 10.1111/j.1399-3046.2009.01181.x
   Ghobrial IM, 2005, LEUKEMIA LYMPHOMA, V46, P191, DOI 10.1080/10428190400012011
   Ghobrial IM, 2005, J CLIN ONCOL, V23, P7574, DOI 10.1200/JCO.2005.01.0934
   Giraldi E, 2011, PEDIATR BLOOD CANCER, V57, P324, DOI 10.1002/pbc.23004
   Glotz D, 2012, TRANSPLANTATION, V94, P784, DOI 10.1097/TP.0b013e318269e64f
   Green M, 2003, PEDIATR CLIN N AM, V50, P1471, DOI 10.1016/S0031-3955(03)00127-5
   Gross TG, 2012, AM J TRANSPLANT, V12, P3069, DOI 10.1111/j.1600-6143.2012.04206.x
   Gross TG, 2005, J CLIN ONCOL, V23, P6481, DOI 10.1200/JCO.2005.08.074
   Gupta S, 2010, PEDIATR TRANSPLANT, V14, P896, DOI 10.1111/j.1399-3046.2010.01370.x
   Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8
   Hurwitz M, 2004, PEDIATR TRANSPLANT, V8, P267, DOI 10.1111/j.1399-3046.2004.00129.x
   Jagadeesh D, 2012, CURR TREAT OPTION ON, V13, P122, DOI 10.1007/s11864-011-0177-x
   Jain AB, 2005, TRANSPLANTATION, V80, P1692, DOI 10.1097/01.tp.0000185570.41571.df
   Jimenez-Rivera C, 2004, PEDIATR TRANSPLANT, V8, P243, DOI 10.1111/j.1399-3046.2004.00156.x
   Knight JS, 2009, J CLIN ONCOL, V27, P3354, DOI 10.1200/JCO.2008.20.0857
   LEBLOND V, 1995, J CLIN ONCOL, V13, P961
   Leblond V, 2001, J CLIN ONCOL, V19, P772
   Loren AW, 2003, BONE MARROW TRANSPL, V31, P145, DOI 10.1038/sj.bmt.1703806
   McCarthy M, 1997, J HEPATOL, V27, P1015, DOI 10.1016/S0168-8278(97)80145-6
   MURPHY SB, 1980, SEMIN ONCOL, V7, P332
   Muti G, 2002, HAEMATOLOGICA, V87, P67
   Ohta H, 2009, INT J HEMATOL, V90, P127, DOI 10.1007/s12185-009-0399-x
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Parker A, 2010, BRIT J HAEMATOL, V149, P693, DOI 10.1111/j.1365-2141.2010.08160.x
   Patel H, 2007, LEUKEMIA LYMPHOMA, V48, P885, DOI 10.1080/10428190701223275
   Picarsic J, 2011, CANCER-AM CANCER SOC, V117, P4540, DOI 10.1002/cncr.26001
   Pillon M, 2004, CANCER, V101, P385, DOI 10.1002/cncr.20382
   Reiter A, 1999, BLOOD, V94, P3294
   Schubert S, 2009, PEDIATR TRANSPLANT, V13, P54, DOI 10.1111/j.1399-3046.2008.00969.x
   SHIPP MA, 1993, NEW ENGL J MED, V329, P987
   Swinnen LJ, 2008, TRANSPLANTATION, V86, P215, DOI 10.1097/TP.0b013e3181761659
   Tarella C, 2007, ASH ANN M, V110, P513
   Trappe R, 2007, ASH ANN M, V110, P390
   Trappe R, 2009, AM J TRANSPLANT, V9, P2331, DOI 10.1111/j.1600-6143.2009.02772.x
   Trappe R, 2012, LANCET ONCOL, V13, P196, DOI 10.1016/S1470-2045(11)70300-X
   Watts RG, 2002, J PEDIAT HEMATOL ONC, V24, P622, DOI 10.1097/00043426-200211000-00005
   Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6
   Windebank K, 2009, PEDIATR BLOOD CANCER, V53, P392, DOI 10.1002/pbc.22070
   Wistinghausen B, 2013, PEDIATR HEMAT ONCOL, V30, P520, DOI 10.3109/08880018.2013.798844
   Zimmermann H, 2012, CANCER-AM CANCER SOC, V118, P4715, DOI 10.1002/cncr.27482
NR 54
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD FEB
PY 2016
VL 100
IS 2
BP 437
EP 445
DI 10.1097/TP.0000000000000845
PG 9
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA DJ6SM
UT WOS:000374343200029
PM 26270449
ER

PT J
AU Yankol, Y
   Fernandez, LA
   Kanmaz, T
   Leverson, GE
   Mezrich, JD
   Foley, D
   Mecit, N
   D'Alessandro, AM
   Acarli, K
   Kalayoglu, M
AF Yankol, Yucel
   Fernandez, Luis A.
   Kanmaz, Turan
   Leverson, Glen E.
   Mezrich, Joshua D.
   Foley, David
   Mecit, Nesimi
   D'Alessandro, Anthony M.
   Acarli, Koray
   Kalayoglu, Munci
TI Results of pediatric living donor compared to deceased donor liver
   transplantation in the PELD/MELD era: Experience from two centers on two
   different continents
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; outcome; living donor; MELD; PELD
ID HEPATIC-ARTERY THROMBOSIS; VASCULAR COMPLICATIONS; SINGLE-CENTER;
   OUTCOMES; ADULT; GRAFTS; VOLUME; SPLIT
AB The LDLT option in the pediatric population allows recipients to be transplanted early. A total of 202 consecutive pediatric liver transplants from two different institutions108 (LDLT) and 94 (DDLT)were retrospectively compared. Overall, one- and three-yr patient and graft survival were similar between DDLT and LDLT. ACR was greater in recipients of DDLT at one and threeyr (50.8% and 61.0%) compared to LDLT (30.8% and 32.2%) (p=0.002). When the data were stratified according to PELD/MELD score, LDLT with a low score had better one- and three-yr graft survival (96.2% and 96.2%) compared to DDLT (88.2% and 85.2%) (p=0.02), with comparable patient survival (p=0.75). Patient and graft survival were similar between DDLT and LDLT in the high PELD/MELD group. Lower incidence of ACR in both low and high PELD/MELD groups was (29.6% and 34.3%) for LDLT compared to DDLT (50.3% and 53.3%, p=0.002 and p=0.028, respectively). Regardless of PELD/MELD score, status, age group, and recipient weight, LDLT provides excellent patient and graft survival with a lower incidence of rejection compared to DDLT.
C1 [Yankol, Yucel; Fernandez, Luis A.; Mezrich, Joshua D.; Foley, David; D'Alessandro, Anthony M.] Univ Wisconsin, Dept Surg, Div Transplantat, Madison, WI 53792 USA.
   [Yankol, Yucel; Kanmaz, Turan; Mecit, Nesimi; Acarli, Koray; Kalayoglu, Munci] Mem Sisli Hosp, Organ Transplantat Ctr, Istanbul, Turkey.
   [Leverson, Glen E.] Univ Wisconsin, Dept Surg Biostat, Sch Med & Publ Hlth, Madison, WI 53792 USA.
RP Fernandez, LA (reprint author), Univ Wisconsin, Dept Surg, Div Organ Transplantat, Ctr Clin Sci H4 782, 600 Highland Ave, Madison, WI 53792 USA.
EM luisf@surgery.wisc.edu
CR Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Emre S, 2012, MT SINAI J MED, V79, P199, DOI 10.1002/msj.21305
   Kamath BM, 2010, PEDIATR CLIN N AM, V57, P401, DOI 10.1016/j.pcl.2010.01.012
   Kanmaz T, 2014, EXP CLIN TRANSPLANT, V12, P41, DOI 10.6002/ect.2013.0016
   Kim WR, 2013, AM J TRANSPLANT, V13, P73, DOI 10.1111/ajt.12021
   McDiarmid SV, 2004, LIVER TRANSPLANT, V10, pS23, DOI 10.1002/lt.20272
   Olthoff KM, 2005, ANN SURG, V242, P314, DOI 10.1097/01.sla.0000179646.37145.cf
   Rodriguez-Davalos MI, 2014, JAMA SURG, V149, P63, DOI 10.1001/jamasurg.2013.3384
   Salvalaggio PR, 2007, TRANSPLANTATION, V84, P926, DOI 10.1097/01.tp.0000281554.00247.92
   Scarinci A, 2010, TRANSPL P, V42, P4403, DOI 10.1016/j.transproceed.2010.07.014
   Tracy ET, 2010, J PEDIATR SURG, V45, P108, DOI 10.1016/j.jpedsurg.2009.10.018
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
NR 16
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2016
VL 20
IS 1
BP 72
EP 82
DI 10.1111/petr.12641
PG 11
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DF5VN
UT WOS:000371420800012
PM 26861217
ER

PT J
AU Selimoglu, MA
   Varol, I
   Karabiber, H
   Tabel, Y
   Keceli, M
   Yilmaz, S
AF Selimoglu, Mukadder Ayse
   Varol, Ilknur
   Karabiber, Hamza
   Tabel, Yilmaz
   Keceli, Meryem
   Yilmaz, Sezai
TI Evaluation of renal functions in pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; glomerular filtration rate; liver transplantation
ID GLOMERULAR-FILTRATION-RATE; ACUTE KIDNEY INJURY; TERM-FOLLOW-UP; RIFLE
   CRITERIA; RISK-FACTORS; CHILDREN; LONG; CYCLOSPORINE; DYSFUNCTION;
   RECIPIENTS
AB AKI is an important complication after LT. As our LT series contains a quite high number of children with ALF unlike published studies, we aimed to determine pre-LT and long-term renal functions in children both with ALF and with CLD. Demographic and disease-related data of 134 transplanted children were evaluated retrospectively. Pre-LT and follow-up GFR and pediatric RIFLE scores were determined. Mean pre-LT GFR was not dependent on the disease presentation or severity of chronic disease. While there was an initial decline until first week of post-LT in CLD children, an increase was observed in ALF. Neither mean GFR nor the pRIFLE on follow-up was different with respect to the type of LT or disease presentation. Mean GFR at first and sixth months were lower in children on cyclosporine compared to tacrolimus (p = 0.001 and p = 0.002, respectively). In conclusion, GFR-time curve was different in children with or without ALF. Type of LT, and severity of the CLD were not risk factors for CKD in any time, but younger age at LT, CLD, and cyclosporine usage were at sixth months of follow-up.
C1 [Selimoglu, Mukadder Ayse; Varol, Ilknur; Karabiber, Hamza; Keceli, Meryem] Inonu Univ, Dept Pediat Gastroenterol Hepatol & Nutr, Fac Med, Malatya, Turkey.
   [Tabel, Yilmaz] Inonu Univ, Dept Pediat Nephrol, Fac Med, Malatya, Turkey.
   [Yilmaz, Sezai] Inonu univ, Dept Gen Surg, Fac Med, Malatya, Turkey.
RP Selimoglu, MA (reprint author), Inonu Univ, Dept Pediat, Fac Med, Malatya, Turkey.
EM ayseselimoglu@hotmail.com
CR Akcan-Arikan A, 2007, KIDNEY INT, V71, P1028, DOI 10.1038/sj.ki.5002231
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Biancofiorea G, 2008, CURR OPIN ORGAN TRAN, V13, P291, DOI 10.1097/MOT.0b013e328300a058
   Bishop JR, 2009, PEDIATR TRANSPLANT, V13, P96, DOI 10.1111/j.1399-3046.2008.00999.x
   Brown RS, 1996, TRANSPLANTATION, V62, P1788, DOI 10.1097/00007890-199612270-00018
   Cabezuelo JB, 2006, KIDNEY INT, V69, P1073, DOI 10.1038/sj.ki.5000216
   Campbell K, 2010, AM J TRANSPLANT, V10, P2673, DOI 10.1111/j.1600-6143.2010.03316.x
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Filler G, 2014, PEDIATR NEPHROL, V29, P183, DOI 10.1007/s00467-013-2426-7
   Fine RN, 2005, PEDIATR TRANSPLANT, V9, P680, DOI 10.1111/j.1399-3046.2005.00381.x
   Gainza FJ, 2002, TRANSPLANT P, V34, P250, DOI 10.1016/S0041-1345(01)02747-6
   Goldstein SL, 2012, BLOOD PURIFICAT, V33, P131, DOI 10.1159/000334143
   Greenberg N, 2012, CLIN CHEM, V58, P391, DOI 10.1373/clinchem.2011.172288
   Harambat J, 2008, TRANSPLANTATION, V86, P1028, DOI 10.1097/TP.0b013e318187748f
   Herlenius G, 2010, PEDIATR TRANSPLANT, V14, P409, DOI 10.1111/j.1399-3046.2010.01301.x
   Herzog D, 2006, TRANSPLANTATION, V81, P672, DOI 10.1097/01.tp.0000185194.62108.a7
   Kalicinski Piotr, 2005, Ann Transplant, V10, P53
   [Anonymous], 2002, AM J KIDNEY DIS, V39, pS1
   Kivela JM, 2011, TRANSPLANTATION, V91, P115, DOI 10.1097/TP.0b013e3181fa94b9
   Loo RM, 2006, PEDIATR TRANSPLANT, V10, P55, DOI 10.1111/j.1399-3046.2005.00399.x
   Matloff RG, 2015, J PEDIATR GASTR NUTR, V61, P182, DOI 10.1097/MPG.0000000000000749
   Matloff RG, 2012, PEDIATR TRANSPLANT, V16, P818, DOI 10.1111/petr.12006
   McCulloch ML, 2005, TRANSPLANT P, V37, P1220, DOI 10.1016/j.transproceed.2004.12.223
   MCDIARMID SV, 1993, TRANSPLANTATION, V56, P847, DOI 10.1097/00007890-199310000-00014
   Menon KVN, 2004, AM J TRANSPLANT, V4, P819, DOI 10.1111/j.1600-6143.2004.00433.x
   Saner FH, 2012, LIVER INT, V32, P179, DOI 10.1111/j.1478-3231.2011.02563.x
   Schwartz GJ, 2009, CLIN J AM SOC NEPHRO, V4, P1832, DOI 10.2215/CJN.01640309
   Schwartz GJ, 2012, KIDNEY INT, V82, P445, DOI 10.1038/ki.2012.169
   Utsumi M, 2013, TRANSPL INT, V26, P842, DOI 10.1111/tri.12138
   Wiesmayr S, 2005, PEDIATR TRANSPLANT, V9, P604, DOI 10.1111/j.1399-3046.2005.00348.x
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2016
VL 20
IS 1
BP 83
EP 88
DI 10.1111/petr.12642
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DF5VN
UT WOS:000371420800013
PM 26607307
ER

PT J
AU Matsuura, T
   Yoshimaru, K
   Yanagi, Y
   Esumi, G
   Hayashida, M
   Taguchi, T
AF Matsuura, Toshiharu
   Yoshimaru, Koichiro
   Yanagi, Yusuke
   Esumi, Genshiro
   Hayashida, Makoto
   Taguchi, Tomoaki
TI Massive pulmonary hemorrhage before living donor liver transplantation
   in infants
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; pulmonary hemorrhage; acute respiratory
   failure; biliary atresia
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; RESPIRATORY-DISTRESS-SYNDROME;
   ALVEOLAR HEMORRHAGE; BERLIN DEFINITION; CHILDREN; FAILURE; PATIENT;
   SUPPORT; INJURY
AB A massive pulmonary hemorrhage in patients with liver cirrhosis is a life-threatening complication that may result in a contraindication of a liver transplantation because of its high mortality rate. Herein, we present two infant biliary atresia cases that successfully underwent an LDLT that was followed by intensive respiratory care for the pretransplant massive pulmonary hemorrhage. Both cases exhibited severe respiratory failure (minimum PaO2/FiO(2); 46 mmHg and 39 mmHg, respectively). To arrest the bleeding, we applied a very high positive pressure ventilation treatment (maximum PIP/PEEP; 38/14 cmH(2)O and 55/15 cmH(2)O, respectively), plasma exchange, several FFP transfusions, and recombinant factor VIIa via intrapulmonary administration. In addition, we used CHDF treatment, applied HFOV transiently, and treated the patient with inhalation of nitric oxide. Although we prepared ECMO for intra-operative use, both cases were successfully managed with conventional mechanical ventilation without using ECMO, which may have worsened the pulmonary hemorrhage due to the use of an anticoagulant. Use of an excessive positive pressure management, although it poses a risk for barotrauma, could be acceptable to arrest the pulmonary bleeding in selected cases of liver failure patients who have no time remaining before LDLT.
C1 [Matsuura, Toshiharu; Yoshimaru, Koichiro; Yanagi, Yusuke; Esumi, Genshiro; Hayashida, Makoto; Taguchi, Tomoaki] Kyushu Univ, Dept Pediat Surg, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
RP Matsuura, T (reprint author), Kyushu Univ, Dept Pediat Surg, Grad Sch Med Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM matsuura@pedsurg.med.kyushu-u.ac.jp
CR Alvarez P, 2015, Open Respir Med J, V9, P92, DOI 10.2174/1874306401509010092
   Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020
   Auzinger G, 2014, LIVER TRANSPLANT, V20, P1141, DOI 10.1002/lt.23926
   Barnes SL, 2012, INTERN MED J, V42, P341, DOI 10.1111/j.1445-5994.2012.02720.x
   Dzierba AL, 2014, PHARMACOTHERAPY, V34, P279, DOI 10.1002/phar.1365
   Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1
   Fujita S, 2005, TRANSPLANTATION, V79, P1637, DOI 10.1097/01.TP.0000160815.04784.4A
   Heslet Lars, 2012, Biologics, V6, P37, DOI 10.2147/BTT.S25507
   Hohenforst-Schmidt W, 2013, DRUG DES DEV THER, V24, P627
   Kolovos NS, 2002, CRIT CARE MED, V30, P577, DOI 10.1097/00003246-200203000-00014
   Krowka MJ, 2013, J HEPATOL, V59, P367, DOI 10.1016/j.jhep.2013.03.026
   Luca DD, 2013, INTENS CARE MED, V39, P2083
   Muellenbach RM, 2012, J TRAUMA ACUTE CARE, V72, P1444, DOI 10.1097/TA.0b013e31824d68e3
   Park JA, 2015, PEDIATRICS, V135, pE216, DOI 10.1542/peds.2014-1782
   Park YH, 2012, TRANSPL P, V44, P757, DOI 10.1016/j.transproceed.2012.01.055
   Sato S, 2009, PEDIATR TRANSPLANT, V13, P790, DOI 10.1111/j.1399-3046.2008.01029.x
   Son SK, 2012, PEDIATR TRANSPLANT, V16, pE281, DOI 10.1111/j.1399-3046.2011.01604.x
   The ARDS Definition Task Force, 2012, JAMA, V307, P2526
   Waxman AB, 2003, NEW ENGL J MED, V348, P1902
   Yen TA, 2013, PEDIATR NEONATOL, V54, P330, DOI 10.1016/j.pedneo.2013.04.005
   Zielinska M, 2014, ADV CLIN EXP MED, V23, P843
NR 21
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2016
VL 20
IS 1
BP 89
EP 95
DI 10.1111/petr.12650
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DF5VN
UT WOS:000371420800014
PM 26691206
ER

PT J
AU Thorvaldson, L
   Remberger, M
   Winiarski, J
   Omazic, B
   Fischler, B
   Sundin, M
AF Thorvaldson, Linda
   Remberger, Mats
   Winiarski, Jacek
   Omazic, Brigitta
   Fischler, Bjorn
   Sundin, Mikael
TI HLA, GVHD, and parenteral nutrition are risk factors for hepatic
   complications in pediatric HSCT
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hematopoietic stem cell transplantation; liver; graft versus host
   disease; child; human leukocyte antigen
ID STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; LIVER-INJURY;
   VENOOCCLUSIVE DISEASE; IRON OVERLOAD; CHILDREN; RECIPIENTS; MORTALITY;
   SURVIVAL
AB Hepatic dysfunction is common after allogeneic hematopoietic stem cell transplantation (HSCT). The aim of this retrospective study was to determine the risk factors, frequency, and outcome of hepatic complications post-HSCT in children. Two hundred and thirty-seven cases of allogeneic HSCT in children were included. Data on biochemical liver function at start of HSCT, at +1, +3, +6, and +9 months, and at each subsequent yearly follow-up were extracted. Patients were stratified into groups with hepatocellular (none and mild, and moderate to severe) and hepatobiliary (none and present) dysfunction. Statistical analysis included variables such as diagnosis, age, conditioning regimen, and HLA type. Results: One hundred and fifty-six (66%) patients displayed hepatocellular dysfunction post-HSCT. In most cases transient, but 32% had a persistent abnormality three yr post-HSCT. Risk factors were chronic GVHD (OR 4.20, p = 0.003) and donor HLA-A*01 (OR 2.97, p = 0.02). HLA-DQB1*03 decreased the risk (OR 0.35, p = 0.02). Hepatobiliary dysfunction was less frequent (12%) but carried a poor prognosis. aGVHD grade II-IV (OR 2.7, p = 0.02) and long-term TPN (OR 3.25, p = 0.01) increased the risk. Conclusion: GVHD is an important risk factor for liver dysfunction post-HSCT. Specific HLA types may also contribute as a risk factor, while others seem to have a protective effect.
C1 [Thorvaldson, Linda; Winiarski, Jacek; Fischler, Bjorn; Sundin, Mikael] Karolinska Inst, Div Pediat, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
   [Remberger, Mats; Omazic, Brigitta] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
   [Remberger, Mats] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden.
   [Winiarski, Jacek; Sundin, Mikael] Astrid Lindgren Childrens Hosp, Hematol Immunol & SCT Sect, Stockholm, Sweden.
   [Omazic, Brigitta] Karolinska Univ Hosp Huddinge, Karolinska Univ Lab, Dept Clin Immunol & Transfus Med, Stockholm, Sweden.
   [Fischler, Bjorn] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Gastroenterol Hepatol & Nutr Sect, Stockholm, Sweden.
RP Sundin, M (reprint author), Karolinska Univ Hosp, Karolinska Inst, Div Pediat B76, CLINTEC, SE-14786 Stockholm, Sweden.
EM mikael.sundin@ki.se
FU Karolinska Institutet; Stockholm County Council; Swedish Childhood
   Cancer Foundation; Signe and Olof Wallenius Foundation; Olle Engkvist
   Byggmastare Foundation
FX This study was supported by the Karolinska Institutet, the Stockholm
   County Council, the Swedish Childhood Cancer Foundation, the Signe and
   Olof Wallenius Foundation, and the Olle Engkvist Byggmastare Foundation.
CR Barker CC, 2005, BONE MARROW TRANSPL, V36, P51, DOI 10.1038/sj.bmt.1705004
   Barker CC, 2003, BONE MARROW TRANSPL, V32, P79, DOI 10.1038/sj.bmt.1704069
   BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007
   Bresters D, 2008, BONE MARROW TRANSPL, V41, P27, DOI 10.1038/sj.bmt.1705887
   Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379
   Dezsofi A, 2015, J PEDIATR GASTR NUTR, V60, P408, DOI 10.1097/MPG.0000000000000632
   Duarte-Rey C, 2009, AUTOIMMUN REV, V8, P325, DOI 10.1016/j.autrev.2008.11.005
   [Anonymous], 2012, AUT HEP
   Frisk P, 1998, ACTA PAEDIATR, V87, P579
   GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001
   Guglielmi FW, 2008, CLIN LIVER DIS, V12, P97, DOI [10.1016/j.cld.2007.11.004, 10.1016/j.cid.2007.11.004]
   JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011
   Leeb S, 2015, ACTA PAEDIATR, V104, P479, DOI 10.1111/apa.12908
   Locasciulli A, 1997, BLOOD, V90, P3799
   Longhi MS, 2010, J AUTOIMMUN, V34, P7, DOI 10.1016/j.jaut.2009.08.010
   Naini BV, 2012, HUM PATHOL, V43, P826, DOI 10.1016/j.humpath.2011.07.008
   Pullarkat V, 2008, BONE MARROW TRANSPL, V42, P799, DOI 10.1038/bmt.2008.262
   Radhakrishnan K, 2013, BIOL BLOOD MARROW TR, V19, P912, DOI 10.1016/j.bbmt.2013.02.019
   Remberger M, 2011, BIOL BLOOD MARROW TR, V17, P1688, DOI 10.1016/j.bbmt.2011.05.001
   Shander A, 2009, VOX SANG, V97, P185, DOI 10.1111/j.1423-0410.2009.01207.x
   Subbarao G, 2006, PEDIATR TRANSPLANT, V10, P682, DOI 10.1111/j.1399-3046.2006.00532.x
   Sundin M, 2012, PEDIATR TRANSPLANT, V16, P866, DOI 10.1111/j.1399-3046.2012.01783.x
   Wang PY, 2014, J PEDIATR GASTR NUTR, V58, P457, DOI 10.1097/MPG.0000000000000245
   Yip VLM, 2015, CLIN REV ALLERG IMMU, V48, P165, DOI 10.1007/s12016-014-8418-y
NR 24
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2016
VL 20
IS 1
BP 96
EP 104
DI 10.1111/petr.12623
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DF5VN
UT WOS:000371420800015
PM 26518451
ER

PT J
AU Greenway, SC
   Crossland, DS
   Hudson, M
   Martin, SR
   Myers, RP
   Prieur, T
   Hasan, A
   Kirk, R
AF Greenway, Steven C.
   Crossland, David S.
   Hudson, Mark
   Martin, Steven R.
   Myers, Robert P.
   Prieur, Tim
   Hasan, Asif
   Kirk, Richard
TI Fontan-associated liver disease: Implications for heart transplantation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE Fontan; heart transplantation; liver disease; combined heart-liver
   transplantation; liver fibrosis
ID MAGNETIC-RESONANCE ELASTOGRAPHY; CENTRAL VENOUS-PRESSURE; MAJOR ADVERSE
   EVENTS; TRANSIENT ELASTOGRAPHY; HEPATIC-FIBROSIS; FAILING FONTAN;
   HEPATOCELLULAR-CARCINOMA; SINGLE VENTRICLE; NONINVASIVE ASSESSMENT;
   BIOCHEMICAL MARKERS
AB Chronic liver diseases are associated with multiple complications, including cirrhosis, portal hypertension, ascites, synthetic dysfunction and hepatocellular carcinoma, and these processes are increasingly recognized in post-Fontan patients. Fontan-associated liver disease (FALD) can be defined as abnormalities in liver structure and function that result from the Fontan circulation and are not related to another disease process. FALD arises due to chronic congestion of the liver created by the elevated venous pressure and low cardiac output of the Fontan circulation, which may be superimposed on previous liver injury. Pathology studies have generally shown that FALD worsens as time post-Fontan increases, but the prevalence of FALD is not well defined because the majority of Fontan patients, even those with significant hepatic fibrosis, appear to be asymptomatic and biochemical or functional hepatic abnormalities are usually subtle or absent. Alternate non-invasive investigations, derived from the study of other chronic liver diseases, have been tested in small series of pediatric and adult Fontan patients, but they have been confounded by congestion and do not correlate well with liver biopsy findings. Liver disease can complicate Fontan circulatory failure and may even be significant enough to be considered a contraindication to heart transplantation or require combined heart liver transplantation. The search for the optimal management strategy continues in the setting of increasing numbers of Fontan patients surviving to adulthood and being referred for heart transplantation. Thus, in this review we attempt to define the scope and significance of FALD and address transplant-related assessment and management of this challenging disorder. (C) 2016 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Greenway, Steven C.; Martin, Steven R.] Univ Calgary, Dept Paediat, Calgary, AB T2N 1N4, Canada.
   [Greenway, Steven C.; Martin, Steven R.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada.
   [Greenway, Steven C.; Prieur, Tim] Univ Calgary, Dept Cardiac Sci, Calgary, AB, Canada.
   [Greenway, Steven C.; Prieur, Tim] Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB, Canada.
   [Crossland, David S.; Hasan, Asif; Kirk, Richard] Freeman Rd Hosp, Dept Paediat Cardiol & Cardiothorac Surg, Newcastle Upon Tyne, Tyne & Wear, England.
   [Hudson, Mark] Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne, Tyne & Wear, England.
   [Myers, Robert P.] Univ Calgary, Div Gastroenterol, Dept Med, Liver Unit, Calgary, AB, Canada.
RP Greenway, SC (reprint author), Alberta Childrens Prov Gen Hosp, Cardiol Sect, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.
EM steven.greenway@albertahealthservices.ca
FU Department of Paediatrics, Alberta Children's Hospital Research
   Institute; Libin Cardiovascular Institute of Alberta
FX This study was supported by the Department of Paediatrics, Alberta
   Children's Hospital Research Institute and the Libin Cardiovascular
   Institute of Alberta (to S.C.G.).
CR Anderson PAW, 2008, J AM COLL CARDIOL, V52, P85, DOI 10.1016/j.jacc.2008.01.074
   Asrani SK, 2013, NEW ENGL J MED, V368, P1756, DOI 10.1056/NEJMc1214222
   Assenza GE, 2013, HEART, V99, P491, DOI 10.1136/heartjnl-2012-303347
   Babaoglu K, 2010, PEDIATR CARDIOL, V31, P861, DOI 10.1007/s00246-010-9685-x
   Baek JS, 2010, HEART, V96, P1750, DOI 10.1136/hrt.2010.201772
   Bhama JK, 2013, J HEART LUNG TRANSPL, V32, P499, DOI 10.1016/j.healun.2013.01.1047
   Bulut OP, 2013, J PEDIATR-US, V163, P201, DOI 10.1016/j.jpeds.2012.12.071
   Camposilvan S, 2008, ANN THORAC SURG, V86, P177, DOI 10.1016/j.athoracsur.2008.03.077
   Cui XW, 2013, WORLD J GASTROENTERO, V19, P6329, DOI 10.3748/wjg.v19.i38.6329
   de Ledinghen V, 2007, J PEDIATR GASTR NUTR, V45, P443
   de Leval MR, 2010, NAT REV CARDIOL, V7, P520, DOI 10.1038/nrcardio.2010.99
   Dearani JA, 2009, CURR OPIN PEDIATR, V21, P565, DOI 10.1097/MOP.0b013e3283303fa7
   Elder RW, 2013, INT J CARDIOL, V168, P3764, DOI 10.1016/j.ijcard.2013.06.008
   Elder RW, 2015, CONGENIT HEART DIS, V10, P159, DOI 10.1111/chd.12212
   Engelmann G, 2012, EUR J PEDIATR, V171, P353, DOI 10.1007/s00431-011-1558-7
   Evans WN, 2014, PEDIATR CARDIOL, V35, P1273, DOI 10.1007/s00246-014-0928-0
   Farr M, 2015, J HEART LUNG TRANSPL, V34, P873, DOI 10.1016/j.healun.2014.12.009
   Fitzpatrick E, 2013, J PEDIATR GASTR NUTR, V56, P72, DOI 10.1097/MPG.0b013e31826f2760
   Ford RM, 2015, TRANSPLANT REV-ORLAN, V29, P33, DOI 10.1016/j.trre.2014.11.003
   Friedman Lawrence S, 2010, Trans Am Clin Climatol Assoc, V121, P192
   Friedrich-Rust M, 2008, J THORAC CARDIOV SUR, V135, P560, DOI 10.1016/j.jtcvs.2007.09.039
   Furukawa T, 2011, PEDIATR INT, V53, P980, DOI 10.1111/j.1442-200X.2011.03497.x
   Gewillig M, 2014, HEART FAIL CLIN, V10, P105, DOI 10.1016/j.hfc.2013.09.010
   Ghaferi AA, 2005, J THORAC CARDIOV SUR, V129, P1348, DOI 10.1016/j.jtcvs.2004.10.005
   Giannico S, 2006, J AM COLL CARDIOL, V47, P2065, DOI 10.1016/j.jacc.2005.12.065
   Ginde S, 2012, CONGENIT HEART DIS, V7, P235, DOI 10.1111/j.1747-0803.2012.00632.x
   Goldberg DJ, 2011, CIRCULATION, V123, P1185, DOI 10.1161/CIRCULATIONAHA.110.981746
   Gressner OA, 2014, CLIN CHIM ACTA, V433, P111, DOI 10.1016/j.cca.2014.02.021
   Guha IN, 2013, INT J CARDIOL, V164, P77, DOI 10.1016/j.ijcard.2011.06.062
   Hayashi T, 2014, PEDIATR CARDIOL, V35, P608, DOI 10.1007/s00246-013-0827-9
   Hebert A, 2014, CIRCULATION, V130, P2021, DOI 10.1161/CIRCULATIONAHA.113.008441
   Hollander SA, 2013, J HEART LUNG TRANSPL, V32, P368, DOI 10.1016/j.healun.2012.11.023
   Hsu RB, 2008, EUR J CARDIO-THORAC, V34, P307, DOI 10.1016/j.ejcts.2008.05.003
   Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542
   Jayakumar KA, 2004, J AM COLL CARDIOL, V44, P2065, DOI 10.1016/j.jacc.2004.08.031
   Johnson JA, 2013, J THORAC CARDIOV SUR, V146, P140, DOI 10.1016/j.jtcvs.2012.09.005
   Kantor Paul F, 2010, Heart Fail Clin, V6, P497, DOI 10.1016/j.hfc.2010.06.002
   Kaulitz R, 1997, HEART, V78, P154
   Kaulitz R, 2014, HERZ, V39, P98, DOI 10.1007/s00059-013-3811-5
   Kendall TJ, 2008, J CLIN PATHOL, V61, P504, DOI 10.1136/jcp.2007.052365
   Kiesewetter CH, 2007, HEART, V93, P579, DOI 10.1136/hrt.2006.094516
   Krieger EV, 2013, INT J CARDIOL, V167, P1918, DOI 10.1016/j.ijcard.2012.05.002
   Kutty SS, 2014, HEPATOLOGY, V59, P251, DOI 10.1002/hep.26631
   Lebray P, 2008, HEPATOLOGY, V48, P2089, DOI 10.1002/hep.22594
   Marelli A, 2010, CAN J CARDIOL, V26, pE65
   Melero-Ferrer Josep Lluis, 2014, World J Pediatr Congenit Heart Surg, V5, P365, DOI 10.1177/2150135114530172
   Millonig G, 2010, J HEPATOL, V52, P206, DOI 10.1016/j.jhep.2009.11.018
   Mondesert B, 2013, CAN J CARDIOL, V29, P811, DOI 10.1016/j.cjca.2012.12.009
   Mori M, 2014, PEDIATR CARDIOL, V35, P569, DOI 10.1007/s00246-014-0881-y
   Narkewicz MR, 2003, J PEDIATR GASTR NUTR, V36, P352, DOI 10.1097/00005176-200303000-00009
   Naveau S, 2009, HEPATOLOGY, V49, P97, DOI 10.1002/hep.22576
   Neeff H, 2011, J GASTROINTEST SURG, V15, P1, DOI 10.1007/s11605-010-1366-9
   O'Leary JG, 2009, CLIN LIVER DIS, V13, P211, DOI 10.1016/j.cld.2009.02.002
   Odegard KC, 2009, J THORAC CARDIOV SUR, V137, P934, DOI 10.1016/j.jtcvs.2008.09.031
   Oka T, 2013, J THORAC CARDIOV SUR, V146, P153, DOI 10.1016/j.jtcvs.2012.09.021
   Poterucha JT, 2015, MAYO CLIN PROC, V90, P882, DOI 10.1016/j.mayocp.2015.04.020
   Pretre R, 2008, ANN THORAC SURG, V86, P1018, DOI 10.1016/j.athoracsur.2008.03.003
   Ratziu V, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-6
   Rossano JW, 2014, ANN THORAC SURG, V97, P1438, DOI 10.1016/j.athoracsur.2013.06.120
   Rychik J, 2012, PEDIATR CARDIOL, V33, P1001, DOI 10.1007/s00246-012-0315-7
   Samsky MD, 2013, J AM COLL CARDIOL, V61, P2397, DOI 10.1016/j.jacc.2013.03.042
   Sarvazyan A, 2011, CURR MED IMAGING REV, V7, P255
   Schwartz MC, 2012, J THORAC CARDIOV SUR, V143, P904, DOI 10.1016/j.jtcvs.2011.08.038
   Schwartz MC, 2013, PEDIATR CARDIOL, V34, P135, DOI 10.1007/s00246-012-0402-9
   Sebastiani G, 2007, WORLD J GASTROENTERO, V13, P525
   Serai SD, 2014, CONGENIT HEART DIS, V9, P7, DOI 10.1111/chd.12144
   Shah H, 2010, J CLIN GASTROENTEROL, V44, P428, DOI 10.1097/MCG.0b013e3181d476fc
   Simpson KE, 2014, J HEART LUNG TRANSPL, V33, P170, DOI 10.1016/j.healun.2013.10.033
   Sinha P, 2014, J THORAC CARDIOV SUR, V147, P1271, DOI 10.1016/j.jtcvs.2013.12.018
   Tsochatzis EA, 2014, LANCET, V383, P1749, DOI 10.1016/S0140-6736(14)60121-5
   Tweddell JS, 2009, ANN THORAC SURG, V88, P1291, DOI 10.1016/j.athoracsur.2009.05.076
   van Nienwenhuizen RC, 1999, HEART, V82, P40
   Venkatesh SK, 2014, MAGN RESON IMAGING C, V22, P433, DOI 10.1016/j.mric.2014.05.001
   Wallihan DB, 2014, J MAGN RESON IMAGING, V40, P1328, DOI 10.1002/jmri.24496
   Wallihan DB, 2013, J MAGN RESON IMAGING, V40, P1328
   Wu FM, 2011, CONGENIT HEART DIS, V6, P190, DOI 10.1111/j.1747-0803.2011.00504.x
   Wu FM, 2015, J HEART LUNG TRANSPL, V34, P883, DOI 10.1016/j.healun.2015.01.993
   Wu FM, 2014, CONGENIT HEART DIS, V9, P438, DOI 10.1111/chd.12159
   Yoo BW, 2014, J THORAC CARDIOV SUR, V148, P1498, DOI 10.1016/j.jtcvs.2014.04.010
NR 79
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JAN
PY 2016
VL 35
IS 1
BP 26
EP 33
DI 10.1016/j.healun.2015.10.015
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA DD7OI
UT WOS:000370113600003
PM 26586487
ER

PT J
AU Dreyzin, A
   Lunz, J
   Venkat, V
   Martin, L
   Bond, GJ
   Soltys, KA
   Sindhi, R
   Mazariegos, GV
AF Dreyzin, Alexandra
   Lunz, John
   Venkat, Veena
   Martin, Lillian
   Bond, Geoffrey J.
   Soltys, Kyle A.
   Sindhi, Rakesh
   Mazariegos, George V.
TI Long-term outcomes and predictors in pediatric liver retransplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; retransplantation; long-term outcomes;
   graft survival
ID LEUKOCYTE ANTIGEN ANTIBODIES; SINGLE-CENTER EXPERIENCE; GRAFT FIBROSIS;
   TRANSPLANTATION; CHILDREN; REJECTION; SURVIVAL
AB Historically, 9-29% of pediatric liver transplant recipients have required retransplantation. Although outcomes have improved over the last decade, currently published patient and graft survival remain lower after retransplant than after primary transplant. Data from liver retransplantation recipients at our institution between 1991 and 2013 were retrospectively reviewed. Kaplan-Meier estimates were used to depict patient and graft survival. Predictors of survival were analyzed using a series of Cox proportional hazards models. Predictors were analyzed separately for patients who had "early" (<= 30 days after primary transplant) and "late" retransplants. Eighty-four patients underwent retransplant at a median time of 241 days. Sixty percent had late retransplants. At one, five, and 10 yr, actuarial patient and graft survival were 73%/71%, 66%/63%, and 58%/53%, respectively. Since 2002, patient and graft survival improved to 86%/86% at one yr and 93%/87% at five yr. While operative complications were a common cause of death after earlier retransplants, since 2002, infection has been the only cause of death. Significant morbidities at five-yr follow-up include renal dysfunction (15%), diabetes (13%), hypertension (26%), chronic rejection (7%), and PTLD (2%). Current survival after pediatric liver retransplantation has improved significantly, but long-term immunosuppressant morbidity remains an opportunity for improvement.
C1 [Dreyzin, Alexandra] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Lunz, John] Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Dept Pathol, Pittsburgh, PA USA.
   [Venkat, Veena] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Div Pediat Gastroenterol, Pittsburgh, PA USA.
   [Martin, Lillian; Bond, Geoffrey J.; Soltys, Kyle A.; Sindhi, Rakesh; Mazariegos, George V.] Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Hillman Ctr Pediat Transplantat,Childrens Hosp Pi, Pittsburgh, PA USA.
RP Mazariegos, GV (reprint author), Hillman Ctr Pediat Transplantat, 4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM george.mazariegos@chp.edu
FU National Institutes of Health through University of Pittsburgh Clinical
   and Translational Science Institute [UL1-TR-000005]; Clinical Scientist
   Training Program at University of Pittsburgh School of Medicine
FX We would like to thank our Research and Clinical Coordinators,
   especially Stacey Gibson, MSN, RN, and Amanda Brown, MS. The project
   described was supported by the National Institutes of Health through
   grant number UL1-TR-000005 through the University of Pittsburgh Clinical
   and Translational Science Institute and the Clinical Scientist Training
   Program at the University of Pittsburgh School of Medicine.
CR Bellido CB, 2012, TRANSPL P, V44, P1526, DOI 10.1016/j.transproceed.2012.05.010
   Bourdeaux C, 2009, TRANSPL INT, V22, P416, DOI 10.1111/j.1432-2277.2008.00807.x
   Davis A, 2009, LIVER TRANSPLANT, V15, P199, DOI 10.1002/lt.21664
   Ekong ED, 2008, LIVER TRANSPLANT, V14, P1582
   Goh A, 2010, LIVER TRANSPLANT, V16, P308, DOI 10.1002/lt.21981
   Heffron TG, 2010, PEDIATR TRANSPLANT, V14, P417, DOI 10.1111/j.1399-3046.2010.01304.x
   Lao OB, 2010, PEDIATR TRANSPLANT, V14, P1019, DOI 10.1111/j.1399-3046.2010.01400.x
   Marti J, 2008, SURGERY, V144, P762, DOI 10.1016/j.surg.2008.06.029
   Miyagawa-Hayashino A, 2012, LIVER TRANSPLANT, V18, P1333, DOI 10.1002/lt.23534
   Ng V, 2008, AM J TRANSPLANT, V8, P386, DOI 10.1111/j.1600-6143.2007.02056.x
   Ng VL, 2012, J PEDIATR-US, V160, P820, DOI 10.1016/j.jpeds.2011.10.038
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Sindhi R, 2011, CURR OPIN ORGAN TRAN, V16, P515, DOI 10.1097/MOT.0b013e32834a94e3
   Taner T, 2014, LIVER TRANSPLANT, V20, P514, DOI 10.1002/lt.23826
   Zeevi A, 2010, LIVER TRANSPLANT, V16, P259, DOI 10.1002/lt.22025
NR 16
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2015
VL 19
IS 8
BP 866
EP 874
DI 10.1111/petr.12588
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DA3BT
UT WOS:000367671600014
PM 26362966
ER

PT J
AU Wan, P
   Li, QG
   Zhang, JJ
   Shen, CH
   Luo, Y
   Chen, QM
   Chen, XS
   Zhang, M
   Han, LZ
   Xia, Q
AF Wan, Ping
   Li, Qigen
   Zhang, Jianjun
   Shen, Conghuan
   Luo, Yi
   Chen, Qimin
   Chen, Xiaosong
   Zhang, Ming
   Han, Longzhi
   Xia, Qiang
TI Influence of graft size matching on outcomes of infantile living donor
   liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE graft-to-recipient weight ratio; liver transplantation; living donor;
   pediatric
ID LATERAL SEGMENT GRAFTS; SINGLE-CENTER EXPERIENCE; ABDOMINAL-WALL
   CLOSURE; WEIGHT
AB We aimed to assess the impact of size mismatching between grafts and recipients on outcomes of infants or small children after LDLT. Between October 2006 and December 2014, 129 LDLT recipients weighing no more than 8 kg were retrospectively analyzed. The entire cohort was categorized into three groups by GRWR: GRWR < 3.0% (group A, n = 38), 3.0%<= GRWR<4.0% (group B, n = 61), and GRWR >= 4.0% (group C, n = 30). Baseline characteristics were similar among groups A, B, and C. Compared with groups A and B, post-transplant alanine aminotransferase and aspartate aminotransferase within seven days were significantly higher in group C; however, differences between total bilirubin and albumin after transplantation were not prominent. Moreover, incidences of surgical complications, perioperative deaths, infections, and acute rejections were all comparable among the three groups. Five-yr patient survival rates for groups A, B, and C were 89.5%, 88.9%, and 81.6%, respectively (p = 0.872), and the graft survival rates were 89.5%, 86.6%, and 81.6%, respectively (p = 0.846). In conclusion, GRWR between 1.9% and 5.8% would not cause noticeable adverse events for infantile LDLT recipients = 8 kg. However, there is still a role for considering reduction in the graft mass as an applicable strategy in selected cases.
C1 [Wan, Ping; Li, Qigen; Zhang, Jianjun; Shen, Conghuan; Luo, Yi; Chen, Xiaosong; Zhang, Ming; Han, Longzhi; Xia, Qiang] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Liver Surg, Shanghai 200127, Peoples R China.
   [Chen, Qimin] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Pediat Surg, Shanghai 200127, Peoples R China.
RP Xia, Q (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Liver Surg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.
EM xiaqiang@medmail.com.cn
FU Key Joint Research Program of Shanghai Health Bureau [2013ZYJB0001];
   subtopic of Scientific and Technological Innovation and Action Project
   of Shanghai Science and Technology Commission [15411950401]
FX The study was supported by the Key Joint Research Program of Shanghai
   Health Bureau (2013ZYJB0001) and a subtopic of Scientific and
   Technological Innovation and Action Project of Shanghai Science and
   Technology Commission (15411950401).
CR BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Maestro OC, 2014, PEDIATR TRANSPLANT, V18, P594, DOI 10.1111/petr.12319
   Chen PX, 2014, WORLD J GASTROENTERO, V20, P282, DOI 10.3748/wjg.v20.i1.282
   Dahm F, 2005, AM J TRANSPLANT, V5, P2605, DOI 10.1111/j.1600-6143.2005.01081.x
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   Fukazawa K, 2011, J HEPATO-BIL-PAN SCI, V18, P216, DOI 10.1007/s00534-010-0334-9
   Fukazawa K, 2013, TRANSPL INT, V26, P724, DOI 10.1111/tri.12111
   Gondolesi GE, 2014, PEDIATR TRANSPLANT, V18, P554, DOI 10.1111/petr.12317
   Hill MJ, 2009, LIVER TRANSPLANT, V15, P1056, DOI 10.1002/lt.21846
   Kanazawa H, 2013, TRANSPLANTATION, V95, P750, DOI 10.1097/TP.0b013e31827a93b4
   Kasahara M, 2013, LIVER TRANSPLANT, V19, P226, DOI 10.1002/lt.23572
   Kasahara M, 2014, EXP CLIN TRANSPLANT, V12, P1, DOI 10.6002/ect.25Liver.L5
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Levesque E, 2013, CLIN TRANSPLANT, V27, P239, DOI 10.1111/ctr.12059
   Lim WX, 2014, TRANSPL P, V46, P767, DOI 10.1016/j.transproceed.2013.10.048
   Mizuta K, 2010, AM J TRANSPLANT, V10, P2547, DOI 10.1111/j.1600-6143.2010.03274.x
   Sakamoto S, 2014, SURGERY, V156, P1232, DOI 10.1016/j.surg.2014.05.003
   Schulze M, 2011, TRANSPL INT, V24, P797, DOI 10.1111/j.1432-2277.2011.01277.x
   Shehata MR, 2012, AM J TRANSPLANT, V12, P3406, DOI 10.1111/j.1600-6143.2012.04268.x
   Sugawara Y, 2001, J AM COLL SURGEONS, V192, P510, DOI 10.1016/S1072-7515(01)00800-6
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5
   Xi ZF, 2013, J DIGEST DIS, V14, P439, DOI 10.1111/1751-2980.12066
   XU HS, 1994, ANN SURG, V219, P46, DOI 10.1097/00000658-199401000-00008
   Xue F, 2014, PEDIATR TRANSPLANT, V18, P166, DOI 10.1111/petr.12216
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2015
VL 19
IS 8
BP 880
EP 887
DI 10.1111/petr.12592
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DA3BT
UT WOS:000367671600016
PM 26395863
ER

PT J
AU Kulkarni, S
   Perez, C
   Pichardo, C
   Castillo, L
   Gagnon, M
   Beck-Sague, C
   Gereige, R
   Hernandez, E
AF Kulkarni, Sakil
   Perez, Carla
   Pichardo, Caren
   Castillo, Lina
   Gagnon, Michael
   Beck-Sague, Consuelo
   Gereige, Rani
   Hernandez, Erick
TI Use of Pediatric Health Information System database to study the trends
   in the incidence, management, etiology, and outcomes due to pediatric
   acute liver failure in the United States from 2008 to 2013
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE acute liver failure; trends; acetaminophen; liver transplant; Pediatric
   Health Information System; hepatic encephalopathy
ID INTRAVENOUS N-ACETYLCYSTEINE; CHILDREN; TRANSPLANTATION; INFANTS; COHORT
AB Data were collected of children admitted with ALF to 16 US pediatric liver transplant centers from 2008 to 2013 using the PHIS for a retrospective analysis of PALF trends. Patient data linked to the principal diagnosis code for acute necrosis of the liver (570.00) were analyzed for the following: demographics, regional differences, changes over time, pharmaceutical trends, procedural trends, associated diagnoses, and patient outcomes. In 52.5% of 583 patients who met the selection criteria for PALF, the etiology remained undetermined. Acetaminophen toxicity (18.7%) was the most common identifiable etiology, and hepatic encephalopathy (38.6%) was the most common complication. Mortality was lower than previously reported; 95.4% survived and 73.2% survived without a liver transplant. Acute respiratory failure (OR = 3.4, p = 0.035), acute kidney injury (OR = 3.6, p = 0.003), and cerebral edema (OR = 3.6, p = 0.02) were independently associated with increased risk of mortality. The use of N-acetylcysteine in non-acetaminophen-related ALF, the use of intracranial pressure monitoring, and the proportion of sepsis decreased significantly during the study period. The PHIS database can be a useful tool to study the future trends of PALF patients.
C1 [Kulkarni, Sakil; Perez, Carla; Pichardo, Caren; Castillo, Lina; Gereige, Rani] Miami Childrens Hosp, Dept Med Educ, Miami, FL USA.
   [Gagnon, Michael] Miami Childrens Hosp, Dept Qual & Safety, Miami, FL USA.
   [Beck-Sague, Consuelo] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Miami, FL 33199 USA.
   [Hernandez, Erick] Miami Childrens Hosp, Dept Pediat Gastroenterol, Miami, FL USA.
RP Kulkarni, S (reprint author), 5544 Poinciana Blvd, St Louis, MO 63123 USA.
EM kulkarni_s@kids.wustl.edu
CR Akhavan A, 2014, ADV UROL, V2014
   Alemayehu H, 2014, PEDIATR SURG INT, V30, P649, DOI 10.1007/s00383-014-3513-y
   Bui Christine L, 2014, Curr Drug Saf, V9, P23
   Deans KJ, 2014, J PEDIATR SURG, V49, P207, DOI 10.1016/j.jpedsurg.2013.09.058
   Deans KJ, 2014, J PEDIATR SURG, V49, P212
   Desai AV, 2014, PEDIATR BLOOD CANCER, V61, P1129, DOI 10.1002/pbc.24930
   Devictor D, 2011, EXPERT REV GASTROENT, V5, P717, DOI [10.1586/egh.11.57, 10.1586/EGH.11.57]
   Dhawan A, 2005, EARLY HUM DEV, V81, P1005, DOI 10.1016/j.earlhumdev.2005.10.003
   DiPaola F, 2014, J PEDIATR-US, V164, P407, DOI 10.1016/j.jpeds.2013.10.044
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Fletcher Donna M, 2004, J AHIMA, V75, P22
   Godbole G, 2011, J PEDIATR GASTR NUTR, V53, P320, DOI 10.1097/MPG.0b013e318222b0cd
   Kortsalioudaki C, 2008, LIVER TRANSPLANT, V14, P25, DOI 10.1002/lt.21246
   Lee WM, 2008, HEPATOLOGY, V47, P1401, DOI 10.1002/hep.22177
   Lee WM, 2009, GASTROENTEROLOGY, V137, P856, DOI 10.1053/j.gastro.2009.06.006
   Leonis MA, 2013, PEDIATRICS, V131, pE740, DOI 10.1542/peds.2011-3035
   Miraglia R, 2006, CARDIOVASC INTER RAD, V29, P1008, DOI 10.1007/s00270-006-0052-5
   Narkewicz MR, 2009, J PEDIATR-US, V155, P801, DOI 10.1016/j.jpeds.2009.06.005
   Oh SH, 2014, J PEDIATR GASTR NUTR, V58, P68, DOI 10.1097/MPG.0b013e3182a80362
   Ostapowicz G, 2002, ANN INTERN MED, V137, P947
   Ozturk Y, 2010, TURK J GASTROENTEROL, V21, P270, DOI 10.4318/tjg.2010.0099
   Ryu JM, 2013, PEDIATR INT, V55, P748, DOI 10.1111/ped.12181
   Schwarz KB, 2014, J PEDIATR GASTR NUTR, V59, P616, DOI 10.1097/MPG.0000000000000512
   Squires RH, 2008, SEMIN LIVER DIS, V28, P153, DOI 10.1055/s-2008-1073115
   Squires RH, 2014, J PEDIATR GASTR NUTR, V58, P1, DOI 10.1097/MPG.0b013e3182a81085
   Squires RH, 2013, HEPATOLOGY, V57, P1542, DOI 10.1002/hep.26001
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Sulkowski JP, 2013, J PEDIATR SURG, V48, P1850, DOI 10.1016/j.jpedsurg.2013.02.062
   Sundaram SS, 2011, J PEDIATR-US, V159, P813, DOI 10.1016/j.jpeds.2011.04.016
   Uribe M, 2008, TRANSPL P, V40, P3253, DOI 10.1016/j.transproceed.2008.03.128
NR 30
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2015
VL 19
IS 8
BP 888
EP 895
DI 10.1111/petr.12596
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DA3BT
UT WOS:000367671600017
PM 26388211
ER

PT J
AU Vali, R
   Punnett, A
   Bajno, L
   Moineddin, R
   Shammas, A
AF Vali, R.
   Punnett, A.
   Bajno, L.
   Moineddin, R.
   Shammas, A.
TI The value of F-18-FDG PET in pediatric patients with post-transplant
   lymphoproliferative disorder at initial diagnosis
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; post-transplant lymphoproliferative disorder; Epstein-Barr
   virus; 2-deoxy-2-[fluorine-18]fluoro-D-glucose positron emission
   tomography; positron emission tomography/computerized tomography;
   transplant; pediatric transplant
ID POSITRON-EMISSION-TOMOGRAPHY; SOLID-ORGAN TRANSPLANTATION;
   NON-HODGKINS-LYMPHOMA; FDG-PET; RENAL-TRANSPLANTATION;
   MALIGNANT-LYMPHOMA; MANAGEMENT; DISEASE; RECIPIENTS; RITUXIMAB
AB PTLD is a serious complication of both solid organ and BMT. This study assessed whether F-18-FDG PET, when added to CT scan, had additional value in the initial evaluation of PTLD in pediatric patients and whether PET/CT at baseline can reliably guide biopsy. This retrospective study evaluated 34 consecutive pediatric patients (14 female), aged 3.5-17.0 yr (mean age: 9.9 yr, s.d.: 4.9 yr), who had undergone F-18-FDG PET/CT from May 2007 to December 2014 at initial diagnosis of PTLD following heart (n = 13), lung (n = 8), kidney (n = 4), liver (n = 3), liver and bowel (n = 3), and bone marrow (n = 3) transplantation. PTLD was diagnosed histopathologically in 33 patients and was based on clinical findings, elevated EBV, and imaging and follow-up results in one patient. On lesion-based analysis, F-18-FDG PET showed more lesions than conventional CT scan (168 vs. 134), but CT revealed 22 lesions negative on PET. On per patient analysis, PET detected more lesions in 13 patients, CT identified more abnormalities in seven, and both showed the same number of lesions in 14. Adding F-18-FDG PET to CT scans upstaged the disease in seven patients (20.5%). A combination of F-18-FDG PET and CT was also useful in guiding biopsy, being positive in 36 of 39 samples (92.3%). These findings indicated that F-18-FDG PET and CT are complementary at initial staging of pediatric PTLD and that F-18-FDG PET/CT scanning can guide biopsies.
C1 [Vali, R.; Bajno, L.; Shammas, A.] Univ Toronto, Hosp Sick Children, Diagnost Imaging Dept, Toronto, ON M5G 1X8, Canada.
   [Punnett, A.] Univ Toronto, Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada.
   [Moineddin, R.] Univ Toronto, Dept Family & Community Med, Toronto, ON M5G 1X8, Canada.
RP Vali, R (reprint author), Univ Toronto, Hosp Sick Children, Diagnost Imaging Dept, Nucl Med, Toronto, ON M5G 1X8, Canada.
EM reza.vali@sickkids.ca
CR Bakker NA, 2006, AM J TRANSPLANT, V6, P1984, DOI 10.1111/j.1600-6143.2006.01459.x
   Bianchi E, 2008, TRANSPLANTATION, V85, P707, DOI 10.1097/TP.0b013e3181661676
   Blaes AH, 2010, EXPERT REV HEMATOL, V3, P35, DOI [10.1586/ehm.09.76, 10.1586/EHM.09.76]
   Burns DM, 2004, BLOOD REV, V18, P193, DOI 10.1016/j.bire.2003.12.002
   Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050
   Choquet S, 2006, BLOOD, V107, P3053, DOI 10.1182/blood-2005-01-0377
   Christensen JA, 2006, AM J ROENTGENOL, V187, P1361, DOI 10.2214/AJR.05.1166
   Dharnidharka VR, 2002, AM J TRANSPLANT, V2, P993, DOI 10.1034/j.1600-6143.2002.21019.x
   Dierickx D, 2013, HAEMATOLOGICA, V98, P771, DOI 10.3324/haematol.2012.074500
   Feng S, 2003, AM J TRANSPLANT, V3, P1481, DOI 10.1046/j.1600-6143.2003.00245.x
   Gallego S, 2010, PEDIATR TRANSPLANT, V14, P61, DOI 10.1111/j.1399-3046.2009.01181.x
   Hicks RJ, 2005, SEMIN NUCL MED, V35, P165, DOI 10.1053/j.semnuclmed.2005.02.003
   Hourigan MJ, 2008, BRIT J HAEMATOL, V141, P904, DOI 10.1111/j.1365-2141.2008.07149.x
   Jagadeesh D, 2012, CURR TREAT OPTION ON, V13, P122, DOI 10.1007/s11864-011-0177-x
   Jerusalem G, 2001, ANN ONCOL, V12, P825, DOI 10.1023/A:1011169332265
   Juweid ME, 2007, J CLIN ONCOL, V25, P571, DOI 10.1200/JCO.2006.08.2305
   Juweid ME, 2006, HEMATOLOGY AM SOC HE, V259-265, P510
   Landgren O, 2009, BLOOD, V113, P4992, DOI 10.1182/blood-2008-09-178046
   LAPELA M, 1995, BLOOD, V86, P3522
   LEBLOND V, 1995, J CLIN ONCOL, V13, P961
   Leblond V, 2001, J CLIN ONCOL, V19, P772
   Marom EM, 2004, J THORAC IMAG, V19, P74, DOI 10.1097/00005382-200404000-00002
   Naumann R, 2004, BRIT J CANCER, V90, P620, DOI 10.1038/sj.bjc.6601561
   Noraini AR, 2009, SINGAP MED J, V50, P1189
   O'Conner AR, 2005, NUCL MED COMMUN, V26, P1107, DOI 10.1097/00006231-200512000-00010
   OKADA J, 1991, J NUCL MED, V32, P686
   Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x
   Panagiotidis E, 2014, LEUKEMIA LYMPHOMA, V55, P515, DOI 10.3109/10428194.2013.813501
   Parker A, 2010, BRIT J HAEMATOL, V149, P693, DOI 10.1111/j.1365-2141.2010.08160.x
   Rakheja R, 2012, AM J ROENTGENOL, V198, P1409, DOI 10.2214/AJR.11.7560
   RODRIGUEZ M, 1995, J NUCL MED, V36, P1790
   Saif Muhammad Wasif, 2010, Yale Journal of Biology and Medicine, V83, P53
   Samuel AM, 2010, INDIAN J CANCER, V47, P360, DOI 10.4103/0019-509X.73551
   Sathiakumar C, 2010, AUSTRALAS PHYS ENG S, V33, P199, DOI 10.1007/s13246-010-0016-6
   Schoder H, 2001, J NUCL MED, V42, P1139
   Schoder H, 2005, J CLIN ONCOL, V23, P4643, DOI 10.1200/JCO.2005.12.072
   Shapiro R, 1999, TRANSPLANTATION, V68, P1851, DOI 10.1097/00007890-199912270-00006
   Takehana CS, 2014, NUCL MED COMMUN, V35, P276, DOI 10.1097/MNM.0000000000000050
   Tanner J E, 2001, Transpl Infect Dis, V3, P60, DOI 10.1034/j.1399-3062.2001.003002060.x
   Taylor AL, 2005, CRIT REV ONCOL HEMAT, V56, P155, DOI 10.1016/j.critrevonc.2005.03.015
   Visioni A, 2011, SURG CLIN N AM, V91, P249, DOI 10.1016/j.suc.2010.10.012
   von Falck C, 2007, EUR J RADIOL, V63, P427, DOI 10.1016/j.ejrad.2007.01.007
NR 42
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2015
VL 19
IS 8
BP 932
EP 939
DI 10.1111/petr.12611
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA DA3BT
UT WOS:000367671600023
PM 26515450
ER

PT J
AU Kim, EY
   Yoon, YC
AF Kim, E. Y.
   Yoon, Y. C.
TI Performing a Right Hemihepatectomy Sequentially After Deceased Donor
   Liver Transplantation-The Solution for a Large-for-size Graft: A Case
   Report
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID LIVING-DONOR; INFANTS; MONOSEGMENTS
AB Background. Large-for-size (LFS) is a serious problem that can develop during liver transplantation (LT) and is related to morbidities such as insufficient blood supply causing graft dysfunction or impractical closure of the abdominal wall leading to graft compression. LFS is usually discussed in pediatric LT and is often managed by reducing the size of the graft before implantation. In contrast, only a few cases about managing unexpected LFS during adult LT have been reported, and no case after the vascular anastomosis has been completed has been reported.
   Case Report. A 36-year-old, 43-kg woman underwent an emergency LT using a deceased donor, although the estimated graft/recipient weight ratio was 3.98%. After completing the vascular anastomosis, a severe hepatic venous outflow obstruction from the graft developed due to compression of the inferior vena cava from the hypertrophied right posterior lobe of the graft. We performed a right hemihepatectomy sequentially after LT, and hepatic blood flow recovered sufficiently based on a Doppler sonogram. The postoperative clinical course was uneventful without vascular or ductal complications, and the primary abdominal wall closure was successfully achieved without wound complications.
   Conclusions. Performing a right hemihepatectomy sequentially after completing the vascular anastomosis during LT could be a very simple and effective solution for unexpected LFS during LT.
C1 [Kim, E. Y.] Catholic Univ, Seoul St Marys Hosp, HBP Surg, Seoul, South Korea.
   [Yoon, Y. C.] Catholic Univ Korea, Incheon St Marys Hosp, HBP Surg, Inchon 6658, South Korea.
RP Yoon, YC (reprint author), Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Surg, Inchon 6658, South Korea.
EM k07yyc@catholic.ac.kr
CR Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   de Santibanes E, 2000, LIVER TRANSPLANT, V6, P108, DOI 10.1002/lt.500060104
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kasahara M, 2003, J PEDIATR SURG, V38, P1108, DOI 10.1016/S0022-3468(03)00206-9
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Mentha G, 1996, TRANSPLANTATION, V62, P1176, DOI 10.1097/00007890-199610270-00026
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Oikawa K, 1998, TRANSPLANT P, V30, P3209, DOI 10.1016/S0041-1345(98)00998-1
   Sakamoto S, 2014, SURGERY, V156, P1232, DOI 10.1016/j.surg.2014.05.003
   Schulze M, 2011, TRANSPL INT, V24, P797, DOI 10.1111/j.1432-2277.2011.01277.x
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2015
VL 47
IS 10
BP 3023
EP 3026
DI 10.1016/j.transproceed.2015.10.030
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA CZ9KM
UT WOS:000367416500042
PM 26707332
ER

PT J
AU Goldschmidt, ML
   Kocoshis, SA
   Tiao, GM
   Alonso, MH
   Nathan, JD
AF Goldschmidt, Monique L.
   Kocoshis, Samuel A.
   Tiao, Gregory M.
   Alonso, Maria H.
   Nathan, Jaimie D.
TI Limited surgical resection for graft salvage following recovery from
   complicated exfoliative rejection in pediatric intestinal recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric transplantation; liver; intestine transplant; allograft;
   complications; graft rejection
ID TRANSPLANTATION; INFECTIONS
AB Complications of ER contribute significantly to morbidity and mortality following intestinal transplantation. The surgical management of three pediatric patients who experienced complications of late ER after composite LSB transplantation is described, highlighting the potential for allograft salvage after limited surgical resection. A retrospective case series was compiled. Data collected included time to ER from transplant, medical management of ER, complications, and surgical management of ER complications. All patients had undergone composite LSB transplantation between one and two yr of age. Time to ER after transplantation was 9.5-26.5months. ER complications included ileal allograft stricture, intramural hematoma with perforation of jejunal allograft, and massive GI hemorrhage secondary to focal ulceration and pseudopolyp formation. With evidence of mucosal regeneration, all three patients underwent limited segmental allograft resection. Two patients continue to maintain satisfactory allograft function 39-44months following operation. The third patient retained adequate allograft function until he developed PTLD, subsequently dying from disseminated Adenovirus infection 51months after resection. Severe disruption of intestinal allograft integrity in ER can lend itself to medically refractory complications. Prompt recognition and surgical correction of complications can play a crucial role in allograft salvage and patient survival after ER.
C1 [Goldschmidt, Monique L.; Kocoshis, Samuel A.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA.
   [Tiao, Gregory M.; Alonso, Maria H.; Nathan, Jaimie D.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Gen & Thorac Surg, Cincinnati, OH 45229 USA.
   [Tiao, Gregory M.; Alonso, Maria H.; Nathan, Jaimie D.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.
RP Goldschmidt, ML (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM monique.goldschmidt@cchmc.org
CR Abu-Elmagd KM, 2009, ANN SURG, V250, P567, DOI 10.1097/SLA.0b013e3181b67725
   Cainelli F, 2002, LANCET INFECT DIS, V2, P539, DOI 10.1016/S1473-3099(02)00370-5
   Couzi L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00003
   Fishbein TM, 2009, NEW ENGL J MED, V361, P998, DOI 10.1056/NEJMra0804605
   Garg M, 2011, J GASTROEN HEPATOL, V26, P1221, DOI 10.1111/j.1440-1746.2011.06783.x
   Hoffman JA, 2009, CURR OPIN ORGAN TRAN, V14, P625, DOI 10.1097/MOT.0b013e3283324e1b
   Iinuma Y, 2013, J PEDIATR SURG, V48, P1123, DOI 10.1016/j.jpedsurg.2013.03.067
   Ishii T, 2003, PEDIATR TRANSPLANT, V7, P185, DOI 10.1034/j.1399-3046.2003.00063.x
   Kato T, 2004, PEDIATR TRANSPLANT, V8, P426, DOI 10.1111/j.1399-3046.2004.00097.x
   Ramos E, 2007, PEDIATR TRANSPLANT, V11, P937, DOI 10.1111/j.1399-3046.2007.00798.x
   Ruiz P, 2004, TRANSPLANT P, V36, P335, DOI 10.1016/j.transproceed.2004.01.079
   Stern M, 2014, TRANSPLANTATION, V98, P1013, DOI 10.1097/TP.0000000000000160
   Yandza T, 2010, TRANSPL P, V42, P100, DOI 10.1016/j.transproceed.2009.12.023
NR 13
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2015
VL 19
IS 7
BP E170
EP E176
DI 10.1111/petr.12563
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CT1SC
UT WOS:000362580100003
PM 26230722
ER

PT J
AU Nure, E
   Lirosi, MC
   Frongillo, F
   Bianco, G
   Silvestrini, N
   Fiorillo, C
   Sganga, G
   Agnes, S
AF Nure, E.
   Lirosi, M. C.
   Frongillo, F.
   Bianco, G.
   Silvestrini, N.
   Fiorillo, C.
   Sganga, G.
   Agnes, S.
TI Overextended Criteria Donors: Experience of an Italian Transplantation
   Center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 38th National Congress of the Italian-Transplantation-Society
CY SEP 24-26, 2014
CL Siena, ITALY
SP Italian Transplantat Soc
ID SINGLE-CENTER EXPERIENCE; EARLY ALLOGRAFT DYSFUNCTION; LIVER-DISEASE
   SCORE; EXTENDED CRITERIA; MARGINAL DONORS; RISK-FACTORS;
   ORGAN-TRANSPLANTATION; GRAFTS; RECIPIENTS; QUALITY
AB The increasing gap between the number of patients who could benefit from liver transplantation and the number of available donors has fueled efforts to maximize the donor pool using marginal grafts that usually were discarded for transplantation. This study included data of all patients who received decreased donor liver grafts between January 2004 and January 2013 (n = 218) with the use of a prospectively collected database. Patients with acute liver failure, retransplantation, pediatric transplantation, and split liver transplantation were excluded. Donors were classified as standard donor (SD), extended criteria donor (ECD), and overextended criteria donor (OECD). The primary endpoints of the study were early allograft primary dysfunction (PDF), primary nonfunction (PNF), and patient survival (PS), whereas incidence of major postoperative complications was the secondary endpoint. In our series we demonstrated that OECD have similar outcome in terms of survival and incidence of complication after liver transplantation as ideal grafts.
C1 [Nure, E.; Lirosi, M. C.; Frongillo, F.; Bianco, G.; Silvestrini, N.; Fiorillo, C.; Sganga, G.; Agnes, S.] Univ Cattolica Sacro Cuore, Dept Surg, Transplantat Serv, Policlin A Gemelli, I-00168 Rome, Italy.
RP Lirosi, MC (reprint author), Policlin A Gemelli, Dept Surg, Transplantat Serv, Largo A Gemelli 8, I-00168 Rome, Italy.
EM mcarmenlirosi@yahoo.it
CR Abecassis M, 2012, AM J TRANSPLANT, V12, P2608, DOI 10.1111/j.1600-6143.2012.04245.x
   ADAM R, 1993, TRANSPLANT P, V25, P1556
   ALEXANDER JW, 1991, TRANSPLANTATION, V51, P135, DOI 10.1097/00007890-199101000-00021
   Attia M, 2008, TRANSPL INT, V21, P713, DOI 10.1111/j.1432-2277.2008.00696.x
   Avolio AW, 2011, AM J TRANSPLANT, V11, P2724, DOI 10.1111/j.1600-6143.2011.03732.x
   Avolio AW, 2006, TRANSPLANT P, V38, P1059, DOI 10.1016/j.transproceed.2006.03.008
   Barshes NR, 2007, AM J TRANSPLANT, V7, P1265, DOI 10.1111/j.1600-6143.2007.01758.x
   Briceno J, 2002, TRANSPLANTATION, V74, P522, DOI 10.1097/01.TP.0000026307.14572.8D
   Briceno J, 1997, TRANSPLANT P, V29, P477, DOI 10.1016/S0041-1345(96)00213-8
   Busuttil RW, 2003, LIVER TRANSPLANT, V9, P651, DOI 10.1053/jlts.2003.50105
   Deschenes M, 1998, TRANSPLANTATION, V66, P302, DOI 10.1097/00007890-199808150-00005
   Gastaca M, 2009, TRANSPL P, V41, P975, DOI 10.1016/j.transproceed.2009.02.016
   Godara Rajesh, 2014, Indian J Gastroenterol, V33, P136, DOI 10.1007/s12664-013-0379-1
   Goldaracena N, 2012, TRANSPL P, V44, P2219, DOI 10.1016/j.transproceed.2012.07.113
   Grande L, 1998, Clin Transpl, P297
   Gruttadauria S, 2008, LIVER TRANSPLANT, V14, P220, DOI 10.1002/lt.21359
   Jimenez-Romero C, 2014, WORLD J GASTROENTERO, V20, P10691, DOI 10.3748/wjg.v20.i31.10691
   Kwon CHD, 2006, TRANSPLANT P, V38, P2106, DOI 10.1016/j.transproceed.2006.07.018
   Lopez-Navidad A, 2003, CLIN TRANSPLANT, V17, P308, DOI 10.1034/j.1399-0012.2003.00119.x
   Maluf DG, 2006, TRANSPLANTATION, V82, P1653, DOI 10.1097/01.tp.0000250571.41361.21
   McCormack L, 2007, ANN SURG, V246, P940, DOI 10.1097/SLA.0b013e31815c2a3f
   McCormack L, 2010, HPB, V12, P523, DOI 10.1111/j.1477-2574.2010.00193.x
   Merion RM, 2006, J HEPATOL, V45, P484, DOI 10.1016/j.jhep.2006.07.016
   Mittler J, 2008, TRANSPLANTATION, V86, P895, DOI 10.1097/TP.0b013e318186ad7a
   Olthoff KM, 2010, LIVER TRANSPLANT, V16, P943, DOI 10.1002/lt.22091
   Pokorny H, 2005, CLIN TRANSPLANT, V19, P532, DOI 10.1111/j.1399-0012.2005.00384.x
   Rauchfuss F, 2010, TRANSPL P, V42, P175, DOI 10.1016/j.transproceed.2009.11.020
   Reddy Mettu Srinivas, 2013, World J Hepatol, V5, P603, DOI 10.4254/wjh.v5.i11.603
   Renz JF, 2005, ANN SURG, V242, P556, DOI 10.1097/01.sla.0000183973.49899.b1
   Schemmer P, 2007, TRANSPL P, V39, P529, DOI 10.1016/j.transproceed.2006.12.002
   STRASBERG SM, 1994, HEPATOLOGY, V20, P829, DOI 10.1002/hep.1840200410
   Tector AJ, 2006, ANN SURG, V244, P439, DOI 10.1097/01.sla.0000234896.18207.fa
   Tekin K, 2004, TRANSPLANTATION, V77, P411, DOI 10.1097/01.TP.0000110318.70879.20
   Vitale A, 2007, TRANSPL P, V39, P1907, DOI 10.1016/j.transproceed.2007.05.032
   YERSIZ H, 1995, TRANSPLANTATION, V60, P790, DOI 10.1097/00007890-199510270-00005
NR 35
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD SEP
PY 2015
VL 47
IS 7
BP 2102
EP 2105
DI 10.1016/j.transproceed.2014.11.077
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA CR8ZW
UT WOS:000361644000004
PM 26361653
ER

PT J
AU Frongillo, F
   Bianco, G
   Silvestrini, N
   Lirosi, MC
   Sanchez, AM
   Nure, E
   Gaspari, R
   Avolio, AW
   Sganga, G
   Agnes, S
AF Frongillo, F.
   Bianco, G.
   Silvestrini, N.
   Lirosi, M. C.
   Sanchez, A. M.
   Nure, E.
   Gaspari, R.
   Avolio, A. W.
   Sganga, G.
   Agnes, S.
TI Acute Liver Failure in an Adult, a Rare Complication of Alagille
   Syndrome: Case Report and Brief Review
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 38th National Congress of the Italian-Transplantation-Society
CY SEP 24-26, 2014
CL Siena, ITALY
SP Italian Transplantat Soc
ID HUMAN JAGGED1; TRANSPLANTATION; MUTATIONS; CHOLESTASIS; MORBIDITY;
   PAUCITY
AB Alagille syndrome (AS) is an autosomal-dominant, multisystem disorder affecting the liver, heart, eyes, skeleton, and face. The manifestations are predominantly pediatric. Diagnosis is based on findings of a paucity of bile ducts on liver biopsy combined with >= 3 of 5 major clinical criteria. Orthotopic liver transplantation (OLT) is the only option for treating patients who developed liver failure, portal hypertension, severe itching, and xanthomatosis. It is difficult to establish clear criteria for OLT; indications are controversial because of the wide variety of clinical symptoms and the multisystem involvement. Generally, ASassociated liver disease is never an acute illness. We report the case of a 28-year-old woman with AS who underwent urgent OLT for acute liver failure. At 24 months posttransplant, the patient is in good clinical condition and with normal hepatic and renal function.
C1 [Frongillo, F.; Bianco, G.; Silvestrini, N.; Lirosi, M. C.; Sanchez, A. M.; Nure, E.; Avolio, A. W.; Sganga, G.; Agnes, S.] Univ Cattolica Sacro Cuore, Dept Surg, Transplantat Serv, I-00168 Rome, Italy.
   [Gaspari, R.] Univ Cattolica Sacro Cuore, Dept Anaestesiol & Intens Care, I-00168 Rome, Italy.
RP Bianco, G (reprint author), Policlin A Gemelli, Dept Surg, Transplantat Serv, Largo A Gemelli 8, I-00168 Rome, Italy.
EM bianco.g@live.com
RI Sanchez, Alejandro/M-6703-2016
OI Sanchez, Alejandro/0000-0002-4840-507X
CR ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1
   Alagille D, 1969, J PAR PEDIAT, P301
   Arnon R, 2012, CLIN TRANSPLANT, V26, pE94, DOI 10.1111/j.1399-0012.2011.01574.x
   DANKS DM, 1977, ARCH DIS CHILD, V52, P360
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Haberal M, 2001, TRANSPLANT P, V33, P2741, DOI 10.1016/S0041-1345(01)02175-3
   HOFFENBERG EJ, 1995, J PEDIATR-US, V127, P220, DOI 10.1016/S0022-3476(95)70298-9
   Kamath BM, 2010, J PEDIATR GASTR NUTR, V50, P11, DOI 10.1097/MPG.0b013e3181c1601f
   Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243
   Lykavieris P, 2001, GUT, V49, P431, DOI 10.1136/gut.49.3.431
   Maldini G, 2005, TRANSPLANT P, V37, P1174, DOI 10.1016/j.transproceed.2004.12.245
   Mattei P, 2006, J PEDIATR SURG, V41, P104, DOI 10.1016/j.pedsurg.2005.10.014
   McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332
   Modi BP, 2007, J PEDIATR SURG, V42, P800, DOI 10.1016/j.jpedsurg.2006.12.032
   Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235
   Quiros-Tejeira RE, 1999, J PEDIATR GASTR NUTR, V29, P431, DOI 10.1097/00005176-199910000-00011
   Turnpenny PD, 2012, EUR J HUM GENET, V20, P251, DOI 10.1038/ejhg.2011.181
   TZAKIS AG, 1993, ARCH SURG-CHICAGO, V128, P337
   Vajro P, 2012, CLIN RES HEPATOL GAS, V36, P275, DOI 10.1016/j.clinre.2012.03.019
NR 21
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD SEP
PY 2015
VL 47
IS 7
BP 2179
EP 2181
DI 10.1016/j.transproceed.2014.11.072
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA CR8ZW
UT WOS:000361644000024
PM 26361673
ER

PT J
AU Choi, JW
   Jae, HJ
   Kim, HC
   Yi, NJ
   Lee, KW
   Suh, KS
   Chung, JW
AF Choi, Jin Woo
   Jae, Hwan Jun
   Kim, Hyo-Cheol
   Yi, Nam-Joon
   Lee, Kwang-Woong
   Suh, Kyung-Suk
   Chung, Jin Wook
TI Long-term outcome of endovascular intervention in hepatic venous outflow
   obstruction following pediatric liver transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID STENT PLACEMENT; COMPLICATIONS; VENOPLASTY; STENOSIS; EXPERIENCE;
   MANAGEMENT; EFFICACY
AB The purpose of our study was to address the long-term outcome of angioplasty and stent placement for hepatic venous outflow obstruction following pediatric liver transplantation. From October 1999 to December 2011, 20 stenotic lesions were confirmed to constitute hepatic venous outflow obstruction in 18 pediatric patients (13 boys, 5 girls) among 152 pediatric patients following liver transplantation and were managed with endovascular intervention. Stent placement was favored over additional angioplasty in patients of preadolescent or adolescent age (>8 years old), after 1 or 2 sessions of balloon angioplasty. The primary patency and assisted primary patency were estimated using the Kaplan-Meier method. A total of 32 procedures (24 balloon angioplasties, 8 stent placements) were conducted. The technical success rate was 90.6% (29/32). Clinical success was achieved in 15 of 18 patients (clinical success rate of 83.3%). Major complications did not occur in our study. Median follow-up was 91.5 months (interquartile range, 54.7-137.3 months) for the 18 patients. The 1-year, 3-year, 5-year, and 10-year primary patencies of the 20 treated lesions were 63.5%, 57.8%, 57.8%, and 57.8%, respectively. The 1-year, 3-year, 5-year, and 10-year assisted-primary patencies of the lesions were 100%, 100%, 100%, and 100%, respectively. Of the 6 patients of preadolescent or adolescent age, 5 patients underwent stent placement procedures, and the stents were patent during the follow-up period of 57.3-162.5 months (median, 72.7 months). In conclusion, endovascular intervention is very effective in hepatic venous outflow obstruction following pediatric liver transplantation. In addition, early stent placement in patients of preadolescent or adolescent age can provide a safe and favorable long-term outcome. Liver Transpl 21:1219-1226, 2015. (c) 2015 AASLD.
C1 [Choi, Jin Woo; Jae, Hwan Jun; Kim, Hyo-Cheol; Chung, Jin Wook] Seoul Natl Univ Hosp, Dept Radiol, Seoul 110744, South Korea.
   [Yi, Nam-Joon; Lee, Kwang-Woong; Suh, Kyung-Suk] Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea.
RP Kim, HC (reprint author), Seoul Natl Univ Hosp, Dept Radiol, 101 Daehak Ro, Seoul 110744, South Korea.
EM angiointervention@gmail.com
OI Yi, Nam-Joon/0000-0002-5467-425X
CR Berrocal T, 2006, RADIOGRAPHICS, V26, P1187, DOI 10.1148/rg.264055081
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Carnevale FC, 2008, J VASC INTERV RADIOL, V19, P1439, DOI 10.1016/j.jvir.2008.06.012
   Cheng YF, 2005, TRANSPLANT INT, V18, P556, DOI 10.1111/j.1432-2277.2005.00088.x
   Huijbregts HJT, 2008, CLIN J AM SOC NEPHRO, V3, P714, DOI 10.2215/CJN.02950707
   Hur BY, 2015, ULTRASONOGRAPHY, V34, P58, DOI 10.14366/usg.14038
   Hwang HJ, 2009, AM J ROENTGENOL, V193, P745, DOI 10.2214/AJR.08.2145
   Kenari SKH, 2015, PEDIATR TRANSPLANT, V19, P18, DOI 10.1111/petr.12407
   Ko GY, 2008, LIVER TRANSPLANT, V14, P1505, DOI 10.1002/lt.21560
   Ko GY, 2002, J VASC INTERV RADIOL, V13, P591, DOI 10.1016/S1051-0443(07)61652-2
   Kubo T, 2006, RADIOLOGY, V239, P285, DOI 10.1148/radiol.2391050387
   Lee JM, 2010, LIVER TRANSPLANT, V16, P513, DOI 10.1002/lt.22021
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1265, DOI 10.1016/j.lts.2003.09.014
   Lorenz JM, 2014, CARDIOVASC INTER RAD, V37, P114, DOI 10.1007/s00270-013-0643-x
   Lorenz JM, 2006, J VASC INTERV RADIOL, V17, P1753, DOI 10.1097/01.RVI.0000241540.31081.52
   McNaughton DA, 2011, RADIOGRAPHICS, V31, P161, DOI 10.1148/rg.311105093
   Miraglia R, 2009, RADIOGRAPHICS, V29, P567, DOI 10.1148/rg.292085037
   Murray KF, 2005, HEPATOLOGY, V41, P1407, DOI 10.1002/hep.20704
   Omary Reed A, 2003, J Vasc Interv Radiol, V14, pS293
   Rutherford RB, 1997, J VASC SURG, V26, P517, DOI 10.1016/S0741-5214(97)70045-4
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   Sakamoto S, 2009, PEDIATR TRANSPLANT, V13, P507, DOI 10.1111/j.1399-3046.2008.01003.x
   Singhal A, 2010, TRANSPL INT, V23, P245, DOI 10.1111/j.1432-2277.2009.01037.x
   Sommovilla J, 2014, PEDIATR TRANSPLANT, V18, P497, DOI 10.1111/petr.12277
   Uller W, 2013, CARDIOVASC INTER RAD, V36, P1562, DOI 10.1007/s00270-013-0595-1
   Yabuta M, 2013, J VASC INTERV RADIOL, V24, P1673, DOI 10.1016/j.jvir.2013.07.010
NR 26
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD SEP
PY 2015
VL 21
IS 9
BP 1219
EP 1226
DI 10.1002/lt.24215
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA CP7VC
UT WOS:000360096000014
PM 26197765
ER

PT J
AU Patrick, K
   Ali, M
   Richardson, SE
   Gassas, A
   Egeler, M
   Krueger, J
   Lowry, J
   Allen, U
   Schechter, T
AF Patrick, Katharine
   Ali, Muhammad
   Richardson, Susan E.
   Gassas, Adam
   Egeler, Maarten
   Krueger, Joerg
   Lowry, Jane
   Allen, Upton
   Schechter, Tal
TI The yield of monitoring for HSV and VZV viremia in pediatric
   hematopoietic stem cell transplant patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE Human herpes virus; varicella; screening; hematopoietic stem cell
   transplantation
ID HERPES-SIMPLEX-VIRUS; BONE-MARROW-TRANSPLANTATION; VISCERAL
   VARICELLA-ZOSTER; RISK-FACTORS; INFECTIOUS COMPLICATIONS; REACTIVATION;
   CHILDREN; DISEASE; VALACYCLOVIR; PROPHYLAXIS
AB Reactivation of HSV and VZV is common following HSCT. Consensus guidelines do not support the use of routine screening for viremia following HSCT in adults, but no such clear guidelines exist in pediatrics. In our center, routine practice was to screen patients weekly for HSV and VZV viremia until engraftment in autologous transplant patients and up to day +100 in allogeneic transplant patients. We conducted a retrospective study of over 500 patients to establish whether this screening identified any patients with HSV or VZV viremia who would not have been identified by clinical signs or symptoms. Over a 4.5-yr period, routine screening identified three cases of HSV viremia and one case of VZV viremia. Two patients had persistent, unexplained fever and two patients had skin or mucosal lesions suggestive of HSV/VZV. We conclude that routine screening for HSV and VZV viremia in pediatric HSCT patients has a very low yield and that viremia can be reliably identified by targeted testing in patients with vesicular skin lesions, oral or genital ulceration, unexplained fever, neurological symptoms, or unexplained abnormal liver transaminases.
C1 [Patrick, Katharine; Ali, Muhammad; Gassas, Adam; Egeler, Maarten; Krueger, Joerg; Lowry, Jane; Schechter, Tal] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada.
   [Richardson, Susan E.] Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada.
   [Allen, Upton] Hosp Sick Children, Div Infect Dis, Toronto, ON M5G 1X8, Canada.
RP Patrick, K (reprint author), Hosp Sick Children, Div Hematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM katharinepatrick@doctors.org.uk
CR Berman JN, 2006, BONE MARROW TRANSPL, V37, P73, DOI 10.1038/sj.bmt.1705191
   Bilgrami S, 1999, BONE MARROW TRANSPL, V23, P469, DOI 10.1038/sj.bmt.1701594
   Bjorklund A, 2007, BONE MARROW TRANSPL, V40, P1055, DOI 10.1038/sj.bmt.1705856
   Boeckh M, 2006, BLOOD, V107, P1800, DOI 10.1182/blood-2005-09-3624
   David DS, 1998, AM J GASTROENTEROL, V93, P810
   Dignani MC, 2002, BONE MARROW TRANSPL, V29, P263, DOI 10.1038/sj/bmt/1703354
   Doki N, 2013, TRANSPL INFECT DIS, V15, P314, DOI 10.1111/tid.12073
   Hackanson B, 2005, CLIN TRANSPLANT, V19, P566, DOI 10.1111/j.1399-0012.2005.00382.x
   Johnson G, 2000, J CLIN MICROBIOL, V38, P3274
   Kaufman B, 1997, CLIN INFECT DIS, V24, P334
   Leung TF, 2000, BONE MARROW TRANSPL, V25, P167, DOI 10.1038/sj.bmt.1702119
   Maltezou HC, 2000, PEDIATR INFECT DIS J, V19, P307, DOI 10.1097/00006454-200004000-00009
   MEYERS JD, 1980, J INFECT DIS, V142, P338
   Mommeja-Marin H, 2003, CLIN INFECT DIS, V37, P1527, DOI 10.1086/379520
   Oshima K, 2010, TRANSPL INFECT DIS, V12, P421, DOI 10.1111/j.1399-3062.2010.00541.x
   RAMSEY PG, 1982, ANN INTERN MED, V97, P813
   SARAL R, 1984, CLIN HAEMATOL, V13, P645
   Sissons JGP, 2002, J INFECTION, V44, P73, DOI 10.1053/jinf.2001.0948
   SPENCER GD, 1986, TRANSPLANTATION, V42, P602, DOI 10.1097/00007890-198612000-00006
   Styczynski J, 2009, BONE MARROW TRANSPL, V43, P757, DOI 10.1038/bmt.2008.386
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Umezawa Y, 2014, TRANSPL INFECT DIS, V16, P195, DOI 10.1111/tid.12181
   Vandenbosch K, 2008, BIOL BLOOD MARROW TR, V14, P867, DOI 10.1016/j.bbmt.2008.05.006
   Vermont CL, 2014, TRANSPL INFECT DIS, V16, P188, DOI 10.1111/tid.12180
NR 24
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2015
VL 19
IS 6
BP 640
EP 644
DI 10.1111/petr.12551
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CN8KF
UT WOS:000358688400020
PM 26148054
ER

PT J
AU Dokumcu, Z
   Divarci, E
   Erdener, A
   Sozbilen, M
   Ergun, O
AF Dokumcu, Zafer
   Divarci, Emre
   Erdener, Ata
   Sozbilen, Murat
   Ergun, Orkan
TI Acquired right diaphragmatic hernia following pediatric living donor
   orthotopic liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE infantile cholestatic jaundice; pediatric liver transplantation; living
   donor liver transplant; surgical complication; diaphragmatic hernia;
   outcome; children
ID OF-THE-LITERATURE
AB ADH following OLT is a rare entity. Herein, we report a case of Alagille syndrome who developed ADH secondary to OLT, and possible etiological causes are discussed in light of the literature.
C1 [Dokumcu, Zafer; Divarci, Emre; Erdener, Ata; Ergun, Orkan] Ege Univ, Dept Pediat Surg, Fac Med, TR-35100 Izmir, Turkey.
   [Sozbilen, Murat; Ergun, Orkan] Ege Univ, Liver Transplantat Unit, Transplantat Ctr, Fac Med, TR-35100 Izmir, Turkey.
RP Dokumcu, Z (reprint author), Ege Univ, Dept Pediat Surg, Fac Med, TR-35100 Izmir, Turkey.
EM zdokumcu@gmail.com
OI Dokumcu, Zafer/0000-0002-4996-7824
CR Cortes M, 2014, LIVER TRANSPLANT, V20, P1429, DOI 10.1002/lt.23977
   Goldman Matthew, 2011, Curr Gastroenterol Rep, V13, P193, DOI 10.1007/s11894-010-0169-1
   Lam HD, 2013, PEDIATR TRANSPLANT, V17, pE77, DOI 10.1111/petr.12052
   Moon SB, 2012, PEDIATR TRANSPLANT, V16, pE106, DOI 10.1111/j.1399-3046.2010.01462.x
   Perwaiz A, 2010, HERNIA, V14, P547, DOI 10.1007/s10029-009-0594-y
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2015
VL 19
IS 6
BP E149
EP E151
DI 10.1111/petr.12548
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CN8KF
UT WOS:000358688400006
PM 26101838
ER

PT J
AU Uchida, H
   Fukuda, A
   Masatoshi, M
   Sasaki, K
   Shigeta, T
   Kanazawa, H
   Nakazawa, A
   Miyazaki, O
   Nosaka, S
   Sakamoto, S
   Kasahara, M
AF Uchida, Hajime
   Fukuda, Akinari
   Masatoshi, Matsunami
   Sasaki, Kengo
   Shigeta, Takanobu
   Kanazawa, Hiroyuki
   Nakazawa, Atsuko
   Miyazaki, Osamu
   Nosaka, Shunsuke
   Sakamoto, Seisuke
   Kasahara, Mureo
TI A central approach to splenorenal shunt in pediatric living donor liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; pediatric liver transplantation;
   portal vein flow; splenorenal shunt
ID LEFT RENAL-VEIN; COMPLICATIONS; LIGATION
AB The management of LSRS is a crucial problem to ensure a sufficient PV flow during pediatric LT. Although several techniques have been indicated to solve this problem, a more appropriate approach to LSRS is still needed in pediatric LT. We herein present a modified surgical approach to the ligation of LSRS via the left side of the IVC for a nine-month-old boy with severe portal hypertension and a history of Kasai portoenterostomy. LSRS was identified and exposed through the left side of the IVC and the dorsal surface of the pancreas from the superior side of the body of the pancreas. The post-operative course was uneventful with an excellent PV flow. The central approach for the ligation of LSRS is worth considering as an alternative procedure for a patient with collateral vessels and a history of multiple laparotomies.
C1 [Uchida, Hajime; Fukuda, Akinari; Masatoshi, Matsunami; Sasaki, Kengo; Shigeta, Takanobu; Kanazawa, Hiroyuki; Sakamoto, Seisuke; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Organ Transplantat Ctr, Tokyo 1578535, Japan.
   [Nakazawa, Atsuko] Natl Ctr Child Hlth & Dev, Div Clin Pathol, Tokyo 1578535, Japan.
   [Miyazaki, Osamu; Nosaka, Shunsuke] Natl Ctr Child Hlth & Dev, Div Radiol, Tokyo 1578535, Japan.
RP Uchida, H (reprint author), Natl Ctr Child Hlth & Dev, Transplantat Ctr, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM uchida-h@ncchd.go.jp
CR BREMS JJ, 1989, ANN SURG, V209, P51, DOI 10.1097/00000658-198901000-00008
   Castillo-Suescun F, 2011, LIVER TRANSPLANT, V17, P891, DOI 10.1002/lt.22304
   Cho SY, 2009, TRANSPL P, V41, P4243, DOI 10.1016/j.transproceed.2009.08.054
   Dehghani SM, 2008, PEDIATR TRANSPLANT, V12, P146, DOI 10.1111/j.1399-3046.2007.00829.x
   desMagnee C, 2011, ANN SURG, V254, P55
   Gurevich M, 2015, ANN SURG
   Lee SG, 2007, TRANSPLANT INT, V20, P45, DOI 10.1111/j.1432-2277.2006.00392.x
   Nakano T, 2008, TRANSPL P, V40, P2515, DOI 10.1016/j.transproceed.2008.07.056
   Piscaglia F, 1999, HEPATOLOGY, V30, P58, DOI 10.1002/hep.510300112
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   Troisi R, 1999, CLIN TRANSPLANT, V13, P380, DOI 10.1034/j.1399-0012.1999.130503.x
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
NR 12
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2015
VL 19
IS 6
BP E142
EP E145
DI 10.1111/petr.12543
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CN8KF
UT WOS:000358688400004
PM 26121997
ER

PT J
AU Kirnap, M
   Akdur, A
   Ozcay, F
   Soy, E
   Yildirim, S
   Moray, G
   Haberal, M
AF Kirnap, Mahir
   Akdur, Aydincan
   Ozcay, Figen
   Soy, Ebru
   Yildirim, Sedat
   Moray, Gokhan
   Haberal, Mehmet
TI Liver Transplant for Fulminant Hepatic Failure: A Single-Center
   Experience
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Liver dysfunction; Acute liver failure; Hepatic coma; Liver
   transplantation
ID CHILDREN
AB Objectives: Acute liver failure is a life-threatening condition with sudden onset liver injury, decreased liver functions, hepatic encephalopathy, and coagulopathy in patients without preexisting liver disease. In this study, we sought to evaluate the results of liver transplant as a treatment for acute liver failure.
   Materials and Methods: Between November 1988 and March 2015, we performed 482 liver transplants in 471 patients. We performed 36 liver transplants in 35 patients because of acute liver failure. Only 5 of these were from deceased donors. Thirty of those 34 patients were pediatric (85%) and 5 were adults (15%).
   Results: Five patients died (4 in early postoperative period and 1 during the 18th month of living-donor liver transplant). We diagnosed 11 acute rejections (32%); 6 biliary leaks (17%); 6 intraabdominal hemorrhage (17%); 5 hepatic arterial thromboses (15%), and 1 venous complication (3%) during the early postoperative period. We have no morbidity or mortality in living-donor liver transplants.
   Conclusions: Living-donor liver transplants are an efficient and successful treatment for acute liver failure patients. In our center, we mostly consider and prefer living-donor liver transplants to deceased-donor liver transplant because of the paucity of organ donation, especially for pediatric patients. Considering acceptable postoperative complications, living-donor liver transplant is a lifesaving treatment for acute liver failure.
C1 [Kirnap, Mahir; Akdur, Aydincan; Soy, Ebru; Yildirim, Sedat; Moray, Gokhan; Haberal, Mehmet] Baskent Univ, Fac Med, Dept Gen Surg & Transplantat, TR-06490 Ankara, Turkey.
   [Ozcay, Figen] Baskent Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Taskent Caddesi 77, TR-06490 Ankara, Turkey.
EM rectorate@baskent.edu.tr
CR BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593
   Bismuth H, 1996, SEMIN LIVER DIS, V16, P415, DOI 10.1055/s-2007-1007254
   Ee LC, 2003, J PAEDIATR CHILD H, V39, P107, DOI 10.1046/j.1440-1754.2003.00087.x
   Fan ST, 2000, ARCH SURG-CHICAGO, V135, P336, DOI 10.1001/archsurg.135.3.336
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   HABERAL M, 1991, TRANSPLANT P, V23, P2563
   Hattori H, 1998, TRANSPLANTATION, V65, P686, DOI 10.1097/00007890-199803150-00015
   Ikegami T, 2008, J AM COLL SURGEONS, V206, P412, DOI 10.1016/j.jamcollsurg.2007.08.018
   Karakayali H, 2007, TRANSPL P, V39, P1157, DOI 10.1016/j.transproceed.2007.02.053
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439
   Siddiqui MS, 2014, CLIN LIVER DIS, V18, P957, DOI 10.1016/j.cld.2014.07.012
   Singanayagam A, 2015, CURR OPIN CRIT CARE, V21, P134, DOI 10.1097/MCC.0000000000000187
   Sokol RJ, 1990, PEDIAT HEPATOLOGY, P315
   Sugawara K, 2012, J GASTROENTEROL, V47, P849, DOI 10.1007/s00535-012-0624-x
   Tanaka K, 1994, TRANSPL INT S1, pS108
   Uemoto S, 2000, TRANSPLANTATION, V70, P152
   Whittington PF, 1993, LIVER DIS CHILDREN, P180
NR 17
TC 0
Z9 0
U1 1
U2 1
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD AUG
PY 2015
VL 13
IS 4
BP 339
EP 343
DI 10.6002/ect.2015.0080
PG 5
WC Transplantation
SC Transplantation
GA CX0OE
UT WOS:000365395600008
PM 26029995
ER

PT J
AU Laurence, JM
   Sapisochin, G
   DeAngelis, M
   Seal, JB
   Miserachs, MM
   Marquez, M
   Zair, M
   Fecteau, A
   Jones, N
   Hrycko, A
   Avitzur, Y
   Ling, SC
   Ng, V
   Cattral, M
   Grant, D
   Kamath, BM
   Ghanekar, A
AF Laurence, Jerome M.
   Sapisochin, Gonzalo
   DeAngelis, Maria
   Seal, John B.
   Miserachs, Mar M.
   Marquez, Max
   Zair, Murtuza
   Fecteau, Annie
   Jones, Nicola
   Hrycko, Alexander
   Avitzur, Yaron
   Ling, Simon C.
   Ng, Vicky
   Cattral, Mark
   Grant, David
   Kamath, Binita M.
   Ghanekar, Anand
TI Biliary complications in pediatric liver transplantation: Incidence and
   management over a decade
SO LIVER TRANSPLANTATION
LA English
DT Article
ID DONOR LIVER; RISK-FACTORS; ANASTOMOTIC STRICTURE; RECONSTRUCTION;
   RECIPIENTS; GRAFT; HEPATECTOMY; MORBIDITY; CHILDREN; OUTCOMES
AB This study analyzed how features of a liver graft and the technique of biliary reconstruction interact to affect biliary complications in pediatric liver transplantation. A retrospective analysis was performed of data collected from 2001 to 2011 in a single high-volume North American pediatric transplant center. The study cohort comprised 173 pediatric recipients, 75 living donor (LD) and 98 deceased donor (DD) recipients. The median follow-up was 70 months. Twenty-nine (16.7%) patients suffered a biliary complication. The majority of leaks (9/12, 75.0%) and the majority of strictures (18/22, 81.8%) were anastomotic. There was no difference in the rate of biliary complications associated with DD (18.4%) and LD (14.7%) grafts (P=0.55). Roux-en-Y (RY) reconstruction was associated with a significantly lower rate of biliary complications compared to duct-to-duct reconstruction (13.3% versus 28.2%, respectively; P=0.048). RY anastomosis was the only significant factor protecting from biliary complications in our population (hazard ratio, 0.30; 95% confidence interval, 0.1-0.85). The leaks were managed primarily by relaparotomy (10/12, 83.3%), and the majority of strictures were managed by percutaneous biliary intervention (14/22, 63.6%). Patients suffering biliary complications had inferior graft survival (P=0.04) at 1, 5, and 10 years compared to patients without biliary complications. Our analysis demonstrates a lower incidence of biliary complications with RY biliary reconstruction, and patients with biliary complications have decreased graft survival. Liver Transpl 21:1082-1090, 2015. (c) 2015 AASLD.
C1 [Laurence, Jerome M.; Sapisochin, Gonzalo; DeAngelis, Maria; Seal, John B.; Miserachs, Mar M.; Marquez, Max; Fecteau, Annie; Jones, Nicola; Hrycko, Alexander; Avitzur, Yaron; Ling, Simon C.; Ng, Vicky; Cattral, Mark; Grant, David; Kamath, Binita M.; Ghanekar, Anand] Hosp Sick Children, Liver Transplant Program, Toronto, ON M5G 1X8, Canada.
   [Fecteau, Annie; Cattral, Mark; Grant, David; Ghanekar, Anand] Hosp Sick Children, Div Gen Surg, Toronto, ON M5G 1X8, Canada.
   [Miserachs, Mar M.; Jones, Nicola; Hrycko, Alexander; Avitzur, Yaron; Ling, Simon C.; Ng, Vicky; Kamath, Binita M.] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada.
   [Laurence, Jerome M.; Sapisochin, Gonzalo; Seal, John B.; Cattral, Mark; Grant, David; Ghanekar, Anand] Univ Hlth Network, Toronto Gen Hosp, Multiorgan Transplant Program, Toronto, ON M5G 2N2, Canada.
   [Laurence, Jerome M.; Sapisochin, Gonzalo; Seal, John B.; Cattral, Mark; Grant, David; Ghanekar, Anand] Univ Hlth Network, Toronto Gen Hosp, Div Gen Surg, Toronto, ON M5G 2N2, Canada.
   [Miserachs, Mar M.; Marquez, Max; Zair, Murtuza; Jones, Nicola; Hrycko, Alexander; Avitzur, Yaron; Ling, Simon C.; Ng, Vicky; Kamath, Binita M.] Univ Toronto, Dept Pediat, Toronto, ON, Canada.
RP Ghanekar, A (reprint author), Univ Hlth Network, Toronto Gen Hosp, NCSB 11 PMB 171,585 Univ Ave, Toronto, ON M5G 2N2, Canada.
EM anand.ghanekar@uhn.ca
FU Ashley's Angels Fund
FX This project was supported by The Ashley's Angels Fund.
CR Akamatsu N, 2011, TRANSPL INT, V24, P379, DOI 10.1111/j.1432-2277.2010.01202.x
   Alawi K, 2008, EXP CLIN TRANSPLANT, V6, P101
   Alonso EM, 2008, LIVER TRANSPLANT, V14, P460, DOI 10.1002/lt.21352
   Atkison PR, 2002, CAN MED ASSOC J, V166, P1663
   Austin MT, 2005, ARCH SURG-CHICAGO, V140, P465, DOI 10.1001/archsurg.140.5.465
   BISMUTH H, 1984, SURGERY, V95, P367
   Broering DC, 2004, ANN SURG, V240, P1013, DOI 10.1097/01.sla.0000146146.97485.6c
   Bucuvalas J, 2009, LIVER TRANSPLANT, V15, pS6, DOI 10.1002/lt.21915
   Cattral MS, 2004, AM J TRANSPLANT, V4, P751, DOI 10.1111/j.1600-6143.2004.00405.x
   Chahal P, 2007, LIVER TRANSPLANT, V13, P1168, DOI 10.1002/lt.21198
   Chok KSH, 2012, J PEDIATR SURG, V47, P1399, DOI 10.1016/j.jpedsurg.2011.12.014
   COLONNA JO, 1992, ANN SURG, V216, P344
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   desRougemont O, 2009, LIVER TRANSPLANT, V15, P96
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Feier FH, 2014, LIVER TRANSPLANT, V20, P882, DOI 10.1002/lt.23896
   Felder SI, 2013, JAMA SURG, V148, P253, DOI 10.1001/jamasurg.2013.601
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   GREIF F, 1994, ANN SURG, V219, P40, DOI 10.1097/00000658-199401000-00007
   Haberal M, 2011, TRANSPL P, V43, P595, DOI 10.1016/j.transproceed.2011.01.009
   HEFFRON TG, 1992, TRANSPLANTATION, V53, P391, DOI 10.1097/00007890-199202010-00024
   Hoekstra H, 2009, LIVER TRANSPLANT, V15, P924, DOI 10.1002/lt.21764
   Hwang S, 2006, LIVER TRANSPLANT, V12, P831, DOI 10.1002/lt.20693
   Icoz G, 2003, LIVER TRANSPLANT, V9, P575, DOI 10.1053/jlts.2003.50129
   Kane R, 2001, TRANSPLANTATION, V72, P463
   Karakayali F, 2013, TRANSPL P, V45, P3524, DOI 10.1016/j.transproceed.2013.09.012
   Karakayali H, 2005, TRANSPLANT P, V37, P3174, DOI 10.1016/j.transproceed.2005.07.023
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   Marubashi S, 2009, TRANSPLANTATION, V88, P1123, DOI 10.1097/TP.0b013e3181ba184a
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   Moreira AM, 2010, CARDIOVASC INTER RAD, V33, P90, DOI 10.1007/s00270-009-9619-2
   Mouzaki M, 2013, PEDIATR TRANSPLANT, V17, P751, DOI 10.1111/petr.12158
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Park JB, 2008, TRANSPLANTATION, V86, P1536, DOI 10.1097/TP.0b013e31818b2316
   Parlak E, 2010, SURG ENDOSC, V24, P466, DOI 10.1007/s00464-009-0591-3
   PECLET MH, 1994, J PEDIATR SURG, V29, P214, DOI 10.1016/0022-3468(94)90321-2
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Qian Ye Ben, 2004, Arch Surg, V139, P1101, DOI 10.1001/archsurg.139.10.1101
   Reichman TW, 2011, LIVER TRANSPLANT, V17, P1404, DOI 10.1002/lt.22420
   Seehofer D, 2013, AM J TRANSPLANT, V13, P253, DOI 10.1111/ajt.12034
   Seo JK, 2009, LIVER TRANSPLANT, V15, P369, DOI 10.1002/lt.21700
   Shah SA, 2007, AM J TRANSPLANT, V7, P161, DOI 10.1111/j.1600-6143.2006.01601.x
   Shah SA, 2005, AM J TRANSPLANT, V5, P2764, DOI 10.1111/j.1600-6143.2005.01094.x
   Shirouzu Y, 2008, LIVER TRANSPLANT, V14, P1761, DOI 10.1002/lt.21599
   SUNG JY, 1992, DIGEST DIS SCI, V37, P689, DOI 10.1007/BF01296423
   Sunku Bhanu, 2006, Liver Transpl, V12, P821, DOI 10.1002/lt.20712
   Wang SF, 2011, LIVER TRANSPLANT, V17, P1127, DOI 10.1002/lt.22381
   Williams ED, 2009, WORLD J GASTROENTERO, V15, P3725, DOI 10.3748/wjg.15.3725
   Zimmerman MA, 2013, LIVER TRANSPLANT, V19, P259, DOI 10.1002/lt.23595
NR 52
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2015
VL 21
IS 8
BP 1082
EP 1090
DI 10.1002/lt.24180
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA CN8KP
UT WOS:000358689500011
PM 25991054
ER

PT J
AU de Goyet, JD
   di Francesco, F
   Sottani, V
   Grimaldi, C
   Tozzi, AE
   Monti, L
   Muiesan, P
AF de Goyet, J. de Ville
   di Francesco, F.
   Sottani, V.
   Grimaldi, C.
   Tozzi, A. E.
   Monti, L.
   Muiesan, P.
TI Splitting livers: Trans-hilar or trans-umbilical division? Technical
   aspects and comparative outcomes
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; practice guidelines; complications of
   liver transplantation; donor hepatectomy
ID LEFT LATERAL SEGMENT; LEFT PORTAL-VEIN; ONE DONOR LIVER; LIVING-DONOR;
   SINGLE-CENTER; 2 RECIPIENTS; BILIARY COMPLICATIONS; SURGICAL TECHNIQUES;
   TRANSPLANTATION; GRAFTS
AB Controversy remains about the best line of division for liver splitting, through Segment IV or through the umbilical fissure. Both techniques are currently used, with the choice varying between surgical teams in the absence of an evidence-based choice. We conducted a single-center retrospective analysis of 47 left split liver grafts that were procured with two different division techniques: classical (N=28, Group A) or through the umbilical fissure and plate (N=19, Group B). The allocation of recipients to each group was at random; a single transplant team performed all transplantations. Demographics, characteristics, technical aspects, and outcomes were similar in both groups. The grafts in Group A, prepared with the classical technique, were procured more often with a single BD orifice compared with the grafts in Group B; however, this was not associated with a higher incidence of biliary problems in this series of transplants (96% actual graft survival rate [median +/- s.d. follow-up: 26 +/- 20months]). Both techniques provide good quality split grafts and an excellent outcome; surgical expertise with a given technique is more relevant than the technique itself. The classical technique, however, seems to be more flexible in various ways, and surgeons may find it to be preferable.
C1 [de Goyet, J. de Ville; di Francesco, F.; Sottani, V.; Grimaldi, C.] Bambino Gesu Pediat Hosp, Dept Pediat Surg, I-00165 Rome, Italy.
   [de Goyet, J. de Ville] Univ Roma Tor Vergata, Pediat Surg Chair, Rome, Italy.
   [Tozzi, A. E.] Bambino Gesu Pediat Hosp, Telemed Unit, I-00165 Rome, Italy.
   [Monti, L.] Bambino Gesu Pediat Hosp, Dept Imaging, Hepatobiliary Radiol Unit, I-00165 Rome, Italy.
   [Muiesan, P.] Queen Elizabeth Hosp NHS, Liver Transplantat & HPB Surg, Birmingham, W Midlands, England.
RP de Goyet, JD (reprint author), Bambino Gesu Pediat Hosp, Dept Surg, Piazza San Onofrio 4, I-00165 Rome, Italy.
EM Jean.devilledegoyet@opbg.net
RI Tozzi, Alberto Eugenio/F-9494-2012
OI Tozzi, Alberto Eugenio/0000-0002-6884-984X
CR Azoulay D, 2001, ARCH SURG-CHICAGO, V136, P956, DOI 10.1001/archsurg.136.8.956
   BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Broering X, 2002, SPLIT LIVER TRANSPLA, P88
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Chaib E, 2007, HEPATO-GASTROENTEROL, V54, P688
   Couinaud C, 1991, CONTROLLED PARTITION, V1, P10
   Couinaud C, 1991, CHIRURGIE, V118, P217
   Darius T, 2014, LIVER TRANSPLANT, V20, P893, DOI 10.1002/lt.23910
   De Goyet JD, 2002, SPLIT LIVER TRANSPLANTATION: THEORETICAL AND PRACTICAL ASPECTS, P75
   de Goyet JD, 2013, PEDIATR TRANSPLANT, V17, P19, DOI 10.1111/j.1399-3046.2012.01784.x
   de Goyet JD, 2009, CURR OPIN ORGAN TRAN, V14, P507, DOI 10.1097/MOT.0b013e32833067f3
   de Ville de Goyet J, 2005, TRANSPLANTATION LIVE, P609
   DEGOYET JD, 1995, TRANSPLANTATION, V59, P1371
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   de Ville de Goyet J, 1996, TRANSPLANTATION LIVE, V1st, P481
   Desphpande RR, 2001, BRIT J SURG, V89, P1078
   EMOND JC, 1990, ANN SURG, V212, P14
   Furuta T, 2009, RADIOGRAPHICS, V29, DOI 10.1148/rg.e37
   HIATT JR, 1994, ANN SURG, V220, P50, DOI 10.1097/00000658-199407000-00008
   Hong JC, 2009, J AM COLL SURGEONS, V208, P682, DOI 10.1016/j.jamcollsurg.2009.01.023
   HOUSSIN D, 1993, BRIT J SURG, V80, P75, DOI 10.1002/bjs.1800800126
   Kasahara M, 2013, LIVER TRANSPLANT, V19, P226, DOI 10.1002/lt.23572
   Kilic M, 2002, TRANSPLANTATION, V73, P1252, DOI 10.1097/00007890-200204270-00011
   Lerut J, 2002, TRANSPLANTATION, V74, P278, DOI 10.1097/00007890-200207270-00020
   Maggi U, 2010, TRANSPL P, V42, P1240, DOI 10.1016/j.transproceed.2010.03.110
   Miraglia R, 2012, DIAGN INTERV RADIOL, V18, P326, DOI 10.4261/1305-3825.DIR.3810-10.2
   Miraglia R, 2008, CARDIOVASC INTER RAD, V31, P993, DOI 10.1007/s00270-008-9378-5
   Mitchell A, 2000, TRANSPLANTATION, V69, P1731
   Noujaim HM, 2003, AM J TRANSPLANT, V3, P318, DOI 10.1034/j.1600-6143.2003.00047.x
   Noujaim HM, 2002, TRANSPLANTATION, V74, P1386, DOI 10.1097/01.TP.0000034628.29925.23
   OTTE JB, 1990, SURGERY, V107, P605
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   RAT P, 1992, SURGERY, V112, P522
   Reichert PR, 2000, ANN SURG, V232, P658, DOI 10.1097/00000658-200011000-00007
   Renz JF, 2000, LIVER TRANSPLANT, V6, P801, DOI 10.1053/jlts.2000.19365
   ROGIERS X, 1995, TRANSPLANTATION, V59, P1081, DOI 10.1097/00007890-199504270-00001
   Russel E, 1990, RADIOLOGY, V174, P373
   Sakamoto S, 2014, SURGERY, V156, P1232, DOI 10.1016/j.surg.2014.05.003
   Salvalaggio PRO, 2005, LIVER TRANSPLANT, V11, P161, DOI 10.1002/lt.20288
   Scatton O, 2015, ANN SURG, V261, P506, DOI 10.1097/SLA.0000000000000642
   Sepulveda A, 2012, LIVER TRANSPLANT, V18, P413, DOI 10.1002/lt.22479
   Smadja C, 1994, SURG LIVER BILIARY T, VI, P11
   Soubrane O, 2006, ANN SURG, V244, P815, DOI 10.1097/01.sla.0000218059.31231.b6
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
NR 47
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2015
VL 19
IS 5
BP 517
EP 526
DI 10.1111/petr.12534
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CL4ZY
UT WOS:000356969200018
ER

PT J
AU Neto, JS
   Feier, FH
   Bierrenbach, AL
   Toscano, CM
   Fonseca, EA
   Pugliese, R
   Candido, HL
   Benavides, MR
   Porta, G
   Chapchap, P
AF Neto, Joao Seda
   Feier, Flavia H.
   Bierrenbach, Ana Luiza
   Toscano, Cristiana M.
   Fonseca, Eduardo A.
   Pugliese, Renata
   Candido, Helry L.
   Benavides, Marcel R.
   Porta, Gilda
   Chapchap, Paulo
TI Impact of Kasai portoenterostomy on liver transplantation outcomes: A
   retrospective cohort study of 347 children with biliary atresia
SO LIVER TRANSPLANTATION
LA English
DT Article
ID HEPATIC PORTOENTEROSTOMY; FAILURE; GRAFT
AB Biliary atresia (BA) is the main diagnosis leading to liver transplantation (LT) in children. When diagnosed early in life, a Kasai portoenterostomy (Kasai-PE) can prevent or postpone LT. Instances of previous operations can result in difficulties during the LT. We hypothesized that a previous Kasai-PE could affect LT outcomes. A retrospective cohort study of 347 BA patients submitted to LT between 1995 and 2013 at Hospital Sirio-Libanes and A. C. Camargo Cancer Center was conducted. Patients were divided into those with a previous Kasai portoenterostomy early failure (K-EF), Kasai portoenterostomy late failure (K-LF), and those with no Kasai portoenterostomy (No-K). Primary outcomes were patient and graft survival. A total of 94 (27.1%) patients had a K-EF, 115 (33.1%) had a K-LF, and 138 (39.8%) had No-K before LT. Children in the K-LF group were older and had lower Pediatric End-Stage Liver Disease (PELD) scores. Patients in both K-EF and K-LF groups had more post-LT biliary complications. After Cox-multivariate analysis adjusting for confounding factors to determine the influence of Kasai-PE on patient and graft survival, the K-LF group had an 84% less probability of dying and a 55% less chance to undergo retransplantation. The K-LF group had a protective effect on posttransplant patient and graft survival. When properly performed, the Kasai procedure can postpone LT and positively affect outcomes. Having a K-EF and having not performed a Kasai-PE had the same effect in patient and graft survival; however, a previous Kasai-PE can increase post-LT complications as biliary complications and bowel perforations. Liver Transpl 21:922-927, 2015. (c) 2015 AASLD.
C1 [Neto, Joao Seda; Feier, Flavia H.; Fonseca, Eduardo A.; Pugliese, Renata; Candido, Helry L.; Benavides, Marcel R.; Porta, Gilda; Chapchap, Paulo] Hosp Sirio Libanes, Hepatol & Liver Transplantat, BR-0130800 Sao Paulo, SP, Brazil.
   [Bierrenbach, Ana Luiza] Hosp Sirio Libanes, Teaching & Res Inst, BR-0130800 Sao Paulo, SP, Brazil.
   [Neto, Joao Seda; Feier, Flavia H.; Fonseca, Eduardo A.; Pugliese, Renata; Candido, Helry L.; Benavides, Marcel R.; Porta, Gilda] AC Camargo Canc Ctr, Hepatol & Liver Transplantat, Sao Paulo, SP, Brazil.
   [Toscano, Cristiana M.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Dept Hlth, Goiania, Go, Brazil.
RP Neto, JS (reprint author), Hosp Sirio Libanes, Hepatol & Liver Transplantat, Rua Barata Ribeiro 414,Cj 65, BR-0130800 Sao Paulo, SP, Brazil.
EM joaoseda@gmail.com
RI Bierrenbach, Ana/F-3185-2014
OI Bierrenbach, Ana/0000-0002-6837-0636
CR Alexopoulos SP, 2012, PEDIATR TRANSPLANT, V16, P373, DOI 10.1111/j.1399-3046.2012.01677.x
   Chardot C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-28
   Cowles RA, 2008, J PEDIATR SURG, V43, P1605, DOI 10.1016/j.jpedsurg.2008.04.012
   Davenport M, 2004, LANCET, V363, P1354, DOI 10.1016/S0140-6736(04)16045-5
   DeRusso PA, 2007, HEPATOLOGY, V46, P1632, DOI 10.1002/hep.21923
   Hartley JL, 2009, LANCET, V374, P1704, DOI 10.1016/S0140-6736(09)60946-6
   Karrer FM, 1996, ARCH SURG-CHICAGO, V131, P493
   LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793
   Lopez-Santamaria M, 1998, PEDIATR SURG INT, V13, P327, DOI 10.1007/s003830050331
   Sandler AD, 1997, J PEDIATR SURG, V32, P416, DOI 10.1016/S0022-3468(97)90594-7
   Neto JS, 2012, LIVER TRANSPLANT, V18, P577, DOI 10.1002/lt.23393
   Urahashi T, 2013, EXP CLIN TRANSPLANT, V11, P259, DOI 10.6002/ect.2012.0188
   Visser BC, 2004, LIVER TRANSPLANT, V10, P1279, DOI 10.1002/lt.20234
   YAMANAKA J, 1994, J PEDIATR SURG, V29, P635, DOI 10.1016/0022-3468(94)90729-3
NR 14
TC 3
Z9 4
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2015
VL 21
IS 7
BP 922
EP 927
DI 10.1002/lt.24132
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA CL5QF
UT WOS:000357014100011
PM 25832004
ER

PT J
AU Chaudhry, AR
   Chaudhry, MR
   Papadimitriou, JC
   Drachenberg, CB
AF Chaudhry, A. R.
   Chaudhry, M. R.
   Papadimitriou, J. C.
   Drachenberg, C. B.
TI Bartonella henselae infection-associated vasculitis and crescentic
   glomerulonephritis leading to renal allograft loss
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Bartonella henselae; solid organ transplant; rejection; vasculitis; cat
   scratch disease; post-transplant lymphoproliferative disorder;
   lymphadenopathy; renal biopsy; kidney transplant; skin biopsy;
   post-infectious complications; necrotizing glomerulonephritis; rapidly
   progressive glomerulonephritis; ANCA; pauci-immune glomerulonephritis
ID CAT-SCRATCH DISEASE; KIDNEY-TRANSPLANT RECIPIENT; BACILLARY EPITHELIOID
   ANGIOMATOSIS; PEDIATRIC LIVER-TRANSPLANT; IMMUNOCOMPROMISED HOST;
   ROCHALIMAEA-HENSELAE; HEMOPHAGOCYTIC SYNDROME; TRANSVERSE MYELITIS;
   UNITED-STATES; PATIENT
AB Bartonella henselae (BH) is the main cause of cat scratch disease (CSD), which more typically presents as a self-limited localized suppurative lymphadenopathy in immunocompetent individuals. In contrast, immunocompromised patients commonly have systemic disease with life-threatening complications. In addition to the angioproliferative lesions, such as bacillary angiomatosis, an increasing number of immune post-infectious complications are being recognized with BH infections, including glomerulonephritis, vasculitis, hemophagocytic syndrome, and neurological problems. We report the case of a renal transplant recipient who developed CSD in the second year post transplantation. In addition to prolonged fever and generalized lymphadenopathy and splenomegaly requiring differentiation from a post-transplant lymphoproliferative disorder, the course was complicated by the development of dermal leukocytoclastic vasculitis and pauci-immune necrotizing and crescentic glomerulonephritis, which led to failure of the renal graft. Glomerulonephritis as a complication of CSD has never been described in a kidney allograft, to our knowledge. Awareness of the diverse clinical symptoms associated with BH, including granulomatous/suppurative lesions and other less common complications can lead to more rapid and accurate diagnosis. Also, as recommended by the current guidelines, a thorough history of pet ownership should be part of the clinical evaluation before and after transplantation for all transplant recipients.
C1 [Chaudhry, A. R.] Sinai Hosp Baltimore, Dept Gen Surg, Baltimore, MD 21201 USA.
   [Chaudhry, M. R.; Papadimitriou, J. C.; Drachenberg, C. B.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.
RP Chaudhry, AR (reprint author), Sinai Hosp Baltimore, Dept Gen Surg, 2401 Belvedere Ave, Baltimore, MD 21201 USA.
EM dr.a.chaudhry@gmail.com
CR Ahsan N, 1998, TRANSPLANTATION, V65, P1000, DOI 10.1097/00007890-199804150-00024
   APALSCH AM, 1993, PEDIATR INFECT DIS J, V12, P769, DOI 10.1097/00006454-199309000-00014
   Bass JW, 1997, PEDIATR INFECT DIS J, V16, P2, DOI 10.1097/00006454-199701000-00003
   Baylor P, 2007, CLIN INFECT DIS, V45, pE42, DOI 10.1086/519998
   Bento C, 2014, NEFROLOGIA, V34, P540, DOI 10.3265/Nefrologia.pre2014.May.12474
   Bhanot Nitin, 2012, Infect Dis Rep, V4, pe2, DOI 10.4081/idr.2012.e2
   BLACK JR, 1986, ARCH INTERN MED, V146, P394, DOI 10.1001/archinte.146.2.394
   Bonatti H, 2006, TRANSPLANT INT, V19, P683, DOI 10.1111/j.1432-2277.2006.00336.x
   Bookman Ian, 2004, Am J Kidney Dis, V43, pe25, DOI 10.1053/j.ajkd.2003.10.027
   Borgmann S, 2012, J BACTERIOL PARASITO, V3, pe112
   Bruckert F, 1997, SKELETAL RADIOL, V26, P431
   CANIZA MA, 1995, CLIN INFECT DIS, V20, P1505
   Carman KB, 2013, PAEDIATR INT CHILD H, V33, P190, DOI 10.1179/2046905512Y.0000000044
   Chan Lisa, 1995, Journal of Emergency Medicine, V13, P769, DOI 10.1016/0736-4679(95)02017-9
   Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952
   Cline MS, 1999, TRANSPLANTATION, V67, P296, DOI 10.1097/00007890-199901270-00019
   COCKERELL CJ, 1990, ARCH DERMATOL, V126, P787, DOI 10.1001/archderm.126.6.787
   Cozzani E, 2012, CLIN EXP DERMATOL, V37, P238, DOI 10.1111/j.1365-2230.2011.04177.x
   Cunningham ET, 2000, AM J OPHTHALMOL, V130, P340, DOI 10.1016/S0002-9394(00)00573-0
   DAGATI V, 1990, NEPHRON, V56, P431
   Dardenne S, 2007, TRANSPLANT P, V39, P311, DOI 10.1016/j.transproceed.2006.10.202
   DEBRE R, 1950, Mars Med, V87, P375
   Dharnidharka VR, 2002, PEDIATR TRANSPLANT, V6, P327, DOI 10.1034/j.1399-3046.2002.01091.x
   Grabas M, 2012, J AM ACAD DERMATOL, V67, pE236, DOI 10.1016/j.jaad.2012.04.044
   Greiner T, 2000, HEMATOLOGY, P133
   Guptill L, 2004, J CLIN MICROBIOL, V42, P652, DOI 10.1128/JCM.42.2.652-659.2004
   Hashkes PJ, 1996, PEDIATR INFECT DIS J, V15, P93, DOI 10.1097/00006454-199601000-00023
   Humar A, 1999, LIVER TRANSPLANT SUR, V5, P249, DOI 10.1002/lt.500050308
   JACKSON LA, 1993, AM J PUBLIC HEALTH, V83, P1707, DOI 10.2105/AJPH.83.12.1707
   Juskevicius Ridas, 2004, Arch Pathol Lab Med, V128, pe12
   Karras A, 2004, TRANSPLANTATION, V77, P238, DOI 10.1097/01.TP.0000107285.86939.37
   KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S
   Kempf VAJ, 2001, EUR J CLIN MICROBIOL, V20, P732, DOI 10.1007/s100960100605
   Klotz SA, 2011, AM FAM PHYSICIAN, V83, P152
   Koehler JE, 2005, NEW ENGL J MED, V353, P1387, DOI 10.1056/NEJMcpc059027
   KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303
   KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531
   KORDICK DL, 1995, J CLIN MICROBIOL, V33, P3245
   Lau KK, 2006, INTERNET J INFECT DI, V5
   Lienhardt B, 2009, J HEART LUNG TRANSPL, V28, P736, DOI 10.1016/j.healun.2009.03.016
   LUCEY D, 1992, CLIN INFECT DIS, V14, P683
   Maalouly C, 2014, ACTA CLIN BELG, V69, P214, DOI 10.1179/2295333714Y.0000000005
   Meininger GR, 2001, AM J SURG PATHOL, V25, P1211, DOI 10.1097/00000478-200109000-00015
   Mosepele M, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/612809
   Moulin C, 2012, TRANSPL INFECT DIS, V14, P403, DOI 10.1111/j.1399-3062.2011.00713.x
   Patel SJ, 2008, OCUL IMMUNOL INFLAMM, V16, P45, DOI 10.1080/09273940801899780
   Patel UD, 2004, NEW ENGL J MED, V350, P1990, DOI 10.1056/NEJMcps032937
   Poudel A, 2014, PEDIATR TRANSPLANT, V18, pE83, DOI 10.1111/petr.12235
   Psarros G, 2012, MEDICINE, V91, P111, DOI 10.1097/MD.0b013e31824dc07a
   Resto-Ruiz S, 2003, DNA CELL BIOL, V22, P431, DOI 10.1089/104454903767650694
   Rheault MN, 2007, PEDIATR TRANSPLANT, V11, P105, DOI 10.1111/j.1399-3046.2006.00581.x
   Robert SC, 2011, BMJ CASE REP 2011, V2011, DOI [10.1136/bcr.08.2011.4705, DOI 10.1136/BCR.08.2011.4705]
   Rolain JM, 2004, ANTIMICROB AGENTS CH, V48, P1921, DOI 10.1128/AAC.48.6.1921-1933.2004
   Rostad CA, 2012, TRANSPL INFECT DIS, V14, pE71, DOI 10.1111/j.1399-3062.2012.00774.x
   Salvado C, 2013, PRESSE MED, V42, P1060, DOI 10.1016/j.lpm.2012.07.031
   Satake K, 2011, MOD RHEUMATOL, V21, P536, DOI 10.1007/s10165-011-0434-7
   Scolfaro C, 2008, TRANSPL INFECT DIS, V10, P431, DOI 10.1111/j.1399-3062.2008.00326.x
   SELBY G, 1979, NEUROLOGY, V29, P1413
   Thudi KR, 2007, LIVER INT, V27, P145, DOI 10.1111/j.1478-3231.2006.01386.x
   Tsuneoka Hidehiro, 2006, Journal of Infection and Chemotherapy, V12, P224, DOI 10.1007/s10156-006-0454-y
   Turner JW, 2005, LANCET, V365, P2062, DOI 10.1016/S0140-6736(05)66701-3
   Verçoza Ana Maria Teixeira, 2014, J. Bras. Nefrol., V36, P406, DOI 10.5935/0101-2800.20140058
NR 62
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD JUN
PY 2015
VL 17
IS 3
BP 411
EP 417
DI 10.1111/tid.12376
PG 7
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA CK2YW
UT WOS:000356082600012
PM 25753276
ER

PT J
AU Samstein, B
   Griesemer, A
   Cherqui, D
   Mansour, T
   Pisa, J
   Yegiants, A
   Fox, AN
   Guarrera, JV
   Kato, T
   Halazun, KJ
   Emond, J
AF Samstein, Benjamin
   Griesemer, Adam
   Cherqui, Daniel
   Mansour, Tarek
   Pisa, Joseph
   Yegiants, Anna
   Fox, Alyson N.
   Guarrera, James V.
   Kato, Tomoaki
   Halazun, Karim J.
   Emond, Jean
TI Fully laparoscopic left-sided donor hepatectomy is safe and associated
   with shorter hospital stay and earlier return to work: A comparative
   study
SO LIVER TRANSPLANTATION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; LEFT LATERAL SECTIONECTOMY; LIVING DONOR;
   LIVER-TRANSPLANTATION; COMPLICATIONS; NEPHRECTOMY; ADULTS
AB Living donor liver transplantation has failed to become a major means of transplantation in the United States, where <5% of the transplants are performed with living donors. At least 30% to 50% of the complications of donor hepatectomy appear to be related to abdominal wall trauma, including hernia, bowel obstruction, and chronic abdominal discomfort. We analyzed our experience with laparoscopically procured donor hepatectomy. We compared 22 full laparoscopic donor hepatectomies to 20 open/hybrid hepatectomies over an 11-year period. Donor and recipient demographics, complications, and graft and recipient outcomes were analyzed. All 22 laparoscopically procured liver allografts were transplanted successfully. The laparoscopically procured grafts took longer to procure (7 hours 58 minutes versus 6 hours 38 minutes; P<0.001). The laparoscopically procured cases had lower blood loss (177.3 versus 3753 cc; P<0.001), a shorter length of stay, and significantly reduced days off work (P=.01). The 1-year graft survival was not different (90% in the laparoscopic group and 85% in the open group; P=0.70). The 1-year patient survival was not different (95% in the laparoscopic group and 85% in the open group; P=0.32). There was a trend toward lower wound issues in the laparoscopic group, but this did not reach significance (the hybrid/open group had a 15% hernia rate versus 5% for the laparoscopic group). In experienced living donor centers, laparoscopic liver donation appears to be feasible for all pediatric recipients and some adult recipients. Outcomes for the recipients of laparoscopically procured grafts do not appear significantly different from outcomes with hybrid/open techniques. Liver Transpl 21:768-773, 2015. (c) 2015 AASLD.
C1 [Samstein, Benjamin; Griesemer, Adam; Mansour, Tarek; Pisa, Joseph; Yegiants, Anna; Guarrera, James V.; Kato, Tomoaki; Emond, Jean] Columbia Univ, Dept Surg, New York, NY USA.
   [Fox, Alyson N.] Columbia Univ, Ctr Liver Dis & Transplantat, New York, NY USA.
   [Cherqui, Daniel] Hop Paul Brousse, AP HP, Ctr Hepatobiliaire, Villejuif, France.
   [Halazun, Karim J.] Emory Univ, Emory Transplant Ctr, Atlanta, GA 30322 USA.
RP Samstein, B (reprint author), PH 14 Rm 202,622 West 168th St, New York, NY 10032 USA.
EM bs212@cumc.columbia.edu
CR Abecassis MM, 2012, AM J TRANSPLANT, V12, P1208, DOI 10.1111/j.1600-6143.2011.03972.x
   Berg CL, 2011, HEPATOLOGY, V54, P1313, DOI 10.1002/hep.24494
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Cherqui D, 2002, LANCET, V359, P392, DOI 10.1016/S0140-6736(02)07598-0
   deSouza A, 2011, SURG ENDOSC, V25, P1031, DOI 10.1007/s00464-010-1309-2
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Halm JA, 2009, HERNIA, V13, P275, DOI 10.1007/s10029-008-0469-7
   Kim KH, 2011, BRIT J SURG, V98, P1302, DOI 10.1002/bjs.7601
   Koffron AJ, 2006, AM J TRANSPLANT, V6, P2522, DOI 10.1111/j.1600-6143.2006.01498.x
   Muzaale AD, 2012, GASTROENTEROLOGY, V142, P273, DOI 10.1053/j.gastro.2011.11.015
   Olthoff KM, 2005, ANN SURG, V242, P314, DOI 10.1097/01.sla.0000179646.37145.cf
   Ratner LE, 1997, TRANSPLANTATION, V63, P229, DOI 10.1097/00007890-199701270-00009
   Rotellar F, 2013, AM J TRANSPLANT, V13, P3269, DOI 10.1111/ajt.12471
   Samstein B, 2013, AM J TRANSPLANT, V13, P2462, DOI 10.1111/ajt.12360
   Scatton O, 2015, ANN SURG, V261, P506, DOI 10.1097/SLA.0000000000000642
   Simforoosh N, 2005, BJU INT, V95, P851, DOI 10.1111/j.1464-410X.2005.05415.x
   Soubrane O, 2013, AM J TRANSPLANT, V13, P2467, DOI 10.1111/ajt.12361
   Strasberg SM, 2005, J HEPATO-BILIARY-PAN, V12, P351, DOI 10.1007/s00534-005-0999-7
   Troisi RI, 2013, AM J TRANSPLANT, V13, P2472, DOI 10.1111/ajt.12362
NR 19
TC 4
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2015
VL 21
IS 6
BP 768
EP 773
DI 10.1002/lt.24116
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA CJ1GJ
UT WOS:000355231400007
PM 25789460
ER

PT J
AU Nadalin, S
   Monti, L
   Grimaldi, C
   di Francesco, F
   Tozzi, AE
   de Goyet, JD
AF Nadalin, S.
   Monti, L.
   Grimaldi, C.
   di Francesco, F.
   Tozzi, A. E.
   de Goyet, J. de Ville
TI Roux-en-Y hepatico-jejunostomy for a left segmental graft: Do not twist
   the loop, stick it!
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary reconstruction; children; complications of liver
   transplantation; pediatric liver transplantation
ID PEDIATRIC LIVER-TRANSPLANTATION; BILIARY COMPLICATIONS; SPLIT;
   RECIPIENTS; RECONSTRUCTION; MANAGEMENT; ALLOGRAFT; CHILDREN
AB Biliary complications remain a major challenge for long-term success after LT, as it is, as a rule, the most common technical - early and late - complication that occurs, and because these complications contribute to a significant number of late graft losses and retransplantations. In the pediatric age group, both biliary atresia, as the patient's condition, and the use of a left liver graft, obtained by a liver division technique, make it necessary for the use of a Roux-en-Y jejunal loop for the biliary reconstruction in the majority of cases. A slight modification of the technique is presented, consisting of a straight positioning along the cut surface (rather than the conventional position that results in a harpoon shape). A favorable outcome in terms of a technical complication and graft survival was observed. This way of doing this is an interesting variation and adds to the surgical armamentarium.
C1 [Nadalin, S.] Univ Tubingen Hosp, Dept Gen Visceral & Transplant Surg, Tubingen, Germany.
   [Monti, L.] Bambino Gesu Pediat Hosp, Hepatobiliary Radiol Unit, Dept Imaging, I-00165 Rome, Italy.
   [Grimaldi, C.; di Francesco, F.; de Goyet, J. de Ville] Bambino Gesu Pediat Hosp, Dept Pediat Surg, I-00165 Rome, Italy.
   [Tozzi, A. E.] Bambino Gesu Pediat Hosp, Telemed Unit, I-00165 Rome, Italy.
   [de Goyet, J. de Ville] Univ Roma Tor Vergata, Rome, Italy.
RP de Goyet, JD (reprint author), Bambino Gesu Pediat Hosp, Dept Surg, Piazza San Onofrio 4, I-00165 Rome, Italy.
EM deville@opbg.net
RI Tozzi, Alberto Eugenio/F-9494-2012
OI Tozzi, Alberto Eugenio/0000-0002-6884-984X
CR ALLISON PR, 1953, BRIT J SURG, V41, P173, DOI 10.1002/bjs.18004116611
   Ando H, 2011, J HEPATO-BIL-PAN SCI, V18, P26, DOI 10.1007/s00534-010-0301-5
   Ayoub WS, 2010, DIGEST DIS SCI, V55, P1540, DOI 10.1007/s10620-010-1217-2
   BESSON A, 1985, AM J SURG, V149, P656, DOI 10.1016/S0002-9610(85)80150-1
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   Bucuvalas J, 2009, LIVER TRANSPLANT, V15, pS6, DOI 10.1002/lt.21915
   Chu J, 2011, PEDIATR TRANSPLANT, V15, pE156, DOI 10.1111/j.1399-3046.2010.01351.x
   Darius T, 2014, LIVER TRANSPLANT, V20, P893, DOI 10.1002/lt.23910
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   de Ville de Goyet J, 2005, TRANSPLANTATION LIVE, P609
   de Ville de Goyet J, 1996, TRANSPLANTATION LIVE, V1st, P481
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   EARLAM R, 1983, BRIT J SURG, V70, P393, DOI 10.1002/bjs.1800700702
   Enestvedt CK, 2013, LIVER TRANSPLANT, V19, P965, DOI 10.1002/lt.23696
   Feier FH, 2014, LIVER TRANSPLANT, V20, P882, DOI 10.1002/lt.23896
   Felder SI, 2013, JAMA SURG, V148, P253, DOI 10.1001/jamasurg.2013.601
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Gras JM, 2008, LIVER TRANSPLANT, V14, P469, DOI 10.1002/lt.21397
   Kasahara M, 2008, J PEDIATR SURG, V43, P1575, DOI 10.1016/j.jpedsurg.2008.02.056
   Kasahara M, 2013, LIVER TRANSPLANT, V19, P226, DOI 10.1002/lt.23572
   Kilic M, 2002, TRANSPLANTATION, V73, P1252, DOI 10.1097/00007890-200204270-00011
   Kohler S, 2009, LANGENBECK ARCH SURG, V394, P1025, DOI 10.1007/s00423-009-0506-8
   Laukkarinen J, 2007, J SURG RES, V143, P270, DOI 10.1016/j.jss.2007.02.034
   Moon SB, 2011, LIVER TRANSPLANT, V17, P717, DOI 10.1002/lt.22262
   Moreira AM, 2010, CARDIOVASC INTER RAD, V33, P90, DOI 10.1007/s00270-009-9619-2
   Muiesan P, 2006, PAEDIAT SURG UROLOGY, P858, DOI 10.1017/CBO9780511545757.066
   Noujaim HM, 2002, TRANSPLANTATION, V74, P1386, DOI 10.1097/01.TP.0000034628.29925.23
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Roux C, 1897, REV GYNECOL CHIR ABD, V1, P67
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   Venturi C, 2014, AM J TRANSPLANT, V14, P1648, DOI 10.1111/ajt.12740
   [Anonymous], 2006, SCAND J GASTROENTE S, DOI DOI 10.1080/00365520600664375
   Wang SF, 2011, LIVER TRANSPLANT, V17, P1127, DOI 10.1002/lt.22381
   Wizorek JJ, 2007, SURG LIVER BILIARY T, P1766
NR 34
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2015
VL 19
IS 4
BP 358
EP 365
DI 10.1111/petr.12474
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CH6YM
UT WOS:000354182500013
PM 25879299
ER

PT J
AU Desai, CS
   Sharma, S
   Gruessner, A
   Fishbein, T
   Kaufman, S
   Khan, KM
AF Desai, Chirag S.
   Sharma, Sanjay
   Gruessner, Angelika
   Fishbein, Thomas
   Kaufman, Stuart
   Khan, Khalid M.
TI Effect of small donor weight and donor-recipient weight ratio on the
   outcome of liver transplantation in children
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplant; hepatic artery thrombosis; liver allograft;
   cadaveric donor; graft survival
ID HEPATIC-ARTERY THROMBOSIS; RISK-FACTORS; VASCULAR COMPLICATIONS;
   RECONSTRUCTION; GRAFTS; EXPERIENCE
AB A small donor weight is a risk factor for HAT with potential for graft loss. To test this hypothesis, we evaluated outcomes of pediatric liver transplants utilizing donors <20kg using the UNOS database from 01/2003 to 01/2012 (n=1311). All isolated liver transplants with whole organ grafts were included. Recipients were divided into four groups based on donor weight: group 1, donor weight <5kg (n=34 [2%]); group 2, 5-10kg (431 [33%]); group 3, 10-15kg (560 [43%]); and group 4, 15-20kg (286 [22%]). Actuarial patient survival for the first year post-transplant was significantly lower in groups 1 and 2 compared to groups 3 and 4 (p=0.002), similarly the one-yr graft function (p<0.0001). The difference was due to graft loss within the first month for groups 1 and 2. HAT was significantly higher in groups 1 and 2 compared to others (p=0.0006). Logistic regression analysis demonstrated donor weight as the most predictive factor with analysis of the ROC curve showing a cutoff point at 7.8kg. The donor-recipient weight ratio did, in none of the models, gain statistical significance.
C1 [Desai, Chirag S.; Fishbein, Thomas; Kaufman, Stuart; Khan, Khalid M.] Georgetown Univ Hosp, Medstar Georgetown Transplant Inst, Washington, DC 20007 USA.
   [Sharma, Sanjay] Army Hosp R&R, Dept GI Surg & Liver Transplantat, New Delhi, India.
   [Gruessner, Angelika] Univ Arizona, MEZCoPH Epidemiol & Biostat, Tucson, AZ USA.
RP Desai, CS (reprint author), Medstar Georgetown Transplant Inst, 2nd Floor,PHC Bldg,Room 2016,3800 Reservoir Rd NW, Washington, DC 20007 USA.
EM chirag.s.desai@gunet.georgetown.edu
CR Alper M, 2005, MICROSURG, V25, P378, DOI 10.1002/micr.20145
   Arnon R, 2011, PEDIATR TRANSPLANT, V15, P650, DOI 10.1111/j.1399-3046.2011.01549.x
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Cauley RP, 2013, LIVER TRANSPLANT, V19, P721, DOI 10.1002/lt.23667
   DelsGaudio M, 2005, CLIN TRANSPLANT, V19, P399
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Farmer DG, 2001, TRANSPLANTATION, V72, P1795, DOI 10.1097/00007890-200112150-00015
   Grevious MA, 2009, PEDIATR TRANSPLANT, V13, P177, DOI 10.1111/j.1399-3046.2008.00966.x
   Hardikar W, 2010, THROMB RES, V126, P191, DOI 10.1016/j.thromres.2010.05.015
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   Kim WR, 2014, AM J TRANSPLANT, V14, P69, DOI 10.1111/ajt.12581
   Lafosse A, 2012, PEDIATR TRANSPLANT, V16, pE150, DOI 10.1111/j.1399-3046.2011.01488.x
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Nguyen NTT, 2012, J SURG RES, V177, P348, DOI 10.1016/j.jss.2012.06.045
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Okazaki M, 2006, LIVER TRANSPLANT, V12, P46, DOI 10.1002/lt.20550
   Orlandini M, 2014, J PEDIAT-BRAZIL, V90, P169, DOI 10.1016/j.jped.2013.08.010
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Warner P, 2011, TRANSPL INT, V24, P401, DOI 10.1111/j.1432-2277.2010.01211.x
   Wei WI, 2004, ARCH SURG-CHICAGO, V139, P304, DOI 10.1001/archsurg.139.3.304
NR 21
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2015
VL 19
IS 4
BP 366
EP 370
DI 10.1111/petr.12459
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CH6YM
UT WOS:000354182500014
PM 25819141
ER

PT J
AU Tannuri, U
   Tannuri, ACA
   Santos, MM
   Miyatani, HT
AF Tannuri, Uenis
   Tannuri, Ana Cristina A.
   Santos, Maria M.
   Miyatani, Helena T.
TI Technique advance to avoid hepatic venous outflow obstruction in
   pediatric living-donor liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living-donor liver transplantation; hepatic venous obstruction;
   pediatric liver transplantation; donor hepatectomy; complications of
   liver transplantation
ID SINGLE-CENTER; EXPERIENCE; LESSONS
AB HVOO represents a serious critical complication of pediatric living-donor liver transplantation because open surgical repair is virtually impossible. Currently, despite several technical innovations and the introduction of triangulated anastomosis for hepatic vein reconstruction, the reported incidence of HVOO is still considerable. The aim of this study was to propose a new technique for hepatic venous reconstruction that avoids the original orifice of the recipient hepatic veins. Instead, anastomosis is performed in a newly created wide longitudinal orifice in the anterior wall of the recipient inferior vena cava. A total of 210 living related-donor liver transplantations were performed using two methods for reconstruction of the hepatic vein. Group 1 included 69 patients subjected to direct anastomosis of the orifice of the graft hepatic vein and a wide orifice created in the recipient inferior vena cava by the confluence of the orifices of the right, left, and middle hepatic veins. Group 2 included 141 patients in whom the original orifices of the recipient hepatic veins were closed, the inferior vena cava was widely opened, and a long longitudinal anastomosis was performed using two lines of continuous sutures. Diagnosis of HVOO was suspected based on clinical findings and ultrasound studies and then confirmed by liver biopsy and interventional radiology examinations. Among the 69 recipients in group 1, 16 patients died due to graft problems during the postoperative period and eight of the survivors (15.1%) presented with HVOO. In group 2 (141 patients), 21 patients died, and there were no cases of HVOO. A comparison of the incidence of HVOO between groups revealed a significant difference (p=0.01). Hepatic venous reconstruction during pediatric living-donor liver transplantation should be performed using a wide longitudinal incision in the anterior wall of the recipient inferior vena cava because this technique eliminated anastomosis complications.
C1 [Tannuri, Uenis; Tannuri, Ana Cristina A.; Santos, Maria M.; Miyatani, Helena T.] Univ Sao Paulo, Liver Transplantat Unit, Childrens Inst, BR-01246903 Sao Paulo, SP, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, SP, Brazil.
EM uenist@usp.br
RI Tannuri, Ana Cristina Aoun/C-4718-2012; Tannuri, Uenis/D-3876-2012
CR Broelsch C E, 1993, Adv Surg, V26, P209
   desVilla VH, 2000, TRANSPLANTATION, V70, P1604
   Engelmann G, 2010, PEDIATR TRANSPLANT, V14, P12, DOI 10.1111/j.1399-3046.2009.01247.x
   Gibelli NEM, 2012, PEDIATR TRANSPLANT, V16, pE383, DOI 10.1111/j.1399-3046.2012.01742.x
   Heffron TG, 2010, PEDIATR TRANSPLANT, V14, P722, DOI 10.1111/j.1399-3046.2009.01259.x
   Hwang S, 2006, LIVER TRANSPLANT, V12, P920, DOI 10.1002/lt.20734
   Kanmaz T, 2014, EXP CLIN TRANSPLANT, V12, P41, DOI 10.6002/ect.2013.0016
   Kumar GK, 2010, PEDIATR SURG INT, V26, P423, DOI 10.1007/s00383-010-2564-y
   Mazariegos G V, 2000, Pediatr Transplant, V4, P322, DOI 10.1034/j.1399-3046.2000.00124.x
   Nakamura T, 2002, TRANSPLANTATION, V73, P1896, DOI 10.1097/00007890-200206270-00008
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   Sakamoto S, 2013, PEDIATR TRANSPLANT, V17, pE25, DOI 10.1111/j.1399-3046.2012.01761.x
   Sommovilla J, 2014, PEDIATR TRANSPLANT, V18, P497, DOI 10.1111/petr.12277
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Zhong JJ, 2013, HEPATO-GASTROENTEROL, V60, P252, DOI 10.5754/hge12639
NR 15
TC 2
Z9 2
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2015
VL 19
IS 3
BP 261
EP 266
DI 10.1111/petr.12429
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CE4BW
UT WOS:000351776800011
PM 25597753
ER

PT J
AU Okada, N
   Sanada, Y
   Hirata, Y
   Yamada, N
   Wakiya, T
   Ihara, Y
   Urahashi, T
   Miki, A
   Kaneda, Y
   Sasanuma, H
   Fujiwara, T
   Sakuma, Y
   Shimizu, A
   Hyodo, M
   Yasuda, Y
   Mizuta, K
AF Okada, Noriki
   Sanada, Yukihiro
   Hirata, Yuta
   Yamada, Naoya
   Wakiya, Taiichi
   Ihara, Yoshiyuki
   Urahashi, Taizen
   Miki, Atsushi
   Kaneda, Yuji
   Sasanuma, Hideki
   Fujiwara, Takehito
   Sakuma, Yasunaru
   Shimizu, Atsushi
   Hyodo, Masanobu
   Yasuda, Yoshikazu
   Mizuta, Koichi
TI The impact of rituximab in ABO-incompatible pediatric living donor liver
   transplantation: The experience of a single center
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE rituximab; pediatric transplantation; living donor liver
   transplantation; ABO-incompatibility
ID ANTIBODY-MEDIATED REJECTION; GRAFT LOCAL INFUSION; BLOOD-GROUP BARRIERS;
   PLASMA-EXCHANGE; SPLENECTOMY; PLASMAPHERESIS; IMMUNOGLOBULIN; JAPAN
AB Previous studies have demonstrated the safety of ABO-incompatible pediatric LDLT using preoperative plasmapheresis and rituximab; however, no reports have described the timing and dosage of rituximab administration for pediatric LDLT. This study aimed to describe a safe and effective dosage and timing of rituximab for patients undergoing pediatric ABO-incompatible LDLT based on the experience of our single center. A total of 192 LDLTs in 187 patients were examined. These cases included 29 ABO-incompatible LDLTs in 28 patients. Rituximab was used beginning in January 2004 in recipients older than twoyr of age (first period: 375mg/m(2) in two cases; second period: 50mg/m(2) in two cases; and 200mg/m(2) in eight cases). Two patients who received 375mg/m(2) rituximab died of Pneumocystis carinii pneumonia and hemophagocytic syndrome. One patient who received 50mg/m(2) rituximab required retransplantation as a consequence of antibody-mediated complications. All eight patients administered 200mg/m(2) survived, and the mean CD20(+) lymphocyte count was 0.1% at the time of LDLT. In the preoperative management of patients undergoing pediatric ABO-incompatible LDLT, the administration of 200mg/m(2) rituximab threewk prior to LDLT was safe and effective.
C1 [Okada, Noriki; Sanada, Yukihiro; Hirata, Yuta; Yamada, Naoya; Wakiya, Taiichi; Ihara, Yoshiyuki; Urahashi, Taizen; Mizuta, Koichi] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Miki, Atsushi; Kaneda, Yuji; Sasanuma, Hideki; Fujiwara, Takehito; Sakuma, Yasunaru; Shimizu, Atsushi; Hyodo, Masanobu; Yasuda, Yoshikazu] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Okada, N (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM r0906no@jichi.ac.jp
CR DEMETRIS AJ, 1988, AM J PATHOL, V132, P489
   Egawa H, 2012, AM J TRANSPLANT, V12, P523, DOI 10.1111/j.1600-6143.2011.03822.x
   Egawa H, 2007, LIVER TRANSPLANT, V13, P579, DOI 10.1002/lt.21092
   Egawa H, 2008, HEPATOLOGY, V47, P143, DOI 10.1002/hep.21928
   Ezeonyeji AN, 2012, RHEUMATOLOGY, V51, P476, DOI 10.1093/rheumatology/ker337
   Gelas T, 2011, PEDIATR TRANSPLANT, V15, P706, DOI 10.1111/j.1399-3046.2011.01541.x
   Goralczyk AD, 2009, J TRANSPLANT, V2009
   GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S
   Heffron T, 2006, LIVER TRANSPLANT, V12, P972, DOI 10.1002/lt.20760
   Ikegami T, 2007, TRANSPL P, V39, P3491, DOI 10.1016/j.transproceed.2007.09.028
   Ikegami T, 2009, TRANSPLANTATION, V88, P303, DOI [10.1097/TP.0b013e3181adcae6, 10.1097/TP.00130181adcae6]
   Lee SD, 2014, HPB, V16, P807, DOI 10.1111/hpb.12215
   Mizuta K, 2010, TRANSPL P, V42, P4127, DOI 10.1016/j.transproceed.2010.11.002
   Monteiro I, 2003, TRANSPLANTATION, V76, P1648, DOI 10.1097/01.TP.0000082723.02477.87
   Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x
   Morioka D, 2008, TRANSPLANTATION, V85, P171, DOI 10.1097/TP.0b013e31815e9672
   Pitosa B, 2010, CYTOM PART B-CLIN CY, V78, P372
   Raut V, 2011, SURG TODAY, V41, P317, DOI 10.1007/s00595-010-4437-3
   Raut V, 2012, TRANSPLANTATION, V93, P99, DOI 10.1097/TP.0b013e318239e8e4
   Sanada Y, 2012, THER APHER DIAL, V16, P368, DOI 10.1111/j.1744-9987.2012.01079.x
   STOOP JW, 1969, CLIN EXP IMMUNOL, V4, P101
   Takeda K, 2010, CLIN TRANSPLANT, V24, P747, DOI 10.1111/j.1399-0012.2009.01164.x
   Tam CS, 2013, LEUKEMIA LYMPHOMA, V54, P934, DOI 10.3109/10428194.2012.728595
   Uchiyama H, 2011, TRANSPLANTATION, V92, P1134, DOI 10.1097/TP.0b013e318231e9f8
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Usuda M, 2005, TRANSPLANTATION, V79, P12, DOI 10.1097/01.TP.0000149337.40911.E4
   Usui M, 2007, CLIN TRANSPLANT, V21, P24, DOI 10.1111/j.1399-0012.2006.00572.x
   Vo AA, 2008, NEW ENGL J MED, V359, P242, DOI 10.1056/NEJMoa0707894
   Wu JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016521
NR 29
TC 2
Z9 2
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2015
VL 19
IS 3
BP 279
EP 286
DI 10.1111/petr.12445
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CE4BW
UT WOS:000351776800014
PM 25689881
ER

PT J
AU Nafady-Hego, H
   Elgendy, H
   Uemoto, S
AF Nafady-Hego, Hanaa
   Elgendy, Hamed
   Uemoto, Shinji
TI Contrast Patterns of Cytomegalovirus and Epstein-Barr Virus Infection in
   Pediatric Living-Donor Liver Transplant Recipients
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 14th Congress of the Middle-East-Society-for-Organ-Transplantation / 5th
   Middle East Transplant Games
CY SEP 10-13, 2014
CL Istanbul, TURKEY
DE Hepatic grafts; Immunosuppression; Rejection; Risk factors
ID POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; STEM-CELL
   TRANSPLANTATION; RISK-FACTORS; RENAL-TRANSPLANTATION;
   ALLOGRAFT-REJECTION; CHILDREN; FK506; DISEASE; COMPLICATIONS; HISTORY
AB Objectives: Cytomegalovirus and Epstein-Barr virus remain leading causes of morbidity and mortality in the living-donor liver transplant population, particularly in pediatric patients. Herein we compare the incidence, timing, and risk factors for infection in this group.
   Materials and Methods: We performed a retrospective study of 344 consecutive pediatric patients 193 women (56.1%) who received living-donor liver transplants at Kyoto University Hospital. Patients were followed-up for maximum 7.1 +/- 3.6 years (range, 0.02-13.2 y) after surgery.
   Results: The mean age at the time of transplant was 3.95 +/- 4.75 years (median, 1.38 y; range, 0.07-17.87 y). A total of 156 patients (45.2%) developed viral infections. Of those patients, 91 (26.5%) developed cytomegalovirus infection, and 93 (27%) developed Epstein-Barr virus. Cytomegalovirus developed at 39.3 +/- 34.6 days, while Epstein-Barr virus developed 3.99 +/- 3.67 years after transplant. Frequent rejection attacks (hazard ratio [HR],1.58; 95% confidence interval [Cl]: 0.14-2.18; P = .006) were an independent predictor for postoperative cytomegalovirus infection, while preoperative cytomegalovirus seropositive results (HR, 1.76; 95% Cl: 1.03-2.18; P = .038), short cold ischemia time (HR, 1.0; 95% Cl: 0.99-1.0; P = .02), larger graft (HR, 1.3; 95% Cl: 1.00-1.73; P=.047), and new cases compared to old cases (HR, 2.27; 95% Cl: 1.14-4.52; P=.019) were independent predictors for postoperative Epstein-Barr virus infection.
   Conclusions: Extended surveillance of cytomegalovirus and Epstein-Barr virus DNAemia is recommended for pediatric patients receiving living-donor liver transplants, particularly infants who are at high risk, and especially those exposed to frequent attacks of rejection and those that receive larger grafts.
C1 [Nafady-Hego, Hanaa] Assiut Univ, Grad Sch Med, Dept Microbiol & Immunol, Assiut, Egypt.
   [Nafady-Hego, Hanaa] Umm Al Qura Univ, Grad Sch Med, Dept Hematol & Immunol, Mecca, Saudi Arabia.
   [Elgendy, Hamed] Assiut Univ, Grad Sch Med, Dept Anesthesia, Assiut, Egypt.
   [Elgendy, Hamed] King Abdullalt Med City, Dept Anesthesiol, Mecca, Saudi Arabia.
   [Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg & Transplantat, Kyoto 6068507, Japan.
RP Nafady-Hego, H (reprint author), Kyoto Univ, Grad Sch Med, Hepatobrliary Pancreat Surg & Transplantat, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.
EM hanaa@kuhp.kyoto-u.ac.jp
CR Amaranto DJ, 2001, J VASC SURG, V54
   Arthurs SK, 2007, LIVER TRANSPLANT, V13, P1703, DOI 10.1002/lt.21280
   Cacciarelli TV, 2001, PEDIATR TRANSPLANT, V5, P359, DOI 10.1034/j.1399-3046.2001.00021.x
   Cirak MY, 2005, MEM I OSWALDO CRUZ, V100, P263, DOI 10.1590/S0074-02762005000300008
   COX KL, 1995, TRANSPLANTATION, V59, P524
   Demetris AJ, 1997, HEPATOLOGY, V25, P658
   DEMETRIS AJ, 1990, AM J SURG PATHOL, V14, P49
   Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928
   Fishman JA, 2007, CLIN TRANSPLANT, V21, P149, DOI 10.1111/j.1399-0012.2006.00618.x
   Funch DP, 2005, AM J TRANSPLANT, V5, P2894, DOI 10.1111/j.1600-6143.2005.01115.x
   Green M, 2001, Transpl Infect Dis, V3, P97, DOI 10.1034/j.1399-3062.2001.003002097.x
   Guthery SL, 2003, TRANSPLANTATION, V75, P987, DOI 10.1097/01.TP.0000057244.03192.BD
   Hurwitz M, 2004, PEDIATR TRANSPLANT, V8, P267, DOI 10.1111/j.1399-3046.2004.00129.x
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Jang JY, 2008, TRANSPL P, V40, P2546, DOI 10.1016/j.transproceed.2008.07.014
   Kim DH, 2004, BONE MARROW TRANSPL, V34, P21, DOI 10.1038/sj.bmt.1704528
   Kim JE, 2010, J KOREAN MED SCI, V25, P527, DOI 10.3346/jkms.2010.25.4.527
   Koshiba T, 2007, TRANSPL IMMUNOL, V17, P94, DOI 10.1016/j.trim.2006.10.004
   Ljungman P, 2008, BONE MARROW TRANSPL, V42, pS70, DOI 10.1038/bmt.2008.120
   Matsukura T, 2002, CLIN TRANSPLANT, V16, P107, DOI 10.1034/j.1399-0012.2002.1o112.x
   Mutimer D, 1997, TRANSPLANTATION, V63, P1411, DOI 10.1097/00007890-199705270-00007
   Nafady-Hego H, 2011, LIVER TRANSPLANT, V17, P976, DOI 10.1002/lt.22278
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Paya C V, 1999, Transpl Infect Dis, V1 Suppl 1, P8
   Rajwal S, 2003, J PEDIATR GASTR NUTR, V37, P87, DOI 10.1097/00005176-200307000-00016
   Razonable RR, 2008, WORLD J GASTROENTERO, V14, P4849, DOI 10.3748/wjg.14.4849
   Saito T, 2007, TRANSPL INT, V20, P419, DOI 10.1111/j.1432-2277.2007.00459.x
   Schubert S, 2009, PEDIATR TRANSPLANT, V13, P54, DOI 10.1111/j.1399-3046.2008.00969.x
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   Singh N, 1997, TRANSPLANTATION, V64, P674, DOI 10.1097/00007890-199709150-00002
   SINGH N, 1988, J INFECT DIS, V158, P124
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   TANAKA K, 1994, AM J SURG, V168, P41, DOI 10.1016/S0002-9610(05)80069-8
   TOKUNAGA Y, 1993, TRANSPLANT INT, V6, P313, DOI 10.1111/j.1432-2277.1993.tb00673.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   UEMOTO S, 1994, J PEDIATR SURG, V29, P514, DOI 10.1016/0022-3468(94)90080-9
   VANDORP WT, 1992, TRANSPLANTATION, V54, P661, DOI 10.1097/00007890-199210000-00019
   WALKER RC, 1995, CLIN INFECT DIS, V20, P1346
   Weikert BC, 2008, CLIN J AM SOC NEPHRO, V3, pS76, DOI 10.2215/CJN.02900707
   Wu JF, 2009, TRANSPLANTATION, V87, P758, DOI 10.1097/TP.0b013e318198d645
NR 41
TC 1
Z9 1
U1 1
U2 1
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD APR
PY 2015
VL 13
SU 1
BP 75
EP 82
DI 10.6002/ect.mesot2014.O26
PG 8
WC Transplantation
SC Transplantation
GA CI8YU
UT WOS:000355058400016
PM 25894132
ER

PT J
AU Al-Otaibi, T
   Gheith, O
   Mosaad, A
   Nampoory, MRN
   Halim, M
   Said, T
   Nair, P
AF Al-Otaibi, Torki
   Gheith, Osama
   Mosaad, Ahmed
   Nampoory, M. R. Naryanan
   Halim, Medhat
   Said, Tarek
   Nair, Prasad
TI Human Leukocyte Antigen-DR Mismatched Pediatric Renal Transplant:
   Patient and Graft Outcome With Different Kidney Donor Sources
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 14th Congress of the Middle-East-Society-for-Organ-Transplantation / 5th
   Middle East Transplant Games
CY SEP 10-13, 2014
CL Istanbul, TURKEY
DE Children; End-stage renal disease; Renal transplant; Human leukocyte
   antigen-DR; Outcome
ID COLLABORATIVE TRANSPLANT; LIVER-TRANSPLANTATION; SURVIVAL;
   COMPATIBILITY; EXPERIENCE; RECIPIENTS; IMPACT; RACE; TERM; UK
AB Objectives: Kidney transplant is well accepted as the optimal therapy for children with end-stage renal disease, and new trends suggest using human leukocyte antigen-DR mismatched grafts. The aim of work was to assess the effect of human leukocyte antigen-DR mismatch on the outcome of pediatric renal transplant recipients, regardless of the source of kidney graft.
   Materials and Methods: According to human leukocyte antigen-DR matching, 104 pediatric patients were categorized into 3 comparable groups. With optimized immunosuppression protocols, long-term graft and patient outcomes were assessed.
   Results: We found that posttransplant complications were comparable in the 3 groups, without significant increase in the risk of infections or malignancies, especially in the full human leukocyte antigen-DR-mismatched group. Moreover, we found no significant difference in the 3 groups regarding long-term graft or patient survival.
   Conclusions: With optimization of immunosuppression, human leukocyte antigen-DR-mismatched donors can be safely accepted for pediatric kidney transplant with comparable long-term patient and graft survival.
C1 [Al-Otaibi, Torki; Gheith, Osama; Mosaad, Ahmed; Nampoory, M. R. Naryanan; Halim, Medhat; Said, Tarek; Nair, Prasad] Hamed Al Essa Organ Transplant Ctr, Dept Nephrol, Kuwait, Kuwait.
   [Gheith, Osama] Mansoura Univ, Urol & Nephrol Ctr, Mansoura, Egypt.
RP Gheith, O (reprint author), Mansoura Univ, Urol & Nephrol Ctr, Mansoura, Egypt.
EM ogheith@yahoo.com
CR Balan V, 2008, HEPATOLOGY, V48, P878, DOI 10.1002/hep.22435
   Berney TMalaiseJ, 2005, NEPHROL DIAL TRANSPL, V20, pii62
   Berney T, 2005, NEPHROL DIAL TRANSPL, V20, P48, DOI 10.1093/ndt/gfh1082
   BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203
   Chesney RW, 2003, PEDIATRICS, V112, P409, DOI 10.1542/peds.112.2.409
   El-Husseini AA, 2005, PEDIATR TRANSPLANT, V9, P763, DOI 10.1111/j.1399-3046.2005.00376.x
   Elshihabi I, 2000, Pediatr Transplant, V4, P235, DOI 10.1034/j.1399-3046.2000.00116.x
   Fine R N, 1985, Kidney Int Suppl, V17, pS15
   Ghoneim MA, 2009, NAT CLIN PRACT NEPHR, V5, P70, DOI 10.1038/ncpneph1017
   Gritsch HA, 2008, AM J TRANSPLANT, V8, P2056, DOI 10.1111/j.1600-6143.2008.02320.x
   Herzberg GZ, 1998, J HEART LUNG TRANSPL, V17, P1195
   Ipsiroglu OS, 2005, WIEN KLIN WOCHENSCHR, V117, P541, DOI 10.1007/s00508-005-0327-x
   Johnson RJ, 2010, TRANSPLANTATION, V89, P387, DOI 10.1097/TP.0b013e3181c9029d
   Karabicak I, 2011, TRANSPL P, V43, P1544, DOI 10.1016/j.transproceed.2011.01.169
   Kasahara M, 2002, TRANSPLANTATION, V74, P1175, DOI 10.1097/01.TP.0000030636.35519.EA
   KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505
   Kleinman A, 2006, PLOS MED, V3, P1673, DOI 10.1371/journal.pmed.0030294
   Magee JC, 2008, AM J TRANSPLANT, V8, P935, DOI 10.1111/j.1600-6143.2008.02172.x
   McDonald R, 2000, Pediatr Transplant, V4, P221, DOI 10.1034/j.1399-3046.2000.00117.x
   Opelz G, 2012, AM J TRANSPLANT, V12, P3031, DOI 10.1111/j.1600-6143.2012.04226.x
   OPELZ G, 1977, TRANSPLANT P, V9, P137
   Opelz G, 2007, TRANSPLANTATION, V84, P137, DOI 10.1097/01.tp.0000269725.74189.b9
   Opelz G, 2010, TRANSPLANTATION, V90, P292, DOI 10.1097/TP.0b013e3181e46a22
   Postlethwaite RJ, 2002, PEDIATR TRANSPLANT, V6, P367, DOI 10.1034/j.1399-3046.2002.02027.x
   Schulpen TWJ, 1996, EUR J PEDIATR, V155, P351, DOI 10.1007/s004310050416
   Schurman SJ, 1997, J PEDIATR-US, V130, P455, DOI 10.1016/S0022-3476(97)70210-5
   Su XM, 2004, AM J TRANSPLANT, V4, P1501, DOI 10.1111/j.1600-6143.2004.00535.x
   Takemoto S, 2004, HUM IMMUNOL, V65, P1489, DOI 10.1016/j.humimm.2004.06.008
   Vu LT, 2011, ARCH SURG-CHICAGO, V146, P824, DOI 10.1001/archsurg.2011.147
NR 29
TC 0
Z9 0
U1 0
U2 0
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD APR
PY 2015
VL 13
SU 1
BP 117
EP 123
DI 10.6002/ect.mesot2014.O65
PG 7
WC Transplantation
SC Transplantation
GA CI8YU
UT WOS:000355058400023
PM 25894139
ER

PT J
AU Jamalidoust, M
   Geramizadeh, B
   Pouladfar, G
   Namayandeh, M
   Asaie, S
   Aliabadi, N
   Nikeghbalian, S
   Ziyaeyan, M
AF Jamalidoust, Marzieh
   Geramizadeh, Bita
   Pouladfar, Gholamreza
   Namayandeh, Mandana
   Asaie, Sadaf
   Aliabadi, Nasrin
   Nikeghbalian, Saman
   Ziyaeyan, Mazyar
TI Epstein-Barr Virus DNAemia in Iranian Liver Transplant Recipients and
   Assessment of Its Variation in Posttransplant Lymphproliferative
   Disorder Patients by Quantitative Polymerase Chain Reaction Assay
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 14th Congress of the Middle-East-Society-for-Organ-Transplantation / 5th
   Middle East Transplant Games
CY SEP 10-13, 2014
CL Istanbul, TURKEY
DE DNA; Hepatic failure; Immunosuppression; Virology
ID STEM-CELL TRANSPLANTATION; REAL-TIME PCR; LYMPHOPROLIFERATIVE DISORDER;
   PERIPHERAL-BLOOD; VIRAL LOAD; DNA LOAD; DISEASE; INFECTION; INVOLVEMENT;
   GUIDELINES
AB Objectives: Epstein-Barr virus primary infection and/or reactivation may play a major role in the incidence of posttransplant lymphoproliferative disorder in organ recipients. We assessed Epstein-Barr virus viral load in liver transplant patients suspected of having Epstein-Barr virus/posttransplant lymphoproliferative disorder at specified times after transplant and evaluated the clinical findings and posttransplant complications.
   Materials and Methods: In the 696 patients who underwent liver transplant in this retrospective study, Epstein-Barr virus viral load was examined intermittently in 127 liver transplant recipients who were suspected to have Epstein-Barr virus infection/disease. Sampling was performed during 4 years from July 2009 to May 2013 using real-time polymerase chain reaction assay. Clinical and pathologic data were gathered by reviewing medical records.
   Results: There were 78 of the 127 suspected patients (61%) who exhibited Epstein-Barr virus DNAemia and 19 patients had posttransplant lymphoproliferative disorder. The median EBV viral load of posttransplant lymphoproliferative disorder patients was significantly higher than unaffected patients. Posttransplant lymphoproliferative disorder was diagnosed clinically in 34 subjects (4.9%). Estimated mortality rate of posttransplant lymphoproliferative disorder patients was 35% during 1.5-year follow-up after transplant.
   Conclusions: Monitoring Epstein-Barr virus load may enable detection of Epstein-Barr virus infection/disease in liver transplant patients suspected of having the virus, even several weeks before the onset of any clinical manifestations, especially in pediatric patients who have high incidence and mortality from posttransplant lymphoproliferative disorder.
C1 [Jamalidoust, Marzieh; Pouladfar, Gholamreza; Namayandeh, Mandana; Asaie, Sadaf; Aliabadi, Nasrin; Ziyaeyan, Mazyar] Shiraz Univ Med Sci, Alborzi Clin Microbiol Res Ctr, Nemazee Hosp, Shiraz, Iran.
   [Jamalidoust, Marzieh] Tarbiat Modares Univ, Fac Med Sci, Dept Virol, Tehran, Iran.
   [Geramizadeh, Bita] Shiraz Univ Med Sci, Dept Pathol, Nemazee Hosp, Shiraz Med Sch, Shiraz, Iran.
   [Nikeghbalian, Saman] Shiraz Univ Med Sci, Dept Surg, Nemazee Hosp, Transplant Ctr, Shiraz, Iran.
RP Ziyaeyan, M (reprint author), Shiraz Univ Med Sci, Alborzi Clin Microbiol Res Ctr, Nemazee Hosp, POB 71937-11351, Shiraz, Iran.
EM ziyaeyanm@sums.ac.ir
FU Professor Alborzi Clinical Microbiology Research Center Fund
FX The authors thank Dr. Nasrin Shokrpour at Center for Development of
   Clinical Research of Nemazee Hospital, Dr. Hassan Khajehei for editorial
   assistance, and Ms. Roosta for her help with statistical analysis. This
   study was supported by the Professor Alborzi Clinical Microbiology
   Research Center Fund. Author contributions: Marzieh Jamalidoust and
   Mazyar Ziyaeyan designed the study; Marzieh Jamalidoust and Gholamreza
   Pouladfar wrote the manuscript; Nasrin Aliabadi and Mandana Namayandeh
   did most of the real-time polymerase chain reaction assays; Sadaf Asaei
   and Mandana Namayandeh gathered and analyzed the patient information;
   Bita Geramizadeh detected and analyzed posttransplant lymphproliferative
   disorder lesions; and Saman Nikeghbalian performed most of the liver
   surgery.
CR Allen U, 2001, PEDIATR TRANSPLANT, V5, P198, DOI 10.1034/j.1399-3046.2001.00059.x
   Baldanti F, 2008, J CLIN MICROBIOL, V46, P3672, DOI 10.1128/JCM.00913-08
   Capello D, 2009, MEDIT J HEMAT INFECT, V1, DOI 10.4084/MJHID.2009.018
   Carpentier L, 2003, J INFECT DIS, V188, P1853, DOI 10.1086/379834
   Cavallo R, 2010, TRANSPL P, V42, P2527, DOI 10.1016/j.transproceed.2010.05.151
   Coppoletta S, 2011, BIOL BLOOD MARROW TR, V17, P901, DOI 10.1016/j.bbmt.2010.10.003
   Everly MJ, 2007, ANN PHARMACOTHER, V41, P1850, DOI 10.1345/aph.1G706
   Geramizadeh B, 2010, ARCH IRAN MED, V13, P417, DOI 010135/AIM.009
   Geramizadeh B, 2012, IRAN RED CRESCENT ME, V14, P724, DOI 10.5812/ircmj.1134
   Green M, 2013, AM J TRANSPLANT, V13, P41, DOI 10.1111/ajt.12004
   Green M, 1998, TRANSPLANTATION, V66, P1641, DOI 10.1097/00007890-199812270-00012
   Grywalska E, 2013, POSTEP HIG MED DOSW, V67, P481
   Gulley ML, 2010, CLIN MICROBIOL REV, V23, P350, DOI 10.1128/CMR.00006-09
   Hess RD, 2004, J CLIN MICROBIOL, V42, P3381, DOI 10.1128/JCM.42.8.3381-3387.2004
   Holman CJ, 2012, CLIN TRANSPLANT, V26, P741, DOI 10.1111/j.1399-0012.2012.01608.x
   Hussein K, 2013, PATHOBIOLOGY, V80, P289, DOI 10.1159/000350331
   Jain A, 2002, ANN SURG, V236, P429, DOI 10.1097/01.SLA.0000033429.89429.89424.F8
   Jang JY, 2008, TRANSPL P, V40, P2546, DOI 10.1016/j.transproceed.2008.07.014
   Kimura H, 2008, REV MED VIROL, V18, P305, DOI 10.1002/rmv.582
   Kullberg-Lindh C, 2006, PEDIATR TRANSPLANT, V10, P83, DOI 10.1111/j.1399-3046.2005.00404.x
   Larsen M, 2007, J NEUROSURG, V106, P924, DOI 10.3171/jns.2007.106.5.924
   Leblond V, 2001, J CLIN ONCOL, V19, P772
   Lee TC, 2005, AM J TRANSPLANT, V5, P2222, DOI 10.1111/j.1600-6143.2005.01002.x
   Leppke S, 2013, TRANSPLANT REV-ORLAN, V27, P50, DOI 10.1016/j.trre.2013.01.002
   Leung E, 2004, Transpl Infect Dis, V6, P156, DOI 10.1111/j.1399-3062.2004.00073.x
   Lieberman PM, 2014, SCIENCE, V343, P1323, DOI 10.1126/science.1252786
   Loginov R, 2006, J CLIN VIROL, V37, P104, DOI 10.1016/j.jcv.2006.06.012
   Mucha K, 2010, NEPHROL DIAL TRANSPL, V25, P2089, DOI 10.1093/ndt/gfq231
   Okano M, 2005, AM J HEMATOL, V80, P64, DOI 10.1002/ajh.20398
   Parker A, 2010, BRIT J HAEMATOL, V149, P675, DOI 10.1111/j.1365-2141.2010.08161.x
   Randhawa P, 1996, AM J KIDNEY DIS, V28, P578, DOI 10.1016/S0272-6386(96)90470-9
   Randhawa PS, 1996, AM J SURG PATHOL, V20, P563, DOI 10.1097/00000478-199605000-00003
   Rasche L, 2014, BONE MARROW TRANSPL, V49, P163, DOI 10.1038/bmt.2013.96
   Ryan JL, 2004, J MOL DIAGN, V6, P378, DOI 10.1016/S1525-1578(10)60535-1
   Sabattini E, 2010, Pathologica, V102, P83
   Schauer E, 2009, PEDIATR TRANSPLANT, V13, P311, DOI 10.1111/j.1399-3046.2008.00918.x
   Tsai DE, 2002, AM J TRANSPLANT, V2, P946, DOI 10.1034/j.1600-6143.2002.21011.x
   Wistinghausen B, 2013, PEDIATR HEMAT ONCOL, V30, P520, DOI 10.3109/08880018.2013.798844
   Xuan L, 2013, TRANSPLANTATION, V96, P560, DOI 10.1097/TP.0b013e31829d38af
NR 39
TC 0
Z9 0
U1 0
U2 1
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD APR
PY 2015
VL 13
SU 1
BP 306
EP 311
DI 10.6002/ect.mesot2014.P148
PG 6
WC Transplantation
SC Transplantation
GA CI8YU
UT WOS:000355058400063
PM 25894179
ER

PT J
AU Teplisky, D
   Tincani, EU
   Halac, E
   Garriga, M
   Cervio, G
   Imventarza, O
   Sierre, S
AF Teplisky, Dario
   Uruena Tincani, Eliana
   Halac, Esteban
   Garriga, Matias
   Cervio, Guillermo
   Imventarza, Oscar
   Sierre, Sergio
TI Ultrasonography, laboratory, and cholangiography correlation of biliary
   complications in pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; children; interventional radiology;
   ultrasonography; bile ducts; cholangiography
ID DIAGNOSIS; CHILDREN; GRAFT
AB The aim of this study is to correlate the US, laboratory, and cholangiography findings in pediatric liver transplant patients with biliary complications, trying to identify reliable decision-making tools for the management of these complications. Retrospective review was carried out of US results in 39 consecutive patients, from 2011 to 2013, with biliary complications after LT, documented by PTC. According to US biliary dilation, patients were classified as: mild, moderate, and severe, and according to laboratory findings as: normal or abnormal serum bilirubin and level of serum GGT. Data were correlated with PTC findings, divided in three groups: mild, moderate, and severe/occlusive BDS. There was no statistically significant correlation between the US findings and the laboratory findings and between US findings with PTC. There was a statistically significant correlation between GGT and cholangiography. In our series, abnormal US could not predict the severity of BDS on PTC. Bilirubin results were not able to predict the US findings either. GGT results demonstrated a statistically significant correlation with the severity of BDS found on PTC. These findings emphasize the role of GGT in the evaluation and decision of biliary interventions in pediatric liver transplant recipients.
C1 [Teplisky, Dario; Uruena Tincani, Eliana; Garriga, Matias; Sierre, Sergio] Hosp Nacl Pediat Prof JP Garrahan, Dept Intervent Radiol, RA-1245 Buenos Aires, DF, Argentina.
   [Halac, Esteban; Cervio, Guillermo; Imventarza, Oscar] Hosp Nacl Pediat Prof JP Garrahan, Dept Liver Transplantat, RA-1245 Buenos Aires, DF, Argentina.
RP Sierre, S (reprint author), Hosp Nacl Pediat Prof JP Garrahan, Dept Intervent Radiol, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
EM sergio.sierre@usa.net
CR Azouz SM, 2011, CURR OPIN ORGAN TRAN, V16, P494, DOI 10.1097/MOT.0b013e32834a8c9c
   Ben-Ari Z, 2004, CLIN TRANSPLANT, V18, P130, DOI 10.1046/j.1399-0012.2003.00135.x
   Berrocal T, 2006, RADIOGRAPHICS, V26, P1187, DOI 10.1148/rg.264055081
   BISMUTH H, 1984, SURGERY, V95, P367
   Boraschi P, 2004, TRANSPLANT P, V36, P2744, DOI 10.1016/j.transproceed.2004.09.038
   de Goyet JD, 2009, CURR OPIN ORGAN TRAN, V14, P507, DOI 10.1097/MOT.0b013e32833067f3
   Emre S, 2011, TRANSPL P, V43, P884, DOI 10.1016/j.transproceed.2011.02.036
   Fukuda A, 2014, TRANSPL P, V46, P1371, DOI 10.1016/j.transproceed.2013.12.054
   Kamath BM, 2010, PEDIATR CLIN N AM, V57, P401, DOI 10.1016/j.pcl.2010.01.012
   Kok T, 1996, J CLIN ULTRASOUND, V24, P103, DOI 10.1002/(SICI)1097-0096(199603)24:3<103::AID-JCU1>3.0.CO;2-L
   Moreira AM, 2010, CARDIOVASC INTER RAD, V33, P90, DOI 10.1007/s00270-009-9619-2
   Petrowsky H, 2009, SEMIN LIVER DIS, V29, P121, DOI 10.1055/s-0029-1192060
   Racadio John M, 2010, Tech Vasc Interv Radiol, V13, P244, DOI 10.1053/j.tvir.2010.04.007
   Shastri YM, 2007, WORLD J GASTROENTERO, V13, P2819
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   Vitellas Kenneth M, 2002, Emerg Radiol, V9, P106
   Yazigi Nada A., 2013, Pediatric Gastroenterology, Hepatology & Nutrition, V16, P207, DOI 10.5223/pghn.2013.16.4.207
   ZEMEL G, 1988, AM J ROENTGENOL, V151, P943
   Zoepf T, 2005, WORLD J GASTROENTERO, V11, P2945
NR 20
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2015
VL 19
IS 2
BP 170
EP 174
DI 10.1111/petr.12421
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA CA1EU
UT WOS:000348656500012
PM 25529070
ER

PT J
AU Yamada, N
   Sanada, Y
   Hirata, Y
   Okada, N
   Wakiya, T
   Ihara, Y
   Miki, A
   Kaneda, Y
   Sasanuma, H
   Urahashi, T
   Sakuma, Y
   Yasuda, Y
   Mizuta, K
AF Yamada, Naoya
   Sanada, Yukihiro
   Hirata, Yuta
   Okada, Noriki
   Wakiya, Taiichi
   Ihara, Yoshiyuki
   Miki, Atsushi
   Kaneda, Yuji
   Sasanuma, Hideki
   Urahashi, Taizen
   Sakuma, Yasunaru
   Yasuda, Yoshikazu
   Mizuta, Koichi
TI Selection of Living Donor Liver Grafts for Patients Weighing 6kg or Less
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LEFT-LATERAL SEGMENT; SINGLE-CENTER EXPERIENCE; SMALL INFANTS;
   TRANSPLANTATION; MONOSEGMENTS; REDUCTION; CHILDREN
AB In the field of pediatric living donor liver transplantation (LDLT), physicians sometimes must reduce the volume of left lateral segment (LLS) grafts to prevent large-for-size syndrome. There are 2 established methods for decreasing the size of an LLS graft: the use of a segment 2 (S2) monosegment graft and the use of a reduced LLS graft. However, no procedure for selecting the proper graft type has been established. In this study, we conducted a retrospective investigation of LDLT and examined the strategy of graft selection for patients weighing 6 kg. LDLT was conducted 225 times between May 2001 and December 2012, and 15 of the procedures were performed in patients weighing 6 kg. We selected S2 monosegment grafts and reduced LLS grafts if the preoperative computed tomography (CT)-volumetry value of the LLS graft was >5% and 4% to 5% of the graft/recipient weight ratio, respectively. We used LLS grafts in 7 recipients, S2 monosegment grafts in 4 recipients, reduced S2 monosegment grafts in 3 recipients, and a reduced LLS graft in 1 recipient. The reduction rate of S2 monosegment grafts for use as LLS grafts was 48.3%. The overall recipient and graft survival rates were both 93.3%, and 1 patient died of a brain hemorrhage. Major surgical complications included hepatic artery thrombosis in 2 recipients, bilioenteric anastomotic strictures in 2 recipients, and portal vein thrombosis in 1 recipient. In conclusion, our graft selection strategy based on preoperative CT-volumetry is highly useful in patients weighing 6 kg. S2 monosegment grafts are effective and safe in very small infants particularly neonates. Liver Transpl 21:233-238, 2015. (c) 2014 AASLD.
C1 [Yamada, Naoya; Sanada, Yukihiro; Hirata, Yuta; Okada, Noriki; Wakiya, Taiichi; Ihara, Yoshiyuki; Urahashi, Taizen; Mizuta, Koichi] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Miki, Atsushi; Kaneda, Yuji; Sasanuma, Hideki; Sakuma, Yasunaru; Yasuda, Yoshikazu] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Yamada, N (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM yn708@jichi.ac.jp
CR BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   desSantibanes E, 2000, LIVER TRANSPLANT, V6, P108
   FERREIRA CT, 2000, J PEDIAT RIO J, V76, pS198
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Kanazawa H, 2013, TRANSPLANTATION, V95, P750, DOI 10.1097/TP.0b013e31827a93b4
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kasahara M, 2008, J PEDIATR SURG, V43, P1575, DOI 10.1016/j.jpedsurg.2008.02.056
   Kasahara M, 2013, LIVER TRANSPLANT, V19, P226, DOI 10.1002/lt.23572
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Magee JC, 2004, AM J TRANSPLANT, V4, P54, DOI 10.1111/j.1600-6143.2004.00398.x
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Mentha G, 1996, TRANSPLANTATION, V62, P1176, DOI 10.1097/00007890-199610270-00026
   Mizuta K, 2010, AM J TRANSPLANT, V10, P2547, DOI 10.1111/j.1600-6143.2010.03274.x
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Shehata MR, 2012, AM J TRANSPLANT, V12, P3406, DOI 10.1111/j.1600-6143.2012.04268.x
   Shirouzu Y, 2010, PEDIATR TRANSPLANT, V14, P709, DOI 10.1111/j.1399-3046.2010.01332.x
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   STARZL TE, 1979, PEDIATRICS, V63, P825
   STRONG R, 1995, SURGERY, V118, P904, DOI 10.1016/S0039-6060(05)80283-1
   Urahashi T, 2012, PEDIATR TRANSPLANT, V16, P783, DOI 10.1111/j.1399-3046.2012.01764.x
NR 24
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2015
VL 21
IS 2
BP 233
EP 238
DI 10.1002/lt.24048
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA CA0AC
UT WOS:000348575400012
PM 25422258
ER

PT J
AU McNeil, JC
   Munoz, FM
   Hulten, KG
   Mason, EO
   Kaplan, SL
AF McNeil, J. C.
   Munoz, F. M.
   Hulten, K. G.
   Mason, E. O.
   Kaplan, S. L.
TI Staphylococcus aureus infections among children receiving a solid organ
   transplant: clinical features, epidemiology, and antimicrobial
   susceptibility
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Staphylococcus aureus; pediatric; transplant
ID BLOOD-STREAM INFECTIONS; RISK-FACTORS; LIVER-TRANSPLANTATION; 3-YEAR
   SURVEILLANCE; PEDIATRIC-PATIENTS; BACTEREMIA; CHLORHEXIDINE; RECIPIENTS;
   COMPLICATIONS; RESISTANCE
AB BackgroundStaphylococcus aureus is among the most common causes of healthcare-associated infection (HAI) in the United States. Patients who have received a solid organ transplant (SOT) represent a unique population for the acquisition of HAIs, given their preoperative organ failure, immunosuppression, and need for invasive procedures. However, limited literature is published on S.aureus infections among children with SOT. We describe the epidemiology, antimicrobial susceptibility, and clinical features of S.aureus infections among pediatric SOT recipients.
   DesignAn ongoing prospective S.aureus surveillance database from 2001 to 2012 was searched for infections in patients with a history of SOT at Texas Children's Hospital. Medical records and antibiotic susceptibility profiles were reviewed; specific attention was applied to the time since transplantation to infection.
   ResultsOut of the total of 696 transplants performed during the study period, 38 pediatric SOT recipients developed 41 S.aureus infections; the highest incidence of infection was among heart recipients. Overall, the most common infectious diagnoses were skin-and-soft-tissue infections (66.1%), followed by bacteremia (15.3%). Among isolates in SOT patients, 47.5%, 16.9%, and 6.7% were resistant to methicillin, clindamycin, or mupirocin, respectively. Three infections (7.3%) occurred in the early post-transplant period (<1month), all of which were bacteremia (P=0.007) and all caused by methicillin-susceptible S.aureus (MSSA). The majority of infections (90.2%) occurred in the late post-transplant period (>6months). In 10 cases (16.9%), S.aureus infection was associated with graft rejection during the same admission.
   ConclusionsS.aureus represents an important cause of morbidity in pediatric SOT recipients. While the majority of infections occurred late after transplant (>6months), those acquired in the early post-transplant period were more often invasive and caused by MSSA in our hospital. Physicians caring for SOT recipients should be aware of the risks posed by this pathogen and the potential concomitant morbidity including graft rejection.
C1 [McNeil, J. C.; Munoz, F. M.; Hulten, K. G.; Mason, E. O.; Kaplan, S. L.] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA.
   [Munoz, F. M.; Mason, E. O.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
RP McNeil, JC (reprint author), 1102 Bates St,Suite 1150, Houston, TX 77030 USA.
EM jm140109@bcm.tmc.edu
FU NIAID [K23AI099159-01A1]
FX This study was supported by NIAID K23AI099159-01A1 (to J.C.M.).
CR Bleasdale SC, 2007, ARCH INTERN MED, V167, P2073, DOI 10.1001/archinte.167.19.2073
   Bouchut JC, 2001, PAEDIATR ANAESTH, V11, P93, DOI 10.1046/j.1460-9592.2001.00574.x
   Carrillo-Marquez MA, 2010, PEDIATR INFECT DIS J, V29, P410, DOI 10.1097/INF.0b013e3181c767b6
   [Anonymous], 2013, CYST FIBR FDN PAT RE
   DeRiso A, 1996, CHEST, V109, P1556, DOI 10.1378/chest.109.6.1556
   Desai D, 2003, LIVER TRANSPLANT, V9, P754, DOI 10.1053/jlts.2003.50142
   Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928
   GEORGE DL, 1991, REV INFECT DIS, V13, P387
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Hsu RB, 2005, AM J TRANSPLANT, V5, P2011, DOI 10.1111/j.1600-6143.2005.00951.x
   Hulten KG, 2006, PEDIATR INFECT DIS J, V25, P349, DOI 10.1097/01.inf.0000207404.50143.1e
   Hulten KG, 2010, INFECT CONT HOSP EP, V31, P183, DOI 10.1086/649793
   Johnson JG, 2013, INFECT CONT HOSP EP, V34, P1326, DOI 10.1086/673983
   Kaplan SL, 2005, CLIN INFECT DIS, V40, P1785, DOI 10.1086/430312
   Laupland KB, 2008, J INFECT DIS, V198, P336, DOI 10.1086/589717
   Linares L, 2011, TRANSPL P, V43, P2145, DOI 10.1016/j.transproceed.2011.05.007
   McNeil J Chase, 2013, J Pediatric Infect Dis Soc, V2, P337, DOI 10.1093/jpids/pit037
   McNeil JC, 2013, PEDIATR INFECT DIS J, V32, P124, DOI 10.1097/INF.0b013e318271c4e0
   McNeil JC, 2014, ANTIMICROB AGENTS CH, V58, P2878, DOI 10.1128/AAC.02707-13
   McNeil JC, 2012, PEDIATR INFECT DIS J, V31, P284, DOI 10.1097/INF.0b013e318239c1fe
   Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376
   Mihu CN, 2008, BIOL BLOOD MARROW TR, V14, P1429, DOI 10.1016/j.bbmt.2008.09.005
   Milstone AM, 2013, LANCET, V381, P1099, DOI 10.1016/S0140-6736(12)61687-0
   Nafady-Hego H, 2011, LIVER TRANSPLANT, V17, P976, DOI 10.1002/lt.22278
   Ramarathnam V, 2013, AM J INFECT CONTROL, V41, P625, DOI 10.1016/j.ajic.2012.08.005
   Shields RK, 2012, J HEART LUNG TRANSPL, V31, P1199, DOI 10.1016/j.healun.2012.08.012
   Singh N, 2000, CLIN INFECT DIS, V30, P322, DOI 10.1086/313658
   Singh N, 2006, INFECT CONT HOSP EP, V27, P122, DOI 10.1086/500651
   Srinivasan A, 2010, PEDIATR INFECT DIS J, V29, P172, DOI 10.1097/INF.0b013e3181b9a363
   Srinivasan A, 2009, AIDS RES HUM RETROV, V25, P1219, DOI 10.1089/aid.2009.0040
   Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019
   Torre-Cisneros J, 2002, EUR J CLIN MICROBIOL, V21, P385, DOI 10.1007/s10096-002-0725-1
   Wisplinghoff H, 2003, PEDIATR INFECT DIS J, V22, P686
   [Anonymous], 2011, SCI REGISTRY TRANSPL
NR 34
TC 0
Z9 0
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD FEB
PY 2015
VL 17
IS 1
BP 39
EP 47
DI 10.1111/tid.12331
PG 9
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA AZ9KL
UT WOS:000348532400007
PM 25573269
ER

PT J
AU Bahador, Z
   Dehghani, SM
   Bahador, A
   Nikeghbalian, S
   Hafezi, N
   Bahador, M
   Malek-Hosseini, SA
AF Bahador, Z.
   Dehghani, S. M.
   Bahador, A.
   Nikeghbalian, S.
   Hafezi, N.
   Bahador, M.
   Malek-Hosseini, S. A.
TI Parents' Education Level and Mortality and Morbidity of Children after
   Liver Transplantation
SO INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE
LA English
DT Article
DE Pediatrics; Liver transplantation; Postoperative complications;
   Educational status; Parents; Medication adherence
ID RECIPIENTS; NONCOMPLIANCE; PREDICTORS; HEART; SURVIVAL; COHORT
AB Background: So far numerous post-transplant outcome predictors have been studied to decrease the loss of resources and grafts after organ transplantation. The role of education, as a predictor, in liver transplantation outcome has so far been studied in several articles. However, in most of the studies it was evaluated as a surrogate for socioeconomic status or other variants. The absolute impact of parents' education has rarely been studied. Adult patients are their own caregivers whereas pediatric liver transplantation recipients are mostly cared by their parents.
   Objective: To evaluate the effect of level of patients' education on the mortality and morbidity of pediatric liver transplant recipients.
   Methods: We studied a group of 91 children who had undergone liver transplantation in our center from March 21, 2012 to July 21, 2013. In this retrospective study, patients' medical charts and questionnaire were used to collect the necessary data. Post-transplantation mortality and complications were divided into two categories: Early (<6 months after liver transplantation), and late (>= 6 months after the transplantation). Parents' educational level was also categorized into 5 groups.
   Results: Multivariate analysis of all groups showed that paternal education is an independent predictor of the late post-transplantation complications (p=0.024). Educational level of children's mothers had no significant correlation with the late post-transplantation complications (p=0.4.5). Neither maternal (p=0.59) nor paternal (p=0.607) education had significant effect on the late post-transplantation mortality.
   Conclusion: Paternal educational level of liver transplanted children is associated with the late post-transplantation complications.
C1 [Bahador, Z.; Hafezi, N.] Shiraz Univ Med Sci, Sch Med, Shiraz, Iran.
   [Dehghani, S. M.] Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Gastroenterohepatol Res Ctr, Shiraz, Iran.
   [Bahador, A.; Nikeghbalian, S.; Bahador, M.; Malek-Hosseini, S. A.] Shiraz Univ Med Sci, Nemazee Hosp, Shiraz Organ Transplant Ctr, Shiraz, Iran.
RP Bahador, Z (reprint author), Shiraz Univ Med Sci, Sch Med, Shiraz, Iran.
EM zbahador@yahoo.com
CR Bonaguidi F, 2010, LIVER TRANSPLANT, V16, P1158, DOI 10.1002/lt.22122
   BUNZEL B, 1994, THORAC CARDIOV SURG, V42, P103, DOI 10.1055/s-2007-1016466
   Bunzel B, 2000, TRANSPLANTATION, V70, P711, DOI 10.1097/00007890-200009150-00001
   Butkus DE, 2001, TRANSPLANTATION, V72, P261, DOI 10.1097/00007890-200107270-00017
   DEGEEST S, 1995, TRANSPLANTATION, V59, P340
   Dobbels F, 2005, TRANSPLANTATION, V79, P1588, DOI 10.1097/01.TP.0000158430.06507.87
   Dobbels F, 2009, TRANSPLANTATION, V87, P1497, DOI 10.1097/TP.0b013e3181a440ae
   Nair S, 2002, LANCET, V359, P287, DOI 10.1016/S0140-6736(02)07494-9
   Parra AV, 2008, INT J CARDIOL, V125, P142, DOI 10.1016/j.ijcard.2007.01.038
   Rabkin JM, 2001, AM J SURG, V181, P475, DOI 10.1016/S0002-9610(01)00595-5
   SCHWEIZER RT, 1990, TRANSPLANTATION, V49, P374, DOI 10.1097/00007890-199002000-00029
   Yoo HY, 2004, LIVER TRANSPLANT, V10, P235, DOI 10.1002/lt.20069
NR 12
TC 0
Z9 0
U1 0
U2 1
PU AVICENNA ORGAN TRANSPLANT CENTER
PI FARS
PA PHASE 2, DOKOHAK RD, SADRA TOWN, SHIRAZ, FARS, 71994-67985, IRAN
SN 2008-6490
EI 2008-6482
J9 INT J TRANSPLANT MED
JI Int. J. Organ Transplant. Med.
PY 2015
VL 6
IS 1
BP 25
EP 30
PG 6
WC Transplantation
SC Transplantation
GA CS9ST
UT WOS:000362432700004
PM 25737774
ER

PT J
AU Zant, R
   Melter, M
   Knoppke, B
   Ameres, M
   Kunkel, J
AF Zant, R.
   Melter, M.
   Knoppke, B.
   Ameres, M.
   Kunkel, J.
TI Kinetics of Interleukin-6, Procalcitonin, and C-Reactive Protein After
   Pediatric Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID INTENSIVE-CARE-UNIT; SEPTIC SHOCK; INFECTIOUS COMPLICATIONS; SURGERY;
   SEPSIS
AB In the early phase after pediatric liver transplantation (pLT) several concomitant factors may reduce the performance of established sepsis markers. To date, their clinical interpretation is hindered by a lack of information on their postoperative kinetics. To gather more information on the postoperative course and their changes in bacterial sepsis, we prospectively studied C-reactive protein (CRP), interleukin-6 (IL-6), and procalcitonin (PCT) on 9 perioperative days in 25 consecutive pLTs. After an initial postoperative peak, IL-6 and CRP levels significantly re-increased in patients with bacterial sepsis (P < .001). In contrast, PCT had very high postoperative levels; therefore severe infection was a comparatively inferior trigger for PCT elevation compared with the initial operation. The area under the receiver operating characteristic curve to diagnose postoperative sepsis for PCT was only 0.52, compared with 0.95 for IL-6 and 0.89 for CRP. None of the studied biomarkers were depressed by poor graft function. In conclusion, PCT performs poorly as a biomarker for sepsis in the early phase after pLT. With a rapid decline of initially elevated levels, IL-6 provides the best kinetics for detection of postoperative bacterial sepsis.
C1 [Zant, R.; Melter, M.; Knoppke, B.; Ameres, M.; Kunkel, J.] KUNO Childrens Univ Hosp, Regensburg, Germany.
RP Zant, R (reprint author), Childrens Univ Hosp Regensburg, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM robert.zant@ukr.de
CR Bouchut JC, 2001, PAEDIATR ANAESTH, V11, P93, DOI 10.1046/j.1460-9592.2001.00574.x
   Celebi S, 2006, INTENS CARE MED, V32, P881, DOI 10.1007/s00134-006-0180-z
   Colic-Hadzic Belkisa, 2009, Med Arh, V63, P9
   De Leon ALPP, 2005, PEDIATR INT, V47, P80, DOI 10.1111/j.1442-200x.2004.01997.x
   Fioretto JR, 2008, CYTOKINE, V43, P160, DOI 10.1016/j.cyto.2008.05.005
   Garcia S, 1998, CLIN TRANSPLANT, V12, P190
   GEORGE DL, 1992, AM J DIS CHILD, V146, P924
   Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2, DOI 10.1097/01.PCC.0000149131.72248.E6
   Khan D, 1989, CLIN TRANSPLANT, V3, P150
   Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1016/j.ccc.2009.08.004
   Kunz D, 2000, CRIT CARE MED, V28, P555
   Mackenzie I, 2006, INTENS CARE MED, V32, P1344, DOI 10.1007/s00134-006-0251-1
   Meisner M, 2005, CURR OPIN CRIT CARE, V11, P473, DOI 10.1097/01.ccx.0000176694.92883.ce
   Meisner M, 1998, INTENS CARE MED, V24, P680, DOI 10.1007/s001340050644
   Oppert M, 2005, CRIT CARE MED, V33, P2457, DOI 10.1097/01.CCM.0000186370.78639.23
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   van den Broek MAJ, 2010, LIVER TRANSPLANT, V16, P402, DOI 10.1002/lt.21987
NR 17
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2014
VL 46
IS 10
BP 3507
EP 3510
DI 10.1016/j.transproceed.2014.08.048
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AX2FM
UT WOS:000346759000052
PM 25498081
ER

PT J
AU Cortes, M
   Tapuria, N
   Khorsandi, SE
   Ibars, EP
   Vilca-Melendez, H
   Rela, M
   Heaton, ND
AF Cortes, Miriam
   Tapuria, Niteen
   Khorsandi, Shirin Elizabeth
   Ibars, Eugenia Pareja
   Vilca-Melendez, Hector
   Rela, Mohamed
   Heaton, Nigel D.
TI Diaphragmatic Hernia After Liver Transplantation in Children: Case
   Series and Review of the Literature
SO LIVER TRANSPLANTATION
LA English
DT Article
ID PLICATION; INJURIES; INFANTS; COMPLICATION; EXPERIENCE; PARALYSIS;
   THERAPY; LESS; AGE
AB A diaphragmatic hernia (DH) is a rare complication of pediatric liver transplantation (LT), with multiple factors implicated in the pathophysiology. It is a potentially life-threatening condition in the absence of early recognition and surgical treatment. A DH after LT has been reported in 16 patients in 7 case series. We report 10 cases from our institution and review the published literature to understand the underlying pathophysiology. The study sample included all children (<18 years of age) who underwent LT from October 1989 to August 2013 at our center and subsequently presented with a DH. Among 4433 LT procedures performed in this time period, 1032 were for children. Ten DH cases were recognized, and risk factors were assessed. The mean age at diagnosis was 4.9 years, all patients with a DH received left lateral segment split grafts, and the mean graft weight was 248 +/- 41 g with a mean graft-to-recipient body weight ratio (GBWR) of 3%+/- 1.22% (range=1.7%-5.0%). The mean cold ischemia time was 510.7 +/- 307.6 minutes (range=60-900 minutes). Six patients had a primary abdominal muscle closure, 3 had a temporary Silastic mesh closure, and 1 had a skin closure only. Postoperative ascites and pleural effusion did not appear to be significant risk factors. All 10 children presented with a right posterolateral DH, with 1 also having a left DH. The small bowel was herniated in the majority. All patients underwent prompt surgical intervention without complications. An early age, a split graft, and a high GBWR may be risk factors for a DH. A high index of suspicion and prompt surgical intervention minimize complications. Liver Transpl 20:1429-1435, 2014. (c) 2014 AASLD.
C1 [Cortes, Miriam; Tapuria, Niteen; Khorsandi, Shirin Elizabeth; Vilca-Melendez, Hector; Rela, Mohamed; Heaton, Nigel D.] Inst Liver Studies, Kings Coll Hosp, Natl Hlth Serv Fdn Trust, Liver Transplantat, London, United Kingdom.
   [Ibars, Eugenia Pareja] Fe Univ Hosp, Hepatobiliopancreat Surg & Liver Transplantat, Valencia, Spain.
   [Cortes, Miriam; Tapuria, Niteen; Khorsandi, Shirin Elizabeth; Vilca-Melendez, Hector; Rela, Mohamed; Heaton, Nigel D.] Natl Hlth Serv Fdn Trust, Kings Coll Hosp, Inst Liver Studies, London, England.
   [Ibars, Eugenia Pareja] La Fe Univ Hosp, Valencia, Spain.
RP Heaton, ND (reprint author), Kings Coll Hosp London, Kings Hlth Partners, Inst Liver Studies, Denmark Hill, London SE5 9RS, England.
EM nigel.heaton@nhs.net
CR Barshes NR, 2004, PEDIATR TRANSPLANT, V8, P196, DOI 10.1111/j.1399-3046.2004.00168.x
   BEATH SV, 1993, BRIT MED J, V307, P825
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Dehghani SM, 2008, PEDIATR TRANSPLANT, V12, P146, DOI 10.1111/j.1399-3046.2007.00829.x
   Earl TM, 2011, J AM COLL SURGEONS, V212, P62, DOI 10.1016/j.jamcollsurg.2010.09.017
   Englert C, 2006, TRANSPLANTATION, V82, P574, DOI 10.1097/01.tp.0000231709.63721.5c
   GLASSMAN LR, 1994, ANN THORAC SURG, V58, P1754
   IWATSUKI S, 1988, TRANSPLANT P, V20, P498
   Kahn J, 2007, CLIN TRANSPLANT, V21, P423, DOI 10.1111/j.1399-0012.2007.00666.x
   Kazimi M, 2010, Pediatr Transplant, V14, pe62, DOI 10.1111/j.1399-3046.2009.01168.x
   Khanna A, 1997, TRANSPLANT INT, V10, P133, DOI 10.1111/j.1432-2277.1997.tb00555.x
   Koplewitz BZ, 2000, PEDIATR RADIOL, V30, P471, DOI 10.1007/s002470000242
   Lam HD, 2013, PEDIATR TRANSPLANT, V17, pE77, DOI 10.1111/petr.12052
   McCabe AJ, 2005, J PEDIATR SURG, V40, P1181, DOI 10.1016/j.jpedsurg.2005.03.063
   Moon SB, 2012, PEDIATR TRANSPLANT, V16, pE106, DOI 10.1111/j.1399-3046.2010.01462.x
   NAKAZATO PZ, 1993, J PEDIATR SURG, V28, P923, DOI 10.1016/0022-3468(93)90698-K
   Okajima H, 2007, PEDIATR TRANSPLANT, V11, P324, DOI 10.1111/j.1399-3046.2006.00658.x
   Organ Donation and Transplantation, ANN ACT REP
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Reber PU, 1998, J TRAUMA, V44, P183, DOI 10.1097/00005373-199801000-00026
   Rubikas R, 2001, EUR J CARDIO-THORAC, V20, P53, DOI 10.1016/S1010-7940(01)00753-9
   Sandler AD, 1997, J PEDIATR SURG, V32, P416, DOI 10.1016/S0022-3468(97)90594-7
   Schaubel D E, 2008, Am J Transplant, V8, P419, DOI 10.1111/j.1600-6143.2007.02086.x
   Shneider BL, 2004, PEDIATR TRANSPLANT, V8, P609, DOI 10.1111/j.1399-3046.2004.00240.x
   Smyrniotis V, 2001, LIVER TRANSPLANT, V7, P1002, DOI 10.1053/jlts.2001.28745
   Smyrniotis V, 1998, TRANSPLANT INT, V11, P281, DOI 10.1111/j.1432-2277.1998.tb00971.x
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   STARZL TE, 1982, HEPATOLOGY, V2, P614
   Starzl TE, 1969, EXPERIENCE HEPATIC T
   Tsunezuka Y, 2001, EUR J CARDIO-THORAC, V20, P205, DOI 10.1016/S1010-7940(01)00751-5
   Vernadakis S, 2012, TRANSPL P, V44, P2770, DOI 10.1016/j.transproceed.2012.09.014
   Whitington Peter F., 2002, JPGN Journal of Pediatric Gastroenterology and Nutrition, V35, pS44, DOI 10.1097/00005176-200207001-00011
   WRIGHT CD, 1985, J THORAC CARDIOV SUR, V90, P195
NR 33
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD DEC
PY 2014
VL 20
IS 12
BP 1429
EP 1435
DI 10.1002/lt.23977
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AU5AN
UT WOS:000345619600001
PM 25124299
ER

PT J
AU Luthold, SC
   Kaseje, N
   Jannot, AS
   Mentha, G
   Majno, P
   Toso, C
   Belli, DC
   McLin, VA
   Wildhaber, BE
AF Luethold, Samuel C.
   Kaseje, Neema
   Jannot, Anne-Sophie
   Mentha, Gilles
   Majno, Pietro
   Toso, Christian
   Belli, Dominique C.
   McLin, Valerie A.
   Wildhaber, Barbara E.
TI Risk factors for early and late biliary complications in pediatric liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; biliary complications; risk factors
ID DUCT-TO-DUCT; HEPATITIS-C; DONOR; MANAGEMENT; AGE; RECONSTRUCTION;
   FIBROSIS; OUTCOMES; OLDER
AB BC are a common source of morbidity after pediatric LT. Knowledge about risk factors may help to reduce their incidence. Retrospective analysis of BC in 116 pediatric patients (123 LT) (single institution, 05/1990-12/2011, medium follow-up 7.9yr). One-, five-, and 10-yr survival was 91.1%, no patient died of BC. Prevalence and risk factors for anastomotic and intrahepatic BC were examined. There were 29 BC in 123 LT (23.6%), with three main categories: 10 (8.1%) primary anastomotic strictures, eight (6.5%) anastomotic leaks, and three (2.4%) intrahepatic strictures. Significant risk factors for anastomotic leaks were total operation time (increase 1.26-fold) and early HAT (<30days post-LT; increase 5.87-fold). Risk factor for primary anastomotic stricture was duct-to-duct choledochal anastomosis (increase 5.96-fold when compared to biliary-enteric anastomosis). Risk factors for intrahepatic strictures were donor age >48yr (increase 1.09-fold) and MELD score >30 (increase 1.2-fold). To avoid morbidity from anastomotic BC in pediatric LT, the preferred biliary anastomosis appears to be biliary-enteric. Operation time should be kept to a minimum, and HAT must by all means be prevented. Children with a high MELD score or receiving livers from older donors are at increased risk for intrahepatic strictures.
C1 [Luethold, Samuel C.; Kaseje, Neema; Wildhaber, Barbara E.] Univ Hosp Geneva, Div Pediat Surg, Geneva, Switzerland.
   [Jannot, Anne-Sophie] Univ Hosp Geneva, Geneva, Switzerland.
   [Mentha, Gilles; Majno, Pietro; Toso, Christian] Univ Hosp Geneva, Div Transplantat, Geneva, Switzerland.
   [Belli, Dominique C.; McLin, Valerie A.] Univ Hosp Geneva, Pediat Gastroenterol Unit, Geneva, Switzerland.
RP Wildhaber, BE (reprint author), Hop Univ Geneve, Rue Willy Donze 6, CH-1211 Geneva 14, Switzerland.
EM barbara.wildhaber@hcuge.ch
FU Swiss National Science Foundation [PP00P3_139021]
FX Our sincere thanks go to the past and present team of the Swiss Center
   for Liver Diseases in Children for their care for our liver transplanted
   children. Christian Toso was supported by a professorship from the Swiss
   National Science Foundation (PP00P3_139021).
CR Ackermann O, 2012, AM J TRANSPLANT, V12, P1496, DOI 10.1111/j.1600-6143.2011.03984.x
   Ayoub WS, 2010, DIGEST DIS SCI, V55, P1540, DOI 10.1007/s10620-010-1217-2
   Berrocal T, 2006, RADIOGRAPHICS, V26, P1187, DOI 10.1148/rg.264055081
   CALNE RY, 1976, ANN SURG, V184, P605, DOI 10.1097/00000658-197611000-00012
   Faber W, 2011, TRANSPL P, V43, P3789, DOI 10.1016/j.transproceed.2011.10.048
   Gabriel M, 2012, ANN HEPATOL, V11, P891
   Gastaca M, 2012, TRANSPL P, V44, P1545, DOI 10.1016/j.transproceed.2012.05.008
   Gunawansa N, 2011, HPB, V13, P391, DOI 10.1111/j.1477-2574.2011.00300.x
   Halme L, 2003, TRANSPLANTATION, V75, P1853, DOI 10.1097/01.TP.0000064620.08328.E5
   Heffron TG, 2003, TRANSPLANT P, V35, P1461, DOI 10.1016/S0041-1345(03)00463-9
   Howell JA, 2012, TRANSPL INT, V25, P765, DOI 10.1111/j.1432-2277.2012.01501.x
   Kamath PS, 2007, HEPATOLOGY, V45, P797, DOI 10.1002/hep.21563
   Karakayali H, 2005, TRANSPLANT P, V37, P3174, DOI 10.1016/j.transproceed.2005.07.023
   Kaseje N, 2012, EUR J PEDIATR SURG, V23, P8
   Lacaille F, 2003, TRANSPLANT P, V35, P961, DOI 10.1016/S0041-1345(03)00184-2
   Lan XA, 2010, WORLD J GASTROENTERO, V16, P3457, DOI 10.3748/wjg.v16.i27.3457
   Lazard D S, 2004, Ann Otolaryngol Chir Cervicofac, V121, P156
   Londono MC, 2008, WORLD J GASTROENTERO, V14, P493, DOI 10.3748/wjg.14.493
   Lu CH, 2012, TRANSPL P, V44, P476, DOI 10.1016/j.transproceed.2011.12.034
   Muiesan P, 2007, J HEPATOL, V46, P340, DOI 10.1016/j.jhep.2006.11.006
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Oliveira P, 2010, PEDIATR TRANSPLANT, V14, P437, DOI 10.1111/j.1399-3046.2009.01278.x
   Oswari H, 2005, J GASTROEN HEPATOL, V20, P1850, DOI 10.1111/j.1440-1746.2005.03926.x
   Pascher A, 2005, TRANSPLANT INT, V18, P627, DOI 10.1111/j.1432-2277.2005.00123.x
   Rayhill SC, 2007, TRANSPLANTATION, V84, P331, DOI 10.1097/01.tp.0000270313.31328.63
   SANCHEZURDAZPAL L, 1992, HEPATOLOGY, V16, P49, DOI 10.1002/hep.1840160110
   Selzner M, 2009, LIVER TRANSPLANT, V15, P1288, DOI [10.1002/lt.21828, 10.1002/It.21828]
   Sundaram V, 2011, LIVER TRANSPLANT, V17, P428, DOI 10.1002/lt.22251
   Tanaka H, 2010, J PEDIATR SURG, V45, P1668, DOI 10.1016/j.jpedsurg.2010.03.010
   Serrano MT, 2010, CLIN TRANSPLANT, V24, P543, DOI 10.1111/j.1399-0012.2009.01135.x
   Uchiyama H, 2012, CLIN TRANSPLANT, V26, pE522, DOI 10.1111/ctr.12019
   Wakiya T, 2011, TRANSPL INT, V24, P984, DOI 10.1111/j.1432-2277.2011.01298.x
   Wojcicki M, 2008, DIGEST SURG, V25, P245, DOI 10.1159/000144653
   Yamada H, 2012, PEDIATR TRANSPLANT, V16, P858, DOI 10.1111/j.1399-3046.2012.01781.x
NR 34
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2014
VL 18
IS 8
BP 822
EP 830
DI 10.1111/petr.12363
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AS6FS
UT WOS:000344360500016
PM 25263826
ER

PT J
AU Shaheen, MF
   Alabdulkarim, MS
   Hamshow, MM
   Abdullah, KO
   O'Hali, WA
AF Shaheen, Mohammed F.
   Alabdulkarim, Moayad S.
   Hamshow, Mohammad M.
   Abdullah, Khalid O.
   O'Hali, Wael A.
TI Outcome of duct-to-duct vs. Roux-en-Y hepaticojejunostomy biliary
   anastomoses in below 15-kg pediatric liver transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; biliary reconstruction; complications
   of liver transplantation; duct-to-duct anastomosis
ID LEFT LATERAL SEGMENT; LIVING-DONOR; RIGHT-LOBE; BILE-DUCT; SURGICAL
   TECHNIQUES; RECONSTRUCTION; COMPLICATIONS; STRICTURES; GRAFT; MANAGEMENT
AB The best type of biliary anastomosis to use in lower weight pediatric liver transplant recipients is debatable. In this study, we share a single center's experience comparing the rate of anastomotic biliary complications based on the type of biliary anastomosis performed in this population of patients. A retrospective review of pediatric liver transplants for recipients weighing <15kg from 11/2003 till 12/2011 was performed. Patients were grouped based on the type of biliary anastomosis into two groups: duct-to-duct (d-d) and Roux-en-Y hepaticojejunostomy (h-j) anastomoses. A total of 24 patients (12 males, 12 females) with a mean age of 26 +/- 20months and a mean weight of 9.27 +/- 2.63kg (range=5.3-13.9kg) were studied. All anastomotic complications occurred in patients who received left lateral segments. No statistical differences were found in the post-operative biliary (p=0.86) or vascular (p=0.99) complications between the two groups. Acknowledging the limited sample size, our data suggest that duct-to-duct anastomosis can be performed safely in pediatric liver transplantation recipients weighing below 15kg.
C1 [Shaheen, Mohammed F.; Alabdulkarim, Moayad S.; Hamshow, Mohammad M.; Abdullah, Khalid O.; O'Hali, Wael A.] King Abdul Aziz Med City, Dept Hepatobiliary Surg & Transplantat, Riyadh 11426, Saudi Arabia.
RP O'Hali, WA (reprint author), King Abdul Aziz Med City, Dept Hepatobiliary Surg & Transplantat, MC 1440,POB 22490, Riyadh 11426, Saudi Arabia.
EM ohaliw@ngha.med.sa
CR Ando H, 2011, J HEPATO-BIL-PAN SCI, V18, P26, DOI 10.1007/s00534-010-0301-5
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Chok KSH, 2012, J PEDIATR SURG, V47, P1399, DOI 10.1016/j.jpedsurg.2011.12.014
   Dalgic A, 2005, TRANSPLANT P, V37, P3137, DOI 10.1016/j.transproceed.2005.08.046
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   Dorobantu B, 2010, HEPATO-GASTROENTEROL, V57, P932
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Fan ST, 2002, ANN SURG, V236, P676, DOI 10.1097/01.SLA.0000033323.01380.AC
   FERREIRA CT, 2000, J PEDIAT RIO J, V76, pS198
   Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927
   Haberal M, 2007, TRANSPL P, V39, P1161, DOI 10.1016/j.transproceed.2007.02.046
   Haberal M, 2011, TRANSPL P, V43, P595, DOI 10.1016/j.transproceed.2011.01.009
   Heffron TG, 2003, TRANSPLANT P, V35, P1461, DOI 10.1016/S0041-1345(03)00463-9
   Heffron TG, 2003, TRANSPLANT P, V35, P3006, DOI 10.1016/j.transproceed.2003.10.035
   Ikegami T, 2011, TRANSPLANTATION, V92, P1147, DOI 10.1097/TP.0b013e3182336073
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Karakas HM, 2008, SURG RADIOL ANAT, V30, P539, DOI 10.1007/s00276-008-0365-y
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Khuroo MS, 2005, J GASTROEN HEPATOL, V20, P217, DOI 10.1111/j.1400-1746.2004.03490.x
   Kimura T, 2006, PEDIATR TRANSPLANT, V10, P248, DOI 10.1111/j.1399-3046.2005.00430.x
   Kirimlioglu V, 2011, TRANSPL P, V43, P917, DOI 10.1016/j.transproceed.2010.11.024
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Lee TC, 2005, AM J TRANSPLANT, V5, P1646, DOI 10.1111/j.1600-6132.2005.00911.x
   Marcos A, 2000, ANN SURG, V231, P824, DOI 10.1097/00000658-200006000-00006
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Nishida S, 2006, J HEPATO-BILIARY-PAN, V13, P511, DOI 10.1007/s00534-005-1081-1
   Nishizaki T, 2001, ANN SURG, V233, P575, DOI 10.1097/00000658-200104000-00014
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Oliveira P, 2010, PEDIATR TRANSPLANT, V14, P437, DOI 10.1111/j.1399-3046.2009.01278.x
   Reichert PR, 2000, ANN SURG, V232, P658, DOI 10.1097/00000658-200011000-00007
   Riediger C, 2010, LIVER TRANSPLANT, V16, P705, DOI 10.1002/lt.22070
   Sakamoto S, 2008, PEDIATR TRANSPLANT, V12, P661, DOI 10.1111/j.1399-3046.2007.00870.x
   Salvalaggio PRO, 2005, LIVER TRANSPLANT, V11, P161, DOI 10.1002/lt.20288
   Schindel D, 2000, J PEDIATR SURG, V35, P940, DOI 10.1053/jpsu.2000.6932
   Shah SA, 2007, AM J TRANSPLANT, V7, P161, DOI 10.1111/j.1600-6143.2006.01601.x
   Sharma S, 2008, LIVER TRANSPLANT, V14, P759, DOI 10.1002/lt.21509
   Shirouzu Y, 2008, LIVER TRANSPLANT, V14, P1761, DOI 10.1002/lt.21599
   Soejima Y, 2006, LIVER TRANSPLANT, V12, P979, DOI 10.1002/lt.20740
   Soejima Y, 2008, TRANSPLANTATION, V86, P1468, DOI 10.1097/TP.0b013e318188d4dc
   Soin AS, 2010, J AM COLL SURGEONS, V211, P24, DOI 10.1016/j.jamcollsurg.2010.02.048
   Suehiro T, 2002, LIVER TRANSPLANT, V8, P495, DOI 10.1053/jlts.2002.32986
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tanaka K, 2002, PEDIATR TRANSPLANT, V6, P452, DOI 10.1034/j.1399-3046.2002.2e018.x
   Tashiro H, 2007, WORLD J SURG, V31, P2222, DOI 10.1007/s00268-007-9217-x
   Testa G, 2000, LIVER TRANSPLANT, V6, P710, DOI 10.1053/jlts.2000.18706
   Venick RS, 2010, TRANSPLANTATION, V89, P600, DOI 10.1097/TP.0b013e3181c5cdc1
   Wojcicki M, 2008, DIGEST SURG, V25, P245, DOI 10.1159/000144653
   Zhang S, 2014, TRANSPL P, V46, P208, DOI 10.1016/j.transproceed.2013.05.014
NR 51
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2014
VL 18
IS 8
BP 831
EP 838
DI 10.1111/petr.12349
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AS6FS
UT WOS:000344360500017
PM 25187071
ER

PT J
AU Youn, JK
   Lee, JM
   Yi, NJ
   Choi, YR
   Suh, SW
   You, T
   Lee, KW
   Jung, CW
   Lee, JW
   Bae, EJ
   Ko, JS
   Kim, WH
   Park, KW
   Suh, KS
AF Youn, Joong Kee
   Lee, Jeong-Moo
   Yi, Nam-Joon
   Choi, Young Rok
   Suh, Suk-Won
   You, Tae
   Lee, Kwang-Woong
   Jung, Chul-Woo
   Lee, Ji-won
   Bae, Eun-Jung
   Ko, Jae Sung
   Kim, Woong-Han
   Park, Kwi-Won
   Suh, Kyung-Suk
TI Pediatric split liver transplantation after Fontan procedure in left
   isomerism combined with biliary atresia: A case report
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary atresia; left isomerism; Fontan operation; hepatopulmonary
   syndrome; liver transplantation
ID SITUS-INVERSUS; HEPATOPULMONARY SYNDROME; OPERATION; MORTALITY; SURGERY;
   COMPLICATIONS; CIRCULATION; PREDICTORS; OUTCOMES; CHILDREN
AB LI is a subset of the heterotaxy syndrome and a rare birth defect that involves the heart and other organs. It can be combined with extracardiac abnormalities, especially BA. CHD can be associated with LI in up to 15% of cases, although it is rare in BA. Pediatric LT for a child with ESLD due to BA combined with LI and CHD is a challenging issue for a transplant surgeon. Herein, we report a successful split LT on a three-yr-old boy with LI who survived after a Fontan procedure due to single ventricle, but who suffered from HPS associated with BA.
C1 [Youn, Joong Kee; Lee, Jeong-Moo; Yi, Nam-Joon; Choi, Young Rok; Suh, Suk-Won; You, Tae; Lee, Kwang-Woong; Park, Kwi-Won; Suh, Kyung-Suk] Seoul Natl Univ, Coll Med, Dept Surg, Seoul 110744, South Korea.
   [Jung, Chul-Woo; Lee, Ji-won] Seoul Natl Univ, Coll Med, Dept Anesthisiol & Pain Med, Seoul 110744, South Korea.
   [Bae, Eun-Jung; Ko, Jae Sung] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 110744, South Korea.
   [Kim, Woong-Han] Seoul Natl Univ, Coll Med, Dept Thorac Surg, Seoul 110744, South Korea.
RP Yi, NJ (reprint author), Seoul Natl Univ, Coll Med, Dept Surg, Div HBP Surg, 101 Daehak Ro, Seoul 110744, South Korea.
EM gsleenj@hanmail.net
OI Yi, Nam-Joon/0000-0002-5467-425X
CR Arguedas MR, 2003, HEPATOLOGY, V37, P192, DOI 10.1053/jhep.2003.50023
   Asrani SK, 2013, NEW ENGL J MED, V368, P1756, DOI 10.1056/NEJMc1214222
   Asrani SK, 2012, HEPATOLOGY, V56, P1160, DOI 10.1002/hep.25692
   Assenza GE, 2013, HEART, V99, P491, DOI 10.1136/heartjnl-2012-303347
   Baek JS, 2010, HEART, V96, P1750, DOI 10.1136/hrt.2010.201772
   Cai JM, 2008, ANN THORAC SURG, V86, P882, DOI 10.1016/j.athoracsur.2008.05.014
   Cetta F, 1996, J AM COLL CARDIOL, V28, P480, DOI 10.1016/0735-1097(96)00135-0
   DRISCOLL DJ, 1992, CIRCULATION, V85, P469
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   FARMER DG, 1995, ANN SURG, V222, P47, DOI 10.1097/00000658-199507000-00008
   FONTAN F, 1971, THORAX, V26, P240, DOI 10.1136/thx.26.3.240
   Kasahara M, 2009, LIVER TRANSPLANT, V15, P1641, DOI 10.1002/lt.21839
   Khairy P, 2008, CIRCULATION, V117, P85, DOI 10.1161/CIRCULATIONAHA.107.738559
   Kim SJ, 2008, J THORAC CARDIOV SUR, V136, P108, DOI 10.1016/j.jtcvs.2007.12.032
   KLINTMALM GB, 1993, SURGERY, V114, P102
   Martinez GP, 2001, J HEPATOL, V34, P651, DOI 10.1016/S0168-8278(00)00108-2
   Matsubara K, 2005, LIVER TRANSPLANT, V11, P1444, DOI 10.1002/lt.20584
   Mondesert B, 2013, CAN J CARDIOL, V29, P811, DOI 10.1016/j.cjca.2012.12.009
   Garbanzo JP, 2006, PEDIATR TRANSPLANT, V10, P923, DOI 10.1111/j.1399-3046.2006.00576.x
   RUBEN GD, 1983, J PEDIATR SURG, V18, P751, DOI 10.1016/S0022-3468(83)80018-9
   Rychik J, 2012, PEDIATR CARDIOL, V33, P1001, DOI 10.1007/s00246-012-0315-7
   Swanson KL, 2005, HEPATOLOGY, V41, P1122, DOI 10.1002/hep.20658
   Tucker O, 2006, LIVER TRANSPLANT, V12, P1720, DOI 10.1002/lt.20952
   Vincenzi R, 2013, LIVER TRANSPLANT, V19, P431, DOI 10.1002/lt.23611
NR 24
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2014
VL 18
IS 8
BP E274
EP E279
DI 10.1111/petr.12364
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AS6FS
UT WOS:000344360500005
PM 25263970
ER

PT J
AU Yang, SC
   Wang, CH
   Chen, CL
   Cheng, KW
   Wu, SC
   Shih, TH
   Jawan, B
   Huang, CJ
AF Yang, Sheng-Chun
   Wang, Chih-Hsien
   Chen, Chao-Long
   Cheng, Kwok-Wai
   Wu, Shao-Chun
   Shih, Tsung-Hsiao
   Jawan, Bruno
   Huang, Chia-Jung
TI Acquired Hyponatremia in Pediatric Living Donor Liver Transplantation
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE Anesthesia; Hyponatremia; Liver Transplantation; Living Donors;
   Pediatrics
ID FLUID THERAPY; CHILDREN; GASTROENTERITIS; COMPLICATIONS
AB Background: The aim of this study was to evaluate the incidence of acquired hyponatremia (AH) in our pediatric living donor liver transplantation (LDLT) patients, and to identify the potential predictive risk factors of the causes of AH.
   Material/Methods: The 189 pediatric LDLT patients were divided into 2 groups: serum sodium level at the end of the surgery lower than 130 mEq/L in GI (n=16) and higher than 130 mEq/L in GII (n=173). Patients' data were analyzed by Mann-Whitney U test, univariate analysis, and multiple binary logistic regression model. The Hosmer-Lemeshow goodness- of-fit test was used to evaluate the logistic model formulated. P value <0.05 was regarded as statistically significant.
   Results: In the multiple binary logistic regression model, the hypotonic solution administration rate (ml/kg/h) was the only independent predictor of AH with a p<0.017. Receiver operating curve (ROC) analysis indicated that giving more than 3.5 ml/kg/h hypotonic solution infusion may cause AH. Preoperative hyponatremia did not increase the incidence of acquired hyponatremia.
   Conclusions: Increasing the administration of hypotonic solution by 1 ml/kg/h in pediatric LDLT would increase the risk of developing AH by 1.272 times. The critical administration rate of hypotonic solution was 3.5 ml/kg/h.
C1 [Yang, Sheng-Chun; Wang, Chih-Hsien; Cheng, Kwok-Wai; Wu, Shao-Chun; Shih, Tsung-Hsiao; Jawan, Bruno; Huang, Chia-Jung] Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan.
   [Yang, Sheng-Chun; Wang, Chih-Hsien; Chen, Chao-Long; Cheng, Kwok-Wai; Wu, Shao-Chun; Shih, Tsung-Hsiao; Jawan, Bruno; Huang, Chia-Jung] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
   [Chen, Chao-Long] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung, Taiwan.
   [Chen, Chao-Long] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Program, Kaohsiung, Taiwan.
RP Huang, CJ (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan.
EM maomd@hotmail.com
CR Armon K, 2008, ARCH DIS CHILD, V93, P285, DOI 10.1136/adc.2006.093823
   Ashrafian H, 2001, EUR J NEUROL, V8, P103, DOI 10.1046/j.1468-1331.2001.00176.x
   Au AK, 2008, J PEDIATR, V152, P33, DOI 10.1016/j.jpeds.2007.08.040
   Eulmesekian PG, 2010, PEDIATR CRIT CARE ME, V11, P479, DOI 10.1097/PCC.0b013e3181ce7154
   Freeman MA, 2012, ACTA PAEDIATR, V101, pE465, DOI 10.1111/j.1651-2227.2012.02780.x
   HALL WA, 1989, PEDIATR NEUROSCI, V15, P269, DOI 10.1159/000120482
   HOLLIDAY MA, 1957, PEDIATRICS, V19, P823
   Hoorn EJ, 2004, PEDIATRICS, V113, P1279, DOI 10.1542/peds.113.5.1279
   Huang CJ, 2013, ANN TRANSPL, V18, P443, DOI 10.12659/AOT.889293
   Jacob Matthias, 2009, Best Pract Res Clin Anaesthesiol, V23, P145
   Jawan B, 2004, TRANSPLANTATION, V77, P1394, DOI 10.1097/01.TP.0000122419.66639.19
   Jawan B, 2003, TRANSPLANT INT, V16, P510, DOI 10.1007/s00147-003-0578-2
   Kato T, 2002, BRAIN DEV-JPN, V24, P179, DOI 10.1016/S0387-7604(02)00013-X
   Kim WR, 2008, NEW ENGL J MED, V359, P1018, DOI 10.1056/NEJMoa0801209
   Montanana PA, 2008, PEDIATR CRIT CARE ME, V9, P589, DOI 10.1097/PCC.0b013e31818d3192
   Moritz M, 2005, PEDIATR NEPHROL, V20, P1687, DOI 10.1007/s00467-005-1933-6
   Moritz ML, 2011, PEDIATRICS, V128, P980, DOI 10.1542/peds.2011-2015
   Moritz ML, 2007, NAT CLIN PRACT NEPHR, V3, P374, DOI 10.1038/ncpneph0526
   Neville KA, 2005, PEDIATRICS, V116, P1401, DOI 10.1542/peds.2004-2376
   Neville KA, 2006, ARCH DIS CHILD, V91, P226, DOI 10.1136/sdc.2005.084103
   Neville KA, 2010, J PEDIAT, V156
   Verbalis JG, 2007, AM J MED, V120, pS1, DOI 10.1016/j.amjmed.2007.09.001
   Way C, 2006, BRIT J ANAESTH, V97, P371, DOI 10.1093/bja/ael185
   Yang Sheng-Chun, 2011, Acta Anaesthesiol Taiwan, V49, P50, DOI 10.1016/j.aat.2011.05.011
NR 24
TC 1
Z9 1
U1 0
U2 1
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD NOV 24
PY 2014
VL 19
BP 609
EP 613
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA CC5MF
UT WOS:000350402000001
PM 25418023
ER

PT J
AU Lebel, MJ
   Chapdelaine, H
   Paradis, L
   Des Roches, A
   Alvarez, F
AF Lebel, Marie-Jeanne
   Chapdelaine, Hugo
   Paradis, Louis
   Des Roches, Anne
   Alvarez, Fernando
TI Increase in de novo food allergies after pediatric liver
   transplantation: Tacrolimus vs. cyclosporine immunosuppression
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; food allergy; liver transplantation; tacrolimus; cyclosporine;
   immunosuppression
ID GASTROINTESTINAL-DISEASE; PEANUT ALLERGY; CHILDREN; FK506; RECIPIENTS;
   IGE; EOSINOPHILIA; PREVALENCE; ACTIVATION; EXPERIENCE
AB Post-TAFA is an uncommon but serious complication of organ transplantation. This study aimed to compare the incidence of FA in CsA and tacrolimus-treated children following OLT and identify risk factors. The medical charts of all patients who underwent OLT at our institution were reviewed. Between 1985 and 2010, 218 OLTs were performed on 188 pediatric recipients, of which 154 were included in the study. Three patients (3%) of the 102 receiving CsA developed FA, compared with nine (17%) in the 52 tacrolimus-treated patients, the latter exceeding general population reported FA prevalence (RR 5.88; 95% CI: 1.66-20.81). All TAFA cases underwent transplantation before the age of three with an incidence of 29% (9/31) in the tacrolimus-treated children in comparison with 7% (3/41) in the CsA group (RR 3.97; 95% CI: 1.17-13.45). Eosinophilia was present in 81% of children receiving tacrolimus compared with 54% in the CsA group (p=0.002). We observed a statistically significant increase incidence of FA in tacrolimus-treated children following an OLT and those under the age of three are particularly vulnerable. The underlying process is still unknown and probably multifactorial.
C1 [Lebel, Marie-Jeanne; Chapdelaine, Hugo; Paradis, Louis; Des Roches, Anne; Alvarez, Fernando] Univ Montreal, Ctr Hosp Univ Mere Enfant St Justine, Montreal, PQ, Canada.
RP Lebel, MJ (reprint author), CHU St Justine, Dept Pediat, 3175 Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM marie-jeanne.lebel@umontreal.ca
CR Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018
   Arikan C, 2003, TRANSPLANT P, V35, P3039, DOI 10.1016/j.transproceed.2003.10.033
   AsanteKorang A, 1996, J HEART LUNG TRANSPL, V15, P415
   Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015
   Blanchard SS, 2006, PEDIATR TRANSPLANT, V10, P529, DOI 10.1111/j.1399-3046.2006.00501.x
   Boyce J. A., 2010, Journal of Allergy and Clinical Immunology, V126, pS1
   Boyle RJ, 2005, LIVER TRANSPLANT, V11, P326, DOI 10.1002/lt.20368
   Chehade M, 2004, J PEDIATR GASTR NUTR, V38, P545, DOI 10.1097/00005176-200405000-00017
   DeMeo MT, 2002, J CLIN GASTROENTEROL, V34, P385, DOI 10.1097/00004836-200204000-00003
   Dewachter P, 2011, AM J TRANSPLANT, V11, P1531, DOI 10.1111/j.1600-6143.2011.03576.x
   Di Mauro A, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-15
   Gabe SM, 1998, GASTROENTEROLOGY, V115, P67, DOI 10.1016/S0016-5085(98)70366-X
   Granot E, 2006, PEDIATR TRANSPLANT, V10, P690, DOI 10.1111/j.1399-3046.2006.00542.x
   Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204
   HENDERSON DJ, 1991, IMMUNOLOGY, V73, P316
   KAY JE, 1989, IMMUNOLOGY, V67, P473
   Kliegman RM, 2011, NELSON TXB PEDIAT
   Lacaille F, 1997, J PEDIATR GASTR NUTR, V25, P228, DOI 10.1097/00005176-199708000-00019
   Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204
   Levy Y, 2009, PEDIATR TRANSPLANT, V13, P63, DOI 10.1111/j.1399-3046.2007.00883.x
   Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049
   LINDBERG RE, 1986, J ALLERGY CLIN IMMUN, V78, P614, DOI 10.1016/0091-6749(86)90078-3
   Lykavieris P, 2003, TRANSPLANTATION, V75, P152, DOI 10.1097/01.TP.0000040084.22472.6A
   Maarof G, 2011, J ALLERGY CLIN IMMUN, V127, P1296, DOI 10.1016/j.jaci.2010.12.1094
   McAlister VC, 2006, AM J TRANSPLANT, V6, P1578, DOI 10.1111/j.1600-6143.2006.01360.x
   Neu J, 2007, NUTR REV, V65, P282, DOI 10.1301/nr.2007.jun.282-285
   Noble C, 2011, PEDIATR TRANSPLANT, V15, P451, DOI 10.1111/j.1399-3046.2011.01486.x
   Ozbek OY, 2009, PEDIATR ALLERGY IMMU, V20, P741, DOI 10.1111/j.1399-3038.2009.00867.x
   Ozdemir O, 2006, PEDIATR TRANSPLANT, V10, P380, DOI 10.1111/j.1399-3046.2005.00474.x
   Romero R, 2003, PEDIATR TRANSPLANT, V7, P484, DOI 10.1046/j.1397-3142.2003.00116.x
   Saeed SA, 2006, PEDIATR TRANSPLANT, V10, P730, DOI 10.1111/j.1399-3046.2006.00538.x
   SAWADA S, 1987, J IMMUNOL, V139, P1797
   Shroff P, 2012, PEDIATR TRANSPLANT, V16, P379, DOI 10.1111/j.1399-3046.2012.01684.x
   Soller L, 2012, J ALLERGY CLIN IMMUN, V130, P986, DOI 10.1016/j.jaci.2012.06.029
   Venter C, 2011, PEDIATR CLIN N AM, V58, P327, DOI 10.1016/j.pcl.2011.02.011
   Wisniewski J, 2012, CLIN TRANSPLANT, V26, pE365, DOI 10.1111/j.1399-0012.2012.01670.x
   ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x
NR 37
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2014
VL 18
IS 7
BP 733
EP 739
DI 10.1111/petr.12342
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AQ5KT
UT WOS:000342848100024
PM 25156571
ER

PT J
AU Sibal, A
   Malhotra, S
   Guru, FR
   Bhatia, V
   Kapoor, A
   Seth, S
   Jerath, N
   Jasuja, S
   Rajkumari, V
   Wadhawan, M
   Aggarwal, DK
   Guleria, S
   Shrivastava, RN
   Gupta, S
AF Sibal, Anupam
   Malhotra, Smita
   Guru, Faisal R.
   Bhatia, Vidyut
   Kapoor, Akshay
   Seth, Swati
   Jerath, Nameet
   Jasuja, Sanjeev
   Rajkumari, Vijaya
   Wadhawan, Manav
   Aggarwal, D. K.
   Guleria, Sandeep
   Shrivastava, R. N.
   Gupta, Subash
TI Experience of 100 solid organ transplants over a five-yr period from the
   first successful pediatric multi-organ transplant program in India
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE survival; solid organ; transplant; India; child
ID DONOR LIVER-TRANSPLANTATION; SINGLE-CENTER EXPERIENCE;
   RENAL-TRANSPLANTATION; CHILDREN; OUTCOMES; INFECTION; REJECTION;
   REGISTRY
AB To analyze the clinical profile and outcome of pediatric patients who had undergone a liver and/or RT at our center over a fiveyr period, case records of all the patients who had undergone a liver or RT were analyzed retrospectively. One hundred solid organ transplants were performed at our center between January 2007 and January 2012. These included 50 liver, 44 renal, one sequential liver and renal, and two CLKT. BA was the most common indication for an LT (38%). At a median follow-up of twoyr threemonths, the patient survival was 88%. The most common indication for an RT was chronic glomerulonephritis (54.5%). At a median follow-up of threeyr, the survival was 91%. The CLKT were performed for hyperoxaluria. Two yr post LT, a sequential RT was performed for ESRD resulting from transplant associated microangiopathy. All patients received a living related graft. The common post-operative complications were infections, vascular complications, and graft dysfunction. Survival rates for liver and RT at our center are comparable to those in the established centers in the West.
C1 [Sibal, Anupam; Malhotra, Smita; Guru, Faisal R.; Bhatia, Vidyut; Kapoor, Akshay; Seth, Swati; Jerath, Nameet; Shrivastava, R. N.] Indraprastha Apollo Hosp, Apollo Ctr Adv Pediat, New Delhi 110076, India.
   [Jasuja, Sanjeev] Indraprastha Apollo Hosp, Dept Nephrol, New Delhi 110076, India.
   [Rajkumari, Vijaya; Aggarwal, D. K.; Guleria, Sandeep] Indraprastha Apollo Hosp, Dept Renal Transplant Surg, New Delhi 110076, India.
   [Wadhawan, Manav; Gupta, Subash] Indraprastha Apollo Hosp, Ctr Liver & Biliary Sci, New Delhi 110076, India.
RP Sibal, A (reprint author), Indraprastha Apollo Hosp, Apollo Hosp Grp, Apollo Ctr Adv Pediat, New Delhi 110076, India.
EM anupamsibal@apollohospitals.com
CR Bhatia V, 2013, INDIAN PEDIATR, V50, P158
   Haberal M, 2008, EXP CLIN TRANSPLANT, V6, P7
   Horslen S, 2007, AM J TRANSPLANT, V7, P1339, DOI 10.1111/j.1600-6143.2007.01780.x
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Kasahara M, 2013, AM J TRANSPLANT, V13, P1830, DOI 10.1111/ajt.12276
   Kaur S, 2011, INDIAN PEDIATR, V48, P51, DOI 10.1007/s13312-011-0024-y
   Kelly DA, 2006, INDIAN PEDIATR, V43, P389
   Kim JE, 2010, J KOREAN MED SCI, V25, P527, DOI 10.3346/jkms.2010.25.4.527
   Kim JM, 2013, J KOREAN MED SCI, V28, P42, DOI 10.3346/jkms.2013.28.1.42
   Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2
   Kranz B, 2008, PEDIATR TRANSPLANT, V12, P474, DOI 10.1111/j.1399-3046.2007.00781.x
   Langnas AM, 1991, AM J SURG, V16, P76
   Magee JC, 2008, AM J TRANSPLANT, V8, P935, DOI 10.1111/j.1600-6143.2008.02172.x
   McDiarmid SV, 2000, CLIN LIVER DIS, V4, P1
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Poonacha P, 2001, Indian Pediatr, V38, P287
   RYCKMAN F, 1993, J PEDIATR SURG, V28, P382
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   Sibal A, 2013, INDIAN PEDIATR, V50, P999, DOI 10.1007/s13312-013-0273-z
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   Vasudevan A, 2008, TRANSPL P, V40, P1095, DOI 10.1016/j.transproceed.2008.03.021
   Wisanuyotin Suwannee, 2009, Journal of the Medical Association of Thailand, V92, P1635
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 23
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2014
VL 18
IS 7
BP 740
EP 745
DI 10.1111/petr.12324
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AQ5KT
UT WOS:000342848100025
PM 25092050
ER

PT J
AU Neto, JS
   Fonseca, EA
   Feier, FH
   Pugliese, R
   Candido, HL
   Benavides, MR
   Porta, G
   Miura, IK
   Danesi, VB
   Guimaraes, T
   Porta, A
   Borges, C
   Godoy, A
   Kondo, M
   Chapchap, P
AF Seda Neto, Joao
   Fonseca, Eduardo A.
   Feier, Flavia H.
   Pugliese, Renata
   Candido, Helry L.
   Benavides, Marcel R.
   Porta, Gilda
   Miura, Irene K.
   Danesi, Vera B.
   Guimaraes, Teresa
   Porta, Adriana
   Borges, Cristian
   Godoy, Andre
   Kondo, Mario
   Chapchap, Paulo
TI Analysis of Factors Associated With Portal Vein Thrombosis in Pediatric
   Living Donor Liver Transplant Recipients
SO LIVER TRANSPLANTATION
LA English
DT Article
ID VENOUS COMPLICATIONS; TECHNICAL ASPECTS; RISK-FACTORS; EXPERIENCE;
   KILOGRAMS; CHILDREN; GRAFTS; RECONSTRUCTION; OBSTRUCTION; IMPACT
AB The technique of vascular reconstruction plays a major role in the outcome of living donor liver transplantation (LDLT). An increased use of vascular grafts (VGs) as replacements for sclerotic portal veins has become a standard technique for our group. The aim of this study was to analyze the factors associated with portal vein thrombosis (PVT) in pediatric LDLT. We performed a retrospective analysis of 486 primary pediatric LDLT procedures performed between October 1995 and May 2013. VGs used for portal reconstruction included living donor inferior mesenteric veins, living donor ovarian veins, recipient internal jugular veins, deceased donor iliac arteries, and deceased donor iliac veins. Thirty-four patients (7.0%) developed PVT. The incidence of PVT dropped from 10.1% to 2%; the overall utilization of VGs increased from 3.5% to 37.1%. In a multivariate analysis, only the use of VGs remained an independent risk factor for the occurrence of PVT (hazard ratio = 7.2, 95% confidence interval = 2.8-18.7, P<0.001). There was no difference in survival rates between patients with PVT and patients without PVT. No patient with PVT underwent retransplantation. In conclusion, the use of VGs was independently associated with the development of PVT. Over time, there was a reduction in the incidence of early PVT in this cohort, and there was a trend toward a reduction in total PVT. The occurrence of isolated PVT in this study was not associated with decreased patient or graft survival. (C) 2014 AASLD.
C1 [Seda Neto, Joao; Fonseca, Eduardo A.; Feier, Flavia H.; Pugliese, Renata; Candido, Helry L.; Benavides, Marcel R.; Porta, Gilda; Miura, Irene K.; Danesi, Vera B.; Guimaraes, Teresa; Porta, Adriana; Borges, Cristian; Kondo, Mario; Chapchap, Paulo] Hosp Sirio Libanes, BR-01308000 Sao Paulo, Brazil.
   [Seda Neto, Joao; Fonseca, Eduardo A.; Feier, Flavia H.; Pugliese, Renata; Candido, Helry L.; Benavides, Marcel R.; Porta, Gilda; Miura, Irene K.; Danesi, Vera B.; Guimaraes, Teresa; Porta, Adriana; Borges, Cristian; Godoy, Andre; Kondo, Mario] AC Camargo Canc Ctr, Sao Paulo, Brazil.
RP Neto, JS (reprint author), Hosp Sirio Libanes, Rua Barata Ribeiro 414,Cj 65, BR-01308000 Sao Paulo, Brazil.
EM joaoseda@gmail.com
CR Alvarez Fernando, 2012, Curr Gastroenterol Rep, V14, P270, DOI 10.1007/s11894-012-0257-5
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Carnevale FC, 2011, PEDIATR TRANSPLANT, V15, P47, DOI 10.1111/j.1399-3046.2010.01350.x
   Carnevale FC, 2009, CARDIOVASC INTER RAD, V32, P1083, DOI 10.1007/s00270-009-9578-7
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   Heffron TG, 2010, PEDIATR TRANSPLANT, V14, P722, DOI 10.1111/j.1399-3046.2009.01259.x
   Kyoden Y, 2008, TRANSPL INT, V21, P1136, DOI 10.1111/j.1432-2277.2008.00752.x
   McDiarmid SV, 2011, ANN SURG, V254, P145, DOI 10.1097/SLA.0b013e31821ad86a
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   Neto JS, 2012, LIVER TRANSPLANT, V18, P577, DOI 10.1002/lt.23393
   SHAW BW, 1985, SURG GYNECOL OBSTET, V161, P66
   Shibasaki S, 2010, CLIN TRANSPLANT, V24, P550, DOI 10.1111/j.1399-0012.2009.01123.x
   Shigeta T, 2011, J PEDIATR SURG, V46, pE19, DOI 10.1016/j.jpedsurg.2011.03.077
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Slater RR, 2011, AM J TRANSPLANT, V11, P1743, DOI 10.1111/j.1600-6143.2011.03578.x
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
NR 25
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2014
VL 20
IS 10
BP 1157
EP 1167
DI 10.1002/lt.23934
PG 11
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AQ7PR
UT WOS:000343012000003
PM 24954288
ER

PT J
AU Benetatos, N
   Scalera, I
   Isaac, JR
   Mirza, DF
   Muiesan, P
AF Benetatos, Nikolaos
   Scalera, Irene
   Isaac, John R.
   Mirza, Darius F.
   Muiesan, Paolo
TI Complex outflow anatomy in left lateral lobe graft and modified venous
   reconstruction in pediatric living donor liver transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE graft outflow obstruction; hepatic vein anatomy of the left lateral
   liver; left hepatic vein; segmental pediatric liver transplantation;
   venous patch
ID HEPATIC VEINS; EXPERIENCE; VENOPLASTY; MIDDLE
AB Hepatic venous outflow reconstruction is of critical significance in pediatric patients undergoing living donor liver transplantation. Accurate knowledge of the anatomical variations is important to obtain appropriate size segmental grafts. The diameter of the hepatic veins and the potential risk of complications at the level of the anastomosis require an adequate primary vascular reconstruction. We describe a venous outflow reconstruction technique, in a living related left lateral lobe graft, with unfavorable hepatic venous anatomy.
C1 [Benetatos, Nikolaos; Scalera, Irene; Isaac, John R.; Mirza, Darius F.; Muiesan, Paolo] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.
RP Muiesan, P (reprint author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham Childrens Hosp, Queen Elizabeth Hosp, Liver & Intestinal Transplantat & HPB Surg, 3rd Floor Nuffield House, Birmingham B15 2TH, W Midlands, England.
EM paolo.muiesan@uhb.nhs.uk
OI Muiesan, Paolo/0000-0002-7389-6691
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 1996, J CLIN ULTRASOUND, V24, P11, DOI 10.1002/jcu.1996.1870240103
   Concejero A, 2006, LIVER TRANSPLANT, V12, P264, DOI 10.1002/lt.20699
   Hwang S, 2013, LIVER TRANSPLANT, V19, P184, DOI 10.1002/lt.23557
   Kilic M, 2008, PEDIATR TRANSPLANT, V12, P677, DOI 10.1111/j.1399-3046.2007.00877.x
   Reichert PR, 2000, ANN SURG, V232, P658, DOI 10.1097/00000658-200011000-00007
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   Sakamoto S, 2011, TRANSPLANTATION, V91, pE38, DOI 10.1097/TP.0b013e3182088bb5
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Varma V., 2011, INT J HEPATOL, V2011, DOI DOI 10.4061/2011/121862
   Wind P, 1999, SURG RADIOL ANAT, V21, P17, DOI 10.1007/s00276-999-0017-x
   Yan JQ, 2005, WORLD J GASTROENTERO, V11, P4220
NR 12
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0934-0874
EI 1432-2277
J9 TRANSPL INT
JI Transpl. Int.
PD OCT
PY 2014
VL 27
IS 10
BP E105
EP E108
DI 10.1111/tri.12388
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AQ5JX
UT WOS:000342845400005
PM 24963596
ER

PT J
AU Zenitani, M
   Ueno, T
   Nara, K
   Nakahata, K
   Uehara, S
   Soh, H
   Oue, T
   Kondo, H
   Nagano, H
   Usui, N
AF Zenitani, Masahiro
   Ueno, Takehisa
   Nara, Keigo
   Nakahata, Kengo
   Uehara, Shuichiro
   Soh, Hideki
   Oue, Takaharu
   Kondo, Hiroki
   Nagano, Hiroaki
   Usui, Noriaki
TI A case of pediatric live-donor liver transplantation with a left lateral
   segment reduction by a linear stapler after reperfusion
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; liver transplant; living donor
ID LIVING DONORS; GRAFT; KG; CHILDREN; SAFE
AB In pediatric LDLT, graft reduction is sometimes required because of the graft size mismatch. Dividing the portal triad and hepatic veins with a linear stapler is a rapid and safe method of reduction. We herein present a case with a left lateral segment reduction achieved using a linear stapler after reperfusion in pediatric LDLT. The patient was a male who had previously undergone Kasai procedure for biliary atresia. We performed the LDLT with his father's lateral segment. According to the pre-operative volumetry, the GV/ SLV ratio was 102.5%. As the patient's PV was narrow, sclerotic and thick, we decided to put an interposition with the IMV graft of the donor between the confluence and the graft PV. The graft PV was anastomosed to the IMV graft. The warm ischemic time was 34 min, and the cold ischemic time was 82 min. The ratio of the graft size to the recipient weight (G/R ratio) was 4.2%. After reperfusion, we found that the graft had poor perfusion and decided to reduce the graft size. We noted good perfusion in the residual area after the lateral edge was clamped with an intestinal clamp. The liver tissue was sufficiently fractured with an intestinal clamp and then was divided with a linear stapler. The final G/R ratio was 3.6%. The total length of the operation was 12 h and 20 min. The amount of blood lost was 430 mL. No surgical complications, including post-operative hemorrhage and bile leakage, were encountered. We believe that using the linear stapler decreased the duration of the operation and was an acceptable technique for reducing the graft after reperfusion.
C1 [Zenitani, Masahiro; Ueno, Takehisa; Nara, Keigo; Nakahata, Kengo; Uehara, Shuichiro; Soh, Hideki; Oue, Takaharu; Usui, Noriaki] Osaka Univ, Grad Sch Med, Dept Pediat Surg, Suita, Osaka 5650871, Japan.
   [Kondo, Hiroki] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan.
   [Nagano, Hiroaki] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Suita, Osaka 5650871, Japan.
RP Ueno, T (reprint author), Osaka Univ, Grad Sch Med, Dept Pediat Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ueno@pedsurg.med.osaka-u.ac.jp
CR Ardiles V, 2013, LANGENBECK ARCH SURG, V398, P79, DOI 10.1007/s00423-012-1020-y
   Balaa FK, 2008, J GASTROINTEST SURG, V12, P338, DOI 10.1007/s11605-007-0236-6
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Rahbari NN, 2014, BRIT J SURG, V101, P200, DOI 10.1002/bjs.9387
   Savlid M, 2013, WORLD J SURG, V37, P799, DOI 10.1007/s00268-012-1884-6
   Schemmer P, 2006, WORLD J SURG, V30, P419, DOI 10.1007/s00268-005-0192-9
   Schulze M, 2011, TRANSPL INT, V24, P797, DOI 10.1111/j.1432-2277.2011.01277.x
   Shirouzu Y, 2010, PEDIATR TRANSPLANT, V14, P709, DOI 10.1111/j.1399-3046.2010.01332.x
NR 11
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2014
VL 18
IS 6
BP E197
EP E199
DI 10.1111/petr.12307
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AN4AU
UT WOS:000340530800004
PM 24977299
ER

PT J
AU Feier, FH
   Chapchap, P
   Pugliese, R
   da Fonseca, EA
   Carnevale, FC
   Moreira, AM
   Zurstrassen, C
   Santos, AC
   Miura, IK
   Baggio, V
   Porta, A
   Guimaraes, T
   Candido, H
   Benavides, M
   Godoy, A
   Leite, KMR
   Porta, G
   Kondo, M
   Seda-Neto, J
AF Feier, Flavia H.
   Chapchap, Paulo
   Pugliese, Renata
   da Fonseca, Eduardo A.
   Carnevale, Francisco C.
   Moreira, Airton M.
   Zurstrassen, Charles
   Santos, Aline C.
   Miura, Irene K.
   Baggio, Vera
   Porta, Adriana
   Guimaraes, Teresa
   Candido, Helry
   Benavides, Marcel
   Godoy, Andre
   Leite, Katia M. R.
   Porta, Gilda
   Kondo, Mario
   Seda-Neto, Joao
TI Diagnosis and Management of Biliary Complications in Pediatric Living
   Donor Liver Transplant Recipients
SO LIVER TRANSPLANTATION
LA English
DT Article
ID DUCT-TO-DUCT; EN-Y HEPATICOJEJUNOSTOMY; ANASTOMOTIC STRICTURE;
   BILE-DUCTS; RECONSTRUCTION; ULTRASOUND; EXPERIENCE; DRAINAGE; MRCP
AB The incidence of biliary complications (BCs) after living donor liver transplantation (LDLT) can reach 40%. Published data on the pediatric population are limited, and treatment protocols vary. Our aim was to describe the clinical scenario for BCs and treatment approaches after LDLT. Between October 1995 and December 2012, 489 pediatric LDLT procedures were performed. BCs developed in 71 patients (14.5%). Biliary strictures (BSs) developed in 45 (9.2%) patients, and bile leaks (BLs) developed in 33 patients (6.7%). The BL diagnosis was clinical in all cases, and 69.7% of the patients underwent surgery. Nearly half of the BS cases had clinical features or suggestive ultrasound findings. Liver biopsy findings suggested BSs in 51.7%. Percutaneous transhepatic cholangiography was performed in 95.6% of the BS patients. The success rate was 77% [mean number of percutaneous biliary interventions (PBIs) 53.961.98, median drainage time58 months]. In conclusion, BL patients can be managed with conservative therapy, even though most of these patients will ultimately be treated with surgery. Diagnosing a BS requires a high degree of clinical suspicion because the available resources for its identification can fail in up to 50% of cases. A higher number of PBIs and the use of a drainage catheter for a longer time may be required to achieve better results with this technique. (C) 2014 AASLD.
C1 [Feier, Flavia H.; Pugliese, Renata; da Fonseca, Eduardo A.; Zurstrassen, Charles; Santos, Aline C.; Miura, Irene K.; Baggio, Vera; Porta, Adriana; Guimaraes, Teresa; Candido, Helry; Benavides, Marcel; Godoy, Andre; Porta, Gilda; Kondo, Mario; Seda-Neto, Joao] AC Camargo Canc Ctr, BR-01308000 Sao Paulo, Brazil.
   [Feier, Flavia H.; Chapchap, Paulo; Pugliese, Renata; da Fonseca, Eduardo A.; Carnevale, Francisco C.; Moreira, Airton M.; Santos, Aline C.; Miura, Irene K.; Baggio, Vera; Porta, Adriana; Guimaraes, Teresa; Candido, Helry; Benavides, Marcel; Leite, Katia M. R.; Porta, Gilda; Kondo, Mario; Seda-Neto, Joao] Sirio Llbanes Hosp, Sao Paulo, Brazil.
   [Leite, Katia M. R.] Univ Sao Paulo, Sch Med, Lab Med Res LIM55, Sao Paulo, Brazil.
RP Seda-Neto, J (reprint author), AC Camargo Canc Ctr, Rua Barata Ribeiro 414,Cj 65, BR-01308000 Sao Paulo, Brazil.
EM joaoseda@gmail.com
RI Carnevale, Francisco /I-6135-2015; 
OI Carnevale, Francisco Cesar/0000-0003-2659-9624
CR Anderson CD, 2010, PEDIATR TRANSPLANT, V14, P358, DOI 10.1111/j.1399-3046.2009.01246.x
   Aufort S, 2008, J RADIOL, V89, P221, DOI 10.1016/S0221-0363(08)70397-4
   Beswick DM, 2012, EUR J RADIOL, V81, P2089, DOI 10.1016/j.ejrad.2011.07.008
   Chen HL, 2008, TRANSPL P, V40, P2534, DOI 10.1016/j.transproceed.2008.07.057
   Chok KSH, 2012, J PEDIATR SURG, V47, P1399, DOI 10.1016/j.jpedsurg.2011.12.014
   Conzen KD, 2011, HPB, V13, P893, DOI 10.1111/j.1477-2574.2011.00394.x
   DeBenedet AT, 2013, DIGEST DIS SCI, V58, P3044, DOI 10.1007/s10620-013-2730-x
   Demetris AJ, 2006, HEPATOLOGY, V44, P489, DOI 10.1002/hep.21280
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Englesbe MJ, 2006, AM J TRANSPLANT, V6, P2978, DOI 10.1111/j.1600-6143.2006.01575.x
   Fan ST, 2002, ANN SURG, V236, P676, DOI 10.1097/01.SLA.0000033323.01380.AC
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   Haberal M, 2011, TRANSPL P, V43, P595, DOI 10.1016/j.transproceed.2011.01.009
   Ikegami T, 2011, TRANSPLANTATION, V92, P1147, DOI 10.1097/TP.0b013e3182336073
   Karakayali H, 2005, TRANSPLANT P, V37, P3174, DOI 10.1016/j.transproceed.2005.07.023
   Kim ES, 2009, GASTROINTEST ENDOSC, V69, P38, DOI 10.1016/j.gie.2008.03.1113
   Kinner S, 2011, EUR J RADIOL, V80, pE20, DOI 10.1016/j.ejrad.2010.06.003
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Kok T, 1996, J CLIN ULTRASOUND, V24, P103, DOI 10.1002/(SICI)1097-0096(199603)24:3<103::AID-JCU1>3.0.CO;2-L
   Krokidis Miltiadis, 2013, Insights Imaging, V4, P77, DOI 10.1007/s13244-012-0200-1
   Lin TS, 2013, LIVER TRANSPLANT, V19, P207, DOI 10.1002/lt.23582
   Liu D, 2008, J VASC INTERV RADIOL, V19, P121, DOI 10.1016/j.jvir.2007.08.033
   Miraglia R, 2008, CARDIOVASC INTER RAD, V31, P993, DOI 10.1007/s00270-008-9378-5
   Miraglia R, 2013, CARDIOVASC INTER RAD, V36, P1670, DOI 10.1007/s00270-013-0660-9
   Mita A, 2008, TRANSPL INT, V21, P320, DOI 10.1111/j.1432-2277.2007.00609.x
   Moreira AM, 2010, CARDIOVASC INTER RAD, V33, P90, DOI 10.1007/s00270-009-9619-2
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Potthoff A, 2013, HEPAT MON, V13, DOI 10.5812/hepatmon.6003
   Racadio John M, 2010, Tech Vasc Interv Radiol, V13, P244, DOI 10.1053/j.tvir.2010.04.007
   Righi D, 2008, RADIOL MED, V113, P429, DOI 10.1007/s11547-008-0252-y
   Salvalaggio PRO, 2005, LIVER TRANSPLANT, V11, P161, DOI 10.1002/lt.20288
   Neto JS, 2012, LIVER TRANSPLANT, V18, P577, DOI 10.1002/lt.23393
   Seehofer D, 2013, AM J TRANSPLANT, V13, P253, DOI 10.1111/ajt.12034
   Shah SA, 2007, AM J TRANSPLANT, V7, P161, DOI 10.1111/j.1600-6143.2006.01601.x
   Shirouzu Y, 2008, LIVER TRANSPLANT, V14, P1761, DOI 10.1002/lt.21599
   Soin AS, 2010, J AM COLL SURGEONS, V211, P24, DOI 10.1016/j.jamcollsurg.2010.02.048
   Sunku Bhanu, 2006, Liver Transpl, V12, P821, DOI 10.1002/lt.20712
   Tanaka H, 2010, J PEDIATR SURG, V45, P1668, DOI 10.1016/j.jpedsurg.2010.03.010
   Wang SF, 2011, LIVER TRANSPLANT, V17, P1127, DOI 10.1002/lt.22381
   Yaprak O, 2012, HPB, V14, P49, DOI 10.1111/j.1477-2574.2011.00401.x
NR 40
TC 11
Z9 12
U1 3
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2014
VL 20
IS 8
BP 882
EP 892
DI 10.1002/lt.23896
PG 11
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AO2YZ
UT WOS:000341196200005
PM 24760734
ER

PT J
AU Darius, T
   Rivera, J
   Fusaro, F
   Lai, Q
   de Magnee, C
   Bourdeaux, C
   Janssen, M
   Clapuyt, P
   Reding, R
AF Darius, Tom
   Rivera, Jairo
   Fusaro, Fabio
   Lai, Quirino
   de Magnee, Catherine
   Bourdeaux, Christophe
   Janssen, Magdalena
   Clapuyt, Philippe
   Reding, Raymond
TI Risk Factors and Surgical Management of Anastomotic Biliary
   Complications After Pediatric Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LIVING-RELATED DONORS; MULTIVARIATE-ANALYSIS; BALLOON DILATATION;
   PRIMARY GRAFTS; BILE-DUCT; STRICTURES; RECIPIENTS; EXPERIENCE; CHILDREN;
   IMPACT
AB Biliary complications (BCs) still remain the Achilles heel of liver transplantation (LT) with an overall incidence of 10% to 35% in pediatric series. We hypothesized that (1) the use of alternative techniques (reduced size, split, and living donor grafts) in pediatric LT may contribute to an increased incidence of BCs, and (2) surgery as a first treatment option for anastomotic BCs could allow a definitive cure for the majority of these patients. Four hundred twenty-nine primary pediatric LT procedures, including 88, 91, 47, and 203 whole, reduced size, split, and living donor grafts, respectively, that were performed between July 1993 and November 2010 were retrospectively reviewed. Demographic and surgical variables were analyzed, and their respective impact on BCs was studied with univariate and multivariate analyses. The modalities of BC management were also reviewed. The 1- and 5-year patient survival rates were 94% and 90%, 89% and 85%, 94% and 89%, and 98% and 94% for whole, reduced size, split, and living donor liver grafts, respectively. The overall incidence of BCs was 23% (n = 98). Sixty were anastomotic complications [47 strictures (78%) and 13 fistulas (22%)]. The graft type was not found to be an independent risk factor for the development of BCs. According to a multivariate analysis, only hepatic artery thrombosis and acute rejection increased the risk of anastomotic BCs (P < 0.001 and P = 0.003, respectively). Anastomotic BCs were managed primarily with surgical repair in 59 of 60 cases with a primary patency rate of 80% (n = 47). These results suggest that (1) most of the BCs were anastomotic complications not influenced by the type of graft, and (2) the surgical management of anastomotic BCs may constitute the first and best therapeutic option. (C) 2014 AASLD.
C1 [Darius, Tom; Rivera, Jairo; Fusaro, Fabio; de Magnee, Catherine; Bourdeaux, Christophe; Janssen, Magdalena; Reding, Raymond] Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, B-1200 Brussels, Belgium.
   [Lai, Quirino] Catholic Univ Louvain, Clin Univ St Luc, Starzl Unit Abdominal Transplantat, B-1200 Brussels, Belgium.
   [Clapuyt, Philippe] Catholic Univ Louvain, Clin Univ St Luc, Dept Pediat Radiol, B-1200 Brussels, Belgium.
   [Rivera, Jairo] Fdn Cardioinfantil IC, Transplant Unit, Bogota, Colombia.
RP Darius, T (reprint author), Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, 10 Hippocrate Ave, B-1200 Brussels, Belgium.
EM tom.darius@uclouvain.be
OI LAI, Quirino/0000-0003-1487-3235
CR Anderson CD, 2010, PEDIATR TRANSPLANT, V14, P358, DOI 10.1111/j.1399-3046.2009.01246.x
   Belenky A, 2004, CARDIOVASC INTER RAD, V27, P491, DOI 10.1007/s00270-003-2675-0
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   D'Alessandro AM, 2007, PEDIATR TRANSPLANT, V11, P661, DOI 10.1111/j.1399-3046.2007.00737.x
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   DE MAGNEE C, 2011, ANN SURG, V254, P55
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Gunji H, 2006, AM J SURG, V192, P276, DOI 10.1016/j.amjsurg.2006.01.046
   Heffron TG, 2003, TRANSPLANT P, V35, P1461, DOI 10.1016/S0041-1345(03)00463-9
   Karakayali F, 2013, TRANSPL P, V45, P3524, DOI 10.1016/j.transproceed.2013.09.012
   KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893
   Lopes TL, 2011, J HEPATO-BIL-PAN SCI, V18, P332, DOI 10.1007/s00534-010-0361-6
   Lorenz JM, 2005, AM J ROENTGENOL, V184, P151
   Lorenz JM, 2001, AM J ROENTGENOL, V176, P761
   Miraglia R, 2008, CARDIOVASC INTER RAD, V31, P993, DOI 10.1007/s00270-008-9378-5
   Moreira AM, 2010, CARDIOVASC INTER RAD, V33, P90, DOI 10.1007/s00270-009-9619-2
   NORTHOVER JMA, 1979, BRIT J SURG, V66, P379, DOI 10.1002/bjs.1800660603
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Parlak E, 2010, SURG ENDOSC, V24, P466, DOI 10.1007/s00464-009-0591-3
   Racadio John M, 2010, Tech Vasc Interv Radiol, V13, P244, DOI 10.1053/j.tvir.2010.04.007
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Reding R, 2003, LANCET, V362, P2068, DOI 10.1016/S0140-6736(03)15104-5
   Ryu CN, 2011, GUT LIVER, V5, P133, DOI 10.5009/gnl.2011.5.2.133
   Schwarzenberg SJ, 2002, PEDIATR TRANSPLANT, V6, P132, DOI 10.1034/j.1399-3046.2002.01053.x
   Sunku Bhanu, 2006, Liver Transpl, V12, P821, DOI 10.1002/lt.20712
NR 27
TC 13
Z9 17
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2014
VL 20
IS 8
BP 893
EP 903
DI 10.1002/lt.23910
PG 11
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AO2YZ
UT WOS:000341196200006
PM 24809592
ER

PT J
AU Danziger-Isakov, L
   Bucavalas, J
AF Danziger-Isakov, L.
   Bucavalas, J.
TI Current Prevention Strategies Against Cytomegalovirus in the Studies in
   Pediatric Liver Transplantation (SPLIT) Centers
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Cytomegalovirus; pediatric transplantation; preemptive therapy;
   prophylaxis
ID SOLID-ORGAN TRANSPLANTATION; ORAL GANCICLOVIR; RECIPIENTS; INFECTION;
   CHILDREN; VALGANCICLOVIR; COMPLICATIONS
AB Cytomegalovirus (CMV) continues to be a significant posttransplant infectious complication after pediatric liver transplant (PLT). The optimal prevention strategy is not currently known. To assess current CMV prevention practices, a web-based survey was conducted within the North American Studies in Pediatric Liver Transplantation (SPLIT) network. Twenty-nine of the 31 centers (94%) surveyed responded. Only seven centers reported evidence-based development of protocols. For most at-risk (donor or recipient CMV seropositive) PLT recipients, a prophylactic strategy predominates current practice. For high-risk (D+/R-), only three centers used non-prophylaxis-based protocols: one preemptive and two sequential/hybrid. Duration of prophylaxis ranged from 84 to 730 days with 14 centers using around 100 days and nine centers using around 200 days. Initial therapy with ganciclovir followed by valganciclovir was the most common strategy. For lower-risk recipients (CMV D-/R-), more centers (10/29) employed a preemptive strategy while the remainder described prophylaxis (15) and sequential/hybrid (3) strategies. Prophylaxis predominates current CMV prevention strategies for at-risk recipients within SPLIT. The variation in duration of therapy provides the opportunity to perform comparative effectiveness studies within SPLIT.
C1 [Danziger-Isakov, L.; Bucavalas, J.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
RP Danziger-Isakov, L (reprint author), Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
EM lara.danziger-isakov@cchmc.org
FU SPLIT research committee; Institutional Clinical and Translational
   Science Award, NIH/NCATS [8UL1TR000077-04]
FX We thankfully acknowledge the support of the SPLIT research committee,
   the participation of SPLIT centers and information provided by Jeff
   Mitchell at EMMES Corporation that allowed the completion of this
   survey. We also thank Elizabeth Heubi for her technical expertise with
   REDCap survey. This project was supported by an Institutional Clinical
   and Translational Science Award, NIH/NCATS Grant Number 8UL1TR000077-04.
   Its contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the NIH.
CR Bedel AN, 2012, LIVER TRANSPLANT, V18, P347, DOI 10.1002/lt.22471
   Englesbe MJ, 2012, AM J TRANSPLANT, V12, P2301, DOI 10.1111/j.1600-6143.2012.04204.x
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Kotton CN, 2013, TRANSPLANTATION, V96, P333, DOI 10.1097/TP.0b013e31829df29d
   Krampe K, 2010, PEDIATR TRANSPLANT, V14, P67, DOI 10.1111/j.1399-3046.2008.01120.x
   Kullberg-Lindh C, 2003, PEDIATR TRANSPLANT, V7, P296, DOI 10.1034/j.1399-3046.2003.00086.x
   Lapidus-Krol E, 2010, PEDIATR TRANSPLANT, V14, P753, DOI 10.1111/j.1399-3046.2010.01330.x
   Lauer MS, 2013, NEW ENGL J MED, V369, P1579, DOI 10.1056/NEJMp1310102
   Madan RP, 2009, TRANSPLANTATION, V87, P1318, DOI 10.1097/TP.0b013e3181a19cda
   Saitoh A, 2011, TRANSPLANTATION, V92, P930, DOI 10.1097/TP.0b013e31822d873d
   Turmelle YP, 2009, PEDIATR TRANSPLANT, V13, P553, DOI 10.1111/j.1399-3046.2008.01061.x
NR 11
TC 4
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2014
VL 14
IS 8
BP 1908
EP 1911
DI 10.1111/ajt.12755
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AL9AZ
UT WOS:000339433100028
PM 24903621
ER

PT J
AU Kindel, SJ
   Joy, BF
   Pahl, E
   Wald, EL
AF Kindel, Steven J.
   Joy, Brian F.
   Pahl, Elfriede
   Wald, Eric L.
TI Eosinophilic esophagitis in children following cardiac transplantation:
   Association with post-transplant lymphoproliferative disorder and other
   transplant outcomes
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric cardiac transplant; eosinophilic esophagitis; post-transplant
   lymphoproliferative disease; calcineurin inhibitors
ID PEDIATRIC HEART-TRANSPLANTATION; GASTROINTESTINAL COMPLICATIONS;
   RECIPIENTS; IMMUNOSUPPRESSION; GASTROENTERITIS; KIDNEY
AB Although cardiac transplantation is life-saving, morbidities from immunosuppression are significant. EoE is a complication of calcineurin inhibitors following liver transplant causing feeding intolerance, weight loss, vomiting, and dysphagia. There are limited reports of EoE following heart transplantation. We performed a retrospective single-center review of pediatric cardiac transplant patients from 2000 to 2010. A case-control analysis of patients with and without EoE was performed evaluating heart transplantation outcomes such as rates of rejection, CAV, PTLD, and graft loss. Eighty-six transplants were performed in 84 patients; 34 (40%) underwent diagnostic endoscopy, and 10 (12%) had EoE. Median time to diagnosis of EoE was 3.7 yr (IQR: 2.0-5.2). There were no differences in demographics or use of induction medications between patients with or without EoE. Patients with EoE had fewer episodes of treated rejection (1.0 vs. 2.5; p = 0.04). Four of 10 (40%) EoE patients had PTLD compared with only 2/24 (8%) of those without EoE (p = 0.048; OR 7.33 [95% CI: 1.1-50.2]). There were no differences in CAV or graft loss between groups. EoE should be considered as a cause of GI symptoms in children after cardiac transplantation and may be associated with fewer rejection episodes and increased rates of PTLD, thus representing a marker of over-immunosuppression.
C1 [Kindel, Steven J.] Childrens Hosp & Med Ctr, Div Cardiol, Omaha, NE 68118 USA.
   [Joy, Brian F.] Nationwide Childrens Hosp, Div Cardiol, Columbus, OH USA.
   [Pahl, Elfriede] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA.
   [Wald, Eric L.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Div Crit Care, Chicago, IL 60611 USA.
   [Wald, Eric L.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA.
RP Kindel, SJ (reprint author), Childrens Hosp & Med Ctr, Div Cardiol, 8200 Dodge St, Omaha, NE 68118 USA.
EM skindel@childrensomaha.org
RI Joy, Brian/C-7462-2013
CR AsanteKorang A, 1996, J HEART LUNG TRANSPL, V15, P415
   Bloom RD, 2007, J AM SOC NEPHROL, V18, P3031, DOI 10.1681/ASN.2007040394
   Chin C, 2000, Pediatr Transplant, V4, P193, DOI 10.1034/j.1399-3046.2000.00112.x
   Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886
   DISESA VJ, 1989, TRANSPLANT P, V21, P2579
   Falco DA, 2002, TRANSPLANTATION, V74, P501, DOI 10.1097/00007890-200208270-00012
   Granot E, 2006, PEDIATR TRANSPLANT, V10, P690, DOI 10.1111/j.1399-3046.2006.00542.x
   Kirk R, 2012, J HEART LUNG TRANSPL, V31, P1065, DOI 10.1016/j.healun.2012.08.001
   Levy AM, 1996, GASTROENTEROLOGY, V110, P952, DOI 10.1053/gast.1996.v110.agast960952
   Liacouras CA, 2011, J ALLERGY CLIN IMMUN, V128, pe6
   Liacouras CA, 2011, J ALLERGY CLIN IMMUN, V128, DOI DOI 10.1016/J.JACI.2011.02.040
   Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040
   Mathis AS, 2007, TRANSPLANT P, V39, P199, DOI 10.1016/j.transproceed.2006.10.011
   MATHUR A, 1994, TRANSPLANTATION, V57, P1042, DOI 10.1097/00007890-199404150-00010
   MERRELL SW, 1989, ARCH SURG-CHICAGO, V124, P889
   Noble C, 2009, PEDIATR TRANSPLANT, V13, P827, DOI 10.1111/j.1399-3046.2008.01063.x
   Paolillo JA, 2001, TRANSPLANTATION, V71, P252, DOI 10.1097/00007890-200101270-00015
   Rakhit A, 2002, J HEART LUNG TRANSPL, V21, P751, DOI 10.1016/S1053-2498(02)00383-2
   Romero R, 2003, PEDIATR TRANSPLANT, V7, P484, DOI 10.1046/j.1397-3142.2003.00116.x
   Saeed SA, 2006, PEDIATR TRANSPLANT, V10, P730, DOI 10.1111/j.1399-3046.2006.00538.x
   Schowengerdt KO, 1997, J HEART LUNG TRANSPL, V16, P1207
   STECK TB, 1993, J HEART LUNG TRANSPL, V12, P244
   Stewart S, 2005, J HEART LUNG TRANSPL, V24, P1710, DOI 10.1016/j.healun.2005.03.019
   Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6
NR 24
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2014
VL 18
IS 5
BP 491
EP 496
DI 10.1111/petr.12302
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AL5GA
UT WOS:000339160400022
PM 24931365
ER

PT J
AU Sommovilla, J
   Doyle, MM
   Vachharajani, N
   Saad, N
   Nadler, M
   Turmelle, YP
   Weymann, A
   Chapman, WC
   Lowell, JA
AF Sommovilla, J.
   Doyle, M. M.
   Vachharajani, N.
   Saad, N.
   Nadler, M.
   Turmelle, Y. P.
   Weymann, A.
   Chapman, W. C.
   Lowell, J. A.
TI Hepatic venous outflow obstruction in pediatric liver transplantation:
   Technical considerations in prevention, diagnosis, and management
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatic vein; stenosis; venogram; piggyback
ID SINGLE-CENTER; EXPERIENCE; SIZE; RECONSTRUCTION; COMPLICATIONS; GRAFTS
AB HVOO creates significant diagnostic and management dilemmas in pediatric liver transplant recipients, particularly with TVGs (split or reduced-size grafts). Numerous technical variations for the hepatic vein to IVC anastomosis have been described to minimize the incidence of this complication, but no consensus for an optimal anastomotic technique exists. One hundred and thirty-four liver transplants (70 TVGs) were performed in 124 patients between 1994 and 2011. These were divided into two cohorts. Group 1 (95 transplants, 41 TVGs) utilized a continuous running anastomosis. Group 2 (39 transplants, 29 TVGs) implemented a triangulated (three-stitch) anastomosis. All were reviewed for demographics, diagnostics, interventions, and outcome. The overall HVOO incidence was seven of 134 transplants (5.2%) and six of 70 transplants utilizing TVGs (8.6%). Group 1 incidence was five of 41 (12.2%) compared with one of 29 (3.4%; p = 0.20, OR 3.89) in Group 2. Liver Doppler was employed in all patients, and only three suggested HVOO. All patients with HVOO underwent venogram, at a median of 81 days post-transplant. All underwent percutaneous venoplasty and required 1-6 treatments, all resulting in HVOO resolution. Incidence of HVOO has improved since adopting the triangulated anastomosis, although not to a level of statistical significance. US is not adequately sensitive to exclude HVOO. Venogram is recommended in patients with prolonged
C1 [Sommovilla, J.; Doyle, M. M.; Vachharajani, N.; Chapman, W. C.; Lowell, J. A.] Washington Univ, St Louis Childrens Hosp, Dept Surg, St Louis, MO 63110 USA.
   [Saad, N.] Washington Univ, St Louis Childrens Hosp, Dept Radiol, St Louis, MO 63110 USA.
   [Nadler, M.; Turmelle, Y. P.; Weymann, A.] Washington Univ, St Louis Childrens Hosp, Dept Pediat, St Louis, MO 63110 USA.
RP Sommovilla, J (reprint author), 660 S Euclid Ave,Campus Box 8901, St Louis, MO 63110 USA.
EM sommovillaj@wudosis.wustl.edu
CR Broelsch CE, 1990, ANN SURG, V212, P375, DOI 10.1016/ 0270- 9139( 91) 90202- 7]
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Darcy Michael D, 2007, Tech Vasc Interv Radiol, V10, P240, DOI 10.1053/j.tvir.2007.09.018
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   Gibelli NEM, 2012, PEDIATR TRANSPLANT, V16, pE383, DOI 10.1111/j.1399-3046.2012.01742.x
   Goelitz Brian W, 2007, Semin Intervent Radiol, V24, P333, DOI 10.1055/s-2007-985746
   Heffron TG, 2010, PEDIATR TRANSPLANT, V14, P722, DOI 10.1111/j.1399-3046.2009.01259.x
   Ko GY, 2008, LIVER TRANSPLANT, V14, P1505, DOI 10.1002/lt.21560
   Ko GY, 2002, J VASC INTERV RADIOL, V13, P591, DOI 10.1016/S1051-0443(07)61652-2
   Kumar GK, 2010, PEDIATR SURG INT, V26, P423, DOI 10.1007/s00383-010-2564-y
   Sakamoto S, 2012, PEDIATR TRANSPLANT, V17, pE25
   Shehata MR, 2012, AM J TRANSPLANT, V12, P3406, DOI 10.1111/j.1600-6143.2012.04268.x
   Tannuri U, 2011, J PEDIATR SURG, V46, P1379, DOI 10.1016/j.jpedsurg.2010.11.047
NR 14
TC 5
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2014
VL 18
IS 5
BP 497
EP 502
DI 10.1111/petr.12277
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AL5GA
UT WOS:000339160400023
PM 24815309
ER

PT J
AU Alhosh, R
   Genyk, Y
   Alexopoulos, S
   Thomas, D
   Zhou, SM
   Yanni, G
   Kerkar, N
AF Alhosh, Rabea
   Genyk, Yuri
   Alexopoulos, Sophoclis
   Thomas, Daniel
   Zhou, Shengmei
   Yanni, George
   Kerkar, Nanda
TI Hepatopulmonary syndrome associated with nodular regenerative
   hyperplasia after liver transplantation in a child
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatopulmonary syndrome; nodular regenerative hyperplasia; liver
   transplantation
AB HPS is a significant complication of portal hypertension in children with chronic liver disease and is an established indication for LT. It is characterized clinically by the triad of pulmonary vascular dilatation causing hypoxemia in the setting of advanced liver disease. NRH, a cause of non-cirrhotic portal hypertension, is characterized by diffuse benign transformation of the hepatic parenchyma into small regenerative nodules with minimal or no fibrosis. Development of NRH and HPS in pediatric LT recipients has not been reported, although occasional cases have been reported in adult LT recipients. In this report, we discuss a case of a three-yr-old male who developed HPS, two yr after LT. Pulmonary and cardiac causes for hypoxemia were ruled out by appropriate investigations including a chest X ray, echocardiogram, cardiac catheterization, and a CT angiographic study. The diagnosis of HPS was confirmed via bubble echocardiogram that demonstrated intrapulmonary shunting. Open liver biopsy revealed marked NRH. The patient underwent liver retransplantation that resulted in complete reversal of his pulmonary symptoms and normal oxygen saturations within three months after LT.
C1 [Alhosh, Rabea; Thomas, Daniel; Yanni, George; Kerkar, Nanda] USC, Keck Sch Med, Childrens Hosp Los Angeles, Div Gastroenterol Hepatol & Nutr,Dept Pediat, Los Angeles, CA USA.
   [Genyk, Yuri; Alexopoulos, Sophoclis] USC, Keck Sch Med, Div Hepatobiliary Surg & Abdominal Organ Transpla, Dept Surg,Childrens Hosp Los Angeles, Los Angeles, CA USA.
   [Zhou, Shengmei] USC, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA USA.
   [Yanni, George] LLUCH, Loma Linda, CA USA.
RP Alhosh, R (reprint author), 4650 Sunset Blvd,MS 78, Los Angeles, CA 90027 USA.
EM ralhosh@chla.usc.edu
CR Avendano CE, 2001, LIVER TRANSPLANT, V7, P1081, DOI 10.1053/jlts.2001.29416
   Devearbhavi H, 2007, LIVER TRANSPLANT, V13, P1552
   Grace JA, 2013, J GASTROEN HEPATOL, V28, P213, DOI 10.1111/jgh.12061
   Hartleb M, 2011, WORLD J GASTROENTERO, V17, P1400, DOI 10.3748/wjg.v17.i11.1400
   Paramesh AS, 2003, PEDIATR TRANSPLANT, V7, P157, DOI 10.1034/j.1399-3046.2003.00033.x
   Reshamwala PA, 2006, HEPATOLOGY, V44, P7, DOI 10.1002/hep.21258
   Rodriguez-Roisin R, 2008, NEW ENGL J MED, V358, P2378, DOI 10.1056/NEJMra0707185
   WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512
   Willis AD, 2011, CLIN TRANSPLANT, V25, P849, DOI 10.1111/j.1399-0012.2010.01378.x
NR 9
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2014
VL 18
IS 5
BP E157
EP E160
DI 10.1111/petr.12281
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AL5GA
UT WOS:000339160400005
PM 24820314
ER

PT J
AU Weiner, J
   Wu, J
   Martinez, M
   Lobritto, S
   Ovchinsky, N
   Rohde, C
   Griesemer, A
   Kato, T
AF Weiner, Joshua
   Wu, June
   Martinez, Mercedes
   Lobritto, Steven
   Ovchinsky, Nadia
   Rohde, Christine
   Griesemer, Adam
   Kato, Tomoaki
TI The use of bi-planar tissue expanders to augment abdominal domain in a
   pediatric intestinal transplant recipient
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE tissue expander; intestinal transplantation; abdominal compartment
   syndrome; pediatric transplantation
ID MULTIVISCERAL TRANSPLANTATION; LIVER-TRANSPLANTATION; WALL CLOSURE;
   SMALL-BOWEL; MANAGEMENT; EXPANSION; EXPERIENCE; ALLOGRAFT; CHILDREN;
   DEFECTS
AB Intestinal transplantation is a well-accepted treatment for SBS. However, patients with SBS often have decreased abdominal capacity, which makes size-matching of donor organs more difficult, thus decreasing organ availability. Reported approaches for addressing this problem include surgically reducing the graft size, leaving an open abdomen for a prolonged period, and cotransplanting rectus fascia as a non-vascularized allograft. Each approach has significant disadvantages. There has been one previous report of tissue expanders used intra-abdominally and two reports of subcutaneous use to increase intra-abdominal capacity prior to transplantation. We report the first use of bi-planar expander placement for this purpose. In our case, a two-yr-old male child with SBS due to malrotation was treated with tissue expanders 10 months prior to intestinal transplantation, thus allowing transplantation of a larger graft with the ability to close the abdomen safely. There were no complications, and the patient is now doing well and tolerating diet off PN. The use of tissue expanders prior to intestinal transplantation is a promising approach for such patients and avoids the morbidity associated with other approaches. This approach requires a multidisciplinary effort by gastroenterology, transplant surgery, and plastic surgery teams.
C1 [Weiner, Joshua; Martinez, Mercedes; Lobritto, Steven; Ovchinsky, Nadia; Griesemer, Adam; Kato, Tomoaki] Columbia Univ Coll Phys & Surg, Ctr Liver Dis & Transplantat, New York, NY 10032 USA.
   [Wu, June; Rohde, Christine] Columbia Univ Coll Phys & Surg, Div Plast Surg, New York, NY 10032 USA.
RP Kato, T (reprint author), Columbia Univ, Med Ctr, PH Room 14-105, New York, NY 10032 USA.
EM tk2388@columbia.edu
CR Adetayo OA, 2012, ANN PLAS SURG, V69, P104, DOI 10.1097/SAP.0b013e31822128f5
   Alexandrides IJ, 2000, PLAST RECONSTR SURG, V106, P805, DOI 10.1097/00006534-200009040-00008
   Allin BSR, 2013, AM J TRANSPLANT, V13, P2211, DOI 10.1111/ajt.12337
   Benedetti E, 2003, BEST PRACT RES CL GA, V17, P1017, DOI 10.1053/ybega.2003.417
   Carlsen BT, 2007, PLAST RECONSTR SURG, V119, P1247, DOI 10.1097/01.prs.0000254401.33682.e9
   CARLSEN BT, 2007, PLAST RECONSTR SURG, V119, P1256
   Clifton MS, 2011, J PEDIATR SURG, V46, P372, DOI 10.1016/j.jpedsurg.2010.11.020
   de Goyet Jean de Ville de, 2000, Transplantation (Baltimore), V69, P555, DOI 10.1097/00007890-200002270-00016
   Ersoy YE, 2013, J KOREAN SURG SOC, V84, P61, DOI 10.4174/jkss.2013.84.1.61
   Fahmy MAB, 2014, ANN PLAS SURG, V73, P563, DOI 10.1097/SAP.0b013e3182840866
   Gerlach UA, 2012, CURR OPIN ORGAN TRAN, V17, P258, DOI 10.1097/MOT.0b013e3283534d7b
   Gondolesi G, 2009, TRANSPLANTATION, V87, P1884, DOI 10.1097/TP.0b013e3181a7697a
   Grevious MA, 2009, PEDIATR TRANSPLANT, V13, P177, DOI 10.1111/j.1399-3046.2008.00966.x
   Gupte GL, 2010, J PEDIATR SURG, V45, P1473, DOI 10.1016/j.jpedsurg.2009.08.026
   Inomata Y, 1997, CLIN TRANSPLANT, V11, P56
   Jawan B, 2000, J CLIN ANESTH, V12, P231, DOI 10.1016/S0952-8180(00)00146-X
   Kato T, 2003, J PEDIATR SURG, V38, P145, DOI 10.1053/jpsu.2003.50033
   Marin-Gutzke M, 2008, PLAST RECONSTR SURG, V121, P359, DOI 10.1097/01.prs.0000300303.72029.e2
   Mcadory R Stephen, 2009, Am Surg, V75, P504
   Paletta CE, 1999, ANN PLAS SURG, V42, P259, DOI 10.1097/00000637-199903000-00006
   Reyes J, 1998, TRANSPLANTATION, V66, P489, DOI 10.1097/00007890-199808270-00013
   Ruiz P, 2007, TRANSPLANTATION, V83, P1, DOI 10.1097/01.tp.0000232694.80537.d5
   Selvaggi G, 2009, TRANSPL P, V41, P521, DOI 10.1016/j.transproceed.2009.01.020
   Sheth J, 2012, PEDIATR TRANSPLANT, V16, P36, DOI 10.1111/j.1399-3046.2011.01597.x
   Stefanidis D, 2009, AM SURGEON, V75, P508
   Thompson Jon S, 2012, Curr Probl Surg, V49, P52, DOI 10.1067/j.cpsurg.2011.10.002
   Vidyadharan R, 2013, PEDIATR TRANSPLANT, V17, P646, DOI 10.1111/petr.12138
   Wang CC, 2006, CLIN TRANSPLANT, V20, P81, DOI 10.1111/j.1399-0012.2005.00431.x
   Watson MJ, 2013, TRANSPL INT, V26, P1184, DOI 10.1111/tri.12187
NR 29
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2014
VL 18
IS 5
BP E174
EP E179
DI 10.1111/petr.12282
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AL5GA
UT WOS:000339160400009
PM 25041331
ER

PT J
AU Benini, BB
   Salzedas-Netto, AA
   de Azevedo, RA
   Martins, JL
   Linhares, MM
   Vicentine, FPP
   Gonzalez, AM
AF Benini, B. B.
   Salzedas-Netto, A. A.
   de Azevedo, R. A.
   Martins, J. L.
   Linhares, M. M.
   Vicentine, F. P. P.
   Gonzalez, A. M.
TI Clinical Evaluation of Hepatic Transection on Pediatric Liver
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13th Congress of the Brazilian-Transplantation-Society
CY OCT 12-15, 2013
CL Rio de Janiero, BRAZIL
SP Brazilian Transplantat Soc
ID LONG-TERM OUTCOMES; GRAFT TYPE; SPLIT; IMPACT
AB Objectives. Liver transplantation is an effective technique in the treatment of end-stage liver disease. The aim of this study was to evaluate the impact of hepatic transection, an advanced surgical technique able to tailor size to generate two grafts to from a single donor.
   Materials and Methods. A retrospective study between January 2000 and September 2013, reviewing 91 pediatric patients who underwent 96 liver transplants from deceased donors. Patients were distributed into two groups: whole organ (WO, n = 39) and transected liver grafts (TLG, n = 57). The following were evaluated: etiology, anthrophometric parameters (age, weight, height, z score weight/age, and height/age), model for end-stage liver disease (MELD) or pediatric end-stage liver disease (PELD), previous surgeries, transfusion of blood components, 1-year survival rate, preoperative laboratory testing, from the second and seventh postoperative days, lactate during surgery, postoperative complications, duration of surgery, duration of cold and warm ischemia, types of biliary reconstruction, and laboratory testing of the donor.
   Results. The anthropometric values showed significant differences (P < .05) between the groups. The average age was 124.7 months in the WO group and 33.6 months in the TLG group (P < .0001), while the weight was 28.0 kg and 7.4 kg, respectively (P < .0001). The analysis of z score weight/age showed that the TLG had greater acute and chronic malnutrition, probably due to the etiology of liver disease, present from birth in patients as young. Red blood transfusion was higher in the TLG group (P < .0006) due to the cut surface of the graft, emphasizing the use and improvement of hemostatic techniques.
   Conclusion. Despite differences between the groups, clinical and surgical complications were similar, showing that liver transection injury didn't change the results of transplantation. There was no impact on liver function, graft, or 1-year patient survival after liver transection. Second postoperative lactate is a predictive factor of death. Transection liver transplantation is an effective method as an alternative to pediatric liver transplantation.
C1 [Benini, B. B.; Salzedas-Netto, A. A.; de Azevedo, R. A.; Martins, J. L.; Linhares, M. M.; Vicentine, F. P. P.; Gonzalez, A. M.] Univ Fed Sao Paulo UNIFESP, Hosp Sao Paulo, Dept Surg, Course Gastroenterol Surg, Sao Paulo, Brazil.
RP Benini, BB (reprint author), R Dr Homem de Melo 138, BR-05007000 Sao Paulo, Brazil.
EM barbarabenini@gmail.com
CR Azoulay D, 2001, ANN SURG, V233, P565, DOI 10.1097/00000658-200104000-00013
   Azoulay D, 1996, ANN SURG, V224, P737, DOI 10.1097/00000658-199612000-00009
   Azouz SM, 2011, CURR OPIN ORGAN TRAN, V16, P494, DOI 10.1097/MOT.0b013e32834a8c9c
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Kamath BM, 2010, PEDIATR CLIN N AM, V57, P401, DOI 10.1016/j.pcl.2010.01.012
   Kasahara M, 2013, AM J TRANSPLANT, V13, P1830, DOI 10.1111/ajt.12276
   Salzedas-Netto AA, 2010, TRANSPL P, V42, P507, DOI 10.1016/j.transproceed.2010.01.040
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
   [Anonymous], 2003, ANN SURG
NR 9
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2014
VL 46
IS 6
BP 1778
EP 1780
DI 10.1016/j.transproceed.2014.05.046
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AO1MS
UT WOS:000341076800030
PM 25131035
ER

PT J
AU Szejnfeld, D
   Fornazari, VAV
   Imada, AC
   Linhares, MM
   Azevedo, RA
   Salzedas-Netto, AA
   Gonzalez, AM
   Goldman, SM
AF Szejnfeld, D.
   Fornazari, V. A. V.
   Imada, A. C.
   Linhares, M. M.
   Azevedo, R. A.
   Salzedas-Netto, A. A.
   Gonzalez, A. M.
   Goldman, S. M.
TI Endovascular Management of Massive Hemobilia as a Late Complication of
   Percutaneous Biliary Drainage in a Pediatric Liver Transplant Recipient:
   A Case Report
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13th Congress of the Brazilian-Transplantation-Society
CY OCT 12-15, 2013
CL Rio de Janiero, BRAZIL
SP Brazilian Transplantat Soc
AB Development of biliary strictures after liver transplantation is not uncommon, and minimally invasive procedures are the first-line treatment of choice in most centers. Hemobilia is an infrequent, usually self-limited complication related to the initial biliary access procedure. Massive hemobilia with severe hemodynamic instability is a rare event, particularly as a delayed complication. The difficulty of obtaining surgical access makes management of this condition highly challenging. Endovascular embolization may represent an important treatment option in this setting.
C1 [Szejnfeld, D.; Fornazari, V. A. V.; Goldman, S. M.] Univ Fed Sao Paulo, Dept Diagnost Imaging, Sao Paulo, Brazil.
   [Imada, A. C.; Linhares, M. M.; Azevedo, R. A.; Salzedas-Netto, A. A.; Gonzalez, A. M.] Univ Fed Sao Paulo, Dept Surg, Sao Paulo, Brazil.
RP Szejnfeld, D (reprint author), Univ Fed Sao Paulo, Dept Diagnost Imaging, Sao Paulo, Brazil.
EM denis.cura@gmail.com
RI Szejnfeld, Denis/K-5158-2015
OI Szejnfeld, Denis/0000-0001-8482-5955
CR Fidelman N, 2008, RADIOLOGY, V247, P880, DOI 10.1148/radiol.2473070529
   Moreira AM, 2010, CARDIOVASC INTER RAD, V33, P90, DOI 10.1007/s00270-009-9619-2
   Park JS, 2003, GASTROINTEST ENDOSC, V57, P78, DOI 10.1067/mge.2003.11
   Sharma S, 2008, LIVER TRANSPLANT, V14, P759, DOI 10.1002/lt.21509
   Tashiro H, 2007, WORLD J SURG, V31, P2222, DOI 10.1007/s00268-007-9217-x
   Zarrinpar Ali, 2012, Adv Surg, V46, P87
NR 6
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2014
VL 46
IS 6
BP 1889
EP 1891
DI 10.1016/j.transproceed.2014.05.022
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AO1MS
UT WOS:000341076800057
PM 25131062
ER

PT J
AU Venturi, C
   Sempoux, C
   Quinones, JA
   Bourdeaux, C
   Hoyos, SP
   Sokal, E
   Reding, R
AF Venturi, C.
   Sempoux, C.
   Quinones, J. A.
   Bourdeaux, C.
   Hoyos, S. P.
   Sokal, E.
   Reding, R.
TI Dynamics of Allograft Fibrosis in Pediatric Liver Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Allograft survival; children; liver fibrosis; liver transplantation;
   long-term outcome; scoring system
ID FOLLOW-UP; AUTOIMMUNE HEPATITIS; PROPE TOLERANCE; GRAFT FIBROSIS;
   SCORING SYSTEM; SINGLE-CENTER; CHILDREN; RECIPIENTS; SURVIVORS; DISEASES
AB Progressive liver allograft fibrosis (LAF) is well known to occur long term, as shown by its high prevalence in late posttransplant liver biopsies (LBs). To evaluate the influence of clinical variables and immunosuppression on LAF progression, LAF dynamic was assessed in 54 pediatric liver transplantation (LT) recipients at 6 months, 3 and 7 years post-LT, reviewing clinical, biochemical data and protocol LBs using METAVIR and the liver allograft fibrosis score, previously designed and validated specifically for LAF assessment. Scoring evaluations were correlated with fibrosis quantification by morphometric analysis. Progressive LAF was found in 74% of long-term patients, 70% of whom had unaltered liver enzymes. Deceased grafts showed more fibrosis than living-related grafts (p=0.0001). Portal fibrosis was observed in correlation with prolonged ischemia time, deceased grafts and lymphoproliferative disease (p=0.001, 0.006 and 0.012, respectively). Sinusoidal fibrosis was correlated with biliary complications (p=0.01). Centrilobular fibrosis was associated with vascular complications (p=0.044), positive autoantibodies (p=0.017) and high gamma-globulins levels (p=0.028). Steroid therapy was not associated with reduced fibrosis (p=0.83). LAF could be viewed as a dynamic process with mostly progression along the time. Peri- and post-LT-associated factors may condition fibrosis development in a specific area of the liver parenchyma.
C1 [Venturi, C.; Bourdeaux, C.; Reding, R.] Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, B-1200 Brussels, Belgium.
   [Sempoux, C.] Catholic Univ Louvain, Clin Univ St Luc, Dept Pathol, B-1200 Brussels, Belgium.
   [Quinones, J. A.] Catholic Univ Louvain, Gastroenterol Lab, B-1200 Brussels, Belgium.
   [Hoyos, S. P.] Autonomous Univ Barcelona, Hosp Vall dHebron, Barcelona, Spain.
   [Sokal, E.] Catholic Univ Louvain, Clin Univ St Luc, Dept Pediat, Gastroenterol & Hepatol Unit, B-1200 Brussels, Belgium.
RP Venturi, C (reprint author), Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, B-1200 Brussels, Belgium.
EM carla.venturi@uclouvain.be
CR Abdalla Ahmed F, 2009, Fibrogenesis Tissue Repair, V2, P2, DOI 10.1186/1755-1536-2-2
   Abraham SC, 2008, AM J SURG PATHOL, V32, P1479, DOI 10.1097/PAS.0b013e31817a8e96
   Bourdeaux C, 2009, TRANSPL INT, V22, P416, DOI 10.1111/j.1432-2277.2008.00807.x
   Bourdeaux C, 2013, PEDIATR TRANSPLANT, V17, P59, DOI 10.1111/petr.12024
   Calne R, 2005, TRANSPLANTATION, V80, P6, DOI 10.1097/01.TP.0000164351.72220.1A
   CHEVALLIER M, 1994, HEPATOLOGY, V20, P349, DOI 10.1016/0270-9139(94)90185-6
   Demetris A, 2000, Hepatology, V31, P792
   Dufour JF, 1997, ANN INTERN MED, V127, P981
   Egawa H, 2012, HEPATOL RES, V42, P895, DOI 10.1111/j.1872-034X.2012.01003.x
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   GARVEY W, 1984, STAIN TECHNOL, V59, P213
   Goodman ZD, 2007, HEPATOLOGY, V45, P886, DOI 10.1002/hep.21595
   Goodman ZD, 2007, J HEPATOL, V47, P598, DOI 10.1016/j.jhep.2007.07.006
   Hammel P, 2001, NEW ENGL J MED, V344, P418, DOI 10.1056/NEJM200102083440604
   JIMENEZ W, 1985, HEPATOLOGY, V5, P815, DOI 10.1002/hep.1840050517
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Lau DTY, 1999, GASTROENTEROLOGY, V117, P1229, DOI 10.1016/S0016-5085(99)70409-9
   Martin SR, 2002, TRANSPLANTATION, V74, P828, DOI 10.1097/00007890-200209270-00017
   Menghini G, 1971, Quad Sclavo Diagn, V7, P1213
   Mieli-Vergani G, 2011, BEST PRACT RES CL GA, V25, P783, DOI 10.1016/j.bpg.2011.10.007
   Miyagawa-Hayashino A, 2012, LIVER TRANSPLANT, V18, P1333, DOI 10.1002/lt.23534
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   PARES A, 1986, J HEPATOL, V2, P33, DOI 10.1016/S0168-8278(86)80006-X
   PUCHTLER H, 1988, HISTOCHEMISTRY, V88, P243
   Reding R, 2003, LANCET, V362, P2068, DOI 10.1016/S0140-6736(03)15104-5
   Rosenthal P, 1997, Liver Transpl Surg, V3, P559
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Scheuer PJ, 2003, HEPATOLOGY, V38, P1356, DOI 10.1016/j.hep.2003.10.010
   Sohrabpour AA, 2012, ALIMENT PHARM THER, V36, P824, DOI 10.1111/apt.12044
   The French METAVIR Cooperative Study Group, 1994, HEPATOLOGY, V20, P15
   Venturi C, 2012, AM J TRANSPLANT, V12, P2986, DOI 10.1111/j.1600-6143.2012.04210.x
NR 33
TC 5
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2014
VL 14
IS 7
BP 1648
EP 1656
DI 10.1111/ajt.12740
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9JE
UT WOS:000338024700025
PM 24934832
ER

PT J
AU Szymczak, M
   Kalicinski, P
   Kwiatkowski, W
   Broniszczak, D
   Stefanowicz, M
AF Szymczak, Marek
   Kalicinski, Piotr
   Kwiatkowski, Wojciech
   Broniszczak, Dorota
   Stefanowicz, Marek
TI Cavo-portal transposition in pediatric liver transplant recipients
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE Children; Portal Vein; Liver Transplantation
ID CAVOPORTAL HEMITRANSPOSITION; PORTACAVAL HEMITRANSPOSITION; VEIN
   THROMBOSIS; SINGLE-CENTER; EXPERIENCE; OVERCOME
AB Background: Cavo-portal transposition (CPT) at liver transplantation (LTx) allows portal revascularization of the liver in recipients in whom portal system thrombosis does not allow performance of porto-portal anastomosis. The aim was to present the cases of 2 children who underwent LTx and CPT in our institution.
   Case Report: 1. A 10-year-old boy, after Kasai procedure and living donor LTx, was qualified for retransplantation 9 years after first LTx complicated with late portal vein thrombosis, portal hypertension, hypersplenism, and multiple GI bleeding episodes, after splenectomy and meso-caval shunt preventing GI bleeding. At retransplant surgery, CPT was done. Actual follow-up was 40 months. Doppler ultrasound and angio CT show normal flow within the graft's portal vein. Biochemical parameters were within normal range. There was no bleeding from the gastrointestinal tract. 2. A 14-month-old child after Kasai procedure was qualified for living donor liver transplantation. During surgery, thrombosis of the recipient portal system was found, which was not diagnosed before. The CPT was done. There were no complications during the postoperative course. The actual follow-up was 32 months, and the patient is doing well, with normal liver and renal function, without hypersplenism or ascites. There was no gastrointestinal bleeding. Doppler ultrasound showed normal intrahepatic portal and arterial flow in the transplanted liver.
   Conclusions: Cavo-portal transposition is an important option in portal vein revascularization in liver transplant recipients without access to the portal system. Long-term observation of these 2 cases did not show any late problems (e. g., bleeding from the gastrointestinal tract, renal function, hyperammonemia, ascites) related to cavo-portal transposition.
C1 [Szymczak, Marek; Kalicinski, Piotr; Kwiatkowski, Wojciech; Broniszczak, Dorota; Stefanowicz, Marek] Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, Warsaw, Poland.
RP Szymczak, M (reprint author), Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, Warsaw, Poland.
EM m.szymczak@czd.pl
CR Azoulay D, 2000, J AM COLL SURGEONS, V190, P493, DOI 10.1016/S1072-7515(99)00299-9
   Borchert DH, 2008, ANN HEPATOL, V7, P200
   CHILD CG, 1953, ANN SURG, V138, P600, DOI 10.1097/00000658-195310000-00013
   Gerunda GE, 2002, LIVER TRANSPLANT, V8, P72, DOI 10.1053/jlts.2002.30404
   Kumar N, 2003, LIVER TRANSPLANT, V9, P874, DOI 10.1053/jlts.2003.50150
   Lipshutz GS, 2006, LIVER TRANSPLANT, V12, P1097, DOI 10.1002/lt.20770
   Orlando G, 2004, TRANSPLANT P, V36, P199, DOI 10.1016/j.transproceed.2003.11.014
   Pinna AD, 2001, TRANSPLANT P, V33, P1329, DOI 10.1016/S0041-1345(00)02495-7
   Selvaggi G, 2007, AM J TRANSPLANT, V7, P454, DOI 10.1111/j.1600-6143.2006.01649.x
   Tzakis AG, 1998, TRANSPLANTATION, V65, P619, DOI 10.1097/00007890-199803150-00004
   Urbani L, 2002, TRANSPLANT P, V34, P3331, DOI 10.1016/S0041-1345(02)03698-9
   Wang C, 2005, TRANSPLANT P, V37, P2163, DOI 10.1016/j.transproceed.2005.03.003
   Yan ML, 2008, HEPATOB PANCREAT DIS, V7, P322
NR 13
TC 0
Z9 1
U1 0
U2 0
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD JUN 10
PY 2014
VL 19
BP 283
EP 287
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AQ8GP
UT WOS:000343063000001
PM 24916138
ER

PT J
AU Fukuda, A
   Sakamoto, S
   Shigeta, T
   Uchida, H
   Hamano, I
   Sasaki, K
   Kanazawa, H
   Loh, DL
   Kakee, N
   Nakazawa, A
   Kasahara, M
AF Fukuda, A.
   Sakamoto, S.
   Shigeta, T.
   Uchida, H.
   Hamano, I.
   Sasaki, K.
   Kanazawa, H.
   Loh, D. L.
   Kakee, N.
   Nakazawa, A.
   Kasahara, M.
TI Clinical Outcomes and Evaluation of the Quality of Life of Living Donors
   for Pediatric Liver Transplantation: A Single-Center Analysis of 100
   Donors
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID HEPATIC LOBE DONATION; SF-36 HEALTH SURVEY; VANCOUVER FORUM; SURGICAL
   COMPLICATIONS; INTESTINE DONOR; PANCREAS; LUNG; CLASSIFICATION;
   GUIDELINES; EXPERIENCE
AB There are few reports about the quality of life (QOL) and morbidities of pediatric living donor liver transplantation (LDLT) donors. We evaluated the potential morbidities and identified the predictive factors regarding the QOL of living donors after pediatric LDLT. This cross-sectional study was a single-center analysis of 100 donors for pediatric LDLT. The severity of morbidities was assessed with the Clavien classification, the QOL was investigated with the short form-36 (SF-36), and the decision-making process regarding donation was analyzed with questionnaires. The median follow-up period was 3.8 years (range, 2.2-6.0 years). A total of 13% of the donors developed postoperative complications of Clavien grades I (7%), 11 (3%), and IIIA (3%). There was no grade IV morbidity or mortality. Eighty-one donors responded to the questionnaire and SF-36. The analysis of the questionnaires revealed that the donors had difficulty in the decision-making process, and suggested that it may be necessary to administer multistep informed consent. We identified unique predictive risk factors for lower SF-36 scores in the donors, which were the time to donation (more than 4 weeks) and the predonation self-oriented perception. The donors who have risk factors require enhanced pre- and post-donation psychological care.
C1 [Fukuda, A.; Sakamoto, S.; Shigeta, T.; Uchida, H.; Hamano, I.; Sasaki, K.; Kanazawa, H.; Loh, D. L.; Nakazawa, A.; Kasahara, M.] Natl Ctr Child Hlth & Dev, Transplantat Ctr, Tokyo 1578535, Japan.
   [Kakee, N.] Natl Res Inst Child Hlth & Dev, Dept Hlth Policy, Tokyo, Japan.
RP Fukuda, A (reprint author), Natl Ctr Child Hlth & Dev, Transplantat Ctr, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM fukuda-a@ncchd.go.jp
FU National Center for Child Health and Development [H21-4, H24-8]
FX Supported by a Grant from the National Center for Child Health and
   Development (H21-4, H24-8).
CR Azoulay D, 2011, AM J TRANSPLANT, V11, P101, DOI 10.1111/j.1600-6143.2010.03284.x
   Barr ML, 2006, TRANSPLANTATION, V81, P1373, DOI 10.1097/01.tp.0000216825.56841.cd
   Basaran O, 2003, TRANSPLANT P, V35, P2768, DOI 10.1016/j.transproceed.2003.09.088
   Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443
   Chan SC, 2006, LIVER TRANSPLANT, V12, P1437, DOI 10.1002/lt.20835
   Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2
   Crowley-Matoka M, 2004, AM J TRANSPLANT, V4, P744, DOI 10.1111/j.1600-6143.2004.00377.x
   Delmonico FL, 2006, TRANSPLANTATION, V82, P1245, DOI 10.1097/01.tp.0000241233.43707.25
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Dubay DA, 2009, AM J TRANSPLANT, V9, P1169, DOI 10.1111/j.1600-6143.2009.02614.x
   Erim Y, 2006, LIVER TRANSPLANT, V12, P1782, DOI 10.1002/lt.20907
   Erim Y, 2007, LIVER TRANSPLANT, V13, P886, DOI 10.1002/lt.21168
   Feltrin A, 2008, TRANSPL INT, V21, P466, DOI 10.1111/j.1432-2277.2007.00632.x
   Florman S, 2006, LIVER TRANSPLANT, V12, P499, DOI 10.1002/lt.20754
   Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1045, DOI 10.1016/S0895-4356(98)00096-1
   Fukuhara S, 1998, J CLIN EPIDEMIOL, V51, P1037, DOI 10.1016/S0895-4356(98)00095-X
   Kim-Schluger L, 2002, TRANSPLANTATION, V73, P1593, DOI 10.1097/00007890-200205270-00012
   Kroencke S, 2006, LIVER TRANSPLANT, V12, P1661, DOI 10.1002/lt.20862
   Miller C, 2013, LIVER TRANSPLANT, V19, P656, DOI 10.1002/lt.23637
   Morimoto T, 1996, TRANSPLANT INT, V9, P208, DOI 10.1111/j.1432-2277.1996.tb00881.x
   Nakamuta M, 2005, TRANSPLANTATION, V80, P608, DOI 10.1097/01.tp.0000166009.77444.f3
   Parikh ND, 2010, LIVER TRANSPLANT, V16, P1352, DOI 10.1002/lt.22181
   Pascher A, 2002, LIVER TRANSPLANT, V8, P829, DOI 10.1053/jlts.2002.34896
   Pruett TL, 2006, TRANSPLANTATION, V81, P1386, DOI 10.1097/01.tp.0000214976.36526.e3
   Ringe B, 2008, TRANSPLANTATION, V85, P790, DOI 10.1097/TP.0b013e318167345e
   Schulz KH, 2009, LIVER TRANSPLANT, V15, P1676, DOI 10.1002/lt.21917
   Surman OS, 2002, NEW ENGL J MED, V346, P1038, DOI 10.1056/NEJM200204043461402
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Trotter JF, 2002, NEW ENGL J MED, V346, P1074, DOI 10.1056/NEJMra011629
   Trotter JF, 2001, LIVER TRANSPLANT, V7, P485, DOI 10.1053/jlts.2001.24646
   Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4
   Verbesey JE, 2005, AM J TRANSPLANT, V5, P2770, DOI 10.1111/j.1600-6143.2005.01092.x
   Walter M, 2003, TRANSPLANT P, V35, P2961, DOI 10.1016/j.transproceed.2003.10.048
   [Anonymous], 2010, TRANSPLANTATION, V90, P229
   [Anonymous], 2008, TRANSPLANTATION, V86, P1013
NR 35
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2014
VL 46
IS 5
BP 1371
EP 1376
DI 10.1016/j.transproceed.2013.12.054
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AK0GJ
UT WOS:000338090600019
PM 24836837
ER

PT J
AU Uchida, H
   Sakamoto, S
   Sasaki, K
   Hamano, I
   Shigeta, T
   Kanazawa, H
   Fukuda, A
   Nosaka, S
   Kubota, M
   Kasahara, M
AF Uchida, Hajime
   Sakamoto, Seisuke
   Sasaki, Kengo
   Hamano, Ikumi
   Shigeta, Takanobu
   Kanazawa, Hiroyuki
   Fukuda, Akinari
   Nosaka, Shunsuke
   Kubota, Masaya
   Kasahara, Mureo
TI Central pontine myelinolysis following pediatric living donor liver
   transplantation: A case report and review of literature
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE sirolimus; neurological complications; pediatric liver transplantation;
   living donor liver transplantation; calcineurin inhibitors
ID NEUROLOGICAL COMPLICATIONS; SIROLIMUS; NEUROTOXICITY; EXPERIENCE;
   RECIPIENTS
AB CPM is one of the most serious neurological complications that can occur after OLT and is characterized by symmetrical demyelinization in the basis pontis. The etiology of CPM remains unclear, although the rapid correction of the serum sodium and CNI concentrations may be associated with the development of CPM. With recent advances in MRI technology, early diagnosis of CPM has become possible. Here, we present the case of a five-yr-old female who developed CNI-associated CPM after undergoing LDLT. A decreased level of consciousness and dysphasia was noted onewk after LDLT, and MRI revealed findings compatible with a diagnosis of CPM. The patient fully recovered from the neurological deficits related to CPM following the switch from the CNI to sirolimus. We propose MRI to be promptly considered for patients with abnormal neurological findings, together with the substitution of CNI with an mTOR inhibitor as a management regimen for CNI-related CPM.
C1 [Uchida, Hajime; Sakamoto, Seisuke; Sasaki, Kengo; Hamano, Ikumi; Shigeta, Takanobu; Kanazawa, Hiroyuki; Fukuda, Akinari; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Transplantat Ctr, Tokyo 1578535, Japan.
   [Nosaka, Shunsuke] Natl Ctr Child Hlth & Dev, Div Radiol, Tokyo 1578535, Japan.
   [Kubota, Masaya] Natl Ctr Child Hlth & Dev, Div Neurol, Tokyo 1578535, Japan.
RP Uchida, H (reprint author), Natl Ctr Child Hlth & Dev, Transplantat Ctr, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM uchida-h@ncchd.go.jp
FU National Center for Child Health and Development [25-6]
FX This work was supported by the Grant from the National Center for Child
   Health and Development (25-6). We would like to thank Dr. Julian Tang
   from the Department of Education for Clinical Research, National Center
   for Child Health and Development, for proofreading and editing this
   manuscript.
CR Basso MS, 2011, PEDIATR TRANSPLANT, V15, P722, DOI 10.1111/j.1399-3046.2011.01560.x
   BOON AP, 1988, LANCET, V2, P458
   BOON AP, 1991, J CLIN PATHOL, V44, P909, DOI 10.1136/jcp.44.11.909
   Chang GJ, 2000, LIVER TRANSPLANT, V6, P734, DOI 10.1053/jlts.2000.19023
   Cui R, 2012, PEDIATR TRANSPLANT, V16, P251
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   ESTOL CJ, 1989, NEUROLOGY, V39, P493
   Forgacs B, 2005, TRANSPLANT P, V37, P1912, DOI 10.1016/j.transproceed.2005.02.101
   Fukazawa K, 2011, ANN TRANSPL, V16, P139
   HALL WA, 1989, PEDIATR NEUROSCI, V15, P269, DOI 10.1159/000120482
   Kato T, 2002, BRAIN DEV-JPN, V24, P179, DOI 10.1016/S0387-7604(02)00013-X
   Lee EM, 2009, EUR NEUROL, V62, P362, DOI 10.1159/000242426
   Lui CC, 2000, TRANSPLANT P, V32, P2215, DOI 10.1016/S0041-1345(00)01640-7
   Maramattom BV, 2004, NEUROLOGY, V63, P1958
   Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061
   Morath C, 2007, NEPHROL DIAL TRANSPL, V22, P61, DOI 10.1093/ndt/gfm652
   Pearce JMS, 2009, EUR NEUROL, V61, P59, DOI 10.1159/000175124
   STARZL TE, 1978, ANN SURG, V187, P236, DOI 10.1097/00000658-197803000-00003
   Vivarelli M, 2006, TRANSPLANT INT, V19, P1022, DOI 10.1111/j.1432-2277.2006.00381.x
   Yu J, 2004, WORLD J GASTROENTERO, V10, P2540
NR 20
TC 0
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2014
VL 18
IS 4
BP E120
EP E123
DI 10.1111/petr.12255
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AG4LZ
UT WOS:000335392700005
PM 24725019
ER

PT J
AU Xue, MG
   Masand, P
   Thompson, P
   Finegold, M
   Leung, DH
AF Xue, Megan
   Masand, Prakash
   Thompson, Patrick
   Finegold, Milton
   Leung, Daniel H.
TI Angiosarcoma successfully treated with liver transplantation and
   sirolimus
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; sirolimus; pediatric liver transplantation;
   child; malignancy
ID HEPATIC ANGIOSARCOMA; MTOR INHIBITOR; RAPAMYCIN; CHILDHOOD; CHILDREN;
   TUMORS; HEMANGIOENDOTHELIOMA; EVEROLIMUS; IMMUNOSUPPRESSANT;
   COMPLICATIONS
AB Malignant liver tumors represent approximately 1% of malignancies in children. HA is a high-grade tumor of endothelial cells that is even more rare in the pediatric population. HA has a limited response to chemotherapy, radiation and resection with universal tumor recurrence with LT and nearly 100% mortality by 18 months. This is the first reported successful case of hepatic angiosarcoma in a child who was treated by LT in combination with sirolimus. Sirolimus antagonizes the mTOR pathway, which regulates cell proliferation, differentiation, and migration, and is being studied as an anti-neoplastic agent for solid tumors.
C1 [Xue, Megan; Thompson, Patrick; Leung, Daniel H.] Baylor Coll Med, Houston, TX 77030 USA.
   [Masand, Prakash] Texas Childrens Hosp, Div Pediat Radiol, Houston, TX 77030 USA.
   [Thompson, Patrick] Texas Childrens Hosp, Div Pediat Hematol & Oncol, Houston, TX 77030 USA.
   [Finegold, Milton] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
   [Finegold, Milton] Texas Childrens Hosp, Houston, TX 77030 USA.
   [Leung, Daniel H.] Texas Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.
RP Xue, MG (reprint author), Baylor Coll Med, One Baylor Plaza, Houston, TX 77030 USA.
EM mmxue@bcm.edu
CR ALT B, 1985, Pediatric Pathology, V4, P331
   Austin MT, 2006, J PEDIATR SURG, V41, P182, DOI 10.1016/j.jpedsurg.2005.10.091
   Awan S, 1996, J PEDIATR SURG, V31, P1729, DOI 10.1016/S0022-3468(96)90065-2
   Bessho K, 2010, EUR J PEDIATR, V169, P215, DOI 10.1007/s00431-009-1009-x
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   Bundscherer A, 2010, ANTICANCER RES, V30, P4017
   Dimashikieh HH, 2004, PEDIATR DEVEL PATHOL, V7, P527, DOI 10.1007/s10024-004-4041-x
   Dunkelberg JC, 2003, LIVER TRANSPLANT, V9, P463, DOI 10.1053/jlts.2003.50079
   Emre S, 2004, PEDIATR TRANSPLANT, V8, P632, DOI 10.1111/j.1399-3046.2004.00268.x
   FALK H, 1981, CANCER, V47, P382, DOI 10.1002/1097-0142(19810115)47:2<382::AID-CNCR2820470228>3.0.CO;2-N
   FERRARI S, 1993, J BIOL CHEM, V268, P16091
   Geramizadeh B, 2011, J PEDIATR SURG, V46, pE9, DOI 10.1016/j.jpedsurg.2010.09.005
   GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222
   Gunawardena SW, 1997, MED PEDIATR ONCOL, V28, P139
   Halefoglu AM, 2007, TURKISH J PEDIATR, V49, P77
   Husted TL, 2006, AM J TRANSPLANT, V6, P392, DOI 10.1111/j.1600-6143.2005.01179.x
   Kalpatthi R, 2007, PEDIATR BLOOD CANCER, V49, P1021, DOI 10.1002/pbc.20801
   Kim Eun Hee, 2011, Korean Journal of Pediatrics, V54, P260, DOI 10.3345/kjp.2011.54.6.260
   Knight RJ, 2007, CLIN TRANSPLANT, V21, P460, DOI 10.1111/j.1399-0012.2007.00668.x
   Kochin IN, 2011, ISR MED ASSOC J, V13, P542
   Law BK, 2005, CRIT REV ONCOL HEMAT, V56, P47, DOI 10.1016/j.critrevonc.2004.09.009
   Lebwohl D, 2013, ANN NY ACAD SCI, V1291, P14, DOI 10.1111/nyas.12122
   Maluf D, 2005, TRANSPLANT P, V37, P2195, DOI 10.1016/j.transproceed.2005.03.060
   Meyers RL, 2007, SURG ONCOL, V16, P195, DOI 10.1016/j.suronc.2007.07.002
   Montalbano M, 2004, TRANSPLANTATION, V78, P264, DOI 10.1097/01.tp.0000128628.31556.b1
   Morgenstern DA, 2014, PEDIATR BLOOD CANCER, V61, P128, DOI 10.1002/pbc.24656
   Nazir Z, 2006, J PEDIATR SURG, V41, DOI 10.1016/j.jpedsurg.2005.10.078
   Ng W. H., 2003, SMJ Singapore Medical Journal, V44, P491
   O'Reilly T, 2010, TRANSL ONCOL, V3, P65, DOI 10.1593/tlo.09277
   Otte JB, 2010, PEDIATR TRANSPLANT, V14, P295, DOI 10.1111/j.1399-3046.2010.01322.x
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Saliba F, 2013, AM J TRANSPLANT, V13, P1734, DOI 10.1111/ajt.12280
   SELBY DM, 1992, PEDIATR PATHOL, V12, P485
   Sharma Pratima, 2013, Gastroenterology, V144, P459, DOI 10.1053/j.gastro.2012.12.015
   Trotter JF, 2003, TRANSPLANT P, V35, p193S, DOI 10.1016/S0041-1345(03)00234-3
NR 35
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2014
VL 18
IS 4
BP E114
EP E119
DI 10.1111/petr.12245
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA AG4LZ
UT WOS:000335392700004
PM 24641525
ER

PT J
AU Kivela, JM
   Kosola, S
   Kalajoki-Helmio, T
   Makisalo, H
   Jalanko, H
   Holmberg, C
   Pakarinen, MP
   Lauronen, J
AF Kivela, Jesper M.
   Kosola, Silja
   Kalajoki-Helmio, Teija
   Makisalo, Heikki
   Jalanko, Hannu
   Holmberg, Christer
   Pakarinen, Mikko P.
   Lauronen, Jouni
TI Late hepatic artery thrombosis after pediatric liver transplantation: A
   cross-sectional study of 34 patients
SO LIVER TRANSPLANTATION
LA English
DT Article
ID VASCULAR COMPLICATIONS; RISK-FACTORS; EXPERIENCE; REDUCE
AB Hepatic artery thrombosis (HAT) after liver transplantation (LT) increases patient morbidity and mortality. Early HAT is considered to occur within the first month after LT, whereas late HAT occurs after the first month. Few studies have addressed late HAT after LT, especially in pediatric patients. Between 1987 and 2007, 99 patients (age < 18 years) underwent deceased donor LT. Thirty-four of 66 eligible patients (52%) underwent magnetic resonance imaging (MRI) according to protocol. On the basis of MRI findings, the patients were grouped as those who experienced late HAT and those who did not. Additionally, potential risk factors for late HAT were analyzed retrospectively. P values were adjusted for multiplicity. The median age at LT was 1.7 years [interquartile range (IQR) = 1.0-9.6 years], and the median follow-up time at MRI was 9.5 years (IQR = 4.0-16.4 years). Late HAT was diagnosed in 15 of the 34 patients [44%, 95% confidence interval (CI) = 29%-61%] undergoing MRI and in 3 of these patients with angiography preceding MRI. Ultrasonography revealed late HAT in 6 of these 15 patients with a sensitivity of 40% (95% CI = 20%-64%). The donor/recipient weight ratio remained significantly higher for the patients with late HAT versus the patients without late HAT after P values were adjusted (5.4 versus 1.9, P = 0.03). No marked differences were observed in laboratory or liver histology parameters between the groups. In conclusion, late HAT is common after pediatric LT. The donor/recipient weight ratio was higher for patients with late HAT, and this was attributable to the lower weight of the recipients. No salient features of late HAT were observed with respect to laboratory or histological parameters, at least in terms of our study's cross-sectional period. Liver Transpl 20:591-600, 2014. (c) 2014 AASLD.
C1 [Kivela, Jesper M.; Jalanko, Hannu; Holmberg, Christer] Childrens Hosp, Dept Pediat Nephrol & Transplantat, Helsinki, Finland.
   [Kosola, Silja; Pakarinen, Mikko P.] Childrens Hosp, Dept Pediat Surg, Helsinki, Finland.
   [Kalajoki-Helmio, Teija] Childrens Hosp, Dept Radiol, Helsinki Med Imaging Ctr, Helsinki, Finland.
   [Makisalo, Heikki] Univ Helsinki, Cent Hosp, Hosp Dist Helsinki & Uusimaa, Dept Transplantat & Liver Surg, Helsinki, Finland.
   [Makisalo, Heikki] Univ Helsinki, Helsinki, Finland.
   [Kivela, Jesper M.] Natl Grad Sch Clin Invest, Helsinki, Finland.
   [Lauronen, Jouni] Finnish Red Cross Blood Serv, Helsinki, Finland.
RP Kivela, JM (reprint author), Univ Helsinki, Cent Hosp, Dept Pediat Nephrol & Transplantat,Biomedicum 2C, Childrens Hosp,Hosp Dist Helsinki & Uusimaa, Room 605,POB 705, FI-00029 Helsinki, Finland.
EM jesper.m.kivela@helsinki.fi
FU Sigrid Juselius Foundation; Finnish Medical Foundation; Mary and Georg
   C. Ehrnrooth Foundation; National Graduate School of Clinical
   Investigation
FX This study was funded by the Sigrid Juselius Foundation, the Finnish
   Medical Foundation, the Mary and Georg C. Ehrnrooth Foundation, and the
   National Graduate School of Clinical Investigation.
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Bhattacharjya S, 2001, TRANSPLANTATION, V71, P1592, DOI 10.1097/00007890-200106150-00018
   Bonett DG, 2002, PSYCHOL METHODS, V7, P370, DOI 10.1037//1082-989X.7.3.370
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Gunsar F, 2003, LIVER TRANSPLANT, V9, P605, DOI 10.1053/jlts.2003.50057
   Horrow MM, 2007, AM J ROENTGENOL, V189, P346, DOI 10.2214/AJR.07.2217
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Kelly DA, 2013, LIVER TRANSPLANT, V19, P798, DOI 10.1002/lt.23697
   Kosola S, 2013, LIVER TRANSPLANT, V19, P145, DOI 10.1002/lt.23565
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   MCDIARMID SV, 1991, J PEDIATR SURG, V26, P710, DOI 10.1016/0022-3468(91)90016-M
   Newson R., BPMEDIAN STATA MODUL
   Newson RB, 2010, STATA J, V10, P568
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Panaro F, 2011, TRANSPL INT, V24, P949, DOI 10.1111/j.1432-2277.2011.01293.x
   Pareja E, 2010, TRANSPL P, V42, P2970, DOI 10.1016/j.transproceed.2010.07.063
   Prasad V, 2013, J CLIN EPIDEMIOL, V66, P361, DOI 10.1016/j.jclinepi.2012.11.005
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   Sanchez SE, 2012, J PEDIATR SURG, V47, P1255, DOI 10.1016/j.jpedsurg.2012.03.035
   Shay R, 2013, TRANSPL P, V45, P330, DOI 10.1016/j.transproceed.2012.05.075
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   Vivarelli M, 2007, LIVER TRANSPLANT, V13, P651, DOI 10.1002/lt.21028
   Wolf D C, 1997, Liver Transpl Surg, V3, P598, DOI 10.1002/lt.500030608
NR 25
TC 5
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAY
PY 2014
VL 20
IS 5
BP 591
EP 600
DI 10.1002/lt.23852
PG 10
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AF8GF
UT WOS:000334953000012
PM 24535829
ER

PT J
AU Cheng, YF
   Ou, HY
   Yu, CY
   Tsang, LLC
   Huang, TL
   Chen, TY
   Concejero, A
   Wang, CC
   Wang, SH
   Lin, TS
   Liu, YW
   Yang, CH
   Yong, CC
   Chiu, KW
   Jawan, B
   Eng, HL
   Chen, CL
AF Cheng, Yu-Fan
   Ou, Hsin-You
   Yu, Chun-Yen
   Tsang, Leo Leung-Chit
   Huang, Tung-Liang
   Chen, Tai-Yi
   Concejero, Allan
   Wang, Chih-Chi
   Wang, Shih-Ho
   Lin, Tsan-Shiun
   Liu, Yueh-Wei
   Yang, Chin-Hsiang
   Yong, Chee-Chien
   Chiu, King-Wah
   Jawan, Bruno
   Eng, Hock-Liew
   Chen, Chao-Long
TI SECTION 8. MANAGEMENT OF PORTAL VENOUS COMPLICATIONS IN PEDIATRIC LIVING
   DONOR LIVER TRANSPLANTATION
SO TRANSPLANTATION
LA English
DT Article
DE Portal vein occlusion; Portal vein complication; Stent; Living donor
   liver transplantation; Pediatric liver transplantation
ID VEIN THROMBOSIS; STENOSIS; EXPERIENCE
AB Portal vein (PV) complications after living donor liver transplant (LDLT) have been a major concern in pediatric liver transplantation. The incidence of PV complications is more in pediatric (0%-33%) than in adult recipients. Early diagnosis and treatment of PV complications may ensure optimal graft function and good recipient survival. Small preoperation PV size (<4 mm) and slow portal flow (<10 cm/s) combined with lower hepatic artery resistance index (<0.65) are strong warning signs that may predict the development of post LDLT PV complications. Portal vein angioplasty/stenting is conventionally performed through the percutaneous transhepatic approach; however, this can also be performed through transjugular, trans-splenic, and intraoperative approaches. Depending on the situation, using optimal method is the key point to minimize complication (5%) and gain high success rate (80%). PV occlusion of greater than 1 year with cavernous transformation seems to be a factor causing technical failure. Good patency rate (100%) with self-expandable metallic stents was noted in long-term follow-up. In conclusion, PV stent placement is an effective, long-term treatment modality to manage PV complications after pediatric LDLT. Early diagnosis and treatment are essential to maximize the use of stent placement and achieve good success rates.
C1 [Cheng, Yu-Fan; Ou, Hsin-You; Yu, Chun-Yen; Tsang, Leo Leung-Chit; Huang, Tung-Liang; Chen, Tai-Yi] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung 83305, Taiwan.
   [Concejero, Allan; Wang, Chih-Chi; Wang, Shih-Ho; Lin, Tsan-Shiun; Liu, Yueh-Wei; Yang, Chin-Hsiang; Yong, Chee-Chien; Chen, Chao-Long] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung 83305, Taiwan.
   [Chiu, King-Wah] Kaohsiung Chang Gung Mem Hosp, Dept Med, Div Hepatogastroenterol, Kaohsiung 83305, Taiwan.
   [Jawan, Bruno] Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung 83305, Taiwan.
   [Eng, Hock-Liew] Kaohsiung Chang Gung Mem Hosp, Dept Pathol, Kaohsiung 83305, Taiwan.
RP Chen, CL (reprint author), Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program, 123 Tai Pei Rd, Kaohsiung 83305, Taiwan.
EM clchen@cgmh.org.tw
FU National Science Council, Taiwan [NSC 96-231-B-182A-009, NSC
   94-231-B-182A-009]
FX This work was supported by Grant NSC 96-231-B-182A-009 and NSC
   94-231-B-182A-009 from the National Science Council, Taiwan.
CR Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Chen CL, 2012, J VASC INTERV RADIOL, V23, P724, DOI 10.1016/j.jvir.2012.01.056
   Cheng YF, 2010, AM J TRANSPLANT, V10, P1276, DOI 10.1111/j.1600-6143.2010.03076.x
   Cheng YF, 2009, LIVER TRANSPLANT, V15, P1378, DOI 10.1002/lt.21813
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Fan Sheung-Tat, 2002, Hepatobiliary Pancreat Dis Int, V1, P166
   Huang TL, 2010, TRANSPL P, V42, P879, DOI 10.1016/j.transproceed.2010.02.036
   Ko GY, 2007, LIVER TRANSPLANT, V13, P530, DOI 10.1002/lt.21068
   LERUT J, 1987, ANN SURG, V205, P404, DOI 10.1097/00000658-198704000-00011
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   OTTO G, 1992, CHIRURG, V63, P730
   Ou HY, 2011, SURGERY, V149, P40, DOI 10.1016/j.surg.2010.04.018
   Lopez Santamaria M, 2001, CIR PEDIAT, V14, P135
   Seu P, 1996, ARCH SURG-CHICAGO, V131, P840
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Unsinn KM, 2003, AM J ROENTGENOL, V181, P1139
NR 17
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD APR 27
PY 2014
VL 97
IS 8
SU S
BP S32
EP S34
DI 10.1097/01.tp.0000446272.05687.ce
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AL4KW
UT WOS:000339102800010
PM 24849830
ER

PT J
AU Lim, WX
   Cheng, YF
   Huang, TL
   Chen, TY
   Tsang, LLC
   Ou, HY
   Yu, CY
   Hsu, HW
   Chen, CL
AF Lim, W. -X.
   Cheng, Y. -F.
   Huang, T. -L.
   Chen, T. -Y.
   Tsang, L. L. -C.
   Ou, H. -Y.
   Yu, C. -Y.
   Hsu, H. -W.
   Chen, C. -L.
TI Graft Regeneration in Pediatric Living Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID BILIARY ATRESIA; INFANTS; SURVIVAL
AB Objective. Due to the shortage of cadaver liver grafts in Asia, more than 90% of biliary atresia (BA) patients require living donor liver transplantation (LDLT), but the factors that influence liver graft regeneration in pediatric patients are still unclear. The aim of this study was to evaluate the potential predisposing factors that encourage liver graft regeneration in pediatric liver transplantation (LT).
   Methods. Case notes and Doppler ultrasound and computed tomography studies performed before and 6 months after transplantation of 103 BA patients who underwent LDLT were reviewed. The predisposing factors that triggered liver regeneration were compiled from statistical analyses and included the following: age, gender, body weight and height, spleen size, graft weight to recipient weight ratio (GRWR), post-transplantation total portal flow, and vascular complications.
   Results. Seventy-two pediatric recipients were enrolled in this study. The liver graft regeneration rate was 29.633 +/- 36.61% (range, -29.53-126.27%). The size of the spleen (P = .001), post-transplantation portal flow (P = .004), and age (P = .04) were correlated lineally with the regeneration rate. The GRWR was negatively correlated with the regeneration rate (P = .001) and was the only independent factor that affected the regeneration rate. When the GRWR was > 3.4, patients tended to have poor and negative graft regeneration (P = .01).
   Conclusion. Large-for-size grafts have negative effect on regeneration rates because liver grafts that are too large can compromise total portal flow and increase vascular complications, especially when the GRWR is > 3.4. Thus, optimal graft size is more essential than other factors in a pediatric LDLT patient.
C1 [Lim, W. -X.; Cheng, Y. -F.; Huang, T. -L.; Chen, T. -Y.; Tsang, L. L. -C.; Ou, H. -Y.; Yu, C. -Y.; Hsu, H. -W.] Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program, Kaohsiung, Taiwan.
   [Lim, W. -X.; Cheng, Y. -F.; Huang, T. -L.; Chen, T. -Y.; Tsang, L. L. -C.; Ou, H. -Y.; Yu, C. -Y.; Hsu, H. -W.] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung, Taiwan.
   [Chen, C. -L.] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung, Taiwan.
   [Chen, C. -L.] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
RP Yu, CY (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, 123 Ta Pei Rd, Kaohsiung, Taiwan.
EM y7192215@ms17.hinet.net
CR BREIMAN RS, 1982, AM J ROENTGENOL, V138, P329
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Cheng YF, 2009, AM J TRANSPLANT, V9, P1382, DOI 10.1111/j.1600-6143.2009.02626.x
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   Guo CB, 2010, TRANSPL P, V42, P1750, DOI 10.1016/j.transproceed.2010.02.086
   Iglesias J, 2004, PEDIATR TRANSPLANT, V8, P228, DOI 10.1111/j.1399-3046.2004.00128.x
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Migliazza L, 2000, J PEDIATR SURG, V35, P5, DOI 10.1016/S0022-3468(00)80066-4
   Mizuta K, 2010, TRANSPL P, V42, P4127, DOI 10.1016/j.transproceed.2010.11.002
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   Saing H, 1999, J PEDIATR SURG, V34, P172
   Schulze M, 2011, TRANSPL INT, V24, P797, DOI 10.1111/j.1432-2277.2011.01277.x
NR 13
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2014
VL 46
IS 3
BP 767
EP 769
DI 10.1016/j.transproceed.2013.10.048
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AG3DB
UT WOS:000335294900028
PM 24767344
ER

PT J
AU Urahashi, T
   Mizuta, K
   Ihara, Y
   Sanada, Y
   Wakiya, T
   Yamada, N
   Okada, N
AF Urahashi, Taizen
   Mizuta, Koichi
   Ihara, Yoshiyuki
   Sanada, Yukihiro
   Wakiya, Taiichi
   Yamada, Naoya
   Okada, Noriki
TI Impact of post-transplant flow cytometric panel-reactive antibodies on
   late-onset hepatic venous outflow obstruction following pediatric living
   donor liver transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE hepatic venous outflow obstruction; flow cytometric panel-reactive
   antibody assay; living donor liver transplantation
ID SINGLE-CENTER EXPERIENCE; VEIN RECONSTRUCTION; ALLOGRAFT-REJECTION;
   ENDOTHELIAL-CELLS; HLA ANTIBODIES; DISEASE; VENOPLASTY; TOLERANCE;
   ANTIGENS
AB The development of late-onset hepatic venous outflow obstruction (LOHVOO) following pediatric living donor liver transplantation (LDLT) can lead to uncontrollable fibrotic damage in liver grafts, even long-term patency of the graft outflow is achieved with appropriate therapeutic modalities. The aim of this study was to verify our hypothesis that some immunological responses, particularly cellular and/or antibody-mediated rejection (AMR), are associated with LOHVOO, which occurs following damage to liver sinusoidal endothelial cells in zone 3 of liver grafts. One hundred and eighty-nine patients underwent LDLT between May 2001 and December 2010 at our institute. Nine patients (4.8%) were identified as having LOHVOO. The preoperative factors, operative factors, and mortality, morbidity, and survival rates were examined and compared between the groups with and without LOHVOO. No statistical differences were observed between the groups with regard to preoperative factors, technical factors, or postoperative complications. However, FlowPRA reactivity was found to be a statistically significant risk factor for LOHVOO (P=0.006). The patients with both class I- and class II-reactive antibodies also had a significant risk of developing LOHVOO (P=0.03) and exhibited significantly higher retransplant rates. In conclusion, although further studies are needed to clarify this phenomenon, the pathophysiological mechanism underlying the development of LOHVOO after LDLT may be explained by immune-mediated responses that facilitate damage in zone 3 of liver grafts.
C1 [Urahashi, Taizen; Mizuta, Koichi; Ihara, Yoshiyuki; Sanada, Yukihiro; Wakiya, Taiichi; Yamada, Naoya; Okada, Noriki] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Urahashi, T (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM turahashi@jichi.ac.jp
CR Abraham SC, 2008, AM J SURG PATHOL, V32, P1479, DOI 10.1097/PAS.0b013e31817a8e96
   Akamatsu N, 2004, TRANSPLANTATION, V77, P1768, DOI 10.1097/01.TP.0000131162.35391.9D
   BARBATIS C, 1981, GUT, V22, P985, DOI 10.1136/gut.22.12.985
   Bayraktar UD, 2007, WORLD J GASTROENTERO, V13, P1912
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cisneros L, 2007, LIVER TRANSPLANT, V13, P1017, DOI 10.1002/lt.21178
   Coppell JA, 2003, BLOOD REV, V17, P63, DOI 10.1016/S0268-960X(03)00002-X
   Darcy Michael D, 2007, Tech Vasc Interv Radiol, V10, P240, DOI 10.1053/j.tvir.2007.09.018
   EGAWA H, 1993, CLIN TRANSPLANT, V7, P306
   Egawa H, 1997, SURGERY, V121, P250, DOI 10.1016/S0039-6060(97)90353-6
   HUBSCHER SG, 1990, J PATHOL, V162, P165, DOI 10.1002/path.1711620210
   Knechtle SJ, 2009, SEMIN LIVER DIS, V29, P91, DOI 10.1055/s-0029-1192058
   KRAUS TW, 1992, BRIT J SURG, V79, P568, DOI 10.1002/bjs.1800790631
   Kubo T, 2006, RADIOLOGY, V239, P285, DOI 10.1148/radiol.2391050387
   Kubota K, 2000, SURGERY, V128, P48, DOI 10.1067/msy.2000.106783
   Limmer A, 2000, NAT MED, V6, P1348
   Mihaylova A, 2006, HUM IMMUNOL, V67, P787, DOI 10.1016/j.humimm.2006.07.011
   Miyagawa-Hayashino A, 2012, LIVER TRANSPLANT, V18, P1333, DOI 10.1002/lt.23534
   Mizuta K, 2012, TRANSPL P, V44, P469, DOI 10.1016/j.transproceed.2011.11.014
   Musat AI, 2011, AM J TRANSPLANT, V11, P500, DOI 10.1111/j.1600-6143.2010.03414.x
   Pei R, 1998, HUM IMMUNOL, V59, P313, DOI 10.1016/S0198-8859(98)00020-2
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   Sakamoto S, 2009, PEDIATR TRANSPLANT, V13, P507, DOI 10.1111/j.1399-3046.2008.01003.x
   Sakashita H, 2007, MODERN PATHOL, V20, P676, DOI 10.1038/modpathol.3800784
   Sebagh M, 2011, LIVER TRANSPLANT, V17, P798, DOI 10.1002/lt.22282
   Sumitran-Holgersson S, 2004, HEPATOLOGY, V40, P1211, DOI 10.1002/hep.20434
   Sze DY, 1999, TRANSPLANTATION, V68, P446, DOI 10.1097/00007890-199908150-00018
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Terasaki PI, 2003, AM J TRANSPLANT, V3, P665, DOI 10.1034/j.1600-6143.2003.00135.x
   Urahashi T, 2011, PEDIATR TRANSPLANT, V15, P798, DOI 10.1111/j.1399-3046.2011.01572.x
   Urahashi T, 2012, EXP CLIN TRANSPLANT, V10, P350, DOI 10.6002/ect.2012.0075
NR 31
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0934-0874
EI 1432-2277
J9 TRANSPL INT
JI Transpl. Int.
PD MAR
PY 2014
VL 27
IS 3
BP 322
EP 329
DI 10.1111/tri.12255
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AA4OE
UT WOS:000331074600014
PM 24299518
ER

PT J
AU Lee, YJ
   Yum, MS
   Kim, EH
   Choi, HW
   Oh, SH
   Kim, DY
   Kim, KM
   Ko, TS
AF Lee, Yun Jeong
   Yum, Mi-Sun
   Kim, Eun-Hee
   Choi, Hae-Won
   Oh, Seak Hee
   Kim, Dae Yeon
   Kim, Kyung Mo
   Ko, Tae-Sung
TI Risk factors for neurological complications and their correlation with
   survival following pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; neurological complication; immunosuppressive
   treatment; children
ID NERVOUS-SYSTEM COMPLICATIONS; HEPATIC-ENCEPHALOPATHY; SINGLE-CENTER;
   CALCINEURIN INHIBITORS; EXPERIENCE; RECIPIENTS; CHILDREN; OUTCOMES;
   DEATH
AB Despite the improved outcomes of LT, post-operative NCs remain a significant cause of morbidity and mortality. The aim of the study was to identify the incidence of and risk factors for NCs in children who underwent LT. The medical records of pediatric patients who underwent LT at Asan Medical Center Children's Hospital between January 1994 and December 2010 were retrospectively analyzed. The onset and types of NC and pretransplant variables associated with NC were evaluated. We identified 190 children (85 boys [44.7%], 105 girls [55.3%]) of mean age 4.1 +/- 4.7yr, who underwent LT. Forty-six NCs occurred in 41 (21.6%) patients after LT, the most common being seizures (n=13, 28.3%) and encephalopathy (n=10, 21.7%). Of the 46 NCs, 24 (52.2%) occurred within three months after LT. Multivariate analysis showed that primary liver disease, preoperative neurological problems, preoperatively higher serum creatinine concentration, and graft failure were significant risk factors for NCs. The survival rate was significantly lower for patients with NCs than for those without (p<0.001). NCs after pediatric LTs were common and associated with a higher mortality rate in our study. Close monitoring and appropriate risk management may improve the long-term outcomes of pediatric patients who undergo LT.
C1 [Lee, Yun Jeong; Yum, Mi-Sun; Kim, Eun-Hee; Choi, Hae-Won; Oh, Seak Hee; Kim, Kyung Mo; Ko, Tae-Sung] Univ Ulsan, Coll Med, Asan Med Ctr, Childrens Hosp,Dept Pediat, Seoul 138736, South Korea.
   [Kim, Dae Yeon] Univ Ulsan, Coll Med, Asan Med Ctr, Childrens Hosp,Dept Pediat Surg, Seoul 138736, South Korea.
RP Ko, TS (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Childrens Hosp,Dept Pediat, 388-1 Pungnap Dong, Seoul 138736, South Korea.
EM tsko@amc.seoul.kr
OI Kim, Kyung Mo/0000-0001-7896-6751
CR Amodio P, 2007, DIGEST LIVER DIS, V39, P740, DOI 10.1016/j.dld.2007.05.004
   Bechstein WO, 2000, TRANSPLANT INT, V13, P313, DOI 10.1111/j.1432-2277.2000.tb01004.x
   Bhaduri BR, 1996, SEMIN LIVER DIS, V16, P349, DOI 10.1055/s-2007-1007248
   Bronster DJ, 2000, CLIN TRANSPLANT, V14, P1, DOI 10.1034/j.1399-0012.2000.140101.x
   Butterworth RF, 2007, METAB BRAIN DIS, V22, P309, DOI 10.1007/s11011-007-9072-3
   Campagna F, 2010, METAB BRAIN DIS, V25, P115, DOI 10.1007/s11011-010-9183-0
   Cordoba J, 2001, J HEPATOL, V35, P598, DOI 10.1016/S0168-8278(01)00181-7
   Dawson TM, 1996, ANN NEUROL, V40, P559, DOI 10.1002/ana.410400403
   Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   Feng S, 2012, JAMA-J AM MED ASSOC, V307, P283, DOI 10.1001/jama.2011.2014
   Fernandez D, 2010, TRANSPLANTATION, V90, P319, DOI 10.1097/TP.0b013e3181e5b7fc
   Frederick RT, 2012, CLIN LIVER DIS, V16, P147, DOI 10.1016/j.cld.2011.12.004
   Garcia-Martinez R, 2011, LIVER TRANSPLANT, V17, P38, DOI 10.1002/lt.22197
   GARG BP, 1993, PEDIATR NEUROL, V9, P444, DOI 10.1016/0887-8994(93)90023-6
   Ghosh PS, 2012, J PEDIATR GASTR NUTR, V54, P540, DOI 10.1097/MPG.0b013e3182407de3
   GRIDELLI B, 1994, TRANSPLANT P, V26, P193
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Kamath BM, 2010, PEDIATR CLIN N AM, V57, P401, DOI 10.1016/j.pcl.2010.01.012
   Kim JM, 2013, J KOREAN MED SCI, V28, P42, DOI 10.3346/jkms.2013.28.1.42
   Lewis MB, 2003, NEUROLOGY, V61, P1174
   Mazariegos GV, 2007, TRANSPL IMMUNOL, V17, P114, DOI 10.1016/j.trim.2006.09.033
   McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511
   MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010
   Oh SH, 2012, TRANSPL P, V44, P484, DOI 10.1016/j.transproceed.2012.02.002
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   Santos MM, 2011, PEDIATR TRANSPLANT, V15, P157, DOI 10.1111/j.1399-3046.2010.01430.x
   Sindhi R, 2005, PEDIATR TRANSPLANT, V9, P391, DOI 10.1111/j.1399-3046.2005.00360.x
   Staatz CE, 2004, LIVER TRANSPLANT, V10, P506, DOI 10.1002/lt.20065
   Tannuri U, 2007, PEDIATR TRANSPLANT, V11, P82, DOI 10.1111/j.1399-3046.2006.00631.x
   Tredger JM, 2008, DRUGS, V68, P1385, DOI 10.2165/00003495-200868100-00004
   Vizzini G, 2011, LIVER TRANSPLANT, V17, P1279, DOI 10.1002/lt.22383
   Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7
NR 33
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2014
VL 18
IS 2
BP 177
EP 184
DI 10.1111/petr.12218
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 304IK
UT WOS:000330740100015
PM 24372703
ER

PT J
AU Quintero, J
   Ortega, J
   Miserachs, M
   Bueno, J
   Bilbao, I
   Charco, R
AF Quintero, Jesus
   Ortega, Juan
   Miserachs, Mar
   Bueno, Javier
   Bilbao, Itxarone
   Charco, Ramon
TI Low plasma levels of antithrombin III in the early post-operative period
   following pediatric liver transplantation: Should they be replaced? A
   single-center pilot study
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE low-molecular-weight heparin; children; anticoagulation; early hepatic
   artery thrombosis
ID HEPATIC-ARTERY THROMBOSIS; VASCULAR COMPLICATIONS; URGENT
   REVASCULARIZATION; FIBRINOLYTIC PROFILES; COAGULATION; HEPARIN;
   ANTICOAGULATION; PROPHYLAXIS; CHILDREN; DONORS
AB eHAT after LT remains a life-threatening complication. In the majority of anticoagulation protocols, heparin is used to prevent thromboses. Our study aimed to monitor AT-III levels in the early post-LT period to assess the need for the administration of AT-III concentrate to ensure the effectiveness of heparin. We monitored coagulation daily by measuring INR, APTT, fibrinogen, platelets, and AT-III. Anticoagulation therapy consisted of LMWH, AT-III, and dipyridamole. AT-III concentrate was administered when AT-III activity was 60%. DUS was performed daily for the first five post-operative days or whenever vascular thrombosis was suspected. Between October 2007 and October 2011, 39 LT were performed in our center. The median age was 26months (6-196) with a median weight of 9kg (5.5-49). AT-III activity was 60% in 27 patients. Lower levels were particularly observed in partial grafts and recipients weighing less than 10kg. Patent arterial flow was present in all 39 LT during the first five post-operative days. AT-III levels were low in 70% of pediatric patients following LT, thereby risking heparin ineffectiveness. These results may implicate low AT-III levels in the etiology of eHAT post-LT. However, this is a small single-center pilot study and further larger prospective trials are required to confirm these results.
C1 [Quintero, Jesus; Miserachs, Mar] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Pediat Liver Transplant Unit, E-08193 Barcelona, Spain.
   [Ortega, Juan] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Pediat Intens Care Unit, E-08193 Barcelona, Spain.
   [Bueno, Javier] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, E-08193 Barcelona, Spain.
   [Bilbao, Itxarone; Charco, Ramon] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, HBP Surg & Transplant Dept, Liver Transplant Unit, E-08193 Barcelona, Spain.
RP Quintero, J (reprint author), Avinguda Vall dHebron 119-129, Barcelona 08035, Spain.
EM 38633jqb@gmail.com
RI Bilbao, Itxarone/N-4358-2014
OI Bilbao, Itxarone/0000-0002-7389-395X
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Bueno J, 2007, TRANSPL P, V39, P2278, DOI 10.1016/j.transproceed.2007-07-042
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Duffy JP, 2009, J AM COLL SURGEONS, V896, P903, DOI DOI 10.1016/J.JAMCOLLSURG.2008.12.032
   FRANCIS CW, 1991, SEMIN HEMATOL, V28, P39
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   Kaneko J, 2005, CLIN TRANSPLANT, V19, P804, DOI 10.1111/j.1399-0012.2005.00425.x
   Kaneko J, 2009, INT J LAB HEMATOL, V31, P81, DOI 10.1111/j.1751-553X.2007.01008.x
   Margarit C, 1998, Transpl Int, V11 Suppl 1, pS248, DOI 10.1111/j.1432-2277.1998.tb01125.x
   Maruzzelli L, 2010, CARDIOVASC INTER RAD, V33, P1111, DOI 10.1007/s00270-010-9848-4
   Mclin VA, 2011, PEDIATR TRANSPLANT, V15, P117, DOI 10.1111/j.1399-3046.2010.01426.x
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Olson ST, 2010, BIOCHIMIE, V92, P1587, DOI 10.1016/j.biochi.2010.05.011
   Polak WG, 2008, CLIN TRANSPLANT, V22, P171, DOI 10.1111/j.1399-0012.2007.00762.x
   Quinsey NS, 2004, INT J BIOCHEM CELL B, V36, P386, DOI 10.1016/S1357-2725(03)00244-9
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   STAHL RL, 1990, HEPATOLOGY, V12, P553, DOI 10.1002/hep.1840120317
   Stewart ZA, 2009, LIVER TRANSPLANT, V15, P1688, DOI 10.1002/lt.21946
   Uchikawa Y, 2009, TRANSPL P, V41, P3784, DOI 10.1016/j.transproceed.2009.04.011
   VELASCO F, 1992, TRANSPLANTATION, V53, P1256, DOI 10.1097/00007890-199206000-00017
   Warnaar N, 2008, CURR OPIN ORGAN TRAN, V13, P298, DOI 10.1097/MOT.0b013e3282fce79d
   Warnaar N, 2010, LIVER TRANSPLANT, V16, P847, DOI 10.1002/lt.22063
NR 23
TC 2
Z9 3
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2014
VL 18
IS 2
BP 185
EP 189
DI 10.1111/petr.12217
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 304IK
UT WOS:000330740100016
PM 24438318
ER

PT J
AU Kanmaz, T
   Yankol, Y
   Mecit, N
   Durmaz, O
   Acarli, K
   Kalayoglu, M
AF Kanmaz, Turan
   Yankol, Yucel
   Mecit, Nesimi
   Durmaz, Ozlem
   Acarli, Koray
   Kalayoglu, Munci
TI Pediatric Liver Transplant: A Single-center Study of 100 Consecutive
   Patients
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Children; Liver transplant; Outcome
ID CHILDREN
AB Objectives: Here, we present the outcomes of 100 consecutive pediatric liver transplant patients in our center.
   Materials and Methods: Five hundred fifteen adult and pediatric liver transplants were performed at Organ Transplantation Center, Sisli Memorial Hospital, Istanbul, Turkey, between August 2006 and November 2012. Of these, the first 100 consecutive pediatric liver transplant patients were retrospectively analyzed.
   Results: One hundred three liver transplants were performed in 100 children (mean age, 4.7 y; age range, 4.4 mo to 17.3 y; 53% female, 47% male; mean body weight, 17.2 kg; range, 4.5 to 75 kg). Biliary atresia (27%) and progressive familial intrahepatic cholestasis (18%) were the most common causes of liver disease. Of all the cases, 88.4% were living-donor liver transplants. Arterial reconstruction was performed under an operating microscope in Most cases. Duct-to-duct biliary anastomoses were preferred in anatomically favorable cases. Mean hospital stay was 17.5 days. Median follow-up was 19.9 months (range, 6 to 66.1 mo). The main complication after surgery was infection (34%). Postoperative technical complications included hepatic arterial thrombosis (3.9%), portal venous thrombosis (6.8%), and biliary leak (6.8%). One-, 3-, and 5-year patient survivals were 89.8%, 89.8%, and 83.8%. There were no serious postoperative complications in the living donors.
   Conclusions: Living-donor liver transplant in pediatric patients is a safe alternative to deceased-donor transplant. It is becoming the most frequent treatment option for end-stage liver disease in pediatric patients in our center, given the paucity of pediatric deceased-donor organs.
C1 [Kanmaz, Turan; Yankol, Yucel; Mecit, Nesimi; Durmaz, Ozlem; Acarli, Koray; Kalayoglu, Munci] Sisli Mem Hosp, Organ Transplantat Ctr, Istanbul, Turkey.
RP Kanmaz, T (reprint author), Mem Hosp, Organ Transplantat Ctr, Pryalepasa Bulvari, TR-34385 Istanbul, Turkey.
EM turan.kanmaz@memorial.com.tr
CR Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Emre S, 2012, MT SINAI J MED, V79, P199, DOI 10.1002/msj.21305
   Haberal M, 2008, EXP CLIN TRANSPLANT, V6, P7
   KALAYOGLU M, 1993, SURGERY, V114, P711
   KALAYOGLU M, 1993, SURGERY, V114, P717
   Kamath BM, 2010, PEDIATR CLIN N AM, V57, P401, DOI 10.1016/j.pcl.2010.01.012
   Lee GS, 1999, TRANSPLANTATION, V68, P909
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   McDiarmid SV, 1998, TRANSPLANTATION, V66, P1604, DOI 10.1097/00007890-199812270-00006
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   Takahashi Y, 2009, PEDIATR SURG INT, V25, P745, DOI 10.1007/s00383-009-2430-y
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
NR 13
TC 4
Z9 4
U1 0
U2 2
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD FEB
PY 2014
VL 12
IS 1
BP 41
EP 45
DI 10.6002/ect.2013.0016
PG 5
WC Transplantation
SC Transplantation
GA AB4TL
UT WOS:000331782700008
PM 24471723
ER

PT J
AU Simpson, KE
   Esmaeeli, A
   Khanna, G
   White, F
   Turnmelle, Y
   Eghtesady, P
   Boston, U
   Canter, CE
AF Simpson, Kathleen E.
   Esmaeeli, Amir
   Khanna, Geetika
   White, Francis
   Turnmelle, Yumirle
   Eghtesady, Pirooz
   Boston, Umar
   Canter, Charles E.
TI Liver cirrhosis in Fontan patients does not affect 1-year post-heart
   transplant mortality or markers of liver function
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE liver cirrhosis; Fontan procedure; heart transplant; pediatric
   cardiology; liver transplant
ID HEPATIC-FIBROSIS; CIRCULATION; OPERATION; DISEASE; COMPLICATIONS;
   CHILDREN; SURGERY; TERM
AB BACKGROUND: Liver cirrhosis is recognized with long-term follow-up of patients after the Fontan procedure. The effect of liver cirrhosis on the use of heart transplant (HT) and on post-HT outcomes is unknown.
   METHODS: We reviewed Fontan patients evaluated for HT from 2004 to 2012 with hepatic computed tomography (CT) imaging, classified as normal, non-cirrhotic changes, or cirrhosis. The primary outcome was 1-year all-cause mortality, and the secondary outcome was differences in serial post-HT liver evaluation.
   RESULTS: CT imaging in 32 Fontan patients evaluated for HT revealed 20 (63%) with evidence of liver disease, including 13 (41%) with cirrhosis. Twenty underwent HT, including 5 non-cirrhotic and 7 cirrhosis patients. Characteristics at listing between normal or non-cirrhotic (n = 13) and cirrhosis (n = 7) groups were similar, except cirrhosis patients were older (median 17.6 vs 9.6 years, p = 0.002) and further from Fontan (median 180 vs 50 months, p < 0.05). Serial liver evaluation was similar, including aspartate aminotransferase, alanine aminotransferase, bilirubin, albumin, and tacrolimus dose at 1, 3, 6, 9, and 12 months. Overall patient survival was 80% at 1 year, with no difference between cirrhosis and non-cirrhosis patients (86% vs 77%, p = 0.681). Liver biopsies were performed in 7 patients before HT, and all specimens showed architectural changes with bridging fibrosis.
   CONCLUSIONS: Most patients evaluated for HT had abnormal liver findings by CT, with cirrhosis in 41%. One-year mortality and serial liver evaluation were similar between groups after HT. Liver cirrhosis identified by CT imaging may not be an absolute contraindication to HT alone in this population. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Simpson, Kathleen E.; Turnmelle, Yumirle; Canter, Charles E.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   [Esmaeeli, Amir] Washington Univ, Sch Med, St Louis, MO 63110 USA.
   [Khanna, Geetika] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA.
   [White, Francis] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
   [Eghtesady, Pirooz; Boston, Umar] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
RP Simpson, KE (reprint author), Washington Univ, 1 Childrens Pl, St Louis, MO 63110 USA.
EM simpson_k@kids.wustl.edu
OI Eghtesady, Pirooz/0000-0001-7161-8391
FU Washington University Institute of Clinical and Translational Sciences
   [UL1TR000448]; National Center for Advancing Translational Sciences
   (NCATS) [TL1TR000449]
FX This publication was supported by the Washington University Institute of
   Clinical and Translational Sciences grant UL1TR000448 and by grant
   TL1TR000449 from the National Center for Advancing Translational
   Sciences (NCATS). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institutes of Health.
CR Asrani SK, 2012, HEPATOLOGY, V56, P1160, DOI 10.1002/hep.25692
   Baek JS, 2010, HEART, V96, P1750, DOI 10.1136/hrt.2010.201772
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   Camposilvan S, 2008, ANN THORAC SURG, V86, P177, DOI 10.1016/j.athoracsur.2008.03.077
   Crespo-Leiro MG, 2008, AM J TRANSPLANT, V8, P1336, DOI 10.1111/j.1600-6143.2008.02227.x
   Ellis EL, 2012, J HEPATOL, V56, P1171, DOI 10.1016/j.jhep.2011.09.024
   Furukawa T, 2011, PEDIATR INT, V53, P980, DOI 10.1111/j.1442-200X.2011.03497.x
   Ginde S, 2012, CONGENIT HEART DIS, V7, P235, DOI 10.1111/j.1747-0803.2012.00632.x
   Guha IN, 2013, INT J CARDIOL, V164, P77, DOI 10.1016/j.ijcard.2011.06.062
   Hollander SA, 2013, J HEART LUNG TRANSPL, V32, P368, DOI 10.1016/j.healun.2012.11.023
   Kendall TJ, 2008, J CLIN PATHOL, V61, P504, DOI 10.1136/jcp.2007.052365
   Khanna G, 2012, PEDIATR RADIOL, V42, P233, DOI 10.1007/s00247-011-2225-x
   Kiesewetter CH, 2007, HEART, V93, P579, DOI 10.1136/hrt.2006.094516
   Lamour JM, 2009, J AM COLL CARDIOL, V54, P160, DOI 10.1016/j.jacc.2009.04.020
   Mitchell Max B, 2004, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V7, P56, DOI 10.1053/j.pcsu.2004.02.013
   Rodighiero V, 1999, CLIN PHARMACOKINET, V37, P399, DOI 10.2165/00003088-199937050-00004
   Rychik J, 2012, PEDIATR CARDIOL, V33, P1001, DOI 10.1007/s00246-012-0315-7
   Schwartz MC, 2013, PEDIATR CARDIOL, V34, P135, DOI 10.1007/s00246-012-0402-9
   Wallihan DB, 2013, PEDIATR RADIOL, V43, P330, DOI 10.1007/s00247-012-2531-y
   Wu FM, 2011, CONGENIT HEART DIS, V6, P190, DOI 10.1111/j.1747-0803.2011.00504.x
NR 20
TC 15
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD FEB
PY 2014
VL 33
IS 2
BP 170
EP 177
DI 10.1016/j.healun.2013.10.033
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA AA5SD
UT WOS:000331159000010
PM 24365764
ER

PT J
AU Xie, M
   Rao, W
   Sun, LY
   Zhu, ZJ
   Deng, YL
   Shen, ZY
   Jia, JD
AF Xie, Man
   Rao, Wei
   Sun, Li-Ying
   Zhu, Zhi-Jun
   Deng, Yong-Lin
   Shen, Zhong-Yang
   Jia, Ji-Dong
TI Tacrolimus-related seizure after pediatric liver transplantation - A
   single-center experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; risk factors; tacrolimus; seizures
ID NEUROLOGICAL COMPLICATIONS; HEPATIC-ENCEPHALOPATHY; NEUROTOXICITY;
   RECIPIENTS; LEUKOENCEPHALOPATHY; POSTTRANSPLANT; PRETRANSPLANT
AB To identify the risk factors for new-onset seizures after pediatric LT and to assess their clinical implications and long-term prognosis. The clinical and laboratory data of 27 consecutive children who underwent LT from January 2007 to December 2010 in our center were analyzed retrospectively. Patients were divided into seizures group and a non-seizures group. Pre-operative, intra-operative, and post-operative data were collected. Seizures occurred in four children, an incidence of 14.8%. All exhibited generalized tonic-clonic seizures within the first twowk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level. Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures. All children who experienced seizures survived with good graft function and remained seizure-free without anti-epileptic drugs over a mean follow-up period of 33.7 +/- 14.6months. High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT. High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for TAC-related seizures.
C1 [Xie, Man; Jia, Ji-Dong] Capital Med Univ, Liver Res Ctr, Beijing Friendship Hosp, Beijing 100050, Peoples R China.
   [Rao, Wei; Sun, Li-Ying; Zhu, Zhi-Jun; Deng, Yong-Lin; Shen, Zhong-Yang] First Cent Hosp, Dept Organ Transplantat, Tianjin, Peoples R China.
RP Jia, JD (reprint author), Capital Med Univ, Liver Res Ctr, Beijing Friendship Hosp, 95 Yong An Rd, Beijing 100050, Peoples R China.
EM jiajdmd@126.com
CR Amodio P, 2007, DIGEST LIVER DIS, V39, P740, DOI 10.1016/j.dld.2007.05.004
   Bechstein WO, 2000, TRANSPLANT INT, V13, P313, DOI 10.1111/j.1432-2277.2000.tb01004.x
   Choi EJ, 2004, EUR NEUROL, V52, P230, DOI 10.1159/000082163
   Dhar R, 2008, NEUROCRIT CARE, V8, P253, DOI 10.1007/s12028-007-9020-4
   DiMartini A, 2009, LIVER TRANSPLANT, V15, P121, DOI 10.1002/lt.21638
   DiMartini A, 2008, LIVER TRANSPLANT, V14, P815, DOI 10.1002/lt.21427
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   Fernandez D, 2010, TRANSPLANTATION, V90, P319, DOI 10.1097/TP.0b013e3181e5b7fc
   Forgacs B, 2005, TRANSPLANT P, V37, P1912, DOI 10.1016/j.transproceed.2005.02.101
   Ghosh PS, 2012, J PEDIATR GASTR NUTR, V54, P540, DOI 10.1097/MPG.0b013e3182407de3
   Lewis MB, 2003, NEUROLOGY, V61, P1174
   Saner FH, 2006, J NEUROL, V253, P612, DOI 10.1007/s00415-006-0069-3
   Saner FH, 2010, J NEUROL, V257, P253, DOI 10.1007/s00415-009-5303-3
   Saner FH, 2007, ARCH MED RES, V38, P75, DOI 10.1016/j.arcmed.2006.07.005
   Santos MM, 2011, PEDIATR TRANSPLANT, V15, P157, DOI 10.1111/j.1399-3046.2010.01430.x
   Senzolo Marco, 2009, Transpl Int, V22, P269, DOI 10.1111/j.1432-2277.2008.00780.x
   Sevmis S, 2007, TRANSPL P, V39, P1211, DOI 10.1016/j.transproceed.2007.02.049
   Singh N, 2000, TRANSPLANTATION, V69, P467, DOI 10.1097/00007890-200002270-00001
   Umeda Y, 2011, EXP CLIN TRANSPLANT, V9, P139
   Vizzini G, 2011, LIVER TRANSPLANT, V17, P1279, DOI 10.1002/lt.22383
   Wijdicks EFM, 1996, NEUROLOGY, V47, P1523
   Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7
   Yilmaz M, 2011, J INT MED RES, V39, P1483
NR 23
TC 1
Z9 1
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2014
VL 18
IS 1
BP 58
EP 63
DI 10.1111/petr.12198
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 282SU
UT WOS:000329194400021
PM 24283660
ER

PT J
AU Cho, YP
   Kim, KM
   Ha, TY
   Ko, GY
   Hwang, JY
   Park, H
   Chung, YS
   Yoon, T
   Hwang, S
   Jun, H
   Kwon, TW
   Lee, SG
AF Cho, Yong-Pil
   Kim, Kyung-Mo
   Ha, Tae-Yong
   Ko, Gi-Young
   Hwang, Jae-Yeon
   Park, Hojong
   Chung, Young Soo
   Yoon, Taein
   Hwang, Shin
   Jun, Heungman
   Kwon, Tae-Won
   Lee, Sung-Gyu
TI Management of late-onset portal vein complications in pediatric
   living-donor liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; living donor liver transplantation; complications of liver
   transplantation; pediatric liver transplantation; portal hypertension
ID STENT PLACEMENT; REX SHUNT; CHILDREN; BYPASS; OBSTRUCTION; DIAGNOSIS;
   STENOSIS; HYPERTENSION; THROMBOSIS; OUTCOMES
AB The purpose of this study was to evaluate retrospectively the results of PTA for late-onset PV complications after pediatric LDLT and to assess whether a meso-Rex shunt is a viable option for treating restenosis of the PV after PTA in selected cases. Seventy-five children who underwent adult-to-child LDLT were included in this study, and there were six late-onset PV complications (8.0%). The initial therapeutic approach was PTA, with or without stent: PTA with balloon dilation for three children, PTA with stent placement for one child, and failure to cannulate the occluded PV for two children. A meso-Rex shunt was performed in the two children after failed PTA: One suffered complete obstruction of the main PV, and the other, restenosis with total thrombosis after PTA with stent. The PTA was a technical and clinical success in four with PV stenosis of the six patients (66.7%), and successful application of a meso-Rex shunt in the other two children resulted in restoration of PV flow. In conclusion, PTA is a safe and effective procedure for treating late-onset PV stenosis after pediatric LDLT. However, in growing pediatric recipients with restenosis of the PV after PTA or chronic PV thrombosis, a meso-Rex shunt may be a better choice for late-onset PV complications.
C1 [Cho, Yong-Pil; Park, Hojong; Chung, Young Soo; Yoon, Taein; Kwon, Tae-Won] Univ Ulsan, Coll Med, Div Vasc Surg, Dept Surg, Seoul 138736, South Korea.
   [Cho, Yong-Pil; Kim, Kyung-Mo; Ha, Tae-Yong; Ko, Gi-Young; Hwang, Jae-Yeon; Park, Hojong; Chung, Young Soo; Yoon, Taein; Hwang, Shin; Kwon, Tae-Won; Lee, Sung-Gyu] Asan Med Ctr, Seoul 138736, South Korea.
   [Kim, Kyung-Mo] Univ Ulsan, Coll Med, Dept Pediat, Seoul 138736, South Korea.
   [Ha, Tae-Yong; Hwang, Shin; Lee, Sung-Gyu] Univ Ulsan, Coll Med, Div Liver Transplantat, Dept Surg, Seoul 138736, South Korea.
   [Ko, Gi-Young; Hwang, Jae-Yeon] Univ Ulsan, Coll Med, Dept Radiol, Seoul 138736, South Korea.
   [Jun, Heungman] Daejeon Sun Hosp, Dept Surg, Taejon, South Korea.
RP Cho, YP (reprint author), Univ Ulsan, Coll Med, Div Vasc Surg, Dept Surg, Asanbyeongwon Gil 86, Seoul 138736, South Korea.
EM ypcho@amc.seoul.kr
CR Alvarez Fernando, 2012, Curr Gastroenterol Rep, V14, P270, DOI 10.1007/s11894-012-0257-5
   Bambini DA, 2000, J PEDIATR SURG, V35, P13, DOI 10.1016/S0022-3468(00)80068-8
   Carnevale FC, 2011, PEDIATR TRANSPLANT, V15, P476, DOI 10.1111/j.1399-3046.2011.01481.x
   de Magnee C, 2011, ANN SURG, V254, P55, DOI 10.1097/SLA.0b013e3182121eb7
   de Ville de Goyet J, 1999, Eur J Surg, V165, P777
   de Ville de Goyet Jean, 2013, Pediatr Transplant, V17, P19, DOI 10.1111/j.1399-3046.2012.01784.x
   de Ville de Goyet Jean, 2012, Semin Pediatr Surg, V21, P219, DOI 10.1053/j.sempedsurg.2012.05.005
   Karakayali H, 2011, TRANSPL P, V43, P601, DOI 10.1016/j.transproceed.2011.01.010
   Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x
   Kim JH, 2009, J VASC INTERV RADIOL, V20, P1454, DOI 10.1016/j.jvir.2009.07.036
   Kim YJ, 2007, LIVER TRANSPLANT, V13, P1145, DOI 10.1002/lt.21076
   Ko GY, 2007, J VASC INTERV RADIOL, V18, P1215, DOI 10.1016/j.jvir.2007.06.029
   Lautz TB, 2013, J AM COLL SURGEONS, V216, P83, DOI 10.1016/j.jamcollsurg.2012.09.013
   Lautz TB, 2009, J PEDIATR SURG, V44, P2067, DOI 10.1016/j.jpedsurg.2009.05.016
   Luoto T, 2012, J PEDIATR SURG, V47, P688, DOI 10.1016/j.jpedsurg.2011.10.065
   Mack CL, 2006, PEDIATRICS, V117, pE405, DOI 10.1542/peds.2005-117
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   Rivera J, 2012, PEDIATR TRANSPLANT, V16, pE235, DOI 10.1111/j.1399-3046.2011.01576.x
   Shneider BL, 2012, PEDIATR TRANSPLANT, V16, P426, DOI 10.1111/j.1399-3046.2012.01652.x
   Superina R, 2006, ANN SURG, V243, P515, DOI 10.1097/01.sla.0000205827.73706.97
NR 20
TC 5
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2014
VL 18
IS 1
BP 64
EP 71
DI 10.1111/petr.12204
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 282SU
UT WOS:000329194400022
PM 24341631
ER

PT J
AU Gulleroglu, K
   Baskin, E
   Bayrakci, U
   Aydin, E
   Ozluoglu, L
   Moray, G
   Haberal, M
AF Gulleroglu, Kaan
   Baskin, Esra
   Bayrakci, Umut
   Aydin, Erdinc
   Ozluoglu, Levent
   Moray, Gokhan
   Haberal, Mehmet
TI Sudden Hearing Loss Associated With Tacrolimus After Pediatric Renal
   Transplant
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Hearing loss; Quality of life; Calcineurin inhibitors; Tacrolimus;
   Pediatric renal transplant
ID LIVER-TRANSPLANTATION
AB Objectives: Hearing impairment is a frequent problem that can easily influence the quality of life for the individual. It may affect one's social and academic life. Knowledge regarding hearing impairment after renal transplant is sparse. It has been suggested that renal transplant improves hearing function. Potential ototoxic side effects may be related to immunosuppression with calcineurin inhibitors. In pediatric renal transplanted patients, we do not have enough information about this subject. We report 2 cases that developed sudden hearing loss after a renal transplant that was associated with high serum levels of tacrolimus.
   Case Reports: Two renal transplanted children (a 15-year-old boy and a 17-year-old girl), in the fourth year of their follow-up after transplant, developed symptomatic bilateral sudden hearing loss. There was a marked hearing impairment for the higher frequencies between 4000 and 8000 Hz in pure-tone audiometry evaluation. Also, a decrease of speech understanding was found, but the patients were not conscious of this problem. Hearing loss in these patients was not associated with any known risk factors such as chronic renal disease, ototoxic drugs, or acoustic trauma. Sudden hearing loss occurred under high serum levels of tacrolimus, and after dosage correction of tacrolimus pure-tone audiometry ruled out hearing loss progression for each patient.
   Conclusions: Awareness of this potential complication of tacrolimus may be helpful for early recognition and treatment.
C1 [Gulleroglu, Kaan; Baskin, Esra; Bayrakci, Umut] Baskent Univ, Pediat Nephrol Dept, TR-06490 Ankara, Turkey.
   [Aydin, Erdinc; Ozluoglu, Levent] Baskent Univ, Dept Otorhinolaryngol, TR-06490 Ankara, Turkey.
   [Moray, Gokhan; Haberal, Mehmet] Baskent Univ, Dept Gen Surg, TR-06490 Ankara, Turkey.
RP Gulleroglu, K (reprint author), Baskent Univ, Pediat Nephrol Dept, 54 Cadde 72-3, TR-06490 Ankara, Turkey.
EM kaangulleroglu@yahoo.com
CR Fortes ME, 2008, LIVER TRANSPLANT, V14, P509, DOI 10.1002/lt.21385
   Marioni G, 2004, ACTA OTO-LARYNGOL, V124, P603, DOI 10.1080/00016480410016225
   MITSCHKE H, 1977, AUDIOLOGY, V16, P530
   Rifai K, 2005, TRANSPLANT P, V37, P1918, DOI 10.1016/j.transproceed.2005.02.102
   Tan TC, 2006, TRANSPLANT REV, V20, P49, DOI 10.1016/j.trre.2006.02.005
   Zhang ZJ, 2000, BRAIN RES, V852, P116, DOI 10.1016/S0006-8993(99)02223-4
NR 6
TC 2
Z9 2
U1 1
U2 2
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD DEC
PY 2013
VL 11
IS 6
BP 562
EP 564
DI 10.6002/ect.2012.0241
PG 3
WC Transplantation
SC Transplantation
GA 287QY
UT WOS:000329558500016
PM 24344948
ER

PT J
AU Karakayali, F
   Kirnap, M
   Akdur, A
   Tutar, N
   Boyvat, F
   Moray, G
   Haberal, M
AF Karakayali, F.
   Kirnap, M.
   Akdur, A.
   Tutar, N.
   Boyvat, F.
   Moray, G.
   Haberal, M.
TI Biliary Complications After Pediatric Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY DEC 12-15, 2012
CL Abu Dhabi, U ARAB EMIRATES
SP Middle E Soc Organ Transplantat
ID DUCT-TO-DUCT; RECONSTRUCTION; MANAGEMENT
AB Objectives. After liver transplantation, biliary complications are more prevalent in pediatric patients, with reported rates varying between 15% and 30%.
   Methods. We retrospectively analyzed biliary complications observed in 84 pediatric liver transplantation patients between July 2006 and September 2012. Biliary reconstruction was accomplished via a duct-to-duct anastomosis in 5 (83.3%) of the 6 patients receiving whole liver grafts and in 44 (56.4%) of the 78 patients who received a segmental live donor graft. For the remaining 34 patients with living donor and 1 patient with whole liver graft, Rouxen-Y hepaticojejunostomy was the preferred method.
   Results. Post-transplantation biliary complications were encountered in 26 patients (30.1%). The biliary complication rate was 38% in 49 duct-to-duct anastomosis, whereas it was 20% in the hepaticojejunostomy group consisting of 35 recipients. Thirteen of the 18 biliary leaks were from duct-to-duct anastomoses and the remaining 5 were from the hepaticojejunostomies and 6 of the 8 biliary strictures were observed in recipients with duct-to-duct anastomosis. In 19 of the 26 patients, the biliary complications were successfully treated with interventional radiologic procedures and 1 was treated with stent placement during endoscopic retrograde cholangiopancreatography.
   Conclusions. Percutaneous interventional procedures are valuable, effective, and life-saving therapeutic alternatives for the treatment of bile leaks and strictures after pediatric liver transplantations.
C1 [Karakayali, F.; Kirnap, M.; Akdur, A.; Moray, G.; Haberal, M.] Baskent Univ, Dept Gen Surg, Fac Med, TR-06490 Ankara, Turkey.
   [Tutar, N.; Boyvat, F.] Baskent Univ, Dept Radiol, Fac Med, TR-06490 Ankara, Turkey.
RP Karakayali, F (reprint author), Baskent Univ, Dept Gen Surg, Fevzi Cakmak Cad 5,Sok 48, TR-06490 Ankara, Turkey.
EM fezaykar@yahoo.com
CR Aytekin C, 2007, DIAGN INTERV RADIOL, V13, P101
   Cantero JMB, 2012, TRANSPL P, V44, P2098, DOI 10.1016/j.transproceed.2012.07.084
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Gonzalez MR, 2012, TRANSPL P, V44, P2093, DOI 10.1016/j.transproceed.2012.07.073
   Haberal M, 2002, TRANSPLANT P, V34, P2145, DOI 10.1016/S0041-1345(02)02884-1
   Haberal M, 2011, TRANSPL P, V43, P595, DOI 10.1016/j.transproceed.2011.01.009
   Karakayali H, 2005, TRANSPLANT P, V37, P3174, DOI 10.1016/j.transproceed.2005.07.023
   Ostroff James W, 2010, Gastroenterol Hepatol (N Y), V6, P264
   Soejima Y, 2003, TRANSPLANTATION, V75, P557, DOI 10.1097/01.TP.0000048220.90971.5A
   Stapleton GN, 1998, BRIT J SURG, V85, P202
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   Tanaka H, 2010, J PEDIATR SURG, V45, P1668, DOI 10.1016/j.jpedsurg.2010.03.010
NR 12
TC 8
Z9 12
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2013
VL 45
IS 10
BP 3524
EP 3527
DI 10.1016/j.transproceed.2013.09.012
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 270FQ
UT WOS:000328304700022
PM 24314949
ER

PT J
AU Acuna, C
   Zuleta, R
   Dalmazzo, R
   Valverde, C
   Uribe, M
   Alba, A
   Buckel, E
   Hunter, B
   Gonzalez, G
   Godoy, J
   Ferrario, M
   Cavallieri, S
   Campos, M
   Pizarro, F
   Wash, A
   Ferron, S
   Diaz, V
   Macho, L
   Herzog, C
   Calabran, L
   Flores, L
   Soto, P
   Heine, C
   Rebolledo, R
   Auad, H
AF Acuna, C.
   Zuleta, R.
   Dalmazzo, R.
   Valverde, C.
   Uribe, M.
   Alba, A.
   Buckel, E.
   Hunter, B.
   Gonzalez, G.
   Godoy, J.
   Ferrario, M.
   Cavallieri, S.
   Campos, M.
   Pizarro, F.
   Wash, A.
   Ferron, S.
   Diaz, V.
   Macho, L.
   Herzog, C.
   Calabran, L.
   Flores, L.
   Soto, P.
   Heine, C.
   Rebolledo, R.
   Auad, H.
TI Pediatric Liver Transplantation Experience and Outcome in Chile
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY DEC 12-15, 2012
CL Abu Dhabi, U ARAB EMIRATES
SP Middle E Soc Organ Transplantat
ID FAILURE; PROGRAM; OPTION
AB Introduction. In 1994 our group began its experience with pediatric liver transplantation. The experience gained during this period is the largest in the country, positioning the Hospital Luis Calvo Mackenna and Clinica Las Condes as major referral centers in the public and private sectors. The aim of this study was to report our experience of our pediatric liver transplantation program during this period.
   Methods. The liver transplantation database of Hospital Luis Calvo Mackenna and Clinica Las Condes between January 1994 and July 2011 was reviewed recording age, gender, indications for transplantation, surgical technique, complications, and survival. Survival rates were calculated using Kaplan-Meier analysis.
   Results. During the period described 230 transplantations were performed in 189 pediatric patients. Fifty-five percent were male patients. The average age was 5 years. The main causes of transplantation were biliary atresia (50%), fulminant hepatic failure (25%), and other cholestatic diseases by 10%. Vascular and biliary complications were the leading cause of graft loss and retransplantation. The overall rate of retransplantation at 5 years was 20%. The technique of living donor was used in 28% of the cases. The 1-year patient actuarial survival rate was 80%, 73% at 5 years, and 68% at 10 years. In the last 3 years the survival rate at 1 year exceeds 90%.
   Discussion. Our program includes more than 90% of the national liver experience. The incorporation of living donor is a milestone that has enabled us to save many patients who previously died while waiting for an organ. Its use in cases of full acute liver failure has allowed us to dramatically reduce mortality on the waiting list. Our results in the last 3 years reflect the experience that results in a significant decrease in mortality, comparing favorably to other series published in the international literature.
C1 [Dalmazzo, R.; Valverde, C.; Uribe, M.; Alba, A.; Hunter, B.; Gonzalez, G.; Godoy, J.; Cavallieri, S.; Calabran, L.; Flores, L.] Hosp Ninos Luis Calvo Mackenna, Clin Las Condes, Santiago, Chile.
   [Buckel, E.; Ferrario, M.; Pizarro, F.; Wash, A.; Herzog, C.] Clin Las Condes, Santiago, Chile.
   [Acuna, C.; Zuleta, R.; Campos, M.; Ferron, S.; Diaz, V.; Macho, L.; Soto, P.] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile.
   [Herzog, C.; Rebolledo, R.; Auad, H.] Univ Chile, Santiago, Chile.
RP Uribe, M (reprint author), Fontecilla 441, Santiago, Chile.
EM muribem@clc.cl
CR Murray KF, 2005, HEPATOLOGY, V41, P1407, DOI 10.1002/hep.20704
   National Institutes of Health Consensus, 1984, HEPATOLOGY, V4, p107S
   Ng VL, 2012, J PEDIATR-US, V160, P820, DOI 10.1016/j.jpeds.2011.10.038
   Perez R, 2010, GLIFAS SOC CHILENA T, P416
   Reding R, 2005, AM J TRANSPLANT, V5, P1587, DOI 10.1111/j.1600-6143.2005.00915.x
   Uribe M, 2005, TRANSPL P, V37, P3378, DOI 10.1016/j.transproceed.2005.09.097
   Uribe M, 2005, TRANSPLANT P, V37, P1567, DOI 10.1016/j.transproceed.2004.09.010
   Uribe M, 2008, TRANSPL P, V40, P3253, DOI 10.1016/j.transproceed.2008.03.128
   Uribe M, 2005, TRANSPL P, V37, P3375, DOI 10.1016/j.transproceed.2005.09.096
   Uribe M, 2007, TRANSPL P, V39, P609, DOI 10.1016/j.transproceed.2006.12.031
   Uribe M, 2009, TRANSPL P, V41, P2679, DOI 10.1016/j.transproceed.2009.06.132
   Wiesner RH, 2001, LIVER TRANSPLANT, V7, P567, DOI 10.1053/jlts.2001.25879
NR 12
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2013
VL 45
IS 10
BP 3724
EP 3725
DI 10.1016/j.transproceed.2013.08.090
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 270FQ
UT WOS:000328304700081
PM 24315008
ER

PT J
AU Uribe, M
   Alba, A
   Gonzalez, G
   Hunter, B
   Heine, C
   Iniguez, R
   Cavallieri, S
   Flores, L
   Soto, P
   Auad, H
   Zuleta, R
   Acuna, C
AF Uribe, M.
   Alba, A.
   Gonzalez, G.
   Hunter, B.
   Heine, C.
   Iniguez, R.
   Cavallieri, S.
   Flores, L.
   Soto, P.
   Auad, H.
   Zuleta, R.
   Acuna, C.
TI Pediatric Liver Transplant Outcome Using Severe Hypernatremic Donors
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY DEC 12-15, 2012
CL Abu Dhabi, U ARAB EMIRATES
SP Middle E Soc Organ Transplantat
ID EXTENDED CRITERIA; FAILURE; CHILE; EXPERIENCE
AB Introduction. Pediatric liver transplantation is limited by donation. In the last 5 years, urgent conditions have forced transplant teams to accept donors with minor suboptimal conditions, termed "extended donor criteria." Among those, the risk of using severe hypernatremic donors (SHD) for liver transplant is not yet well established. The aim of this study is to report the outcome of pediatric patients receiving grafts from SHD.
   Methods. Clinical records of patients transplanted in the last 3 years at Hospital Luis Calvo Mackenna, Santiago, Chile, were reviewed. Outcome was evaluated in terms of patient and graft survival and complications potentially associated to the donor condition.
   Results. Five of 33 deceased donor transplants presented with SHD. All recipients were waiting transplant in an acute condition, one of them in acute liver failure (ALF). No living related donor was available. Donors' serum sodium was 169 to 193 mEq/L before medical management and between 157 and 172 mEq/L at procurement. One patient died from sepsis related to biliary complications, and the patient suffering ALF developed primary graft nonfunction, received a second transplant 2 weeks later, and recovered to stable medical condition. No other complication was registered in these patients.
   Discussion. Our findings allow us to postulate that hypernatremic deceased donors may be used for pediatric liver transplant under special circumstances.
C1 [Uribe, M.; Alba, A.; Gonzalez, G.; Hunter, B.; Heine, C.; Iniguez, R.; Cavallieri, S.; Flores, L.; Soto, P.; Auad, H.; Zuleta, R.; Acuna, C.] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile.
   Univ Chile, Santiago, Chile.
RP Uribe, M (reprint author), Hosp Ninos Luis Calvo Mackenna, Pediat Liver Transplant Program, Fontecilla 441, Santiago, Chile.
EM muribem@clc.cl
CR Al-Sarraf AJ, 2010, EXP CLIN TRANSPLANT, V8, P321
   Alkofer B, 2006, SEMIN LIVER DIS, V26, P221, DOI 10.1055/s-2006-947292
   Castaneda-Martinez PD, 2010, TRANSPL P, V42, P2383, DOI 10.1016/j.transproceed.2010.06.011
   Gastaca M, 2009, TRANSPL P, V41, P975, DOI 10.1016/j.transproceed.2009.02.016
   Harring TR, 2011, CLIN LIVER DIS, V15, P879, DOI 10.1016/j.cld.2011.08.006
   Lopez-Navidad A, 2003, CLIN TRANSPLANT, V17, P308, DOI 10.1034/j.1399-0012.2003.00119.x
   Mangus RS, 2010, TRANSPLANTATION, V90, P438, DOI 10.1097/TP.0b013e3181e764c0
   Uribe M, 2003, TRANSPLANT P, V35, P2511, DOI 10.1016/j.transproceed.2003.09.025
   Uribe M, 2010, TRANSPL P, V42, P293, DOI 10.1016/j.transproceed.2009.12.050
   Uribe M, 2005, TRANSPLANT P, V37, P1567, DOI 10.1016/j.transproceed.2004.09.010
   Uribe M, 2005, TRANSPL P, V37, P3375, DOI 10.1016/j.transproceed.2005.09.096
NR 11
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2013
VL 45
IS 10
BP 3726
EP 3727
DI 10.1016/j.transproceed.2013.08.078
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 270FQ
UT WOS:000328304700082
PM 24315009
ER

PT J
AU Uribe, M
   Alba, A
   Hunter, B
   Gonzalez, G
   Godoy, J
   Ferrario, M
   Buckel, E
   Cavallieri, S
   Heine, C
   Rebolledo, R
   Auad, H
   Acuna, C
AF Uribe, M.
   Alba, A.
   Hunter, B.
   Gonzalez, G.
   Godoy, J.
   Ferrario, M.
   Buckel, E.
   Cavallieri, S.
   Heine, C.
   Rebolledo, R.
   Auad, H.
   Acuna, C.
TI Liver Transplantation in Children Weighing Less Than 10 kg: Chilean
   Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 13th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY DEC 12-15, 2012
CL Abu Dhabi, U ARAB EMIRATES
SP Middle E Soc Organ Transplantat
ID BODY-MASS INDEX; KILOGRAMS
AB Background. Orthotopic liver transplantation is the treatment of choice for most terminal liver diseases in children. In small children (<= 10 kg), this procedure is challenging and has special considerations. The aim of this study is to describe the experience of a Chilean liver transplantation program in this subgroup of patients.
   Methods. The liver transplant database of Hospital Luis Calvo Mackenna and Clinica Las Condes was reviewed. All children less than 10 kg undergoing liver transplantation between January 1994 and July 2011 were included. Patient and graft outcomes and main complications were analyzed.
   Results. We have performed 230 pediatric liver transplantations, 49 of them in 41 patients weighing less than 10 kg. The first indication for transplantation was biliary atresia in 25 patients (61%). A living related donor was used in 23 cases (51%). Actuarial survival was 75.7% at 1 year and 67.1% at 5 years. The main cause of death was infection, and the leading cause of graft loss was vascular complication.
   Discussion. Our transplant program includes 2 centers that perform more than 90% of pediatric liver transplantations in Chile, including public health pediatric patients from all around the country. Patients weighing less than 10 kg represent the most challenging group in pediatric liver transplantation due to higher rates of vascular and biliary complications and postoperative infections.
C1 [Uribe, M.; Alba, A.; Hunter, B.; Gonzalez, G.; Godoy, J.; Cavallieri, S.; Acuna, C.] Hosp Ninos Luis Calvo Mackenna, Santiago, Chile.
   [Ferrario, M.; Buckel, E.] Clin Las Condes, Santiago, Chile.
   [Heine, C.; Rebolledo, R.; Auad, H.] Univ Chile, Santiago, Chile.
RP Uribe, M (reprint author), Hosp Ninos Luis Calvo Mackenna, Clin Las Condes, Liver Transplant Program, Fontecilla 441, Santiago, Chile.
EM muribem@clc.cl
CR Arnon R, PEDIAT TRANSPLANT, V15, P650
   Buckel E, 2003, TRANSPLANT P, V35, P2509, DOI 10.1016/j.transproceed.2003.09.024
   Dick AAS, 2009, LIVER TRANSPLANT, V15, P968, DOI 10.1002/lt.21785
   Haberal M, 2006, TRANSPL P, V38, P3585, DOI 10.1016/j.transproceed.2006.10.016
   Iglesias J, 2004, PEDIATR TRANSPLANT, V8, P228, DOI 10.1111/j.1399-3046.2004.00128.x
   Kaur S, INDIAN PEDIAT, V48, P51
   LaRosa C, PEDIAT TRANSPLANT, V15, P128
   National Institutes of Health Consensus, 1984, HEPATOLOGY, V4, p107S
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   OTTE JB, 1994, HEPATOLOGY, V20, pS41, DOI 10.1002/hep.1840200711
   Pelletier SJ, 2007, LIVER TRANSPLANT, V13, P1678, DOI 10.1002/lt.21183
   Perez R, 2010, GLIFAS SOC CHILENA T, P416
   Polak WG, 2008, CLIN TRANSPLANT, V22, P171, DOI 10.1111/j.1399-0012.2007.00762.x
   Polak WG, 2009, CLIN TRANSPLANT, V23, P546, DOI 10.1111/j.1399-0012.2009.00994.x
   Uribe M, 2005, TRANSPL P, V37, P3375, DOI 10.1016/j.transproceed.2005.09.096
   Williams R, 2009, TRANSPLANTATION, V87, P1268, DOI 10.1097/TP.0b013e3181a36a4a
NR 16
TC 2
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2013
VL 45
IS 10
BP 3731
EP 3733
DI 10.1016/j.transproceed.2013.08.092
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 270FQ
UT WOS:000328304700084
PM 24315011
ER

PT J
AU Legarda, M
   Gordon, G
   Lloyd, C
   Baumann, U
   Kelly, DA
   Shaw, N
   McKiernan, P
AF Legarda, Maria
   Gordon, Graham
   Lloyd, Carla
   Baumann, Ulrich
   Kelly, Deirdre A.
   Shaw, Nick
   McKiernan, Patrick
TI Vitamin D deficiency and insufficiency after pediatric liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE vitamin D; liver transplantation; paediatric transplantation
ID BONE-MINERAL DENSITY; CHILDREN; DISEASE; ASSOCIATION; ADOLESCENTS;
   POPULATION
AB Vitamin D deficiency and insufficiency are increasingly recognized in the general population, including healthy children. There is also an increasing emphasis on the importance of vitamin D status following pediatric liver transplantation and specifically its relationship to metabolic bone disease and growth retardation. Vitamin D insufficiency has also been associated with multiple immunological and metabolic disorders in adults. To our knowledge, this has not been systematically evaluated in children undergoing liver transplantation to date. Between October 2004 and August 2008, serum 25-(OH)-vitamin D levels were measured in 199 children who had undergone liver transplantation at Birmingham Children's Hospital. Potential factors contributing to vitamin D levels were evaluated. Additionally, we evaluated a possible relationship between vitamin D levels and immunological phenomena and metabolic complications. Median 25-(OH)-vitamin D level was 19.5ng/mL (range: 4.4-71.4ng/mL). A total of 105 children (53%) had insufficient vitamin D levels and 28 children (14%) showed vitamin D deficiency. The only factors found to be associated with vitamin D deficiency were season of sample, ethnicity, and PTH levels. Vitamin D deficiency was more prevalent during the first year after transplantation. We did not find a significant relationship between vitamin D levels and graft function or any other immunological and metabolic complications. Vitamin D insufficiency and deficiency are common in children after liver transplantation, especially in winter and spring and in non-white patients. Initial post-transplant period and high PTH are significantly associated with vitamin D deficiency. Vitamin D status should be monitored following pediatric liver transplantation and vitamin D supplementation provided as required.
C1 [Legarda, Maria; Gordon, Graham; Lloyd, Carla; Kelly, Deirdre A.; McKiernan, Patrick] Birmingham Childrens Hosp, Liver Unit, Birmingham, W Midlands, England.
   [Baumann, Ulrich] Hannover Med Sch, Pediat Gastroenterol & Hepatol Unit, Hannover, Germany.
   [Shaw, Nick] Birmingham Childrens Hosp, Dept Endocrinol, Birmingham, W Midlands, England.
RP Legarda, M (reprint author), Birmingham Childrens Hosp, Liver Unit, Birmingham, W Midlands, England.
EM maria.legarda@nuh.nhs.uk
RI Legarda, Maria/A-9890-2015
OI Legarda, Maria/0000-0002-0269-2392
CR ABSOUD M, 2011, PLOS ONE, V6
   American Diabetes Association, 2011, DIABETES CARE S1, V34, pS11, DOI DOI 10.2337/DC11-S011
   Anker SD, 2012, JAMA-J AM MED ASSOC, V307, P722, DOI 10.1001/jama.2012.159
   Bikle DD, 2010, TRENDS ENDOCRIN MET, V21, P375, DOI 10.1016/j.tem.2010.01.003
   Bitetto D, 2010, LIVER INT, V30, P417, DOI 10.1111/j.1478-3231.2009.02154.x
   D'Antiga L, 2002, TRANSPLANTATION, V73, P1788, DOI 10.1097/00007890-200206150-00015
   D'Antiga L, 2004, TRANSPLANTATION, V78, P899, DOI 10.1097/01.TP.0000136987.38729.C0
   Docio S, 1998, J BONE MINER RES, V13, P544, DOI 10.1359/jbmr.1998.13.4.544
   Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604
   Helenius I, 2006, J BONE MINER RES, V21, P380, DOI 10.1359/JBMR.051107
   Hogler Wolfgang, 2010, Pediatr Endocrinol Rev, V7, P266
   Kitson MT, 2012, J HEPATOL, V57, P897, DOI 10.1016/j.jhep.2012.04.033
   Kumar J, 2009, PEDIATRICS, V124, pe371
   Liberal R, 2013, J AUTOIMMUN, V41, P126, DOI 10.1016/j.jaut.2012.11.002
   Maalouf NM, 2005, J CLIN ENDOCR METAB, V90, P4118
   Mimouni FB, 2010, J PEDIATR GASTR NUTR, V51, pS121, DOI 10.1097/MPG.0b013e3181f63a47
   Misra M, 2008, PEDIATRICS, V122, P398, DOI 10.1542/peds.2007-1894
   Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
   Morris Howard A, 2010, Clin Biochem Rev, V31, P129
   Morris Howard A, 2005, Clin Biochem Rev, V26, P21
   Nightingale S, 2011, J PEDIATR GASTR NUTR, V53, P326, DOI 10.1097/MPG.0b013e3182258656
   Pincikova T, 2011, EUR J CLIN NUTR, V65, P102, DOI 10.1038/ejcn.2010.194
   Reis JP, 2009, PEDIATRICS, V124, pe362
   Saland JM, 2004, PEDIATR TRANSPLANT, V8, P400, DOI 10.1111/j.1399-3046.2004.00167.x
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   SEDRANI SH, 1988, EUR J CLIN NUTR, V42, P243
   Southerland J C, 2001, Curr Gastroenterol Rep, V3, P399, DOI 10.1007/s11894-001-0082-8
   Sylvester Francisco A., 1999, Current Opinion in Pediatrics, V11, P402, DOI 10.1097/00008480-199910000-00006
   Urena-Torres P, 2011, AM J KIDNEY DIS, V58, P544, DOI 10.1053/j.ajkd.2011.04.029
   Valta H, 2008, AM J TRANSPLANT, V8, P150, DOI 10.1111/j.1600-6143.2007.02015.x
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Williams Sandra, 2009, Ethn Dis, V19, pS5
   Winzenberg T, 2011, BRIT MED J, V342, DOI 10.1136/bmj.c7254
   Zittermann A, 2005, BRIT J NUTR, V94, P483, DOI 10.1079/BJN20051544
   Zwillinger D., 2003, STANDARD MATH TABLES
NR 35
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2013
VL 17
IS 7
BP 631
EP 637
DI 10.1111/petr.12135
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 230UU
UT WOS:000325369400015
PM 23962009
ER

PT J
AU Vidyadharan, R
   van Bommel, ACM
   Kuti, K
   Gupte, GL
   Sharif, K
   Richard, BM
AF Vidyadharan, R.
   van Bommel, A. C. M.
   Kuti, K.
   Gupte, G. L.
   Sharif, K.
   Richard, B. M.
TI Use of tissue expansion to facilitate liver and small bowel transplant
   in young children with contracted abdominal cavities
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE tissue expander; pediatric; abdominal closure; liver and small bowel
   transplant; end-stage liver disease; complications
ID INTESTINAL TRANSPLANTATION; LIVING DONORS; SINGLE-CENTER; WALL; CLOSURE;
   UK; COMPLICATIONS; EXPERIENCE; EXPANDERS; INFANTS
AB Liver and small bowel transplant is an established treatment for infants with IFALD. Despite organ reduction techniques, mortality on the waiting list remains high due to shortage of size-matched pediatric donors. Small abdominal cavity volume due to previous intestinal resection poses a significant challenge to achieve abdominal closure post-transplant. Seven children underwent tissue expansion of abdominal skin prior to multiorgan transplant. In total, 17 tissue expanders were placed subcutaneously in seven children. All seven subjects underwent re-exploration to deal with complications: hematoma, extrusion, infection, or port related. Three expanders had to be removed. Four children went on to have successful combined liver and small bowel transplant. Two children died on the waiting list of causes not related to the expander and one child died from sepsis attributed to an infected expander. Tissue expansion can generate skin to facilitate closure of abdomen post-transplant, thus allowing infants with small abdominal volumes to be considered for transplant surgery. Tissue expansion in children with end-stage liver disease and portal hypertension is associated with a very high complication rate and needs to be closely monitored during the expansion process.
C1 [Vidyadharan, R.; Kuti, K.; Richard, B. M.] Birmingham Childrens Hosp NHS Fdn Trust, Dept Plast Surg, Birmingham B4 6NH, W Midlands, England.
   [van Bommel, A. C. M.] Univ Med Ctr Utrecht, Dept Plast Surg, Utrecht, Netherlands.
   [Gupte, G. L.; Sharif, K.] Birmingham Childrens Hosp NHS Fdn Trust, Liver Transplant Unit, Birmingham B4 6NH, W Midlands, England.
RP Vidyadharan, R (reprint author), Birmingham Childrens Hosp NHS Fdn Trust, Dept Plast Surg, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.
EM Ramesh.Vidyadharan@bch.nhs.uk
CR Adetayo OA, 2012, ANN PLAS SURG, V69, P104, DOI 10.1097/SAP.0b013e31822128f5
   Chiang YC, 1998, TRANSPLANT P, V30, P3173, DOI 10.1016/S0041-1345(98)00981-6
   Clifton MS, 2011, J PEDIATR SURG, V46, P372, DOI 10.1016/j.jpedsurg.2010.11.020
   de Ville de Goyet J, 2000, TRANSPLANTATION, V69, P555
   Diamond IR, 2011, JPEN-PARENTER ENTER, V35, P596, DOI 10.1177/0148607111413598
   Gangemi A, 2009, TRANSPLANTATION, V87, P1027, DOI 10.1097/TP.0b013e31819cc3bf
   Ghafari JL, 2011, PEDIATR TRANSPLANT, V15, P425, DOI 10.1111/j.1399-3046.2011.01501.x
   Giovanelli M, 2009, TRANSPLANTATION, V87, P1695, DOI 10.1097/TP.0b013e3181a5e9f8
   Grevious MA, 2009, PEDIATR TRANSPLANT, V13, P177, DOI 10.1111/j.1399-3046.2008.00966.x
   Gupte GL, 2010, J PEDIATR SURG, V45, P1473, DOI 10.1016/j.jpedsurg.2009.08.026
   Gupte GL, 2007, ARCH DIS CHILD, V92, P147, DOI 10.1136/adc.2005.090068
   LAFOSSE A, 2011, PEDIATR TRANSPLANT, V16, pE150
   Levi DM, 2003, LANCET, V361, P2173, DOI 10.1016/S0140-6736(03)13769-5
   LoGiudice J, 2003, J CRANIOFAC SURG, V14, P866, DOI 10.1097/00001665-200311000-00008
   National Health Service Blood and Transplant, ORG DON TRANSPL ACT, P68
   Paletta CE, 1999, ANN PLAS SURG, V42, P259, DOI 10.1097/00000637-199903000-00006
   Rushton SN, 2013, TRANSPLANTATION, V95, P234, DOI 10.1097/TP.0b013e318278301b
   Sandler A, 2004, J PEDIATR SURG, V39, P738, DOI 10.1016/j.jpedsurg.2004.01.040
   Selvaggi G, 2009, TRANSPL P, V41, P521, DOI 10.1016/j.transproceed.2009.01.020
   Sheth J, 2012, PEDIATR TRANSPLANT, V16, P36, DOI 10.1111/j.1399-3046.2011.01597.x
   Tzakis AG, 2005, ANN SURG, V242, P480, DOI 10.1097/01.sla..0000183347.61361.7a
NR 21
TC 1
Z9 1
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2013
VL 17
IS 7
BP 646
EP 652
DI 10.1111/petr.12138
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 230UU
UT WOS:000325369400017
PM 23992350
ER

PT J
AU Soubrane, O
   Cotta, FP
   Scatton, O
AF Soubrane, O.
   Cotta, F. Perdigao
   Scatton, O.
TI Pure Laparoscopic Right Hepatectomy in a Living Donor
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Laparoscopy; liver graft; living donor
ID LIVER-TRANSPLANTATION; HEPATIC LOBECTOMY; OUTCOMES; COMPLICATIONS;
   METAANALYSIS; NEPHRECTOMY; DONATION; SURGERY
AB After reporting the first laparoscopic hepatectomy in a living donor for pediatric liver transplantation, we now report a case of pure laparoscopic right hepatectomy for adult transplantation. A 50-year-old female volunteered for living donation to her sister who suffered from primary biliary cirrhosis. The volume of the planned hepatic graft (segments 5-8) was 620cm(3), representing 56% of her entire liver. Five ports were used in the donor to perform the operative procedure. The right hepatic artery and portal vein were isolated. Parenchymal division was performed using an ultrasonic dissector, bipolar coagulation and clips for hemostasis. Cholangiography was performed and the right bile duct was cut at the level of a marker thread. The right liver graft was placed in a bag and removed through a 10-cm suprapubic incision. The veins of segments 5 and 8 were recanalized and the graft was transplanted in the recipient. The postoperative course was uneventful for both the donor and recipient. This case offers evidence that the right liver can be procured via a total laparoscopic approach. This technique may allow for an early rehabilitation for the living donor.
   The authors report the technical details of a case of pure laparoscopic right hepatectomy in a live liver donor for intra-familial adult-to-adult transplantation. See editorial by Akoad and Pomfret on page 2243 and case reports on pages 2462 and 2472.
C1 [Soubrane, O.; Cotta, F. Perdigao; Scatton, O.] Univ Paris 06, Hop St Antoine, Serv Hepatobiliary Surg & Liver Transplant, Paris, France.
RP Soubrane, O (reprint author), Univ Paris 06, Hop St Antoine, Serv Hepatobiliary Surg & Liver Transplant, Paris, France.
EM soubrane@sat.aphp.fr
CR Abecassis MM, 2012, AM J TRANSPLANT, V12, P1208, DOI 10.1111/j.1600-6143.2011.03972.x
   Baker TB, 2009, SURGERY, V146, P817, DOI 10.1016/j.surg.2009.05.022
   Buell JF, 2009, ANN SURG, V250, P825, DOI 10.1097/SLA.0b013e3181b3b2d8
   Catalano OA, 2008, RADIOGRAPHICS, V28, P359, DOI 10.1148/rg.282075099
   Cheah YL, 2013, LIVER TRANSPLANT, V19, P499, DOI 10.1002/lt.23575
   Cherqui D, 2002, LANCET, V359, P392, DOI 10.1016/S0140-6736(02)07598-0
   Ghobrial RM, 2008, GASTROENTEROLOGY, V135, P468, DOI 10.1053/j.gastro.2008.04.018
   Ibrahim S, 2006, LIVER TRANSPLANT, V12, P950, DOI 10.1002/lt.20746
   Kim KH, 2011, BRIT J SURG, V98, P1302, DOI 10.1002/bjs.7601
   Koffron AJ, 2006, AM J TRANSPLANT, V6, P2522, DOI 10.1111/j.1600-6143.2006.01498.x
   Lin NC, 2013, ANN SURG, V257, P205, DOI 10.1097/SLA.0b013e31827da7fe
   Marsh JW, 2009, J HEPATOL, V51, P715, DOI 10.1016/j.jhep.2009.04.023
   Mirnezami R, 2011, HPB, V13, P295, DOI 10.1111/j.1477-2574.2011.00295.x
   Nanidis TG, 2008, ANN SURG, V247, P58, DOI 10.1097/SLA.0b013e318153fd13
   Nguyen KT, 2009, ANN SURG, V250, P831, DOI 10.1097/SLA.0b013e3181b0c4df
   Organ Procurement and Transplantation Network, TRANSPL DON TYP
   Schweitzer EJ, 2000, ANN SURG, V232, P392, DOI 10.1097/00000658-200009000-00011
   Soubrane O, 2006, ANN SURG, V244, P815, DOI 10.1097/01.sla.0000218059.31231.b6
   Thenappan A, 2011, AM J SURG, V201, P450, DOI 10.1016/j.amjsurg.2010.10.007
   Tzanis D, 2013, J HEPATO-BIL-PAN SCI, V20, P120, DOI 10.1007/s00534-012-0554-2
   Vauthey JN, 2002, LIVER TRANSPLANT, V8, P233, DOI 10.1053/jlts.2002.31654
NR 21
TC 29
Z9 30
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2013
VL 13
IS 9
BP 2467
EP 2471
DI 10.1111/ajt.12361
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 208KS
UT WOS:000323678200030
PM 23865716
ER

PT J
AU Troisi, RI
   Wojcicki, M
   Tomassini, F
   Houtmeyers, P
   Vanlander, A
   Berrevoet, F
   Smeets, P
   Van Vlierberghe, H
   Rogiers, X
AF Troisi, R. I.
   Wojcicki, M.
   Tomassini, F.
   Houtmeyers, P.
   Vanlander, A.
   Berrevoet, F.
   Smeets, P.
   Van Vlierberghe, H.
   Rogiers, X.
TI Pure Laparoscopic Full-Left Living Donor Hepatectomy for Calculated
   Small-for-Size LDLT in Adults: Proof of Concept
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Laparoscopic liver donor hepatectomy; living donor liver
   transplantation; portal vein pressure; small-for-size grafts; transit
   time flow measurement
ID LIVER-TRANSPLANTATION; INFLOW MODULATION; HYBRID METHOD; SINGLE-CENTER;
   GRAFT; PRESSURE; SAFETY
AB Adult-to-adult living donor liver transplantation (A2ALDLT) is an accepted mode of treatment for end-stage liver disease. Right-lobe grafts have usually been preferred in view of the higher graft volume, which lowers the risk of a small-for-size syndrome. However, donor left hepatectomy is associated with less morbidity than when it is compared to right hepatectomy. Laparoscopic donor hepatectomy (LDH) has been considered almost exclusively in pediatric transplantation. The results of laparoscopic left-liver graft procurement for calculated small-for-size A2ALDLT in four donors are presented. The graft-to-recipient body weight ratio was <0.8 in all recipients. The mean portal vein flow and the pressure and hepatic artery flows were measured at 190 +/- 56mL/min/100g, 13 +/- 1.4mm/Hg and 109 +/- 19mL/min, respectively. No early postoperative donor complications were recorded. One graft was lost due to intrahepatic abscesses. Asymptomatic stenosis of a right posterior duct was treated with a Roux-en-Y loop 4 months later in one donor. We show that LDH of the full-left lobe is feasible. LDH is a very demanding operation, potentially decreasing donor morbidity. Standardization of this procedure, making it accessible to the growing number of experienced laparoscopic liver surgeons, could help renewing the interest for A2ALDLT in the Western world.
   This report of laparoscopic procurement of full-left liver grafts for small-for-size adult-to-adult living donor liver transplants shows that this operation is technically feasible and has the potential to diminish donor morbidity. See editorial by Akoad and Pomfret on page 2243 and case reports on pages 2462 and 2467.
C1 [Troisi, R. I.; Tomassini, F.; Vanlander, A.; Berrevoet, F.; Rogiers, X.] Ghent Univ Hosp & Med Sch, Liver Transplantat Serv, Dept Gen & Hepatobiliary Surg, Ghent, Belgium.
   [Wojcicki, M.; Houtmeyers, P.] Ghent Univ Hosp & Med Sch, Dept Plast Surg, Ghent, Belgium.
   [Smeets, P.] Ghent Univ Hosp & Med Sch, Dept Radiol, Ghent, Belgium.
   [Van Vlierberghe, H.] Ghent Univ Hosp & Med Sch, Dept Gastroenterol, Ghent, Belgium.
RP Troisi, RI (reprint author), Ghent Univ Hosp & Med Sch, Liver Transplantat Serv, Dept Gen & Hepatobiliary Surg, Ghent, Belgium.
EM roberto.troisi@ugent.be
RI Troisi, Roberto Ivan/E-8737-2015
FU European Society of Organ Transplantation
FX M.W. is a recipient of a Short Stay and Study Grant from the European
   Society of Organ Transplantation. The authors wish to thank Prof. Stan
   Monstrey, head of the local Dept. of Plastic Surgery for his logistic
   assistance.
CR Botha JF, 2010, LIVER TRANSPLANT, V16, P649, DOI 10.1002/lt.22043
   Brown RS, 2008, GASTROENTEROLOGY, V134, P1802, DOI 10.1053/j.gastro.2008.02.092
   Ishizawa T, 2010, BRIT J SURG, V97, P1369, DOI 10.1002/bjs.7125
   Kawasaki S, 1998, ANN SURG, V227, P269, DOI 10.1097/00000658-199802000-00017
   Nguyen KT, 2011, ARCH SURG-CHICAGO, V146, P348, DOI 10.1001/archsurg.2010.248
   Koffron AJ, 2007, SURGERY, V142, P463, DOI 10.1016/j.surg.2007.08.006
   Lo CM, 2003, TRANSPLANTATION, V75, pS13
   Mangal M, 2012, J RECONSTR MICROSURG, V28, P359, DOI 10.1055/s-0032-1313763
   Miller Charles M, 2008, Transplant Rev (Orlando), V22, P206, DOI 10.1016/j.trre.2008.02.001
   Nguyen KT, 2009, ANN SURG, V250, P831, DOI 10.1097/SLA.0b013e3181b0c4df
   Ozgor D, 2012, TRANSPL P, V44, P1604, DOI 10.1016/j.transproceed.2012.04.002
   Sainz-Barriga M, 2011, LIVER TRANSPLANT, V17, P836, DOI 10.1002/lt.22295
   Soejima Y, 2012, AM J TRANSPLANT, V12, P1877, DOI 10.1111/j.1600-6143.2012.04022.x
   Soubrane O, 2006, ANN SURG, V244, P815, DOI 10.1097/01.sla.0000218059.31231.b6
   Soyama A, 2012, TRANSPL P, V44, P353, DOI 10.1016/j.transproceed.2012.01.050
   Surman OS, 2003, LANCET, V362, P674, DOI 10.1016/S0140-6736(03)14239-0
   Taketomi A, 2009, TRANSPLANTATION, V87, P445, DOI 10.1097/TP.0b013e3181943d46
   Troisi RI, 2012, LIVER TRANSPLANT, V18, pS101
   Trotter JF, 2006, LIVER TRANSPLANT, V12, P1485, DOI 10.1002/lt.20875
   Yamada T, 2008, AM J TRANSPLANT, V8, P847, DOI 10.1111/j.1600-6143.2007.02144.x
NR 20
TC 26
Z9 26
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2013
VL 13
IS 9
BP 2472
EP 2478
DI 10.1111/ajt.12362
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 208KS
UT WOS:000323678200031
PM 23914734
ER

PT J
AU Chen, CY
   Tseng, HS
   Lin, NC
   Wang, JB
   Tsai, HL
   Loong, CC
   Hsia, CY
   Liu, CS
AF Chen, Cheng-Yen
   Tseng, Hsiou-Shan
   Lin, Niang-Cheng
   Wang, Jen-Bing
   Tsai, Hsin-Lin
   Loong, Che-Chuan
   Hsia, Cheng-Yuan
   Liu, Chinsu
TI A bidirectional approach for portal vein stent placement in a child with
   complete portal vein occlusion after living donor liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE child; liver transplantation; portal vein thrombosis; stent
ID REX SHUNT; COMPLICATIONS; ANGIOPLASTY; THROMBOSIS; STENOSES
AB Delayed PV complications are not rare in pediatric liver transplantation. Although PTPV offers a treatment and minimizes surgical revision, in case of complete PV thrombosis (PVT), the failure rate of PTPV is high. Herein, we report a successful technique of PTPV in a case of complete PVT with a stent placement using a bidirectional approach in a child with living donor liver transplantation.
C1 [Chen, Cheng-Yen; Wang, Jen-Bing; Tsai, Hsin-Lin; Liu, Chinsu] Taipei Vet Gen Hosp, Div Pediat Surg, Taipei 112, Taiwan.
   [Hsia, Cheng-Yuan] Taipei Vet Gen Hosp, Div Gen Surg, Taipei 112, Taiwan.
   [Chen, Cheng-Yen; Lin, Niang-Cheng; Tsai, Hsin-Lin; Loong, Che-Chuan; Hsia, Cheng-Yuan; Liu, Chinsu] Taipei Vet Gen Hosp, Div Transplantat Surg, Dept Surg, Taipei 112, Taiwan.
   [Tseng, Hsiou-Shan] Taipei Vet Gen Hosp, Dept Radiol, Taipei 112, Taiwan.
   [Chen, Cheng-Yen; Tseng, Hsiou-Shan; Lin, Niang-Cheng; Tsai, Hsin-Lin; Loong, Che-Chuan; Hsia, Cheng-Yuan; Liu, Chinsu] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
RP Liu, CS (reprint author), Taipei Vet Gen Hosp, Dept Surg, Div Transplantat Surg, Div Pediat Surg, 201,Sect 2,Shih Pai Rd, Taipei 112, Taiwan.
EM csliu@vghtpe.gov.tw
CR Carnevale FC, 2006, CARDIOVASC INTER RAD, V29, P457, DOI 10.1007/s00270-005-0046-8
   Carnevale FC, 2009, CARDIOVASC INTER RAD, V32, P1083, DOI 10.1007/s00270-009-9578-7
   Cheng YF, 2010, AM J TRANSPLANT, V10, P1276, DOI 10.1111/j.1600-6143.2010.03076.x
   de Goyet JD, 2013, PEDIATR TRANSPLANT, V17, P19, DOI 10.1111/j.1399-3046.2012.01784.x
   de Magnee C, 2011, ANN SURG, V254, P55, DOI 10.1097/SLA.0b013e3182121eb7
   Funaki B, 2000, RADIOLOGY, V215, P147
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   Krebs-Schmitt D, 2009, PEDIATR TRANSPLANT, V13, P540, DOI 10.1111/j.1399-3046.2008.01109.x
   Lautz Kim S, 2012, J VASC INTERV RADIOL, V23, P377
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   Rivera J, 2012, PEDIATR TRANSPLANT, V16, pE235, DOI 10.1111/j.1399-3046.2011.01576.x
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   ZAJKO AB, 1994, J VASC INTERV RADIOL, V5, P121, DOI 10.1016/S1051-0443(94)71467-6
NR 14
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2013
VL 17
IS 6
BP E137
EP E140
DI 10.1111/petr.12121
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 190DF
UT WOS:000322317700002
PM 23834675
ER

PT J
AU Florescu, MC
   Miles, CD
   Florescu, DF
AF Florescu, Marius C.
   Miles, Clifford D.
   Florescu, Diana F.
TI What do we know about adenovirus in renal transplantation?
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE adenovirus; disease; infection; kidney transplantation; renal
   transplantation
ID PEDIATRIC LUNG-TRANSPLANT; OF-THE-LITERATURE; TUBULOINTERSTITIAL
   NEPHRITIS; INTRAVENOUS IMMUNOGLOBULIN; INFECTIOUS COMPLICATIONS;
   MARROW-TRANSPLANTATION; LIVER-TRANSPLANTATION; HEMORRHAGIC CYSTITIS;
   QUANTITATIVE PCR; RECIPIENTS
AB Adenoviruses are common pathogens that have the potential to cause opportunistic infections with significant morbidity and mortality in immunocompromised hosts. The significance of adenoviral infection and disease is incompletely known in the setting of kidney transplantation. Reported adenovirus infections in renal transplant recipients have typically manifested as hemorrhagic cystitis and tubulointerstitial nephritis, less severe diseases than often seen in other solid organ transplant recipients (i.e. pneumonia, hepatitis and enteritis). The prevalent adenovirus subgroups associated with cystitis and nephritis are B1 and B2 with the serotypes 7, 11, 34, 35. However, disseminated or severe adenovirus infections, including fatal cases, have been described in renal transplant recipients. There is uncertainty regarding monitoring of and treatment of this virus. Although not supported by randomized clinical trials, cidofovir is used for the treatment of adenovirus disease not responding to reduction of immunosuppression.
C1 [Florescu, Marius C.; Miles, Clifford D.] Univ Nebraska Med Ctr, Div Nephrol, Omaha, NE USA.
   [Florescu, Diana F.] Univ Nebraska Med Ctr, Div Infect Dis, Omaha, NE USA.
   [Florescu, Diana F.] Univ Nebraska Med Ctr, Transplant Surg Div, Omaha, NE USA.
RP Florescu, MC (reprint author), Univ Nebraska Med Ctr, Div Nephrol, Omaha, NE USA.
EM mflorescu@unmc.edu
OI Miles, Clifford/0000-0003-0517-6104
FU Chimerix Inc.; CSL Behring
FX The authors thank Dr. Volker Nickeleit and Dr. Harsharan Singh, Division
   of Nephropathology at UNC; Dr. David Howell, Pathology Department at
   Duke University for providing the pictures of adenovirus within the
   transplanted kidney. The authors thank Mrs. Ashley Calhoon for
   preparation of the manuscript. D. F. F. has the following financial
   disclosures: received grant from Chimerix Inc. and CSL Behring.
CR Alsaad KO, 2007, NEPHROL DIAL TRANSPL, V22, P1257, DOI 10.1093/ndt/gfl843
   Anderson EJ, 2008, PEDIATR TRANSPLANT, V12, P219, DOI 10.1111/j.1399-3046.2007.00851.x
   Ardehali H, 2001, TRANSPLANTATION, V71, P998, DOI 10.1097/00007890-200104150-00029
   Asim M, 2003, AM J KIDNEY DIS, V41, P696, DOI 10.1053/ajkd.2003.50133
   Broeders EN, 2008, TRANSPL INT, V21, P57, DOI 10.1111/j.1432-2277.2007.00556.x
   de Mezerville MH, 2006, PEDIATR INFECT DIS J, V25, P815, DOI 10.1097/01.inf.0000233542.48267.fd
   Doan ML, 2007, J HEART LUNG TRANSPL, V26, P883, DOI 10.1016/j.healun.2007.06.009
   Echavarria M, 2008, CLIN MICROBIOL REV, V21, P704, DOI 10.1128/CMR.00052-07
   Emovon OE, 2003, NEPHROL DIAL TRANSPL, V18, P2436, DOI 10.1093/ndt/gfg365
   Engelmann G, 2009, PEDIATR TRANSPLANT, V13, P421, DOI 10.1111/j.1399-3046.2008.01014.x
   Florescu DF, 2012, BIOL BLOOD MARROW TR, V18, P731, DOI 10.1016/j.bbmt.2011.09.007
   Florescu DF, 2010, TRANSPLANTATION, V90, P198, DOI 10.1097/TP.0b013e3181e0de97
   Friedrichs N, 2003, PATHOL RES PRACT, V199, P565, DOI 10.1078/0344-0338-00463
   Garnett C T, 2007, Methods Mol Med, V130, P193
   Gilead Sciences Inc, 2000, VIST CID INJ
   GREEN M, 1991, TRANSPLANT P, V23, P3038
   Green M, 2003, TRANSPLANT INFECT, P412
   Hoffman JA, 2006, PEDIATR TRANSPLANT, V10, P17, DOI 10.1111/j.1399-3046.2006.00427.x
   Hoffman JA, 2001, BIOL BLOOD MARROW TR, V7, P388, DOI 10.1053/bbmt.2001.v7.pm11529489
   Hoffman JA, 2009, CURR OPIN ORGAN TRAN, V14, P625, DOI 10.1097/MOT.0b013e3283324e1b
   Hofland CA, 2004, TRANSPLANT P, V36, P3025, DOI 10.1016/j.transproceed.2004.10.090
   Humar A, 2005, AM J TRANSPLANT, V5, P2555, DOI 10.1111/j.1600-6143.2005.01033.x
   Humar A, 2006, TRANSPLANTATION, V82, pS9, DOI 10.1097/01.tp.0000230432.39447.8b
   Ison MG, 2009, AM J TRANSPLANT, V9, pS161, DOI 10.1111/j.1600-6143.2009.02907.x
   Jeulin H, 2010, J CLIN MICROBIOL, V48, P3132, DOI 10.1128/JCM.00976-10
   Keven K, 2003, Transpl Infect Dis, V5, P181, DOI 10.1111/j.1399-3062.2003.00035.x
   KOGA S, 1993, J UROLOGY, V149, P838
   Lankester AC, 2004, CLIN INFECT DIS, V38, P1521, DOI 10.1086/420817
   Legrand F, 2001, BONE MARROW TRANSPL, V27, P621, DOI 10.1038/sj.bmt.1702820
   Lenaerts L, 2006, ANTIVIR RES, V71, P172, DOI 10.1016/j.antiviral.2006.04.007
   Leruez-Ville M, 2004, CLIN INFECT DIS, V38, P45
   Lim AKH, 2005, AM J TRANSPLANT, V5, P2062, DOI 10.1111/j.1600-6143.2005.00945.x
   Liu M, 2009, TRANSPL INFECT DIS, V11, P304, DOI 10.1111/j.1399-3062.2009.00397.x
   Ljungman P, 2003, BONE MARROW TRANSPL, V31, P481, DOI 10.1038/sj.bmt.1703798
   Ljungman P, 2004, EUR J CLIN MICROBIOL, V23, P583, DOI 10.1007/s10096-004-1165-x
   Mahr JA, 1999, IMMUNOL REV, V168, P121, DOI 10.1111/j.1600-065X.1999.tb01287.x
   Mawhorter S, 2008, CURR OPIN ORGAN TRAN, V13, P581, DOI 10.1097/MOT.0b013e3283186bbc
   McGilvray ID, 2003, AM J TRANSPLANT, V3, P501, DOI 10.1034/j.1600-6143.2003.00066.x
   McGrath D, 1998, J INFECT DIS, V177, P459
   McLaughlin GE, 2003, AM J TRANSPLANT, V3, P224, DOI 10.1034/j.1600-6143.2003.00007.x
   MICHAELS MG, 1992, J INFECT DIS, V165, P170
   Morfin F, 2005, ANTIVIR THER, V10, P225
   MYEROWITZ RL, 1975, AM J MED, V59, P591, DOI 10.1016/0002-9343(75)90267-3
   Nagafuji K, 2004, BONE MARROW TRANSPL, V34, P909, DOI 10.1038/sj.bmt.1704682
   Painter W, 2012, ANTIMICROB AGENTS CH, V56, P2726, DOI 10.1128/AAC.05983-11
   Pinchoff RJ, 2003, TRANSPLANTATION, V76, P183, DOI 10.1097/01.TP.0000072808.93060.0F
   POLLOCK CA, 1989, TRANSPLANTATION, V47, P952, DOI 10.1097/00007890-198906000-00007
   Refaat M, 2008, J HEART LUNG TRANSPL, V27, P699, DOI [10.1016/j.healun.2008.03.001, 10.1016/j.healun.2008.03.00I]
   Ribaud P, 1999, CLIN INFECT DIS, V28, P690, DOI 10.1086/517222
   Rosario RF, 2006, TRANSPL INFECT DIS, V8, P54, DOI 10.1111/j.1399-3062.2006.00137.x
   Ruuskanen Olli, 2002, P515
   Saquib R, 2010, TRANSPL INFECT DIS, V12, P77, DOI 10.1111/j.1399-3062.2009.00452.x
   Seidemann K, 2004, AM J TRANSPLANT, V4, P2102, DOI 10.1111/j.1600-6143.2004.00631.x
   SHINOHARA Y, 1992, TRANSPLANT P, V24, P1565
   Shiramizu T, 1986, Tokai J Exp Clin Med, V11, P371
   Storsley L, 2011, J AM SOC NEPHROL, V22, P1423, DOI 10.1681/ASN.2010090941
   Sujeet K, 2011, TRANSPL INFECT DIS, V13, P174, DOI 10.1111/j.1399-3062.2010.00577.x
   Suparno Chakrabarti, 2004, Leuk Lymphoma, V45, P873
   Varma MC, 2011, AM J TRANSPLANT, V11, P623, DOI 10.1111/j.1600-6143.2010.03408.x
   Watcharananan SP, 2011, AM J TRANSPLANT, V11, P1308, DOI 10.1111/j.1600-6143.2011.03479.x
   YAGISAWA T, 1989, TRANSPLANT P, V21, P2097
NR 61
TC 10
Z9 11
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD AUG
PY 2013
VL 28
IS 8
BP 2003
EP 2010
DI 10.1093/ndt/gft036
PG 9
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 219FC
UT WOS:000324490500013
PM 23493328
ER

PT J
AU Hibi, T
   Nishida, S
   Levi, DM
   Sugiyama, D
   Fukazawa, K
   Tekin, A
   Fan, J
   Selvaggi, G
   Ruiz, P
   Tzakis, AG
AF Hibi, Taizo
   Nishida, Seigo
   Levi, David M.
   Sugiyama, Daisuke
   Fukazawa, Kyota
   Tekin, Akin
   Fan, Ji
   Selvaggi, Gennaro
   Ruiz, Phillip
   Tzakis, Andreas G.
TI Long-term deleterious effects of aortohepatic conduits in primary liver
   transplantation: Proceed with caution
SO LIVER TRANSPLANTATION
LA English
DT Article
ID HEPATIC-ARTERY THROMBOSIS; PEDIATRIC LIVER; RISK-FACTORS; CENTRAL
   PERIVENULITIS; FOLLOW-UP; REVASCULARIZATION; ADULT; RECONSTRUCTION;
   EXPERIENCE; GRAFT
AB Aortohepatic conduits provide a vital alternative for graft arterialization during liver transplantation. Conflicting results exist with respect to the rates of comorbidities, and long-term survival data on primary grafts are lacking. To identify the complications associated with aortohepatic conduits in primary liver transplantation and their impact on survival, we conducted a single-center, retrospective cohort analysis of all consecutive adult (n = 1379) and pediatric primary liver transplants (n = 188) from 1998 to 2009. The outcomes of aortohepatic conduits were compared to those of standard arterial revascularization. Adults with a conduit (n = 267) demonstrated, in comparison with adults with standard arterialization (n = 1112), an increased incidence of late (>1 month after transplantation) hepatic artery thrombosis (HAT; 4.1% versus 0.7%, P < 0.001) and ischemic cholangiopathy (7.5% versus 2.7%, P < 0.001) and a lower 5-year graft survival rate (61% versus 70%, P = 0.01). The adjusted hazard ratio (HR) for graft loss in the conduit group was 1.38 [95% confidence interval (CI) = 1.03-1.85, P = 0.03]. Notably, the use of conduits (HR = 4.91, 95% CI = 1.92-12.58) and a warm ischemia time > 60 minutes (HR = 11.12, 95% CI = 3.06-40.45) were independent risk factors for late HAT. Among children, the complication profiles were similar for the conduit group (n = 81) and the standard group (n = 107). In the pediatric cohort, although the 5-year graft survival rate for the conduit group (69%) was significantly impaired in comparison with the rate for the standard group (81%, P = 0.03), the use of aortohepatic conduits did not emerge as an independent predictor of diminished graft survival via a multivariate analysis. In conclusion, in adult primary liver transplantation, the placement of an aortohepatic conduit should be strictly limited because of the greater complication rates (notably late HAT) and impaired graft survival; for children, its judicious use may be acceptable. Liver Transpl 19:916-925, 2013. (c) 2013 AASLD.
C1 [Hibi, Taizo; Nishida, Seigo; Levi, David M.; Tekin, Akin; Fan, Ji; Selvaggi, Gennaro; Ruiz, Phillip; Tzakis, Andreas G.] Univ Miami, Jackson Mem Hosp, Miami Transplant Inst, Miami, FL 33136 USA.
   [Hibi, Taizo; Levi, David M.; Tekin, Akin; Fan, Ji; Selvaggi, Gennaro] Univ Miami, Leonard M Miller Sch Med, DeWitt Daughtry Family Dept Surg, Miami, FL USA.
   [Fukazawa, Kyota] Univ Miami, Leonard M Miller Sch Med, Dept Anesthesiol Perioperat Med & Pain Management, Div Solid Organ Transplantat, Miami, FL USA.
   [Ruiz, Phillip] Univ Miami, Leonard M Miller Sch Med, Dept Pathol, Miami, FL USA.
   [Nishida, Seigo] Carolinas Med Ctr, Transplant Ctr, Charlotte, NC 28203 USA.
   [Sugiyama, Daisuke] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo, Japan.
   [Tzakis, Andreas G.] Cleveland Clin Florida, Transplant Ctr, Weston, FL USA.
RP Tzakis, AG (reprint author), Cleveland Clin Florida, Transplant Ctr, 2950 Cleveland Clin Blvd, Weston, FL 33331 USA.
EM tzakisa@ccf.org
RI Sugiyama, Daisuke/L-4347-2013
CR Abecassis M, 2012, AM J TRANSPLANT, V12, P2608, DOI 10.1111/j.1600-6143.2012.04245.x
   Aloia TA, 2010, LIVER TRANSPLANT, V16, P950, DOI 10.1002/lt.22098
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Bhattacharjya S, 2001, TRANSPLANTATION, V71, P1592, DOI 10.1097/00007890-200106150-00018
   BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   Chiu JJ, 2009, ANN MED, V41, P19, DOI 10.1080/07853890802186921
   Del Gaudio M, 2005, CLIN TRANSPLANT, V19, P399, DOI 10.1111/j.1399-0012.2005.00363.x
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Gunsar F, 2003, LIVER TRANSPLANT, V9, P605, DOI 10.1053/jlts.2003.50057
   HENNEIN HA, 1993, SURGERY, V113, P279
   Hubscher SG, 2008, LIVER TRANSPLANT, V14, P596, DOI 10.1002/lt.21451
   Kimia B. B., 2003, International Journal of Computer Vision, V54, P159
   Krasinskas AM, 2008, LIVER TRANSPLANT, V14, P625, DOI 10.1002/lt.21404
   Lei M, 1997, J VASC SURG, V25, P637, DOI 10.1016/S0741-5214(97)70289-1
   Margarit C, 1998, Transpl Int, V11 Suppl 1, pS251, DOI 10.1111/j.1432-2277.1998.tb01126.x
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Meek DS, 2004, J COMPUT APPL MATH, V170, P59, DOI 10.1016/j.cam.2003.12.038
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Muiesan P, 1998, LIVER TRANSPLANT SUR, V4, P232, DOI 10.1002/lt.500040314
   Muralidharan V, 2004, TRANSPLANT INT, V17, P163, DOI 10.1007/s00147-004-0701-z
   Nikitin D, 2008, LIVER TRANSPLANT, V14, P1486, DOI 10.1002/lt.21575
   Nishida S, 2002, CLIN TRANSPLANT, V16, P334, DOI 10.1034/j.1399-0012.2002.01149.x
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Nishida S, 2004, BRIT J SURG, V91, P705, DOI 10.1002/bjs.4550
   Nishida Seigo, 2006, HPB (Oxford), V8, P182, DOI 10.1080/13651820500542135
   Panaro F, 2011, TRANSPL INT, V24, P949, DOI 10.1111/j.1432-2277.2011.01293.x
   Pararas N, 2009, ANN SURG, V250, P273, DOI 10.1097/SLA.0b013e3181b17161
   Santamaria ML, 1996, J PEDIATR SURG, V31, P600, DOI 10.1016/S0022-3468(96)90506-0
   SHAKED AA, 1991, SURG GYNECOL OBSTET, V173, P198
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   TZAKIS A, 1989, TRANSPLANT INT, V2, P121, DOI 10.1111/j.1432-2277.1989.tb01852.x
   TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013
   Valente JF, 1996, TRANSPLANTATION, V61, P61, DOI 10.1097/00007890-199601150-00013
   Vivarelli M, 2004, ARCH SURG-CHICAGO, V139, P1069, DOI 10.1001/archsurg.139.10.1069
   Vivarelli M, 2007, LIVER TRANSPLANT, V13, P651, DOI 10.1002/lt.21028
   Warner P, 2011, TRANSPL INT, V24, P401, DOI 10.1111/j.1432-2277.2010.01211.x
   Zamboni F, 2002, DIGEST LIVER DIS, V34, P122, DOI 10.1016/S1590-8658(02)80241-9
NR 39
TC 6
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2013
VL 19
IS 8
BP 916
EP 925
DI 10.1002/lt.23689
PG 10
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 199HQ
UT WOS:000322985700014
PM 23897778
ER

PT J
AU Acquazzino, MA
   Fischer, RT
   Langnas, A
   Coulter, DW
AF Acquazzino, Melissa A.
   Fischer, Ryan T.
   Langnas, Alan
   Coulter, Don W.
TI Refractory autoimmune hemolytic anemia after intestinal transplant
   responding to conversion from a calcineurin to mTOR inhibitor
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE intestinal transplant; hemolytic anemia; calcineurin inhibition; mTOR
   inhibitor
ID LIVER-TRANSPLANT; SIROLIMUS; TACROLIMUS; RECIPIENTS; RESCUE
AB AIHA is a rare and serious complication of solid organ transplantation. Herein, we report four cases of warm or mixed AIHA in pediatric patients following combined liver, small bowel and pancreas transplant. The hemolysis was refractory to multiple treatment modalities including steroids, rituximab, IVIG, plasmapheresis, cytoxan, discontinuation of prophylactic penicillin, and a change in immunosuppression from tacrolimus to cyclosporine. All patients had resolution or marked improvement of hemolysis after discontinuation of maintenance of CNI and initiation of sirolimus immunosuppression. One patient developed nephrotic syndrome but responded to a change in immunosuppression to everolimus. Three of the four patients continue on immunosuppression with sirolimus or everolimus without further hemolysis, evidence of rejection or medication side effects. Based on our experience and review of similar cases in the literature, we have proposed a treatment algorithm for AIHA in the pediatric intestinal transplant patient population that recommends an early change in immunosuppressive regimen from CNIs to sirolimus therapy.
C1 [Acquazzino, Melissa A.] Univ Nebraska Med Ctr, Dept Pediat, Omaha, NE 68198 USA.
   [Fischer, Ryan T.] Childrens Mercy Hosp & Clin, Dept Pediat Gastroenterol & Hepatol, Kansas City, MO USA.
   [Langnas, Alan] Univ Nebraska Med Ctr, Dept Transplant Surg, Omaha, NE 68198 USA.
   [Coulter, Don W.] Univ Nebraska Med Ctr, Dept Pediat Hematol & Oncol, Omaha, NE 68198 USA.
RP Coulter, DW (reprint author), Univ Nebraska Med Ctr, Dept Pediat Hematol & Oncol, Nebraska Med Ctr Omaha 982168, Omaha, NE 68198 USA.
EM dwcoulter@unmc.edu
FU Cheryl Lozier Foundation
FX Dr. Fischer is supported in part by a grant from the Cheryl Lozier
   Foundation.
CR Andres AM, 2010, PEDIATR TRANSPLANT, V14, P931, DOI 10.1111/j.1399-3046.2010.01363.x
   Botija G, 2010, TRANSPL INT, V23, P1033, DOI 10.1111/j.1432-2277.2010.01091.x
   Domenech C, 2008, TRANSPL INT, V21, P397, DOI 10.1111/j.1432-2277.2007.00619.x
   Ettenger R, 2008, PEDIATR TRANSPLANT, V12, P456, DOI 10.1111/j.1399-3046.2007.00832.x
   Gehrs BC, 2002, AM J HEMATOL, V69, P258, DOI 10.1002/ajh.10062
   Hymes LC, 2011, PEDIATR TRANSPLANT, V15, P437, DOI 10.1111/j.1399-3046.2011.01477.x
   Kato T, 2007, ANN SURG, V246, P436, DOI 10.1097/SLA.0b013e3181485124
   Petz LD, 1998, TRANSFUSION, V38, P224, DOI 10.1046/j.1537-2995.1998.38398222864.x
   Schaffer M, 2007, LANGENBECK ARCH SURG, V392, P297, DOI 10.1007/s00423-007-0174-5
   Schappi MG, 2008, PEDIATR TRANSPLANT, V12, P809, DOI 10.1111/j.1399-3046.2008.00934.x
   Sokol RJ, 2002, TRANSFUSION, V42, P198, DOI 10.1046/j.1537-2995.2002.00026.x
   Teachey DT, 2009, PEDIATR BLOOD CANCER, V53, P1114, DOI 10.1002/pbc.22183
   Valentini RP, 2006, PEDIATR TRANSPLANT, V10, P358, DOI 10.1111/j.1399-3046.2005.00460.x
   Weinreich J, 2011, EUR SURG RES, V47, P39, DOI 10.1159/000327972
   Wong W, 2007, PEDIATR TRANSPLANT, V11, P931, DOI 10.1111/j.1399-3046.2007.00795.x
NR 15
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2013
VL 17
IS 5
BP 466
EP 471
DI 10.1111/petr.12101
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 175SZ
UT WOS:000321254700014
PM 23730873
ER

PT J
AU Ramos, E
   Hernandez, F
   Andres, A
   Martinez-Ojinaga, E
   Molina, M
   Sarria, J
   Lopez-Santamaria, M
   Prieto, G
AF Ramos, Esther
   Hernandez, Francisco
   Andres, Ane
   Martinez-Ojinaga, Eva
   Molina, Manuel
   Sarria, Jesus
   Lopez-Santamaria, Manuel
   Prieto, Gerardo
TI Post-transplant lymphoproliferative disorders and other malignancies
   after pediatric intestinal transplantation: Incidence, clinical features
   and outcome
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplant lymphoproliferative; Epstein-Barr virus;
   immunosuppression; intestinal transplantation
ID SOLID-ORGAN TRANSPLANTATION; DE-NOVO MALIGNANCIES; VIRAL LOAD CARRIAGE;
   LIVER-TRANSPLANTATION; RISK-FACTORS; RECIPIENTS; DISEASE;
   IMMUNOSUPPRESSION; INDUCTION; CHILDREN
AB PTLDs are a well-recognized and potentially fatal complication after intestinal transplantation. We analyzed the incidence, clinical features, and outcome in a 63 intestinal transplantation series performed in our unit between October 1999 and July 2011. Types of graft included ISB (n=23), LSB (n=20), and MV (n=20). Patients were categorized into three groups of immunosuppression: I (n=43) received basiliximab, tacrolimus, and steroids; II (n=11) thymoglobulin and tacrolimus, and III (n=9) alemtuzumab and tacrolimus. EBV status was serially assessed. All PTLD cases were biopsied to establish histopathological diagnosis. The incidence of PTLD was 14.2% (9/63). Median onset of PTLD after transplant was fourmonths (range: 0.5-28), within first postoperative year in 6 (66.6%) patients. Fever was the most common symptom. Graft removal was needed in four patients (44%). The patient survival rate was 66.6% (6/9). We have not found any association between PTLD and immunosuppression regimen or transplant type. However, there was a statistical association with EBV active infection.
C1 [Ramos, Esther; Hernandez, Francisco; Andres, Ane; Martinez-Ojinaga, Eva; Molina, Manuel; Sarria, Jesus; Lopez-Santamaria, Manuel; Prieto, Gerardo] Univ Hosp La Paz, Intestinal Rehabil Unit, Madrid 28046, Spain.
   [Ramos, Esther; Hernandez, Francisco; Andres, Ane; Martinez-Ojinaga, Eva; Molina, Manuel; Sarria, Jesus; Lopez-Santamaria, Manuel; Prieto, Gerardo] Univ Hosp La Paz, Madrid 28046, Spain.
RP Ramos, E (reprint author), Univ Hosp La Paz, Intestinal Rehabil Unit, Madrid 28046, Spain.
EM erboluda@salud.madrid.org
CR Aberg F, 2008, LIVER TRANSPLANT, V14, P1428, DOI 10.1002/lt.21475
   Abu-Elmagd KM, 2009, TRANSPLANTATION, V88, P926, DOI 10.1097/TP.0b013e3181b7509c
   Allen U, 2001, PEDIATR TRANSPLANT, V5, P198, DOI 10.1034/j.1399-3046.2001.00059.x
   Bakker NA, 2005, CLIN TRANSPLANT, V19, P327, DOI 10.1111/j.1399-0012.2005.00342.x
   Bingler MA, 2008, AM J TRANSPLANT, V8, P442, DOI 10.1111/j.1600-6143.2007.02080.x
   Blaes AH, 2005, CANCER, V104, P1661, DOI 10.1002/cncr.21391
   Caillard S, 2006, TRANSPLANTATION, V81, P888, DOI 10.1097/01.tp.0000203554.54242.56
   Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050
   Cherikh WS, 2003, TRANSPLANTATION, V76, P1289, DOI 10.1097/01.TP.00000100826.58738.2B
   Choquet S, 2006, BLOOD, V107, P3053, DOI 10.1182/blood-2005-01-0377
   Cockfield S M, 2001, Transpl Infect Dis, V3, P70, DOI 10.1034/j.1399-3062.2001.003002070.x
   Davis JE, 2004, TISSUE ANTIGENS, V63, P285, DOI 10.1111/j.0001-2815.2004.00227.x
   Dharnidharka VR, 2002, PEDIATR TRANSPLANT, V6, P396, DOI 10.1034/j.1399-3046.2002.00021.x
   Grant D, 2005, ANN SURG, V241, P607, DOI 10.1097/01.sla.0000157265.85388.a1
   Green M, 2000, TRANSPLANTATION, V70, P593, DOI 10.1097/00007890-200008270-00010
   Green M, 2009, PEDIATR TRANSPLANT, V13, P319, DOI 10.1111/j.1399-3046.2008.00926.x
   Gross TG, 2010, PEDIATR CLIN N AM, V57, P481, DOI 10.1016/j.pcl.2010.01.011
   Kahan BD, 2005, TRANSPLANTATION, V80, P749, DOI 10.1097/01.TP.0000173770.42403.F7
   Katz BZ, 2007, PEDIATR TRANSPLANT, V11, P58, DOI 10.1111/j.1399-3046.2006.00609.x
   Kauffman HM, 2005, TRANSPLANTATION, V80, P883, DOI 10.1097/01.TP.0000184006.43152.8D
   Kirk AD, 2007, AM J TRANSPLANT, V7, P2619, DOI 10.1111/j.1600-6143.2007.01972.x
   Lau AH, 2010, PEDIATR TRANSPLANT, V14, P549, DOI 10.1111/j.1399-3046.2009.01283.x
   Leblond V, 2004, J HEPATOL, V40, P728, DOI 10.1016/j.jhep.2004.03.006
   Manez R, 1997, J INFECT DIS, V176, P1462
   McLaughlin K, 2000, LIVER TRANSPLANT, V6, P570, DOI 10.1053/jlts.2000.7578
   NALESNIK MA, 1988, AM J PATHOL, V133, P173
   Nalesnik N, 2000, POSTTRANSPLANTATION
   Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x
   Parker A, 2010, BRIT J HAEMATOL, V149, P675, DOI 10.1111/j.1365-2141.2010.08161.x
   Reshef R, 2011, AM J TRANSPLANT, V11, P336, DOI 10.1111/j.1600-6143.2010.03387.x
   Stojanova J, 2011, PHARMACOL RES, V63, P1, DOI 10.1016/j.phrs.2010.10.016
   Tsao L, 2007, ARCH PATHOL LAB MED, V131, P1209
   Webber SA, 2007, PEDIAT SOLID ORGAN T, P114, DOI 10.1002/9781444312720.ch13
NR 33
TC 4
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2013
VL 17
IS 5
BP 472
EP 478
DI 10.1111/petr.12103
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 175SZ
UT WOS:000321254700015
PM 23730927
ER

PT J
AU Davidovich, E
   Asher, R
   Shapira, J
   Brand, HS
   Veerman, ECI
   Shapiro, R
AF Davidovich, Esti
   Asher, Ran
   Shapira, Joseph
   Brand, Henk S.
   Veerman, Enno C. I.
   Shapiro, Rivka
TI Mucosal pH, Dental Findings, and Salivary Composition in Pediatric Liver
   Transplant Recipients
SO TRANSPLANTATION
LA English
DT Article
DE Liver transplantation; Saliva; Mucosal pH
ID WHOLE-SALIVA; ORAL-HEALTH; FLOW-RATE; GINGIVAL ENLARGEMENT;
   PERIODONTAL-DISEASE; CYSTIC-FIBROSIS; YOUNG-ADULTS; CHILDREN; PROTEIN;
   COMPLICATIONS
AB Background. Oral health and dental maintenance have become part of the standard of care for pediatric liver transplant recipients. These individuals tend to suffer particularly from dental problems, such as gingival enlargement, gingivitis, poor oral hygiene, dental hypoplasia, and caries. Saliva composition influences oral hygiene and disease states. We investigated saliva composition and its association with the oral health of young recipients of liver transplants.
   Methods. In 70 patients, 36 liver transplant recipients (ages 2-23 years) and 34 healthy controls (ages 4-21 years), we measured the following variables: (a) oral hygiene, (b) gingival inflammation, (c) caries status, (d) dental calculus formation, (e) oral mucosal pH, and (f) salivary protein composition.
   Results. Lower mean decayed, missing, and filled teeth index (P=0.0038), higher mean gingival index (P=0.0001), and higher mean calculus score (P=0.003) were found in the transplanted study group compared with the control. The mean mucosal pH for seven intraoral sites was higher in the transplant group (P=0.0006). The median salivary albumin concentration was significantly lower in the transplant group (P=0.01), as was the median salivary albumin/total protein ratio (P=0.0002).
   Conclusions. In post-liver transplant pediatric recipients, low incidence of caries, together with high incidence of dental calculus, could be attributed to elevated oral mucosal pH. Salivary albumin and immunoglobulin A levels were relatively low in these patients. Clinicians should pay particular attention to the oral health and dental care of liver transplanted children.
C1 [Davidovich, Esti; Asher, Ran; Shapira, Joseph] Hebrew Univ Jerusalem, Hadassah Sch Dent Med, Dept Pediat Dent, Jerusalem, Israel.
   [Brand, Henk S.; Veerman, Enno C. I.] Acad Ctr Dent Amsterdam ACTA, Dept Periodontol & Oral Biochem, Amsterdam, Netherlands.
   [Brand, Henk S.] Acad Ctr Dent Amsterdam ACTA, Dept Oral Maxillofacial Surg, Amsterdam, Netherlands.
   [Shapiro, Rivka] Schneider Childrens Med Ctr Israel, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel.
   [Shapiro, Rivka] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
RP Shapiro, R (reprint author), Schneider Childrens Med Ctr Israel, Inst Gastroenterol Nutr & Liver Dis, POB 12272, Petah Tiqwa, Israel.
EM rshapiro@post.tau.ac.il
CR Aframian DJ, 2006, ORAL DIS, V12, P420, DOI 10.1111/j.1601-0825.2005.01217.x
   Amaral Thais Helena Andreolli do, 2008, Spec Care Dentist, V28, P254, DOI 10.1111/j.1754-4505.2008.00048.x
   Baht M, 1991, J PUBLIC HLTH DENT, V51, P5
   Bardow A, 2004, CLIN ORAL PHYSL, P17
   BAUM BJ, 1993, ANN NY ACAD SCI, V694, P17
   BEN-ARYEH H, 1985, Journal of Oral Medicine, V40, P123
   BENARYEH H, 1986, BIOCHEM MED METAB B, V36, P260, DOI 10.1016/0885-4505(86)90134-9
   BENARYEH H, 1984, J DENT RES, V63, P1147, DOI 10.1177/00220345840630091001
   BENARYEH H, 1990, ARCH ORAL BIOL, V35, P929, DOI 10.1016/0003-9969(90)90075-L
   BENARYEH H, 1993, ORAL SURG ORAL MED O, V75, P696, DOI 10.1016/0030-4220(93)90425-4
   Bosch JA, 1996, PSYCHOSOM MED, V58, P374
   Bots CP, 2007, CLIN NEPHROL, V67, P25
   Bradly RM, 1995, ESSENTIALS ORAL PHYS, P160
   CARNOY C, 1993, AM J RESP CELL MOL, V9, P323
   Childs EW, 2010, AM J SURG, V199, P542, DOI 10.1016/j.amjsurg.2009.11.002
   Davidovich E, 2005, J CLIN PERIODONTOL, V32, P1076, DOI 10.1111/j.1600-051X.2005.00812.x
   Davidovich E, 2009, NEPHROL DIAL TRANSPL, V24, P2439, DOI 10.1093/ndt/gfp101
   Davidovich E, 2010, INT J PAEDIATR DENT, V20, P235, DOI 10.1111/j.1365-263X.2010.01045.x
   Dawes C, 2006, J CAN DENT ASSOC, V72, P923
   MA deFonseca, 2010, GEN DENT, V58, P204
   Diaz-Ortiz Maria Luisa, 2005, Med Oral Patol Oral Cir Bucal, V10, P72
   Edgar W., 1992, BR DENT J, V25, P305
   Emre S, 2012, MT SINAI J MED, V79, P199, DOI 10.1002/msj.21305
   Englesbe MJ, 2012, AM J TRANSPLANT, V12, P2301, DOI 10.1111/j.1600-6143.2012.04204.x
   Guggenheimer J, 2003, ORAL SURG ORAL MED O, V95, P383, DOI 10.1067/moe.2003.150
   Hoek GH, 2002, EUR J ORAL SCI, V110, P480, DOI 10.1034/j.1600-0722.2002.21370.x
   JARA L, 1991, Archivos de Biologia y Medicina Experimentales, V24, P57
   Jawadi AH, 2004, PEDIATR DENT, V26, P283
   Kao Richard T, 2010, J Calif Dent Assoc, V38, P263
   KLEIN H., 1938, Public Health Reports, V53, P751, DOI 10.2307/4582532
   Goncalves Lda R, 2011, J PERIODONTAL RES, V46, P599
   Leme AFP, 2006, J DENT RES, V85, P878
   Lenander-Lumikari M, 1998, ARCH ORAL BIOL, V43, P151, DOI 10.1016/S0003-9969(97)00110-6
   Lin Yai-Tin, 2003, Chang Gung Med J, V26, P184
   Lin YT, 2010, J PERIODONTOL, V81, P1250, DOI 10.1902/jop.2010.090743
   Lins L, 2011, TRANSPL P, V43, P1319, DOI 10.1016/j.transproceed.2011.03.063
   LOE HARALD, 1963, ACTA ODONTOL SCAND, V21, P533, DOI 10.3109/00016356309011240
   Lundgren T, 1996, J CLIN PERIODONTOL, V23, P1068, DOI 10.1111/j.1600-051X.1996.tb01805.x
   Majewski R F, 1993, J Clin Pediatr Dent, V18, P32
   MANDEL I D, 1976, Oral Sciences Reviews, V8, P25
   Marsh PD, 2004, CARIES RES, V38, P204, DOI 10.1159/000077756
   Mass E, 2002, Pediatr Dent, V24, P581
   McDonald RE, 2004, DENT CHILD ADOLESCEN, P449
   Mellanen L, 2001, J ORAL PATHOL MED, V30, P553, DOI 10.1034/j.1600-0714.2001.300908.x
   Melvin J E, 1991, Curr Opin Dent, V1, P795
   Mohebbi N, 2009, AM J PHYSIOL-RENAL, V297, pF499, DOI 10.1152/ajprenal.90489.2008
   MOORE S, 1994, FREE RADICAL RES, V21, P417, DOI 10.3109/10715769409056594
   Ng VL, 2012, J PEDIATR-US, V160, P820, DOI 10.1016/j.jpeds.2011.10.038
   Petersen PE, 2005, B WORLD HEALTH ORGAN, V83, P686
   Saether K, 1998, ACTA ODONTOL SCAND, V56, P281, DOI 10.1080/000163598428455
   Sardenberg Fernanda, 2010, J Dent Child (Chic), V77, P102
   Sciubba JJ, 2006, LANCET ONCOL, V7, P175, DOI 10.1016/S1470-2045(06)70580-0
   Sculley DV, 2002, P NUTR SOC, V61, P137, DOI 10.1079/PNS2001141
   Shapiro R, 2001, TRANSPLANTATION, V72, P428, DOI 10.1097/00007890-200108150-00012
   Sheehy Evelyn C., 1999, Pediatric Dentistry, V21, P272
   Shiboski CH, 2009, PEDIATR DENT, V31, P38
   Shiboski CH, 2009, J PUBLIC HEALTH DENT, V69, P48, DOI 10.1111/j.1752-7325.2008.00092.x
   SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968
   Siudikiene J, 2008, CARIES RES, V42, P354, DOI 10.1159/000151582
   SLOMIANY BL, 1982, J DENT RES, V61, P1163, DOI 10.1177/00220345820610101001
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sommer S, 2010, J CLIN PEDIATR DENT, V35, P199
   Soto-Rojas AE, 2002, ARCH MED RES, V33, P95, DOI 10.1016/S0188-4409(01)00371-X
   Vesterinen M, 2007, QUINTESSENCE INT, V38, P211
   Vieira Mara L S O, 2002, Spec Care Dentist, V22, P115, DOI 10.1111/j.1754-4505.2002.tb01173.x
   Watanabe S, 1995, ARCH ORAL BIOL, V40, P78
NR 66
TC 0
Z9 0
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUL 15
PY 2013
VL 96
IS 1
BP 102
EP 107
DI 10.1097/TP.0b013e3182962c58
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299EJ
UT WOS:000330378000017
PM 23680932
ER

PT J
AU Garcia, MC
   Chapman, JR
   Shaw, PJ
   Gottlieb, DJ
   Ralph, A
   Craig, JC
   Tong, A
AF Garcia, Maria C.
   Chapman, Jeremy R.
   Shaw, Peter J.
   Gottlieb, David J.
   Ralph, Angelique
   Craig, Jonathan C.
   Tong, Allison
TI Motivations, Experiences, and Perspectives of Bone Marrow and Peripheral
   Blood Stem Cell Donors: Thematic Synthesis of Qualitative Studies
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Bone marrow donation; Peripheral blood stem cell donation; Hematopoietic
   stem cell transplantation; Systematic review; Quality of life
ID LIVING KIDNEY DONORS; PEDIATRIC SIBLING DONORS; LIVER-TRANSPLANTATION;
   ALLOGENEIC TRANSPLANTATION; PSYCHOSOCIAL-ASPECTS; HEMATOPOIETIC SCT;
   OF-LIFE; DONATION; PROGRAM; PAIN
AB Hematopoietic stem cell (HSC) transplantation using bone marrow and peripheral blood stem cells is a life-saving treatment for patients with leukemia or other blood disorders. However, donors face the risk of physical and psychosocial complications. We aimed to synthesize qualitative studies on the experiences and perspectives of HSC donors. We searched MEDLINE, Embase, PsycINFO, CINAHL, Google Scholar, and reference lists of relevant articles to November 13, 2012. Thematic synthesis was used to analyze the findings. Thirty studies involving 1552 donors were included. The decision to donate included themes of saving life, family loyalty, building a positive identity, religious conviction, fear of invasive procedures, and social pressure and obligation. Five themes about the donation experience were identified: mental preparedness (pervasive pain, intense disappointment over recipient death, exceeding expectations, and valuing positive recipient gains), burden of responsibility (striving to be a quality donor, unresolved guilt, and exacerbated grief), feeling neglected (medical dismissiveness and family inattention), strengthened relationships (stronger family ties, establishing blood bonds), and personal sense of achievement (satisfaction and pride, personal development, hero status, and social recognition). Although HSC donation was appreciated as an opportunity to save life, some donors felt anxious and unduly compelled to donate. HSC donors became emotionally invested and felt responsible for their recipient's outcomes and were profoundly grieved and disappointed if the transplantation was unsuccessful. To maximize donor satisfaction and mitigate the psychosocial risks for HSC donors, strategies to address the emotional challenges of anxiety, sense of coercion, guilt, and grief in donors are warranted. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Garcia, Maria C.; Ralph, Angelique; Craig, Jonathan C.; Tong, Allison] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
   [Garcia, Maria C.; Ralph, Angelique; Craig, Jonathan C.; Tong, Allison] Childrens Hosp, Ctr Kidney Res, Westmead, NSW 2145, Australia.
   [Chapman, Jeremy R.] Westmead Hosp, Ctr Transplant & Renal Res, Westmead, NSW 2145, Australia.
   [Shaw, Peter J.] Childrens Hosp, Dept Oncol, Westmead, NSW, Australia.
   [Gottlieb, David J.] Westmead Hosp, Sydney Cellular Therapies Lab, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia.
   [Gottlieb, David J.] Westmead Hosp, Dept Haematol, Blood & Marrow Transplant Serv, Westmead, NSW 2145, Australia.
   [Gottlieb, David J.] Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW, Australia.
   [Gottlieb, David J.] Univ Sydney, Fac Med, Western Clin Sch, Dept Med, Westmead, NSW 2145, Australia.
RP Tong, A (reprint author), Childrens Hosp, Ctr Kidney Res, Sydney, Westmead, NSW 2145, Australia.
EM allison.tong@sydney.edu.au
RI Craig, Jonathan/E-2813-2013; 
OI Craig, Jonathan/0000-0002-2548-4035; Tong, Allison/0000-0001-8973-9538
FU Australian Research Council [DE120101710]
FX Supported by the Australian Research Council (DE120101710).
CR Andersen MH, 2007, CLIN TRANSPLANT, V21, P702, DOI 10.1111/j.1399-0012.2007.00726.x
   Atkinson Miriam, 2005, Nurs Stand, V19, P41
   Avalos BR, 2011, BIOL BLOOD MARROW TR, V17, P1739, DOI 10.1016/j.bbmt.2011.07.003
   BARTHOLOME WG, 1995, PEDIATRICS, V96, P981
   Bredeson C, 2004, BIOL BLOOD MARROW TR, V10, P405, DOI 10.1016/j.bbmt.2004.02.003
   BUTTERWORTH VA, 1993, BLOOD, V81, P1947
   Butterworth VA, 1992, J DEATH DYING, V26, P161
   Chan KW, 1996, J PEDIATR-US, V128, P644, DOI 10.1016/S0022-3476(96)80129-6
   Chang G, 1998, PSYCHOSOM MED, V60, P163
   Chang G, 2003, PSYCHOSOMATICS, V44, P59, DOI 10.1176/appi.psy.44.1.59
   Chen SH, 2011, TZU CHI MED J, V23, P16
   Christopher K A, 2000, Oncol Nurs Forum, V27, P693
   Confer DL, 2011, BONE MARROW TRANSPL, V46, P1409, DOI 10.1038/bmt.2010.323
   Copelan EA, 2006, NEW ENGL J MED, V354, P1813, DOI 10.1056/NEJMra052638
   de Oliveira-Cardoso EA, 2010, REV LAT-AM ENFERM, V18, P911, DOI 10.1590/S0104-11692010000500011
   Diekema DS, 2010, PEDIATRICS, V125, P392, DOI 10.1542/peds.2009-3078
   Fortanier C, 2002, BONE MARROW TRANSPL, V29, P145, DOI 10.1038/sj.bmt.1703338
   Fujita M, 2006, LIVER TRANSPLANT, V12, P768, DOI 10.1002/lt.20689
   GARDNER GG, 1977, PEDIATRICS, V60, P625
   Haljamae U, 2003, CLIN TRANSPLANT, V17, P503, DOI 10.1046/j.1399-0012.2003.00078.x
   Holroyd E, 2000, SOC SCI MED, V51, P29, DOI 10.1016/S0277-9536(99)00427-X
   Horowitz MM, 2005, AM SOC HEM PROGR BOO, P469
   JOHNSON JE, 1973, J PERS SOC PSYCHOL, V27, P261, DOI 10.1037/h0034767
   Kennedy GA, 2003, BONE MARROW TRANSPL, V31, P1033, DOI 10.1038/sj.bmt.1704053
   Kusakabe T, 2008, GASTROENTEROL NURS, V31, P263, DOI 10.1097/01.SGA.0000334032.48629.c0
   LESKO LM, 1994, SUPPORT CARE CANCER, V2, P35, DOI 10.1007/BF00355238
   Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263
   Ljungman P, 2006, BONE MARROW TRANSPL, V37, P439, DOI 10.1038/sj.bmt.1705265
   MacLeod KD, 2003, J PEDIATR PSYCHOL, V28, P223, DOI 10.1093/jpepsy/jsg010
   Miller JP, 2008, BIOL BLOOD MARROW TR, V14, P29, DOI 10.1016/j.bbmt.2008.05.018
   Molassiotis A, 1999, BONE MARROW TRANSPL, V24, P903, DOI 10.1038/sj.bmt.1702000
   Munzenberger N, 1999, PSYCHO-ONCOL, V8, P55, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<55::AID-PON333>3.3.CO;2-S
   National Marrow Donor Program, 2011, NAT MARR DON PROGR
   *NHMRC, 2007, ORG TISS DON LIV DON
   Nishimori M, 2002, BLOOD, V99, P1995, DOI 10.1182/blood.V99.6.1995
   O'Donnell PV, 2010, BLOOD, V115, P5097, DOI 10.1182/blood-2010-01-262915
   Packman W, 2010, BONE MARROW TRANSPL, V45, P1134, DOI 10.1038/bmt.2010.74
   Packman WL, 2003, ART THER, V20, P83
   Packman Wendy, 2004, J Pediatr Oncol Nurs, V21, P233, DOI 10.1177/1043454203262698
   Packman WL, 1997, J PSYCHOSOC ONCOL, V15, P81
   Papachristou C, 2008, CLIN TRANSPLANT, V23, P382
   Parmar G, 2003, PSYCHO-ONCOL, V12, P91, DOI 10.1002/pon.652
   Perrin KO, 1996, AM J NURS, V96, P88
   Pillay B, 2012, BONE MARROW TRANSPL, V47, P1361, DOI 10.1038/bmt.2012.22
   POSTLETHWAITE RJ, 1995, ARCH DIS CHILD, V73, P30
   POT-MEES C C, 1987, Journal of Psychosocial Oncology, V5, P73, DOI 10.1300/J077v05n02_07
   Pradel Francoise G, 2003, Prog Transplant, V13, P203
   Pulsipher MA, 2006, PEDIATR BLOOD CANCER, V46, P422, DOI 10.1002/pbc.20708
   Pulsipher MA, 2009, BLOOD, V113, P3604, DOI 10.1182/blood-2008-08-175323
   Scheper-Hughes N, 2007, AM J TRANSPLANT, V7, P507, DOI 10.1111/j.1600-6143.2006.01679.x
   Shama WI, 1998, SOC WORK HEALTH CARE, V27, P89, DOI 10.1300/J010v27n01_06
   SIMMONS RG, 1993, J HEALTH SOC BEHAV, V34, P285, DOI 10.2307/2137368
   Snethen J. A., 2001, J FAMILY NURSING, V7, P92, DOI 10.1177/107484070100700106
   STRONCEK D, 1989, TRANSFUSION, V29, P317, DOI 10.1046/j.1537-2995.1989.29489242797.x
   STRONCEK DF, 1993, BLOOD, V81, P1940
   Styczynski J, 2012, BLOOD, V119, P2935, DOI 10.1182/blood-2011-04-349688
   SULS J, 1989, J CONSULT CLIN PSYCH, V57, P372, DOI 10.1037//0022-006X.57.3.372
   Switzer GE, 1997, SOC SCI MED, V45, P137, DOI 10.1016/S0277-9536(96)00327-9
   Tait AR, 2003, ANESTHESIOLOGY, V98, P609, DOI 10.1097/00000542-200303000-00006
   Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45
   Tong A, 2012, AM J KIDNEY DIS, V60, P15, DOI 10.1053/j.ajkd.2011.11.043
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   van Walraven SM, 2012, PSYCHO-ONCOLOGY, V21, P168, DOI 10.1002/pon.1885
   Van Walraven S, 2009, BONE MARROW TRANSPL, V45, P1269
   Walter M, 2006, CLIN TRANSPLANT, V20, P410, DOI 10.1111/j.1399-0012.2006.00464.x
   Wanner M, 2009, BMC HLTH SERV RES, V9, p2 2
   WEITHORN LA, 1982, CHILD DEV, V53, P1589, DOI 10.1111/j.1467-8624.1982.tb03482.x
   [Anonymous], 2010, WHO GUID PRINC HUM C
   Wiener LS, 2008, PSYCHO-ONCOL, V17, P304, DOI 10.1002/pon.1222
   Wiley F M, 1984, J Assoc Pediatr Oncol Nurses, V1, P8
   Wilkins Krista L, 2007, Oncol Nurs Forum, V34, pE28, DOI 10.1188/07.ONF.E28-E35
   Wilkins Krista Lynn, 2007, Cancer Nurs, V30, pE29
   Williams S, 2003, J CLIN APHERESIS, V18, P1, DOI 10.1002/jca.10042
   WMDA, 2012, WORLD MARR DON ASS I
   Wolcott D, 1987, PSYCHIATR MED, V4, P299
NR 75
TC 4
Z9 4
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUL
PY 2013
VL 19
IS 7
BP 1046
EP 1058
DI 10.1016/j.bbmt.2013.04.012
PG 13
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 173QH
UT WOS:000321093500010
PM 23603456
ER

PT J
AU Urahashi, T
   Mara, Y
   Sanada, Y
   Wakiya, T
   Yamada, N
   Okada, N
   Mizuta, K
AF Urahashi, Taizen
   Mara, Yoshiyuki
   Sanada, Yukihiro
   Wakiya, Taiichi
   Yamada, Naoya
   Okada, Noriki
   Mizuta, Koichi
TI Effect of Repeat Kasai Hepatic Portoenterostomy on Pediatric Live-Donor
   Liver Graft for Biliary Atresia
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Biliary atresia; Kasai hepatic portoenterostomy; Repeat hepatic
   portoenterostomy; Pediatric living-donor liver transplant
ID SINGLE-CENTER EXPERIENCE; TRANSPLANTATION; ERA; IMPACT
AB Objectives: Treatment for patients with biliary atresia is a Kasai hepatic portoenterostomy; however, the efficacy of repeat Kasai hepatic portoenterostomy is unclear. This study sought to examine the effect of a prior Kasai hepatic portoenterostomy, especially a repeat Kasai hepatic portoenterostomy, on the outcomes of living-donor liver transplant.
   Materials and Methods: One hundred twenty-six of 170 children that underwent a living-donor liver transplant between May 2001, and March 2010, received a living-donor liver transplant for biliary atresia. These patients were divided into 2 groups according to the number of previous portoenterostomies: 1 (group A, n=100) or 2 or more Kasai hepatic portoenterostomies (group B, n=26). Portoenterostomy was performed twice in 24 patients in group B, 3 times in 1, and 4 times in I. Preoperative, operative factors, mortality, morbidity, and survival rates were examined and compared between groups.
   Results: The surgical factors such as operative time, blood loss per weight, cold ischemia time, and weight of the native liver were significantly greater in group B than they were in group A. The patient survival rates were comparable in the 2 groups (94.5% in group A and 93.3% in group B), and the difference was not statistically significant. No statistically significant difference was observed between the groups with regard to vascular complications, biliary complications, and other factors including postoperative variables. Bowel perforation requiring surgical repair was more frequent in group B than it was in group A.
   Conclusions: Repeat Kasai hepatic portoenterostomy might have a negative effect on patients who undergo living-donor liver transplant for biliary atresia patients with potential lethal complications such as bowel perforation. More biliary atresia patients could have a liver transplant, with improved survival and better life expectancy, if they have inadequate biliary drainage after the initial Kasai hepatic portoenterostomy.
C1 [Urahashi, Taizen; Mara, Yoshiyuki; Sanada, Yukihiro; Wakiya, Taiichi; Yamada, Naoya; Okada, Noriki; Mizuta, Koichi] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Urahashi, T (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM turahashz@jichi.ac.jp
CR Altman RP, 1997, ANN SURG, V226, P348, DOI 10.1097/00000658-199709000-00014
   ALTMAN RP, 1979, J PEDIATR SURG, V14, P305, DOI 10.1016/S0022-3468(79)80488-1
   Greenfeld J, 1997, ANN SURG, V226, P353
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Carceller A, 2000, J PEDIATR SURG, V35, P717, DOI 10.1053/jpsu.2000.6034
   Chardot C, 1999, HEPATOLOGY, V30, P606, DOI 10.1002/hep.510300330
   CROMBLEHOLME TM, 1989, J PEDIATR SURG, V24, P665, DOI 10.1016/S0022-3468(89)80715-8
   Davenport M, 2004, LANCET, V363, P1354, DOI 10.1016/S0140-6736(04)16045-5
   Dehghani SM, 2008, PEDIATR TRANSPLANT, V12, P146, DOI 10.1111/j.1399-3046.2007.00829.x
   FREITAS L, 1987, J PEDIATR SURG, V22, P857, DOI 10.1016/S0022-3468(87)80655-3
   Goss JA, 1996, ANN SURG, V224, P276, DOI 10.1097/00000658-199609000-00004
   Goss JA, 1996, ANN SURG, V224, P284
   Hasegawa T, 2003, PEDIATR SURG INT, V19, P256, DOI 10.1007/s00383-002-0846-8
   Inomata Y, 1997, J PEDIATR SURG, V32, P1201
   Kasai M, 1978, World J Surg, V2, P571
   LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793
   Lykavieris P, 2005, HEPATOLOGY, V41, P366, DOI 10.1002/hep.20547
   McKiernan PJ, 2000, LANCET, V355, P25, DOI 10.1016/S0140-6736(99)03492-3
   MEISTER RK, 1993, J PEDIATR SURG, V28, P387
   Ohi R, 1998, SURG TODAY, V28, P1229
   OHI R, 1985, J PEDIATR SURG, V20, P256, DOI 10.1016/S0022-3468(85)80116-0
   Pape L, 2009, LIVER TRANSPLANT, V15, P876, DOI 10.1002/lt.21711
   RYCKMAN F, 1993, J PEDIATR SURG, V28, P382
   Ryckman F, 1993, J PEDIATR SURG, V28, P386
   Sanada Y, 2011, PEDIATR SURG INT, V27, P23, DOI 10.1007/s00383-010-2722-2
   Sandler AD, 1997, J PEDIATR SURG, V32, P416, DOI 10.1016/S0022-3468(97)90594-7
   Sugawara Y, 2004, HEPATO-GASTROENTEROL, V51, P192
   Tannuri ACA, 2011, TRANSPL P, V43, P181, DOI 10.1016/j.transproceed.2010.11.012
   Uchida Y, 2006, AM J TRANSPLANT, V6, P2443, DOI 10.1111/j.1600-6143.2006.01487.x
   Visser BC, 2004, LIVER TRANSPLANT, V10, P1279, DOI 10.1002/lt.20234
   WOOD RP, 1990, J PEDIATR SURG, V25, P153
   Wood RP, 1990, J PEDIATR SURG, V25, P160
NR 32
TC 3
Z9 4
U1 0
U2 2
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD JUN
PY 2013
VL 11
IS 3
BP 259
EP 263
DI 10.6002/ect.2012.0188
PG 5
WC Transplantation
SC Transplantation
GA 194DD
UT WOS:000322610300010
PM 23530849
ER

PT J
AU El-Hinnawi, A
   Nishida, S
   Levi, D
   Selvaggi, G
   Tekin, A
   Fan, J
   Ernesto, P
   Kyota, F
   Tzakis, AG
AF El-Hinnawi, A.
   Nishida, S.
   Levi, D.
   Selvaggi, G.
   Tekin, A.
   Fan, J.
   Ernesto, P.
   Kyota, F.
   Tzakis, A. G.
TI Use of the Recipient Celiac Trunk for Hepatic Artery Reconstruction in
   Orthotopic Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Berlin Symposium on Xenotransplantation / 24th International Congress of
   the Transplantation-Society (TTS)
CY JUL 13-19, 2012
CL Robert Koch Inst, Berlin, GERMANY
SP Transplantat Soc (TTS), Int Xenotransplantat Assoc (IXA)
HO Robert Koch Inst
ID THROMBOSIS
AB Arterial complications contribute to significant morbidity and mortality after liver transplantation (OLT). If hepatic artery inflow to the graft is inadequate, alternative approaches can be considered, such as supraceliac or infrarenal aortic conduits and splenic artery as an arterial inflow. Between January 2005 and January 2012, we performed 928 OLTs. We used the recipient celiac trunk for arterial inflow in 9 patients (1%). evaluated retrospectively, We the indications, results, and outcome of this technique. Doppler ultrasound of the liver was used to evaluate arterial flow. Eight cases are first transplant and 1 case is a second transplant. Five cases are pediatric recipients and four cases are adult recipients. Male to female ratio is 3/6. Average follow-up is 23 months. No complications were encountered as a result of sacrificing the branches of the celiac axis. The conclusion is that the celiac trunk provides an adequate arterial inflow in OLT when the recipient's hepatic artery is not suitable to use.
C1 [El-Hinnawi, A.; Nishida, S.; Levi, D.; Selvaggi, G.; Tekin, A.; Fan, J.; Ernesto, P.; Kyota, F.; Tzakis, A. G.] Cleveland Clin Florida, Weston, FL 33331 USA.
RP Tzakis, AG (reprint author), Cleveland Clin, 2950 Cleveland Clin Blvd, Weston, FL 33331 USA.
EM tzakisa@ccf.org
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   DODD GD, 1994, RADIOLOGY, V192, P657
   Figueras J, 1997, TRANSPLANTATION, V64, P655, DOI 10.1097/00007890-199708270-00020
   Garcia-Criado A, 2009, AM J ROENTGENOL, V193, P128, DOI 10.2214/AJR.07.3919
   Nikitin D, 2008, LIVER TRANSPLANT, V14, P1486, DOI 10.1002/lt.21575
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Vanderlan Wesley B, 2008, Cases J, V1, P82, DOI 10.1186/1757-1626-1-82
NR 7
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2013
VL 45
IS 5
BP 1928
EP 1930
DI 10.1016/j.transproceed.2013.01.028
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 176PL
UT WOS:000321316500054
PM 23769075
ER

PT J
AU Radhakrishnan, K
   Bishop, J
   Jin, ZZ
   Kothari, K
   Bhatia, M
   George, D
   Garvin, JH
   Martinez, M
   Ovchinsky, N
   Lobritto, S
   Elsayed, Y
   Satwani, P
AF Radhakrishnan, Kavita
   Bishop, Jacquelyn
   Jin, Zhezhen
   Kothari, Komal
   Bhatia, Monica
   George, Diane
   Garvin, James H., Jr.
   Martinez, Mercedes
   Ovchinsky, Nadia
   Lobritto, Steven
   Elsayed, Yasmin
   Satwani, Prakash
TI Risk Factors Associated with Liver Injury and Impact of Liver Injury on
   Transplantation-Related Mortality in Pediatric Recipients of Allogeneic
   Hematopoietic Stem Cell Transplantation
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Children; Hepatic injury; Hyperbilirubinemia; Bone marrow
   transplantation; Reduced intensity conditioning regimen
ID BONE-MARROW-TRANSPLANTATION; HEPATIC VENOOCCLUSIVE DISEASE; BLOOD;
   CYCLOPHOSPHAMIDE; COMPLICATIONS; INFECTIONS; PROPHYLAXIS; BUSULFAN;
   CHILDREN
AB In adults, hepatic complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with significant morbidity and transplantation-related mortality (TRM). However, there is a paucity of parallel data on the incidence of, and risk factors for, liver injury (LI) and the impact of LI on TRM in pediatric allo-HSCT recipients. We compared total bilirubin, direct bilirubin, and alanine aminotransferase values before allo-HSCT and at 1 month, day +100, and 12 months after allo-HSCT in 248 patients who received either a myeloablative conditioning (MAC) regimen (n = 109) or a reduced-toxicity/reduced-intensity conditioning (RTC/RIC) regimen (n = 139). LI was defined as grade >= 2 hyperbilirubinemia according to the National Cancer Institute's Common Terminology Criteria for Adverse Events 3.0/4.0 (total bilirubin, >1.95 mg/dL, 1.5 times above the upper limit of normal for our laboratory). Univariate and multi-variate logistic regression models were used to identify risk factors for LI and TRM. The incidence of LI at 1 month after allo-HSCT was 14.1%. The median bilirubin level was 3.5 mg/dL (range, 1.97 to 32.2 mg/dL). Only LI as defined by total bilirubin level, but not by direct bilirubin or alanine aminotransferase level, was found to be a significant predictor for TRM. The 1-year TRM was 60.7% (95% confidence interval, 42.6% to 78.7%) in patients with LI at 1 month after allo-HSCT, compared with 14.6% (95% confidence interval, 9.9% to 19.4%) (P<.0001) in patients those who did not have liver injury. Multivariate analysis identified age (P = .03), total body irradiation (P = .007), bacterial bloodstream infection (BBSI) (P = .001), and invasive fungal infection (IFI) (P = .002) as significant risk factors for developing LI at 1 month. On multivariate analysis for risk factors for TRM, only LI at 1 month after allo-HSCT (P < .0001), primary graft failure (P = .001), BBSI (P = .003), and systemic viral infection (P = .04) were identified as significant risk factors for TRM. LI before allo-HSCT conditioning was not associated with higher TRM. Although the incidence of LI in pediatric allo-HSCT recipients is low, LI is associated with very high TRM. BBSI and IFI are the primary risk factors for LI. (C) 2013 American Society for Blood and Marrow Transplantation.
C1 [Radhakrishnan, Kavita; Bishop, Jacquelyn; Kothari, Komal; Bhatia, Monica; George, Diane; Garvin, James H., Jr.; Martinez, Mercedes; Ovchinsky, Nadia; Lobritto, Steven; Elsayed, Yasmin; Satwani, Prakash] Columbia Univ, New York Presbyterian Morgan Stanley Childrens Ho, Dept Pediat, New York, NY 10032 USA.
   [Jin, Zhezhen] Columbia Univ, New York Presbyterian Morgan Stanley Childrens Ho, Dept Biostat, New York, NY 10032 USA.
RP Satwani, P (reprint author), Columbia Univ, New York Presbyterian Morgan Stanley Childrens Ho, Div Pediat Blood & Bone Marrow Transplantat, 3959 Broadway,CHN 10-02, New York, NY 10032 USA.
EM ps2087@columbia.edu
FU Doris Duke Charitable Foundation
FX This research was supported in part by grants from the Doris Duke
   Charitable Foundation. The authors have no conflicts of interest.
CR Arai S, 2002, J HEMATOTH STEM CELL, V11, P215, DOI 10.1089/152581602753658420
   Azar N, 1996, TRANSPLANTATION, V62, P56, DOI 10.1097/00007890-199607150-00012
   Barba P, 2011, BIOL BLOOD MARROW TR, V17, P1653, DOI 10.1016/j.bbmt.2011.04.009
   Barrell Catherine, 2012, Oncol Nurs Forum, V39, pE451, DOI 10.1188/12.ONF.E451-E458
   Barrell C, 2012, AM J INFECT CONTROL, V40, P434, DOI 10.1016/j.ajic.2011.06.002
   Carreras E, 1998, BLOOD, V92, P3599
   El-Sayed MH, 2004, EUR J GASTROEN HEPAT, V16, P1347, DOI 10.1097/00042737-200412000-00019
   ESSELL JH, 1992, BLOOD, V79, P2784
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Fischer MA, 2005, CLIN INFECT DIS, V41, P301, DOI 10.1086/431586
   Gooley TA, 2005, HEPATOLOGY, V41, P345, DOI 10.1002/hep.20529
   Gooley TA, 2010, NEW ENGL J MED, V363, P2091, DOI 10.1056/NEJMoa1004383
   Hogan WJ, 2004, BLOOD, V103, P78, DOI 10.1182/blood-2003-04-1311
   Kusumi E, 2006, BIOL BLOOD MARROW TR, V12, P1302, DOI 10.1016/j.bbmt.2006.07.013
   LOCASCIULLI A, 1994, BONE MARROW TRANSPL, V14, P833
   McDonald GB, 2003, BLOOD, V101, P2043, DOI 10.1182/blood-2002-06-1860
   MCDONALD GB, 1987, SEMIN LIVER DIS, V7, P210, DOI 10.1055/s-2008-1040578
   McDonald GB, 2010, HEPATOLOGY, V51, P1450, DOI 10.1002/hep.23533
   Philpott NJ, 1998, COMPLICATIONS EARLY
   Rogoza K, 2008, BIOL BLOOD MARROW TR, V14, P576
   Roman E, 2008, PEDIATR BLOOD CANCER, V50, P325, DOI 10.1002/pbc.21239
   Ruutu T, 2002, BLOOD, V100, P1977, DOI 10.1182/blood-2001-12-0159
   Sakai M, 2009, BONE MARROW TRANSPL, V44, P441, DOI 10.1038/bmt.2009.56
   Satwani P, 2009, BIOL BLOOD MARROW TR, V15, P1587, DOI 10.1016/j.bbmt.2009.08.006
   Satwani P, 2011, BIOL BLOOD MARROW TR, V17, P1472, DOI 10.1016/j.bbmt.2011.02.006
   Satwani P, 2012, BIOL BLOOD MARROW TR, V18, P324, DOI 10.1016/j.bbmt.2011.11.007
   Shereck E, 2007, PEDIATR BLOOD CANCER, V49, P615, DOI 10.1002/pbc.21158
   Simon M, 2001, BONE MARROW TRANSPL, V27, P627, DOI 10.1038/sj.bmt.1702854
   Strasser SI, 1999, THOMAS HEMATOPOIETIC
   Team RDC, 2011, R LANG ENV STAT COMP
   Thornley Ian, 2004, Biol Blood Marrow Transplant, V10, P635, DOI 10.1016/j.bbmt.2004.06.004
   Wadleigh M, 2003, BLOOD, V102, P1578, DOI 10.1182/blood-2003-01-0255
   Waxman IM, 2009, PEDIATR TRANSPLANT, V13, P464, DOI 10.1111/j.1399-3046.2008.01000.x
NR 33
TC 4
Z9 5
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUN
PY 2013
VL 19
IS 6
BP 912
EP 917
DI 10.1016/j.bbmt.2013.02.019
PG 6
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 156TX
UT WOS:000319847900013
PM 23467127
ER

PT J
AU Mozer-Glassberg, Y
   Shamir, R
   Steinberg, R
   Kadmon, G
   Har-Lev, E
   Mor, E
   Shapiro, R
   Schonfeld, T
   Nahum, E
AF Mozer-Glassberg, Yael
   Shamir, Raanan
   Steinberg, Ran
   Kadmon, Gili
   Har-Lev, Efrat
   Mor, Eytan
   Shapiro, Rivka
   Schonfeld, Tommy
   Nahum, Elhanan
TI Hypogammaglobulinemia in the early period after liver transplantation in
   children
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE children; hypogammaglobulinemia; immunoglobulins; liver transplantation
ID RISK-FACTORS; LUNG TRANSPLANTATION; INFECTIOUS COMPLICATIONS;
   ENDOTHELIAL-CELLS; IGG; RECIPIENTS; OUTCOMES; IMMUNOGLOBULIN;
   ASSOCIATION; CIRRHOSIS
AB Data, on the kinetic and serum levels of immunoglobulins in the immediate post-liver transplantation (LTx) period, are sparse with existing studies limited to adults or case reports of children. The aim of this study is to describe the phenomenon of hypogammaglobulinemia (HGG) in the immediate post-transplantation period among children undergoing LTx. A retrospective 10-yr chart review was conducted of all children who underwent LTx at a fourth-level pediatric medical center. Fifty-seven, of the 76 children who underwent LTx, were included in the study. Seventeen (29.8%) (mean age, 6.8 +/- 5.2yr) had HGG (11-IgG, 1-IgG+IgA, 1-IgG+IgM, 4-IgG+IgA+IgM), detected at 2 to 25d after transplantation. Abdominal fluid was drained for 5 to 42d; the amount drained until detection of HGG measured 27-668mL/kg. HGG was associated with increased infection rate 0.9 episodes/patient vs. 0.17 episodes/patient (p<0.01) in children without detected HGG. In conclusion, HGG is not rare in the immediate post-LTx period in children, and it may place patients at increased risk of infection. Further studies are needed to delineate the rate of occurrence, risk factors, and clinical implications of hypogammaglobulinemia in this patient population.
C1 [Mozer-Glassberg, Yael; Shamir, Raanan; Shapiro, Rivka] Schneider Childrens Med Ctr Israel, Inst Gastroenterol Nutr & Liver Dis, Petha Tikva, Israel.
   [Steinberg, Ran] Schneider Childrens Med Ctr Israel, Pediat Solid Organ Transplant Unit, Petha Tikva, Israel.
   [Kadmon, Gili; Har-Lev, Efrat; Schonfeld, Tommy; Nahum, Elhanan] Schneider Childrens Med Ctr Israel, Pediat Crit Care Unit, Petha Tikva, Israel.
   [Mor, Eytan] Rabin Med Ctr Petach Tikva, Dept Transplantat, Petah Tiqwa, Israel.
   [Mozer-Glassberg, Yael; Shamir, Raanan; Steinberg, Ran; Kadmon, Gili; Har-Lev, Efrat; Mor, Eytan; Shapiro, Rivka; Schonfeld, Tommy; Nahum, Elhanan] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
RP Nahum, E (reprint author), Schneider Childrens Med Ctr Israel, 14th Kaplan St, Petha Tikva, Israel.
EM enahum@clalit.org.il
CR Aydogdu S, 2005, PEDIATR TRANSPLANT, V9, P723, DOI 10.1111/j.1399-3046.2005.00366.x
   BOGERS WMJM, 1991, CLIN EXP IMMUNOL, V85, P128
   Bonnel AR, 2011, CLIN GASTROENTEROL H, V9, P727, DOI 10.1016/j.cgh.2011.02.031
   Bouchut JC, 2001, PAEDIATR ANAESTH, V11, P93, DOI 10.1046/j.1460-9592.2001.00574.x
   Broeders EN, 2008, TRANSPL INT, V21, P57, DOI 10.1111/j.1432-2277.2007.00556.x
   Bunchorntavakul Chalermrat, 2012, World J Hepatol, V4, P158, DOI 10.4254/wjh.v4.i5.158
   BUTLER WT, 1973, J CLIN INVEST, V52, P2629, DOI 10.1172/JCI107455
   Corales R, 2000, Transpl Infect Dis, V2, P133, DOI 10.1034/j.1399-3062.2000.020306.x
   Doron S, 2006, TRANSPLANTATION, V81, P697, DOI 10.1097/01.tp.0000180531.66518.9e
   Smedsrod B, 2004, COMP HEPATOL, V12, P3
   Ganschow R, 2005, PEDIATR TRANSPLANT, V9, P215, DOI 10.1111/j.1399-3046.2005.00291.x
   Garcia S, 1998, CLIN TRANSPLANT, V12, P190
   Gonzalez-Quintela A, 2003, TRANSPL IMMUNOL, V11, P73, DOI 10.1016/S0966-3274(02)00084-9
   Kaido T, 2012, NUTRITION, V28, P1104, DOI 10.1016/j.nut.2012.02.007
   Kawut SM, 2005, TRANSPLANTATION, V79, P1723, DOI 10.1097/01.TP.0000159136.72693.35
   KOSUGI I, 1992, J HEPATOL, V16, P106, DOI 10.1016/S0168-8278(05)80102-3
   Nafady-Hego H, 2011, LIVER TRANSPLANT, V17, P976, DOI 10.1002/lt.22278
   Robertson J, 2009, PEDIATR TRANSPLANT, V13, P754, DOI 10.1111/j.1399-3046.2008.01067.x
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   VANTHIEL DH, 1992, TRANSPLANTATION, V54, P269, DOI 10.1097/00007890-199208000-00015
   Yip NH, 2006, AM J RESP CRIT CARE, V173, P917, DOI 10.1164/rccm.200510-1609OC
NR 21
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD MAY-JUN
PY 2013
VL 27
IS 3
BP E289
EP E294
DI 10.1111/ctr.12116
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 156OT
UT WOS:000319832700011
PM 23551332
ER

PT J
AU Martensson, T
   Priftakis, P
   Casswall, T
   Ringden, O
   Mattsson, J
   Remberger, M
   Hassan, M
   Gustafsson, B
AF Martensson, T.
   Priftakis, P.
   Casswall, T.
   Ringden, O.
   Mattsson, J.
   Remberger, M.
   Hassan, M.
   Gustafsson, B.
TI Increased risk of gastrointestinal acute GVHD following the addition of
   melphalan to busulfan/cyclophosphamide conditioning
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE juvenile myelomonocytic leukemia; myelodysplastic syndrome; melphalan;
   busulfan; graft-versus-host disease; gut toxicity
ID STEM-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; JUVENILE MYELOMONOCYTIC
   LEUKEMIA; HIGH-DOSE BUSULFAN; HEPATIC VENOOCCLUSIVE DISEASE;
   BONE-MARROW-TRANSPLANTATION; HEMORRHAGIC CYSTITIS; MYELODYSPLASTIC
   SYNDROME; BLOOD TRANSPLANTATION; INTRAVENOUS BUSULFAN
AB Risk factors associated with the development of aGVHD in the gastrointestinal tract have not been studied in depth. We retrospectively assessed 25 pediatric patients with MDS and JMML and compared the treatment outcome of two different conditioning regimens. Seventeen children (68%) underwent conditioning with busulfan (Bu), cyclophosphamide (Cy), and melphalan (Mel) and eight children (32%) with Bu and Cy. Gastrointestinal aGVHD stages IIIV (day 0100) were observed in 47% (eight of 17) of the patients in the BuCyMel group and in none (0 of 8) in the BuCy group (p<0.05). In patients who developed gastrointestinal aGVHD stages IIIIV, a 24-h variation in the Bu concentration with a nighttime peak was noted. HC and liver aGVHD stages IIIV were observed in 47% (eight of 17) and 35% (six of 17) after BuCyMel conditioning and in 0% (0 of 17) and 12.5% (one of eight) after BuCy conditioning. The overall survival rate was 53% (nine of 17) in the BuCyMel group and 62.5% (five of eight) in the BuCy group. In conclusion, the addition of melphalan to the BuCy conditioning regimen resulted in severe gastrointestinal complications and did not improve overall survival.
C1 [Martensson, T.; Priftakis, P.; Casswall, T.; Gustafsson, B.] Astrid Lindgren Childrens Hosp, Stockholm, Sweden.
   [Martensson, T.; Priftakis, P.; Casswall, T.; Gustafsson, B.] Karolinska Univ Hosp Huddinge, Stockholm, Sweden.
   [Martensson, T.; Priftakis, P.; Casswall, T.; Gustafsson, B.] Karolinska Inst, CLINTEC, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
   [Ringden, O.; Mattsson, J.] Karolinska Univ Hosp Huddinge, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden.
   [Ringden, O.; Mattsson, J.] Karolinska Univ Hosp Huddinge, Div Therapeut Immunol, Stockholm, Sweden.
   [Remberger, M.] Karolinska Inst, Karolinska Univ Hosp Huddinge, Stockholm, Sweden.
   [Hassan, M.] Karolinska Inst, Dept Lab Med, Stockholm, Sweden.
   [Hassan, M.] Karolinska Univ Hosp Huddinge, Novum, KFC, ECM, Stockholm, Sweden.
RP Martensson, T (reprint author), Karolinska Univ, Karolinska Inst, Astrid Lindgren Childrens Hosp Huddinge, Dept Clin Sci Intervent & Technol,CLINTEC, S-14186 Stockholm, Sweden.
EM thomas.martensson@karolinska.se
RI Hassan, Moustapha/H-9260-2015; 
OI Hassan, Moustapha/0000-0003-1927-5859; Mattsson,
   Jonas/0000-0002-2163-6644
FU Mary Beves foundation; Samariten foundation; Swedish Childhood Cancer
   Foundation; Swedish Cancer Foundation; Government Public Health Grant
   (ALF)
FX The authors would like to acknowledge the following Grants: Mary Beves
   foundation, the Samariten foundation, the Swedish Childhood Cancer
   Foundation, the Swedish Cancer Foundation and the Government Public
   Health Grant (ALF).
CR Awasthi S, 1996, DRUG METAB DISPOS, V24, P371
   Baraldo M, 2008, EXPERT OPIN DRUG MET, V4, P175, DOI 10.1517/17425255.4.2.175
   Bartelink IH, 2009, BIOL BLOOD MARROW TR, V15, P231, DOI 10.1016/j.bbmt.2008.11.022
   Bouligand J, 2003, BONE MARROW TRANSPL, V32, P979, DOI 10.1038/sj.bmt.1704275
   Chan RJ, 2009, LEUKEMIA RES, V33, P355, DOI 10.1016/j.leukres.2008.08.022
   Cheuk DKL, 2007, BONE MARROW TRANSPL, V40, P935, DOI 10.1038/sj.bmt.1705835
   Dalianis T, 2011, ANTICANCER RES, V31, P939
   Eapen M, 2004, J CLIN ONCOL, V22, P4872, DOI 10.1200/JCO.2004.02.189
   FERRARA JLM, 1991, NEW ENGL J MED, V324, P667
   Fry TJ, 2010, PEDIATR BLOOD CANCER, V55, P1043, DOI 10.1002/pbc.22733
   Gibbs JP, 1996, CANCER RES, V56, P3678
   Giebel S, 2003, BONE MARROW TRANSPL, V31, P987, DOI 10.1038/sj.bmt.1704054
   GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001
   Goldberg J, 2005, BIOL BLOOD MARROW TR, V11, P101, DOI 10.1016/j.bbmt.2004.10.007
   Gorczynska E, 2005, BIOL BLOOD MARROW TR, V11, P797, DOI 10.1016/j.bbmt.2005.06.007
   Hagen LEM, 2011, PEDIATR TRANSPLANT, V15, P659, DOI 10.1111/j.1399-3046.2011.01553.x
   Hasle H, 2004, LEUKEMIA, V18, P2008, DOI 10.1038/sj.leu.2403489
   Hasle H, 2007, CURR OPIN PEDIATR, V19, P1, DOI 10.1097/MOP.0b013e3280128ce8
   HASSAN M, 1994, BLOOD, V84, P2144
   Hassan M, 2000, BONE MARROW TRANSPL, V25, P915, DOI 10.1038/sj.bmt.1702377
   HASSAN M, 1991, CANCER CHEMOTH PHARM, V28, P130, DOI 10.1007/BF00689702
   Hassan Z, 2007, CLIN TRANSPLANT, V21, P659, DOI 10.1111/j.1399-0012.2007.00705.x
   Holler E, 2004, BLOOD, V104, P889, DOI 10.1182/blood-2003-10-3543
   Jacobsohn DA, 2004, BONE MARROW TRANSPL, V34, P901, DOI 10.1038/sj.bmt.1704681
   Johansson JE, 2007, DIGEST DIS SCI, V52, P2340, DOI 10.1007/s10620-006-9404-x
   JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011
   Liu DH, 2010, BIOL BLOOD MARROW TR, V16, P1567, DOI 10.1016/j.bbmt.2010.05.001
   Locatelli F, 2005, BLOOD, V105, P410, DOI 10.1182/blood-2004-05-1944
   MERESSE V, 1992, BONE MARROW TRANSPL, V10, P135
   Niemeyer CM, 2008, BRIT J HAEMATOL, V140, P610, DOI 10.1111/j.1365-2141.2007.06958.x
   Pescovitz MD, 2001, CLIN TRANSPLANT, V15, P23, DOI 10.1111/j.1399-0012.2001.00023.x
   PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825
   Strahm B, 2011, LEUKEMIA, V25, P455, DOI 10.1038/leu.2010.297
   Tran HT, 2000, BONE MARROW TRANSPL, V26, P463, DOI 10.1038/sj.bmt.1702561
   Tsuboi K, 2003, BONE MARROW TRANSPL, V32, P903, DOI 10.1038/sj.bmt.1704240
   VASSAL G, 1993, CANCER RES, V53, P1534
   Wall DA, 2005, BIOL BLOOD MARROW TR, V11, P637, DOI 10.1016/j.bbmt.2005.05.003
   Zhang YKJ, 2009, DRUG METAB DISPOS, V37, P106, DOI 10.1124/dmd.108.024174
   Zwaveling J, 2005, BONE MARROW TRANSPL, V35, P17, DOI 10.1038/sj.bmt.1704707
NR 39
TC 3
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2013
VL 17
IS 3
BP 285
EP 293
DI 10.1111/petr.12061
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 133CL
UT WOS:000318114900021
PM 23489519
ER

PT J
AU Kitajima, T
   Sakamoto, S
   Uchida, H
   Hamano, I
   Kobayashi, M
   Kanazawa, H
   Fukuda, A
   Kasahara, M
AF Kitajima, Toshihiro
   Sakamoto, Seisuke
   Uchida, Hajime
   Hamano, Ikumi
   Kobayashi, Megumi
   Kanazawa, Hiroyuki
   Fukuda, Akinari
   Kasahara, Mureo
TI Living donor liver transplantation with alternative porto-left gastric
   vein anastomosis in patients with post-Kasai extrahepatic portal vein
   obstruction
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE extrahepatic portal vein obstruction; cavernous transformation;
   porto-left gastric vein anastomosis; liver transplantation; living donor
ID THROMBOSIS
AB EPVO is a common cause of prehepatic portal hypertension in pediatric patients and sometimes results in cavernous transformation of the PV. We herein present the cases of two patients who underwent LDLT for EPVO with post-Kasai biliary atresia. PV reconstruction was performed with a porto-left gastric vein anastomosis. The patient who underwent PV reconstruction using an interposition vein graft is doing well without surgical complications, whereas PV anastomotic stenosis was detected three months after LDLT in the patient who did not receive an interposition vein graft. The availability of vein grafts is limited in the LDLT setting. In such cases, performing PV reconstruction with varicose veins using interposition vein grafts is a feasible and valuable alternative option for obtaining a sufficient portal blood flow. Our experiences suggest that using interposition vein grafts may be appropriate for preventing the anastomotic stenosis caused by the fragility of varicose veins.
C1 [Kitajima, Toshihiro] Toranomon Gen Hosp, Dept Surg Gastroenterol, Tokyo, Japan.
   [Kitajima, Toshihiro; Sakamoto, Seisuke; Uchida, Hajime; Hamano, Ikumi; Kobayashi, Megumi; Kanazawa, Hiroyuki; Fukuda, Akinari; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Tokyo 1578535, Japan.
RP Kitajima, T (reprint author), Natl Ctr Child Hlth & Dev, Dept Transplant Surg, 2-10-1 Okura Setagaya Ward, Tokyo 1578535, Japan.
EM t.kitajima0407@gmail.com
OI Fukuda, Akinari/0000-0003-4684-0446
CR de Magnee C, 2011, ANN SURG, V254, P55, DOI 10.1097/SLA.0b013e3182121eb7
   Egawa H, 2006, LIVER TRANSPLANT, V12, P1512, DOI 10.1002/lt.20777
   Kim SJ, 2011, CLIN TRANSPLANT, V25, P111, DOI 10.1111/j.1399-0012.2010.01217.x
   Matsuura T, 2011, J PEDIATR SURG, V46, P2291, DOI 10.1016/j.jpedsurg.2011.09.015
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Sharif K, 2010, J PEDIATR SURG, V45, P272, DOI 10.1016/j.jpedsurg.2009.08.019
   Yerdel MA, 2000, TRANSPLANTATION, V69, P1873, DOI 10.1097/00007890-200005150-00023
NR 7
TC 1
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2013
VL 17
IS 3
BP E100
EP E103
DI 10.1111/petr.12067
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 133CL
UT WOS:000318114900005
PM 23480790
ER

PT J
AU Lam, HD
   Juan, MJ
   Soltys, KA
   Sindhi, R
   Mazariegos, G
   Bond, G
AF Lam, Hwai-Ding
   Juan Mejia
   Soltys, Kyle A.
   Sindhi, Rakesh
   Mazariegos, George
   Bond, Geoffrey
TI Right diaphragmatic hernia after liver transplant in pediatrics: A case
   report and review of the literature
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; diaphragmatic hernia
ID KIDNEY-TRANSPLANTATION; SIROLIMUS; COMPLICATIONS; ADULT
AB Diaphragmatic hernias (DH) are an unusual complication after pediatric liver transplantation; however, they have been reported with increased frequency in the past few years. DHs are responsible for nearly half of the small bowel obstructions requiring surgical intervention in this patient population. It has been suggested that the use of a left lobe liver graft, surgical trauma, malnourishment, elevated intra-abdominal pressures, and mTor inhibitors may predispose to development of DH. The use of a segmental graft may increase the recognition of diaphragmatic hernia because the surgically damaged right hemi-diaphragm often remains exposed to underlying viscera, instead of being covered by the right hepatic lobe. Treatment is surgical reduction, with up to 20% of the patients requiring resection of the herniated intestine. Herein we describe a case of DH after left segmental liver transplant in a two- yr-old boy that presented one month post left lobe split liver transplant with abdominal pain, anorexia, and respiratory distress. Just like in the majority of the reported cases, an urgent laparotomy with primary repair was performed. No resection of the herniated segment of intestine was required. For pediatric patients with otherwise unexplained respiratory or gastrointestinal symptoms after a left lateral segment liver transplant, right-sided diaphragmatic hernias should always be high in the differential diagnosis.
C1 [Lam, Hwai-Ding; Juan Mejia; Soltys, Kyle A.; Sindhi, Rakesh; Mazariegos, George; Bond, Geoffrey] Childrens Hosp Pittsburgh UPMC, Hillman Ctr Pediat Transplantat, Starzl Transplantat Inst, Pittsburgh, PA 15224 USA.
RP Bond, G (reprint author), Childrens Hosp Pittsburgh UPMC, 4401 Penn Ave,FP-6,Room 6136,Mail Stop CHL-03-06-, Pittsburgh, PA 15224 USA.
EM bondgj@upmc.edu
OI Mazariegos, George/0000-0002-2624-8632
CR Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Dean PG, 2004, TRANSPLANTATION, V77, P1555, DOI 10.1097/01.TP.0000123082.31092.53
   Earl TM, 2011, J AM COLL SURGEONS, V212, P62, DOI 10.1016/j.jamcollsurg.2010.09.017
   Englert C, 2006, TRANSPLANTATION, V82, P574, DOI 10.1097/01.tp.0000231709.63721.5c
   Kazimi M, 2010, Pediatr Transplant, V14, pe62, DOI 10.1111/j.1399-3046.2009.01168.x
   McCabe AJ, 2005, J PEDIATR SURG, V40, P1181, DOI 10.1016/j.jpedsurg.2005.03.063
   Moon SB, 2012, PEDIATR TRANSPLANT, V16, pE106, DOI 10.1111/j.1399-3046.2010.01462.x
   Okajima H, 2007, PEDIATR TRANSPLANT, V11, P324, DOI 10.1111/j.1399-3046.2006.00658.x
   Troppmann C, 2003, TRANSPLANTATION, V76, P426, DOI 10.1097/01.TP.0000072016.13090.4E
   Valente JF, 2003, AM J TRANSPLANT, V3, P1128, DOI 10.1034/j.1600-6143.2003.00185.x
   Wagner D, 2010, LIVER TRANSPLANT, V16, P783, DOI 10.1002/lt.22079
   Zisa Monica, 2011, Updates Surg, V63, P55, DOI 10.1007/s13304-011-0045-z
NR 12
TC 4
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2013
VL 17
IS 3
BP E77
EP E80
DI 10.1111/petr.12052
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 133CL
UT WOS:000318114900001
PM 23442132
ER

PT J
AU Unal, B
   Gonultas, F
   Aydin, C
   Otan, E
   Kayaalp, C
   Yilmaz, S
AF Unal, B.
   Gonultas, F.
   Aydin, C.
   Otan, E.
   Kayaalp, C.
   Yilmaz, S.
TI Hepatic Artery Thrombosis-Related Risk Factors After Living Donor Liver
   Transplantation: Single-Center Experience From Turkey
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the
   Turkish-Transplantation-Centers-Coordination-Association (TTCCA)
CY SEP 26-29, 2012
CL Bursa, TURKEY
SP Turkish Transplantat Ctr Coordinat Assoc (TTCCA)
ID URGENT REVASCULARIZATION; SPLENIC ARTERY; VASCULAR COMPLICATIONS;
   RECONSTRUCTION; GRAFT; VEIN
AB Aim. The purpose of this retrospective study is to evaluate the risk factors hepatic artery thrombosis (HAT) after orthotopic liver transplantation (OLT) in a consecutive series from a single center.
   Materials and Methods. Between January 2010 and May 2012, we performed 278 living donor liver transplantations, including 189 males and 89 females. We compared the risk factors between HAT and non-HAT groups according to the following variables: age, gender, body mass index (BMI), graft weight, use of graft, Child-Pugh and model for end stage liver disease score, level of hemoglobin, blood pressure, operation time, blood transfusion, presence of ascites, international normalized ratio (INR) level, and etiology.
   Results. Eighteen patients, including 15 males and 3 female, had HAT after the operation (mean age, 45.1 years; age range, 22-60 years). There were no pediatric patients in the HAT group. HAT rate was 6.5% in our series. Graft loss and retransplantation due to HAT was 38.7% in a 2-year period. Biliary leakage was observed in 72 (25.8%) living donor liver transplantations; this rate was higher in patients with HAT (n = 8; 44.4%). The infection rate was 50% (n = 9) in the HAT group and was 32.7% (n = 91) in the non-HAT group. Mean INR value was 2.15 in the HAT group and 1.72 in the non-HAT group. When we compared the groups according to use of graft for anastomosis, biliary lekage, infection, and INR value, the differences were statistically significant (P < .05).
   Conclusion. Although the results of OLT have improved over the past years, HAT is still associated with substantial morbidity, high incidence of graft failure, and high mortality rates. The most important findings associated with HAT in our series were found as INR levels, bile leakage, and resistant infections. Use of vascular graft for hepatic artery anastomosis was found to increase HAT risk.
C1 [Unal, B.; Gonultas, F.; Aydin, C.; Otan, E.; Kayaalp, C.; Yilmaz, S.] Inonu Univ, Sch Med, Inst Liver Transplantat, TR-44280 Malatya, Turkey.
RP Unal, B (reprint author), Inonu Univ, Tip Fak, Turgut Ozal Tip Merkezi, Genel Cerrahi Anabilim Dali, TR-44280 Malatya, Turkey.
EM bulent.unal@inonu.edu.tr
OI Kayaalp, Cuneyt/0000-0003-4657-2998
CR Asakura T, 2000, TRANSPLANT P, V32, P2250, DOI 10.1016/S0041-1345(00)01787-5
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Bhattacharjya S, 2001, TRANSPLANTATION, V71, P1592, DOI 10.1097/00007890-200106150-00018
   CHERQUI D, 1994, AM J SURG, V167, P327, DOI 10.1016/0002-9610(94)90210-0
   Figueras J, 1997, TRANSPLANTATION, V64, P655, DOI 10.1097/00007890-199708270-00020
   GARCIAVALDECASAS JC, 1990, TRANSPLANT P, V22, P2376
   KATZ E, 1992, TRANSPLANTATION, V53, P1373
   LANGNAS AN, 1991, TRANSPLANTATION, V51, P86, DOI 10.1097/00007890-199101000-00013
   Mali VP, 2012, TRANSPL P, V44, P1373, DOI 10.1016/j.transproceed.2012.01.129
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   TZAKIS AG, 1985, SEMIN LIVER DIS, V5, P375, DOI 10.1055/s-2008-1040635
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
NR 16
TC 8
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2013
VL 45
IS 3
BP 974
EP 977
DI 10.1016/j.transproceed.2013.02.070
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 137SF
UT WOS:000318457000034
PM 23622602
ER

PT J
AU Trevizol, AP
   David, AI
   Yamashita, ET
   Pecora, RA
   D'Albuquerque, LA
AF Trevizol, A. P.
   David, A. I.
   Yamashita, E. T.
   Pecora, R. A.
   D'Albuquerque, L. A.
TI Intestinal and Multivisceral Retransplantation Results: Literature
   Review
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th Congress of the Luso-Brazilian-Transplantation-Society
CY OCT 04-06, 2012
CL Coimbra, PORTUGAL
SP Luso-Brazilian Transplantat Soc, Spanish Transplantat Soc
ID ACUTE CELLULAR REJECTION; SINGLE-CENTER; LIVER-DISEASE; SMALL-BOWEL;
   TRANSPLANTATION; EXPERIENCE; FAILURE; IMMUNOSUPPRESSION; ASSOCIATION;
   MANAGEMENT
AB Background. Intestinal/multivisceral transplantation (IT/MVT) is the gold standard treatment for patients with intestinal failure and complications related to total parenteral nutrition, gastrointestinal inoperable indolent tumors, or diffuse portal trombosis. Currently, the reported 1-year patient survival rate is around 80%, similar to other solid organ abdominal transplantations. Unfortunately, the patient survival decreases after the first year with the 5-year rate not close to 70% yet. Acute cellular rejection is the main cause of graft loss. Its early diagnosis may make it possible to improve survival of retransplantations.
   Objective. To analyze the reported results published in the last 5 years by leading transplant centers to evaluate IT/MVT retransplantation results.
   Methods. We performed a literature review using PubMed focusing on multivisceral and intestinal retransplantation in articles published between 2006 and 2012. In relation to the first transplantation, we analyzed demographics, imunosuppression, rejection, infection as well as graft and patient survival rates.
   Results. Two centers reported results on intestinal and multivisceral retransplantations. Mazariegos et al reported their experience with 15 intestinal retransplantations in 14 pediatric recipients. Four patients died from posttransplant lymphoperliferative disease, severe acute cellular rejection, fungal sepsis, or bleeding from a pseudoaneurysm at a mean time of 5.7 months post-transplantation. Total parenteral nutrition was weaned at a median time of 32 days. Abu-Elmaged et al reported 47 cases with a 5-year survival of 47% for all retransplant modalities. Retransplantation with liver-contained visceral allograft achieved a 5-year survival rate of 61% compared with 16% for liver-free visceral grafts.
   Conclusion. Despite those huge improvements, some transplanted patients develop severe acute cellular rejection, culminating in graft loss and retransplantation. Repots on multivisceral and intestinal retransplantation outcomes suggest that it is a viable procedure with appropriate patient survival after primary graft loss.
C1 [Trevizol, A. P.; Yamashita, E. T.] Santa Casa Med Sch, Sao Paulo, Brazil.
   [David, A. I.; Pecora, R. A.; D'Albuquerque, L. A.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Liver & Gastrointestinal Transplant Div, Sao Paulo, Brazil.
RP David, AI (reprint author), Rua Pamplona 1808,Apto 52, Sao Paulo, Brazil.
EM andredavidmd@gmail.com
RI D'ALBUQUERQUE, LUIZ/I-4011-2012; David, Andre/H-2005-2011
OI David, Andre/0000-0001-9520-5241
CR Abu-Elmagd KM, 2009, ANN SURG, V250, P567, DOI 10.1097/SLA.0b013e3181b67725
   Bond GJ, 2005, J PEDIATR SURG, V40, P274, DOI 10.1016/j.jpedsurg.2004.09.020
   Chatzipetrou MA, 2001, SURGERY, V129, P277, DOI 10.1067/msy.2001.110770
   David AI, 2006, TRANSPLANT P, V38, P1731, DOI 10.1016/j.transproceed.2006.05.016
   Desai CS, 2012, TRANSPLANTATION, V93, P120, DOI 10.1097/TP.0b013e31823aa54d
   Farmer DG, 2004, TRANSPLANT P, V36, P331, DOI 10.1016/j.transproceed.2004.01.099
   Fishbein TM, 2003, GASTROENTEROLOGY, V124, P1615, DOI 10.1016/S0016-5085(03)00375-5
   Goulet O, 2000, Curr Opin Clin Nutr Metab Care, V3, P329, DOI 10.1097/00075197-200009000-00002
   Hibi T, 2012, AM J TRANSPLANT, V12, pS27, DOI 10.1111/j.1600-6143.2012.04155.x
   Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x
   Kelly DA, 2006, GASTROENTEROLOGY, V130, pS70, DOI 10.1053/j.gastro.2005.10.066
   Lauro A, 2008, TRANSPL P, V40, P1575, DOI 10.1016/j.transproceed.2008.03.153
   Loinaz C, 2004, TRANSPLANT P, V36, P312, DOI 10.1016/j.transproceed.2004.01.084
   Mazariegos GV, 2008, TRANSPLANTATION, V86, P1777, DOI 10.1097/TP.0b013e3181910f51
   Nathan JD, 2007, J PEDIATR SURG, V42, P143, DOI 10.1016/j.jpedsurg.2006.09.049
   Pironi L, 2003, DIGEST LIVER DIS, V35, P314, DOI 10.1016/S1590-8658(03)00074-4
   Reyes J, 2005, AM J TRANSPLANT, V5, P1430, DOI 10.1111/j.1600-6143.2005.00874.x
   Sindhi R, 2010, CURR OPIN ORGAN TRAN, V15, P349, DOI 10.1097/MOT.0b013e328339489c
   Tsai HL, 2011, TRANSPLANTATION, V92, P709, DOI 10.1097/TP.0b013e318229f752
   Tzakis AG, 2005, ANN SURG, V242, P480, DOI 10.1097/01.sla..0000183347.61361.7a
   Vianna RM, 2008, TRANSPLANTATION, V85, P1290, DOI 10.1097/TP.0b013e31816dd450
   Zeevi A, 2009, HUM IMMUNOL, V70, P645, DOI 10.1016/j.humimm.2009.06.009
   [Anonymous], 2012, OPTN ANNUAL REPORT 2
NR 23
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2013
VL 45
IS 3
BP 1133
EP 1136
DI 10.1016/j.transproceed.2013.03.007
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 137SF
UT WOS:000318457000077
PM 23622645
ER

PT J
AU Vincenzi, R
   Seda-Neto, J
   da Fonseca, EA
   Ketzer, BM
   Benavides, M
   Candiao, HL
   Porta, G
   Miura, IK
   Pugliese, R
   Danesi, VB
   Guimaraes, TC
   Porta, A
   Borges, CB
   Kondo, M
   Chapchap, P
AF Vincenzi, Rodrigo
   Seda-Neto, Joao
   da Fonseca, Eduardo Antunes
   Ketzer, Bernardo Mazzini
   Benavides, Marcel
   Candiao, Helry Lopes
   Porta, Gilda
   Miura, Irene Kazue
   Pugliese, Renata
   Danesi, Vera Baggio
   Guimaraes, Teresa Cristina
   Porta, Adriana
   Borges, Cristian Barbieri
   Kondo, Mario
   Chapchap, Paulo
TI Technical aspects and outcomes of living donor liver transplantation for
   pediatric patients with situs inversus
SO LIVER TRANSPLANTATION
LA English
DT Article
ID BILIARY ATRESIA
AB The vascular anomalies encountered in patients with biliary atresia associated with polysplenia syndrome and situs inversus (SI) demand technical refinements when liver transplantation is being performed. The available data describing the technique used in living donor liver transplantation (LDLT) in this population are limited; the short vascular stumps of the donor's liver can impart additional technical difficulties during vascular reconstruction. Here we describe our experience with 9 children with biliary atresia and SI who underwent LDLT. In our series, the retrohepatic vena cava was absent for 7 patients, 7 had a preduodenal portal vein (PV), and 4 had a variant arterial anatomy. The donor's left hepatic vein was anastomosed to the confluence of the recipient's 3 hepatic veins in 7 patients. Vascular grafts were used for PV reconstruction in 3 cases. A left lateral segment graft was used in all but 1 patient who needed a graft reduction. All grafts were placed in the upper left abdomen. There were no vascular complications after transplantation. All patients were alive and well at a median follow-up of 55 months. In conclusion, LDLT can be successfully performed in pediatric patients with SI. Complex vascular anomalies associated with the use of partial liver grafts obtained from living donors are not associated with an increased occurrence of vascular complications. Liver Transpl 19:431436, 2013. (c) 2013 AASLD.
C1 [Vincenzi, Rodrigo; Seda-Neto, Joao; da Fonseca, Eduardo Antunes; Ketzer, Bernardo Mazzini; Benavides, Marcel; Candiao, Helry Lopes; Porta, Gilda; Miura, Irene Kazue; Pugliese, Renata; Danesi, Vera Baggio; Guimaraes, Teresa Cristina; Porta, Adriana; Borges, Cristian Barbieri; Kondo, Mario; Chapchap, Paulo] AC Camargo Hosp, Sirio Libanes Hosp, BR-01308000 Sao Paulo, Brazil.
RP Seda-Neto, J (reprint author), AC Camargo Hosp, Sirio Libanes Hosp, Rua Barata Ribeiro 414,Cj 65, BR-01308000 Sao Paulo, Brazil.
EM joaoseda@gmail.com
CR BLEGEN HM, 1949, ANN SURG, V129, P244, DOI 10.1097/00000658-194902000-00009
   Davenport M, 2006, J PEDIATR-US, V149, P393, DOI 10.1016/j.jpeds.2006.05.030
   FARMER DG, 1995, ANN SURG, V222, P47, DOI 10.1097/00000658-199507000-00008
   Kasahara M, 2009, LIVER TRANSPLANT, V15, P1641, DOI 10.1002/lt.21839
   Lee HH, 2004, TRANSPLANT P, V36, P2282, DOI 10.1016/j.transproceed.2004.08.080
   Maggard MA, 1999, TRANSPLANTATION, V68, P1206, DOI 10.1097/00007890-199910270-00025
   Matsubara K, 2005, LIVER TRANSPLANT, V11, P1444, DOI 10.1002/lt.20584
   Mattei P, 1998, PEDIATR SURG INT, V14, P104, DOI 10.1007/s003830050452
   Sanada Y, 2008, LIVER TRANSPLANT, V14, P1659, DOI 10.1002/lt.21583
   Neto JS, 2012, LIVER TRANSPLANT, V18, P577, DOI 10.1002/lt.23393
   Seda-Neto J, 2008, TRANSPLANTATION, V86, P697, DOI 10.1097/TP.0b013e318183ed22
   Sugawara Y, 2001, LIVER TRANSPLANT, V7, P829, DOI 10.1053/jlts.2001.26923
NR 12
TC 2
Z9 2
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD APR
PY 2013
VL 19
IS 4
BP 431
EP 436
DI 10.1002/lt.23611
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 117OG
UT WOS:000316962200014
PM 23447137
ER

PT J
AU Lee, SH
   Gwak, MS
   Choi, SJ
   Shin, YH
   Ko, JS
   Kim, GS
   Lee, SY
   Kim, MH
   Park, HG
   Lee, SK
   Jeon, HJ
AF Lee, Sang Hyun
   Gwak, Mi Sook
   Choi, Soo Joo
   Shin, Young Hee
   Ko, Justin Sangwook
   Kim, Gaab Soo
   Lee, Suk Young
   Kim, Myung Hee
   Park, Hui Gyeong
   Lee, Suk-Koo
   Jeon, Hee Jung
TI Intra-operative cardiac arrests during liver transplantation a
   retrospective review of the first 15yr in Asian population
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE Asian; cardiac arrest; intra-operative; liver transplantation; survival
   rates
ID SUCCESSFUL CARDIOPULMONARY-RESUSCITATION; FATAL PULMONARY-EMBOLISM;
   ANTIFIBRINOLYTIC DRUGS; VENOUS THROMBOEMBOLISM; RISK-FACTORS;
   THROMBOSIS; COMPLICATION; PREDICTORS; DONOR
AB Although many report intra-operative cardiac arrests (ICAs) in liver transplantation (LT), the incidence, major causes, and outcome remain unclear. We aimed to investigate retrospectively, the incidence, nature, and outcome of ICA in Asian population and to identify risk factors for ICA. Consecutive 1071 LTs in an institution during 19962011 (adult 920, pediatric 151/living donor liver transplantation, LDLT 841, deceased donor liver transplantation, DDLT 230) were reviewed. ICA occurred in 14 adult LTs (1.5%), but none in pediatrics. ICA occurred 1.0% and 3.3% in LDLT and DDLT, respectively. Stages of ICA incidence were three at pre-anhepatic, one at anhepatic, and 10 at neohepatic stage. Post-reperfusion syndrome (PRS) with hyperkalemia and bleeding were the major causes of ICA. While LDLT showed miscellaneous causes for ICA at various stages, DDLT incurred ICAs at neohepatic stage only. Interestingly, we did not find pulmonary thromboembolism (PTE) to incur ICA. Risk factor analysis showed no association of pre-operative patient condition, donor types, and intra-operative parameters. In this review, the incidence of ICA was low in Asian population with LDLT predominance, and while PTE was not the cause of ICA, the neohepatic stage with PRS and bleeding was the most vulnerable period to anticipate ICA.
C1 [Lee, Sang Hyun; Gwak, Mi Sook; Choi, Soo Joo; Shin, Young Hee; Ko, Justin Sangwook; Kim, Gaab Soo; Kim, Myung Hee; Park, Hui Gyeong] Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea.
   [Lee, Suk Young] Jukjeon Dent Hosp, Dept Anesthesiol & Pain Med, Taegu, South Korea.
   [Lee, Suk-Koo] Sungkyunkwan Univ, Samsung Med Ctr, Dept Surg, Sch Med, Seoul 135710, South Korea.
RP Choi, SJ (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Samsung Seoul Hosp, Dept Anesthesiol & Pain Med,Sch Med, 50 Ilwon Dong, Seoul 135710, South Korea.
EM sjoochoi@skku.edu
CR Adrie C, 2005, J AM COLL CARDIOL, V46, P21, DOI 10.1016/j.jacc.2005.03.046
   Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD
   Adrie Christophe, 2004, Curr Opin Crit Care, V10, P208, DOI 10.1097/01.ccx.0000126090.06275.fe
   Bang SR, 2010, TRANSPL P, V42, P4148, DOI 10.1016/j.transproceed.2010.10.017
   BAUBILLIER E, 1994, TRANSPLANTATION, V57, P1664
   Cherian TP, 2010, TRANSPL INT, V23, P1113, DOI 10.1111/j.1432-2277.2010.01105.x
   ENARSON DA, 1977, HEART LUNG, V6, P1020
   Engelken FJ, 2010, EMERG MED J, V28, P173
   Fitzsimons MG, 2001, ANESTH ANALG, V92, P1418
   Gologorsky E, 2001, LIVER TRANSPLANT, V7, P783, DOI 10.1053/jlts.2001.26928
   Huang YR, 2004, DI YI JUN YI DA XUE, V24, P1210
   Keenan CR, 2007, CURR OPIN PULM MED, V13, P377
   Klatsky AL, 2000, AM J CARDIOL, V85, P1334, DOI 10.1016/S0002-9149(00)00766-9
   Lerner AB, 2005, ANESTH ANALG, V101, P1608, DOI 10.1213/01.ANE.0000184256.28981.2B
   Lisman T, 2010, J HEPATOL, V53, P362, DOI 10.1016/j.jhep.2010.01.042
   Manji M, 1998, BRIT J ANAESTH, V80, P685
   Montagnana M, 2010, J THROMB THROMBOLYS, V29, P489, DOI 10.1007/s11239-009-0365-8
   NAVALGUND AA, 1988, ANESTH ANALG, V67, P400
   O'Connor CJ, 2000, ANESTH ANALG, V91, P296, DOI 10.1097/00000539-200008000-00009
   Perkins JD, 2008, LIVER TRANSPLANT, V14, P575
   Ramsay MAE, 2004, LIVER TRANSPLANT, V10, P310, DOI 10.1002/lt.20064
   Sakai T, 2012, BRIT J ANAESTH, V108, P469, DOI 10.1093/bja/aer392
   Schneider D, 2006, J NATL MED ASSOC, V98, P1967
   Shi Xue-Yin, 2006, Hepatobiliary Pancreat Dis Int, V5, P185
   Sopher M, 1997, ANESTHESIOLOGY, V87, P429, DOI 10.1097/00000542-199708000-00033
   Tang YY, 2011, CIRCULATION, V123, P2219, DOI 10.1161/CIRCULATIONAHA.110.976134
   Theuerkauf I, 2002, CHIRURG, V73, P380, DOI 10.1007/s00104-001-0369-1
   Ulukaya S, 2007, TRANSPL P, V39, P3527, DOI 10.1016/j.transproceed.2007.09.039
   Wakeno-Takahashi M, 2005, J CLIN ANESTH, V17, P218, DOI 10.1016/j.jclinane.2004.06.011
   Warnaar N, 2008, J THROMB HAEMOST, V6, P297, DOI 10.1111/j.1538-7836.2007.02831.x
   White RH, 2009, THROMB RES, V123, pS11, DOI 10.1016/S0049-3848(09)70136-7
   Wong WH, 2002, ANESTHESIOLOGY, V96, P1261, DOI 10.1097/00000542-200205000-00032
   Xia VW, 2010, LIVER TRANSPLANT, V16, P1421, DOI 10.1002/lt.22182
   Yang YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026861
NR 34
TC 3
Z9 3
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD MAR-APR
PY 2013
VL 27
IS 2
BP E126
EP E136
DI 10.1111/ctr.12085
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 123XA
UT WOS:000317423900006
PM 23432470
ER

PT J
AU Jensen, MK
   Campbell, KM
   Alonso, MH
   Nathan, JD
   Ryckman, FC
   Tiao, GM
AF Jensen, M. Kyle
   Campbell, Kathleen M.
   Alonso, Maria H.
   Nathan, Jaimie D.
   Ryckman, Frederick C.
   Tiao, Greg M.
TI Management and long-term consequences of portal vein thrombosis after
   liver transplantation in children
SO LIVER TRANSPLANTATION
LA English
DT Article
ID VENOUS COMPLICATIONS; RISK-FACTORS; EXPERIENCE; RECIPIENTS; OUTCOMES;
   GRAFTS
AB Portal vein thrombosis (PVT) occurs in 12% of pediatric recipients of liver transplantation (LT). Known complications of PVT include portal hypertension, allograft loss, and mortality. The management of PVT is varied. A single-center, case-control study of pediatric LT recipients with portal vein (PV) changes after LT was performed. Cases were categorized as early PVT (if PVT was detected within 30 days of transplantation) or late PVT (if PVT was detected more than 30 days after transplantation or if early PVT persisted beyond 30 days). Two non-PVT control patients were matched on the basis of the recipient weight, transplant indication, and allograft type to each patient with PVT. Thirty-two of the 415 LT recipients (7.7%) received 37 allografts and developed PVT. In comparison with control patients, a higher proportion of patients with PVT had PVT present before LT (13.3% versus 0%, P = 0.01). Patients with early PVT usually returned to the operating room, and 9 of 15 patients (60%) had PV flow restored. Patients with late PVT had lower white blood cell (4.9 [1000/L] versus 6.8 [1000/L], P < 0.01) and platelet counts (140 [1000/L] versus 259 [1000/L], P < 0.01), an elevated international normalized ratio (1.2 versus 1.0, P < 0.001), and more gastrointestinal bleeding (25% versus 8.3%, P = 0.03) compared to controls. Patients with PVT were also less frequently at the expected grade level (52% versus 88%, P < 0.001). The patient survival rates were 84%, 78%, and 78% and 91%, 84%, and 79% for cases and controls at 1, 5, and 10 years, respectively. The allograft survival rates were 90%, 80%, and 80% for cases and 94%, 89%, and 87% for controls at 1, 5, and 10 years, respectively. In conclusion, patients with early and late PVT had preserved allograft function, and there was no impact on mortality. Patients diagnosed with early PVT often underwent operative interventions with successful restoration of flow. Patients diagnosed with late PVT experienced variceal bleeding, and some required portosystemic shunting procedures. Academic delays were also more common. In late PVT, the clinical presentation dictates care because the optimal management algorithm has not yet been determined. Multi-institutional studies are needed to confirm these findings and improve patient outcomes. Liver Transpl 19:315321, 2013. (c) 2013 AASLD.
C1 [Jensen, M. Kyle] Univ Utah, Primary Childrens Med Ctr, Salt Lake City, UT USA.
   [Campbell, Kathleen M.; Alonso, Maria H.; Nathan, Jaimie D.; Ryckman, Frederick C.; Tiao, Greg M.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
RP Tiao, GM (reprint author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, 3333 Burnett Ave, Cincinnati, OH 45229 USA.
EM greg.tiao@cchmc.org
FU US Department of Health and Human Services/Health Resources and Services
   Administration
FX The data and analyses reported in the 2009 Annual Report of the US Organ
   Procurement and Transplantation Network and the Scientific Registry of
   Transplant Recipients (http://www.srtr.org/annual_reports) have been
   supplied by the United Network for Organ Sharing and the Minneapolis
   Medical Research Foundation under contract with the US Department of
   Health and Human Services/Health Resources and Services Administration.
   The authors alone are responsible for reporting and interpreting these
   data; the views expressed herein are those of the authors and not
   necessarily those of the US Government.
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   de Goyet JD, 2013, PEDIATR TRANSPLANT, V17, P19, DOI 10.1111/j.1399-3046.2012.01784.x
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   HARPER PL, 1988, LANCET, V2, P924
   Heffron TG, 2010, PEDIATR TRANSPLANT, V14, P722, DOI 10.1111/j.1399-3046.2009.01259.x
   Kishi Y, 2008, HEPATO-GASTROENTEROL, V55, P1008
   Li ZF, 2008, WORLD J GASTROENTERO, V14, P2377, DOI 10.3748/wjg.14.2377
   Mack CL, 2006, PEDIATRICS, V117, pE405, DOI 10.1542/peds.2005-117
   Moon JI, 2010, TRANSPL P, V42, P871, DOI 10.1016/j.transproceed.2010.02.059
   Ou HY, 2011, SURGERY, V149, P40, DOI 10.1016/j.surg.2010.04.018
   Pinto Raquel B., 2003, J. Pediatr. (Rio J.), V79, P165, DOI 10.1590/S0021-75572003000200012
   Raffa S, 2012, CLIN GASTROENTEROL H, V10, P72, DOI 10.1016/j.cgh.2011.09.010
   Sorensen LG, 2011, AM J TRANSPLANT, V11, P303, DOI 10.1111/j.1600-6143.2010.03363.x
   Superina R, 2006, ANN SURG, V243, P515, DOI 10.1097/01.sla.0000205827.73706.97
   Takahashi Y, 2009, PEDIATR SURG INT, V25, P745, DOI 10.1007/s00383-009-2430-y
   Tao YF, 2009, HEPATOB PANCREAT DIS, V8, P34
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Waits SA, 2011, LIVER TRANSPLANT, V17, P1066, DOI 10.1002/lt.22371
   Yadav SK, 2010, J HEPATOL, V52, P348, DOI 10.1016/j.jhep.2009.12.012
NR 21
TC 6
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAR
PY 2013
VL 19
IS 3
BP 315
EP 321
DI 10.1002/lt.23583
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 107JG
UT WOS:000316212000011
PM 23495080
ER

PT J
AU Feier, FH
   Neto, JS
   Porta, G
   Fonseca, EA
   Vincenzi, R
   Candido, HL
   Benavides, M
   Ketzer, B
   Pugliese, R
   Miura, IK
   Baggio, V
   Guimaraes, T
   Porta, A
   Foronda, G
   Donizete, E
   da Silva, JP
   Faria, L
   Kondo, M
   Chapchap, P
AF Feier, Flavia H.
   Seda Neto, Joao
   Porta, Gilda
   Fonseca, Eduardo A.
   Vincenzi, Rodrigo
   Candido, Helry L.
   Benavides, Marcel
   Ketzer, Bernardo
   Pugliese, Renata
   Miura, Irene K.
   Baggio, Vera
   Guimaraes, Teresa
   Porta, Adriana
   Foronda, Gustavo
   Donizete, Enis
   da Silva, Jose P.
   Faria, Lucilia
   Kondo, Mario
   Chapchap, Paulo
TI Liver transplantation after stage II palliation for hypoplastic left
   heart syndrome
SO LIVER TRANSPLANTATION
LA English
DT Article
ID BILIARY ATRESIA; CHILDREN; DISEASE; EXPERIENCE; SURGERY; PATIENT
AB The association of biliary atresia (BA) with congenital heart diseases has been extensively described, and there are a number of reports on the outcomes of patients in this group who undergo liver transplantation (LT). The intraoperative management and the timing of LT for patients with end-stage liver disease are matters of debate, especially when complex heart diseases are involved. This report describes the outcome after LT for a pediatric recipient with BA and hypoplastic left heart syndrome. The patient underwent Norwood-Sano and Glenn procedures for heart palliation before LT. He was cyanotic, was severely malnourished, and had complications secondary to chronic liver failure. At the time of transplantation, the child was 16 months old and weighed 5175 g. Despite the critical clinical scenario and the long hospitalization period, there were no cardiac, vascular, or biliary complications after LT. At the age of 48 months, the patient was awaiting the final cardiac repair. In conclusion, the presence of complex cardiac malformations may not be a contraindication to LT. An experienced surgical team and a multidisciplinary approach are key to a successful outcome. Liver Transpl 19:322327, 2013. (c) 2013 AASLD.
C1 [Feier, Flavia H.; Seda Neto, Joao; Porta, Gilda; Fonseca, Eduardo A.; Vincenzi, Rodrigo; Candido, Helry L.; Benavides, Marcel; Ketzer, Bernardo; Pugliese, Renata; Miura, Irene K.; Baggio, Vera; Guimaraes, Teresa; Porta, Adriana; Kondo, Mario; Chapchap, Paulo] Sirio Libanes Hosp, Hepatol & Liver Transplantat Unit, BR-01308000 Sao Paulo, Brazil.
   [Foronda, Gustavo; Donizete, Enis] Sirio Libanes Hosp, BR-01308000 Sao Paulo, Brazil.
   [Faria, Lucilia] Sirio Libanes Hosp, Pediat Intens Care Unit, BR-01308000 Sao Paulo, Brazil.
   [da Silva, Jose P.] Portuguese Char Hosp Sao Paulo, Cardiac Surg Unit, Sao Paulo, Brazil.
RP Neto, JS (reprint author), Sirio Libanes Hosp, Hepatol & Liver Transplantat Unit, Rua Barata Ribeiro 414,Cj 65, BR-01308000 Sao Paulo, Brazil.
EM joaoseda@gmail.com
CR Bailey Philip D Jr, 2009, Anesthesiol Clin, V27, P285, DOI 10.1016/j.anclin.2009.05.004
   Barnea O, 1998, CIRCULATION, V98, P1407
   Becker DJ, 2004, J PEDIATR SURG, V39, P1411, DOI 10.1016/j.jpedsurg.2004.05.031
   Carlo WF, 2011, J THORAC CARDIOV SUR, V142, P511, DOI 10.1016/j.jtcvs.2011.01.030
   Concejero A, 2007, TRANSPLANTATION, V84, P484, DOI 10.1097/01.tp.0000277599.25079.94
   Feierman DE, 2006, PEDIATR ANESTH, V16, P669, DOI 10.1111/j.1460-9592.2005.01823.x
   Feinstein JA, 2012, J AM COLL CARDIOL, V59, pS1, DOI 10.1016/j.jacc.2011.09.022
   Imamura M, 2007, ANN THORAC SURG, V84, P1746, DOI 10.1016/j.athoracsur.2007.05.068
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   Kimura T, 2007, PEDIATR TRANSPLANT, V11, P540, DOI 10.1111/j.1399-3046.2007.00699.x
   Manzoni D, 2007, PEDIATR TRANSPLANT, V11, P876, DOI 10.1111/j.1399-3046.2007.00755.x
   Garbanzo JP, 2006, PEDIATR TRANSPLANT, V10, P923, DOI 10.1111/j.1399-3046.2006.00576.x
   Raichlin E, 2009, TRANSPLANTATION, V88, P219, DOI 10.1097/TP.0b013e3181ac60db
   Singhal A, 2009, PEDIATR TRANSPLANT, V13, P1041, DOI 10.1111/j.1399-3046.2009.01092.x
   Sumpelmann R, 2007, CURR OPIN ANESTHESIO, V20, P216
   Taille C, 2003, TRANSPLANTATION, V75, P1482, DOI 10.1097/01.TP.0000061612.78954.6C
   Tanano H, 1999, J PEDIATR SURG, V34, P1687, DOI 10.1016/S0022-3468(99)90645-0
   TISONE G, 1988, TRANSPLANTATION, V46, P162, DOI 10.1097/00007890-198807000-00032
   Torres A, 2002, J PEDIATR SURG, V37, P1399, DOI 10.1053/jpsu.2002.35377
   Tweddell JS, 2002, CIRCULATION, V106, pI82, DOI 10.1161/01.cir.0000032878.55215.bd
   Urahashi T, 2011, PEDIATR SURG INT, V27, P817, DOI 10.1007/s00383-011-2866-8
   Walker Scott G, 2004, Semin Pediatr Surg, V13, P188, DOI 10.1053/j.sempedsurg.2004.04.005
   Watkins S, 2012, PEDIATR CARDIOL, V33, P697, DOI 10.1007/s00246-012-0197-8
NR 23
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAR
PY 2013
VL 19
IS 3
BP 322
EP 327
DI 10.1002/lt.23593
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 107JG
UT WOS:000316212000012
PM 23239564
ER

PT J
AU Chen, CY
   Ho, MC
   Wu, JF
   Jeng, YM
   Chen, HL
   Chang, MH
   Lee, PH
   Hu, RH
   Ni, YH
AF Chen, Ching-Yi
   Ho, Ming-Chih
   Wu, Jia-Feng
   Jeng, Yung-Ming
   Chen, Huey-Ling
   Chang, Mei-Hwei
   Lee, Po-Huang
   Hu, Rey-Heng
   Ni, Yen-Hsuan
TI Development of autoantibodies after pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE de novo autoimmune hepatitis; antinuclear antibody; anti-smooth muscle
   antibody
ID NOVO AUTOIMMUNE HEPATITIS; LATE GRAFT DYSFUNCTION; CARDIAC
   TRANSPLANTATION; IMMUNE HEPATITIS; CYCLOSPORINE-A; ANTIBODIES; CHILDREN;
   EXPERIENCE; RECIPIENTS; FREQUENCY
AB Dn-AIH is a long-term complication after LT. The aim of this study was to analyze the occurrence of autoantibodies in pediatric recipients and the clinical significance. From 1992 to 2008, 96 pediatric LT for non-autoimmune liver diseases were performed in 94 children in our institution. Serum autoantibodies were checked in 68 subjects (73.9%). A positive autoantibody was defined as titers 1:40 for ANA, or 1:20 for ASMA, anti-LKM, and AMA. Autoantibodies were detectable in 51 of 68 patients (75.0%). There was positivity for ANA in 30 patients, ASMA in 32, and AMA in three, while anti-LKM was all negative. Immunosuppressive treatment with CsA, more than one episode of rejection, and abnormal ALT were risk factors for the development of autoantibodies. The incidence of the development of autoantibodies was 75.0% in pediatric LT cases in this study. ASMA was the most commonly found autoantibody. Autoantibodies may not play a sentinel role for dn-AIH after LT.
C1 [Chen, Ching-Yi; Wu, Jia-Feng; Chen, Huey-Ling; Chang, Mei-Hwei; Ni, Yen-Hsuan] Natl Taiwan Univ, Coll Med, Dept Pediat, Taipei, Taiwan.
   [Chen, Ching-Yi; Wu, Jia-Feng; Chen, Huey-Ling; Chang, Mei-Hwei; Ni, Yen-Hsuan] Natl Taiwan Univ, Childrens Hosp, Taipei, Taiwan.
   [Ho, Ming-Chih; Lee, Po-Huang; Hu, Rey-Heng] Natl Taiwan Univ, Dept Surg, Taipei 10764, Taiwan.
   [Jeng, Yung-Ming] Natl Taiwan Univ, Dept Pathol, Taipei 10764, Taiwan.
RP Ni, YH (reprint author), Coll Med, Dept Pediat, 15F,8,Chung Shan South Rd, Taipei 100, Taiwan.
EM rhhu@ntu.edu.tw; yhni@ntu.edu.tw
OI Chang, Mei Hwei/0000-0002-3648-9261; LEE, PO-HUANG/0000-0001-5831-035X;
   Ho, Ming-Chih/0000-0003-3660-1062; WU, JIA-FENG/0000-0001-6343-1658; HU,
   REY-HENG/0000-0001-6709-031X; Ni, Yen-Hsuan/0000-0002-1158-5249
CR Aguilera I, 2001, CLIN EXP IMMUNOL, V126, P535, DOI 10.1046/j.1365-2249.2001.01682.x
   Alvarez F., 1999, Journal of Hepatology, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Andries S, 2001, TRANSPLANTATION, V72, P267, DOI 10.1097/00007890-200107270-00018
   Avitzur Y, 2007, J PEDIATR GASTR NUTR, V45, P222, DOI 10.1097/MPG.0b013e31805ce219
   Damoiseaux JGMC, 1998, FOLIA BIOL-PRAGUE, V44, P1
   Dubel L, 1998, TRANSPLANTATION, V65, P1072, DOI 10.1097/00007890-199804270-00011
   DUNN MJ, 1991, TRANSPLANTATION, V51, P806, DOI 10.1097/00007890-199104000-00014
   DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0
   Gupta P, 2001, TRANSPLANTATION, V71, P664, DOI 10.1097/00007890-200103150-00016
   Hadzic N, 2003, HEPATOLOGY, V38, p202A
   Heneghan MA, 2001, HEPATOLOGY, V34, P464, DOI 10.1053/jhep.2001.26756
   Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322
   Hernandez HM, 2001, J PEDIATR GASTR NUTR, V32, P131, DOI 10.1097/00005176-200102000-00007
   Jones DEJ, 1999, HEPATOLOGY, V30, P53, DOI 10.1002/hep.510300103
   Kasapcopur O, 1999, TURKISH J PEDIATR, V41, P67
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Lytton SD, 2002, CLIN EXP IMMUNOL, V127, P293, DOI 10.1046/j.1365-2249.2002.01754.x
   MARTINI A, 1989, AM J DIS CHILD, V143, P493
   Mieli-Vergani G, 2004, J HEPATOL, V40, P3, DOI 10.1016/j.jhep.2003.10.022
   Richter A, 2007, CLIN TRANSPLANT, V21, P427, DOI 10.1111/j.1399-0012.2007.00667.x
   Riva S, 2006, LIVER TRANSPLANT, V12, P573, DOI 10.1002/lt.20673
   Salcedo M, 2002, HEPATOLOGY, V35, P349, DOI 10.1053/jhep.2002.31167
   Salcedo M, 2009, LIVER TRANSPLANT, V15, P530, DOI 10.1002/lt.21721
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Spada M, 2001, TRANSPLANT P, V33, P1747, DOI 10.1016/S0041-1345(00)02826-8
   Ueno T, 2011, PEDIATR TRANSPLANT, V15, P470, DOI 10.1111/j.1399-3046.2011.01483.x
   Varani S, 2002, J MED VIROL, V66, P56, DOI 10.1002/jmv.2111
NR 30
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2013
VL 17
IS 2
BP 144
EP 148
DI 10.1111/petr.12032
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 097IK
UT WOS:000315467000015
PM 23217026
ER

PT J
AU Nosaka, S
   Isobe, Y
   Kasahara, M
   Miyazaki, O
   Sakamoto, S
   Uchida, H
   Shigeta, T
   Masaki, H
AF Nosaka, Shunsuka
   Isobe, Yoshinori
   Kasahara, Mureo
   Miyazaki, Osamu
   Sakamoto, Seisuke
   Uchida, Hajime
   Shigeta, Takanobu
   Masaki, Hidekazu
TI Recanalization of post-transplant late-onset long segmental portal vein
   thrombosis with bidirectional transhepatic and transmesenteric approach
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE angioplasty; vascular stent; complications; portal vein; thrombosis;
   living-donor liver transplantation
ID DONOR LIVER-TRANSPLANTATION; VENOUS STENOSIS; CHILDREN; ANGIOPLASTY;
   COMPLICATIONS; MANAGEMENT; IMPACT; SIZE
AB PV complications are the most frequent vascular complications in pediatric LT. We have experienced a case with chronic postoperative PVT that necessitates combined transhepatic and transmesenteric approach and have confirmed mid-term patency. An eight-yr-old boy had successful LDLT with a left lateral segment graft at the age of twomonths for HBV-related acute liver failure. Seven years after transplantation, the patient suddenly showed a melena with hypovolemic shock. Doppler ultrasound and CT revealed intrahepatic bile duct dilatation and main PVT with collateral formation at hepatic hilus and mesenterium of the Roux-en-Y jejunal loop. Urgent splenic artery embolization was performed to control the bleeding and was temporarily effective. Therefore, recanalization of PVO was attempted. Because of long segmental PVO and steep angle between the intrahepatic PV and the portal trunk, bidirectional transhepatic and transmesenteric approach was selected and resulted in deploying three metallic stents necessitating additional infusion thrombolytic therapy. The patient is now followed as an outpatient with patent stents for twoyr since the procedure. For the rescue of these patients, recanalization of obstructed PV trunk with bidirectional approach would be feasible with better graft survival and less invasiveness than conventional surgical interventions.
C1 [Nosaka, Shunsuka; Miyazaki, Osamu; Masaki, Hidekazu] Natl Ctr Child Hlth & Dev, Dept Radiol, Tokyo 1578535, Japan.
   [Isobe, Yoshinori] Natl Hosp Org Tokyo Med Ctr, Dept Radiol, Tokyo, Japan.
   [Kasahara, Mureo; Sakamoto, Seisuke; Uchida, Hajime; Shigeta, Takanobu] Natl Ctr Child Hlth & Dev, Dept Transplantat, Tokyo 1578535, Japan.
RP Nosaka, S (reprint author), Natl Ctr Child Hlth & Dev, Dept Radiol, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM nosaka-s@ncchd.go.jp
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Carnevale FC, 2011, PEDIATR TRANSPLANT, V15, P47, DOI 10.1111/j.1399-3046.2010.01350.x
   Carnevale FC, 2009, CARDIOVASC INTER RAD, V32, P1083, DOI 10.1007/s00270-009-9578-7
   Cheng YF, 2009, LIVER TRANSPLANT, V15, P1378, DOI 10.1002/lt.21813
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Funaki B, 2000, RADIOLOGY, V215, P147
   Funaki B, 1997, AM J ROENTGENOL, V169, P551
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   Hotta R, 2007, PEDIATR SURG INT, V23, P939, DOI 10.1007/s00383-007-1974-y
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Meisheri Ila V, 2010, Afr J Paediatr Surg, V7, P86, DOI 10.4103/0189-6725.62854
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   ROLLINS NK, 1992, RADIOLOGY, V182, P731
   Sanada Y, 2010, LIVER TRANSPLANT, V16, P332, DOI 10.1002/lt.21995
   Shibata T, 2005, RADIOLOGY, V235, P1078, DOI 10.1148/radiol.2353040489
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
NR 16
TC 2
Z9 2
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2013
VL 17
IS 2
BP E71
EP E75
DI 10.1111/petr.12050
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 097IK
UT WOS:000315467000007
PM 23442104
ER

PT J
AU Kosola, S
   Lampela, H
   Jalanko, H
   Makisalo, H
   Lohi, J
   Arola, J
   Pakarinen, MP
AF Kosola, Silja
   Lampela, Hanna
   Jalanko, Hannu
   Makisalo, Heikki
   Lohi, Jouko
   Arola, Johanna
   Pakarinen, Mikko P.
TI Low-dose steroids associated with milder histological changes after
   pediatric liver transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LONG-TERM SURVIVORS; METABOLIC SYNDROME; GRAFT FIBROSIS; DONOR AGE;
   FOLLOW-UP; RECIPIENTS; ALLOGRAFT; BIOPSIES; HEPATITIS; DISEASE
AB Controversy remains about the role of protocol liver biopsy for symptom-free recipients and about the long-term use of low-dose steroids after pediatric liver transplantation (LT). We conducted a national cross-sectional study of pediatric recipients who underwent LT between 1987 and 2007. Liver biopsy samples were taken from 54 patients (82% of survivors) after a median posttransplant follow-up of 11 years, and they were reviewed by 2 pathologists blinded to the clinical data. Biopsy samples from 18 patients (33%) showed nearly normal histology with no inflammation, fibrosis, or steatosis. Portal inflammation was detected in 14 samples (26%), showed no correlation with anti-nuclear antibodies, and was less frequent in the 35 patients whose immunosuppression included steroids (14% versus 47% of patients not using steroids, P = 0.008). Fibrosis was present in 21 biopsy samples (39%). According to the Metavir classification, 16 were stage 1, 3 were stage 2, and 2 were stage 3. The fibrosis stage correlated negatively with serum prealbumin levels (r = 0.364, P = 0.007) and positively with chronic cholestasis (cytokeratin 7 staining; r = 0.529, P < 0.001) and portal inflammation (r = 0.350, P = 0.01). Microvesicular steatosis was found in 23 biopsy samples (43% of patients in 5%-80% of hepatocytes), and it correlated with the body mass index (r = 0.458, P < 0.001) but not with steroid use. The age of the allograft (donor age plus follow-up time) correlated with higher serum gamma-glutamyltransferase (r = 0.472, P < 0.001) and conjugated bilirubin levels (r = 0.420, P = 0.002) as well as chronic cholestasis (r = 0.299, P = 0.03). The biopsy findings led to treatment changes in 10 patients (19%), whereas only 1 complication (subcapsular hematoma) was encountered. In conclusion, continuing low-dose steroids indefinitely after pediatric LT may have a positive effect on the long-term histological state of the liver graft. Allograft aging may lead to chronic cholestasis and thus contribute to the development of liver fibrosis. Liver Transpl 19:145154, 2013. (c) 2012 AASLD.
C1 [Kosola, Silja; Lampela, Hanna; Jalanko, Hannu; Pakarinen, Mikko P.] Univ Helsinki, Childrens Hosp, Cent Hosp, FI-00029 Helsinki, Finland.
   [Lohi, Jouko; Arola, Johanna] Univ Helsinki, HUSLAB Pathol, Cent Hosp, FI-00029 Helsinki, Finland.
   [Lohi, Jouko; Arola, Johanna] Univ Helsinki, FI-00029 Helsinki, Finland.
RP Kosola, S (reprint author), Univ Helsinki, Childrens Hosp, Cent Hosp, Room 609,POB 705, FI-00029 Helsinki, Finland.
EM silja.kosola@hus.fi
RI Lampela, Hanna/O-3619-2014
OI Lampela, Hanna/0000-0001-9619-1099
FU Helsinki University Central Hospital; Finnish Pediatric Research
   Foundation; Finnish Transplantation Society; Sigrid Juselius Foundation;
   Paivikki and Sakari Sohlberg Foundation; Academy of Finland
FX This study was supported by Helsinki University Central Hospital
   (through a grant), the Finnish Pediatric Research Foundation, the
   Finnish Transplantation Society, the Sigrid Juselius Foundation, the
   Paivikki and Sakari Sohlberg Foundation, and the Academy of Finland.
CR Aguilera I, 2011, LIVER TRANSPLANT, V17, P779, DOI 10.1002/lt.22302
   Al-Sinani S, 2009, PEDIATR TRANSPLANT, V13, P160, DOI 10.1111/j.1399-3046.2008.01043.x
   Bateman AC, 2010, HISTOPATHOLOGY, V56, P415, DOI 10.1111/j.1365-2559.2009.03391.x
   Bell LE, 2008, AM J TRANSPLANT, V8, P2230, DOI 10.1111/j.1600-6143.2008.02415.x
   Berenguer M, 2002, HEPATOLOGY, V36, P202, DOI 10.1053/jhep.2002.33993
   Berenguer M, 2001, LIVER TRANSPLANT, V7, P790, DOI 10.1053/jlts.2001.23794
   Bostrom P, 2005, ARTERIOSCL THROM VAS, V25, P1945, DOI 10.1161/01.ATV.0000179676.41064.d4
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   Demetris AJ, 2006, HEPATOLOGY, V44, P489, DOI 10.1002/hep.21280
   Desmet VJ, 2011, VIRCHOWS ARCH, V458, P261, DOI 10.1007/s00428-011-1049-2
   Desmet VJ, 2011, VIRCHOWS ARCH, V458, P251, DOI 10.1007/s00428-011-1048-3
   Dumortier J, 2010, AM J GASTROENTEROL, V105, P613, DOI 10.1038/ajg.2009.717
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Guthery SL, 2003, LIVER TRANSPLANT, V9, P365, DOI 10.1053/jlts.2003.50071
   Herzog D, 2008, LIVER TRANSPLANT, V14, P946, DOI 10.1002/lt.21444
   Hoare M, 2010, J HEPATOL, V53, P950, DOI 10.1016/j.jhep.2010.06.009
   Hoofnagle JH, 1996, HEPATOLOGY, V24, P89, DOI 10.1002/hep.510240116
   Hubscher S, 2009, LIVER TRANSPLANT, V15, pS19, DOI 10.1002/lt.21902
   Hubscher SG, 2011, J HEPATOL, V55, P702, DOI 10.1016/j.jhep.2011.03.005
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Kosola S, 2012, AM J TRANSPLANT, V12, P2815, DOI 10.1111/j.1600-6143.2012.04147.x
   Laish I, 2011, LIVER TRANSPLANT, V17, P15, DOI 10.1002/lt.22198
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McDiarmid SV, 2012, AM J TRANSPLANT, V12, P1367, DOI 10.1111/j.1600-6143.2012.04085.x
   Mells G, 2008, TRANSPLANTATION, V85, P1686, DOI 10.1097/TP.0b013e318176b1fd
   Pagadala M, 2009, LIVER TRANSPLANT, V15, P1662, DOI 10.1002/lt.21952
   Peeters PMJG, 2000, TRANSPLANTATION, V70, P1581, DOI 10.1097/00007890-200012150-00008
   Saari A, 2011, ANN MED, V43, P235, DOI 10.3109/07853890.2010.515603
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Sebagh M, 2003, HEPATOLOGY, V37, P1293, DOI 10.1053/jhep.2003.50231
   Shaikh OS, 2007, LIVER TRANSPLANT, V13, P943, DOI 10.1002/lt.21202
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   [Anonymous], 1994, HEPATOLOGY 1
NR 36
TC 6
Z9 6
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2013
VL 19
IS 2
BP 145
EP 154
DI 10.1002/lt.23565
PG 10
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 090MH
UT WOS:000314982700005
PM 23109058
ER

PT J
AU Hwang, S
   Kim, KH
   Kim, DY
   Kim, KM
   Ahn, CS
   Moon, DB
   Ha, TY
   Song, GW
   Jung, DH
   Namgoong, JM
   Park, GC
   Cronin, DC
   Lee, SG
AF Hwang, Shin
   Kim, Ki-Hun
   Kim, Dae-Yeon
   Kim, Kyoung-Mo
   Ahn, Chul-Soo
   Moon, Deok-Bog
   Ha, Tae-Yong
   Song, Gi-Won
   Jung, Dong-Hwan
   Namgoong, Jung-Man
   Park, Gil-Chun
   Cronin, David C., II
   Lee, Sung-Gyu
TI Anomalous hepatic vein anatomy of left lateral section grafts and
   customized unification venoplasty for pediatric living donor liver
   transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID RIGHT LOBE GRAFTS; MEDIAL SEGMENT; RECONSTRUCTION; OUTFLOW;
   COMPLICATIONS; PROCUREMENT
AB In liver transplantation, a left lateral section (LLS) graft may have an unusual variant left hepatic vein (LHV) anatomy. This study was designed to analyze the incidence of unusual LHV variants and to determine technical methods for effective reconstruction in infant recipients weighing approximately 10 kg or less. The study comprised 3 parts: an LHV variation analysis, a simulation-based design for the technical modification of graft LHV venoplasty, and its clinical application. The LHV anatomy of 300 potential LLS graft donors was classified into 4 types according to the number and location of the hepatic vein openings: (1) a single opening (n = 218 or 72.7%); (2) 2 large adjacent openings (n = 29 or 9.7%); (3) 2 adjacent openings, 1 large and 1 small (n = 34 or 11.3%); and (4) 2 widely spaced openings (n = 19 or 6.3%). Types 2 and 3 required wedged unification venoplasty, and type 4 required additional vein interposition. In a series of 49 cases using LLS grafts, the graft hepatic vein complication rate was 4.5% at 3 years; stenting was necessary for 1 of the 36 type 1 LHV grafts (2.8%) and for 1 of the 13 type 2-4 LHV grafts (7.7%, P = 0.46). A customized interposition-wedged unification venoplasty technique for coping with type 4 vein variations was developed with a simulation-based approach, and it was successfully applied to a 10-month-old male infant receiving an LLS graft with a type 4 LHV. In conclusion, nearly all LHV variations can be effectively managed with customized unification venoplasty. These venoplasty techniques represent beneficial surgical options as part of graft standardization for hepatic vein reconstruction in pediatric living donor liver transplantation. Liver Transpl 19:184190, 2013. (c) 2012 AASLD.
C1 [Hwang, Shin; Kim, Ki-Hun; Ahn, Chul-Soo; Moon, Deok-Bog; Ha, Tae-Yong; Song, Gi-Won; Jung, Dong-Hwan; Namgoong, Jung-Man; Park, Gil-Chun; Lee, Sung-Gyu] Univ Ulsan, Div Hepatobiliary Surg & Liver Transplantat, Dept Surg, Asan Med Ctr,Coll Med, Seoul 138736, South Korea.
   [Kim, Dae-Yeon] Univ Ulsan, Div Pediat Surg, Dept Surg, Asan Med Ctr,Coll Med, Seoul 138736, South Korea.
   [Kim, Kyoung-Mo] Univ Ulsan, Dept Pediat, Asan Med Ctr, Coll Med, Seoul 138736, South Korea.
   [Cronin, David C., II] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Transplant Surg, Milwaukee, WI 53226 USA.
RP Lee, SG (reprint author), Univ Ulsan, Div Hepatobiliary Surg & Liver Transplantat, Dept Surg, Asan Med Ctr,Coll Med, 388-1 Poongnap Dong, Seoul 138736, South Korea.
EM sglee2@amc.seoul.kr
CR de Villa VH, 2000, TRANSPLANTATION, V70, P1604, DOI 10.1097/00007890-200012150-00011
   Hwang S, 2012, TRANSPL P, V44, P457, DOI 10.1016/j.transproceed.2012.01.072
   Hwang S, 2005, LIVER TRANSPLANT, V11, P449, DOI 10.1002/lt.20387
   Hwang S, 2006, LIVER TRANSPLANT, V12, P156, DOI 10.1002/lt.20574
   Hwang S, 2004, LIVER TRANSPLANT, V10, P763, DOI 10.1002/lt.20178
   Hwang S, 2010, LIVER TRANSPLANT, V16, P639, DOI 10.1002/lt.22045
   Hwang S, 2006, HEPATO-GASTROENTEROL, V53, P773
   Hwang S, 2006, HEPATO-GASTROENTEROL, V53, P928
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1265, DOI 10.1016/j.lts.2003.09.014
   Mochizuki K, 2012, ANN TRANSPL, V17, P31
   Radtke A, 2010, TRANSPLANTATION, V89, P1518, DOI 10.1097/TP.0b013e3181dd6bac
   Sakamoto S, 2011, TRANSPLANTATION, V91, pE38, DOI 10.1097/TP.0b013e3182088bb5
   Schulze M, 2011, TRANSPL INT, V24, P797, DOI 10.1111/j.1432-2277.2011.01277.x
   Seda-Neto J, 2008, TRANSPLANTATION, V86, P697, DOI 10.1097/TP.0b013e318183ed22
   Shirouzu Y, 2011, CLIN TRANSPLANT, V25, P625, DOI 10.1111/j.1399-0012.2010.01322.x
   Takemura N, 2005, LIVER TRANSPLANT, V11, P356, DOI 10.1002/lt.20374
   Tannuri U, 2011, J PEDIATR SURG, V46, P1379, DOI 10.1016/j.jpedsurg.2010.11.047
   Yi NJ, 2008, WORLD J SURG, V32, P1722, DOI 10.1007/s00268-008-9641-6
NR 18
TC 4
Z9 4
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2013
VL 19
IS 2
BP 184
EP 190
DI 10.1002/lt.23557
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 090MH
UT WOS:000314982700009
PM 23045153
ER

PT J
AU Boyer, O
   Noto, C
   De Serre, NPM
   Gubler, MC
   Dechaux, M
   Goulet, O
   Niaudet, P
   Lacaille, F
AF Boyer, Olivia
   Noto, Cristian
   De Serre, Natacha Patey-Mariaud
   Gubler, Marie-Claire
   Dechaux, Michele
   Goulet, Olivier
   Niaudet, Patrick
   Lacaille, Florence
TI Renal function and histology in children after small bowel
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE calcineurin inhibitors; nephrotoxicity; pediatric; chronic kidney
   disease; small bowel transplantation; tacrolimus
ID CHRONIC KIDNEY-DISEASE; ORTHOTOPIC LIVER-TRANSPLANTATION;
   GLOMERULAR-FILTRATION RATE; INTESTINAL TRANSPLANTATION; CALCINEURIN
   INHIBITORS; MYCOPHENOLATE-MOFETIL; MANAGEMENT STRATEGIES; PLASMA
   CREATININE; NEPHROTOXICITY; RECIPIENTS
AB Boyer O, Noto C, Patey-Mariaud De Serre N, Gubler M-C, Dechaux M, Goulet O, Niaudet P, Lacaille F. Renal function and histology in children after small bowel transplantation. Abstract: CKD is a frequent long-term complication after SBTx. CNIs are a well-known factor, but probably not the only cause. We assessed the incidence, risk factors, and severity of CKD in 27 children with SBTx (15 combined liver/SBTx) and prednisone/TAC-based maintenance immunosuppression. Median follow-up was seven yr (321). A renal biopsy was performed in 14 patients, 118 yr post-SBTx. A reduced GFR was observed in 17 children (63%) during the follow-up with none requiring dialysis. CNI toxicity was observed in 11/14 biopsies, as early as two yr post-transplant, and could occur with a normal mGFR. The dose of TAC was reduced by 50% in 13 patients with CKD and/or significant kidney histological lesions, and six were also given MMF. This led to a significant improvement in renal function: mGFR normalized in eight patients and improved or stabilized in five. No rejection occurred. At last follow-up, 37% had CKD stage 2 and 15% had CKD stage 3. In conclusion, CKD is frequent in children after SBTx and probably multifactorial. Less nephrotoxic immunosuppressive protocols may improve mGFR and should be further considered. The kidney histology helps in designing personalized immunosuppression strategies for patients.
C1 [Boyer, Olivia; Niaudet, Patrick] Reference Ctr Hereditary Renal Dis Children & Ado, Pediat Nephrol Unit, Paris, France.
   [Boyer, Olivia; Niaudet, Patrick] INSERM, U983, Paris, France.
   [Lacaille, Florence] Hop Necker Enfants Malad, Assistance Publ Hop Paris, Hepatogastroenterol Nutr Unit, F-75015 Paris, France.
   [Boyer, Olivia; Noto, Cristian; De Serre, Natacha Patey-Mariaud; Gubler, Marie-Claire; Dechaux, Michele; Goulet, Olivier; Niaudet, Patrick; Lacaille, Florence] Paris Descartes Sorbonne Paris Cite Univ, Paris, France.
   [Noto, Cristian; Goulet, Olivier; Lacaille, Florence] Pediat Hepatogastroenterol Nutr Unit, Paris, France.
   [Noto, Cristian; Lacaille, Florence] Reference Ctr Rare Digest Dis Children MaRDI, Paris, France.
   [De Serre, Natacha Patey-Mariaud] Hop Necker Enfants Malad, Pathol Unit, F-75015 Paris, France.
   [Dechaux, Michele] Hop Necker Enfants Malad, Physiol Unit, F-75015 Paris, France.
RP Lacaille, F (reprint author), Hop Necker Enfants Malad, Assistance Publ Hop Paris, Hepatogastroenterol Nutr Unit, 149 Rue Sevres, F-75015 Paris, France.
EM florence.lacaille@nck.aphp.fr
CR Arora-Gupta N, 2004, PEDIATR TRANSPLANT, V8, P145, DOI 10.1046/j.1399-3046.2003.00132.x
   Aw MM, 2001, TRANSPLANTATION, V72, P746, DOI 10.1097/00007890-200108270-00034
   Barkmann A, 2000, TRANSPLANTATION, V69, P1886, DOI 10.1097/00007890-200005150-00025
   Boyer O, 2005, TRANSPLANTATION, V79, P1405, DOI 10.1097/01.TP.0000156990.11135.60
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Campistol JM, 2000, TRANSPLANTATION, V69, pSS5
   Cohen AJ, 2002, LIVER TRANSPLANT, V8, P916, DOI 10.1053/jlts.2002.35668
   Falkenhain ME, 1996, TRANSPLANTATION, V62, P364, DOI 10.1097/00007890-199608150-00011
   Filler G, 2008, PEDIATR TRANSPLANT, V12, P393, DOI 10.1111/j.1399-3046.2007.00885.x
   Filler G, 2011, PEDIATR TRANSPLANT, V15, P25, DOI 10.1111/j.1399-3046.2010.01439.x
   Fisher NC, 2000, TRANSPLANTATION, V69, pSS18
   Fogo AB, 2009, PEDIAT NEPHROLOGY, P565, DOI 10.1007/978-3-540-76341-3_24
   Gonwa TA, 2001, TRANSPLANTATION, V72, P1934, DOI 10.1097/00007890-200112270-00012
   Herlenius G, 2008, TRANSPLANTATION, V86, P108, DOI 10.1097/TP.0b013e31817613f8
   Hogg RJ, 2003, PEDIATRICS, V111, P1416, DOI 10.1542/peds.111.6.1416
   Jennette JC, 2007, HEPTINSTALLS PATHOLO, P1347
   Karie-Guigues S, 2009, LIVER TRANSPLANT, V15, P1083, DOI 10.1002/lt.21803
   Kivela JM, 2011, TRANSPLANTATION, V91, P115, DOI 10.1097/TP.0b013e3181fa94b9
   Lacaille F, 1998, TRANSPLANT P, V30, P2526, DOI 10.1016/S0041-1345(98)00710-6
   Lacaille F, 2008, GUT, V57, P455, DOI 10.1136/gut.2007.133389
   LAINE J, 1994, J PEDIATR-US, V125, P863, DOI 10.1016/S0022-3476(05)82000-1
   MacDonald AS, 2000, TRANSPLANTATION, V69, pSS31
   Mazariegos GV, 2010, AM J TRANSPLANT, V10, P1020, DOI 10.1111/j.1600-6143.2010.03044.x
   McDiarmid S V, 1996, Kidney Int Suppl, V53, pS77
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Pageaux GP, 2004, J HEPATOL, V41, P176, DOI 10.1016/j.jhep.2004.05.003
   PLATZ KP, 1994, TRANSPLANTATION, V58, P170, DOI 10.1097/00007890-199405820-00007
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   Schwarz A, 2010, AM J TRANSPLANT, V10, P2017, DOI 10.1111/j.1600-6143.2010.03224.x
   Ueno T, 2006, TRANSPLANT P, V38, P1759, DOI 10.1016/j.transproceed.2006.05.026
   Watson MJ, 2008, TRANSPLANTATION, V86, P117, DOI 10.1097/TP.0b013e31817d55ae
NR 32
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2013
VL 17
IS 1
BP 65
EP 72
DI 10.1111/j.1399-3046.2012.01767.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 075PO
UT WOS:000313899200022
PM 22882667
ER

PT J
AU Sakamoto, S
   Nakazawa, A
   Shigeta, T
   Uchida, H
   Kanazawa, H
   Fukuda, A
   Karaki, C
   Nosaka, S
   Kasahara, M
AF Sakamoto, Seisuke
   Nakazawa, Atsuko
   Shigeta, Takanobu
   Uchida, Hajime
   Kanazawa, Hiroyuki
   Fukuda, Akinari
   Karaki, Ciaki
   Nosaka, Shunsuke
   Kasahara, Mureo
TI Devastating outflow obstruction after pediatric split liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatic venous outflow obstruction; sinusoidal obstruction syndrome;
   pediatric split liver transplantation
ID INTRAHEPATIC PORTOSYSTEMIC SHUNT; VENOOCCLUSIVE DISEASE; FAILURE;
   ETIOLOGY
AB Sakamoto S, Nakazawa A, Shigeta T, Uchida H, Kanazawa H, Fukuda A, Karaki C, Nosaka S, Kasahara M. Devastating outflow obstruction after pediatric split liver transplantation. Abstract: HVOO is a rare complication after pediatric LT, which may lead to graft failure. There are various causes of HVOO, such as mechanical anastomotic obstruction and SOS. A 10-month-old female underwent split LT from a deceased donor for ALF. Her postoperative course was uneventful. However, her liver function suddenly deteriorated a month later. A liver biopsy revealed centrilobular injury, and D-US suggested outflow obstruction. Venography was performed to reveal hepatic venous narrowing inside the graft. She received another graft from a living donor because of progressive graft failure in spite of successful venoplasty with stent insertion. The macroscopic findings of the explanted graft did not show an anastomotic stricture of the hepatic vein, although the pathological findings revealed necrosis of the first graft due to SOS. SOS might cause severe consequences with concomitant mechanical outflow obstruction after pediatric LT.
C1 [Sakamoto, Seisuke] Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Div Transplantat, Setagaya Ku, Tokyo 1578535, Japan.
   [Nakazawa, Atsuko] Natl Ctr Child Hlth & Dev, Div Pathol, Tokyo 1578535, Japan.
   [Nosaka, Shunsuke] Natl Ctr Child Hlth & Dev, Div Radiol, Tokyo 1578535, Japan.
RP Sakamoto, S (reprint author), Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Div Transplantat, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM sakamoto-si@ncchd.go.jp
OI Fukuda, Akinari/0000-0003-4684-0446
FU Ministry of Education; Ministry of Health, Labor and Welfare, Japan;
   Foundation for Growth Science, Japan
FX This work was supported in part by grants from the Scientific Research
   Fund of the Ministry of Education and by a Research Grant for
   Immunology, Allergy and Organ Transplant from the Ministry of Health,
   Labor and Welfare, Japan and Foundation for Growth Science, Japan.
CR Campos-Varela I, 2012, LIVER TRANSPLANT, V18, P201, DOI 10.1002/lt.22351
   DeLeve LD, 2002, SEMIN LIVER DIS, V22, P27, DOI 10.1055/s-2002-23204
   Izaki T, 2004, PEDIATR TRANSPLANT, V8, P301, DOI 10.1111/j.1399-3046.2004.00171.x
   Kitajima K, 2010, CLIN TRANSPLANT, V24, P139, DOI 10.1111/j.1399-0012.2009.00971.x
   Liatsos C, 2001, BRIT J HAEMATOL, V113, P567, DOI 10.1046/j.1365-2141.2001.02628.x
   Mazariegos G V, 2000, Pediatr Transplant, V4, P322, DOI 10.1034/j.1399-3046.2000.00124.x
   Mor E, 2001, TRANSPLANTATION, V72, P1237, DOI 10.1097/00007890-200110150-00009
   Nakazawa Y, 2003, TRANSPLANTATION, V75, P727, DOI 10.1097/01.TP.0000053403.49028.AA
   Richardson PG, 2010, BIOL BLOOD MARROW TR, V16, P1005, DOI 10.1016/j.bbmt.2010.02.009
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   Sakamoto S, 2008, PEDIATR TRANSPLANT, V12, P167, DOI 10.1111/j.1399-3046.2007.00718.x
   Sebagh M, 1999, HEPATOLOGY, V30, P1144, DOI 10.1002/hep.510300514
   Senzolo M, 2006, TRANSPLANTATION, V82, P132, DOI 10.1097/01.tp.0000225799.76828.ce
   Shimojima N, 2006, LIVER TRANSPLANT, V12, P1418, DOI 10.1002/lt.20850
   SHULMAN HM, 1994, HEPATOLOGY, V19, P1171, DOI 10.1016/0270-9139(94)90864-8
   STERNECK M, 1991, HEPATOLOGY, V14, P806, DOI 10.1002/hep.1840140511
NR 16
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2013
VL 17
IS 1
BP E25
EP E28
DI 10.1111/j.1399-3046.2012.01761.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 075PO
UT WOS:000313899200012
PM 22805415
ER

PT J
AU Squires, JE
   Sisk, RA
   Balistreri, WF
   Kohli, R
AF Squires, James E.
   Sisk, Robert A.
   Balistreri, William F.
   Kohli, Rohit
TI Isolated unilateral cytomegalovirus retinitis: A rare long-term
   complication after pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE immunosuppression; tacrolimus; retina; children; ocular; complications;
   hepatic
ID ORAL GANCICLOVIR; RECIPIENTS; DISEASE; VALGANCICLOVIR; INFECTION;
   PROPHYLAXIS; PREVENTION; EFFICACY; OUTCOMES; SAFETY
AB Squires JE, Sisk RA, Balistreri WF, Kohli R. Isolated unilateral cytomegalovirus retinitis: A rare long-term complication after pediatric liver transplantation. Abstract: To highlight the rare yet devastating complication of CMV retinitis in a minimally immunosuppressed patient eight yr after liver transplantation for biliary atresia. A 22-yr-old female status-post deceased donor liver transplant at age 13 secondary to biliary atresia receiving single agent immunosuppression presented with acute, unilateral, profound decrease in visual acuity. The patient was diagnosed to have acute onset unilateral CMV retinitis. Retinal examination uncovered classical appearance of retinal whitening and retinal hemorrhages with extensive macular involvement. CMV retinitis can occur as a late complication following liver transplantation. Additionally, CMV retinal disease can occur in the absence of laboratory evidence of CMV infection and independent of additional clinical features suggesting CMV disease. Currently, there is no standard of care regarding screening for CMV retinitis, and thus, further research is needed to define the need for potential changes in current clinical practices and post-transplant screening protocols.
C1 [Squires, James E.; Balistreri, William F.; Kohli, Rohit] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Pediatr Liver Care Ctr, Dept Pediat, Cincinnati, OH 45229 USA.
   [Sisk, Robert A.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat Ophthalmol, Cincinnati, OH 45229 USA.
RP Kohli, R (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Liver Care Ctr, Cincinnati, OH 45229 USA.
EM rohit.kohli@cchmc.org
RI Kohli, Rohit/H-3020-2013
OI Kohli, Rohit/0000-0002-0198-7703
FU NIH/NIDDK [K08 DK084310-01]
FX This work was supported by NIH/NIDDK K08 DK084310-01.
CR Aw M M, 2000, Pediatr Transplant, V4, P100, DOI 10.1034/j.1399-3046.2000.00095.x
   Baumal CR, 1996, ARCH PEDIAT ADOL MED, V150, P1186
   Bedel AN, 2012, LIVER TRANSPLANT, V18, P347, DOI 10.1002/lt.22471
   Committee SRW, 2010, AM ACAD OPHTHALMOLOG, V12, P203
   Egli A, 2008, TRANSPL INFECT DIS, V10, P27, DOI 10.1111/j.1399-3062.2007.00285.x
   Eid AJ, 2008, TRANSPL INFECT DIS, V10, P13, DOI 10.1111/j.1399-3062.2007.00241.x
   Fishburne BC, 1998, AM J OPHTHALMOL, V125, P104, DOI 10.1016/S0002-9394(99)80245-1
   Humar A, 2010, AM J TRANSPLANT, V10, P1228, DOI 10.1111/j.1600-6143.2010.03074.x
   Kotton CN, 2010, TRANSPLANTATION, V89, P779, DOI 10.1097/TP.0b013e3181cee42f
   Kuo IC, 2004, AM J OPHTHALMOL, V138, P338, DOI 10.1016/j.ajo.2004.04.015
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Martin JM, 2011, PEDIATR TRANSPLANT, V15, P229, DOI 10.1111/j.1399-3046.2010.01454.x
   Paya C, 2004, AM J TRANSPLANT, V4, P611, DOI 10.1111/j.1600-6143.2004.00382.x
   Shibolet O, 2003, TRANSPLANT INT, V16, P861, DOI 10.1007/s00147-003-0643-x
   WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9
NR 15
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2013
VL 17
IS 1
BP E16
EP E19
DI 10.1111/j.1399-3046.2012.01752.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 075PO
UT WOS:000313899200009
PM 22738313
ER

PT J
AU Wakiya, T
   Sanada, Y
   Mizuta, K
   Urahashi, T
   Ihara, Y
   Yamada, N
   Okada, N
   Egami, S
   Nakata, M
   Hakamada, K
   Yasuda, Y
AF Wakiya, T.
   Sanada, Y.
   Mizuta, K.
   Urahashi, T.
   Ihara, Y.
   Yamada, N.
   Okada, N.
   Egami, S.
   Nakata, M.
   Hakamada, K.
   Yasuda, Y.
TI A Comparison of Open Surgery and Endovascular Intervention for Hepatic
   Artery Complications After Pediatric Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID PROTOCOL DOPPLER ULTRASONOGRAPHY; URGENT REVASCULARIZATION; THROMBOSIS;
   RECONSTRUCTION; MANAGEMENT; STENOSIS; IMPACT
AB There are currently 2 major therapeutic options for the treatment of hepatic artery complications: endovascular intervention and open surgery. We herein report a retrospective analysis of 14 pediatric patients with hepatic artery complications after pediatric living donor liver transplantation (LDLT) at our institution. We divided them into an open surgery group and an endovascular intervention group based on their primary treatment, and compared the results and outcomes. We then evaluated which procedure is more effective and less invasive. In the open surgery group, recurrent stenosis or spasm of the hepatic artery occurred in 3 of the 8 patients (37.5%). In the endovascular intervention group, 5 of the 6 patients were technically successfully treated by only endovascular treatment. Of the 5 successfully treated patients, 3 developed recurrent stenosis (60%). There were significant differences in the mean length of the operation for the first treatment of hepatic artery complications (open surgery, 428 minutes vs endovascular intervention, 160 minutes; P = .01) and in the mean value of the posttreatment aspartate aminotransferase (AST)/alanine aminotransferase (ALT) (open surgery > endovascular intervention; P = .04/.05). Although endovascular intervention needs to be examined in further studies to reduce the rate of relapse, it is a less invasive method for the patient and graft than open surgery.
C1 [Wakiya, T.; Sanada, Y.; Mizuta, K.; Urahashi, T.; Ihara, Y.; Yamada, N.; Okada, N.; Egami, S.] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Wakiya, T.; Hakamada, K.] Hirosaki Univ, Sch Med, Dept Surg, Hirosaki, Aomori 036, Japan.
   [Nakata, M.] Jichi Med Univ, Dept Radiol, Shimotsuke, Tochigi 3290498, Japan.
   [Yasuda, Y.] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Wakiya, T (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM wakiya@jichi.ac.jp
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   Heaton N, 2008, BRIT J SURG, V95, P919, DOI 10.1002/bjs.6060
   Heran MKS, 2010, PEDIATR RADIOL, V40, P237, DOI 10.1007/s00247-009-1499-8
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kim BW, 2006, TRANSPLANT P, V38, P3128, DOI 10.1016/j.transproceed.2006.08.164
   Kodama Y, 2006, LIVER TRANSPLANT, V12, P465, DOI 10.1002/lt.20724
   Maruzzelli L, 2010, CARDIOVASC INTER RAD, V33, P1111, DOI 10.1007/s00270-010-9848-4
   Massault PP, 1997, TRANSPLANT P, V29, P439, DOI 10.1016/S0041-1345(96)00178-9
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   NOACK K, 1993, TRANSPLANTATION, V56, P495, DOI 10.1097/00007890-199309000-00001
   Orons P., 2005, J VASC INTERV RADIOL, V6, P523
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Saad Wael E A, 2007, Tech Vasc Interv Radiol, V10, P207, DOI 10.1053/j.tvir.2007.09.015
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Singhal A, 2010, TRANSPL INT, V23, P245, DOI 10.1111/j.1432-2277.2009.01037.x
   Uchida Y, 2009, CLIN TRANSPLANT, V23, P392, DOI 10.1111/j.1399-0012.2008.00924.x
   Wakiya T, 2011, TRANSPL INT, V24, P984, DOI 10.1111/j.1432-2277.2011.01298.x
   Warnaar N, 2010, LIVER TRANSPLANT, V16, P847, DOI 10.1002/lt.22063
NR 23
TC 6
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2013
VL 45
IS 1
BP 323
EP 329
DI 10.1016/j.transproceed.2012.08.012
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 090VD
UT WOS:000315007200065
PM 23375320
ER

PT J
AU Shay, R
   Taber, D
   Pilch, N
   Meadows, H
   Tischer, S
   McGillicuddy, J
   Bratton, C
   Baliga, P
   Chavin, K
AF Shay, R.
   Taber, D.
   Pilch, N.
   Meadows, H.
   Tischer, S.
   McGillicuddy, J.
   Bratton, C.
   Baliga, P.
   Chavin, K.
TI Early Aspirin Therapy May Reduce Hepatic Artery Thrombosis in Liver
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID RISK-FACTORS; SURGERY
AB Background. Hepatic artery thrombosis (HAT) remains among the leading causes of early graft loss after liver transplantation. Our transplant center began using universal aspirin prophylactic therapy immediately posttransplantation in 2007. The aim of this study was to determine the safety and efficacy of early aspirin therapy on clinical outcomes.
   Methods. This large-scale, cross-sectional analysis included all adult liver transplantations performed between 2000 and 2009. Pediatric and multiorgan transplants were excluded. Patients were grouped and compared based on whether they received early initiation of aspirin 325 mg PO daily posttransplantation.
   Results. A total of 541 adult liver transplantations occurred during the study period; 439 had complete documentation and were analyzed. Clinical outcomes show aspirin patients had similar rates of early and late HAT, but had significantly lower early HAT, defined as HAT occurring within the first 30 days posttransplant, leading to graft loss. Other clinical outcomes were similar between groups including bleeding events and wound complications.
   Conclusions. Immediate initiation of aspirin therapy after liver transplantation may reduce the rate of HAT leading to early graft loss, without increasing bleeding or other complication rates.
C1 [Shay, R.; Taber, D.; McGillicuddy, J.; Bratton, C.; Baliga, P.; Chavin, K.] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA.
   [Pilch, N.; Meadows, H.; Tischer, S.] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA.
RP Taber, D (reprint author), Med Univ S Carolina, Div Transplant Surg, 96 Jonathan Lucas St,CSB 409, Charleston, SC 29425 USA.
EM taberd@musc.edu
CR Awtry EH, 2000, CIRCULATION, V101, P1206
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Crossin JD, 2003, RADIOGRAPHICS, V23, P1093, DOI 10.1148/rg.235035031
   Drazan K, 1996, AM SURGEON, V62, P237
   Esch JSA, 2010, PLATELETS, V21, P348, DOI 10.3109/09537101003739897
   Fritsma GA, 2001, JAAPA, V572
   Gluckman TJ, 2011, J AM COLL CARDIOL, V57, P1069, DOI 10.1016/j.jacc.2010.08.650
   Gukop P, 2011, HEART SURG FORUM, V14, pE7, DOI 10.1532/HSF98.20101087
   Heffron TG, 2003, TRANSPLANT P, V35, P1447, DOI 10.1016/S0041-1345(03)00459-7
   Makin AJ, 2003, ABC ANTITHROMBOTIC S, P24
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Patrono D, 2007, NAT CLIN PRACT CARD, V4, P42
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   Vivarelli M, 2007, LIVER TRANSPLANT, V13, P651, DOI 10.1002/lt.21028
   Wolf D C, 1997, Liver Transpl Surg, V3, P598, DOI 10.1002/lt.500030608
NR 15
TC 15
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2013
VL 45
IS 1
BP 330
EP 334
DI 10.1016/j.transproceed.2012.05.075
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 090VD
UT WOS:000315007200066
PM 23267805
ER

PT J
AU Kim, YJ
   Boeckh, M
   Cook, L
   Stempel, H
   Jerome, KR
   Boucek, R
   Burroughs, L
   Englund, JA
AF Kim, Y. -J.
   Boeckh, M.
   Cook, L.
   Stempel, H.
   Jerome, K. R.
   Boucek, R., Jr.
   Burroughs, L.
   Englund, J. A.
TI Cytomegalovirus infection and ganciclovir resistance caused by UL97
   mutations in pediatric transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE CMV; pediatric transplant; UL97 mutation; antiviral
ID SOLID-ORGAN TRANSPLANTATION; STEM-CELL TRANSPLANTATION; ANTIVIRAL DRUGS;
   DISEASE; VIRUS; DNA; GUIDELINES; EMERGENCE; CHILDREN; PATIENT
AB Background Cytomegalovirus (CMV) infection may cause serious disease after hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT), but few reports describe ganciclovir (GCV) resistance in pediatric patients. Objectives This study was performed to describe the clinical impact of CMV infection with UL97 mutation in pediatric transplant recipients. Methods Quantitative surveillance data for CMV infection in pediatric patients between October 2001 and February 2007 at the University of Washington were analyzed. Testing for UL97 mutation was performed in selected patients with prolonged CMV viremia despite therapy. Data associated with the detection of UL97 mutations were reviewed. Results CMV was detected in 89 pediatric transplant recipients. Among these, 39 had undergone HCT and 50 SOT (12 heart, 22 kidney, 15 liver, and 1 bilateral lung transplants). CMV with at least one UL97 sequence variation was detected in 5 patients: 4 HCT recipients (4/39, 10%) and 1 heart transplant recipient (1/50, 2%). All 5 pediatric patients were CMV seropositive before transplantation. Underlying conditions included chronic myelogenous leukemia, primary immunodeficiency disorders, and hypoplastic left heart syndrome. One known GCV drug similar to resistant mutation was detected in 2 HCT recipients (A594V). Three strain variants with mutations considered to have no significant impact on UL97 function (H469Y, N510S, and D605E) were detected. Two of these 5 patients died, 1 because of uncontrolled CMV infection and 1 with other complications. Conclusions UL97 drug-resistant mutations occur in pediatric transplant recipients with CMV viremia and can cause serious disease. Screening for mutations conferring resistance to CMV antivirals should be considered for patients with persistent viremia during therapy and the sequences of UL97 mutations evaluated.
C1 [Kim, Y. -J.; Boeckh, M.; Cook, L.; Jerome, K. R.; Burroughs, L.; Englund, J. A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Kim, Y. -J.; Stempel, H.; Boucek, R., Jr.; Burroughs, L.; Englund, J. A.] Seattle Childrens Hosp, Seattle, WA USA.
   [Kim, Y. -J.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
   [Boeckh, M.; Cook, L.; Jerome, K. R.; Englund, J. A.] Univ Washington, Seattle, WA 98195 USA.
RP Englund, JA (reprint author), 4800 Sand Point Way,NE 5441, Seattle, WA 98105 USA.
EM Janet.englund@seattlechildrens.org
FU Adamas; GlaxoSmith Kline; Roche; ADMA; Chimerix; MedImmune Inc.;
   Novartis Pharmaceuticals Corporation; Sanofi-Pasteur; Boryung Pharm. Co.
   Ltd.
FX Potential conflicts of interest: M.J.B. has disclosed the following
   relevant financial relationships: received grants for clinical research
   from Adamas, GlaxoSmith Kline, and Roche; served as an advisor or
   consultant for Baxter HealthCare Pharmaceuticals and Roche/Genentech,
   Inc. J.A.E. has disclosed the following relevant financial
   relationships: received grants for clinical research from Adamas, ADMA,
   Chimerix, MedImmune Inc., and Novartis Pharmaceuticals Corporation.
   Y.-J.K. has disclosed the following relevant financial relationships:
   received grants for clinical research from Sanofi-Pasteur and Boryung
   Pharm. Co. Ltd.
CR BIRON KK, 1986, P NATL ACAD SCI USA, V83, P8769, DOI 10.1073/pnas.83.22.8769
   Blackman SC, 2004, J PEDIAT HEMATOL ONC, V26, P601, DOI 10.1097/01.mph.0000135283.77668.6a
   Boeckh M, 2003, BIOL BLOOD MARROW TR, V9, P543, DOI 10.1016/S1083-8791(03)00287-8
   Boeckh M, 2004, J CLIN MICROBIOL, V42, P1142, DOI 10.1128/JCM.42.3.1142-1148.2004
   Boivin G, 2005, TRANSPL INFECT DIS, V7, P166, DOI 10.1111/j.1399-3062.2005.00112.x
   Bueno Javier, 2002, Paediatr Drugs, V4, P279, DOI 10.2165/00148581-200204050-00001
   Castor J, 2007, J CLIN MICROBIOL, V45, P2681, DOI 10.1128/JCM.00526-07
   Chou S, 2002, J INFECT DIS, V185, P162, DOI 10.1086/338362
   Chou SW, 2010, ANTIMICROB AGENTS CH, V54, P2371, DOI 10.1128/AAC.00186-10
   Chou SW, 2005, ANTIMICROB AGENTS CH, V49, P2710, DOI 10.1128/AAC.49.7.2710-2715.2005
   Drew WL, 2006, J CLIN VIROL, V35, P485, DOI 10.1016/j.jcv.2005.09.021
   Dykewicz CA, 2001, BIOL BLOOD MARROW TR, V7, p19S, DOI 10.1053/bbmt.2001.v7.pm11777100
   Eckle T, 2002, BONE MARROW TRANSPL, V30, P433, DOI 10.1038/sj.bmt.1703666
   Eckle T, 2000, BLOOD, V96, P3286
   ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505
   Erice A, 1999, CLIN MICROBIOL REV, V12, P286
   Ghisetti V, 2004, J MED VIROL, V73, P223, DOI 10.1002/jmv.20079
   Gilbert C, 2002, DRUG RESIST UPDATE, V5, P88, DOI 10.1016/S1368-7646(02)00021-3
   Hantz S, 2010, J ANTIMICROB CHEMOTH, V65, P2628, DOI 10.1093/jac/dkq368
   Humar A, 2002, J INFECT DIS, V186, P829, DOI 10.1086/342601
   Ijichi O, 2002, ANTIVIR RES, V53, P135, DOI 10.1016/S0166-3542(01)00202-9
   Jabs DA, 2001, J INFECT DIS, V183, P333, DOI 10.1086/317931
   Li F, 2007, CLIN INFECT DIS, V45, P439, DOI 10.1086/519941
   Limaye AP, 2000, LANCET, V356, P645, DOI 10.1016/S0140-6736(00)02607-6
   Lurain NS, 2002, J INFECT DIS, V186, P760, DOI 10.1086/342844
   Patel SR, 2005, J PEDIAT HEMATOL ONC, V27, P411, DOI 10.1097/01.mph.0000174242.80167.9d
   Sia IG, 2000, J INFECT DIS, V181, P717, DOI 10.1086/315242
   STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191
   Tomblyn M, 2009, BONE MARROW TRANSPL, V44, P453, DOI 10.1038/bmt.2009.254
   Torres-Madriz G, 2008, CLIN INFECT DIS, V47, P702, DOI 10.1086/590934
   Trofe J, 2008, ANN PHARMACOTHER, V42, P1447, DOI 10.1345/aph.1L065
   Zhou L, 2006, TRANSPLANT P, V38, P2926, DOI 10.1016/j.transproceed.2006.08.161
NR 32
TC 9
Z9 10
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD DEC
PY 2012
VL 14
IS 6
BP 611
EP 617
DI 10.1111/j.1399-3062.2012.00760.x
PG 7
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 051TA
UT WOS:000312149100018
PM 23198963
ER

PT J
AU Shehata, MR
   Yagi, S
   Okamura, Y
   Iida, T
   Hori, T
   Yoshizawa, A
   Hata, K
   Fujimoto, Y
   Ogawa, K
   Okamoto, S
   Ogura, Y
   Mori, A
   Teramukai, S
   Kaido, T
   Uemoto, S
AF Shehata, M. R.
   Yagi, S.
   Okamura, Y.
   Iida, T.
   Hori, T.
   Yoshizawa, A.
   Hata, K.
   Fujimoto, Y.
   Ogawa, K.
   Okamoto, S.
   Ogura, Y.
   Mori, A.
   Teramukai, S.
   Kaido, T.
   Uemoto, S.
TI Pediatric Liver Transplantation Using Reduced and Hyper-Reduced Left
   Lateral Segment Grafts: A 10-Year Single-Center Experience
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Living-donor liver transplantation; monosegment; partial left lateral
   segment graft; reduced and hyper-reduced graft
ID FULMINANT HEPATIC-FAILURE; INFANTS YOUNGER; MONOSEGMENTS; CHILDREN;
   SIZE; IMMUNOSUPPRESSION; COMPLICATIONS; SURVIVAL; AGE
AB Few studies have examined the long-term outcomes and prognostic factors associated with pediatric living living-donor liver transplantation (LDLT) using reduced and hyper-reduced left lateral segment grafts. We conducted a retrospective, single-center assessment of the outcomes of this procedure, as well as clinical factors that influenced graft and patient survival. Between September 2000 and December 2009, 49 patients (median age: 7 months, weight: 5.45 kg) underwent LDLT using reduced (partial left lateral segment; n = 5, monosegment; n = 26), or hyper-reduced (reduced monosegment grafts; n = 18) left lateral segment grafts. In all cases, the estimated graft-to-recipient body weight ratio of the left lateral segment was more than 4%, as assessed by preoperative computed tomography volumetry, and therefore further reduction was required. A hepatic artery thrombosis occurred in two patients (4.1%). Portal venous complications occurred in eight patients (16.3%). The overall patient survival rate at 1, 3 and 10 years after LDLT were 83.7%, 81.4% and 78.9%, respectively. Multivariate analysis revealed that recipient age of less than 2 months and warm ischemic time of more than 40 min affected patient survival. Pediatric LDLT using reduced and hyper-reduced left lateral segment grafts appears to be a feasible option with acceptable graft survival and vascular complication rates.
C1 [Shehata, M. R.; Yagi, S.; Okamura, Y.; Iida, T.; Hori, T.; Yoshizawa, A.; Hata, K.; Fujimoto, Y.; Ogawa, K.; Okamoto, S.; Ogura, Y.; Mori, A.; Kaido, T.; Uemoto, S.] Kyoto Univ, Dept Hepatobiliary Pancreas & Transplant Surg, Kyoto, Japan.
   [Teramukai, S.] Kyoto Univ, Dept Clin Trial Design & Management, Translat Res Ctr, Kyoto, Japan.
RP Yagi, S (reprint author), Kyoto Univ, Dept Hepatobiliary Pancreas & Transplant Surg, Kyoto, Japan.
EM shintaro@kuhp.kyoto-u.ac.jp
CR Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Broelsch CE, 1990, ANN SURG, V212, P375, DOI 10.1016/ 0270- 9139( 91) 90202- 7]
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   Mazumdar M, 2000, STAT MED, V19, P113, DOI 10.1002/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.3.CO;2-F
   McDonald JC, 1996, ANN SURG, V223, P662
   Mentha G, 1996, TRANSPLANTATION, V62, P1176, DOI 10.1097/00007890-199610270-00026
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Sindhi R, 2005, AM J TRANSPLANT, V5, P96, DOI 10.1111/j.1600-6143.2004.00639.x
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   STRONG R, 1995, SURGERY, V118, P904, DOI 10.1016/S0039-6060(05)80283-1
   Sundaram SS, 2003, LIVER TRANSPLANT, V9, P783, DOI 10.1053/jlts.2003.50104
   Thomas N, 2010, PEDIATR TRANSPLANT, V14, P426, DOI 10.1111/j.1399-3046.2010.01294.x
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 25
TC 15
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD DEC
PY 2012
VL 12
IS 12
BP 3406
EP 3413
DI 10.1111/j.1600-6143.2012.04268.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 047QE
UT WOS:000311854800025
PM 22994696
ER

PT J
AU Otto, AK
   Neal, MD
   Mazariegos, GV
   Slivka, A
   Kane, TD
AF Otto, Alana K.
   Neal, Matthew D.
   Mazariegos, George V.
   Slivka, Adam
   Kane, Timothy D.
TI Endoscopic retrograde cholangiopancreatography is safe and effective for
   the diagnosis and treatment of pancreaticobiliary disease following
   abdominal organ transplant in children
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE endoscopic retrograde cholangiopancreatography; pediatrics;
   transplantation
ID POST-ERCP PANCREATITIS; BILIARY COMPLICATIONS; TECHNICAL OUTCOMES;
   MANAGEMENT; RISK
AB ERCP is a diagnostic and therapeutic imaging modality widely used in adult pancreaticobiliary disease, including the treatment of anastomotic strictures following liver and small bowel transplant. We have previously reported a large series of ERCP in children and demonstrated its safety and utility in pediatric disease. The aim of this study was to evaluate the safety of and indications for ERCP following abdominal organ transplant among pediatric patients by performing a subgroup analysis of our large cohort. Forty-eight ERCPs were performed on 25 children ages 62 days to 20 yr following isolated liver, isolated small bowel, or composite graft transplant. Mean time from transplantation at the time of ERCP was 18 months. The most common indication for ERCP was the evaluation of non-specific hepatobiliary complaints, including abdominal pain and elevated liver enzymes. ERCP was also commonly performed for the evaluation or treatment of known or suspected biliary tree strictures. Seventy-seven percent of cases included therapeutic intervention, including sphincterotomy in 40%, stent placement in 29%, and stone extraction in 19%. The overall complication rate among post-transplant patients was low (2.9%) and not significantly different than the complication rate reported in our previous study. A history of abdominal organ transplant was not associated with an increased risk of complication following ERCP (OR = 0.41, 95% CI = 0.053.33). In our experience, ERCP can be safely performed in children following liver, small bowel, and composite graft transplant with outcomes similar to those seen in a general pediatric population and may be especially useful for the diagnosis and treatment for biliary strictures following transplant. Further investigation of the relationship between the timing of ERCP relative to transplant and the safety of the procedure is needed.
C1 [Otto, Alana K.; Neal, Matthew D.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Div Pediat Gen & Thorac Surg, Pittsburgh, PA 15224 USA.
   [Mazariegos, George V.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Div Pediat Transplantat,Ctr Pediat Transplantat, Pittsburgh, PA 15224 USA.
   [Slivka, Adam] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Med, Pittsburgh, PA 15224 USA.
   [Kane, Timothy D.] Childrens Natl Med Ctr, Div Pediat Gen & Thorac Surg, Washington, DC 20010 USA.
RP Otto, AK (reprint author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh UPMC, Div Pediat Gen & Thorac Surg, 4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM ako9@pitt.edu
OI Mazariegos, George/0000-0002-2624-8632
CR Andriulli A, 2007, AM J GASTROENTEROL, V102, P1781, DOI 10.1111/j.1572-0241.2007.01279.x
   Artifon ELA, 2010, PANCREAS, V39, P530, DOI 10.1097/MPA.0b013e3181c306c0
   Bailey AA, 2008, ENDOSCOPY, V40, P296, DOI 10.1055/s-2007-995566
   Cheng CL, 2006, AM J GASTROENTEROL, V101, P139, DOI 10.1111/j.1572-0241.2006.00380.x
   Morelli G, 2008, GASTROINTEST ENDOSC, V67, P879, DOI 10.1016/j.gie.2007.08.046
   Otto AK, 2011, SURG ENDOSC, V25, P2536, DOI 10.1007/s00464-011-1582-8
   Papachristou GI, 2011, GASTROINTEST ENDOSC, V73, P1165, DOI 10.1016/j.gie.2011.01.024
   Paris C, 2010, J PEDIATR SURG, V45, P938, DOI 10.1016/j.jpedsurg.2010.02.009
   Sanna C, 2009, TRANSPL P, V41, P1319, DOI 10.1016/j.transproceed.2009.03.086
   Sanna C, 2011, GUT LIVER, V5, P328, DOI 10.5009/gnl.2011.5.3.328
   Varadarajulu S, 2004, GASTROINTEST ENDOSC, V60, P367, DOI 10.1016/S0016-5107(04)01721-3
   Varadarajulu S, 2006, GASTROINTEST ENDOSC, V64, P338, DOI 10.1016/j.gie.2005.05.016
NR 12
TC 5
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2012
VL 16
IS 8
BP 829
EP 834
DI 10.1111/j.1399-3046.2012.01771.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 033NM
UT WOS:000310804300018
PM 22905881
ER

PT J
AU Backes, AN
   Tannuri, ACA
   de Mello, ES
   Gibelli, NEM
   Andrade, WD
   Tannuri, U
AF Backes, Ariane N.
   Tannuri, Ana Cristina A.
   de Mello, Evandro Sobroza
   Gibelli, Nelson Elias M.
   Andrade, Wagner de Castro
   Tannuri, Uenis
TI Transmission of clear cell tumor in a graft liver from cadaveric donor:
   Case report
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE complications of liver transplantation; liver transplantation;
   malignancy; pediatric liver transplantation; children; pediatrics
ID TRANSPLANT RECIPIENTS; ALLOGRAFT RECIPIENTS; MALIGNANT-MELANOMA;
   CARCINOMA
AB Neoplasms in children after organ transplantation are related to the type and intensity of immunosuppression and the donorrecipient serostatus, especially in relation to the EpsteinBarr virus. The patient was a two-yr-old female child with biliary atresia who underwent a liver transplantation from a female cadaver donor. Two adults received kidney transplants from the same donor. Nine months after transplantation, one of the adult recipients developed an urothelial tumor in the kidney graft. Imaging tests were repeated monthly in the liver-transplanted child and revealed no abnormalities. However, one yr and two months after the transplantation, the patient developed episodes of fever. At that time, imaging and liver biopsy showed a clear cell tumor of urothelial origin in the graft and the disease was limited to the liver. The patient underwent liver retransplantation, and she is currently free of tumor recurrence. Although rare, the occurrence of tumors in the post-transplant period from cadaver donors, without previously diagnosed tumors, is one of the many problems encountered in the complex world of organ transplantation.
C1 [Tannuri, Uenis] Univ Sao Paulo, Fac Med, Sch Med, Pediat Surg & Liver Transplantat Div, BR-01246903 Sao Paulo, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Fac Med, Sch Med, Pediat Surg & Liver Transplantat Div, Ave Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM uenist@usp.br
RI Tannuri, Ana Cristina Aoun/C-4718-2012; Tannuri, Uenis/D-3876-2012;
   Gibelli, Nelson Elias Mendes/I-7176-2016
CR Baehner R, 2000, HUM PATHOL, V31, P1425, DOI 10.1016/S0046-8177(00)80015-5
   Birkeland SA, 2002, TRANSPLANTATION, V74, P1409, DOI 10.1097/01.TP.0000034717.19606.B5
   Buell JF, 2005, TRANSPLANTATION, V80, pS254, DOI 10.1097/01.tp.0000186382.81130.ba
   Kasiske BL, 2004, AM J TRANSPLANT, V4, P905, DOI 10.1111/j.1600-6143.2004.00450.x
   Kauffman HM, 2002, TRANSPLANTATION, V74, P358
   Kim KK, 2009, CLIN TRANSPLANT, V23, P571
   Loren AW, 2003, TRANSPLANTATION, V76, P741, DOI 10.1097/01.TP.0000080561.31826.FE
   Morath C, 2005, TRANSPLANTATION, V80, pS164, DOI 10.1097/01.tp.0000186911.54901.21
   Morris-Stiff G, 2004, AM J TRANSPLANT, V4, P444, DOI 10.1111/j.1600-6143.2004.00335.x
   Penn I, 1996, TRANSPLANTATION, V61, P274, DOI 10.1097/00007890-199601270-00019
   Penn I, 1997, Ann Transplant, V2, P7
   Pinho-Apezzato ML, 2010, TRANSPL P, V42, P1763, DOI 10.1016/j.transproceed.2010.01.077
   SCHMIDT R, 1995, BRIT J UROL, V75, P572, DOI 10.1111/j.1464-410X.1995.tb07409.x
   Scolfaro C, 2008, TRANSPL INFECT DIS, V10, P431, DOI 10.1111/j.1399-3062.2008.00326.x
   Stephens JK, 2000, TRANSPLANTATION, V70, P232
   Tyden G, 2000, TRANSPLANTATION, V70, P1650
   Wu CY, 2007, PEDIATR TRANSPLANT, V11, P811, DOI 10.1111/j.1399-3046.2007.00779.x
NR 17
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2012
VL 16
IS 8
BP E352
EP E355
DI 10.1111/j.1399-3046.2012.01711.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 033NM
UT WOS:000310804300005
PM 22574830
ER

PT J
AU Vernadakis, S
   Paul, A
   Kykalos, S
   Fouzas, I
   Kaiser, GM
   Sotiropoulos, GC
AF Vernadakis, S.
   Paul, A.
   Kykalos, S.
   Fouzas, I.
   Kaiser, G. M.
   Sotiropoulos, G. C.
TI Incarcerated Diaphragmatic Hernia After Right Hepatectomy for Living
   Donor Liver Transplantation: Case Report of an Extremely Rare Late Donor
   Complication
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 16th Panhellenic Transplantation Congress
CY NOV 25-27, 2011
CL Thessaloniki, GREECE
SP Hellen Transplantat Soc
AB Living donor liver transplantation has evolved to an indispensable surgical strategy to minimize the mortality of adult and pediatric patients awaiting transplantation. The crucial prerequisite to performing this procedure is a minimal risk of donor morbidity and mortality. A 46-year-old woman underwent right hepatectomy for living donor liver transplantation. Two and a half years after liver donation, she presented with upper abdominal pain and fullness. Radiographic evaluation revealed an incarcerated diaphragmatic hernia of the right hemithorax. After emergency laparotomy and evaluation of the right hemithorax, a partial jejunal resection was performed due to ischemic findings. The diaphragmatic hernia was repaired. Diaphragmatic hernia is a rarely reported complication of right donor hepatectomy for transplantation and should be considered to be a potential late complication.
C1 [Vernadakis, S.; Paul, A.; Kykalos, S.; Fouzas, I.; Kaiser, G. M.; Sotiropoulos, G. C.] Univ Hosp Essen, Dept Gen Visceral & Transplantat Surg, Essen, Germany.
RP Vernadakis, S (reprint author), Hufelandstr 55, D-45147 Essen, Germany.
EM svernadakis@yahoo.com
CR Eren S, 2005, EUR J RADIOL, V54, P448, DOI 10.1016/j.ejrad.2004.09.008
   Ghobrial RM, 2008, GASTROENTEROLOGY, V135, P468, DOI 10.1053/j.gastro.2008.04.018
   Hawxby Alan M, 2006, Hepatobiliary Pancreat Dis Int, V5, P459
   Sugita M, 2003, Surg Endosc, V17, P1849, DOI 10.1007/s00464-002-4554-1
NR 4
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2012
VL 44
IS 9
BP 2770
EP 2772
DI 10.1016/j.transproceed.2012.09.014
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 043GO
UT WOS:000311531100080
PM 23146519
ER

PT J
AU Venturi, C
   Sempoux, C
   Bueno, J
   Pinas, JC
   Bourdeaux, C
   Abarca-Quinones, J
   Rahier, J
   Reding, R
AF Venturi, C.
   Sempoux, C.
   Bueno, J.
   Ferreres Pinas, J. C.
   Bourdeaux, C.
   Abarca-Quinones, J.
   Rahier, J.
   Reding, R.
TI Novel Histologic Scoring System for Long-Term Allograft Fibrosis After
   Liver Transplantation in Children
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Children; liver fibrosis; liver transplantation; long term; scoring
ID CHRONIC HEPATITIS-C; FOLLOW-UP; TRANSIENT ELASTOGRAPHY; GRAFT FIBROSIS;
   IMAGE-ANALYSIS; RECIPIENTS; DISEASE; COMPLICATIONS; DIAGNOSIS; CIRRHOSIS
AB The existing systems for scoring fibrosis were not developed to evaluate transplanted livers. Our aim was to design and validate a novel fibrosis scoring system specifically adapted to assess liver allograft fibrosis (LAF). Clinical data, histology, transient elastography (TE) and AST/platelet ratio index (APRI) were reviewed in 38 pediatric liver transplant (LT) recipients. Protocol liver biopsies performed at 6 months and 7 years post-LT were reviewed by three pathologists who assessed LAF using the METAVIR and Ishak systems. LAF was also scored separately in portal (03), sinusoidal (03) and centrolobular areas (03). Scoring evaluations were correlated with fibrosis quantification using morphometry, and also with TE and APRI. Statistical correlations between morphometry and METAVIR were 0.571 (p < 0.000) and 0.566 (p < 0.000) for the Ishak system. The novel score (09) for separate assessment of portal, sinusoidal and centrolobular fibrosis showed a better correlation with morphometry (0.731; p < 0.000) and high intra-/interobserver agreement (0.966; p < 0.000 and 0.794; p < 0.000, respectively). No correlation was found between TE or APRI and morphometry or the three histologic scores. In conclusion, this novel semiquantitative fibrosis scoring system seems to more accurately reflect LAF than the existing scoring system and may become a practical tool for staging fibrosis in LT.
C1 [Venturi, C.; Bourdeaux, C.; Reding, R.] Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, B-1200 Brussels, Belgium.
   [Sempoux, C.; Rahier, J.] Catholic Univ Louvain, Clin Univ St Luc, Dept Pathol, B-1200 Brussels, Belgium.
   [Bueno, J.] Autonomous Univ Barcelona, Pediat Digest Surg & Transplant Unit, E-08193 Barcelona, Spain.
   [Ferreres Pinas, J. C.] Autonomous Univ Barcelona, Hosp Vall dHebron, Dept Pathol, E-08193 Barcelona, Spain.
   [Abarca-Quinones, J.] Catholic Univ Louvain, Gastroenterol Lab, B-1200 Brussels, Belgium.
RP Venturi, C (reprint author), Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, B-1200 Brussels, Belgium.
EM carla.venturi@uclouvain.be
CR Abdalla Ahmed F, 2009, Fibrogenesis Tissue Repair, V2, P2, DOI 10.1186/1755-1536-2-2
   Abraham SC, 2008, AM J SURG PATHOL, V32, P1479, DOI 10.1097/PAS.0b013e31817a8e96
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   Breton E, 2009, ARCH PEDIATRIE, V16, P1005, DOI 10.1016/j.arcped.2009.03.021
   Brunt EM, 2010, WORLD J GASTROENTERO, V16, P5286, DOI 10.3748/wjg.v16.i42.5286
   Castera L, 2006, HEPATOLOGY, V43, P373, DOI 10.1002/hep.21019
   CHEVALLIER M, 1995, ANN PATHOL, V15, P372
   CHEVALLIER M, 1994, HEPATOLOGY, V20, P349, DOI 10.1016/0270-9139(94)90185-6
   Demetris A, 2000, Hepatology, V31, P792
   Dumortier J, 2010, AM J GASTROENTEROL, V105, P613, DOI 10.1038/ajg.2009.717
   Egawa H, 2012, HEPATOL RES
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Fischer HP, 1996, J HEPATOL, V24, P35
   Foucher J, 2006, GUT, V55, P403, DOI 10.1136/gut.2005.069153
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   GARVEY W, 1984, STAIN TECHNOL, V59, P213
   GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237
   Goodman ZD, 2007, HEPATOLOGY, V45, P886, DOI 10.1002/hep.21595
   Goodman ZD, 2007, J HEPATOL, V47, P598, DOI 10.1016/j.jhep.2007.07.006
   Gouw ASH, 2002, TRANSPLANTATION, V73, P243, DOI 10.1097/00007890-200201270-00016
   Herzog D, 2008, LIVER TRANSPLANT, V14, P946, DOI 10.1002/lt.21444
   Huss Sebastian, 2010, Fibrogenesis Tissue Repair, V3, P10, DOI 10.1186/1755-1536-3-10
   ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6
   JIMENEZ W, 1985, HEPATOLOGY, V5, P815, DOI 10.1002/hep.1840050517
   Kelly DA, 2006, PEDIATR TRANSPLANT, V10, P712, DOI 10.1111/j.1399-3046.2006.00567.x
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511
   Martin SR, 2002, TRANSPLANTATION, V74, P828, DOI 10.1097/00007890-200209270-00017
   Menghini G, 1971, Quad Sclavo Diagn, V7, P1213
   Mieli-Vergani G, 2011, BEST PRACT RES CL GA, V25, P783, DOI 10.1016/j.bpg.2011.10.007
   ORREGO H, 1979, GUT, V20, P673, DOI 10.1136/gut.20.8.673
   Peeters PMJG, 2000, TRANSPLANTATION, V70, P1581, DOI 10.1097/00007890-200012150-00008
   Pilette C, 1998, J HEPATOL, V28, P439, DOI 10.1016/S0168-8278(98)80318-8
   PUCHTLER H, 1988, HISTOCHEMISTRY, V88, P243
   Reding R, 2003, LANCET, V362, P2068, DOI 10.1016/S0140-6736(03)15104-5
   Rosenthal P, 1997, Liver Transpl Surg, V3, P559
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Scheuer Peter J, 2002, Clin Liver Dis, V6, P335, DOI 10.1016/S1089-3261(02)00009-0
   Scheuer PJ, 2003, HEPATOLOGY, V38, P1356, DOI 10.1016/j.hep.2003.10.010
   Shaheen AAM, 2007, HEPATOLOGY, V46, P912, DOI 10.1002/hep.21835
   Talwalkar JA, 2007, CLIN GASTROENTEROL H, V5, P1214, DOI 10.1016/j.cgh.2007.07.020
   Valls C, 2005, AM J ROENTGENOL, V184, P812
   Van Hul NKM, 2009, HEPATOLOGY, V49, P1625, DOI 10.1002/hep.22820
   Venturi C, 2011, PEDIATR TRANSPLANT, V15, P449, DOI 10.1111/j.1399-3046.2011.01511.x
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   Witters P, 2009, J CYST FIBROS, V8, P392, DOI 10.1016/j.jcf.2009.08.001
   [Anonymous], 1994, HEPATOLOGY 1
NR 50
TC 15
Z9 16
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2012
VL 12
IS 11
BP 2986
EP 2996
DI 10.1111/j.1600-6143.2012.04210.x
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 029EW
UT WOS:000310478600017
PM 22882699
ER

PT J
AU Imadome, KI
   Fukuda, A
   Kawano, F
   Imai, Y
   Ichikawa, S
   Mochizuki, M
   Shigeta, T
   Kakiuchi, T
   Sakamoto, S
   Kasahara, M
   Fujiwara, S
AF Imadome, Ken-Ichi
   Fukuda, Akinari
   Kawano, Fuyuko
   Imai, Yumi
   Ichikawa, Sayumi
   Mochizuki, Masashi
   Shigeta, Takanobu
   Kakiuchi, Toshihiko
   Sakamoto, Seisuke
   Kasahara, Mureo
   Fujiwara, Shigeyoshi
TI Effective control of Epstein-Barr virus infection following pediatric
   liver transplantation by monitoring of viral DNA load and lymphocyte
   surface markers
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE Epstein-Barr virus; lymphoproliferative disorder; liver transplantation;
   real-time PCR; tetramer; flow cytometry; LMP2
ID POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; STEM-CELL TRANSPLANTATION;
   EBV REACTIVATION; QUANTITATIVE-ANALYSIS; HIGH-RISK; RECIPIENTS;
   DISORDERS; THERAPY; PCR; RECONSTITUTION
AB Imadome K-I, Fukuda A, Kawano F, Imai Y, Ichikawa S, Mochizuki M, Shigeta T, Kakiuchi T, Sakamoto S, Kasahara M, Fujiwara S. Effective control of EpsteinBarr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers. Abstract: EBV-associated PTLD is a serious complication of liver transplantation. We performed periodical molecular EBV monitoring in 140 consecutive pediatric patients who had living-related liver transplantation in the National Center for Child Health and Development, Tokyo. Sixty-three of the 140 patients showed elevation of EBV DNA level to >102 copies/mu g DNA and were further examined immunologically by flow cytometry, and the dose of tacrolimus and/or cyclosporine A was adjusted according to the results. The decrease in CD4/CD8 ratio and the increase in the number of HLA-DR+CD8+ cells were observed in parallel with the decrease in EBV DNA load and in the number of CD19+CD23+ cells following the reduction in immunosuppressive drugs. Analysis with HLA tetramers in a patient demonstrated a dramatic increase in the number of CD8+ T cells specific to the EBV latent protein LMP2 accompanying the decline of EBV DNA load, suggesting that T cells of this specificity were actually involved in the control of EBV infection. No clinically apparent PTLD has developed in the 140 recipients, suggesting that our program of EBV control by molecular EBV monitoring coupled with lymphocyte phenotype analyses is effective in controlling EBV infection in pediatric liver transplant recipients.
C1 [Imadome, Ken-Ichi; Kawano, Fuyuko; Imai, Yumi; Ichikawa, Sayumi; Mochizuki, Masashi; Fujiwara, Shigeyoshi] Natl Res Inst Child Hlth & Dev, Dept Infect Dis, Setagaya Ku, Tokyo 1578535, Japan.
   [Fukuda, Akinari; Shigeta, Takanobu; Kakiuchi, Toshihiko; Sakamoto, Seisuke; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Div Transplant Surg, Setagaya Ku, Tokyo, Japan.
RP Fujiwara, S (reprint author), Natl Res Inst Child Hlth & Dev, Dept Infect Dis, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM imadome@nch.go.jp; shige@nch.go.jp
OI Fukuda, Akinari/0000-0003-4684-0446
FU National Center for Child Health and Development [21A-4, 22A-9]; 
   [21591404];  [22590374];  [22590430]
FX We thank Norio Shimizu and Ken Watanabe for technical advice on the
   measurement of EBV DNA load by real-time PCR. This study was supported
   by The Grant of National Center for Child Health and Development (21A-4
   and 22A-9) and the Grant-in-Aid for Scientific Research (C) (21591404,
   22590374, and 22590430).
CR Allen UD, 2005, PEDIATR TRANSPLANT, V9, P450, DOI 10.1111/j.1399-3046.2005.00318.x
   Annels NE, 2006, CLIN INFECT DIS, V42, P1743, DOI 10.1086/503838
   Axelrod DA, 2003, PEDIATR TRANSPLANT, V7, P223, DOI 10.1034/j.1399-3046.2003.00080.x
   Bingler MA, 2008, AM J TRANSPLANT, V8, P442, DOI 10.1111/j.1600-6143.2007.02080.x
   Cacciarelli TV, 2001, PEDIATR TRANSPLANT, V5, P359, DOI 10.1034/j.1399-3046.2001.00021.x
   Clave E, 2004, TRANSPLANTATION, V77, P76, DOI 10.1097/01.TP.0000093997.83754.2B
   D'Alessandro AM, 2007, PEDIATR TRANSPLANT, V11, P661, DOI 10.1111/j.1399-3046.2007.00737.x
   D'Antiga L, 2007, LIVER TRANSPLANT, V13, P343, DOI 10.1002/lt.20958
   Fernandez MC, 2009, PEDIATR TRANSPLANT, V13, P307, DOI 10.1111/j.1399-3046.2008.00914.x
   Green M, 2009, PEDIATR TRANSPLANT, V13, P319, DOI 10.1111/j.1399-3046.2008.00926.x
   Gregorek H, 2010, PEDIATR TRANSPLANT, V14, P629, DOI 10.1111/j.1399-3046.2010.01293.x
   Hislop AD, 2007, ANNU REV IMMUNOL, V25, P587, DOI 10.1146/annurev.immunol.25.022106.141553
   Holmes RD, 2002, PEDIATR TRANSPLANT, V6, P456, DOI 10.1034/j.1399-3046.2002.02043.x
   Holmes RD, 2002, TRANSPLANTATION, V74, P367, DOI 10.1097/00007890-200208150-00013
   Kimura H, 1999, J CLIN MICROBIOL, V37, P132
   Leblond V, 2004, J HEPATOL, V40, P728, DOI 10.1016/j.jhep.2004.03.006
   Lee TC, 2005, AM J TRANSPLANT, V5, P2222, DOI 10.1111/j.1600-6143.2005.01002.x
   Macedo C, 2011, J IMMUNOL, V186, P5854, DOI 10.4049/jimmunol.1001024
   Meij P, 2003, BLOOD, V101, P4290, DOI 10.1182/blood-2002-10-3001
   Nakamura H, 1998, INT J CANCER, V76, P587, DOI 10.1002/(SICI)1097-0215(19980518)76:4<587::AID-IJC23>3.0.CO;2-3
   Newell KA, 1996, TRANSPLANTATION, V62, P370, DOI 10.1097/00007890-199608150-00012
   Nourse JP, 2011, AM J TRANSPLANT, V11, P888, DOI 10.1111/j.1600-6143.2011.03499.x
   Opelz G, 2009, TRANSPLANTATION, V88, P962, DOI 10.1097/TP.0b013e3181b9692d
   Pageaux GP, 1998, TRANSPLANTATION, V65, P397, DOI 10.1097/00007890-199802150-00018
   Paya CV, 1999, TRANSPLANTATION, V68, P1517, DOI 10.1097/00007890-199911270-00015
   Rickinson AB, 2007, FIELDS VIROLOGY, P2655
   Rosselet A, 2009, CLIN TRANSPLANT, V23, P74, DOI 10.1111/j.1399-0012.2008.00904.x
   Rowe DT, 1997, J CLIN MICROBIOL, V35, P1612
   Schaffer K, 2011, LIVER TRANSPLANT, V17, P1420, DOI 10.1002/lt.22406
   Sebelin-Wulf K, 2007, TRANSPL IMMUNOL, V17, P203, DOI 10.1016/j.trim.2006.10.006
   Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165
   Takeuchi K, 2006, PATHOL INT, V56, P112, DOI 10.1111/j.1440-1827.2006.01936.x
   Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4
   van Esser JWJ, 2001, BLOOD, V98, P972, DOI 10.1182/blood.V98.4.972
NR 34
TC 11
Z9 11
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2012
VL 16
IS 7
BP 748
EP 757
DI 10.1111/j.1399-3046.2012.01750.x
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 014VG
UT WOS:000309403200032
PM 22764883
ER

PT J
AU Dopazo, C
   Gupte, GL
   Sharif, K
   Perera, MTPR
   Hartley, J
   Muiesan, P
   Mayer, DA
   Bromley, P
   Bennett, J
   Kelly, DA
   van Mourik, I
   Mckiernan, P
   Beath, SV
   Mirza, DF
AF Dopazo, Cristina
   Gupte, Girish L.
   Sharif, Khalid
   Perera, M. Thamara P. R.
   Hartley, Jane
   Muiesan, Paolo
   Mayer, David A.
   Bromley, Peter
   Bennett, John
   Kelly, Deidre A.
   van Mourik, Indra
   Mckiernan, Patrick
   Beath, Sue V.
   Mirza, Darius F.
TI Combined Liver-Intestine Grafts Compared With Isolated Intestinal
   Transplantation in Children: A Single-Center Experience
SO TRANSPLANTATION
LA English
DT Article
DE Pediatric intestinal transplantation; Patient survival; Postoperative
   complications
ID SMALL-BOWEL TRANSPLANTATION; MULTIVISCERAL TRANSPLANTATION;
   UNITED-STATES; FAILURE; THROMBOCYTOPENIA; DONOR; PREDICTORS; STRATEGIES;
   RECIPIENTS; EVOLUTION
AB Background. Intestinal transplantation is known to be associated with a high risk of early complications and mortality.
   Methods. We analyzed prospective data of 51 primary small bowel transplantations from December 1999 to August 2009 and identified perioperative factors that impact on early mortality (<= 6 months after transplantation) after isolated intestinal (IITx; n=12) and combined liver-intestinal transplantation (CLITx group; n=39).
   Results. Ten patients died during the first 6 months after transplantation, all of them in CLITx group (n=10/51, 19%). Multivariate analyses demonstrated intraoperative red blood cell transfusion greater than 70 mL/kg (P=0.019, odds ratio [OR]=13.79) and base excess 30-min after reperfusion less than -16 (P=0.001, OR=14.05), thrombocytopenia (<50,000 per dL) between day 1 and day 15 after transplantation (P=0.047, OR=5.22), and occurrence of vascular complications (P=0.003, OR=8.96) during the posttransplantation period as predictors of early mortality in CLITx group.
   Conclusion. Risk of mortality at 6 months after intestinal transplantation increased when the liver is included as combined graft. Strategies to reduce mortality such as refining selection for transplantation and early referral before the development of liver failure should be a priority.
C1 [Dopazo, Cristina; Gupte, Girish L.; Sharif, Khalid; Perera, M. Thamara P. R.; Hartley, Jane; Muiesan, Paolo; Kelly, Deidre A.; van Mourik, Indra; Mckiernan, Patrick; Beath, Sue V.; Mirza, Darius F.] Birmingham Childrens Hosp, Liver Unit Including Small Bowel Transplantat, Birmingham, W Midlands, England.
   [Perera, M. Thamara P. R.; Muiesan, Paolo; Mayer, David A.; Mirza, Darius F.] Univ Hosp Birmingham, Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.
   [Bromley, Peter; Bennett, John] Birmingham Childrens Hosp, Dept Anesthesia & Crit Care, Birmingham, W Midlands, England.
RP Mirza, DF (reprint author), Univ Hosp Birmingham, Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.
EM darius.mirza@uhb.nhs.uk
OI Muiesan, Paolo/0000-0002-7389-6691
CR Abu-Elmagd K, 2000, ANN SURG, V232, P680, DOI 10.1097/00000658-200011000-00010
   Abu-Elmagd KM, 2009, TRANSPL INT, V22, P96, DOI 10.1111/j.1432-2277.2008.00785.x
   Beath S, 2008, TRANSPLANTATION, V85, P1378, DOI 10.1097/TP.0b013e31816dd513
   Berg CL, 2009, AM J TRANSPLANT, V9, P907, DOI 10.1111/j.1600-6143.2009.02567.x
   Bueno J, 1999, J PEDIATR SURG, V34, P27, DOI 10.1016/S0022-3468(99)90223-3
   Chang FY, 2000, TRANSPLANTATION, V69, P70, DOI 10.1097/00007890-200001150-00014
   Chang JH, 2008, WORLD J GASTROENTERO, V14, P5723, DOI 10.3748/wjg.14.5723
   Corno V, 2005, TRANSPLANT P, V37, P1141, DOI 10.1016/j.transproceed.2004.11.034
   de Ville de Goyet J, 2000, TRANSPLANTATION, V69, P55
   Gaynor JJ, 2006, TRANSPLANTATION, V81, P1133, DOI 10.1097/01.tp.0000205754.58604.a8
   Giovanelli M, 2009, TRANSPLANTATION, V87, P1695, DOI 10.1097/TP.0b013e3181a5e9f8
   Girish GL, 2010, J PEDIATR SURG, V45, P1473
   Grant D, 2005, ANN SURG, V241, P607, DOI 10.1097/01.sla.0000157265.85388.a1
   Gupte GL, 2007, ARCH DIS CHILD, V92, P147, DOI 10.1136/adc.2005.090068
   Ishii T, 2003, PEDIATR TRANSPLANT, V7, P185, DOI 10.1034/j.1399-3046.2003.00063.x
   Kato T, 2006, TRANSPLANT P, V38, P1705, DOI 10.1016/j.transproceed.2006.05.060
   Kato T, 2006, ANN SURG, V243, P756, DOI 10.1097/01.sla.0000219696.11261.13
   Kumar GK, 2010, PEDIATR SURG INT, V26, P423, DOI 10.1007/s00383-010-2564-y
   Mazariegos GV, 2010, AM J TRANSPLANT, V10, P1020, DOI 10.1111/j.1600-6143.2010.03044.x
   Mazariegos George V, 2009, Curr Gastroenterol Rep, V11, P226
   MCCAUGHAN GW, 1992, J HEPATOL, V16, P16, DOI 10.1016/S0168-8278(05)80089-3
   Pirenne J, 2009, CURR OPIN ORGAN TRAN, V14, P250, DOI 10.1097/MOT.0b013e32832b2eb7
   Reyes J, 1998, J PEDIATR SURG, V33, P243, DOI 10.1016/S0022-3468(98)90440-7
   Sauvat F, 2006, TRANSPLANT P, V38, P1689, DOI 10.1016/j.transproceed.2006.05.033
   Sheth J, 2012, PEDIATR TRANSPLANT, V16, P36, DOI 10.1111/j.1399-3046.2011.01597.x
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Siniscalchi A, 2006, TRANSPLANT P, V38, P1148, DOI 10.1016/j.transproceed.2006.02.010
   Siniscalchi A, 2006, TRANSPLANT P, V38, P820, DOI 10.1016/j.transproceed.2006.01.035
   Siniscalchi A, 2007, TRANSPLANTATION, V84, P346, DOI 10.1097/01.tp.0000275376.63674.1c
   Sudan DL, 2002, TRANSPLANT P, V34, P940, DOI 10.1016/S0041-1345(02)02681-7
   Westrope C, 2011, PEDIATR TRANSPLANT, V15, pE96, DOI 10.1111/j.1399-3046.2010.01298.x
NR 31
TC 8
Z9 9
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD OCT 27
PY 2012
VL 94
IS 8
BP 859
EP 865
DI 10.1097/TP.0b013e318265c508
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 027PN
UT WOS:000310365400014
PM 23018880
ER

PT J
AU Murase, K
   Chihara, Y
   Takahashi, K
   Okamoto, S
   Segawa, H
   Fukuda, K
   Tanaka, K
   Uemoto, S
   Mishima, M
   Chin, K
AF Murase, Kimihiko
   Chihara, Yuichi
   Takahashi, Kenichi
   Okamoto, Shinya
   Segawa, Hajime
   Fukuda, Kazuhiko
   Tanaka, Koichi
   Uemoto, Shinji
   Mishima, Michiaki
   Chin, Kazuo
TI Use of noninvasive ventilation for pediatric patients after liver
   transplantation: Decrease in the need for reintubation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID POSITIVE AIRWAY PRESSURE; POSTOPERATIVE PULMONARY COMPLICATIONS;
   RANDOMIZED CONTROLLED-TRIAL; EXTUBATION FAILURE; MECHANICAL VENTILATION;
   RESPIRATORY-FAILURE; INTENSIVE-CARE; RISK-FACTORS; HYPOXEMIA; OUTCOMES
AB Noninvasive ventilation (NIV) refers to ventilation delivered through a noninvasive interface (a nasal or face mask) rather than an invasive interface (an endotracheal tube or tracheostomy). The role of NIV in preventing reintubation after abdominal surgery in pediatric patients is uncertain. Therefore, we evaluated the role of NIV for this purpose in pediatric patients after liver transplantation. We successfully started using NIV for respiratory complications (RCs) in pediatric patients undergoing liver transplantation in 1999. For this report, we screened all medical records of patients under the age of 12 years who underwent liver transplantation between 2001 and 2009, and we retrieved data for cases at high risk of extubation failure. We retrospectively compared the clinical outcomes of patients who received NIV during their intensive care unit (ICU) stay and patients who did not. Data for 94 cases (92 patients) were included in this analysis. NIV was used in 47 patients during their ICU stay. The rate of reintubation for RCs was significantly lower in NIV patients versus non-NIV patients [3/47 (6.4%) versus 11/47 (23.4%), P = 0.02]. Furthermore, the discharge rate from the ICU was significantly better for NIV patients versus non-NIV patients. The use of NIV after extubation prevented the worsening of atelectasis and stabilized respiratory conditions in this cohort. No major changes in operative procedures or other treatments during the examined period were found. In conclusion, NIV is acceptable and promising for the respiratory management of pediatric patients undergoing liver transplantation. Its use may stabilize respiratory conditions and decrease the need for reintubation in pediatric liver transplant patients, and it may also facilitate an early ICU discharge. Liver Transpl 18:1217-1225, 2012. (c) 2012 AASLD.
C1 [Chin, Kazuo] Kyoto Univ, Grad Sch Med, Dept Resp Care & Sleep Control Med, Sakyo Ku, Kyoto 6068507, Japan.
   [Murase, Kimihiko; Chihara, Yuichi; Mishima, Michiaki] Kyoto Univ, Grad Sch Med, Dept Resp Med, Kyoto 6068507, Japan.
   [Segawa, Hajime; Fukuda, Kazuhiko] Kyoto Univ, Grad Sch Med, Dept Anesthesiol, Kyoto 6068507, Japan.
   [Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg & Transplantat, Kyoto 6068507, Japan.
   [Takahashi, Kenichi] Red Cross Otsu Hosp, Dept Resp Med, Otsu, Shiga, Japan.
   [Okamoto, Shinya] Kyoto Univ Hosp, Dept Pediat Surg, Kyoto 606, Japan.
   [Tanaka, Koichi] Fdn Biomed Res & Innovat, Kobe, Hyogo, Japan.
RP Chin, K (reprint author), Kyoto Univ, Grad Sch Med, Dept Resp Care & Sleep Control Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM chink@kuhp.kyoto-u.ac.jp
FU Japanese Ministry of Education, Culture, Sports, Science, and
   Technology; Respiratory Failure Research Group (Japanese Ministry of
   Health, Labor, and Welfare); Japan Vascular Disease Research Foundation
FX This work was supported by grants from the Japanese Ministry of
   Education, Culture, Sports, Science, and Technology, the Respiratory
   Failure Research Group (Japanese Ministry of Health, Labor, and
   Welfare), and the Japan Vascular Disease Research Foundation.
CR Araz C, 2004, TRANSPLANT P, V36, P214, DOI 10.1016/j.transproceed.2003.11.029
   Chihara Y, 2011, LIVER TRANSPLANT, V17, P144, DOI 10.1002/lt.22207
   Chin K, 2005, LIVER TRANSPLANT, V11, P188, DOI 10.1002/lt.20297
   Edmunds S, 2001, CHEST, V119, P897, DOI 10.1378/chest.119.3.897
   Epstein SK, 2009, RESP CARE, V54, P198
   Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489
   Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736
   Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345
   Frutos-Vivar F, 2006, CHEST, V130, P1664, DOI 10.1378/chest.130.6.1664
   Hasegawa S, 1996, TRANSPLANTATION, V62, P943, DOI 10.1097/00007890-199610150-00012
   Javouhey E, 2008, INTENS CARE MED, V34, P1608, DOI 10.1007/s00134-008-1150-4
   Keenan SP, 2002, JAMA-J AM MED ASSOC, V287, P3238, DOI 10.1001/jama.287.24.3238
   Kurachek SC, 2003, CRIT CARE MED, V31, P2657, DOI 10.1097/01.CCM.0000094228.90557.85
   LINDBERG P, 1992, ACTA ANAESTH SCAND, V36, P546
   LINDNER KH, 1987, CHEST, V92, P66, DOI 10.1378/chest.92.1.66
   Mayordomo-Colunga J, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-29
   Norregaard O, 2002, EUR RESPIR J, V20, P1332, DOI 10.1183/09031936.02.00404802
   ROSENBERG J, 1994, EUR J SURG, V160, P137
   Schechter MS, 2007, RESP CARE, V52, P1382
   Squadrone V, 2005, JAMA-J AM MED ASSOC, V293, P589, DOI 10.1001/jama.293.5.589
   STOCK MC, 1985, CHEST, V87, P151, DOI 10.1378/chest.87.2.151
   Thomas K, 1999, CRIT CARE MED, V27, P1594, DOI 10.1097/00003246-199908000-00035
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Xue FS, 1999, ANESTH ANALG, V88, P213, DOI 10.1097/00000539-199901000-00040
   Yanez LJ, 2008, PEDIATR CRIT CARE ME, V9, P484, DOI 10.1097/PCC.0b013e318184989f
   Zarbock A, 2009, CHEST, V135, P1252, DOI 10.1378/chest.08-1602
NR 26
TC 5
Z9 5
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2012
VL 18
IS 10
BP 1217
EP 1225
DI 10.1002/lt.23491
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 021WS
UT WOS:000309916700013
PM 22692821
ER

PT J
AU Englesbe, MJ
   Kelly, B
   Goss, J
   Fecteau, A
   Mitchell, J
   Andrews, W
   Krapohl, G
   Magee, JC
   Mazariegos, G
   Horslen, S
   Bucuvalas, J
AF Englesbe, M. J.
   Kelly, B.
   Goss, J.
   Fecteau, A.
   Mitchell, J.
   Andrews, W.
   Krapohl, G.
   Magee, J. C.
   Mazariegos, G.
   Horslen, S.
   Bucuvalas, J.
TI Reducing Pediatric Liver Transplant Complications: A Potential Roadmap
   for Transplant Quality Improvement Initiatives Within North America
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Best practices; biliary complications; hepatic artery thrombosis;
   pediatric liver transplantation; quality collaboration; quality
   improvement
ID SURGICAL QUALITY; BILIARY ATRESIA; UNITED-STATES; OUTCOMES; EXPERIENCE;
   RECIPIENTS; MORTALITY; CHILDREN; UPDATE; CANADA
AB Though robust clinical data are available within transplantation, these data are not used for broad-based, multicentered quality improvement initiates. This article describes a targeted quality improvement initiative within the Studies of Pediatric Liver Transplantation (SPLIT) Registry. Using standard statistical techniques and clinical expertise to adjust for data and statistical reliability, we identified the pediatric liver transplant centers in North America with the lowest hepatic artery thrombosis rate and biliary complication rates. A survey was completed to establish current practices within the entire SPLIT group. Surgeons from the highest performing centers presented a detailed, technically oriented overview of their current practices. The presentations and discussion that followed were recorded and form the basis of the best practices described herein. We frame this work as a unique six-step approach roadmap that may serve as an efficient and cost effective model for novel broad-based quality improvement initiatives within transplantation.
C1 [Englesbe, M. J.; Krapohl, G.; Magee, J. C.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
   [Kelly, B.] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA.
   [Goss, J.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Fecteau, A.] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Mitchell, J.] EMMES Corp, Boston, MA USA.
   [Andrews, W.] Univ Missouri, Sch Med, Dept Surg, Kansas City, MO 64108 USA.
   [Mazariegos, G.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
   [Horslen, S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
   [Bucuvalas, J.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA.
RP Englesbe, MJ (reprint author), Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
EM englesbe@med.umich.edu
OI Mazariegos, George/0000-0002-2624-8632; Englesbe,
   Michael/0000-0001-8691-9111
FU NIH-NIDDK [K08 DK0827508]
FX Michael J. Englesbe is supported by NIH-NIDDK (K08 DK0827508).
CR Alonso-Vielba J, 1994, An Otorrinolaringol Ibero Am, V21, P159
   Anderson CD, 2008, AM J TRANSPLANT, V8, P1197, DOI 10.1111/j.1600-6143.2008.02223.x
   Anderson CD, 2010, PEDIATR TRANSPLANT, V14, P358, DOI 10.1111/j.1399-3046.2009.01246.x
   [Anonymous], 2012, PHYS UPD BLUE CROSS
   Birkmeyer NJO, 2005, SURGERY, V138, P815, DOI 10.1016/j.surg.2005.06.037
   Bucuvalas JC, 2008, AM J TRANSPLANT, V8, P2506, DOI 10.1111/j.1600-6143.2008.02432.x
   Campbell DA, 2010, ARCH SURG-CHICAGO, V145, P985, DOI 10.1001/archsurg.2010.220
   Campbell Darrell A Jr, 2008, Adv Surg, V42, P169, DOI 10.1016/j.yasu.2008.03.005
   Campbell K, 2010, AM J TRANSPLANT, V10, P2673, DOI 10.1111/j.1600-6143.2010.03316.x
   Cohn JA, 2007, AM J TRANSPLANT, V7, P1656, DOI 10.1111/j.1600-6143.2007.01791.x
   Dimick JB, 2006, J AM COLL SURGEONS, V202, P933, DOI 10.1016/j.jamcollsurg.2006.02.015
   Dimick JB, 2004, JAMA-J AM MED ASSOC, V292, P847, DOI 10.1001/jama.292.7.847
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Englesbe MJ, 2006, AM J TRANSPLANT, V6, P2978, DOI 10.1111/j.1600-6143.2006.01575.x
   Englesbe MJ, 2007, ANN SURG, V246, P1100, DOI 10.1097/SLA.0b013e31815c3fe5
   Englesbe MJ, 2006, AM J TRANSPLANT, V6, P666, DOI 10.1111/j.1600-6143.2006.01267.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   McDiarmid S V, 2003, Clin Transpl, P119
   McDiarmid SV, 2011, ANN SURG, V254, P145, DOI 10.1097/SLA.0b013e31821ad86a
   McDiarmid SV, 2001, TRANSPLANT P, V33, P3604, DOI 10.1016/S0041-1345(01)02550-7
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   Moscucci M, 2006, CIRCULATION, V113, P814, DOI 10.1161/CIRCULATIONAHA.105.541995
   O'Connor GT, 1998, ANN THORAC SURG, V66, P1323, DOI 10.1016/S0003-4975(98)00762-0
   OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841
   Pans A, 1998, WORLD J SURG, V22, P482
   Pans A, 1998, WORLD J SURG, V22, P479
   Share DA, 2011, HEALTH AFFAIR, V30, P636, DOI 10.1377/hlthaff.2010.0526
   Utterson EC, 2005, J PEDIATR-US, V147, P180, DOI 10.1016/j.jpeds.2005.04.073
NR 29
TC 9
Z9 10
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2012
VL 12
IS 9
BP 2301
EP 2306
DI 10.1111/j.1600-6143.2012.04204.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 994QC
UT WOS:000307945000009
PM 22883313
ER

PT J
AU Bonatti, HJR
   Axt, J
   Hunter, EB
   Lott, SL
   Frangoul, H
   Gillis, L
   Correa, H
   Kelly, B
AF Bonatti, Hugo J. R.
   Axt, Jason
   Hunter, Ellen Bailey
   Lott, Sarah Louise
   Frangoul, Haydar
   Gillis, Lynette
   Correa, Hernan
   Kelly, Beau
TI Castleman disease in a pediatric liver transplant recipient: A case
   report and literature review
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; post-transplant lymphoproliferative
   disorders; human herpesvirus 8
ID HHV8 ASSOCIATED DISEASES; KAPOSIS-SARCOMA; LYMPH-NODE;
   HUMAN-HERPESVIRUS-8; LESIONS; UPDATE; IMMUNOSUPPRESSION; VALGANCICLOVIR;
   INFECTION; PATIENT
AB Bonatti HJR, Axt J, Hunter EB, Lott SL, Frangoul H, Gillis L, Correa H, Kelly B. Castleman disease in a pediatric liver transplant recipient: A case report and literature review. ?Pediatr Transplantation 2011. (c) 2011 John Wiley & Sons A/S. Abstract: Castleman disease is a rare hematologic disorder, closely linked to the HHV-8, and most commonly observed in immunocompromised individuals. Thirteen months following a liver transplant for CPS-1 defect, a 15-month-old boy presented with fevers, anemia, and growth retardation. Abdominal CT scan showed splenomegaly and generalized lymphadenopathy. Histology of chest wall lymph nodes revealed a mixed CD3+ T-cell and CD20+ B-cell population with atretic germinal centers consistent with multicentric Castleman disease. Qualitative DNA PCR detected HHV-8 in the resected lymph node and in the blood, supporting the diagnosis. Immunosuppression was tapered, and he was transitioned from tacrolimus to sirolimus. His graft function remained stable, and repeat imaging showed regression of the lymphadenopathy. The child is living one yr after Castleman disease diagnosis with a well-functioning graft. Castleman disease is a potential complication of solid organ transplant and HHV-8 infection. Reduction in immunosuppression and switch to sirolimus may be an effective strategy to treat this condition.
C1 [Kelly, Beau] Vanderbilt Univ, Div Hepatobiliary Surg & Liver Transplantat, Dept Surg, Med Ctr, Nashville, TN 37232 USA.
   [Lott, Sarah Louise; Correa, Hernan] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
   [Frangoul, Haydar; Gillis, Lynette] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
   Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN USA.
RP Kelly, B (reprint author), Vanderbilt Univ, Div Hepatobiliary Surg & Liver Transplantat, Dept Surg, Med Ctr, 1211 Med Ctr Dr, Nashville, TN 37232 USA.
EM beau.kelly@vanderbilt.edu
CR Al Otaibi T, 2007, TRANSPL P, V39, P1276, DOI 10.1016/j.transproceed.2007.03.059
   Barozzi P, 2009, TRANSPLANTATION, V88, P597, DOI 10.1097/TP.0b013e3181b15d56
   Boeckle E, 2005, TRANSPLANT P, V37, P1905, DOI 10.1016/j.transproceed.2005.03.144
   Bonatti H, 2007, TRANSPLANT INT, V20, P238, DOI 10.1111/j.1432-2277.2006.00430.x
   Cagirgan S, 1997, NEPHRON, V76, P352
   Campeau PM, 2010, MOL GENET METAB, V100, pS84, DOI 10.1016/j.ymgme.2010.02.012
   Casper C, 2005, BRIT J HAEMATOL, V129, P3, DOI 10.1111/j.1365-2141.2004.05311.x
   Concato C, 2008, TRANSPL P, V40, P3683, DOI 10.1016/j.transproceed.2008.06.085
   Cronin DMP, 2009, ADV ANAT PATHOL, V16, P236, DOI 10.1097/PAP.0b013e3181a9d4d3
   Crumpacker CS, 2008, J INFECT DIS, V198, P6, DOI 10.1086/588821
   DiNardo CD, 2010, CURR OPIN HEMATOL, V17, P368, DOI 10.1097/MOH.0b013e328339018c
   Diociaiuti A, 2000, Transpl Int, V13 Suppl 1, pS410, DOI 10.1111/j.1432-2277.2000.tb02072.x
   Gaitonde S, 2007, HISTOPATHOLOGY, V50, P954, DOI 10.1111/j.1365-2559.207.02702.x
   Gross TG, 2010, PEDIATR CLIN N AM, V57, P481, DOI 10.1016/j.pcl.2010.01.011
   Hengge UR, 2002, LANCET INFECT DIS, V2, P281, DOI 10.1016/S1473-3099(02)00263-3
   Hengge UR, 2002, LANCET INFECT DIS, V2, P344, DOI 10.1016/S1473-3099(02)00288-8
   Hille JJ, 2002, ORAL DIS, V8, P161, DOI 10.1034/j.1601-0825.2002.00028.x
   Lebbe C, 2001, NEPHROLOGIE, V22, P313
   Lebbe Celeste, 2008, Transplant Rev (Orlando), V22, P252, DOI 10.1016/j.trre.2008.05.004
   Lim EJ, 2011, AM J TRANSPLANT, V11, P169, DOI 10.1111/j.1600-6143.2010.03366.x
   Luppi M, 2002, LEUKEMIA LYMPHOMA, V43, P517, DOI 10.1080/10428190290011994
   MANDEL C, 1993, BRIT J RADIOL, V66, P264
   Manuelli M, 2010, TRANSPL P, V42, P1314, DOI 10.1016/j.transproceed.2010.03.051
   Matsushima A.Y., 1999, AM J SURG PATHOL, V23, P1393
   Ruozi B, 2010, EUR J PHARM SCI, V41, P254, DOI 10.1016/j.ejps.2010.06.012
   Serraino D, 2001, EUR J EPIDEMIOL, V17, P871, DOI 10.1023/A:1015678312153
   Theate I, 2003, CLIN TRANSPLANT, V17, P451, DOI 10.1034/j.1399-0012.2003.00098.x
   Waterston A, 2004, ACTA ONCOL, V43, P698, DOI 10.1080/02841860410002752
NR 28
TC 4
Z9 5
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2012
VL 16
IS 6
BP E229
EP E234
DI 10.1111/j.1399-3046.2011.01570.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 983GD
UT WOS:000307106800008
PM 22032720
ER

PT J
AU Cui, R
   Fayek, S
   Rand, EB
   Feygin, T
   Khrichenko, D
   Shaked, A
AF Cui, Rosa
   Fayek, Sameh
   Rand, Elizabeth B.
   Feygin, Tamara
   Khrichenko, Dmitry
   Shaked, Abraham
TI Central pontine myelinolysis: A case report and clinical-pathological
   review
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE calcineurin inhibitors; sirolimus; neurological complications;
   pediatric; liver transplantation; tacrolimus
ID ORTHOTOPIC LIVER-TRANSPLANTATION; SINGLE-CENTER EXPERIENCE; EXTRAPONTINE
   MYELINOLYSIS; NEUROLOGICAL COMPLICATIONS; CALCINEURIN INHIBITORS; MR
   FINDINGS; RECIPIENTS; HYPONATREMIA; SIROLIMUS; LEUKOENCEPHALOPATHY
AB Cui R, Fayek S, Rand EB, Feygin T, Khrichenko D, Shaked A. Central pontine myelinolysis: A case report and clinicalpathological review. Pediatr Transplantation 2011. (c) 2011 John Wiley & Sons A/S. Abstract: An 11-yr-old child presented with acute mental status changes and spastic quadriplegia after orthotopic liver transplantation. Magnetic resonance (MR) imaging findings were consistent with central pontine and EPM. Initial immunosuppression included tacrolimus, mycophenolate mofetil, and corticosteroids. Given that neurotoxicity is a well-established side effect of CNI, the patient was converted to rapamycin and subsequently experienced significant neurologic recovery. The temporal resolution of the patients symptoms suggests that prompt recognition of central pontine and EPM and conversion from tacrolimus to rapamycin during the early post-operative course may have therapeutic benefits for patients undergoing pediatric transplant with CNI-related neurotoxicity.
C1 [Cui, Rosa; Shaked, Abraham] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
   [Fayek, Sameh] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA.
   [Rand, Elizabeth B.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.
   [Feygin, Tamara; Khrichenko, Dmitry] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA.
RP Cui, R (reprint author), Hosp Univ Penn, Dept Surg, 3400 Spruce St,2 Dulles, Philadelphia, PA 19104 USA.
EM Rosa.Cui@uphs.upenn.edu
CR Abbasoglu O, 1998, CLIN TRANSPLANT, V12, P263
   ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154
   Ashrafian J, 2001, EUR J NEUROL, V8, P103
   Bibl D, 1999, LANCET, V353, P353
   Bonham A, 1998, TRANSPLANTATION, V66, P1596
   BOON AP, 1991, J CLIN PATHOL, V44, P909, DOI 10.1136/jcp.44.11.909
   Bronster DJ, 2000, CLIN TRANSPLANT, V14, P1, DOI 10.1034/j.1399-0012.2000.140101.x
   Brown WD, 2000, CURR OPIN NEUROL, V13, P691, DOI 10.1097/00019052-200012000-00014
   Chang GJ, 2000, LIVER TRANSPLANT, V6, P734, DOI 10.1053/jlts.2000.19023
   Chu K, 2001, ACTA NEUROL SCAND, V104, P385, DOI 10.1034/j.1600-0404.2001.00096.x
   Dell-Olio D, 2009, PEDIATR TRANSPLANT, V13, P670, DOI 10.1111/j.1399-3046.2009.01184.x
   DEWITT LD, 1984, NEUROLOGY, V34, P570
   DROOGAN AG, 1992, ULSTER MED J, V61, P98
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   ESTOL CJ, 1989, NEUROLOGY, V39, P493
   Fernandez D, 2010, TRANSPLANTATION, V90, P319, DOI 10.1097/TP.0b013e3181e5b7fc
   Forgacs B, 2005, TRANSPLANT P, V37, P1912, DOI 10.1016/j.transproceed.2005.02.101
   Fryer JP, 1996, TRANSPLANTATION, V61, P658, DOI 10.1097/00007890-199602270-00026
   Fugate JE, 2010, MAYO CLIN PROC, V85, P427, DOI 10.4065/mcp.2009.0590
   GHIDONI P, 1994, TRANSPLANT P, V26, P3602
   Gibelli NEM, 2009, TRANSPL P, V41, P901, DOI 10.1016/j.transproceed.2009.01.054
   Hagiwara K, 2008, INTERNAL MED, V47, P431, DOI 10.2169/internalmedicine.47.0634
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Ke QH, 2006, J INT MED RES, V34, P264
   Ke Qing-hong, 2006, Zhejiang Da Xue Xue Bao Yi Xue Ban, V35, P424
   Kim J, 2007, J NEUROL SCI, V253, P66, DOI 10.1016/j.jns.2006.10.012
   Kochi S, 2000, LIFE SCI, V66, P2255, DOI 10.1016/S0024-3205(00)00554-3
   Lee EM, 2009, EUR NEUROL, V62, P362, DOI 10.1159/000242426
   Liang TB, 2005, ZHONGHUA QIGUAN YIZH, V26, P292
   Mangat KS, 2002, NEURORADIOLOGY, V44, P768, DOI 10.1007/s00234-002-0845-4
   Markiewicz M, 2003, TRANSPLANT P, V35, P2284, DOI 10.1016/S0041-1345(03)00785-1
   MARTIN PJ, 1995, POSTGRAD MED J, V71, P430
   McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511
   McKee A, 1988, NEUROLOGY, V28, P1211
   MESSERT B, 1979, NEUROLOGY, V29, P147
   Nagata M, 2004, AM J NEURORADIOL, V25, P803
   Norenberg MD, 2010, METAB BRAIN DIS, V25, P97, DOI 10.1007/s11011-010-9175-0
   RIPPE DJ, 1987, J COMPUT ASSIST TOMO, V11, P724, DOI 10.1097/00004728-198707000-00037
   Sindhi R, 2005, PEDIATR TRANSPLANT, V9, P391, DOI 10.1111/j.1399-3046.2005.00360.x
   Singh N, 2000, TRANSPLANTATION, V69, P467, DOI 10.1097/00007890-200002270-00001
   SINGH N, 1994, MEDICINE, V73, P110, DOI 10.1097/00005792-199403000-00004
   STARZL TE, 1978, ANN SURG, V187, P236, DOI 10.1097/00000658-197803000-00003
   STERNS RH, 1994, J AM SOC NEPHROL, V4, P1522
   Takei Y, 2003, INTERNAL MED, V42, P867, DOI 10.2169/internalmedicine.42.867
   Tredger JM, 2008, DRUGS, V68, P1385, DOI 10.2165/00003495-200868100-00004
   Vivarelli M, 2010, TRANSPL P, V42, P2570
   Vivarelli M, 2006, TRANSPLANT INT, V19, P1022, DOI 10.1111/j.1432-2277.2006.00381.x
   Yu J, 2004, WORLD J GASTROENTERO, V10, P2540
NR 48
TC 1
Z9 2
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2012
VL 16
IS 6
BP E251
EP E256
DI 10.1111/j.1399-3046.2011.01591.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 983GD
UT WOS:000307106800013
PM 22023701
ER

PT J
AU Rivera, J
   Fusaro, F
   de Magnee, C
   Clapuyt, P
   Reding, R
AF Rivera, Jairo
   Fusaro, Fabio
   de Magnee, Catherine
   Clapuyt, Philippe
   Reding, Raymond
TI Meso-Rex shunt for immediate portal revascularization in pediatric liver
   transplantation: First report
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; portal reconstruction;
   intraoperative complications
ID VEIN THROMBOSIS; COMPLICATIONS; HYPERTENSION; CHILDREN; RECONSTRUCTION;
   RECIPIENTS; STENOSIS; GRAFTS; BYPASS; DONORS
AB Rivera J, Fusaro F, de Magnee C, Clapuyt P, Reding R. Meso-Rex shunt for immediate portal revascularization in pediatric liver transplantation: First report. Pediatr Transplantation 2011. (c) 2011 John Wiley & Sons A/S. Abstract: We describe the case of a 13-month-old girl transplanted for biliary atresia with PV hypoplasia. She received the left liver lobe of her mother and presented intraoperative portal thrombosis. Because of technical reasons, the opportunity to have conventional PV reconstruction using the donor left PV stump was lost. Immediate conversion to a meso-Rex shunt, using the recipient jugular vein as a bridge between the superior mesenteric vein and the graft Rex recessus, allowed excellent portal revascularization of the transplant. We suggest that synchronous meso-Rex shunt may constitute a valid alternative to truncal PV anastomosis during pediatric LT.
C1 [Rivera, Jairo; Fusaro, Fabio; de Magnee, Catherine; Reding, Raymond] Catholic Univ Louvain, Clin Univ St Luc, Pediat Surg & Transplant Unit, B-1200 Brussels, Belgium.
   [Rivera, Jairo] Fdn Cardioinfantil IC, Transplant Unit, Bogota, Colombia.
   [Clapuyt, Philippe] Catholic Univ Louvain, Pediat Radiol Unit, Clin Univ St Luc, B-1200 Brussels, Belgium.
RP Reding, R (reprint author), Clin Univ St Luc, Pediat Surg & Transplant Unit 1401, 10 Hippocrate Ave, B-1200 Brussels, Belgium.
EM raymond.reding@uclouvain.be
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Bueno J, 2010, AM J TRANSPLANT, V10, P2148, DOI 10.1111/j.1600-6143.2010.03236.x
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   Dasgupta R, 2006, J PEDIATR SURG, V41, P108, DOI 10.1016/j.jpedsurg.2005.10.059
   de Magnee C, 2011, ANN SURG, V254, P55, DOI 10.1097/SLA.0b013e3182121eb7
   Alberti D, 1998, J PEDIATR SURG, V33, P597
   deGoyet JD, 1996, TRANSPLANTATION, V62, P71, DOI 10.1097/00007890-199607150-00015
   DEGOYET JD, 1992, TRANSPLANTATION, V53, P231
   Gibelli NEM, 2011, TRANSPL P, V43, P194, DOI 10.1016/j.transproceed.2010.11.011
   Ko GY, 2007, J VASC INTERV RADIOL, V18, P1215, DOI 10.1016/j.jvir.2007.06.029
   Krebs-Schmitt D, 2009, PEDIATR TRANSPLANT, V13, P540, DOI 10.1111/j.1399-3046.2008.01109.x
   Lerut J, 1998, TRANSPLANT INT, V11, P70, DOI 10.1111/j.1432-2277.1998.tb00961.x
   Marwan IK, 1999, SURGERY, V125, P265, DOI 10.1067/msy.1999.95114
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Moon JI, 2010, TRANSPL P, V42, P871, DOI 10.1016/j.transproceed.2010.02.059
   Ou HY, 2010, SURGERY, V149, P40
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Sharif K, 2010, J PEDIATR SURG, V45, P272, DOI 10.1016/j.jpedsurg.2009.08.019
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Superina R, 2006, ANN SURG, V243, P515, DOI 10.1097/01.sla.0000205827.73706.97
   Takahashi Y, 2009, PEDIATR SURG INT, V25, P745, DOI 10.1007/s00383-009-2430-y
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Yamanaka J, 2000, HEPATO-GASTROENTEROL, V47, P1371
NR 23
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2012
VL 16
IS 6
BP E235
EP E237
DI 10.1111/j.1399-3046.2011.01576.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 983GD
UT WOS:000307106800009
PM 21923884
ER

PT J
AU Sanada, Y
   Urahashi, T
   Ihara, Y
   Wakiya, T
   Okada, N
   Yamada, N
   Mizuta, K
AF Sanada, Yukihiro
   Urahashi, Taizen
   Ihara, Yoshiyuki
   Wakiya, Taiichi
   Okada, Noriki
   Yamada, Naoya
   Mizuta, Koichi
TI Liver transplantation for a pediatric patient with hemophilia B
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hemophilia B; factor IX concentrate; factor IX activity; liver
   transplantation
ID RECOMBINANT FACTOR-IX
AB Sanada Y, Urahashi T, Ihara Y, Wakiya T, Okada N, Yamada N, Mizuta K. Liver transplantation for a pediatric patient with hemophilia B. ?Pediatr Transplantation 2012: 00: 000000. (c) 2012 John Wiley & Sons A/S. Abstract: Hemophilia exposes patients to greater risks of bleeding complications during the perioperative period. However, there are no current protocols for factor replacement during LT. We herein describe a case of pediatric living donor LDLT performed for a patient with hemophilia B using perioperative short-term factor replacement. A 4-yr-old female patient with an extrahepatic portosystemic shunt and asymptomatic hemophilia B (factor IX activity 18.7%) underwent an ABO-compatible LDLT using a left lobe graft. The bleeding volume was 2980 mL. Freeze-dried human blood coagulation factor IX concentrate (Novact M, Kaketsuken, Japan) was administered at the induction of anesthesia and at the end of LDLT by bolus infusion (80 U/kg) and was continued by bolus infusion (40 U/kg) on POD 1, 2, 3, and 4. On POD 1, 5, 8, and 12, the factor IX plasma levels were 34.5%, 64.9%, 43.5%, and 53.1%, respectively. The postoperative course was uneventful, and the patient is currently doing well at 2.5 yr after LDLT. Factor concentrate should be administered at the induction of anesthesia and at the end of LT by bolus infusion, and thereafter be continued for a few days after LT by bolus infusion.
C1 [Sanada, Yukihiro; Urahashi, Taizen; Ihara, Yoshiyuki; Wakiya, Taiichi; Okada, Noriki; Yamada, Naoya; Mizuta, Koichi] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Sanada, Y (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM yuki371@jichi.ac.jp
CR BONTEMPO FA, 1987, BLOOD, V69, P1721
   BRETTLER DB, 1990, BLOOD, V76, P254
   De Pietri L, 2008, TRANSPL P, V40, P2077, DOI 10.1016/j.transproceed.2008.05.054
   Franchini M, 2006, AM J HEMATOL, V81, P698
   Gordon FH, 1998, GUT, V42, P744
   Kardry Z, 1995, TRANSPLANTATION INT, V8, P485
   Lambing A, 2011, HAEMOPHILIA, V17, P1
   LERUT JP, 1995, J HEPATOL, V22, P583, DOI 10.1016/0168-8278(95)80454-4
   LEWIS JH, 1985, NEW ENGL J MED, V312, P1189
   McCarthy M, 1996, GUT, V39, P870, DOI 10.1136/gut.39.6.870
   MERION RM, 1988, SURGERY, V104, P929
   Ragni MV, 2002, HAEMOPHILIA, V8, P91, DOI 10.1046/j.1365-2516.2002.00587.x
   Wilde J, 2002, BRIT J HAEMATOL, V117, P952, DOI 10.1046/j.1365-2141.2002.03528.x
   Yokoyama Y, 2011, HPB OXFORD, V13, P40
NR 14
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2012
VL 16
IS 6
BP E193
EP E195
DI 10.1111/j.1399-3046.2012.01651.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 983GD
UT WOS:000307106800001
PM 22452579
ER

PT J
AU Kamath, BM
   Yin, WR
   Miller, H
   Anand, R
   Rand, EB
   Alonso, E
   Bucuvalas, J
AF Kamath, Binita M.
   Yin, Wanrong
   Miller, Heather
   Anand, Ravinder
   Rand, Elizabeth B.
   Alonso, Estella
   Bucuvalas, John
CA Studies Pediat Liver Transplantati
TI Outcomes of liver transplantation for patients with alagille syndrome:
   The studies of pediatric liver transplantation experience
SO LIVER TRANSPLANTATION
LA English
DT Article
ID EXTERNAL BILIARY DIVERSION; INTRACTABLE PRURITUS; CHOLESTASIS;
   MUTATIONS; MORBIDITY; ANOMALIES; CHILDREN; PAUCITY; DISEASE
AB Alagille syndrome (ALGS) is a multisystem disorder that manifests as childhood cholestasis. Reports of liver transplantation (LT) for patients with ALGS have come largely from single centers, which have reported survival rates of 57% to 79%. The aim of this study was to determine LT outcomes for patients with ALGS. We performed a retrospective analysis of the Studies of Pediatric Liver Transplantation database, which contains information about 3153 pediatric LT recipients. Data were available for 91 patients with ALGS and for 236 age-matched patients with biliary atresia (BA). The frequency of complex cardiac anomalies was lower in the LT group with ALGS versus published ALGS series (5% versus 13%). The pretransplant glomerular filtration rate (GFR) was <90 mL/minute/1.73 m2 in 18% of the LT patients with ALGS and in 5% of the LT patients with BA (P < 0.001). The height deficit at listing was worse for the ALGS patients (66%) versus the BA patients (22%). The 1-year patient survival rates were 87% for the ALGS patients and 96% for the BA patients (P = 0.002). The deaths in the ALGS group mostly occurred within the first 30 days. No pretransplant factors associated with death were identified in the ALGS group. A survival analysis revealed that biliary (P = 0.02), vascular (P < 0.001), central nervous system (CNS; P < 0.001), and renal complications (P < 0.001) after LT were associated with death in the ALGS group. Renal insufficiency in the ALGS patients worsened after LT, and at 1 year, GFR was <90 mL/minute/1.73 m2 in 22% of the LT patients with ALGS but in only 8% of the patients with BA (P = 0.0014). More LT pediatric patients with ALGS either were currently receiving special education (50% versus 30% for BA patients, P = 0.02) or had received special education in the past (60% versus 36%, P = 0.01). Vascular, CNS, and renal complications were increased in the ALGS patients after LT, and this reflected multisystem involvement. Although the 1-year survival rate was modestly lower for the ALGS patients versus the BA patients, the clustering of deaths within the first 30 days is notable and warrants increased vigilance and further investigation. Liver Transpl, 2012. (c) 2012 AASLD.
C1 [Kamath, Binita M.; Miller, Heather] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada.
   [Kamath, Binita M.; Miller, Heather] Univ Toronto, Dept Pediat, Toronto, ON, Canada.
   [Yin, Wanrong; Anand, Ravinder] Emmes Corp, Rockville, MD USA.
   [Rand, Elizabeth B.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
   [Alonso, Estella] Childrens Mem Hosp, Chicago, IL 60614 USA.
   [Bucuvalas, John] Childrens Hosp Med Ctr, Cincinnati, OH USA.
RP Kamath, BM (reprint author), Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM binita.kamath@sickkids.ca
FU  [5U01DK61693-5];  [3U01DK61693-5S1]
FX This study was supported by grants 5U01DK61693-5 and 3U01DK61693-5S1.
CR ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2
   Arnon R, 2010, PEDIATR TRANSPLANT, V14, P622, DOI 10.1111/j.1399-3046.2009.01286.x
   Campbell K, 2010, AM J TRANSPLANT, V10, P2673, DOI 10.1111/j.1600-6143.2010.03316.x
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Emerick KM, 2002, HEPATOLOGY, V35, P1501, DOI 10.1053/jhep.2002.33332
   Gurkan A, 1999, TRANSPLANTATION, V67, P416, DOI 10.1097/00007890-199902150-00013
   HOFFENBERG EJ, 1995, J PEDIATR-US, V127, P220, DOI 10.1016/S0022-3476(95)70298-9
   Hori T, 2010, AM J TRANSPLANT, V10, P1951, DOI 10.1111/j.1600-6143.2010.03196.x
   Kamath BM, 2012, AM J MED GENET A, V158A, P85, DOI 10.1002/ajmg.a.34369
   Kamath BM, 2010, J PEDIATR GASTR NUTR, V50, P580, DOI 10.1097/MPG.0b013e3181d98ea8
   Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   Kaye AJ, 2010, J PEDIATR GASTR NUTR, V51, P319, DOI 10.1097/MPG.0b013e3181df5fd8
   Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243
   Lykavieris P, 2001, GUT, V49, P431, DOI 10.1136/gut.49.3.431
   McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332
   McElhinney DB, 2002, CIRCULATION, V106, P2567, DOI 10.1161/01.CIR.0000037221.45902.69
   Ng VL, 2000, J PEDIATR GASTR NUTR, V30, P152, DOI 10.1097/00005176-200002000-00011
   Quiros-Tejeira RE, 1999, J PEDIATR GASTR NUTR, V29, P431, DOI 10.1097/00005176-199910000-00011
   Subramaniam P, 2011, J PEDIATR GASTR NUTR, V52, P84, DOI 10.1097/MPG.0b013e3181f1572d
   TZAKIS AG, 1993, ARCH SURG-CHICAGO, V128, P337
NR 21
TC 16
Z9 18
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2012
VL 18
IS 8
BP 940
EP 948
DI 10.1002/lt.23437
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 979XU
UT WOS:000306858200010
PM 22454296
ER

PT J
AU Shneider, BL
   Bosch, J
   de Franchis, R
   Emre, SH
   Groszmann, RJ
   Ling, SC
   Lorenz, JM
   Squires, RH
   Superina, RA
   Thompson, AE
   Mazariegos, GV
AF Shneider, Benjamin L.
   Bosch, Jaime
   de Franchis, Roberto
   Emre, Sukru H.
   Groszmann, Roberto J.
   Ling, Simon C.
   Lorenz, Jonathan M.
   Squires, Robert H.
   Superina, Riccardo A.
   Thompson, Ann E.
   Mazariegos, George V.
TI Portal Hypertension in Children: Expert Pediatric Opinion on the Report
   of the Baveno V Consensus Workshop on Methodology of Diagnosis and
   Therapy in Portal Hypertension
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
ID CLINICAL-PREDICTION RULE; HEPATOPULMONARY SYNDROME; VENOUS OBSTRUCTION;
   ESOPHAGEAL-VARICES; VEIN OBSTRUCTION; ENDOSCOPY
AB Shneider BL, Bosch J, de Franchis R, Emre SH, Groszmann RJ, Ling SC, Lorenz JM, Squires RH, Superina RA, Thompson AE, Mazariegos GV. Portal Hypertension in Children: Expert Pediatric Opinion on the Report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Abstract: Complications of portal hypertension in children lead to significant morbidity and are a leading indication for consideration of liver transplantation. Approaches to the management of sequelae of portal hypertension are well described for adults and evidence-based approaches have been summarized in numerous meta-analyses and conferences. In contrast, there is a paucity of data to guide the management of complications of portal hypertension in children. An international panel of experts was convened on April 8, 2011 at The Childrens Hospital of Pittsburgh of UPMC to review and adapt the recent report of the Baveno V Consensus Workshop on the Methodology of Diagnosis and Therapy in Portal Hypertension to the care of children. The opinions of that expert panel are reported.
C1 [Shneider, Benjamin L.; Squires, Robert H.; Thompson, Ann E.; Mazariegos, George V.] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15224 USA.
   [Bosch, Jaime] Hosp Clin IDIBAPS, Barcelona, Spain.
   [Bosch, Jaime] CIBERehd, Barcelona, Spain.
   [de Franchis, Roberto] L Sacco Univ Hosp, Milan, Italy.
   [Emre, Sukru H.; Groszmann, Roberto J.] Yale New Haven Med Ctr, New Haven, CT 06504 USA.
   [Ling, Simon C.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   [Ling, Simon C.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada.
   [Lorenz, Jonathan M.] Univ Chicago Hosp, Chicago, IL USA.
   [Superina, Riccardo A.] Childrens Mem Hosp, Chicago, IL 60614 USA.
RP Shneider, BL (reprint author), UPMC, Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA.
EM benjamin.shneider@chp.edu
OI Mazariegos, George/0000-0002-2624-8632
CR ABRAMS GA, 1995, GASTROENTEROLOGY, V109, P1283, DOI 10.1016/0016-5085(95)90589-8
   BEPPU K, 1981, GASTROINTEST ENDOSC, V27, P213, DOI 10.1016/S0016-5107(81)73224-3
   Bosch J, 2008, HEPATOLOGY, V47, P1604, DOI 10.1002/hep.22216
   Gana JC, 2010, J PEDIATR GASTR NUTR, V50, P188, DOI 10.1097/MPG.0b013e3181b64437
   Gana JC, 2011, GASTROENTEROLOGY, V141, P2009, DOI 10.1053/j.gastro.2011.08.049
   de Franchis R, 2010, J HEPATOL, V53, P762, DOI 10.1016/j.jhep.2010.06.004
   Duche M, 2010, GASTROENTEROLOGY, V139, P1952, DOI 10.1053/j.gastro.2010.07.004
   KHUROO MS, 1993, HEPATOLOGY, V17, P807, DOI 10.1016/0270-9139(93)90156-H
   Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240
   Miraglia R, 2010, J HEPATOL, V53, P624, DOI 10.1016/j.jhep.2010.04.027
   Noli K, 2008, PEDIATRICS, V121, pE522, DOI 10.1542/peds.2007-1075
   Sarin SK, 2002, SEMIN LIVER DIS, V22, P43, DOI 10.1055/s-2002-23206
   Shneider B, 2006, PEDIATR TRANSPLANT, V10, P893, DOI 10.1111/j.1399-3046.2006.00597.x
   Superina R, 2006, ANN SURG, V243, P515, DOI 10.1097/01.sla.0000205827.73706.97
   Superina R, 2006, PEDIATR TRANSPLANT, V10, P908, DOI 10.1111/j.1399-3046.2006.00598.x
   Zargar SA, 2002, HEPATOLOGY, V36, P666, DOI 10.1053/jhep.2002.35278
NR 16
TC 35
Z9 37
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2012
VL 16
IS 5
BP 426
EP 437
DI 10.1111/j.1399-3046.2012.01652.x
PG 12
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 970LW
UT WOS:000306131700017
PM 22409296
ER

PT J
AU Karnsakul, W
   Intihar, P
   Konewko, R
   Roy, A
   Colombani, PM
   Lau, H
   Schwarz, KB
AF Karnsakul, W.
   Intihar, P.
   Konewko, R.
   Roy, A.
   Colombani, P. M.
   Lau, H.
   Schwarz, K. B.
TI Living donor liver transplantation in children: A single North American
   center experience over two decades
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; pediatric liver transplantation;
   hospital charges; healthcare costs; biliary atresia
ID DISEASE SCORE; COMPLICATIONS; COST; OUTCOMES; FAILURE; PREDICTORS;
   RECIPIENTS; SYSTEM; IMPACT; ADULTS
AB Karnsakul W, Intihar P, Konewko R, Roy A, Colombani PM, Lau H, Schwarz KB. Living donor liver transplantation in children: A single North American center experience over two decades. Abstract: Little data concerning hospital charges and long-term outcomes of LDLT in North American children according to transplant indications have been published. To compare outcomes of patient and graft survival and healthcare charges for LDLT for those with BA vs. other diagnoses (non-BA). A retrospective review of 52 children receiving 53 LDLT (38 BA and 14 non-BA) from 1992 to 2010 at our institution was performed. One-, five-, and 10-yr patient and graft survival data were comparable to national figures reported to UNOS. Average one-yr charges for recipients and donors were $242 849 for BA patients and $183 614 for non-BA (p = 0.074). BA patients were 1.23 +/- 1.20 yr of age vs. 4.25 +/- 5.02 for non-BA, p = 0.045. Examination of the total population of patients who were alive in 2010 in five chronological groupings showed that the crude five-yr survival rates were 19921995: 9/11 (82%); 19951997: 6/10 (60%); 19971999: 8/10 (80%); 19992001: 9/10 (90%); and 20012003: 7/7 (100%). Thus, examination of the clinical and financial data together over the entire period of the transplant program suggests that the dramatic improvement in patient survival was accomplished without a dramatic increase in indexed charges. All 53 donors survived, and only 10% had complications requiring hospitalization. LDLT in children results in excellent outcomes for patients and donors. Ways to lower costs and maximize graft outcome should be investigated.
C1 [Karnsakul, W.; Roy, A.; Schwarz, K. B.] Johns Hopkins Med Inst, Dept Pediat, Div Pediat Gastroenterol & Nutr, Baltimore, MD 21205 USA.
   [Intihar, P.] Johns Hopkins Med Inst, Johns Hopkins Dept Financial Anal, Baltimore, MD 21205 USA.
   [Konewko, R.] Johns Hopkins Med Inst, Johns Hopkins Comprehens Transplant Ctr, Baltimore, MD 21205 USA.
   [Colombani, P. M.; Lau, H.] Johns Hopkins Med Inst, Dept Surg, Div Pediat Surg, Baltimore, MD 21205 USA.
RP Karnsakul, W (reprint author), Johns Hopkins Univ, Sch Med, Div Pediat Gastroenterol & Nutr, Brady 320,600 N Wolfe St, Baltimore, MD 21287 USA.
EM wkarnsa1@jhmi.edu
CR Aberg F, 2011, LIVER TRANSPLANT, V17, P1333, DOI 10.1002/lt.22388
   Axelrod DA, 2007, AM J TRANSPLANT, V7, P283
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Brown RS, 1998, LIVER TRANSPLANT SUR, V4, P170, DOI 10.1002/lt.500040211
   Bucuvalas JC, 2002, PEDIATR TRANSPLANT, V6, P30, DOI 10.1034/j.1399-3046.2002.1r058.x
   Bucuvalas JC, 2001, J PEDIATR-US, V139, P66, DOI 10.1067/mpd.2001.115068
   Cole CR, 2004, J PEDIATR-US, V144, P729, DOI 10.1016/j.jpeds.2004.03.032
   Colombani PM, 2000, J PEDIATR SURG, V35, P9, DOI 10.1016/S0022-3468(00)80067-6
   Dennis L, 2000, AASLD NEWS, V1, P4
   EMOND JC, 1993, TRANSPLANTATION, V55, P835, DOI 10.1097/00007890-199304000-00029
   Feng S, 2012, JAMA-J AM MED ASSOC, V18, P283
   Feng S, 2006, LIVER TRANSPLANT, V12, P578, DOI 10.1002/lt.20650
   Goldstein MJ, 2003, WORLD J SURG, V27, P356, DOI 10.1007/s00268-002-6598-8
   Hashikura Y, 2009, TRANSPLANTATION, V15, P110
   Inomata Y, 1999, TRANSPLANT P, V31, P381, DOI 10.1016/S0041-1345(98)01671-6
   Kim WR, 1995, CLIN TRANSPL, V53, P315
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Kogure T, 2006, J GASTROENTEROL, V41, P1005, DOI 10.1007/s00535-006-1887-x
   Liu B, 2009, TRANSPL P, V41, P1703, DOI 10.1016/j.transproceed.2008.11.014
   Lo CM, 2003, TRANSPLANTATION, V75, pS12, DOI 10.1097/01.TP.0000046534.45645.47
   Mack CL, 2001, LIVER TRANSPLANT, V7, P890, DOI 10.1053/jlts.2001.27963
   Middleton PF, 2006, LIVER TRANSPLANT, V12, P24, DOI 10.1002/lt.20663
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   Miloh T, 2010, PEDIATR TRANSPLANT, V14, P863, DOI 10.1111/j.1399-3046.2010.01356.x
   Otte JB, 2001, PEDIATR TRANSPLANT, V5, P1
   Otte JB, 1999, ACTA GASTRO-ENT BELG, V62, P355
   PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817
   Renz JF, 2000, LIVER TRANSPLANT, V6, pS73, DOI 10.1053/jlts.2000.18686
   Rogiers X, 1999, LANGENBECK ARCH SURG, V384, P528, DOI 10.1007/s004230050239
   RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7
   Schiano TD, 2001, HEPATOLOGY, V33, P3, DOI 10.1053/jhep.2001.21489
   Shouval DS, 2009, J PEDIATR GASTR NUTR, V48, P451, DOI 10.1097/MPG.0b013e318196c379
   Showstack J, 1999, JAMA-J AM MED ASSOC, V281, P1381, DOI 10.1001/jama.281.15.1381
   Simpson MA, 2011, LIVER TRANSPLANT, V17, P1226, DOI 10.1002/lt.22342
   Tannuri ACA, 2011, TRANSPL P, V43, P161, DOI 10.1016/j.transproceed.2010.11.013
   WIESNER RH, 1992, HEPATOLOGY, V16, P1290, DOI 10.1016/0270-9139(92)90026-6
   Yagi T, 2000, TRANSPLANT P, V32, P2156, DOI 10.1016/S0041-1345(00)01613-4
NR 38
TC 4
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
EI 1399-3046
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2012
VL 16
IS 5
BP 486
EP 495
DI 10.1111/j.1399-3046.2012.01725.x
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 970LW
UT WOS:000306131700025
PM 22672018
ER

PT J
AU Shigeta, T
   Sakamoto, S
   Kanazawa, H
   Fukuda, A
   Kakiuchi, T
   Karaki, C
   Uchida, H
   Matsuno, N
   Tanaka, H
   Kasahara, M
AF Shigeta, Takanobu
   Sakamoto, Seisuke
   Kanazawa, Hiroyuki
   Fukuda, Akinari
   Kakiuchi, Toshihiko
   Karaki, Chiaki
   Uchida, Hajime
   Matsuno, Naoto
   Tanaka, Hideaki
   Kasahara, Mureo
TI Diaphragmatic hernia in infants following living donor liver
   transplantation: Report of three cases and a review of the literature
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE diaphragmatic hernia; pediatric liver transplantation; living donor
   liver transplantation
ID CHILDREN
AB Shigeta T, Sakamoto S, Kanazawa H, Fukuda A, Kakiuchi T, Karaki C, Uchida H, Matsuno N, Tanaka H, Kasahara M. Diaphragmatic hernia in infants following living donor liver transplantation: Report of three cases and a review of the literature. Abstract: DH is a rare complication following LT. This report presents three cases of right-sided DH after LT using a left-sided graft. All of the patients were younger than one yr of age, and they were critically ill owing to their original disease, characterized by biliary atresia, progressive familiar intrahepatic cholestasis, and acute liver failure. DH occurred with sudden onset within three months after LT. All of the cases were promptly diagnosed and treated. A literature review of 24 cases of DH identified four factors associated with DH: left-sided graft, right-sided DH, relatively delayed onset of DH, and age-specific chief complaint. DH following LT should be considered as a potential surgical complication when a left-sided graft is used, especially in small infants with coagulopathy and malnutrition.
C1 [Shigeta, Takanobu] Natl Ctr Child Hlth & Dev, Transplantat Ctr, Dept Transplant Surg, Setagaya Ku, Tokyo 1578535, Japan.
   [Tanaka, Hideaki] Natl Ctr Child Hlth & Dev, Dept Pediat Surg, Tokyo 1578535, Japan.
RP Shigeta, T (reprint author), Natl Ctr Child Hlth & Dev, Transplantat Ctr, Dept Transplant Surg, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM shigeta-t@ncchd.go.jp
OI Fukuda, Akinari/0000-0003-4684-0446
CR Aktas S, 2011, EXP CLIN TRANSPLANT, V9, P63
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Earl TM, 2011, J AM COLL SURGEONS, V212, P62, DOI 10.1016/j.jamcollsurg.2010.09.017
   Englert C, 2006, TRANSPLANTATION, V82, P574, DOI 10.1097/01.tp.0000231709.63721.5c
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kazimi M, 2010, Pediatr Transplant, V14, pe62, DOI 10.1111/j.1399-3046.2009.01168.x
   Mack C L, 2000, Pediatr Transplant, V4, P39, DOI 10.1034/j.1399-3046.2000.00080.x
   Manczur TI, 2002, TRANSPLANTATION, V73, P228, DOI 10.1097/00007890-200201270-00013
   McCabe AJ, 2005, J PEDIATR SURG, V40, P1181, DOI 10.1016/j.jpedsurg.2005.03.063
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   Moon SB, 2012, PEDIATR TRANSPLANT, V16, pE106, DOI 10.1111/j.1399-3046.2010.01462.x
   Okajima H, 2007, PEDIATR TRANSPLANT, V11, P324, DOI 10.1111/j.1399-3046.2006.00658.x
   Perwaiz A, 2010, HERNIA, V14, P547, DOI 10.1007/s10029-009-0594-y
   Rossetto Anna, 2011, Updates Surg, V63, P51, DOI 10.1007/s13304-010-0039-2
   Schumpelick V, 2000, SURG CLIN N AM, V80, P213, DOI 10.1016/S0039-6109(05)70403-5
   Tanaka H, 2010, J PEDIATR SURG, V45, P1668, DOI 10.1016/j.jpedsurg.2010.03.010
   Tsao K, 2011, J PEDIATR SURG, V46, P1158, DOI 10.1016/j.jpedsurg.2011.03.050
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Wagner D, 2010, LIVER TRANSPLANT, V16, P783, DOI 10.1002/lt.22079
NR 20
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2012
VL 16
IS 5
BP 496
EP 500
DI 10.1111/j.1399-3046.2012.01722.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 970LW
UT WOS:000306131700026
PM 22672688
ER

PT J
AU Eberhardt, CS
   Merlini, L
   McLin, VA
   Wildhaber, BE
AF Eberhardt, Christiane S.
   Merlini, Laura
   McLin, Valerie A.
   Wildhaber, Barbara E.
TI Cholestasis as the leading sign of a transmesenteric hernia in a
   split-liver transplanted child - A case report and review of literature
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE transmesenteric; internal hernia; Roux-en-Y-loop; cholestasis;
   liver-transplantation; children
ID LAPAROSCOPIC GASTRIC BYPASS; INTERNAL HERNIA; SMALL-BOWEL; CT FINDINGS;
   OBSTRUCTION; COMPLICATIONS; MULTICENTER; PREVENTION; EMPHASIS; SURGERY
AB Eberhardt CS, Merlini L, McLin VA, Wildhaber BE. Cholestasis as the leading sign of a transmesenteric hernia in a split-liver transplanted child A case report and review of literature. Abstract: Internal hernias are an extremely rare complication after pediatric liver transplantation, and its presentation with cholestasis has not been described to date. We report the case of a 12-yr-old boy who presented with moderate abdominal pain 11 yr after split liver transplantation and biliary-enteric anastomosis. He developed severe jaundice within 24 h of initial presentation. Imaging studies revealed ascites, dilation of the intrahepatic bile ducts, a dilated Roux-en-Y-loop, with the loop truncated at the level of the mesenteric artery, which performed a narrow right-to-left loop. At laparotomy, a transmesenteric internal hernia at the root of the jejunal mesentery was identified, originating from the creation of the Y-loop; the Roux-en-Y-loop and its adjacent intestinal loops had slipped through the opening. The Roux-en-Y loop was ischemic from strangulation, and the rest of the intestine well perfused. No surgical resection was necessary following reduction. The patient recovered completely. We discuss diagnosis and management of internal hernias, and review radiological signs. Internal transmesenteric hernias can occur at any time after liver transplantation and prompt diagnosis and surgical treatment are vital.
C1 [Eberhardt, Christiane S.; Wildhaber, Barbara E.] Univ Geneva Childrens Hosp, Dept Pediat Surg, Geneva, Switzerland.
   [Merlini, Laura] Univ Geneva Childrens Hosp, Dept Pediat Radiol, Geneva, Switzerland.
   [McLin, Valerie A.] Univ Geneva Childrens Hosp, Dept Pediat, Geneva, Switzerland.
RP Wildhaber, BE (reprint author), Hop Univ Geneve, Hop Enfants, Rue Willy Donze 6, CH-1211 Geneva 14, Switzerland.
EM barbara.wildhaber@hcuge.ch
CR Blachar A, 2002, RADIOLOGY, V223, P625, DOI 10.1148/radiol.2233011323
   Blachar A, 2001, RADIOLOGY, V218, P384
   Blachar A, 2001, RADIOLOGY, V221, P422, DOI 10.1148/radiol.2212010126
   Garza E, 2004, AM J SURG, V188, P796, DOI 10.1016/j.amjsurg.2004.08.049
   Higa KD, 2003, OBES SURG, V13, P350, DOI 10.1381/096089203765887642
   Hongo N, 2010, ABDOM IMAGIN
   Iannuccilli J D, 2009, Clin Radiol, V64, P373, DOI 10.1016/j.crad.2008.10.008
   Kawakami M, 2002, HEPATO-GASTROENTEROL, V49, P1030
   Khanna A, 1997, TRANSPLANT INT, V10, P133, DOI 10.1111/j.1432-2277.1997.tb00555.x
   Liu CL, 2004, CLIN TRANSPLANT, V18, P211, DOI 10.1046/j.1399-0012.2003.00125.x
   Lockhart ME, 2007, AM J ROENTGENOL, V188, P745, DOI 10.2214/AJR.06.0541
   Martin LC, 2006, AM J ROENTGENOL, V186, P703, DOI 10.2214/AJR.05.0644
   Meyers M., 1994, DYNAMIC RADIOLOGY AB
   Okajima H, 2007, PEDIATR TRANSPLANT, V11, P324, DOI 10.1111/j.1399-3046.2006.00658.x
   Page MP, 2008, J PEDIATR SURG, V43, P755, DOI 10.1016/j.jpedsurg.2007.11.044
   Sauerland S, 2006, SURG ENDOSC, V20, P14, DOI 10.1007/s00464-005-0564-0
   Silecchia G, 2006, OBES SURG, V16, P125, DOI 10.1381/096089206775565249
   Silecchia G, 2008, SURG ENDOSC, V22, P2492, DOI 10.1007/s00464-008-9885-0
   Smyrniotis V, 2001, LIVER TRANSPLANT, V7, P1002, DOI 10.1053/jlts.2001.28745
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2012
VL 16
IS 5
BP E172
EP E176
DI 10.1111/j.1399-3046.2011.01496.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 970LW
UT WOS:000306131700009
PM 21504521
ER

PT J
AU Unal, B
   Piskin, T
   Koz, S
   Ulutas, O
   Yilmaz, M
   Yilmaz, S
AF Unal, B.
   Piskin, T.
   Koz, S.
   Ulutas, O.
   Yilmaz, M.
   Yilmaz, S.
TI En Bloc and Dual Kidney Transplantation: Two Initial Cases from a New
   Kidney Transplantation Center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the
   Turkish-Transplantation-Centers-Coordination-Association (TTCCA)
CY OCT 12-16, 2011
CL Antalya, TURKEY
SP Turkish Transplantat Ctr Coordinat Assoc (TTCCA)
ID RENAL-TRANSPLANTATION; DONORS; COMPLICATIONS
AB Aim. The aim of this study was to share our initial successful experiences with en bloc dual kidney transplantation.
   Cases. En bloc kidney were obtained, for case 1 from a 3-year-old deceased pediatric donor who had undergone cadaveric liver transplantation due to fulminant hepatitis A virus infection 1 week prior. The donor length was 97 cm and weight 13 kg. According to the age and weight of the donor, we selected a 50-year-old respectively. For case 2, a kidney was retrieved from a 20-month-old pediatric donor after development of hypoxic brain injury secondary to status epilepticus. The donor lengh and weight were 75 cm and 13 kg respectively. A 30-year-old female patient was of 162 cm and 59 kg. The suprarenal aorta, suprarenal vena cava, and caval and aortic lumbar branches were closed with running sutures during the backtable procedures. After the classic Gibson incision, the donor aorta was anastomosed to the recipient right common iliac artery, and the donor inferior vena cava to the recipient right common iliac vein in end-to-side fashion. The ureters were implanted with mucosa-to-mucosa ureteroneocystostomies separately according to the Lich-Gregoir technique. After the vascular anastomoses the kidneys had immediate good perfusion in both cases. Postoperative recovery was rapid, the recipients were discharged uneventfullly.
   Conclusion. En bloc dual kidney transplantation from young pediatric patients to adult recipients can be performed with low mortality and morbidity even by new centers.
C1 [Unal, B.; Piskin, T.; Yilmaz, M.; Yilmaz, S.] Inonu Univ, Sch Med, Dept Gen Surg & Organ Transplantat, TR-44069 Malatya, Turkey.
   [Koz, S.; Ulutas, O.] Inonu Univ, Sch Med, Dept Internal Med, TR-44069 Malatya, Turkey.
RP Unal, B (reprint author), Inonu Univ, Dept Gen Surg, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey.
EM bulent.unal@inonu.edu.tr
CR Amante AJ, 1996, J UROLOGY, V155, P852, DOI 10.1016/S0022-5347(01)66326-2
   Asadpour Amir, 2011, Saudi J Kidney Dis Transpl, V22, P72
   Blanchet P, 2000, TRANSPLANT P, V32, P2769, DOI 10.1016/S0041-1345(00)01874-1
   Bunnapradist S, 2003, J AM SOC NEPHROL, V14, P1031, DOI 10.1097/01.ASN.0000054494.85680.1C
   Ebadzadeh Mohammad Reza, 2008, Urol J, V5, P144
   Ekser B, 2006, TRANSPLANT INT, V19, P485, DOI 10.1111/j.1432-2277.2006.00309.x
   FINE RN, 1988, AM J KIDNEY DIS, V12, P1
   Ghazanfar A, 2011, EXP CLIN TRANSPLANT, V9, P60
   KHAULI RB, 1993, J UROLOGY, V150, P22
   Kocak T, 2004, UROL INT, V72, P252, DOI 10.1159/000077125
   Lee RS, 2003, J UROLOGY, V169, P855, DOI 10.1097/01.ju.0000050260.43438.6f
   Snanoudj R, 2009, AM J TRANSPLANT, V9, P2542, DOI 10.1111/j.1600-6143.2009.02797.x
   Wolters HH, 2005, TRANSPLANT INT, V18, P453, DOI 10.1111/j.1432-2277.2004.00068.x
NR 13
TC 3
Z9 4
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2012
VL 44
IS 6
BP 1700
EP 1702
DI 10.1016/j.transproceed.2012.05.054
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 987QY
UT WOS:000307433400062
PM 22841247
ER

PT J
AU Gu, LH
   Fang, H
   Li, FH
   Li, P
   Zhu, CX
   Zhu, JJ
   Zhang, SJ
AF Gu, Li H.
   Fang, Hua
   Li, Feng H.
   Li, Ping
   Zhu, Cai X.
   Zhu, Jian J.
   Zhang, Shi J.
TI Prediction of early hepatic artery thrombosis by intraoperative color
   Doppler ultrasound in pediatric segmental liver transplantation
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE color Doppler ultrasound; hemodynamic; hepatic artery thrombosis; liver
   transplantation; pediatric
ID RISK-FACTORS; VASCULAR COMPLICATIONS; SINGLE-CENTER; BLOOD-FLOW; ADULT;
   HEMODYNAMICS; EXPERIENCE; RECIPIENTS; DIAGNOSIS; CHILDREN
AB Gu LH, Fang H, Li FH, Li P, Zhu CX, Zhu JJ, Zhang SJ. Prediction of early hepatic artery thrombosis by intraoperative color Doppler ultrasound in pediatric segmental liver transplantation. Abstract: Early hepatic artery thrombosis (eHAT) after transplantation is associated with a high incidence of graft failure and mortality in pediatric segmental liver transplantation (LT). The evaluation of intraoperative color Doppler ultrasound (CD-US) parameters and their sensitivity and specificity for the prediction of eHAT were important. Pediatric segmental LTs were performed in 49 consecutive patients from October 2006 to December 2010 in our hospital. A total of seven patients (14.3%) experienced eHAT (within one month) after LT. The intraoperative hepatic artery (HA) diameter (p = 0.026), hepatic arterial peak systolic velocity (HAPSV) (p = 0.006), and hepatic artery resistance index (HARI) (p = 0.000) had significant difference between eHAT group and non-eHAT group. Taking a HA diameter <2 mm, a HAPSV of <40 cm/s and a HARI of <0.6 as threshold to predict eHAT, the sensitivity and specificity were 85.7%, 85.7%, 85.7%, and 61.9%, 76.2%, 88.1%, respectively. A HARI of <0.6 was shown to be the most sensitive and specific single parameter for predicting eHAT.
C1 [Gu, Li H.; Fang, Hua; Li, Feng H.; Li, Ping; Zhu, Cai X.; Zhang, Shi J.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Ultrasound, Shanghai 200127, Peoples R China.
   [Zhu, Jian J.] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Transplantat Ctr, Shanghai 200127, Peoples R China.
RP Li, FH (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Ultrasound, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.
EM renjilfh@163.com
FU Shanghai leading academic discipline project [S30203]
FX This work was supported by Shanghai leading academic discipline project
   (S30203). Thanks for the help from the staff of transplantation center
   in Renji Hospital.
CR Abbasoglu O, 1998, TRANSPLANTATION, V66, P598, DOI 10.1097/00007890-199809150-00008
   Abou El-Ella K, 2001, TRANSPLANT P, V33, P2712, DOI 10.1016/S0041-1345(01)02157-1
   Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Boyvat F, 2006, TRANSPLANT P, V38, P3656, DOI 10.1016/j.transproceed.2006.10.169
   Broniszczak D, 2006, TRANSPLANT P, V38, P1456, DOI 10.1016/j.transproceed.2006.02.094
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Garcia-Criado A, 2003, AM J ROENTGENOL, V181, P831
   HENDERSON JM, 1992, HEPATOLOGY, V16, P715, DOI 10.1002/hep.1840160316
   Huang TL, 2001, TRANSPLANT P, V33, P899, DOI 10.1016/S0041-1345(00)02368-X
   Jain A, 2006, TRANSPLANT INT, V19, P27, DOI 10.1111/j.1432-2277.2005.00224.x
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   Kasahara Mureo, 2010, Nihon Geka Gakkai Zasshi, V111, P268
   Lin M, 2002, ANZ J SURG, V72, P798, DOI 10.1046/j.1445-2197.2002.02552.x
   Lisman T, 2009, TRANSPL INT, V22, P162, DOI 10.1111/j.1432-2277.2008.00762.x
   Margarit C, 2000, TRANSPL INT, V13, P150
   Miraglia R, 2009, RADIOGRAPHICS, V29, P567, DOI 10.1148/rg.292085037
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   Nikeghbalian S, 2007, TRANSPL P, V39, P1195, DOI 10.1016/j.transproceed.2007.02.017
   Nolten A, 1996, RADIOLOGY, V198, P553
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Omori S, 2010, J PEDIATR SURG, V45, P545, DOI 10.1016/j.jpedsurg.2009.06.015
   Pareja E, 2010, TRANSPL P, V42, P2970, DOI 10.1016/j.transproceed.2010.07.063
   PAULSEN AW, 1992, HEPATOLOGY, V16, P100, DOI 10.1002/hep.1840160118
   Ravindra KV, 2005, J PEDIATR SURG, V40, P643, DOI 10.1016/j.jpedsurg.2004.12.003
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   Stange B, 2001, TRANSPLANT P, V33, P1408, DOI 10.1016/S0041-1345(00)02530-6
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   Sugawara Y, 2002, TRANSPLANT P, V34, P3325, DOI 10.1016/S0041-1345(02)03576-5
   Vaidya Sandeep, 2007, Ultrasound Q, V23, P239, DOI 10.1097/ruq.0b013e31815d6e1d
   Vivarelli M, 2004, ARCH SURG-CHICAGO, V139, P1069, DOI 10.1001/archsurg.139.10.1069
   Warner P, 2011, TRANSPL INT, V6, P1432
NR 32
TC 4
Z9 4
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JUL-AUG
PY 2012
VL 26
IS 4
BP 571
EP 576
DI 10.1111/j.1399-0012.2011.01580.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 986LZ
UT WOS:000307344400026
PM 22324884
ER

PT J
AU Suzuki, M
   Mujtaba, MA
   Sharfuddin, AA
   Yaqub, MS
   Mishler, DP
   Faiz, S
   Vianna, RM
   Mangus, RS
   Tector, JA
   Taber, TE
AF Suzuki, M.
   Mujtaba, M. A.
   Sharfuddin, A. A.
   Yaqub, M. S.
   Mishler, D. P.
   Faiz, S.
   Vianna, R. M.
   Mangus, R. S.
   Tector, J. A.
   Taber, T. E.
TI Risk factors for native kidney dysfunction in patients with abdominal
   multivisceral/small bowel transplantation
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE calcineurin inhibitor toxicity; intestinal transplant; kidney disease;
   kidney function; kidney injury
ID GLOMERULAR-FILTRATION-RATE; INTESTINAL TRANSPLANTATION; RENAL-FUNCTION;
   LIVER-TRANSPLANTATION; RECIPIENTS; EXPERIENCE; SIROLIMUS; FORMULAS;
   INJURY; ORGAN
AB Kidney dysfunction is a recognized complication after non-renal solid organ transplantation, particularly after intestinal transplant. In our study, we reviewed data on 33 multivisceral transplant (MVT)- and 15 isolated small bowel (ISB)-transplant patients to determine risk factors for kidney dysfunction. Kidney function was estimated by modified diet in renal disease (MDRD) and Schwartz formula for adults and children, respectively. Acute kidney injury (AKI) was defined as an increase in the serum Cr (sCr) greater than twofold. Kidney function declined significantly at one yr after transplantation with 46% of subjects showing an estimated GFR (eGFR) <60 mL/min. Patients with an episode of AKI were more likely to have reduced eGFR than those without AKI (p < 0.025). In linear regression analyses, age, pre-transplant sCr, eGFR at postoperative day (POD) 30, 90, 180, 270, and tacrolimus level at POD 7 showed significant correlation with one yr post-transplant eGFR (p < 0.05). Pediatric patients and patients with MVT had lesser decline in kidney function compared with adults or patients with ISB. In conclusion, risk factors for post-transplant kidney dysfunction in intestinal transplantation included age, pre-transplant sCr, AKI episode, eGFR at POD 30, 90, 180, 270, and tacrolimus level at POD 7.
C1 [Suzuki, M.; Mujtaba, M. A.; Sharfuddin, A. A.; Yaqub, M. S.; Mishler, D. P.; Faiz, S.; Taber, T. E.] Indiana Univ Hlth, Dept Med, Div Nephrol, Indianapolis, IN 46202 USA.
   [Vianna, R. M.; Mangus, R. S.; Tector, J. A.] Indiana Univ Hlth, Dept Surg, Div Transplant, Indianapolis, IN 46202 USA.
RP Mujtaba, MA (reprint author), Indiana Univ Hlth, Dept Med, Div Nephrol, 550 N Univ Blvd,UH 4601, Indianapolis, IN 46202 USA.
EM mmujtaba@iupui.edu
RI Vianna, Rodrigo/K-9023-2016
OI Vianna, Rodrigo/0000-0001-8856-7439
CR Broekroelofs J, 2000, J HEART LUNG TRANSPL, V19, P256, DOI 10.1016/S1053-2498(99)00133-3
   Campistol JM, 2000, TRANSPLANTATION, V69, pSS5
   Cantarovich M, 2006, TRANSPLANTATION, V82, P433, DOI 10.1097/01.tp.0000228888.31242.2b
   Delanaye P, 2006, CLIN TRANSPLANT, V20, P596, DOI 10.1111/j.1399-0012.2006.00523.x
   Fairbanks KD, 2003, LIVER TRANSPLANT, V9, P1079, DOI 10.1053/jlts.2003-50183
   Fishbein TM, 2009, NEW ENGL J MED, V361, P998, DOI 10.1056/NEJMra0804605
   Freeman RB, 2008, AM J TRANSPLANT, V8, P958, DOI 10.1111/j.1600-6143.2008.02174.x
   Go AS, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-22
   Gonwa T, 2004, LIVER TRANSPLANT, V10, P301, DOI 10.1002/lt.20017
   Gupte GL, 2009, CURR OPIN ORGAN TRAN, V14, P267, DOI 10.1097/MOT.0b013e32832ac0f5
   Hahr AJ, 2010, CARDIOL CLIN, V28, P467, DOI 10.1016/j.ccl.2010.04.006
   Herlenius G, 2008, TRANSPLANTATION, V86, P108, DOI 10.1097/TP.0b013e31817613f8
   Hoste EAJ, 2010, CONTRIB NEPHROL, V165, P1, DOI 10.1159/000313737
   Kniepeiss D, 2003, TRANSPLANT INT, V16, P504, DOI 10.1007/s00147-003-0579-1
   Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD
   Lauro A, 2007, CLIN TRANSPLANT, V21, P177, DOI 10.1111/j.1399-0012.2006.00620.x
   Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.000018298.39709.84
   LEWIS RM, 1991, J HEART LUNG TRANSPL, V10, P63
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415
   Stratta P, 2005, KIDNEY INT, V68, P1453, DOI 10.1111/j.1523-1755.2005.00558.x
   Tzakis AG, 2005, ANN SURG, V242, P480, DOI 10.1097/01.sla..0000183347.61361.7a
   Vianna RM, 2008, TRANSPLANTATION, V85, P1290, DOI 10.1097/TP.0b013e31816dd450
   Vianna RM, 2008, TRANSPLANTATION, V85, P1784, DOI 10.1097/TP.0b013e31817889a1
NR 24
TC 10
Z9 10
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JUL-AUG
PY 2012
VL 26
IS 4
BP E351
EP E358
DI 10.1111/j.1399-0012.2012.01672.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 986LZ
UT WOS:000307344400004
PM 22694120
ER

PT J
AU Pongpaibul, A
   Venick, RS
   McDiarmid, SV
   Lassman, CR
AF Pongpaibul, Ananya
   Venick, Robert S.
   McDiarmid, Sue V.
   Lassman, Charles R.
TI Histopathology of de novo autoimmune hepatitis
SO LIVER TRANSPLANTATION
LA English
DT Article
ID PEDIATRIC LIVER-TRANSPLANTATION; LATE GRAFT DYSFUNCTION; RISK-FACTORS;
   REJECTION; CHILDREN
AB De novo autoimmune hepatitis (DAIH) is a well-recognized complication of pediatric liver transplantation (LT). The diagnosis is largely based on elevated liver function test results and the development of autoimmune antibodies. The histology of DAIH was first described in 1998. We present detailed histological data from the largest series to date of pretreatment and posttreatment biopsy samples from pediatric LT patients with DAIH. The histological evaluation included first an assessment of the predominant pattern of injury (hepatitis, rejection, or bile duct obstruction). Then, the necroinflammatory activity (interface, lobular, and perivenular), plasma cell density, rejection activity index, and fibrosis were scored. Seventy of 685 pediatric patients (10.2%) who underwent LT developed DAIH according to clinical and biopsy findings. Fifty-one pretreatment biopsy samples and 38 posttreatment biopsy samples were available for a retrospective review. The predominant pattern of injury (hepatitis, rejection, or bile duct obstruction) was determined, and biopsy samples were scored for the necroinflammatory activity (interface, lobular, and perivenular), plasma cell density, rejection activity index, and fibrosis. The most common pattern of injury was lobular hepatitis, which was frequently unaccompanied by interface necroinflammatory activity or prominent plasma cell infiltrates. Seven of the 51 cases had features strongly suggestive of acute rejection. Posttreatment biopsy samples showed a reduction in the degree of necroinflammatory activity and plasma cell infiltrates. In most patients, the degree of fibrosis was stable or had regressed. Because the histological features of DAIH are variable and nonspecific, a high index of suspicion and correlation with autoimmune antibodies are necessary to establish the diagnosis. In the majority of patients with DAIH, treatment appears to yield good clinical outcomes and histological improvements. Liver Transpl, 2012. (C) 2012 AASLD.
C1 [Lassman, Charles R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Pongpaibul, Ananya] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pathol, Nakhon Pathom, Thailand.
RP Lassman, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 10833 Le Conte Ave,CHS 13-145, Los Angeles, CA 90095 USA.
EM classman@mednet.ucla.edu
CR Abraham SC, 2008, AM J SURG PATHOL, V32, P1479, DOI 10.1097/PAS.0b013e31817a8e96
   Andries S, 2001, TRANSPLANTATION, V72, P267, DOI 10.1097/00007890-200107270-00018
   BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007
   Demetris AJ, 2006, HEPATOLOGY, V44, P489, DOI 10.1002/hep.21280
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   Gupta P, 2001, TRANSPLANTATION, V71, P664, DOI 10.1097/00007890-200103150-00016
   Hadzic N, 2003, HEPATOLOGY, V38, p202A
   Hernandez HM, 2001, J PEDIATR GASTR NUTR, V32, P131, DOI 10.1097/00005176-200102000-00007
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Miyagawa-Hayashino A, 2004, TRANSPLANTATION, V78, P128, DOI 10.1097/01.TP.0000132328.33460.43
   Petz W, 2002, TRANSPLANT P, V34, P1958, DOI 10.1016/S0041-1345(02)03137-8
   Richter A, 2007, CLIN TRANSPLANT, V21, P427, DOI 10.1111/j.1399-0012.2007.00667.x
   Salcedo M, 2002, HEPATOLOGY, V35, P349, DOI 10.1053/jhep.2002.31167
   Spada M, 2001, TRANSPLANT P, V33, P1747, DOI 10.1016/S0041-1345(00)02826-8
   Venick RS, 2007, AM J TRANSPLANT, V7, P955, DOI 10.1111/j.1600-6143.2006.01717.x
   [Anonymous], 1997, HEPATOLOGY, V25, P658
NR 17
TC 3
Z9 4
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2012
VL 18
IS 7
BP 811
EP 818
DI 10.1002/lt.23422
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 972YR
UT WOS:000306318100010
PM 22378542
ER

PT J
AU Oura, T
   Yamashita, K
   Suzuki, T
   Fukumori, D
   Watanabe, M
   Hirokata, G
   Wakayama, K
   Taniguchi, M
   Shimamura, T
   Miura, T
   Okimura, K
   Maeta, K
   Haga, H
   Kubota, K
   Shimizu, A
   Sakai, F
   Furukawa, H
   Todo, S
AF Oura, T.
   Yamashita, K.
   Suzuki, T.
   Fukumori, D.
   Watanabe, M.
   Hirokata, G.
   Wakayama, K.
   Taniguchi, M.
   Shimamura, T.
   Miura, T.
   Okimura, K.
   Maeta, K.
   Haga, H.
   Kubota, K.
   Shimizu, A.
   Sakai, F.
   Furukawa, H.
   Todo, S.
TI Long-Term Hepatic Allograft Acceptance Based on CD40 Blockade by
   ASKP1240 in Nonhuman Primates
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE ASKP1240; CD40-CD154 costimulation blockade; liver transplantation;
   monoclonal antibody; nonhuman primates
ID PEDIATRIC LIVER-TRANSPLANTATION; ANTI-CD40 MONOCLONAL-ANTIBODY; GERMINAL
   CENTER FORMATION; CD4(+) T-CELLS; KIDNEY-TRANSPLANTATION; OPERATIONAL
   TOLERANCE; CYNOMOLGUS MONKEYS; CARDIAC ALLOGRAFTS; CD40-CD40 LIGAND;
   GENE-THERAPY
AB Blockade of the CD40CD154 costimulatory signal is an attractive strategy for immunosuppression and tolerance induction in organ transplantation. Treatment with anti-CD154 monoclonal antibodies (mAbs) results in potent immunosuppression in nonhuman primates (NHPs). Despite plans for future clinical use, further development of these treatments was halted by complications. As an alternative approach, we have been focusing on the inhibition of the counter receptor, CD40 and have shown that a novel human anti-CD40 mAb, ASKP1240, markedly prolongs renal allograft survival in NHPs, although allografts eventually underwent chronic allograft nephropathy. On the basis of our previous findings that a CD40CD154 costimulation blockade induces tolerance to hepatic, but not cardiac, allografts in rodents, we tested here our hypothesis that a blockade of CD40 by ASKP1240 allows acceptance of hepatic allografts in NHPs. A 2-week ASKP1240 induction treatment prolonged liver allograft survival in NHPs; however, the graft function deteriorated due to chronic rejection. In contrast, a 6-month ASKP1240 maintenance monotherapy efficiently suppressed both cellular and humoral alloimmune responses and prevented rejection on the hepatic allograft. No serious side effects, including thromboembolic complications, were noted in the ASKP1240-treated monkeys. We conclude that CD40 blockade by ASKP1240 would be a desirable immunosuppressant for clinical liver transplantation.
C1 [Oura, T.; Yamashita, K.; Suzuki, T.; Fukumori, D.; Watanabe, M.; Hirokata, G.; Wakayama, K.; Taniguchi, M.; Shimamura, T.; Furukawa, H.; Todo, S.] Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Sapporo, Hokkaido, Japan.
   [Miura, T.; Okimura, K.; Maeta, K.] Kyowa Hakko Kirin Co Ltd, Pharmacol Res Labs, Shizuoka, Japan.
   [Haga, H.; Kubota, K.] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Hokkaido 060, Japan.
   [Shimizu, A.] Nippon Med Sch, Dept Pathol, Tokyo 113, Japan.
   [Sakai, F.] Astellas Phama Inc, Tsukuba, Ibaraki, Japan.
RP Todo, S (reprint author), Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Sapporo, Hokkaido, Japan.
EM kenchan@med.hokudai.ac.jp; stodo@med.hokudai.ac.jp
RI Todo, Satoru/G-5659-2012
FU Kyowa Hakko Kirin Co., Ltd (Shizuoka, Japan); Astellas Pharma Inc.
   (Tsukuba, Japan)
FX This work was in part supported by grants aided from Kyowa Hakko Kirin
   Co., Ltd (Shizuoka, Japan) and Astellas Pharma Inc. (Tsukuba, Japan).
CR Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247
   Aoyagi T, 2009, AM J TRANSPLANT, V9, P1732, DOI 10.1111/j.1600-6143.2009.02693.x
   Ashokkumar C, 2009, AM J TRANSPLANT, V9, P179, DOI 10.1111/j.1600-6143.2008.02459.x
   Chang GJ, 2002, SURGERY, V132, P149, DOI 10.1067/msy.2002.125169
   Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293
   Cheng F, 2008, TRANSPL P, V40, P2167, DOI 10.1016/j.transproceed.2008.06.052
   COOPER RA, 1980, SEMIN HEMATOL, V17, P103
   Demetris A, 2000, Hepatology, V31, P792
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157
   Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292
   GOTOH M, 1991, TRANSPLANT P, V23, P3265
   Guillonneau C, 2007, J CLIN INVEST, V117, P1096, DOI 10.1172/JCI28801
   Guillot C, 2002, J IMMUNOL, V168, P1600
   Haanstra KG, 2003, TRANSPLANTATION, V75, P637, DOI 10.1097/01.TP.0000054835.58014.C2
   Hering BJ, 2006, NAT MED, V12, P301, DOI 10.1038/nm1369
   Imai A, 2007, TRANSPLANTATION, V84, P1020, DOI 10.1097/01.tp.0000286058.79448.c7
   Kanmaz T, 2004, TRANSPLANTATION, V77, P914, DOI 10.1097/01.TP.0000116392.72152.75
   KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7
   Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162
   Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536
   Kowalski RJ, 2006, TRANSPLANTATION, V82, P663, DOI 10.1097/01.tp.0000234837.02126.70
   Koyama I, 2007, AM J TRANSPLANT, V7, P1055, DOI 10.1111/j.1600-6143.2006.01703.x
   Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0
   Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002
   Lee JK, 1998, NAT MED, V4, P1383, DOI 10.1038/3973
   MARKUS BH, 1988, TRANSPLANTATION, V46, P372
   Marteius T, 2009, TRANSPL IMMUNOL, V21, P244, DOI 10.1016/j.trim.2009.06.004
   Mauiyyedi S, 2001, J AM SOC NEPHROL, V12, P574
   MONDEN M, 1990, TRANSPLANT P, V22, P66
   Musat AI, 2011, AM J TRANSPLANT, V11, P500, DOI 10.1111/j.1600-6143.2010.03414.x
   NEUHAUS P, 1982, RES EXP MED, V180, P239, DOI 10.1007/BF01852296
   Nomura M, 2002, TRANSPLANTATION, V73, P1403, DOI 10.1097/00007890-200205150-00008
   Pearson TC, 2002, TRANSPLANTATION, V74, P933, DOI 10.1097/01.TP.0000020751.87264.61
   Pitcher CJ, 2002, J IMMUNOL, V168, P29
   Pons JA, 2008, TRANSPLANTATION, V86, P1370, DOI 10.1097/TP.0b013e318188d3e6
   Preston EH, 2005, AM J TRANSPLANT, V5, P1032, DOI 10.1111/j.1600-6143.2005.00796.x
   Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533
   Sayegh MH, 1998, NEW ENGL J MED, V338, P1813
   Starzl TE, 2001, LIVER TRANSPLANT, V7, P918, DOI 10.1053/jlts.2001.0070918
   Taylor PA, 2002, BLOOD, V99, P4601, DOI 10.1182/blood.V99.12.4601
   Terasaki PI, 2003, AM J TRANSPLANT, V3, P665, DOI 10.1034/j.1600-6143.2003.00135.x
   Turgeon Nicole A, 2009, Transplant Rev (Orlando), V23, P25, DOI 10.1016/j.trre.2008.08.001
   Valujskikh A, 2007, J AM SOC NEPHROL, V18, P2252, DOI 10.1681/ASN.2007020151
   van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2
   Weaver TA, 2009, NAT MED, V15, P746, DOI 10.1038/nm.1993
   Yamashita K, 2003, TRANSPLANTATION, V76, P1089, DOI 10.1097/01.TP.0000085651.20586.30
NR 47
TC 20
Z9 21
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2012
VL 12
IS 7
BP 1740
EP 1754
DI 10.1111/j.1600-6143.2012.04014.x
PG 15
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 965TE
UT WOS:000305789400012
PM 22420525
ER

PT J
AU Akhter, K
   Timpone, J
   Matsumoto, C
   Fishbein, T
   Kaufman, S
   Kumar, P
AF Akhter, K.
   Timpone, J.
   Matsumoto, C.
   Fishbein, T.
   Kaufman, S.
   Kumar, P.
TI Six-month incidence of bloodstream infections in intestinal transplant
   patients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE bloodstream infections; intestinal transplant
ID MULTIVISCERAL TRANSPLANTATION; BACTERIAL-INFECTIONS; SMALL-BOWEL;
   COMPLICATIONS; RECIPIENTS
AB Background. Intestinal transplantation has emerged as an established treatment for life-threatening intestinal failure. The most common complication and cause of death is infection. Risk of infection is highest during the first 6 months, as a consequence of maximal immunosuppression, greater than that required for any other organ allograft.
   Methods. We performed a retrospective chart review of all (56) adult and pediatric (<18 years) small bowel transplant patients at our institution between November 2003 and July 2007, and analyzed the 6-month post-transplant incidence of bloodstream infections (BSIs). We evaluated multiple risk factors, including inclusion of a colon or liver, total bilirubin >5, surgical complications, and acute rejection.
   Results. A BSI developed in 34 of the 56 patients, with a total of 85 BSI episodes. Of these BSI episodes, 65.9% were due to gram-positive organisms, 34.1% gram-negative organisms, and 2.4% due to fungi. The most common isolates were Enterococcus species, Enterobacter species, Klebsiella species, and coagulase-negative staphylococci. Inclusion of the liver and/or a preoperative bilirubin >5 mg/dL appeared to increase the incidence of BSI (P = 0.0483 and 0.0005, respectively). Acute rejection and colonic inclusion did not appear to affect the incidence of BSI (P = 0.9419 and 0.8248, respectively). The BSI incidence was higher in children (P = 0.0058).
   Conclusions. BSIs are a common complication of intestinal transplantation. Risk factors include age <18, inclusion of the liver, and pre-transplant bilirubin >5. Acute rejection and colon inclusion do not appear to be associated with increased BSI risk.
C1 [Akhter, K.] Orlando Hlth, Infect Dis Fac Practice, Orlando, FL USA.
   [Timpone, J.; Kumar, P.] Georgetown Univ Hosp, Div Infect Dis, Washington, DC 20007 USA.
   [Matsumoto, C.; Fishbein, T.; Kaufman, S.] Georgetown Univ Hosp, Div Transplant Surg, Washington, DC 20007 USA.
RP Akhter, K (reprint author), Orlando Hlth Infect Dis Fac Practice, 77 W Underwood St,4th Floor,Suite B,MP 79, Orlando, FL 32806 USA.
EM kauser.akhter@orlandohealth.com
CR Abu-Elmagd KM, 1999, TRANSPLANT P, V31, P582, DOI 10.1016/S0041-1345(98)01565-6
   Cicalese L, 2001, TRANSPLANTATION, V71, P1414, DOI 10.1097/00007890-200105270-00010
   Cicalese L., 2000, Transplantation Proceedings, V32, P1210, DOI 10.1016/S0041-1345(00)01189-1
   Fishbein TM, 2009, NEW ENGL J MED, V361, P1416
   Fishbein TM, 2009, NEW ENGL J MED, V361, P998, DOI 10.1056/NEJMra0804605
   Fishbein TM, 2003, GASTROENTEROLOGY, V124, P1615, DOI 10.1016/S0016-5085(03)00375-5
   Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407
   Fryer JP, 2007, GASTROENTEROL CLIN N, V36, P145, DOI 10.1016/j.gtc.2007.01.001
   Guaraldi G, 2005, TRANSPLANTATION, V80, P1742, DOI 10.1097/01.tp.0000185622.91708.57
   Guaraldi G, 2004, TRANSPLANT P, V36, P383, DOI 10.1016/j.transproceed.2003.12.004
   John M, 2005, PEDIATR TRANSPLANT, V10, P198
   Kato T, 2002, WORLD J SURG, V26, P226
   Kato T, 2008, TRANSPLANTATION, V86, P293, DOI 10.1097/TP.0b013e31817ef01c
   Langnas A, 2002, TRANSPLANT P, V34, P958, DOI 10.1016/S0041-1345(02)02716-1
   Loinaz C, 2006, HEPATO-GASTROENTEROL, V53, P234
   Loinaz C, 2003, TRANSPLANT P, V35, P1929, DOI 10.1016/S0041-1345(03)00728-0
   Matsumoto C, 2006, TRANSPLANT P, V38, P1676, DOI 10.1016/j.transproceed.2006.05.034
   Mermel LA, 2001, CLIN INFECT DIS, V32, P1249, DOI 10.1086/320001
   Oltean M, 2006, TRANSPLANT P, V38, P2683, DOI 10.1016/j.transproceed.2006.07.035
   Primeggia J, 2010, INF DIS SOC AM IDSA
   Ruiz P, 2004, TRANSPLANT P, V36, P335, DOI 10.1016/j.transproceed.2004.01.079
   Snydman D R, 1999, Transpl Infect Dis, V1, P21, DOI 10.1034/j.1399-3062.1999.10103.x
   Sweet SC, 2006, AM J TRANSPLANT, V6, P1132, DOI 10.1111/j.1600-6143.2006.02171.x
   TODO S, 1995, ANN SURG, V222, P270, DOI 10.1097/00000658-199509000-00006
   Vianna Rodrigo M, 2008, Adv Surg, V42, P129, DOI 10.1016/j.yasu.2008.03.008
NR 25
TC 11
Z9 11
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD JUN
PY 2012
VL 14
IS 3
BP 242
EP 247
DI 10.1111/j.1399-3062.2011.00683.x
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 956FY
UT WOS:000305076700004
PM 22093913
ER

PT J
AU Polat, KY
   Tosun, MS
   Ertekin, V
   Aydinli, B
   Emre, S
AF Polat, K. Y.
   Tosun, M. S.
   Ertekin, V.
   Aydinli, B.
   Emre, S.
TI Brucella infection with pancytopenia after pediatric liver
   transplantation
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Brucella; brucellosis; pancytopenia; liver transplant; child
ID SOLID-ORGAN; RECIPIENTS; COMPLICATIONS; CHILDREN
AB Brucellosis is considered the most widespread zoonosis in the world. It has been reported that the prevalence of seropositivity among the Turkish population varies from 3% to 14%. We present a case of brucellosis after pediatric liver transplantation. A 15-year-old boy with the diagnosis of neuro Wilson's disease underwent deceased-donor liver transplantation. The postoperative immunosuppressive protocol consisted of steroids and tacrolimus. Two months after the operation the patient experienced fever to 40 degrees C. The patient complained of poor appetite, headache, and diarrhea. He had had pancytopenia. Despite administration of appropriate antibiotics, antiviral and antifungal agents, fever persisted for > 1 month. Multiple blood, urine, stool, and sputum cultures were negative. Bone marrow aspirate revealed hypocellularity. Liver biopsy was performed, but rejection was not observed on biopsy specimen. Brucella serology was positive and Brucella agglutination titer was 1:320. Bone marrow culture was positive for Brucella but blood culture was negative. The patient was then treated with oral doxycyline and rifampin for 8 weeks. No previous case report about Brucella infection after liver transplantation has appeared in the literature, to our knowledge; our case is presented as the first. Bone marrow hypoplasia is a rare feature of Brucella infection. Our patient with brucellosis and pancytopenia had had hypocellular bone marrow. The clinical and hematologic findings resolved with treatment of the infection. Brucella infection should be suspected in liver transplanted recipients with fever of unknown origin, especially in a recipient who has lived in an endemic area. Brucella also should be considered as a possible diagnosis in patients with pancytopenia.
C1 [Tosun, M. S.] Ataturk Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, Erzurum, Turkey.
   [Polat, K. Y.] Mem Atasehir Hosp, Dept Transplant Surg, Istanbul, Turkey.
   [Ertekin, V.] Istanbul Univ, Dept Pediat Gastroenterol Hepatol & Nutr, Istanbul Fac Med, Istanbul, Turkey.
   [Aydinli, B.] Ataturk Univ, Fac Med, Dept Transplant Surg, Erzurum, Turkey.
   [Emre, S.] Yale Univ, Dept Transplant Surg & Immunol, New Haven, CT USA.
RP Tosun, MS (reprint author), Ataturk Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, Erzurum, Turkey.
EM mahyasultan@hotmail.com
CR Al-Anazi Khalid A, 2009, Cases J, V2, P91, DOI 10.1186/1757-1626-2-91
   Al Dahouk S, 2011, EXPERT REV ANTI-INFE, V91, P833
   Bishara J, 1999, Transpl Infect Dis, V1, P138, DOI 10.1034/j.1399-3062.1999.010208.x
   Chiu Loretta M, 2004, Prog Transplant, V14, P114
   Christopher Supriya, 2010, J Lab Physicians, V2, P55, DOI 10.4103/0974-2727.72149
   Cocci S, 2010, LIVER TRANSPLANT, V16, P2015
   Ertekin V, 2004, TROP DOCT, V34, P57
   Ertem M, 2000, BONE MARROW TRANSPL, V26, P225, DOI 10.1038/sj.bmt.1702480
   Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928
   Karakukcu M, 2004, J PEDIAT HEMATOL ONC, V26, P803
   Kotton CN, 2007, CLIN INFECT DIS, V44, P857, DOI 10.1086/511859
   NICHOLSON V, 1994, SURG CLIN N AM, V74, P1223
   Paterson DL, 1997, CLIN INFECT DIS, V25, P1430, DOI 10.1086/516138
   Pickering LK, 2000, 2000 RED BOOK REPORT, P192
   Tanir G, 2009, PEDIATR INT, V51, P114, DOI 10.1111/j.1442-200X.2008.02661.x
   Yildirmak Y, 2003, J PEDIAT HEMATOL ONC, V25, P63, DOI 10.1097/00043426-200301000-00012
   Yousif B, 2001, AM J NEPHROL, V21, P66, DOI 10.1159/000046223
NR 17
TC 7
Z9 9
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD JUN
PY 2012
VL 14
IS 3
BP 326
EP 329
DI 10.1111/j.1399-3062.2011.00709.x
PG 4
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 956FY
UT WOS:000305076700017
PM 22260451
ER

PT J
AU Mali, VP
   Aw, M
   Quak, SH
   Loh, DL
   Prabhakaran, K
AF Mali, V. P.
   Aw, M.
   Quak, S. H.
   Loh, D. L.
   Prabhakaran, K.
TI Vascular Complications in Pediatric Liver Transplantation; Single-Center
   Experience from Singapore
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID HEPATIC-ARTERY THROMBOSIS; PORTAL-VEIN THROMBOSIS; VENOUS COMPLICATIONS;
   RISK-FACTORS; RECONSTRUCTION; STENOSIS; CHILDREN; INFANTS; GRAFTS;
   DONORS
AB Aim. Vascular complications (VC) are a major cause of significant morbidity and mortality in pediatric liver transplantation (LT). We reviewed our series to study the evolution of vascular reconstructions and its effect on the incidence of VC after LT, particularly with regard to the portal vein (PV).
   Methods. The medical records of 81 pediatric LT performed in 76 children (38 boys) from 1991 to 2010 in the National University Hospital, Singapore, were reviewed to identify VC pertaining to PV, hepatic artery (HA), and hepatic veins (14V) and to analyse the data for the entire series and in 2 consecutive cohorts: initial 40 LT (group 1) and subsequent 41 LT (group 2). Specific interventions in group 2 were characterized by surgical innovations for reconstruction of the difficult PV and routine use of Doppler ultrasound intraoperatively and postoperatively.
   Results. The overall incidence of VC was 19.7% (n = 16) and individually HA thrombosis 4.9% (n = 4), HA stenosis 1.2% (n = 1), PV thrombosis 12.3% (n = 9), PV stenosis 1.2% (n = 1), and HV thrombosis 1.2% (n = 1). The overall 1- and 5-year survival rates in our series were 89% and 85%, respectively. The 1- and 5-year survival rates in patients with and without VC were 81.25% and 68.75% and 90.8% and 89.2%, respectively. The incidence of VC decreased from 27.5% in group 1 to 12.1% in group 2 (p = .08). The major contribution to this appears to be a decrease in PV complications from 17.5% in group 1 to 7.3% in group 2 (P = .1). The incidence of HA (3 vs 2) and HV (1 vs 0) complications was similar between the 2 groups.
   Conclusions. Vascular reconstructions in small recipients are technically challenging and associated with a learning curve. Application of meticulous techniques in general, surgical innovations to the difficult PV in particular and attention to postoperative monitoring contribute toward a major reduction in VC.
C1 [Mali, V. P.; Loh, D. L.; Prabhakaran, K.] Natl Univ Singapore Hosp, Dept Paediat Surg, Singapore 119228, Singapore.
   [Aw, M.; Quak, S. H.] Natl Univ Singapore Hosp, Dept Paediat Hepatol & Gastroenterol, Singapore 119228, Singapore.
RP Prabhakaran, K (reprint author), Natl Univ Singapore Hosp, Dept Paediat Surg, NUHS Tower Block,Level 12,1E Kentridge Rd, Singapore 119228, Singapore.
EM surprabh@nus.edu.sg
RI Aw, Marion/D-8882-2015
CR BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   de Magnee C, 2011, ANN SURG, V254, P55, DOI 10.1097/SLA.0b013e3182121eb7
   Dickson BC, 2004, U TORONTO MED J, V81, P166
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   Gill P, 2009, TRANSPLANTATION, V88, P595, DOI 10.1097/TP.0b013e3181b11fa7
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   Heffron TG, 2010, PEDIATR TRANSPLANT, V14, P722, DOI 10.1111/j.1399-3046.2009.01259.x
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Kadry Z, 2002, TRANSPLANTATION, V74, P696, DOI 10.1097/01.TP.0000024447.45019.C2
   KALAYOGLU M, 1990, TRANSPLANT P, V22, P1489
   Kawamoto S, 1998, SURG TODAY, V28, P1237
   Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x
   Khalaf H, 2010, TRANSPL P, V42, P865, DOI 10.1016/j.transproceed.2010.02.037
   La Barba Giuliano, 2004, Liver Transpl, V10, P710, DOI 10.1002/lt.20163
   Mali VP, 2011, PEDIAT TRANSPLAN AUG
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Rahbar A, 2005, J VIROL, V79, P2211, DOI 10.1128/JVI.79.4.2211-2220.2005
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Sakamoto Y, 1999, BRIT J SURG, V86, P886, DOI 10.1046/j.1365-2168.1999.01166.x
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   STAHL RL, 1990, HEPATOLOGY, V12, P553, DOI 10.1002/hep.1840120317
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   Sugawara Y, 2002, TRANSPLANT P, V34, P3325, DOI 10.1016/S0041-1345(02)03576-5
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   Tannuri U, 2010, J PEDIATR SURG, V46, P1379
   TISONE G, 1988, TRANSPLANTATION, V46, P162, DOI 10.1097/00007890-198807000-00032
   Uchida Y, 2009, CLIN TRANSPLANT, V23, P392, DOI 10.1111/j.1399-0012.2008.00924.x
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 36
TC 7
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2012
VL 44
IS 5
BP 1373
EP 1378
DI 10.1016/j.transproceed.2012.01.129
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 959KX
UT WOS:000305312400037
PM 22664018
ER

PT J
AU Ackermann, O
   Branchereau, S
   Franchi-Abella, S
   Pariente, D
   Chevret, L
   Debray, D
   Jacquemin, E
   Gauthier, F
   Hill, C
   Bernard, O
AF Ackermann, O.
   Branchereau, S.
   Franchi-Abella, S.
   Pariente, D.
   Chevret, L.
   Debray, D.
   Jacquemin, E.
   Gauthier, F.
   Hill, C.
   Bernard, O.
TI The Long-Term Outcome of Hepatic Artery Thrombosis After Liver
   Transplantation in Children: Role of Urgent Revascularization
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Graft survival; hepatic artery thrombosis; liver transplantation in
   children; long-term outcome; surgical emergency revascularization
ID REDUCED-SIZE GRAFTS; VASCULAR COMPLICATIONS; SINGLE-CENTER;
   RISK-FACTORS; EXPERIENCE
AB Hepatic artery thrombosis (HAT), one of the most severe complications of pediatric orthotopic liver transplantation (OLT), often compromises graft and/or child survival. Of 590 OLT performed in 516 children over a 20-year period, 45 were complicated by early HAT, during the first 2 weeks after transplantation. Systematic Doppler ultrasonographic detection of HAT allowed successful surgical revascularization in 19 instances, resulting in a 20-year graft survival rate of 77% versus 24% of cases when revascularization was not attempted or failed. A combination of surgical emergency revascularization, biliary interventional radiology, biliary surgery and/or retransplantation resulted in an 80% 20-year patient survival rate, identical to that of transplanted children who did not experience early HAT. The majority of long-term survivors with their initial graft had normal liver tests, no biliary dilation on ultrasonography and minimal or moderate fibrosis on liver histology. A failed attempt at revascularization did not significantly alter patient survival. Despite these encouraging results, for the children and their parents to overcome the entire process in terms of reoperations, repeated radiological interventions, number of hospitalizations and emotional stress, remains an ordeal of such magnitude that it justifies renewed efforts to progress in the prevention of this complication.
C1 [Ackermann, O.; Branchereau, S.; Franchi-Abella, S.; Pariente, D.; Chevret, L.; Debray, D.; Jacquemin, E.; Gauthier, F.; Bernard, O.] Hop Bicetre, AP HP, Paris, France.
   [Ackermann, O.; Branchereau, S.; Chevret, L.; Debray, D.; Jacquemin, E.; Gauthier, F.; Bernard, O.] Univ Paris 11, Paris, France.
   [Hill, C.] Inst Gustave Roussy, Villejuif, France.
RP Ackermann, O (reprint author), Hop Bicetre, AP HP, Paris, France.
EM oanez.ackermann@bct.aphp.fr
RI jacquemin, emmanuel/J-8673-2013
FU Fondation Rumsey-Cartier
FX The authors thank Mathilde Dreyfus for English language editing, for
   which funding was provided by the Fondation Rumsey-Cartier.
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Cacciarelli TV, 1999, TRANSPLANTATION, V15, P650
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   JURIM O, 1995, J PEDIATR SURG, V30, P53, DOI 10.1016/0022-3468(95)90609-6
   Kaneko J, 2004, TRANSPLANT P, V36, P3087, DOI 10.1016/j.transproceed.2004.10.065
   Kim HB, 2010, LIVER TRANSPLANT, V16, P812, DOI 10.1002/lt.22115
   Madalosso C, 1998, TRANSPLANTATION, V66, P294, DOI 10.1097/00007890-199808150-00003
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Panossian A, 2009, J RECONSTR MICROSURG, V25, P439, DOI 10.1055/s-0029-1223853
   Pastacaldi S, 2001, LIVER TRANSPLANT, V7, P75, DOI 10.1053/jlts.2001.22040
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   Uchida Y, 2009, CLIN TRANSPLANT, V23, P392, DOI 10.1111/j.1399-0012.2008.00924.x
   Warnaar N, 2010, LIVER TRANSPLANT, V16, P847, DOI 10.1002/lt.22063
NR 21
TC 15
Z9 16
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2012
VL 12
IS 6
BP 1496
EP 1503
DI 10.1111/j.1600-6143.2011.03984.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 948SM
UT WOS:000304522900020
PM 22390346
ER

PT J
AU Singhal, A
   Vadlamudi, S
   Stokes, K
   Cassidy, FP
   Corn, A
   Shrago, SS
   Wright, HI
   Kohli, V
AF Singhal, Ashish
   Vadlamudi, Saraschand
   Stokes, Kenneth
   Cassidy, Francis P.
   Corn, Ayumi
   Shrago, Stan S.
   Wright, Harlan I.
   Kohli, Vivek
TI Liver histology as predictor of outcome in patients with acute liver
   failure
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE acute; biopsy; failure; fulminant; histology; liver; transjugular;
   transplantation
ID FULMINANT HEPATIC-FAILURE; EARLY INDICATORS; UNITED-STATES; BIOPSY
AB Acute liver failure (ALF) is a clinical syndrome associated with significant morbidity and mortality with a highly unpredictable outcome. We retrospectively analyzed 71 ALF patients (53 males; mean age = 27.5 +/- 15.6 years) that underwent transjugular liver biopsy (TJLB) at our institution. The aims of this study are (i) to report our experience with TJLB in these patients, and (ii) to examine the role of liver histology in predicting their outcome. We also compared the histopathological findings between TJLB and explanted liver specimens in 31 patients who underwent liver transplantation (LT). Biopsy specimens were satisfactory for histopathological analyses in 69 (97.1%) patients, confirmed the clinical diagnosis in 56 (81.2%) patients, and altered the diagnosis in 13 (18.8%) patients. Minor complications were encountered in four (5.6%) patients. Percentage of hepatocyte necrosis was the only histological parameter that has significant discriminatory prognostic value, with no survivors having >75% necrosis without LT. In conclusions, TJLB is a safe technique for obtaining liver tissue in both adult and pediatric patients with ALF. Histological characteristics, mainly etiological diagnosis and degree of hepatocyte necrosis may assist in clinical decision-making for need of LT in these patients.
C1 [Singhal, Ashish; Vadlamudi, Saraschand; Wright, Harlan I.; Kohli, Vivek] INTEGRIS Baptist Med Ctr, Nazih Zuhdi Transplant Inst, Oklahoma City, OK 73112 USA.
   [Stokes, Kenneth; Cassidy, Francis P.] INTEGRIS Baptist Med Ctr, Dept Intervent Radiol, Oklahoma City, OK 73112 USA.
   [Corn, Ayumi; Shrago, Stan S.] INTEGRIS Baptist Med Ctr, Dept Pathol, Oklahoma City, OK 73112 USA.
RP Kohli, V (reprint author), INTEGRIS Baptist Med Ctr, Nazih Zuhdi Transplant Inst, 3300 NW Expressway, Oklahoma City, OK 73112 USA.
EM vivek.kohli@gmail.com
CR Akdogan Meral, 2003, Turk J Gastroenterol, V14, P164
   Cholongitas E, 2006, GUT, V55, P1789, DOI 10.1136/gut.2005.090415
   Dhiman RK, 1998, DIGEST DIS SCI, V43, P1311, DOI 10.1023/A:1018876328561
   DONALDSON BW, 1993, HEPATOLOGY, V18, P1370, DOI 10.1016/0270-9139(93)90226-D
   Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250
   HANAU C, 1995, HEPATOLOGY, V21, P345, DOI 10.1016/0270-9139(95)90091-8
   HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1016/0270-9139(95)90434-4
   HORNEY JT, 1977, GASTROENTEROLOGY, V73, P639
   Kalambokis G, 2007, J HEPATOL, V47, P284, DOI 10.1016/j.jhep.2007.05.001
   KARVOUNTZIS GG, 1974, GASTROENTEROLOGY, V67, P870
   Kjaergard LL, 2003, JAMA-J AM MED ASSOC, V289, P217, DOI 10.1001/jama.289.2.217
   Lee WM, 2003, SEMIN LIVER DIS, V23, P217
   Macedo G, 2000, TRANSPLANT P, V32, P2643, DOI 10.1016/S0041-1345(00)01818-2
   Mammen T, 2008, J VASC INTERV RADIOL, V19, P351, DOI 10.1016/j.jvir.2007.09.002
   Miraglia R, 2006, CARDIOVASC INTER RAD, V29, P1008, DOI 10.1007/s00270-006-0052-5
   OGRADY JG, 1993, LANCET, V342, P273
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439
   Ostapowicz G, 2002, ANN INTERN MED, V137, P947
   RAKELA J, 1985, MAYO CLIN PROC, V60, P289
   Sacks D, 2003, J VASC INTERV RADIOL, V14, pS199, DOI DOI 10.1097/01.RVI.0000094584.83406.3E.MEDLINE
   Sokol FLJ, 1985, J PEDIAT, V107, P549
   WARE AJ, 1975, GASTROENTEROLOGY, V68, P519
NR 22
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD JUN
PY 2012
VL 25
IS 6
SI SI
BP 658
EP 662
DI 10.1111/j.1432-2277.2012.01470.x
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 942IA
UT WOS:000304036200011
PM 22487361
ER

PT J
AU Ecevit, C
   Unal, F
   Baran, M
   Aydogdu, S
AF Ecevit, Cigdem
   Unal, Fatih
   Baran, Masallah
   Aydogdu, Sema
TI Parenthood in pediatric liver transplant patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pregnancy; parenthood
ID PREGNANCY; RECIPIENTS; TACROLIMUS; EXPERIENCE
AB Ecevit C, Unal F, Baran M, Aydogdu S. Parenthood in pediatric liver transplant patients. Abstract: Liver transplantation has become a universally accepted treatment for numerous congenital and acquired hepatic disorders that cause liver failure. Without liver transplantation, patients in their reproductive years are afflicted with oligospermia or azoospermia in men and amenorrhea in women, with infertility being a consequence in both sexes. The aim of this study is to describe our experiences concerning the parenthood of pediatric individuals who are successful recipients of liver transplantations coming into the reproductive years of life. We retrospectively analyzed data of 207 pediatric liver transplanted patients (96 women, 111 men). Among them, three women conceived and delivered four babies, and two men admitted to paternity of two children after they all had been recipients of liver transplants. All female transplant recipients had received tacrolimus-based immunosuppression. Preterm delivery was the most clinically important complication among these patients. Only one of the female patients experienced hypercalcemia during the pregnancy. None had any other complications such as hypertension, preeclampsia, cholestasis, or diabetes. There was no graft insufficiency, rejection, or birth defect. We concluded that maternity and paternity in liver transplant patients show normal outcomes even though this procedure occurs in childhood, and pregnancy did not seem to impair graft function in patients receiving immunosuppressive drugs.
C1 [Ecevit, Cigdem; Unal, Fatih; Baran, Masallah; Aydogdu, Sema] Ege Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, TR-35320 Izmir, Turkey.
RP Ecevit, C (reprint author), Ege Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, Huzur Mah Serce Sok Turkuaz Apt 5,D 13 Narlidere, TR-35320 Izmir, Turkey.
EM ctecevit@hotmail.com
CR Armenti VT, 2000, LIVER TRANSPLANT, V6, P671, DOI 10.1053/jlts.2000.18703
   Casele HL, 1998, TRANSPLANTATION, V65, P581, DOI 10.1097/00007890-199802270-00023
   Christopher V, 2006, LIVER TRANSPLANT, V12, P1138, DOI 10.1002/lt.20810
   Coscia Lisa A, 2010, Clin Transpl, P65
   Jain AB, 2003, TRANSPLANTATION, V76, P827, DOI 10.1097/01.TP.0000084823.89528.89
   Janssen NM, 2000, ARCH INTERN MED, V160, P610, DOI 10.1001/archinte.160.5.610
   Kainz A, 2000, TRANSPLANTATION, V70, P1718, DOI 10.1097/00007890-200012270-00010
   KIRK EP, 1991, AM J OBSTET GYNECOL, V164, P1629
   MADERSBACHER S, 1994, J UROLOGY, V151, P1251
   Malatesta MFD, 2006, TRANSPL IMMUNOL, V15, P297, DOI 10.1016/j.trim.2006.01.001
   McKay DB, 2005, AM J TRANSPLANT, V5, P1592, DOI 10.1111/j.1600-6143.2005.00969.x
   Nagy S, 2003, OBSTET GYNECOL, V102, P121, DOI 10.1016/S0029-7844(03)00369-7
   Raakow R, 2001, TRANSPLANT P, V33, P1450, DOI 10.1016/S0041-1345(00)02549-5
   Radomski J S, 1995, Liver Transpl Surg, V1, P281, DOI 10.1002/lt.500010502
   Riely CA, 2001, LIVER TRANSPL S1, V7, P74
   Surti B, 2008, LIVER INT, V28, P1200, DOI 10.1111/j.1478-3231.2008.01871.x
   VILLE Y, 1993, AM J OBSTET GYNECOL, V168, P896
   WALCOTT WO, 1978, AM J OBSTET GYNECOL, V132, P340
   Zuber J, 2008, AM J TRANSPLANT, V7, P1471
NR 19
TC 3
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2012
VL 16
IS 4
BP 346
EP 349
DI 10.1111/j.1399-3046.2012.01671.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 941WO
UT WOS:000303998800017
PM 22404458
ER

PT J
AU Hill, AL
   Maeda, K
   Bonham, CA
   Concepcion, W
AF Hill, Amy L.
   Maeda, Katsuhide
   Bonham, Clark A.
   Concepcion, Waldo
TI Pediatric combined heart-liver transplantation performed en bloc: A
   single-center experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE combined heart-liver transplant; pediatric transplantation; operative
   technique
AB Hill AL, Maeda K, Bonham CA, Concepcion W. Pediatric combined heartliver transplantation performed en bloc: A single-center experience. Abstract: Pediatric CHLT is rarely performed in transplant centers and even fewer are performed en bloc. In the hands of an experienced surgeon with the appropriate patient selection, CHLT performed en bloc may have several operative and immunologic benefits, thereby resulting in improved outcomes for the transplant recipient. A single-institutional, retrospective review from 1/1/06 to 12/31/10 was conducted. Three pediatric patients with end-stage heart and liver disease who were considered low immunologic risk were included. All were managed by the same surgeon with a herein-described CHLT donor and recipient operation. Data were collected on patient and graft survival, rejection episodes, infectious complications, operative time, intraoperative transfusion requirements, and immunosuppression regimens. One-yr patient and graft survival rates were 100%. No patients experienced antibody-mediated or cell-mediated rejection. No patients had postoperative infections, and all patients were free of opportunistic infections at one-yr post-transplant. All patients were maintained safely on steroid-free immunosuppression. There were no intraoperative complications. In pediatric end-stage heart and liver disease patients with low immunologic risk, it is reasonable to proceed with en bloc CHLT so long as there is an experienced surgeon to perform the case. This offers operative and immunologic advantages to the recipient while maintaining equivalent, if not improved, recipient and graft outcomes.
C1 [Hill, Amy L.; Bonham, Clark A.; Concepcion, Waldo] Stanford Univ, Dept Surg, Stanford, CA 94305 USA.
   [Hill, Amy L.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
   [Maeda, Katsuhide] Stanford Univ, Dept Cardiothorac Surg, Stanford, CA 94305 USA.
RP Concepcion, W (reprint author), Stanford Univ, Sch Med, Dept Transplant Surg, 750 Welch Rd,Ste 319,MC 5731, Palo Alto, CA 94304 USA.
EM wconcepcion@stanfordmed.org
CR STARZL TE, 1984, LANCET, V1, P1382
   Te HS, 2008, J HEART LUNG TRANSPL, V27, P753, DOI 10.1016/j.healun.2008.04.004
NR 2
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2012
VL 16
IS 4
BP 392
EP 397
DI 10.1111/j.1399-3046.2012.01695.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 941WO
UT WOS:000303998800024
PM 22583978
ER

PT J
AU Moon, SB
   Jung, SM
   Kwon, CH
   Kim, SJ
   Joh, JW
   Seo, JM
   Lee, SK
AF Moon, Suk-Bae
   Jung, Soo-Min
   Kwon, Choon-Hyuk
   Kim, Sung-Joo
   Joh, Jae-Won
   Seo, Jeong-Meen
   Lee, Suk-Koo
TI Posteromedial diaphragmatic hernia following pediatric liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; diaphragmatic hernia; children
AB Moon S-B, Jung S-M, Kwon C-H, Kim S-J, Joh J-W, Seo J-M, Lee S-K. Posteromedial diaphragmatic hernia following pediatric liver transplantation. Abstract: Diaphragmatic hernia is a rare complication following pediatric LT. Here, four children who developed right-sided posteromedial diaphragmatic hernias after LT are reported. The primary disease was biliary atresia in two patients, hemangioendothelioma in one, and angiosarcoma in one patient. All of the patients underwent living-donor LT using a left lateral graft. The patients presented with abdominal and/or pulmonary signs and symptoms. The diaphragmatic hernias were diagnosed at 28 days to seven months post-transplant by standard radiographs or chest CT. The defects were located at the posteromedial aspect of the diaphragm and were closed by primary closure. After diaphragm repair, the post-operative course was unremarkable and there were no recurrences. Thermal or mechanical injuries to the bare area, especially in cases of excessive adhesion between the liver and diaphragm after Kasai operation, were the possible causes of the posteromedial diaphragmatic hernia after pediatric LT.
C1 [Moon, Suk-Bae; Jung, Soo-Min; Kwon, Choon-Hyuk; Kim, Sung-Joo; Joh, Jae-Won; Seo, Jeong-Meen; Lee, Suk-Koo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea.
RP Lee, SK (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, 50 Ilwon Dong, Seoul 135710, South Korea.
EM sukkoo.lee@samsung.com
OI Joh, Jae-Won/0000-0003-1732-6210
CR CHARNSANGAVEJ C, 1982, RADIOLOGY, V144, P485
   de Goyet JD, 2002, TRANSPLANTATION, V73, P166
   Englert C, 2006, TRANSPLANTATION, V82, P574, DOI 10.1097/01.tp.0000231709.63721.5c
   HARTZ RS, 1984, J THORAC CARDIOV SUR, V87, P141
   Mack C L, 2000, Pediatr Transplant, V4, P39, DOI 10.1034/j.1399-3046.2000.00080.x
   Manczur TI, 2002, TRANSPLANTATION, V73, P228, DOI 10.1097/00007890-200201270-00013
   McCabe AJ, 2005, J PEDIATR SURG, V40, P1181, DOI 10.1016/j.jpedsurg.2005.03.063
   Midorikawa Y, 1999, SURGERY, V126, P484, DOI 10.1067/msy.2099.99573
   Smyrniotis V, 1998, TRANSPLANT INT, V11, P281, DOI 10.1111/j.1432-2277.1998.tb00971.x
   Tsunezuka Y, 2001, EUR J CARDIO-THORAC, V20, P205, DOI 10.1016/S1010-7940(01)00751-5
NR 10
TC 7
Z9 7
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2012
VL 16
IS 4
BP E106
EP E109
DI 10.1111/j.1399-3046.2010.01462.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 941WO
UT WOS:000303998800002
PM 21235708
ER

PT J
AU Lee, HY
   Lu, CH
   Lu, HF
   Chen, CL
   Wang, CH
   Cheng, KW
   Wu, SC
   Jawan, B
   Huang, CJ
AF Lee, H. -Y.
   Lu, C. -H.
   Lu, H. -F.
   Chen, C. -L.
   Wang, C. -H.
   Cheng, K. -W.
   Wu, S. -C.
   Jawan, B.
   Huang, C. -J.
TI Relationship Between Postoperative Lung Atelectasis and Position of the
   Endotracheal Tube in Pediatric Living-Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 12th Congress of the Asian-Society-of-Transplantation (AST)
CY SEP 25-28, 2011
CL Seoul, SOUTH KOREA
SP Asian Soc Transplantat (AST)
ID PULMONARY COMPLICATIONS; RISK-FACTORS; RECIPIENTS
AB Objective. The aims of current study were: 1) to evaluate the incidence of lung atelectasis; and 2) to investigate whether or not the position of the endotracheal (ET) tube is associated with this complication.
   Methods. The Medical records and chest roentgenograms of 183 pediatric patients who underwent living-donor liver transplantation were retrospectively reviewed and analyzed. Patients without atelectasis were grouped in group I (GI) and those with atelectasis in group II (GII). The patients' characteristics and ET tube level between groups were compared with unpaired Student's t test. Multiple binary logistic regressions were also performed to identify the important risk factors associated with lung atelectasis.
   Results. Right upper lung (RUL) atelectsis could be found in ET tube at any level from T1 to T5, with incidence rates of 12.7%, 15.2%, 26.3%, 6.7%, and 100% for T1, T2, T3, T4, and T5, respectively. The incidence of atelectasis is 16.6%, and all of the atelectasis occurred in the RUL. No significant difference between groups was observed in the patients' characteristics, except for the amount of preoperative ascites. The likelihood of this risk factor could not be confirmed by multivariate binary logistic regression analysis.
   Conclusions. The incidence of lung atelectasis in our study was 16.6%, which all occurred in the RUL. No predictive risk factor from the patients' characteristics could be found, and no correlation between the level of the ET tube and the occurrence of RUL atelectasis could be observed.
C1 [Lee, H. -Y.; Lu, H. -F.; Wang, C. -H.; Cheng, K. -W.; Wu, S. -C.; Jawan, B.; Huang, C. -J.] Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung 833, Taiwan.
   [Lu, C. -H.] Kaohsiung Chang Gung Mem Hosp, Dept Radiol, Kaohsiung 833, Taiwan.
   [Chen, C. -L.] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung 833, Taiwan.
   [Chen, C. -L.] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Program, Kaohsiung 833, Taiwan.
   Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
RP Huang, CJ (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, 123 Tapei Rd, Kaohsiung 833, Taiwan.
EM maomd@hotmail.com
CR Bozbas SS, 2008, EXP CLIN TRANSPLANT, V6, P264
   Hong SK, 2006, TRANSPLANT P, V38, P2979, DOI 10.1016/j.transproceed.2006.08.090
   Jawan B, 2004, TRANSPLANTATION, V77, P1394, DOI 10.1097/01.TP.0000122419.66639.19
   Jawan B, 2003, LIVER TRANSPLANT, V9, P760, DOI 10.1053/jlts.2003.50131
   Kaditis AG, 2008, ANESTH ANALG, V106, P775, DOI 10.1213/ane.0b013e318162c20a
   Lin CC, 2004, TRANSPLANT P, V36, P2338, DOI 10.1016/j.transproceed.2004.07.044
   Lin YH, 2010, J INT MED RES, V38, P1845
   Pirat A, 2004, TRANSPLANT P, V36, P218, DOI 10.1016/j.transproceed.2003.11.026
   Siniscalchi A, 2009, TRANSPL P, V41, P1240, DOI 10.1016/j.transproceed.2009.02.046
   Woodring JH, 1996, J THORAC IMAG, V11, P92, DOI 10.1097/00005382-199621000-00002
NR 10
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2012
VL 44
IS 4
BP 875
EP 877
DI 10.1016/j.transproceed.2012.03.004
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 944YT
UT WOS:000304240400014
PM 22564571
ER

PT J
AU Neto, JS
   Pugliese, R
   Fonseca, EA
   Vincenzi, R
   Pugliese, V
   Candido, H
   Stein, AB
   Benavides, M
   Ketzer, B
   Teng, H
   Porta, G
   Miura, IK
   Baggio, V
   Guimaraes, T
   Porta, A
   Rodrigues, CA
   Carnevale, FC
   Carone, E
   Kondo, M
   Chapchap, P
AF Seda Neto, Joao
   Pugliese, Renata
   Fonseca, Eduardo A.
   Vincenzi, Rodrigo
   Pugliese, Vincenzo
   Candido, Helry
   Stein, Alberto B.
   Benavides, Marcel
   Ketzer, Bernardo
   Teng, Hsiang
   Porta, Gilda
   Miura, Irene K.
   Baggio, Vera
   Guimaraes, Teresa
   Porta, Adriana
   Rodrigues, Celso Arrais
   Carnevale, Francisco C.
   Carone, Eduardo
   Kondo, Mario
   Chapchap, Paulo
TI Four hundred thirty consecutive pediatric living donor liver
   transplants: Variables associated with posttransplant patient and graft
   survival
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LONG-TERM; SURGICAL TECHNIQUES; CHILDREN; COMPLICATIONS; GROWTH;
   MORTALITY; OUTCOMES; IMPACT; VEIN
AB The availability of living donors allows transplant teams to indicate living donor liver transplantation (LDLT) early in the course of liver disease before the occurrence of life-threatening complications. Late referral to transplant centers is still a problem and can compromise the success of the procedure. The aim of this study was to examine the perioperative factors associated with patient and graft survival for 430 consecutive pediatric LDLT procedures at Sirio-Libanes Hospital/A. C. Camargo Hospital (Sao Paulo, Brazil) between October 1995 and April 2011. The studied pretransplant variables included the following: recipient age and body weight, Pediatric End-Stage Liver Disease score, z score for height/age, bilirubin, albumin, international normalized ratio, hemoglobin, sodium, presence of ascites, and previous surgery. The analyzed technical aspects included the graft-to-recipient weight ratio and the use of vascular grafts for portal vein reconstruction. In addition, the occurrence of hepatic artery thrombosis (HAT), portal vein thrombosis (PVT), and biliary complications was also analyzed. The liver grafts included 348 left lateral segments, 5 monosegments, 51 left lobes, and 9 right lobes. In a univariate analysis, an age < 12 months, a low body weight (=10 kg), malnutrition, hyperbilirubinemia, and HAT were associated with decreased patient and graft survival after LDLT. In a multivariate analysis, a body weight = 10 kg and HAT were significantly associated with decreased patient and graft survival. The use of vascular grafts significantly increased the occurrence of PVT. In conclusion, a low body weight (=10 kg) and the occurrence of HAT independently determined worse patient and graft survival in this large cohort of pediatric LDLT patients. Liver Transpl, 2012. (C) 2012 AASLD.
C1 [Seda Neto, Joao; Pugliese, Renata; Fonseca, Eduardo A.; Vincenzi, Rodrigo; Pugliese, Vincenzo; Candido, Helry; Stein, Alberto B.; Benavides, Marcel; Ketzer, Bernardo; Teng, Hsiang; Porta, Gilda; Miura, Irene K.; Baggio, Vera; Guimaraes, Teresa; Porta, Adriana; Rodrigues, Celso Arrais; Carnevale, Francisco C.; Carone, Eduardo; Kondo, Mario; Chapchap, Paulo] AC Camargo Hosp, Sirio Libanes Hosp, BR-01308000 Sao Paulo, Brazil.
RP Neto, JS (reprint author), AC Camargo Hosp, Sirio Libanes Hosp, Rua Barata Ribeiro 414,CJ 65, BR-01308000 Sao Paulo, Brazil.
EM joaoseda@gmail.com
RI Carnevale, Francisco /I-6135-2015; 
OI Carnevale, Francisco Cesar/0000-0003-2659-9624
CR Barr ML, 2006, TRANSPLANTATION, V81, P1373, DOI 10.1097/01.tp.0000216825.56841.cd
   Barshes NR, 2006, J PEDIATR GASTR NUTR, V43, P89, DOI 10.1097/01.mpg.0000226378.03247.1f
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Dehghani SM, 2007, TRANSPL P, V39, P3175, DOI 10.1016/j.transproceed.2007.07.080
   DeRusso PA, 2007, HEPATOLOGY, V46, P1632, DOI 10.1002/hep.21923
   El Moghazy WM, 2010, LIVER TRANSPLANT, V16, P453, DOI 10.1002/lt.22010
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   MALATACK JJ, 1987, J PEDIATR-US, V111, P479, DOI 10.1016/S0022-3476(87)80105-1
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   Seda-Neto J, 2008, TRANSPLANTATION, V86, P697, DOI 10.1097/TP.0b013e318183ed22
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Sieders E, 2000, TRANSPLANTATION, V70, P1448, DOI 10.1097/00007890-200011270-00009
   Soltys KA, 2007, AM J TRANSPLANT, V7, P2165, DOI 10.1111/j.1600-6143.2007.01893.x
   Somsouk M, 2011, LIVER TRANSPLANT, V17, P129, DOI 10.1002/lt.22218
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tanaka K, 2005, J HEPATOL, V42, P25, DOI 10.1016/j.jhep.2004.11.004
   Uchida Y, 2009, CLIN TRANSPLANT, V23, P392, DOI 10.1111/j.1399-0012.2008.00924.x
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
NR 23
TC 18
Z9 20
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAY
PY 2012
VL 18
IS 5
BP 577
EP 584
DI 10.1002/lt.23393
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 929FW
UT WOS:000303047700011
PM 22271646
ER

PT J
AU Florescu, DF
   Langnas, AN
   Grant, W
   Mercer, DF
   Botha, J
   Qiu, F
   Shafer, L
   Kalil, AC
AF Florescu, D. F.
   Langnas, A. N.
   Grant, W.
   Mercer, D. F.
   Botha, J.
   Qiu, F.
   Shafer, L.
   Kalil, A. C.
TI Incidence, risk factors, and outcomes associated with cytomegalovirus
   disease in small bowel transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE cytomegalovirus; small bowel transplantation; infection; disease;
   pediatric; intestinal transplantation
ID SOLID-ORGAN TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; INTESTINAL
   TRANSPLANTATION; INFECTIOUS COMPLICATIONS; KIDNEY-TRANSPLANTATION;
   RENAL-TRANSPLANTATION; RECEIVING MYCOPHENOLATE; ADENOVIRUS INFECTION;
   CMV DISEASE; LIVER
AB Despite improved prophylaxis, monitoring, and more efficient immunosuppression, CMV infection remains a common opportunistic infection in transplant recipients. We assessed the incidence of CMV disease in pediatric SBT recipients, the timing of CMV disease after transplantation, and its impact on patient outcome. The medical records of 98 SBT recipients were reviewed. We performed descriptive analysis, regression analysis, and Kaplan-Meier curves to determine the time-to-event after transplantation. Fifty-three percent patients were male and 47% female, with a mean age of 38.3 months. Thirty-five percent of patients received prophylactic VGC, 55% GCV, 10% a combination of GCV/VGC, and 99% CMV immunoglobulins. A total of 24.5% recipients were CMV D+/R- (CMV serostatus donor positive/recipient negative). Seven (c. 7%) patients developed CMV disease. CMV disease was associated with 2.5 times (0.52-12.1; p = 0.25) higher rate of CMV mismatch and 11.1 times (1.3-95.9; p = 0.03) higher risk of death. CMV prophylaxis increased time-to-death (p = 0.074). Time-to-CMV disease was shorter in patients with enteritis (p < 0.0001), and CMV disease was associated with shorter time-to-death after transplantation (p = 0.001). CMV disease in SBT recipients was associated with an 11-fold mortality increase and a fourfold faster time-to-death. Time-to-death was significantly shorter with CMV enteritis.
C1 [Florescu, D. F.; Shafer, L.; Kalil, A. C.] Univ Nebraska Med Ctr, Dept Internal Med, Transplant Infect Dis Program, Div Infect Dis, Omaha, NE 68198 USA.
   [Langnas, A. N.; Grant, W.; Mercer, D. F.; Botha, J.] Univ Nebraska Med Ctr, Transplant Div, Dept Surg, Omaha, NE 68198 USA.
   [Qiu, F.] Univ Nebraska Med Ctr, Biostat Dept, Omaha, NE 68198 USA.
RP Florescu, DF (reprint author), Univ Nebraska Med Ctr, Dept Internal Med, Transplant Infect Dis Program, Div Infect Dis, Omaha, NE 68198 USA.
EM dflorescu@unmc.edu
CR Abu-Elmagd KM, 2009, ANN SURG, V250, P567, DOI 10.1097/SLA.0b013e3181b67725
   Basic-Jukic N, 2005, TRANSPL P, V37, P850, DOI 10.1016/j.transproceed.2004.12.228
   Bernabeu-Wittel M, 2002, EUR J CLIN MICROBIOL, V21, P173, DOI 10.1007/s10096-001-0684-y
   Bonaros N, 2008, CLIN TRANSPLANT, V22, P89, DOI 10.1111/j.1399-0012.2007.00750.x
   Bueno J, 1997, CLIN INFECT DIS, V25, P1078, DOI 10.1086/516113
   de Maar E F, 2002, Transpl Infect Dis, V4, P17, DOI 10.1034/j.1399-3062.2002.01002.x
   Dummer JS, 2005, MANDELL DOUGLAS BENN, P2477
   Falagas ME, 1997, CLIN INFECT DIS, V25, P314, DOI 10.1086/514555
   Fisher RA, 2002, TRANSPLANTATION, V74, P573, DOI 10.1097/00007890-200208270-00025
   Florescu DF, 2009, 27 EUR SOC PED INF D
   Florescu DF, 2010, TRANSPLANTATION, V90, P198, DOI 10.1097/TP.0b013e3181e0de97
   Giral M, 2001, J AM SOC NEPHROL, V12, P1758
   Humar A, 2009, AM J TRANSPLANT, V9, pS78, DOI 10.1111/j.1600-6143.2009.02897.x
   Humar A, 2002, J INFECT DIS, V186, P829, DOI 10.1086/342601
   IWAKI Y, 1991, LANCET, V337, P818
   Jain A, 2005, TRANSPLANT P, V37, P3182, DOI 10.1016/j.transproceed.2005.07.032
   Kalil AC, 2009, AM TRANSPL C 09 MAY
   Kalil AC, 2005, ANN INTERN MED, V143, P870
   Kalil AC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005512
   Kuypers D. R. J., 2002, Transplantation Proceedings, V34, P1164, DOI 10.1016/S0041-1345(02)02812-9
   Levitsky J, 2008, CLIN TRANSPLANT, V22, P222, DOI 10.1111/j.1399-0012.2007.00778.x
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Lopez C, 1972, Proc Clin Dial Transplant Forum, V2, P107
   LOPEZ C, 1974, AM J MED, V56, P280, DOI 10.1016/0002-9343(74)90609-3
   MANEZ R, 1995, TRANSPLANTATION, V59, P1010, DOI 10.1097/00007890-199504150-00016
   McLaughlin GE, 2003, AM J TRANSPLANT, V3, P224, DOI 10.1034/j.1600-6143.2003.00007.x
   Meier-Kriesche HU, 1999, TRANSPLANTATION, V68, P1496, DOI 10.1097/00007890-199911270-00012
   MOELLERING RC, 1992, CLIN INFECT DIS, V14, P1173
   Moreso F, 1998, CLIN TRANSPLANT, V12, P198
   Munoz MA, 2002, TRANSPLANT P, V34, P97, DOI 10.1016/S0041-1345(01)02683-5
   Paterson DL, 1998, TRANSPLANTATION, V66, P593, DOI 10.1097/00007890-199809150-00007
   Paya CV, 2003, TRANSPLANT INFECT, P298
   Pinchoff RJ, 2003, TRANSPLANTATION, V76, P183, DOI 10.1097/01.TP.0000072808.93060.0F
   ROCHE JK, 1981, INT J CANCER, V27, P659, DOI 10.1002/ijc.2910270513
   Rubin RH, 2007, CURR OPIN INFECT DIS, V20, P399, DOI 10.1097/QCO.0b013e328285a358
   Sarmiento JM, 2000, CLIN TRANSPLANT, V14, P136, DOI 10.1034/j.1399-0012.2000.140206.x
   Sarmiento JM, 1998, CLIN TRANSPLANT, V12, P371
   Satoh S, 2005, TRANSPL P, V37, P1751, DOI 10.1016/j.transproceed.2005.03.072
   Shanahan A, 2009, TRANSPL INFECT DIS, V11, P513, DOI 10.1111/j.1399-3062.2009.00443.x
   Sia IG, 2000, J INFECT DIS, V181, P717, DOI 10.1086/315242
   ter Meulen CG, 2000, NEPHROL DIAL TRANSPL, V15, P711, DOI 10.1093/ndt/15.5.711
   Turgeon N, 2000, Transpl Infect Dis, V2, P2, DOI 10.1034/j.1399-3062.2000.020102.x
   Ziring D, 2005, TRANSPLANTATION, V79, P702, DOI 10.1097/01.TP.0000154911.15693.80
NR 43
TC 15
Z9 15
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2012
VL 16
IS 3
BP 294
EP 301
DI 10.1111/j.1399-3046.2011.01628.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 923KZ
UT WOS:000302619500025
PM 22212495
ER

PT J
AU Cimsit, B
   Tichy, EM
   Patel, SB
   Rosencrantz, R
   Emre, S
AF Cimsit, Bayindir
   Tichy, Eric M.
   Patel, Sonya B.
   Rosencrantz, Richard
   Emre, Sukru
TI Treatment of adenovirus hepatitis with cidofovir in a pediatric liver
   transplant recipient
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE adenovirus; cidofovir; pediatric liver transplant; hepatitis
ID INTRAVENOUS CIDOFOVIR; QUANTITATIVE PCR; INFECTION; THERAPY;
   SUSCEPTIBILITY; RIBAVIRIN; IMPACT
AB AdV hepatitis is a rarely reported complication after pediatric liver transplantation that is associated with high rates of morbidity, mortality and graft failure. Successful treatment of AdV relies on early diagnosis of disease by quantitative PCR measurement of adenoviral DNA in blood and histological evidence in tissue biopsy. Pharmacologic treatment largely consists of antiviral therapy with CDV, an acyclic nucleoside phosphonate analog and reduction in immunosuppression. This report describes a case of AdV hepatitis in a pediatric liver transplant recipient successfully treated with a modified, renal sparing dosing of CDV.
C1 [Emre, Sukru] Yale Univ, Sch Med, Sect Transplantat & Immunol, New Haven, CT 06520 USA.
   [Tichy, Eric M.; Patel, Sonya B.] Yale New Haven Med Ctr, New Haven, CT 06504 USA.
RP Emre, S (reprint author), Yale Univ, Sch Med, Sect Transplantat & Immunol, 333 Cedar St,FMB 121, New Haven, CT 06520 USA.
EM sukru.emre@yale.edu
CR Anderson EJ, 2008, PEDIATR TRANSPLANT, V12, P219, DOI 10.1111/j.1399-3046.2007.00851.x
   Arav-Boger R, 2000, PEDIATR INFECT DIS J, V19, P1097, DOI 10.1097/00006454-200011000-00016
   Carter BA, 2002, TRANSPLANTATION, V74, P1050, DOI 10.1097/00007890-200210150-00027
   Echavarria M, 2008, CLIN MICROBIOL REV, V21, P704, DOI 10.1128/CMR.00052-07
   Engelmann G, 2009, PEDIATR TRANSPLANT, V13, P421, DOI 10.1111/j.1399-3046.2008.01014.x
   Gavin PJ, 2002, PEDIATRICS, V110, P1
   Hoffman JA, 2006, PEDIATR TRANSPLANT, V10, P17, DOI 10.1111/j.1399-3046.2006.00427.x
   Hoffman JA, 2009, CURR OPIN ORGAN TRAN, V14, P625, DOI 10.1097/MOT.0b013e3283324e1b
   KONERU B, 1987, JAMA-J AM MED ASSOC, V258, P489
   Lenaerts L, 2008, REV MED VIROL, V18, P357, DOI 10.1002/rmv.589
   Leruez-Ville M, 2004, CLIN INFECT DIS, V38, P45
   Ljungman P, 2004, EUR J CLIN MICROBIOL, V23, P583, DOI 10.1007/s10096-004-1165-x
   Martin-Davila P, 2005, J CLIN VIROL, V33, P138, DOI 10.1016/j.jcv.2004.09.032
   MICHAELS MG, 1992, J INFECT DIS, V165, P170
   Morfin F, 2005, ANTIVIR THER, V10, P225
   Morfin F, 2004, J MED VIROL, V72, P257, DOI 10.1002/jmv.10577
   Morfin F, 2009, ANTIVIR THER, V14, P55
   Nagafuji K, 2004, BONE MARROW TRANSPL, V34, P909, DOI 10.1038/sj.bmt.1704682
   Nichols WG, 2008, CLIN MICROBIOL REV, V21, P274, DOI 10.1128/CMR.00045-07
   Seidemann K, 2004, AM J TRANSPLANT, V4, P2102, DOI 10.1111/j.1600-6143.2004.00631.x
   Wallot MA, 2006, PEDIATR TRANSPLANT, V10, P121, DOI 10.1111/j.1399-3046.2005.00411.x
NR 21
TC 1
Z9 1
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2012
VL 16
IS 3
BP E90
EP E93
DI 10.1111/j.1399-3046.2010.01443.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 923KZ
UT WOS:000302619500006
PM 21226811
ER

PT J
AU Tomaino, J
   Keegan, T
   Miloh, T
   Kerkar, N
   Mercer, S
   Birge, M
   Rocca, J
   Suchy, F
   Arnon, R
AF Tomaino, J.
   Keegan, T.
   Miloh, T.
   Kerkar, N.
   Mercer, S.
   Birge, M.
   Rocca, J.
   Suchy, F.
   Arnon, R.
TI Stevens-Johnson syndrome after Mycoplasma pneumonia infection in
   pediatric post-liver transplant recipient: Case report and review of the
   literature
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; Mycoplasma pneumonia; Stevens-Johnson syndrome
ID SYRUP-URINE-DISEASE; RENAL-TRANSPLANTATION; CHILD
AB Although Mycoplasma pneumonia infection is relatively common among school-aged children, it rarely leads to SJS. Herein, we report a seven-yr-old girl who presented with a Mycoplasma pneumonia infection that progressed to SJS five months after liver transplant. We suggest that children presenting with symptoms of Mycoplasma pneumonia infection in the immunosuppressed post-liver transplant setting be properly diagnosed and treated rapidly, as well as observed for symptoms of SJS and potentially serious extrapulmonary complications.
C1 [Tomaino, J.; Keegan, T.; Miloh, T.; Kerkar, N.; Mercer, S.; Birge, M.; Rocca, J.; Suchy, F.; Arnon, R.] Mt Sinai Med Ctr, New York, NY 10029 USA.
RP Arnon, R (reprint author), Mt Sinai Med Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM ronen.arnon@mountsinai.org
CR Beersma MFC, 2005, J CLIN MICROBIOL, V43, P2277, DOI 10.1128/JCM.43.5.2277-2285.2005
   Fritsch P O, 2000, Am J Clin Dermatol, V1, P349, DOI 10.2165/00128071-200001060-00003
   GINSBURG CM, 1982, PEDIATR INFECT DIS J, V1, P155, DOI 10.1097/00006454-198205000-00005
   Gurcan HM, 2007, ANN PHARMACOTHER, V41, P812, DOI 10.1345/aph.1K037
   Joo DJ, 2009, TRANSPL INT, V22, P667, DOI 10.1111/j.1432-2277.2008.00819.x
   Kalman S, 2004, PEDIATR TRANSPLANT, V8, P493, DOI 10.1111/j.1399-3046.2004.00169.x
   Khanna A, 2006, LIVER TRANSPLANT, V12, P876, DOI 10.1002/lt.20744
   Lacouture ME, 2003, CLEV CLIN J MED, V70, P1071
   LEVY M, 1991, CLIN PEDIATR, V30, P42, DOI 10.1177/000992289103000107
   Narita M, 2001, J INFECTION, V42, P154, DOI 10.1053/jinf.2000.0769
   Okoli K, 2009, BLOOD COAGUL FIBRIN, V20, P595, DOI 10.1097/MBC.0b013e32832d6ccb
   Schwerk N, 2010, PEDIATR TRANSPLANT, V14, pE26, DOI 10.1111/j.1399-3046.2009.01130.x
   SCIMECA PG, 1994, PEDIATR HEMAT ONCOL, V11, P557
   Tsai V, 2011, J EMERG MED, V40, P324, DOI 10.1016/j.jemermed.2008.02.027
   WAJNER M, 1995, J INHERIT METAB DIS, V18, P165, DOI 10.1007/BF00711757
   Wolf R, 2010, CLIN DERMATOL, V28, P344, DOI 10.1016/j.clindermatol.2009.06.020
NR 16
TC 4
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2012
VL 16
IS 3
BP E74
EP E77
DI 10.1111/j.1399-3046.2010.01424.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 923KZ
UT WOS:000302619500002
PM 21176015
ER

PT J
AU Lin, TL
   Chiang, LW
   Chen, CL
   Wang, SH
   Lin, CC
   Liu, YW
   Yong, CC
   Lin, TS
   Li, WF
   Jawan, B
   Cheng, YF
   Chen, TY
   Concejero, AM
   Wang, CC
AF Lin, Ting-Lung
   Chiang, Li-Wei
   Chen, Chao-Long
   Wang, Shih-Hor
   Lin, Chih-Che
   Liu, Yueh-Wei
   Yong, Chee-Chien
   Lin, Tsan-Shiun
   Li, Wei-Feng
   Jawan, Bruno
   Cheng, Yu-Fan
   Chen, Tai-Yi
   Concejero, Allan M.
   Wang, Chih-Chi
TI Intra-operative management of low portal vein flow in pediatric living
   donor liver transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE inferior mesenteric vein cannulation; living donor liver
   transplantation; portal vein complication; stent
ID VASCULAR COMPLICATIONS; RISK-FACTORS; VENOUS COMPLICATIONS; BILIARY
   ATRESIA; STENT PLACEMENT; TISSUE EXPANDER; RECONSTRUCTION; EXPERIENCE;
   THROMBOSIS; STENOSIS
AB For pediatric living donor liver transplantation, portal vein complications cause significant morbidity and graft failure. Routine intra-operative Doppler ultrasound is performed after graft reperfusion to evaluate the flow of portal vein. This retrospective study reviewed 65 children who had undergone living donor liver transplantation. Seven patients were detected with suboptimal portal vein flow velocity following vascular reconstruction and abdominal closure. They underwent immediate on-table interventions to improve the portal vein flow. Both surgical and endovascular modalities were employed, namely, graft re-positioning, collateral shunt ligation, thrombectomy, revision of anastomosis, inferior mesenteric vein cannulation, and endovascular stenting. The ultrasonographic follow-up assessment for all seven patients demonstrated patent portal vein and satisfactory flow. We reviewed our experience on the different modalities and proposed an approach for our future intra-operative management to improve portal vein flow at the time of liver transplantation.
C1 [Lin, Ting-Lung; Chiang, Li-Wei; Chen, Chao-Long; Wang, Shih-Hor; Lin, Chih-Che; Liu, Yueh-Wei; Yong, Chee-Chien; Lin, Tsan-Shiun; Li, Wei-Feng; Concejero, Allan M.; Wang, Chih-Chi] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program,Dept Surg, Kaohsiung 833, Taiwan.
   [Jawan, Bruno] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program,Dept Anesthesiol, Kaohsiung 833, Taiwan.
   [Cheng, Yu-Fan; Chen, Tai-Yi] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program,Dept Diagnost Radiol, Kaohsiung 833, Taiwan.
RP Wang, CC (reprint author), Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program,Dept Surg, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.
EM ufel4996@ms26.hinet.net
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Chen CL, 1997, J GASTROEN HEPATOL, V12, pS342, DOI 10.1111/j.1440-1746.1997.tb00519.x
   Cheng YF, 2010, AM J TRANSPLANT, V10, P1276, DOI 10.1111/j.1600-6143.2010.03076.x
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   Choi JY, 2007, J CLIN ULTRASOUND, V35, P483, DOI 10.1002/jcu.20384
   de Villa VH, 2000, TRANSPLANTATION, V70, P1604, DOI 10.1097/00007890-200012150-00011
   Inomata Y, 1997, CLIN TRANSPLANT, V11, P56
   Inoue Y, 2008, TRANSPL INT, V21, P428, DOI 10.1111/j.1432-2277.2007.00622.x
   Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x
   Kim YJ, 2007, LIVER TRANSPLANT, V13, P1145, DOI 10.1002/lt.21076
   Ko GY, 2007, J VASC INTERV RADIOL, V18, P1215, DOI 10.1016/j.jvir.2007.06.029
   Kyoden Y, 2008, TRANSPL INT, V21, P1136, DOI 10.1111/j.1432-2277.2008.00752.x
   Lerut K, 1993, TRANSPL INT, V6, P299
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Moon JI, 2010, TRANSPL P, V42, P871, DOI 10.1016/j.transproceed.2010.02.059
   Ou HY, 2011, SURGERY, V149, P40, DOI 10.1016/j.surg.2010.04.018
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Shibasaki S, 2010, CLIN TRANSPLANT, V24, P550, DOI 10.1111/j.1399-0012.2009.01123.x
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Steiber AC, 1997, TRANSPLANTATION, V64, P654
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Waldman DL, 1998, J ULTRAS MED, V17, P1
   Wang CC, 2006, CLIN TRANSPLANT, V20, P81, DOI 10.1111/j.1399-0012.2005.00431.x
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 28
TC 5
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD MAY
PY 2012
VL 25
IS 5
BP 586
EP 591
DI 10.1111/j.1432-2277.2012.01464.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 921KE
UT WOS:000302475700015
PM 22448749
ER

PT J
AU Rhee, KW
   Oh, SH
   Kim, KM
   Kim, DY
   Lee, YJ
   Kim, T
   Kim, MN
AF Rhee, K. W.
   Oh, S. H.
   Kim, K. M.
   Kim, D. Y.
   Lee, Y. J.
   Kim, T.
   Kim, M. -N.
TI Early Bloodstream Infection After Pediatric Living Donor Living
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID LIVER-TRANSPLANTATION; RISK-FACTORS; CHILDREN
AB To determine the perioperative risk factors for bacterial infections after pediatric living donor liver transplantation (LDLT), we investigated the clinical profiles of 149 children who underwent pediatric LDLT between 1994 and 2008. Bacterial infections were diagnosed based on guidelines proposed by the Centers for Disease Control. We observed 36 bloodstream infections (BSIs) in 32/149 (21.5%) patients (0.24 infections per patient), which, 21(58.3%) BSIs in 19 patients were due to gram-positive and 15 (41.7%) in 13 patients to gram-negative organisms. The most common pathogens of early BSI were coagulase-negative Staphylococcus; (n = 11; 30.6%) and Klebsiella pneumoniae (n = 8; 22.2%). The most common site of early BSI was catheter-related (n = 14; 38.9%). Multivariate analysis showed that age 1 year (P < .05; odds ratio [OR] = 3.90; 95% CI, 1.83-15.26) and bile duct complications (P < .05; OR = 6.2, 95% CI = 3.21-35.23) were significant independent risk factors for early BSIs. More cautious management of pediatric LDLTs may be necessary for younger age children particularly with postoperative biliary complications.
C1 [Rhee, K. W.; Oh, S. H.; Kim, K. M.; Lee, Y. J.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat,Childrens Hosp, Seoul 138736, South Korea.
   [Kim, D. Y.; Kim, T.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat Surg,Childrens Hosp, Seoul 138736, South Korea.
   [Kim, M. -N.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul 138736, South Korea.
RP Kim, KM (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat,Childrens Hosp, 388-1 Pungnap Dong, Seoul 138736, South Korea.
EM kmkim@amc.seoul.kr
OI Kim, Kyung Mo/0000-0001-7896-6751
CR Bouchut JC, 2001, PAEDIATR ANAESTH, V11, P93, DOI 10.1046/j.1460-9592.2001.00574.x
   Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   GEORGE DL, 1991, REV INFECT DIS, V13, P387
   Kim JE, 2010, J KOREAN MED SCI, V25, P527, DOI 10.3346/jkms.2010.25.4.527
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
NR 8
TC 5
Z9 8
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2012
VL 44
IS 3
BP 794
EP 796
DI 10.1016/j.transproceed.2012.01.014
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 929PD
UT WOS:000303077000052
PM 22483498
ER

PT J
AU Joo, DJ
   Ju, MK
   Huh, KH
   Kim, MS
   Choi, GH
   Choi, JS
   Jeon, KO
   Kim, SI
AF Joo, D. J.
   Ju, M. K.
   Huh, K. H.
   Kim, M. S.
   Choi, G. H.
   Choi, J. S.
   Jeon, K. O.
   Kim, S. I.
TI Does Lymphocyte Cross-Matching Predict Acute Rejection and Graft
   Survival in Liver Transplantation?
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID ANTIBODY-MEDIATED REJECTION; MICROCHIMERISM
AB Introduction. The role of lymphocyte cross-matches (LCM) remains controversial in the liver transplant field. The aim of this study was to correlate the risk for acute rejection episodes and graft survival in liver transplantation with pretransplant LCM results.
   Patients and Methods. We enrolled 184 adult liver transplantation patients, excluding pediatric and second grafts. The 129 living donor and 55 deceased donor liver transplantations were divided into 2 groups: LCM (+); (n = 20) and LCM (-); (n = 164).
   Results. There were no differences in the demographic features, such as gender and recipient age, original disease, Model for End-Stage Liver Disease score, donor type, number of human leukocyte antigen mismatches, and cold ischemia times. There were no hyperacute rejection episodes in the LCM (+) group. Also, posttransplant complications such as acute rejection episode, biliary complication, or hepatic artery thrombosis were not different. Acute rejection episodes occurred in 5.0% of the LCM (+) group and 15.2% of the LCM () group (P = .317). Bile duct complications after transplantation arose in 20.0% of the LCM (+) group and in 32.9% of the LCM (-) group (P = .312). The 2 groups showed no difference in graft survival rate analyzed by the Kaplan-Meier method according to LCM results.
   Conclusion. Pretransplant LCM results were not associated with overall graft survival or acute rejection episodes in this study.
C1 [Joo, D. J.; Ju, M. K.; Huh, K. H.; Kim, M. S.; Choi, G. H.; Choi, J. S.; Kim, S. I.] Yonsei Univ, Dept Surg, Coll Med, Seoul 120752, South Korea.
   [Joo, D. J.; Ju, M. K.; Huh, K. H.; Kim, M. S.; Choi, G. H.; Choi, J. S.; Jeon, K. O.; Kim, S. I.] Yonsei Univ, Res Inst Transplantat, Coll Med, Seoul 120752, South Korea.
RP Kim, MS (reprint author), Yonsei Univ, Dept Surg, Coll Med, 134 Shinchon Dong, Seoul 120752, South Korea.
EM ysms91@yuhs.ac
FU Research Institute for Transplantation, Yonsei University College of
   Medicine
FX Supported by the 2010-2011 research grant of the Research Institute for
   Transplantation, Yonsei University College of Medicine.
CR Balan V, 2008, HEPATOLOGY, V48, P878, DOI 10.1002/hep.22435
   Bettens F, 2005, LIVER TRANSPLANT, V11, P290, DOI 10.1002/lt.20360
   Della-Guardia B, 2008, TRANSPL P, V40, P870, DOI [10.1016/j.transproceed.2008.02.061, 10.1016/j.transproceed,2008.02.061]
   Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406
   Hisanaga M, 1996, TRANSPLANTATION, V61, P40, DOI 10.1097/00007890-199601150-00010
   Hori T, 2010, SURGERY, V147, P840, DOI 10.1016/j.surg.2009.11.022
   Kasahara M, 2002, TRANSPLANTATION, V74, P1175, DOI 10.1097/01.TP.0000030636.35519.EA
   Kozlowski T, 2011, LIVER TRANSPLANT, V17, P357, DOI 10.1002/lt.22233
   Leffell MS, 2009, CURR OPIN ORGAN TRAN, V14, P398, DOI 10.1097/MOT.0b013e32832c5983
   Matinlauri IH, 2005, CLIN TRANSPLANT, V19, P626, DOI 10.1111/j.1399-0012.2005.00364.x
   Rosen HR, 2008, GASTROENTEROLOGY, V134, P1789, DOI 10.1053/j.gastro.2008.02.062
   Sugawara Y, 2003, LIVER TRANSPLANT, V9, P1062, DOI 10.1053/jlts.2003.50209
   Takakura K, 2001, CLIN TRANSPLANT, V15, P309, DOI 10.1034/j.1399-0012.2001.150502.x
NR 13
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2012
VL 44
IS 2
BP 418
EP 420
DI 10.1016/j.transproceed.2012.01.071
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 913YD
UT WOS:000301912400029
PM 22410032
ER

PT J
AU Mizuta, K
   Urahashi, T
   Ihara, Y
   Sanada, Y
   Wakiya, T
   Yamada, N
   Okada, N
   Egami, S
   Hishikawa, S
   Hyodo, M
   Sakuma, Y
   Fujiwara, T
   Kawarasaki, H
   Yasuda, Y
AF Mizuta, K.
   Urahashi, T.
   Ihara, Y.
   Sanada, Y.
   Wakiya, T.
   Yamada, N.
   Okada, N.
   Egami, S.
   Hishikawa, S.
   Hyodo, M.
   Sakuma, Y.
   Fujiwara, T.
   Kawarasaki, H.
   Yasuda, Y.
TI Living Donor Liver Transplantation in Children With Cholestatic Liver
   Disease: A Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID PRIMARY SCLEROSING CHOLANGITIS; LONG-TERM OUTCOMES; PEDIATRIC-PATIENTS;
   ALAGILLE SYNDROME
AB Objectives. Cholestatic liver disease (CLD) is the main indication for liver transplantation in children. This retrospective study evaluated the outcomes of living donor liver transplantation (LDLT) in children with CLD.
   Methods. One hundred fifty-nine children with CLD who underwent 164 LDLT between May 2001 and May 2011 were evaluated. Their original diseases were biliary atresia (n = 145, 91%), Alagille syndrome (n = 8, 5%), primary sclerosing cholangitis (n = 2), and the others (n = 4). The mean age and body weight of the recipients at LDLT was 42 53 months and 14.0 +/- 11.0 kg, respectively.
   Results. Parents were living donors in 98%. The left lateral segment was the most common type of graft (77%). There were no reoperations and no mortality in any living donor. Recipients' postoperative surgical complications consisted mainly of hepatic arterial problems (7%), hepatic vein stenosis (5%), portal vein stenosis (13%), biliary stricture (18%), intestinal perforation (3%). The overall rejection rate was 31%. Cytomegalovirus infection and Epstein-Barr virus disease were observed in 26% and 5%, respectively. Retransplantation was performed five times in four patients; the main cause was hepatic vein stenosis (n = 3). Four patients died; the main cause was gastrointestinal perforation (n = 2). The body height of Alagille syndrome patients less than 2 years old significantly improved compared with older patients after LDLT. The 1-, 5-, and 10-year patient survival rates were 98%, 97%, and 97%, respectively.
   Conclusions. LDLT for CLD is an effective treatment with excellent long-term outcomes.
C1 [Mizuta, K.; Urahashi, T.; Ihara, Y.; Sanada, Y.; Wakiya, T.; Yamada, N.; Okada, N.; Egami, S.; Hishikawa, S.] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Hyodo, M.; Sakuma, Y.; Fujiwara, T.; Yasuda, Y.] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Kawarasaki, H.] Oyama Municipal Hosp, Oyama, Japan.
RP Mizuta, K (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM Koimizu@jichi.ac.jp
CR ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2
   Kamath BM, 2010, J PEDIATR GASTR NUTR, V50, P11, DOI 10.1097/MPG.0b013e3181c1601f
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   LaRusso NF, 2006, HEPATOLOGY, V44, P746, DOI 10.1002/hep.21337
   Mendizabal M, 2011, LIVER TRANSPLANT, V17, P243, DOI 10.1002/lt.22240
   Miloh T, 2011, LIVER TRANSPLANT, V17, P925, DOI 10.1002/lt.22320
   Mizuta K, 2010, TRANSPL P, V42, P4127, DOI 10.1016/j.transproceed.2010.11.002
   Mizuta K, 2010, AM J TRANSPLANT, V10, P2547, DOI 10.1111/j.1600-6143.2010.03274.x
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184
   Saito T, 2007, PEDIATR TRANSPLANT, V11, P764, DOI 10.1111/j.1399-3046.2007.00744.x
   Sanada Y, 2011, PEDIATR SURG INT, V27, P23, DOI 10.1007/s00383-010-2722-2
   Santos Jorge L, 2010, Curr Gastroenterol Rep, V12, P30, DOI 10.1007/s11894-009-0081-8
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
NR 14
TC 5
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2012
VL 44
IS 2
BP 469
EP 472
DI 10.1016/j.transproceed.2011.11.014
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 913YD
UT WOS:000301912400044
PM 22410047
ER

PT J
AU Lu, CH
   Tsang, LLC
   Huang, TL
   Chen, TY
   Ou, HY
   Yu, CY
   Chen, CL
   Cheng, YF
AF Lu, C. -H.
   Tsang, L. L. -C.
   Huang, T. -L.
   Chen, T. -Y.
   Ou, H. -Y.
   Yu, C. -Y.
   Chen, C. -L.
   Cheng, Y. -F.
TI Biliary Complications and Management in Pediatric Living Donor Liver
   Transplantation for Underlying Biliary Atresia
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID DIAGNOSIS
AB Background. Biliary complications are a major problem in pediatric liver transplantation. The aim of this study was to evaluate the management and outcomes of biliary complication after pediatric living donor liver transplantation (LDLT).
   Methods. From 1994 to 2010, 157 pediatric LDLT due to biliary atresia were performed in our center. Doppler ultrasound was initially performed daily for 2 weeks postoperatively to evaluate biliary and vascular complications. Computed tomography and or magnetic resonance cholangiography were performed when complications were suspected. They were treated using radiological or surgical interventions.
   Results. Among the 157 cases, we observed 10 (6.3%) biliary complications, which were divided into three groups: bile leakage (n = 3); biliaty stricture without vascular complication (n = 4); and biliary stricture with vascular complication (n = 3). The three cases bile leakages recovered after interventional procedures. The seven biliary strictures underwent percutaneous transhepatic cholangial drainage (PTCD). All cases without vascular complications were completely cured after PTCD or a subsequent surgical re-anastomosis. In the vascular complication group, early recorrection of the HA occlusion with successful PTCD treatment were performed in two cases, but one other case with diffuse ischemic biliary destruction had a poor result.
   Conclusion. Successful interventional radiographic approaches are effective for anastomotic biliary complications but with poor results in diffuse ischemic biliary destruction.
C1 [Lu, C. -H.; Tsang, L. L. -C.; Chen, T. -Y.; Ou, H. -Y.; Yu, C. -Y.; Cheng, Y. -F.] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung 833, Taiwan.
   [Chen, C. -L.] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung 833, Taiwan.
   [Lu, C. -H.; Tsang, L. L. -C.; Chen, T. -Y.; Ou, H. -Y.; Yu, C. -Y.; Cheng, Y. -F.] Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Program, Kaohsiung 833, Taiwan.
   Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
RP Cheng, YF (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.
EM cheng.yufan@msa.hinet.net
CR Chen HL, 2008, TRANSPL P, V40, P2534, DOI 10.1016/j.transproceed.2008.07.057
   DODD GD, 1994, RADIOLOGY, V192, P657
   Osorio RW, 1993, TRANSPLANTATION, V55, P1047
   Schindel D, 2000, J PEDIATR SURG, V35, P940, DOI 10.1053/jpsu.2000.6932
   Yoon PW, 1997, PEDIATRICS, V99, P376, DOI 10.1542/peds.99.3.376
NR 5
TC 7
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2012
VL 44
IS 2
BP 476
EP 477
DI 10.1016/j.transproceed.2011.12.034
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 913YD
UT WOS:000301912400046
PM 22410049
ER

PT J
AU Huang, TL
   Chen, TY
   Tsang, LL
   Ou, HY
   Yu, CY
   Wang, CC
   Wang, SH
   Lin, CC
   Liu, YW
   Yong, CC
   Chiu, KW
   Eng, HL
   Jawan, B
   Cheng, YF
   Chen, CL
AF Huang, T. L.
   Chen, T. Y.
   Tsang, L. L.
   Ou, H. Y.
   Yu, C. Y.
   Wang, C. C.
   Wang, S. H.
   Lin, C. C.
   Liu, Y. W.
   Yong, C. C.
   Chiu, K. W.
   Eng, H. L.
   Jawan, B.
   Cheng, Y. F.
   Chen, C. L.
TI Hemodynamics of Portal Venous Stenosis Before and After Treatment in
   Pediatric Liver Transplantation: Evaluation with Doppler Ultrasound
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID VEIN STENOSIS; RISK-FACTORS; COMPLICATIONS; THROMBOSIS; ANGIOPLASTY;
   SONOGRAPHY; RECIPIENTS
AB Aim. The aim of this study was to evaluate portal vein stenosis (PVS) in pediatric liver transplantation (PLT) using Doppler ultrasound (DUS) before and after interventional management for hemodynamic changes.
   Materials and Methods. From 2000 to 2010, we encountered 11 PVS cases among 180 PLT that were evaluated using DUS and computed tomography (CT) angiography (CTA); all underwent portal stenting. DUS was used to monitor portal hemodynamics. For the diagnosis of PVS, we investigated multiple parameters including stenotic size (SS), stenotic ratio (SR) (SR [%] = PRE-SS/PRE [PRE = stenotic size]), portal flow velocity ratio (VR) (VR = VS/PRE [PRE = velocity at prestenotic site; VS = peak velocity at stenotic site]), spleen size, and platelet count.
   Results. The incidence of PVS was 5.6% (11/180). The PV was 2.5 mm using DUS and 2.7 mm using CTA. The average SR was 65% fitting the criterion. Low prestenotic portal flow <12 cm/sec and high peak velocity in the stenotic segment (up to 147 cm/sec) were observed in 6 cases. The VR value was high at 7.5:1 and there was splenomegaly with thrombocytopenia. After portal vein stenting, hyperperfusion occurred might after reopening the stenosis: the flow increased to an average of 34 cm/sec and then flow decreased slowly to a stable level 2 weeks later. The size of the spleen decreased from 17 to 12 cm and the thrombocytopenia also improved with platelet counts increasing from 67 x 10(3) to 178 x 10(3)/mu l at 2 months follow-up. The changes in portal flow, portal vein size, spleen size, and platelet count were significant (P < .05).
   Conclusion. PVS is diagnosed using DUS by increased intrahepatic PV dilatation, peak flow at the stenotic site, discrepant VR. Early portal stenting showed a better prognosis. DUS is essential and effective for hemodynamic monitoring and management of PVS.
C1 [Huang, T. L.; Chen, T. Y.; Tsang, L. L.; Ou, H. Y.; Yu, C. Y.; Cheng, Y. F.] Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung 83305, Taiwan.
   [Wang, C. C.; Wang, S. H.; Lin, C. C.; Liu, Y. W.; Yong, C. C.; Chen, C. L.] Kaohsiung Chang Gung Mem Hosp, Dept Gen Surg, Kaohsiung 83305, Taiwan.
   [Chiu, K. W.; Eng, H. L.; Jawan, B.] Kaohsiung Chang Gung Mem Hosp, Liver Transplant Program, Kaohsiung 83305, Taiwan.
   Chang Gung Univ, Coll Med, Kaohsiung 83305, Taiwan.
RP Cheng, YF (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Diagnost Radiol, 123 Ta Pei Rd, Kaohsiung 83305, Taiwan.
EM cheng.yufan@msa.hinet.net
FU Chang Gung Memorial Hospital [CMRPG870962]; National Science Council,
   Taiwan [NSC100-2314-B-182A-071]
FX Supported by grants number CMRPG870962 from the Chang Gung Memorial
   Hospital and grant number NSC100-2314-B-182A-071 from the National
   Science Council, Taiwan.
CR Cheng YF, 2006, AM J TRANSPLANT, V6, P2994, DOI 10.1111/j.1600-6143.2006.01562.x
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   Chong WK, 2007, AJR, V188, P515
   DODD GD, 1994, RADIOLOGY, V192, P657
   FUJIMOTO M, 1995, TRANSPLANT INT, V8, P119, DOI 10.1111/j.1432-2277.1995.tb01486.x
   Huang TL, 2010, TRANSPL P, V42, P879, DOI 10.1016/j.transproceed.2010.02.036
   Huang TL, 1998, TRANSPLANT P, V30, P3186, DOI 10.1016/S0041-1345(98)00987-7
   Ko GY, 2007, LIVER TRANSPLANT, V13, P530, DOI 10.1002/lt.21068
   Kyoden Y, 2008, TRANSPL INT, V21, P1136, DOI 10.1111/j.1432-2277.2008.00752.x
   Lee J, 1996, AM J ROENTGENOL, V167, P85
   Legmann P, 1993, EUR RADIOL, V3, P371, DOI 10.1007/BF00167472
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Moon JI, 2010, TRANSPL P, V42, P871, DOI 10.1016/j.transproceed.2010.02.059
   Mullan CP, 2010, AM J ROENTGENOL, V195, P1438, DOI 10.2214/AJR.10.4636
   Ou HY, 2011, SURGERY, V149, P40, DOI 10.1016/j.surg.2010.04.018
   ROLLINS NK, 1992, RADIOLOGY, V182, P731
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Takahashi Y, 2009, PEDIATR SURG INT, V25, P745, DOI 10.1007/s00383-009-2430-y
NR 18
TC 3
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2012
VL 44
IS 2
BP 481
EP 483
DI 10.1016/j.transproceed.2012.01.047
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 913YD
UT WOS:000301912400048
PM 22410051
ER

PT J
AU Kim, T
   Kim, DY
   Kim, KM
   Seo, JJ
   Park, KM
   Lee, YJ
   Lee, SG
AF Kim, T.
   Kim, D. -Y.
   Kim, K. M.
   Seo, J. J.
   Park, K. M.
   Lee, Y. -J.
   Lee, S. -G.
TI Pediatric Liver Transplantation for Hepatoblastoma: A Single Center
   Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID INTERNATIONAL-SOCIETY; ONCOLOGY; SIOPEL-1; TUMOR
AB The objective of this study was to review our experience with liver transplantation (OLT) for hepatoblastoma (HB) patients. We evaluated retrospectively clinical features of seven pediatric patients with HB who underwent OLT at our institute from 2007 to February 2011. We investigated pretreatment extent of disease (PRETEXT) stage at diagnosis, type of procedure, complications, changes in serum alphafetoprotein (AFP) level, recurrences and metastases. The median age at surgery was 47 months (range, 11 months to 10.3 years). OLT was performed for PRETEXT stage III with a central location (n = 2) and for PRETEXT stage IV cases (n = 5). Five children underwent live donor OLT (LDLT) and two deceased donor OLT including one split deceased donor OLT. One patient received a hepatic vein stent insertion due to stenosis and another experienced biliary leakage which was treated with percutaneous drainage and conservative management. Postoperative serum AFP level remained below 20 ngimL during follow-up period in six patients who were free of recurrences or metastases. Postoperative serum AFP levels in one patient with pulmonary metastasis were never below 20 ng/mL and increased gradually thereafter. A Pulmonary metastasis was discovered in the 2(nd) month post-operative. The other 6 patients are free of tumor recurrences with 29.9 month median follow-up.
   Although the number of cases is small without long term follow-up data, OLT for unresectable HE confined to the liver following chemotherapy seemed to show good clinical results. The role of post transplantation serum AFP levels needs further investigation.
C1 [Kim, T.; Kim, D. -Y.; Kim, K. M.; Seo, J. J.; Park, K. M.; Lee, Y. -J.; Lee, S. -G.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat,Dept Surg, Seoul, South Korea.
RP Kim, DY (reprint author), Asan Med Ctr, Dept Pediat Surg, 86 Asanbyungwon Gil, Seoul 138736, South Korea.
EM kimdy@amc.seoul.kr
OI Kim, Kyung Mo/0000-0001-7896-6751
CR Browne M, 2008, J PEDIATR SURG, V43, P1973, DOI 10.1016/j.jpedsurg.2008.05.031
   Faraj W, 2008, LIVER TRANSPLANT, V14, P1614, DOI 10.1002/lt.21586
   Otte JB, 2004, PEDIATR BLOOD CANCER, V42, P74, DOI 10.1002/pbc.10376
   Pritchard J, 2000, J CLIN ONCOL, V18, P3819
   REYNOLDS M, 1992, J PEDIATR SURG, V27, P1080
   Sasaki F, 2002, J PEDIATR SURG, V37, P851, DOI 10.1053/jpsu.2002.32886
   Schnater JM, 2002, CANCER, V94, P1111, DOI 10.1002/cncr.10282
   STOCKER JT, 1994, SEMIN DIAGN PATHOL, V11, P136
NR 8
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2012
VL 44
IS 2
BP 523
EP 525
DI 10.1016/j.transproceed.2012.01.069
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 913YD
UT WOS:000301912400058
PM 22410061
ER

PT J
AU Ko, JS
   Yi, NJ
   Suh, KS
   Seo, JK
AF Ko, Jae Sung
   Yi, Nam-Joon
   Suh, Kyung Suk
   Seo, Jeong Kee
TI Pediatric liver transplantation for fibropolycystic liver disease
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE congenital hepatic fibrosis; Caroli's disease; polycystic kidney
   disease; pediatric liver transplantation
ID POLYCYSTIC KIDNEY-DISEASE; CONGENITAL HEPATIC-FIBROSIS; CAROLIS-DISEASE;
   RENAL-TRANSPLANTATION; RESECTION; PROTEIN; ENCODES; FAMILY; IMPACT; GENE
AB Fibropolycystic liver disease includes CHF, Caroli's syndrome, and Caroli's disease. Patients with Caroli's disease and Caroli's syndrome have an increased risk of recurrent cholangitis, intrahepatic calculi, biliary cirrhosis, and cholangiocarcinoma. The aim of this study was to examine the post-transplantation outcomes of children with fibropolycystic liver disease. Of the 158 children transplanted at Seoul National University Hospital, there were four patients with Caroli's syndrome, two patients with CHF, and one patient with Caroli's disease. One patient underwent combined liver/kidney transplantation. Associated renal manifestations included ARPKD in three children and nephronophthisis in one child. The indications for LT were recurrent cholangitis, decompensated cirrhosis, and refractory complications of portal hypertension. Both graft and patient survival rates were 100% at a median follow-up period of two yr after LT. Three children with growth failure achieved catch-up growth after LT. In three patients with ARPKD, mean serum creatinine levels increased from 0.53 mg/dL at the time of LT to 0.91 mg/dL at the last follow-up (p = 0.01). LT is an excellent option for children with complications from fibropolycystic liver disease. Renal function should be monitored cautiously after LT in the patients with ARPKD.
C1 [Ko, Jae Sung; Seo, Jeong Kee] Seoul Natl Univ, Dept Pediat, Coll Med, Seoul 110744, South Korea.
   [Yi, Nam-Joon; Suh, Kyung Suk] Seoul Natl Univ, Dept Surg, Coll Med, Seoul 110744, South Korea.
RP Seo, JK (reprint author), Seoul Natl Univ, Dept Pediat, Childrens Hosp, 101 Daehangno, Seoul 110744, South Korea.
EM jkseo@snu.ac.kr
RI Yi, Nam-Joon/J-5574-2012; Seo, Jeong Kee/J-5512-2012; Suh,
   Kyung-Suk/J-5508-2012
FU SNUH [0420100430]
FX This study was supported by grant no. 0420100430 from the SNUH Research
   Fund.
CR Arikan C, 2004, PEDIATR TRANSPLANT, V8, P558, DOI 10.1111/j.1399-3046.2004.00224.x
   CAMPANA HA, 1974, AM J DIG DIS, V19, P325, DOI 10.1007/BF01072522
   Davis CL, 2002, LIVER TRANSPLANT, V8, P91, DOI 10.1053/jlts.2002.31516
   Davis ID, 2003, PEDIATR TRANSPLANT, V7, P364, DOI 10.1034/j.1399-3046.2003.00094.x
   De Kerckhove L, 2006, TRANSPLANT INT, V19, P381, DOI 10.1111/j.1432-2277.2006.00292.x
   Dehghani SM, 2009, PEDIATR TRANSPLANT, V13, P536, DOI 10.1111/j.1399-3046.2008.01117.x
   DESMET VJ, 1992, HEPATOLOGY, V16, P1069, DOI 10.1002/hep.1840160434
   Drenth JPH, 2010, BEST PRACT RES CL GA, V24, P573, DOI 10.1016/j.bpg.2010.08.007
   EVANSJONES G, 1990, J PEDIATR SURG, V25, P1259, DOI 10.1016/0022-3468(90)90524-D
   Goilav B, 2006, PEDIATR TRANSPLANT, V10, P294, DOI 10.1111/j.1399-3046.2005.00456.x
   Gunay-Aygun M, 2009, AM J MED GENET C, V151C, P296, DOI 10.1002/ajmg.c.30225
   Habib S, 2006, LIVER TRANSPLANT, V12, P416, DOI 10.1002/lt.20719
   KAPLAN BS, 1988, AM J MED GENET, V29, P639, DOI 10.1002/ajmg.1320290323
   Kassahun WT, 2005, SURGERY, V138, P888, DOI 10.1016/j.surg.2005.05.002
   Khan K, 2002, AM J TRANSPLANT, V2, P360, DOI 10.1034/j.1600-6143.2002.20412.x
   Magid MS, 2000, SEMIN LIVER DIS, V20, P385, DOI 10.1055/s-2000-9425
   Meier C, 2008, PEDIATR TRANSPLANT, V12, P483, DOI 10.1111/j.1399-3046.2007.00879.x
   Millwala F, 2008, LIVER TRANSPLANT, V14, P11, DOI 10.1002/lt.21366
   MURRAYLYON IM, 1972, GUT, V13, P319
   Nagral Aabha, 2007, Indian J Gastroenterol, V26, P88
   Onuchic LF, 2002, AM J HUM GENET, V70, P1305, DOI 10.1086/340448
   Rossi M, 2008, TRANSPL P, V40, P2075, DOI 10.1016/j.transproceed.2008.05.058
   Shneider BL, 2005, PEDIATR TRANSPLANT, V9, P634, DOI 10.1111/j.1399-3046.2005.00342.x
   Taylor ACF, 1998, EUR J GASTROEN HEPAT, V10, P105, DOI 10.1097/00042737-199802000-00001
   TSUCHIDA Y, 1995, HEPATO-GASTROENTEROL, V42, P175
   Ulrich F, 2008, ANN SURG, V247, P357, DOI 10.1097/SLA.0b013e31815cca88
   WAISMAN Y, 1991, Pediatric Emergency Care, V7, P157, DOI 10.1097/00006565-199106000-00008
   Wang ZX, 2008, HEPATOB PANCREAT DIS, V7, P97
   Ward CJ, 2002, NAT GENET, V30, P259, DOI 10.1038/ng833
   Zerres K, 1996, ACTA PAEDIATR, V85, P437, DOI 10.1111/j.1651-2227.1996.tb14056.x
NR 30
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2012
VL 16
IS 2
BP 195
EP 200
DI 10.1111/j.1399-3046.2012.01661.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 898BF
UT WOS:000300709600020
PM 22360404
ER

PT J
AU Kosola, S
   Lampela, H
   Lauronen, J
   Makisalo, H
   Jalanko, H
   Qvist, E
   Pakarinen, MP
AF Kosola, S.
   Lampela, H.
   Lauronen, J.
   Makisalo, H.
   Jalanko, H.
   Qvist, E.
   Pakarinen, M. P.
TI General Health, Health-Related Quality of Life and Sexual Health After
   Pediatric Liver Transplantation: A Nationwide Study
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Liver; transplantation; pediatric transplantation; quality of life;
   sexuality; SF-36; surgical complications
ID ADOLESCENT HEALTH; CORE SCALES; CHILDREN; RECIPIENTS; IMPACT;
   RELIABILITY; OVERWEIGHT; OUTCOMES; HRQOL; SELF
AB The long-term impact of pediatric liver transplantation (LT) and its complications on general health, health-related quality of life (HRQoL) and sexual health were assessed. We conducted a national cross-sectional study of all pediatric recipients who underwent LT between 1987 and 2007. Of 66 survivors, 57 participants (86%) were compared to randomly chosen healthy controls (n = 141) at 10.7 +/- 6.6 years posttransplant. PedsQL4.0, SF-36, DISF-SR and AUDIT questionnaires for appropriate age groups were used. Patients and controls <7 years had similar HRQoL and 54% of patients aged over 7 scored within the controls normal range on all HRQoL domains. In adult survivors, physical functioning and general health were decreased (p < 0.05). Biliary complications, reoperations and obesity were independently associated with reduced HRQoL (p < 0.05 for all). Still 64% of adult survivors considered their health excellent. Sexual health was similar to controls but LT recipients may experience problems with their orgasm strength (p = 0.050) and condom-based contraception was more common after LT than among controls (58% and 12%, p < 0.001). In conclusion, normal HRQoL and sexual health are achievable post-LT.
C1 [Kosola, S.; Makisalo, H.] Univ Helsinki, Cent Hosp, Childrens Hosp, Dept Surg, Helsinki, Finland.
RP Kosola, S (reprint author), Univ Helsinki, Cent Hosp, Childrens Hosp, Dept Surg, Helsinki, Finland.
EM silja.kosola@hus.fi
RI Lampela, Hanna/O-3619-2014
OI Lampela, Hanna/0000-0001-9619-1099
FU Helsinki Central Hospital Fund; Sigrid Juselius Foundation; Paivikki and
   Sakari Sohlberg Foundation; Foundation for Pediatric Research
FX We thank Janne Pitkaniemi for indispensable statistical expertise. This
   study was supported by grants from the Helsinki Central Hospital Fund,
   the Sigrid Juselius Foundation, the Paivikki and Sakari Sohlberg
   Foundation and the Foundation for Pediatric Research.
CR Aberg F, 2009, LIVER TRANSPLANT, V15, P64, DOI 10.1002/lt.21651
   Alonso EM, 2008, LIVER TRANSPLANT, V14, P460, DOI 10.1002/lt.21352
   Alonso EM, 2010, J PEDIATR-US, V156, P270, DOI 10.1016/j.jpeds.2009.08.048
   Avitzur Y, 2004, TRANSPLANTATION, V78, P566, DOI 10.1097/01.TP.0000131663.87106.1A
   Bucuvalas JC, 2003, LIVER TRANSPLANT, V9, P62, DOI 10.1053/jlts.2002.50012
   Bucuvalas J, 2009, LIVER TRANSPLANT, V15, pS6, DOI 10.1002/lt.21915
   Centers for Disease Control and Prevention, GROWTH CHARTS 2010
   Cole CR, 2004, PEDIATR TRANSPLANT, V8, P222, DOI 10.1111/j.1399-3046.2004.00126.x
   Derogatis LR, 1997, J SEX MARITAL THER, V23, P291
   Dommergues JP, 2010, AM J TRANSPLANT, V10, P1634, DOI 10.1111/j.1600-6143.2010.03054.x
   Duffy JP, 2010, ANN SURG, V252, P652, DOI 10.1097/SLA.0b013e3181f5f23a
   Estraviz B, 2007, CLIN TRANSPLANT, V21, P481, DOI 10.1111/j.1399-0012.2007.00672.x
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Fallon EM, 2005, J PEDIATR-US, V147, P443, DOI 10.1016/j.jpeds.2005.05.039
   [Anonymous], 2007, J AM COLL SURGEONS
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   Haavisto A, 2011, PEDIATR TRANSPLANT, V15, P184, DOI 10.1111/j.1399-3046.2010.01451.x
   Hartley JL, 2009, LANCET, V374, P1704, DOI 10.1016/S0140-6736(09)60946-6
   Ho JK, 2006, LIVER TRANSPLANT, V12, P1478, DOI 10.1002/lt.20831
   Kalyva E, 2011, PEDIATR DIABETES, V12, P34, DOI 10.1111/j.1399-5448.2010.00653.x
   Kivela JM, 2011, TRANSPLANTATION, V91, P115, DOI 10.1097/TP.0b013e3181fa94b9
   Kosola S, 2010, PEDIATR TRANSPLANT, V14, P646, DOI 10.1111/j.1399-3046.2010.01312.x
   Laaksonen C, 2007, J ADV NURS, V59, P542, DOI 10.1111/j.1365-2648.2007.04347.x
   Limbers CA, 2011, PEDIATR TRANSPLANT, V15, P245, DOI 10.1111/j.1399-3046.2010.01453.x
   Maglakelidze N, 2011, TRANSPL P, V43, P376, DOI 10.1016/j.transproceed.2010.12.015
   McDiarmid SV, 2010, LIVER TRANSPLANT, V16, pS13, DOI 10.1002/lt.22170
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Midgley DE, 2000, LIVER TRANSPLANT, V6, P333, DOI 10.1053/lv.2000.6139
   Petersen S, 2009, ACTA PAEDIATR, V98, P1504, DOI 10.1111/j.1651-2227.2009.01360.x
   Sarna L, 2008, QUAL LIFE RES, V17, P1217, DOI 10.1007/s11136-008-9404-8
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Sundaram SS, 2007, AM J TRANSPLANT, V7, P982, DOI 10.1111/j.1600-6143.2006.01722.x
   Suris JC, 2008, PEDIATRICS, V122, pE1113, DOI 10.1542/peds.2008-1479
   Swallen KC, 2005, PEDIATRICS, V115, P340, DOI 10.1542/peds.2004-0678
   Taylor R, 2005, LIVER TRANSPLANT, V11, P7
   Taylor R, 2005, LIVER TRANSPLANT, V11, P51, DOI 10.1002/lt.20294
   Taylor RM, 2009, AM J TRANSPLANT, V9, P1179, DOI 10.1111/j.1600-6143.2009.02604.x
   Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006
   Wallander JL, 2009, OBESITY, V17, P1363, DOI 10.1038/oby.2008.668
   Wilson D, 1999, PREV MED, V29, P139, DOI 10.1006/pmed.1999.0523
   Yeo M, 2005, BRIT MED J, V330, P721, DOI 10.1136/bmj.330.7493.721
NR 41
TC 14
Z9 14
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD FEB
PY 2012
VL 12
IS 2
BP 420
EP 427
DI 10.1111/j.1600-6143.2011.03819.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 883HP
UT WOS:000299625200023
PM 22050653
ER

PT J
AU Sheth, J
   Sharif, K
   Lloyd, C
   Gupte, G
   Kelly, D
   de Goyet, JD
   Millar, AJ
   Mirza, DF
   Chardot, C
AF Sheth, J.
   Sharif, K.
   Lloyd, C.
   Gupte, G.
   Kelly, D.
   de Goyet, J. de Ville
   Millar, A. J.
   Mirza, D. F.
   Chardot, C.
TI Staged abdominal closure after small bowel or multivisceral
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE intestinal transplantation; surgery
ID PEDIATRIC LIVER-TRANSPLANTATION; TEMPORARY WOUND CLOSURE; VACUUM PACK
   TECHNIQUE; INTESTINAL TRANSPLANTATION; HEPATIC TRANSPLANTATION; WALL
   CLOSURE; 7-YEAR EXPERIENCE; DONOR LIVER; MANAGEMENT; CHILDREN
AB Following paediatric SBMT, size discrepancy between the recipient's abdomen and the graft may lead to ACS, graft dysfunction, and death. We report our experience with SAC in these patients. Between 04/1993 and 03/2009, 57 children underwent 62 SBMTs. When abdominal wall tension seemed excessive for safe PAC, SAC was performed, using a Silastic (R) sheet and a vacuum occlusive dressing. Transplantations with SAC (23 combined liver and small bowel [CLB]) were compared with those with PAC [14 ISB and 25 CLB]. Indications for transplantation, preoperative status (after stratification for ISB/CLB transplants), age at transplantation, donor-to-recipient weight ratio, reduction in bowel and/or liver, and incidence of wound complications were not different in both groups. Post-operative intubation, stay in intensive care unit, and hospital stay were prolonged after SAC. Two deaths were related to ACS after PAC, none after SAC. Since 2000, one-yr patient survival is 73% after ISB transplantation and 57% vs. 75% after CLB transplantation with PAC vs. SAC, respectively (NS). SAC safely reduces severe ACS after paediatric SBMT and can be combined with graft reduction for transplantation of small recipients.
C1 [Sheth, J.; Sharif, K.; Lloyd, C.; Gupte, G.; Kelly, D.; de Goyet, J. de Ville; Millar, A. J.; Mirza, D. F.; Chardot, C.] Birmingham Childrens Hosp, Liver Unit Including Small Bowel Transplantat, Birmingham, W Midlands, England.
RP Chardot, C (reprint author), Univ Paris 05, Hop Necker Enfants Malad, Serv Chirurg Pediat Viscerale, 149 Rue Sevres, F-75015 Paris, France.
EM christophe.chardot@nck.aphp.fr
CR Alexandrides IJ, 2000, PLAST RECONSTR SURG, V106, P805, DOI 10.1097/00006534-200009040-00008
   Barker DE, 2000, J TRAUMA, V48, P201, DOI 10.1097/00005373-200002000-00001
   Biancofiore G, 2004, TRANSPLANT P, V36, P547, DOI 10.1016/j.transproceed.2004.02.029
   BISMUTH H, 1984, SURGERY, V95, P367
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Carlotti APCP, 2009, PEDIATR CRIT CARE ME, V10, P115, DOI 10.1097/PCC.0b013e31819371b2
   Carlsen BT, 2007, PLAST RECONSTR SURG, V119, P1247, DOI 10.1097/01.prs.0000254401.33682.e9
   CARLSEN BT, 2007, PLAST RECONSTR SURG, V119, P1256
   Charles CA, 2004, DERMATOL SURG, V30, P1236, DOI 10.1111/j.1524-4725.2004.30383.x
   Cohen M, 2001, PLAST RECONSTR SURG, V108, P83, DOI 10.1097/00006534-200107000-00014
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   de Ville de Goyet J, 2000, TRANSPLANTATION, V69, P555
   Delriviere L, 2000, TRANSPLANTATION, V69, P1392, DOI 10.1097/00007890-200004150-00031
   Drosou A, 2005, J AM ACAD DERMATOL, V52, P854, DOI 10.1016/j.jaad.2004.11.069
   Giovanelli M, 2009, TRANSPLANTATION, V87, P1695, DOI 10.1097/TP.0b013e3181a5e9f8
   Gondolesi G, 2009, TRANSPLANTATION, V87, P1884, DOI 10.1097/TP.0b013e3181a7697a
   Grevious MA, 2009, PEDIATR TRANSPLANT, V13, P177, DOI 10.1111/j.1399-3046.2008.00966.x
   Jafri MA, 2007, LIVER TRANSPLANT, V13, P258, DOI 10.1002/lt.21027
   Jernigan TW, 2003, ANN SURG, V238, P349, DOI 10.1097/01.sla.0000086544.42647.84
   Jernigan TW, 2003, ANN SURG, V238, P355
   Karpelowsky JS, 2009, PEDIATR TRANSPLANT, V13, P285, DOI 10.1111/j.1399-3046.2008.01086.x
   Kaufman SS, 2001, CURR OPIN PEDIATR, V13, P425, DOI 10.1097/00008480-200110000-00007
   KRASNA IH, 1995, J PEDIATR SURG, V30, P23, DOI 10.1016/0022-3468(95)90601-0
   Mazariegos George V, 2009, Curr Gastroenterol Rep, V11, P226
   Ong TH, 1996, J PEDIATR SURG, V31, P295, DOI 10.1016/S0022-3468(96)90019-6
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Ryckman FC, 1991, J PEDIATR SURG, V26, P427
   RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7
   Seaman DS, 1996, TRANSPLANTATION, V62, P1034, DOI 10.1097/00007890-199610150-00027
   SHUN A, 1992, CLIN TRANSPLANT, V6, P315
   Stewart RM, 2000, J TRAUMA, V48, P206
   van As AB, 2007, ACTA CLIN BELG, V1, P215
   Zanfi C, 2008, TRANSPLANTATION, V85, P1607, DOI 10.1097/TP.0b013e318174db6f
NR 33
TC 9
Z9 10
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2012
VL 16
IS 1
BP 36
EP 40
DI 10.1111/j.1399-3046.2011.01597.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 877CM
UT WOS:000299154200013
PM 21981601
ER

PT J
AU Miraglia, R
   Maruzzelli, L
   Spada, M
   Riva, S
   Luca, A
   Gridelli, B
AF Miraglia, Roberto
   Maruzzelli, Luigi
   Spada, Marco
   Riva, Silvia
   Luca, Angelo
   Gridelli, Bruno
TI Transjugular liver biopsy in pediatric patients with left split liver
   transplantation and severe coagulation impairment
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE rejection; children; interventional radiology; complication; ascites
ID ACCURATE HISTOLOGICAL INTERPRETATION; NEEDLE
AB The aim of this study is to report our experience in TJLB performed in pediatric patients who underwent partial LT using a left lateral segments graft. Eight consecutive TJLBs were performed in six patients with contraindication to percutaneous biopsy owing to severe coagulation impairment and ascites. All procedures were performed using an 18-gauge automated core needle biopsy. Median age of the patients was 44 months (range, 11-198). Median patients' weight was 13 kg (range, 8-45). Technical success was achieved in all cases without complications. The specimens were adequate for the diagnosis in all cases.
C1 [Miraglia, Roberto; Maruzzelli, Luigi; Luca, Angelo] Mediterranean Inst Transplantat & Adv Specialized, Dept Radiol, Palermo, Italy.
   [Spada, Marco; Gridelli, Bruno] Mediterranean Inst Transplantat & Adv Specialized, Dept Transplantat Surg, Palermo, Italy.
   [Riva, Silvia] Mediterranean Inst Transplantat & Adv Specialized, Dept Pediat Hepatol, Palermo, Italy.
RP Miraglia, R (reprint author), IsMeTT, Dept Radiol, Via Tricomi 1, I-90127 Palermo, Italy.
EM rmiraglia@ismett.edu
RI miraglia, roberto/B-2051-2016
CR Abujudeh H, 2004, Emerg Radiol, V10, P268, DOI 10.1007/s10140-003-0318-z
   Atar E, 2010, CARDIOVASC INTER RAD, V33, P560, DOI 10.1007/s00270-009-9743-z
   Azoulay D, 1996, TRANSPLANTATION, V61, P406, DOI 10.1097/00007890-199602150-00015
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   Cholongitas E, 2006, GUT, V55, P1789, DOI 10.1136/gut.2005.090415
   Cholongitas E, 2007, LIVER INT, V27, P646, DOI 10.1111/j.1478-3231.2007.01496.x
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   Habdank K, 2003, AM J ROENTGENOL, V180, P1393
   Kalambokis G, 2007, J HEPATOL, V47, P284, DOI 10.1016/j.jhep.2007.05.001
   Kim KR, 2008, LIVER TRANSPLANT, V14, P971, DOI 10.1002/lt.21448
   Miller MJ, 2010, J VASC INTERV RADIOL, V21, P508, DOI 10.1016/j.jvir.2009.11.024
   Miraglia R, 2011, EUR J RADIOL, V3, pE269
   RILEY SA, 1984, LANCET, V2, P436
   Rockey DC, 2009, HEPATOLOGY, V49, P1017, DOI 10.1002/hep.22742
   Romero M, 1999, Gastroenterol Hepatol, V22, P493
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Vibhakorn S, 2009, CARDIOVASC INTER RAD, V32, P508, DOI 10.1007/s00270-008-9412-7
NR 17
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2012
VL 16
IS 1
BP 58
EP 62
DI 10.1111/j.1399-3046.2011.01605.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 877CM
UT WOS:000299154200016
PM 22081991
ER

PT J
AU Elgendy, HM
   El Moghazy, WM
   Uemoto, S
   Fukuda, K
AF Elgendy, Hamed M.
   El Moghazy, Walid M.
   Uemoto, Shinji
   Fukuda, Kazuhiko
TI Pre transplant serum magnesium level predicts outcome after pediatric
   living donor liver transplantation
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE magnesium; mortality; graft; liver; transplantation
ID STEM-CELL TRANSPLANTATION; SINGLE-CENTER EXPERIENCE; IONIZED MAGNESIUM;
   HYPOMAGNESEMIA; DEFICIENCY; MORTALITY; BONE; COMPLICATIONS; METABOLISM;
   TACROLIMUS
AB Background: Hypomagnesaemia is a frequent complication after liver transplantation (LTx) however; magnesium is not routinely replaced in the perioperative period.
   Material/Methods: The incidence of hypomagnesaemia before and after pediatric LTx was studied in 673 pediatric patients who underwent living-donor liver transplantation (LDLT).
   Results: The mean serum Mg levels before LTx was normal, 2.03+/-0.28 mg/dl, exhibited marked decrease on 5th postoperative (PO) day, 1.79+/-0.45, p<0.001, comparing with the pre-transplant value. It reached its nadir in the 1st PO month, p<0.001. Up to the 5th PO year, serum Mg did not achieve the lower limit of normal, 1.77+/-0.24, p<0.001 and incidence of hypomagnesaemia was 60.7% (242/399). Univariate analyses of variables that can predict graft loss and patient death after LDLT demonstrated that recipient factors, pre and post transplant serum Mg and blood product transfusions were potentially risk factors significantly affected the outcome. Multivariate analysis of potential risk factors showed that pre transplant serum Mg <1.8 mg/dl, (Hazard ratio (HR) 2.362 [confidence interval (CI) 1.350-4.133]; p=0.003) and pre transplant BUN, (HR 1.046 [CI 1.014-1.079]; p=0.005) were independent predictors of graft loss and patient death.
   Conclusions: hypomagnesaemia is common before and after pediatric LDLT. Pre transplant hypomagnesaemia and high BUN are independent risk factors for graft loss or patient death. Pre transplant hypomagnesaemia patients exhibited decreased survival of their graft. Post transplant hypomagnesaemia was a potentially risk factor for graft loss.
C1 [Elgendy, Hamed M.; Fukuda, Kazuhiko] Kyoto Univ, Dept Anaesthesia, Kyoto, Japan.
   [Elgendy, Hamed M.] Assiut Univ, Dept Anaesthesia, Assiut 71526, Egypt.
   [Elgendy, Hamed M.] McGill Univ, Royal Victoria Hosp, Dept Anaesthesia, Montreal, PQ H3A 1A1, Canada.
   [El Moghazy, Walid M.; Uemoto, Shinji] Kyoto Univ, Dept Hepatopancreatobiliary Surg & Transplantat, Kyoto, Japan.
   [El Moghazy, Walid M.] Sohag Univ, Dept Surg, Sohag, Egypt.
RP Elgendy, HM (reprint author), Assiut Univ, Dept Anaesthesia, Assiut Univ Hosp, Main Campus, Assiut 71526, Egypt.
EM helgendy70@gmail.com
OI Elmoghazy, Walid/0000-0001-9590-0930
CR Adachi Takehiko, 2003, J Anesth, V17, P116, DOI 10.1007/s005400300027
   Aisa Y, 2005, TRANSPLANTATION, V80, P1046, DOI 10.1097/01.TP.0000174340.40585.D4
   Bacigalupo A, 1999, BONE MARROW TRANSPL, V24, P653, DOI 10.1038/sj.bmt.1701953
   Beier K, 2011, CRIT CARE MED, V39, P305, DOI 10.1097/CCM.0b013e3181ffe22a
   BENNETT MWR, 1993, TRANSPLANTATION, V56, P859, DOI 10.1097/00007890-199310000-00016
   Choi JH, 2005, CAN J ANAESTH, V52, P156
   Diaz J, 1996, TRANSPLANTATION, V61, P835, DOI 10.1097/00007890-199603150-00028
   DYCKNER T, 1978, ACTA MED SCAND, V204, P269
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   Faghihi T, 2009, ANN TRANSPL, V14, P51
   Fuentebella J, 2009, PEDIATR CLIN N AM, V56, P1201, DOI 10.1016/j.pcl.2009.06.006
   Gopal Palepu B, 2009, Indian J Crit Care Med, V13, P113, DOI 10.4103/0972-5229.58535
   Hassan G, 2007, TRANSPL P, V39, P1190, DOI 10.1016/j.transproceed.2007.04.009
   KOBAYASHI A, 1974, ARCH DIS CHILD, V49, P641
   Koivisto M, 2002, CLIN TRANSPLANT, V16, P325, DOI 10.1034/j.1399-0012.2002.01141.x
   Kulpmann W R, 1996, Scand J Clin Lab Invest Suppl, V224, P235
   Lanzinger MJ, 2003, J CLIN ANESTH, V15, P245, DOI 10.1016/S0952-8180(03)00059-X
   Mohsin N, 2003, TRANSPLANT P, V35, P2652, DOI 10.1016/j.transproceed.2003.09.055
   Navaneethan SD, 2006, TRANSPLANT P, V38, P1320, DOI 10.1016/j.transproceed.2006.02.077
   Perez-Ruiz F, 2001, TRANSPLANTATION, V71, P696, DOI 10.1097/00007890-200103150-00022
   Rayssiguier Yves, 2005, Clin Calcium, V15, P245
   RUBEIZ GJ, 1993, CRIT CARE MED, V21, P203, DOI 10.1097/00003246-199302000-00010
   Rude RK, 2003, CALCIFIED TISSUE INT, V72, P32, DOI 10.1007/s00223-001-1091-1
   RYAN MF, 1991, ANN CLIN BIOCHEM, V28, P19
   RYZEN E, 1989, J AM COLL NUTR, V8, P580
   Saleem AF, 2009, INDIAN J PEDIATR, V76, P1227, DOI 10.1007/s12098-009-0258-z
   SALEM M, 1995, CRIT CARE MED, V23, P108, DOI 10.1097/00003246-199501000-00019
   SANCHEZCAPUCHINO A, 1994, ANAESTHESIA, V49, P912, DOI 10.1111/j.1365-2044.1994.tb04275.x
   Scott V L, 1996, Liver Transpl Surg, V2, P343, DOI 10.1002/lt.500020503
   Staatz CE, 2004, LIVER TRANSPLANT, V10, P506, DOI 10.1002/lt.20065
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   UEMOTO S, 1991, TRANSPLANT P, V23, P3007
   Van Laecke S, 2009, AM J TRANSPLANT, V9, P2140, DOI 10.1111/j.1600-6143.2009.02752.x
   Van Laecke S, 2010, LIVER TRANSPLANT, V16, P1278, DOI 10.1002/lt.22146
   Vannini SDP, 1999, TRANSPLANT INT, V12, P244, DOI 10.1111/j.1432-2277.1999.tb01208.x
   Yu J, 2004, WORLD J GASTROENTERO, V10, P2540
NR 37
TC 3
Z9 3
U1 0
U2 0
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PY 2012
VL 17
IS 2
BP 29
EP 37
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 228KG
UT WOS:000325184300004
PM 22743720
ER

PT J
AU Studniarz, M
   Czubkowski, P
   Cielecka-Kuszyk, J
   Jankowska, I
   Teisseyre, M
   Kaminska, D
   Markiewicz, M
   Broniszczak, D
   Pawlowska, J
AF Studniarz, Monika
   Czubkowski, Piotr
   Cielecka-Kuszyk, Joanna
   Jankowska, Irena
   Teisseyre, Mikolaj
   Kaminska, Diana
   Markiewicz, Malgorzata
   Broniszczak, Dorota
   Pawlowska, Joanna
TI Amoxicillin/clavulanic acid-induced cholestatic liver injury after
   pediatric liver transplantation
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE drug toxicity; amoxicillin; clavulanic acid; cholestasis; pediatric
   liver transplantation
ID INTRAHEPATIC BILIARY EPITHELIUM; BILE-DUCT SYNDROME; CLAVULANIC ACID;
   AUGMENTIN; THERAPY
AB Background: Amoxicillin/clavulanic acid-induced liver injury is a well recognized complication. Presentation and outcome may vary, which is related to individual liver maturity, genetic predisposition, enzyme heterogeneity, intensity of treatment, and drug interactions. In most cases withdrawing the drug is sufficient treatment; however, cases of progressive liver damage leading to liver transplantation have been reported.
   Case Report: We present the case of an 8-year-old patient after liver transplantation who developed drug induced liver injury (DILI) after amoxicillin/clavulanic acid treatment for upper respiratory tract infection. Jaundice appeared 2 days after cessation of treatment. Clinical presentation and liver biopsy were consistent with DILI. Because of rapidly increasing bilirubin levels, we used 3 boluses of methylprednisolone and ursodeoxycholic acid. The treatment reversed progression of the cholestasis and full recovery was achieved in 3 months.
   Conclusions: In most cases of DILI, withdrawing the toxic drug is sufficient treatment, but we must be aware of a possible fatal outcome in case of progressive cholestasis. Corticosteroids may have beneficial effects in these patients.
C1 [Studniarz, Monika; Czubkowski, Piotr; Jankowska, Irena; Teisseyre, Mikolaj; Kaminska, Diana; Pawlowska, Joanna] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol & Immunol, PL-04730 Warsaw, Poland.
   [Cielecka-Kuszyk, Joanna] Childrens Mem Hlth Inst, Dept Pathol, PL-04730 Warsaw, Poland.
   [Markiewicz, Malgorzata; Broniszczak, Dorota] Childrens Mem Hlth Inst, Dept Paediat Surg & Transplantat, PL-04730 Warsaw, Poland.
RP Czubkowski, P (reprint author), Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol & Immunol, Dzieci Polskich 20 St, PL-04730 Warsaw, Poland.
EM piotr.czubkowski@mp.pl
CR Alvaro D, 2002, GASTROENTEROLOGY, V122, P1058, DOI 10.1053/gast.2002.32374
   Chawla A, 2000, J PEDIATR-US, V136, P121, DOI 10.1016/S0022-3476(00)90064-7
   DAVIES MH, 1994, J HEPATOL, V20, P112, DOI 10.1016/S0168-8278(05)80476-3
   Ganschow R, 2006, PEDIATR TRANSPLANT, V10, P220, DOI 10.1111/j.1399-3046.2005.00413.x
   HAUTEKEETE ML, 1995, J HEPATOL, V22, P71, DOI 10.1016/0168-8278(95)80262-2
   O'Donohue J, 2000, GUT, V47, P717, DOI 10.1136/gut.47.5.717
   RYLEY NG, 1995, J HEPATOL, V23, P278, DOI 10.1016/0168-8278(95)80471-4
   Smith LA, 2005, J PEDIATR GASTR NUTR, V41, P469, DOI 10.1097/01.mpg.0000178086.44155.73
   STRICKER BHC, 1989, DIGEST DIS SCI, V34, P1576, DOI 10.1007/BF01537113
   Tatekawa Y, 2005, J PEDIATR SURG, V40, P1574, DOI 10.1016/j.jpedsurg.2005.06.017
   Velayudham Lakshumanan S, 2003, Expert Opin Drug Saf, V2, P287
NR 11
TC 4
Z9 5
U1 0
U2 1
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD JAN-MAR
PY 2012
VL 17
IS 1
BP 128
EP 131
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 973UN
UT WOS:000306385400017
PM 22466919
ER

PT J
AU Yoon, SO
   Yu, E
   Cho, YM
   Suh, C
   Kim, KM
   Han, DJ
   Lee, SG
   Huh, J
AF Yoon, Sun Och
   Yu, Eunsil
   Cho, Yong Mee
   Suh, Cheolwon
   Kim, Kyung Mo
   Han, Duck Jong
   Lee, Seung Gyu
   Huh, Jooryung
TI Post-transplant lymphoproliferative disorders: clinicopathological
   analysis of 43 cases in a single center, 1990-2009
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE organ transplantation; post-transplant lymphoproliferative disorders;
   Republic of Korea
ID PROGNOSTIC-FACTORS; ORGAN-TRANSPLANTATION; IDENTIFICATION; SURVIVAL;
   DISEASE
AB Post-transplant lymphoproliferative disorders (PTLDs) are a heterogeneous set of complications of organ transplantation associated with poor patient prognosis. We analyzed the clinicopathological features of PTLDs in 43 adult and pediatric recipients of solid organ or bone marrow transplantation at a large transplant service in the Republic of Korea between 1990 and 2009. Of 4545 solid organ and 747 bone marrow transplant recipients, 37 (0.81%) and 6 (0.8%), respectively, developed heterogeneous types of PTLDs. The cumulative incidences of PTLDs during this period were 1.79% (4/223) for heart transplant recipients, 0.78% (17/2192) for kidney transplant recipients, and 0.77% (16/2067) for liver transplant recipients. The patterns of disease onset, histology, and patient survival were associated with the types of organs transplanted. There is a trend for shorter overall survival (OS) in recipients with early-onset PTLDs and monomorphic PTLD histology, while kidney transplant recipients showed favorable OS. This study may be the first comprehensive analysis of the characteristics of PTLDs in Korean patients.
C1 [Yoon, Sun Och; Yu, Eunsil; Cho, Yong Mee; Huh, Jooryung] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea.
   [Yoon, Sun Och] Yonsei Univ, Coll Med, Dept Pathol, Gangnam Severance Hosp, Seoul, South Korea.
   [Suh, Cheolwon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol Internal Med, Seoul 138736, South Korea.
   [Kim, Kyung Mo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat, Seoul 138736, South Korea.
   [Han, Duck Jong; Lee, Seung Gyu] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea.
RP Huh, J (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 388-1 Poongnap Dong, Seoul 138736, South Korea.
EM jrhuh@amc.seoul.kr
CR Andreome P, 2003, ARCH INTERN MED, V163, P1997, DOI 10.1001/archinte.163.17.1997
   Bakker NA, 2005, CLIN TRANSPLANT, V19, P327, DOI 10.1111/j.1399-0012.2005.00342.x
   Caillard S, 2006, AM J TRANSPLANT, V6, P2735, DOI 10.1111/j.1600-6143.2006.01540.x
   Choquet Sylvain, 2002, Recent Results Cancer Res, V159, P67
   Domingo-Domenech E, 2001, HAEMATOLOGICA, V86, P715
   Evens AM, 2010, J CLIN ONCOL, V28, P1038, DOI 10.1200/JCO.2009.25.4961
   Fohrer C, 2006, BRIT J HAEMATOL, V134, P602, DOI 10.1111/j.1365-2141.2006.06228.x
   LEBLOND V, 1995, J CLIN ONCOL, V13, P961
   Leblond V, 2001, J CLIN ONCOL, V19, P772
   Norin S, 2004, MED ONCOL, V21, P273, DOI 10.1385/MO:21:3:273
   Oton AB, 2008, LEUKEMIA LYMPHOMA, V49, P1738, DOI 10.1080/10428190802239162
   Swerdlow SH, 2008, WHO CLASSIFICATION T
NR 12
TC 6
Z9 7
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JAN-FEB
PY 2012
VL 26
IS 1
BP 67
EP 73
DI 10.1111/j.1399-0012.2010.01392.x
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 898DH
UT WOS:000300715100020
PM 21269330
ER

PT J
AU Mclin, VA
   Anand, R
   Daniels, SR
   Yin, W
   Alonso, EM
AF McLin, V. A.
   Anand, R.
   Daniels, S. R.
   Yin, W.
   Alonso, E. M.
CA SPLIT Res Grp
TI Blood Pressure Elevation in Long-Term Survivors of Pediatric Liver
   Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Children; blood pressure; liver transplant; long-term; risk factors
ID RENAL-FAILURE; RISK-FACTORS; CHILDREN; HYPERTENSION; ADOLESCENTS;
   PROGRESSION; CYCLOSPORINE; RECIPIENTS; DISEASE; HYPERLIPIDEMIA
AB As pediatric liver transplant (LT) recipients come of age, additional insight into long-term medical complications of immunosuppression is warranted. The aims of this study were to estimate the prevalence of elevated blood pressure (BP) in long-term survivors of pediatric LT using the data from the Studies in Pediatric Liver Transplantation (SPLIT) database and to identify predictive factors. Patients enrolled in the BP arm of the SPLIT cohort participated in the study. All patients were of at least 5 years but =10 years post-LT. Automated BP measurements were obtained at anniversary visits. BP measures were classified as normal, borderline or elevated according to standard criteria. Patients taking antihypertensive medications were classified as elevated. Eight hundred and fifteen patients participated. The prevalence of elevated BP measurements 5 to 10 years post-LT was 17.5 to 27.5%. Of total 62.5% patients presented with at least one additional elevated BP at a later follow up visit. Multivariate analysis revealed the following parameters to be predictive of elevated BP: age at transplant, steroid use at last BP measurement and cGFR at last BP measurement. Pediatric LT patients show a high prevalence of elevated BP measurements 5 to 10 years following LT, which is related to age at LT, decreased cGFR and recent steroid use.
C1 [McLin, V. A.] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.
   [McLin, V. A.] Texas Childrens Hosp, Texas Childrens Liver Ctr, Houston, TX 77030 USA.
   [Anand, R.; Yin, W.] EMMES Corp, Rockville, MD USA.
   [Daniels, S. R.] Univ Colorado, Childrens Hosp, Denver, CO 80202 USA.
   [Alonso, E. M.] Childrens Mem Hosp, Chicago, IL 60614 USA.
RP Mclin, VA (reprint author), Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.
EM valerie.mclin@hcuge.ch
FU National Institute of Diabetes and Digestive and Kidney Diseases [U01
   DK061693]
FX This project was supported by grant number U01 DK061693 of the National
   Institute of Diabetes and Digestive and Kidney Diseases. The authors
   thank all the participating SPLIT centers.
CR Ader JL, 1998, CURR OPIN NEPHROL HY, V7, P539, DOI 10.1097/00041552-199809000-00009
   Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302
   Calne R Y, 1979, Proc Eur Dial Transplant Assoc, V16, P305
   CALNE RY, 1979, LANCET, V2, P1033
   Canzanello VJ, 1998, LIVER TRANSPLANT SUR, V4, P328
   Daniels SR, 1998, CIRCULATION, V97, P1907
   Davidson J, 2003, TRANSPLANTATION, V75, pSS3, DOI 10.1097/01.TP.0000069952.49242.3E
   Harambat J, 2008, TRANSPLANTATION, V86, P1028, DOI 10.1097/TP.0b013e318187748f
   Johnston SD, 2002, TRANSPLANTATION, V73, P901, DOI 10.1097/00007890-200203270-00012
   Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103
   Kobashigawa JA, 1997, TRANSPLANTATION, V63, P331, DOI 10.1097/00007890-199702150-00001
   Kuczmarski RJ, 2000, ADV DATA, V314, P1
   LAUER RM, 1989, PEDIATRICS, V84, P633
   Locatelli F, 1996, NEPHROL DIAL TRANSPL, V11, P461
   Lurbe E, 2009, J HYPERTENS, V27, P1719, DOI 10.1097/HJH.0b013e32832f4f6b
   MCDIARMID SV, 1992, TRANSPLANTATION, V53, P109, DOI 10.1097/00007890-199201000-00021
   McNiece KL, 2007, J PEDIATR-US, V150, P640, DOI 10.1016/j.jpeds.2007.01.052
   McNiece KL, 2007, J PEDIAT, V150, p644e1
   Mells G, 2007, TRANSPLANTATION, V83, P1141, DOI 10.1097/01.tp.0000262706.28513.6a
   Mitsnefes M, 2003, J AM SOC NEPHROL, V14, P2618, DOI 10.1097/01.ASN.0000089565.04535.4B
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Ostchega Y, 2009, AM J HYPERTENS, V22, P59, DOI 10.1038/ajh.2008.312
   Portman Ronald J, 2005, Curr Probl Pediatr Adolesc Health Care, V35, P262, DOI 10.1016/j.cppeds.2005.06.001
   Reuben A, 2001, LIVER TRANSPLANT, V7, pS13, DOI 10.1053/jlts.2001.29167
   Rodriguez BL, 2010, J PEDIATR-US, V157, P245, DOI 10.1016/j.jpeds.2010.02.021
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   Simonetti GD, J HYPERTENS, V28, P1109
   Smith JM, 2004, PEDIATR TRANSPLANT, V8, P445, DOI 10.1111/j.1399-3046.2004.00209.x
   Staples A, 2010, CURR OPIN PEDIATR, V22, P161, DOI 10.1097/MOP.0b013e328336ebb0
   [Anonymous], 2004, ANN DAT REP
   Textor SC, 2000, LIVER TRANSPLANT, V6, P521, DOI 10.1053/jlts.2000.9737
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   WHITE DJG, 1979, TRANSPLANT P, V11, P855
   Wingen AM, 1997, LANCET, V349, P1117, DOI 10.1016/S0140-6736(96)09260-4
   Wuhl E, 2009, NEW ENGL J MED, V361, P1639
   Zimmermann F A, 1979, Chir Forum Exp Klin Forsch, P339
   [Anonymous], 2004, PEDIATRICS S, V114, P555
NR 37
TC 16
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2012
VL 12
IS 1
BP 183
EP 190
DI 10.1111/j.1600-6143.2011.03772.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 875XU
UT WOS:000299069300022
PM 21992721
ER

PT J
AU Schneider, N
   Scanga, A
   Stokes, L
   Perri, R
AF Schneider, N.
   Scanga, A.
   Stokes, L.
   Perri, R.
TI Portal Vein Stenosis: A Rare Yet Clinically Important Cause of
   Delayed-onset Ascites after Adult Deceased Donor Liver Transplantation:
   Two Case Reports
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID VENOUS COMPLICATIONS; VASCULAR COMPLICATIONS; MANAGEMENT; ANGIOPLASTY;
   THROMBOSIS; PLACEMENT
AB Vascular complications following liver transplantation are well documented. While complications involving the portal vein are less common than the hepatic artery, portal vein complications can lead to potentially life-threatening sequelae including graft loss. Portal vein stenosis is an infrequent complication following liver transplant. The majority of these complications are seen in living donor liver transplants and pediatric liver transplants. We present 2 cases of delayed onset portal vein stenosis in adult deceased donor liver transplantation (ADDLT). The first patient presented with refractory ascites twelve months after ADDLT. He was diagnosed and successfully treated with percutaneous transhepatic portovenography and venoplasty. The second patient had a history of irradiation to his portal bed in the setting of cholangiocarcinoma. He developed refractory ascites and esophageal variceal bleeding >2 years after ADDLT. He underwent percutaneous transhepatic portovenoplasty, but eventually required placement of a portal stent due to continued problems with recurrent ascites. These 2 cases highlight the importance of considering portal vein stenosis in the differential diagnosis of late-onset ascites following liver transplantation, especially if there have been any predisposing risk factors such as portal bed irradiation or prior splenectomy.
C1 [Schneider, N.] Vanderbilt Univ, Div Gastroenterol & Hepatol, Dept Med, Vanderbilt Digest Dis Ctr,Vanderbilt Clin 1660, Nashville, TN 37232 USA.
   [Stokes, L.] Vanderbilt Univ, Dept Radiol, Sch Med, Nashville, TN 37232 USA.
RP Schneider, N (reprint author), Vanderbilt Univ, Div Gastroenterol & Hepatol, Dept Med, Vanderbilt Digest Dis Ctr,Vanderbilt Clin 1660, Nashville, TN 37232 USA.
EM natasha.schneider@vanderbilt.edu
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 2010, AM J TRANSPLANT, V10, P1276, DOI 10.1111/j.1600-6143.2010.03076.x
   Cheng YF, 2009, LIVER TRANSPLANT, V15, P1378, DOI 10.1002/lt.21813
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Funaki B, 2000, RADIOLOGY, V215, P147
   Glockner JF, 1999, AM J ROENTGENOL, V173, P1055
   Gonzalez-Tutor A, 2000, ANGIOLOGY, V51, P511, DOI 10.1177/000331970005100610
   Huang TL, 2010, TRANSPL P, V42, P879, DOI 10.1016/j.transproceed.2010.02.036
   Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x
   Ko GY, 2007, LIVER TRANSPLANT, V13, P530, DOI 10.1002/lt.21068
   Mantel HTJ, 2007, LIVER TRANSPLANT, V13, P1372, DOI 10.1002/lt.21107
   McDaniel HM, 1997, TRANSPLANTATION, V63, P607, DOI 10.1097/00007890-199702270-00021
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Olcott E W, 1990, J Vasc Interv Radiol, V1, P17, DOI 10.1016/S1051-0443(90)72496-7
   Park KB, 2005, KOREAN J RADIOL, V6, P161
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   Sood D, 2009, TRANSPL INT, V22, P496, DOI 10.1111/j.1432-2277.2008.00797.x
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Wei BJ, 2009, WORLD J GASTROENTERO, V15, P1880, DOI 10.3748/wjg.15.1880
   ZAJKO AB, 1994, J VASC INTERV RADIOL, V5, P121, DOI 10.1016/S1051-0443(94)71467-6
NR 20
TC 8
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2011
VL 43
IS 10
BP 3829
EP 3834
DI 10.1016/j.transproceed.2011.09.068
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 869TD
UT WOS:000298620200049
PM 22172855
ER

PT J
AU Sanada, Y
   Mizuta, K
   Urahashi, T
   Ihara, Y
   Wakiya, T
   Okada, N
   Yamada, N
   Egami, S
   Hishikawa, S
   Ushijima, K
   Otomo, S
   Sakamoto, K
   Yasuda, Y
   Kawarasaki, H
AF Sanada, Y.
   Mizuta, K.
   Urahashi, T.
   Ihara, Y.
   Wakiya, T.
   Okada, N.
   Yamada, N.
   Egami, S.
   Hishikawa, S.
   Ushijima, K.
   Otomo, S.
   Sakamoto, K.
   Yasuda, Y.
   Kawarasaki, H.
TI Hepatic Arterial Buffer Response after Pediatric Living Donor Liver
   Transplantation: Report of a Case
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID FOR-SIZE GRAFT; PORTACAVAL-SHUNT; SOMATOSTATIN; SPLENECTOMY; MODULATION;
   PRESSURE; LIGATION; INJURY; IMPACT; PHASE
AB Background. Excessive portal pressure at an early stage after living-donor liver transplantation (LDLT) can damage sinusoidal endothelial cells and hepatocytes through shear stress leading to graft failure, or hepatic arterial complications due to low hepatic artery flow from a hepatic arterial buffer response. We encountered a case in which excessive portal vein flow was observed from an early stage after pediatric LDLT. The hepatic artery flow decreased due to a hepatic arterial buffer response.
   Case report. A 6-month-old boy with biliary atresia showed excessive portal vein flow early after LDLT with a decreasing hepatic artery flow without anastomotic stenosis from postoperative day 3. The PV flow gradually exhibited a decrease at approximately postoperative day 8 and, similtaneously, hepatic artery flow exhibited improvement.
   Conclusion. Because excessive portal pressure after LDLT is reversible, it has been suggested that it may be possible to prevent the progress of hepatic arterial complications if temporary portal pressure modulation can be performed for cases among the high-risk group for hepatic arterial complications.
C1 [Sanada, Y.; Mizuta, K.; Urahashi, T.; Ihara, Y.; Wakiya, T.; Okada, N.; Yamada, N.; Egami, S.; Hishikawa, S.; Kawarasaki, H.] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Ushijima, K.] Jichi Med Univ, Dept Clin Pharmacol, Shimotsuke, Tochigi 3290498, Japan.
   [Otomo, S.; Sakamoto, K.] Jichi Med Univ Hosp, Dept Pharm, Shimotsuke, Tochigi, Japan.
   [Yasuda, Y.] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Sanada, Y (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM yuki371@jichi.ac.jp
CR Boillot O, 2002, LANCET, V359, P406, DOI 10.1016/S0140-6736(02)07593-1
   Bolognesi M, 2002, HEPATOLOGY, V35, P601, DOI 10.1053/jhep.2002.31352
   Demetris AJ, 2006, AM J SURG PATHOL, V30, P986, DOI 10.1097/00000478-200608000-00009
   Ikegami T, 2008, SURG TODAY, V38, P971, DOI 10.1007/s00595-008-3771-1
   Ikegami T, 2008, HEPATO-GASTROENTEROL, V55, P670
   Ito T, 2003, TRANSPLANTATION, V75, P1313, DOI 10.1097/01.TP.0000063707.90525.10
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Kiuchi T, 2003, LIVER TRANSPLANT, V9, pS29, DOI 10.1053/jlts.2003.50198
   Man K, 2003, ANN SURG, V237, P256, DOI 10.1097/00000658-200302000-00015
   Niiya T, 1999, J Hepatobiliary Pancreat Surg, V6, P275, DOI 10.1007/s005340050118
   Nishizaki T, 2001, ANN SURG, V233, P575, DOI 10.1097/00000658-200104000-00014
   Ozden I, 2007, EXP CLIN TRANSPLANT, V5, P686
   Shimada M, 2004, HEPATO-GASTROENTEROL, V51, P625
   Suehiro T, 2005, TRANSPLANT INT, V18, P923, DOI 10.1111/j.1432-2277.2005.00159.x
   Troisi R, 2008, AM J TRANSPLANT, V8, P847
   Umeda Y, 2008, TRANSPLANTATION, V86, P673, DOI 10.1097/TP.0b013e318181e02d
   Xu X, 2006, LIVER TRANSPLANT, V12, P621, DOI 10.1002/lt.20630
   Yamada T, 2008, AM J TRANSPLANT, V8, P847, DOI 10.1111/j.1600-6143.2007.02144.x
NR 18
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2011
VL 43
IS 10
BP 4019
EP 4024
DI 10.1016/j.transproceed.2011.08.094
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 869TD
UT WOS:000298620200087
PM 22172893
ER

PT J
AU Urahashi, T
   Mizuta, K
   Sanada, Y
   Wakiya, T
   Umehara, M
   Hishikawa, S
   Hyodo, M
   Sakuma, Y
   Fujiwara, T
   Yasuda, Y
   Kawarasaki, H
AF Urahashi, T.
   Mizuta, K.
   Sanada, Y.
   Wakiya, T.
   Umehara, M.
   Hishikawa, S.
   Hyodo, M.
   Sakuma, Y.
   Fujiwara, T.
   Yasuda, Y.
   Kawarasaki, H.
TI Pediatric liver retransplantation from living donors can be considered
   as a therapeutic option for patients with irreversible living donor
   graft failure
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric living donor liver transplantation; retransplantation; outcome
ID LONG-TERM SURVIVAL; TRANSPLANTATION; CHILDREN; OUTCOMES
AB Liver retransplantation (re-LT) is required in patients with irreversible graft failure, but it is a significant issue that remains medically, ethically, and economically controversial, especially in living donor liver transplantation (LDLT). The aim of this study was to evaluate the outcome, morbidity, mortality, safety and prognostic factors to improve the outcome of pediatric living donor liver retransplantation (re-LDLT). Six of 172 children that underwent LDLT between January 2001 and March 2010 received a re-LDLT and one received a second re-LDLT. The overall re-LDLT rate was 3.5%. All candidates had re-LDLT after the initial LDLT. The overall actuarial survival of these patients was 83.3% and 83.3% at one and five yr, respectively. These rates are significantly worse than the rates of pediatric first LDLT. Vascular complications occurred in four patients and were successfully treated by interventional radiologic therapy. There were no post-operative biliary complications. One case expired because of hemophagocytic syndrome after re-LDLT. Although pediatric re-LDLT is medically, ethically, and economically controversial, it is a feasible option and should be offered to children with irreversible graft failure. Further investigations, including multicenter studies, are therefore essential to identify any prognostic factors that may improve the present poor outcome after re-LDLT.
C1 [Urahashi, T.; Mizuta, K.; Sanada, Y.; Wakiya, T.; Umehara, M.; Hishikawa, S.; Kawarasaki, H.] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Hyodo, M.; Sakuma, Y.; Fujiwara, T.; Yasuda, Y.] Jichi Med Univ, Dept Gastrointestinal Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Urahashi, T (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM turahashi@jichi.ac.jp
CR Andrews W, 1996, J PEDIATR SURG, V31, P619, DOI 10.1016/S0022-3468(96)90660-0
   Biggins SW, 2002, LIVER TRANSPLANT, V8, P313, DOI 10.1053/jlts.2002.31746
   Broniszczak D, 2003, TRANSPLANT P, V35, P2271, DOI 10.1016/S0041-1345(03)00803-0
   Davis A, 2009, LIVER TRANSPLANT, V15, P199, DOI 10.1002/lt.21664
   Deshpande Rahul R., 2002, Transplantation (Baltimore), V74, P1124, DOI 10.1097/00007890-200210270-00012
   Eckhoff DE, 1994, J Pediatr Surg, V29, P9
   ECKHOFF DE, 1994, J PEDIATR SURG, V29, P1135, DOI 10.1016/0022-3468(94)90295-X
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Langham M, 1999, J PEDIATR SURG, V34, P849
   Lernar SM, 2005, TRANSPLANTATION LIVE, P767, DOI 10.1016/B978-0-7216-0118-2.50056-2
   Markmann JF, 1999, TRANSPLANTATION, V67, P422, DOI 10.1097/00007890-199902150-00015
   Newell KA, 1998, TRANSPLANTATION, V65, P1172, DOI 10.1097/00007890-199805150-00005
   Ng V, 2008, AM J TRANSPLANT, V8, P386, DOI 10.1111/j.1600-6143.2007.02056.x
   Ogura Y, 2003, TRANSPLANTATION, V76, P943, DOI 10.1097/01.TP.0000080068.22576.3B
   Ogura Y, 2008, Evolution of Living-Donor Liver Transplantation, P123
   Ryckman FC, 1999, J PEDIATR SURG, V34, P845, DOI 10.1016/S0022-3468(99)90385-8
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   UBEL PA, 1993, JAMA-J AM MED ASSOC, V270, P2469, DOI 10.1001/jama.270.20.2469
   Uribe M, 2007, TRANSPL P, V39, P609, DOI 10.1016/j.transproceed.2006.12.031
NR 19
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2011
VL 15
IS 8
BP 798
EP 803
DI 10.1111/j.1399-3046.2011.01572.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 858YS
UT WOS:000297840300013
PM 21923885
ER

PT J
AU Ates, M
   Dirican, A
   Ozgor, D
   Aydin, C
   Isik, B
   Ara, C
   Yilmaz, M
   Selimoglu, MA
   Kayaalp, C
   Yilmaz, S
AF Ates, Mustafa
   Dirican, Abuzer
   Ozgor, Dincer
   Aydin, Cemalettin
   Isik, Burak
   Ara, Cengiz
   Yilmaz, Mehmet
   Selimoglu, M. Ayse
   Kayaalp, Cuneyt
   Yilmaz, Sezai
TI Living Donor Liver Transplantation for Acute Liver Failure in Pediatric
   Patients Caused by the Ingestion of Fireworks Containing Yellow
   Phosphorus
SO LIVER TRANSPLANTATION
LA English
DT Article
ID WHITE PHOSPHORUS; BURN
AB Yellow phosphorus is a protoplasmic toxicant that targets the liver. The ingestion of fireworks containing yellow phosphorus, either by children who accidentally consume them or by adults who are attempting suicide, often results in death due to acute liver failure (ALF). We present the outcomes of 10 children who ingested fireworks containing yellow phosphorus. There were 6 boys and 4 girls, and their ages ranged from 21 to 60 months. One patient remained stable without liver complications and was discharged. Three patients died of hepatorenal failure and cardiovascular collapse, and living donor liver transplantation (LDLT) was performed for 6 patients. The patients had grade II or III encephalopathy, a mean alanine aminotransferase level of 1148.2 IU/L, a mean aspartate aminotransferase level of 1437.5 IU/L, a mean total bilirubin level of 6.9 mg/dL, a mean international normalized ratio of 6.6, a mean Pediatric End-Stage Liver Disease score of 33.7, and a mean Child-Pugh score of 11.3. Postoperatively, 2 patients had persistent encephalopathy and died on the second or third postoperative day, and 1 patient died of cardiac arrest on the first postoperative day despite a well-functioning graft. The other 3 patients were still alive at a mean of 204 days. In conclusion, the ingestion of fireworks containing yellow phosphorus causes ALF with a high mortality rate. When signs of irreversible ALF are detected, emergency LDLT should be considered as a lifesaving procedure; however, if yellow phosphorus toxicity affects both the brain and the heart in addition to the liver, the mortality rate remains very high despite liver transplantation. Liver Transpl 17:1286-1291, 2011. (C) 2011 AASLD.
C1 [Ates, Mustafa; Dirican, Abuzer; Ozgor, Dincer; Aydin, Cemalettin; Isik, Burak; Ara, Cengiz; Yilmaz, Mehmet; Kayaalp, Cuneyt; Yilmaz, Sezai] Inonu Univ, Fac Med, Dept Gen Surg, Div Liver Transplantat, TR-44080 Malatya, Turkey.
   [Selimoglu, M. Ayse] Inonu Univ, Fac Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, TR-44080 Malatya, Turkey.
RP Ates, M (reprint author), Inonu Univ, Fac Med, Dept Gen Surg, Div Liver Transplantat, Turgut Ozal Mah 2 Cad 1 Sokak,Almira Sitesi A Blo, TR-44080 Malatya, Turkey.
EM drmustafaates@hotmail.com
OI Kayaalp, Cuneyt/0000-0003-4657-2998
CR [Anonymous], 1997, TOX PROF WHIT PHOSPH
   Akman SA, 2009, PEDIATR TRANSPLANT, V13, P1034, DOI 10.1111/j.1399-3046.2008.01119.x
   Brent J, 2005, CRITICAL CARE TOXICO, P851
   Davis KG, 2002, MIL MED, V167, P83
   DIAZRIVERA RS, 1950, MEDICINE, V29, P269
   ELDAD A, 1991, BURNS, V17, P198, DOI 10.1016/0305-4179(91)90103-N
   FAHIM FA, 1990, GEN PHARMACOL, V21, P899, DOI 10.1016/0306-3623(90)90452-R
   GHOSHAL AK, 1971, EXP MOL PATHOL, V14, P212, DOI 10.1016/0014-4800(71)90066-9
   Krishnakumar N, 1997, J Assoc Physicians India, V45, P885
   Makalinao IR, 1999, WATUSI POISONING MON
   MARIN GA, 1971, NEW ENGL J MED, V284, P125, DOI 10.1056/NEJM197101212840303
   MCCARRON MM, 1981, CLIN TOXICOL, V18, P693
   Nikkanen HE, 2006, GOLDFRANKS TOXICOLOG, P1486
   Santos O, 2009, ANN HEPATOL, V8, P162
   SIMON FA, 1976, JAMA-J AM MED ASSOC, V235, P1343, DOI 10.1001/jama.235.13.1343
   TALLEY RC, 1972, AM HEART J, V84, P139, DOI 10.1016/0002-8703(72)90318-3
   URBANO O, 1995, J CLIN GASTROENTEROL, V21, P139
NR 17
TC 4
Z9 4
U1 2
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD NOV
PY 2011
VL 17
IS 11
BP 1286
EP 1291
DI 10.1002/lt.22384
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 843VF
UT WOS:000296701600005
PM 21761550
ER

PT J
AU Gelas, T
   McKiernan, PJ
   Kelly, DA
   Mayer, DA
   Mirza, DF
   Sharif, K
AF Gelas, Thomas
   McKiernan, Patrick J.
   Kelly, Deirdre A.
   Mayer, David A.
   Mirza, Darius F.
   Sharif, Khalid
TI ABO-incompatible pediatric liver transplantation in very small
   recipients: Birmingham's experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE ABO incompatibility; pediatric liver transplantation; infant
ID HEART-TRANSPLANTATION; SMALL INFANTS; CHILDREN; MONOSEGMENTS; KILOGRAMS;
   OUTCOMES; IMPACT
AB Liver transplantation (LT) for very small recipients is challenging but in experienced centres, good results can be achieved. Despite the risk of antibody-mediated acute rejection, some studies have demonstrated the safety of ABO incompatible liver transplantation (ILT) in children and particularly in infants. The aim of our study was to describe the outcome of liver transplantation in infants < 5 kg and the safety of using ILT in this group. All LT performed between 1991 and 2010 in children < 5 kg were reviewed. Twenty-nine patients were included, five of whom had an ILT. Acute liver failure was encountered in 20 cases. The recipient age and weight at transplantation were respectively 63 days (range: 14-268 days) and 4 kg (range: 2.4-5 kg). The graft-to-recipient ratio was 6.1% (range 2.3-9%). An aortic conduit and delayed abdominal closure were used respectively in 76% and 81% of the procedures. The ABO compatible liver transplantation (CLT) and ILT groups were similar regarding recipient's demographics, graft types or technical transplantation data. The one-and five-yr patient and graft survival were respectively 62%, 62% and 62%, 57.9% with a median follow-up of 95 months. Vascular complications occurred in six cases (21.4%) and biliary complications were encountered in five patients (17%). Acute and chronic rejection developed respectively in 37% and 26% of the recipients. The five patients undergoing ILT are all alive without graft lost after a median follow-up of 34 months (range 755 months). When compared with the CLT group, no significant differences were found regarding patient or graft survival, vascular or biliary complications and rejection rates. In our experience, ILT in small infants has short and long term outcomes comparable to ABO-compatible grafts and excellent results can be achieved with a standard immunosuppressive protocol. To avoid mortality on the waiting list for neonatal recipients, ABO-incompatible liver grafts can be used safely.
C1 [Gelas, Thomas; McKiernan, Patrick J.; Kelly, Deirdre A.; Mayer, David A.; Mirza, Darius F.; Sharif, Khalid] Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England.
RP Gelas, T (reprint author), Birmingham Childrens Hosp, Liver Unit, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.
EM thomas.gelas@chu-lyon.fr
CR CACCIARELLI TV, 1995, TRANSPLANTATION, V60, P757, DOI 10.1097/00007890-199510150-00024
   DEMETRIS AJ, 1988, AM J PATHOL, V132, P489
   Dipchand AI, 2010, AM J TRANSPLANT, V10, P389, DOI 10.1111/j.1600-6143.2009.02934.x
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Egawa H, 2007, LIVER TRANSPLANT, V13, P579, DOI 10.1002/lt.21092
   Egawa H, 2008, HEPATOLOGY, V47, P143, DOI 10.1002/hep.21928
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Fan XH, 2004, NAT MED, V10, P1227, DOI 10.1038/nm1126
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   HAPP WM, 1920, J EXP MED, V3, P313
   Heffron T, 2006, LIVER TRANSPLANT, V12, P972, DOI 10.1002/lt.20760
   Hussein MH, 2011, PEDIATR SURG INT, V27, P263, DOI 10.1007/s00383-010-2784-1
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Liu YJ, 1996, HUM HERED, V46, P181, DOI 10.1159/000154350
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   RENARD TH, 1992, TRANSPLANTATION, V53, P116, DOI 10.1097/00007890-199201000-00022
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   STARZL TE, 1968, NEW ENGL J MED, V278, P642, DOI 10.1056/NEJM196803212781202
   Stewart ZA, 2009, LIVER TRANSPLANT, V15, P883, DOI 10.1002/lt.21723
   Sundaram SS, 2008, J PEDIATR GASTR NUTR, V47, P486, DOI 10.1097/MPG.0b013e318175d7d2
   Tanabe M, 2002, TRANSPLANTATION, V73, P1959, DOI 10.1097/00007890-200206270-00021
   Tanabe M, 2010, EUR J CLIN INVEST, V40, P943, DOI 10.1111/j.1365-2362.2010.02339.x
   West LJ, 2001, NEW ENGL J MED, V344, P793, DOI 10.1056/NEJM200103153441102
   WU J, 2001, PLOS ONE, V1
   Yamada Y, 2006, J PEDIATR SURG, V41, P1976, DOI 10.1016/j.jpedsurg.2006.08.021
   YANDZA T, 1994, TRANSPLANTATION, V58, P46, DOI 10.1097/00007890-199407000-00009
NR 29
TC 11
Z9 13
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2011
VL 15
IS 7
BP 706
EP 711
DI 10.1111/j.1399-3046.2011.01541.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 835PT
UT WOS:000296049000015
PM 21762327
ER

PT J
AU Spearman, CWN
   Goddard, E
   McCulloch, MI
   Hairwadzi, HN
   Sonderup, MW
   Kahn, D
   Millar, AJW
AF Spearman, C. W. N.
   Goddard, E.
   McCulloch, M. I.
   Hairwadzi, H. N.
   Sonderup, M. W.
   Kahn, D.
   Millar, A. J. W.
TI Pregnancy following liver transplantation during childhood and
   adolescence
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pediatric; pregnancy; outcomes
ID MYCOPHENOLATE-MOFETIL; ORGAN-TRANSPLANTATION; RENAL-TRANSPLANTATION;
   RECIPIENTS; CYCLOSPORINE; IMMUNOSUPPRESSANT; EXPERIENCE; MANAGEMENT;
   TACROLIMUS; EXPOSURE
AB More than 80% of pediatric transplant recipients will survive to reach adulthood, and many will consider having children. We report on outcomes and management of five pregnancies in four women undergoing orthotopic liver transplantation during childhood or adolescence and followed up at our Transplant Center. A retrospective clinical folder audit was performed. Mean age at transplantation was 13.3 +/- 3.4 yr (range, 10-18 yr). Mean interval between transplantation and pregnancy was 15.4 +/- 4.9 yr (range, 10-22 yr). Mean maternal age at conception was 28 +/- 3.5 yr (range, 23-32 yr). Mean gestational age was 36.6 +/- 1.7 wk. Mean birth weight was 2672 +/- 249 g. Immunosuppression was cyclosporin based in three women and tacrolimus based in one woman. Pregnancy complications necessitating the induction of labor included fetal distress and rising maternal liver enzymes in two women, cholestasis of pregnancy and impaired renal graft function in one woman, fetal distress and preeclampsia in one woman. Modes of delivery were normal vaginal delivery in three women and cesarean section in one woman. No maternal or fetal deaths and no congenital malformations occurred. No episodes of rejection occurred during pregnancy. Two women experienced acute cellular rejection requiring an increase in baseline immunosuppression in the first year, following delivery. No graft losses occurred during a mean follow-up of 44 +/- 17.9 months post-delivery. With careful management, pregnancy post-liver transplantation can have a successful outcome.
C1 [Spearman, C. W. N.] Univ Cape Town, Groote Schuur Hosp, Div Hepatol, Dept Med,Med Sch, ZA-7925 Cape Town, South Africa.
   [Spearman, C. W. N.; Goddard, E.; McCulloch, M. I.; Millar, A. J. W.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Sch Med, ZA-7925 Cape Town, South Africa.
   [Spearman, C. W. N.; Hairwadzi, H. N.; Sonderup, M. W.] Univ Cape Town, Sch Med, Dept Med, ZA-7925 Cape Town, South Africa.
   [Goddard, E.; McCulloch, M. I.] Univ Cape Town, Sch Med, Dept Paediat, ZA-7925 Cape Town, South Africa.
   [Kahn, D.] Univ Cape Town, Sch Med, Dept Surg, ZA-7925 Cape Town, South Africa.
   [Millar, A. J. W.] Univ Cape Town, Sch Med, Dept Paediat Surg, ZA-7925 Cape Town, South Africa.
RP Spearman, CWN (reprint author), Univ Cape Town, Groote Schuur Hosp, Div Hepatol, Dept Med,Med Sch, ZA-7925 Cape Town, South Africa.
EM wendy.spearman@uct.ac.za
CR Armenti Vincent T, 2005, Clin Transpl, P69
   Armenti Vincent T, 2008, Transplant Rev (Orlando), V22, P223, DOI 10.1016/j.trre.2008.05.001
   Armenti Vincent T, 2006, Clin Transpl, P57
   Armenti VT, 2000, LIVER TRANSPLANT, V6, P671, DOI 10.1053/jlts.2000.18703
   ARMENTI VT, 2006, HIGH RISK PREGNANCY, P1174
   Bonanno C, 2007, SEMIN PERINATOL, V31, P348, DOI 10.1053/j.semperi.2007.09.004
   Burra P, 2007, TRANSPL INT, V20, P397, DOI 10.1111/j.1432-2277.2006.00440.x
   Casele HL, 1998, TRANSPLANTATION, V65, P581, DOI 10.1097/00007890-199802270-00023
   Christopher V, 2006, LIVER TRANSPLANT, V12, P1138, DOI 10.1002/lt.20810
   Coscia Lisa A, 2009, Clin Transpl, P103
   COULAM CB, 1982, TRANSPLANT P, V14, P605
   Dei Malatesta Marialuisa Framarino, 2006, Transpl Immunol, V15, P297, DOI 10.1016/j.trim.2006.01.001
   EBPG EXP GROU, 2002, NEPHROL DIAL TRAN S4, V17, P50
   FLECHNER SM, 1985, AM J KIDNEY DIS, V5, P60
   Fuchs KM, 2007, SEMIN PERINATOL, V31, P363, DOI 10.1053/j.semperi.2007.09.006
   Jabiry-Zieniewicz Z, 2007, TRANSPL P, V39, P1530, DOI 10.1016/j.transproceed.2007.02.063
   Jackson P, 2009, AM J MED GENET A, V149A, P1231, DOI 10.1002/ajmg.a.32715
   Jain A, 1997, TRANSPLANTATION, V64, P559, DOI 10.1097/00007890-199708270-00002
   Jain AB, 2003, TRANSPLANTATION, V76, P827, DOI 10.1097/01.TP.0000084823.89528.89
   Josephson MA, 2007, ADV CHRONIC KIDNEY D, V14, P156, DOI 10.1053/j.ackd.2007.01.006
   Kallen B, 2005, BJOG-INT J OBSTET GY, V112, P904, DOI 10.1111/j.1471-0528.2005.00607.x
   KAUFFMAN RE, 1994, PEDIATRICS, V93, P137
   Kelly DA, 2006, PEDIATR TRANSPLANT, V10, P712, DOI 10.1111/j.1399-3046.2006.00567.x
   Le Ray C, 2004, OBSTET GYNECOL, V103, P1091, DOI 10.1097/01.AOG.0000124986.32858.ba
   Liu Lawrence U, 2007, Clin Liver Dis, V11, P397, DOI 10.1016/j.cld.2007.04.003
   McKay DB, 2006, NEW ENGL J MED, V354, P1281, DOI 10.1056/NEJMra050431
   McKay DB, 2005, AM J TRANSPLANT, V5, P1592, DOI 10.1111/j.1600-6143.2005.00969.x
   McKay Dianne B, 2006, Prog Transplant, V16, P127
   Moretti ME, 2003, TRANSPLANTATION, V75, P2144, DOI 10.1097/01.TP.0000066352.86763.D0
   Nagy S, 2003, OBSTET GYNECOL, V102, P121, DOI 10.1016/S0029-7844(03)00369-7
   Novartis Pharmaceuticals Corp, 2009, MYC AC PACK INS
   Paulen ME, 2010, CONTRACEPTION, V82, P102, DOI 10.1016/j.contraception.2010.02.007
   Petri M, 2003, AUTOIMMUNITY, V36, P51, DOI 10.1080/0891693031000067296
   Pisoni CN, 2008, EXPERT OPIN DRUG SAF, V7, P219, DOI [10.1517/14740338.7.3.219 , 10.1517/14740330802066108]
   Rinella Mary Eugenia, 2006, Ann Hepatol, V5, P212
   Roche Laboratories, 2009, MYC MOF PACK INS
   Sibanda N, 2007, TRANSPLANTATION, V83, P1301, DOI 10.1097/01.tp.0000263357.44975.d0
   Sifontis NM, 2006, TRANSPLANTATION, V82, P1698, DOI 10.1097/01.tp.0000252683.74584.29
   SIFONTIS NM, 2007, AM J TRANSPLANT S, V2, pA1264
   Sivaraman P, 2004, TRANSPLANT P, V36, P1999, DOI 10.1016/j.transproceed.2004.08.029
   Sucato GS, 2005, PEDIATR TRANSPLANT, V9, P346, DOI 10.1111/j.1399-3046.2005.00266.x
   Surti B, 2008, LIVER INT, V28, P1200, DOI 10.1111/j.1478-3231.2008.01871.x
   Thomas AG, 1997, OBSTET GYNECOL, V90, P916, DOI 10.1016/S0029-7844(97)00535-8
   Tjeertes IFA, 2007, J PERINATOL, V27, P62, DOI 10.1038/sj.jp.7211631
   Umans JG, 2007, ADV CHRONIC KIDNEY D, V14, P191, DOI 10.1053/j.ackd.2007.01.009
   Waite E, 2006, MT SINAI J MED, V73, P1148
   WALCOTT WO, 1978, AM J OBSTET GYNECOL, V132, P340
NR 47
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2011
VL 15
IS 7
BP 712
EP 717
DI 10.1111/j.1399-3046.2011.01554.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 835PT
UT WOS:000296049000016
PM 22004545
ER

PT J
AU Amir, A
   Shapiro, R
   Shulman, LM
   Mor, E
   Steinberg, R
   Fleishhacker, H
   Bergerin, R
   Avitzur, Y
AF Amir, Achiya
   Shapiro, Rivka
   Shulman, Lester M.
   Mor, Eytan
   Steinberg, Ran
   Fleishhacker, Hava
   Bergerin, Rachel
   Avitzur, Yaron
TI BK Virus Infection and Its Effect on Renal Function in Pediatric
   Liver-Transplant Recipients: A Cross-Sectional, Longitudinal,
   Prospective Study
SO TRANSPLANTATION
LA English
DT Article
DE BK virus; Children; Liver transplantation; Renal function
ID NATIVE KIDNEYS; POLYOMAVIRUS NEPHROPATHY; JC-VIRUS; ORGAN; PREVALENCE;
   HEART; RECOMMENDATIONS; REPLICATION
AB Background. Chronic renal failure (CRF) is a well-documented complication of liver transplantation. BK virus (BKV) is a common cause of CRF in renal-transplant recipients and has been sporadically associated with renal failure after nonrenal solid-organ transplantation. The aims of the study were to determine the prevalence of BK viruria and viremia in pediatric liver-transplant recipients, assess the natural course of BKV infection over time, and examine the association between BKV positivity and renal function.
   Methods. A prospective, cross-sectional study of 59 pediatric liver-transplant recipients. Blood and urine samples were collected at enrollment for creatinine level and BKV polymerase chain reaction test. BKV-positive patients underwent repeated testing and follow-up. The medical files were reviewed for clinical data.
   Results. Median age at enrollment was 11.5 years, and median time from transplantation was 61 months. One child (1.7%) had viremia, and nine children (15.3%) had viruria (median: 610 copies/mL). All cases of viruria/viremia resolved spontaneously, nine of them within 10 months. There were no significant differences in demographic or clinical variables between the BKV-positive and BKV-negative children. None of the BKV-positive patients had evidence of renal dysfunction.
   Conclusions. Pediatric liver-transplant recipients have a low prevalence of BK viruria/viremia. BKV infection is associated with low viral loads and resolves spontaneously within a relatively short period, without residua. BKV is not associated with CRF postliver transplantation. BKV testing should not be part of the routine follow-up of children after liver transplantation.
C1 [Amir, Achiya] Schneider Childrens Med Ctr Israel, Dept Pediat B, Petah Tiqwa, Israel.
   [Shapiro, Rivka; Fleishhacker, Hava; Bergerin, Rachel; Avitzur, Yaron] Schneider Childrens Med Ctr Israel, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel.
   [Shulman, Lester M.] Chaim Sheba Med Ctr, Cent Virol Lab, IL-52621 Tel Hashomer, Israel.
   [Mor, Eytan] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Mor, Eytan] Rabin Med Ctr, Dept Organ Transplantat, Petah Tiqwa, Israel.
   [Steinberg, Ran] Schneider Childrens Med Ctr Israel, Organ Transplant Unit, Petah Tiqwa, Israel.
RP Avitzur, Y (reprint author), Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM yaron.avitzur@sickkids.ca
CR ARTHUR RR, 1989, J CLIN MICROBIOL, V27, P1174
   Blanckaert K, 2006, NEPHROL DIAL TRANSPL, V21, P3364, DOI 10.1093/ndt/gfl404
   Brinkert F, 2010, PEDIATR TRANSPLANT, V14, P105, DOI 10.1111/j.1399-3046.2009.01139.x
   Doucette KE, 2008, TRANSPLANTATION, V85, P1733, DOI 10.1097/TP.0b013e3181722ead
   Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126
   Green M, 2009, PEDIATR TRANSPLANT, V13, P319, DOI 10.1111/j.1399-3046.2008.00926.x
   Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9
   Hirsch HH, 2005, TRANSPLANTATION, V79, P1277, DOI 10.1097/01.TP.0000156165.83160.09
   Levey AS, 2003, ANN INTERN MED, V139, P137
   Limaye AP, 2005, AM J TRANSPLANT, V5, P614, DOI 10.1111/j.1600-6143.2004.00715.x
   Loeches B, 2009, Transplant Proc, V41, P1033, DOI 10.1016/j.transproceed.2009.02.021
   Megged O, 2011, J PEDIAT HEMATOL ONC, V33, P190, DOI 10.1097/MPH.0b013e3181fce388
   Munoz P, 2005, CLIN INFECT DIS, V41, P1720, DOI 10.1086/498118
   Nickeleit V, 2006, TRANSPLANT INT, V19, P960, DOI 10.1111/j.1432-2277.2006.00360.x
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Peinemann F, 2000, EUR J PEDIATR, V159, P182, DOI 10.1007/s004310050047
   Pillebout E, 2005, AM J TRANSPLANT, V5, P1120, DOI 10.1111/j.1600-6143.2005.00852.x
   Puliyanda DP, 2006, CLIN TRANSPLANT, V20, P289, DOI 10.1111/j.1399-0012.2005.00480.x
   RAHNDHAWA PS, 1999, TRANSPLANTATION, V67, P103
   Randhawa P, 2005, J MED VIROL, V77, P238, DOI 10.1002/jmv.20442
   Razonable RR, 2005, J INFECT DIS, V192, P1349, DOI 10.1086/466532
   Salama M, 2008, LIVER TRANSPLANT, V14, P1787, DOI 10.1002/lt.21627
   Schmid H, 2005, AM J TRANSPLANT, V5, P1562, DOI 10.1111/j.1600-6143.2005.00883.x
   Schwartz GJ, 2009, J AM SOC NEPHROL, V20, P629, DOI 10.1681/ASN.2008030287
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Splendiani G, 2004, TRANSPLANT P, V36, P713, DOI 10.1016/j.transproceed.2004.03.020
NR 26
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD OCT 27
PY 2011
VL 92
IS 8
BP 943
EP 946
DI 10.1097/TP.0b013e31822e0b9a
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 836VX
UT WOS:000296146200026
PM 21876478
ER

PT J
AU Schechter, T
   Gassas, A
   Weitzman, S
   Grant, D
   Pollock-BarZiv, S
   Dipchand, A
   Alexander, S
   Ali, M
   Avitzur, Y
   Doyle, J
AF Schechter, T.
   Gassas, A.
   Weitzman, S.
   Grant, D.
   Pollock-BarZiv, S.
   Dipchand, A.
   Alexander, S.
   Ali, M.
   Avitzur, Y.
   Doyle, J.
TI Hematopoietic stem-cell transplantation following solid-organ
   transplantation in children
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE pediatric; solid-organ transplantation; hematopoietic stem-cell
   transplantation
ID BONE-MARROW-TRANSPLANTATION; ORTHOTOPIC LIVER-TRANSPLANTATION; SEVERE
   APLASTIC-ANEMIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS;
   SINGLE-CENTER EXPERIENCE; NON-B HEPATITIS; NON-A; HEART-TRANSPLANTATION;
   RECIPIENTS; MANAGEMENT
AB Reports of hematopoietic stem-cell transplantation (HSCT) following solid-organ transplantation have been described in adults mainly as case reports. These reports demonstrate feasibility but likely do not reflect true outcomes due to a positive reporting bias. We report herein the outcomes of all our pediatric recipients of allogeneic HSCT following previous solid-organ transplantation between 2000 and 2009. Four children were identified. Two patients underwent heart transplantation followed by cord-blood allogeneic HSCT for T-cell lymphoma/post transplant lymphoproliferative disease (PTLD) and two patients underwent liver transplantation followed by living-donor allogeneic HSCT for severe aplastic anemia (SAA). The mean time between transplants was 4.2 years (range 1.5-6 years). All patients engrafted; however, all patients died from 37 days to 1 year after HSCT. Causes of death included infections (n = 2), multi-organ failure (n = 1) and solid-organ graft rejection (n = 1). Though three patients survived beyond day + 100, multiple complications were observed including EBV re-activation followed by EBV-positive PTLD (n = 1) and five episodes of severe infections. The patients transplanted for lymphoma did not have evidence of recurrence at last follow-up. Although feasibilty has been shown with this cohort, we conclude that allogeneic HSCT in immunosuppressed patients following solid-organ transplantation remains a very high risk procedure that results in severe morbidity and mortality in children. Bone Marrow Transplantation (2011) 46, 1321-1325; doi: 10.1038/bmt.2011.153; published online 8 August 2011
C1 [Schechter, T.; Gassas, A.; Weitzman, S.; Alexander, S.; Ali, M.; Doyle, J.] Hosp Sick Children, Dept Paediat, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada.
   [Grant, D.; Pollock-BarZiv, S.; Dipchand, A.; Avitzur, Y.] Hosp Sick Children, SickKids Transplant Ctr, Toronto, ON M5G 1X8, Canada.
RP Schechter, T (reprint author), Hosp Sick Children, Dept Paediat, Div Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM tal.schechter-finkelstein@sickkids.ca
CR Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004
   CATTRAL MS, 1994, HEPATOLOGY, V20, P813, DOI 10.1002/hep.1840200407
   Chiang KY, 2003, BONE MARROW TRANSPL, V31, P633, DOI 10.1038/sj.bmt.1703952
   Dai QY, 2004, BONE MARROW TRANSPL, V34, P667, DOI 10.1038/sj.bmt.1704605
   Dey B, 1998, MEDICINE, V77, P355, DOI 10.1097/00005792-199809000-00005
   Dharnidharka VR, 2002, AM J TRANSPLANT, V2, P993, DOI 10.1034/j.1600-6143.2002.21019.x
   Draoua HY, 2004, BRIT J HAEMATOL, V127, P429, DOI 10.1111/j.1365-2141.2004.05212.x
   Feyler S, 2007, BONE MARROW TRANSPL, V40, P443, DOI 10.1038/sj.bmt.1705752
   Hadzic N, 2008, J HEPATOL, V48, P68, DOI 10.1016/j.jhep.2007.08.017
   Hagglund H, 1997, TRANSPLANTATION, V64, P1207
   Haldas J, 2002, LEUKEMIA LYMPHOMA, V43, P447, DOI 10.1080/10428190290006332
   Herzig KA, 2003, TRANSPLANT INT, V16, P529, DOI 10.1007/s00147-003-0596-0
   Jaffe E. S., 2001, TUMOURS HAEMATOPOIET
   KAWAHARA K, 1991, BLOOD, V78, P1140
   Kobbe G, 2002, TRANSPLANTATION, V74, P1198, DOI 10.1097/01.TP.0000031541.69369.B5
   Langer RM, 2003, TRANSPL P, V35, P1396, DOI 10.1016/S0041-1345(03)00472-X
   Lundell R, 2004, AM J SURG PATHOL, V28, P967, DOI 10.1097/00000478-200407000-00019
   Mangat JS, 2007, J HEART LUNG TRANSPL, V26, P658, DOI 10.1016/j.healun.2007.03.014
   Manlhiot C, 2010, J HEART LUNG TRANSPL, V29, P648, DOI 10.1016/j.healun.2010.01.013
   Nalesnik M A, 1997, Ann Transplant, V2, P33
   Penn I, 2000, ADV RENAL REPLACE TH, V7, P147
   Perkins JL, 2001, BONE MARROW TRANSPL, V28, P523, DOI 10.1038/sj.bmt.1703177
   Rajakariar R, 2004, AM J TRANSPLANT, V4, P1534, DOI 10.1111/j.1600-6143.2004.00521.x
   Thaunat O, 2005, BONE MARROW TRANSPL, V35, P419, DOI 10.1038/sj.bmt.1704772
   Trede NS, 1997, BONE MARROW TRANSPL, V20, P257, DOI 10.1038/sj.bmt.1700872
   TZAKIS AG, 1988, NEW ENGL J MED, V319, P393, DOI 10.1056/NEJM198808183190702
   Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6
   Williams KM, 2008, PEDIATR BLOOD CANCER, V50, P667, DOI 10.1002/pbc.21171
   Yoshimi A, 2009, BIOL BLOOD MARROW TR, V15, P389, DOI 10.1016/j.bbmt.2008.11.021
   YOUSEM SA, 1989, HUM PATHOL, V20, P361, DOI 10.1016/0046-8177(89)90046-4
NR 30
TC 6
Z9 6
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD OCT
PY 2011
VL 46
IS 10
BP 1321
EP 1325
DI 10.1038/bmt.2011.153
PG 5
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 838HR
UT WOS:000296279000006
PM 21822316
ER

PT J
AU Wakiya, T
   Sanada, Y
   Mizuta, K
   Umehara, M
   Urahashi, T
   Egami, S
   Hishikawa, S
   Nakata, M
   Hakamada, K
   Yasuda, Y
   Kawarasaki, H
AF Wakiya, Taiichi
   Sanada, Yukihiro
   Mizuta, Koichi
   Umehara, Minoru
   Urahashi, Taizen
   Egami, Satoshi
   Hishikawa, Shuji
   Nakata, Manabu
   Hakamada, Kenichi
   Yasuda, Yoshikazu
   Kawarasaki, Hideo
TI Endovascular interventions for hepatic artery complications immediately
   after pediatric liver transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE endovascular treatment; hepatic artery complication; living donor liver
   transplantation; outcome; pediatric
ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; URGENT REVASCULARIZATION;
   THROMBOSIS; RECONSTRUCTION; EXPERIENCE; MANAGEMENT; STENOSES; IMPACT
AB Hepatic artery complications after living donor liver transplantation (LDLT) can directly affect both graft and recipient outcomes. For this reason, early diagnosis and treatment are essential. In the past, relaparotomy was generally employed to treat them. Following recent advances in interventional radiology, favorable outcomes have been reported with endovascular treatment. However, there is ongoing discussion regarding the best and safe time for definitive endovascular interventions. We herein report a retrospective analysis for six children with early hepatic artery complication after pediatric LDLT who underwent endovascular treatment as primary therapy at our institution. We evaluate the usefulness of endovascular treatment for hepatic artery complication and its optimal timing. The mean patient age was 11.9 months and mean body weight at LDLT was 6.7 kg. The mean duration between the transplantation and first endovascular treatment was 5.3 days. Five of the six patients were technically successful treated by only endovascular treatment. Of these five patients, two developed biliary complications. Endovascular procedures were performed 10 times in six patients without any complications and nine of the 10 procedures were successful. By selecting optimal devices, our findings suggest that endovascular treatment can be feasible and safe in the earliest time period after pediatric LDLT.
C1 [Wakiya, Taiichi; Sanada, Yukihiro; Mizuta, Koichi; Umehara, Minoru; Urahashi, Taizen; Egami, Satoshi; Hishikawa, Shuji; Kawarasaki, Hideo] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Wakiya, Taiichi; Umehara, Minoru; Hakamada, Kenichi] Hirosaki Univ, Dept Surg, Sch Med, Aomori, Japan.
   [Nakata, Manabu] Jichi Med Univ, Dept Radiol, Shimotsuke, Tochigi 3290498, Japan.
   [Yasuda, Yoshikazu] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Wakiya, T (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM wakiya@jichi.ac.jp
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Boyvat F, 2008, TRANSPL P, V40, P22, DOI 10.1016/j.transproceed.2007.12.027
   Denys AL, 2002, AM J ROENTGENOL, V178, P1175
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   Hasegawa T, 2002, PEDIATR TRANSPLANT, V6, P244, DOI 10.1034/j.1399-3046.2002.01081.x
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Heaton N, 2008, BRIT J SURG, V95, P919, DOI 10.1002/bjs.6060
   Ho MC, 2004, TRANSPLANT P, V36, P2249, DOI 10.1016/j.transproceed.2004.08.099
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   Kim BW, 2006, TRANSPLANT P, V38, P3128, DOI 10.1016/j.transproceed.2006.08.164
   Kodama Y, 2006, LIVER TRANSPLANT, V12, P465, DOI 10.1002/lt.20724
   Massault PP, 1997, TRANSPLANT P, V29, P439, DOI 10.1016/S0041-1345(96)00178-9
   Matsuda H, 2006, SURG TODAY, V36, P245, DOI 10.1007/s00595-005-3131-3
   Miraglia R, 2009, WORLD J GASTROENTERO, V15, P684, DOI 10.3748/wjg.15.684
   Orons P., 2005, J VASC INTERV RADIOL, V6, P523
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Saad Wael E A, 2007, Tech Vasc Interv Radiol, V10, P207, DOI 10.1053/j.tvir.2007.09.015
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Uchida Y, 2009, CLIN TRANSPLANT, V23, P392, DOI 10.1111/j.1399-0012.2008.00924.x
   Ueno T, 2006, LIVER TRANSPLANT, V12, P422, DOI 10.1002/lt.20628
   WAKIYA T, 2010, PEDIAT TRANSPLA 1227, DOI DOI 10.1111/J.1399-3046.2010.01441.X.
   Warnaar N, 2010, LIVER TRANSPLANT, V16, P847, DOI 10.1002/lt.22063
NR 25
TC 6
Z9 6
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD OCT
PY 2011
VL 24
IS 10
BP 984
EP 990
DI 10.1111/j.1432-2277.2011.01298.x
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 819XP
UT WOS:000294868100007
PM 21752103
ER

PT J
AU Romano, F
   Stroppa, P
   Bravi, M
   Casotti, V
   Lucianetti, A
   Guizzetti, M
   Sonzogni, A
   Colledan, M
   D'Antiga, L
AF Romano, Fabrizio
   Stroppa, Paola
   Bravi, Michela
   Casotti, Valeria
   Lucianetti, Alessandro
   Guizzetti, Michela
   Sonzogni, Aurelio
   Colledan, Michele
   D'Antiga, Lorenzo
TI Favorable outcome of primary liver transplantation in children with
   cirrhosis and hepatocellular carcinoma
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatocellular carcinoma; cirrhosis; children; liver transplantation
ID PEDIATRIC-ONCOLOGY SIOP; INTERNATIONAL-SOCIETY; HEPATIC-TUMORS; EXPANDED
   CRITERIA; MILAN CRITERIA; SPLIT-LIVER; HEPATOBLASTOMA; CHILDHOOD;
   EXPERIENCE; SURVIVAL
AB The outcome of HCC after transplantation (OLT) in children is not well known. Unfavorable features based on adult reports may lead to contraindicate OLT even in children. We reviewed a cohort of children with cirrhosis and HCC to evaluate their outcome after primary transplantation. We considered children with cirrhosis and HCC who had a primary OLT. We retrospectively recorded demographic, medical and surgical features, and MC as predictors of outcome. Among 456 children transplanted in the last 15 yr, 10 (2%), median age at diagnosis 1.8 yr (range 0.5-7.2), had HCC in biliary atresia (3), BSEP deficiency (3), tyrosinemia type 1 (2), complications of choledocal cyst and glycogen storage disease type IV (1 each). At HCC discovery, median AFP was 2322 ng/mL (3-35 000), high or rising in 9/10 patients. Six patients were outside the MC. Median time on the waiting list was 38 days (1-152). Two patients died from early complications of OLT. In the other eight patients, there was no tumor recurrence after a median follow-up of four yr. Children with cirrhosis may develop HCC at a very young age. The outcome appears excellent even outside MC. Primary liver transplantation is advisable for children with cirrhosis, HCC, and no extrahepatic disease.
C1 [Stroppa, Paola; Bravi, Michela; Casotti, Valeria; D'Antiga, Lorenzo] Osped Riuniti Bergamo, Paediat Liver GI & Transplantat, I-24128 Bergamo, Italy.
   [Romano, Fabrizio] S Gerardo Hosp, Dept Surg Sci, Milan, Italy.
   [Sonzogni, Aurelio] Osped Riuniti Bergamo, Pathol Unit, I-24128 Bergamo, Italy.
RP D'Antiga, L (reprint author), Osped Riuniti Bergamo, Paediat Liver GI & Transplantat, Largo Barozzi 1, I-24128 Bergamo, Italy.
EM ldantiga@ospedaliriuniti.bergamo.it
CR ANTIGA L, 2007, CANCER, V110, P1050
   ANTIGA L, 2002, TRANSPLANTATION, V73, P80
   Arikan C, 2006, PEDIATR TRANSPLANT, V10, P42, DOI 10.1111/j.1399-3046.2005.00395.x
   Austin MT, 2006, J PEDIATR SURG, V41, P182, DOI 10.1016/j.jpedsurg.2005.10.091
   Beaunoyer M, 2007, PEDIATR TRANSPLANT, V11, P655, DOI 10.1111/j.1399-3046.2007.00751.x
   BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005
   Bismuth H, 1999, SEMIN LIVER DIS, V19, P311, DOI 10.1055/s-2007-1007120
   Brown J, 2000, EUR J CANCER, V36, P1418, DOI 10.1016/S0959-8049(00)00074-5
   Chen JC, 1998, J PEDIATR SURG, V33, P1350, DOI 10.1016/S0022-3468(98)90005-7
   Czauderna P, 2002, J CLIN ONCOL, V20, P2798, DOI 10.1200/JCO.2002.06.102
   Czauderna P, 2002, MED PEDIATR ONCOL, V39, P519, DOI 10.1002/mpo.10178
   Darbari A, 2003, HEPATOLOGY, V38, P560, DOI 10.1053/jhep.2003.50375
   Decaens T, 2006, LIVER TRANSPLANT, V12, P1761, DOI 10.1002/lt.20884
   De Ugarte DA, 2006, PEDIAT SURG, P502
   EDMONDSON HA, 1954, CANCER, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Herrero JI, 2008, LIVER TRANSPLANT, V14, P272, DOI 10.1002/lt.21368
   Ismail H, 2009, PEDIATR TRANSPLANT, V13, P682, DOI 10.1111/j.1399-3046.2009.01062.x
   Kalicinski P, 2008, ANN TRANSPL, V13, P37
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Kim H, 2000, LIVER, V20, P173, DOI 10.1034/j.1600-0676.2000.020002173.x
   Knisely AS, 2006, HEPATOLOGY, V44, P478, DOI 10.1002/hep.21287
   Kosola S, 2010, PEDIATR TRANSPLANT, V14, P646, DOI 10.1111/j.1399-3046.2010.01312.x
   Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104
   Mazzoferro V, 2009, LANCET ONCOL, V10, P35, DOI 10.1016/S1470-2045(08)70284-5
   McDiarmid SV, 2010, LIVER TRANSPLANT, V16, pS13, DOI 10.1002/lt.22170
   Moore SW, 1997, PEDIATR SURG INT, V12, P266, DOI 10.1007/s003830050128
   Onaca N, 2007, LIVER TRANSPLANT, V13, P391, DOI 10.1002/lt.21095
   Otte JB, 2004, PEDIATR BLOOD CANCER, V42, P74, DOI 10.1002/pbc.10376
   Otte JB, 2010, CANCER TREAT REV, V36, P360, DOI 10.1016/j.ctrv.2010.02.013
   Otte Jean-Bernard, 2005, Semin Pediatr Surg, V14, P233, DOI 10.1053/j.sempedsurg.2005.06.006
   PROKURAT A, 2002, ANN DIAGN PAEDIAT PA, V6, P51
   Reyes JD, 2000, J PEDIATR-US, V136, P795, DOI 10.1067/mpd.2000.106223
   Reynolds M, 2001, Semin Pediatr Surg, V10, P140, DOI 10.1053/spsu.2001.24887
   Santra S, 2008, EXPERT OPIN PHARMACO, V9, P1229, DOI [10.1517/14656566.9.7.1229, 10.1517/146565608D2042343]
   Sevmis S, 2008, PEDIATR TRANSPLANT, V12, P52, DOI 10.1111/j.1399-3046.2007.00777.x
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Tatekawa Y, 2001, J PEDIATR SURG, V36, P436, DOI 10.1053/jpsu.2001.21600
   Yao FY, 2007, AM J TRANSPLANT, V7, P2587, DOI 10.1111/j.1600-6143.2007.01965.x
   Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563
   Zavaglia C, 2005, AM J GASTROENTEROL, V100, P2708, DOI 10.1111/j.1572-0241.2005.00289.x
NR 41
TC 8
Z9 8
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2011
VL 15
IS 6
BP 573
EP 579
DI 10.1111/j.1399-3046.2011.01528.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 810ZM
UT WOS:000294170200012
PM 21797955
ER

PT J
AU Fukuda, A
   Sakamoto, S
   Shigeta, T
   Kakiuchi, T
   Matsuno, N
   Tanaka, H
   Kitamura, M
   Nosaka, S
   Nakazawa, A
   Kasahara, M
AF Fukuda, Akinari
   Sakamoto, Seisuke
   Shigeta, Takanobu
   Kakiuchi, Toshihiko
   Matsuno, Naoto
   Tanaka, Hideaki
   Kitamura, Masayuki
   Nosaka, Shunsuke
   Nakazawa, Atsuko
   Kasahara, Mureo
TI Hepatobiliary scintigraphy for the assessment of biliary stricture after
   pediatric living donor liver transplantation for hepaticojejunostomy
   reconstruction: The value of the excretion rate at 60 min
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE complications of liver transplantation; pediatric liver transplantation;
   living donor liver transplantation; hepatobiliary scintigraphy; biliary
   stricture
ID DUCT-TO-DUCT; COMPLICATIONS; BILE; RECIPIENTS
AB HBS is performed to determine the presence of biliary stricture after liver transplantation. We focused on the Ex-60 after an intravenous injection of tracer during HBS. The aim of this study was to review the cutoff values for the diagnosis of biliary stricture by HBS after pediatric LDLT. We analyzed 114 HBS studies using (99m)Tc-PMT in 80 cases after pediatric LDLT. HBS was performed three months after LDLT on a routine basis and/or was performed when ultrasonography and blood test findings indicated biliary stricture. A ROC curve analysis was performed to identify the cutoff value for the correlation between Ex-60 and biliary stricture. The Ex-60 (mean +/- s.d.) in the cases diagnosed as having biliary stricture and in normal subjects were 49.1 +/- 20.2% vs. 78.0 +/- 9.7% (p < 0.01), respectively. As a result of an ROC curve analysis of the Ex-60, the recommended cutoff value to diagnose biliary stricture was set at 69.2% (sensitivity 87.0%, specificity 81.8%). In cases where the Ex-60 by (99m)Tc-PMT HBS is < 69.2%, it is recommended that further treatment for biliary stricture should be provided.
C1 [Fukuda, Akinari; Sakamoto, Seisuke; Shigeta, Takanobu; Kakiuchi, Toshihiko; Matsuno, Naoto; Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Div Transplant Surg, Setagaya Ku, Tokyo 1578535, Japan.
   [Tanaka, Hideaki] Natl Ctr Child Hlth & Dev, Div Pediat Surg, Setagaya Ku, Tokyo 1578535, Japan.
   [Kitamura, Masayuki; Nosaka, Shunsuke] Natl Ctr Child Hlth & Dev, Div Radiol, Setagaya Ku, Tokyo 1578535, Japan.
   [Nakazawa, Atsuko] Natl Ctr Child Hlth & Dev, Div Pathol, Setagaya Ku, Tokyo 1578535, Japan.
RP Fukuda, A (reprint author), Natl Ctr Child Hlth & Dev, Div Transplant Surg, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM fukuda-a@ncchd.go.jp
OI Fukuda, Akinari/0000-0003-4684-0446
CR Concannon RC, 2009, PEDIATR TRANSPLANT, V13, P977, DOI 10.1111/j.1399-3046.2008.01099.x
   de Graaf W, 2010, J NUCL MED, V51, P742, DOI 10.2967/jnumed.109.069435
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Gondolesi GE, 2004, TRANSPLANTATION, V77, P1842, DOI 10.1097/01.tp.0000123077.78702.0c
   Halme L, 2003, TRANSPLANTATION, V75, P1853, DOI 10.1097/01.TP.0000064620.08328.E5
   HOWMANGILES R, 1993, J NUCL MED, V34, P214
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Kansoul HA, 2007, ACTA RADIOL, V48, P597, DOI 10.1080/02841850701342120
   Kasahara M, 2010, TRANSPL P, V42, P3862, DOI 10.1016/j.transproceed.2010.08.054
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kasahara M, 2008, J PEDIATR SURG, V43, P1575, DOI 10.1016/j.jpedsurg.2008.02.056
   KATOAZUMA M, 1982, J NUCL MED, V23, P517
   Kim JS, 2002, EUR J NUCL MED MOL I, V29, P473, DOI 10.1007/s00259-001-0706-0
   Matsuoka S, 2001, ANN NUCL MED, V15, P57
   NOACK K, 1993, TRANSPLANTATION, V56, P495, DOI 10.1097/00007890-199309000-00001
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Reynoso-Paz S, 1999, HEPATOLOGY, V30, P351, DOI 10.1002/hep.510300218
   SANCHEZURDAZPAL L, 1993, ANN SURG, V218, P152, DOI 10.1097/00000658-199308000-00006
   Sharma S, 2008, LIVER TRANSPLANT, V14, P759, DOI 10.1002/lt.21509
   Singh AK, 2010, RADIOGRAPHICS, V30, P339, DOI 10.1148/rg.302095124
   Tanaka H, 2010, J PEDIATR SURG, V45, P1668, DOI 10.1016/j.jpedsurg.2010.03.010
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tashiro H, 2007, WORLD J SURG, V31, P2222, DOI 10.1007/s00268-007-9217-x
   Thethy S, 2004, CLIN TRANSPLANT, V18, P647, DOI 10.1111/j.1399-0012.2004.00254.x
   Tulchinsky Mark, 2010, J Nucl Med Technol, V38, P210, DOI 10.2967/jnmt.110.082289
NR 25
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2011
VL 15
IS 6
BP 594
EP 600
DI 10.1111/j.1399-3046.2011.01532.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 810ZM
UT WOS:000294170200015
PM 21790918
ER

PT J
AU Honda, M
   Yamamoto, H
   Hayashida, S
   Suda, H
   Ohya, Y
   Lee, KJ
   Takeichi, T
   Asonuma, K
   Inomata, Y
AF Honda, Masaki
   Yamamoto, Hidekazu
   Hayashida, Shintaro
   Suda, Hiroko
   Ohya, Yuki
   Lee, Kwang-Jong
   Takeichi, Takayuki
   Asonuma, Katsuhiro
   Inomata, Yukihiro
TI Factors predicting persistent thrombocytopenia after living donor liver
   transplantation in pediatric patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; thrombocytopenia; adverse events
ID HEPATIC-ARTERY THROMBOSIS; ACTIVATION; CYTOKINES; CIRRHOSIS; ADAMTS13;
   EVENTS
AB Thrombocytopenia is common after LT for pediatric end-stage liver diseases. Seventy-six pediatric patients (<= 15 yr old) who underwent LDLT were evaluated for the incidence and predictive factors of post-transplant thrombocytopenia (PLT < 100 000/mm(3)). The prevalence of thrombocytopenia at two wk and at 12 months post-transplant was 22/76 (28.9%) and 11/62 (17.7%), respectively. Thrombocytopenia at two wk after LDLT was significantly associated with age at transplant, preoperative PLT, GRWR, acute rejection, and CMV infection in univariate analysis. Moreover, preoperative PLT, GRWR, and acute rejection had a strong correlation in multivariate analysis. Thrombocytopenia at 12 months after LDLT was associated only with preoperative PLT. We also demonstrated that vascular complications caused thrombocytopenia and that successful treatment recovered the PLT. These results showed that, in addition to considering the preoperative PLT, post-operative monitoring of platelets is very helpful for the early detection of adverse events related to the graft liver in pediatric liver transplant patients.
C1 [Honda, Masaki; Yamamoto, Hidekazu; Hayashida, Shintaro; Suda, Hiroko; Ohya, Yuki; Lee, Kwang-Jong; Takeichi, Takayuki; Asonuma, Katsuhiro; Inomata, Yukihiro] Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat & Pediat Surg, Kumamoto 8608556, Japan.
RP Inomata, Y (reprint author), Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat & Pediat Surg, 1-1-1 Honjo, Kumamoto 8608556, Japan.
EM yino@fc.kuh.kumamoto-u.ac.jp
CR Adinolfi LE, 2001, BRIT J HAEMATOL, V113, P590, DOI 10.1046/j.1365-2141.2001.02824.x
   Bernardo A, 2004, BLOOD, V104, P100, DOI 10.1182/blood-2004-01-0107
   Broniszczak D, 2006, TRANSPLANT P, V38, P1456, DOI 10.1016/j.transproceed.2006.02.094
   Chang JH, 2008, WORLD J GASTROENTERO, V14, P5723, DOI 10.3748/wjg.14.5723
   Chatzipetrou MA, 1999, TRANSPLANTATION, V67, P702, DOI 10.1097/00007890-199903150-00010
   Egami S, 2002, TRANSPLANTATION, V74, P1639, DOI 10.1097/01.TP.0000034239.28160.57
   Faeh M, 2001, BRIT J HAEMATOL, V112, P493, DOI 10.1046/j.1365-2141.2001.02567.x
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   HOFFMANN MW, 1993, TRANSPLANTATION, V55, P329, DOI 10.1097/00007890-199302000-00019
   Iglesias-Berengue J, 2003, TRANSPLANT P, V35, P1904, DOI 10.1016/S0041-1345(03)00589-X
   Ko S, 2006, LIVER TRANSPLANT, V12, P859, DOI 10.1002/lt.20733
   Martin TG, 1997, ANN INTERN MED, V127, P285
   MCCAUGHAN GW, 1992, J HEPATOL, V16, P16, DOI 10.1016/S0168-8278(05)80089-3
   Nascimbene A, 2007, J HEPATOL, V47, P651, DOI 10.1016/j.jhep.2007.06.012
   Ohira M, 2009, LIVER TRANSPLANT, V15, P208, DOI 10.1002/lt.21663
   Ooi CY, 2010, PEDIATR TRANSPLANT, V14, P476, DOI 10.1111/j.1399-3046.2009.01252.x
   PeckRadosavljevic M, 1997, J HEPATOL, V27, P127, DOI 10.1016/S0168-8278(97)80291-7
   Plaimauer B, 2002, BLOOD, V100, P3626, DOI 10.1182/blood-2002-05-1397
   PLEVAK DJ, 1988, TRANSPLANT P, V20, P630
   PORTE RJ, 1994, J HEPATOL, V21, P592, DOI 10.1016/S0168-8278(94)80107-X
   RANDOUX O, 1995, TRANSPLANT P, V27, P1710
   Richards EM, 1997, BRIT J HAEMATOL, V98, P315, DOI 10.1046/j.1365-2141.1997.2363056.x
   Sanjo A, 2003, J GASTROEN HEPATOL, V18, P638, DOI 10.1046/j.1440-1746.2003.03026.x
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
NR 25
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2011
VL 15
IS 6
BP 601
EP 605
DI 10.1111/j.1399-3046.2011.01533.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 810ZM
UT WOS:000294170200016
PM 21790916
ER

PT J
AU Yuksekkaya, HA
   Arikan, C
   Tumgor, G
   Aksoylar, S
   Kilic, M
   Aydogdu, S
AF Yuksekkaya, Hasan Ali
   Arikan, Cigdem
   Tumgor, Gokhan
   Aksoylar, Serap
   Kilic, Murat
   Aydogdu, Sema
TI Late-onset graft-versus-host disease after pediatric living-related
   liver transplantation for Langerhans cell histiocytosis
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE graft-versus-host disease; pediatric liver transplantation; chimerism;
   live donor; human leukocyte antigen antigens
ID SOLID-ORGAN-TRANSPLANTATION; DONOR; RECIPIENT; ALLOGRAFT;
   IMMUNOSUPPRESSION; CHIMERISM
AB GVHD is the most common and well-known cause of morbidity and mortality following allogeneic BM transplantation. The GVHD following OLT is an uncommon complication but has a high mortality and poses a major diagnostic and therapeutic challenge. We herein discussed a 12-month-old girl with multi-system LCH, who developed end-stage liver disease despite intensive chemotherapy. She underwent ABO-compatible liver transplantation at 28 months while in remission from LCH. The donor was her 26-yr-old father. Post-operative course was uneventful. The GVHD manifested with skin rash and BM supression on post-transplant day 94 and confirmed by both microchimerism and skin biopsy. Prednisolone, basiliximab, and ATG were administered immediately but the bone marow suppression was not improved and the patient died because of Candida sepsis at six-month post-transplant. GVHD after OLT should be keep in mind in patients with rash and BM suppression after liver transplantation. In LDLT, a patient who carries risk factors should investigated for optimal HLA matching.
C1 [Arikan, Cigdem] Ege Univ, Sch Med, Organ Transplantat & Res Ctr, Dept Pediat Gastroenterol Hepatol & Nutr, Izmir, Turkey.
   [Aksoylar, Serap] Ege Univ, Sch Med, Dept Pediat Oncol, Izmir, Turkey.
   [Kilic, Murat] Ege Univ, Sch Med, Dept Gen Surg, Izmir, Turkey.
RP Arikan, C (reprint author), Ege Univ, Sch Med, Organ Transplantat & Res Ctr, Dept Pediat Gastroenterol Hepatol & Nutr, Izmir, Turkey.
EM cigdem.arikan@ege.edu.tr
CR BHADURI BR, 1990, TRANSPLANT P, V22, P2378
   Braier J, 2002, MED PEDIATR ONCOL, V38, P178, DOI 10.1002/mpo.1306
   BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107
   DEEG HJ, 1985, TRANSPLANTATION, V40, P162, DOI 10.1097/00007890-198508000-00011
   Dunn SP, 2001, TRANSPLANTATION, V71, P1483, DOI 10.1097/00007890-200105270-00022
   Hadzic N, 2000, TRANSPLANTATION, V70, P815, DOI 10.1097/00007890-200009150-00019
   JAMIESON NV, 1991, TRANSPLANT INT, V4, P67, DOI 10.1111/j.1432-2277.1991.tb01950.x
   Jonsson JR, 1997, HEPATOLOGY, V26, P1111
   Kamei H, 2006, LIVER TRANSPLANT, V12, P140, DOI 10.1002/lt.20573
   KIUCHI T, 1998, TRANSPL INT, V11, P383
   Lehner F, 2002, TRANSPLANTATION, V73, P307, DOI 10.1097/00007890-200201270-00030
   Nemoto T, 2003, TRANSPLANTATION, V75, P733, DOI 10.1097/01.TP.0000053401.91094.CA
   Newell KA, 1997, J PEDIATR-US, V131, P98, DOI 10.1016/S0022-3476(97)70131-8
   Pinna A D, 1999, Pediatr Transplant, V3, P236, DOI 10.1034/j.1399-3046.1999.00043.x
   Pollack MS, 2005, HUM IMMUNOL, V66, P28, DOI 10.1016/j.humimm.2004.09.014
   Rinon M, 2002, TRANSPLANT P, V34, P109, DOI 10.1016/S0041-1345(01)02828-7
   Romagnuolo J, 2000, CAN J GASTROENTEROL, V14, P637
   SCHLITT HJ, 1993, TRANSPLANTATION, V56, P1001, DOI 10.1097/00007890-199310000-00042
   Smith DM, 2003, TRANSPLANTATION, V75, P118, DOI 10.1097/01.TP.0000039845.31111.B1
   Soejima Y, 2004, LIVER TRANSPLANT, V10, P460, DOI 10.1002/lt.20101
   STIEBER AC, 1990, TRANSPLANTATION, V50, P338
   Sudhindran S, 2003, AM J TRANSPLANT, V3, P1024, DOI 10.1034/j.1600-6143.2003.00108.x
   Taylor AL, 2004, AM J TRANSPLANT, V4, P466, DOI 10.1111/j.1600-6143.2004.00406.x
   Taylor AL, 2004, TRANSPLANTATION, V77, P441, DOI 10.1097/01.TP.0000103721.29729.FE
   Triulzi DJ, 2001, TRANSFUSION, V41, P419, DOI 10.1046/j.1537-2995.2001.41030419.x
   Urbano-Ispizua A, 2002, BLOOD, V100, P724, DOI 10.1182/blood-2001-11-0057
   Whitington PF, 1996, TRANSPLANTATION, V62, P1516, DOI 10.1097/00007890-199611270-00025
NR 27
TC 3
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2011
VL 15
IS 6
BP E105
EP E109
DI 10.1111/j.1399-3046.2008.00899.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 810ZM
UT WOS:000294170200001
PM 21884342
ER

PT J
AU Nafady-Hego, H
   Elgendy, H
   El Moghazy, W
   Fukuda, K
   Uemoto, S
AF Nafady-Hego, Hanaa
   Elgendy, Hamed
   El Moghazy, Walid
   Fukuda, Kazuhiko
   Uemoto, Shinji
TI Pattern of Bacterial and Fungal Infections in the First 3 Months After
   Pediatric Living Donor Liver Transplantation: An 11-Year Single-Center
   Experience
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SURGICAL SITE INFECTION; RISK-FACTORS; INTERNATIONAL CONSENSUS;
   ALLOGRAFT-REJECTION; COMPLICATIONS; RECIPIENTS; CHILDREN; PROPHYLAXIS;
   BACTEREMIA; MANAGEMENT
AB Infection after pediatric living donor liver transplantation (LDLT) is a major cause of morbidity and mortality. Here, we sought to determine the incidence, timing, location, and risk factors for bacterial and fungal infections. We retrospectively investigated infection for 3 postoperative months in 345 consecutive pediatric patients (56.2% were females) who underwent primary LDLT at Kyoto University Hospital, Japan. A total of 179 patients (51.9%) developed at least 1 bacterial and/or fungal infection episode, with an infection rate of 2.5 per patient. The predominant infection site was the surgical site (52%). Most of the bacterial and fungal infection occurred within the first month. Enterococcus species followed by multidrug-resistant Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus were the predominant bacterial pathogens. All fungal isolates were Candida species. Prolonged preoperative hospital stay more than 7 days (P = 0.025) and bile leak (P = 0.047) were independent predictors of bacterial infection. Preoperative ascites (P = 0.009) and prolonged insertion of intravascular catheters (P = 0.001) independently predicted fungal infections. Bacterial and fungal infections were responsible for 42.9% of the causes of death in our study. To avoid bacterial and fungal infections after LDLT, broader-spectrum prophylaxis to cover the range of organisms seen in these infections should be considered as a more favorable treatment regimen to prevent prophylaxis failure, especially for patients with a preoperative hospital stay more than 7 days or operative complications in the form of a bile leak. Early drain removal and prophylactic antifungal drugs should be considered for patients with preoperative ascites. Cooperation between attending physicians and infectious disease physicians can improve the outcome of patients after LDLT. Liver Transpl 17:976-984, 2011. (C) 2011 AASLD.
C1 [Nafady-Hego, Hanaa] Kyoto Univ, Grad Sch Med, Dept Hepatopancreatobiliary Surg & Transplantat, Sakyo Ku, Kyoto 6068507, Japan.
   [Elgendy, Hamed; Fukuda, Kazuhiko] Kyoto Univ, Grad Sch Med, Dept Anesthesia, Kyoto 6068507, Japan.
   [Nafady-Hego, Hanaa] Assiut Univ, Grad Sch Med, Dept Microbiol & Immunol, Assiut, Egypt.
   [Elgendy, Hamed] Assiut Univ, Grad Sch Med, Dept Anesthesia, Assiut, Egypt.
   [El Moghazy, Walid] Sohag Univ, Grad Sch Med, Dept Surg, Sohag, Egypt.
RP Nafady-Hego, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Hepatopancreatobiliary Surg & Transplantat, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.
EM hanaa@kuhp.kyoto-u.ac.jp
OI Elmoghazy, Walid/0000-0001-9590-0930
CR Araz C, 2004, TRANSPLANT P, V36, P214, DOI 10.1016/j.transproceed.2003.11.029
   Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335
   Asensio A, 2008, LIVER TRANSPLANT, V14, P799, DOI 10.1002/lt.21435
   Aydogdu S, 2005, PEDIATR TRANSPLANT, V9, P723, DOI 10.1111/j.1399-3046.2005.00366.x
   Bouchut JC, 2001, PAEDIATR ANAESTH, V11, P93, DOI 10.1046/j.1460-9592.2001.00574.x
   Cakir M, 2010, PEDIATR TRANSPLANT, V14, P82, DOI 10.1111/j.1399-3046.2009.01136.x
   DEMETRIS AJ, 1990, AM J SURG PATHOL, V14, P49
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Fortun J, 2003, J ANTIMICROB CHEMOTH, V52, P813, DOI 10.1093/jac/dkg450
   Fridell JA, 2002, TRANSPLANTATION, V74, P1721, DOI 10.1097/01.TP.0000039334.85487.AB
   Garcia S, 1998, CLIN TRANSPLANT, V12, P190
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   GEORGE DL, 1992, AM J DIS CHILD, V146, P924
   Gladdy RA, 1999, LIVER TRANSPLANT SUR, V5, P16, DOI 10.1002/lt.500050105
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Iinuma Y, 2004, TRANSPLANTATION, V78, P704, DOI 10.1097/01.tp.000013017817216.28
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Jain A, 2002, TRANSPLANT P, V34, P1955, DOI 10.1016/S0041-1345(02)03136-6
   Kim JE, 2010, J KOREAN MED SCI, V25, P527, DOI 10.3346/jkms.2010.25.4.527
   Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376
   Nagao M, 2010, CLIN MICROBIOL INFEC, V16, P1783, DOI 10.1111/j.1469-0691.2010.03156.x
   ROSENTHAL P, 1994, AM J GASTROENTEROL, V89, P480
   SAINTVIL D, 1991, J PEDIATR SURG, V26, P908, DOI 10.1016/0022-3468(91)90835-H
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   Singh N, 2006, INFECT CONT HOSP EP, V27, P122, DOI 10.1086/500651
   Takakura S, 2006, INFECT CONT HOSP EP, V27, P964, DOI 10.1086/504934
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tanaka Koichi, 2003, Keio Journal of Medicine, V52, P73
   TOKUNAGA Y, 1993, TRANSPLANT INT, V6, P313, DOI 10.1111/j.1432-2277.1993.tb00673.x
   UEMOTO S, 1994, J PEDIATR SURG, V29, P514, DOI 10.1016/0022-3468(94)90080-9
   WAGENER MM, 1992, AM J INFECT CONTROL, V20, P239, DOI 10.1016/S0196-6553(05)80197-X
   Warren NG, 1999, MANUAL CLIN MICROBIO, P1184
   [Anonymous], 1999, AM J HLTH SYST PHARM, V56, P1839
   [Anonymous], 1997, HEPATOLOGY, V25, P658
NR 35
TC 15
Z9 17
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2011
VL 17
IS 8
BP 976
EP 984
DI 10.1002/lt.22278
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 800CU
UT WOS:000293337700013
PM 21786404
ER

PT J
AU Ueno, T
   Tanaka, N
   Ihara, Y
   Takama, Y
   Yamada, H
   Mushiake, S
   Fukuzawa, M
AF Ueno, Takehisa
   Tanaka, Natsumi
   Ihara, Yoshiyuki
   Takama, Yuichi
   Yamada, Hiroyuki
   Mushiake, Sotaro
   Fukuzawa, Masahiro
TI Graft fibrosis in patients with biliary atresia after pediatric
   living-related liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplant; protocol biopsy; graft fibrosis; living donor
ID FOLLOW-UP; RECIPIENTS
AB Although an LDLT can successfully treat biliary atresia (BA), some patients develop liver fibrosis or inflammation. To study the incidence and risk factors associated with these complications, we performed serial protocol biopsies. Twenty-four patients with BA who received a pediatric LDLT underwent protocol biopsies. All patients received standard tacrolimus-based immunosuppression and steroids. The last available biopsies were assessed. The mean age at the time of transplant was 4.8 yr and the follow-up period ranged from 1.2 to 12.3 yr. The GRWR ranged from 0.8% to 4.5%. The mean time from transplantation to the latest biopsy was 4.7 yr. No complications occurred with the biopsy protocol. The last available biopsies for 13 (54%) and 4 (17%) patients indicated grade 1 and grade 2 portal fibrosis, respectively, and 14 patients (54%) had inflammation. No ductopenia was detected. A younger age at LDLT was significantly correlated with graft fibrosis (p = 0.036). These results indicate that biopsy-proven fibrosis can be detected in patients with BA after LDLT, even in the context of normal liver function blood tests. Therefore, a serial biopsy is a safe and effective follow-up procedure for pediatric LDLT.
C1 [Ueno, Takehisa; Tanaka, Natsumi; Ihara, Yoshiyuki; Takama, Yuichi; Fukuzawa, Masahiro] Osaka Univ, Grad Sch Med, Dept Pediat Surg, Suita, Osaka 5650871, Japan.
   [Yamada, Hiroyuki; Mushiake, Sotaro] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan.
RP Ueno, T (reprint author), Osaka Univ, Grad Sch Med, Dept Pediat Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ueno@pedsurg.med.osaka-u.ac.jp
CR BUBAK ME, 1991, HEPATOLOGY, V14, P1063, DOI 10.1016/0270-9139(91)90129-J
   Demetris A, 2000, Hepatology, V31, P792
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Hasegawa T, 2000, J PEDIATR SURG, V35, P1643, DOI 10.1053/jpsu.2000.18342
   Peeters PMJG, 2000, TRANSPLANTATION, V70, P1581, DOI 10.1097/00007890-200012150-00008
   Rosenthal P, 1997, Liver Transpl Surg, V3, P559
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Sebagh M, 2003, HEPATOLOGY, V37, P1293, DOI 10.1053/jhep.2003.50231
   Takahara T, 1997, HEPATOLOGY, V26, P1521
NR 10
TC 7
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2011
VL 15
IS 5
BP 470
EP 475
DI 10.1111/j.1399-3046.2011.01483.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 794OB
UT WOS:000292908600011
PM 21771230
ER

PT J
AU Carnevale, FC
   Machado, AD
   Moreira, AM
   Christine, A
   dos Santos, B
   da Motta-Leal, JM
   Suzuki, L
   Cerri, GG
   Tannuri, U
AF Carnevale, Francisco Cesar
   Machado, Alexandre de Tarso
   Moreira, Airton Mota
   Christine, Aline
   dos Santos, Barbosa
   da Motta-Leal-Filho, Joaquim Mauricio
   Suzuki, Lisa
   Cerri, Giovanni Guido
   Tannuri, Uenis
TI Long-term results of the percutaneous transhepatic venoplasty of portal
   vein stenoses after pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE child; post-operative complication; interventional radiology; balloon
   angioplasty and stent
ID VASCULAR COMPLICATIONS; ENDOVASCULAR TREATMENT; STENT PLACEMENT; VENOUS
   STENOSIS; DOPPLER US; CHILDREN; ANGIOPLASTY; MIDTERM; DONORS; MANAGEMENT
AB This paper has the objective to evaluate retrospectively the long-term results of transhepatic treatment of PV stenoses after pediatric LT. During an eight-yr period, 15 children with PV stenoses underwent PTA with balloon dilation or stent placement in case of PTA failure after LT. Patients' body weights ranged from 9.3 to 46 kg (mean, 15.5 kg). PV patency was evaluated in the balloon dilation and in the stent placement groups. Technical and clinical successes were achieved in all cases with no complication. Eleven patients (11/15; 73.3%) were successfully treated by single balloon dilation. Four patients (4/15; 26.7%) needed stent placement. One patient was submitted to stent placement during the same procedure because of PTA failure. The other three developed clinical signs of portal hypertension because of PV restenoses two, eight, and twenty-eight months after the first PTA. They had to be submitted to a new procedure with stent placement. The follow-up time ranged from 3 to 8.1 yr (mean, 6.3 yr). In conclusion, transhepatic treatment of PV stenoses after pediatric LT with balloon dilation or stent placement demonstrated to be a safe and effective treatment that results in long-term patency.
C1 Univ Fed Minas Gerais, Endovasc Unit, Hosp Clin, Belo Horizonte, MG, Brazil.
   [Carnevale, Francisco Cesar; Moreira, Airton Mota; Christine, Aline; dos Santos, Barbosa; da Motta-Leal-Filho, Joaquim Mauricio; Cerri, Giovanni Guido] Univ Sao Paulo, Hosp Clin, Inst Radiol, Intervent Radiol Unit, Sao Paulo, Brazil.
   [Suzuki, Lisa; Tannuri, Uenis] Univ Sao Paulo, Hosp Clin, Childrens Inst, Liver Transplantat Unit, Sao Paulo, Brazil.
RP Machado, AD (reprint author), Univ Fed Minas Gerais, Endovasc Unit, Hosp Clin, Belo Horizonte, MG, Brazil.
EM alextm@medicina.ufmg.br
RI Tannuri, Uenis/D-3876-2012; da Motta Leal Filho, Joaquim/E-2200-2013;
   Carnevale, Francisco /I-6135-2015; 
OI Carnevale, Francisco Cesar/0000-0003-2659-9624; Motta-Leal-Filho,
   Joaquim/0000-0001-9844-6833
CR Andreassi Maria Grazia, 2004, Cardiovasc Ultrasound, V2, P25, DOI 10.1186/1476-7120-2-25
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Broniszczak D, 2006, TRANSPLANT P, V38, P1456, DOI 10.1016/j.transproceed.2006.02.094
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   CALLEJA J, 1995, TRANSPLANT INT, V8, P74
   Carnevale FC, 2006, CARDIOVASC INTER RAD, V29, P457, DOI 10.1007/s00270-005-0046-8
   Carnevale FC, 2008, J VASC INTERV RADIOL, V19, P1439, DOI 10.1016/j.jvir.2008.06.012
   Cavallari A, 2001, HEPATO-GASTROENTEROL, V48, P179
   Chen HL, 2008, TRANSPL P, V40, P2534, DOI 10.1016/j.transproceed.2008.07.057
   Cheng YF, 2001, TRANSPLANT INT, V14, P223, DOI 10.1007/s001470100324
   Connolly B, 2006, PEDIATR RADIOL, V36, P163, DOI 10.1007/s00247-006-0192-4
   Funaki B, 2000, RADIOLOGY, V215, P147
   Funaki B, 1997, AM J ROENTGENOL, V169, P551
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   Glanemann M, 2001, TRANSPLANT INT, V14, P48, DOI 10.1007/s001470050742
   Godoy MA, 1996, J VASC INTERV RADIOL, V7, P273, DOI 10.1016/S1051-0443(96)70779-0
   Kim YJ, 2007, LIVER TRANSPLANT, V13, P1145, DOI 10.1002/lt.21076
   Ko GY, 2007, LIVER TRANSPLANT, V13, P530, DOI 10.1002/lt.21068
   Lee SY, 2004, RADIOLOGY, V230, P443, DOI 10.1148/radiol.2302021318
   MILLIS JM, 1996, TRANSPLANTATION, V27, P62
   Olcott E W, 1990, J Vasc Interv Radiol, V1, P17, DOI 10.1016/S1051-0443(90)72496-7
   Perkins James D, 2006, Liver Transpl, V12, P321
   Porrett PM, 2009, LIVER TRANSPLANT, V15, pS12, DOI 10.1002/lt.21893
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   ROLLINS NK, 1992, RADIOLOGY, V182, P731
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Sulieman A, 2007, BRIT J RADIOL, V80, P731, DOI 10.1259/bjr/16010686
   Suzuki L, 2008, PEDIATR RADIOL, V38, P403, DOI 10.1007/s00247-007-0733-5
   Tang SS, 2001, CLIN TRANSPLANT, V15, P380, DOI 10.1034/j.1399-0012.2001.150603.x
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
   Vignali C, 2004, TRANSPLANT P, V36, P552, DOI 10.1016/j.transproceed.2004.02.038
   Wang JF, 2006, TRANSPLANT P, V38, P1461, DOI 10.1016/j.transproceed.2006.02.113
   ZAJKO AB, 1994, J VASC INTERV RADIOL, V5, P121, DOI 10.1016/S1051-0443(94)71467-6
NR 33
TC 11
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2011
VL 15
IS 5
BP 476
EP 481
DI 10.1111/j.1399-3046.2011.01481.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 794OB
UT WOS:000292908600012
PM 21585632
ER

PT J
AU Nielsen, D
   Briem-Richter, A
   Sornsakrin, M
   Fischer, L
   Nashan, B
   Ganschow, R
AF Nielsen, Dirk
   Briem-Richter, Andrea
   Sornsakrin, Marijke
   Fischer, Lutz
   Nashan, Bjoern
   Ganschow, Rainer
TI The use of everolimus in pediatric liver transplant recipients: First
   experience in a single center
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE everolimus; children; liver transplantation; immunosuppression
ID LOW-DOSE CYCLOSPORINE; SDZ-RAD; CALCINEURIN INHIBITOR; RENAL-FUNCTION;
   PHARMACOKINETICS; MULTICENTER; RAPAMYCIN; IMMUNOSUPPRESSION;
   TOLERABILITY; CONVERSION
AB The role of mTOR inhibitors, such as EVL, has not been established for pediatric liver transplant recipients up to now, although data from adult solid organ graft transplantation are very promising. Major complications following pediatric liver transplantation in the long-term course include chronic graft rejection and CNI-derived nephrotoxicity. The purpose of our study was to report first results using EVL as a rescue therapy in pediatric liver transplant recipients for the following indications: chronic graft dysfunction n = 12, suspected CNI toxicity n = 3, hepatoblastoma n = 2, and recurrence of primary sclerosing cholangitis post-Ltx n = 1. Four patients with chronic graft dysfunction developed completely normal liver function tests using EVL, six patients showed partial improvement, and two patients did not respond at all. One patient with CNI-induced nephropathy showed a slightly improved GFR. Both patients with hepatoblastoma did not develop any metastasis post-Ltx. First experience with EVL in pediatric liver transplant recipients shows promising results in patients with chronic graft failure when standard immunosuppression has failed. The future role of EVL in immunosuppressive protocols for children post-Ltx has to be proven by controlled clinical trials.
C1 [Briem-Richter, Andrea; Sornsakrin, Marijke; Ganschow, Rainer] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hepatol & Liver Transplantat, D-20246 Hamburg, Germany.
   [Nielsen, Dirk; Briem-Richter, Andrea; Sornsakrin, Marijke] Univ Med Ctr Hamburg Eppendorf, Dept Gen Pediat, D-20246 Hamburg, Germany.
   [Fischer, Lutz; Nashan, Bjoern] Univ Med Ctr Hamburg Eppendorf, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Ganschow, R (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hepatol & Liver Transplantat, Martinistr 52, D-20246 Hamburg, Germany.
EM ganschow@uke.de
CR Albano L, 2009, TRANSPLANTATION, V88, P69, DOI 10.1097/TP.0b013e3181aa7d87
   Castroagudin JF, 2009, LIVER TRANSPLANT, V15, P1792, DOI 10.1002/lt.21920
   Chan L, 2008, TRANSPLANTATION, V85, P821, DOI 10.1097/TP.0b013e318166927b
   Crowe A, 1999, DRUG METAB DISPOS, V27, P627
   De Simone P, 2009, TRANSPL INT, V22, P279, DOI 10.1111/j.1432-2277.2008.00768.x
   De Simone P, 2009, LIVER TRANSPLANT, V15, P1262, DOI [10.1002/lt.21827, 10.1002/It.21827]
   HOLDAAS H, 2008, CLIN TRANSPLANT, V10, P1
   Hoyer PF, 2003, TRANSPLANTATION, V75, P2082, DOI 10.1097/01.TP.0000070139.63068.54
   Kauffman HM, 2005, TRANSPLANTATION, V80, P883, DOI 10.1097/01.TP.0000184006.43152.8D
   Kirchner GI, 2004, CLIN PHARMACOKINET, V43, P83, DOI 10.2165/00003088-200443020-00002
   Kovarik JM, 2003, J CLIN PHARMACOL, V43, P141, DOI 10.1177/0091270002239822
   Lehmkuhl HB, 2007, J HEART LUNG TRANSPL, V26, P700, DOI 10.1016/j.healun.2007.02.008
   Levy G, 2006, LIVER TRANSPLANT, V12, P1640, DOI 10.1002/lt.20707
   Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19
   Masetti M, 2010, AM J TRANSPLANT, V10, P1
   Nashan B, 2004, TRANSPLANTATION, V78, P1332, DOI 10.1097/01.TP.0000140186.97461.49
   Neuhaus P, 2001, LIVER TRANSPLANT, V7, P473, DOI 10.1053/jlts.2001.24645
   Pape L, 2007, PEDIATR TRANSPLANT, V11, P291, DOI 10.1111/j.1399-3046.2006.00651.x
   Pascual J, 2006, TRANSPLANT REV, V20, P1, DOI 10.1016/j.trre.2005.10.005
   Schuler W, 1997, TRANSPLANTATION, V64, P36, DOI 10.1097/00007890-199707150-00008
   Tredger JM, 2006, PEDIATR TRANSPLANT, V10, P879, DOI 10.1111/j.1399-3046.2006.00604.x
   Van Damme-Lombaerts R, 2002, PEDIATR TRANSPLANT, V6, P147, DOI 10.1034/j.1399-3046.2002.01070.x
   Viklicky O, 2000, TRANSPLANTATION, V69, P497, DOI 10.1097/00007890-200002270-00006
NR 23
TC 10
Z9 10
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2011
VL 15
IS 5
BP 510
EP 514
DI 10.1111/j.1399-3046.2011.01515.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 794OB
UT WOS:000292908600018
PM 21696525
ER

PT J
AU Miyamura, T
   Yoshida, R
   Yagi, T
   Matsukawa, H
   Chayama, K
   Ishida, T
   Washio, K
   Morishita, N
   Oda, M
   Morishima, T
AF Miyamura, Takako
   Yoshida, Ryuichi
   Yagi, Takahito
   Matsukawa, Hiroyoshi
   Chayama, Kousuke
   Ishida, Toshiaki
   Washio, Kana
   Morishita, Naoto
   Oda, Megumi
   Morishima, Tsuneo
TI Successful treatment of unresectable advanced hepatoblastoma: Living
   liver transplantation after surgical removal of lung metastasis
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatoblastoma; living liver transplantation; metastasis
ID PEDIATRIC-ONCOLOGY SIOP; INTERNATIONAL-SOCIETY; PREOPERATIVE
   CHEMOTHERAPY; MODERN-ERA; CHILDREN; CHILDHOOD; TUMORS; SURVIVAL; RISK
AB Hepatoblastoma is a rare malignant tumor of the liver in children. Intensive combination chemotherapy has increased the number of surgically resectable cases and improved prognosis markedly. However, unresectable cases and cases with residual metastasis, including lung metastases, have a poor prognosis. In these refractory cases, treatment strategy has not been established. On the other hand, living liver transplantation has been shown to be effective in cases of advanced hepatoblastoma, but its effectiveness in cases with residual distant metastases after chemotherapy remains unclear. We report one successful case of advanced unresectable hepatoblastoma with multiple lung metastases. Intensive chemotherapy consisting of high-dose chemotherapy with autologous hematopoietic stem cell transplantation was not effective. We performed living liver transplantation after surgical resection of residual lung metastases, which were histologically viable. After liver transplantation, the level of tumor marker decreased gradually. The patient experienced no severe complications. This case suggested that living liver transplantation could be effective in cases of advanced refractory hepatoblastoma after control of distant metastases.
C1 [Miyamura, Takako; Chayama, Kousuke; Ishida, Toshiaki; Washio, Kana; Morishita, Naoto; Oda, Megumi; Morishima, Tsuneo] Okayama Univ, Grad Sch Med & Dent, Dept Pediat, Okayama 7008558, Japan.
   [Yoshida, Ryuichi; Yagi, Takahito; Matsukawa, Hiroyoshi] Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Transplant Surg & Surg Oncol, Okayama 7008558, Japan.
RP Miyamura, T (reprint author), Okayama Univ, Grad Sch Med & Dent, Dept Pediat, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
EM miyamu@md.okayama-u.ac.jp
CR Aronson DC, 2005, J CLIN ONCOL, V23, P1245, DOI 10.1200/JCO.2005.07.145
   Avila LF, 2006, EUR J PEDIATR SURG, V16, P411, DOI 10.1055/s-2006-924730
   Brown J, 2000, EUR J CANCER, V36, P1418, DOI 10.1016/S0959-8049(00)00074-5
   Bucuvalas John C, 2008, Curr Opin Organ Transplant, V13, P247, DOI 10.1097/MOT.0b013e3282f94aab
   Carceller A, 2001, J PEDIATR SURG, V36, P755, DOI 10.1053/jpsu.2001.22953
   Cassas-Medley AT, 2007, J PEDIATR SURG, V42, P184
   Czauderna P, 2005, EUR J CANCER, V41, P1031, DOI 10.1016/j.ejca.2005.02.004
   Ehrlich PF, 1997, J PEDIATR SURG, V32, P999, DOI 10.1016/S0022-3468(97)90386-9
   Faraj W, 2008, LIVER TRANSPLANT, V14, P1614, DOI 10.1002/lt.21586
   FILLER RM, 1991, SURGERY, V110, P591
   Ijichi O, 2006, PEDIATR TRANSPLANT, V10, P635, DOI 10.1111/j.1399-3046.2006.00517.x
   Ikeda H, 1997, J PEDIATR-US, V130, P557, DOI 10.1016/S0022-3476(97)70239-7
   Kasahara M, 2005, AM J TRANSPLANT, V5, P2229, DOI 10.1111/j.1600-6143.2005.01003.x
   KATAZENSTEIN HM, 2002, J CLIN ONCOL, V20, P3438
   Katzenstein HM, 2002, J PEDIAT HEMATOL ONC, V24, P751, DOI 10.1097/00043426-200212000-00014
   Litten JB, 2008, ONCOLOGIST, V13, P812, DOI 10.1634/theoncologist.2008-0011
   Molmenti EP, 2002, AM J TRANSPLANT, V2, P535, DOI 10.1034/j.1600-6143.2002.20607.x
   Nishimura SI, 2002, PEDIATR INT, V44, P300, DOI 10.1046/j.1442-200X.2002.01549.x
   ORTEGA JA, 1991, J CLIN ONCOL, V9, P2167
   Otte JB, 2004, PEDIATR BLOOD CANCER, V42, P74, DOI 10.1002/pbc.10376
   Otte JB, 2005, PEDIATR TRANSPLANT, V9, P557, DOI 10.1111/j.1399-3046.2005.00354.x
   Perilongo G, 2000, CANCER, V89, P1845, DOI 10.1002/1097-0142(20001015)89:8<1845::AID-CNCR27>3.0.CO;2-D
   Perilongo G, 2004, EUR J CANCER, V40, P411, DOI 10.1016/j.ejca.2003.06.003
   Perilongo G, 2000, Lancet Oncol, V1, P94, DOI 10.1016/S1470-2045(00)00018-8
   Reynolds P, 2004, CANCER, V100, P1070, DOI 10.1002/cncr.20061
   Squires RH, 2008, SEMIN LIVER DIS, V28, P153, DOI 10.1055/s-2008-1073115
   STRINGER MD, 1995, BRIT J SURG, V82, P386, DOI 10.1002/bjs.1800820334
   WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7
NR 28
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2011
VL 15
IS 5
BP E87
EP E91
DI 10.1111/j.1399-3046.2009.01262.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 794OB
UT WOS:000292908600001
PM 20070564
ER

PT J
AU Schulze, M
   Dresske, B
   Deinzer, J
   Braun, F
   Kohl, M
   Schulz-Jurgensen, S
   Borggrefe, J
   Burdelski, M
   Broring, DC
AF Schulze, Maren
   Dresske, Bettina
   Deinzer, Julia
   Braun, Felix
   Kohl, Martina
   Schulz-Juergensen, Sebastian
   Borggrefe, Jan
   Burdelski, Martin
   Broering, Dieter Clemens
TI Implications for the usage of the left lateral liver graft for infants
   <= 10 kg, irrespective of a large-for-size situation - are monosegmental
   grafts redundant?
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE biliary complications; graft body weight ratio; intraoperative
   ultrasound; large-for-size; temporary abdominal closure
ID LIVING-DONOR; TRANSPLANTATION; CHILDREN; KILOGRAMS
AB Organ donor shortage for infant liver transplant recipients has lead to an increase in splitting and living donation. For cases in which even transplantation of the left lateral graft (Couinaud's segments II + III) results in a "large for size situation" with an estimated graft body weight ratio (GBWR) of >4%, monosegmental liver transplantation was developed. This, however, bears complications because of greater parenchymal surface and suboptimal vascular flow. We exclusively use the left lateral graft from living donors or split grafts. Temporary abdominal closure is attempted in cases of increased pressure. We report of 41 pediatric transplants in 38 children <= 10 kg. Within this group, there were 23 cases with a GBWR of 4, and 15 cases with a GBWR <4. There was no statistical difference in vascular or biliary complications. Despite a more frequent rate of temporary abdominal closure, we did not find a higher rate of intra-abdominal infections. Overall, patient and graft survival was excellent in both groups (one death, three re-transplants). We noticed, however, that the ventro-dorsal diameter of the graft appears to be more relevant to potential graft necrosis than the actual graft size. In conclusion, the usage of monosegmental grafts seems unnecessary if transplantation of left lateral grafts is performed by an experienced multidisciplinary team, and temporary abdominal closure is favored in cases of increased abdominal pressure.
C1 [Kohl, Martina; Schulz-Juergensen, Sebastian; Burdelski, Martin] Univ Schleswig Holstein, Dept Pediat Gastroenterol, Kiel, Germany.
   [Borggrefe, Jan] Univ Schleswig Holstein, Dept Radiol, Kiel, Germany.
RP Schulze, M (reprint author), Univ Hosp Schleswig Holstein, Dept Gen & Thorac Surg, Campus Kiel,Arnold Heller Str 3,Haus 18, D-24105 Kiel, Germany.
EM maren.schulze@uksh-kiel.de
CR BISMUTH H, 1984, SURGERY, V95, P367
   BRAUN F, 2009, GASTROENTEROLOGE, V4, P516
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   Broering DC, 2003, J HEPATOL, V38, P119, DOI 10.1016/S0168-8278(03)00009-6
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Emre S, 2002, PEDIATR TRANSPLANT, V6, P43, DOI 10.1034/j.1399-3046.2002.1r072.x
   Enne M, 2004, PEDIATR TRANSPLANT, V8, P189, DOI 10.1046/j.1399-3046.2003.00140.x
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   HOUSSIN D, 1992, SURGERY, V111, P532
   Iglesias J, 2004, PEDIATR TRANSPLANT, V8, P228, DOI 10.1111/j.1399-3046.2004.00128.x
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kasahara M, 2003, J PEDIATR SURG, V38, P1108, DOI 10.1016/S0022-3468(03)00206-9
   KASHARA M, 2008, J PEDIATR SURG, V43, P1575
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   MACHENS HG, 1994, SURGERY, V115, P255
   Mentha G, 1996, TRANSPLANTATION, V62, P1176, DOI 10.1097/00007890-199610270-00026
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   RAIA S, 1989, LANCET, V2, P497
   Saing H, 1999, J PEDIATR SURG, V34, P1721, DOI 10.1016/S0022-3468(99)90653-X
   Santibanes E, 2000, LIVER TRANSPLANT, V6, P108
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   STRONG R, 1995, SURGERY, V118, P904, DOI 10.1016/S0039-6060(05)80283-1
   Thomas N, 2010, PEDIATR TRANSPLANT, V14, P426, DOI 10.1111/j.1399-3046.2010.01294.x
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 26
TC 13
Z9 14
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD AUG
PY 2011
VL 24
IS 8
BP 797
EP 804
DI 10.1111/j.1432-2277.2011.01277.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 788RL
UT WOS:000292462000010
PM 21649741
ER

PT J
AU Oh, SH
   Kim, KM
   Kim, DY
   Kim, T
   Hwang, S
   Park, KM
   Lee, YJ
   Lee, SG
AF Oh, S. H.
   Kim, K. M.
   Kim, D. Y.
   Kim, T.
   Hwang, S.
   Park, K. -M.
   Lee, Y. -J.
   Lee, S. -G.
TI Incidence and Risk Factors for the Development of Prolonged Severe
   Intrahepatic Cholestasis After Pediatric Living-Donor Liver
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
AB The aim of this study is to evaluate the incidence, etiology, and risk facrors for prolonged severe intrahepatic cholestasis (PSIC) after 129 pediatric living-donor liver transplantations (LDLT). The incidence of PSIC was 25.6% (n = 33). Twenty-eight (84.8%) versus 5 (15.2%) children experienced early versus late PSIC, respectively. Among these 33 children with PSIC, 8 (24.2%) received a donor liver with mild to moderate fatty change, 4 (12.1%) with low graft-body weight ratios, and 4 (12.1%) with ABO incompatibility. The predominant etiologies were acute rejection (n = 15; 45.5%), chronic rejection (n = 6; 18.2%), virus (n = 3; 9.1%), vascular complications (n = 4; 12.1%), and initial graft dysfunction (n = 10; 30.3%). ABO incompatibility (P = .032; odds ratio [OR] 3.25), chronic rejection (P = .012; OR 4.76), and vascular complications (P = .046; OR 1.82) were significant variables associated with PSIC. Donor selection with ABO compatibility as well as early detection and management of chronic rejection and vascular complications may be important to prevet PSIC in LDLT.
C1 [Oh, S. H.; Kim, K. M.] Univ Ulsan, Coll Med, Childrens Hosp, Dept Pediat,Asan Med Ctr, Seoul 138736, South Korea.
RP Kim, KM (reprint author), Univ Ulsan, Coll Med, Childrens Hosp, Dept Pediat,Asan Med Ctr, 388-1 Pungnap Dong, Seoul 138736, South Korea.
EM kmkim@amc.seoul.kr
OI Kim, Kyung Mo/0000-0001-7896-6751
CR ADLER M, 1988, TRANSPLANT P, V20, P644
   Ben-Ari Z, 2003, LIVER TRANSPLANT, V9, P1005, DOI 10.1053/jlts.2003.50212
   Corbani A, 2008, CLIN LIVER DIS, V12, P111, DOI 10.1016/j.cld.2007.11.001
   Fusai G, 2006, LIVER TRANSPLANT, V12, P1626, DOI 10.1002/lt.20870
   HUH SY, 2009, PEDIATRICS, V24, P703
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   SANCHEZURDAZPAL L, 1993, HEPATOLOGY, V17, P605, DOI 10.1002/hep.1840170413
   WILLIAMS JW, 1986, AM J SURG, V151, P65, DOI 10.1016/0002-9610(86)90013-9
NR 8
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2011
VL 43
IS 6
BP 2400
EP 2402
DI 10.1016/j.transproceed.2011.06.013
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 810CC
UT WOS:000294102000064
PM 21839277
ER

PT J
AU Ueno, T
   Wada, M
   Hoshino, K
   Yonekawa, Y
   Fukuzawa, M
AF Ueno, T.
   Wada, M.
   Hoshino, K.
   Yonekawa, Y.
   Fukuzawa, M.
TI Current Status of Intestinal Transplantation in Japan
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
AB The development of total parenteral nutrition (TPN) has dramatically improved the prognosis of patients afflicted with intestinal failure. However, TPN-related complications, which remain a problem for patients with intestinal failure can be addressed by intestinal transplantation, which can significantly improve their prognosis and quality of life. The first intestinal transplantation in Japan occurred in 1996. Of the 17 intestinal transplantations performed to date, six were obtained from deceased donors and 11 from living donors. The primary indications were: short gut syndrome (n = 8), intestinal function disorder (n = 7), and retransplantation (n = 2). In our experience, the 1-year and 5-year patient survival rates are 87% and 69%. All nine patients receiving transplants in the last 7 years have survived, which seem to be acceptable results for the treatment of intestinal failure. Relatively few intestinal transplantations have been performed to date, mainly due to the lack of national health insurance coverage for the procedure and the ban of the use of donors below 15 years of age. Liver failure patients are also ineligible because liver-intestine or multiorgan transplants are not allowed by current guidelines. Case numbers may increase in the future as the result of allowing for pediatric donors in the new Act on Organ Transplantation, which went into effect in July 2010. We continue to work on reforming national insurance coverage to cover multiorgan transplantations.
C1 [Ueno, T.] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan.
   [Wada, M.] Tohoku Univ, Sendai, Miyagi 980, Japan.
   [Hoshino, K.] Keio Univ, Tokyo 108, Japan.
   [Yonekawa, Y.] Kyoto Univ, HBP Surg & Transplantat, Kyoto, Japan.
RP Ueno, T (reprint author), Osaka Univ, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ueno@pedsurg.med.osaka-u.ac.jp
CR *JAP SOC INT TRANS, 2009, ISHOKU, V44, P589
   [Anonymous], 2005, ANN SURG
   Tzakis AG, 2005, ANN SURG, V242, P480, DOI 10.1097/01.sla..0000183347.61361.7a
   Wales PW, 2004, J PEDIATR SURG, V39, P690, DOI 10.1016/j.jpedsurg.2004.01.036
NR 4
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2011
VL 43
IS 6
BP 2405
EP 2407
DI 10.1016/j.transproceed.2011.05.043
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 810CC
UT WOS:000294102000065
PM 21839278
ER

PT J
AU Moon, SB
   Moon, JI
   Kwon, CHD
   Kim, SJ
   Seo, JM
   Joh, JW
   Lee, SK
AF Moon, Suk-Bae
   Moon, Ju-Ik
   Kwon, Choon-Hyuk David
   Kim, Sung-Joo
   Seo, Jeong-Meen
   Joh, Jae-Won
   Lee, Suk-Koo
TI Graft Rotation and Late Portal Vein Complications in Pediatric Living
   Donor Liver Transplantation Using Left-Sided Grafts: Long-Term Computed
   Tomography Observations
SO LIVER TRANSPLANTATION
LA English
DT Article
ID VENOUS OUTFLOW OBSTRUCTION; CHILDREN
AB Right-side rotation of the graft is an uncommon event after pediatric living donor liver transplantation (LDLT) with a left-sided graft. However, graft rotation might lead to gradual portal vein (PV) stretching and late portal vein complications (PVCs). The goal of this study was to quantify the degree of graft rotation (R) by computed tomography (CT) and to determine the effect of graft rotation on the development of late PVCs. One hundred ten patients underwent LDLT with left-sided grafts between 1996 and 2009; CT images were available and were reviewed for 66 of these patients. To quantify R, the following variables were measured with CT: the longest distance between the midline and the extrahepatic PV at the level of the hepatic hilum (A), the distance between the midline and the center of the superior mesenteric vein at the level of the confluence of the splenic vein and superior mesenteric vein (B), and the inner transverse diameter of the body cavity at the level at which A was measured (C). R was calculated as (A - B)/C. In patients with a patent PV (n = 59) and in patients with late PVCs (n = 7), the median R values were 0.16 (range = 0.03-0.38) and 0.25 (range = 0.13-0.39), respectively; there was a significant difference between the 2 groups (P = 0.003). Multivariate analysis showed that R >= 0.2 was the only independent risk factor for the development of late PVCs (P = 0.021). In conclusion, the gradual stretching of the PV after right-side rotation of left-sided grafts might play an important role in the development of late PVCs. PV patency should be closely monitored when graft rotation is noted during clinical follow-up. Liver Transpl 17:717-722, 2011. (C) 2011 AASLD.
C1 [Moon, Suk-Bae; Kwon, Choon-Hyuk David; Kim, Sung-Joo; Seo, Jeong-Meen; Joh, Jae-Won; Lee, Suk-Koo] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, Seoul 135710, South Korea.
   [Moon, Ju-Ik] Konkuk Univ, Sch Med, Dept Surg, Chungju, South Korea.
RP Lee, SK (reprint author), Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, 81 Irwon Ro, Seoul 135710, South Korea.
EM sukkoo.lee@samsung.com
OI Joh, Jae-Won/0000-0003-1732-6210
CR Anderson CD, 2008, AM J TRANSPLANT, V8, P1197, DOI 10.1111/j.1600-6143.2008.02223.x
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Goldstein MJ, 2003, WORLD J SURG, V27, P356, DOI 10.1007/s00268-002-6598-8
   Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x
   Kumar GK, 2010, PEDIATR SURG INT, V26, P423, DOI 10.1007/s00383-010-2564-y
   LERUT J, 1987, ANN SURG, V205, P404, DOI 10.1097/00000658-198704000-00011
   Moon JI, 2010, TRANSPL P, V42, P871, DOI 10.1016/j.transproceed.2010.02.059
   Nikitin D, 2009, LIVER TRANSPLANT, V15, P400, DOI 10.1002/lt.21698
   Pomposelli JJ, 2007, AM J TRANSPLANT, V7, P1869, DOI 10.1111/j.1600-6143.2007.01843.x
   Sakamoto S, 2010, LIVER TRANSPLANT, V16, P1207, DOI 10.1002/lt.22135
   STRONG R, 1988, SURGERY, V104, P104
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
NR 14
TC 5
Z9 5
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2011
VL 17
IS 6
BP 717
EP 722
DI 10.1002/lt.22262
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 770TB
UT WOS:000291110300014
PM 21618693
ER

PT J
AU Arnon, R
   Annunziato, R
   Miloh, T
   Wasserstein, M
   Sogawa, H
   Wilson, M
   Suchy, F
   Kerkar, N
AF Arnon, Ronen
   Annunziato, Rachel
   Miloh, Tamir
   Wasserstein, Melissa
   Sogawa, Hiroshi
   Wilson, Monique
   Suchy, Frederick
   Kerkar, Nanda
TI Liver transplantation for hereditary tyrosinemia type I: Analysis of the
   UNOS database
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE tyrosinemia; complications of liver transplantation; congenital liver
   disease; pediatric transplantation; graft survival; liver
   transplantation
ID HEPATOCELLULAR-CARCINOMA; EXPERIENCE; NTBC
AB Patients with HT-1 can develop progressive liver disease and have a high incidence of HCC. LT is indicated in patients with fulminant liver failure, HCC or decompensated chronic liver disease refractory to NTBC. To determine the need for LT and outcomes after LT in children with HT-1. Children with HT-1 who had LT between 10/1987 and 5/2008 were identified from the UNOS database. Of 11 467 children in the UNOS database, 125 (1.1%) required LT secondary to HT-1. Mean age at LT was two and half yr (s.d. +/- 3.6 yr). Mean age at LT during the first 10 yr of the study (1.82, s.d. +/- 2.86 yr) was significantly lower than in the last decade (3.70, s.d. +/- 4.42 yr), p = 0.01. Nearly half of the patients (58, 46.4%) were transplanted between 1988 and 1992. Overall, one- and five-yr patient survival was 90.4% and 90.4%, respectively. LT is a valuable option for children with HT-1 with fulminant liver failure or when medical treatment fails. The rate of LT for children with HT-1 has decreased and age at transplant increased over the last decade most probably reflecting the effect of early diagnosis and treatment with NTBC.
C1 [Arnon, Ronen; Miloh, Tamir; Kerkar, Nanda] Mt Sinai Med Ctr, Recanati Miller Transplantat Inst, New York, NY 10029 USA.
   [Arnon, Ronen; Miloh, Tamir; Wasserstein, Melissa; Sogawa, Hiroshi; Suchy, Frederick; Kerkar, Nanda] Mt Sinai Sch Med, Dept Pediat, New York, NY USA.
   [Annunziato, Rachel; Wilson, Monique] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
RP Arnon, R (reprint author), Mt Sinai Med Ctr, Recanati Miller Transplantat Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM Ronen.arnon@mountsinai.org
CR Al-Dhalimy M, 2002, MOL GENET METAB, V75, P38, DOI 10.1006/mgme.2001.3266
   ARNON R, 2010, PEDIATR TRANSPLANT, V6, P796
   Ashorn Merja, 2006, Paediatr Drugs, V8, P47, DOI 10.2165/00148581-200608010-00004
   Holme E, 1998, J INHERIT METAB DIS, V21, P507, DOI 10.1023/A:1005410820201
   Holme E, 2000, Clin Liver Dis, V4, P805, DOI 10.1016/S1089-3261(05)70142-2
   HOLME E, 1995, CURR OPIN PEDIATR, V7, P716
   Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741
   Karakayali H, 2007, TRANSPL P, V39, P1153, DOI 10.1016/j.transproceed.2007.02.054
   Kaye C. I., 2006, PEDIATRICS, V118, P934
   McKiernan PJ, 2006, DRUGS, V66, P743, DOI 10.2165/00003495-200666060-00002
   MIELES LA, 1990, DIGEST DIS SCI, V35, P153, DOI 10.1007/BF01537237
   Mohan N, 1999, EUR J PEDIATR, V158, pS49, DOI 10.1007/PL00014321
   Paradis K, 1996, CLIN INVEST MED, V19, P311
   PEREZCERDA C, 1995, J INHERIT METAB DIS, V18, P119, DOI 10.1007/BF00711744
   Pierik LJWM, 2005, J INHERIT METAB DIS, V28, P871, DOI 10.1007/s10545-005-0059-0
   Poon TCW, 2003, CLIN CHEM, V49, P752, DOI 10.1373/49.5.752
   Russo PA, 2001, PEDIATR DEVEL PATHOL, V4, P212, DOI 10.1007/s100240010146
   van Spronsen FJ, 2005, J PEDIATR GASTR NUTR, V40, P90, DOI 10.1097/00005176-200501000-00017
   WIJBURG FA, 1995, J INHERIT METAB DIS, V18, P115, DOI 10.1007/BF00711743
NR 19
TC 12
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2011
VL 15
IS 4
BP 400
EP 405
DI 10.1111/j.1399-3046.2011.01497.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 765VA
UT WOS:000290735600013
PM 21504522
ER

PT J
AU Ghafari, JL
   Bhati, C
   John, E
   Tzvetanov, IG
   Testa, G
   Jeon, H
   Oberholzer, J
   Benedetti, E
AF Ghafari, Jamie L.
   Bhati, Chandra
   John, Eunice
   Tzvetanov, Ivo G.
   Testa, Giuliano
   Jeon, Hoonbae
   Oberholzer, Jose
   Benedetti, Enrico
TI Long-term follow-up in adult living donors for combined liver/bowel
   transplant in pediatric recipients: A single center experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE intestinal transplantation; combined liver bowel transplant;
   living-related donor
ID SMALL-BOWEL; LIVER-TRANSPLANTATION
AB Pediatric candidates for combined liver/bowel transplant (LBTx) experience a very high mortality on the cadaver waiting list. Our transplant center has successfully used adult living donors to treat pediatric candidates for LBTx. We report the long-term follow-up of this unique cohort of organ donors. The charts of six adult donors for LBTx performed between 2004 and 2007 were reviewed. All the pertinent clinical data were carefully reviewed and integrated with phone interviews of all donors. A total of six children (average age 13.5 months) received living donor LBTx. Average follow-up for the donors was 42 months (range 29-51). The donors' median age was 25 yr (19-32); five women and one man. The average median hospital stay was nine days. There were no peri-operative complications. At present all donors remain in good health. Three of the five mothers became pregnant after donation. Five of the six children are currently alive and well whereas one died with functioning grafts six months post-transplant due to plasmoblastic lymphoma. Living donor LBTx is an effective therapy for combined hepatic and intestinal failure in children less than five yr. The donor operation can be performed with minimal morbidity.
C1 [Ghafari, Jamie L.; Bhati, Chandra; John, Eunice; Tzvetanov, Ivo G.; Jeon, Hoonbae; Oberholzer, Jose; Benedetti, Enrico] Univ Illinois, Div Transplantat, Chicago, IL USA.
   [Testa, Giuliano] Univ Chicago, Med Ctr, Div Transplantat, Chicago, IL 60637 USA.
RP Benedetti, E (reprint author), Dept Surg, 840 S Wood St,Suite 402, Chicago, IL 60612 USA.
EM Enrico@uic.edu
OI Bhati, Chandra/0000-0002-4333-5551
CR Benedetti E, 2006, ANN SURG, V244, P694, DOI 10.1097/01.sla.0000232555.02880.84
   Gangemi A, 2009, TRANSPLANTATION, V87, P1027, DOI 10.1097/TP.0b013e31819cc3bf
   GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A
   *OPTN SRTR, 2008, 2008 ANN REP INT CHA
   ROGIERS X, 1995, TRANSPLANTATION, V59, P1081, DOI 10.1097/00007890-199504270-00001
   Testa G, 2004, ANN SURG, V240, P779, DOI 10.1097/01.sla.0000143266.59408.d7
   Testa G, 2008, TRANSPLANTATION, V85, P713, DOI 10.1097/TP.0b013e31816616c1
   TODO S, 1991, TRANSPLANT P, V23, P3093
   ZHONG R, 1991, TRANSPLANTATION, V52, P550, DOI 10.1097/00007890-199109000-00033
NR 9
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2011
VL 15
IS 4
BP 425
EP 429
DI 10.1111/j.1399-3046.2011.01501.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 765VA
UT WOS:000290735600016
PM 21585630
ER

PT J
AU Nesher, E
   Island, E
   Tryphonopoulos, P
   Moon, J
   Nishida, S
   Selvaggi, G
   Tekin, A
   Levi, DM
   Tzakis, A
AF Nesher, E.
   Island, E.
   Tryphonopoulos, P.
   Moon, J.
   Nishida, S.
   Selvaggi, G.
   Tekin, A.
   Levi, D. M.
   Tzakis, A.
TI Split Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID ONE DONOR LIVER; LIVING DONOR; RIGHT-LOBE; SURGICAL COMPLICATIONS; ADULT
   RECIPIENTS; OUTCOMES; CLASSIFICATION; EXPERIENCE; MORTALITY; COHORT
AB We analyzed the results of 55 patients who underwent split liver transplantation at our center between September 1996 and December 2008, 30 adults (54.5%) and 25 children (45.5%). Median follow-up was 12 years. Overall patient survival was 71%, adult 70% and pediatric 72%. Mean patient survival was 61.58 months, and mean graft survival was 44.35 months. Pediatric survival and pediatric graft survival after 1 and 5 years were 84% and 72% and 72% and 52.4%, respectively. Adult survival and adult graft survival after 1 and 5 years were 75% and 66.2% and 60.7% and 51.5%, respectively. Twelve patients required retransplantation, 6 for primary nonfunction, 3 for chronic rejection, and 3 for vascular complications. Blood groups of the recipient patients were: 34 O, 14 A, 7 B, and 0 AB. The use of split liver for adult and pediatric populations allows us to expand the cadaveric donor pool and has the potential to significantly reduce waiting list mortality, especially for certain blood groups.
C1 [Nesher, E.] Univ Miami, Liver GI Transplant Program, Sch Med, Div Transplantat,Dept Surg, Miami, FL 33136 USA.
RP Nesher, E (reprint author), Univ Miami, Liver GI Transplant Program, Sch Med, Div Transplantat,Dept Surg, Highland Profess Bldg,1801 NW 9th Ave,3rd Floor, Miami, FL 33136 USA.
EM eviatar.nesher@gmail.com
CR Azoulay D, 2001, ANN SURG, V233, P565, DOI 10.1097/00000658-200104000-00013
   Azoulay D, 1996, ANN SURG, V224, P737, DOI 10.1097/00000658-199612000-00009
   BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723
   Chan SC, 2008, ANN SURG, V248, P411, DOI 10.1097/SLA.0b013e31818584e6
   Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2
   DEGOYET JD, 1995, TRANSPLANTATION, V59, P1371
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   DUFFY JP, 2007, CLIN TRANSPL, V165
   EMOND JC, 1990, ANN SURG, V212, P14
   Fan ST, 2003, ANN SURG, V238, P864, DOI 10.1097/01.sla.0000098618.11382.77
   Freise CE, 2008, AM J TRANSPLANT, V8, P2569, DOI 10.1111/j.1600-6143.2008.02440.x
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Hashikura Y, 2009, TRANSPLANTATION, V88, P19
   Hwang S, 2006, LIVER TRANSPLANT, V12, P831, DOI 10.1002/lt.20693
   Icoz G, 2003, LIVER TRANSPLANT, V9, P575, DOI 10.1053/jlts.2003.50129
   Kokudo N, 2005, AM J TRANSPLANT, V5, P1694, DOI 10.1111/j.1600-6143.2005.00917.x
   Marcos A, 2000, LIVER TRANSPLANT, V6, P296, DOI 10.1053/lv.2000.6354
   Marsh JW, 2009, J HEPATOL, V51, P715, DOI 10.1016/j.jhep.2009.04.023
   NASHAN B, 2001, TRANSPL 2001 CHIC IL
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Renz JF, 2004, ANN SURG, V239, P172, DOI 10.1097/01.sla.0000109150.89438.bd
   Reyes J, 2000, J PEDIATR SURG, V35, P283, DOI 10.1016/S0022-3468(00)90026-5
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Rogiers X, 1996, TRANSPLANTATION, V61, P1059, DOI 10.1097/00007890-199604150-00012
   Shah SA, 2007, AM J TRANSPLANT, V7, P161, DOI 10.1111/j.1600-6143.2006.01601.x
   Shah SA, 2007, AM J TRANSPLANT, V7, P998, DOI 10.1111/j.1600-6143.2006.01692.x
   SMITH B, 1969, J PEDIATR SURG, V4, P126, DOI 10.1016/0022-3468(69)90193-6
   Yersiz H, 2006, TRANSPLANT P, V38, P602, DOI 10.1016/j.transproceed.2005.12.064
NR 28
TC 7
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2011
VL 43
IS 5
BP 1736
EP 1741
DI 10.1016/j.transproceed.2010.11.031
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 786CI
UT WOS:000292279800065
PM 21693268
ER

PT J
AU Campsen, J
   Zimmerman, MA
   Narkewicz, MR
   Sokol, RJ
   Mandell, MS
   Kam, I
   Dovel, D
   Karrer, FM
AF Campsen, Jeffrey
   Zimmerman, Michael A.
   Narkewicz, Michael R.
   Sokol, Ronald J.
   Mandell, Mercedes S.
   Kam, Igal
   Dovel, Diane
   Karrer, Frederick M.
TI Choledochoduodenostomy in pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplant; choledochoduodenostomy; Roux-en-Y
   choledochojejunostomy; biliary reconstruction; complications
ID EN-Y HEPATICOJEJUNOSTOMY; BILIARY RECONSTRUCTION; BILE-DUCT;
   HEPATICODUODENOSTOMY
AB Reconstruction of the bile ducts during pediatric liver transplantation is generally performed by a Roux-en-Y CDJ because direct duct-to-duct anastomosis CC is often not possible. Anastomosis of the donor liver bile duct to the duodenum CDD provides another option. We provide preliminary evidence that CDD is an alternative technique for biliary reconstruction when CC is not possible in pediatric liver transplant recipients that have a hostile abdomen or to preserve bowel length.
   Methods:
   From 2007 to 2008, a total of 19 pediatric cadaveric liver transplants were performed at our center. Four of the 19 had a bile duct reconstruction by CDD.
   Results:
   CDD reconstruction was used in patients who received a liver transplant for a diagnosis of PSC, congenital hepatic fibrosis, biliary atresia, and Alagille syndrome. The ages of the patients were 17 and 10 yr and 10 and 17 months. Three grafts were whole cadaveric livers, and one was a reduced left lobe. CDD was used to revise a prior anastomosis in one patient who had a previous Roux-en-Y that was unusable during the retransplant, and another to repair a stricture in a second patient with a CC. We also performed a CDD in a patient with a hostile abdomen from previous surgery, and another patient to avoid short gut syndrome that a Roux-en-Y may have created. All patients are alive with functioning grafts with a follow-up of at least one yr. None of the patients developed clinically significant biliary complications (leak, stricture, cholangitis).
   Conclusion:
   Our preliminary experience suggests that CDD is an option for biliary reconstruction in pediatric transplant patients with hostile abdomens or to preserve bowel length.
C1 [Campsen, Jeffrey; Zimmerman, Michael A.; Kam, Igal; Dovel, Diane; Karrer, Frederick M.] Univ Colorado, Denver Sch Med, Dept Surg, Div Transplant Surg, Aurora, CO USA.
   [Narkewicz, Michael R.; Sokol, Ronald J.] Univ Colorado, Denver Sch Med, Pediat Gastroenterol Hepatol & Nutr Dept Pediat, Aurora, CO USA.
   [Mandell, Mercedes S.] Univ Colorado, Denver Sch Med, Dept Anesthesiol, Aurora, CO USA.
RP Karrer, FM (reprint author), Childrens Hosp, Dept Pediat Surg, 13123 E 16th Ave, Aurora, CO 80045 USA.
EM karrer.fritz@tchden.org
CR Bennet W, 2009, WORLD J SURG, V33, P1022, DOI 10.1007/s00268-008-9885-1
   Campsen J, 2009, TRANSPLANTATION, V87, P1842, DOI 10.1097/TP.0b013e3181a6bb5e
   Heffron TG, 2003, TRANSPLANT P, V35, P1461, DOI 10.1016/S0041-1345(03)00463-9
   Hendrickson RJ, 2004, CURR OPIN PEDIATR, V16, P309, DOI 10.1097/01.mop.0000127160.82531.77
   Kamisawa T, 2008, WORLD J GASTROENTERO, V14, P6622, DOI 10.3748/wjg.14.6622
   Moraca RJ, 2002, ARCH SURG-CHICAGO, V137, P889, DOI 10.1001/archsurg.137.8.889
   Moraca RJ, 2002, ARCH SURG-CHICAGO, V137, P893
   OKADA A, 1990, SURG GYNECOL OBSTET, V171, P291
   Shimotakahara A, 2005, PEDIATR SURG INT, V21, P5, DOI 10.1007/s00383-004-1252-1
   Suchy FJ, 2007, LIVER DISEASE IN CHILDREN, 3RD EDITION, P1
NR 10
TC 3
Z9 5
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2011
VL 15
IS 3
BP 237
EP 239
DI 10.1111/j.1399-3046.2010.01338.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 751OT
UT WOS:000289628100009
PM 21214697
ER

PT J
AU Fehervari, I
   Szonyi, L
   Fazakas, J
   Gerlei, Z
   Lazar, I
AF Fehervari, Imre
   Szonyi, Laszlo
   Fazakas, Janos
   Gerlei, Zsuzsa
   Lazar, Istvan
TI TIPS stent migration into the heart with 6-year follow-up
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE TIPS; combined liver-kidney transplantation; complication of
   intervention; long term follow up
ID INTRAHEPATIC PORTOSYSTEMIC SHUNT; PORTAL-HYPERTENSION
AB Background: The transjugular intrahepatic portosystemic shunt (TIPS) is widely used for the treatment of portal hypertension in adults, but no studies have defined the best approach to treat portal hypertension in pediatric patients. Pediatric use of TIPS is rare even in large centers of adult practice. The migration of stents has also been reported as a complication in adults. There is no standard way to treat this type of complication, and it is not always clear whether immediate removal or watchful waiting is safer for the patient.
   Case Report: We report the case of an 11-year-old patient who underwent urgent TIPS implantation due to variceal bleeding, after unsuccessful sclerotherapy. During the procedure, due to the deep impact of the stent, a second, telescopic, stent was inserted. The portal pressure decreased, no further bleeding occurred, and the patient was listed for transplantation. Three weeks later a routine chest X-ray discovered the migration of the second stent into the right ventricle. No interventional radiological removal or open heart surgery was available for the transplant waiting list patient. The patient underwent uneventful combined liver-kidney transplantation. During the 6-year follow-up period the child had no signs of hemodynamic instability, and his somatic and mental development were appropriate.
   Conclusions: To our knowledge this case is the first publication on a heart-impacted TIPS stent in a child. The watchful waiting was justified by uneventful combined liver-kidney transplantation and long-term follow-up. This case also underlines the need for best practice guidelines in pediatric portal hypertension.
C1 [Fehervari, Imre; Fazakas, Janos; Gerlei, Zsuzsa] Semmelweis Univ, Transplantat & Surg Dept, Budapest, Hungary.
   [Szonyi, Laszlo] Semmelweis Univ, Dept Pediat 1, Budapest, Hungary.
   [Lazar, Istvan] Borsod Cty Teaching Hosp, Miskolc, Hungary.
RP Fehervari, I (reprint author), Semmelweis Univ, Transplantat & Surg Dept, Budapest, Hungary.
EM drfehervariimre@t-online.hu
CR Cao S, 1997, J PEDIATR SURG, V32, P125, DOI 10.1016/S0022-3468(97)90117-2
   DASILVA RF, 2008, TRANSPL P, V10, P3778
   FREEDMAN AM, 1993, RADIOGRAPHICS, V13, P1185
   Heyman MB, 1999, J PEDIATR GASTR NUTR, V29, P240, DOI 10.1097/00005176-199909000-00004
   Huppert PE, 2002, CARDIOVASC INTER RAD, V25, P484, DOI 10.1007/s00270-002-1913-6
   RUMI MN, 1999, TRANSPLANTATION, V11, P1492
   Shneider B, 2006, PEDIATR TRANSPLANT, V10, P893, DOI 10.1111/j.1399-3046.2006.00597.x
   Te HS, 2001, TRANSPLANTATION, V71, P1000, DOI 10.1097/00007890-200104150-00030
NR 8
TC 2
Z9 2
U1 0
U2 0
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD APR-JUN
PY 2011
VL 16
IS 2
BP 109
EP 112
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 799YB
UT WOS:000293321500016
PM 21716194
ER

PT J
AU Crane, J
   Hakim, N
AF Crane, Jeremy
   Hakim, Nadey
TI The Use of an Implantable Doppler Flow Probe in Kidney Transplantation:
   First Report in the Literature
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Renal; Surveillance; Vascular; Artery; Postoperative
ID ULTRASOUND
AB Objectives: After a kidney transplant, surveillance of the graft blood supply is crucial. Any delay in detecting compromised graft perfusion affects organ survival. Current practice uses Doppler ultrasound to monitor vessel patency and graft perfusion and is performed repeatedly after kidney and pancreas transplant. We have used an implantable probe that allows for easy vessel attachment and safe, continuous, audible monitoring of vascular anastomoses. It has been used to observe microvascular tissue transplants, free flaps, and pediatric liver transplants, but as yet, it has not been used to monitor kidney allografts. We feel a transplanted kidney could benefit greatly from continuous blood flow monitoring.
   Materials and Methods: To assess the feasibility of the probe in a renal transplant patient, we used the probe in 15 consecutive transplant recipients.
   Results: Only 1 Doppler ultrasound was ordered during the 15 admissions compared with scans that are routinely ordered. There were no complications and all probes were removed easily.
   Conclusions: This probe can identify transplanted organs that are threatened owing to flagging or cessation of the blood supply, and allow for immediate intervention. This technique may save precious organs. Further controlled studies are needed to assess the use of the probe in routine clinical practice.
C1 [Crane, Jeremy; Hakim, Nadey] Univ London Imperial Coll Sci Technol & Med, Kidney & Transplant Inst, Hammersmith Hosp, London, England.
RP Hakim, N (reprint author), Imperial Coll Healthcare NHS Trust, Transplant Unit, Du Cane Rd, London W12 0HS, England.
EM nadey@globalnet.co.uk
CR Baxter GM, 2001, CLIN RADIOL, V56, P802, DOI 10.1053/crad.2001.0812
   Cronin DC, 2002, TRANSPLANTATION, V74, P887, DOI 10.1097/01.TP.0000027976.23051.4A
   Kind GM, 1998, PLAST RECONSTR SURG, V101, P1274
   Kind GM, 1998, PLAST RECONSTR SURG, V101, P1268, DOI 10.1097/00006534-199804050-00016
   Lebkowska U, 2007, TRANSPL P, V39, P2727, DOI 10.1016/j.transproceed.2007.08.043
   Matas AJ, 2002, KIDNEY INT, V62, P704, DOI 10.1046/j.1523-1755.2002.00491.x
   Merz E, 2005, ULTRASCHALL MED, V26, P7, DOI 10.1055/s-2004-813948
   Oliver DW, 2005, BRIT J PLAST SURG, V58, P366, DOI 10.1016/j.bjps.2004.12.003
   Smit JM, 2009, J PLAST RECONSTR AES, V62, P1286, DOI 10.1016/j.bjps.2008.06.007
   Weist K, 2000, INFECT CONT HOSP EP, V21, P761, DOI 10.1086/501729
NR 10
TC 1
Z9 1
U1 0
U2 0
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD APR
PY 2011
VL 9
IS 2
BP 118
EP 120
PG 3
WC Transplantation
SC Transplantation
GA 776GT
UT WOS:000291523200006
PM 21453229
ER

PT J
AU Rosencrantz, R
   Cimsit, B
   Seashore, M
   Arvelakis, A
   Kulkarni, S
   Ghiroli, M
   Emre, S
AF Rosencrantz, R.
   Cimsit, B.
   Seashore, M.
   Arvelakis, A.
   Kulkarni, S.
   Ghiroli, M.
   Emre, S.
TI Pediatric Liver Transplantation for Inherited Metabolic Liver Disease: A
   Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 22nd Congress of the Spanish-Liver-Transplantation-Society (SETH)
CY OCT 29-30, 2010
CL Madrid, SPAIN
SP Spanish Liver Transplantation Soc
ID HEPATOCELLULAR-CARCINOMA; WILSONS-DISEASE; CHILDREN; OUTCOMES
AB Objective. We performed single-center outcome comparison of pediatric recipients who underwent liver transplantation for either genetic or metabolic disease including the clinical impact of using heterozygote parents as living donors.
   Materials and Methods. Pediatric liver transplant recipients from September 2007 to December 2010 were included. Patients were separated into 2 categories by etiology of liver disease: (1) genetic or metabolic liver disease (G/M) and (2) nongenetic or metabolic liver disease (non-G/M), which included all other remaining etiologies combined. Patient demographics, recipient and donor characteristics, graft type, operative data, recipient complications, allograft and patient survival were analyzed.
   Results. Forty liver transplants were performed on 40 patients; 18 were transplanted for G/M; mean waiting time was 101 days for G/M group and 57 days for non-G/M group; 9 patients were listed as status 1; 5 were granted PELD/MELD exceptions; the overall mean PELD/MELD score was 21. Four G/M patients had hepatocellular carcinoma in the explant without microvascular invasion. Overall complications requiring either surgery or interventional radiology occurred in 14 patients G/M (n = 5); CMV viremia was seen in 11 patients (G/M, n = 1); detectable EBV DNA was detectable in 8 patients (G/M, n = 4), acute cellular rejection was seen in 10 (G/M, n = 5), postransplant lymphoproliferative disease occurred in 2 G/M patients; and 1 G/M patient showed significantly improved posttransplant neurologic motor function. Children with G/M who received a living donor liver transplant from heterozygote parents did well without any signs of expressing underlying metabolic disease. Posttransplant graft and patient overall survival at 12 months for G/M and non-G/M was 100%, and at 36 months, 83% and 100%, respectively.
   Conclusion. The majority of children transplanted for either genetic or metabolic disease were status 1 or awarded UNOS exception points. Cadaveric split livers and live donors including obligate heterozygotes resulted in excellent allograft and patient survival outcomes. In metabolic and genetic liver diseases, close follow-up and timely transplantation can preclude malignant spread and prevent disease progression and consequences, as well as reverse neurologic sequelae.
C1 [Rosencrantz, R.; Cimsit, B.; Seashore, M.; Arvelakis, A.; Kulkarni, S.; Ghiroli, M.; Emre, S.] Yale Univ, Sch Med, Sect Transplantat & Immunol, Dept Surg, New Haven, CT 06520 USA.
RP Emre, S (reprint author), Yale Univ, Sch Med, Sect Transplantat & Immunol, Dept Surg, 333 Cedar St,FMB 121, New Haven, CT 06520 USA.
EM sukru.emre@yale.edu
CR Arnon R, 2010, PEDIATR TRANSPLANT, V14, P796, DOI 10.1111/j.1399-3046.2010.01339.x
   Bhadri VA, 2005, J PEDIATR GASTR NUTR, V41, P676, DOI 10.1097/01.mpg.0000179759.60048.c4
   Clayton Peter T, 2002, Semin Neonatol, V7, P49, DOI 10.1053/siny.2001.0086
   Darbari A, 2003, HEPATOLOGY, V38, P560, DOI 10.1053/jhep.2003.50375
   Dragani TA, 2010, J HEPATOL, V52, P252, DOI 10.1016/j.jhep.2009.11.015
   Emre S, 2001, LIVER TRANSPLANT, V7, P220, DOI 10.1053/jlts.2001.22455
   Hansen K, 2008, LIVER TRANSPLANT, V14, P391, DOI 10.1002/lt.21470
   Ikegami T, 2010, TRANSPL P, V42, P3624, DOI 10.1016/j.transproceed.2010.07.091
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   KAYLER I, 2003, AM J TRANSPLANT, V3, P334
   Knisely AS, 2006, HEPATOLOGY, V44, P478, DOI 10.1002/hep.21287
   Morioka D, 2005, TRANSPLANTATION, V80, P623, DOI 10.1097/01.tp.0000167995.46778.72
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Peeters PMJG, 2001, EUR J PEDIATR SURG, V11, P28, DOI 10.1055/s-2001-12188
   PRASAD A, 1997, J CHILD NEUROL, P301
   Savas N, 2006, PEDIATR TRANSPLANT, V10, P639, DOI 10.1111/j.1399-3046.2006.00562.x
   Shneider BL, 2005, LIVER TRANSPLANT, V11, P788, DOI 10.1002/lt.20401
   Sze YK, 2009, TRANSPLANTATION, V87, P87, DOI 10.1097/TP.0b013e31818bc0c4
   TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013
   Yoshitoshi EY, 2009, TRANSPLANTATION, V87, P261, DOI 10.1097/TP.0b013e3181919984
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2011
VL 43
IS 3
BP 896
EP 900
DI 10.1016/j.transproceed.2011.02.035
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 754MZ
UT WOS:000289860300053
PM 21486623
ER

PT J
AU Martin, SR
   Alvarez, F
   Anand, R
   Song, CH
   Yin, WR
AF Martin, Steven R.
   Alvarez, Fernando
   Anand, Ravinder
   Song, Changhong
   Yin, Wanrong
CA SPLIT Res Grp
TI Outcomes in Children Who Underwent Transplantation for Autoimmune
   Hepatitis
SO LIVER TRANSPLANTATION
LA English
DT Article
ID ORTHOTOPIC LIVER-TRANSPLANTATION; RECURRENCE; DISEASE; REJECTION
AB The outcomes of 113 children with autoimmune hepatitis (AIH), registered with Studies of Pediatric Liver Transplantation and who underwent transplantation between 1995 and 2006, were compared with those who underwent transplantation for other diagnoses (non-AIH). A total of 4.9% of liver transplants were for AIH; 81% of these patients had AIH type 1 and most underwent transplantation for complications of chronic disease (60%), the majority in females (72%). Transplantation for fulminant AIH was more common in males (52.5% versus 47.5% chronic; P = 0.042). Patients with AIH differed from non-AIH patients by: age (13.0 +/- 0.4 versus 4.6 +/- 0.1 years; P < 0.0001), sex (64.6% female versus 52.9%; P = 0.016), ethnicity (48.7% white versus 58.2%; P < 0.0001), initial immunosuppression (tacrolimus-based: 72.6% versus 62.6%; P = 0.045; mycophenolate mofetil use: 31.0% versus 21.6%; P = 0.02), and immunosuppression at 2 years after transplant (monotherapy: 51.9% versus 17.3%; P < 0.0001). Late (>3 months), but not steroid-resistant or chronic, rejection was more common in AIH (log-rank P = 0.0015). The 5-year posttransplant survival for AIH was 86% (95% confidence interval: 73-93). Patient and graft survival, infectious and metabolic complications, and retransplantation rates did not differ between AIH and non-AIH groups. In conclusion, the higher risk for late acute rejection and greater degree of immunosuppression does not compromise outcomes of liver transplantation for AIH. Children who undergo transplantation for AIH in North America are typically female adolescents with complications of chronic AIH type 1 and include more children of African American or Latino American origin compared to the overall liver transplant population. These observations may inform detection, treatment, and surveillance strategies designed to reduce the progression of autoimmune hepatitis and subsequently, the need for transplantation. Liver Transpl 17:393-401, 2011. (C) 2011 AASLD.
C1 [Martin, Steven R.; Alvarez, Fernando] Univ Montreal, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada.
   [Anand, Ravinder; Song, Changhong; Yin, Wanrong] EMMES Corp, Rockville, MD USA.
RP Martin, SR (reprint author), Alberta Childrens Prov Gen Hosp, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.
EM stevenr.martin@albertahealthservices.ca
FU National Institute of Diabetes and Digestive and Kidney Diseases,
   National Institutes of Health [UO1 DK061693-01A1]
FX The Studies of Pediatric Liver Transplantation (SPLIT) is sponsored by a
   grant from the National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institutes of Health (UO1 DK061693-01A1). Additional
   support is provided by Astellas Pharma US, Inc., and Genzyme.
CR Alvarez F, 2001, LIVER DIS CHILDREN, P429
   Bahar RJ, 2001, TRANSPLANTATION, V72, P829, DOI 10.1097/00007890-200109150-00015
   Cattan P, 2002, TRANSPLANT INT, V15, P34
   Gautam M, 2006, LIVER TRANSPLANT, V12, P1813, DOI 10.1002/lt.20910
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   Hayashi M, 1998, LIVER TRANSPLANT SUR, V4, P208, DOI 10.1002/lt.500040313
   MAGGIORE G, 1993, J PEDIATR GASTR NUTR, V17, P376, DOI 10.1097/00005176-199311000-00007
   Manns MP, 2001, GASTROENTEROLOGY, V120, P1502, DOI 10.1053/gast.2001.24227
   Molmenti EP, 2002, LIVER TRANSPLANT, V8, P519, DOI 10.1053/jlts.2002.32981
   Prados E, 1998, TRANSPLANTATION, V66, P1645, DOI 10.1097/00007890-199812270-00013
   Ratziu V, 1999, J HEPATOL, V30, P131, DOI 10.1016/S0168-8278(99)80017-8
   Reich DJ, 2000, HEPATOLOGY, V32, P693, DOI 10.1053/jhep.2000.16666
   Schramm C, 2010, LIVER TRANSPLANT, V16, P461, DOI 10.1002/lt.22018
   SMITH A, 2006, TRANSPLANTATION S2, V82, P981
   Sundaram SS, 2008, J PEDIATR GASTR NUTR, V47, P486, DOI 10.1097/MPG.0b013e318175d7d2
   Verma S, 2007, HEPATOLOGY, V46, P1828, DOI 10.1002/hep.21884
   Vogel A, 2004, CLIN TRANSPLANT, V18, P62, DOI 10.1111/j.1399-0012.2004.00117.x
   WRIGHT HL, 1992, TRANSPLANTATION, V53, P136, DOI 10.1097/00007890-199201000-00027
   Zeni MB, 2007, PEDIATRICS, V119, pS61, DOI 10.1542/peds.2006-0289J
NR 19
TC 6
Z9 9
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD APR
PY 2011
VL 17
IS 4
BP 393
EP 401
DI 10.1002/lt.22244
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 743FV
UT WOS:000289004000006
PM 21445922
ER

PT J
AU Haberal, M
   Karakayali, H
   Atiq, A
   Sevmis, S
   Moray, G
   Ozcay, F
   Boyvat, F
AF Haberal, M.
   Karakayali, H.
   Atiq, A.
   Sevmis, S.
   Moray, G.
   Ozcay, F.
   Boyvat, F.
TI Duct-to-Duct Biliary Reconstruction Without a Stent in Pediatric
   Living-Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 12th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY OCT 18-21, 2010
CL Tunis, TUNISIA
SP Middle E Soc Organ Transplantat (MESOT)
ID EN-Y HEPATICOJEJUNOSTOMY; COMPLICATIONS; TUBE;
   CHOLEDOCHOCHOLEDOCHOSTOMY; ANASTOMOSIS
AB Purpose. In pediatric liver transplantation, Roux-en-Y hepaticojejunostomy is often preferred for biliary reconstruction, especially in living-donor liver transplantation (LDLT). Limited numbers of duct-to-duct biliary reconstructions have been presented in pediatric recipients. We retrospectively reviewed our experiences with duct-to-duct biliary reconstruction without a stent in pediatric LDLT recipients.
   Materials and Methods. Since September 2006, 32 LDLTs were performed using a duct-to-duct biliary reconstruction without a stent in 31 children (16 boys and 15 girls; overall mean age, 8.3 +/- 5.1 years). We transplanted 19 left lobe grafts, 11 left lateral segments, 1 monosegment, and 1 reduced-size right lobe graft. Twenty-eight grafts had a single bile duct; the remaining 4, two bile ducts. We created a single orifice at the back table for the grafts that had 2 bile ducts.
   Results. Two recipients developed bile leakage in the early postoperative period; 3 bile duct stenoses occurred in the late postoperative period. All biliary complications were successfully treated with interventional radiologic or endoscopic approaches. There was no morbidity and no graft loss owing to biliary complications. During a mean follow-up of 23.5 +/- 13.6 months (range, 4-44), 4 children died and the remaining 27 (88%) are doing well with satisfactory liver function.
   Conclusion. Our results showed that duct-to-duct biliary reconstruction without a stent was a safe technique for biliary reconstruction even among pediatric cases.
C1 [Haberal, M.; Karakayali, H.; Atiq, A.; Sevmis, S.; Moray, G.] Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
   [Ozcay, F.] Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
   [Boyvat, F.] Baskent Univ, Fac Med, Dept Radiol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR BISMUTH H, 1987, TRANSPLANT P, V19, P2413
   Broelsch CE, 2003, LIVER TRANSPLANT, V9, pS50, DOI 10.1053/jlts.2003.50218
   EVANS RA, 1990, CLIN RADIOL, V41, P190, DOI 10.1016/S0009-9260(05)80966-3
   HABERAL M, 2009, THERAPY, V6, P727, DOI 10.2217/thy.09.36
   Haberal M, 2008, TRANSPL P, V40, P240, DOI 10.1016/j.transproceed.2007.11.069
   Haberal M, 2007, TRANSPL P, V39, P1161, DOI 10.1016/j.transproceed.2007.02.046
   Haberal M, 2007, EXP CLIN TRANSPLANT, V5, P585
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kimura T, 2006, PEDIATR TRANSPLANT, V10, P248, DOI 10.1111/j.1399-3046.2005.00430.x
   LERUT J, 1987, TRANSPLANTATION, V43, P47, DOI 10.1097/00007890-198701000-00011
   Liu CS, 2009, PEDIATR TRANSPLANT, V13, P693, DOI 10.1111/j.1399-3046.2008.01040.x
   Nuno J, 1997, TRANSPLANT P, V29, P564, DOI 10.1016/S0041-1345(96)00268-0
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   ROLLES K, 1994, TRANSPLANTATION, V57, P402, DOI 10.1097/00007890-199402150-00015
   Sakamoto S, 2008, PEDIATR TRANSPLANT, V12, P661, DOI 10.1111/j.1399-3046.2007.00870.x
   Scatton O, 2001, ANN SURG, V233, P432, DOI 10.1097/00000658-200103000-00019
   Shirouzu Y, 2008, LIVER TRANSPLANT, V14, P1761, DOI 10.1002/lt.21599
   STARZL TE, 1982, HEPATOLOGY, V2, P614
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   Tanaka H, 2010, J PEDIATR SURG, V45, P1668, DOI 10.1016/j.jpedsurg.2010.03.010
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Vallera R A, 1995, Liver Transpl Surg, V1, P143, DOI 10.1002/lt.500010302
NR 23
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2011
VL 43
IS 2
BP 595
EP 597
DI 10.1016/j.transproceed.2011.01.009
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 743OP
UT WOS:000289028200057
PM 21440772
ER

PT J
AU Karakayali, H
   Sevmis, S
   Boyvat, F
   Aktas, S
   Ozcay, F
   Moray, G
   Arslan, G
   Haberal, M
AF Karakayali, H.
   Sevmis, S.
   Boyvat, F.
   Aktas, S.
   Ozcay, F.
   Moray, G.
   Arslan, G.
   Haberal, M.
TI Diagnosis and Treatment of Late-Onset Portal Vein Stenosis After
   Pediatric Living-Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 12th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY OCT 18-21, 2010
CL Tunis, TUNISIA
SP Middle E Soc Organ Transplantat (MESOT)
ID VENOUS COMPLICATIONS; ANGIOPLASTY; EXPERIENCE; CHILDREN
AB Purpose. Portal vein stenosis is a relatively rare complication after living-donor liver transplantation, which sometimes leads to a life-threatening event owing to gastrointestinal bleeding or graft failure. This study sought to evaluate the diagnoses and management of late-onset portal vein stenosis in pediatric living-donor liver transplants.
   Materials and Methods. Since September 2001, we performed 123 living-donor liver transplant procedures in 120 children, among which 109 children with a functioning graft at 6 months after living-donor liver transplant are included in this analysis. Seven instances of portal vein stenosis were diagnosed and were analyzed retrospectively.
   Results. The median age of the children was 5.3 years, and the median body weight was 19.2 kg. Portal vein stenosis was diagnosed at 11.2 +/- 3.1 months after living-donor liver transplantation. Whereas 3 children were asymptomatic, splenomegaly and/or massive ascites were observed in the remaining 4. Additionally, platelet counts were below the normal limit in 4 children. All children were treated with transhepatic balloon dilatation except 1. Intraluminal stent placement was needed in 1 child owing to resistance of balloon dilatation. The mean pressure gradient decreased from 12.4 to 3.2 mmHg after successful treatment. We did not observe any treatment-related complications. Portal venous patency was maintained in all children during posttreatment follow-up of 43.2 +/- 20.4 months. There were no recurrences of portal vein stenosis. One child died; the remaining 6 children are alive with good graft function at 49.8 +/- 23.9 months of follow-up.
   Conclusion. Although most portal vein stenosis is asymptomatic, splenomegaly and platelet counts are 2 important markers for portal vein stenosis. Early detection of portal vein stenosis with these 2 markers can lead to successful interventional percutaneous approaches and avoid graft loss.
C1 [Karakayali, H.; Sevmis, S.; Aktas, S.; Moray, G.; Haberal, M.] Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
   [Boyvat, F.] Baskent Univ, Fac Med, Dept Radiol, TR-06490 Ankara, Turkey.
   [Ozcay, F.] Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
   [Arslan, G.] Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   Funaki B, 2000, RADIOLOGY, V215, P147
   Hotta R, 2007, PEDIATR SURG INT, V23, P939, DOI 10.1007/s00383-007-1974-y
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Kawano Y, 2009, TRANSPL INT, V22, P1151, DOI 10.1111/j.1432-2277.2009.00932.x
   MARUJO WC, 1991, TRANSPLANT P, V23, P1484
   Park KB, 2005, KOREAN J RADIOL, V6, P161
   Prabhakaran K, 2005, PEDIATR SURG INT, V21, P609, DOI 10.1007/s00383-005-1482-x
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   Shibata T, 2005, RADIOLOGY, V235, P1078, DOI 10.1148/radiol.2353040489
   STARZL TE, 1982, HEPATOLOGY, V2, P614
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Woo David H, 2007, Tech Vasc Interv Radiol, V10, P233, DOI 10.1053/j.tvir.2007.09.017
NR 17
TC 7
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2011
VL 43
IS 2
BP 601
EP 604
DI 10.1016/j.transproceed.2011.01.010
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 743OP
UT WOS:000289028200059
PM 21440774
ER

PT J
AU Sevmis, S
   Karakayali, H
   Tutar, NU
   Boyvat, F
   Ozcay, F
   Torgay, A
   Haberal, M
AF Sevmis, S.
   Karakayali, H.
   Tutar, N. U.
   Boyvat, F.
   Ozcay, F.
   Torgay, A.
   Haberal, M.
TI Management of Early Hepatic Arterial Thrombosis After Pediatric
   Living-Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 12th Congress of the Middle-East-Society-for-Organ-Transplantation
   (MESOT)
CY OCT 18-21, 2010
CL Tunis, TUNISIA
SP Middle E Soc Organ Transplantat (MESOT)
ID URGENT REVASCULARIZATION; COMPLICATIONS; RECONSTRUCTION; THROMBOLYSIS;
   STENOSIS
AB Purpose. Early hepatic arterial thrombosis after living-donor liver transplantation is a cause of graft loss and patient mortality. We analyzed early hepatic arterial thrombosis after pediatric living-donor liver transplantation.
   Materials and Methods. Since September 2001, we performed 122 living-donor liver transplants on 119 children. Ten hepatic arterial thromboses developed in the early postoperative period. The 7 male and 4 female patients of overall mean age of 6.3 +/- 6.1 years underwent 5 left lateral segment, 3 right lobe, and 2 left lobe transplantations.
   Results. Among 10 children with hepatic arterial thrombosis, 8 diagnoses were made before any elevation of liver function tests. One child displayed fever at the time of the hepatic arterial thrombosis. The median time for diagnosis was 5 days. Hepatic arterial thrombosis was treated with interventional radiologic techniques in 9 children, with 1 undergoing surgical exploration owing to failed radiologic approaches, and a reanastomosis using a polytetrafluoroethylene graft. Successful revascularization was achieved in all children, except 1. Four children died, the remaining 6 are alive with good graft function. During the mean follow-up of 52.7 +/- 18.8 months, multiple intrahepatic biliary stenoses were identified in 1 child.
   Conclusion. Routine Doppler ultrasonography is effective for the early diagnosis of hepatic arterial thrombosis. Interventional radiologic approaches such as arterial thrombolysis and intraluminal stent placement should be the first therapeutic choices for patients with early hepatic arterial thrombosis; if radiologic methods fail, one must consider surgical exploration or retransplantation.
C1 [Sevmis, S.; Karakayali, H.; Haberal, M.] Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
   [Tutar, N. U.; Boyvat, F.] Baskent Univ, Fac Med, Dept Radiol, TR-06490 Ankara, Turkey.
   [Ozcay, F.] Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
   [Torgay, A.] Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Bjerkvik S, 1995, Transplantation, V59, P1746
   Boyvat F, 2003, TRANSPLANT P, V35, P2791, DOI 10.1016/j.transproceed.2003.09.086
   Cotroneo AR, 2002, J VASC INTERV RADIOL, V13, P619, DOI 10.1016/S1051-0443(07)61657-1
   Drazan K, 1996, AM SURGEON, V62, P237
   FIGUERAS J, 1995, TRANSPLANTATION, V59, P1356
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   Griffith JF, 1996, PEDIATR RADIOL, V26, P388, DOI 10.1007/BF01387311
   Haberal M, 2007, EXP CLIN TRANSPLANT, V5, P585
   Haberal M, 2008, EXP CLIN TRANSPLANT, V6, P7
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Kim BW, 2006, TRANSPLANT P, V38, P3128, DOI 10.1016/j.transproceed.2006.08.164
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   Massault PP, 1997, TRANSPLANT P, V29, P439, DOI 10.1016/S0041-1345(96)00178-9
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Saad Wael E A, 2007, Vasc Endovascular Surg, V41, P19, DOI 10.1177/1538574406296210
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   Zhou J, 2005, TRANSPLANT P, V37, P4426, DOI 10.1016/j.transproceed.2005.10.113
NR 22
TC 10
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2011
VL 43
IS 2
BP 605
EP 608
DI 10.1016/j.transproceed.2011.01.011
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 743OP
UT WOS:000289028200060
PM 21440775
ER

PT J
AU Chihara, Y
   Egawa, H
   Tsuboi, T
   Oga, T
   Handa, T
   Yamamoto, K
   Mishima, M
   Tanaka, K
   Uemoto, S
   Chin, K
AF Chihara, Yuichi
   Egawa, Hiroto
   Tsuboi, Tomomasa
   Oga, Toru
   Handa, Tomohiro
   Yamamoto, Kazuhiko
   Mishima, Michiaki
   Tanaka, Koichi
   Uemoto, Shinji
   Chin, Kazuo
TI Immediate Noninvasive Ventilation May Improve Mortality in Patients With
   Hepatopulmonary Syndrome After Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID RESPIRATORY-FAILURE
AB Hepatopulmonary syndrome (HPS) is defined as hypoxemia induced by intrapulmonary vascular dilations associated with liver disease. Although liver transplantation (LT) is the only effective therapy established for severe HPS, patients with a partial pressure of arterial oxygen (PaO(2)) less than 60 mm Hg have a poor prognosis. We treated a 4-year-old boy with HPS whose preoperative PaO(2) level was 48.8 mm Hg. After LT, he had persistent severe hypoxemia, although he was receiving high-flow oxygen. Noninvasive ventilation (NIV) was introduced, and his respiratory insufficiency promptly improved. Therefore, NIV therapy immediately after extubation following transplantation was administered to the next 4 consecutive HPS patients whose preoperative PaO(2) was less than 60 mm Hg. The NIV treatment of these 5 patients could have been responsible for preventing severe postoperative complications as well as reintubation and hospital death. NIV therapy for both pediatric and adult patients with severe HPS immediately after extubation might protect them from severe hypoxemia after transplantation and from complications necessitating reintubation and might improve their prognosis. Liver Transpl 17:144-148, 2011. (C) 2011 AASLD.
C1 [Chihara, Yuichi; Mishima, Michiaki] Kyoto Univ Hosp, Dept Resp Med, Kyoto 606, Japan.
   [Handa, Tomohiro] Kyoto Univ Hosp, Dept Rehabil, Kyoto 606, Japan.
   [Uemoto, Shinji] Kyoto Univ Hosp, Dept Transplant Surg, Kyoto 606, Japan.
   [Egawa, Hiroto] Asahi Univ, Murakami Mem Hosp, Dept Surg, Gifu, Japan.
   [Tsuboi, Tomomasa; Oga, Toru; Chin, Kazuo] Kyoto Univ, Grad Sch Med, Dept Resp Care & Sleep Control Med, Kyoto, Japan.
   [Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy, Tokyo, Japan.
   [Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan.
   [Tanaka, Koichi] Fdn Biomed Res & Innovat, Kobe, Hyogo, Japan.
RP Chin, K (reprint author), Kyoto Univ, Kyoto Univ Hosp, Grad Sch Med, Dept Resp Care & Sleep Control Med,Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM chink@kuhp.kyoto-u.ac.jp
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology
   [20590921, 22590860]; Respiratory Failure Research Group; Japanese
   Ministry of Health, Labor, and Welfare; Japan Vascular Disease Research
   Foundation
FX This work was supported by grants from the Japanese Ministry of
   Education, Culture, Sports, Science, and Technology (20590921 and
   22590860); by the Respiratory Failure Research Group; by health sciences
   research grants (Comprehensive Research on Life-Style Related Diseases
   Including Cardiovascular Diseases and Diabetes Mellitus) from the
   Japanese Ministry of Health, Labor, and Welfare; and by the Japan
   Vascular Disease Research Foundation.
CR Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235
   Antonelli M, 2008, CRIT CARE, V12, DOI 10.1186/cc6853
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   Feltracco P, 2008, TRANSPL P, V40, P1979, DOI 10.1016/j.transproceed.2008.05.006
   Nava S, 2005, CRIT CARE MED, V33, P2465, DOI 10.1097/01.CCM.0000186416.44752.72
   Palma DT, 2008, HEPATOLOGY, V47, P1257, DOI 10.1002/hep.22143
   Rodriguez-Roisin R, 2004, EUR RESPIR J, V24, P861, DOI 10.1183/09031936.04.00010904
   Rodriguez-Roisin R, 2008, NEW ENGL J MED, V358, P2378, DOI 10.1056/NEJMra0707185
   RODRIGUEZROISIN R, 1987, AM REV RESPIR DIS, V135, P1085
   SHAPIRO BA, 1985, CLIN APPL RESP CARE, P180
   Swanson KL, 2005, HEPATOLOGY, V41, P1122, DOI 10.1002/hep.20658
   Uemoto S, 1997, TRANSPLANTATION, V63, P407, DOI 10.1097/00007890-199702150-00014
NR 12
TC 9
Z9 9
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2011
VL 17
IS 2
BP 144
EP 148
DI 10.1002/lt.22207
PG 5
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 716YU
UT WOS:000287010200008
PM 21280187
ER

PT J
AU Gotoh, K
   Ito, Y
   Suzuki, E
   Kaneko, K
   Kiuchi, T
   Ando, H
   Kimura, H
AF Gotoh, Kensei
   Ito, Yoshinori
   Suzuki, Eitaro
   Kaneko, Kenitiro
   Kiuchi, Tetsuya
   Ando, Hisami
   Kimura, Hiroshi
TI Effectiveness and safety of inactivated influenza vaccination in
   pediatric liver transplant recipients over three influenza seasons
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE influenza vaccination; liver transplantation; immunogenicity; children
ID IMMUNE-RESPONSE
AB Annual influenza vaccination is recommended for pediatric liver transplant recipients, who are at high risk of influenza-related complications. However, effectiveness and safety of vaccination may differ among influenza seasons in this population and have not been fully evaluated. Subjects comprised 38 pediatric liver transplant recipients with or without influenza vaccination through the 2006-2007, 2007-2008 and 2008-2009 influenza seasons. Recipients received inactivated trivalent (AH1/AH3/B) influenza vaccine, and comparisons were made to non-vaccinated recipients with regard to effectiveness and safety. No significant differences were seen between recipient groups for acute allograft rejection, acute febrile illness, or influenza virus infection. No serious systemic adverse events were observed in vaccinated recipients. Seroprotection rate (defined as the proportion of recipients with HI antibody titer >= 1:40), seroconversion rate (proportion of recipients with a >= 4-fold increase in HI titers), and geometric mean titers were mostly elevated after vaccination for the three influenza antigens in each season. These three indicators of immunogenicity showed similar results in both vaccinated recipients and vaccinated healthy children in the 2007-2008 season. These findings suggest that pediatric liver transplant patients may respond safely to inactivated seasonal influenza vaccines in a similar manner to healthy children, and effectiveness varies among influenza seasons.
C1 [Gotoh, Kensei; Ito, Yoshinori] Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Suzuki, Eitaro] Suzuki Pediat Clin, Ube, Yamaguchi, Japan.
   [Kaneko, Kenitiro; Ando, Hisami] Nagoya Univ, Grad Sch Med, Dept Pediat Surg, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Kiuchi, Tetsuya] Nagoya Univ, Grad Sch Med, Dept Transplant Surg, Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Kimura, Hiroshi] Nagoya Univ, Grad Sch Med, Dept Virol, Showa Ku, Nagoya, Aichi 4668550, Japan.
RP Ito, Y (reprint author), Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM yoshi-i@med.nagoya-u.ac.jp
RI Kimura, Hiroshi/I-2246-2012
FU Japan Society for the Promotion of Science [20591276]; Ministry of
   Health, Labor, and Welfare of Japan [H21-Shinko-Ippan-094]
FX This study was supported by a grant from the Japan Society for the
   Promotion of Science (Grants-in-Aid for Scientific Research [C]
   [20591276] to Y.I.), and a grant from the Ministry of Health, Labor, and
   Welfare of Japan for research on measures for emerging and reemerging
   infections ([H21-Shinko-Ippan-094] to H.K.).
CR APALSCH AM, 1995, CLIN INFECT DIS, V20, P394
   Burbach G, 1999, TRANSPLANTATION, V67, P753, DOI 10.1097/00007890-199903150-00019
   Duchini A, 2001, LIVER TRANSPLANT, V7, P311, DOI 10.1053/jlts.2001.23010
   Gaeta GB, 2009, VACCINE, V27, P3373, DOI 10.1016/j.vaccine.2009.01.077
   Mack D R, 1996, Liver Transpl Surg, V2, P431, DOI 10.1002/lt.500020605
   Madan RP, 2008, CLIN INFECT DIS, V46, P712, DOI 10.1086/527391
   MAUCH TJ, 1994, PEDIATRICS, V94, P225
   PICKERING LK, 2009, RED BOOK 2009 REPORT, P378
   Soesman NMR, 2000, J MED VIROL, V61, P85, DOI 10.1002/(SICI)1096-9071(200005)61:1<85::AID-JMV14>3.0.CO;2-H
   Vilchez R A, 2002, Transpl Infect Dis, V4, P177, DOI 10.1034/j.1399-3062.2002.t01-4-02001.x
NR 10
TC 11
Z9 11
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2011
VL 15
IS 1
BP 112
EP 116
DI 10.1111/j.1399-3046.2010.01420.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 707ZF
UT WOS:000286329400024
PM 21108713
ER

PT J
AU Kivela, JM
   Raisanen-Sokolowski, A
   Pakarinen, MP
   Makisalo, H
   Jalanko, H
   Holmberg, C
   Lauronen, J
AF Kivela, Jesper M.
   Raisanen-Sokolowski, Anne
   Pakarinen, Mikko P.
   Makisalo, Heikki
   Jalanko, Hannu
   Holmberg, Christer
   Lauronen, Jouni
TI Long-Term Renal Function in Children After Liver Transplantation
SO TRANSPLANTATION
LA English
DT Article
DE Liver transplantation; Glomerular filtration rate; Pediatric; Renal
   function
ID GLOMERULAR-FILTRATION-RATE; PLASMA CREATININE CONCENTRATION; FOLLOW-UP;
   RECIPIENTS; DYSFUNCTION; DISEASE; KIDNEY; ADOLESCENTS; SURVIVORS;
   FAILURE
AB Background. Reduced renal function after liver transplantation (LT) is a long-term extrahepatic complication of major concern caused at least partly by calcineurin inhibitor nephrotoxicity. We report on long-term renal function after LT in children from a single center and analyze the usefulness of glomerular filtration rate (GFR) estimation methods in the follow-up of pediatric LT patients.
   Methods. Fifty-seven pediatric patients were included. GFRs were measured by 51-labeled chromium ethylenediaminetetraacetic acid clearance before LT, at discharge, 6, 12, 18, and 24 months after transplantation and annually thereafter and corrected with the modified Brochner-Mortensen equation. GFR values of cases with an ethylenediaminetetraacetic acid distribution volume less than 15% or more than 35% were excluded.
   Results. The mean GFR for overall follow-up was 76.0 mL/min/1.73 m(2) (+/-22.2 mL/min/1.73 m2). The GFR declined significantly from 5 to 7 years (80.2 [+/-17.7] to 72.9 [+/-13.3] mL/min/1.73 m(2), respectively; P<0.05). Thirteen percent, 21%, 31%, and 33% of patients had stage 3 chronic kidney disease at 5, 7, 10, and 15 years after LT, respectively. The cyclosporine A trough level was a significant time-dependent factor in the regression model, and after time was removed from the model, proteinuria was the most significant factor. GFR estimation methods overestimated measured GFR; 11% with updated Schwartz, 50% with Schwartz 1987, and 31% with Counahan-Barratt.
   Conclusions. This study underlines the importance of long-term renal function surveillance after LT performed on children. Although measuring GFR remains the preferred function surveillance method, the updated Schwartz formula is also acceptable.
C1 [Lauronen, Jouni] Univ Helsinki, Biomedicum Helsinki, Hosp Children & Adolescents, Helsinki 00029, Finland.
   [Kivela, Jesper M.; Jalanko, Hannu; Holmberg, Christer; Lauronen, Jouni] Univ Helsinki, Cent Hosp, Dept Pediat Nephrol & Transplantat, Hosp Children & Adolescents, Helsinki 00029, Finland.
   [Raisanen-Sokolowski, Anne] Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki 00029, Finland.
   [Pakarinen, Mikko P.] Univ Helsinki, Cent Hosp, Dept Pediat Surg, Hosp Children & Adolescents, Helsinki 00029, Finland.
   [Makisalo, Heikki] Univ Helsinki, Cent Hosp, Dept Transplantat & Liver Surg, Helsinki 00029, Finland.
RP Lauronen, J (reprint author), Univ Helsinki, Biomedicum Helsinki, Hosp Children & Adolescents, Haartmaninkatu 8,P Floor,Room CP28A, Helsinki 00029, Finland.
EM jouni.lauronen@helsinki.fi
CR Aberg F, 2007, TRANSPL INT, V20, P591, DOI 10.1111/j.1432-2277.2007.00482.x
   Avitzur Y, 2004, TRANSPLANTATION, V78, P566, DOI 10.1097/01.TP.0000131663.87106.1A
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Charlton M, 2009, LIVER TRANSPLANT, V15, pS83, DOI 10.1002/lt.21914
   CHIN SE, 1992, PEDIATR NEPHROL, V6, P407
   COHEN AJ, 2002, LIVER TRANSPLANT, V8, P922
   COUNAHAN R, 1976, ARCH DIS CHILD, V51, P875
   Dubourg L, 2002, KIDNEY INT, V62, P1454, DOI 10.1046/j.1523-1755.2002.00576.x
   Fleming JS, 2004, NUCL MED COMMUN, V25, P759, DOI 10.1097/mnm.0000136715.71820.4a
   Harambat J, 2008, TRANSPLANTATION, V86, P1028, DOI 10.1097/TP.0b013e318187748f
   HAYCOCK GB, 1978, J PEDIATR-US, V93, P62, DOI 10.1016/S0022-3476(78)80601-5
   Herlenius G, 2010, PEDIATR TRANSPLANT, V14, P409, DOI 10.1111/j.1399-3046.2010.01301.x
   Herzog D, 2006, TRANSPLANTATION, V81, P672, DOI 10.1097/01.tp.0000185194.62108.a7
   Iseki K, 2003, KIDNEY INT, V63, P1468, DOI 10.1046/j.1523-1755.2003.00868.x
   Kelly D, 2004, LANCET, V364, P1054, DOI 10.1016/S0140-6736(04)17060-8
   Kim JY, 2010, TRANSPLANTATION, V89, P215, DOI 10.1097/TP.0b013e3181c353e5
   LAINE J, 1994, J PEDIATR-US, V125, P863, DOI 10.1016/S0022-3476(05)82000-1
   MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018
   Mention K, 2005, PEDIATR TRANSPLANT, V9, P201, DOI 10.1111/j.1399-3046.2005.00289.x
   National Kidney Foundation, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   NICKELEIT V, 2009, TRANSPLANTATION PATH, P73
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Pham PTT, 2009, CURR OPIN ORGAN TRAN, V14, P231, DOI 10.1097/MOT.0b013e32832b34a4
   Sanchez EQ, 2010, TRANSPLANTATION, V89, P232, DOI 10.1097/TP.0b013e3181c42ff9
   Schwartz GJ, 2009, J AM SOC NEPHROL, V20, P629, DOI 10.1681/ASN.2008030287
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   Seikaly MG, 1996, PEDIATR NEPHROL, V10, P709
   Siirtola A, 2006, TRANSPLANTATION, V81, P327, DOI 10.1097/01.tp.0000189173.46727.18
   Valta H, 2008, AM J TRANSPLANT, V8, P150, DOI 10.1111/j.1600-6143.2007.02015.x
NR 32
TC 22
Z9 22
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD JAN 15
PY 2011
VL 91
IS 1
BP 115
EP 120
DI 10.1097/TP.0b013e3181fa94b9
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 700CI
UT WOS:000285709700018
PM 21452415
ER

PT J
AU Broniszczak, D
   Apanasiewicz, A
   Czubkowski, P
   Kalicinski, P
   Ismail, H
   Ostoja-Chyzynska, A
   Markiewicz-Kijewska, M
AF Broniszczak, Dorota
   Apanasiewicz, Artur
   Czubkowski, Piotr
   Kalicinski, Piotr
   Ismail, Hor
   Ostoja-Chyzynska, Anna
   Markiewicz-Kijewska, Malgorzata
TI Liver transplantation in children with biliary atresia and polysplenia
   syndrome
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE liver transplantation; biliary atresia; polysplenia syndrome
ID SPLENIC MALFORMATION SYNDROME
AB Background: Children with biliary atresia and polysplenia syndrome (BA-PS) have always been considered as high risk liver transplant recipients due to technical problems during transplant surgery. We report single-center experience with liver transplantation in children with this syndrome.
   Material/Methods: Between 2000 and 2010, 401 liver transplantations were performed in 358 children, including 6 patients with BA-PS, who underwent living (5 patients) or deceased (1 patient) donor liver transplantation. Patients demonstrated various malformations: absence of retrohepatic vena cava (3), intestinal malrotation (3), preduodenal portal vein (1), hepatic artery anomalies (3), cardiac anomalies (2), and situs inversus (1). Transplantations were performed at the patient age of 8 months to 11 years.
   Results: There were no serious technical problems during the operations, and we did not have to use vascular conduits for graft revascularization in any case. All patents were alive at follow-up between 14 and 123 months after transplantation (mean 75 months). We observed, however, increased incidence of PV thrombosis and biliary complications in these patients, which did not influence patient and graft survival. In 1 child with graft failure due to chronic rejection after discontinuation of immunosuppression due to PTLD, retransplantation was performed.
   Conclusions: Results of liver transplantation in children with BA-PS are as good as for other indications and non-syndromic BA in an experienced pediatric liver transplant center. Although there were no serious technical problems during deceased or living related donor transplantation in these children, close observation for possible vascular complications should be the routine in the postoperative period.
C1 [Broniszczak, Dorota; Apanasiewicz, Artur; Kalicinski, Piotr; Ismail, Hor; Ostoja-Chyzynska, Anna; Markiewicz-Kijewska, Malgorzata] Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, Warsaw, Poland.
   [Czubkowski, Piotr] Childrens Mem Hlth Inst, Dept Gastroenterol, Warsaw, Poland.
RP Broniszczak, D (reprint author), Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, Dzieci Polskich 20 Str, Warsaw, Poland.
EM dorbro1@poczta.onet.pl
CR DAVENPORT M, 1993, SURGERY, V113, P662
   Davenport M, 2006, J PEDIATR-US, V149, P393, DOI 10.1016/j.jpeds.2006.05.030
   HOFFMAN MA, 1989, J PEDIATR SURG, V24, P1020, DOI 10.1016/S0022-3468(89)80206-4
   LILLY JR, 1974, J PEDIATR SURG, V9, P707, DOI 10.1016/0022-3468(74)90109-2
   Mattei P, 1998, PEDIATR SURG INT, V14, P104, DOI 10.1007/s003830050452
   Varela-Fascinetto G, 1998, ANN SURG, V227, P583, DOI 10.1097/00000658-199804000-00022
   VAZQUEZ J, 1995, J PEDIATR SURG, V30, P485, DOI 10.1016/0022-3468(95)90062-4
NR 7
TC 2
Z9 4
U1 0
U2 1
PU INDEX COPERNICUS INT
PI WARSAW
PA AL JEROZOLIMSKIE 146 C STR, WARSAW, 02-305, POLAND
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD JAN-MAR
PY 2011
VL 16
IS 1
BP 14
EP 17
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 762VI
UT WOS:000290509200002
PM 21436769
ER

PT J
AU Sanada, Y
   Mizuta, K
   Yano, T
   Hatanaka, W
   Okada, N
   Wakiya, T
   Umehara, M
   Egami, S
   Urahashi, T
   Hishikawa, S
   Fujiwara, T
   Sakuma, Y
   Hyodo, M
   Yamamoto, H
   Yasuda, Y
   Kawarasaki, H
AF Sanada, Yukihiro
   Mizuta, Koichi
   Yano, Tomonori
   Hatanaka, Wataru
   Okada, Noriki
   Wakiya, Taiichi
   Umehara, Minoru
   Egami, Satoshi
   Urahashi, Taizen
   Hishikawa, Shuji
   Fujiwara, Takehito
   Sakuma, Yasunaru
   Hyodo, Masanobu
   Yamamoto, Hironori
   Yasuda, Yoshikazu
   Kawarasaki, Hideo
TI Double-balloon enteroscopy for bilioenteric anastomotic stricture after
   pediatric living donor liver transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE bilioenteric anastomotic stricture; double-balloon enteroscopy;
   hepaticojejunostomy; interventional radiology; pediatric living donor
   liver transplantation
ID EN-Y ANASTOMOSIS; BILIARY COMPLICATIONS; CHOLEDOCHOJEJUNOSTOMY;
   RECONSTRUCTION; MANAGEMENT; ERCP
AB P>Bilioenteric anastomotic stricture after liver transplantation is still frequent and early detection and treatment is important. We established the management using double-balloon enteroscopy (DBE) and evaluated the intractability for bilioenteric anastomotic stricture after pediatric living donor liver transplantation (LDLT). We underwent DBE at Jichi Medical University from May 2003 to July 2009 for 25 patients who developed bilioenteric anastomotic stricture after pediatric LDLT. The patients were divided into two types according to the degree of dilatation of the anastomotic sites before and after interventional radiology (IVR) using DBE. Type I is an anastomotic site macroscopically dilated to five times or more, and Type II is an anastomotic site dilated to less than five times. The rate of DBE reaching the bilioenteric anastomotic sites was 68.0% (17/25), and the success rate of IVR was 88.2% (15/17). There were three cases of Type I and 12 cases of Type II. Type II had a significantly longer cold ischemic time and higher recurrence rate than Type I (P = 0.005 and P = 0.006). In conclusion, DBE is a less invasive and safe treatment method that is capable of reaching the bilioenteric anastomotic site after pediatric LDLT and enables IVR to be performed on strictures, and its treatment outcomes are improving. Type II and long cold ischemic time are risk factors for intractable bilioenteric anastomotic stricture.
C1 [Sanada, Yukihiro; Mizuta, Koichi; Okada, Noriki; Wakiya, Taiichi; Umehara, Minoru; Egami, Satoshi; Urahashi, Taizen; Hishikawa, Shuji; Kawarasaki, Hideo] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Yano, Tomonori; Hatanaka, Wataru; Yamamoto, Hironori] Jichi Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Shimotsuke, Tochigi 3290498, Japan.
   [Fujiwara, Takehito; Sakuma, Yasunaru; Hyodo, Masanobu; Yasuda, Yoshikazu] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
RP Sanada, Y (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM yuki371@jichi.ac.jp
CR Chahal P, 2007, LIVER TRANSPLANT, V13, P1168, DOI 10.1002/lt.21198
   COLONNA JO, 1992, ANN SURG, V216, P344
   Davidson BR, 2000, LIVER TRANSPLANT, V6, P201, DOI 10.1016/S1527-6465(00)80012-X
   Haruta H, 2005, LIVER TRANSPLANT, V11, P1608, DOI 10.1002/lt.20623
   Kawano Y, 2008, LIVER TRANSPLANT, V14, P385, DOI 10.1002/lt.21357
   Koornstra JJ, 2008, NETH J MED, V66, P275
   Kuno A, 2004, GASTROINTEST ENDOSC, V60, P1032, DOI 10.1016/S0016-5107(04)02191-1
   Mita A, 2008, TRANSPL INT, V21, P320, DOI 10.1111/j.1432-2277.2007.00609.x
   Monkemuller K, 2009, SURG ENDOSC, V23, P1961, DOI 10.1007/s00464-008-0239-8
   Nishimura N, 2010, GASTROINTEST ENDOSC, V71, P287, DOI 10.1016/j.gie.2009.08.010
   Rerknimitr R, 2002, GASTROINTEST ENDOSC, V55, P224, DOI 10.1067/mge.2002.120813
   Ryozawa S, 2009, J HEPATO-BILIARY-PAN, V16, P613, DOI 10.1007/s00534-009-0132-4
   Todo S, 2005, J HEPATOL, V43, P22, DOI 10.1016/j.jhep.2005.05.004
   Williams ED, 2009, WORLD J GASTROENTERO, V15, P3725, DOI 10.3748/wjg.15.3725
   Yamamoto H, 2001, GASTROINTEST ENDOSC, V53, P216, DOI 10.1067/mge.2001.112181
NR 15
TC 11
Z9 12
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD JAN
PY 2011
VL 24
IS 1
BP 85
EP 90
DI 10.1111/j.1432-2277.2010.01156.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 689DH
UT WOS:000284907000016
PM 20738835
ER

PT J
AU Tannuri, ACA
   Gibelli, NEM
   Ricardi, LRS
   Santos, MM
   Maksoud, JG
   Pinho-Apezzato, ML
   Silva, MM
   Velhote, MCP
   Ayoub, AAR
   Andrade, WC
   Leal, AJ
   Miyatani, HT
   Tannuri, U
AF Tannuri, A. C. A.
   Gibelli, N. E. M.
   Ricardi, L. R. S.
   Santos, M. M.
   Maksoud-Filho, J. G.
   Pinho-Apezzato, M. L.
   Silva, M. M.
   Velhote, M. C. P.
   Ayoub, A. A. R.
   Andrade, W. C.
   Leal, A. J.
   Miyatani, H. T.
   Tannuri, U.
TI Living Related Donor Liver Transplantation in Children
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Luso Brazilian Congress of Transplant
CY OCT 02-05, 2010
CL Porto, PORTUGAL
ID BILIARY COMPLICATIONS; HEPATIC-ARTERY; RECONSTRUCTION; EXPERIENCE;
   THROMBOSIS
AB Objective. The objective of this study was to report our experience with pediatric orthotopic liver transplantation (OLT) with living related donors.
   Methods. We performed a retrospective chart analysis of 121 living related donor liver transplantations (LRDLT) from June 1998 to June 2010.
   Results. Indications were biliary atresia (BA; n = 81), primary sclerosing cholangitis (n = 5), alpha-1 antitrypsin deficiency (n = 4); cholestasis (n = 9), fulminant hepatic failure (n = 8), autoimmune hepatitis (n = 2), Alagille syndrome (n = 4), hepatoblastoma (n = 3), tyrosinemia (n = 2), and congenital hepatic fibrosis (n = 3). The age of the recipients ranged from 7-174 months (median, 22) and the weights ranged from 6-58 kg (median, 10). Forty-nine children (40.5%) weighed <= 10 kg. The grafts included the left lateral segment (n = 108), the left lobe (n = 12), and the right lobe (n = 1). The donors included 71 mothers, 45 fathers, 2 uncles, 1 grandmother, 1 grandfather, and 1 sister with a median age of 29 years (range, 16-53 ys) and a median weight of 68 kg (range, 47-106). Sixteen patients (12.9%) required retransplantation, most commonly due to hepatic artery thrombosis (HAT; n = 13; 10.7%). The other complications were biliary stenosis (n = 25; 20.6%), portal vein thrombosis (PVT; n = 11; 9.1%), portal vein stenosis (n = 5; 4.1%), hepatic vein stenosis (n = 6; 4.9%), and lymphoproliferative disorders (n = 8; 6.6%). The ultimate survival rate of recipients was 90.3% after 1 year and 75.8% after 3 years. Causes of early death within 1 month were HAT (n = 6), PVT (n = 2), severe graft dysfunction (n = 1), sepsis (n = 1), and intraoperative death in children with acute liver failure (n = 2). Causes of late deaths included lymphoproliferative disease (n = 3), chronic rejection (n = 2), biliary complications (n = 3), and recurrent disease (n = 3; hepatoblastoma and primary sclerosing cholangitis).
   Conclusions. Despite the heightened possibility of complications (mainly vascular), LRDLT represented a good alternative to transplantation from cadaveric donors in pediatric populations. It was associated with a high survival ratio.
C1 [Tannuri, A. C. A.; Gibelli, N. E. M.; Ricardi, L. R. S.; Santos, M. M.; Maksoud-Filho, J. G.; Pinho-Apezzato, M. L.; Silva, M. M.; Velhote, M. C. P.; Ayoub, A. A. R.; Andrade, W. C.; Leal, A. J.; Miyatani, H. T.; Tannuri, U.] Univ Sao Paulo, Fac Med, Dept Pediat,Hosp Clin, Pediat Surg & Liver Transplantat Div,Inst Crianca, BR-01246903 Sao Paulo, Brazil.
RP Gibelli, NEM (reprint author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM nelson.gibelli@icr.usp.br
RI Tannuri, Ana Cristina Aoun/C-4718-2012; Tannuri, Uenis/D-3876-2012
CR Bahador A, 2009, TRANSPL P, V41, P2864, DOI 10.1016/j.transproceed.2009.07.046
   Gibelli NEM, 2009, TRANSPL P, V41, P955, DOI 10.1016/j.transproceed.2009.01.055
   Heaton N, 2008, BRIT J SURG, V95, P919, DOI 10.1002/bjs.6060
   Kawachi S, 2002, SURGERY, V132, P48, DOI 10.1067/msy.2002.125314
   KOBORI L, 2008, ORVOSI HETILAP, V149, P127
   Marcos A, 2000, ANN SURG, V231, P824, DOI 10.1097/00000658-200006000-00006
   Matsuda H, 2006, SURG TODAY, V36, P245, DOI 10.1007/s00595-005-3131-3
   Otte JB, 2004, PEDIATR TRANSPLANT, V8, P317, DOI 10.1111/j.1399-3046.2004.00205.x
   Otte JB, 2003, TRANSPLANTATION, V75, P1625, DOI 10.1097/01.TP.0000065020.55959.4A
   Pastacaldi S, 2001, LIVER TRANSPLANT, V7, P75, DOI 10.1053/jlts.2001.22040
   POMPOSELLI JJ, 2006, TRANSPLANTATION S2, V82, P705
   RASMUSSEN A, 1994, TRANSPLANT P, V26, P1792
   Sieders E, 2000, TRANSPLANTATION, V70, P1448, DOI 10.1097/00007890-200011270-00009
   Takahashi Y, 2009, PEDIATR SURG INT, V25, P745, DOI 10.1007/s00383-009-2430-y
   Wamaar N, 2010, LIVER TRANSPLANT, V16, P847
   Wojcicki M, 2008, DIGEST SURG, V25, P245, DOI 10.1159/000144653
   Yang Y, 2010, WORLD J GASTROENTERO, V16, P2682, DOI 10.3748/wjg.v16.i21.2682
NR 17
TC 14
Z9 16
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2011
VL 43
IS 1
BP 161
EP 164
DI 10.1016/j.transproceed.2010.11.013
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 725XB
UT WOS:000287679100031
PM 21335177
ER

PT J
AU Backes, AN
   Gibelli, NEM
   Tannuri, ACA
   Santos, MM
   Pinho-Apezzato, ML
   Andrade, WC
   Maksoud, JG
   Queiroz, AJR
   Tannuri, U
AF Backes, A. N.
   Gibelli, N. E. M.
   Tannuri, A. C. A.
   Santos, M. M.
   Pinho-Apezzato, M. L.
   Andrade, W. C.
   Maksoud-Filho, J. G.
   Queiroz, A. J. R.
   Tannuri, U.
TI Hepatic Artery Graft in Pediatric Liver Transplantation: Single-Center
   Experience With 58 Cases
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Luso Brazilian Congress of Transplant
CY OCT 02-05, 2010
CL Porto, PORTUGAL
ID REVASCULARIZATION; RECONSTRUCTION; THROMBOSIS; CONDUITS; INTERPOSITION
AB Introduction. The use of arterial grafts (AG) in pediatric orthotopic liver transplantation (OLT) is an alternative in cases of poor hepatic arterial inflow, small or anomalous recipient hepatic arteries, and retransplantations (re-OLT) due to hepatic artery thrombosis (HAT). AG have been crucial to the success of the procedure among younger children. Herein we have reported our experience with AG.
   Methods. We retrospectively reviewed data from June 1989 to June 2010 among OLT in which we used AG, analyzing indications, short-term complications, and long-term outcomes.
   Results. Among 437 pediatric OLT, 58 children required an AG. A common iliac artery interposition graft was used in 57 cases and a donor carotid artery in 1 case. In 38 children the graft was used primarily, including 94% (36/38) in which it was due to poor hepatic arterial inflow. Ductopenia syndromes (n = 14), biliary atresia (BA; n = 11), and fulminant hepatitis (n = 8) were the main preoperative diagnoses among these children. Their mean weight was 18.4 kg and mean age was 68 months. At the mean follow-up of 27 months, multiple-organ failure and primary graft nonfunction (PNF) were the short-term causes of death in 9 children (26.5%). Among the remaining 29 patients, 2 (6,8%) developed early graft thrombosis requiring re-OLT; 5 (17%) developed biliary complications, and 1 (3.4%) had asymptomatic arterial stenosis. In 20 children, a graft was used during retransplantation. The main indication was HAT (75%). BA (n = 15), ductopenia syndromes (n = 2), and primary sclerosing cholangitis (n = 2) were the main diagnoses. Their mean weight was 16.7 kg and age was 65 months. At a mean follow-up of 53 months, 7 children died due to multiple-organ failure or PNF. Among the remaining 13 patients, 3 developed biliary complications and 1 had arterial stenosis. No thrombosis was observed.
   Conclusion. The data suggested that use of an AG is useful alternative in pediatric OLT. The technique is safe with a low risk of thrombosis.
C1 [Backes, A. N.; Gibelli, N. E. M.; Tannuri, A. C. A.; Santos, M. M.; Pinho-Apezzato, M. L.; Andrade, W. C.; Maksoud-Filho, J. G.; Queiroz, A. J. R.; Tannuri, U.] Univ Sao Paulo, Fac Med, Inst Crianca,Hosp Clin, Pediat Surg & Liver Transplantat Div,Dept Pediat, BR-01246903 Sao Paulo, Brazil.
RP Gibelli, NEM (reprint author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM nelson.gibelli@icr.usp.br
RI Tannuri, Ana Cristina Aoun/C-4718-2012; Tannuri, Uenis/D-3876-2012
CR BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   Del Gaudio M, 2005, CLIN TRANSPLANT, V19, P399, DOI 10.1111/j.1399-0012.2005.00363.x
   Martinez JA, 1999, TRANSPLANTATION, V68, P672, DOI 10.1097/00007890-199909150-00013
   MAZAFERRO V, 1989, TRANSPLANTATION, V47, P971
   Meyer C, 2000, TRANSPLANT P, V32, P2791, DOI 10.1016/S0041-1345(00)01887-X
   Muiesan P, 1998, LIVER TRANSPLANT SUR, V4, P232, DOI 10.1002/lt.500040314
   Muralidharan V, 2004, TRANSPLANT INT, V17, P163, DOI 10.1007/s00147-004-0701-z
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   SANSALONE CV, 1994, TRANSPLANT P, V26, P3535
   Santamaria ML, 1996, J PEDIATR SURG, V31, P600, DOI 10.1016/S0022-3468(96)90506-0
   SHAKED AA, 1991, SURG GYNECOL OBSTET, V173, P198
   Stange B, 2000, TRANSPLANT P, V32, P533, DOI 10.1016/S0041-1345(00)00877-0
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   Tannuri U, 2006, PEDIATR TRANSPLANT, V10, P101, DOI 10.1111/j.1399-3046.2005.00392.x
   TISONE G, 1988, TRANSPLANTATION, V46, P162, DOI 10.1097/00007890-198807000-00032
   TODO S, 1987, TRANSPLANT P, V19, P2406
   TZAKIS A, 1989, TRANSPLANT INT, V2, P121, DOI 10.1111/j.1432-2277.1989.tb01852.x
   YANAGA K, 1989, TRANSPLANT P, V21, P3511
   Zamboni F, 2002, DIGEST LIVER DIS, V34, P122, DOI 10.1016/S1590-8658(02)80241-9
NR 19
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2011
VL 43
IS 1
BP 177
EP 180
DI 10.1016/j.transproceed.2010.11.006
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 725XB
UT WOS:000287679100035
PM 21335181
ER

PT J
AU Gibelli, NEM
   Tannuri, ACA
   Tannuri, U
   Santos, MM
   Pinho-Apezzato, ML
   Maksoud, JG
   Velhote, MCP
   Ayoub, AAR
   Silva, MM
   Andrade, WC
AF Gibelli, N. E. M.
   Tannuri, A. C. A.
   Tannuri, U.
   Santos, M. M.
   Pinho-Apezzato, M. L.
   Maksoud-Filho, J. G.
   Velhote, M. C. P.
   Ayoub, A. A. R.
   Silva, M. M.
   Andrade, W. C.
TI Rex Shunt for Acute Portal Vein Thrombosis After Pediatric Liver
   Transplantation in Children With Biliary Atresia
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Luso Brazilian Congress of Transplant
CY OCT 02-05, 2010
CL Porto, PORTUGAL
ID RISK-FACTORS; RECONSTRUCTION; HYPERTENSION; RECIPIENTS
AB Background/Purpose. Posttransplantation portal vein thrombosis (PVT) can have severe health consequences, and portal hypertension and other consequences of the long-term privation of portal inflow to the graft may be hazardous, especially in young children. The Rex shunt has been used successfully to treat PVT patients since 1998. In 2007, we started to perform this surgery in patients with idiopathic PVT and late posttransplantation PVT. Herein we have reported our experience with this technique in acute posttransplantation PVT.
   Methods. Three patients of ages 12, 15, and 18 months underwent cadaveric (n = 1) or living donor (n = 2) orthotopic liver transplantation (OLT). All patients had biliary atresia with portal vein hypoplasia; they developed acute PVT on the first postoperative day. They underwent a mesenteric-portal surgical shunt (Rex shunt) using a left internal jugular vein autograft (n = 2) or cadaveric iliac vein graft (n = 1) on the first postoperative day.
   Results. The 8-month follow-up has confirmed shunt patency by postoperative Doppler ultrasound. There have been no biliary complications to date.
   Conclusions. The mesenteric-portal shunt (Rex shunt) using an autograft of the left internal jugular or a cadaveric vein graft should be considered for children with acute PVT after OLT. These children usually have small portal veins; reanastomosis is often unsuccessful. In addition, this technique has the advantage to avoid manipulation of the hepatic hilum and biliary anastomosis. Although this study was based on a limited experience, we concluded that this technique is feasible, with great benefits to and low risks for these patients.
C1 [Gibelli, N. E. M.; Tannuri, A. C. A.; Tannuri, U.; Santos, M. M.; Pinho-Apezzato, M. L.; Maksoud-Filho, J. G.; Velhote, M. C. P.; Ayoub, A. A. R.; Silva, M. M.; Andrade, W. C.] Univ Sao Paulo, Fac Med, Dept Pediat,Pediat Surg & Liver Transplantat Div, Inst Crianca,Hosp Clin, BR-01246903 Sao Paulo, Brazil.
RP Gibelli, NEM (reprint author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM nelson.gibelli@icr.usp.br
RI Tannuri, Ana Cristina Aoun/C-4718-2012; Tannuri, Uenis/D-3876-2012
CR Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   de Goyet JD, 1999, EUR J SURG, V165, P777
   Alberti D, 1998, J PEDIATR SURG, V33, P597
   deGoyet JD, 1996, TRANSPLANTATION, V62, P71, DOI 10.1097/00007890-199607150-00015
   Gibelli NEM, 2009, TRANSPL P, V41, P955, DOI 10.1016/j.transproceed.2009.01.055
   Harihara Y, 1999, TRANSPLANTATION, V68, P1199, DOI 10.1097/00007890-199910270-00022
   Marwan IK, 1999, SURGERY, V125, P265, DOI 10.1067/msy.1999.95114
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   Shibasaki S, 2010, CLIN TRANSPLANT, V24, P550, DOI 10.1111/j.1399-0012.2009.01123.x
NR 9
TC 8
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2011
VL 43
IS 1
BP 194
EP 195
DI 10.1016/j.transproceed.2010.11.011
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 725XB
UT WOS:000287679100040
PM 21335186
ER

PT J
AU Steinbruck, K
   Enne, M
   Fernandes, R
   Martinho, JM
   Balbi, E
   Agoglia, L
   Roma, J
   Pacheco-Moreira, LF
AF Steinbrueck, K.
   Enne, M.
   Fernandes, R.
   Martinho, J. M.
   Balbi, E.
   Agoglia, L.
   Roma, J.
   Pacheco-Moreira, L. F.
TI Vascular Complications After Living Donor Liver Transplantation: A
   Brazilian, Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Luso Brazilian Congress of Transplant
CY OCT 02-05, 2010
CL Porto, PORTUGAL
ID HEPATIC-ARTERY THROMBOSIS; PORTAL-VEIN THROMBOSIS; RISK-FACTORS;
   RECONSTRUCTION; CHILDREN
AB Background. In living donor liver transplantation (LDLT), vascular complications are more frequently seen than in deceased donor transplantation. Early arterial, portal vein, or hepatic vein thromboses are complications that can lead to graft loss and patient death. The aim of this study was to assess the incidence, treatment, and outcome of vascular complications after LDLT in a single Brazilian center.
   Methods. Between December 2001 and December 2010, we performed 130 LDLT. Sixty-four recipients were children (27 weighing <10 kg).
   Results. Nine recipients had vascular complications. Hepatic artery thrombosis (HAT) occurred in 4 (3.1%), portal vein thrombosis (PVT) in 3 (2.3%), and hepatic vein thrombosis (HVT) and hepatic arterial stenosis (HAS) in 1 (0.8%) patient each. Complications were identified by Doppler and confirmed by angiography or angiotomography. Patients with HAT were listed for retransplantation. One died before retransplant. Two children were submitted to retransplantation; one is still alive, with neurologic sequelae. One adult with HAT was retransplanted with a deceased donor graft and is doing well 58 months after surgery. Two patients with PVT died as a consequence of graft malfunction. In the other case, portal vein arterialization was performed, but patient died 11 months posttransplant. HVT was detected after cardiac reanimation and was treated with an endovascular stent. This patient died 3 months after LDLT. HAS was diagnosed after liver abscess development and was successfully treated by endovascular angioplasty. No recurrence was observed after 22 months. Follow-up ranged from 9 to 117 months.
   Conclusion. Pediatric patients are more prone to develop vascular complications after LDLT. Long-term survival was statistically lower for recipients with vascular complications (33.3% vs 77.7%; P = .008).
C1 [Steinbrueck, K.; Enne, M.; Fernandes, R.; Balbi, E.; Agoglia, L.; Roma, J.; Pacheco-Moreira, L. F.] Bonsucesso Fed Hosp MS, Liver Transplantat Unit, Rio De Janeiro, Brazil.
   [Steinbrueck, K.; Fernandes, R.; Martinho, J. M.; Agoglia, L.; Roma, J.] Univ Fed Fluminense, Med Sci Postgrad Program, Niteroi, RJ, Brazil.
RP Steinbruck, K (reprint author), Hosp Fed Bonsucesso, Serv Transplante Hepat & Cirurgia Hepatobiliar, Av Londres 616,Predio 3-2 Andar, Rio De Janeiro, Brazil.
EM drsteinbruck@yahoo.com.br
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   DUFFY JP, 2009, J Am Coll Surg, V208, P200
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Kim BS, 2003, AM J ROENTGENOL, V181, P467
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   LILLY JR, 1974, J PEDIATR SURG, V9, P707, DOI 10.1016/0022-3468(74)90109-2
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   Pacheco-Moreira LF, 2006, PEDIATR TRANSPLANT, V10, P311, DOI 10.1111/j.1399-3046.2005.00465.x
   Pawlak J, 2003, TRANSPLANT P, V35, P2313, DOI 10.1016/S0041-1345(03)00836-4
   Sakamoto Y, 1999, BRIT J SURG, V86, P886, DOI 10.1046/j.1365-2168.1999.01166.x
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 20
TC 16
Z9 16
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2011
VL 43
IS 1
BP 196
EP 198
DI 10.1016/j.transproceed.2010.12.007
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 725XB
UT WOS:000287679100041
PM 21335187
ER

PT J
AU Kaller, T
   Langguth, N
   Ganschow, R
   Nashan, B
   Schulz, KH
AF Kaller, Tanja
   Langguth, Nadine
   Ganschow, Rainer
   Nashan, Bjoern
   Schulz, Karl-Heinz
TI Attention and Executive Functioning Deficits in Liver-Transplanted
   Children
SO TRANSPLANTATION
LA English
DT Article
DE Liver transplantation; Children; Cognitive functioning; Attention
ID QUALITY-OF-LIFE; ANTERIOR CINGULATE CORTEX; ORGAN-TRANSPLANTATION;
   COGNITIVE-ABILITIES; IMMUNOSUPPRESSION; NEUROTOXICITY; COMPLICATIONS;
   RECIPIENTS; BEHAVIOR; OUTCOMES
AB Aims. Liver-transplanted children have an increased risk for serious developmental problems. We examined attention and executive functioning and their relation to intelligence and several disease-related variables after transplantation.
   Methods. This is a monocentric, cross-sectional study with no reference group. Children's mean age at transplantation was 3.4 +/- 3.8 years (n = 137, age 10.2 +/- 3.8 years). Assessment included attention and executive functioning (Test of Attentional Performance [TAP]/Test of Attentional Performance [children's version] [KITAP]) and intelligence (Wechsler Intelligence Scale for Children, 3rd edition/Kaufman Assessment Battery for Children).
   Results. In most TAP and KITAP Subscales, children scored in the lower normal range, but reaction times, errors, and omissions were significantly below the population mean. Most notable deficits became manifest in the subscales Sustained Attention and Working Memory where 47% respectively 38% of the present sample scored below the normal range. Most TAP and KITAP Subscales, particularly Alertness and Go/NoGo, were highly correlated with Wechsler Intelligence Scale for Children, 3rd edition and Kaufman Assessment Battery for Children Subscales indicating that liver-transplanted children with longer reaction times display lower intelligence scores. Regression analysis revealed that decelerated reaction times in the subscales TAP-Go/NoGo, Divided Attention (KITAP and TAP), and KITAP-Sustained Attention were associated with type of donation, duration of disease, age at transplantation, and sex (R(2) = 0.14 to R(2) = 0.25).
   Conclusion. Results provide evidence suggesting that liver-transplanted children are at risk of developmental deficits regarding attention and executive functioning. Especially intrinsic alertness and working memory performance seem to be insufficient. This might result in deficient initiating, sustaining, and controlling of action. In summary, results demonstrate the need for an early and comprehensive developmental screening after pediatric liver transplantation.
C1 [Kaller, Tanja; Langguth, Nadine; Schulz, Karl-Heinz] Univ Hosp Eppendorf, Inst Med Psychol, D-20246 Hamburg, Germany.
   [Ganschow, Rainer] Univ Hosp Eppendorf, Childrens Hosp, D-20246 Hamburg, Germany.
   [Nashan, Bjoern; Schulz, Karl-Heinz] Univ Hosp Eppendorf, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Kaller, T (reprint author), Univ Hosp Eppendorf, Inst Med Psychol, Martinistr 52,W26, D-20246 Hamburg, Germany.
EM t.kaller@uke.uni-hamburg.de
FU Homann Foundation; Jovita Foundation; Paul und Helmi Nitsch-Foundation;
   Registered Association Hamburg Heals Children
FX This work was supported by Homann Foundation, Jovita Foundation, and
   Paul und Helmi Nitsch-Foundation and the Registered Association Hamburg
   Heals Children.
CR Adeback P, 2003, PEDIATR TRANSPLANT, V7, P385, DOI 10.1034/j.1399-3046.2003.00081.x
   Alonso EM, 2009, CURR OPIN ORGAN TRAN, V14, P522, DOI 10.1097/MOT.0b013e3283307a62
   Bucuvalas JC, 2008, AM J TRANSPLANT, V8, P2506, DOI 10.1111/j.1600-6143.2008.02432.x
   Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2
   Campagna F, 2010, METAB BRAIN DIS, V25, P115, DOI 10.1007/s11011-010-9183-0
   Conrad CD, 2008, REV NEUROSCIENCE, V19, P395
   Coull JT, 1996, NEUROPSYCHOLOGIA, V34, P1085, DOI 10.1016/0028-3932(96)00029-2
   DiMartini A, 2008, CRIT CARE CLIN, V24, P949, DOI 10.1016/j.ccc.2008.05.001
   Everts R, 2008, CHILD NEUROPSYCHOL, V14, P323, DOI 10.1080/09297040701792383
   Gilmour S, 2009, AM J TRANSPLANT, V9, P294, DOI 10.1111/j.1600-6143.2008.02480.x
   Grantham-McGregor Sally, 2003, Forum Nutr, V56, P272
   GRANTHAMMCGREGOR S, 1995, J NUTR, V125, pS2233
   Gritti A, 2006, PEDIATR TRANSPLANT, V10, P205, DOI 10.1111/j.1399-3046.2005.00426.x
   Hauben M, 1996, PHARMACOTHERAPY, V16, P576
   Kaller T, 2005, TRANSPLANTATION, V79, P1252, DOI 10.1097/01.TP.0000161251.20520.42
   Kaller T, 2010, PEDIATR TRANSPLANT, V14, P496, DOI 10.1111/j.1399-3046.2009.01257.x
   Kamath BM, 2010, PEDIATR CLIN N AM, V57, P401, DOI 10.1016/j.pcl.2010.01.012
   Kaufman A. S., 1994, K ABC KAUFMAN ASSESS
   Kennard BD, 1999, J DEV BEHAV PEDIATR, V20, P17, DOI 10.1097/00004703-199902000-00003
   Krull K, 2003, PEDIATR TRANSPLANT, V7, P111, DOI 10.1034/j.1399-3046.2003.00026.x
   MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835
   MARROCCO RT, 1994, CURR OPIN NEUROBIOL, V4, P166, DOI 10.1016/0959-4388(94)90067-1
   Mazariegos GV, 2007, PEDIATR TRANSPLANT, V11, P835, DOI 10.1111/j.1399-3046.2007.00769.x
   McDiarmid SV, 2001, LIVER TRANSPLANT, V7, pS77, DOI 10.1053/jlts.2001.28643
   Melchers P., 2001, KAUFMAN ASSESSMENT B
   Meyer T, 2006, TRANSPLANT P, V38, P3559, DOI 10.1016/j.transproceed.2006.10.050
   O'Carroll RE, 2008, NEUROCHEM RES, V33, P683, DOI 10.1007/s11064-007-9522-7
   O'Carroll RE, 2003, LIVER TRANSPLANT, V9, P712, DOI 10.1053/jlts.2003.50138
   O'Carroll Ronan E, 2008, Psychol Health Med, V13, P239, DOI 10.1080/13548500701403363
   Pillai AA, 2009, WORLD J GASTROENTERO, V15, P4225, DOI 10.3748/wjg.15.4225
   POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25
   Schellig D., 2009, HDB NEUROPSYCHOLOGIS
   Schulz KH, 2003, TRANSPLANTATION, V75, P1236, DOI 10.1097/01.TP.0000062843.10397.32
   Schwering K L, 1997, Pediatr Transplant, V1, P138
   Senzolo M, 2009, TRANSPL P, V41, P1295, DOI 10.1016/j.transproceed.2009.03.087
   Stevenson T, 2010, PEDIATR TRANSPLANT, V14, P268, DOI 10.1111/j.1399-3046.2009.01228.x
   STEWART SM, 1991, PEDIATRICS, V87, P367
   STEWART SM, 1992, J DEV BEHAV PEDIATR, V13, P331
   STEWART SM, 1994, HEALTH PSYCHOL, V13, P3, DOI 10.1037/0278-6133.13.1.3
   Sturm W., 2009, LEHRBUCH KLIN NEUROP
   STURM W, 2005, ATTENTION DISORDERS
   TEWES U, 1999, HAMBURGWECHSLER INTE
   Tiao Gregory M, 2006, Semin Pediatr Surg, V15, P218, DOI 10.1053/j.sempedsurg.2006.03.008
   Tornqvist J, 1999, Pediatr Transplant, V3, P115, DOI 10.1034/j.1399-3046.1999.00026.x
   WECHSLER D, 1991, MANUAL WECHSLER INTE, pCH5
   Wechsler D. L., 1991, WECHSLER INTELLIGENC
   WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962
   Yssaad-Fesselier R, 2009, TRANSPLANTATION, V87, P1427, DOI 10.1097/TP.0b013e3181a27b58
   Fimm B., 1993, TESTBATTERIE AUFMERK
   Zimmermann P, 2002, TESTBATTERIE AUFMERK
   Zivkovic SA, 2010, NEUROL CLIN, V28, P235, DOI 10.1016/j.ncl.2009.09.011
NR 51
TC 12
Z9 12
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD DEC 27
PY 2010
VL 90
IS 12
BP 1567
EP 1573
DI 10.1097/TP.0b013e3181fe1398
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 695NG
UT WOS:000285377100050
PM 21197714
ER

PT J
AU Campbell, K
   Ng, V
   Martin, S
   Magee, J
   Goebel, J
   Anand, R
   Martz, K
   Bucuvalas, J
AF Campbell, K.
   Ng, V.
   Martin, S.
   Magee, J.
   Goebel, J.
   Anand, R.
   Martz, K.
   Bucuvalas, J.
CA SPLIT Renal Function Working Grp
TI Glomerular Filtration Rate Following Pediatric Liver Transplantation-The
   SPLIT Experience
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE glomerular filtration rate; multicenter studies; pediatric liver
   transplantation; long-term outcomes; renal dysfunction
ID CALCINEURIN INHIBITOR THERAPY; CHRONIC KIDNEY-DISEASE;
   CHRONIC-RENAL-FAILURE; MYCOPHENOLATE-MOFETIL; CYCLOSPORINE; RECIPIENTS;
   CHILDREN; LONG; DYSFUNCTION; NEPHROTOXICITY
AB Impaired kidney function is a well-recognized complication following liver transplantation (LT). Studies of this complication in children have been limited by small numbers and insensitive outcome measures. Our aim was to define the prevalence of, and identify risk factors for, post-LT kidney dysfunction in a multicenter pediatric cohort using measured glomerular filtration rate (mGFR). We conducted a cross-sectional study of 397 patients enrolled in the Studies in Pediatric Liver Transplantation (SPLIT) registry, using mGFR < 90 mL/min/1.73 m2 as the primary outcome measure. Median age at LT was 2.2 years. Primary diagnoses were biliary atresia (44.6%), fulminant liver failure (9.8%), metabolic liver disease (16.4%), chronic cholestatic liver disease (13.1%), cryptogenic cirrhosis (4.3%) and other (11.8%). At a mean of 5.2 years post-LT, 17.6% of patients had a mGFR < 90 mL/min/1.73 m2. In univariate analysis, factors associated with this outcome were transplant center, age at LT, primary diagnosis, calculated GFR (cGFR) at LT and 12 months post-LT, primary immunosuppression, early post-LT kidney complications, age at mGFR, height and weight Z-scores at 12 months post-LT. In multivariate analysis, independent variables associated with a mGFR < 90 mL/min/1.73 m2 were primary immunosuppression, age at LT, cGFR at LT and height Z-score at 12 months post-LT.
C1 [Campbell, K.; Goebel, J.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA.
   [Ng, V.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   [Martin, S.] CHU St Justine, Montreal, PQ, Canada.
   [Magee, J.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
   [Anand, R.; Martz, K.; Bucuvalas, J.] EMMES Corp, Rockville, MD USA.
RP Campbell, K (reprint author), Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA.
EM Kathleen.campbell@cchmc.org
CR Alonso EM, 2009, AM J TRANSPLANT, V9, P1389, DOI 10.1111/j.1600-6143.2009.02634.x
   ANDREWS WS, 1991, TRANSPLANT P, V23, P1452
   Arora-Gupta N, 2004, PEDIATR TRANSPLANT, V8, P145, DOI 10.1046/j.1399-3046.2003.00132.x
   Avitzur Y, 2004, TRANSPLANTATION, V78, P566, DOI 10.1097/01.TP.0000131663.87106.1A
   Bartosh SM, 1997, CLIN TRANSPLANT, V11, P354
   Beckebaum S, 2009, TRANSPL P, V41, P2567, DOI 10.1016/j.transproceed.2009.06.152
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Bucuvalas JC, 2006, J PEDIATR GASTR NUTR, V43, pS41, DOI 10.1097/01.mpg.0000226389.64236.dc
   Burra P, 2009, DIGEST LIVER DIS, V41, P350, DOI 10.1016/j.dld.2008.09.018
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Cooney GF, 1997, CLIN PHARMACOKINET, V32, P481, DOI 10.2165/00003088-199732060-00004
   Dell-Olio D, 2009, PEDIATR TRANSPLANT, V13, P670, DOI 10.1111/j.1399-3046.2009.01184.x
   DEVINENI R, 1984, CAN J SURG, V27, P252
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   *EMM, 2007, STUD PED LIV TRANSPL
   Evans HM, 2005, TRANSPLANTATION, V79, P1575, DOI 10.1097/01.TP.0000163504.29054.3F
   Fanta S, 2008, PHARMACOGENET GENOM, V18, P77, DOI 10.1097/FPC.0b013e3282f3ef72
   Fernandez M, 2000, EXP NEPHROL, V8, P299
   Filler G, 2008, PEDIATR TRANSPLANT, V12, P393, DOI 10.1111/j.1399-3046.2007.00885.x
   Filler G, 2006, PEDIATR TRANSPLANT, V10, P953, DOI 10.1111/j.1399-3046.2006.00592.x
   Fisher NC, 1998, TRANSPLANTATION, V66, P59, DOI 10.1097/00007890-199807150-00010
   Fukudo M, 2008, PHARMACOGENET GENOM, V18, P413, DOI 10.1097/FPC.0b013e3282f9ac01
   GONWA TA, 1988, TRANSPLANT P, V20, P401
   Gonwa TA, 2001, TRANSPLANTATION, V72, P1934, DOI 10.1097/00007890-200112270-00012
   GRATWOHL A, 1983, TRANSPLANTATION, V36, P40, DOI 10.1097/00007890-198307000-00009
   Harambat J, 2008, TRANSPLANTATION, V86, P1028, DOI 10.1097/TP.0b013e318187748f
   Herzog D, 2006, TRANSPLANTATION, V81, P672, DOI 10.1097/01.tp.0000185194.62108.a7
   *HLTH RES SERV ADM, 2007, TRANSPL DAT 1997 200
   Kearns GL, 2003, NEW ENGL J MED, V349, P1157
   Kuczmarski R. J., 2002, 2000 CDC GROWTH CHAR
   Lane PH, 2002, AM J PHYSIOL-RENAL, V283, pF589, DOI 10.1152/ajpendal.00368.2001
   Lane PH, 2005, ADV CHRONIC KIDNEY D, V12, P372, DOI 10.1053/j.ackd.2005.07.009
   Lane PH, 2001, PEDIATR NEPHROL, V16, P1033
   Langer WJ, 2008, PEDIATR NEPHROL, V23, P275, DOI 10.1007/s00467-007-0642-8
   Levey AS, 2003, ANN INTERN MED, V139, P137
   McDiarmid S V, 1996, Kidney Int Suppl, V53, pS77
   MCDIARMID SV, 1989, TRANSPLANTATION, V47, P314, DOI 10.1097/00007890-198902000-00025
   Mention K, 2005, PEDIATR TRANSPLANT, V9, P201, DOI 10.1111/j.1399-3046.2005.00289.x
   MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Pawarode A, 2003, LIVER TRANSPLANT, V9, P741, DOI 10.1053/jlts.2003.50113
   PLATZ KP, 1994, TRANSPLANTATION, V58, P170, DOI 10.1097/00007890-199405820-00007
   POWELLJACKSON PR, 1983, TRANSPLANTATION, V36, P505, DOI 10.1097/00007890-198311000-00007
   Samyn M, 2005, LIVER TRANSPLANT, V11, P344, DOI 10.1012/lt.20330
   Sarwal M, 2007, AM J TRANSPLANT, V7, P2227, DOI 10.1111/j.1600-6143.2007.01936.x
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Sharma P, 2009, LIVER TRANSPLANT, V15, P1142, DOI 10.1002/lt.21821
   Shimizu MHM, 2004, EXP GERONTOL, V39, P825, DOI 10.1016/j.exger.2004.02.009
   Tredger JM, 2008, DRUGS, V68, P1385, DOI 10.2165/00003495-200868100-00004
   Tsimaratos M, 2000, TRANSPLANTATION, V69, P2055, DOI 10.1097/00007890-200005270-00014
   WHEATLEY HC, 1987, TRANSPLANTATION, V43, P641, DOI 10.1097/00007890-198705000-00007
NR 51
TC 23
Z9 23
U1 0
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD DEC
PY 2010
VL 10
IS 12
BP 2673
EP 2682
DI 10.1111/j.1600-6143.2010.03316.x
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 686LS
UT WOS:000284698400019
PM 21114644
ER

PT J
AU Gunasekaran, G
   Bencsath, K
   Hupertz, V
   Fung, JJ
   Pettersson, G
   Miller, C
AF Gunasekaran, Ganesh
   Bencsath, Kalman
   Hupertz, Vera
   Fung, John J.
   Pettersson, Gosta
   Miller, Charles
TI Deep Hypothermia With Circulatory Arrest to Aid in the Management of
   Suprahepatic Vena Cava Stenosis After Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID ANASTOMOTIC STENOSIS; VASCULAR ANASTOMOSES; BALLOON ANGIOPLASTY;
   ABSORBABLE SUTURE; STENT PLACEMENT; COMPLICATIONS
AB Liver transplantation is the treatment of choice for many liver diseases in the pediatric population. Complications involving late suprahepatic vena cava obstructions after liver transplantation are not common, but they tend to be more frequently seen in pediatric recipients. When such complications have occurred, approaches involving direct abdominal surgery or interventional radiology guidance have been used with satisfactory results. We present a case report of an alternative approach to a suprahepatic vena cava complication. An 18-year-old man who underwent pediatric liver transplantation for biliary atresia presented with a symptomatic total occlusion of the suprahepatic caval anastomosis that could not be crossed with a wire. We used a right atrial approach and hypothermic circulatory (cardiac) arrest. The anastomotic stricture was easily identified and excised. The postoperative course was uneventful with a rapid resolution of the symptoms. Because the occlusion was not amenable to angioplasty or stenting, a direct surgical approach was necessary. The right atrial approach with hypothermic cardiac arrest gave us direct access to the obliterated cavoatrial anastomosis through a virgin area and allowed us to avoid the difficulties and dangers of the large collaterals in the abdomen. Liver Transpl 16:1434-1436, 2010. (C) 2010 AASLD.
C1 [Gunasekaran, Ganesh; Bencsath, Kalman; Hupertz, Vera; Fung, John J.; Pettersson, Gosta; Miller, Charles] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
RP Gunasekaran, G (reprint author), Cleveland Clin Fdn, 9500 Euclid Ave A100, Cleveland, OH 44195 USA.
EM gain_g@hotmail.com
RI Fung, John/A-2679-2012
CR Baccin Carlos E, 2008, Cardiovasc Intervent Radiol, V31 Suppl 2, pS166, DOI 10.1007/s00270-007-9261-9
   BERGER H, 1993, CARDIOVASC INTER RAD, V16, P384, DOI 10.1007/BF02603146
   Berrocal T, 2006, RADIOGRAPHICS, V26, P1187, DOI 10.1148/rg.264055081
   Bilbao JI, 2000, CARDIOVASC INTER RAD, V23, P149, DOI 10.1007/s002709910031
   Borsa JJ, 1999, J VASC INTERV RADIOL, V10, P17, DOI 10.1016/S1051-0443(99)70003-5
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Carnevale FC, 2004, PEDIATR TRANSPLANT, V8, P576, DOI 10.1111/j.1399-3046.2004.00213.x
   CHIU IS, 1988, J THORAC CARDIOV SUR, V95, P112
   CONTIS JC, 1993, TRANSPLANT P, V25, P1878
   Garcia ND, 2003, ANN VASC SURG, V17, P686, DOI 10.1007/s10016-003-0077-z
   Kalkat Maninder S, 2008, Interact Cardiovasc Thorac Surg, V7, P981, DOI 10.1510/icvts.2008.180026
   Lee JM, 2010, LIVER TRANSPLANT, V16, P513, DOI 10.1002/lt.22021
   Mazzola A, 2007, ANN THORAC SURG, V83, P1564, DOI 10.1016/j.athoracsur.2006.04.028
   Mizuno S, 2005, CLIN TRANSPLANT, V19, P215, DOI 10.1111/j.1399-0012.2004.00321.x
   Molmenti EP, 2004, LIVER TRANSPLANT, V10, P1216, DOI 10.1002/lt.20191
   Pfammatter T, 1997, AM J ROENTGENOL, V168, P477
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   ROSE BS, 1988, CARDIOVASC INTER RAD, V11, P79, DOI 10.1007/BF02577064
   SIMO G, 1995, CARDIOVASC INTER RAD, V18, P212
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 20
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD DEC
PY 2010
VL 16
IS 12
BP 1434
EP 1436
DI 10.1002/lt.22183
PG 3
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 693IA
UT WOS:000285216600014
PM 21117254
ER

PT J
AU Fredericks, EM
   Dore-Stites, D
   Well, A
   Magee, JC
   Freed, GL
   Shieck, V
   Lopez, MJ
AF Fredericks, Emily M.
   Dore-Stites, Dawn
   Well, Andrew
   Magee, John C.
   Freed, Gary L.
   Shieck, Victoria
   Lopez, M. James
TI Assessment of transition readiness skills and adherence in pediatric
   liver transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE transition; adolescence; adherence; pediatric liver transplantation;
   self-management
ID SOLID-ORGAN TRANSPLANTATION; ADULT CARE; FAMILY RESPONSIBILITY; ILLNESS
   MANAGEMENT; NONADHERENCE; ADOLESCENTS; SERVICES; OUTCOMES; ALLOCATION;
   VALIDITY
AB To examine transition readiness, adherence, and health outcomes in pediatric liver transplant recipients using a clinically administered screening measure. Seventy-one pediatric liver transplant recipients (11-20 yr) and 58 parents completed a clinic-based TRS measuring perceived and demonstrated self-management skills, AoR for health-related tasks, regimen knowledge, and psychosocial adjustment. Adherence was measured using s.d. of immunosuppressants, proportion of immunosuppressant blood levels out of target range, and clinic attendance. Health outcomes included liver test panels, biopsies, rejection episodes, and hospitalizations. Results indicate that all domains of transition readiness, with the exception of demonstrated skills, and non-adherence were positively correlated with age. Proportion of immunosuppressant blood levels below target range was positively correlated with self-management skills and increased responsibility for medication tasks. Parent regimen knowledge was associated with clinic attendance. Health outcomes were significantly related to medication non-adherence, but not to transition readiness domains. Medication adherence is considered to be a key factor in the transition from pediatric to adult-centered transplant care. Non-adherence is associated with an increased risk for medical complications and is potentially modifiable. Interventions to promote self-management skills and adherence should be an essential component of transition planning.
C1 [Fredericks, Emily M.] Univ Michigan Hlth Syst, Taubman Ctr 1924, Dept Pediat, Div Child Behav Hlth, Ann Arbor, MI 48109 USA.
   [Magee, John C.] Univ Michigan Hlth Syst, Dept Surg, Ann Arbor, MI 48109 USA.
RP Fredericks, EM (reprint author), Univ Michigan Hlth Syst, Taubman Ctr 1924, Dept Pediat, Div Child Behav Hlth, SPC 5318,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM emfred@med.umich.edu
RI lyp, maggie/G-1471-2011
FU NCRR CTSA [UL1RR024986]
FX This publication was made possible by Grant Number UL1RR024986 from NCRR
   CTSA funding to Dr. Fredericks. We thank Dr. Trivellore Raghunathan for
   his statistical consultation and thoughtful review of this manuscript.
CR ANDERSON BJ, 1990, J PEDIATR PSYCHOL, V15, P477, DOI 10.1093/jpepsy/15.4.477
   ANNUNZIATO RA, 2009, J PEDIAT PSYCHOL
   Annunziato RA, 2007, PEDIATR TRANSPLANT, V11, P608, DOI 10.1111/j.1399-3046.2007.00689.x
   Bell LE, 2008, AM J TRANSPLANT, V8, P2230, DOI 10.1111/j.1600-6143.2008.02415.x
   Berquist RK, 2008, PEDIATR TRANSPLANT, V12, P194, DOI 10.1111/j.1399-3046.2007.00809.x
   Betz Cecily L, 2004, Issues Compr Pediatr Nurs, V27, P179, DOI 10.1080/01460860490497903
   BLUM RW, 1993, J ADOLESCENT HEALTH, V14, P570, DOI 10.1016/1054-139X(93)90143-D
   Bucuvalas JC, 2005, J PEDIATR-US, V146, P744, DOI 10.1016/j.jpeds.2005.01.036
   Butler JA, 2004, TRANSPLANTATION, V77, P769, DOI 10.1097/01.TP.0000110408.83054.88
   Chisholm MA, 2005, NEPHROL DIAL TRANSPL, V20, P181, DOI 10.1093/ndt/gfh576
   Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037//1040-3590.7.3.309
   Creer TL, 2000, PROMOTING ADHERENCE TO MEDICAL TREATMENT IN CHRONIC CHILDHOOD ILLNESS: CONCEPTS, METHODS, AND INTERVENTIONS, P95
   DeVellis R. F., 2003, SCALE DEV THEORY APP
   Dobbels F, 2005, PEDIATR TRANSPLANT, V9, P381, DOI 10.1111/j.1399-3046.2005.00356.x
   Ellis DA, 2008, J ADOLESCENT HEALTH, V42, P146, DOI 10.1016/j.jadohealth.2007.08.012
   Flippin MS, 2000, J HEART LUNG TRANSPL, V19, P343, DOI 10.1016/S1053-2498(00)00061-9
   Fredericks EM, 2007, AM J TRANSPLANT, V7, P1974, DOI 10.1111/j.1600-6143.2007.01878.x
   Fredericks EM, 2008, PEDIATR TRANSPLANT, V12, P289, DOI 10.1111/j.1399-3046.2008.00901.x
   Kennedy A, 2008, CURR OPIN PEDIATR, V20, P403, DOI 10.1097/MOP.0b013e328305e128
   Kieckhefer G M, 2000, Pediatr Nurs, V26, P354
   Knauth A, 2006, CARDIOL CLIN, V24, P619, DOI 10.1016/j.ccl.2006.08.010
   Lemanek KL, 2001, J PEDIATR PSYCHOL, V26, P253, DOI 10.1093/jpepsy/26.5.253
   MAGEE J, 2006, 6 ANN ASTS WINT S AR
   McDonagh JE, 2008, ARTHRIT RHEUM-ARTHR, V59, P1199, DOI 10.1002/art.23921
   McDonagh JE, 2007, PEDIATR TRANSPLANT, V11, P578, DOI 10.1111/j.1399-3046.2007.00756.x
   McDonagh JE, 2009, CURR OPIN ORGAN TRAN, V14, P526, DOI 10.1097/MOT.0b013e32832ffb2a
   McDonagh J., 2008, ARTHRITIS RHEUM, V59, P1200
   McDonagh JE, 2005, PEDIATR TRANSPLANT, V9, P364, DOI 10.1111/j.1399-3046.2004.00287.x
   Naar-King S, 2009, J PEDIATR PSYCHOL, V34, P187, DOI 10.1093/jpepsy/jsn065
   Paone Mary C, 2006, Prog Transplant, V16, P291
   Rapoff MA, 1999, ADHERENCE PEDIAT MED
   Rummel R. J., 1970, APPL FACTOR ANAL
   Sawyer SM, 1997, J PAEDIATR CHILD H, V33, P88, DOI 10.1111/j.1440-1754.1997.tb01005.x
   Scal P, 1999, J ADOLESCENT HEALTH, V24, P259, DOI 10.1016/S1054-139X(98)00127-X
   Schafer-Keller P, 2008, AM J TRANSPLANT, V8, P616, DOI 10.1111/j.1600-6143.2007.02127.x
   Shemesh E, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e29
   Shemesh E, 2004, PEDIATRICS, V113, P825, DOI 10.1542/peds.113.4.825
   Sudan DL, 1998, ANN SURG, V227, P289, DOI 10.1097/00000658-199802000-00020
   Venkat VL, 2008, PEDIATR TRANSPLANT, V12, P67, DOI 10.1111/j.1399-3046.2007.00794.x
   Viner R, 1999, ARCH DIS CHILD, V81, P271
   Wainwright SP, 1997, J ADV NURS, V26, P968
   Walders N, 2000, J ASTHMA, V37, P89, DOI 10.3109/02770900009055432
   Watson AR, 2000, PEDIATR NEPHROL, V14, P469
   Watson AR, 2005, PEDIATR NEPHROL, V20, P113, DOI 10.1007/s00467-004-1763-y
NR 44
TC 54
Z9 54
U1 1
U2 8
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2010
VL 14
IS 8
BP 944
EP 953
DI 10.1111/j.1399-3046.2010.01349.x
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 693MZ
UT WOS:000285229500003
PM 20598086
ER

PT J
AU Mizuta, K
   Sanada, Y
   Wakiya, T
   Urahashi, T
   Umehara, M
   Egami, S
   Hishikawa, S
   Okada, N
   Kawano, Y
   Saito, T
   Hayashida, M
   Takahashi, S
   Yoshino, H
   Shimizu, A
   Takatsuka, Y
   Kitamura, T
   Kita, Y
   Uno, T
   Yoshida, Y
   Hyodo, M
   Sakuma, Y
   Fujiwara, T
   Ushijima, K
   Sugimoto, K
   Ohmori, M
   Ohtomo, S
   Sakamoto, K
   Nakata, M
   Yano, T
   Yamamoto, H
   Kobayashi, E
   Yasuda, Y
   Kawarasaki, H
AF Mizuta, K.
   Sanada, Y.
   Wakiya, T.
   Urahashi, T.
   Umehara, M.
   Egami, S.
   Hishikawa, S.
   Okada, N.
   Kawano, Y.
   Saito, T.
   Hayashida, M.
   Takahashi, S.
   Yoshino, H.
   Shimizu, A.
   Takatsuka, Y.
   Kitamura, T.
   Kita, Y.
   Uno, T.
   Yoshida, Y.
   Hyodo, M.
   Sakuma, Y.
   Fujiwara, T.
   Ushijima, K.
   Sugimoto, K.
   Ohmori, M.
   Ohtomo, S.
   Sakamoto, K.
   Nakata, M.
   Yano, T.
   Yamamoto, H.
   Kobayashi, E.
   Yasuda, Y.
   Kawarasaki, H.
TI Living-Donor Liver Transplantation in 126 Patients with Biliary Atresia:
   Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 23rd International Congress of the-Transplantation-Society
CY AUG 15-19, 2010
CL Vancouver, CANADA
SP Transplantat Soc
ID RISK-FACTORS; OUTCOMES
AB Objectives. To describe our experience with 126 consecutive living-donor liver transplantation (LDLT) procedures performed because of biliary atresia and to evaluate the optimal timing of the operation.
   Patients and Methods. Between May 2001 and January 2010,126 patients with biliary atresia underwent 130 LDLT procedures. Mean (SD) patient age was 3.3 (4.2) years, and body weight was 13.8 (10.7) kg. Donors included 64 fathers, 63 mothers, and 3 other individuals. The left lateral segment was the most commonly used graft (75%). Patients were divided into 3 groups according to body weight: group 1, less than 8 kg (n = 40); group 2,8 to 20 kg (n = 63); and group 3, more than 20 kg (n = 23). Medical records were reviewed retrospectively. Follow up was 4.5 (2.7) years.
   Results. All group 3 donors underwent left lobectomy, and all group 1 donors underwent left lateral segmentectomy. No donors required a second operation or died. Comparison of the 3 groups demonstrated that recipient Pediatric End-Stage Liver Disease score in group 1 was highest, operative blood loss in group 2 was lowest (78 mL/kg), and operative time in group 3 was longest (1201 minutes). Hepatic artery complications occurred more frequently in group 1(17.9%), and biliary stenosis (43.5%) and gastrointestinal perforation (8.7%) occurred more frequently in group 3. The overall patient survival rates at 1, 5, and 9 years was 98%, 97%, and 97%, respectively. Five-year patient survival rate in groups 1,2, and 3 were 92.5%, 100%, and 95.7%, respectively. Gastrointestinal perforation (n = 2) was the primary cause of death.
   Conclusions. Living-donor liver transplantation is an effective treatment of biliary atresia, with good long-term outcome. It seems that the most suitable time to perform LDLT to treat biliary atresia is when the patient weighs 8 to 20 kg.
C1 [Mizuta, K.] Jichi Med Univ, Sch Med, Dept Transplant Surg, Liver Transplant Team, Shimotsuke, Tochigi 3290498, Japan.
RP Mizuta, K (reprint author), Jichi Med Univ, Sch Med, Dept Transplant Surg, Liver Transplant Team, Yakushiji 3311-1, Shimotsuke, Tochigi 3290498, Japan.
EM koimizu@jichi.ac.jp
CR Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Guo CB, 2010, TRANSPL P, V42, P1750, DOI 10.1016/j.transproceed.2010.02.086
   Hartley JL, 2009, LANCET, V374, P1704, DOI 10.1016/S0140-6736(09)60946-6
   Haruta H, 2005, LIVER TRANSPLANT, V11, P1608, DOI 10.1002/lt.20623
   Hashikura Y, 2009, TRANSPLANTATION, V88, P110, DOI 10.1097/TP.0b013e3181aaccb0
   Kawano Y, 2008, LIVER TRANSPLANT, V14, P385, DOI 10.1002/lt.21357
   Kyoden Y, 2008, LIVER TRANSPLANT, V14, P186, DOI 10.1002/lt.21344
   Lopez-Benitez R, 2008, PEDIATR TRANSPLANT, V12, P606, DOI 10.1111/j.1399-3046.2008.00925.x
   Oh SH, 2010, PEDIATR TRANSPLANT, V14, P870, DOI 10.1111/j.1399-3046.2010.01357.x
   Ohya Y, 2009, PEDIATR TRANSPLANT, V13, P868, DOI 10.1111/j.1399-3046.2008.01075.x
   Okamoto T, 2008, J PEDIATR SURG, V43, P489, DOI 10.1016/j.jpedsurg.2007.10.029
   Uchida Y, 2006, AM J TRANSPLANT, V6, P2443, DOI 10.1111/j.1600-6143.2006.01487.x
   Utterson EC, 2005, J PEDIATR-US, V147, P180, DOI 10.1016/j.jpeds.2005.04.073
   WAKIYA T, 2010, PEDIAT TRAN IN PRESS
NR 14
TC 10
Z9 13
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2010
VL 42
IS 10
BP 4127
EP 4131
DI 10.1016/j.transproceed.2010.11.002
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 700IQ
UT WOS:000285732200060
PM 21168643
ER

PT J
AU Miyagi, S
   Enomoto, Y
   Sekiguchi, S
   Kawagishi, N
   Satomi, S
AF Miyagi, S.
   Enomoto, Y.
   Sekiguchi, S.
   Kawagishi, N.
   Satomi, S.
TI The Effects of Gabexate Mesilate on the Microsurgical Reconstruction of
   the Hepatic Artery in Living Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 23rd International Congress of the-Transplantation-Society
CY AUG 15-19, 2010
CL Vancouver, CANADA
SP Transplantat Soc
ID PROTEASE INHIBITOR; REPERFUSION INJURY; THROMBOSIS
AB Objectives. Microsurgical reconstruction of hepatic artery is essential but require challenging techniques especially for living donor liver transplantation (LDLT), because the recipient artery is short, located deep, and usable vessel grafts are limited. Furthermore, hepatic artery thrombosis (HAT) can be a lethal complication. Therefore, we began the systemic administration of gabexate mesilate, a strong serine protease inhibitor. It has often been effective to treat disseminated intravascular coagulation. The purpose of this study was to examine the effects of gabexate mesilate on the microvascular reconstruction.
   Methods. From 1991 to 2009, we performed 134 microsurgical reconstructions of LDLT. This retrospective investigation of those cases divided them into four groups: group I, anticoagulation with heparin (n = 3); group II, heparin and gabexate mesilate (20 mg/kg/d; n = 26); group III, heparin and full-dose gabexate mesilate (40 mg/kg/d; n = 72); and group IV, full-dose gabexate mesilate alone (n = 33). Groups I and II were mainly pediatric cases (left lobe grafts only); groups III and IV, adult cases (left: right = 57:48). Using ultrasonography to 14 days, we investigated HAT by examining pulsatile index, resistive index, and acceleration time.
   Results. HAT occurred in groups I, II, III, and IV at 33.3% (1/3), 11.5% (3/26), 6.9% (5/72), and 0% (0/33), respectively. The 5-year survival rates of groups III + IV versus groups I + II were 82.4% and 71.1%, respectively (P < .05). In HAT cases, even before the event the acceleration times were delayed to over 100 milliseconds.
   Conclusion. Gabexate mesilate administration was safe for and protective of microvascular reconstructions in LDLT.
C1 [Miyagi, S.] Tohoku Univ, Div Transplantat Reconstruct & Endoscop Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan.
RP Miyagi, S (reprint author), Tohoku Univ, Div Transplantat Reconstruct & Endoscop Surg, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
EM msmsmiyagi@yahoo.co.jp
CR Aramoto H, 1993, Nihon Rinsho, V51, P93
   Isobe J, 1979, Adv Exp Med Biol, V120B, P385
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   Kim BW, 2006, TRANSPLANT P, V38, P3128, DOI 10.1016/j.transproceed.2006.08.164
   Luh SP, 1999, J SURG RES, V87, P152, DOI 10.1006/jsre.1999.5730
   Mikami K, 2005, J GASTROENTEROL, V40, P260, DOI 10.1007/s00535-004-1534-3
   Miyagi S, 2004, TRANSPLANTATION, V77, P1487, DOI 10.1097/01.TP.0000122418.87680.C1
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Tsukamoto S, 1999, TRANSPLANTATION, V67, P1396, DOI 10.1097/00007890-199906150-00002
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2010
VL 42
IS 10
BP 4158
EP 4160
DI 10.1016/j.transproceed.2010.10.007
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 700IQ
UT WOS:000285732200068
PM 21168651
ER

PT J
AU Shigeta, T
   Imadome, K
   Sakamoto, S
   Fukuda, A
   Kakiuchi, T
   Matsuno, N
   Tanaka, H
   Nakazawa, A
   Kasahara, M
AF Shigeta, T.
   Imadome, K.
   Sakamoto, S.
   Fukuda, A.
   Kakiuchi, T.
   Matsuno, N.
   Tanaka, H.
   Nakazawa, A.
   Kasahara, M.
TI Epstein-Barr Virus Infection after Pediatric Living-Related Liver
   Transplantation-Management and Risk Factors
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 23rd International Congress of the Transplantation-Society
CY AUG 15-19, 2010
CL Vancouver, CANADA
SP Transplantat Soc
ID POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE
AB Introduction. Posttransplant lymphoproliferative disorder (PTLD) is one of the severe complications after pediatric liver transplantation. Epstein-Barr virus (EBV) infection is a major risk factor developing PTLD. This study evaluates the risk factors, incidence, and clinical presentation of EBV infection at our institute.
   Patients and Methods. This study examines 81 children who underwent living-related liver transplantation (LRLT) from November 2005 to December 2009. The immunosuppression protocol consisted of tacrolimus and low-dose steroids, which were withdrawn by 3 months after LRLT. Additional immunosuppression was indicated for the selected cases because of recurrent rejection or renal insufficiency. Fifteen ABO blood type incompatible LRLTs were enrolled into this study. EBV was periodically monitored by the use of a real-time quantitative polymerase chain reaction (cut-of value, >10(2) copies/Jug DNA). The median follow-up period was 637 days (range, 85 to 1548 days). These patients were divided into two groups: EBV infection versus EBV noninfection, for analysis of risk factors by univariate analysis.
   Results. The incidence of EBV infection was 50.6% (n = 41) with the mean onset of 276 279 postoperative days (range, 7 to 1229 days). Nine cases (22.5%) presented clinical symptoms related to EBV infection, consisting of adenoid hypetrophy (n = 5), Evans's syndroms (n = 2), hemophagocytic syndrome (n = 1), and erythema nodosum (n = 1). There was no case of PTLD. The combination of a preoperative EBV seropositive donor and an EBV seronegative recipient was a high risk factor for postoperative EBV infection among the recipients (56.1% versus 26.8%, P < .05). The mean age at operation among the EBV infection group was younger than that of the EBV noninfection group (22 +/- 30 months versus 62 +/- 68 months; P < .05). The incidence of acute rejection episodes and cytomegalovirus infections; ABO blood type incompatible LRLT, and the length of steroid treatment and the additional irnmunosuppression were not significantly different between the two groups.
   Conclusion. There were various clinical presentations related to EBV infection; however, none of our patients developed PTLD. Careful monitoring of EBV infection especially for cases with donor seropositivity is important to prevent disease progression.
C1 [Shigeta, T.; Sakamoto, S.; Fukuda, A.; Kakiuchi, T.; Matsuno, N.; Kasahara, M.] Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Setagaya Ku, Tokyo 1578535, Japan.
   [Imadome, K.] Natl Res Inst Child Hlth & Dev, Dept Infect Dis, Setagaya Ku, Tokyo 1578535, Japan.
   [Tanaka, H.] Natl Ctr Child Hlth & Dev, Dept Pediat Surg, Setagaya Ku, Tokyo 1578535, Japan.
   [Nakazawa, A.] Natl Ctr Child Hlth & Dev, Dept Clin Pathol, Setagaya Ku, Tokyo 1578535, Japan.
RP Shigeta, T (reprint author), Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM shigeta-t@ncchd.go.jp
CR BUSUTTIL RW, 2005, TRANSPLANTATION LIVE, P1247
   Fernandez MC, 2009, PEDIATR TRANSPLANT, V13, P307, DOI 10.1111/j.1399-3046.2008.00914.x
   Hurwitz M, 2004, PEDIATR TRANSPLANT, V8, P267, DOI 10.1111/j.1399-3046.2004.00129.x
   Kerkar N, 2010, PEDIATR TRANSPLANT, V14, P504, DOI 10.1111/j.1399-3046.2009.01258.x
   Lee TC, 2005, AM J TRANSPLANT, V5, P2222, DOI 10.1111/j.1600-6143.2005.01002.x
   Paya CV, 1999, TRANSPLANTATION, V68, P1517, DOI 10.1097/00007890-199911270-00015
   Smets F, 2002, PEDIATR TRANSPLANT, V6, P280, DOI 10.1034/j.1399-3046.2002.02029.x
   Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165
   Yokoyama S, 2009, LIVER TRANSPLANT, V15, P446, DOI 10.1002/lt.21595
   Yokoyama S, 2007, TRANSPLANTATION, V84, P798, DOI 10.1097/01.tp.0000280544.06865.07
NR 10
TC 6
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2010
VL 42
IS 10
BP 4178
EP 4180
DI 10.1016/j.transproceed.2010.09.134
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 700IQ
UT WOS:000285732200074
PM 21168657
ER

PT J
AU Miloh, T
   Kerkar, N
   Parkar, S
   Emre, S
   Annunziato, R
   Mendez, C
   Arnon, R
   Suchy, F
   Rodriguez-Laiz, G
   Martin, JDR
   Sturdevant, M
   Iyer, K
AF Miloh, Tamir
   Kerkar, Nanda
   Parkar, Sanobar
   Emre, Sukru
   Annunziato, Rachel
   Mendez, Carlos
   Arnon, Ronen
   Suchy, Frederick
   Rodriguez-Laiz, Gonzalo
   Martin, Juan Del Rio
   Sturdevant, Mark
   Iyer, Kishore
TI Improved outcomes in pediatric liver transplantation for acute liver
   failure
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE acute liver failure; liver transplantation; children; pediatric; living
   donor
ID FULMINANT HEPATIC-FAILURE; CHILDREN; EXPERIENCE; SPLIT; SURVIVAL;
   PATIENT
AB OLT is a life-saving option for ALF. Aim: To evaluate our outcomes in pediatric OLT for ALF. Methods: Retrospective review of our data between 1992 and 2007. Results: Of 142 children with ALF, 126 were listed, of which 40 spontaneously improved, nine died, and 77 underwent OLT (median waiting time four days). Fifty-three children received deceased donor grafts (34 whole and 19 split grafts), and there were 24 living donor grafts. The one- and five-yr patient survival was 87% and 80%, and graft survival 83% and 79%, respectively. Thirteen patients died after OLT, and there were nine retransplants in seven patients. Patient weight, length of stay, creatinine, and infection were significantly associated with death; increased weight and black ethnicity were associated with graft loss on univariate analysis, but not on multivariate analysis. There were no significant differences in patient survival (one and five yr), graft loss, or other complications between the groups. Conclusion: We report the largest single-center study of OLT in pediatric ALF, demonstrating no difference in outcomes between different graft types. Our liberal use of segmental grafts may allow earlier OLT in this high-risk cohort and contribute to our excellent outcomes.
C1 [Miloh, Tamir; Kerkar, Nanda; Parkar, Sanobar; Arnon, Ronen; Suchy, Frederick; Rodriguez-Laiz, Gonzalo; Martin, Juan Del Rio; Sturdevant, Mark; Iyer, Kishore] Mt Sinai Hosp, Dept Pediat, New York, NY 10029 USA.
   [Miloh, Tamir; Kerkar, Nanda; Parkar, Sanobar; Arnon, Ronen; Suchy, Frederick; Rodriguez-Laiz, Gonzalo; Martin, Juan Del Rio; Sturdevant, Mark; Iyer, Kishore] Mt Sinai Hosp, Recanati Miller Transplant Inst, New York, NY 10029 USA.
   [Emre, Sukru] Yale Univ, Dept Surg Transplant & Pediat, New Haven, CT USA.
   [Annunziato, Rachel] Fordham Univ, Dept Psychol, New York, NY 10023 USA.
RP Miloh, T (reprint author), Mt Sinai Hosp, Dept Pediat, 1 Gustave L Levy Pl,Box 1104, New York, NY 10029 USA.
EM tamir.miloh@mountsinai.org
OI Rodriguez Laiz, Gonzalo/0000-0002-8265-8468
CR Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Becker NS, 2008, LIVER TRANSPLANT, V14, P1125, DOI 10.1002/lt.21491
   Campsen J, 2008, LIVER TRANSPLANT, V14, P1273, DOI 10.1002/lt.21500
   Centeno MA, 2002, PEDIATR CRIT CARE ME, V3, P227, DOI 10.1097/00130478-200207000-00004
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Emre S, 1999, LIVER TRANSPLANT SUR, V5, P161, DOI 10.1002/lt.500050315
   Farmer DG, 2009, ANN SURG, V250, P484, DOI 10.1097/SLA.0b013e3181b480ad
   Fruchtman SM, 2004, BIOL BLOOD MARROW TR, V10, P741, DOI 10.1016/j.bbmt.2004.07.003
   Goss JA, 1998, ARCH SURG-CHICAGO, V133, P839, DOI 10.1001/archsurg.133.8.839
   Karakayali H, 2007, TRANSPL P, V39, P1157, DOI 10.1016/j.transproceed.2007.02.053
   Lee WM, 2008, HEPATOLOGY, V47, P1401, DOI 10.1002/hep.22177
   Lee WS, 2005, J PEDIATR GASTR NUTR, V40, P575, DOI 10.1097/01.MPG.0000158524.30294.E2
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   Mack CL, 2001, LIVER TRANSPLANT, V7, P890, DOI 10.1053/jlts.2001.27963
   Mahadeb P, 2009, PEDIATR TRANSPLANT, V13, P414, DOI 10.1111/j.1399-3046.2008.01008.x
   Miloh T, 2009, SEMIN LIVER DIS, V29, P134, DOI 10.1055/s-0029-1202551
   Nadalin S, 2007, TRANSPL INT, V20, P519, DOI 10.1111/j.1432-2277.2007.00474.x
   Ng V, 2008, AM J TRANSPLANT, V8, P386, DOI 10.1111/j.1600-6143.2007.02056.x
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Rhee C, 2006, LIVER TRANSPLANT, V12, P1347, DOI 10.1002/lt.20806
   Squires RH, 2008, SEMIN LIVER DIS, V28, P153, DOI 10.1055/s-2008-1073115
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Strauss A, 2009, PEDIATR TRANSPLANT, V13, P838, DOI 10.1111/j.1399-3046.2008.01071.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Uemoto S, 2000, TRANSPLANTATION, V70, P152
NR 25
TC 14
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2010
VL 14
IS 7
BP 863
EP 869
DI 10.1111/j.1399-3046.2010.01356.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 665WR
UT WOS:000283067800015
PM 20609170
ER

PT J
AU Oh, SH
   Kim, KM
   Kim, DY
   Lee, YJ
   Rhee, KW
   Jang, JY
   Chang, SH
   Lee, SY
   Kim, JS
   Choi, BH
   Park, SJ
   Yoon, CH
   Ko, GY
   Sung, KB
   Hwang, GS
   Choi, KT
   Yu, E
   Song, GW
   Ha, TY
   Moon, DB
   Ahn, CS
   Kim, KH
   Hwang, S
   Park, KM
   Lee, YJ
   Lee, SG
AF Oh, Seak Hee
   Kim, Kyung Mo
   Kim, Dae Yeon
   Lee, Yeoun Joo
   Rhee, Kang Won
   Jang, Joo Young
   Chang, Soo Hee
   Lee, Sun Youn
   Kim, Joon-Sung
   Choi, Bo Hwa
   Park, Sung-Jong
   Yoon, Chong Hyun
   Ko, Gi-Young
   Sung, Kyu-Bo
   Hwang, Gyu-Sam
   Choi, Kyu-Taek
   Yu, Eunsil
   Song, Gi-Won
   Ha, Tae-Yong
   Moon, Deok-Bog
   Ahn, Chul-Soo
   Kim, Ki-Hun
   Hwang, Shin
   Park, Kwang-Min
   Lee, Young-Joo
   Lee, Sung-Gyu
TI Long-term outcomes of pediatric living donor liver transplantation at a
   single institution
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; children; outcome
ID HEPATIC-ARTERY THROMBOSIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE;
   EPSTEIN-BARR-VIRUS; CENTER EXPERIENCE; RECIPIENTS; CHILDREN; SURVIVAL;
   SIZE; DEFINITIONS; TACROLIMUS
AB There have only been a few studies on the long-term outcomes and prognostic factors after pediatric LDLT. We conducted a retrospective, single-center assessment of the outcomes as well as the demographic and clinical factors that influenced the poor outcomes in 113 children aged < 16 (median age 21 months; 6 months-15.5 yr) who underwent 115 LDLTs, predominantly for biliary atresia (60.9%) and FHF (14.8%), between 1994 and 2006 at Asan Medical Center. Left lateral segment or left lobe grafts were implanted into most of these children (86.9%) according to routine procedures. The overall rates of graft survival at one, five, and 10 yr were 89.6%, 83.0%, and 81.5%, respectively, and the overall rates of patient survival were 92.9%, 86.3%, and 84.8%, respectively. Virus-related disease (41.2%) and chronic rejection (29.4%) were the major causes of mortality. On multivariate analysis, UNOS status 1a and 1b and chronic rejection were significant risk factors for both graft and patient loss, whereas the PELD score > 25 was a significant risk factor for graft loss. Patient and graft survival may be related not only to post-operative complications, but also to the patient's preoperative clinical condition.
C1 [Oh, Seak Hee; Kim, Kyung Mo; Lee, Yeoun Joo; Rhee, Kang Won; Jang, Joo Young; Chang, Soo Hee; Lee, Sun Youn; Kim, Joon-Sung; Choi, Bo Hwa; Park, Sung-Jong] Univ Ulsan, Coll Med, Childrens Hosp, Dept Pediat,Asan Med Ctr, Seoul 138736, South Korea.
   [Kim, Dae Yeon] Univ Ulsan, Coll Med, Childrens Hosp, Asan Med Ctr,Dept Pediat Surg, Seoul 138736, South Korea.
   [Yoon, Chong Hyun] Univ Ulsan, Coll Med, Childrens Hosp, Asan Med Ctr,Dept Pediat Radiol, Seoul 138736, South Korea.
   [Ko, Gi-Young; Sung, Kyu-Bo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul 138736, South Korea.
   [Hwang, Gyu-Sam; Choi, Kyu-Taek] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol, Seoul 138736, South Korea.
   [Yu, Eunsil] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea.
   [Song, Gi-Won; Ha, Tae-Yong; Moon, Deok-Bog; Ahn, Chul-Soo; Kim, Ki-Hun; Hwang, Shin; Lee, Sung-Gyu] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg,Div Hepatobiliary Surg & Liver Trasnspl, Seoul 138736, South Korea.
   [Park, Kwang-Min; Lee, Young-Joo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg,Div Hepatobiliary & Pancreas Surg, Seoul 138736, South Korea.
RP Kim, KM (reprint author), Univ Ulsan, Coll Med, Childrens Hosp, Dept Pediat,Asan Med Ctr, 388-1 Pungnap Dong, Seoul 138736, South Korea.
EM kmkim@amc.seoul.kr
OI Kim, Kyung Mo/0000-0001-7896-6751
CR Barshes NR, 2006, LIVER TRANSPLANT, V12, P475, DOI 10.1002/lt.20703
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Carnevale FC, 2008, J VASC INTERV RADIOL, V19, P1439, DOI 10.1016/j.jvir.2008.06.012
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Cochran JB, 2007, PEDIATR EMERG CARE, V23, P129, DOI 10.1097/PEC.0b013e3180308f4b
   Demetris A, 2000, Hepatology, V31, P792
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Egawa H, 2008, J HEPATO-BILIARY-PAN, V15, P131, DOI 10.1007/s00534-007-1298-2
   Emre S, 2002, PEDIATR TRANSPLANT, V6, P43, DOI 10.1034/j.1399-3046.2002.1r072.x
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   Harris NL, 1999, J CLIN ONCOL, V17, P3835
   Holmes RD, 2002, PEDIATR TRANSPLANT, V6, P456, DOI 10.1034/j.1399-3046.2002.02043.x
   Hwang S, 2006, LIVER TRANSPLANT, V12, P920, DOI 10.1002/lt.20734
   Jain A, 2003, TRANSPLANTATION, V75, P1020, DOI 10.1097/01.TP.0000056168.79903.20
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Jang JY, 2008, TRANSPL P, V40, P2546, DOI 10.1016/j.transproceed.2008.07.014
   Kim JS, 2008, TRANSPL P, V40, P2512, DOI 10.1016/j.transproceed.2008.07.013
   Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Ko GY, 2007, J VASC INTERV RADIOL, V18, P1215, DOI 10.1016/j.jvir.2007.06.029
   Lee SG, 1996, TRANSPLANT P, V28, P2383
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   McDiarmid SV, 1998, J PEDIATR GASTR NUTR, V26, P90, DOI 10.1097/00005176-199801000-00016
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   McDiarmid SV, 2004, LIVER TRANSPLANT, V10, pS23, DOI 10.1002/lt.20272
   McDiarmid SV, 1998, TRANSPLANTATION, V66, P1604, DOI 10.1097/00007890-199812270-00006
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   OZAWA K, 1992, ANN SURG, V216, P547, DOI 10.1097/00000658-199211000-00004
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   Tanaka A, 1996, TRANSPLANT INT, V9, P15, DOI 10.1111/j.1432-2277.1996.tb00847.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   Wiesner RH, 2004, LIVER TRANSPLANT, V10, pS17, DOI 10.1002/lt.20273
NR 39
TC 14
Z9 22
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2010
VL 14
IS 7
BP 870
EP 878
DI 10.1111/j.1399-3046.2010.01357.x
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 665WR
UT WOS:000283067800016
PM 20609169
ER

PT J
AU Gupta, S
   Fricker, FJ
   Gonzalez-Peralta, RP
   Slayton, WB
   Schuler, PM
   Dharnidharka, VR
AF Gupta, Sushil
   Fricker, Frederick J.
   Gonzalez-Peralta, Regino P.
   Slayton, William B.
   Schuler, Pamela M.
   Dharnidharka, Vikas R.
TI Post-transplant lymphoproliferative disorder in children: Recent
   outcomes and response to dual rituximab/low-dose chemotherapy
   combination
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; Epstein-Barr virus; outcome; PTLD; rituximab; solid organ;
   transplantation
ID SOLID-ORGAN TRANSPLANTATION; SINGLE-AGENT RITUXIMAB;
   HEALTHY-INDIVIDUALS; ANTIBODY RITUXIMAB; PEDIATRIC-PATIENTS; DISEASE;
   PTLD; RECIPIENTS; IMMUNOSUPPRESSION; REDUCTION
AB PTLD is a major complication after transplantation. Treatment options for PTLD are not standardized, usually sequential, starting with reduction in immunosuppression. Recently, we have used a dual combination of rituximab and reduced dose chemotherapy (R/C) directly after failed RI. We retrospectively identified 30 pediatric PTLD cases across four organ systems at our center from 1995 to 2008. We assessed recent outcomes of PTLD in children, comparing the responses to different regimens. Two-yr failure-free survival was best in renal and heart recipients (80-88%), followed by liver (57%) and lung (0%). Of note, two patients were Epstein-Barr peripheral blood viral load low positive but tumor EBER negative. Three patients had no detectable viral load but were EBER positive. The R/C regimen (n = 8) had the highest CR rate (100%), low recurrence (12%) and lowest mortality (12%). Interferon (n = 4) had 75% CR, 33% recurrence and 25% mortality. Rituximab/prednisone (n = 5) had 80% CR, 50% recurrence and 20% mortality. Other chemotherapy (n = 7, including all 4 T-cell PTLDs) had 57% CR, 0% recurrence and 14% mortality. Direct dual R/C combination therapy after failed RI is effective and offers another treatment option for B-cell PTLD.
C1 [Dharnidharka, Vikas R.] Univ Florida, Hlth Sci Ctr, Div Pediat Nephrol, Coll Med,Dept Pediat, Gainesville, FL 32610 USA.
   Shands Childrens Hosp, Gainesville, FL USA.
RP Dharnidharka, VR (reprint author), Univ Florida, Hlth Sci Ctr, Div Pediat Nephrol, Coll Med,Dept Pediat, 1600 SW Archer Rd,POB 100296,Room HD 214, Gainesville, FL 32610 USA.
EM vikasmd@peds.ufl.edu
CR Allen UD, 2005, PEDIATR TRANSPLANT, V9, P450, DOI 10.1111/j.1399-3046.2005.00318.x
   Aull MJ, 2004, TRANSPLANTATION, V78, P1676, DOI 10.1097/01.TP.0000144333.19106.58
   Boyle GJ, 1997, J PEDIATR-US, V131, P309, DOI 10.1016/S0022-3476(97)70173-2
   Choquet S, 2006, BLOOD, V107, P3053, DOI 10.1182/blood-2005-01-0377
   Choquet S, 2007, HAEMATOL-HEMATOL J, V92, P273, DOI 10.3324/haematol.10595
   Cohen AH, 2000, AM J RESP CRIT CARE, V161, P1252
   COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005
   Davis CL, 1998, TRANSPLANTATION, V66, P1770, DOI 10.1097/00007890-199812270-00035
   Dharnidharka VR, 2009, PEDIATR NEPHROL, V24, P731, DOI 10.1007/s00467-007-0582-3
   Dharnidharka VR, 2009, POSTTRANSPLANT LYMPH, P17
   Evens AM, 2010, J CLIN ONCOL, V28, P1038, DOI 10.1200/JCO.2009.25.4961
   Fernandez MC, 2009, PEDIATR TRANSPLANT, V13, P307, DOI 10.1111/j.1399-3046.2008.00914.x
   FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102
   Gallego S, 2010, PEDIATR TRANSPLANT, V14, P61, DOI 10.1111/j.1399-3046.2009.01181.x
   Gross TG, 2005, J CLIN ONCOL, V23, P6481, DOI 10.1200/JCO.2005.08.074
   Gross TG, 1998, ANN ONCOL, V9, P339, DOI 10.1023/A:1008263226895
   Hayashi RJ, 2001, J PEDIAT HEMATOL ONC, V23, P14, DOI 10.1097/00043426-200101000-00005
   HEBERT D, 1998, PEDIATR TRANSPLANT, V1, P107
   Henry DD, 2008, TRANSPL INFECT DIS, V10, P426, DOI 10.1111/j.1399-3062.2008.00328.x
   Kerkar N, 2010, PEDIATR TRANSPLANT, V14, P504, DOI 10.1111/j.1399-3046.2009.01258.x
   McDonald RA, 2008, AM J TRANSPLANT, V8, P984, DOI 10.1111/j.1600-6143.2008.02167.x
   MIYASHITA EM, 1995, CELL, V80, P593, DOI 10.1016/0092-8674(95)90513-8
   MORRISON VA, 1994, AM J MED, V97, P14, DOI 10.1016/0002-9343(94)90043-4
   Newell KA, 1996, TRANSPLANTATION, V62, P370, DOI 10.1097/00007890-199608150-00012
   Oertel SHK, 2005, AM J TRANSPLANT, V5, P2901, DOI 10.1111/j.1600-6143.2005.01098.x
   Orjuela M, 2003, CLIN CANCER RES, V9, p3945S
   SHAPIRO RS, 1988, NEW ENGL J MED, V318, P1334
   Svoboda J, 2006, TRANSPLANT INT, V19, P259, DOI 10.1111/j.1432-2277.2006.00284.x
   Swerdlow SH, 1997, SEMIN DIAGN PATHOL, V14, P2
   SWINNEN LJ, 1995, BLOOD, V86, P3333
   Swinnen LJ, 2008, TRANSPLANTATION, V86, P215, DOI 10.1097/TP.0b013e3181761659
   Trappe R, 2009, AM J TRANSPLANT, V9, P2331, DOI 10.1111/j.1600-6143.2009.02772.x
   Trappe R, 2007, TRANSPLANTATION, V83, P912, DOI 10.1097/01.tp.0000258647.50947.78
   Trappe RU, 2007, TRANSPLANTATION, V84, P1708, DOI 10.1097/01.tp.0000295987.12996.19
   Tsai DE, 2001, TRANSPLANTATION, V71, P1076, DOI 10.1097/00007890-200104270-00012
   WAGNER HJ, 1992, J CLIN MICROBIOL, V30, P2826
   Walling DM, 2003, J VIROL, V77, P6546, DOI 10.1128/JVI.77.11.6546-6550.2003
   Webber S, 2004, BLOOD, V104, p213A
   Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6
   Younes BS, 2000, TRANSPLANTATION, V70, P94
NR 40
TC 15
Z9 15
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2010
VL 14
IS 7
BP 896
EP 902
DI 10.1111/j.1399-3046.2010.01370.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 665WR
UT WOS:000283067800020
PM 20642490
ER

PT J
AU Cag, M
   Audet, M
   Saouli, AC
   Panaro, F
   Piardi, T
   Cinqualbre, J
   Wolf, P
AF Cag, M.
   Audet, M.
   Saouli, A. C.
   Panaro, F.
   Piardi, T.
   Cinqualbre, J.
   Wolf, P.
TI Does Arterialisation Time Influence Biliary Tract Complications After
   Orthotopic Liver Transplantation?
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID CARDIAC DEATH; REPERFUSION INJURY; SINGLE-CENTER; STRICTURES;
   EXPERIENCE; UNIVERSITY; ISCHEMIA; DONATION; OUTCOMES; DONORS
AB Background. In the cardiac death donor era, many reports deal with biliary tract complications and concerns about ischemic reperfusion injury owing to the exclusive arterial vascularization of the biliary tree, the warm ischemia time has been implicated as responsible for biliary lesions during organ procurement. We defined the arterialization time as the second warm ischemia time. Our purpose was to study the correlation between the arterialization time during liver implantation and the appearance of biliary lesions.
   Methods. We retrospectively collected data from the last 5-years of orthotopic liver transplantation: namely, indications, cold perfusion fluid, cold ischemia time, operative procedure times, and acute rejection events. We excluded split-liver transplantations, retransplantations, pediatric patients, transplantations for cholestatic disease, cases where hepatic artery thrombosis happened before biliary complications, or patients with post-transplant cytomegalovirus infection. We defined 2 groups: A) without biliary complications; and B) with biliary complications. We compared the mean arterialization time using Student t test to define whether the warm ischemic time during implantation was responsible for biliary tract complications. A P value of <.05 was considered to be significant.
   Results. Between 2004 and the end of 2008, we grafted 402 patients among whom 243 met the inclusion criteria: 198 in group A and 45 in group B. Only the cold ischemia time was significantly different between the 2 groups (P = .039).
   Conclusion. After the anhepatic time, the surgeon may take time for the arterial anastomosis without fearing increased biliary damage.
C1 [Cag, M.; Audet, M.; Saouli, A. C.; Panaro, F.; Piardi, T.; Cinqualbre, J.; Wolf, P.] Hop Hautepierre, Strasbourg, France.
RP Cag, M (reprint author), 1 Ave Moliere, F-67098 Strasbourg, France.
EM murat.cag@chru-strasbourg.fr
CR Abt P, 2003, TRANSPLANTATION, V75, P1659, DOI 10.1097/01.TP.0000062574.18648.7C
   Buis CI, 2006, J HEPATO-BILIARY-PAN, V13, P517, DOI 10.1007/s00534-005-1080-2
   de Rougemont O, 2009, LIVER TRANSPLANT, V15, P1172, DOI [10.1002/lt.21876, 10.1002/It.21876]
   Detry O, 2009, TRANSPL P, V41, P582, DOI 10.1016/j.transproceed.2009.01.001
   Foley DP, 2005, ANN SURG, V242, P724, DOI 10.1097/01.sla.0000186178.07110.92
   Herrera Eulo Lupi, 2006, Archivos de Cardiologia de Mexico, V76, pS6
   HICKMAN R, 1990, HEPATOLOGY, V11, P471, DOI 10.1002/hep.1840110319
   Maheshwari A, 2007, LIVER TRANSPLANT, V13, P1645, DOI 10.1002/It.21212
   MCMASTER P, 1980, BRIT J SURG, V67, P321, DOI 10.1002/bjs.1800670507
   Nakamura N, 2005, TRANSPLANTATION, V79, P427, DOI 10.1097/01.TP.0000152800.19986.9E
   Nishida S, 2006, J HEPATO-BILIARY-PAN, V13, P511, DOI 10.1007/s00534-005-1081-1
   Pacholczyk M, 2006, TRANSPLANT P, V38, P247, DOI 10.1016/j.transproceed.2005.12.076
   Polese L, 2007, TRANSPL P, V39, P1942, DOI 10.1016/j.transproceed.2007.05.053
   SANKARY HN, 1995, HEPATOLOGY, V21, P63, DOI 10.1016/0270-9139(95)90409-3
   Sanna C, 2009, TRANSPL P, V41, P1319, DOI 10.1016/j.transproceed.2009.03.086
   Sanni A, 2006, TRANSPLANT P, V38, P2677, DOI 10.1016/j.transproceed.2006.08.008
   STARZL TE, 1982, HEPATOLOGY, V2, P614
   Tixier D, 2007, RECOMMANDATIONS TECH
   Wang KX, 2008, CHINESE MED J-PEKING, V121, P2004
   1957, COUINAUD FOIE ETUDES
NR 20
TC 3
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2010
VL 42
IS 9
BP 3630
EP 3633
DI 10.1016/j.transproceed.2010.08.061
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 689ZO
UT WOS:000284969800052
PM 21094829
ER

PT J
AU Sakamoto, S
   Egawa, H
   Kanazawa, H
   Shibata, T
   Miyagawa-Hayashino, A
   Haga, H
   Ogura, Y
   Kasahara, M
   Tanaka, K
   Uemoto, S
AF Sakamoto, Seisuke
   Egawa, Hiroto
   Kanazawa, Hiroyuki
   Shibata, Toshiya
   Miyagawa-Hayashino, Aya
   Haga, Hironori
   Ogura, Yasuhiro
   Kasahara, Mureo
   Tanaka, Koichi
   Uemoto, Sinji
TI Hepatic Venous Outflow Obstruction in Pediatric Living Donor Liver
   Transplantation Using Left-Sided Lobe Grafts: Kyoto University
   Experience
SO LIVER TRANSPLANTATION
LA English
DT Article
ID VEIN RECONSTRUCTION; VASCULAR COMPLICATIONS; SURGICAL TECHNIQUES;
   MONOSEGMENTS; STENOSIS; BLOCK; SIZE
AB The goals of this study were to evaluate the incidence of hepatic venous outflow obstruction (HVOO) in pediatric patients after living donor liver transplantation (LDLT) using left-sided lobe grafts and to assess the therapeutic modalities used for the treatment of this complication at a single center. Four hundred thirteen primary LDLT procedures were performed with left-sided lobe grafts between 1996 and 2006. All transplants identified with HVOO from a cohort of 380 grafts with survival greater than 90 days were evaluated with respect to the patient demographics, therapeutic intervention, recurrence, and outcome. Seventeen cases (4.5%) were identified with HVOO. Eight patients experienced recurrence after the initial balloon venoplasty. Two patients finally required stent placement after they experienced recurrence shortly after the initial balloon venoplasty. A univariate analysis revealed that a smaller recipient-to-donor body weight ratio and the use of reduced grafts were statistically significant risk factors. The cases with grafts with multiple hepatic veins had a higher incidence of HVOO. In conclusion, the necessity of repeated balloon venoplasty and stent placement was related to poor graft survival. Therefore, the prevention of HVOO should be a high priority in LDLT. When grafts with multiple hepatic veins and/or significant donor-recipient size mismatching are encountered, the use of a patch graft is recommended. Stent placement should be carefully considered because of the absence of data on the long-term patency of stents and stent-related complications. New stenting devices, such as drug-eluting and biodegradable stents, may be promising for the management of HVOO. Liver Transpl 16: 1207-1214, 2010. (C) 2010 AASLD.
C1 [Sakamoto, Seisuke; Egawa, Hiroto; Kanazawa, Hiroyuki; Ogura, Yasuhiro; Uemoto, Sinji] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan.
   [Shibata, Toshiya] Kyoto Univ, Grad Sch Med, Dept Radiol, Kyoto 6068507, Japan.
   [Miyagawa-Hayashino, Aya; Haga, Hironori] Kyoto Univ, Grad Sch Med, Dept Diagnost Pathol, Kyoto 6068507, Japan.
   [Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Tokyo, Japan.
   [Tanaka, Koichi] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan.
RP Sakamoto, S (reprint author), Kyoto Univ, Grad Sch Med, Dept Surg, 54 Kawara Cho, Kyoto 6068507, Japan.
EM sseisuke@kuhp.kyoto-u.ac.jp
FU Japanese Ministry of Education; Japanese Ministry of Health, Labor, and
   Welfare [17591328]
FX This work was supported in part by grants from the Scientific Research
   Fund of the Japanese Ministry of Education and by a research grant for
   immunology, allergy, and organ transplantation from the Japanese
   Ministry of Health, Labor, and Welfare (17591328).
CR Akamatsu N, 2004, TRANSPLANTATION, V77, P1768, DOI 10.1097/01.TP.0000131162.35391.9D
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   DHILLON AP, 1994, HEPATOLOGY, V19, P106
   EGAWA H, 1993, CLIN TRANSPLANT, V7, P306
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   EGAWA H, 2003, LIVING DONOR LIVER T, P75
   Egawa H, 1997, SURGERY, V121, P250, DOI 10.1016/S0039-6060(97)90353-6
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kedhi E, 2010, LANCET, V375, P201, DOI 10.1016/S0140-6736(09)62127-9
   Kilic M, 2008, PEDIATR TRANSPLANT, V12, P677, DOI 10.1111/j.1399-3046.2007.00877.x
   Ko GY, 2002, J VASC INTERV RADIOL, V13, P591, DOI 10.1016/S1051-0443(07)61652-2
   Kubo T, 2006, RADIOLOGY, V239, P285, DOI 10.1148/radiol.2391050387
   Kubota K, 2000, SURGERY, V128, P48, DOI 10.1067/msy.2000.106783
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   Lorenz JM, 2006, J VASC INTERV RADIOL, V17, P1753, DOI 10.1097/01.RVI.0000241540.31081.52
   Makuuchi M, 2003, TRANSPLANTATION, V75, pS23, DOI 10.1097/01.TP.0000046617.21019.17
   Mazariegos G V, 2000, Pediatr Transplant, V4, P322, DOI 10.1034/j.1399-3046.2000.00124.x
   MICHAEL D, 2007, TECH VASC INTERV RAD, V10, P240
   Mizuno S, 2008, DIGEST SURG, V25, P67, DOI 10.1159/000118033
   Navarro F, 1999, TRANSPLANTATION, V68, P646, DOI 10.1097/00007890-199909150-00009
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Sakamoto S, 2009, PEDIATR TRANSPLANT, V13, P507, DOI 10.1111/j.1399-3046.2008.01003.x
   TAKAYAMA T, 1994, TRANSPLANTATION, V58, P116
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Ueda M, 2003, LIVING DONOR LIVER T, P33
NR 28
TC 23
Z9 25
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2010
VL 16
IS 10
BP 1207
EP 1214
DI 10.1002/lt.22135
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 665XH
UT WOS:000283070000011
PM 20879019
ER

PT J
AU Haller, W
   Milford, DV
   Goodship, THJ
   Sharif, K
   Mirza, DF
   McKiernan, PJ
AF Haller, W.
   Milford, D. V.
   Goodship, T. H. J.
   Sharif, K.
   Mirza, D. F.
   McKiernan, P. J.
TI Successful Isolated Liver Transplantation in a Child with Atypical
   Hemolytic Uremic Syndrome and a Mutation in Complement Factor H
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Complement regulation; factor H; hemolytic uremic syndrome; pediatric
   liver transplantation; plasmapheresis; renal dysfunction
ID KIDNEY TRANSPLANTATION; ECULIZUMAB
AB A male infant was diagnosed with atypical hemolytic uremic syndrome (aHUS) at the age of 5.5 months. Sequencing of the gene (CFH) encoding complement factor H revealed a heterozygous mutation (c.3644G > A, p.Arg1215Gln). Despite maintenance plasmapheresis he developed recurrent episodes of aHUS and vascular access complications while maintaining stable renal function. At the age of 5 years he received an isolated split liver graft following a previously established protocol using pretransplant plasma exchange (PE) and intratransplant plasma infusion. Graft function, renal function and disease remission are preserved 2 years after transplantation. Preemptive liver transplantation prior to the development of end stage renal disease is a valuable option in the management of aHUS associated with CFH mutations.
C1 [Haller, W.; Sharif, K.; McKiernan, P. J.] Birmingham Childrens Hosp NHS Fdn Trust, Liver Unit, Birmingham, W Midlands, England.
   [Milford, D. V.] Birmingham Childrens Hosp NHS Fdn Trust, Dept Paediat Nephrol, Birmingham, W Midlands, England.
   [Goodship, T. H. J.] Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne, Tyne & Wear, England.
   [Mirza, D. F.] Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2TH, W Midlands, England.
RP Haller, W (reprint author), Birmingham Childrens Hosp NHS Fdn Trust, Liver Unit, Birmingham, W Midlands, England.
EM wolfram.haller@rch.org.au
FU UK Medical Research Council [G0701325]
FX THJ Goodship is supported by the UK Medical Research Council (Grant
   G0701325).
CR Ariceta G, 2009, PEDIATR NEPHROL, V24, P687, DOI 10.1007/s00467-008-0964-1
   Cheong HI, 2004, PEDIATR NEPHROL, V19, P454, DOI 10.1007/s00467-003-1371-2
   Eason JD, 2008, AM J TRANSPLANT, V8, P2243, DOI 10.1111/j.1600-6143.2008.02416.x
   Gruppo RA, 2009, NEW ENGL J MED, V360, P544, DOI 10.1056/NEJMc0809959
   Jalanko H, 2008, AM J TRANSPLANT, V8, P216, DOI 10.1111/j.1600-6143.2007.02029.x
   Lehtinen MJ, 2009, J BIOL CHEM, V284, P15650, DOI 10.1074/jbc.M900814200
   Loirat C, 2008, PEDIATR NEPHROL, V23, P1957, DOI 10.1007/s00467-008-0872-4
   Mache CJ, 2009, CLIN J AM SOC NEPHRO, V4, P1312, DOI 10.2215/CJN.01090209
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Nurnberger J, 2009, NEW ENGL J MED, V360, P542, DOI 10.1056/NEJMc0808527
   Pham PTT, 2007, NAT CLIN PRACT NEPHR, V3, P507, DOI 10.1038/ncpneph0574
   Remuzzi G, 2002, LANCET, V359, P1671, DOI 10.1016/S0140-6736(02)08560-4
   Remuzzi G, 2005, AM J TRANSPLANT, V5, P1146, DOI 10.1111/j.1600-6143.2005.00783.x
   Saland JM, 2006, AM J TRANSPLANT, V6, P1948, DOI 10.1111/j.1600-6143.2006.01375.x
   Saland JM, 2009, J AM SOC NEPHROL, V20, P940, DOI 10.1681/ASN.2008080906
   Saland JM, 2009, CLIN J AM SOC NEPHRO, V4, P201, DOI 10.2215/CJN.02170508
   Sellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392, DOI 10.1681/ASN.2006080811
   Shapiro R, 2001, TRANSPLANTATION, V72, P428, DOI 10.1097/00007890-200108150-00012
   Taylor CM, 2001, LANCET, V358, P1200, DOI 10.1016/S0140-6736(01)06339-5
   Zimmerhackl LB, 2007, PEDIATR NEPHROL, V22, P10, DOI 10.1007/s00467-006-0210-7
NR 20
TC 19
Z9 21
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2010
VL 10
IS 9
BP 2142
EP 2147
DI 10.1111/j.1600-6143.2010.03228.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 643PD
UT WOS:000281309400025
PM 20738267
ER

PT J
AU Bueno, J
   Perez-Lafuente, M
   Venturi, C
   Segarra, A
   Barber, I
   Molino, JA
   Romero, A
   Ortega, J
   Bilbao, I
   Martinez-Ibanez, V
   Charco, R
AF Bueno, J.
   Perez-Lafuente, M.
   Venturi, C.
   Segarra, A.
   Barber, I.
   Molino, J. A.
   Romero, A.
   Ortega, J.
   Bilbao, I.
   Martinez-Ibanez, V.
   Charco, R.
TI No-Touch Hepatic Hilum Technique to Treat Early Portal Vein Thrombosis
   After Pediatric Liver Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Angioplasty; biliary atresia; children; liver transplantation; portal
   vein thrombosis
ID STENT PLACEMENT; VENOUS STENOSIS; CHILDREN; RECONSTRUCTION;
   COMPLICATIONS; EXPERIENCE; RECIPIENTS
AB A 'no-touch' hilum technique used to treat early portal vein complications post-liver transplantation in five children with body weight < 10 kg is described. Four patients developed thrombosis and one portal flow absence secondary to collateral steal flow. A vascular sheath was placed through the previous laparotomy in the ileocolic vein (n = 2), inferior mesenteric vein (n = 1) or graft umbilical vein (n = 1). Portal clots were mechanically fragmented with balloon angioplasty. In addition, coil embolization of competitive collaterals (n = 3) and stent placement (n = 1) were performed. The catheter was left in place and exteriorized through the wound (n = 2) or a different transabdominal wall puncture (n = 3). A continuous transcatheter perfusion of heparin was subsequently administered. One patient developed recurrent thrombosis 24 h later which was resolved with the same technique. Catheters were removed surgically after a mean of 10.6 days. All patients presented portal vein patency at the end of follow-up. Three patients are alive after 5 months, 1.5 and 3.5 years, respectively; one patient required retransplantation 18 days postprocedure and the remaining patient died of adenovirus infection 2 months postprocedure. In conclusion, treatment of early portal vein complications following pediatric liver transplantation with this novel technique is feasible and effective.
C1 [Bueno, J.; Venturi, C.; Bilbao, I.; Charco, R.] Autonomous Univ Barcelona, Hosp Univ Valle Hebron, Pediat Liver Transplantat Unit, Barcelona, Spain.
   [Bueno, J.; Molino, J. A.; Martinez-Ibanez, V.] Autonomous Univ Barcelona, Hosp Univ Valle Hebron, Dept Pediat Surg, Barcelona, Spain.
   [Perez-Lafuente, M.; Segarra, A.; Romero, A.] Autonomous Univ Barcelona, Hosp Univ Valle Hebron, Intervent Radiol Unit, Barcelona, Spain.
   [Barber, I.] Autonomous Univ Barcelona, Hosp Univ Valle Hebron, Dept Pediat Radiol, Barcelona, Spain.
   [Ortega, J.] Autonomous Univ Barcelona, Hosp Univ Valle Hebron, Pediat Intens Care Unit, Barcelona, Spain.
   [Bilbao, I.; Charco, R.] Autonomous Univ Barcelona, Hosp Univ Valle Hebron, HBP Surg & Transplant Dept, Barcelona, Spain.
RP Bueno, J (reprint author), Autonomous Univ Barcelona, Hosp Univ Valle Hebron, Pediat Liver Transplantat Unit, Barcelona, Spain.
EM jbueno@vhebron.net
RI Charco, Ramon/H-8522-2012; Bilbao, Itxarone/N-4358-2014
OI Bilbao, Itxarone/0000-0002-7389-395X
CR Azoulay D, 2002, ANN SURG, V236, P713, DOI 10.1097/01.SLA.0000036264.66247.65
   AZOULAY D, 1993, SURG GYNECOL OBSTET, V176, P599
   Bueno J, 2007, TRANSPL P, V39, P2278, DOI 10.1016/j.transproceed.2007-07-042
   Carnevale FC, 2006, CARDIOVASC INTER RAD, V29, P457, DOI 10.1007/s00270-005-0046-8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Cherukuri R, 1998, TRANSPLANTATION, V65, P1124, DOI 10.1097/00007890-199804270-00018
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   Funaki B, 2000, RADIOLOGY, V215, P147
   Gomez-Gutierrez M, 2005, TRANSPLANT P, V37, P3906, DOI 10.1016/j.transproceed.2005.10.063
   HANAZAKI K, 1993, J SURG RES, V57, P380
   Hotta R, 2007, PEDIATR SURG INT, V23, P939, DOI 10.1007/s00383-007-1974-y
   Kim YJ, 2007, LIVER TRANSPLANT, V13, P1145, DOI 10.1002/lt.21076
   Ko GY, 2007, J VASC INTERV RADIOL, V18, P1215, DOI 10.1016/j.jvir.2007.06.029
   Ko GY, 2007, LIVER TRANSPLANT, V13, P530, DOI 10.1002/lt.21068
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   Moon DB, 2007, LIVER TRANSPLANT, V13, P1279, DOI 10.1002/lt.21252
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   THIEM HV, 2003, TRANSPLANTATION, V75, P1692
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Woo David H, 2007, Tech Vasc Interv Radiol, V10, P233, DOI 10.1053/j.tvir.2007.09.017
NR 20
TC 5
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2010
VL 10
IS 9
BP 2148
EP 2153
DI 10.1111/j.1600-6143.2010.03236.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 643PD
UT WOS:000281309400026
PM 20887425
ER

PT J
AU Heffron, TG
   Pillen, T
   Smallwood, G
   Henry, S
   Sekar, S
   Casper, K
   Solis, D
   Tang, WH
   Fasola, C
   Romero, R
AF Heffron, Thomas G.
   Pillen, Todd
   Smallwood, Gregory
   Henry, Stuart
   Sekar, Sundari
   Casper, Katherine
   Solis, David
   Tang, Wenhao
   Fasola, Carlos
   Romero, Rene
TI Incidence, impact, and treatment of portal and hepatic venous
   complications following pediatric liver transplantation: A single-center
   12 year experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pediatric liver transplantation; partial liver
   transplant; portal vein thrombosis; portal vein stenosis; hepatic vein
   outflow obstruction
ID VASCULAR COMPLICATIONS; VEIN RECONSTRUCTION; OUTFLOW OBSTRUCTION;
   THROMBOSIS; STENOSIS; GRAFTS; SPLIT; SIZE
AB PVT or PVS and HVOO are known causes of graft and patient loss after pediatric liver transplantation. Increased incidences of these complications have been reported in partial livers including DDSLT or LDLT. From 1997 to 2008, 241 consecutive pediatric patients received 271 hepatic grafts at a single center. Median follow-up is 1856 days. Surgical technique, demographics, lab values, and radiologic imaging procedures were obtained utilizing OTTR (R) to evaluate the relationship of portal and hepatic complications with risk factors, patient and graft survival. Grafts were composed of 115/271 (42.4%) partial livers of which 90 (33.2%) were DDSLT and 25 (9.2%) LDLT. Of 271 patients, 156 (57.6%) received whole-sized grafts. There were six PVC in five patients with one patient requiring retransplantation (0.34%) and no patient deaths. Utilizing all three hepatic vein orifices on the recipient hepatic vena cava and the donor hepatic vein cut short enables a wide hepatic outflow tract unlikely to twist. None of the 241 patients developed early or late complications of the hepatic vein. None of the last 128 consecutive patients who received 144 grafts over seven and a half yr have developed either early or late complications of the hepatic or portal vein. Partial-graft actuarial survival was similar to whole-graft survival (87.2% vs. 85.3% at one yr; 76.6% vs. 80.2 at three yr; p = 0.488). Likewise, patient survival was similar between partial grafts and whole grafts (93.8% vs. 93.1% at one yr; 89.8% vs. 87.2% at three yr; p = 0.688) with median follow-up of 1822 (+/- 1334) days. Patients receiving partial livers were significantly younger and smaller than patients receiving whole livers (p < 0.001). Portal and hepatic venous complications may have negative effects on patient or graft survival after pediatric liver transplantation. In our series, there was one graft and no patient loss related to portal or hepatic venous complications after pediatric liver transplantation over 12 yr.
C1 [Heffron, Thomas G.; Pillen, Todd; Smallwood, Gregory; Henry, Stuart; Sekar, Sundari; Casper, Katherine; Solis, David; Tang, Wenhao; Fasola, Carlos; Romero, Rene] Childrens Healthcare Atlanta, Atlanta, GA 30322 USA.
   [Heffron, Thomas G.; Fasola, Carlos] Emory Univ, Ctr Transplantat, Atlanta, GA 30322 USA.
   [Smallwood, Gregory; Romero, Rene] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
RP Heffron, TG (reprint author), Childrens Healthcare Atlanta, 1405 Clifton Rd NE, Atlanta, GA 30322 USA.
EM thomas.heffron@choa.org
CR Anderson CD, 2008, AM J TRANSPLANT, V8, P1197, DOI 10.1111/j.1600-6143.2008.02223.x
   Becker NS, 2008, LIVER TRANSPLANT, V14, P1125, DOI 10.1002/lt.21491
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   EMOND JC, 1990, ANN SURG, V212, P14
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   Kilic M, 2008, PEDIATR TRANSPLANT, V12, P677, DOI 10.1111/j.1399-3046.2007.00877.x
   Kishi Y, 2008, HEPATO-GASTROENTEROL, V55, P1008
   Ko EY, 2003, RADIOLOGY, V229, P806, DOI 10.1148/radiol.2293020700
   KO GK, 2008, LIVER TRANSPLANT, V4, P1505
   Kubo T, 2006, RADIOLOGY, V239, P285, DOI 10.1148/radiol.2391050387
   Mazariegos G V, 2000, Pediatr Transplant, V4, P322, DOI 10.1034/j.1399-3046.2000.00124.x
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Navarro F, 1999, TRANSPLANTATION, V68, P646, DOI 10.1097/00007890-199909150-00009
   Saing H, 2002, J PEDIATR SURG, V37, P1673, DOI 10.1053/jpsu.2002.36690
   Sakamoto S, 2009, PEDIATR TRANSPLANT, V13, P507, DOI 10.1111/j.1399-3046.2008.01003.x
   Sano K, 2002, ANN SURG, V236, P241, DOI 10.1097/01.SLA.0000021845.89475.00
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Sindhi R, 1999, J PEDIATR SURG, V34, P107, DOI 10.1016/S0022-3468(99)90238-5
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   [Anonymous], SCI REGISTRY TRANSPL
NR 27
TC 20
Z9 23
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2010
VL 14
IS 6
BP 722
EP 729
DI 10.1111/j.1399-3046.2009.01259.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 639UK
UT WOS:000280999900010
PM 20345612
ER

PT J
AU Nightingale, S
   O'Loughlin, EV
   Dorney, SFA
   Shun, A
   Verran, DJ
   Strasser, SI
   McCaughan, GW
   Jermyn, V
   Van Asperen, P
   Gaskin, KJ
   Stormon, MO
AF Nightingale, Scott
   O'Loughlin, Edward V.
   Dorney, Stuart F. A.
   Shun, Albert
   Verran, Deborah J.
   Strasser, Simone I.
   McCaughan, Geoffrey W.
   Jermyn, Vicki
   Van Asperen, Peter
   Gaskin, Kevin J.
   Stormon, Michael O.
TI Isolated liver transplantation in children with cystic fibrosis - An
   Australian experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; cystic fibrosis; pediatric transplantation
ID BILE-DUCT STENOSIS; COMBINED LUNG; PANCREAS TRANSPLANTATION; HEPATIC
   CIRRHOSIS; DISEASE; OUTCOMES; CENTERS; PATIENT
AB CF liver disease is an uncommon indication for pediatric LT. Determining optimal timing and type (isolated liver versus multi-organ) of transplantation for those with severe liver disease can be challenging and involves consideration of the extent of liver disease (PHT, synthetic dysfunction) and extrahepatic factors such as pulmonary function. We present the experience of isolated LT for CF at our center. Eight children received one allograft each (3.9% of all grafts). One- and four-yr survivals are both 75%. The two deaths occurred within the first two months after LT, and in both cases, invasive fungal infections were implicated, one following treatment for acute severe rejection. All had significant PHT, and six had synthetic dysfunction. All had roux-en Y biliary anastomoses and none developed long-term biliary complications. Seven had pulmonary colonization with Pseudomonas aeruginosa and six with fungus at time of transplantation. Mean pre-LT FEV1 was 80% (range 59-116%) predicted, and lung function post-LT was stable. Isolated LT in children with CF is successful in those with relatively preserved pulmonary function, which does not appear to deteriorate as a consequence. Roux-en Y biliary anastomosis and antifungal prophylaxis should be a part of management of these patients.
C1 [Stormon, Michael O.] Childrens Hosp Westmead, Dept Gastroenterol, Sydney, NSW 2145, Australia.
   [Shun, Albert; Verran, Deborah J.; McCaughan, Geoffrey W.; Stormon, Michael O.] Australian Natl Liver Transplantat Unit, Sydney, NSW, Australia.
   [Verran, Deborah J.; Strasser, Simone I.; McCaughan, Geoffrey W.] Royal Prince Alfred Hosp, Sydney, NSW, Australia.
   [Van Asperen, Peter; Gaskin, Kevin J.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia.
   [Gaskin, Kevin J.] Childrens Hosp Westmead, James Fairfax Inst Paediat Nutr, Sydney, NSW 2145, Australia.
RP Stormon, MO (reprint author), Childrens Hosp Westmead, Dept Gastroenterol, Locked Bag 4001, Sydney, NSW 2145, Australia.
EM MichaeS6@chw.edu.au
OI Nightingale, Scott/0000-0003-0986-7105
CR *AUSTR NAT LIV TRA, LIV TRANSPL AUSTR NA
   Barshes NR, 2005, TRANSPLANTATION, V80, P1161, DOI 10.1097/01.tp.0000165717.23652.09
   Bartlett JR, 2009, JAMA-J AM MED ASSOC, V302, P1076, DOI 10.1001/jama.2009.1295
   Chavez-Cartaya R, 1999, TRANSPLANT P, V31, P2411, DOI 10.1016/S0041-1345(99)00407-8
   Colombo C, 2002, HEPATOLOGY, V36, P1374, DOI 10.1053/jhep.2002.37136
   Couetil JPA, 1997, TRANSPLANT INT, V10, P33, DOI 10.1111/j.1432-2277.1997.tb00533.x
   COUETIL JPA, 1995, J THORAC CARDIOV SUR, V110, P1415, DOI 10.1016/S0022-5223(95)70064-1
   COX KL, 1987, PEDIATRICS, V80, P571
   Efrati O, 2003, EUR J GASTROEN HEPAT, V15, P1073, DOI 10.1097/01.meg.0000085471.12407.92
   FAJARDO EU, 2001, AN ESP PEDIATR, V54, P228
   FEIGELSON J, 1993, ARCH DIS CHILD, V68, P653
   Fridell JA, 2005, TRANSPL P, V37, P3567, DOI 10.1016/j.transproceed.2005.09.091
   Fridell JA, 2003, J PEDIATR SURG, V38, P1152, DOI 10.1016/S0022-3468(03)00260-4
   GASKIN KJ, 1988, NEW ENGL J MED, V318, P340, DOI 10.1056/NEJM198802113180602
   GASKIN KJ, 1990, LANCET, V335, P1098, DOI 10.1016/0140-6736(90)92672-5
   Gooding I, 2005, LIVER TRANSPLANT, V11, P1522, DOI 10.1002/lt.20465
   Grannas G, 2008, TRANSPLANTATION, V85, P524, DOI 10.1097/TP.0b013e3181636f3f
   Lamireau T, 2006, CAN J GASTROENTEROL, V20, P475
   Lindblad A, 1999, HEPATOLOGY, V30, P1151, DOI 10.1002/hep.510300527
   MACK DR, 1995, J PEDIATR-US, V127, P881, DOI 10.1016/S0022-3476(95)70022-6
   Mekeel KL, 2007, LIVER TRANSPLANT, V13, P406, DOI 10.1002/lt.21070
   Melzi ML, 2006, TRANSPLANT INT, V19, P726, DOI 10.1111/j.1432-2277.2006.00344.x
   MIELES LA, 1989, LANCET, V1, P1073
   Molmenti EP, 2003, PEDIATR TRANSPLANT, V7, P93, DOI 10.1034/j.1399-3046.2003.00021.x
   Nash KL, 2008, AM J TRANSPLANT, V8, P162, DOI 10.1111/j.1600-6143.2007.02028.x
   NOBLEJAMIESON G, 1994, ARCH DIS CHILD, V71, P349
   NobleJamieson G, 1996, J ROY SOC MED, V89, P31
   SCOTTJUPP R, 1991, ARCH DIS CHILD, V66, P698
   STERN RC, 1994, CLIN TRANSPLANT, V8, P1
   Young AL, 2005, TRANSPLANTATION, V80, P605, DOI 10.1097/01.tp.0000167007.58199.9b
NR 30
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2010
VL 14
IS 6
BP 779
EP 785
DI 10.1111/j.1399-3046.2010.01341.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 639UK
UT WOS:000280999900018
PM 20557476
ER

PT J
AU Arnon, R
   Kerkar, N
   Davis, MK
   Anand, R
   Yin, WR
   Gonzalez-Peralta, RP
AF Arnon, Ronen
   Kerkar, Nanda
   Davis, Michael K.
   Anand, Ravinder
   Yin, Wanrong
   Gonzalez-Peralta, Regino P.
CA SPLIT Res Grp
TI Liver transplantation in children with metabolic diseases: The studies
   of pediatric liver transplantation experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE metabolic disorders; children; liver transplant; outcome
ID BILIARY ATRESIA; CHILDHOOD; SURVIVORS; FAILURE; SPLIT
AB Metabolic diseases are the second largest indication for LT in children after BA. There are limited data on the long-term post-transplant outcome in this unique group of patients. Therefore, our aim was to assess post-liver transplant outcomes and to evaluate risk factors for mortality and graft loss in children with metabolic disorders in comparison to those with non-metabolic diagnoses. We reviewed all patients enrolled in the SPLIT registry. Between 1995 and 2008, 446 of 2997 (14.9%) children enrolled in SPLIT underwent liver transplant for metabolic diseases. One-yr and five-yr patient survival for children with metabolic diseases was 94.6% and 88.9% and for those with other diseases 90.7% and 86.1% (log-rank p = 0.05), respectively. One-yr and five-yr graft survival for children with metabolic disorders was 90.8% and 83.8%, and for those with other diseases 85.4% and 78.0% (log-rank p = 0.005), respectively. Children with metabolic diseases were less likely to experience gastrointestinal complications (5.6% vs. 10.7%, p = 0.001), portal vein thrombosis (2.9% vs. 5.2%, p = 0.04), and reoperations within 30 days post-transplant (33.4% vs. 37.8%, p = 0.05) than those with other indications. In conclusion, children who underwent liver transplant for metabolic disease had similarly excellent patient survival as, and better graft survival than, those who received a liver allograft for other indications.
C1 [Arnon, Ronen; Kerkar, Nanda] Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
   [Arnon, Ronen; Kerkar, Nanda] Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Surg, Recanati Miller Transplant Inst, New York, NY 10029 USA.
   [Davis, Michael K.; Gonzalez-Peralta, Regino P.] Univ Florida, Div Pediat Gastroenterol Hepatol & Nutr, Gainesville, FL USA.
   [Davis, Michael K.; Gonzalez-Peralta, Regino P.] Shands Childrens Hosp, Gainesville, FL USA.
   [Anand, Ravinder; Yin, Wanrong] EMMES Corp, Rockville, MD USA.
RP Kerkar, N (reprint author), Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Pediat, 1 Gustave,L Levy Pl,Box 1104, New York, NY 10029 USA.
EM Nanda.Kerkar@mountsinai.org
FU National Institute of Diabetes and Digestive and Kidney Diseases,
   National Institutes of Health [U01-DK061693-01A1]; Astellas Pharma US;
   Roche Laboratories
FX This work was supported by the National Institute of Diabetes and
   Digestive and Kidney Diseases, National Institutes of Health
   (U01-DK061693-01A1), and unrestricted grants from Astellas Pharma US and
   Roche Laboratories.
CR Austin MT, 2006, J PEDIATR SURG, V41, P182, DOI 10.1016/j.jpedsurg.2005.10.091
   Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Barshes NR, 2005, LIVER TRANSPLANT, V11, P1193, DOI 10.1002/lt.20509
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   COX DR, 1972, J R STAT SOC B, V34, P187
   Kane R, 2001, TRANSPLANTATION, V72, P463
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kayler LK, 2003, AM J TRANSPLANT, V3, P334, DOI 10.1034/j.1600-6143.2003.00058.x
   Kuczmarski RJ, 2002, VITAL HLTH STAT, V11, P1
   Kuczmarski R. J., 2000, ADV DATA VITAL HLTH
   McDiarmid SV, 1998, LIVER TRANSPLANT SUR, V4, pS34
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Peeters PMJG, 2001, EUR J PEDIATR SURG, V11, P28, DOI 10.1055/s-2001-12188
   Prachalias AA, 2000, TRANSPL INT, V13, P207, DOI 10.1111/j.1432-2277.2000.tb01068.x
   Rodrigues F, 2005, LIVER TRANSPLANT, V11, P1417, DOI 10.1002/lt.20497
   Sze YK, 2009, TRANSPLANTATION, V87, P87, DOI 10.1097/TP.0b013e31818bc0c4
   Tung J, 2000, J PEDIATR GASTR NUTR, V31, P557, DOI 10.1097/00005176-200011000-00019
   Zhang Kristine Y, 2007, Clin Liver Dis, V11, P265, DOI 10.1016/j.cld.2007.04.002
NR 18
TC 19
Z9 19
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2010
VL 14
IS 6
BP 796
EP 805
DI 10.1111/j.1399-3046.2010.01339.x
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 639UK
UT WOS:000280999900020
PM 20557477
ER

PT J
AU Fernandez, D
   El-Azzabi, TI
   Jain, V
   Lloyd, C
   Wassmer, E
   Peake, D
   Gupte, GL
AF Fernandez, Daphin
   El-Azzabi, Tarek I.
   Jain, Vivek
   Lloyd, Carla
   Wassmer, Evangeline
   Peake, Deirdre
   Gupte, Girish L.
TI Neurologic Problems After Pediatric Liver Transplantation and Combined
   Liver and Bowel Transplantations: A Single Tertiary Centre Experience
SO TRANSPLANTATION
LA English
DT Article
DE Liver transplantation; Pediatric patients; Small bowel transplantation;
   Neurologic complications
ID COMPLICATIONS; RECIPIENTS; LEUKOENCEPHALOPATHY
AB Background. Neurologic problems postpediatric liver transplant have been reported in up to 46% of cases, and mortality is higher in the pediatric age group compared with adults.
   Methods. An internal audit was performed in all children undergoing solid organ transplant in the Liver unit at Birmingham Children's Hospital to identify children with neurologic complications.
   Results. One hundred seventeen children underwent 127 pediatric liver transplant and combined liver and small bowel transplant episodes over a 4-year period. Neurologic problems were present after 31 of 127 (24.4%) transplant episodes involving 29 children. Seizures were the most common presentation (n=17; 54.8%), followed by encephalopathy (n=11; 35.4%) and posterior reversible leukoencephalopathy syndrome (n=6; 19.3%). Other complications noted were central nervous system infection (n=4; 12.9%), cerebrovascular accident (n=3; 9.6%), peripheral neuropathy (n=2; 6.4%) and tremor, transient blurring of vision, auditory hallucinations and choreoathetosis (n=1; 3.2%) each. There were 27 deaths (23%) in 117 children after transplantation, and the mortality rate in the group with neurologic problem was 13.3% (n=4) compared with 26.7% (n=23) in children without neurologic problem (odds ratio 0.45, 95% confidence interval 0.142-1.439). In contrast to other studies, our study showed that the mortality rate was not higher in children with neurologic problems.
   Conclusion. Neurologic problems were relatively common after pediatric liver transplantation and combined liver and bowel transplantations; however, the mortality was lower when compared with previously reported studies.
C1 [Lloyd, Carla; Gupte, Girish L.] Birmingham Childrens Hosp Fdn NHS Trust, Liver Unit Including Small Bowel Transplantat, Birmingham B4 6NH, W Midlands, England.
   [Peake, Deirdre] Royal Belfast Childrens Hosp, Dept Pediat Neurol, Belfast, Antrim, North Ireland.
   [Fernandez, Daphin; El-Azzabi, Tarek I.; Jain, Vivek; Wassmer, Evangeline; Peake, Deirdre] Birmingham Childrens Hosp Fdn NHS Trust, Dept Neurol, Birmingham B4 6NH, W Midlands, England.
RP Gupte, GL (reprint author), Birmingham Childrens Hosp Fdn NHS Trust, Liver Unit Including Small Bowel Transplantat, Steelhouse Lane, Birmingham B4 6NH, W Midlands, England.
EM girish.gupte@bch.nhs.uk
CR Bechstein WO, 2000, TRANSPLANT INT, V13, P313, DOI 10.1111/j.1432-2277.2000.tb01004.x
   Boin IFSF, 2001, TRANSPLANT P, V33, P3695, DOI 10.1016/S0041-1345(01)02507-6
   Bronster DJ, 2000, CLIN TRANSPLANT, V14, P1, DOI 10.1034/j.1399-0012.2000.140101.x
   Doja A, 2006, J CHILD NEUROL, V21, P384, DOI 10.2310/7010.2006.00114
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   GARG BP, 1993, PEDIATR NEUROL, V9, P444, DOI 10.1016/0887-8994(93)90023-6
   Ghaus N, 2001, J NEUROL, V248, P1042, DOI 10.1007/s004150170023
   GRIDELLI B, 1994, TRANSPLANT P, V26, P193
   HALL WA, 1989, PEDIATR NEUROSCI, V15, P269, DOI 10.1159/000120482
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Keough WL, 2003, PEDIATR CLIN N AM, V50, P1451, DOI 10.1016/S0031-3955(03)00126-3
   Lewis MB, 2003, NEUROLOGY, V61, P1174
   MAWK JR, 1988, CHILD NERV SYST, V4, P26
   MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010
   PUJOL A, 1994, NEUROLOGY, V44, P1226
   Rand EB, 2003, GASTROENTEROL CLIN N, V32, P913, DOI 10.1016/S0889-8553(03)00048-7
   Singh N, 2000, TRANSPLANTATION, V69, P467, DOI 10.1097/00007890-200002270-00001
   Smets F, 2000, J HEPATOL, V32, P100, DOI 10.1016/S0168-8278(00)80195-6
   Vecino MC, 1999, TRANSPLANT P, V31, P3048, DOI 10.1016/S0041-1345(99)00665-X
   WESTROPE C, PEDIAT TRAN IN PRESS
   Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7
NR 21
TC 7
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 15
PY 2010
VL 90
IS 3
BP 319
EP 324
DI 10.1097/TP.0b013e3181e5b7fc
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 634KY
UT WOS:000280581200017
PM 20574418
ER

PT J
AU Arnon, R
   Annunziato, R
   Miloh, T
   Suchy, F
   Sakworawich, A
   Hiroshi, S
   Kishore, I
   Kerkar, N
AF Arnon, Ronen
   Annunziato, Rachel
   Miloh, Tamir
   Suchy, Frederick
   Sakworawich, Arnond
   Hiroshi, Sogawa
   Kishore, Iyer
   Kerkar, Nanda
TI Orthotopic liver transplantation for children with Alagille syndrome
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary; cholestasis; end-stage liver disease; liver transplantation;
   outcome; pediatric
ID EXTERNAL BILIARY DIVERSION; INTRACTABLE PRURITUS; INTRAHEPATIC
   CHOLESTASIS; ARTERIOHEPATIC DYSPLASIA; BILE-DUCTS; RETRANSPLANTATION;
   SURVIVAL; OUTCOMES
AB AGS is an inherited disorder involving the liver, heart, eyes, face, and skeleton. Aim: To determine the outcome of LT in children with AGS compared to those with BA. Methods: Children with AGS and BA who had a LT between 10/1987 and 5/2008 were identified from the UNOS database. Results: Of 11 467 children who received a liver transplant, 461 (4.0%) had AGS and 3056 (26.7%) had BA. One- and five-yr patient survival was significantly lower in patients with AGS in comparison with patients with BA (AGS; 82.9%, 78.4%, BA; 89.9%, 84%, respectively). Early death (< 30 days from transplant) was significantly higher in AGS than in BA. One- and five-yr graft survival was significantly lower in AGS than in BA (AGS; 74.7%, 61.5%, BA; 81.6%, 70.0%, respectively). Death from graft failure, neurological, and cardiac complications was significantly higher in patients with AGS than in patients with BA. Serum creatinine at transplant, prior LT, and cold ischemic time > 12 h were identified as risk factors for death. Conclusion: Children with AGS were older at the time of LT and their one- and five-yr patient and graft survival were significantly lower compared to BA. Risk factors for poor outcome in AGS after LT were identified.
C1 [Arnon, Ronen; Miloh, Tamir; Suchy, Frederick; Hiroshi, Sogawa; Kishore, Iyer; Kerkar, Nanda] Mt Sinai Med Ctr, Recanati Miller Transplantat Inst, New York, NY 10029 USA.
   [Annunziato, Rachel; Sakworawich, Arnond] Fordham Univ, New York, NY 10023 USA.
RP Arnon, R (reprint author), Mt Sinai Med Ctr, Recanati Miller Transplantat Inst, 1 Gustave L Levy Pl,Box 1104, New York, NY 10029 USA.
EM Ronen.Arnon@mountsinai.org
CR ADAMS PC, 1986, DIGEST DIS SCI, V31, P438, DOI 10.1007/BF01311683
   ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1
   ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2
   DANKS DM, 1977, ARCH DIS CHILD, V52, P360
   Davis A, 2009, LIVER TRANSPLANT, V15, P199, DOI 10.1002/lt.21664
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Emerick KM, 2002, HEPATOLOGY, V35, P1501, DOI 10.1053/jhep.2002.33332
   Englert C, 2006, PEDIATR TRANSPLANT, V10, P154, DOI 10.1111/j.1399-3046.2005.00432.x
   Ganschow R, 2001, TRANSPLANT P, V33, P3608, DOI 10.1016/S0041-1345(01)02553-2
   Harambat J, 2008, TRANSPLANTATION, V86, P1028, DOI 10.1097/TP.0b013e318187748f
   Kamath BM, 2003, GASTROENTEROL CLIN N, V32, P857, DOI 10.1016/S0889-8553(03)00054-2
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   Lykavieris P, 2001, GUT, V49, P431, DOI 10.1136/gut.49.3.431
   Maldini G, 2005, TRANSPLANT P, V37, P1174, DOI 10.1016/j.transproceed.2004.12.245
   Mattei P, 2006, J PEDIATR SURG, V41, P104, DOI 10.1016/j.pedsurg.2005.10.014
   Modi BP, 2007, J PEDIATR SURG, V42, P800, DOI 10.1016/j.jpedsurg.2006.12.032
   Ng VL, 2000, J PEDIATR GASTR NUTR, V30, P152, DOI 10.1097/00005176-200002000-00011
   Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235
   Quiros-Tejeira RE, 1999, J PEDIATR GASTR NUTR, V29, P431, DOI 10.1097/00005176-199910000-00011
   Reese PP, 2009, AM J TRANSPLANT, V9, P309, DOI 10.1111/j.1600-6143.2008.02488.x
   Reese PP, 2008, TRANSPLANTATION, V85, P1737, DOI 10.1097/TP.0b013e3181722f75
   RUSSO P A, 1987, Pediatric Pathology, V7, P557
   Stahl JE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002468
   TZAKIS AG, 1993, ARCH SURG-CHICAGO, V128, P337
   WHITINGTON PF, 1988, GASTROENTEROLOGY, V95, P130
NR 25
TC 12
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2010
VL 14
IS 5
BP 622
EP 628
DI 10.1111/j.1399-3046.2009.01286.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 623TA
UT WOS:000279765900011
PM 20070561
ER

PT J
AU Gregorek, H
   Jankowska, I
   Dzierzanowska-Fangrat, K
   Teisseyre, J
   Sawicka, A
   Kasztelewicz, B
   Pawlowska, J
AF Gregorek, Hanna
   Jankowska, Irena
   Dzierzanowska-Fangrat, Katarzyna
   Teisseyre, Joanna
   Sawicka, Anna
   Kasztelewicz, Beata
   Pawlowska, Joanna
TI Long-term monitoring of Epstein-Barr virus DNA load and humoral
   parameter abnormalities in pediatric liver transplant recipients before
   development of malignancy
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; Epstein-Barr virus infection;
   dysgammaglobulinemia; monoclonal gammopathy
ID POSTTRANSPLANT-LYMPHOPROLIFERATIVE-DISORDER; UNDETERMINED SIGNIFICANCE;
   MONOCLONAL GAMMOPATHIES; DISEASE; RISK; PCR
AB EBV loads and abnormalities of humoral responses were monitored in 51 pediatric liver transplant recipients as a proposed non-invasive laboratory tool for early detection of changes preceding severe clinical complications. EBV DNA load, concentrations of IgM, IgG, IgA, and monoclonal proteins were determined in each blood sample. EBV DNA was detected in 70.6% of the children, dysgammaglobulinemia of one or more Ig isotype was present in 41.2% of them. MG detected in 43.1% of patients correlated with the presence of EBV DNA (p = 0.003) and was usually preceded by hypergammaglobulinemia. The median maximum EBV load was significantly higher in EBV DNA+/MG+ patients than in EBV DNA+/MG- patients (p = 0.04), although there was no correlation between current viral load and appearance of MG. Four of 15 EBV DNA-negative patients developed MG, preceded by hypergammaglobulinemia in two. Minimization or cessation of immunosuppression in 42 patients, in whom abnormal biomarkers and/or clinical symptoms raised suspicion of disease progression, permitted complete resolution of abnormalities in all but one patient who developed B-NHL and died. Simultaneous monitoring of protein profiles and EBV DNA load together with thorough physical evaluation of children after LTx is important for early implementation of suitable preemptive therapy.
C1 [Gregorek, Hanna; Dzierzanowska-Fangrat, Katarzyna; Sawicka, Anna; Kasztelewicz, Beata] Childrens Mem Hlth Inst, Dept Clin Microbiol & Immunol, PL-04730 Warsaw, Poland.
   [Jankowska, Irena; Pawlowska, Joanna] Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol & Immunol, PL-04730 Warsaw, Poland.
   [Teisseyre, Joanna] Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, PL-04730 Warsaw, Poland.
RP Gregorek, H (reprint author), Childrens Mem Hlth Inst, Dept Clin Microbiol & Immunol, Al Dzieci Polskich 20, PL-04730 Warsaw, Poland.
EM h.gregorek@czd.pl
RI Kasztelewicz, Beata/F-1174-2010; 
OI Kasztelewicz, Beata/0000-0003-1504-5589
FU CMHI Warsaw, Poland [S91/06, 165/06]; Polish Committee for Scientific
   Research [2 P05D 037 30]
FX This study was supported by the internal grants no. S91/06 and 165/06
   funded by the CMHI Warsaw, Poland, and by grant no. 2 P05D 037 30 from
   the Polish Committee for Scientific Research. The study was presented in
   part at the 1st Joint Meeting of European National Societies of
   Immunology and the 16th European Congress of Immunology, Paris, France,
   2006. We thank Dr. M. Syczewska for her helpful discussions on
   statistical analysis.
CR Allen UD, 2005, PEDIATR TRANSPLANT, V9, P450, DOI 10.1111/j.1399-3046.2005.00318.x
   Axelrod DA, 2003, PEDIATR TRANSPLANT, V7, P223, DOI 10.1034/j.1399-3046.2003.00080.x
   BROWN NA, 1982, J IMMUNOL, V128, P24
   Chadburn A, 1998, CANCER, V82, P1978
   Fernandez MC, 2009, PEDIATR TRANSPLANT, V13, P307, DOI 10.1111/j.1399-3046.2008.00914.x
   Jabs WJ, 2001, J CLIN MICROBIOL, V39, P564, DOI 10.1128/JCM.39.2.564-569.2001
   Kyle RA, 2003, BLOOD, V102, P3759, DOI 10.1182/blood-2003-03-0801
   KYLE RA, 1994, CLIN CHEM, V40, P2154
   Kyle RA, 2003, IMMUNOL REV, V194, P112, DOI 10.1034/j.1600-065X.2003.00056.x
   Leblond V, 1998, J CLIN ONCOL, V16, P2052
   Leblond V, 2004, J HEPATOL, V40, P728, DOI 10.1016/j.jhep.2004.03.006
   Levenson BM, 2009, PEDIATR TRANSPLANT, V13, P134, DOI 10.1111/j.1399-3046.2008.00965.x
   LUCAS KG, 1998, LEUKEMIA LYMPHOMA, V25, P1
   McDiarmid SV, 1998, TRANSPLANTATION, V66, P1604, DOI 10.1097/00007890-199812270-00006
   Pageaux GP, 1998, TRANSPLANTATION, V65, P397, DOI 10.1097/00007890-199802150-00018
   PHAM H, 1994, TRANSPLANTATION, V58, P253
   PHAM H, 1988, LIVER TRANSPLANT SUR, V4, P146
   Rosselet A, 2009, CLIN TRANSPLANT, V23, P74, DOI 10.1111/j.1399-0012.2008.00904.x
   Tsai DE, 2005, CLIN TRANSPLANT, V19, P644, DOI 10.1111/j.1399-0012.2005.00388.x
   Wandinger KP, 2000, NEUROLOGY, V55, P178
NR 20
TC 3
Z9 3
U1 1
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2010
VL 14
IS 5
BP 629
EP 635
DI 10.1111/j.1399-3046.2010.01293.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 623TA
UT WOS:000279765900012
PM 20158667
ER

PT J
AU El Moghazy, WM
   Ogura, Y
   Mutsuko, M
   Harada, K
   Koizumi, A
   Uemoto, S
AF El Moghazy, Walid Mohamed
   Ogura, Yasuhiro
   Mutsuko, Minata
   Harada, Kouji
   Koizumi, Akio
   Uemoto, Shinji
TI Pediatric living-donor liver transplantation for acute liver failure:
   analysis of 57 cases
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE graft loss; outcome; refractory rejection; survival
ID FULMINANT HEPATIC-FAILURE; SINGLE-CENTER; UNKNOWN ETIOLOGY; JAPAN;
   CHILDREN; IMMUNOSUPPRESSION; MONOSEGMENTS; EXPERIENCE; REJECTION;
   MORBIDITY
AB We reviewed 57 pediatric patients admitted with acute liver failure to Kyoto University Hospital in Japan over a period of 15 years to compare the etiology and the long-term outcome of infants and children after living donor liver transplantation (LDLT). Patients were divided into two groups according to age at the time of liver transplantation, infants group (<1 year, n = 20), and children group (1-18 years, n = 37). The overall survival rates were 73.6%, 69.5% and 67.2% at 1, 5, and 10 years after LDLT respectively. Age of recipients at the time of LDLT had a strong impact on their outcome, Children had significantly better outcome than infants (P = 0.001). Surgical complications were comparable between both groups. Infants had higher rates of acute cellular rejection (ACR), which was associated with features of hepatitis in many cases. Refractory ACR was the leading cause of death in eight out of 12 infants, while it resulted in loss of one child only. Cox's proportional hazard regression model was used to examine potential risk factors for graft loss and it shows that age <1 year was associated with high risk of graft loss [hazard ratio (HR) = 11.393; CI = 1.961-76.1763] (P < 0.05). In conclusion, Infants had poorer prognosis than children and refractory ACR was the leading cause of death. Using additional immunosuppressant for cases with severe and atypical rejections is recommended.
C1 [El Moghazy, Walid Mohamed; Ogura, Yasuhiro; Uemoto, Shinji] Kyoto Univ, Dept Hepatobiliary Pancreas & Transplant Surg, Kyoto, Japan.
   [El Moghazy, Walid Mohamed; Mutsuko, Minata; Harada, Kouji; Koizumi, Akio] Kyoto Univ, Dept Hlth & Environm Sci, Kyoto, Japan.
   [El Moghazy, Walid Mohamed] Sohag Univ, Dept Surg, Sohag, Egypt.
RP El Moghazy, WM (reprint author), Kyoto Univ Hosp, Dept Hepatobiliary Pancreas & Transplant Surg, Sakyo Ku, 54 Kawaracho Cho, Kyoto 6068507, Japan.
EM moghazyw@gmail.com
OI Elmoghazy, Walid/0000-0001-9590-0930
CR Akamatsu N, 2008, HEPATOL RES, V38, pS60, DOI 10.1111/j.1872-034X.2008.00429.x
   Broering DC, 2004, ANN SURG, V240, P1013, DOI 10.1097/01.sla.0000146146.97485.6c
   Broering DC, 2004, ANN SURG, V240, P1024
   DEVLIN J, 1995, HEPATOLOGY, V21, P1018
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Fujiwara K, 2008, HEPATOL RES, V38, P646, DOI 10.1111/j.1872-034X.2008.00322.x
   Goss JA, 1998, ARCH SURG-CHICAGO, V133, P839, DOI 10.1001/archsurg.133.8.839
   Haga H, 2006, LIVER TRANSPLANT, V12, P457, DOI 10.1002/lt.20652
   Ikai I, 1996, TRANSPLANT P, V28, P56
   Ikegami T, 2008, J AM COLL SURGEONS, V206, P412, DOI 10.1016/j.jamcollsurg.2007.08.018
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Inomata Y, 2000, TRANSPLANTATION, V69, P258, DOI 10.1097/00007890-200001270-00011
   Ishikawa K, 2002, J GASTROENTEROL, V37, P523, DOI 10.1007/s005350200081
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Lee WS, 2005, J PEDIATR GASTR NUTR, V40, P575, DOI 10.1097/01.MPG.0000158524.30294.E2
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785
   Sakamoto S, 2008, PEDIATR TRANSPLANT, V12, P167, DOI 10.1111/j.1399-3046.2007.00718.x
   Sindhi R, 2005, AM J TRANSPLANT, V5, P96, DOI 10.1111/j.1600-6143.2004.00639.x
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Takikawa Y, 2008, HEPATOL RES, V38, pS14, DOI 10.1111/j.1872-034X.2008.00421.x
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tanaka K, 2003, LIVING DONOR LIVER T
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Uemoto S, 2000, TRANSPLANTATION, V70, P152
   Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4
   Whitington PF, 2001, J PEDIATR GASTR NUTR, V33, P529, DOI 10.1097/00005176-200111000-00004
NR 27
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD AUG
PY 2010
VL 23
IS 8
BP 823
EP 830
DI 10.1111/j.1432-2277.2010.01059.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 619TV
UT WOS:000279454100008
ER

PT J
AU Faraj, W
   Mukherji, D
   Fakih, H
   Majzoub, N
   Khalife, M
AF Faraj, Walid
   Mukherji, Deborah
   Fakih, Hawraa
   Majzoub, Nadim
   Khalife, Mohamed
TI Liver transplantation in Lebanon: A hard lesson to learn
SO ANNALS OF TRANSPLANTATION
LA English
DT Article
DE liver transplantation; cadaveric donation; living donor graft; Lebanon
ID MIDDLE-EAST; ORGAN DONATION; EXPERIENCE; SURVIVAL
AB Background: The aim of this study is to review all liver transplants performed at the American University of Beirut Medical Center from 1998 to present.
   Material/Methods: From 1998 to present, 15 liver transplants were performed in our institution. Of these, 10 were adults and 5 children. Indications for adult transplants were: 2 alcoholic liver cirrhosis, 2 cryptogenic, hepatitis B, hepatitis C with HCC, 1 subacute liver failure, 1 Budd Chiari syndrome, 1 biliary cirrhosis secondary to iatrogenic common bile duct injury, and 1 multiple hydatid disease of the liver. Pediatric transplant indications were: 2 cryptogenic liver cirrhosis, 1 extrahepatic biliary atresia, 1 familial hypercholesterolemia, and 1 congenital hepatic fibrosis. Of the 14 transplants, 4 were living related liver transplants.
   Results: Patient survival was 67% at 1,5 and 10 years. There were 5 deaths at a median of 9 days (range 1-56) post-transplantation. The causes of death were: 2 primary non-functions, 1 intraoperative cardiac arrest, 1 portal and hepatic artery thrombosis, and 1 severe cellular rejection. There were 2 biliary complications and 2 major vascular complications. All 9 survivors are well, with normal liver function tests at a median follow-up time of 70 months (range 13-131) after transplantation.
   Conclusions: Although our numbers are small, the 10-year survival rate is acceptable compared to other series. Cadaveric organ donations and transplantations should be encouraged so that more transplants can be performed. Living related liver transplant is an important alternative source of organs, but should not replace cadaveric donation.
C1 [Faraj, Walid; Mukherji, Deborah; Fakih, Hawraa; Majzoub, Nadim; Khalife, Mohamed] Amer Univ Beirut, Med Ctr, Dept Surg, HPB & Liver Transplant Unit, Beirut, Lebanon.
RP Faraj, W (reprint author), Amer Univ Beirut, Med Ctr, Dept Surg, HPB & Liver Transplant Unit, Beirut, Lebanon.
EM wf07@aub.edu.lb
OI El Majzoub, Nadim/0000-0002-6803-478X
CR Al-Sebayel M, 2007, ANN SAUDI MED, V27, P333
   Bahador A, 2009, TRANSPL P, V41, P2864, DOI 10.1016/j.transproceed.2009.07.046
   Bo WT, 2008, TRANSPL P, V40, P3507, DOI 10.1016/j.transproceed.2008.06.096
   BUSUTTIL RW, 1994, ANN SURG, V219, P490, DOI 10.1097/00000658-199405000-00007
   Daar AS, 1999, TRANSPLANT P, V31, P1070, DOI 10.1016/S0041-1345(98)01909-5
   Faraj W, 2010, TRANSPL P, V42, P713, DOI 10.1016/j.transproceed.2010.02.058
   Haberal M, 2006, TRANSPLANT P, V38, P2111, DOI 10.1016/j.transproceed.2006.06.035
   Karakayali H, 2005, TRANSPLANT P, V37, P2905, DOI 10.1016/j.transproceed.2005.07.025
   Kemmer NM, 2009, TRANSPLANTATION, V88, P392, DOI 10.1097/TP.0b013e3181aed68c
   Malek-Hosseini SA, 2005, TRANSPLANT P, V37, P3157, DOI 10.1016/j.transproceed.2005.07.005
   McBride Maureen A, 2003, Clin Transpl, P53
   Saeed Bassam, 2007, Saudi J Kidney Dis Transpl, V18, P270
   Shaheen FAM, 2009, ETHNIC DIS, V19, P16
   STARZL TE, 1968, SURGERY, V63, P549
   van der Meulen JHP, 2007, TRANSPLANTATION, V84, P572, DOI 10.1097/01.tp.0000280540.76370.37
NR 15
TC 2
Z9 2
U1 0
U2 0
PU INDEX COPERNICUS INT
PI WARSAW
PA AL JEROZOLIMSKIE 146 C STR, WARSAW, 02-305, POLAND
SN 1425-9524
J9 ANN TRANSPL
JI Ann. Transpl.
PD JUL-SEP
PY 2010
VL 15
IS 3
BP 25
EP 29
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 739CE
UT WOS:000288689200004
PM 20877263
ER

PT J
AU Shibasaki, S
   Taniguchi, M
   Shimamura, T
   Suzuki, T
   Yamashita, K
   Wakayama, K
   Hirokata, G
   Ohta, M
   Kamiyama, T
   Matsushita, M
   Furukawa, H
   Todo, S
AF Shibasaki, Susumu
   Taniguchi, Masahiko
   Shimamura, Tsuyoshi
   Suzuki, Tomomi
   Yamashita, Kenichiro
   Wakayama, Kenji
   Hirokata, Gentaro
   Ohta, Minoru
   Kamiyama, Toshiya
   Matsushita, Michiaki
   Furukawa, Hiroyuki
   Todo, Satoru
TI Risk factors for portal vein complications in pediatric living donor
   liver transplantation
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE liver transplantation; living donor; pediatric; portal vein
   complications
ID VASCULAR COMPLICATIONS; BILIARY ATRESIA; VENOUS STENOSIS; SINGLE-CENTER;
   EXPERIENCE; CHILDREN; RECONSTRUCTION; THROMBOSIS; RECIPIENTS; KILOGRAMS
AB Background:
   Portal vein (PV) complications in pediatric living donor liver transplantation (LDLT) are often asymptomatic in the early stages after transplantation and can be serious enough to lead to graft failure. There have been few reports on risk factors for PV complications in LDLT. The aim of this study is to investigate the influence of hepatic inflow upon PV complications and to predict patients at risk for these complications.
   Material/method:
   From 1997 to 2008, 46 pediatric patients underwent LDLT at our center. Portal venous and hepatic arterial flows and PV diameter were analyzed.
   Results:
   PV complications were identified in seven patients (15.2%) and occurred at a younger age and lower weight. As a result of appropriate treatment, none of the patients suffered graft failure. Analysis of the 46 patients and 27 patients under two yr of age indentified smaller PV diameter in recipient and larger discrepancy of PV diameter as risk factors. Portal venous flow tended to be low, in contrast to hepatic arterial flow, which tended to be high.
   Conclusion:
   PV size strongly influences PV complications. Other factors such as younger age, low portal venous flow, and high hepatic arterial flow may be risk factors for PV complications.
C1 [Taniguchi, Masahiko] Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
   [Shimamura, Tsuyoshi; Ohta, Minoru] Hokkaido Univ, Div Organ Transplantat, Sapporo, Hokkaido 0608638, Japan.
   [Suzuki, Tomomi; Furukawa, Hiroyuki] Hokkaido Univ, Dept Organ Transplantat & Regenerat, Sapporo, Hokkaido 0608638, Japan.
   [Yamashita, Kenichiro] Hokkaido Univ, Grad Sch Med, Dept Mol Surg, Sapporo, Hokkaido 0608638, Japan.
RP Taniguchi, M (reprint author), Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Kita Ku, N-15,W-7, Sapporo, Hokkaido 0608638, Japan.
EM tonny@isis.ocn.ne.jp
RI Todo, Satoru/G-5659-2012
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Bueno J, 2007, TRANSPL P, V39, P2278, DOI 10.1016/j.transproceed.2007-07-042
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   Corno V, 2005, TRANSPLANT P, V37, P1141, DOI 10.1016/j.transproceed.2004.11.034
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Doria C, 2003, INT SURG, V88, P184
   Funaki B, 2000, RADIOLOGY, V215, P147
   Hotta R, 2007, PEDIATR SURG INT, V23, P939, DOI 10.1007/s00383-007-1974-y
   JAKAB F, 1995, HEPATO-GASTROENTEROL, V42, P18
   Karakayali H, 2007, TRANSPL P, V39, P1153, DOI 10.1016/j.transproceed.2007.02.054
   LERUT J, 1987, ANN SURG, V205, P404, DOI 10.1097/00000658-198704000-00011
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   Olcott E W, 1990, J Vasc Interv Radiol, V1, P17, DOI 10.1016/S1051-0443(90)72496-7
   RAIA S, 1989, LANCET, V2, P497
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Sugawara Y, 2006, LIVER TRANSPLANT, V12, P1233, DOI 10.1002/lt.20786
   Tiao GM, 2005, J PEDIATR SURG, V40, P268, DOI 10.1016/j.jpedsurg.2004.09.021
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 28
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JUL-AUG
PY 2010
VL 24
IS 4
BP 550
EP 556
DI 10.1111/j.1399-0012.2009.01123.x
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 639RI
UT WOS:000280991700023
PM 19925458
ER

PT J
AU Warnaar, N
   Polak, WG
   de Jong, KP
   de Boer, MT
   Verkade, HJ
   Sieders, E
   Peeters, PMJG
   Porte, RJ
AF Warnaar, Nienke
   Polak, Wojciech G.
   de Jong, Koert P.
   de Boer, Marieke T.
   Verkade, Henkjan J.
   Sieders, Egbert
   Peeters, Paul M. J. G.
   Porte, Robert J.
TI Long-Term Results of Urgent Revascularization for Hepatic Artery
   Thrombosis After Pediatric Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID VASCULAR COMPLICATIONS; DOPPLER ULTRASOUND; STENT PLACEMENT; CHILDREN;
   SURVIVAL; DONORS; RECONSTRUCTION; MANAGEMENT; STENOSIS; INFANTS
AB Hepatic artery thrombosis (HAT) after pediatric orthotopic liver transplantation (OLT) is a serious complication resulting in bile duct necrosis and often requiring retransplantation. Immediate surgical thrombectomy/thrombolysis has been reported to be a potentially successful treatment for restoring blood flow and avoiding urgent retransplantation. The long-term results of this strategy remain to be determined. In 232 pediatric liver transplants, we analyzed long-term outcomes after urgent revascularization for early HAT. HAT developed in 32 patients (13.7%). In 16 children (50%), immediate surgical thrombectomy was performed in an attempt to salvage the graft. Fourteen patients (44%) underwent urgent retransplantation, and 2 (6%) died before further intervention. Immediate thrombectomy resulted in long-term restoration of the hepatic artery flow in 6 of 16 patients (38%) and in 1- and 5-year graft and patient survival rates of 83% and 67%, respectively. In 10 patients, revascularization was unsuccessful, and retransplantation was inevitable. The 1- and 5-year patient survival rates in this group decreased to 50% and 40%, respectively. After immediate retransplantation, the 5-year patient survival rate was 71%. In conclusion, immediate surgical thrombectomy for HAT after pediatric OLT results in long-term graft salvage in about one-third of patients. However, when thrombectomy is unsuccessful, long-term patient survival is lower than the survival of patients who underwent immediate retransplantation. Liver Transpl 16:847-855, 2010. (C) 2010 AASLD.
C1 [Warnaar, Nienke; Polak, Wojciech G.; de Jong, Koert P.; de Boer, Marieke T.; Sieders, Egbert; Peeters, Paul M. J. G.; Porte, Robert J.] Univ Groningen, Univ Med Ctr Groningen, Div Hepatobiliary Surg & Liver Transplantat, Dept Surg, NL-9700 RB Groningen, Netherlands.
   [Verkade, Henkjan J.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, NL-9700 RB Groningen, Netherlands.
RP Porte, RJ (reprint author), Univ Groningen, Univ Med Ctr Groningen, Div Hepatobiliary Surg & Liver Transplantat, Dept Surg, POB 30-001, NL-9700 RB Groningen, Netherlands.
EM r.j.porte@chir.umcg.nl
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   BJERKVIK PS, 1995, TRANSPLANTATION, V59, P1746, DOI 10.1097/00007890-199506270-00021
   Boyvat F, 2006, TRANSPLANT P, V38, P3656, DOI 10.1016/j.transproceed.2006.10.169
   Broniszczak D, 2006, TRANSPLANT P, V38, P1456, DOI 10.1016/j.transproceed.2006.02.094
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Cotroneo AR, 2002, J VASC INTERV RADIOL, V13, P619, DOI 10.1016/S1051-0443(07)61657-1
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   FIGUERAS J, 1995, TRANSPLANTATION, V59, P1356
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   HESSELINK EJ, 1989, TRANSPLANT P, V21, P2462
   Horrow MM, 2007, AM J ROENTGENOL, V189, P346, DOI 10.2214/AJR.07.2217
   Jain A, 2006, TRANSPLANT INT, V19, P27, DOI 10.1111/j.1432-2277.2005.00224.x
   KLINTMALM GB, 1988, TRANSPLANT P, V20, P610
   Kok T, 1998, TRANSPLANT INT, V11, P272, DOI 10.1111/j.1432-2277.1998.tb00969.x
   KOK T, 1995, PEDIATR RADIOL, V25, P517, DOI 10.1007/BF02015783
   LALLIER M, 1995, J PEDIATR SURG, V30, P1122, DOI 10.1016/0022-3468(95)90002-0
   LANGNAS AN, 1991, TRANSPLANTATION, V51, P86, DOI 10.1097/00007890-199101000-00013
   Massault PP, 1997, TRANSPLANT P, V29, P439, DOI 10.1016/S0041-1345(96)00178-9
   Mazariegos GV, 1999, LIVER TRANSPLANT SUR, V5, P429, DOI 10.1002/lt.500050518
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   Polak WG, 2008, CLIN TRANSPLANT, V22, P171, DOI 10.1111/j.1399-0012.2007.00762.x
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   Sakamoto Y, 1999, BRIT J SURG, V86, P886, DOI 10.1046/j.1365-2168.1999.01166.x
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Sieders E, 2000, TRANSPLANTATION, V70, P1448, DOI 10.1097/00007890-200011270-00009
   Singhal A, 2010, TRANSPL INT, V23, P245, DOI 10.1111/j.1432-2277.2009.01037.x
   STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343
   STARZL TE, 1984, SURG GYNECOL OBSTET, V158, P223
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   TZAKIS AG, 1985, TRANSPLANTATION, V40, P667, DOI 10.1097/00007890-198512000-00019
   YANAGA K, 1990, ARCH SURG-CHICAGO, V125, P628
   Zanotelli ML, 2004, TRANSPLANT P, V36, P945, DOI 10.1016/j.transproceed.2004.03.104
NR 38
TC 19
Z9 20
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2010
VL 16
IS 7
BP 847
EP 855
DI 10.1002/lt.22063
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 623QY
UT WOS:000279758100007
PM 20583091
ER

PT J
AU Castaneda-Martinez, PD
   Alcaide-Ortega, RI
   Fuentes-Garcia, VE
   Hernandez-Plata, JA
   Nieto-Zermeno, J
   Reyes-Lopez, A
   Varela-Fascinetto, G
AF Castaneda-Martinez, P. D.
   Alcaide-Ortega, R. I.
   Fuentes-Garcia, V. E.
   Hernandez-Plata, J. A.
   Nieto-Zermeno, J.
   Reyes-Lopez, A.
   Varela-Fascinetto, G.
TI Anesthetic Risk Factors Associated With Early Mortality in Pediatric
   Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Joint Meeting of the
   International-Pancreas-and-Islet-Transplant-Association/International-Xe
   notransplantation-Association
CY OCT 12-16, 2009
CL Venice, ITALY
SP Int Pancreas & Islet Transplant Assoc, Int Xenotransplantat Assoc
ID PERIOPERATIVE CARE; EXPERIENCE; CHILDREN; PATIENT; COMPLICATIONS;
   DISEASE
AB Introduction. Early mortality in pediatric patients after liver transplantation (30 days) may be due to surgical and anesthetic perioperative factors.
   Objective. To identify anesthetic risk factors associated with early mortality in pediatric patients who undergo liver transplantation (OLT).
   Materials and Methods. This retrospective study of all patients who underwent a deceased or living donor liver transplantation evaluated demographic variables of age, weight, gender, degree of malnutrition, and etiology, as well as qualitative variables of anesthesia time, bleeding, massive transfusion, acid-base balance, electrolyte and metabolic disorders, as well as graft prereperfusion postreperfusion characteristics. Chi-square tests with corresponding odds ratio (OR) and 95% confidence intervals as well as Interactions were tested among significant variables using multivariate logistic regression models. P <= .05 was considered significant.
   Results. We performed 64 OLT among whom early death occurred in 20.3% (n = 13). There were deaths associated with malnutrition (84.6% vs 43.6%) in the control group (P < .01); massive bleeding, 76.9% (n = 10) versus 25.8% in the control group (P < .05) including transfusions in 84.6% (n = 11) versus 43.6% in the control group (P < .03); preperfusion metabolic acidosis in 84.6% (n = 11) versus 72.5% (n = 37; P < .05); posttransplant hyperglycemia in 69.2% (n = 9) versus 23.5% (n = 12; P < .01); and postreperfusion hyperlactatemia in 92.3% (n = 12) versus 68.6% (n = 35; P < .045).
   Conclusion. Prereperfusion metabolic acidosis, postreperfusion hyperlactatemia, and hyperglycemia were significantly more prevalent among patients who died early. However, these factors were exacerbated by malnutrition, bleeding, and massive transfusions. Postreperfusion hypokalemia and hypernatremia showed high but not significant frequencies in both groups.
C1 [Castaneda-Martinez, P. D.; Alcaide-Ortega, R. I.; Fuentes-Garcia, V. E.; Hernandez-Plata, J. A.; Nieto-Zermeno, J.; Reyes-Lopez, A.; Varela-Fascinetto, G.] Hosp Infantil Mexico Dr Federico Gomez, Dept Anesthesiol & Transplants, Mexico City 06720, DF, Mexico.
RP Castaneda-Martinez, PD (reprint author), Hosp Infantil Mexico Dr Federico Gomez, Dept Anestesiol & Algol, Dr Marquez 162 Colonia Doctores, Mexico City 06720, DF, Mexico.
EM pdelfin1@hotmail.com
CR Araz C, 2004, TRANSPLANT P, V36, P214, DOI 10.1016/j.transproceed.2003.11.029
   ASHOKKUMAR J, 2006, TRANSPLANT INT, V19, P27
   Bucuvalas John C, 2008, Curr Opin Organ Transplant, V13, P247, DOI 10.1097/MOT.0b013e3282f94aab
   CARTON EG, 1994, ANESTH ANALG, V78, P120
   CARTON EG, 1994, ANESTH ANALG, V78, P382, DOI 10.1213/00000539-199402000-00031
   CASTANEDAMARTIN PD, 38 C MEX AN MONT 200, P283
   Davis MK, 2008, PEDIATR TRANSPLANT, V12, P137, DOI 10.1111/j.1399-3046.2007.00803.x
   Englert C, 2007, TRANSPLANTATION, V84, P1361, DOI 10.1097/01.tp.0000282869.94152.4f
   FARRUGIA DA, 2004, CLIN LATINOAMERICANA, V2, P143
   Feierman DE, 2006, PEDIATR ANESTH, V16, P669, DOI 10.1111/j.1460-9592.2005.01823.x
   GREGORY B, 2001, PAEDIAT ANAEST, V11, P3
   Harambat J, 2008, PEDIATR TRANSPLANT, V12, P847, DOI 10.1111/j.1399-3046.2008.00950.x
   Hendrickson RJ, 2004, CURR OPIN PEDIATR, V16, P309, DOI 10.1097/01.mop.0000127160.82531.77
   LLONA T, 2009, ANESTH ANALG, V108, P1083
   Mahadeb P, 2009, PEDIATR TRANSPLANT, V13, P414, DOI 10.1111/j.1399-3046.2008.01008.x
   Massicotte L, 2004, ANESTH ANALG, V98, P1245, DOI 10.1213/01.ANE.0000111184.21278.07
   MOLENAAR I, 2007, AM J TRANSPLANT, V4, P185
   OBBERGH L, 2000, ANESTHESIOLOGY, V92, P683
   PETER MDD, 2006, ANESTH ANALG, V103, P587
   Steadman Randolph H, 2004, Anesthesiol Clin North America, V22, P687, DOI 10.1016/j.atc.2004.06.009
   Steib A, 2001, CAN J ANAESTH, V48, P1075
   Varela-Fascinetto G, 2005, TRANSPLANT P, V37, P1201, DOI 10.1016/j.transproceed.2005.01.010
   Varela-Fascinetto G, 2005, REV INVEST CLIN, V57, P273
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 24
TC 7
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2010
VL 42
IS 6
BP 2383
EP 2386
DI 10.1016/j.transproceed.2010.06.011
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 639EK
UT WOS:000280953400096
PM 20692486
ER

PT J
AU Ooi, CY
   Brandao, LR
   Zolpys, L
   De Angelis, M
   Drew, W
   Jones, N
   Ling, SC
   Fecteau, A
   Ng, VL
AF Ooi, Chee Yee
   Brandao, Leonardo R.
   Zolpys, Lauren
   De Angelis, Maria
   Drew, Wendy
   Jones, Nicola
   Ling, Simon C.
   Fecteau, Annie
   Ng, Vicky Lee
TI Thrombotic events after pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; thrombotic events; deep vein
   thrombosis; central venous line; hepatic artery thrombosis;
   thrombophilia
ID HEPATIC-ARTERY THROMBOSIS; CATHETER-RELATED THROMBOSIS; VENOUS
   THROMBOEMBOLIC COMPLICATIONS; FACTOR-V-LEIDEN; VASCULAR COMPLICATIONS;
   VEIN THROMBOSIS; CANADIAN REGISTRY; CHILDREN; ASSOCIATION; SURVIVAL
AB TE may contribute to morbidity and mortality after LT. The objectives were to determine the incidence of early TE post-pediatric LT and compare differences between children with and without TE. A retrospective review of 88 transplanted children (January 2002-October 2007) was performed to determine the incidence of Doppler-confirmed DVT and ATE in the first month post-LT. Fourteen (16%) patients developed TE: DVT in seven (8%) and ATE in seven (8%) patients. Six of 88 (6.8%) developed symptomatic CVL-related DVT. Median (range) time post-LT to DVT and ATE were 7 (4-18) and 8 (1-31) days, respectively. There was no significant difference in age/body weight at LT between patients with or without DVT and ATE. There was no significant difference between patients with or without HAT in age and weight at LT, cold ischemic time, duration of surgery, hematocrit levels, whole-organ graft type, intraoperative FFP, high-risk CMV status, or early acute cellular rejection. In conclusion, the incidence of early TE post-pediatric LT was 16%, including DVT in 8%. Prospective studies are necessary to evaluate the role of prophylactic anticoagulation and potential modifiable risk factors post-pediatric LT.
C1 [Ooi, Chee Yee; De Angelis, Maria; Jones, Nicola; Ling, Simon C.; Fecteau, Annie; Ng, Vicky Lee] Univ Toronto, SickKids Transplant Ctr, Toronto, ON M5S 1A1, Canada.
   [Ooi, Chee Yee; Drew, Wendy; Jones, Nicola; Ling, Simon C.; Ng, Vicky Lee] Univ Toronto, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5S 1A1, Canada.
   [Brandao, Leonardo R.; Zolpys, Lauren] Univ Toronto, Div Hematol & Oncol, Toronto, ON M5S 1A1, Canada.
   [Brandao, Leonardo R.; Jones, Nicola; Ling, Simon C.; Fecteau, Annie; Ng, Vicky Lee] Univ Toronto, Dept Pediat, Toronto, ON M5S 1A1, Canada.
   [Fecteau, Annie] Hosp Sick Children, Div Gen Surg, Toronto, ON, Canada.
RP Ng, VL (reprint author), Hosp Sick Children, Div Gastroenterol & Nutr, Toronto, ON, Canada.
EM vicky.ng@sickkids.ca
CR ANDREW M, 1995, J PEDIATR-US, V126, P358, DOI 10.1016/S0022-3476(95)70448-5
   ANDREW M, 1994, BLOOD, V83, P1251
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   Dubois J, 2007, CAN MED ASSOC J, V177, P1185, DOI 10.1503/cmaj.070316
   Dunn TB, 2006, CLIN TRANSPLANT, V20, P132, DOI 10.1111/j.1399-0012.2005.00432.x
   Fratino G, 2005, ANN ONCOL, V16, P648, DOI 10.1093/annonc/mdi111
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Heffron TG, 2003, TRANSPLANT P, V35, P1447, DOI 10.1016/S0041-1345(03)00459-7
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Ishitani M, 1997, TRANSPLANT P, V29, P2861, DOI 10.1016/S0041-1345(97)00709-4
   Jain A, 2006, TRANSPLANT INT, V19, P27, DOI 10.1111/j.1432-2277.2005.00224.x
   Journeycake JM, 2006, J CLIN ONCOL, V24, P4575, DOI 10.1200/JCO.2005.05.5343
   KANG YG, 1985, ANESTH ANALG, V64, P888
   KOKSOY C, 1995, CLIN RADIOL, V50, P687, DOI 10.1016/S0009-9260(05)83313-6
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   Lin M, 2002, ANZ J SURG, V72, P798, DOI 10.1046/j.1445-2197.2002.02552.x
   Madalosso C, 1998, TRANSPLANTATION, V66, P294, DOI 10.1097/00007890-199808150-00003
   Male C, 2005, THROMB HAEMOSTASIS, V94, P516, DOI 10.1160/TH03-02-0091
   Massicotte MP, 1998, J PEDIATR-US, V133, P770, DOI 10.1016/S0022-3476(98)70149-0
   MAZZAFERRO V, 1989, TRANSPLANT P, V21, P2466
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   Monagle P, 2000, PEDIATR RES, V47, P763, DOI 10.1203/00006450-200006000-00013
   Monagle P, 2008, CHEST, V133, p887S, DOI 10.1378/chest.08-0762
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   Ng V, 2008, AM J TRANSPLANT, V8, P386, DOI 10.1111/j.1600-6143.2007.02056.x
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Petaja J, 1996, J THORAC CARDIOV SUR, V112, P883, DOI 10.1016/S0022-5223(96)70087-9
   Proposito D, 2001, Ann Ital Chir, V72, P187
   Scholz G, 1969, Med Welt, V41, P2248
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   STAHL RL, 1990, HEPATOLOGY, V12, P553, DOI 10.1002/hep.1840120317
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   TISONE G, 1988, TRANSPLANTATION, V46, P162, DOI 10.1097/00007890-198807000-00032
   Willems M, 2003, LIVER TRANSPLANT, V9, P870, DOI 10.1053/jlts.2003.50136
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 40
TC 9
Z9 9
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2010
VL 14
IS 4
BP 476
EP 482
DI 10.1111/j.1399-3046.2009.01252.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 594IA
UT WOS:000277528900011
PM 19849808
ER

PT J
AU Irtan, S
   Maisin, A
   Baudouin, V
   Nivoche, Y
   Azoulay, R
   Jacqz-Aigrain, E
   El Ghoneimi, A
   Aigrain, Y
AF Irtan, S.
   Maisin, A.
   Baudouin, V.
   Nivoche, Y.
   Azoulay, R.
   Jacqz-Aigrain, E.
   El Ghoneimi, A.
   Aigrain, Y.
TI Renal transplantation in children: Critical analysis of age related
   surgical complications
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric renal transplantation; surgical complications; thrombosis
ID UROLOGICAL COMPLICATIONS; KIDNEY-TRANSPLANTATION; GRAFT THROMBOSIS;
   EXTRAVESICAL URETERONEOCYSTOSTOMY; URETERAL OBSTRUCTION;
   RANDOMIZED-TRIAL; RECIPIENTS; ANASTOMOSIS; STENTS; ALLOGRAFTS
AB To determine age-related risk factors of urological and vascular complications. We performed a retrospective analysis of the data of 202 renal transplantations in 193 children between 1989 and 2007 at a single institution. Out of 193 grafts (combined renal and liver grafts were excluded), we observed urological complications in 42 cases (21.7%) leading to graft loss in one case and vascular complications in 27 cases (13.9%) leading to graft loss in seven. The urological complications were VUR (n = 25, 12.4%), ureteral stricture (n = 10, 5%), anastomotic leak (n = 4, 2%), ureteral necrosis (n = 2, 1%), and incrustative pyelitis (n = 1, 0.5%). Vascular complications were arterial stricture (n = 14, 7.2%), arterial thrombosis (n = 4, 2%), venous thrombosis (n = 2, 1%), and others (n = 7). Donors aged less than six yr were a risk factor of vascular complications leading to graft loss (p = 0.0001), whereas patients with PUV had more urological complications (p = 0.001). Overall patient and graft survival is 93.1% and 84% at five yr, respectively. Surgical complications remain a major cause of graft loss (12%) and morbidity in children's kidney transplantation (38.9%). Young age of donors is the major risk factor of early graft loss as a result of vascular complication. However, donor selection based on age is limited by the shortage of organs.
C1 [Maisin, A.; Baudouin, V.] Robert Debre Hosp, Dept Paediat Nephrol, Paris, France.
   [Nivoche, Y.] Robert Debre Hosp, Dept Paediat Anaesthesia, Paris, France.
   [Azoulay, R.] Robert Debre Hosp, Dept Paediat Radiol, Paris, France.
   [Jacqz-Aigrain, E.] Robert Debre Hosp, Dept Clin Paediat Pharmacol, Paris, France.
RP Irtan, S (reprint author), Hop Necker Enfants Malad, Dept Pediat Surg, 149 Rue Sevres, F-75015 Paris, France.
EM sabineirtan@aol.com
OI Jacqz-Aigrain, Evelyne/0000-0002-4285-7067
CR Bakir N, 1996, NEPHROL DIAL TRANSPL, V11, P140
   BENOIT G, 1985, ANN UROL, V19, P165
   Berg UB, 1997, TRANSPLANTATION, V64, P1424, DOI 10.1097/00007890-199711270-00008
   Berger PM, 1998, J NEPHROL, V11, P20
   BERGMEIJER JH, 1990, TRANSPLANT INT, V3, P146
   Beyga ZT, 1998, J NEPHROL, V11, P137
   Borboroglu PG, 2004, TRANSPLANTATION, V77, P698, DOI 10.1097/01.TP.0000114462.10593.9F
   Bouhafs A, 2002, ANN UROL, V36, P301
   De Coppi P, 2006, TRANSPLANTATION, V82, P1042, DOI 10.1097/01.tp.0000236043.73906.25
   Dominguez J, 2000, TRANSPLANTATION, V70, P597, DOI 10.1097/00007890-200008270-00011
   Dubourg L, 2002, KIDNEY INT, V62, P1454, DOI 10.1046/j.1523-1755.2002.00576.x
   Fontaine E, 1994, Prog Urol, V4, P193
   Fontana I, 1999, Pediatr Transplant, V3, P206, DOI 10.1034/j.1399-3046.1999.00017.x
   French CG, 2001, PEDIATR TRANSPLANT, V5, P21, DOI 10.1034/j.1399-3046.2001.00024.x
   GAGNADOUX MF, 1994, J RADIOL, V75, P57
   GEDROYC WMW, 1988, BRIT J UROL, V62, P123, DOI 10.1111/j.1464-410X.1988.tb04289.x
   HARMON WE, 1991, TRANSPLANTATION, V51, P406, DOI 10.1097/00007890-199102000-00026
   HARMON WE, 1992, TRANSPLANTATION, V54, P232, DOI 10.1097/00007890-199208000-00008
   Herz DB, 2001, J UROLOGY, V166, P1853, DOI 10.1016/S0022-5347(05)65704-7
   Ismail H, 1997, Pediatr Transplant, V1, P43
   KELLER H, 1994, TRANSPLANT INT, V7, P253, DOI 10.1111/j.1432-2277.1994.tb01570.x
   Kranz B, 2006, PEDIATR TRANSPLANT, V10, P788, DOI 10.1111/j.1399-3046.2005.00483.x
   Kumar A, 1998, TRANSPLANT P, V30, P2995, DOI 10.1016/S0041-1345(98)00902-6
   Lapointe SP, 2001, J UROLOGY, V166, P1046, DOI 10.1016/S0022-5347(05)65916-2
   LOJANAPIWAT B, 1994, J AM COLL SURGEONS, V179, P21
   Mangus RS, 2004, AM J TRANSPLANT, V4, P1889, DOI 10.1111/j.1600-6143.2004.00595.x
   Nagra A, 2004, PEDIATR NEPHROL, V19, P531, DOI 10.1007/s00467-004-1458-4
   Ostrowski M, 1999, Ann Transplant, V4, P54
   PLEASS HCC, 1995, TRANSPLANT P, V27, P1091
   RAYNAUD A, 1986, AM J ROENTGENOL, V146, P853
   RIGG KM, 1994, TRANSPLANT INT, V7, P120, DOI 10.1111/j.1432-2277.1994.tb01231.x
   SALVATIERRA O, 1977, J UROLOGY, V117, P421
   SALVATIERRA O, 1974, J UROLOGY, V112, P445
   Shaul DB, 1999, J PEDIATR SURG, V34, P1725, DOI 10.1016/S0022-3468(99)90654-1
   SHELDON CA, 1992, J PEDIATR SURG, V27, P629, DOI 10.1016/0022-3468(92)90464-I
   SHOSKES DA, 1995, J UROLOGY, V153, P18, DOI 10.1097/00005392-199501000-00008
   Simpson CM, 2006, PEDIATR NEPHROL, V21, P79, DOI 10.1007/s00467-005-2043-1
   Tavakoli A, 2007, J UROLOGY, V177, P2260, DOI 10.1016/j.juro.2007.01.152
   URRUTIA MJM, 2006, J PEDIAT UROL, V2, P340
   *US REN DAT SYST, 2005, 2005 ANN DAT REP
   VANLIEBURG AF, 1995, J PEDIATR SURG, V30, P615, DOI 10.1016/0022-3468(95)90144-2
NR 41
TC 11
Z9 11
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2010
VL 14
IS 4
BP 512
EP 519
DI 10.1111/j.1399-3046.2009.01260.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 594IA
UT WOS:000277528900016
PM 20070565
ER

PT J
AU Gozzini, S
   Perera, MTPR
   Mayer, DA
   Mirza, DF
   Kelly, DA
   Muiesan, P
   Sharif, K
AF Gozzini, S.
   Perera, M. T. P. R.
   Mayer, D. A.
   Mirza, D. F.
   Kelly, D. A.
   Muiesan, P.
   Sharif, K.
TI Liver transplantation in children using non-heart-beating donors (NHBD)
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE non-heart-beating donation; pediatric liver transplantation; split liver
   transplantation
ID CONTROLLED NONHEARTBEATING DONORS; SINGLE-CENTER EXPERIENCE; CARDIAC
   DEATH; GRAFTS; FUTURE
AB Selected livers from controlled NHBD are accepted for OLT in adults. Recent evidence has shown good medium-term outcome. The purpose of this study was to report our experience of pediatric OLT with whole and partial grafts from NHBD, analyzing complications and outcome. Retrospective review of all the recipients who underwent primary OLT between December 2005 and December 2008, using livers from NHBD. Four children (one male child) mean age was 9.5 yr (0.2-17), mean weight was 26 kg (range 2.6-48), underwent OLT using NHBD. Mean donor age was 14.2 yr, and mean WIT (systolic BP < 50 mmHg to cold perfusion) 12.2 min (range 10-15). Two children received reduced grafts and two full grafts. Mean cold ischemia time was 7.18 h (range 6-8). Liver function tests one wk and nine months post-OLT confirmed a good graft function. One child was treated for two episodes of acute rejection. Post-transplant complications included two cases of mild ischemic cholangiopathy treated conservatively. Graft and patient survival was 100% with a mean follow-up of 19 months (range 8.1-43.4). Short- to medium-term follow-up suggests that liver grafts from young NHBD with short warm and cold ischemia times can be safely utilized in pediatric transplantation.
C1 [Gozzini, S.; Perera, M. T. P. R.; Mayer, D. A.; Mirza, D. F.; Kelly, D. A.; Muiesan, P.; Sharif, K.] Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England.
RP Sharif, K (reprint author), Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England.
EM khalid.sharif@bch.nhs.uk
RI Perera, Thamara/D-2758-2009; 
OI Muiesan, Paolo/0000-0002-7389-6691; Perera, Thamara/0000-0002-5417-3850
CR Abt P, 2003, TRANSPLANTATION, V75, P1659, DOI 10.1097/01.TP.0000062574.18648.7C
   Abt PL, 2004, ANN SURG, V239, P87, DOI 10.1097/01.sla.0000103063.82181.2c
   BERG CL, 2007, AM J TRANSPLANT, V9, P907
   D'Alessandro AM, 2000, SURGERY, V128, P579, DOI 10.1067/msy.2000.108421
   KOOTSTRA G, 1995, TRANSPLANT P, V27, P2893
   Manzarbeitia CY, 2004, TRANSPLANTATION, V78, P211, DOI 10.1097/01.tp.0000128327.95311.e3
   Merion RM, 2006, ANN SURG, V244, P555, DOI 10.1097/01.sla.0000239006.33633.39
   Monbaliu D, 2005, TRANSPLANTATION, V79, P1226, DOI 10.1097/01.TP.0000153508.71684.99
   Muiesan P, 2005, ANN SURG, V242, P732, DOI 10.1097/01.sla.0000186177.26112.d2
   Muiesan P, 2003, TRANSPLANTATION, V75, P1443, DOI 10.1097/01.TP.0000069024.86527.0B
   Muiesan P, 2006, AM J TRANSPLANT, V6, P1012, DOI 10.1111/j.1600-6143.2006.01293.x
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Perera MTPR, 2009, TRANSPL INT, V22, P757, DOI 10.1111/j.1432-2277.2009.00886.x
   Reddy S, 2004, LIVER TRANSPLANT, V10, P1223, DOI 10.1002/lt.20268
   Reich DJ, 2000, TRANSPLANTATION, V70, P1159, DOI 10.1097/00007890-200010270-00006
NR 15
TC 7
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2010
VL 14
IS 4
BP 554
EP 557
DI 10.1111/j.1399-3046.2009.01280.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 594IA
UT WOS:000277528900022
PM 20070562
ER

PT J
AU Jones, VS
   McCall, JL
   Thomas, G
   Stormon, M
   Shun, A
AF Jones, V. S.
   McCall, J. L.
   Thomas, G.
   Stormon, M.
   Shun, A.
TI Reverse portal flow after liver transplantation-ominous or acceptable?
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatofugal flow; reverse portal flow; liver transplantation; rejection;
   pediatric
ID LIVING-DONOR; BLOOD-FLOW; VEIN; GRAFT
AB Reversal of portal flow or hepatofugal flow after liver transplantation is a rare complication after liver transplantation. The available reports in the literature suggest that it is an ominous condition that requires immediate operative intervention, failing which prognosis would be grim. We report two children from two different centers who developed hepatofugal flow in the immediate post-operative period after liver transplantation. The possible etiologies in these patients were acute rejection in one and absence of an MHV causing inadequate hepatic venous outflow in the other. Both patients were treated non-operatively with steroids and immunosuppression. Spontaneous reversal to a normal hepatopetal flow occurred in both and the patients continue to be well six months after the transplant. Our experience contradicts the viewpoint that hepatofugal flow equates to mortality in the absence of surgical intervention. It remains to be defined as to which patients with hepatofugal flow will benefit from surgical intervention.
C1 [Jones, V. S.; Thomas, G.; Stormon, M.; Shun, A.] Childrens Hosp Westmead, Dept Pediat Surg, Sydney, NSW 2145, Australia.
   [McCall, J. L.] Auckland City Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand.
RP Jones, VS (reprint author), Childrens Hosp Westmead, Dept Pediat Surg, Corner Hawkesbury Rd & Hainsworth St,Locked Bag 4, Sydney, NSW 2145, Australia.
EM vincijones@yahoo.co.in
CR Garcia-Valdecasas JC, 2003, LIVER TRANSPLANT, V9, P564, DOI 10.1053/jlts.2003.50069
   Hwang S, 2005, LIVER TRANSPLANT, V11, P449, DOI 10.1002/lt.20387
   Kajikawa M, 1996, SURG TODAY, V26, P719
   Kaneko T, 2003, HEPATO-GASTROENTEROL, V50, P1825
   Kita Y, 2001, TRANSPLANT INT, V14, P217, DOI 10.1007/s001470100327
   Kyoden Y, 2005, ABDOM IMAGING, V30, P303, DOI 10.1007/s00261-004-0269-1
   Kyoden Y, 2007, HEPATO-GASTROENTEROL, V54, P1164
   Lee SungGyu, 2003, J Hepatobiliary Pancreat Surg, V10, P16
   Sugimoto H, 2001, J Hepatobiliary Pancreat Surg, V8, P573, DOI 10.1007/s005340100028
NR 9
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2010
VL 14
IS 4
BP E34
EP E37
DI 10.1111/j.1399-3046.2008.01121.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 594IA
UT WOS:000277528900001
PM 19175516
ER

PT J
AU Urschel, S
   Cremer, S
   Birnbaum, J
   DallaPozza, R
   Fuchs, A
   Jager, G
   Schmitz, C
   Belohradsky, BH
   Netz, H
AF Urschel, Simon
   Cremer, Sabine
   Birnbaum, Julia
   DallaPozza, Robert
   Fuchs, Alexandra
   Jaeger, Gundula
   Schmitz, Christoph
   Belohradsky, Bernd H.
   Netz, Heinrich
TI Lack of serologic immunity against vaccine-preventable diseases in
   children after thoracic transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE immunosuppression; pediatric heart-transplantation; post-transplant
   complications; serological immunity; vaccination
ID STEROID WITHDRAWAL; ANTIBODY-RESPONSE; LIVER-TRANSPLANT; PEDIATRIC
   LIVER; VIRUS-VACCINE; FOLLOW-UP; RECIPIENTS; HEART; IMMUNIZATION;
   DIPHTHERIA
AB P>We investigated whether children after heart- (HTx) or heart-lung transplantation (HLTx) show protective antibody levels against recommended vaccinations, whether vaccination schedules are completed and which factors influence serologic immunity. We performed a cross sectional ELISA - quantification of specific antibodies in 46 patients after pediatric thoracic Tx. Findings were correlated to vaccination history, age at Tx, clinical course and immunosuppressive regimen. We found protective antibody levels against diphtheria in 74% of patients, against tetanus in 22%, against Haemophilus influenzae type b in 30% and against Streptococcus pneumoniae in 59%. Antibody concentrations against live attenuated vaccines were significantly lower in children transplanted in the first 2 years of life. Antibodies were absent for measles in 55% of late - and 81% of early transplanted children, for mumps in 66%/94%, for rubella in 30%/56% and for Varicella in 34%/63%. We found significant correlation of low antibody concentrations and age at Tx. Patients without protective antibody concentrations had significantly longer use of steroids. Vaccination schedules were incomplete or delayed in the majority of patients associated with more days in hospital pre-Tx. Our study shows that closer adherence to pretransplantation vaccination schedules and also post-transplantation monitoring of antibody levels are required in transplant patients.
C1 [Urschel, Simon; Birnbaum, Julia; DallaPozza, Robert; Fuchs, Alexandra; Netz, Heinrich] Univ Munich, Dept Pediat Cardiol & Intens Care, Munich, Germany.
   [Jaeger, Gundula] Max Von Pettenkofer Inst, Dept Virol, D-8000 Munich, Germany.
   [Schmitz, Christoph] Univ Munich, Klinikum Grosshadern, Dept Cardiac Surg, D-8000 Munich, Germany.
RP Urschel, S (reprint author), Univ Alberta, Dept Pediat, Hlth Res Innovat Facil, Rm 6-002, Edmonton, AB T6G 2E1, Canada.
EM urschel@ualberta.ca
CR DEHAAS PW, 1983, T ROY SOC TROP MED H, V77, P267, DOI 10.1016/0035-9203(83)90086-X
   Dengler TJ, 1999, VACCINE, V17, P867, DOI 10.1016/S0264-410X(98)00272-2
   DICK B, 1975, S AFR MED J, V49, P1951
   Dittmann S, 2000, J INFECT DIS, V181, pS10, DOI 10.1086/315534
   Fonseca-Aten Monica, 2006, Semin Pediatr Surg, V15, P153, DOI 10.1053/j.sempedsurg.2006.03.009
   Fraund S, 1999, J HEART LUNG TRANSPL, V18, P220, DOI 10.1016/S1053-2498(98)00013-8
   Huang J, 2004, J HEART LUNG TRANSPL, V23, P716, DOI 10.1016/j.jhealun.2003.08.001
   Kano H, 2002, TRANSPLANTATION, V74, P543, DOI 10.1097/00007890-200208270-00020
   Khan S, 2006, PEDIATR TRANSPLANT, V10, P78, DOI 10.1111/j.1399-3046.2005.00403.x
   KILPI TM, 2008, HUM VACCIN, V5, P18
   Kirk R, 2008, J HEART LUNG TRANSPL, V27, P970, DOI 10.1016/j.healun.2008.06.016
   Kroger Andrew T., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Kruger S, 2001, AM J KIDNEY DIS, V38, P1264, DOI 10.1053/ajkd.2001.29223
   Kumar D, 2007, AM J TRANSPLANT, V7, P633, DOI 10.1111/j.1600-6143.2007.01668.x
   Lee CF, 2006, BRIT MED J, V332, P328, DOI 10.1136/bmj.38719.435833.7C
   Madan RP, 2008, CLIN INFECT DIS, V46, P712, DOI 10.1086/527391
   Meiser B, 2007, J HEART LUNG TRANSPL, V26, P598, DOI 10.1016/j.healun.2007.03.011
   Orenstein W A, 1986, Dev Biol Stand, V65, P13
   REITER S, 2006, EPID B, V48, P430
   Sanchez V, 2002, TRANSPLANT P, V34, P164, DOI 10.1016/S0041-1345(01)02712-9
   Sarmiento E, 2006, Int Immunopharmacol, V6, P2027, DOI 10.1016/j.intimp.2006.09.011
   Sauerbrei A, 1997, BONE MARROW TRANSPL, V20, P381, DOI 10.1038/sj.bmt.1700909
   SCHMID D, 2008, EURO SURVEILL, V13, P16
   Schmitt HJ, 2003, LANCET INFECT DIS, V3, P103, DOI 10.1016/S1473-3099(03)00519-X
   Schneerson R, 1999, CLIN INFECT DIS, V28, pS136
   Skendzel LP, 1996, AM J CLIN PATHOL, V106, P170
   *STIK, 2005, EPIDEMIOL B, V30, P257
   *STIKO, 2005, EPIDEMIOL B S, V30, P1
   STORSAETER J, 1992, AM J DIS CHILD, V146, P167
   Urschel S, 2005, AIDS, V19, P2103, DOI 10.1097/01.aids.0000194795.20928.2b
   Vidhun JR, 2005, PEDIATR NEPHROL, V20, P418, DOI 10.1007/s00467-004-1786-4
   WAGNER D, 1994, CLIN INVESTIGATOR, V72, P350
   Weinberg A, 2006, AM J TRANSPLANT, V6, P565, DOI 10.1111/j.1600-6143.2005.01210.x
   WHO, 2008, WHO REP GLOB TOB EP, P1
   Wichmann O, 2007, PEDIATR INFECT DIS J, V26, P782, DOI 10.1097/INF.0b013e318060aca1
   ZAMORA I, 1994, PEDIATR NEPHROL, V8, P190
NR 36
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD JUN
PY 2010
VL 23
IS 6
BP 619
EP 627
DI 10.1111/j.1432-2277.2009.01030.x
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 591UN
UT WOS:000277330500013
PM 20028497
ER

PT J
AU Guo, CB
   Li, YC
   Zhang, MM
   Yan, LN
   Pu, CL
   Kang, Q
   Jin, XQ
AF Guo, C-B
   Li, Y-C
   Zhang, M-M
   Yan, L-N
   Pu, C-L
   Kang, Q.
   Jin, X-Q
TI Early Postoperative Care of Liver Transplantation for Infants With
   Biliary Atresia During Pediatric Intensive Care Unit Stay
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID SINGLE-CENTER EXPERIENCE; KILOGRAMS; CHILDREN
AB Subject. The aim of this study was to present our institutional experience with the pediatric intensive care unit (PICU) stays of liver recipients to understand prevention of complications.
   Methods. This retrospective review included 22 infants who weighed 8.8 kg or less and underwent 23 transplantations. No grafts were from executed prisoners. We summarized the diagnosis, evaluation, medicine usage, and therapeutic intervention associated with subjects experiencing complications of rejection episodes, surgery, or infection during their ICU stay.
   Results. There was one perioperative death from primary graft nonfunction. The most common postoperative complications were infections, gastrointestinal bleeding, and vascular complications. Rejection episodes occurred among 25% of patients. The most common isolated pathogenic bacteria was Staphylococcus epidermidis. Median initial ICU stay was 10 days. Mean requirement for artificial ventilation was 37.6 hour. Mean times of use of dobutamine, prostaglandin E1, and dopamine was 3.3, 7.5, and 8.8 days, respectively. Parenteral nutrition was started at a mean of 12 hours and oral food intake at a mean of 72 hours.
   Conclusions. Although challenging, orthotopic liver transplantation (OLT) in small infants can be successfully performed with meticulous surgical technique and keen postoperative surveillance.
C1 [Guo, C-B; Li, Y-C; Zhang, M-M; Pu, C-L; Kang, Q.; Jin, X-Q] Chongqing Med Univ, Childrens Hosp, Dept Hepatobiliary Surg, Chongqing 400014, Peoples R China.
   [Yan, L-N] Sichuan Univ, W China Hosp, Dept Hepatobiliary Surg, Chengdu 610064, Peoples R China.
RP Zhang, MM (reprint author), Chongqing Med Univ, Childrens Hosp, Dept Hepatobiliary Surg, 136 Zhongshan 2nd Rd, Chongqing 400014, Peoples R China.
EM zhangmingman-a@163.com
CR BEATH S, 1993, J PEDIATR SURG, V28, P1044
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Cintorino D, 2006, TRANSPLANT P, V38, P1099, DOI 10.1016/j.transproceed.2006.02.147
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   Pfitzmann R, 2007, LIVER TRANSPLANT, V13, P248, DOI 10.1002/lt.20904
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   Ulukaya S, 2003, PEDIATR TRANSPLANT, V7, P381, DOI 10.1034/j.1399-3046.2003.00072.x
NR 10
TC 3
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2010
VL 42
IS 5
BP 1750
EP 1754
DI 10.1016/j.transproceed.2010.02.086
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 616UQ
UT WOS:000279236100074
PM 20620515
ER

PT J
AU Pinho-Apezzato, ML
   Tannuri, U
   Tannuri, ACA
   Mello, ES
   Lima, F
   Gibelli, NE
   Santos, MM
   Ayoub, AA
   Maksoud, JG
   Velhote, MC
   Silva, MM
   Andrade, WC
   Miyatani, HT
AF Pinho-Apezzato, M. L.
   Tannuri, U.
   Tannuri, A. C. A.
   Mello, E. S.
   Lima, F.
   Gibelli, N. E.
   Santos, M. M.
   Ayoub, A. A.
   Maksoud-Filho, J. G.
   Velhote, M. C.
   Silva, M. M.
   Andrade, W. C.
   Miyatani, H. T.
TI Multiple Clinical Presentations of Lymphoproliferative Disorders in
   Pediatric Liver Transplant Recipients: A Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID SIROLIMUS; CHILDREN; DISEASE
AB Posttransplantation lymphoproliferative disorder (PTLD) is a serious complication following solid organ transplantation that has been linked to Epstein-Barr virus (EBV) infection. The aim of this article was to describe a single-center experience with the multiplicity of clinical presentations of PTLD. Among 350 liver transplantations performed in 303 children, 13 survivor children displayed a histological diagnosis of PTLD (13/242 survivors; 5.4%). The age at diagnosis ranged from 12 to 258 months (median, 47), and the time from transplantation ranged from 1 to 84 months (median, 13). Ten of these children (76.9%) were EBV-naive prior to transplantation. Fever was present in all cases. The clinical signs at presentation were anemia (92.3%), diarrhea and vomiting (69.2%), recurrent upper airway infections (38.4%), Waldeyer ring lymphoid tissue hypertrophy (23.0%), abdominal mass lesions (30.7%), massive cervical and mediastinal adenopathy (15.3%), or gastrointestinal and respiratory symptoms (30.7%). One child developed fulminant hepatic allograft failure secondary to graft involvement by PTLD. Polymorphic PTLD was diagnosed in 6 patients; 7 had the diagnosis of lymphoma. Treatment consisted of stopping immunosuppression as well as starting intravenous gancyclovir and anti-CD20 monoclonal antibody therapy. The mortality rate was 53.8%. The clinical presentation of PTLD varied from fever of unknown origin to fulminant hepatic failure. The other symptoms that may be linked to the diagnosis of PTLD are pancytopenia, tonsil and adenoid hypertrophy, cervical or mediastinal lymph node enlargement, as well as abdominal masses. Despite numerous advances, the optimal treatment approach for PTLD is not completely known and the mortality rate is still high.
C1 [Tannuri, U.] Univ Sao Paulo, Fac Med, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Fac Med, Sch Med, Ave Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM uenist@usp.br
RI Tannuri, Ana Cristina Aoun/C-4718-2012; Tannuri, Uenis/D-3876-2012;
   Gibelli, Nelson Elias Mendes/I-7176-2016
CR Birkeland SA, 2003, TRANSPLANTATION, V76, P153, DOI 10.1097/01.TP.0000072015.08302.E9
   Fernandez MC, 2009, PEDIATR TRANSPLANT, V13, P307, DOI 10.1111/j.1399-3046.2008.00914.x
   Gibelli NEM, 2009, TRANSPL P, V41, P901, DOI 10.1016/j.transproceed.2009.01.054
   Gupta P, 2005, PEDIATR TRANSPLANT, V9, P269, DOI 10.1111/j.1399-3046.2005.00305.x
   Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8
   Hurwitz M, 2004, PEDIATR TRANSPLANT, V8, P267, DOI 10.1111/j.1399-3046.2004.00129.x
   Jain A, 2002, ANN SURG, V236, P429, DOI 10.1097/01.SLA.0000033429.89429.89424.F8
   Lattyak BV, 1998, LARYNGOSCOPE, V108, P1195, DOI 10.1097/00005537-199808000-00018
   Roque J, 2006, TRANSPLANT P, V38, P930, DOI 10.1016/j.transproceed.2006.02.046
   Sindhi R, 2001, TRANSPLANTATION, V72, P851, DOI 10.1097/00007890-200109150-00019
   Smets F, 2000, TRANSPLANTATION, V69, P982
   SOKAL EM, 1993, TRANSPLANTATION, V56, P1394, DOI 10.1097/00007890-199312000-00023
   Starzl T, 1968, ANN SURG, V168, P416
   Timuragaoglu A, 2006, TRANSPLANT P, V38, P641, DOI 10.1016/j.transproceed.2005.12.093
   Webber SA, 2007, PEDIAT SOLID ORGAN T, P114, DOI 10.1002/9781444312720.ch13
   YOUSEM SA, 1989, HUM PATHOL, V20, P361, DOI 10.1016/0046-8177(89)90046-4
NR 16
TC 8
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2010
VL 42
IS 5
BP 1763
EP 1768
DI 10.1016/j.transproceed.2010.01.077
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 616UQ
UT WOS:000279236100078
PM 20620519
ER

PT J
AU Mimuro, J
   Mizuta, K
   Kawano, Y
   Hishikawa, S
   Hamano, A
   Kashiwakura, Y
   Ishiwata, A
   Ohmori, T
   Madoiwa, S
   Kawarasaki, H
   Sakata, Y
AF Mimuro, Jun
   Mizuta, Koichi
   Kawano, Yoichi
   Hishikawa, Shuji
   Hamano, Akiei
   Kashiwakura, Yuji
   Ishiwata, Akira
   Ohmori, Tsukasa
   Madoiwa, Seiji
   Kawarasaki, Hideo
   Sakata, Yoichi
TI Impact of acute cellular rejection on coagulation and fibrinolysis
   biomarkers within the immediate post-operative period in pediatric liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplant rejection; coagulation; fibrinolysis; plasminogen
   activator inhibitor 1
ID DISSEMINATED INTRAVASCULAR COAGULATION; CLEAVING PROTEASE ADAMTS13;
   ALLOGRAFT-REJECTION; VENOOCCLUSIVE DISEASE; PLASMINOGEN; CELLS;
   EXPRESSION; RECIPIENTS; BUSULFAN; THERAPY
AB We studied restoration of the coagulation and fibrinolysis system in pediatric patients following liver transplantation and biomarkers of blood coagulation and fibrinolysis for suspecting the occurrence of acute cellular rejection. Coagulation activity recovered rapidly within two days following transplantation, but it took approximately 21-28 days for full recovery of the coagulation and fibrinolysis factors synthesized in the liver. PAI-1 levels were significantly higher in patients at the time of acute cellular rejection compared with levels after control of AR, and levels on days 14 and 28 in patients without AR. Plasma protein C and plasminogen levels at the time of rejection were significantly lower than those on day 14 in patients without AR. Statistical analysis suggested that an increase in plasma PAI-1 at a single time point in the post-operative period is a reliable marker among the coagulation and fibrinolysis factors for suspecting the occurrence of acute cellular rejection. These data suggested that appropriate anticoagulation may be required for 14 days after liver transplantation in order to avoid vascular complications and measurement of plasma PAI-1 levels may be useful for suspecting the occurrence of acute cellular rejection in pediatric patients following liver transplantation.
C1 [Mimuro, Jun; Hamano, Akiei; Kashiwakura, Yuji; Ishiwata, Akira; Ohmori, Tsukasa; Madoiwa, Seiji; Sakata, Yoichi] Jichi Med Univ, Div Cell & Mol Med, Ctr Mol Med, Sch Med, Shimotsuke, Tochigi 3290498, Japan.
   [Mizuta, Koichi; Kawano, Yoichi; Hishikawa, Shuji; Kawarasaki, Hideo] Jichi Med Univ, Div Transplant Surg, Sch Med, Shimotsuke, Tochigi 3290498, Japan.
RP Mimuro, J (reprint author), Jichi Med Univ, Div Cell & Mol Med, Ctr Mol Med, Sch Med, Shimotsuke, Tochigi 3290498, Japan.
EM mimuro-j@jichi.ac.jp
FU Japanese Ministry of Education and Science; Japanese Ministry of Health,
   Labor and Welfare;  [20591155];  [21591249];  [21790920]
FX This study was supported by Grants-in-Aid for Scientific Research
   (20591155, 21591249, and 21790920) and Support Program for Strategic
   Research Infrastructure from the Japanese Ministry of Education and
   Science, and Health Labor and Science Research Grants for Research on
   HIV/ AIDS and Research on Intractable Diseases from the Japanese
   Ministry of Health, Labor and Welfare.
CR ANTHONY J, 1997, HEPATOLOGY, V25, P658
   Boleslawski E, 2004, TRANSPLANTATION, V77, P1815, DOI 10.1097/01.tp.0000129914.75547.b3
   Boleslawski E, 2008, CLIN TRANSPLANT, V22, P494, DOI 10.1111/j.1399-0012.2008.00815.x
   CAKALOGLU Y, 1994, HEPATOLOGY, V20, P309, DOI 10.1016/0270-9139(94)90179-1
   Carreras E, 2007, BIOL BLOOD MARROW TR, V13, P1448, DOI 10.1016/j.bbmt.2007.08.002
   Dix SP, 1996, BONE MARROW TRANSPL, V17, P225
   Esmon CT, 2006, SEMIN THROMB HEMOST, V32, P49, DOI 10.1055/s-2006-939554
   Goldstein DR, 2003, J CLIN INVEST, V111, P1571, DOI 10.1172/JCI200317573
   KLINTMALM GBG, 1989, HEPATOLOGY, V10, P978, DOI 10.1002/hep.1840100615
   Kowalski RJ, 2006, TRANSPLANTATION, V82, P663, DOI 10.1097/01.tp.0000234837.02126.70
   Madoiwa S, 2006, INT J HEMATOL, V84, P398, DOI 10.1532/IJH97.05190
   Mimuro J, 2008, THROMB RES, V122, P91, DOI 10.1016/j.thromres.2007.09.011
   MIYATA T, 1982, P NATL ACAD SCI-BIOL, V79, P6132, DOI 10.1073/pnas.79.20.6132
   Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528
   Muller C, 1981, Z Gesamte Inn Med, V36, P660
   Ono T, 2006, BLOOD, V107, P528, DOI 10.1182/blood-2005-03-1087
   Ormonde DG, 1999, LIVER TRANSPLANT SUR, V5, P261, DOI 10.1002/lt.500050418
   Pihusch M, 2005, TRANSPLANTATION, V80, P1376, DOI 10.1097/01.tp.0000183288.67746.44
   SAKATA Y, 1980, J BIOL CHEM, V255, P5442
   Sato Y, 2008, TRANSPL P, V40, P2501, DOI 10.1016/j.transproceed.2008.08.050
   Tarlinton DM, 2008, TRANSPLANTATION, V85, P1698, DOI 10.1097/TP.0b013e3181777a39
   Turner N, 2006, J THROMB HAEMOST, V4, P1396, DOI 10.1111/j.1538-7836.2006.01959.x
   Uemura M, 2005, BLOOD, V106, P922, DOI 10.1182/blood-2005-01-0152
   van den Berg AP, 1998, TRANSPLANTATION, V65, P1066, DOI 10.1097/00007890-199804270-00010
   Wiesner RH, 1998, HEPATOLOGY, V28, P638, DOI 10.1002/hep.510280306
   Yano Y, 2008, EUR HEART J, V29, P1729, DOI 10.1093/eurheartj/ehn027
   Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200
NR 27
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2010
VL 14
IS 3
BP 369
EP 376
DI 10.1111/j.1399-3046.2009.01248.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 581BL
UT WOS:000276495900017
PM 19793340
ER

PT J
AU Bartlett, A
   Vara, R
   Muiesan, P
   Mariott, P
   Dhawan, A
   Mieli-Vergani, G
   Rela, M
   Heaton, N
AF Bartlett, Adam
   Vara, Roshni
   Muiesan, Paolo
   Mariott, Paul
   Dhawan, Anil
   Mieli-Vergani, Giorgina
   Rela, Mohamed
   Heaton, Nigel
TI A single center experience of donation after cardiac death liver
   transplantation in pediatric recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pediatric; outcome; donation after cardiac death
ID HEART-BEATING DONORS
AB Many centers are now performing DCD adult LT. There has been a reluctance to transplant pediatric recipients with DCD livers due to concern over the medium to long-term outcome. We describe the outcome of 14 children (median age seven yr, 8 months-16 yr) that underwent LT with DCD grafts from July 2001 to December 2007. Donors had a median age of 23 yr (10-64), intensive care stay of five d (2-14) and bilirubin of 9 mmol/L (6-60). Median warm and cold ischemic time was 16 min (11-29) and seven h (5.5-8.4). Livers were transplanted as a whole organ (4), reduced graft (8), formal split (1) or auxiliary transplant (1). Compared to DBD recipients AST was significantly higher on the first three post-operative days and there was no difference in the INR, bilirubin or GGT out to 12 months. There were no biliary or vascular complications and patient and graft survival is 100% at a median follow-up of 41.8 months (1.7-74 months). LT with DCD grafts in pediatric recipients can be performed with low morbidity and excellent short-to-medium term patient and graft outcome.
C1 [Bartlett, Adam; Muiesan, Paolo; Mariott, Paul; Rela, Mohamed; Heaton, Nigel] Kings Coll London, Sch Med, Kings Coll Hosp NHS Fdn Trust, Inst Liver Studies & Transplantat, London WC2R 2LS, England.
   [Vara, Roshni; Dhawan, Anil; Mieli-Vergani, Giorgina] Kings Coll London, Sch Med, Kings Coll Hosp NHS Fdn Trust, Pediat Liver Ctr, London WC2R 2LS, England.
RP Bartlett, A (reprint author), Auckland City Hosp, New Zealand Liver Transplant Unit, Private Bag 92024, Auckland, New Zealand.
EM adamb@adhb.govt.nz
RI Dhawan, Anil/B-6730-2009; 
OI Muiesan, Paolo/0000-0002-7389-6691
CR Abt PL, 2004, ANN SURG, V239, P87, DOI 10.1097/01.sla.0000103063.82181.2c
   Bartlett A, 2007, AM J TRANSPLANT, V7, P1689, DOI 10.1111/j.1600-6143.2007.01834.x
   D'Alessandro AM, 2000, SURGERY, V128, P579, DOI 10.1067/msy.2000.108421
   Feng S, 2006, AM J TRANSPLANT, V6, P783, DOI 10.1111/j.1600-6143.2006.01242.x
   Foley DP, 2005, ANN SURG, V242, P724, DOI 10.1097/01.sla.0000186178.07110.92
   Kimber RM, 2001, POSTGRAD MED J, V77, P681, DOI 10.1136/pmj.77.913.681
   Muiesan P, 2005, ANN SURG, V242, P732, DOI 10.1097/01.sla.0000186177.26112.d2
   Muiesan P, 2006, AM J TRANSPLANT, V6, P1012, DOI 10.1111/j.1600-6143.2006.01293.x
   Starzl T E, 1990, Curr Probl Surg, V27, P49
NR 9
TC 12
Z9 14
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2010
VL 14
IS 3
BP 388
EP 392
DI 10.1111/j.1399-3046.2009.01206.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 581BL
UT WOS:000276495900020
PM 20519017
ER

PT J
AU Wellen, JR
   Anderson, CD
   Doyle, M
   Shenoy, S
   Nadler, M
   Turmelle, Y
   Shepherd, R
   Chapman, WC
   Lowell, JA
AF Wellen, J. R.
   Anderson, C. D.
   Doyle, M.
   Shenoy, S.
   Nadler, M.
   Turmelle, Y.
   Shepherd, R.
   Chapman, W. C.
   Lowell, J. A.
TI The role of liver transplantation for hepatic adenomatosis in the
   pediatric population: Case report and review of the literature
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplant; Hepatic adenomatosis; pediatric
ID FOCAL NODULAR HYPERPLASIA; MANAGEMENT
AB Hepatic adenomas are benign lesions often found in young women during childbearing age. These tumors are often solitary but can also be multiple in which case this is referred to as hepatic adenomatosis (HA). HA is defined as having greater than or equal to ten adenomas within an otherwise normal liver. We present a case of a teenager with HA who underwent an orthotopic liver transplant for complications of her HA. To date there are only four reports of teenagers, without an underlying glycogen storage disease, who have undergone a liver transplant for HA. Liver transplantation within the pediatric population is an acceptable treatment for HA that are deemed unresectable.
C1 [Wellen, J. R.; Anderson, C. D.; Doyle, M.; Shenoy, S.; Nadler, M.; Turmelle, Y.; Shepherd, R.; Chapman, W. C.; Lowell, J. A.] Washington Univ, Sch Med, Sect Transplantat, St Louis, MO 63110 USA.
RP Lowell, JA (reprint author), Washington Univ, Sch Med, Sect Transplantat, Box 8109,660 S Euclid, St Louis, MO 63110 USA.
EM lowellj@wustl.edu
CR Chiche L, 2000, ANN SURG, V231, P74, DOI 10.1097/00000658-200001000-00011
   FLEJOU JF, 1985, GASTROENTEROLOGY, V89, P1132
   Fujita S, 2006, TRANSPLANTATION, V81, P490, DOI 10.1097/01.tp.0000197481.80367.32
   Grazioli L, 2000, RADIOLOGY, V216, P395
   KERLIN P, 1983, GASTROENTEROLOGY, V84, P994
   LEESE T, 1988, ANN SURG, V208, P558, DOI 10.1097/00000658-198811000-00003
   MAYS ET, 1984, SEMIN LIVER DIS, V4, P147, DOI 10.1055/s-2008-1040654
   MONACO AP, 1964, ANN SURG, V159, P513, DOI 10.1097/00000658-196415940-00006
   PORTER LE, 1987, GASTROENTEROLOGY, V92, P735
   PROPST A, 1995, AM J GASTROENTEROL, V90, P1345
   Ribeiro A, 1998, LIVER TRANSPLANT SUR, V4, P388, DOI 10.1002/lt.500040505
   Yoshidome H, 1999, AM SURGEON, V65, P1070
NR 12
TC 4
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2010
VL 14
IS 3
BP E16
EP E19
DI 10.1111/j.1399-3046.2008.01123.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 581BL
UT WOS:000276495900003
PM 19490491
ER

PT J
AU Manzia, TM
   Toti, L
   Angelico, R
   Di Cocco, P
   Orlando, G
   Tisone, G
AF Manzia, T. M.
   Toti, L.
   Angelico, R.
   Di Cocco, P.
   Orlando, G.
   Tisone, G.
TI Steroid-Free Immunosuppression After Liver Transplantation Does Not
   Increase the Risk of Graft Fibrosis
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 33rd Congress of the Italian-Tranplantation-Society
CY DEC 13-15, 2009
CL Milan, ITALY
SP Italian Tranplantat Soc
AB Background. Steroid-free immunosuppression after liver transplantation (OLT) is effective and safe in the short and mid terms. However, research has shown a higher risk for late fibrosis among pediatric liver transplant recipients who have steroids withdrawn. Our aim was to test this hypothesis in the adult population.
   Patients and Methods. The study involved 27 adults, 14 of whom were on a regimen of cyclosporine, azathioprine, and steroid (group A) and 13 cyclosporine and azathioprine steroid-free immunosuppression (group B). The main end point of the study was liver graft histology in the late stage after OLT, with emphasis on the evolution of fibrosis, which was scored according to Ishak. The secondary end points were patient and graft survivals, liver and kidney functions, rejection rates, infections, and tumors, as well as the incidences of cardiovascular and metabolic complications.
   Results. After a mean follow-up of 89.3 +/- 21 months, the mean fibrosis scores did not differ between the 2 groups (2.2 +/- 1.5 vs 1.9 +/- 1.2; P = NS). One group A patient developed a severe acute rejection episode. The 7-year patient and graft survivals, as well as liver and kidney functions, incidence of infections, and cardiovascular and metabolic complications were comparable. Patients receiving steroids showed a trend toward an higher rate of de novo malignancies.
   Conclusion. Steroid-free immunosuppression did not increase the risk of graft fibrosis in the long term.
C1 [Manzia, T. M.; Toti, L.; Angelico, R.] Univ Roma Tor Vergata, Surg Clin, S Eugenio Hosp, Transplant Unit,Dept Surg, I-00144 Rome, Italy.
   [Di Cocco, P.; Orlando, G.; Tisone, G.] Univ Aquila, Transplant Unit, I-67100 Laquila, Italy.
RP Manzia, TM (reprint author), Univ Roma Tor Vergata, Surg Clin, S Eugenio Hosp, Transplant Unit,Dept Surg, Viale Umanesimo 10, I-00144 Rome, Italy.
EM tomanzia@libero.it
OI Manzia, Tommaso Maria/0000-0002-4636-3478; Toti,
   Luca/0000-0001-8407-5939
CR Evans HM, 2000, HEPATOLOGY, V32, p227A
   ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6
   KLINTMALM GBG, 1989, HEPATOLOGY, V10, P978, DOI 10.1002/hep.1840100615
   LAKE J R, 1992, Seminars in Liver Disease, V12, P73, DOI 10.1055/s-2007-1007378
   STEGALL MD, 1995, TRANSPLANTATION, V60, P1057
   Tisone G, 2006, J HEPATOL, V44, P702, DOI 10.1016/j.jhep.2005.11.047
   Tisone G, 1999, TRANSPLANTATION, V67, P1308, DOI 10.1097/00007890-199905270-00003
   Tisone G, 1999, TRANSPLANT P, V31, P2908, DOI 10.1016/S0041-1345(99)00611-9
   Tisone G, 1998, Transpl Int, V11 Suppl 1, pS267, DOI 10.1111/j.1432-2277.1998.tb01130.x
NR 9
TC 1
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1237
EP 1239
DI 10.1016/j.transproceed.2010.03.118
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000061
PM 20534270
ER

PT J
AU Maggi, U
   Caccamo, L
   Reggiani, P
   Laura, R
   Bertoli, P
   Camagni, S
   Paterson, IM
   Rossi, G
AF Maggi, U.
   Caccamo, L.
   Reggiani, P.
   Laura, R.
   Bertoli, P.
   Camagni, S.
   Paterson, I. M.
   Rossi, G.
TI Hypoperfusion of Segment 4 in Right In Situ Split-Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 33rd Congress of the Italian-Tranplantation-Society
CY DEC 13-15, 2009
CL Milan, ITALY
SP Italian Tranplantat Soc
ID ONE DONOR LIVER; CADAVERIC-LIVER; POOL
AB To expand the donor pool, split-liver transplantation has been implemented in recent years. In the classic technique, the arterial axis with the artery for segment 4 (S4) coming from the left hepatic artery (HA) is included with the right graft. To give a surgical advantage to pediatric recipients in our center, the left HA, the common HA, and the celiac trunk are generally retained with the left liver. Thus the artery for S4 is sacrificed. We compared the outcomes of S4 in 290 whole grafts (WG; group A) with 28 right in situ split-liver grafts (SSLG; group B), which were transplanted over the past 10 years (January 1999 December 2009). The rates of major biliary and of hemorrhagic complications were similar. In most of cases (16/24, 66%) S4, on computerized tomographic scan appeared to show signs of hypoperfusion, sometimes with a peripheral aspect of hyperperfusion in the arterial phase. Si showed signs of hypoperfusion in only 2 cases. A biliary collection near the resection line present in 8 cases was treated in 6 of them with percutaneous drainage and in 2 with laparotomy. These complications did not influence graft or patient survival. Graft survivals at 1, 5, and 10 years for WG and SSLG were not different among the groups: 85%, 74%, and 66% vs 89%, 79%, and 63%, respectively (P = .8). Although our technique cannot be considered to be anatomically correct, the ischemia of S4 did not influence the outcome. The rate of retransplantations for hepatic artery thrombosis was 17.9% in RSSG and 3.4% in WG (P = .001), which was probably due at least in part to the insertion of interposition grafts.
C1 [Maggi, U.; Caccamo, L.; Reggiani, P.; Laura, R.; Bertoli, P.; Camagni, S.; Rossi, G.] Fdn IRCCS Osped Maggiore Policlin, Unita Operat Chirurg Gen & Trapianti Fegato, I-20121 Milan, Italy.
   [Paterson, I. M.] Frimley Pk Hosp, Dept Surg, Surrey, England.
RP Maggi, U (reprint author), Fdn IRCCS Osped Maggiore Policlin, Unita Operat Chirurg Gen & Trapianti Fegato, Via Francesco Sforza 35, I-20121 Milan, Italy.
EM u.maggi@tiscali.it
RI Caccamo, Lucio/J-4957-2015; Maggi, Umberto/M-3074-2015; Rossi,
   Giorgio/M-3445-2015
OI Caccamo, Lucio/0000-0002-5292-1376; Maggi, Umberto/0000-0002-5337-2866;
   Rossi, Giorgio/0000-0002-5588-1306
CR BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723
   BUSUTTIL RW, 1999, ANN SURG, V229, P312
   Cardillo M, 2006, LIVER TRANSPLANT, V12, P402, DOI 10.1002/lt.20720
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Lee KW, 2008, AM J TRANSPLANT, V8, P1186, DOI 10.1111/j.1600-6143.2008.02211.x
   Nunez A, 2003, TRANSPLANTATION, V76, P1134, DOI 10.1097/01.TP.0000088665.04964.CC
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Renz JF, 2003, AM J TRANSPLANT, V3, P1323, DOI 10.1046/j.1600-6135.2003.00254-x
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Rogiers X, 2002, SPLIT LIVER TRANSPLA
   Spada M, 2009, WORLD J GASTROENTERO, V15, P648, DOI 10.3748/wjg.15.648
   Yersiz Hasan, 2003, J Hepatobiliary Pancreat Surg, V10, P11
NR 12
TC 7
Z9 9
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1240
EP 1243
DI 10.1016/j.transproceed.2010.03.110
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000062
PM 20534271
ER

PT J
AU Colledan, M
   Stroppa, P
   Bravi, M
   Casotti, V
   Lucianetti, A
   Pinelli, D
   Zambelli, M
   Guizzetti, M
   Corna, V
   Aluffi, A
   Sonzogni, V
   Sonzogni, A
   D'Antiga, L
   Codazzi, D
AF Colledan, M.
   Stroppa, P.
   Bravi, M.
   Casotti, V.
   Lucianetti, A.
   Pinelli, D.
   Zambelli, M.
   Guizzetti, M.
   Corna, V.
   Aluffi, A.
   Sonzogni, V.
   Sonzogni, A.
   D'Antiga, L.
   Codazzi, D.
TI Intestinal Transplantation in Children: The First Successful Italian
   Series
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 33rd Congress of the Italian-Tranplantation-Society
CY DEC 13-15, 2009
CL Milan, ITALY
SP Italian Tranplantat Soc
AB The preliminary experience of the first Italian program of pediatric intestinal transplantation is presented herein. A multidisciplinary group with broad experience in pediatric solid organ transplantation started the program. Nine children with complications of chronic intestinal failure were listed for transplantation. One child died on the waiting list; one received an isolated liver transplantation; three isolated intestinal; three multivisceral; and one, a combined liver/intestine transplantation. There was no in-hospital mortality, and all children were weaned from parenteral nutrition. The recipient of the multivisceral graft died after 14 months for unknown causes. All other recipients are alive after a median follow-up of 13 months. Patient and graft actuarial survivals for recipients of intestinal grafts were 100% at 1 year and 75% at 2 years.
C1 [Colledan, M.; Lucianetti, A.; Pinelli, D.; Zambelli, M.; Guizzetti, M.; Corna, V.; Aluffi, A.] Osped Riuniti Bergamo, Ctr Trapianto Fegato & Intestino, I-24121 Bergamo, Italy.
RP Colledan, M (reprint author), Osped Riuniti Bergamo, Ctr Trapianto Fegato & Intestino, 1 Largo Barozzi, I-24121 Bergamo, Italy.
EM mcolledan@ospedaliriuniti.bergamo.it
CR Grant D, 2005, ANN SURG, V241, P607, DOI 10.1097/01.sla.0000157265.85388.a1
   Kato T, 2006, ANN SURG, V243, P756, DOI 10.1097/01.sla.0000219696.11261.13
   Sauvat F, 2006, TRANSPLANT P, V38, P1689, DOI 10.1016/j.transproceed.2006.05.033
NR 3
TC 0
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1251
EP 1252
DI 10.1016/j.transproceed.2010.03.046
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000064
PM 20534273
ER

PT J
AU Schramm, C
   Bubenheim, M
   Adam, R
   Karam, V
   Buckels, J
   O'Grady, JG
   Jamieson, N
   Pollard, S
   Neuhaus, P
   Manns, MM
   Porte, R
   Castaing, D
   Paul, A
   Traynor, O
   Garden, J
   Friman, S
   Ericzon, BG
   Fischer, L
   Vitko, S
   Krawczyk, M
   Metselaar, HJ
   Foss, A
   Kilic, M
   Rolles, K
   Burra, P
   Rogiers, X
   Lohse, AW
AF Schramm, Christoph
   Bubenheim, Michael
   Adam, Rene
   Karam, Vincent
   Buckels, John
   O'Grady, John G.
   Jamieson, Neville
   Pollard, Stephen
   Neuhaus, Peter
   Manns, Michael M.
   Porte, Robert
   Castaing, Denis
   Paul, Andreas
   Traynor, Oscar
   Garden, James
   Friman, Styrbjorn
   Ericzon, Bo-Goran
   Fischer, Lutz
   Vitko, Stefan
   Krawczyk, Marek
   Metselaar, Herold J.
   Foss, Aksel
   Kilic, Murat
   Rolles, Keith
   Burra, Patrizia
   Rogiers, Xavier
   Lohse, Ansgar W.
CA European Liver Intestine Transplan
TI Primary Liver Transplantation for Autoimmune Hepatitis: A Comparative
   Analysis of the European Liver Transplant Registry
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SINGLE-CENTER EXPERIENCE; DISEASE; RECURRENCE; PROGNOSIS; CIRRHOSIS;
   SURVIVAL; CRITERIA; IMPACT
AB The principal aim of this study was to compare the probability of and potential risk factors for death and graft loss after primary adult and pediatric liver transplantation in patients undergoing transplantation for autoimmune hepatitis (AIH) to those in patients undergoing transplantation for primary biliary cirrhosis (PBC; used as the reference group) or alcoholic cirrhosis (used as an example of a nonautoimmune liver disease). The 5-year survival of patients undergoing transplantation for AIH (n = 827) was 0.73 [95% confidence interval (CI) = 0.67-0.77]. This was similar to that of patients undergoing transplantation for alcoholic cirrhosis (0.74, 95% CI = 0.72-0.76, n = 6424) but significantly worse than that of patients undergoing transplantation for PBC (0.83, 95% CI = 0.80-0.85, n = 1588). Fatal infectious complications occurred at an increased rate in patients with AIH (hazard ratio = 1.8, P = 0.002 with PBC as the reference). The outcome of pediatric AIH patients was similar to that of adult patients undergoing transplantation up to the age of 50 years. However, the survival of AIH patients undergoing transplantation beyond the age of 50 years (0.61 at 5 years, 95% CI = 0.51-0.70) was significantly reduced in comparison with the survival of young adult AIH patients (0.78 at 18-34 years, 95% CI = 0.70-0.86) and in comparison with the survival of patients of the same age group with PBC or alcoholic cirrhosis. In conclusion, age significantly affects patient survival after liver transplantation for AN. The increased risk of dying of infectious complications in the early postoperative period, especially above the age of 50 years, should be acknowledged in the management of AIH patients with advanced-stage liver disease who are listed for liver transplantation. It should be noted that not all risk factors relevant to patient and graft survival could be analyzed with the European Liver Transplant Registry database. Liver Transpl 16:461-469, 2010. (C) 2010 AASLD.
C1 [Schramm, Christoph; Lohse, Ansgar W.] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, D-20246 Hamburg, Germany.
   [Bubenheim, Michael] Univ Hosp Rouen, Dept Biostat, Rouen, France.
   [Adam, Rene; Karam, Vincent; Castaing, Denis] Hop Paul Brousse, Ctr Hepatobiliaire, Paris, France.
   [Buckels, John] Queen Elizabeth Hosp, Dept Surg, Birmingham B15 2TH, W Midlands, England.
   [O'Grady, John G.] Kings Coll Hosp London, Liver Unit, London, England.
   [Jamieson, Neville] Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England.
   [Pollard, Stephen] St Jamess & Seacroft Univ Hosp, Liver Unit, Leeds, W Yorkshire, England.
   [Neuhaus, Peter] Charite Campus Virchow Klinikum, Klin Allgemein Viszeral & Transplantat Chirurg, Berlin, Germany.
   [Manns, Michael M.] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30623 Hannover, Germany.
   [Porte, Robert] Univ Groningen Hosp, Dept Surg, Groningen, Netherlands.
   [Paul, Andreas] Univ Klinikum Essen, Klin Allgemeine & Transplantat Chirurg, Essen, Germany.
   [Traynor, Oscar] St Vincents Univ Hosp, Liver Transplant Unit, Dublin 4, Ireland.
   [Garden, James] Univ Edinburgh, Royal Infirm, Liver Transplantat Unit, Edinburgh EH3 9YW, Midlothian, Scotland.
   [Friman, Styrbjorn] Sahlgrens Univ Hosp, Dept Surg, Gothenburg, Sweden.
   [Ericzon, Bo-Goran] Huddinge Univ Hosp, Dept Transplantat Surg, S-14186 Huddinge, Sweden.
   [Fischer, Lutz] Univ Med Ctr Hamburg Eppendorf, Dept Hepatobiliary & Transplantat Surg, Hamburg, Germany.
   [Vitko, Stefan] Inst Clin & Expt Med, Transplant Ctr, Prague, Czech Republic.
   [Krawczyk, Marek] Med Univ Warsaw, Dept Gen Transplant & Liver Surg, Warsaw, Poland.
   [Metselaar, Herold J.] Univ Med Ctr Rotterdam, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
   [Foss, Aksel] Univ Hosp, Rikshosp, Div Surg, Sect Transplantat,Dept Med, Oslo, Norway.
   [Kilic, Murat] Ege Univ, Sch Med, Dept Surg, Div Hepatobiliary & Liver Transplantat, Izmir, Turkey.
   [Rolles, Keith] Royal Free Hosp, Liver Transplantat Unit, London NW3 2QG, England.
   [Burra, Patrizia] Univ Hosp, Dept Surg & Gastroenterol Sci, Padua, Italy.
   [Rogiers, Xavier] Ghent Univ Hosp, Ctr Dis Liver & Biliary Tract, Dept Surg, B-9000 Ghent, Belgium.
RP Schramm, C (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Martinistr 52, D-20246 Hamburg, Germany.
EM cschramm@uke.de
OI Karam, Vincent/0000-0002-7391-0190; Schramm,
   Christoph/0000-0002-4264-1928
CR Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   Ahmed M, 1997, TRANSPLANT P, V29, P496, DOI 10.1016/S0041-1345(96)00223-0
   Al-Chalabi T, 2008, J HEPATOL, V48, P140, DOI 10.1016/j.jhep.2007.08.013
   Campsen J, 2008, LIVER TRANSPLANT, V14, P1281, DOI 10.1002/lt.21525
   Czaja AJ, 2004, HEPATOLOGY, V39, P1631, DOI 10.1002/hep.20235
   Czaja AJ, 2005, HEPATOLOGY, V41, P207, DOI 10.1002/hep.20539
   Gonzalez-Koch A, 2001, LIVER TRANSPLANT, V7, P302, DOI 10.1053/jlts.2001.21449
   Gotz G, 1999, TRANSPLANT P, V31, P430, DOI 10.1016/S0041-1345(98)01692-3
   Heffron TG, 2003, TRANSPLANT P, V35, P1435, DOI 10.1016/S0041-1345(03)00457-3
   Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322
   Kalbfieisch J., 1980, STAT ANAL FAILURE TI
   Kanzler S, 2001, Z GASTROENTEROL, V39, P339, DOI 10.1055/s-2001-13708
   Karam V, 2003, TRANSPLANTATION, V75, P2167, DOI 10.1097/01.TP.0000080271.20145.07
   Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
   LOHSE AW, 1995, HEPATOLOGY, V22, P381, DOI 10.1016/0270-9139(95)90554-5
   Mieli-Vergani G, 2009, J PEDIATR GASTR NUTR, V49, P158, DOI 10.1097/MPG.0b013e3181a1c265
   Mieli-Vergani G, 2008, WORLD J GASTROENTERO, V14, P3360, DOI 10.3748/wjg.14.3360
   Milkiewicz P, 1999, LIVER, V19, P50, DOI 10.1111/j.1478-3231.1999.tb00009.x
   Narumi S, 1999, TRANSPLANT P, V31, P1955, DOI 10.1016/S0041-1345(99)00227-4
   Neuberger J, 2002, SEMIN LIVER DIS, V22, P379, DOI 10.1055/s-2002-35707
   Parker DR, 1997, QJM-MON J ASSOC PHYS, V90, P289, DOI 10.1093/qjmed/90.4.289
   Prados E, 1998, TRANSPLANTATION, V66, P1645, DOI 10.1097/00007890-199812270-00013
   Ratziu V, 1999, J HEPATOL, V30, P131, DOI 10.1016/S0168-8278(99)80017-8
   Reich DJ, 2000, HEPATOLOGY, V32, P693, DOI 10.1053/jhep.2000.16666
   Roberts SK, 1996, GASTROENTEROLOGY, V110, P848, DOI 10.1053/gast.1996.v110.pm8608895
   Rowe IA, 2008, TRANSPL INT, V21, P459, DOI 10.1111/j.1432-2277.2007.00628.x
   Schramm C, 2001, AM J GASTROENTEROL, V96, P1587
   Seaberg E C, 1998, Clin Transpl, P17
   Tandon P, 2008, SEMIN LIVER DIS, V28, P26, DOI 10.1055/s-2008-1040319
   Toda G, 1997, J HEPATOL, V26, P1207, DOI 10.1016/S0168-8278(97)80453-9
   Vogel A, 2004, CLIN TRANSPLANT, V18, P62, DOI 10.1111/j.1399-0012.2004.00117.x
   ZUMBUSCHENFELDE KHM, 1995, NEW ENGL J MED, V333, P1004
NR 32
TC 28
Z9 34
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD APR
PY 2010
VL 16
IS 4
BP 461
EP 469
DI 10.1002/lt.22018
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 582BN
UT WOS:000276570300009
PM 20373456
ER

PT J
AU Khalaf, H
AF Khalaf, H.
TI Vascular Complications After Deceased and Living Donor Liver
   Transplantation: A Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th Congress of the Asian-Society-of-Transplantation
CY OCT 01-04, 2009
CL Beirut, LEBANON
SP Asian Soc Transplantat
ID HEPATIC-ARTERY THROMBOSIS; PORTAL-VEIN THROMBOSIS; DOPPLER US; STENOSIS;
   MANAGEMENT; ANGIOPLASTY; ANGIOGRAPHY; DIAGNOSIS; VOLUME
AB Introduction. Vascular complications (VC) after liver transplantation (OLT) are one of the most feared problems that frequently result in graft and patient loss. Herein we have reported our experience with VC after either deceased donor liver transplantation (DDLT) or living donor liver transplantation (LDLT).
   Patients and Methods. Between April 2001 and September 2009, we performed 224 OLT: 155 DDLT and 69 LDLT. The overall male/female ratio was 136/88 and the adult/pediatric ratio vas 208/16. We retrospectively identified and analyzed vascular complications in both groups.
   Results. In the DDLT group, 11/155 recipients (7%) suffered vascular complications; hepatic artery thrombosis (HAT; n = 5; 3.2%), portal vein thrombosis occurred (n = 4; 2.6%); hepatic vein stenosis (n = 1; 0.6%), and severe postoperative bleeding due to a slipped splenic artery ligature (n = 1, 0.6%). In the DDLT group, 4/11 (36.4%) patients died as a direct result of the vascular complications. In the LDLT group, 9/69 recipients (13%) suffered vascular complications: HAT (n = 3; 4.3%), portal vein problems (n = 5; 7.2%), and hepatic vein stenosis (n = 1; 1.5%). Among LDLT, 3/9 (33.3%) patients died as a direct result of the vascular complications. In both groups vascular complications were associated with poorer patient and graft survival.
   Conclusions. In our experience, the incidence of vascular complications was significantly higher among the LDLT group compared with the DDLT group. Vascular complications were associated with poorer graft and patient survival rates in both groups.
C1 [Khalaf, H.] King Faisal Specialist Hosp & Res Ctr, Dept Liver Transplantat & Hepatobiliary Pancreat, Riyadh 11211, Saudi Arabia.
RP Khalaf, H (reprint author), POB 3354, Riyadh 11211, Saudi Arabia.
EM hatem@khalaf.us
CR Bekker J, 2009, AM J TRANSPLANT, V9, P746, DOI 10.1111/j.1600-6143.2008.02541.x
   Brancatelli G, 2002, TRANSPLANTATION, V73, P237, DOI 10.1097/00007890-200201270-00015
   Broniszczak D, 2006, TRANSPLANT P, V38, P1456, DOI 10.1016/j.transproceed.2006.02.094
   BUCKELS JAC, 1989, TRANSPLANT P, V21, P2460
   Carnevale FC, 2004, PEDIATR TRANSPLANT, V8, P576, DOI 10.1111/j.1399-3046.2004.00213.x
   Cavallari A, 2001, HEPATO-GASTROENTEROL, V48, P179
   Chen HL, 2008, TRANSPL P, V40, P2534, DOI 10.1016/j.transproceed.2008.07.057
   Chen TY, 2000, TRANSPLANT P, V32, P2252, DOI 10.1016/S0041-1345(00)01788-7
   Cheng YF, 2004, LIVER TRANSPLANT, V10, P248, DOI 10.1002/lt.20055
   Coelho GR, 2008, TRANSPL P, V40, P3545, DOI 10.1016/j.transproceed.2008.06.066
   Corno V, 2005, TRANSPLANT P, V37, P1141, DOI 10.1016/j.transproceed.2004.11.034
   Duffy JP, 2009, J AM COLL SURGEONS, V208, P896, DOI 10.1016/j.jamcollsurg.2008.12.032
   EGAWA H, 1993, CLIN TRANSPLANT, V7, P306
   Gill P, 2009, TRANSPLANTATION, V88, P595, DOI 10.1097/TP.0b013e3181b11fa7
   Han B, 2009, TRANSPLANTATION, V87, P1591, DOI 10.1097/TP.0b013e3181a4e9ba
   Hom BK, 2006, RADIOLOGY, V241, P267, DOI 10.1148/radiol.2411050597
   Karatzas T, 1997, TRANSPLANT P, V29, P2853, DOI 10.1016/S0041-1345(97)00706-9
   Kawano Y, 2007, HEPATO-GASTROENTEROL, V54, P1821
   Kim BS, 2003, AM J ROENTGENOL, V181, P467
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   Lisman T, 2009, TRANSPL INT, V22, P162, DOI 10.1111/j.1432-2277.2008.00762.x
   Llado L, 2007, CLIN TRANSPLANT, V21, P716, DOI 10.1111/j.1399-0012.2007.00728.x
   LODHIA N, 2009, DIG DIS SCI
   MARUJO WC, 1991, TRANSPLANT P, V23, P1484
   Miraglia R, 2007, PEDIATR TRANSPLANT, V11, P222, DOI 10.1111/j.1399-3046.2006.00625.x
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   Nikeghbalian S, 2007, TRANSPL P, V39, P1195, DOI 10.1016/j.transproceed.2007.02.017
   Pawlak J, 2003, TRANSPLANT P, V35, P2313, DOI 10.1016/S0041-1345(03)00836-4
   Salvalaggio PR, 2007, TRANSPLANTATION, V84, P926, DOI 10.1097/01.tp.0000281554.00247.92
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Tamsel S, 2007, ABDOM IMAGING, V32, P339, DOI 10.1007/s00261-006-9041-z
   Vignali C, 2004, TRANSPLANT P, V36, P552, DOI 10.1016/j.transproceed.2004.02.038
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
   Zanotelli ML, 2004, TRANSPLANT P, V36, P945, DOI 10.1016/j.transproceed.2004.03.104
NR 37
TC 22
Z9 25
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2010
VL 42
IS 3
BP 865
EP 870
DI 10.1016/j.transproceed.2010.02.037
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 588VV
UT WOS:000277103500049
PM 20430192
ER

PT J
AU Moon, JI
   Jung, GO
   Choi, GS
   Kim, JM
   Shin, M
   Kim, EY
   Kwon, CHD
   Kim, SJ
   Joh, JW
   Lee, SK
AF Moon, J. I.
   Jung, G. O.
   Choi, G. -S.
   Kim, J. M.
   Shin, M.
   Kim, E. Y.
   Kwon, C. H. D.
   Kim, S. -J.
   Joh, J. -W.
   Lee, S. -K.
TI Risk Factors for Portal Vein Complications After Pediatric Living Donor
   Liver Transplantation With Left-sided Grafts
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th Congress of the Asian-Society-of-Transplantation
CY OCT 01-04, 2009
CL Beirut, LEBANON
SP Asian Soc Transplantat
ID VASCULAR COMPLICATIONS; THROMBOSIS
AB Purpose. Portal vein complications (PVC) after pediatric living donor liver transplantation (LDLT) have rarely been reported. We evaluated the long-term incidence and of the risk factors for PVC after pediatric LDLT.
   Methods. From April 1997 to November 2008, 96 pediatric patients underwent LDLT using left lateral segments or left lobes. We investigated recipient factors, donor factors, and operative factors through medical records. The portal vein sizes in 96 recipients ranged from 2.7 mm to 13.0 mm (median = 5.0 mm). Portal vein reconstruction was usually performed with the graft portal vein anastomosed to the bifurcation of the recipient right and left portal veins, the so-called "branch patch".
   Results. PVC occured in 11 patients (11.5%) including early PVC (n = 3), late PVC (n = 8). The disease-free survivals at 1, 5, and 10 years after LDLT were 94.7%, 88.7%, and 86.0%. Upon univariate analysis, a portal vein size < 5 mm graft-to-recipient weight ratio (GRWR) 4%, transfusion volume 270 mL were significant risk factors for PVC. Body weight < 8 kg and previous operative history tendes to be adverse for PVC. Upon multivariate analysis by Cox regression, portal vein size < 5 mm was a highly significant factor for PVC after pediatric LDLT (hazard ratio = 5.627, P =.027).
   Conclusion. The disease-free survival at 10 years after LDLT was 86.0%. If the recipient's portal vein size < 5 mm received a large-for-size graft (GRWR >= 4%), it is important to observe by regular Doppler ultrasonography follow-up to detect PVC.
C1 [Moon, J. I.; Jung, G. O.; Choi, G. -S.; Kim, J. M.; Shin, M.; Kim, E. Y.; Kwon, C. H. D.; Kim, S. -J.; Joh, J. -W.; Lee, S. -K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea.
RP Lee, SK (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, 50 Ilwon Dong, Seoul 135710, South Korea.
EM sukkoo.lee@samsung.com
RI Kim, Sung Joo/C-9604-2011; kim, jm/O-5935-2014; 
OI Joh, Jae-Won/0000-0003-1732-6210
CR Anderson CD, 2008, AM J TRANSPLANT, V8, P1197, DOI 10.1111/j.1600-6143.2008.02223.x
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   LERUT J, 1987, ANN SURG, V205, P404, DOI 10.1097/00000658-198704000-00011
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Saing H, 2002, J PEDIATR SURG, V37, P1673, DOI 10.1053/jpsu.2002.36690
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   STARZL TE, 1984, SURG GYNECOL OBSTET, V159, P164
   STRONG R, 1988, SURGERY, V104, P104
   Suzuki L, 2008, PEDIATR RADIOL, V38, P403, DOI 10.1007/s00247-007-0733-5
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 14
TC 16
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2010
VL 42
IS 3
BP 871
EP 875
DI 10.1016/j.transproceed.2010.02.059
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 588VV
UT WOS:000277103500050
PM 20430193
ER

PT J
AU Venick, RS
   Farmer, DG
   McDiarmid, SV
   Duffy, JP
   Gordon, SA
   Yersiz, H
   Hong, JC
   Vargas, JH
   Ament, ME
   Busuttil, RW
AF Venick, Robert S.
   Farmer, Douglas G.
   McDiarmid, Sue V.
   Duffy, John P.
   Gordon, Sherilyn A.
   Yersiz, Hasan
   Hong, Johnny C.
   Vargas, Jorge H.
   Ament, Marvin E.
   Busuttil, Ronald W.
TI Predictors of Survival Following Liver Transplantation in Infants: A
   Single-Center Analysis of More Than 200 Cases
SO TRANSPLANTATION
LA English
DT Article
DE Pediatric; Infant; Liver transplantation; Survival
ID HEPATIC-ARTERY THROMBOSIS; BILIARY ATRESIA; UNITED-STATES; SPLIT LIVER;
   CENTER EXPERIENCE; PEDIATRIC TRANSPLANTATION; POSTTRANSPLANT SURVIVAL;
   RISK-FACTORS; CHILDREN; RECIPIENTS
AB Background. Infants (<12 months) who require liver transplantation (LTx) represent a particularly challenging and understudied group of patients.
   Methods. This retrospective study aimed to describe a large single-center experience of infants who received isolated LTx, illustrate important differences in infants versus older children, and identify pretransplant factors which influence survival. More than 25 pre-LTx demographic, laboratory, and operative variables were analyzed using the Log-rank test and Cox proportional hazards model.
   Results. Between 1984 and 2006, 216 LTx were performed in 186 infants with a mean follow-up time of 62 months. Median age at LTx was 9 months, the majority had cholestatic liver disease, were hospitalized pre-LTx, and received whole grafts. Leading indications for re-LTx (n=30) included vascular complications (43%) and graft nonfunction (40%), whereas leading causes of death were sepsis and multiorgan failure. One-, 5-, and 10-year graft and patient survivals were 75%/72%/68% and 79%/77%/75%, respectively. Relative to older pediatric recipients, infants had worse overall patient survival (P=0.05). The following were significant univariate predictors of graft loss: age less than 6 months and reduced cadaveric grafts; and of patient loss: age less than 6 months, calculated CrCl less than 90, pre-LTx hospitalization, pre-LTx mechanical ventilation, repeat LTx, infants transplanted for reasons other than cholestatic liver disease, and patients transplanted between 1984 and 1994.
   Conclusions. Long-term outcomes for infants undergoing LTx are excellent and have improved over time. As the largest, single-center analysis of LTx in infants, this study elucidates a unique set of predictors that can aid in medical decision making.
C1 [Venick, Robert S.; McDiarmid, Sue V.; Vargas, Jorge H.; Ament, Marvin E.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Los Angeles, CA 90095 USA.
   [Farmer, Douglas G.; Duffy, John P.; Gordon, Sherilyn A.; Yersiz, Hasan; Hong, Johnny C.; Busuttil, Ronald W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
RP Venick, RS (reprint author), Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, POB 91752, Los Angeles, CA 90095 USA.
EM Rvenick@mednet.ucla.edu
FU NIH; American Society of Transplantation Clinical Faculty Development
   Award
FX This work was supported by the NIH Loan Repayment Program (R. S. V.) and
   the American Society of Transplantation Clinical Faculty Development
   Award (R. S. V.).
CR ALONSO EM, 2005, TRANSPLANTATION LIVE, P287, DOI 10.1016/B978-0-7216-0118-2.50026-4
   Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Barshes NR, 2006, LIVER TRANSPLANT, V12, P475, DOI 10.1002/lt.20703
   Barshes NR, 2005, LIVER TRANSPLANT, V11, P1193, DOI 10.1002/lt.20509
   BEATH SV, 1993, BRIT MED J, V307, P825
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BROELSCH CE, 1988, ANN SURG, V208, P410, DOI 10.1097/00000658-198810000-00003
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Colombani PM, 2003, AM J TRANSPLANT, V3, P53, DOI 10.1034/j.1600-6143.3.s4.6.x
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Cox KL, 1999, J GASTROEN HEPATOL, V14, pS61
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   ESQUIVEL CO, 2005, TRANSPLANTATION LIVE, P1335, DOI 10.1016/B978-0-7216-0118-2.50087-2
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927
   Ghobrial RM, 2000, ANN SURG, V232, P312, DOI 10.1097/00000658-200009000-00003
   Goss JA, 1996, ANN SURG, V224, P276, DOI 10.1097/00000658-199609000-00004
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   *HHS HRSA DOT, ANN REP US ORG PROC, P489
   Horslen S, 2007, AM J TRANSPLANT, V7, P1339, DOI 10.1111/j.1600-6143.2007.01780.x
   Iglesias J, 2004, PEDIATR TRANSPLANT, V8, P228, DOI 10.1111/j.1399-3046.2004.00128.x
   JURIM O, 1995, J PEDIATR SURG, V30, P53, DOI 10.1016/0022-3468(95)90609-6
   Kiuchi T, 2001, Clin Transpl, P195
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   MAZZAFERRO V, 1989, TRANSPLANT P, V21, P2466
   McDiarmid S V, 2000, Clin Liver Dis, V4, P879, DOI 10.1016/S1089-3261(05)70146-X
   McDiarmid SV, 2007, INDIAN J PEDIATR, V74, P387, DOI 10.1007/s12098-007-0066-2
   McDiarmid SV, 1995, TRANSPLANTATION, V60, P1443, DOI 10.1097/00007890-199560120-00013
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   Newell KA, 1998, TRANSPLANTATION, V65, P1172, DOI 10.1097/00007890-199805150-00005
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Saing H, 1999, J PEDIATR SURG, V34, P1721, DOI 10.1016/S0022-3468(99)90653-X
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Sindhi R, 1999, J PEDIATR SURG, V34, P107, DOI 10.1016/S0022-3468(99)90238-5
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Sundaram SS, 2003, LIVER TRANSPLANT, V9, P783, DOI 10.1053/jlts.2003.50104
   TIAO G, 2005, J PEDIATR SURG, V40, P269
   TZAKIS AG, 1985, TRANSPLANTATION, V40, P667, DOI 10.1097/00007890-198512000-00019
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Utterson EC, 2005, J PEDIATR-US, V147, P180, DOI 10.1016/j.jpeds.2005.04.073
   Van der Werf WJ, 1998, J PEDIATR SURG, V33, P20, DOI 10.1016/S0022-3468(98)90353-0
   van Rossum Lyonne K, 2005, Pediatr Nephrol, V20, P1769
   Venick RS, 2007, AM J TRANSPLANT, V7, P955, DOI 10.1111/j.1600-6143.2006.01717.x
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   WIESENHAANSTELL.GC, 2000, PEDIATR TRANSPLANT, V4, P124
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 60
TC 18
Z9 20
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAR 15
PY 2010
VL 89
IS 5
BP 600
EP 605
DI 10.1097/TP.0b013e3181c5cdc1
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 571AF
UT WOS:000275719900015
PM 19997060
ER

PT J
AU Dehghani, SM
   Honar, N
   Inaloo, S
   Gholami, S
   Kazemi, K
   Bahador, A
   Haghighat, M
   Malek-Hosseini, SA
AF Dehghani, Seyed Mohsen
   Honar, Naser
   Inaloo, Soroor
   Gholami, Siavash
   Kazemi, Kourosh
   Bahador, Ali
   Haghighat, Mahmood
   Malek-Hosseini, Seyed Ali
TI Neuromuscular Complication After Liver Transplant in Children: A
   Single-Center Experience
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Immunosuppression; Pediatric; Neurologic complications
ID NEUROLOGICAL COMPLICATIONS; RENAL-TRANSPLANTATION; PEDIATRIC-PATIENTS;
   TACROLIMUS
AB Objectives: Neurologic complications are a significant cause of morbidity in children after liver transplant. In this study, we sought to evaluate the neurologic complications in children after liver transplant.
   Materials and Methods: All children aged younger than 18 years old who had undergone liver transplant between June 2004 and June 2007 were included in this prospective study. There were 30 boys (62.5%) and 18 girls (37.5%) (mean age, 9.6 +/- 4.3 years; mean duration of follow-up, 21.6 +/- 9.4 months). The most common indications for liver transplant were biliary atresia (n=12, 25%), Wilson disease (n=7, 14.6%), tyrosinemia (n=7, 14.6%), progressive familial intrahepatic cholestasis (n=6, 12.5%), and autoimmune cirrhosis (n=5, 10.4%).
   Results: Immunosuppressive medication consisted tacrolimus (n=44, 91.7%) or cyclosporine (n=4, 8.3%) combined with mycophenolate mofetil (n=33, 68.7%) and prednisolone (n=18, 37.5%). The most-common neurologic complications were tremor (n=8, 16.7%), convulsions (n=6, 12.5%), insomnia (n=6, 12.5%), headache (n=5, 10.4%), muscle cramps (n=5, 10.4%), paresthesia (n=3, 6.2%), and weakness (n=3, 6.2%).
   Conclusions: We conclude that the most-common neurologic complication after liver transplant in children in contrast to other studies is tremor, same as adult patients. This may be due to higher rate of use of tacrolimus in our patients.
C1 [Dehghani, Seyed Mohsen; Gholami, Siavash; Kazemi, Kourosh; Bahador, Ali; Malek-Hosseini, Seyed Ali] Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Shiraz 7193711351, Iran.
   [Inaloo, Soroor] Shiraz Univ Med Sci, Pediat Neurol Dept, Shiraz 7193711351, Iran.
RP Dehghani, SM (reprint author), Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Gastroenterohepatol Res Ctr, Nemazee Hosp, Zand Ave, Shiraz 7193711351, Iran.
EM dehghanism@sums.ac.ir
CR Alehan F, 2007, J CHILD NEUROL, V22, P406, DOI 10.1177/0883073807301932
   Araz C, 2004, TRANSPLANT P, V36, P214, DOI 10.1016/j.transproceed.2003.11.029
   Boin IFSF, 2001, TRANSPLANT P, V33, P3695, DOI 10.1016/S0041-1345(01)02507-6
   Erol I, 2007, PEDIATR TRANSPLANT, V11, P152, DOI 10.1111/j.1399-3046.2006.00620.x
   Ferrari Uta, 2005, Headache, V45, P211, DOI 10.1111/j.1526-4610.2005.05046.x
   GARG BP, 1993, PEDIATR NEUROL, V9, P444, DOI 10.1016/0887-8994(93)90023-6
   GRIDELLI B, 1994, TRANSPLANT P, V26, P193
   Kemper MJ, 2003, CLIN TRANSPLANT, V17, P130, DOI 10.1034/j.1399-0012.2003.00028.x
   Lewis MB, 2003, NEUROLOGY, V61, P1174
   MARSDEN CD, 1980, PSYCHOL MED, V10, P55
   MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010
   Neuhaus P, 1994, Transpl Int, V7 Suppl 1, pS27, DOI 10.1111/j.1432-2277.1994.tb01305.x
   Pirsch JD, 1997, TRANSPLANTATION, V63, P977, DOI 10.1097/00007890-199704150-00013
   Rand EB, 2003, GASTROENTEROL CLIN N, V32, P913, DOI 10.1016/S0889-8553(03)00048-7
   Shibolet O, 2001, TRANSPLANT P, V33, P2959, DOI 10.1016/S0041-1345(01)02271-0
   STEIN DP, 1992, ANN NEUROL, V31, P644, DOI 10.1002/ana.410310612
   Vecino MC, 1999, TRANSPLANT P, V31, P3048, DOI 10.1016/S0041-1345(99)00665-X
   Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7
NR 18
TC 1
Z9 2
U1 0
U2 2
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD MAR
PY 2010
VL 8
IS 1
BP 9
EP 13
PG 5
WC Transplantation
SC Transplantation
GA 580BX
UT WOS:000276423000003
PM 20199365
ER

PT J
AU Sanada, Y
   Kawano, Y
   Mizuta, K
   Egami, S
   Hayashida, M
   Wakiya, T
   Fujiwara, T
   Sakuma, Y
   Hydo, M
   Nakata, M
   Yasuda, Y
   Kawarasaki, H
AF Sanada, Yukihiro
   Kawano, Youichi
   Mizuta, Koichi
   Egami, Satoshi
   Hayashida, Makoto
   Wakiya, Taiichi
   Fujiwara, Takehito
   Sakuma, Yasunaru
   Hydo, Masanobu
   Nakata, Manabu
   Yasuda, Yoshikazu
   Kawarasaki, Hideo
TI Strategy to Prevent Recurrent Portal Vein Stenosis Following
   Interventional Radiology in Pediatric Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID INTENSITY WARFARIN THERAPY; LONG-TERM; VENOUS THROMBOEMBOLISM; ORAL
   ANTICOAGULATION; PRACTICE GUIDELINE; COMPLICATIONS; MANAGEMENT;
   THROMBOSIS; CHILDREN
AB Portal vein complications after liver transplantation (LT) are serious complications that can lead to graft liver (allure Although the treatment of interventional radiology (IVR) by means of balloon dilatation for portal vein stenosis (PVS) after LT is an effective method, the high rate of recurrent PVS is an agonizing problem Anticoagulant therapy for PVS is an important factor for preventing short-term recurrence following IVR, but no established regimen has been reported for the prevention of recurrent PVS following IVR In our population of 197 pediatric patients who underwent living donor liver transplantation (LDLT), 22 patients (22/197, 11 2%) suffered PVS In the 9 earliest patients, unfractionated heparin was the only anticoagulant therapy given following IVR. In the 13 more recent patients, 3-agent anticoagulant therapy using low-molecular-weight heparin, warfarin, and aspirin was employed. In the initial group of 9 patients, 5 patients (55.6%) suffered recurrent PVS and required repeat balloon dilatation. Among the 13 more recent patients, none experienced recurrent PVS (P = 0 002). In conclusion, our 3-agent anticoagulant therapy following IVR for PVS in pediatric LDLT can be an effective therapeutic strategy for preventing recurrent PVS Liver Transpl 16:332-339, 2010. (C) 2010 AASLD.
C1 [Sanada, Yukihiro; Kawano, Youichi; Mizuta, Koichi; Egami, Satoshi; Hayashida, Makoto; Wakiya, Taiichi; Kawarasaki, Hideo] Jichi Med Univ, Dept Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Fujiwara, Takehito; Sakuma, Yasunaru; Hydo, Masanobu; Yasuda, Yoshikazu] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Nakata, Manabu] Jichi Med Univ, Dept Radiol, Shimotsuke, Tochigi 3290498, Japan.
RP Sanada, Y (reprint author), Jichi Med Univ, Dept Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
CR Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302
   Bonduel MM, 2006, THROMB RES, V118, P85, DOI 10.1016/j.thromres.2004.12.017
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Cheng YF, 2001, TRANSPLANT INT, V14, P223, DOI 10.1007/s001470100324
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   Dangas G, 1996, AM HEART J, V132, P428, DOI 10.1016/S0002-8703(96)90442-1
   Funaki B, 2000, RADIOLOGY, V215, P147
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   Geerts WH, 2008, CHEST, V133, P381
   Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422
   Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201
   Lo CM, 2003, TRANSPLANTATION, V75, pS12, DOI 10.1097/01.TP.0000046534.45645.47
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029
   Segal JB, 2007, ANN INTERN MED, V146, P211
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   Shibata T, 2005, RADIOLOGY, V235, P1078, DOI 10.1148/radiol.2353040489
   Snow V, 2007, ANN INTERN MED, V146, P204
   Streif W, 1999, BLOOD, V94, P3007
   Sutor AH, 2004, SEMIN THROMB HEMOST, V30, P31
   Tait RC, 1996, ARCH DIS CHILD, V74, P228
   Ueda M, 2008, AM J TRANSPLANT, V8, P1
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Yamanaka J, 2000, HEPATO-GASTROENTEROL, V47, P1371
NR 26
TC 3
Z9 3
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAR
PY 2010
VL 16
IS 3
BP 332
EP 339
DI 10.1002/lt.21995
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 570WU
UT WOS:000275710000012
PM 20209593
ER

PT J
AU Heffron, TG
   Pillen, T
   Smallwood, G
   Rodriguez, J
   Sekar, S
   Henry, S
   Vos, M
   Casper, K
   Gupta, NA
   Fasola, CG
   Romero, R
AF Heffron, Thomas G.
   Pillen, Todd
   Smallwood, Gregory
   Rodriguez, John
   Sekar, Sundari
   Henry, Stuart
   Vos, Miriam
   Casper, Katherine
   Gupta, Nitika Arora
   Fasola, Carlos G.
   Romero, Rene
TI Pediatric liver transplantation for acute liver failure at a single
   center: A 10-yr experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pediatric liver transplantation; acute liver
   failure; fulminant liver failure; ABO incompatible
ID FULMINANT HEPATIC-FAILURE; CHILDREN; DONORS; RISK
AB Children transplanted for ALF urgently require an optimal graft and have lower post-transplant survival compared with children transplanted for chronic liver disease. Over 10 yr, 33 consecutive children transplanted for ALF were followed. Demographics, encephalopathy, intubation, dialysis, laboratory values, graft type ABOI, XL (GRWR > 5%), DDSLT, LDLT and WLT were evaluated. Complications and survival were determined. ALF accounted for 33/201 (16.4%) of transplants during this period. Twelve of 33 received ABOI, five XL grafts, 18 DDSLT, and three LDLT. Waiting time pretransplant was 2.1 days. One- and three-yr patient survival in the ALF group was 93.4% and 88.9%, and graft survivals were 86.4% and 77.7%. Median follow-up was 1452 days. ABOI one- and three yr patient and graft survival in the ALF was 91.6% and 78.6%. No difference in graft or patient survival was noted in the ALF and chronic liver disease group or the ABOI and the ABO compatible group. A combination of ABO incompatible donor livers, XL grafts, DDSLT, LDLT and WLT led to a short wait time and subsequent graft and patient survival comparable to patients with non-acute disease.
C1 [Heffron, Thomas G.; Pillen, Todd; Smallwood, Gregory; Rodriguez, John; Sekar, Sundari; Henry, Stuart; Vos, Miriam; Casper, Katherine; Gupta, Nitika Arora; Fasola, Carlos G.; Romero, Rene] Childrens Healthcare Atlanta, Atlanta, GA 30322 USA.
   [Heffron, Thomas G.; Fasola, Carlos G.] Emory Univ, Ctr Transplantat, Atlanta, GA 30322 USA.
   [Smallwood, Gregory; Vos, Miriam; Gupta, Nitika Arora; Romero, Rene] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
RP Heffron, TG (reprint author), Childrens Healthcare Atlanta, 1405 Clifton Rd NE, Atlanta, GA 30322 USA.
EM thomas.heffron@choa.org
CR Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Becker NS, 2008, LIVER TRANSPLANT, V14, P1125, DOI 10.1002/lt.21491
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Bucuvalas John, 2006, Clin Liver Dis, V10, P149, DOI 10.1016/j.cld.2005.10.006
   DHAWAN A, 2008, PEDIATR TRANSPLANT, V12, P167
   EMOND JC, 1990, ANN SURG, V212, P14
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Goss JA, 1998, ARCH SURG-CHICAGO, V133, P839, DOI 10.1001/archsurg.133.8.839
   Heffron T, 2006, LIVER TRANSPLANT, V12, P972, DOI 10.1002/lt.20760
   Heffron TG, 2003, TRANSPLANTATION, V75, P2040, DOI 10.1097/01.TP.0000065740.69296.DA
   Heffron T, 2007, PEDIATR TRANSPLANT, V11, P374, DOI 10.1111/j.1399-3046.2006.00675.x
   Kato T, 2006, TRANSPLANT P, V38, P3607, DOI 10.1016/j.transproceed.2006.10.038
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Liu E, 2006, J HEPATOL, V44, P134, DOI 10.1016/j.jhep.2005.06.021
   O'Grady JG, 2007, LIVER TRANSPLANT, V13, P786, DOI 10.1002/lt.21159
   PINELLI D, 2005, TRANSPL P, V7, P1146
   Poddar U, 2002, ARCH DIS CHILD, V87, P54, DOI 10.1136/adc.87.1.54
   Shah U, 2000, PEDIATRICS, V105, P436, DOI 10.1542/peds.105.2.436
   Squires RH, 2008, SEMIN LIVER DIS, V28, P153, DOI 10.1055/s-2008-1073115
   Tanaka A, 1996, TRANSPLANT INT, V9, P15, DOI 10.1111/j.1432-2277.1996.tb00847.x
   Trey C, 1970, Prog Liver Dis, V3, P282
NR 21
TC 6
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2010
VL 14
IS 2
BP 228
EP 232
DI 10.1111/j.1399-3046.2009.01202.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 553TL
UT WOS:000274389600014
PM 19519799
ER

PT J
AU Al-Hussaini, A
   Taylor, RM
   Samyn, M
   Bansal, S
   Heaton, N
   Rela, M
   Mieli-Vergani, G
   Dhawan, A
AF Al-Hussaini, Abdulrahman
   Taylor, Rachel M.
   Samyn, Marianne
   Bansal, Sanjay
   Heaton, Nigel
   Rela, Mohammed
   Mieli-Vergani, Giorgina
   Dhawan, Anil
TI Long-term outcome and management of hepatopulmonary syndrome in children
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; macroaggregated albumin; liver transplantation
ID INFERIOR VENA-CAVA; LIVER-TRANSPLANTATION; PORTOSYSTEMIC SHUNT;
   NITRIC-OXIDE; HYPOXEMIA; DISEASE; CIRRHOSIS; PREVALENCE; MORTALITY;
   REVERSAL
AB We aim to report a single center experience of the management and long term outcome of HPS in pediatric liver transplant recipients. A retrospective review of children with HPS from 1990 to 2004. Inclusion criteria: liver disease or portal hypertension, hypoxemia (PaO(2) < 70 mmHg or SaO(2) < 95%) and intrapulmonary shunting documented by macroaggregated albumin scan ratio of > 4% (classified mild group [< 20%], moderate group [20-40%] and severe group [> 40%]). Resolution of HPS post-liver transplant was defined as PaO(2) > 70 mmHg or SaO(2) > 95%. Eighteen children (six male [34%], median age at diagnosis of HPS 8.6 [1-15.5] yr) had HPS: biliary atresia (n = 8), idiopathic biliary cirrhosis (n = 4), progressive intrahepatic cholestasis (n = 2), miscellaneous (n = 4). The majority had mild shunting (n = 8). Fourteen underwent transplantation with resolution of HPS in 13. Six developed complications: hepatic artery thrombosis (n = 4), biliary (n = 2). Four children died (28%), two pretransplant. There was a tendency towards shunt fraction worsening to a slower degree over time. One-yr survival rate post-transplant was 93%. Median PaO(2) was significantly lower in non-survivors compared to survivors (43 vs. 55.2 mmHg, p = 0.03). There was correlation between oxygen parameters pretransplant and time to HPS resolution post-transplant. HPS is reversible after transplant, but is associated with increasing mortality and morbidity.
C1 [Al-Hussaini, Abdulrahman; Taylor, Rachel M.; Samyn, Marianne; Bansal, Sanjay; Mieli-Vergani, Giorgina; Dhawan, Anil] Kings Coll London, Kings Coll Hosp NHS Fdn Trust, Paediat Liver Ctr, Sch Med, London SE5 9RS, England.
   [Heaton, Nigel; Rela, Mohammed] Kings Coll London, Kings Coll Hosp NHS Fdn Trust, Dept Liver Transplantat & Surg, London SE5 9RS, England.
RP Dhawan, A (reprint author), Kings Coll London, Kings Coll Hosp NHS Fdn Trust, Paediat Liver Ctr, Sch Med, Denmark Hill, London SE5 9RS, England.
EM anil.dhawan@kch.nhs.uk
RI Dhawan, Anil/B-6730-2009
CR Alexander J, 1997, Liver Transpl Surg, V3, P54, DOI 10.1002/lt.500030108
   Anel RML, 2001, CLIN INFECT DIS, V32, pE131, DOI 10.1086/320149
   Arguedas MR, 2003, HEPATOLOGY, V37, P192, DOI 10.1053/jhep.2003.50023
   BARBE T, 1995, J PEDIATR-US, V126, P571, DOI 10.1016/S0022-3476(95)70351-9
   CAMILLE T, 2003, TRANSPLANTATION, V75, P1482
   Castro M, 1996, CLIN CHEST MED, V17, P35, DOI 10.1016/S0272-5231(05)70297-5
   De BK, 2000, GASTROENTEROLOGY, V118, P192, DOI 10.1016/S0016-5085(00)70428-8
   Durand P, 1998, TRANSPLANTATION, V65, P437, DOI 10.1097/00007890-199802150-00026
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   FEWTRELL MS, 1994, ARCH DIS CHILD, V70, P501
   Garcia-Casasola G, 2003, J CLIN GASTROENTEROL, V37, P89, DOI 10.1097/00004836-200307000-00026
   GRIMON G, 1994, J NUCL MED, V35, P1328
   Gupta NA, 2007, LIVER TRANSPLANT, V13, P680, DOI 10.1002/lt.21113
   KENEDY TC, 1977, CHEST, V72, P305
   Krowka MJ, 2004, LIVER TRANSPLANT, V10, P174, DOI 10.1002/lt.20016
   Krowka MJ, 1997, MAYO CLIN PROC, V72, P44
   KROWKA MJ, 1994, CHEST, V105, P1528, DOI 10.1378/chest.105.5.1528
   Krowka MJ, 2000, CHEST, V118, P615, DOI 10.1378/chest.118.3.615
   Lasch HM, 2001, LIVER TRANSPLANT, V7, P147, DOI 10.1053/jlts.2001.21287
   Mimidis KP, 1998, SCAND J GASTROENTERO, V33, P988
   Noli K, 2008, PEDIATRICS, V121, pE522, DOI 10.1542/peds.2007-1075
   Paramesh AS, 2003, PEDIATR TRANSPLANT, V7, P157, DOI 10.1034/j.1399-3046.2003.00033.x
   Rodriguez-Roisin R, 2008, NEW ENGL J MED, V358, P2378, DOI 10.1056/NEJMra0707185
   Rolla G, 1998, ANN INTERN MED, V129, P375
   Schenk P, 2000, ANN INTERN MED, V133, P701
   Schiffer E, 2006, AM J TRANSPLANT, V6, P1430, DOI 10.1111/j.1600-6143.2006.01334.x
   Spencer LT, 2000, J PEDIATR-US, V137, P575, DOI 10.1067/mpd.2000.107841
   Tiao Gregory M, 2006, Semin Pediatr Surg, V15, P218, DOI 10.1053/j.sempedsurg.2006.03.008
   Tumgor G, 2008, PEDIATR TRANSPLANT, V12, P353, DOI 10.1111/j.1399-3046.2007.00807.x
   Uemoto S, 1997, TRANSPLANTATION, V63, P407, DOI 10.1097/00007890-199702150-00014
   Van Obbergh LJ, 1998, PAEDIATR ANAESTH, V8, P59, DOI 10.1046/j.1460-9592.1998.00720.x
   Vedernikov YP, 1997, AM J OBSTET GYNECOL, V176, P603, DOI 10.1016/S0002-9378(97)70555-6
NR 32
TC 17
Z9 17
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2010
VL 14
IS 2
BP 276
EP 282
DI 10.1111/j.1399-3046.2009.01218.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 553TL
UT WOS:000274389600021
PM 19686444
ER

PT J
AU Fernandes, R
   Pacheco-Moreira, LF
   Enne, M
   Steinbruck, K
   Alves, JAD
   Filho, GD
   Gouvea, G
   Martinho, JMDG
AF Fernandes, R.
   Pacheco-Moreira, L. F.
   Enne, M.
   Steinbruck, K.
   Alves, J. A. D. S.
   Filho, G. D.
   Gouvea, G.
   Martinho, J. M. D. S. G.
TI Surgical Complications in 100 Donor Hepatectomies for Living Donor Liver
   Transplantation in a Single Brazilian Center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID OUTCOMES; GRAFT
AB The rising demand for liver transplantation has continued to outspace the availability of deceased donor organs, leading to the need for other treatment options including living donor liver transplantation (LDLT). A precise evaluation of surgical complications is the most important issue in this setting. There are controversies about donor morbidity with reports ranging from 13%-75%. The aim of this study was to retrospectively analyze 100 LDLTs performed in a single Brazilian center from December 2002 to August 2008, stratifying the complications according to Clavien's scoring system. None of the donors experienced life-threatening complications or died. The majority of donors (n = 74) did not suffer any complication. Twenty-eight complications were observed in 26 patients. Fifty-seven hepatectomies were performed for adult and 43 for pediatric transplantations. According to the Brisbane classifications, we performed 49 right and 2 left hepatectomies as well as 49 left lateral segmentectomies. According to Clavien, the complications were as follows: grade I (n = 11; 39.2%); grade II (n = 8; 28.5%); and grade III (n = 9; 32.3%). No patient presented with grade IV or V. The most common problem a biliary tract injury, similar to other series. In this Brazilian series, hepatectomy for LDLT was a safe procedure with low morbidity, regardless of the type of liver resection. This practice will probably continue to grow to alleviate the pressure of growing waiting lists.
C1 [Fernandes, R.; Pacheco-Moreira, L. F.; Enne, M.; Steinbruck, K.; Alves, J. A. D. S.; Filho, G. D.; Gouvea, G.; Martinho, J. M. D. S. G.] Bonsucesso Gen Hosp MS, Liver Transplantat Unit, Rio De Janeiro, Brazil.
RP Fernandes, R (reprint author), Hosp Geral Bonsucesso, Serv Transplante Hepat & Cirurgia Hepatobiliar, Av Londres 616,Predio 3-2 Andar, BR-21041030 Rio De Janeiro, Brazil.
EM rei.fernandes.jr@gmail.com
CR Akamatsu T, 2002, GASTROINTEST ENDOSC, V55, P55, DOI 10.1067/mge.2002.120388
   Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443
   BISMUTH H, 1984, SURGERY, V95, P367
   CLAVIEN PA, 1994, ANN SURG, V220, P109, DOI 10.1097/00000658-199408000-00002
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   Ghobrial RM, 2008, GASTROENTEROLOGY, V135, P468, DOI 10.1053/j.gastro.2008.04.018
   Hwang S, 2006, LIVER TRANSPLANT, V12, P920, DOI 10.1002/lt.20734
   Marcos A, 1999, TRANSPLANTATION, V68, P798, DOI 10.1097/00007890-199909270-00012
   Miller C, 2003, TRANSPLANT P, V35, P964, DOI 10.1016/S0041-1345(03)00186-6
   Miller C, 2004, LIVER TRANSPLANT, V10, P1315, DOI 10.1002/lt.20227
   Pacheco-Moreira LF, 2006, PEDIATR TRANSPLANT, V10, P311, DOI 10.1111/j.1399-3046.2005.00465.x
   RAIA S, 1989, LANCET, V2, P497
   Sevmis S, 2008, TRANSPL P, V40, P245, DOI 10.1016/j.transproceed.2007.11.009
   Shio S, 2008, AM J GASTROENTEROL, V103, P1393, DOI 10.1111/j.1572-0241.2008.01786.x
   Strasberg SM, 2005, J HEPATO-BILIARY-PAN, V12, P351, DOI 10.1007/s00534-005-0999-7
   Trotter JF, 2006, LIVER TRANSPLANT, V12, P1485, DOI 10.1002/lt.20875
   YAMAOKA Y, 1994, TRANSPLANTATION, V57, P1127, DOI 10.1097/00007890-199404150-00024
NR 17
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2010
VL 42
IS 2
BP 421
EP 423
DI 10.1016/j.transproceed.2010.01.012
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 575FD
UT WOS:000276051400005
PM 20304155
ER

PT J
AU Salzedas-Netto, AA
   Amadei, HL
   Castro, CCL
   Mattar, RH
   Medeiros, KL
   Linhares, MM
   Duarte, AAB
   Chinen, ES
   Marino, GC
   Matos, CA
   Lopes, G
   Martins, JL
   Gonzalez, AM
AF Salzedas-Netto, A. A.
   Amadei, H. L.
   Castro, C. C. L.
   Mattar, R. H.
   Medeiros, K. L.
   Linhares, M. M.
   Duarte, A. A. B.
   Chinen, E. S.
   Marino, G. C.
   Matos, C. A.
   Lopes-Filho, G.
   Martins, J. L.
   Gonzalez, A. M.
TI Impact of Liver Ex Situ Transection on Pediatric Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID EXPERIENCE
AB Ex situ hepatic transection (ESHT) has allowed transplantation of younger and smaller patients than whole liver grafts. Liver transection is a technical challenge due to the prolonged back table time, possible graft lesions, and increased surgical bleeding from the cut surface. We compare the outcomes of whole versus transected liver grafts in pediatric liver transplantation.
   Methods. We retrospectively studied 41 pediatric patients who underwent 42 consecutive liver transplants (1 retransplant) from cadaveric donors. The study included all patients <18 years old who were transplanted at our institution from December 2001 to September 2009. Patients were distributed into 2 groups: whole organ (WO; n = 20) and transected liver grafts (TLG; n = 21). The ESHT grafts included 17 splits and 5 reduced size livers. We evaluated the age, weight, blood component transfusions, 1-year survival, laboratory tests at 2nd and 7th days postoperatively, surgical complications, reoperations, rejection episodes, cold ischemia time, biliary reconstruction type, and donor laboratory tests. Data were analyzed using Fisher and Student's t-tests.
   Results. The mean age was 115 months (range, 7 months to 17.6 years) in the WO group and 43.3 months (range, 5 months to 16.25 years) in the TLG group (P = .0003). Mean weight was 19.8 kg (range, 5.8-67) and 9.7 Kg (range, 5.2-57) in the WO and TLG groups, respectively (P = .0079). Red blood cell transfusion was higher in the TLG group (P = .0479). Laboratory tests showed no difference between the 2 groups considering hepatic lesions or function markers. One-year patient survivals were 90% and 85.8% among the WO and LTG, respectively (P = .588). The overall 1-year survival rate was 88.8%.
   Conclusion. ESHT allowed smaller and younger children to be transplanted. There was an increased necessity of red blood cell transfusions after hepatic transection. There was no impact on liver function or 1-year patient or graft survival after ESHT.
C1 [Salzedas-Netto, A. A.; Amadei, H. L.; Castro, C. C. L.; Mattar, R. H.; Medeiros, K. L.; Linhares, M. M.; Duarte, A. A. B.; Chinen, E. S.; Marino, G. C.; Matos, C. A.; Lopes-Filho, G.; Martins, J. L.; Gonzalez, A. M.] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
RP Salzedas-Netto, AA (reprint author), Alameda Arapanes 105, BR-04524000 Sao Paulo, Brazil.
EM alcidessalzedas@yahoo.com.br
CR Audet M, 2008, TRANSPL P, V40, P1932, DOI 10.1016/j.transproceed.2008.05.031
   ENGELMANN G, 2009, PEDIAT TRANSPLA 0929
   [Anonymous], 2009, COCHRANE DB SYST REV
   Lee TC, 2005, AM J TRANSPLANT, V5, P1646, DOI 10.1111/j.1600-6132.2005.00911.x
   Pamecha V, 2009, HPB, V11, P275, DOI 10.1111/j.1477-2574.2009.00057.x
   Rahbari NN, 2009, ANN SURG ONCOL, V16, P630, DOI 10.1245/s10434-008-0266-7
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
NR 7
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2010
VL 42
IS 2
BP 507
EP 510
DI 10.1016/j.transproceed.2010.01.040
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 575FD
UT WOS:000276051400029
PM 20304179
ER

PT J
AU Enne, M
   Pacheco-Moreira, L
   Balbi, E
   Cerqueira, A
   Alves, J
   Valladares, MA
   Santalucia, G
   Martinho, JM
AF Enne, Marcelo
   Pacheco-Moreira, Lucio
   Balbi, Elizabeth
   Cerqueira, Alexandre
   Alves, Jefferson
   Valladares, Marcia Angelica
   Santalucia, Giuseppe
   Martinho, Jose-Manoel
TI Hepatic artery reconstruction in pediatric living donor liver
   transplantation under 10 kg, without microscope use
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; hepatic artery; microsurgery
ID SINGLE-CENTER; THROMBOSIS; COMPLICATIONS; EXPERIENCE; STENOSIS; CHILDREN
AB Arterial reconstructions are pivotal, particularly in pediatric LDLT. We describe microsurgical reconstruction technique with 6x loupes and the clinical course of the first 23 less than 10 kg recipients in an initial LDLT program at a developing country. From March 2002 to October 2008, 286 liver transplantation were performed in 279 patients at our unit. There were 73 children and 206 adults. Among the children, 23 weighing less than 10 kg were recipients from living donors. Arterial reconstructions were with end-to-end interrupted suture using a 6x magnification loupe, according to the untied suture technique. All patients were prospectively followed by color Doppler ultrasound protocol. In our initial experience there were no arterial complications. With mean 24 months of follow-up, 19 patients (82%) are alive with good graft function. Hepatic artery in LDLT can be safely reconstructed with microsurgical techniques without microscope using, with 6x loupe magnification, and can achieve good results in patients under 10 kg.
C1 [Enne, Marcelo; Pacheco-Moreira, Lucio; Balbi, Elizabeth; Cerqueira, Alexandre; Alves, Jefferson; Valladares, Marcia Angelica; Santalucia, Giuseppe; Martinho, Jose-Manoel] Hosp Geral Bonsucesso, Liver Transplantat Unit, Minist Saude, BR-21041030 Rio De Janeiro, Brazil.
RP Enne, M (reprint author), Hosp Geral Bonsucesso, Liver Transplantat Unit, Minist Saude, Av Londres 616 Bonsucesso, BR-21041030 Rio De Janeiro, Brazil.
EM marceloenne@gmail.com
CR Abbasoglu O, 1997, TRANSPLANTATION, V63, P250, DOI 10.1097/00007890-199701270-00013
   *ABTO, 2008, REG BRAS TRANSPL ANO
   Chiang YC, 1996, TRANSPLANT P, V28, P2417
   Furuta S, 1997, Liver Transpl Surg, V3, P388, DOI 10.1002/lt.500030405
   Guarrera JV, 2004, TRANSPLANT INT, V17, P585, DOI 10.1007/s00147-004-0782-8
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Ikegami T, 2000, HEPATO-GASTROENTEROL, V47, P1103
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Matsuda H, 2006, SURG TODAY, V36, P245, DOI 10.1007/s00595-005-3131-3
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   McDiamid SV, 2001, LIVER TRANSPLANT, V7, P77
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   ORONS PD, 1995, AM J ROENTGENOL, V165, P1145
   Pacheco-Moreira LF, 2006, PEDIATR TRANSPLANT, V10, P311, DOI 10.1111/j.1399-3046.2005.00465.x
   Pastacaldi S, 2001, LIVER TRANSPLANT, V7, P75, DOI 10.1053/jlts.2001.22040
   RAIA S, 1989, LANCET, V2, P497
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   ROY A, 1993, ANN CHIR, V47, P816
   SERLETTI JM, 1995, PLAST RECONSTR SURG, V95, P270, DOI 10.1097/00006534-199502000-00006
   Shackleton CR, 1997, AM J SURG, V173, P431, DOI 10.1016/S0002-9610(97)00066-4
   SHENAQ SM, 1995, PLAST RECONSTR SURG, V95, P262
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
   Tanyel FC, 2000, J PEDIATR SURG, V35, P607, DOI 10.1053/jpsu.2000.0350607
   TZAKIS AG, 1985, TRANSPLANTATION, V40, P667, DOI 10.1097/00007890-198512000-00019
   Uchiyama H, 2002, SURGERY, V131, pS200, DOI 10.1067/msy.2002.119577
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
   Zanotelli ML, 2004, TRANSPLANT P, V36, P945, DOI 10.1016/j.transproceed.2004.03.104
NR 30
TC 3
Z9 4
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2010
VL 14
IS 1
BP 48
EP 51
DI 10.1111/j.1399-3046.2009.01219.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 542FJ
UT WOS:000273478100010
PM 19656321
ER

PT J
AU Krampe, K
   Briem-Richter, A
   Fischer, L
   Nashan, B
   Ganschow, R
AF Krampe, Katrin
   Briem-Richter, Andrea
   Fischer, Lutz
   Nashan, Bjoern
   Ganschow, Rainer
TI The value of immunoprophylaxis for cytomegalovirus infection with
   intravenous immunoglobulin in pediatric liver transplant recipients
   receiving a low-dose immunosupressive regimen
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; cytomegalovirus; liver transplantation; intravenous
   immunoglobulins; immunosuppression
ID SOLID-ORGAN TRANSPLANTATION; CMV-HYPERIMMUNE GLOBULIN; PREEMPTIVE
   THERAPY; ORAL GANCICLOVIR; DISEASE; PREVENTION; TRIAL; PROPHYLAXIS;
   KIDNEY; HEART
AB The incidence of CMV infection following pediatric Ltx is particularly high, which can be attributed to the increased number of patients at high risk for primary infection (donor CMV+, recipient CMV-). Current approaches to cope with this complication producing post-operative morbidity include prophylactic or preemptive ganciclovir therapy. As the risk for symptomatic CMV infection is directly correlated with the intensity of immunosuppression, the aim of our study was to assess the value of IVIG in order to protect children receiving low-dose immunosuppression from CMV disease. Twenty-eight consecutive children (median age 62.2 months) at high risk prospectively received three infusions of IVIG on days four, 14, and 28 post-transplant and were monitored for six months post-Ltx. Immunosuppression consisted of cyclosporine (initial trough levels 170-200 mu g/L) and prednisolone (starting dose 15 mg/m2) as well as basiliximab induction therapy. Patient survival was 100% and graft survival was 92.9%. Two subjects developed laboratory findings of CMV infection (8%) and one child suffered from tissue invasive CMV disease (4%). Three patients were excluded from the study because of protocol violations. We conclude that there was a low incidence of CMV disease among a prospective cohort receiving low-dose immunosuppression and a standard IVIG product.
C1 [Krampe, Katrin; Briem-Richter, Andrea; Ganschow, Rainer] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Gastroenterol & Hepatol, D-20246 Hamburg, Germany.
   [Fischer, Lutz; Nashan, Bjoern] Univ Med Ctr Hamburg Eppendorf, Dept Pediat & Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Ganschow, R (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.
EM ganschow@uke.uni-hamburg.de
CR American Society of Transplantation, 2004, AM J TRANSPLANT S10, V4, P51
   Bonaros N, 2008, CLIN TRANSPLANT, V22, P89, DOI 10.1111/j.1399-0012.2007.00750.x
   BOWMAN JS, 1991, CLIN TRANSPLANT, V5, P294
   Campbell AL, 2004, PEDIATR TRANSPLANT, V8, P619, DOI 10.1111/j.1399-3046.2004.00242.x
   Demetris AJ, 1997, HEPATOLOGY, V25, P658
   Emery VC, 2000, LANCET, V355, P2032, DOI 10.1016/S0140-6736(00)02350-3
   Gane E, 1997, LANCET, V350, P1729, DOI 10.1016/S0140-6736(97)05535-9
   Gerna G, 2003, TRANSPLANTATION, V75, P1012, DOI 10.1097/01.TP.0000057239.32192.B9
   Green M, 2002, PEDIATR TRANSPLANT, V6, P20, DOI 10.1034/j.1399-3046.2002.1p048.x
   Pescovitz MD, 2007, TRANSPLANTATION, V84, pS2, DOI 10.1097/01.tp.0000280538.30629.99
   Preiksaitis JK, 2005, AM J TRANSPLANT, V5, P218, DOI 10.1111/j.1600-6143.2004.00692.x
   Razonable RR, 2003, J INFECT DIS, V187, P1801, DOI 10.1086/375194
   Renoult E, 2008, PEDIATR TRANSPLANT, V12, P420, DOI 10.1111/j.1399-3046.2007.00799.x
   Schiff R I, 1994, Pediatr Allergy Immunol, V5, P127, DOI 10.1111/j.1399-3038.1994.tb00230.x
   Sester U, 2005, AM J TRANSPLANT, V5, P1483, DOI 10.1111/j.1600-6143.2005.00871.x
   SNYDMAN DR, 1993, ANN INTERN MED, V119, P984
   Strippoli GFM, 2006, TRANSPLANTATION, V81, P139, DOI 10.1097/01.tp.0000183970.71366.da
NR 17
TC 12
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2010
VL 14
IS 1
BP 67
EP 71
DI 10.1111/j.1399-3046.2008.01120.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 542FJ
UT WOS:000273478100013
PM 19175517
ER

PT J
AU Cakir, M
   Arikan, C
   Akman, SA
   Baran, M
   Saz, UE
   Yagci, RV
   Zeytunlu, M
   Kilic, M
   Aydogdu, S
AF Cakir, Murat
   Arikan, Cigdem
   Akman, Sezin Asik
   Baran, Masallah
   Saz, Ulas Eylem
   Yagci, Rasit Vural
   Zeytunlu, Murat
   Kilic, Murat
   Aydogdu, Sema
TI Infectious complications in pediatric liver transplantation candidates
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE infections; children; cirrhosis; liver transplantation
ID BACTERIAL-INFECTIONS; BILIARY ATRESIA; CIRRHOSIS; RECIPIENTS; MORBIDITY;
   MORTALITY; DISEASE
AB We analyzed infections that occurred within one month prior to LT, identified factors associated with their occurrence and effect of infections on post-transplant mortality. The study group included 40 consecutive children who underwent LT. Sites and types of infection and culture results were recorded prospectively. IID was assessed. Risk factors for the infectious events were analyzed. Forty infection episodes were found in 24 patients (60%); 90% were bacterial, 7.5% fungal, and 2.5% viral. Overall, IID was 38.2 per 1000 patient days. Sites of bacterial infection were urinary tract in 13 events (36.1%) and blood stream in 11 events (30.5%). Bacteremia (culture positive infection episodes) was identified in 19 events (52.7%). Gram-negative isolates were twice as frequent as Gram-positive infections (63.1% vs. 36.9%). Risk factors for the infectious complications were young age, low body weight, prior abdominal surgery, chronic liver disease related to biliary problems, presence of ascites, portal hypertension and cirrhosis, and high PELD score (p < 0.05 for all). Infectious complications in pediatric LT candidates are common. Preventive measures are important not only to reduce the infectious complications but also to prevent the post-operative mortality.
C1 [Cakir, Murat; Arikan, Cigdem; Baran, Masallah; Saz, Ulas Eylem; Yagci, Rasit Vural; Aydogdu, Sema] Ege Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, Izmir, Turkey.
   [Akman, Sezin Asik] Izmir Tepecik Training & Res Hosp, Dept Pediat, Izmir, Turkey.
   [Zeytunlu, Murat; Kilic, Murat] Ege Univ, Organ Transplantat & Res Ctr, Izmir, Turkey.
RP Arikan, C (reprint author), Ege Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, Izmir, Turkey.
EM cigdem.arikan@ege.edu.tr
CR Ahmed AFKU, 2001, J PEDIATR SURG, V36, P240, DOI 10.1053/jpsu.2001.20063
   Aydogdu S, 2005, PEDIATR TRANSPLANT, V9, P723, DOI 10.1111/j.1399-3046.2005.00366.x
   Baskin E, 2007, PEDIATR TRANSPLANT, V11, P402, DOI 10.1111/j.1399-3046.2006.00674.x
   Cheruvattath R, 2007, J CLIN GASTROENTEROL, V41, P403, DOI 10.1097/01.mcg.0000248018.08515.f9
   Christou L, 2007, AM J GASTROENTEROL, V102, P1510, DOI 10.1111/j.1572-0241.2007.01286.x
   Chuang JH, 2001, WORLD J SURG, V25, P1512
   Dehghani SM, 2007, PEDIATR TRANSPLANT, V11, P21, DOI 10.1111/j.1399-3046.2006.00619.x
   Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927
   GARNER JS, 1986, AM J INFECT CONTROL, V14, P110, DOI 10.1016/0196-6553(86)90019-2
   Guaraldi G, 2005, TRANSPLANTATION, V80, P1742, DOI 10.1097/01.tp.0000185622.91708.57
   Kawecki D, 2007, TRANSPL P, V39, P2816, DOI 10.1016/j.transproceed.2007.08.048
   KUSNE S, 1988, MEDICINE, V67, P132
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Mack CL, 2004, PEDIATR RES, V56, P79, DOI 10.1203/01.PDR.0000130480.51066.FB
   Mack CL, 2005, PEDIATR RES, V57, p87R
   Navasa M, 1999, ITAL J GASTROENTEROL, V31, P616
   Rowe D T, 2001, Transpl Infect Dis, V3, P79, DOI 10.1034/j.1399-3062.2001.003002079.x
   Tandon P, 2008, SEMIN LIVER DIS, V28, P26, DOI 10.1055/s-2008-1040319
   Toba K, 1993, Nihon Ronen Igakkai Zasshi, V30, P487
   Yang Ying-Ying, 2005, J Chin Med Assoc, V68, P447
NR 20
TC 6
Z9 8
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2010
VL 14
IS 1
BP 82
EP 86
DI 10.1111/j.1399-3046.2009.01136.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 542FJ
UT WOS:000273478100016
PM 19490485
ER

PT J
AU Meyburg, J
   Hoerster, F
   Schmidt, J
   Poeschl, J
   Hoffmann, GF
   Schenk, JP
AF Meyburg, Jochen
   Hoerster, Friederike
   Schmidt, Jan
   Poeschl, Johannes
   Hoffmann, Georg F.
   Schenk, Jens-Peter
TI Monitoring of Intraportal Liver Cell Application in Children
SO CELL TRANSPLANTATION
LA English
DT Article
DE Hepatocyte transplantation; Urea cycle disorders; Acute liver failure;
   Portal vein pressure (PVP); Portal vein flow (PVF); Ornithine
   transcarbamylase deficiency; Carbamoylphosphate synthase deficiency;
   Citrullinemia
ID ISOLATED HEPATOCYTE TRANSPLANTATION; PORTAL HEMODYNAMIC-CHANGES; ALBUMIN
   PARTICLES; NONHUMAN-PRIMATES; RAT-LIVER; SAFETY; REPOPULATION;
   DEFICIENCY; VEIN; FEASIBILITY
AB Despite recent advances and promising results in children, liver cell transplantation (LCT) should still be regarded as an experimental therapy. Several substantial complications are known from animal studies and individual patients. However, safety data on liver cell infusion in children are scarce. We used LCT in four children of different ages (3 weeks to 11 years, 3-40 kg) and underlying diseases [acute liver failure (n = 1), urea cycle disorders (n = 2), and Crigler-Najjar syndrome (n = 1)]. Vital parameters, portal vein flow (PVF), portal vein pressure (PVP), and liver enzymes were measured every 5 min during cell application and hourly thereafter between applications. An application protocol with discontinuation rules depending on changes in PVF and PVP was developed and successfully applied. Application was feasible in all children despite the catastrophic overall condition of the patient with acute liver failure. No application-related changes in vital parameters were found, and none of the children experienced clinical signs of portal vein thrombosis, pulmonary embolism, or anaphylactic reactions. Time courses for changes in PVF, PVP, and liver enzymes were obtained. Thorough monitoring of portal vein pressure and duplex sonography according to a defined protocol is likely to increase safety of cell application in pediatric LCT.
C1 [Meyburg, Jochen; Hoerster, Friederike; Hoffmann, Georg F.] Univ Childrens Hosp, Dept Gen Pediat, D-69120 Heidelberg, Germany.
   [Schmidt, Jan] Univ Hosp, Dept Visceral & Transplantat Surg, Heidelberg, Germany.
   [Poeschl, Johannes] Univ Childrens Hosp, Dept Neonatol, D-69120 Heidelberg, Germany.
   [Schenk, Jens-Peter] Univ Hosp, Div Pediat Radiol, Dept Diagnost & Intervent Radiol, Heidelberg, Germany.
RP Meyburg, J (reprint author), Univ Childrens Hosp, Dept Gen Pediat, Neuenheimer Feld 430, D-69120 Heidelberg, Germany.
EM jochen.meyburg@med.uni-heidelberg.de
CR Allen KJ, 2008, LIVER TRANSPLANT, V14, P688, DOI 10.1002/lt.21443
   Ambrosino G, 2005, CELL TRANSPLANT, V14, P151, DOI 10.3727/000000005783983250
   Baccarani U, 2005, TRANSPLANT INT, V18, P750, DOI 10.1111/j.1432-2277.2005.00127.x
   Bilir BM, 2000, LIVER TRANSPLANT, V6, P32, DOI 10.1016/S1527-6465(00)80030-1
   Dhawan A, 2004, TRANSPLANTATION, V78, P1812, DOI 10.1097/01.TP.0000146386.77076.47
   Fisher RA, 2006, TRANSPLANTATION, V82, P441, DOI 10.1097/01.tp.0000231689.44266.ac
   Fox IJ, 1998, NEW ENGL J MED, V338, P1422, DOI 10.1056/NEJM199805143382004
   GROSSMAN M, 1992, HUM GENE THER, V3, P501, DOI 10.1089/hum.1992.3.5-501
   GRUNERT D, 1990, KLIN PADIATR, V202, P24, DOI 10.1055/s-2007-1025481
   Gupta S, 1999, HEPATOLOGY, V29, P509, DOI 10.1002/hep.510290213
   Horslen SP, 2003, PEDIATRICS, V111, P1262, DOI 10.1542/peds.111.6.1262
   Ilan Y, 1997, TRANSPLANTATION, V64, P8, DOI 10.1097/00007890-199707150-00003
   Kocken JM, 1996, TRANSPLANTATION, V62, P358, DOI 10.1097/00007890-199608150-00010
   Meyburg J, 2008, TRANSPL P, V40, P936, DOI 10.1016/j.transproceed.2008.03.043
   Meyburg J, 2009, TRANSPLANTATION, V87, P636, DOI 10.1097/TP.0b013e318199936a
   Meyburg J, 2009, CELL TRANSPLANT, V18, P777, DOI 10.3727/096368909X470775
   Muraca M, 2002, LANCET, V359, P317, DOI 10.1016/S0140-6736(02)07529-3
   Muraca M, 2002, TRANSPLANTATION, V73, P890, DOI 10.1097/00007890-200203270-00010
   Najimi M, 2004, J PEDIATR GASTR NUTR, V39, P311, DOI 10.1097/00005176-200410000-00001
   Ng V L, 2000, Clin Liver Dis, V4, P929, DOI 10.1016/S1089-3261(05)70147-1
   Puppi J, 2008, AM J TRANSPLANT, V8, P452, DOI 10.1111/j.1600-6143.2007.02058.x
   Quaglia A, 2008, CELL TRANSPLANT, V17, P1403
   Rajvanshi P, 1999, J HEPATOL, V30, P299, DOI 10.1016/S0168-8278(99)80077-4
   Rajvanshi P, 1996, GASTROENTEROLOGY, V111, P1092, DOI 10.1016/S0016-5085(96)70078-1
   Raper SE, 1996, ANN SURG, V223, P116, DOI 10.1097/00000658-199602000-00002
   Schneider A, 2003, TRANSPLANTATION, V75, P296, DOI 10.1097/01.TP.0000044454.43076.7B
   Sokal EM, 2003, TRANSPLANTATION, V76, P735, DOI 10.1097/01.TP.0000077420.81365.53
   Stephenne X, 2005, AM J TRANSPLANT, V5, P2058, DOI 10.1111/j.1600-6143.2005.00935.x
   Stephenne X, 2006, GASTROENTEROLOGY, V130, P1317, DOI 10.1053/j.gastro.2006.01.008
   Stephenne X, 2007, LIVER TRANSPLANT, V13, P599, DOI 10.1002/lt.21128
   Strom SC, 1997, TRANSPLANT P, V29, P2103, DOI 10.1016/S0041-1345(97)00252-2
   Vons C, 2001, TRANSPLANTATION, V72, P811, DOI 10.1097/00007890-200109150-00012
   Yu CH, 2004, J BIOMED SCI, V11, P756, DOI 10.1159/000081822
NR 33
TC 14
Z9 14
U1 0
U2 0
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA
SN 0963-6897
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2010
VL 19
IS 5
BP 629
EP 638
DI 10.3727/096368909X485058
PG 10
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA 630FA
UT WOS:000280257200011
PM 20053320
ER

PT J
AU Zanfi, C
   Lauro, A
   Cescon, M
   Dazzi, A
   Ercolani, G
   Grazi, GL
   Zanello, M
   Vivarelli, M
   Del Gaudio, M
   Ravaioli, M
   Cucchetti, A
   Vetrone, G
   Tuci, F
   Di Gioia, P
   Lazzarotto, T
   D'Errico, A
   Bagni, A
   Faenza, S
   Siniscalchi, A
   Pironi, L
   Pinna, AD
AF Zanfi, C.
   Lauro, A.
   Cescon, M.
   Dazzi, A.
   Ercolani, G.
   Grazi, G. L.
   Zanello, M.
   Vivarelli, M.
   Del Gaudio, M.
   Ravaioli, M.
   Cucchetti, A.
   Vetrone, G.
   Tuci, F.
   Di Gioia, P.
   Lazzarotto, T.
   D'Errico, A.
   Bagni, A.
   Faenza, S.
   Siniscalchi, A.
   Pironi, L.
   Pinna, A. D.
TI Comprehensive Surgical Intestinal Rescue and Transplantation Program in
   Adult Patients: Bologna Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th International Symposium on Small Bowel Transplantation
CY SEP 09-12, 2009
CL Bologna, ITALY
AB Introduction. Surgical approaches to complicated benign intestinal failure are accepted worldwide, especially in the pediatric population. Intestinal transplant surgery is thought to rescue patients in whom complications of total parenteral nutrition (TPN) develop.
   Objective. To report our experience with surgical intestinal rescue in an adult population with intestinal failure.
   Patients and Methods. An intestinal rehabilitation program initiated at our institution included comprehensive medical rehabilitation, surgical bowel rescue, and transplantation. From 2000 to 2009, of 81 adult patients referred by our gastroenterologists for bowel rehabilitation, 42 (51,8%) underwent 43 transplantations (32 isolated intestinal grafts and 11 multivisceral grafts). Underlying diseases were primarily short-bowel syndrome, Gardner syndrome, and intestinal pseudo-obstruction. Thirty-nine patients (48,2%) underwent surgical rescue (40 cases) consisting of bowel resection, adhesiolysis, stricturoplasty, liver transplantation with portocaval hemitransposition (6 cases in 5 patients). Underlying diseases were primarily intestinal fistulas, stenosis, or perforations, short-bowel syndrome, cocoon syndrome, and complete portal thrombosis.
   Results. After a mean (SD) follow-up of 1043 (1016) days, in the transplantation population, 21 patients (50%) are alive, with a 1-, 3-, 5-year patient survival of 76%, 59%, and 52%, respectively, and graft survival of 66%, 54%, and 48%, respectively. After 901 (404) days in the rescue population, 32 patients (82%) are alive (2 died, and 5 were lost to follow-up); in 75%, TPN 25% was discontinued, and are receiving oral feeding with TPN support. The 1- and 3-year survival rate was 100% and 83%, respectively.
   Conclusions. Deaths occurred primarily in the transplantation population. Intestinal surgical rescue, when possible, is optimal.
C1 [Zanfi, C.; Lauro, A.; Cescon, M.; Dazzi, A.; Ercolani, G.; Grazi, G. L.; Zanello, M.; Vivarelli, M.; Del Gaudio, M.; Ravaioli, M.; Cucchetti, A.; Vetrone, G.; Tuci, F.; Di Gioia, P.; Faenza, S.; Siniscalchi, A.; Pinna, A. D.] Univ Bologna, S Orsola M Malpighi Hosp, Liver & Multiorgan Transplant Unit, I-40138 Bologna, Italy.
   [Lazzarotto, T.] Univ Bologna, S Orsola M Malpighi Hosp, Microbiol Unit, I-40138 Bologna, Italy.
   [D'Errico, A.; Bagni, A.] Univ Bologna, S Orsola M Malpighi Hosp, Pathol F Addarii Inst, I-40138 Bologna, Italy.
   [Pironi, L.] Univ Bologna, S Orsola M Malpighi Hosp, Chron Intestinal Failure Ctr, I-40138 Bologna, Italy.
RP Zanfi, C (reprint author), Univ Bologna, S Orsola M Malpighi Hosp, Liver & Multiorgan Transplant Unit, PAD 25,Via Massarenti 9, I-40138 Bologna, Italy.
EM nufito@libero.it
RI Cucchetti, Alessandro/B-5194-2014; 
OI Cucchetti, Alessandro/0000-0001-5269-1964; Ercolani,
   Giorgio/0000-0003-4334-5167; VIVARELLI, MARCO/0000-0003-0500-9461
CR BIANCHI A, 1980, J PEDIATR SURG, V15, P145, DOI 10.1016/S0022-3468(80)80005-4
   Fishbein TM, 2002, J GASTROINTEST SURG, V6, P554, DOI 10.1016/S1091-255X(01)00026-9
   FRYER JP, 2008, CURR OPINION ORGAN T, V13, P226
   Santamaria ML, 2007, NUTR HOSP, V22, P113
   Vianna Rodrigo M, 2008, Adv Surg, V42, P129, DOI 10.1016/j.yasu.2008.03.008
NR 5
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2010
VL 42
IS 1
BP 39
EP 41
DI 10.1016/j.transproceed.2009.12.020
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 564LI
UT WOS:000275215400009
PM 20172277
ER

PT J
AU Uribe, M
   Alba, A
   Hunter, B
   Valverde, C
   Godoy, J
   Ferrario, M
   Buckel, E
   Cavallieri, S
   Rebolledo, R
   Herzog, C
   Calabran, L
   Flores, L
   Soto, P
AF Uribe, M.
   Alba, A.
   Hunter, B.
   Valverde, C.
   Godoy, J.
   Ferrario, M.
   Buckel, E.
   Cavallieri, S.
   Rebolledo, R.
   Herzog, C.
   Calabran, L.
   Flores, L.
   Soto, P.
TI Chilean Experience in Liver Transplantation for Acute Liver Failure in
   Children
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Conference of the
   International-Society-for-Organ-Donation-and-Procurement
CY OCT 04-10, 2009
CL Berlin, GERMANY
SP Int Soc Organ Donat & Procurement
ID FULMINANT HEPATIC-FAILURE; PROGRAM
AB Background. Acute liver failure (ALF) in children is a life-threatening condition, associated with high mortality, and in almost one third of the cases, with no other therapeutic option than orthotopic liver transplant (OLT). The aim of this study was to present our experience with OLT for ALF in pediatric patients in Chile. Patients fulfilling the criteria for ALF who were transplanted in our centers were prospectively included in an excel Microsoft database. We analyzed demographics, etiology, surgical techniques, complications, and long-term results.
   Patients and Methods. Between 1994 and 2009, we transplanted 52 pediatric patients with ALF. The most frequent known etiology was acute hepatitis A in 9 cases (18%), but in 26 cases (50%) it was impossible to determine the etiology. Thirty-one patients were males (63%). The overall mean age was 7.5 years and the mean weight, 28.1 kg. Thirty-five (67%) received a cadaveric graft. Among them in 1.8 cases (34%) the liver had to be reduced but 17 (33%) received whole livers. There were 17 (33%) recipients of living-related livers. Twenty-two patients needed reoperation, including 13 due to surgical complications (59%) and 9 (41%) as planned interventions. Ten patients were retransplanted.
   Results. Actuarial survival of patients at 1 year was 80% and at 5 and 10 years, 72%. Graft survival at I year was 79%, at 5 years 69%, and at 10 years 50%.
   Conclusion. We have reported a series of pediatric liver transplant patients due to ALF whose results were comparable to other reported series. Living donor transplantation for ALF should be considered and offers a low morbidity rate without mortality.
C1 Clin Las Condes, Ctr Trasplante, Santiago, Chile.
   Hosp Luis Calvo, Santiago, Chile.
RP Uribe, M (reprint author), Fontecilla 441, Santiago, Chile.
EM muribem@clc.cl
CR Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Cox KL, 1999, J GASTROEN HEPATOL, V14, pS61
   DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1016/0270-9139(92)90008-W
   DHAWAN A, 2008, LIVER TRANSPL S, V2, pS80
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   Nicolette L, 1998, J PEDIATR SURG, V33, P998, DOI 10.1016/S0022-3468(98)90521-8
   RiveraPenera T, 1997, J PEDIATR GASTR NUTR, V24, P128, DOI 10.1097/00005176-199702000-00004
   Squires RH, 2008, SEMIN LIVER DIS, V28, P153, DOI 10.1055/s-2008-1073115
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Uribe M, 2005, TRANSPL P, V37, P3378, DOI 10.1016/j.transproceed.2005.09.097
   Uribe M, 2003, TRANSPLANT P, V35, P2511, DOI 10.1016/j.transproceed.2003.09.025
   Uribe M, 2008, TRANSPL P, V40, P3253, DOI 10.1016/j.transproceed.2008.03.128
   Uribe M, 2005, TRANSPL P, V37, P3375, DOI 10.1016/j.transproceed.2005.09.096
NR 14
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2010
VL 42
IS 1
BP 293
EP 295
DI 10.1016/j.transproceed.2009.12.050
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 564LI
UT WOS:000275215400065
PM 20172334
ER

PT J
AU Concannon, RC
   Howman-Giles, R
   Shun, A
   Stormon, MO
AF Concannon, Rebecca C.
   Howman-Giles, Robert
   Shun, Albert
   Stormon, Michael O.
TI Hepatobiliary scintigraphy for the assessment of biliary strictures
   after pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary strictures; hepatobiliary scintigraphy; liver transplant;
   pediatric
ID HEPATIC-ARTERY THROMBOSIS; BILE-DUCT COMPLICATIONS; CHOLANGIOGRAPHY;
   RECIPIENTS; CHILDREN; TRACT
AB HBS is used in the management of liver transplantation, a significant complication of which is biliary stricture. Strictures may be intraparenchymal within segments and main duct (non-anastomotic) or at the biliary-enteric anastomosis (anastomotic). Strictures are definitively diagnosed, and often managed, by PTC. This is invasive, technically challenging, and requires general anesthesia in young children. HBS may allow early detection of these complications and is non-invasive. The aim of this study was to review the scintigraphic pattern of biliary strictures using 99mTcDISIDA HBS following pediatric orthotopic liver transplantation, and to assess its role in the diagnostic algorithm of suspected biliary strictures. All available hepatobiliary studies performed post-transplant in 101 episodes of liver transplantation in 92 pediatric patients were reviewed. Twenty-three (23%) patients had known biliary strictures. Twenty-two patients had adequate studies available for review; five had intrahepatic (non-anastomotic) strictures alone, nine had a stricture of the anastomosis alone, and eight had both intrahepatic and anastomotic strictures. HBS patterns (either segmental or global changes) correlated very highly with clinically significant biliary strictures. All patients with known strictures had abnormal HBS; hence, in patients with abnormal liver function tests post-liver transplant, a normal HBS makes strictures very unlikely. We propose that HBS can thus be used to determine if further investigation is required.
C1 [Concannon, Rebecca C.; Howman-Giles, Robert] Childrens Hosp Westmead, Dept Nucl Med, Sydney, NSW, Australia.
   [Howman-Giles, Robert; Stormon, Michael O.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia.
   [Shun, Albert] Childrens Hosp Westmead, Dept Surg, Sydney, NSW, Australia.
   [Stormon, Michael O.] Childrens Hosp Westmead, Dept Gastroenterol, Sydney, NSW, Australia.
RP Howman-Giles, R (reprint author), Childrens Hosp Westmead, Dept Nucl Med, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM rhowmang@mail.usyd.edu.au
CR ANSELMI M, 1990, BRIT J SURG, V77, P1233, DOI 10.1002/bjs.1800771113
   BROWN PH, 1988, J NUCL MED, V29, P623
   BROWN RKJ, 1986, J NUCL MED, V27, P1428
   ENGELER CM, 1992, EUR J NUCL MED, V19, P865, DOI 10.1007/BF00168162
   GELFAND MJ, 1992, CLIN NUCL MED, V17, P542, DOI 10.1097/00003072-199207000-00002
   HAWKINS RA, 1988, SEMIN NUCL MED, V18, P199, DOI 10.1016/S0001-2998(88)80028-X
   HOWMANGILES R, 1993, J NUCL MED, V34, P214
   KARADEMIR S, 1994, CLIN TRANSPLANT, V8, P54
   Kim JS, 2002, EUR J NUCL MED MOL I, V29, P473, DOI 10.1007/s00259-001-0706-0
   Kim JS, 2000, EUR J NUCL MED, V27, P170, DOI 10.1007/s002590050023
   Kurzawinski TR, 1997, BRIT J SURG, V84, P620, DOI 10.1046/j.1365-2168.1997.02653.x
   LALLIER M, 1993, J PEDIATR SURG, V28, P1102, DOI 10.1016/0022-3468(93)90139-C
   LANTSBERG S, 1990, NUCL MED COMMUN, V11, P761, DOI 10.1097/00006231-199011000-00005
   LOKEN MK, 1986, J NUCL MED, V27, P451
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Mochizuki T, 1991, Ann Nucl Med, V5, P103
   Nishida S, 2006, J HEPATO-BILIARY-PAN, V13, P511, DOI 10.1007/s00534-005-1081-1
   PARIENTE D, 1991, PEDIATR RADIOL, V21, P175, DOI 10.1007/BF02011040
   PECLET MH, 1994, J PEDIATR SURG, V29, P214, DOI 10.1016/0022-3468(94)90321-2
   Proposito D, 2001, Ann Ital Chir, V72, P187
   Saing H, 2002, J PEDIATR SURG, V37, P1673, DOI 10.1053/jpsu.2002.36690
   Schindel D, 2000, J PEDIATR SURG, V35, P940, DOI 10.1053/jpsu.2000.6932
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   Vilca-Melendez H, 2004, POSTGRAD MED J, V80, P571, DOI 10.1136/pgmj.2003.018598
NR 26
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2009
VL 13
IS 8
BP 977
EP 983
DI 10.1111/j.1399-3046.2008.01099.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 520AD
UT WOS:000271811200006
PM 19032415
ER

PT J
AU Kawano, Y
   Mizuta, K
   Sugawara, Y
   Egami, S
   Hisikawa, S
   Sanada, Y
   Fujiwara, T
   Sakuma, Y
   Hyodo, M
   Yoshida, Y
   Yasuda, Y
   Sugimoto, E
   Kawarasaki, H
AF Kawano, Youichi
   Mizuta, Koichi
   Sugawara, Yasuhiko
   Egami, Satoshi
   Hisikawa, Shuji
   Sanada, Yukihiro
   Fujiwara, Takehito
   Sakuma, Yasunaru
   Hyodo, Masanobu
   Yoshida, Yoshiyuki
   Yasuda, Yoshikazu
   Sugimoto, Eiji
   Kawarasaki, Hideo
TI Diagnosis and treatment of pediatric patients with late-onset portal
   vein stenosis after living donor liver transplantation
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE complication; interventional radiology; living donor liver
   transplantation; pediatric; portal vein stenosis
ID VASCULAR COMPLICATIONS; LONG-TERM; VENOUS COMPLICATIONS; DOPPLER US;
   ANGIOPLASTY; THROMBOSIS; ANGIOGRAPHY; PREVENTION; RECIPIENTS; CHILDREN
AB P>Portal vein stenosis (PVS) after living donor liver transplantation (LDLT) is a serious complication that can lead to graft failure. Few studies of the diagnosis and treatment of late-onset (>= 3 months after liver transplantation) PVS have been reported. One hundred thirty-three pediatric (median age 7.6 years, range 1.3-26.8 years) LDLT recipients were studied. The patients were followed by Doppler ultrasound (every 3 months) and multidetector helical computed tomography (once a year). Twelve patients were diagnosed with late-onset PVS 0.5-6.9 years after LDLT. All cases were successfully treated with balloon dilatation. Five cases required multiple treatments. Early diagnosis of late-onset PVS and interventional radiology therapy treatment may prevent graft loss.
C1 [Kawano, Youichi; Mizuta, Koichi; Egami, Satoshi; Hisikawa, Shuji; Sanada, Yukihiro; Kawarasaki, Hideo] Jichi Med Univ, Dept Transplant Surg, Ctr Mol Med, Shimotsuke, Tochigi 3290498, Japan.
   [Sugawara, Yasuhiko] Univ Tokyo, Grad Sch Med, Dept Surg, Artificial Organ & Transplantat Div, Tokyo, Japan.
   [Fujiwara, Takehito; Sakuma, Yasunaru; Hyodo, Masanobu; Yasuda, Yoshikazu] Jichi Med Univ, Ctr Mol Med, Dept Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Yoshida, Yoshiyuki; Sugimoto, Eiji] Jichi Med Univ, Ctr Mol Med, Dept Radiol, Shimotsuke, Tochigi 3290498, Japan.
RP Kawano, Y (reprint author), Jichi Med Univ, Dept Transplant Surg, Ctr Mol Med, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM y-kawano@jichi.ac.jp
CR Berrocal T, 2006, RADIOGRAPHICS, V26, P1187, DOI 10.1148/rg.264055081
   Brancatelli G, 2002, TRANSPLANTATION, V73, P237, DOI 10.1097/00007890-200201270-00015
   Brouwer MA, 2002, CIRCULATION, V106, P659, DOI 10.1161/01.CIR.0000024408.81821.32
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chang FY, 2000, TRANSPLANTATION, V69, P70, DOI 10.1097/00007890-200001150-00014
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Chatzipetrou MA, 1999, TRANSPLANTATION, V67, P702, DOI 10.1097/00007890-199903150-00010
   Cheng YF, 2001, TRANSPLANT INT, V14, P223, DOI 10.1007/s001470100324
   Cheng YF, 2004, LIVER TRANSPLANT, V10, P248, DOI 10.1002/lt.20055
   Chu WCW, 2005, J PEDIATR SURG, V40, P1605, DOI 10.1016/j.jpedsurg.2005.06.024
   Funaki B, 2000, RADIOLOGY, V215, P147
   Funaki B, 1997, AM J ROENTGENOL, V169, P551
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   HOLBERT BL, 1995, RADIOL CLIN N AM, V33, P521
   Katyal S, 2000, AM J ROENTGENOL, V175, P1735
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   Lee J, 1996, AM J ROENTGENOL, V167, P85
   LERUT J, 1987, ANN SURG, V205, P404, DOI 10.1097/00000658-198704000-00011
   Lo CM, 2003, TRANSPLANTATION, V75, pS12, DOI 10.1097/01.TP.0000046534.45645.47
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Nghiem HV, 1996, RADIOGRAPHICS, V16, P825
   Park KB, 2005, KOREAN J RADIOL, V6, P161
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029
   Rossi C, 2004, TRANSPLANTATION, V78, P938, DOI 10.1097/01.tp.0000137104.38602.9f
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   Shibata T, 2005, RADIOLOGY, V235, P1078, DOI 10.1148/radiol.2353040489
   Sobhonslidsuk A, 2002, AM J GASTROENTEROL, V97, P535, DOI 10.1111/j.1572-0241.2002.05527.x
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Stafford-Johnson DB, 1998, RADIOLOGY, V207, P153
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Tamsel S, 2007, ABDOM IMAGING, V32, P339, DOI 10.1007/s00261-006-9041-z
   Tamura S, 2005, TRANSPLANTATION, V80, P169, DOI 10.1097/01.TP.0000165048.00487.8E
   Teo C, 1999, CHILD NERV SYST, V15, P103, DOI 10.1007/s003810050343
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
   Ueda M, 2008, AM J TRANSPLANT, V8, P2097, DOI 10.1111/j.1600-6143.2008.02360.x
   Woo David H, 2007, Tech Vasc Interv Radiol, V10, P233, DOI 10.1053/j.tvir.2007.09.017
   Yamanaka J, 2000, HEPATO-GASTROENTEROL, V47, P1371
   ZAJKO AB, 1994, J VASC INTERV RADIOL, V5, P121, DOI 10.1016/S1051-0443(94)71467-6
NR 40
TC 18
Z9 18
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0934-0874
J9 TRANSPL INT
JI Transpl. Int.
PD DEC
PY 2009
VL 22
IS 12
BP 1151
EP 1158
DI 10.1111/j.1432-2277.2009.00932.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 512LV
UT WOS:000271251800004
PM 19663938
ER

PT J
AU Yang, S
   Wu, Z
   Wu, W
   Lin, W
   Xu, T
   Cai, J
   Wang, Q
   Liao, L
   Tan, J
AF Yang, S.
   Wu, Z.
   Wu, W.
   Lin, W.
   Xu, T.
   Cai, J.
   Wang, Q.
   Liao, L.
   Tan, J.
TI Characteristics of Long-Term Immunosuppressive Therapy in Chinese
   Pediatric Renal Transplant Patients: A Single-Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID MYCOPHENOLATE-MOFETIL; AZATHIOPRINE; CHILDREN
AB We performed this study to investigate the trend and characteristics of various immunosuppressive regimens as well as their efficacy and safety for long-term survival of Chinese pediatric renal allograft recipients.
   Methods. Thirty-four patients who underwent kidney transplantation between January 1985 and July 2002 had >= 5 years follow up. We retrospectively reviewed the baseline characteristics, patient and kidney survival rates, renal function, immunosuppressive regimens, drug levels, and adverse effects of immunosuppressive medications.
   Results. The 1-, 3-, and 5-year recipient versus graft survival rates were 100% and 97.1%; 91.2% and 88.2%; 85.3% and 82.4%, respectively. The proportions of patients treated with cyclosporine- or tacrolimus-based immunosuppressive regimen at these times were 48.5%/51.5%; 60.0%/40.0%; and 53.6/46.4%. There were no significant differences in the dosages and drug levels after 1 year (P > .05). The proportions of azathioprine versus mycophenolate mofetil adjunctive therapy were 21.3/78.8%; 23.3%/70%; and 32.1%/60.7%, respectively. Forty percent of the surviving recipients developed complications, including hypertension, hyperlipidemia, gingival hyperplasia, hirsutism, liver dysfunction, herpes zoster, diabetes mellitus or cataracts.
   Conclusions. Cyclosporine or tacrolimus, plus mycophenolate mofetil or azathioprine, and prednisone triple therapies showed promising long-term results with similar efficacy and safety in pediatric renal recipients. Periodic drug level monitoring is required to facilitate individualization of immunosuppressive regimens. Drug doses and levels differed markedly from non-Chinese patients because of the ethnic discrepancy.
C1 [Yang, S.; Wu, Z.; Wu, W.; Lin, W.; Xu, T.; Cai, J.; Wang, Q.; Liao, L.; Tan, J.] Fuzhou Gen Hosp, Transplant Ctr, Fuzhou, Peoples R China.
RP Tan, J (reprint author), Organ Transplant Inst, 156 Fuzhou Xier Huan Rd, Fuzhou 350025, Fujian Province, Peoples R China.
EM doctortjm@yahoo.com
OI Wu, Zhixian/0000-0002-0708-6770
FU Major Research Project Fund of Fujian Province [2002Y007]; Technology
   Innovation Platform Project Fund of Fujian Province [2008J1006]
FX This study was supported by: Major Research Project Fund of Fujian
   Province (No. 2002Y007) and Technology Innovation Platform Project Fund
   of Fujian Province granted to Provincial Transplantation Biological Key
   Laboratory (No. 2008J1006).
CR Attallah N, 2005, TRANSPLANT P, V37, P2060, DOI 10.1016/j.transproceed.2005.03.009
   Butani L, 1999, TRANSPLANTATION, V68, P83
   Delucchi A, 2006, REV MED CHILE, V134, P1393, DOI 10.4067/S0034-98872006001100006
   Ettenger R, 2005, TRANSPLANTATION, V80, pS201, DOI 10.1097/01.tp.0000186957.32801.c0
   Fernando ON, 2006, TRANSPLANT P, V38, P1992, DOI 10.1016/j.transproceed.2006.06.041
   Filler G, 2007, TRANSPL P, V39, P1241, DOI 10.1016/j.transproceed.2007.03.049
   Kalyoncu M, 2006, PEDIATR TRANSPLANT, V10, P168, DOI 10.1111/j.1399-3046.2005.00436.x
   Kim JS, 2005, PEDIATR TRANSPLANT, V9, P162, DOI 10.1111/j.1399-3046.2005.00263.x
   Lee MN, 2007, PEDIATR TRANSPLANT, V11, P388, DOI 10.1111/j.1399-3046.2006.00618.x
   Magee JC, 2004, AM J TRANSPLANT, V4, P54, DOI 10.1111/j.1600-6143.2004.00398.x
   Neu AM, 2003, PEDIATR TRANSPLANT, V7, P217, DOI 10.1034/j.1399-3046.2003.00079.x
   Pourfarziani V, 2007, TRANSPL P, V39, P1237, DOI 10.1016/j.transproceed.2007.03.006
   Smith JM, 2002, PEDIATR TRANSPLANT, V6, P493, DOI 10.1034/j.1399-3046.2002.02042.x
   Vidhun JR, 2005, PEDIATR NEPHROL, V20, P418, DOI 10.1007/s00467-004-1786-4
NR 14
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2009
VL 41
IS 10
BP 4169
EP 4171
DI 10.1016/j.transproceed.2009.08.081
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 535LD
UT WOS:000272968800027
PM 20005361
ER

PT J
AU Bucuvalas, J
AF Bucuvalas, John
TI Long-Term Outcomes in Pediatric Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID FULMINANT HEPATIC-FAILURE; CARDIOVASCULAR RISK-FACTORS; SINGLE-CENTER
   EXPERIENCE; LATE GRAFT LOSS; CALCINEURIN INHIBITORS;
   INTERNATIONAL-SOCIETY; RENAL DYSFUNCTION; FOLLOW-UP; RECIPIENTS;
   HEPATOBLASTOMA
AB 1. Critical clinical outcomes for pediatric liver transplantation (LT) recipients include (1) patient and graft survival, (2) complications (immune and nonimmune) of chronic immunosuppressive medications, and (3) long-term graft function.
   2. Recurrence of malignancy, sepsis, and posttransplant lymphoproliferative disorder account for more than 65% of deaths occurring more than I year after LT.
   3. Chronic rejection, late hepatic artery thrombosis, and biliary strictures account for 70% of graft loss occurring more than 1 year after LT.
   4. Late histological changes in the allograft are emerging as a common problem in patients more than 5 years after LT. The pathogenesis of these findings and the impact on graft survival remain to be determined. Liver Transpl. 15:S6-S11, 2009. (C) 2009 AASLD.
C1 Cincinnati Childrens Hosp, Cincinnati, OH 45229 USA.
RP Bucuvalas, J (reprint author), Cincinnati Childrens Hosp, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM john.bucuvalas@cchmc.org
CR Abraham SC, 2008, AM J SURG PATHOL, V32, P1479, DOI 10.1097/PAS.0b013e31817a8e96
   Aronson DC, 2005, J CLIN ONCOL, V23, P1245, DOI 10.1200/JCO.2005.07.145
   Aw MM, 2001, TRANSPLANTATION, V72, P746, DOI 10.1097/00007890-200108270-00034
   Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F
   Bucuvalas JC, 2008, AM J TRANSPLANT, V8, P2506, DOI 10.1111/j.1600-6143.2008.02432.x
   Bucuvalas John C, 2008, Curr Opin Organ Transplant, V13, P247, DOI 10.1097/MOT.0b013e3282f94aab
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Daniel Donna M, 2004, Jt Comm J Qual Saf, V30, P69
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Fredericks EM, 2007, AM J TRANSPLANT, V7, P1974, DOI 10.1111/j.1600-6143.2007.01878.x
   Fuchs J, 2002, EUR J PEDIATR SURG, V12, P255, DOI 10.1055/s-2002-34484
   Herzog D, 2008, LIVER TRANSPLANT, V14, P946, DOI 10.1002/lt.21444
   HUBSCHER SG, 1993, J HEPATOL, V18, P173, DOI 10.1016/S0168-8278(05)80244-2
   Magee JC, 2008, AM J TRANSPLANT, V8, P935, DOI 10.1111/j.1600-6143.2008.02172.x
   Mahadeb P, 2009, PEDIATR TRANSPLANT, V13, P414, DOI 10.1111/j.1399-3046.2008.01008.x
   Mendicino M, 2005, CIRCULATION, V112, P248, DOI 10.1161/CIRCULATIONAHA.105.534271
   Molina RA, 2004, AM J TRANSPLANT, V4, P1656, DOI 10.1111/j.1600-6143.2004.00559.x
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Ortega JA, 2000, J CLIN ONCOL, V18, P2665
   Otte JB, 2004, PEDIATR BLOOD CANCER, V42, P74, DOI 10.1002/pbc.10376
   Pageaux GP, 2006, LIVER TRANSPLANT, V12, P1755, DOI 10.1002/lt.20903
   Perilongo G, 2000, Lancet Oncol, V1, P94, DOI 10.1016/S1470-2045(00)00018-8
   Rolando N, 2000, HEPATOLOGY, V32, P734, DOI 10.1053/jhep.2000.17687
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Shemesh E, 2008, PEDIATR TRANSPLANT, V12, P316, DOI 10.1111/j.1399-3046.2007.00791.x
   Shemesh E, 2004, PEDIATRICS, V113, P825, DOI 10.1542/peds.113.4.825
   Shemesh E, 2008, PEDIATR TRANSPLANT, V12, P281, DOI 10.1111/j.1399-3046.2008.00920.x
   Shemesh E, 2008, LIVER TRANSPLANT, V14, P1229, DOI 10.1002/lt.21582
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   Shneider BL, 2005, LIVER TRANSPLANT, V11, P788, DOI 10.1002/lt.20401
   Soltys KA, 2007, AM J TRANSPLANT, V7, P2165, DOI 10.1111/j.1600-6143.2007.01893.x
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Suita S, 2004, J PEDIATR SURG, V39, P195, DOI 10.1016/j.jpedsurg.2003.10.012
   Textor SC, 2000, LIVER TRANSPLANT, V6, P521, DOI 10.1053/jlts.2000.9737
   Tiao GM, 2005, J PEDIATR-US, V146, P204, DOI 10.1016/j.jpeds.2004.09.011
   Varo E, 2002, TRANSPLANT P, V34, P1553, DOI 10.1016/S0041-1345(02)03018-X
   Venkat VL, 2008, PEDIATR TRANSPLANT, V12, P67, DOI 10.1111/j.1399-3046.2007.00794.x
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   YAZIGI N, 2008, AM J TRANSPLANT, V8, P328
NR 43
TC 24
Z9 24
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD NOV
PY 2009
VL 15
IS 11
BP S6
EP S11
DI 10.1002/lt.21915
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 517HS
UT WOS:000271604600002
PM 19877291
ER

PT J
AU Hubscher, S
AF Huebscher, Stefan
TI What Does the Long-Term Liver Allograft Look Like for the Pediatric
   Recipient?
SO LIVER TRANSPLANTATION
LA English
DT Article
ID TRANSPLANT RECIPIENTS; FOLLOW-UP; CENTRAL PERIVENULITIS; GRAFT FIBROSIS;
   REJECTION; HEPATITIS; AUTOANTIBODIES; SURVIVORS; BIOPSIES; CHILDREN
AB 1. Histological abnormalities are commonly present in late posttransplant biopsies from pediatric liver allograft: recipients.
   2. Many of the changes are seen in children who appear to be clinically well with good graft function.
   3. In comparison with adults, children may be more prone to developing late rejection (possibly related to noncompliance with immunosuppression) and biliary/vascular complications, but they are much less likely to suffer problems with disease recurrence.
   4. De novo autoimmune hepatitis occurs in 5% to 10% of children after transplantation and may represent a hepatitic form of late cellular rejection. Most cases respond to treatment with increased immunosuppression.
   5. Recent studies have shown a high frequency of unexplained (idiopathic) chronic hepatitis in late posttransplant biopsies from children. This is associated with the development of graft fibrosis and cirrhosis.
   6. Further studies are required to investigate the role of protocol liver biopsies in determining therapeutic strategies in children who appear to have good graft function according to noninvasive investigations. Liver Transpl 15:S19-S24, 2009. (C) 2009 AASLD.
C1 Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England.
RP Hubscher, S (reprint author), Univ Birmingham, Dept Pathol, Birmingham B15 2TT, W Midlands, England.
EM s.g.hubscher@bham.ac.uk
CR Abraham SC, 2008, AM J SURG PATHOL, V32, P1479, DOI 10.1097/PAS.0b013e31817a8e96
   Avitzur Y, 2007, J PEDIATR GASTR NUTR, V45, P222, DOI 10.1097/MPG.0b013e31805ce219
   Demetris AJ, 2006, HEPATOLOGY, V44, P489, DOI 10.1002/hep.21280
   Demetris AJ, 2008, LIVER TRANSPLANT, V14, P750, DOI 10.1002/lt.21518
   Devarbhavi H, 2007, LIVER TRANSPLANT, V13, P1552, DOI 10.1002/lt.21142
   Ekong UD, 2008, LIVER TRANSPLANT, V14, P1582, DOI 10.1002/lt.21549
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Herzog D, 2008, LIVER TRANSPLANT, V14, P946, DOI 10.1002/lt.21444
   Huang RQ, 2004, LIVER TRANSPLANT, V10, P1461, DOI 10.1002/lt.20293
   Hubscher SG, 2007, MACSWEENS PATHOLOGY, P815
   Hubscher SG, 2009, SEMIN LIVER DIS, V29, P74, DOI 10.1055/s-0029-1192057
   Hubscher SG, 2008, LIVER TRANSPLANT, V14, P596, DOI 10.1002/lt.21451
   Jain A, 2006, TRANSPLANT INT, V19, P27, DOI 10.1111/j.1432-2277.2005.00224.x
   Mells G, 2008, TRANSPLANTATION, V85, P1686, DOI 10.1097/TP.0b013e318176b1fd
   Ng VL, 2008, PEDIATRICS, V122, pE1128, DOI 10.1542/peds.2008-1363
   Peeters PMJG, 2000, TRANSPLANTATION, V70, P1581, DOI 10.1097/00007890-200012150-00008
   Richter A, 2007, CLIN TRANSPLANT, V21, P427, DOI 10.1111/j.1399-0012.2007.00667.x
   Scheenstra R, 2009, HEPATOLOGY, V49, P880, DOI 10.1002/hep.22686
   Shaikh OS, 2007, LIVER TRANSPLANT, V13, P943, DOI 10.1002/lt.21202
   Sundaram SS, 2006, LIVER TRANSPLANT, V12, P58, DOI 10.1002/lt.20661
   Venkat VL, 2008, PEDIATR TRANSPLANT, V12, P67, DOI 10.1111/j.1399-3046.2007.00794.x
NR 22
TC 21
Z9 22
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD NOV
PY 2009
VL 15
IS 11
BP S19
EP S24
DI 10.1002/lt.21902
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 517HS
UT WOS:000271604600004
PM 19877293
ER

PT J
AU Dehghani, SM
   Shakiba, MA
   Ziaeyan, M
   Imanieh, MH
   Haghighat, M
   Bahador, A
   Nikeghbalian, S
   Salahi, H
   Alborzi, A
   Malek-Hosseini, SA
AF Dehghani, Seyed Mohsen
   Shakiba, Mohammad Ali
   Ziaeyan, Maziyar
   Imanieh, Mohammad Hadi
   Haghighat, Mahmood
   Bahador, Ali
   Nikeghbalian, Saman
   Salahi, Heshmatollah
   Alborzi, Abdolvahab
   Malek-Hosseini, Seyed Ali
TI Vaccination status in pediatric liver transplant candidates
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE vaccination; children; liver transplantation
ID IMMUNIZATION; CHILDREN; RECIPIENTS; IMMUNITY
AB Infection is a recognized and potentially serious complication in children following solid organ transplantation. This problem is particularly important for young children undergoing any organ transplantation who often have not completed standard childhood immunizations at the time of transplantation and who are therefore at risk for vaccine-preventable infections. To evaluate the vaccination status in liver transplant candidates, vaccination charts of 100 patients who were referred to Organ Transplant Center of Nemazee Hospital were reviewed and the vaccination status considered appropriate according to the recommendation of NIP and the patients' age. Fifty-eight percent of patients were completely vaccinated for HBV, 85% for OPV, 97% for BCG, 63% for DTP, and 58% of the patients were completely vaccinated for MMR. We concluded that the vaccination charts should be periodically reviewed and updated to prevent the vaccine-preventable disease in liver transplant candidates not only before but also after transplant. Every effort should be made to assure that candidates are immunized early in the course of their disease. Also it may be indicated to recommend a special guideline for immunization of liver transplant candidates and add other vaccines such as Haemophilus influenzae and Streptococcus pneumoniae vaccine to their vaccination program.
C1 [Dehghani, Seyed Mohsen] Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Gastroenterohepatol Res Ctr, Nemazee Hosp, Shiraz 7193711351, Iran.
   [Dehghani, Seyed Mohsen; Shakiba, Mohammad Ali; Imanieh, Mohammad Hadi; Haghighat, Mahmood] Shiraz Univ Med Sci, Nemazee Hosp, Dept Pediat Gastroenterol, Shiraz 7193711351, Iran.
   [Ziaeyan, Maziyar; Alborzi, Abdolvahab] Shiraz Univ Med Sci, Nemazee Hosp, Alborzi Clin Microbiol Res Ctr, Shiraz 7193711351, Iran.
RP Dehghani, SM (reprint author), Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Gastroenterohepatol Res Ctr, Nemazee Hosp, Shiraz 7193711351, Iran.
EM dehghanism@sums.ac.ir
CR Balloni A, 1999, VACCINE, V17, P2507, DOI 10.1016/S0264-410X(99)00064-X
   Burroughs M, 2000, CLIN INFECT DIS, V30, P857, DOI 10.1086/313823
   Chaves TSS, 2008, PEDIATR TRANSPLANT, V12, P432, DOI 10.1111/j.1399-3046.2007.00820.x
   Diana A, 2007, PEDIATR TRANSPLANT, V11, P31, DOI 10.1111/j.1399-3046.2006.00596.x
   Kano H, 2002, TRANSPLANTATION, V74, P543, DOI 10.1097/00007890-200208270-00020
   Khan S, 2006, PEDIATR TRANSPLANT, V10, P78, DOI 10.1111/j.1399-3046.2005.00403.x
   Prelog M, 2007, PEDIATR TRANSPLANT, V11, P73, DOI 10.1111/j.1399-3046.2006.00602.x
   Verma A, 2006, PEDIATR TRANSPLANT, V10, P536, DOI 10.1111/j.1399-3046.2006.00527.x
   [Anonymous], 2004, AM J TRANSPLANT S10, V4, P160
NR 9
TC 3
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2009
VL 13
IS 7
BP 820
EP 822
DI 10.1111/j.1399-3046.2009.01177.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 505CS
UT WOS:000270666600005
PM 19413722
ER

PT J
AU Strauss, A
   Grabhorn, E
   Sornsakrin, M
   Briem-Richter, A
   Fischer, L
   Nashan, B
   Ganschow, R
AF Strauss, Annette
   Grabhorn, Enke
   Sornsakrin, Marijke
   Briem-Richter, Andrea
   Fischer, Lutz
   Nashan, Bjoern
   Ganschow, Rainer
TI Liver transplantation for fulminant hepatic failure in infancy: A single
   center experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; children; fulminant hepatic failure
ID CHILDREN; PREDICTORS; SURVIVAL
AB FHF is characterized by a high percentage of unknown causes leading to acute liver failure and furthermore by an increased morbidity and mortality prior to and post-Ltx. In different transplant centers, the reasons leading to FHF differ significantly as well as outcome. We report our single center experience with 30 pediatric patients receiving a liver transplant for FHF, out of a total of 83 children presenting with FHF. The time to transfer patients to the transplant center after the diagnosis of FHF was long, with a median of 14 days (Ltx group) and 12 days (controls), respectively. In nearly half of the patients (n = 14) in the Ltx group, we were not able to establish an exact diagnosis prior to Ltx: 50% suffered from encephalopathy, and 13 patients were treated in the intensive care unit prior to transplant. Because of the availability of different surgical techniques, all children received a timely transplant [split (n = 18), living donor (n = 9), whole organ (n = 2), and reduced liver (n = 1)]. Patient survival was 93.4%, and graft survival was 83.4% for at least one yr follow-up. Severe complications following Ltx included three cases with aplastic anemia and one child suffering from systemic mitochondrial depletion syndrome. The survival of patients treated medically was 83%. We conclude that a strong focus should be made on early referral to a specialized center and on improvement of diagnostic tools to timely detect the underlying reason for FHF. Results following Ltx for FHF are good.
C1 [Strauss, Annette; Grabhorn, Enke; Sornsakrin, Marijke; Briem-Richter, Andrea; Ganschow, Rainer] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Hepatol, D-20246 Hamburg, Germany.
   [Fischer, Lutz; Nashan, Bjoern] Univ Med Ctr Hamburg Eppendorf, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Ganschow, R (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.
EM ganschow@uke.uni-hamburg.de
RI Grabhorn, Enke/F-9785-2011
CR Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   Cochran JB, 2007, PEDIATR EMERG CARE, V23, P129, DOI 10.1097/PEC.0b013e3180308f4b
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Escorsell A, 2007, LIVER TRANSPLANT, V13, P1389, DOI 10.1002/lt.21119
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1016/0270-9139(95)90434-4
   Jain A, 2000, ANN SURG, V232, P490, DOI 10.1097/00000658-200010000-00004
   Kilic M, 2007, TRANSPLANTATION, V84, P475, DOI 10.1097/01.tp.0000276987.55382.e2
   Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2
   Nadalin S, 2007, TRANSPL INT, V20, P519, DOI 10.1111/j.1432-2277.2007.00474.x
   Polson J, 2007, LIVER TRANSPLANT, V13, P1362, DOI 10.1002/lt.21144
   Rhee C, 2006, LIVER TRANSPLANT, V12, P1347, DOI 10.1002/lt.20806
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
NR 16
TC 6
Z9 6
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2009
VL 13
IS 7
BP 838
EP 842
DI 10.1111/j.1399-3046.2008.01071.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 505CS
UT WOS:000270666600009
PM 19067912
ER

PT J
AU Gokce, S
   Durmaz, O
   Celtik, C
   Aydogan, A
   Bas, F
   Turkoglu, U
   Ozden, I
   Sokucu, S
AF Gokce, Selim
   Durmaz, Ozlem
   Celtik, Coskun
   Aydogan, Aysen
   Bas, Firdevs
   Turkoglu, Umit
   Ozden, Ilgin
   Sokucu, Semra
TI Investigation of impaired carbohydrate metabolism in pediatric liver
   transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; immunsuppressive treatment; steroids;
   complications; risk factors
ID POSTTRANSPLANT DIABETES-MELLITUS; RENAL-ALLOGRAFT RECIPIENTS;
   INSULIN-RESISTANCE; GLUCOSE-METABOLISM; RISK-FACTORS; CHILDREN;
   CYCLOSPORINE; TACROLIMUS; IMMUNOSUPPRESSION; HYPERINSULINISM
AB OGTT was performed in 28 liver transplants maintained with tacrolimus to investigate carbohydrate metabolism and assess risk factors for development of PTDM. None had PTDM that was detected by OGTT. Early PTDM in four cases (14.3%) resolved in follow-up. Five new cases (17.9%) demonstrated DCM (DCM = IGT +/- hyperinsulinemia). Fasting measurements were normal in two hyperinsulinemic cases. With one (20%, p > 0.05) exception none of the children with DCM were overweight or had a family history of diabetes. All five (100%) children with DCM had been given high cumulative dosage of steroids 18 (78.3%) - without DCM (p > 0.05). The median age of children with DCM was greater [4.3 (12.7-18.0) vs. 7.0 (2.3-18.0) yr, p < 0.01] and duration of follow-up longer [5.3 (2.3-7.0) vs. 2.5 (0.7-7.3) yr, p < 0.05]. Four children (80%) with DCM were pubertal (p < 0.05). However, neither age nor duration of follow-up or pubertal stage had significant effect on DCM development. Early PTDM is a transient phenomenon and is not predictive for future development of diabetes. DCM is frequently observed in liver transplanted children. Albeit the children with DCM were given high cumulative dose of steroids, were older, mostly were pubertal, and had longer duration of follow-up, we cannot draw firm conclusions on effects of the risk factors on carbohydrate metabolism because of the small sample size and relatively short duration of follow-up. Unlike fasting measurements, OGTT can detect all children with DCM.
C1 [Gokce, Selim; Durmaz, Ozlem; Celtik, Coskun; Aydogan, Aysen; Sokucu, Semra] Istanbul Univ, Istanbul Med Sch, Dept Pediat Gastro Hepatol & Nutr, Istanbul, Turkey.
   [Bas, Firdevs] Istanbul Univ, Istanbul Med Sch, Dept Pediat Endocrinol, Istanbul, Turkey.
   [Turkoglu, Umit] Istanbul Univ, Istanbul Med Sch, Dept Pediat, Istanbul, Turkey.
   [Ozden, Ilgin] Istanbul Univ, Istanbul Med Sch, Dept Gen Surg, Hepatopancreaticobiliary Unit, Istanbul, Turkey.
RP Sokucu, S (reprint author), Istanbul Univ, Istanbul Med Sch, Dept Pediat Gastro Hepatol & Nutr, Istanbul, Turkey.
EM semraso@hotmail.com
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   American Diabetes Association Report of the expert committee on the diagnosis and classification of diabetes mellitus, 2003, DIABETES CARE, V26, P5
   ARNER P, 1983, DIABETES CARE, V6, P23, DOI 10.2337/diacare.6.1.23
   ARSLANIAN SA, 1994, DIABETES, V43, P908, DOI 10.2337/diabetes.43.7.908
   Baid S, 2001, TRANSPLANTATION, V72, P1066, DOI 10.1097/00007890-200109270-00015
   BOUDREAUX JP, 1987, TRANSPLANTATION, V44, P376, DOI 10.1097/00007890-198709000-00010
   Cosio FG, 2001, KIDNEY INT, V59, P732, DOI 10.1046/j.1523-1755.2001.059002732.x
   Depczynski B, 2000, DIABETIC MED, V17, P15, DOI 10.1046/j.1464-5491.2000.00206.x
   Dietz WH, 1998, J PEDIATR-US, V132, P191
   Genuth S, 2003, DIABETES CARE, V26, P3160
   Giordano M, 2006, J ENDOCRINOL INVEST, V29, P330
   Glaser NS, 1998, WESTERN J MED, V168, P11
   Goran MI, 2001, DIABETES, V50, P2444, DOI 10.2337/diabetes.50.11.2444
   Greenspan LC, 2002, PEDIATR NEPHROL, V17, P1
   Harris SB, 1996, CAN FAM PHYSICIAN, V42, P869
   HATHOUT E, 2007, PEDIAT TRANSPLANT, V30
   HIMES JH, 1994, AM J CLIN NUTR, V59, P307
   Jain A, 2000, TRANSPLANTATION, V70, P617, DOI 10.1097/00007890-200008270-00015
   Jain A, 1998, TRANSPLANT P, V30, P1403, DOI 10.1016/S0041-1345(98)00290-5
   John PR, 2002, LIVER TRANSPLANT, V8, P708, DOI 10.1053/jlts.2002.34638
   Kasiske BL, 2003, AM J TRANSPLANT, V3, P178, DOI 10.1034/j.1600-6143.2003.00010.x
   KNOEBLER H, 1998, J CLIN GASTROENTEROL, V26, P30
   Kuczmarski RJ, 2000, ADV DATA, V1, P27
   MARUHAMA Y, 1981, DIABETES, V30, P14, DOI 10.2337/diabetes.30.1.14
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Miles AMV, 1998, TRANSPLANTATION, V65, P380, DOI 10.1097/00007890-199802150-00014
   Montori VM, 2002, DIABETES CARE, V25, P583, DOI 10.2337/diacare.25.3.583
   Navasa M, 1996, J HEPATOL, V25, P64, DOI 10.1016/S0168-8278(96)80329-1
   Prokai A, 2008, PEDIATR TRANSPLANT, V12, P643, DOI 10.1111/j.1399-3046.2007.00862.x
   REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P46
   Sheiner PA, 2000, TRANSPLANTATION, V69, P781
   Steinmuller T, 2000, EXP CLIN ENDOCR DIAB, V108, P401, DOI 10.1055/s-2000-8136
   SUMRANI NB, 1991, TRANSPLANTATION, V51, P343, DOI 10.1097/00007890-199102000-00014
   Trail K C, 1996, Liver Transpl Surg, V2, P276, DOI 10.1002/lt.500020405
   Tueche SG, 2003, TRANSPLANT P, V35, P1466, DOI 10.1016/S0041-1345(03)00528-1
   Weir MR, 1999, AM J KIDNEY DIS, V34, P1, DOI 10.1016/S0272-6386(99)70101-0
   *WORLD MED ASS DEC, ETH PRINC MED RES IN
   ZANNOLLI R, 1993, AM J DIS CHILD, V147, P837
   [Anonymous], 1994, N ENGL J MED, V331, P1110
   [Anonymous], 1994, LANCET, V344, P423
NR 40
TC 1
Z9 1
U1 1
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2009
VL 13
IS 7
BP 873
EP 880
DI 10.1111/j.1399-3046.2008.01076.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 505CS
UT WOS:000270666600015
PM 19037912
ER

PT J
AU Faraci, M
   Cappelli, B
   Lanino, E
   Morreale, G
   Fioredda, F
   Giudice, CL
   Giacchino, R
AF Faraci, M.
   Cappelli, B.
   Lanino, E.
   Morreale, G.
   Fioredda, F.
   Giudice, C. L.
   Giacchino, R.
TI Hepatitis B reactivation in allogeneic hemopoietic stem cell
   transplantation setting: A pediatric experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; HBV reactivation; HSCT
ID BONE-MARROW-TRANSPLANTATION; VIRUS-INFECTION; HEMATOLOGICAL
   MALIGNANCIES; LAMIVUDINE PROPHYLAXIS; LIVER-TRANSPLANTATION; RECEIVE
   CHEMOTHERAPY; CHILDREN; PREVENTION; IMMUNOGLOBULIN; CARRIERS
AB Reactivation of HBV is a well known complication in patients undergoing HSCT. Lamivudine treatment appears to prevent hepatitis B virus reactivation and to decrease the mortality in at risk HSCT patients. We describe HBV reactivation occurred in three allogeneic HSCT pediatric patients coming from Eastern Europe, one of whom was successfully treated with lamivudine. Our experience confirms that HBV-DNA may persist as intra-hepatic infection or in extra-hepatic sites and that HBV reactivation may appear during immunodepression. Careful and complete screening for HBV markers is mandatory before HSCT, especially in children coming from countries at risk for HBV. Furthermore, a treatment with lamivudine could also represent an efficacious prophylaxis in pediatric patients to avoid HBV reactivation and to decrease the development of severe hepatic disease.
C1 [Giacchino, R.] G Gaslini Childrens Hosp, Infect Dis Unit, Dept Hematol & Oncol, Genoa, Italy.
   [Faraci, M.; Cappelli, B.; Lanino, E.; Morreale, G.; Fioredda, F.] G Gaslini Childrens Hosp, Bone Marrow Transplant Unit, Genoa, Italy.
   [Giudice, C. L.] G Gaslini Childrens Hosp, Transfus Serv, Genoa, Italy.
RP Giacchino, R (reprint author), G Gaslini Childrens Hosp Largo, G Gaslini 5, I-16147 Genoa, Italy.
EM raffaellagiacchino@ospedale-gaslini.ge.it
FU Italian Ministry of Health
FX This work was partially supported by a grant from The Italian Ministry
   of Health "Ricerca Finalizzata - 2006."
CR Barclay S, 2008, J CLIN VIROL, V41, P243, DOI 10.1016/j.jcv.2007.11.017
   Ciesek S, 2008, J INFECT DIS, V197, P355, DOI 10.1086/525286
   El-Sayed MH, 2004, PEDIATR HEMAT ONCOL, V21, P145, DOI 10.1080/08880010490273019
   Gane EJ, 2007, GASTROENTEROLOGY, V132, P931, DOI 10.1053/j.gastro.2007.01.005
   Gigliotti AR, 2003, J PEDIAT HEMATOL ONC, V25, P184, DOI 10.1097/00043426-200303000-00002
   Gish RG, 2006, CLIN GASTROENTEROL H, V4, P666, DOI 10.1016/j.cgh.2006.03.017
   Hagmann S, 2003, CLIN INFECT DIS, V37, P1434, DOI 10.1086/378739
   Idilman R, 2005, J ANTIMICROB CHEMOTH, V55, P828, DOI 10.1093/jac/dki114
   Jonas MM, 2002, NEW ENGL J MED, V346, P1706, DOI 10.1056/NEJMoa012452
   Katz LH, 2008, J VIRAL HEPATITIS, V15, P89, DOI 10.1111/j.1365-2893.2007.00902.x
   Lalazar G, 2007, BRIT J HAEMATOL, V136, P699, DOI 10.1111/j.1365-2141.2006.06465.x
   Lau GKK, 2002, BLOOD, V99, P2324, DOI 10.1182/blood.V99.7.2324
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Li YH, 2006, CANCER, V106, P1320, DOI 10.1002/cncr.21701
   LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839
   LYKAVIERIS P, 1993, J PEDIATR GASTR NUTR, V16, P321, DOI 10.1097/00005176-199304000-00018
   Marzano A, 2007, DIGEST LIVER DIS, V39, P397, DOI 10.1016/j.dld.2006.12.017
   SHAPIRA R, 2001, TRANSPLANTATION, V27, P333
   Tavil B, 2006, PEDIATR TRANSPLANT, V10, P966, DOI 10.1111/j.1399-3046.2006.00570.x
   Yeo W, 2003, J MED VIROL, V70, P553, DOI 10.1002/jmv.10430
   Yeung LTF, 2002, BONE MARROW TRANSPL, V30, P459, DOI 10.1038/sj.bmt.1703675
   Yim HJ, 2006, HEPATOLOGY, V43, pS173, DOI 10.1002/hep.20956
NR 22
TC 3
Z9 3
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2009
VL 13
IS 7
BP 923
EP 926
DI 10.1111/j.1399-3046.2008.01080.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 505CS
UT WOS:000270666600023
PM 19032422
ER

PT J
AU Perera, MTPR
   Silva, MA
   Sharif, K
   McKiernan, PJ
   Kelly, DA
   Lloyd, C
   Milford, DV
   Mayer, DA
   Mirza, DF
AF Perera, M. Thamara P. R.
   Silva, Michael A.
   Sharif, Khalid
   McKiernan, Patrick J.
   Kelly, Deirdre A.
   Lloyd, Carla
   Milford, David V.
   Mayer, David A.
   Mirza, Darius F.
TI Improved Outcomes of Combined Liver and Kidney Transplants in Small
   Children (< 15 kg)
SO TRANSPLANTATION
LA English
DT Article
DE Multiorgan transplant; Bile leak; Vascular thrombosis; Small children;
   Graft failure
ID THAN 15 KG; THROMBOSIS; INFANTS
AB Background. Combined liver and kidney transplantation (CLKT) is a surgical challenge in small children because of technical aspects, lack of pediatric donors, and restrictions related to the size of the abdominal cavity. We report outcomes after CLKT in this challenging group of smaller children.
   Method. A review of prospective data on all children undergoing CLKT at the Birmingham Children's Hospital between 1994 and 2008 was performed. An analysis of perioperative data, complications, and survival in children less than 15 kg was carried out, with figures expressed as median (range) and compared with that of children more than 15 kg.
   Results. A total of 23 children underwent CLKT (14 male [61%] and age 8.6 [1.6-16.7] years), of which 8 (35%) were less than or equal to 15 kg, median age 2.2 (1.6-5.4) years, weight 11.6 (9.1-14.9) kg, and height 76 (66-95) cm, followed up for a median 26 (12-126) months. Donor details included age 13 (3-40) years, weight 60 (15-78) kg, and height 156 (83-168) cm. The median donor-to-recipient weight ratio was 4.8 compared with 1.7 for larger children. The median waiting time was 291 (48-523) compared with 150 (6-455) days for children more than 15 kg. Four of eight (50%) children received preoperative renal support, when compared with 10 of 16 (62%) children more than 15 kg. The intensive care unit and inpatient stay was 2 (2-22) days and 25 (19-93) days, respectively. Mortality was seen in one of eight because of sepsis and multiorgan failure. When compared with children more than 15 kg, survival figures at I and 2 years were 87% versus 93% and 78%, respectively.
   Conclusions. CLKT in small children results in comparable outcomes despite challenges related to donor-recipient size mismatch and longer waiting times. Consequently, body size/stature should not be a limiting factor for multiorgan transplantation.
C1 [Perera, M. Thamara P. R.; Silva, Michael A.; Mayer, David A.; Mirza, Darius F.] Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, W Midlands, England.
   [Sharif, Khalid; McKiernan, Patrick J.; Kelly, Deirdre A.; Lloyd, Carla; Mayer, David A.; Mirza, Darius F.] Birmingham Childrens Hosp, Liver Unit, Birmingham, W Midlands, England.
   [Milford, David V.] Birmingham Childrens Hosp, Nephrol Unit, Birmingham, W Midlands, England.
RP Mirza, DF (reprint author), Univ Hosp Birmingham NHS Trust, Queen Elizabeth Hosp, Liver Unit, Nuffield House 3rd Floor, Birmingham B15 2TH, W Midlands, England.
EM darius.mirza@uhb.nhs.uk
RI Perera, Thamara/D-2758-2009
CR Burdelski M, 1999, EUR J PEDIATR, V158, pS34, DOI 10.1007/PL00014322
   Fangmann J, 1996, Transpl Int, V9 Suppl 1, pS73, DOI 10.1111/j.1432-2277.1996.tb01690.x
   Fontana I, 2008, TRANSPL P, V40, P2065, DOI 10.1016/j.transproceed.2008.05.020
   Furness PD, 2001, J UROLOGY, V166, P1042, DOI 10.1016/S0022-5347(05)65915-0
   Klassen AC, 1998, MED CARE, V36, P281, DOI 10.1097/00005650-199803000-00006
   MARGREITER R, 1984, LANCET, V1, P1077
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Neipp M, 2002, TRANSPLANTATION, V73, P409, DOI 10.1097/00007890-200202150-00015
   Nguan CYC, 2007, AM J SURG, V193, P119, DOI 10.1016/j.amjsurg.2006.03.008
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Oswari H, 2005, J GASTROEN HEPATOL, V20, P1850, DOI 10.1111/j.1440-1746.2005.03926.x
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   Singh A, 1997, TRANSPLANTATION, V63, P1263, DOI 10.1097/00007890-199705150-00012
   STRONG R, 1988, SURGERY, V104, P104
   Van der Werf WJ, 1998, J PEDIATR SURG, V33, P20, DOI 10.1016/S0022-3468(98)90353-0
   VOGEL W, 1988, TRANSPLANTATION, V45, P491, DOI 10.1097/00007890-198802000-00050
NR 17
TC 10
Z9 10
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD SEP 15
PY 2009
VL 88
IS 5
BP 711
EP 715
DI 10.1097/TP.0b013e3181b29f0c
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 493MO
UT WOS:000269741200017
PM 19741470
ER

PT J
AU Dehghani, SM
   Eshraghian, A
   Bahador, A
   Kakaei, F
   Geramizadek, B
   Malek-Hosseini, SA
AF Dehghani, Seyed Mohsen
   Eshraghian, Ahad
   Bahador, Ali
   Kakaei, Farzad
   Geramizadek, Bita
   Malek-Hosseini, Seyed Ali
TI De Novo Inflammatory Bowel Disease After Pediatric Orthotopic Liver
   Transplant: A Case Report
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE Ulcerative colitis; Liver transplant; Children
ID PRIMARY SCLEROSING CHOLANGITIS; COMPLICATIONS FOLLOWING TRANSPLANTATION;
   ULCERATIVE-COLITIS; CROHNS-DISEASE; IMMUNOSUPPRESSION; MANAGEMENT;
   RECIPIENTS; ETIOLOGY; DIARRHEA
AB Objectives: The improvement of pre-existing inflammatory bowel disease after orthotopic liver transplant might be anticipated. However, both the exacerbation of inflammatory bowel disease and de novo inflammatory bowel disease after orthotopic liver transplant (despite sufficient allograft immunosuppressive therapy) have been described.
   Materials and Methods: We present a case of ulcerative colitis in a pediatric liver transplant recipient.
   Results: A 13-year-old boy with cryptogenic liver cirrhosis received an orthotopic liver transplant from a deceased donor. Five months later, he presented with watery diarrhea and abdominal distention. He was treated with the immunosuppressive agents tacrolimus (0.15 mg/kg/d) and mycophenolate mofetil (20 mg/kg/d). A general physical examination revealed a boy with stable vital signs and without fever. The only positive finding was enlargement of the abdomen without tenderness. Many pus cells and a few red blood cells were detected in the patient's stool, but the results of a stool culture for bacteria were negative. Because of his chronic diarrhea, this patient underwent colonoscopy, which revealed diffuse erythematous mucosa, multiple ulcers, exudate, and pseudopolyps with a diffuse loss of vascularity. Those findings are indicators of colitis. The results of histopathologic examination of the colonic mucosa suggested ulcerative colitis. The patient was treated with mesalamine and prednisolone, and a repeat colonoscopy revealed an improvement in his bowel disease.
   Conclusions: De novo inflammatory bowel disease should be considered in patients in whom chronic diarrhea develops after an orthotopic liver transplant. We suggest that colonoscopy and biopsy should always be performed if other causes of diarrhea have been excluded.
C1 [Dehghani, Seyed Mohsen] Shiraz Univ Med Sci, Gastroenterohepatol Res Ctr, Shiraz Transplant Res Ctr, Nemazee Hosp, Shiraz 7193711351, Iran.
RP Dehghani, SM (reprint author), Shiraz Univ Med Sci, Gastroenterohepatol Res Ctr, Shiraz Transplant Res Ctr, Nemazee Hosp, Shiraz 7193711351, Iran.
EM dehghanism@sums.ac.ir
OI Kakaei, Farzad/0000-0003-1632-7393
CR Altiparmak MR, 2002, CLIN TRANSPLANT, V16, P212, DOI 10.1034/j.1399-0012.2002.01129.x
   Befeler AS, 1998, TRANSPLANTATION, V65, P393, DOI 10.1097/00007890-199802150-00017
   Chalasani N, 1998, AM J GASTROENTEROL, V93, P481
   Cuoco L, 1997, AM J GASTROENTEROL, V92, P2134
   Ginsburg PM, 2005, LIVER TRANSPLANT, V11, P881, DOI 10.1002/lt.20500
   Haagsma EB, 2003, ALIMENT PHARM THERAP, V18, P33, DOI 10.1046/j.0269-2813.2003.01613.x
   Helderman JH, 2001, CLIN TRANSPLANT, V15, P29, DOI 10.1111/j.1399-0012.2001.00029.x
   Khan S, 1999, J PEDIATR GASTR NUTR, V28, P206, DOI 10.1097/00005176-199902000-00023
   LARUSSO NF, 1984, NEW ENGL J MED, V310, P899, DOI 10.1056/NEJM198404053101407
   MACDONALD TT, 1994, BAILLIERE CLIN GASTR, V8, P1, DOI 10.1016/S0950-3528(06)80017-5
   Papadakis KA, 2004, GUT, V53, P1389, DOI 10.1136/gut.2004.042523
   Papatheodoridis GV, 1998, GUT, V43, P639
   Ramji A, 2002, DIGEST DIS SCI, V47, P522, DOI 10.1023/A:1017951632444
   Riley TR, 1997, AM J GASTROENTEROL, V92, P279
   Rubin RH, 2001, CLIN TRANSPLANT, V15, P11, DOI 10.1111/j.1399-0012.2001.00011.x
   SHAKED A, 1992, ANN SURG, V215, P598, DOI 10.1097/00000658-199206000-00006
   STEPHENS J, 1993, TRANSPLANT P, V25, P1122
   Van de Vrie W, 2003, EUR J GASTROEN HEPAT, V15, P657, DOI 10.1097/01.meg.0000059133.68845.f7
   Vu F, 2006, GASTROEN CLIN BIOL, V30, P1096, DOI 10.1016/S0399-8320(06)73484-4
   Wahbeh G, 2003, PEDIATR TRANSPLANT, V7, P464, DOI 10.1046/j.1399-3046.2003.00098.x
   Worns MA, 2006, AM J GASTROENTEROL, V101, P1931, DOI 10.1111/j.1572-0241.00624.x
NR 21
TC 4
Z9 4
U1 0
U2 3
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD SEP
PY 2009
VL 7
IS 3
BP 145
EP 148
PG 4
WC Transplantation
SC Transplantation
GA 496YW
UT WOS:000270017400002
PM 19715523
ER

PT J
AU Liu, CS
   Loong, CC
   Hsia, CY
   Peng, CK
   Tsai, HL
   Tsou, MY
   Wei, CF
AF Liu, Chinsu
   Loong, Che-Chuan
   Hsia, Cheng-Yuan
   Peng, Cheng-Kang
   Tsai, Hsin-Lin
   Tsou, Mei-Yung
   Wei, Choufu
TI Duct-to-duct biliary reconstruction in selected cases in pediatric
   living-donor left-lobe liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary reconstruction; duct-to-duct anastomosis;
   living-donor-left-lobe; liver transplantation; pediatric
AB The feasibility of D-D biliary reconstruction in pediatric LDLT using left-lobe graft has been discussed in few reports. The use of a trans-anastomotic biliary tube seemed to be the favorable method to avoid the complications according to these reports. We had performed left-lobe LDLT for seven pediatric cases and D-D was done originally. Three cases were converted to R-Y hepaticojejunostomy due to radical resection of hepatoduodenal ligament (n = 1) and severe kinking of D-D (n = 2). Four cases received D-D using 6-0 PDS interrupted sutures without external stent tube. One D-D case died of intra-cerebral hemorrhage 10 days after operation with a functioning graft. There was one biliary leakage in a D-D patient who required PTCD stent for 4 months without any sequale. From our limited experience, D-D biliary reconstruction without external stent tube in left-lobe LDLT is feasible in certain pediatric cases having normal extra-hepatic bile ducts. In smaller recipient with larger graft, the use of a trans-anastomotic biliary tube can prevent anastomotic kinking although we suggest R-Y biliary reconstruction is better for this condition.
C1 [Tsou, Mei-Yung] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei 11217, Taiwan.
   [Peng, Cheng-Kang] Natl Yang Ming Univ, Sch Med, Dept Surg, Div Plast Surg, Taipei 112, Taiwan.
   [Loong, Che-Chuan; Hsia, Cheng-Yuan] Natl Yang Ming Univ, Sch Med, Dept Surg, Div Gen Surg, Taipei 112, Taiwan.
   [Liu, Chinsu; Tsai, Hsin-Lin; Wei, Choufu] Natl Yang Ming Univ, Sch Med, Dept Surg, Div Pediat Surg, Taipei 112, Taiwan.
RP Liu, CS (reprint author), Taipei Vet Gen Hosp, Dept Surg, Div Pediat Surg, 201 Sec 2,Shih Pai Rd, Taipei 11217, Taiwan.
EM csliu@vghtpe.gov.tw
CR Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kimura T, 2006, PEDIATR TRANSPLANT, V10, P248, DOI 10.1111/j.1399-3046.2005.00430.x
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Sakamoto S, 2008, PEDIATR TRANSPLANT, V12, P661, DOI 10.1111/j.1399-3046.2007.00870.x
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
NR 8
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2009
VL 13
IS 6
BP 693
EP 696
DI 10.1111/j.1399-3046.2008.01040.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 481FW
UT WOS:000268793800006
PM 19067924
ER

PT J
AU Bahador, A
   Salahi, H
   Nikeghbalian, S
   Dehghani, SM
   Dehghani, M
   Kakaei, F
   Kazemi, K
   Rajaei, E
   Gholami, S
   Malek-Hosseini, SA
AF Bahador, A.
   Salahi, H.
   Nikeghbalian, S.
   Dehghani, S. M.
   Dehghani, M.
   Kakaei, F.
   Kazemi, K.
   Rajaei, E.
   Gholami, S.
   Malek-Hosseini, S. A.
TI Pediatric Liver Transplantation in Iran: A 9-Year Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th Congress of the Middle-East-Society-for-Organ-Transplantation
CY NOV 17-20, 2008
CL Shiraz, IRAN
ID SINGLE-CENTER; RECIPIENTS; CHILDREN
AB Background. Liver transplantation (OLT) is accepted as the standard therapy for end-stage liver disease. The current shortage of organ donors has led to the use of split grafts and living related donors to provide timely liver transplants for these children. Herein we have reported our experience with pediatric OLT over a 9-year period.
   Materials and methods. We retrospectively studied 138 infants and children who underwent OLT from April 1999 to August 2008 including pretransplantation status, medical and surgical complications, and survival.
   Results. There were 83 (60.1%) boys and 55 (39.9%) girls. The mean patient age was 9.1 +/- 5.6 years (range = 0.5-18) with a mean weight of 28.1 +/- 17.0 kg (range = 7-80). The main indications were Wilson's disease (20.3%); cryptogenic cirrhosis (16.7%); autoimmune cirrhosis (14.5%); biliary atresia (13.8%); tyrosinemia (9.4%); and progressive familial intrahepatic cholestasis (8.7%). We used living related donors in 54 (39.1%) and split livers in 20 (14.5%) cases with 64 (46.4%) patients receiving a whole liver from a deceased donor. The mean follow-up was 25.3 +/- 20.3 months (range = 1-100). The mortality rate was 27.5% with a 26.1% in-hospital mortality. The main causes of mortality were vascular complications (32.6%); primary nonfunction (1.9.6%); sepsis (17.4%); chronic rejection (17.4%); and biliary complications (6.5%). The mortality rate among patients under 10 kg (58.8%) was higher than that of patients over 10 kg (23.1%). Among those patients who were discharged from the hospital (73.9%), the most common cause of mortality was chronic rejection from noncompliance (n = 4), chronic rejection (n = 3 cases), or posttransplant lymphoproliferative disease (n = 2).
   Conclusion. Our results demonstrated that pediatric OLT is a feasible undertaking in Iran. The organ shortage in our area led to liberal use of living related and split-liver techniques. The overall results of pediatric OLT in Iran were acceptable.
C1 [Bahador, A.; Salahi, H.; Nikeghbalian, S.; Dehghani, S. M.; Dehghani, M.; Kakaei, F.; Kazemi, K.; Rajaei, E.; Gholami, S.; Malek-Hosseini, S. A.] Shiraz Univ Med Sci, Shiraz Transplant Ctr, Dept Hepatobiliary & Transplantat Surg, Shiraz, Iran.
RP Kakaei, F (reprint author), Namazi Hosp, Shiraz Transplant Ctr, Namazi Sq, Shiraz 7193711351, Iran.
EM fkakaei@yahoo.com
OI Kakaei, Farzad/0000-0003-1632-7393
CR ARIKAN C, 2002, TRANSPLANTATION S, V74, P3526
   Aydogdu S, 2005, PEDIATR TRANSPLANT, V9, P723, DOI 10.1111/j.1399-3046.2005.00366.x
   Balistreri WF, 1998, LIVER TRANSPLANT SUR, V4, pS18
   Bonanno AP, 2008, TRANSPL P, V40, P720, DOI 10.1016/j.transproceed.2008.02.068
   Brolese A, 2007, TRANSPL P, V39, P1939, DOI 10.1016/j.transproceed.2007.05.041
   D'Alessandro AM, 2007, PEDIATR TRANSPLANT, V11, P661, DOI 10.1111/j.1399-3046.2007.00737.x
   Mesquita MCD, 2008, J PEDIAT, V84, P395, DOI 10.2223/JPED.1810
   Dehghani SM, 2008, PEDIATR TRANSPLANT, V12, P146, DOI 10.1111/j.1399-3046.2007.00829.x
   Dehghani SM, 2007, PEDIATR TRANSPLANT, V11, P256, DOI 10.1111/j.1399-3046.2006.00665.x
   Ganschow R, 2000, Pediatr Transplant, V4, P273, DOI 10.1034/j.1399-3046.2000.00127.x
   Garcia S, 1998, CLIN TRANSPLANT, V12, P190
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Guariso G, 2007, PEDIATR TRANSPLANT, V11, P755, DOI 10.1111/j.1399-3046.2007.00739.x
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Muiesan P, 2007, J HEPATOL, V46, P340, DOI 10.1016/j.jhep.2006.11.006
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   ROGIERS MX, 1994, TRANSPL P, V6, P3620
NR 18
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD SEP
PY 2009
VL 41
IS 7
BP 2864
EP 2867
DI 10.1016/j.transproceed.2009.07.046
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 500HB
UT WOS:000270288400048
PM 19765458
ER

PT J
AU Nikeghbalian, S
   Nejatollahi, SM
   Salahi, H
   Bahador, A
   Dehghani, SM
   Kazemi, K
   Dehghani, M
   Kakaei, F
   Ghaffaripour, S
   Sattari, H
   Gholami, S
   Anvari, E
   Malek-Hosseini, SA
AF Nikeghbalian, S.
   Nejatollahi, S. M.
   Salahi, H.
   Bahador, A.
   Dehghani, S. M.
   Kazemi, K.
   Dehghani, M.
   Kakaei, F.
   Ghaffaripour, S.
   Sattari, H.
   Gholami, S.
   Anvari, E.
   Malek-Hosseini, S. A.
TI Experience of Living Donor Liver Transplantation in Iran: A
   Single-Center Report
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th Congress of the Middle-East-Society-for-Organ-Transplantation
CY NOV 17-20, 2008
CL Shiraz, IRAN
ID RIGHT LOBE GRAFTS; COMPLICATIONS; MORBIDITY; OUTCOMES; MARS;
   HEPATECTOMY; FAILURE; LESSONS; SYSTEM
AB Background. Living donor liver transplantation (LDLT) has been accepted as a valuable treatment for patients with end-stage liver disease seeking to overcome the shortage of organs and the waiting list mortality. The aim of this study was to report our experience with LDLT.
   Methods. We retrospectively analyzed 50 LDLTs performed in our organ transplant center from January 1997 to March 2008. We reviewed the demographic data, family history, operative and hospital stay durations as well as postoperation complications among donors and recipients. We also performed a retrospective analysis of recipient chemical and biochemical data.
   Results. Among 50 patients (30 males and 20 females) of overall mean age of 7.21 +/- 5.35 who underwent LDLT (10 right lobe, 38 left lobe, and 2 left lateral segments), 47 received a liver graft from their parent, two from a brother, and one from an uncle. The most common indications for LDLT were end-stage liver disease due to Wilson's disease (16%), cryptogenic cirrhosis (16%), tyrosinemia (14%), biliary atresia (12%), autoimmune hepatitis (12%), and progressive familial intrahepatic cholestasis (12%). The mean follow-up was 16.91 +/- 23.74 months. There were 13 (26%) recipient mortalities including vascular complications; three to sepsis after bowel perforation, two from liver dysfunction, two from chronic rejection due to noncompliance, and one from diffuse aspergillosis. The morbidity rate was 50%, including 19 reexplorations during the hospital course and five biliary complications.
   Conclusion. This study demonstrated that LDLT can decrease the number of patients awaiting liver transplantation especially in the pediatric group. However, because of relatively high mortality and morbidity, we must improve our treatment outcomes.
C1 [Nikeghbalian, S.; Nejatollahi, S. M.; Salahi, H.; Bahador, A.; Dehghani, S. M.; Kazemi, K.; Dehghani, M.; Kakaei, F.; Ghaffaripour, S.; Sattari, H.; Gholami, S.; Anvari, E.; Malek-Hosseini, S. A.] Shiraz Univ Med Sci, Shiraz Transplant Ctr, Dept Hepatobiliary & Transplantat Surg, Shiraz, Iran.
RP Kakaei, F (reprint author), Namazi Hosp, Shiraz Transplant Ctr, Namazi Sq, Shiraz 7193711351, Iran.
EM fkakaei@yahoo.com
RI Ghaffaripour, Sina/H-4552-2011; 
OI Kakaei, Farzad/0000-0003-1632-7393; anvari, enayat/0000-0001-7508-071X
CR Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443
   Broelsch CE, 2000, LIVER TRANSPLANT, V6, pS64, DOI 10.1053/jlts.2000.19015
   Broering DC, 2004, ANN SURG, V240, P1013, DOI 10.1097/01.sla.0000146146.97485.6c
   Chan SC, 2007, ANN SURG, V245, P110, DOI 10.1097/01.sla.0000225085.82193.08
   Fan ST, 2000, ANN SURG, V231, P126, DOI 10.1097/00000658-200001000-00018
   Fan ST, 2000, ARCH SURG-CHICAGO, V135, P336, DOI 10.1001/archsurg.135.3.336
   Fujita S, 2000, TRANSPLANT INT, V13, P333, DOI 10.1111/j.1432-2277.2000.tb01006.x
   Grewal HP, 1998, ANN SURG, V228, P214, DOI 10.1097/00000658-199808000-00011
   Hwang S, 2006, LIVER TRANSPLANT, V12, P920, DOI 10.1002/lt.20734
   Ito T, 2003, TRANSPLANTATION, V76, P158, DOI 10.1097/01.TP.0000072372.42396.47
   Lo CM, 1997, ANN SURG, V226, P261, DOI 10.1097/00000658-199709000-00005
   Marcos A, 2000, LIVER TRANSPLANT, V6, P296, DOI 10.1053/lv.2000.6354
   Marcos A, 1999, TRANSPLANTATION, V68, P798, DOI 10.1097/00007890-199909270-00012
   Mitzner SR, 2000, LIVER TRANSPLANT, V6, P277, DOI 10.1053/lv.2000.6355
   Morioka D, 2007, ANN SURG, V245, P315, DOI 10.1097/01.sla.0000236600.24667.a4
   Nadalin S, 2006, HPB (Oxford), V8, P10, DOI 10.1080/13651820500465626
   Novelli G, 2002, LIVER, V22, P43, DOI 10.1034/j.1600-0676.2002.00008.x
   Ohkohchi N, 1998, TRANSPLANT P, V30, P3218, DOI 10.1016/S0041-1345(98)01002-1
   Pomfret EA, 2003, LIVER TRANSPLANT, V9, pS45, DOI 10.1053/jlts.2003.50231
   Shah SA, 2005, AM J TRANSPLANT, V5, P2764, DOI 10.1111/j.1600-6143.2005.01094.x
   Sorkine P, 2001, CRIT CARE MED, V29, P1332, DOI 10.1097/00003246-200107000-00006
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Wachs ME, 1998, TRANSPLANTATION, V66, P1313, DOI 10.1097/00007890-199811270-00008
NR 23
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD SEP
PY 2009
VL 41
IS 7
BP 2868
EP 2871
DI 10.1016/j.transproceed.2009.07.009
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 500HB
UT WOS:000270288400049
PM 19765459
ER

PT J
AU Bahador, A
   Salahi, H
   Nikeghbalian, S
   Dehghani, SM
   Kakaei, F
   Sabet, B
   Kazemi, K
   Rajaei, E
   Gholami, S
   Malek-Hosseini, SA
AF Bahador, A.
   Salahi, H.
   Nikeghbalian, S.
   Dehghani, S. M.
   Kakaei, F.
   Sabet, B.
   Kazemi, K.
   Rajaei, E.
   Gholami, S.
   Malek-Hosseini, S. A.
TI Split Liver Transplantation in Shiraz Transplant Center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 11th Congress of the Middle-East-Society-for-Organ-Transplantation
CY NOV 17-20, 2008
CL Shiraz, IRAN
ID ONE DONOR LIVER; EXPERIENCE
AB Background. Cadaveric organ splitting emerged from an improved understanding of the surgical anatomy of the liver as a possible mechanism to expand the organ pool. In this study, we have reported our first series of split liver transplantations (SLT).
   Materials and Methods. From June 2006 to June 2008, we performed 17 pairs of SLT: 70.6% ex situ and 29.4% in situ. The mean age of the donors (32 males, 2 females) was 23.15 +/- 9 years. All of them had been stable at the time of harvest according to vital signs, liver function tests, electrolytes, and urine output. The decision on splitting was made by the surgical team according to the donor's status and the urgency of the recipient.
   Results. The main indications were biliary atresia (17.6%) followed by Wilson disease (14.7%) and cryptogenic cirrhosis (14.7%). The left lateral segment and the left lobe were used in 6 and 11 cases, respectively. In-hospital mortalities for the pediatric and adult groups were 68.4% and 26.7%, respectively. Primary graft nonfunction (52.9%), vascular complications (29.4%), sepsis (11.8%), and biliary complications (5.9%) were the main causes of mortality.
   Conclusion. Our experience indicated that SLT showed a high rate of mortality and morbidity.
C1 [Bahador, A.; Salahi, H.; Nikeghbalian, S.; Dehghani, S. M.; Kakaei, F.; Sabet, B.; Kazemi, K.; Rajaei, E.; Gholami, S.; Malek-Hosseini, S. A.] Shiraz Univ Med Sci, Shiraz Transplant Ctr, Dept Hepatobiliary & Transplantat Surg, Shiraz, Iran.
RP Nikeghbalian, S (reprint author), Namazi Hosp, Shiraz Transplant Ctr, Namazi Sq, Shiraz 7193711351, Iran.
EM nikeghbals@gmail.com
OI Kakaei, Farzad/0000-0003-1632-7393
CR Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723
   BISMUTH H, 1982, WORLD J SURG, V6, P3
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   EMOND JC, 1990, ANN SURG, V212, P14
   Gruttadauria S, 2005, TRANSPLANT P, V37, P2567, DOI 10.1016/j.transproceed.2005.06.020
   Malek Hosseini S A, 1995, Transplant Proc, V27, P2618
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   PINNA AD, 1997, TRANSPL P, V29, P617
   Renz JF, 2004, ANN SURG, V239, P172, DOI 10.1097/01.sla.0000109150.89438.bd
   Tisone G, 2004, TRANSPLANT P, V36, P525, DOI 10.1016/j.transproceed.2004.02.022
NR 11
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD SEP
PY 2009
VL 41
IS 7
BP 2872
EP 2874
DI 10.1016/j.transproceed.2009.07.052
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 500HB
UT WOS:000270288400050
PM 19765460
ER

PT J
AU Stewart, ZA
   Locke, JE
   Montgomery, RA
   Singer, AL
   Cameron, AM
   Segev, DL
AF Stewart, Zoe A.
   Locke, Jayme E.
   Montgomery, Robert A.
   Singer, Andrew L.
   Cameron, Andrew M.
   Segev, Dorry L.
TI ABO-Incompatible Deceased Donor Liver Transplantation in the United
   States: A National Registry Analysis
SO LIVER TRANSPLANTATION
LA English
DT Article
ID BLOOD-GROUP BARRIERS; HEART-TRANSPLANTATION; CHILDREN; RISK;
   COMPLICATIONS; AGE; IMMUNOSUPPRESSION; PLASMAPHERESIS; IMPUTATION;
   RECIPIENTS
AB In the United States, ABO-incompatible liver transplantation (ILT) is limited to emergent situations when ABO-compatible liver transplantation (CLT) is unavailable. We analyzed the United Network for Organ Sharing database of ILT performed from 1990-2006 to assess ILT outcomes for infant (0-1 years; N = 156), pediatric (2-17 years; N = 170), and adult (> 17 years; N = 667) patients. Since 2000, the number of ILT has decreased annually, and there has been decreased use of blood type B donors and increased use of blood type A donors. Furthermore, ILT graft survival has improved for all age groups in recent years, beyond the improved graft survival attributable to era effect based on comparison to respective age group CLT. On matched control analysis, graft survival was significantly worse for adult ILT as compared to adult CLT. However, infant and pediatric ILTs did not have worse graft survival versus age-matched CLT. Adjusted analyses identified age-specific characteristics impacting ILT graft loss. For infants, transplant after 2000 and donor age < 9 years were associated with reduced risk of ILT graft loss. For pediatric patients, female recipient sex and donor age > 50 years were associated with increased risk of ILT graft loss. For adults, life support, repeat transplant, split grafts, and hepatocellular carcinoma were associated with increased risk of ILT graft loss. The current study identifies important trends in ILT in the United States in the modern immunosuppression era, as well as specific recipient, donor, and graft characteristics impacting ILT graft survival that could be utilized to guide ILT organ allocation in exigent circumstances. Liver Transpl 15:883-893, 2009. (C) 2009 AASLD.
C1 [Stewart, Zoe A.; Locke, Jayme E.; Montgomery, Robert A.; Singer, Andrew L.; Cameron, Andrew M.; Segev, Dorry L.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
RP Segev, DL (reprint author), Johns Hopkins Univ, Sch Med, Dept Surg, Ross 771B,720 Rutland Ave, Baltimore, MD 21205 USA.
EM dorry@jhmi.edu
FU Health Resources and Services Administration [231-00-0115]
FX The UNOS National Data Registry is supported in part by Health Resources
   and Services Administration contract 231-00-0115. The analyses described
   here are the responsibility of the authors alone and do not necessarily
   reflect the views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the U.S. Government.
CR Ambler G, 2007, STAT METHODS MED RES, V16, P277, DOI 10.1177/0962280206074466
   Boyle JM, 2006, AM J KIDNEY DIS, V48, P787, DOI 10.1053/j.ajkd.2006.08.002
   Busquets J, 2007, J GASTROINTEST SURG, V11, P458, DOI 10.1007/s11605-007-0116-0
   DEMETRIS AJ, 1988, AM J PATHOL, V132, P489
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Eid A, 1998, TRANSPLANT P, V30, P701, DOI 10.1016/S0041-1345(98)00014-1
   Fan XH, 2004, NAT MED, V10, P1227, DOI 10.1038/nm1126
   FARGES O, 1995, TRANSPLANTATION, V59, P1124, DOI 10.1097/00007890-199504270-00009
   FERRIANI VPL, 1990, ACTA PAEDIATR SCAND, V79, P322, DOI 10.1111/j.1651-2227.1990.tb11464.x
   FISCHEL RJ, 1989, TRANSPLANT P, V21, P2221
   Fishbein TM, 1999, TRANSPLANTATION, V67, P1071, DOI 10.1097/00007890-199904150-00024
   FONG SW, 1974, TRANSFUSION, V14, P551
   GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S
   Hanto DW, 2003, LIVER TRANSPLANT, V9, P22, DOI 10.1053/jlts.2002.50011
   Heffron T, 2006, LIVER TRANSPLANT, V12, P972, DOI 10.1002/lt.20760
   Lang M, 2002, TRANSPLANT P, V34, P1501, DOI 10.1016/S0041-1345(02)02947-0
   LO CM, 1994, TRANSPLANTATION, V58, P543, DOI 10.1097/00007890-199409150-00003
   RENARD TH, 1992, TRANSPLANTATION, V53, P116, DOI 10.1097/00007890-199201000-00022
   RENARD TH, 1993, TRANSPLANT P, V25, P1953
   Royston Patrick, 2005, STATA J, V5, P527
   SANCHEZURDAZPAL L, 1993, ANN SURG, V218, P152, DOI 10.1097/00000658-199308000-00006
   Segev DL, 2007, HEPATOLOGY, V46, P1907, DOI 10.1002/hep.21888
   Skogsberg U, 2006, TRANSPLANT P, V38, P2667, DOI 10.1016/j.transproceed.2006.07.025
   Skogsberg U, 2006, XENOTRANSPLANTATION, V13, P154, DOI 10.1111/j.1399-3089.2006.00286.x
   Stegall M, 2003, LIVER TRANSPLANT, V9, P31, DOI 10.1053/jlts.2003.00000
   Toso C, 2007, TRANSPL INT, V20, P675, DOI 10.1111/j.1432-2277.2007.00492.x
   TRIULZI DJ, 1992, TRANSFUSION, V32, P829, DOI 10.1046/j.1537-2995.1992.32993110754.x
   van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015
   Varela-Fascinetto G, 1999, TRANSPLANT P, V31, P467, DOI 10.1016/S0041-1345(98)01711-4
   West LJ, 2001, NEW ENGL J MED, V344, P793, DOI 10.1056/NEJM200103153441102
   Yamada Y, 2006, J PEDIATR SURG, V41, P1976, DOI 10.1016/j.jpedsurg.2006.08.021
   YANDZA T, 1994, TRANSPLANTATION, V58, P46, DOI 10.1097/00007890-199407000-00009
   ZIMMERLI M, 1991, INFUSIONSTHERAPIE, V18, P91
NR 33
TC 23
Z9 33
U1 1
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2009
VL 15
IS 8
BP 883
EP 893
DI 10.1002/lt.21723
PG 11
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 480MO
UT WOS:000268739200009
PM 19642117
ER

PT J
AU Dehghani, SM
   Nikeghbalian, S
   Eshraghian, A
   Haghighat, M
   Imanieh, MH
   Bahador, A
   Kazemi, K
   Malek-Hosseini, SA
AF Dehghani, Seyed Mohsen
   Nikeghbalian, Saman
   Eshraghian, Ahad
   Haghighat, Mahmood
   Imanieh, Mohammad Hadi
   Bahador, Ali
   Kazemi, Kourosh
   Malek-Hosseini, Seyed Ali
TI New-onset diabetes mellitus presenting with diabetic ketoacidosis after
   pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; diabetes mellitus; diabetic ketoacidosis;
   tacrolimus
ID HEPATITIS-C; CYCLOSPORINE; IMMUNOSUPPRESSION; PREVENTION; FK506
AB The development of NODM is a common metabolic complication after liver transplantation. Presentation of post-liver transplant diabetes mellitus with DKA is rare especially among pediatric patients. We reported three pediatric patients who presented with DKA after liver transplantation. The underlying diseases leading to transplantation were cryptogenic liver cirrhosis, Wilson disease, and congenital hepatic fibrosis. None of the three patients had a history of diabetes prior to transplantation and all of them were cases of NODM after transplantation. All three patients presented with severe hyperglycemia, significant ketosis, and metabolic acidosis of variable severity. All of them received tacrolimus as one of the immunosuppressant agents. The patients received a liver transplant from a DD. The patients were treated with intravenous insulin injection (0.1 U/kg/h) and recovered from DKA, but one case expired in the intensive care unit because of bacterial sepsis after recovery from DKA. Our experience suggests that PTDM may result in ketoacidosis, and we emphasize the importance of paying more attention to glucose metabolism and risk of diabetes mellitus in patients with immunosuppressive therapy, especially tacrolimus.
C1 [Dehghani, Seyed Mohsen] Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Gastroenterohepatol Res Ctr, Nemazee Hosp, Shiraz 7193711351, Iran.
   [Dehghani, Seyed Mohsen; Haghighat, Mahmood; Imanieh, Mohammad Hadi] Shiraz Univ Med Sci, Nemazee Hosp, Dept Pediat Gastroenterol, Shiraz 7193711351, Iran.
RP Dehghani, SM (reprint author), Shiraz Univ Med Sci, Shiraz Transplant Res Ctr, Gastroenterohepatol Res Ctr, Nemazee Hosp, Shiraz 7193711351, Iran.
EM dehghanism@sums.ac.ir
CR AlDosary AA, 2002, LIVER TRANSPLANT, V8, P356, DOI 10.1053/jlts.2002.31745
   BENDING JJ, 1987, BRIT MED J, V294, P401
   Benhamou PY, 2002, DIABETES METAB, V28, P166
   Bigam DL, 2000, HEPATOLOGY, V32, P87, DOI 10.1053/jhep.2000.8270
   Bostom AD, 2002, AM J TRANSPLANT, V2, P491, DOI 10.1034/j.1600-6143.2002.20602.x
   Dehghani Seyed Mohsen, 2008, Indian J Gastroenterol, V27, P83
   Kasiske BL, 2003, AM J TRANSPLANT, V3, P178, DOI 10.1034/j.1600-6143.2003.00010.x
   Keshavarz R, 2002, PEDIATR EMERG CARE, V18, P22, DOI 10.1097/00006565-200202000-00007
   KRENTZ AJ, 1993, DIABETES, V42, P1753, DOI 10.2337/diabetes.42.12.1753
   LOERTCHER R, 1989, RENAL TRANSPLANTATIO, P219
   NEUHAUS P, 1994, LANCET, V344, P423
   ONWUBALILI JK, 1992, NEPHROL DIAL TRANSPL, V7, P346
   Saliba F, 2007, LIVER TRANSPLANT, V13, P136, DOI 10.1002/lt.21010
   Yoshida EM, 2000, TRANSPLANT INT, V13, P69, DOI 10.1111/j.1432-2277.2000.tb01039.x
NR 14
TC 11
Z9 12
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2009
VL 13
IS 5
BP 536
EP 539
DI 10.1111/j.1399-3046.2008.01117.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 467QD
UT WOS:000267756100005
PM 19207220
ER

PT J
AU Krebs-Schmitt, D
   Briem-Richter, A
   Grabhorn, E
   Burdelski, M
   Helmke, K
   Broering, DC
   Ganschow, R
AF Krebs-Schmitt, D.
   Briem-Richter, A.
   Grabhorn, E.
   Burdelski, M.
   Helmke, K.
   Broering, D. C.
   Ganschow, R.
TI Effectiveness of Rex shunt in children with portal hypertension
   following liver transplantation or with primary portal hypertension
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE children; liver transplantation; portal hypertension; Rex shunt
ID VEIN THROMBOSIS; BYPASS
AB Portal vein thrombosis can occur as a result of primary anomalies, after liver transplantation, and for other reasons. It may result in severe complications secondary to portal hypertension, such as bleeding from esophageal or gastric varices, hypersplenism, or impaired somatic growth. In this retrospective study, we analyzed the outcome of 25 children who underwent a Rex shunt procedure. The following venous grafts were used as the shunt: the autologous internal or external jugular vein (n = 17) or a cryopreserved graft (n = 5); in three patients the umbilical vein was recanalized. The median follow up time was 109 months (range 18 days-146 months). The best results were achieved in patients in whom an autologous jugular vein segment was used as a vascular graft for the Rex shunt (shunt patency of 88%). In patients with a functioning shunt no further lower or upper gastrointestinal bleeding occurred. And in the entire study population hypersplenism syndrome improved after surgery. In our large cohort of pediatric patients, the Rex shunt has shown to be an effective method to eliminate portal hypertension and to revascularize the liver and thereby prevents the possible consequences of long-term portosystemic shunting.
C1 [Krebs-Schmitt, D.; Briem-Richter, A.; Grabhorn, E.; Ganschow, R.] Univ Med Ctr, Dept Pediat Gastroenterol & Hepatol, Hamburg, Germany.
   [Burdelski, M.] Univ Med Ctr, Dept Pediat Gastroenterol, Kiel, Germany.
   [Helmke, K.] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Radiol, D-20246 Hamburg, Germany.
   [Broering, D. C.] Univ Med Ctr, Dept Hepatobiliary Surg, Kiel, Germany.
RP Krebs-Schmitt, D (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.
EM d.schmitt@uke.uni-hamburg.de
RI Broering, Dieter/B-1890-2010; Grabhorn, Enke/F-9785-2011
CR Bambini DA, 2000, J PEDIATR SURG, V35, P13, DOI 10.1016/S0022-3468(00)80068-8
   BAMBINI DA, 2000, J PEDIATR SURG, V35, P18
   Dasgupta R, 2006, J PEDIATR SURG, V41, P108, DOI 10.1016/j.jpedsurg.2005.10.059
   Alberti D, 1998, J PEDIATR SURG, V33, P597
   DEGOYET JD, 1992, TRANSPLANTATION, V53, P231
   Fuchs J, 2003, J PEDIATR GASTR NUTR, V36, P213, DOI 10.1097/00005176-200302000-00010
   Ganschow R, 2000, Pediatr Transplant, V4, P273, DOI 10.1034/j.1399-3046.2000.00127.x
   Stenger AM, 2001, TRANSPLANT P, V33, P1739, DOI 10.1016/S0041-1345(00)02663-4
   Stenger AM, 1999, CHIRURG, V70, P476
   Stringer MD, 2007, PEDIATR SURG INT, V23, P539, DOI 10.1007/s00383-007-1920-z
   Superina R, 2006, ANN SURG, V243, P515, DOI 10.1097/01.sla.0000205827.73706.97
   Superina R, 2006, PEDIATR TRANSPLANT, V10, P908, DOI 10.1111/j.1399-3046.2006.00598.x
   Thornton RH, 2005, J VASC INTERV RADIOL, V16, P399, DOI 10.1097/01.RVI.0000151143.49846.E0
NR 13
TC 16
Z9 18
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2009
VL 13
IS 5
BP 540
EP 544
DI 10.1111/j.1399-3046.2008.01109.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 467QD
UT WOS:000267756100006
PM 19210267
ER

PT J
AU Turmelle, YP
   Nadler, ML
   Anderson, CD
   Doyle, MB
   Lowell, JA
   Shepherd, RW
AF Turmelle, Yumirle P.
   Nadler, Michelle L.
   Anderson, Christopher D.
   Doyle, Maria B.
   Lowell, Jeffrey A.
   Shepherd, Ross W.
TI Towards minimizing immunosuppression in pediatric liver transplant
   recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE immunosuppression; liver transplant; outcome; pediatric
ID GLOMERULAR-FILTRATION-RATE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE;
   TERM-FOLLOW-UP; RENAL-FUNCTION; RISK-FACTORS; CHRONIC REJECTION; LONG;
   TOLERANCE; CHILDREN; THERAPY
AB Immunosuppression regimens after liver transplantation focus mainly on preventing rejection and subsequent graft loss. However, in children, morbidity and mortality rates from infections exceed those from rejection after transplant, and immunosuppression can hinder growth, renal function, and graft tolerance. We hypothesized that early steroid withdrawal, with a primary aim of TAC monotherapy would yield no penalty in terms of rejection and graft loss, while reducing risks of infection and maximizing growth. We prospectively evaluated 64 consecutive pediatric liver transplant recipients. One yr patient/graft survival was 93/90%, respectively. At one yr post-transplant, 75.4% of patients were on TAC monotherapy. No deaths or graft losses were caused by infection. Sixty-one percent of patients had at least one episode of rejection, most within three months following transplant and 3.8% were treated for chronic rejection. One non-compliant adolescent died from chronic rejection. CMV, EBV, and lymphoproliferative disease rates were 3.1%, 5.3%, 1.8%, respectively. Pretransplant and one yr post-transplant glomerular filtration rates were unchanged. One yr improved catch-up growth was observed. We conclude that immunosuppression minimization after pediatric liver transplant yields no serious complications from rejection, and might confer advantages with respect to infection, renal function, growth, and is deserving of wider application and study.
C1 [Turmelle, Yumirle P.; Shepherd, Ross W.] Washington Univ, Dept Pediat Gastroenterol & Nutr, Sch Med, St Louis, MO 63130 USA.
   [Anderson, Christopher D.; Doyle, Maria B.; Lowell, Jeffrey A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Nadler, Michelle L.; Anderson, Christopher D.; Lowell, Jeffrey A.; Shepherd, Ross W.] St Louis Childrens Hosp, Liver Care Ctr, St Louis, MO 63110 USA.
RP Turmelle, YP (reprint author), St Louis Childrens Hosp, Dept Pediat Gastroenterol & Nutr, 1 Childrens Pl, St Louis, MO 63110 USA.
EM turmelle_y@kids.wustl.edu
RI Shepherd, Ross/M-9713-2014
OI Shepherd, Ross/0000-0002-5348-5107
CR Arora-Gupta N, 2004, PEDIATR TRANSPLANT, V8, P145, DOI 10.1046/j.1399-3046.2003.00132.x
   Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Bishop GA, 2001, LIVER TRANSPLANT, V7, P161, DOI 10.1053/jlts.2001.22321
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   Cacciarelli TV, 2001, PEDIATR TRANSPLANT, V5, P359, DOI 10.1034/j.1399-3046.2001.00021.x
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Cao S, 1999, Pediatr Transplant, V3, P22, DOI 10.1034/j.1399-3046.1999.00002.x
   Cho JH, 1997, TRANSPLANT P, V29, P452, DOI 10.1016/S0041-1345(96)00195-9
   Cintorino D, 2006, TRANSPLANT P, V38, P1099, DOI 10.1016/j.transproceed.2006.02.147
   Diem HVT, 2003, TRANSPLANTATION, V75, P1664, DOI 10.1097/01.TP.0000063938.49112.C2
   DISTANT DA, 1993, J AM SOC NEPHROL, V4, P129
   EVANS GO, 1981, ANN CLIN BIOCHEM, V18, P295
   Fan XH, 2004, NAT MED, V10, P1227, DOI 10.1038/nm1126
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   FUNG JJ, 1991, TRANSPLANT P, V23, P3105
   GONWA TA, 1991, TRANSPLANTATION, V51, P428, DOI 10.1097/00007890-199102000-00030
   Gupta P, 2001, TRANSPLANTATION, V72, P1098, DOI 10.1097/00007890-200109270-00020
   Guthery SL, 2003, TRANSPLANTATION, V75, P987, DOI 10.1097/01.TP.0000057244.03192.BD
   Hurwitz M, 2004, PEDIATR TRANSPLANT, V8, P267, DOI 10.1111/j.1399-3046.2004.00129.x
   Jain A, 2001, PEDIATR TRANSPLANT, V5, P93, DOI 10.1034/j.1399-3046.2001.005002093.x
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Koshiba T, 2007, TRANSPL IMMUNOL, V17, P94, DOI 10.1016/j.trim.2006.10.004
   Lee TC, 2005, AM J TRANSPLANT, V5, P2222, DOI 10.1111/j.1600-6143.2005.01002.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   Mazariegos GV, 2007, TRANSPL IMMUNOL, V17, P114, DOI 10.1016/j.trim.2006.09.033
   McDiarmid SV, 1999, TRANSPLANTATION, V67, P404, DOI 10.1097/00007890-199902150-00011
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   MCDIARMID SV, 1989, TRANSPLANTATION, V47, P314, DOI 10.1097/00007890-198902000-00025
   Miller J, 2004, TRANSPLANTATION, V77, P940, DOI 10.1097/01.TP.0000117781.50131.55
   Pawarode A, 2003, LIVER TRANSPLANT, V9, P741, DOI 10.1053/jlts.2003.50113
   Renz JF, 2001, LIVER TRANSPLANT, V7, P1040, DOI 10.1053/jlts.2001.29413
   Shepherd RW, 2008, AM J TRANSPLANT, V8, P396, DOI 10.1111/j.1600-6143.2007.02068.x
   Soltys KA, 2007, AM J TRANSPLANT, V7, P2165, DOI 10.1111/j.1600-6143.2007.01893.x
   *SPLIT RES GROUP, 2000, TRANSPLANTATION, V72, P463
   Starzl TE, 2004, P NATL ACAD SCI USA, V101, P14607, DOI 10.1073/pnas.0404829101
   WHEATLEY HC, 1987, TRANSPLANTATION, V43, P641, DOI 10.1097/00007890-198705000-00007
   Wiesmayr S, 2005, PEDIATR TRANSPLANT, V9, P604, DOI 10.1111/j.1399-3046.2005.00348.x
NR 38
TC 5
Z9 6
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2009
VL 13
IS 5
BP 553
EP 559
DI 10.1111/j.1399-3046.2008.01061.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 467QD
UT WOS:000267756100008
PM 19067920
ER

PT J
AU Uutela, A
   Qvist, E
   Holmberg, C
   Pihko, H
   Jalanko, H
AF Uutela, Aki
   Qvist, Erik
   Holmberg, Christer
   Pihko, Helena
   Jalanko, Hannu
TI Headache in children and adolescents after organ transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE headache; calcineurin inhibitors; pediatric transplantation; adolescents
ID RENAL-TRANSPLANTATION; LIVER-TRANSPLANTATION; LUNG-TRANSPLANTATION;
   CYCLOSPORINE; SCHOOLCHILDREN; COMPLICATIONS; PREVALENCE
AB The prevalence and characteristics of headache were studied in a national cohort of 177 pediatric patients with kidney, liver, and heart transplants. All patients received triple drug immunosuppression with CsA, Aza, and MP. Data on headaches were collected by sending two questionnaires and reviewing the medical records. Statements on headache were found in the medical records of 46% of the patients. According to a questionnaire, two thirds had experienced headaches sometime after transplantation, and 40% had present headaches. The episodes had significantly affected the quality of life in a third of the patients, and resulted in neurological examination in 15%. Most of the subjects (61%) described typical episode as mild or moderate, and 39% as severe or very severe. The usual episodes lasted < 4 h in 73% of the patients and > 4 h in 27%. The headache could be classified as migraine, probable migraine or headache without specific features in 33%, 31%, and 36%, respectively. Most patients (82%) had used pain-killers, mainly acetaminophen and ibuprofen. Headache episodes may significantly impair the quality of life in children and adolescents after organ transplantation.
C1 [Uutela, Aki; Qvist, Erik; Holmberg, Christer; Jalanko, Hannu] Univ Helsinki, Dept Pediat Nephrol & Transplantat, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.
   [Pihko, Helena] Univ Helsinki, Dept Pediat Neurol, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.
RP Jalanko, H (reprint author), Univ Helsinki, Dept Pediat Nephrol & Transplantat, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland.
EM hannu.jalanko@hus.fi
FU Sigrid Juselius Foundation; Pediatric Research Foundation; Paivikki and
   Sakari Sohlberg Foundation; Helsinki University Central Hospital
FX This work was supported by grants from the Sigrid Juselius Foundation,
   the Pediatric Research Foundation, the Paivikki and Sakari Sohlberg
   Foundation, the Helsinki University Central Hospital Research Fund. We
   thank the patients and their families for the excellent co-operation.
CR Anttila P, 2006, LANCET NEUROL, V5, P268, DOI 10.1016/S1474-4422(06)70376-3
   AROMAA M, 2000, J HEADACHE PAIN, V1, P11, DOI 10.1007/s101940050004
   Ashkenazi A, 2006, CNS DRUGS, V20, P125, DOI 10.2165/00023210-200620020-00004
   Benfield MR, 2003, PEDIATR TRANSPLANT, V7, P321, DOI 10.1034/j.1399-3046.2003.00029.x
   Boucek MM, 2006, J HEART LUNG TRANSPL, V25, P893, DOI 10.1016/j.healun.2006.05.014
   BRNA PM, 2006, SEMIN PEDIAT NEUROL, V13, P22
   Carlsson J, 1996, ACTA PAEDIATR, V85, P692, DOI 10.1111/j.1651-2227.1996.tb14128.x
   Ferrari Uta, 2005, Headache, V45, P211, DOI 10.1111/j.1526-4610.2005.05046.x
   Francis PJ, 2003, PEDIATR NEPHROL, V18, P1265, DOI 10.1007/s00467-003-1274-2
   GUIJTEENBECK J, 1999, J NEUROL, V246, P339
   Hricik DE, 2001, AM J KIDNEY DIS, V38, P580, DOI 10.1053/ajkd.2001.26884
   The International Classification of Headache Disorders, 2004, CEPHALALGIA S1, V24, P9, DOI DOI 10.1111/J.1468-2982.2003.00824.X
   LUCEY MR, 1990, LANCET, V335, P11, DOI 10.1016/0140-6736(90)90137-T
   Maghrabi K, 1998, CLIN NEUROL NEUROSUR, V100, P224, DOI 10.1016/S0303-8467(98)00031-6
   MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010
   Muiesan P, 2007, J HEPATOL, V46, P340, DOI 10.1016/j.jhep.2006.11.006
   Pirsch JD, 1997, TRANSPLANTATION, V63, P977, DOI 10.1097/00007890-199704150-00013
   Sillanpaa M, 1996, HEADACHE, V36, P466, DOI 10.1046/j.1526-4610.1996.3608466.x
   STEIGER MJ, 1994, J NEUROL NEUROSUR PS, V57, P1258, DOI 10.1136/jnnp.57.10.1258
   Virtanen R, 2007, CEPHALALGIA, V27, P294, DOI 10.1111/j.1468-2982.2007.01277.x
   Wong M, 1999, NEUROLOGY, V53, P1542
NR 21
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2009
VL 13
IS 5
BP 565
EP 570
DI 10.1111/j.1399-3046.2008.00973.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 467QD
UT WOS:000267756100010
PM 18466199
ER

PT J
AU Simons, LE
   Gilleland, J
   Blount, RL
   Amaral, S
   Berg, A
   Mee, LL
AF Simons, Laura E.
   Gilleland, Jordan
   Blount, Ronald L.
   Amaral, Sandra
   Berg, Alexandra
   Mee, Laura L.
TI Multidimensional Adherence Classification System: Initial development
   with adolescent transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric transplant; medication adherence; clinical outcome; mortality
ID LIVER-TRANSPLANT; MEDICATION ADHERENCE; RENAL-TRANSPLANTATION;
   NONCOMPLIANCE; NONADHERENCE; REJECTION; CHILDREN; BARRIERS
AB As transplantation has progressively become a more viable option for children with life-threatening illness, ensuring that adolescents do not lose their new organ secondary to medication non-adherence is paramount. The first step to addressing non-adherence is adequate assessment of this construct. In this investigation, we introduce the MACS. The MACS includes self-report and drug assay levels. Self-report is a subjective measure with a low false-positive rate, but is vulnerable to social desirability. Drug assays are an objective measure of drug ingestion, but values suggestive of non-adherence may be influenced by medical complications and timing. The MACS builds on the strengths of both methods and attempts to contain their weaknesses. The sample in this study consisted of 82 adolescent solid organ transplant recipients. The non-adherence rate using the MACS in this sample was 61%. Initial data to support this system are promising. The occurrence of rejection episodes and mortality were significantly related to membership in the Genuinely Non-adherent category. Beyond providing initial support for the MACS, we discuss the clinical implications of this adherence classification system.
C1 [Simons, Laura E.] Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA.
   [Simons, Laura E.] Harvard Univ, Sch Med, Boston, MA USA.
   [Gilleland, Jordan; Blount, Ronald L.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
   [Amaral, Sandra] Childrens Healthcare Atlanta, Renal Transplant Program, Dept Pediat, Atlanta, GA USA.
   [Amaral, Sandra; Mee, Laura L.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Mee, Laura L.] Childrens Healthcare Atlanta, Transplant Program, Dept Pediat, Atlanta, GA USA.
RP Simons, LE (reprint author), Childrens Hosp Boston Waltham, Pediat Pain Rehabil Ctr, 9 Hope Ave, Waltham, MA 02453 USA.
EM laura.simons@childrens.harvard.edu
CR Butler JA, 2004, TRANSPLANTATION, V77, P786, DOI 10.1097/01.TP.0000110412.20050.36
   Chisholm MA, 2005, NEPHROL DIAL TRANSPL, V20, P181, DOI 10.1093/ndt/gfh576
   Falkenstein K, 2004, PEDIATR TRANSPLANT, V8, P233, DOI 10.1111/j.1399-3046.2004.00136.x
   Feinstein S, 2005, PEDIATRICS, V115, P969, DOI 10.1542/peds.2004-0211
   Franke GH, 1999, NEPHRON, V83, P31, DOI 10.1159/000045470
   Laederach-Hofmann K, 2000, GEN HOSP PSYCHIAT, V22, P412, DOI 10.1016/S0163-8343(00)00098-0
   La Greca AM, 2003, HDB PEDIAT PSYCHOL, P119
   Lurie S, 2000, Pediatr Transplant, V4, P200, DOI 10.1034/j.1399-3046.2000.00110.x
   Marhefka SL, 2004, AIDS CARE, V16, P323, DOI 10.1080/09540120410001665330
   Matas AJ, 1999, ANN SURG, V230, P493, DOI 10.1097/00000658-199910000-00005
   Matsui DM, 1997, PEDIATR CLIN N AM, V44, P1, DOI 10.1016/S0031-3955(05)70459-4
   Meyers KEC, 1996, TRANSPLANTATION, V62, P186, DOI 10.1097/00007890-199607270-00007
   Rapoff MA, 1999, ADHERENCE PEDIAT MED
   Ringewald JM, 2001, J PEDIATR-US, V139, P75, DOI 10.1067/mpd.2001.115067
   Schafer-Keller P, 2008, AM J TRANSPLANT, V8, P616, DOI 10.1111/j.1600-6143.2007.02127.x
   Shaw RJ, 2003, PEDIATR TRANSPLANT, V7, P489, DOI 10.1046/j.1397-3142.2003.00117.x
   Shellmer DA, 2007, PEDIATR TRANSPLANT, V11, P422, DOI 10.1111/j.1399-3046.2007.00681.x
   Shemesh E, 2008, PEDIATR TRANSPLANT, V12, P316, DOI 10.1111/j.1399-3046.2007.00791.x
   Shemesh E, 2004, PEDIATRICS, V113, P825, DOI 10.1542/peds.113.4.825
   Simons LE, 2007, J PEDIATR PSYCHOL, V32, P831, DOI 10.1093/jpepsy/jsm030
   Smith JM, 2002, PEDIATR TRANSPLANT, V6, P493, DOI 10.1034/j.1399-3046.2002.02042.x
   Venkat VL, 2008, PEDIATR TRANSPLANT, V12, P67, DOI 10.1111/j.1399-3046.2007.00794.x
   Watson AR, 2000, PEDIATR NEPHROL, V14, P469
   ZELIKOVSKY N, 2004, NAT C CHILD HLTH PSY
   Zelikovsky N, 2008, PEDIATR TRANSPLANT, V12, P300, DOI 10.1111/j.1399-3046.2007.00886.x
   Zelikovsky Nataliya, 2008, Pediatr Nurs, V34, P141
NR 26
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2009
VL 13
IS 5
BP 590
EP 598
DI 10.1111/j.1399-3046.2008.01038.x
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 467QD
UT WOS:000267756100014
PM 18992064
ER

PT J
AU Vajro, P
   Sokal, EM
   Maddaluno, S
   Esposito, M
   Caranci, F
   Capuano, G
   Caropreso, M
   Lenta, S
AF Vajro, P.
   Sokal, E. M.
   Maddaluno, S.
   Esposito, M.
   Caranci, F.
   Capuano, G.
   Caropreso, M.
   Lenta, S.
TI Brain abscess due to Klebsiella pneumoniae in a liver-transplanted child
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE Brain abscess; Klebsiella pneumoniae; pediatric liver transplantation
ID NEUROLOGICAL COMPLICATIONS; INFECTIONS; RECIPIENTS; ADULT
AB P>Brain abscesses are a rare, severe complication of orthotopic liver transplantation (OLT). They are almost exclusively due to fungi, Nocardia, or Toxoplasma, and usually occur within months of surgery. Here we report the case of an adolescent who developed a brain abscess due to Klebsiella pneumoniae 11.5 years after OLT. Fever was absent and laboratory parameters were not indicative of infectious disease, and therefore the diagnosis of a central nervous system neoplasm was considered. Subsequent magnetic resonance imaging and spectroscopy led to a diagnosis of a brain abscess, and to prompt appropriate antibiotic treatment. This case shows that K. pneumoniae may cause a brain abscess long after liver transplantation. The appearance of neurological symptoms should alert clinicians to consider a brain abscess even in the absence of overt clinical/laboratory signs of inflammation, which may be blunted by chronic immunosuppression.
C1 [Vajro, P.; Maddaluno, S.; Esposito, M.; Capuano, G.; Caropreso, M.; Lenta, S.] Univ Naples Federico 2, Dept Pediat, I-80131 Naples, Italy.
   [Sokal, E. M.] Catholic Univ Louvain, Dept Pediat, Hosp St Luc, Brussels, Belgium.
   [Caranci, F.] Univ Naples Federico 2, Dept Neurol Sci, Serv Neuroradiol, I-80131 Naples, Italy.
RP Vajro, P (reprint author), Univ Naples Federico 2, Dept Pediat, Via S Pansini 5, I-80131 Naples, Italy.
EM vajro@unina.it
OI VAJRO, PIetro/0000-0002-9418-5880
CR Amodio P, 2007, DIGEST LIVER DIS, V39, P740, DOI 10.1016/j.dld.2007.05.004
   Baddley JW, 2002, CLIN TRANSPLANT, V16, P419, DOI 10.1034/j.1399-0012.2002.02033.x
   Basu S, 2001, INFECTION, V29, P283, DOI 10.1007/s15010-001-1082-1
   Brennan KC, 2005, AM J NEURORADIOL, V26, P1695
   Bucuvalas John C, 2008, Curr Opin Organ Transplant, V13, P247, DOI 10.1097/MOT.0b013e3282f94aab
   Chow E, 2005, SCAND J INFECT DIS, V37, P511, DOI 10.1080/00365540510038965
   CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006
   ENZMANN DR, 1980, AM J ROENTGENOL, V135, P263
   Kao Pao-Tsuan, 2003, Journal of Microbiology Immunology and Infection, V36, P129
   Karampekios S, 2005, EUR RADIOL, V15, P485, DOI 10.1007/s00330-004-2556-1
   Kastrup Oliver, 2005, NeuroRx, V2, P324, DOI 10.1007/BF03206674
   KRAJEWSKI R, 1992, CHILD NERV SYST, V8, P279, DOI 10.1007/BF00300796
   Lai PH, 2007, SURG NEUROL, V68, pS25, DOI 10.1016/j.sumeu.2007.07.080
   Marcolini J, 2002, J INFECTION, V44, P205, DOI 10.1053/jinf.2002.0957
   MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010
   Ni Yuen-Hua, 2004, Journal of Microbiology Immunology and Infection, V37, P231
   Pham PTT, 2004, TRANSPLANTATION, V77, P1215, DOI 10.1097/01.TP.0000118413.92211.B6
   SCHLIAMSER SE, 1988, SCAND J INFECT DIS, V20, P1, DOI 10.3109/00365548809117210
   Selby R, 1997, ARCH SURG-CHICAGO, V132, P304
   Sheehan JP, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/6/E6
   Singh N, 2000, Transpl Infect Dis, V2, P101, DOI 10.1034/j.1399-3062.2000.020302.x
   Snyder J, 2002, J PEDIATR GASTR NUTR, V35, P564, DOI 10.1097/00005176-200210000-00019
   STAPLETON SR, 1993, ACTA NEUROCHIR, V121, P15, DOI 10.1007/BF01405177
   Wald ER, 2001, PEDIATRICS, V108, P798
NR 24
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2009
VL 11
IS 4
BP 341
EP 345
DI 10.1111/j.1399-3062.2009.00395.x
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 480EI
UT WOS:000268714600011
PM 19422671
ER

PT J
AU Petroski, RA
   Grady, KL
   Rodgers, S
   Backer, CL
   Kulikowska, A
   Canter, C
   Pahl, E
AF Petroski, Rebecca A.
   Grady, Kathleen L.
   Rodgers, Sherrie
   Backer, Carl L.
   Kulikowska, Agnieszka
   Canter, Charles
   Pahl, Elfriede
TI Quality of Life in Adult Survivors Greater Than 10 Years After Pediatric
   Heart Transplantation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 28th Annual Meeting of the
   International-Society-for-Heart-and-Lung-Transplantation
CY APR 09-12, 2008
CL Boston, MA
SP Int Soc Heart & Lung Transplantat
ID RISK-FACTORS; LUNG-TRANSPLANTATION; 20-YEAR SURVIVORS; OUTCOMES; IMPACT;
   LIVER; ADOLESCENTS; PREDICTORS; RECIPIENTS; REJECTION
AB Background: This study assessed quality of life (QOL) in adult survivors of pediatric heart transplantation who Survived >= 10 years after transplantation.
   Methods: Prospective data were collected from heart transplant recipients who were aged >= 18 years and had survived >= 10 years after transplantation (transplantation between July 3, 1986, and April 4, 1997). QOL data were collected from patients using the Medical Outcomes Study 36-Item Short Form (SF-36) Health Survey. Clinical data were collected from medical records. Statistical analyses included frequencies and measures of central tendency.
   Results: Twenty-three patients (65% men, 91% white) completed the study. At the study initiation, they were a mean age of 9.0 +/- 7.1 years at transplantation, and were a mean age of 25.2 +/- 5.5 years (range, 18-34 years) and a mean of 16.2 +/- 3.0 years (range, 11-22 years) post-transplantation. Most were in school or working. Mean patient QOL scores from the SF-36v2 survey were 50.56 +/- 0.5 (range, 27.3- 68.9) for physical health and 49.88 +/- 11.72 (range, 23.56 - 62.84) for mental health, similar to the general United States population. Late complications were frequent, including transplant coronary artery disease, 3; repeat heart transplantation, 2; post-transplantation lymphoproliferative disorder, 6; kidney transplantation, 5; acute late rejection, 5; and arrhythmias, 4.
   Conclusion: This report of QOL in adult survivors of pediatric heart transplantation shows patient perception of physical and mental health is similar to the general population despite serious late complications. A multicenter study is planned to further evaluate QOL in this unique cohort. J Heart Lung Transplant 2009;28:661- 6. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation.
C1 [Kulikowska, Agnieszka; Canter, Charles] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   [Petroski, Rebecca A.; Rodgers, Sherrie; Pahl, Elfriede] Childrens Mem Hosp, Div Cardiol, Dept Pediat, Chicago, IL 60614 USA.
   [Backer, Carl L.] Northwestern Univ, Childrens Mem Hosp, Div Cardiovasc Thorac Surg, Chicago, IL 60614 USA.
   [Grady, Kathleen L.] NW Mem Hosp, Dept Surg, Div Cardiothorac Surg, Chicago, IL 60611 USA.
RP Pahl, E (reprint author), Childrens Mem Hosp, Div Cardiol, Dept Pediat, 2300 Childrens Plaza,MC 21, Chicago, IL 60614 USA.
EM epahl@childrensmemorial.org
CR Alonso EM, 2004, PEDIATR TRANSPLANT, V8, P381, DOI 10.1111/j.1399-3046.2004.00164.x
   Aravot D., 2000, Transplantation Proceedings, V32, P731, DOI 10.1016/S0041-1345(00)00960-X
   Boucek MM, 2007, J HEART LUNG TRANSPL, V26, P796, DOI 10.1016/j.healun.2007.06.006
   Chin C, 2006, J HEART LUNG TRANSPL, V25, P1420, DOI 10.1016/j.healun.2006.09.020
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cupples S, 2006, J HEART LUNG TRANSPL, V25, P716, DOI 10.1016/j.healun.2006.02.005
   DeMaso DR, 2004, J HEART LUNG TRANSPL, V23, P473, DOI 10.1016/S1053-2498(03)00215-8
   Deuse T, 2008, AM J TRANSPLANT, V8, P1769, DOI 10.1111/j.1600-6143.2008.02310.x
   Grady KL, 2007, J HEART LUNG TRANSPL, V26, P535, DOI 10.1016/j.healun.2007.01.042
   Grady KL, 2007, J HEART LUNG TRANSPL, V26, P1182, DOI 10.1016/j.healun.2007.08.001
   Karam VH, 2003, TRANSPLANTATION, V76, P1699, DOI 10.1097/01.TP.0000092955.28529.1E
   Katz BZ, 2007, PEDIATR TRANSPLANT, V11, P58, DOI 10.1111/j.1399-3046.2006.00609.x
   Lee CK, 2007, J HEART LUNG TRANSPL, V26, P458, DOI 10.1016/j.healun.2007.01.036
   Littlefield C, 1996, GEN HOSP PSYCHIAT, V18, pS36
   Mendoza F, 2006, PEDIATR TRANSPLANT, V10, P60, DOI 10.1111/j.1399-3046.2005.00401.x
   Pahl E, 2005, J HEART LUNG TRANSPL, V24, P645, DOI 10.1016/j.healun.2004.03.021
   Pahl E, 2000, Pediatr Transplant, V4, P268, DOI 10.1034/j.1399-3046.2000.00122.x
   Pahl E, 2001, J HEART LUNG TRANSPL, V20, P279, DOI 10.1016/S1053-2498(00)00228-X
   Politi P, 2004, TRANSPLANTATION, V78, P257, DOI 10.1097/01.tp.0000133537.87951.f2
   Pollock-BarZiv SM, 2003, TRANSPLANT P, V35, P2468, DOI 10.1016/j.transproceed.2003.08.028
   Ross M, 2006, J HEART LUNG TRANSPL, V25, P261, DOI 10.1016/j.healun.2005.09.011
   Sigfusson G, 1997, J PEDIATR-US, V130, P862, DOI 10.1016/S0022-3476(97)70270-1
   Simons LE, 2008, PEDIATR TRANSPLANT, V12, P187, DOI 10.1111/j.1399-3046.2007.00805.x
   Spilker B., 1996, QUALITY LIFE PHARMAC
   UZARK KC, 1992, J HEART LUNG TRANSPL, V11, P1160
   Ware JE, 1997, SF 36 HLTH SURVEY MA
   Webber SA, 2003, J HEART LUNG TRANSPL, V22, P869, DOI 10.1016/S1053-2498(02)00819-7
   White-Williams C, 2005, J HEART LUNG TRANSPL, V24, P2255, DOI 10.1016/j.healun.2005.08.006
NR 28
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JUL
PY 2009
VL 28
IS 7
BP 661
EP 666
DI 10.1016/j.healun.2009.04.004
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA 470QM
UT WOS:000267993700002
PM 19560692
ER

PT J
AU Takebe, A
   Schrem, H
   Ringe, B
   Lehner, F
   Strassburg, C
   Klempnauer, J
   Becker, T
AF Takebe, Atsushi
   Schrem, Harald
   Ringe, Bastian
   Lehner, Frank
   Strassburg, Christian
   Klempnauer, Juergen
   Becker, Thomas
TI Extended Right Liver Grafts Obtained by an Ex Situ Split Can Be Used
   Safely for Primary and Secondary Transplantation with Acceptable Biliary
   Morbidity
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SINGLE-CENTER EXPERIENCE; BILE-DUCT COMPLICATIONS; LIVING DONOR; TRACT
   COMPLICATIONS; INSTITUTION EXPERIENCE; RECONSTRUCTIVE SURGERY; ADULT
   PATIENTS; CHILDREN; OUTCOMES; STRICTURES
AB Split liver transplantation (SLT) is clearly beneficial for pediatric recipients. However, the increased risk of biliary complications in adult recipients of SLT in comparison with whole liver transplantation (WLT) remains controversial. The objective of this study was to investigate the incidence and clinical outcome of biliary complications in an SILT group using split extended right grafts (ERGs) after ex situ splitting in comparison with WLT in adults. The retrospectively collected data for 80 consecutive liver transplants using ERGs after ex situ splitting between 1998 and 2007 were compared with the data for 80 liver transplants using whole liver grafts in a matched-pair analysis paired by the donor age, recipient age, indications, Model for End-Stage Liver Disease score, and high-urgency status. The cold ischemic time was significantly longer in the SLT group (P = 0.006). As expected, bile leakage from the transected surface occurred only in the SLT group (15%) without any mortality or graft loss. The incidence of all other early or late biliary complications (eg, anastomotic leakage and stenosis) was not different between SLT and WLT. The 1- and 5-year patient and graft survival rates showed no statistical difference between SLT and WLT [83.2% and 82.0% versus 88.5% and 79.8% (P = 0.92) and 70.8% and 67.5% versus 83.6% and 70.0% (P = 0.16), respectively]. In conclusion, ERGs can be used safely without any increased mortality and with acceptable morbidity, and they should also be considered for retransplantation. The significantly longer cold ischemic time in the SLT group indicates the potential for improved results and should thus be considered in the design of allocation policies. Liver Transpl 15:730-737, 2009. (C) 2009 AASLD.
C1 [Takebe, Atsushi; Schrem, Harald; Ringe, Bastian; Lehner, Frank; Klempnauer, Juergen; Becker, Thomas] Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, D-30625 Hannover, Germany.
   [Strassburg, Christian] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany.
   [Takebe, Atsushi] Kobe Univ, Grad Sch Med, Div Hepatobiliary Pancreat Surg, Kobe, Hyogo 657, Japan.
RP Becker, T (reprint author), Hannover Med Sch, Dept Gen Abdominal & Transplantat Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM becker.thomas@mh-hannover.de
CR Abbasoglu O, 1997, TRANSPLANTATION, V63, P250, DOI 10.1097/00007890-199701270-00013
   Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   Azoulay D, 1996, ANN SURG, V224, P746, DOI 10.1097/ 00000658- 199612000- 00009]
   Azoulay D, 1996, ANN SURG, V224, P737, DOI 10.1097/00000658-199612000-00009
   Balzan S, 2004, LIVER TRANSPLANT, V10, P703, DOI 10.1002/lt.20119
   Bismuth H, 2001, ANN SURG, V234, P721
   Broering DC, 2004, ANN SURG, V240, P1013, DOI 10.1097/01.sla.0000146146.97485.6c
   Broering DC, 2002, J AM COLL SURGEONS, V195, P648, DOI 10.1016/S1072-7515(02)01339-X
   Broering DC, 2004, ANN SURG, V240, P1024
   Broering DC, 2001, ANN SURG, V234, P713, DOI 10.1097/00000658-200112000-00002
   BUSUTTIL RW, 2005, ANN SING, V241, P916
   BUSUTTIL RW, 1987, ANN SURG, V206, P387, DOI 10.1097/00000658-198710000-00001
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Busuttil RW, 2005, ANN SURG, V241, P905, DOI 10.1097/01.sla.0000164077.77912.98
   COLONNA JO, 1992, ANN SURG, V216, P344
   Colonna JO, 1992, ANN SURG, V216, P350
   Corno V, 2006, TRANSPLANT INT, V19, P492, DOI 10.1111/j.1432-2277.2006.00323.x
   DEGOYET JD, 1995, TRANSPLANTATION, V59, P1371
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   GREIF F, 1994, ANN SURG, V219, P40, DOI 10.1097/00000658-199401000-00007
   Halme L, 2003, TRANSPLANTATION, V75, P1853, DOI 10.1097/01.TP.0000064620.08328.E5
   Hockerstedt AV, 2003, ANN SURG, V238, P862
   Kashyap R, 2001, TRANSPLANT P, V33, P1486, DOI 10.1016/S0041-1345(00)02563-X
   LERUT J, 1987, TRANSPLANTATION, V43, P47, DOI 10.1097/00007890-198701000-00011
   Malago M, 2003, ANN SURG, V238, P853, DOI 10.1097/01.sla.0000098619.71694.74
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   Mirza DF, 1998, BRIT J SURG, V85, P494
   Noujaim HM, 2003, AM J TRANSPLANT, V3, P318, DOI 10.1034/j.1600-6143.2003.00047.x
   Olthoff KM, 2005, ANN SURG, V242, P314, DOI 10.1097/01.sla.0000179646.37145.cf
   Olthoff KM, 2005, ANN SURG, V242, P323
   Pascher A, 2005, TRANSPLANT INT, V18, P627, DOI 10.1111/j.1432-2277.2005.00123.x
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Reichert PR, 1998, LIVER TRANSPLANT SUR, V4, P343, DOI 10.1002/lt.500040517
   Renz JF, 2004, ANN SURG, V239, P172, DOI 10.1097/01.sla.0000109150.89438.bd
   Renz John F, 2003, J Hepatobiliary Pancreat Surg, V10, P31
   SANCHEZURDAZPAL L, 1992, HEPATOLOGY, V16, P49, DOI 10.1002/hep.1840160110
   SANCHEZURDAZPAL L, 1993, ANN SURG, V218, P152, DOI 10.1097/00000658-199308000-00006
   Schlitt HJ, 1999, ANN SURG, V229, P137, DOI 10.1097/00000658-199901000-00018
   Shaked A, 2001, ANN SURG, V234, P311
   Silva MA, 2006, LIVER TRANSPLANT, V12, P146, DOI 10.1002/lt.20566
   Spada M, 2005, TRANSPLANT P, V37, P1164, DOI 10.1016/j.transproceed.2005.01.037
   Stahl JE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002468
   STRATTA RJ, 1989, SURGERY, V106, P675
   Stratta RJ, 1989, SURGERY, V106, P683
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Sutcliffe R, 2004, LIVER TRANSPLANT, V10, P928, DOI 10.1002/lt.20146
   Trotter JF, 2002, NEW ENGL J MED, V346, P1074, DOI 10.1056/NEJMra011629
   Tung BY, 1999, DIGEST DIS, V17, P133, DOI 10.1159/000016918
   Washburn K, 2005, AM J TRANSPLANT, V5, P1652, DOI 10.1111/j.16700-6143.2005.00933.x
   Wilms C, 2006, ANN SURG, V244, P872, DOI [0.1097/ 01. sla. 0000247254.76747. f3], DOI 10.1097/01.SLA.0000247254.76747.F3]]
   Wilms C, 2006, ANN SURG, V244, P865, DOI 10.1097/01.sla.0000247254.76747.f3
   Wojcicki M, 2006, LIVER TRANSPLANT, V12, P839, DOI 10.1002/lt.20729
   Yan Ji-Qi, 2005, Hepatobiliary Pancreat Dis Int, V4, P339
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
   [Anonymous], 2003, ANN SURG
NR 55
TC 7
Z9 10
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2009
VL 15
IS 7
BP 730
EP 737
DI 10.1002/lt.21745
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 468CU
UT WOS:000267792200009
PM 19562706
ER

PT J
AU Uchida, Y
   Sakamoto, S
   Egawa, H
   Ogawa, K
   Ogura, Y
   Taira, K
   Kasahara, M
   Uryuhara, K
   Takada, Y
   Kamiyama, Y
   Tanaka, K
   Uemoto, S
AF Uchida, Yoichiro
   Sakamoto, Seisuke
   Egawa, Hiroto
   Ogawa, Kohei
   Ogura, Yasuhiro
   Taira, Kaoru
   Kasahara, Mureo
   Uryuhara, Kenji
   Takada, Yasutsugu
   Kamiyama, Yasuo
   Tanaka, Koichi
   Uemoto, Shinji
TI The impact of meticulous management for hepatic artery thrombosis on
   long-term outcome after pediatric living donor liver transplantation
SO CLINICAL TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT World Transplant Congress
CY JUL 22-27, 2006
CL Boston, MA
DE biliary complication; hepatic artery thrombosis; liver transplantation;
   living donor; pediatric
ID SINGLE-CENTER; REVASCULARIZATION; RECONSTRUCTION; COMPLICATIONS;
   ANASTOMOSIS; CHILDREN; SURVIVAL
AB To analyze the risk factors in the development of hepatic artery thrombosis (HAT) and assess the impact of our perioperative management for HAT on the long-term outcome after pediatric living donor liver transplantation (LDLT), we reviewed 382 patients under 12 yr of age who underwent 403 LDLT from January 1996 to December 2005. One- and 10-yr patient survival rates were 78% and 78% in the patients with HAT (27 patients; 6.7%), and 84% and 76% in the patients without HAT, respectively (p = n.s.). Univariate analysis showed gender (female), body weight (lower), and graft-to-recipient weight ratio (higher) were significant risk factors in the patients with HAT (p < 0.05). Patients with Doppler ultrasound signal loss of the hepatic artery (HA) accompanied by an increase of liver enzymes underwent thrombectomy and reanastomosis (S-group, n = 13), and patients with a weak HA signal underwent anticoagulant therapy (M-group, n = 13). One patient underwent re-LDLT. One- and five-yr patient survival rates were 83% and 83% in the S-group, and 77% and 77% in the M-group (p = n.s.). The incidence of biliary complications in the S-group (58%) was significantly higher than that of the M-group (15%). For a successful long-term outcome, the early detection of HAT and prompt medical and surgical intervention are crucial to minimize the insult of HAT.
C1 [Uchida, Yoichiro; Sakamoto, Seisuke; Egawa, Hiroto; Ogawa, Kohei; Ogura, Yasuhiro; Taira, Kaoru; Takada, Yasutsugu; Uemoto, Shinji] Kyoto Univ, Dept Surg, Sakyo Ku, Kyoto 6068507, Japan.
   [Uchida, Yoichiro; Kamiyama, Yasuo] Kansai Med Univ, Dept Surg, Osaka, Japan.
   [Kasahara, Mureo] Natl Ctr Child Hlth & Dev, Dept Transplant Surg, Tokyo, Japan.
   [Uryuhara, Kenji] Kobe City Gen Hosp, Dept Transplant Surg, Kobe, Hyogo, Japan.
RP Uchida, Y (reprint author), Kyoto Univ, Dept Surg, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.
EM uchiday@kuhp.kyoto-u.ac.jp
CR Dalgic A, 2003, PEDIATR TRANSPLANT, V7, P149, DOI 10.1034/j.1399-3046.2003.00017.x
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   Guarrera JV, 2004, TRANSPLANT INT, V17, P585, DOI 10.1007/s00147-004-0782-8
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Inomata Y, 1999, TRANSPLANTATION, V67, P1314, DOI 10.1097/00007890-199905270-00004
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Jain A, 2006, TRANSPLANT INT, V19, P27, DOI 10.1111/j.1432-2277.2005.00224.x
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Mimuro A, 2003, GASTROINTEST ENDOSC, V58, P283, DOI 10.1067/mge.2003.354
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Nakamura N, 2005, TRANSPLANTATION, V79, P427, DOI 10.1097/01.TP.0000152800.19986.9E
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Rabkin JM, 1998, AM J SURG, V175, P354, DOI 10.1016/S0002-9610(98)00051-8
   Sheiner PA, 1997, TRANSPLANTATION, V64, P1295, DOI 10.1097/00007890-199711150-00011
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Stringer MD, 2001, J PEDIATR SURG, V36, P888, DOI 10.1053/jpsu.2001.23963
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Uchida Y, 2006, AM J TRANSPLANT, V6, P2443, DOI 10.1111/j.1600-6143.2006.01487.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Zheng Shu-sen, 2005, Zhonghua Yi Xue Za Zhi, V85, P1665
   Zheng Shu-Sen, 2004, Hepatobiliary Pancreat Dis Int, V3, P21
NR 23
TC 24
Z9 27
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD JUN-JUL
PY 2009
VL 23
IS 3
BP 392
EP 399
DI 10.1111/j.1399-0012.2008.00924.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 473LP
UT WOS:000268208500013
PM 19191812
ER

PT J
AU Mahadeb, P
   Gras, J
   Sokal, E
   Otte, JB
   Lerut, J
   Detaille, T
   de Clety, SC
   Reding, R
AF Mahadeb, Parikshat
   Gras, Jeremie
   Sokal, Etienne
   Otte, Jean-Bernard
   Lerut, Jan
   Detaille, Thierry
   de Clety, Stephan Clement
   Reding, Raymond
TI Liver transplantation in children with fulminant hepatic failure: The
   UCL experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; children; fulminant; hepatic; failure
ID INFANTS
AB The outcome of pediatric LT for FHF was shown to be poor in our center. To better understand such results, recipient and transplant parameters with a putative impact on post-transplant outcome were analyzed in LT for FHF. Between March 1984 and June 2002, 33 children with FHF received a primary liver allograft. The overall results in this series were studied with respect to pre-operative demographic and metabolic variables, peri-operative events, and outcome. Five-yr patient and graft survivals were 71% and 66%, respectively, with a retransplantation rate at 18%. Incidences of perioperative hemorrhage, of HAT and PVT were 14%, 8%, and 4%, respectively. Five-yr acute rejection-free survival rate was 55%. These data confirm the worse outcome following LT for FHF when compared with LT in elective, non-malignant indications such as BA; results in FHF could not be related to surgical or immunological complications in the post-transplant period and it is hypothesized that the MOF associated with FHF contributes to early post-transplant mortality which would justify special management, including aggressive renal and hepatic support.
C1 [Reding, Raymond] Catholic Univ Louvain, Pediat Surg Unit, Pediat Liver Transplant Program, Clin Univ St Luc, B-1200 Brussels, Belgium.
   [Detaille, Thierry; de Clety, Stephan Clement] Catholic Univ Louvain, Clin Univ St Luc, Pediat Intens Care Unit, B-1200 Brussels, Belgium.
RP Reding, R (reprint author), Catholic Univ Louvain, Pediat Surg Unit, Pediat Liver Transplant Program, Clin Univ St Luc, 10 Hippocrate Ave, B-1200 Brussels, Belgium.
EM reding@chex.ucl.ac.be
RI Lerut, Jan/B-9571-2016
OI Lerut, Jan/0000-0002-4718-9950
CR Bernuau J, 1991, HEPATOLOGY, V14, P49
   BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417
   BISMUTH H, 1995, ANN SURG, V222, P109, DOI 10.1097/00000658-199508000-00002
   DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1016/0270-9139(92)90008-W
   Dhawan A, 2004, PEDIATR TRANSPLANT, V8, P584, DOI 10.1111/j.1399-3046.2004.00292.x
   HERNANDEZ JAF, 2003, GASTROENTEROL HEPATO, V26, P333
   LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793
   Nicolette L, 1998, J PEDIATR SURG, V33, P998, DOI 10.1016/S0022-3468(98)90521-8
   Nussler A, 2006, J HEPATOL, V45, P144, DOI 10.1016/j.jhep.2006.04.002
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Poddar U, 2002, ARCH DIS CHILD, V87, P54, DOI 10.1136/adc.87.1.54
   PSACHAROPOULOS HT, 1980, ARCH DIS CHILD, V55, P252
   Reding R, 2005, AM J TRANSPLANT, V5, P1587, DOI 10.1111/j.1600-6143.2005.00915.x
   SCHIODT FV, 1999, LIVER TRANSPLANT SUR, V5, P23
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   Schweizer P., 1986, PEDIATR SURG INT, V1, P30
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Tsai MH, 2005, INT J CLIN PRACT, V59, P1289, DOI 10.1111/j.1368-5031.2005.00604.x
NR 19
TC 12
Z9 12
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2009
VL 13
IS 4
BP 414
EP 420
DI 10.1111/j.1399-3046.2008.01008.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 441NC
UT WOS:000265774900007
PM 19017285
ER

PT J
AU Martin-Pena, A
   Cordero, E
   Fijo, J
   Sanchez-Moreno, A
   Martin-Govantes, J
   Torrubia, F
   Cisneros, J
AF Martin-Pena, Almudena
   Cordero, Elisa
   Fijo, Julia
   Sanchez-Moreno, Ana
   Martin-Govantes, Juan
   Torrubia, Francisco
   Cisneros, Jose
TI Prospective study of infectious complications in a cohort of pediatric
   renal transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric renal transplantation; infection; epidemiology
ID URINARY-TRACT-INFECTIONS; ONSET CYTOMEGALOVIRUS DISEASE; BLOOD-STREAM
   INFECTIONS; EPSTEIN-BARR-VIRUS; LIVER-TRANSPLANTATION; ESCHERICHIA-COLI;
   ANTIMICROBIAL SUSCEPTIBILITY; KIDNEY-PRESERVATION; RISK-FACTORS;
   CHILDREN
AB Infections are frequent and serious in pediatric RT recipients; however, the information available is scarce. The aim of this study was to determine the incidence, etiology, and risk factors for infection in these patients. This was a prospective, observational study of a consecutive pediatric RT recipient cohort. Risk factors for infection and descriptive analyses during the first two post-transplantation years were performed. Twenty-one patients (58.3%) had at least one infection (incidence 1.5 episodes/patient/first year of transplantation). There were 33 bacterial infections (73.3%), 11 viral infections (24.4%), and one protozoal infection. UTI was the most common syndrome (48.3%), followed by CMV infection (15.5%). The main microorganisms isolated were Escherichia coli (28.9%), 46.1% of which were ESBL producers, and CMV (20%). Patient and graft survival at the end of follow-up were 97.2% and 83.3%, respectively. The only risk factor for infection was cold ischemia time > 800 min (OR 5.7, CI 95% 1.7-19.3). Conclusions: In pediatric RT recipients, UTI is the most frequent syndrome. Bacterial infections are the most common, with a high rate of ESBL producer strains. Despite their good prognosis, infections are a cause of morbidity that could potentially be reduced by decreasing cold ischemia times.
C1 [Fijo, Julia; Sanchez-Moreno, Ana; Martin-Govantes, Juan] Hosp Univ Virgen del Rocio, Unidad Nefrol Pediat, Seville 41013, Spain.
   [Torrubia, Francisco] Hosp Univ Virgen del Rocio, Serv Urol, Seville 41013, Spain.
RP Martin-Pena, A (reprint author), Hosp Univ Virgen del Rocio, Serv Enfermedades Infecciosas, Ave Manuel Siurot S-N, Seville 41013, Spain.
EM denamartin@hotmail.com
RI IBIS, INFECCIOSAS/O-1940-2015; IBIS, TUBERCULOSIS/O-9334-2015
FU Ministerio de Sanidad y Consumo; Instituto de Salud Carlos III; Spanish
   Network of Infection in Transplantation [RESITRA G03/075]; Spanish
   Network for the Research in Infectius Diseases [REIPI RD06/0008]
FX This work was supported by Ministerio de Sanidad y Consumo, Instituto de
   Salud Carlos III, Spanish Network of Infection in Transplantation
   (RESITRA G03/075) and Spanish Network for the Research in Infectius
   Diseases (REIPI RD06/0008).
CR Andreu A, 2005, ENFERM INFEC MICR CL, V23, P4
   Bernabeu-Wittel M, 2005, J INFECTION, V51, P188, DOI 10.1016/j.jinf.2004.10.014
   BREINIG MK, 1987, J INFECT DIS, V156, P273
   Charfeddine K, 2005, TRANSPLANT P, V37, P2823, DOI 10.1016/j.transproceed.2005.05.009
   Cisneros JM, 1998, CLIN INFECT DIS, V27, P324, DOI 10.1086/514649
   DAMMELOMBAERTS R, 2001, PEDIATR TRANSPLANT, V5, P447
   Dharnidharka VR, 2006, TRANSPLANTATION, V81, P1662, DOI 10.1097/01.tp.0000226068.66819.37
   Dharnidharka VR, 2001, SEMIN NEPHROL, V21, P521, DOI 10.1053/snep.2001.24947
   El-Husseini AA, 2006, PEDIATR NEPHROL, V21, P1464, DOI 10.1007/s00467-006-0150-2
   Fellay J, 2005, TRANSPLANT P, V37, P949, DOI 10.1016/j.transproceed.2004.11.066
   Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407
   Flynn JT, 1997, AM J NEPHROL, V17, P146, DOI 10.1159/000169089
   Fonseca-Aten Monica, 2006, Semin Pediatr Surg, V15, P153, DOI 10.1053/j.sempedsurg.2006.03.009
   Gandolfo MT, 2007, TRANSPLANTATION, V83, P254, DOI 10.1097/01.tp.0000251782.07786.3f
   Garcia S, 1998, CLIN TRANSPLANT, V12, P190
   Ginevri F, 2003, TRANSPLANTATION, V75, P1266, DOI 10.1097/01.TP.0000061767.32870.72
   Groothoff JW, 2002, KIDNEY INT, V61, P621, DOI 10.1046/j.1523-1755.2002.00156.x
   Hijosa MM, 2004, CLIN NEPHROL, V61, P246
   Jamieson NV, 2007, TRANSPLANTATION, V83, P255, DOI 10.1097/01.tp.0000251783.40861.97
   John U, 2006, NEPHROL DIAL TRANSPL, V21, P3269, DOI 10.1093/ndt/gfl464
   Junquera S, 2005, ENFERM INFEC MICR CL, V23, P197, DOI 10.1157/13073144
   Khosroshahi HT, 2006, TRANSPLANT P, V38, P2062, DOI 10.1016/j.transproceed.2006.06.111
   Kim YK, 2002, ANTIMICROB AGENTS CH, V46, P1481, DOI 10.1128/AAC.46.5.1481-1491.2002
   Kramer MS, 1988, CLIN EPIDEMIOLOGY BI
   KRIEGER JN, 1980, UROLOGY, V15, P362, DOI 10.1016/0090-4295(80)90471-9
   KUSNE S, 1988, MEDICINE, V67, P132
   Limaye AP, 2004, TRANSPLANTATION, V78, P1390, DOI 10.1097/01.TP.0000145989.22373.03
   Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620
   Maraha B, 2001, CLIN MICROBIOL INFEC, V7, P619, DOI 10.1046/j.1198-743x.2001.00329.x
   McCulloch MI, 2006, SAMJ S AFR MED J, V96, P955
   Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P378, DOI 10.1111/j.1600-6143.2004.00332.x
   NUNO J, 1995, TRANSPLANT P, V27, P2323
   Offner G, 1999, KIDNEY INT, V55, P1509, DOI 10.1046/j.1523-1755.1999.00356.x
   Opelz G, 2007, TRANSPLANTATION, V83, P247, DOI 10.1097/01.tp.0000251781.36117.27
   Pelle G, 2007, AM J TRANSPLANT, V7, P899, DOI 10.1111/j.1600-6143.2006.01700.x
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115
   Rodriguez-Bano J, 2006, CLIN INFECT DIS, V43, P1407
   Singh N, 2005, TRANSPLANTATION, V79, P85, DOI 10.1097/01.TP.0000146844.65273.62
   Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165
   Their M, 2000, TRANSPLANTATION, V69, P1617
   Torre-Cisneros J, 2005, ENFERM INFEC MICR CL, V23, P424, DOI 10.1157/13078802
NR 41
TC 7
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2009
VL 13
IS 4
BP 457
EP 463
DI 10.1111/j.1399-3046.2008.01019.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 441NC
UT WOS:000265774900013
PM 18673356
ER

PT J
AU Verzaro, R
   Spada, M
   Cintorino, D
   di Francesco, F
   Riva, S
   Caruso, S
   Gridelli, B
AF Verzaro, Roberto
   Spada, Marco
   Cintorino, Davide
   di Francesco, Fabrizio
   Riva, Silvia
   Caruso, Settimo
   Gridelli, Bruno
TI Arterial anastomosis in a pediatric patient receiving a right extended
   split liver transplant: A case report
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE split liver transplantation; arterial anastomosis; pediatric liver
   transplant; hepatic artery thrombosis; splenic artery in transplantation
ID RECIPIENT SPLENIC ARTERY; RECONSTRUCTION; GRAFT; EXPERIENCE; THROMBOSIS;
   LIGATION; DONORS; ADULT; AORTA
AB We report a case of a pediatric patient who received a right-extended liver transplant. The size of the recipient hepatic artery did not match with the donor right hepatic arterial stump. Moreover, recipient arterial anatomy made the direct anastomosis difficult or at increased risk for complications. The recipient's splenic artery was then mobilized, divided and anastomosed to the donor's right hepatic artery. The spleen was preserved and revascularization through collaterals is demonstrated by Angio CT Scan. Doppler US of the transplanted liver demonstrated good flow through the liver and the patient was discharged with perfect liver function. Splenic artery is perfectly suited for hepatic artery anastomosis. The use of splenic artery is favored in particular situations as in the case of a pediatric recipient receiving a right-extended liver graft with small caliber artery.
C1 [Caruso, Settimo] Mediterranean Inst Transplantat IsMeTT, Dept Radiol, I-90127 Palermo, Italy.
   [Verzaro, Roberto; Spada, Marco; Cintorino, Davide; di Francesco, Fabrizio; Riva, Silvia; Gridelli, Bruno] Mediterranean Inst Transplantat IsMeTT, Div Transplantat, Dept Surg, I-90127 Palermo, Italy.
RP Verzaro, R (reprint author), Mediterranean Inst Transplantat IsMeTT, Dept Radiol, Via Tricomi 1, I-90127 Palermo, Italy.
EM rverzaro@ismett.edu
CR ANDERSSON R, 1989, ACTA CHIR SCAND, V155, P451
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   Cescon M, 2006, ANN SURG, V244, P805, DOI 10.1097/01.sla.0000218076.85213.60
   CHERQUI D, 1994, AM J SURG, V167, P327, DOI 10.1016/0002-9610(94)90210-0
   Cintorino D, 2006, TRANSPLANT P, V38, P1096, DOI 10.1016/j.transproceed.2006.02.146
   Figueras J, 1997, TRANSPLANTATION, V64, P655, DOI 10.1097/00007890-199708270-00020
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   Kamei H, 2006, TRANSPLANT INT, V19, P945, DOI 10.1111/j.1432-2277.2006.00386.x
   KATZ E, 1992, TRANSPLANTATION, V53, P1373
   Kilic M, 2002, TRANSPLANTATION, V73, P1252, DOI 10.1097/00007890-200204270-00011
   LEHAR SC, 1990, J COMPUT ASSIST TOMO, V14, P362, DOI 10.1097/00004728-199005000-00007
   Marcos A, 2003, LIVER TRANSPLANT, V9, P570, DOI 10.1053/jlts.2003.50093
   Nishida S, 2004, BRIT J SURG, V91, P705, DOI 10.1002/bjs.4550
   ROGIERS X, 1995, TRANSPLANTATION, V60, P770
   SCHWALKE MA, 1991, J TRAUMA, V31, P385, DOI 10.1097/00005373-199103000-00013
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Verzaro R, 2001, PEDIATR TRANSPLANT, V5, P64, DOI 10.1034/j.1399-3046.2001.00033.x
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2009
VL 13
IS 4
BP 503
EP 506
DI 10.1111/j.1399-3046.2008.01004.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 441NC
UT WOS:000265774900020
PM 18822102
ER

PT J
AU Madan, RP
   Campbell, AL
   Shust, GF
   Kahn, AR
   Wistinghausen, B
   Posada, R
   Kerkar, N
   Shneider, BL
   Emre, S
   Herold, BC
AF Madan, Rebecca P.
   Campbell, Andrew L.
   Shust, Gail F.
   Kahn, Alissa R.
   Wistinghausen, Birte
   Posada, Roberto
   Kerkar, Nanda
   Shneider, Benjamin L.
   Emre, Sukru
   Herold, Betsy C.
TI A Hybrid Strategy for the Prevention of Cytomegalovirus-Related
   Complications in Pediatric Liver Transplantation Recipients
SO TRANSPLANTATION
LA English
DT Article
DE Cytomegalovirus; Preemptive therapy; Pediatric liver transplantation
ID BARR-VIRUS DISEASE; PREEMPTIVE THERAPY; INTRAVENOUS GANCICLOVIR; ORGAN
   TRANSPLANTATION; CHRONIC REJECTION; IMMUNE-RESPONSES; ORAL ACYCLOVIR;
   RISK-FACTOR; VIRAL LOAD; VALGANCICLOVIR
AB Background. This single center, retrospective study describes experience with a hybrid prevention strategy combining short-course antiviral prophylaxis and preemptive cytomegalovirus (CMV) polymerase chain reaction (PCR) monitoring.
   Methods. One hundred twenty-two pediatric liver transplantation recipients were followed up for a median of 2.3 years Posttransplantation. Subjects received a minimum of 14 days of postoperative ganciclovir, followed by monthly CMV PCR monitoring.
   Results. Forty-three CMV seronegative recipients received seropositive grafts and were considered high risk for CMV; 79 subjects were routine risk. CMV was detected by PCR in the absence of symptoms in 34.4% of subjects and was more likely in high risk than in routine risk recipients (58.1% vs. 21.8%, P=0.0001). Twelve subjects (9.8%) developed CMV disease (8 high risk vs. 4 routine risk, P=0.03). Three subjects developed acute rejection in the 6 months after detection of CMV, but CMV was preceded by rejection in 13 subjects. There were no mortalities secondary to CMV. A total of 38.5% of subjects were spared antiviral medications beyond their initial postoperative prophylaxis.
   Conclusions. These results suggest that a hybrid preventative approach for CMV is a reasonable alternative to prolonged antiviral prophylaxis and may reduce unnecessary exposure to antiviral therapy. However, patients who receive intensified immunosuppression after acute rejection are at increased risk for CMV and may require extended prophylaxis and closer monitoring.
C1 [Madan, Rebecca P.] Albert Einstein Coll Med, Dept Pediat, Div Pediat Infect Dis, Bronx, NY 10461 USA.
   [Campbell, Andrew L.] Abbott Labs, Abbott Pk, IL 60064 USA.
   [Kahn, Alissa R.; Wistinghausen, Birte; Posada, Roberto; Kerkar, Nanda] Mt Sinai Sch Med, Dept Pediat, New York, NY USA.
   [Shneider, Benjamin L.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
   [Emre, Sukru] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA.
RP Madan, RP (reprint author), Albert Einstein Coll Med, Dept Pediat, Div Pediat Infect Dis, Forchheimer 702,1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM rmadan@aecom.yu.edu
CR Almyroudis NG, 2007, TRANSPL INFECT DIS, V9, P286, DOI 10.1111/j.1399-3062.2007.00235.x
   Arthurs SK, 2008, CLIN INFECT DIS, V46, P840, DOI 10.1086/528718
   Avetisyan G, 2007, BONE MARROW TRANSPL, V40, P865, DOI 10.1038/sj.bmt.1705825
   Bingler MA, 2008, AM J TRANSPLANT, V8, P442, DOI 10.1111/j.1600-6143.2007.02080.x
   Clark BS, 2004, TRANSPLANTATION, V77, P1480, DOI 10.1097/01.TP.0000123081.81022.33
   Couchoud C, 1998, TRANSPLANTATION, V65, P641, DOI 10.1097/00007890-199803150-00007
   D'Alessandro AM, 2007, PEDIATR TRANSPLANT, V11, P661, DOI 10.1111/j.1399-3046.2007.00737.x
   Diaz-Pedroche C, 2006, TRANSPLANTATION, V82, P30, DOI 10.1097/01.tp.0000225830.76907.d0
   Faqi AS, 1997, HUM EXP TOXICOL, V16, P505
   Fridell JA, 2002, TRANSPLANTATION, V74, P1721, DOI 10.1097/01.TP.0000039334.85487.AB
   Gamadia LE, 2003, BLOOD, V101, P2686, DOI 10.1182/blood-2002-08-2502
   George MJ, 1997, AM J MED, V103, P106
   Green M, 2006, AM J TRANSPLANT, V6, P1906, DOI 10.1111/j.1600-6143.2006.01394.x
   Green M, 1997, CLIN INFECT DIS, V25, P1344, DOI 10.1086/516139
   Gupta P, 2001, TRANSPLANTATION, V72, P1098, DOI 10.1097/00007890-200109270-00020
   Halme L, 2003, TRANSPLANTATION, V75, P1853, DOI 10.1097/01.TP.0000064620.08328.E5
   HIBBERD PL, 1995, ANN INTERN MED, V123, P18
   HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013
   Hodson EM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005129.pub2
   Hodson EM, 2005, LANCET, V365, P2105, DOI 10.1016/S0140-6736(05)66553-1
   Humar A, 1999, TRANSPLANTATION, V68, P1879, DOI 10.1097/00007890-199912270-00011
   Husni RN, 1998, CLIN INFECT DIS, V26, P753, DOI 10.1086/514599
   Kalil AC, 2005, ANN INTERN MED, V143, P870
   Li F, 2007, CLIN INFECT DIS, V45, P439, DOI 10.1086/519941
   Li L, 2007, PEDIATR TRANSPLANT, V11, P187, DOI 10.1111/j.1399-3046.2006.00641.x
   Limaye AP, 2004, TRANSPLANTATION, V78, P1390, DOI 10.1097/01.TP.0000145989.22373.03
   Singh N, 2005, TRANSPLANTATION, V79, P85, DOI 10.1097/01.TP.0000146844.65273.62
   Singh N, 2008, LIVER TRANSPLANT, V14, P240, DOI 10.1002/lt.21362
   Small LN, 2006, CLIN INFECT DIS, V43, P869, DOI 10.1086/507337
   Steininger C, 2004, J INFECT DIS, V190, P1908, DOI 10.1086/424677
   Turgeon N, 1998, TRANSPLANTATION, V66, P1780, DOI 10.1097/00007890-199812270-00036
   Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6
NR 32
TC 18
Z9 20
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 15
PY 2009
VL 87
IS 9
BP 1318
EP 1324
DI 10.1097/TP.0b013e3181a19cda
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 445JW
UT WOS:000266048100010
PM 19424031
ER

PT J
AU Karpelowsky, JS
   Thomas, G
   Shun, A
AF Karpelowsky, Jonathan S.
   Thomas, Gordon
   Shun, Albert
TI Definitive abdominal wall closure using a porcine intestinal submucosa
   biodegradable membrane in pediatric transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; transplant; porcine submucosa collagen graft; abdominal wall
   closure
ID ARTERIAL BLOOD-FLOW; LIVER-TRANSPLANTATION; INTRAABDOMINAL PRESSURE;
   RECIPIENTS; REPAIR; GRAFT; MESH; CHILDREN; MODEL
AB Abdominal closure in children less than 10 kg following liver or kidney transplantation can be challenging. Excessive pressure attained from a tight closure can result in abdominal compartment syndrome, graft compromise and loss. Concerns over using prosthetic patches are that of infection and dehiscence. We report a series of definitive abdominal wall closure using a biodegradable membrane from porcine intestinal submucosa (Surgisis((R)); Cook Biotech Incorporated, West Lafayette, IN, USA). A prospective collection and follow up of liver and kidney transplant patients weighing less than 10 kg who required abdominal wall augmentation with Surgisis((R)) in order to achieve satisfactory closure. There were 10 liver and two renal transplant patients. The average weight of the liver transplant patients was 6.6 kg (5.4-8.5 kg) and the renal 9.8 kg. The average area of Surgisis((R)) used was 71.2 cm(2) (25-160 cm(2)) and length of follow up was 15.3 months (1-27 months). Concomitant measures to aid abdominal closure included bilateral recipient nephrectomy for the renal patients and reduction by 33% of the lateral segmental grafts in two liver transplant patients. Delayed closure occurred in all patients except one and the average days to closure from the first surgery was 3.75 days (0-6 days). Following liver transplantation one patient died from multiple organ failure at one month secondary to hemophagocytosis from underlying combined immune deficiency syndrome and one patient with hepatic artery thrombosis was salvaged at re-exploration. There were two wound complications, one patient developed two small sinuses and some skin dehiscence which healed over four months and the second developed a skin sinus following trans-patch liver biopsy which healed in three wk. Both had positive microbial cultures but neither necessitated removal of the graft. There were no incisional hernias. Surgisis((R)) is a safe method for facilitating abdominal closure in pediatric transplant patients. It appears to have long-term durability with no incisional hernias on short- and medium-term follow up, and is fairly resistant to infection.
C1 [Karpelowsky, Jonathan S.; Thomas, Gordon; Shun, Albert] Childrens Hosp Westmead, Dept Pediat Surg, Sydney, NSW, Australia.
RP Karpelowsky, JS (reprint author), Red Cross War Mem Childrens Hosp, Klipfontein Rd, ZA-7705 Cape Town, South Africa.
EM jonathan.karpelowsky@uct.ac.za
CR ALEXANDER SR, 1990, PEDIATR NEPHROL, V4, P542
   Ansaloni L, 2007, Hernia, V11, P321, DOI 10.1007/s10029-007-0225-4
   Ayubi FS, 2008, HERNIA, V12, P373, DOI 10.1007/s10029-008-0359-z
   Badylak S, 2000, J PEDIATR SURG, V35, P1097, DOI 10.1053/jpsu.2000.7834
   Benfield MR, 2003, PEDIATR TRANSPLANT, V7, P321, DOI 10.1034/j.1399-3046.2003.00029.x
   Biancofiore G, 2003, ARCH SURG-CHICAGO, V138, P703, DOI 10.1001/archsurg.138.7.703
   Biancofiore G, 2004, TRANSPLANT P, V36, P547, DOI 10.1016/j.transproceed.2004.02.029
   BROELSCH CE, 1988, ANN SURG, V208, P410, DOI 10.1097/00000658-198810000-00003
   Cacclarelli TV, 1999, TRANSPLANTATION, V68, P650, DOI 10.1097/00007890-199909150-00010
   Catena F, 2005, Hernia, V9, P29, DOI 10.1007/s10029-004-0273-y
   Dasgupta Roshni, 2007, Pediatr Surg Int, V23, P923, DOI 10.1007/s00383-007-1909-7
   DAYTON MT, 1986, ARCH SURG-CHICAGO, V121, P954
   Francioni G, 1999, Chir Ital, V51, P21
   Franklin M E Jr, 2002, Hernia, V6, P171
   Gupta A, 2006, Hernia, V10, P419, DOI 10.1007/s10029-006-0130-2
   HARMON WE, 1992, TRANSPLANTATION, V54, P232, DOI 10.1097/00007890-199208000-00008
   Hodde J, 2007, ACTA CHIR BELG, V107, P641
   HOUSSIN D, 1989, TRANSPLANT P, V21, P2277
   Johnson EK, 2007, MIL MED, V172, P1119
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Morris-Stiff GJ, 1998, J AM COLL SURGEONS, V186, P352, DOI 10.1016/S1072-7515(98)00002-7
   Nery JR, 1998, TRANSPLANT P, V30, P2640, DOI 10.1016/S0041-1345(98)00762-3
   PAYEN DM, 1990, SURGERY, V107, P417
   Pentlow A, 2008, PEDIATR TRANSPLANT, V12, P20, DOI 10.1111/j.1399-3046.2007.00824.x
   Poulose BK, 2005, J SURG RES, V123, P262, DOI 10.1016/j.jss.2004.08.011
   TYRELL J, 1989, SURG GYNECOL OBSTET, V168, P227
   Wiebe S, 2004, PEDIATR RADIOL, V34, P432, DOI 10.1007/s00247-003-1094-3
NR 27
TC 14
Z9 15
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2009
VL 13
IS 3
BP 285
EP 289
DI 10.1111/j.1399-3046.2008.01086.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 428ZX
UT WOS:000264891700006
PM 19032420
ER

PT J
AU Fernandez, MC
   Bes, D
   De Davila, M
   Lopez, S
   Cambaceres, C
   Dip, M
   Imventarza, O
AF Fernandez, Maria C.
   Bes, David
   De Davila, Maria
   Lopez, Susana
   Cambaceres, Carlos
   Dip, Marcelo
   Imventarza, Oscar
TI Post-transplant lymphoproliferative disorder after pediatric liver
   transplantation: Characteristics and outcome
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplant lymphoproliferative; pediatric liver transplantation;
   Epstein-Barr virus infections; outcome
ID EPSTEIN-BARR-VIRUS; TACROLIMUS FK506 THERAPY; DISEASE; RECIPIENTS;
   INFECTION; CHILDREN; MANAGEMENT
AB Post-Transplant Lymphoproliferative Disorder (PTLD) is a life threatening complication in organ transplant recipients. Risk factors include primary Epstein-Barr virus infection, intensity of immunosupression and cytomegalovirus infection.
   To evaluate the incidence, clinical presentation, risk factors, histopathologic appearance and outcome of pediatric liver recipients with PTLD at our institution.
   Retrospective, descriptive and observational analysis. Between November 1992 and December 2005, 383 liver transplants were performed. The diagnosis of PTLD was based on clinical history and physical examination and confirmed by histologic appearance and immunohistologic staining. Knowles' classification was used for histopathologic diagnosis.
   The incidence of PTLD was 5.7% (n: 22p). The average onset after tansplantation (OLT) was 24.9 months. Clinical manifestations were malaise, anorexia, fever of more than 3 days, peripheral adenopathy, tonsillar hypertrophy, abdominal mass, hepatosplenomegaly, snoring, interstitial pulmonary infiltrate, G.T.-tract bleeding, rash, submaxilar mass. Histopathologic diagnosis were Plasmocytic Hyperplasia (n: 10), Polymorphic Lymphoproliferative Disorder (n: 8), Non-Hodgkin Lymphoma (n: 4). Mortality was 18%.
   The clinical presentations were protean and not specific. A high index of suspicion is important for early diagnosis as it correlates with more benign lesions and more favorable outcume. The lower mortality rate in our series is concordant with that reported in more recent articles.
C1 [Fernandez, Maria C.; Bes, David] Hosp Nacl Pediat, Dept Pediat, Buenos Aires, DF, Argentina.
   [De Davila, Maria] Hosp Nacl Pediat, Serv Anat Patol, Buenos Aires, DF, Argentina.
   [Lopez, Susana] Hosp Nacl Pediat, Serv Hepatol, Buenos Aires, DF, Argentina.
   [Cambaceres, Carlos; Dip, Marcelo; Imventarza, Oscar] Hosp Nacl Pediat, Serv Transplante Hepat, Buenos Aires, DF, Argentina.
RP Fernandez, MC (reprint author), Hosp Nacl Pediat, Dept Pediat, Prof Dr Juan P Garrahan, Buenos Aires, DF, Argentina.
EM mcfernan1@yahoo.com.ar
CR Cacciarelli TV, 2001, PEDIATR TRANSPLANT, V5, P359, DOI 10.1034/j.1399-3046.2001.00021.x
   Cacciarelli TV, 1998, TRANSPLANTATION, V66, P1047, DOI 10.1097/00007890-199810270-00014
   Collins MH, 2001, PEDIATR TRANSPLANT, V5, P250, DOI 10.1034/j.1399-3046.2001.005004250.x
   COX KL, 1995, TRANSPLANTATION, V59, P524
   Fellner MD, 2003, J CLIN VIROL, V28, P323, DOI 10.1016/S1386-6532(03)00077-5
   Green M, 1999, Pediatr Transplant, V3, P271, DOI 10.1034/j.1399-3046.1999.00066.x
   Green M, 2001, AM J TRANSPLANT, V1, P103, DOI 10.1034/j.1600-6143.2001.10202.x
   HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011
   Holmes RD, 2002, PEDIATR TRANSPLANT, V6, P456, DOI 10.1034/j.1399-3046.2002.02043.x
   HURWITZ M, 2004, PEDIATR TRANSPLANT, V8, P210
   Jaffe ES, 2001, WHO CLASSIFICATION T
   MALATACK JJ, 1991, J PEDIATR-US, V118, P667, DOI 10.1016/S0022-3476(05)80024-1
   Newell KA, 1996, TRANSPLANTATION, V62, P370, DOI 10.1097/00007890-199608150-00012
   RANDHAWA PS, 1992, NEW ENGL J MED, V327, P1710, DOI 10.1056/NEJM199212103272403
NR 14
TC 21
Z9 23
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2009
VL 13
IS 3
BP 307
EP 310
DI 10.1111/j.1399-3046.2008.00914.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 428ZX
UT WOS:000264891700009
PM 18346039
ER

PT J
AU Ghabril, M
   Dickson, RC
   Krishna, M
   Bonatti, H
   Aranda-Michel, J
   Keaveny, AP
   Satyanarayana, R
   Hewitt, W
   Hughes, CB
   Nguyen, JH
AF Ghabril, Marwan
   Dickson, Rolland C.
   Krishna, Murli
   Bonatti, Hugo
   Aranda-Michel, Jaime
   Keaveny, Andrew P.
   Satyanarayana, Raj
   Hewitt, Winston
   Hughes, Christopher B.
   Nguyen, Justin H.
TI Liver Transplantation Using Young Pediatric Donor Grafts in Adults With
   Hepatitis C Infection
SO TRANSPLANTATION
LA English
DT Article
DE Pediatric donor; Hepatitis C; Liver transplantation; Small for size
ID FIBROSIS PROGRESSION; VIRUS-INFECTION; RECIPIENTS; SURVIVAL; AGE;
   TRENDS; IMPACT; SIZE
AB Background. The impact of using grafts from donor's age less than or equal to 13 years on adult hepatitis C virus (HCV) recipients in terms of survival and HCV recurrence is undefined. To determine if adults undergoing liver transplantation for HCV who receive a graft from a donor age less than or equal to 13 years have similar outcomes to recipients of organs from 18- to 35-year-old donors.
   Methods. Records from adult HCV patients undergoing liver transplantation between April 1998 and April 2004 who received whole grafts from non-HCV donors less than 35 years old after brain death were reviewed. Patients with donor age less than or equal to 13 years (group 1) and 18 to 35 years (group 2) were compared for patient and graft survival, allograft rejection, biliary complications, and HCV recurrence.
   Results. Fifty-one HCV patients were analyzed. The two groups were similar except that group 1 donors and recipients were smaller in size. One year patient and graft survival for groups 1 vs. 2 were 93% vs. 94% and 93% vs. 83%, respectively (P=NS). Biliary complications, HCV recurrence, and advanced fibrosis free survival were not significantly different.
   Conclusion. Whole liver grafts from donors age less than or equal to 13 years can potentially be used in selected size-matched adult HCV patients in the absence of an acceptable pediatric recipient.
C1 [Ghabril, Marwan; Dickson, Rolland C.; Aranda-Michel, Jaime; Keaveny, Andrew P.; Satyanarayana, Raj] Mayo Clin, Div Gastroenterol & Hepatol, Dept Med, Jacksonville, FL 32224 USA.
   [Krishna, Murli] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA.
   [Bonatti, Hugo] Mayo Clin, Dept Surg, Jacksonville, FL 32224 USA.
   [Hewitt, Winston; Hughes, Christopher B.; Nguyen, Justin H.] Mayo Clin, Dept Transplantat, Jacksonville, FL 32224 USA.
RP Dickson, RC (reprint author), Mayo Clin, Div Gastroenterol & Hepatol, Dept Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM dickson.rolland1@mayo.edu
OI Ghabril, Marwan/0000-0002-4784-3246
FU Health Resources and Services Administration [234-2005-370011C]
FX This study was supported by the Health Resources and Services
   Administration grant 234-2005-370011C (in part).
CR ADAM R, 1993, TRANSPLANT P, V25, P1105
   BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007
   Ben-Haim M, 2001, LIVER TRANSPLANT, V7, P948, DOI 10.1053/jlts.2001.29033
   Boillot O, 2002, LANCET, V359, P406, DOI 10.1016/S0140-6736(02)07593-1
   Condron SL, 2005, TRANSPLANTATION, V80, P145, DOI 10.1097/01.TP.0000164291.35925.7A
   Emre S, 2001, LIVER TRANSPLANT, V7, P41, DOI 10.1053/jlts.2001.20940
   Feng S, 2006, LIVER TRANSPLANT, V12, P578, DOI 10.1002/lt.20650
   Ghabril M, 2008, AM J TRANSPLANT, V8, P404, DOI 10.1111/j.1600-6143.2007.02082.x
   Machicao VI, 2004, TRANSPLANTATION, V77, P84, DOI 10.1097/01.TP.0000095896.07048.BB
   McDiarmid S, 2001, LIVER TRANSPLANT, V7, P48, DOI 10.1053/jlts.2001.21699
   McDiarmid SV, 2000, TRANSPLANTATION, V70, P1283, DOI 10.1097/00007890-200011150-00005
   MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098
   Neumann UP, 2004, J HEPATOL, V41, P830, DOI 10.1016/j.jhep.2004.06.029
   OLEARY JG, 2007, HEPATOLOGY, V46
   Reddy KS, 2000, CLIN TRANSPLANT, V14, P370, DOI 10.1034/j.1399-0012.2000.14040202.x
   Rifai K, 2004, J HEPATOL, V41, P446, DOI 10.1016/j.jhep.2004.05.013
   TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013
   Yasutomi M, 2001, LIVER TRANSPLANT, V7, P38, DOI 10.1053/jlts.2001.18482
NR 18
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD APR 27
PY 2009
VL 87
IS 8
BP 1174
EP 1179
DI 10.1097/TP.0b013e31819ea72f
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 437BU
UT WOS:000265461600012
PM 19384164
ER

PT J
AU Gangemi, A
   Tzvetanov, IG
   Beatty, E
   Oberholzer, J
   Testa, G
   Sankary, HN
   Kaplan, B
   Benedetti, E
AF Gangemi, Antonio
   Tzvetanov, Ivo G.
   Beatty, Elizabeth
   Oberholzer, Jose
   Testa, Giuliano
   Sankary, Howard N.
   Kaplan, Bruce
   Benedetti, Enrico
TI Lessons Learned in Pediatric Small Bowel and Liver Transplantation From
   Living-Related Donors
SO TRANSPLANTATION
LA English
DT Article
DE Intestinal transplantation; Combined liver bowel transplant;
   Living-related donor
AB Background. Children are the primary candidates for intestinal transplant with more than 70% requiring a combined liver-bowel transplant. We report our single-center experience with living donor intestinal transplantation (LDITx) and combined living donor intestinal and liver transplant (CLDILTx) in pediatric patients.
   Patients and Methods. Between October 2002 and June 2006, 13 living donor intestinal grafts were transplanted in 10 recipients. In five cases CLDILTx was performed. The intestinal grafts consisted of a 150-cm segment of ileum, whereas the liver transplant was completed using standard left lateral grafts.
   Results. No complications occurred in any donors. In CLDILTx recipients, the patient survival at 1 and 2 years was 100%, the liver graft survival 100%, and the bowel graft survival 80%; the patient who lost the initial intestinal graft was successfully retransplanted. In LDITx recipients, the patient and graft survival at 1 and 3 years were 60% and 50%, respectively. Two isolated LDITx recipients, both 6 months of age and low body weight (mean, 6 vs. 9 kg) died within 4 months posttransplant. One LDITx recipient developed chronic rejection 3.5 years after the original transplant and died after retransplant. All patients who are alive with functioning grafts are currently on full enteral feeding without need for any intravenous supplementation, except for a recipient of CLDILTx, currently on total parenteral nutrition for late fistula.
   Conclusions. The early outcomes of intestinal transplantation from living donors are promising, particularly for candidates in need of CLDLITx. In this subgroup, the elimination of the high mortality on the cadaver waiting list (similar to 30%) represents a substantial advantage.
C1 [Gangemi, Antonio; Tzvetanov, Ivo G.; Beatty, Elizabeth; Oberholzer, Jose; Testa, Giuliano; Sankary, Howard N.; Kaplan, Bruce; Benedetti, Enrico] Univ Illinois, Dept Surg, Div Transplantat, Chicago, IL 60680 USA.
RP Benedetti, E (reprint author), 840 S Wood St,Suite 402, Chicago, IL 60612 USA.
EM Enrico@uic.edu
CR Benedetti E, 2006, ANN SURG, V244, P694, DOI 10.1097/01.sla.0000232555.02880.84
   Grant D, 2005, ANN SURG, V241, P607, DOI 10.1097/01.sla.0000157265.85388.a1
   Ishii T, 2006, PEDIATR TRANSPLANT, V10, P244, DOI 10.1111/j.1399-3046.2005.00421.x
   *OPTN SRTR, 2005, ANN REP INT CHAR 200
   Panaro F, 2004, PEDIATR TRANSPLANT, V8, P65, DOI 10.1046/j.1397-3142.2003.00134.x
   Porubsky M, 2006, PEDIATR TRANSPLANT, V10, P701, DOI 10.1111/j.1399-3046.2006.00520.x
   Testa G, 2004, ANN SURG, V240, P779, DOI 10.1097/01.sla.0000143266.59408.d7
   Testa G, 2005, TRANSPLANTATION, V79, P1401, DOI 10.1097/01.TP.0000157280.75015.14
NR 8
TC 11
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD APR 15
PY 2009
VL 87
IS 7
BP 1027
EP 1030
DI 10.1097/TP.0b013e31819cc3bf
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 433DQ
UT WOS:000265184900012
PM 19352122
ER

PT J
AU Mekeel, K
   Moss, A
   Reddy, KS
   Douglas, D
   Mulligan, D
AF Mekeel, Kristin
   Moss, Adyr
   Reddy, Kunam Sudhakar
   Douglas, David
   Mulligan, David
TI Sclerosing Peritonitis and Mortality After Liver Transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID PEDIATRIC INTESTINAL TRANSPLANTATION; ENCAPSULATING PERITONITIS;
   ABDOMINAL COCOON; TAMOXIFEN; FIBROSIS; PATIENT; ASCITES
AB Sclerosing peritonitis describes the development of a peel or rind of fibrosis that spreads over the peritoneal surface and can lead to recalcitrant ascites, bowel obstruction, and sepsis. It is well described as a complication of peritoneal dialysis, especially with episodes of bacterial peritonitis. It is also a complication of end-stage liver disease with ascites and liver transplantation. This article describes 3 cases of sclerosing peritonitis present at the time of liver transplantation or soon after. All 3 patients had massive refractory ascites with episodes of spontaneous bacterial peritonitis prior to transplantation. Two patients had evidence of a fibrous peel at the time of transplantation. Postoperatively, all 3 patients continued to have refractory ascites and episodes of peritonitis, along with partial small bowel obstructions, abdominal pain, and malnutrition. Two patients also had constriction of the graft, including biliary obstruction and inferior vena cava and outflow obstruction, which has not been previously described. All 3 patients eventually died from complications related to the sclerosing peritonitis. Liver Transpl 15: 435-439, 2009. (C) 2008 AASLD.
C1 [Mekeel, Kristin; Moss, Adyr; Reddy, Kunam Sudhakar; Mulligan, David] Mayo Clin Hosp, Div Transplant Surg, Phoenix, AZ 85254 USA.
   [Douglas, David] Mayo Clin Hosp, Div Transplant Med, Phoenix, AZ 85254 USA.
RP Mekeel, K (reprint author), Mayo Clin Hosp, Div Transplant Surg, Phoenix, AZ 85254 USA.
EM mekeel.kristin@mayo.edu
CR Abul S, 2002, J ROY COLL SURG EDIN, V47, P579
   Carbonnel F, 1995, GASTROEN CLIN BIOL, V19, P876
   Cleffken B, 2008, J PEDIATR SURG, V43, DOI 10.1016/j.jpedsurg.2007.11.012
   Courtney AE, 2006, NEPHROL DIAL TRANSPL, V21, P532, DOI 10.1093/ndt/gfi275
   Eltoum MA, 2006, PERITON DIALYSIS INT, V26, P203
   Garosi G, 2006, CONTRIB NEPHROL, V150, P62, DOI 10.1159/000093503
   Koak Y, 2008, EUR J GASTROEN HEPAT, V20, P148, DOI 10.1097/MEG.0b013e3282cf4d98
   Lin CH, 2005, WORLD J GASTROENTERO, V11, P5412
   Macedo C, 2005, PEDIATR TRANSPLANT, V9, P187, DOI 10.1111/j.1399-3046.2005.00278.x
   Maguire D, 2001, AM J SURG, V182, P151, DOI 10.1016/S0002-9610(01)00685-7
   Minutolo V, 2008, G Chir, V29, P173
   Moustafellos P, 2006, TRANSPLANT P, V38, P2913, DOI 10.1016/j.transproceed.2006.08.179
   Nakayama M, 2005, PERITON DIALYSIS INT, V25, pS107
   Noguchi S, 2002, PEDIATR DEVEL PATHOL, V5, P3
   Pepels MJAE, 2006, NETH J MED, V64, P346
   Ramos E, 2007, PEDIATR TRANSPLANT, V11, P937, DOI 10.1111/j.1399-3046.2007.00798.x
   Sachdev A, 2006, AUST NZ J OBSTET GYN, V46, P58, DOI 10.1111/j.1479-828X.2006.00517.x
   Sigaroudinia MO, 2008, J PEDIATR SURG, V43, DOI 10.1016/j.jpedsurg.2008.01.019
   Stanley MM, 1996, DIGEST DIS SCI, V41, P571, DOI 10.1007/BF02282343
   Suh Won Na, 2007, The Korean Journal of Internal Medicine, V22, P125
   Xu P, 2007, WORLD J GASTROENTERO, V13, P3649
   Yamamoto S, 2004, J GASTROENTEROL, V39, P172, DOI 10.1007/s00535-003-1269-6
NR 22
TC 6
Z9 6
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD APR
PY 2009
VL 15
IS 4
BP 435
EP 439
DI 10.1002/lt.21702
PG 5
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 430LV
UT WOS:000264991500011
PM 19326414
ER

PT J
AU Carius, LP
   Pacheco-Moreira, LF
   Balbi, E
   Leal, CRG
   Gonzalez, AC
   Agoglia, LV
   Araujo, C
   Enne, M
   Martinho, JM
AF Carius, L. P.
   Pacheco-Moreira, L. F.
   Balbi, E.
   Leal, C. R. G.
   Gonzalez, A. C.
   Agoglia, L. V.
   Araujo, C.
   Enne, M.
   Martinho, J. M.
TI Living Donor Liver Transplantation for Acute Liver Failure: A Single
   Center Experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Portuguese-Brazilian Transplantation Conference
CY OCT 01-04, 2008
CL Algarve, PORTUGAL
ID FULMINANT HEPATIC-FAILURE; CHILDREN
AB Objective. Orthotopic liver transplantation (OLT) is the principal therapy for acute liver failure (ALF). The mortality on the waiting list for deceased donor liver transplantation (DDLT) is high, principally in countries where donation rates are low. Living donor liver transplantation (LDLT) seems an option for the treatment of ALF, although some ethical issues need to be considered. Herein we have evaluated LDLT results among patients with ALF and discussed the ethical aspects of procedures performed in emergency situations.
   Patients and Methods. From March 2002 to October 2008, we performed 301 liver transplantations, including 103 from living donors. ALF was responsible for 10.6% of all transplantations; LDLT was only considered for pediatric recipients among whom 7 children displayed ALF.
   Results. One patient died on postoperative day 33 due to hepatic artery thrombosis. One patient died at 2 months after transplantation due to biliary sepsis, resulting in an overall survival rate of 71%. The average time for donor discharge was 5 days. No mortality or major complications were observed.
   Conclusions. The survival of children with ALF undergoing LDLT was comparable to published data. Furthermore, despite the fact that the available time to prepare the donors was limited, no serious complications were observed in the postoperative period. Thus, using living donors for children with ALF is an effective, safe alternative that can be extremely useful in countries with low donation rates.
C1 [Carius, L. P.; Pacheco-Moreira, L. F.; Balbi, E.; Leal, C. R. G.; Gonzalez, A. C.; Agoglia, L. V.; Araujo, C.; Enne, M.; Martinho, J. M.] Bonsucesso Gen Hosp, Liver Transplantat Unit, BR-21041030 Rio De Janeiro, Brazil.
RP Pacheco-Moreira, LF (reprint author), Bonsucesso Gen Hosp, Liver Transplantat Unit, Av Londres 616, BR-21041030 Rio De Janeiro, Brazil.
EM pacheco.lucio@gmail.com
CR Campsen J, 2008, LIVER TRANSPLANT, V14, P1273, DOI 10.1002/lt.21500
   Emre S, 1999, LIVER TRANSPLANT SUR, V5, P161, DOI 10.1002/lt.500050315
   Ikegami T, 2008, J AM COLL SURGEONS, V206, P412, DOI 10.1016/j.jamcollsurg.2007.08.018
   Karakayali H, 2007, TRANSPL P, V39, P1157, DOI 10.1016/j.transproceed.2007.02.053
   Kilic M, 2007, TRANSPLANTATION, V84, P475, DOI 10.1097/01.tp.0000276987.55382.e2
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   Mack CL, 2001, LIVER TRANSPLANT, V7, P890, DOI 10.1053/jlts.2001.27963
   Miwa S, 1999, HEPATOLOGY, V30, P1521, DOI 10.1002/hep.510300621
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439
   RAIA S, 1989, LANCET, V2, P497
   RIORDAN SM, 2005, TRANSPLANTATION LIVE, P161, DOI 10.1016/B978-0-7216-0118-2.50016-1
   Uemoto S, 2000, TRANSPLANTATION, V70, P152
NR 12
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2009
VL 41
IS 3
BP 895
EP 897
DI 10.1016/j.transproceed.2009.02.007
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 437RJ
UT WOS:000265504300031
PM 19376382
ER

PT J
AU Grevious, MA
   Iqbal, R
   Raofi, V
   Beatty, E
   Oberholzer, J
   Cohen, M
   Abcarian, H
   Testa, G
   Benedetti, E
AF Grevious, Mark A.
   Iqbal, Ronak
   Raofi, Vandad
   Beatty, Elizabeth
   Oberholzer, Jose'
   Cohen, Mimis
   Abcarian, Herand
   Testa, Giuliano
   Benedetti, Enrico
TI Staged approach for abdominal wound closure following combined liver and
   intestinal transplantation from living donors in pediatric patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE abdominal wall reconstruction; intestine; liver transplant; pediatric
   wound closure; living donor; short gut syndrome; mesh reconstruction
ID VACUUM PACK TECHNIQUE; BOWEL TRANSPLANTATION; 7-YEAR EXPERIENCE; WALL
   CLOSURE; RECONSTRUCTION; NUTRITION; DEFECTS
AB Primary closure of the abdominal wall after combined liver and intestine transplantation from a living donor into a pediatric patient is usually not possible, because of the size of the donor organ, graft edema, and preexisting scars or stomas of the abdominal wall. Closure under tension may lead to abdominal compartment syndrome with vascular compromise and necrosis of the transplanted organ. We describe our experience of abdominal wound closure after liver and intestinal transplant in the pediatric patient using a staged approach. From February 2003 to June 2006, we managed five pediatric liver and intestinal living donor transplant recipients. Because of the large post-transplantation abdominal wall defect, a staged technique of abdominal wound closure was utilized. Initially, an absorbable Polygalactin mesh was sutured around the layer of the defect. As soon as adequate granulation tissue was formed over the mesh a STSG was applied. From the wound stand point all five patients were managed successfully with staged wound closure after transplantation. Granulation tissue filled and covered the mesh within 7.6 wk. A STSG was then used to cover the defect. All infants recovered well and none had a significant wound complication in the immediate post-operative period following STSG. At a mean follow-up of 24 months only one patient developed an entero-cutaneous fistula five months post-transplant. Staged abdominal wall coverage with the use of Polygalactin mesh followed by STSG is a simple and effective technique. A closed wound is achieved in a timely fashion with protection of the viscera. Residual ventral hernia will need to be managed in the future with one of several reconstructive techniques.
C1 [Grevious, Mark A.; Cohen, Mimis] Univ Illinois, Div Plast Surg, Chicago, IL 60612 USA.
   [Iqbal, Ronak; Abcarian, Herand] Univ Illinois, Dept Gen Surg, Chicago, IL 60612 USA.
   [Raofi, Vandad; Beatty, Elizabeth; Oberholzer, Jose'; Testa, Giuliano; Benedetti, Enrico] Univ Illinois, Div Transplantat, Chicago, IL 60612 USA.
RP Grevious, MA (reprint author), Univ Illinois, Div Plast Surg, 820 S Wood St,CSN Suite 515, Chicago, IL 60612 USA.
EM mgrev@uic.edu
CR Alexandrides IJ, 2000, PLAST RECONSTR SURG, V106, P805, DOI 10.1097/00006534-200009040-00008
   Barker DE, 2000, J TRAUMA, V48, P201, DOI 10.1097/00005373-200002000-00001
   Benedetti E, 2006, ANN SURG, V244, P694, DOI 10.1097/01.sla.0000232555.02880.84
   Cohen M, 2001, PLAST RECONSTR SURG, V108, P83, DOI 10.1097/00006534-200107000-00014
   Detre K M, 1989, Clin Transpl, P9
   Grevious MA, 2006, CLIN PLAST SURG, V33, P181, DOI 10.1016/j.cps.2005.12.002
   Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x
   Kelly DA, 1998, NUTRITION, V14, P153, DOI 10.1016/S0899-9007(97)00232-3
   Levi DM, 2003, LANCET, V361, P2173, DOI 10.1016/S0140-6736(03)13769-5
   Nagy KK, 1996, AM SURGEON, V62, P331
   Nathan JD, 2007, J PEDIATR SURG, V42, P143, DOI 10.1016/j.jpedsurg.2006.09.049
   Nery JR, 1998, TRANSPLANT P, V30, P2640, DOI 10.1016/S0041-1345(98)00762-3
   Ong TH, 1996, J PEDIATR SURG, V31, P295, DOI 10.1016/S0022-3468(96)90019-6
   RAMIREZ OM, 1990, PLAST RECONSTR SURG, V86, P519, DOI 10.1097/00006534-199009000-00023
   Selvaggi G, 2004, TRANSPLANT P, V36, P1561, DOI 10.1016/j.transproceed.2004.05.037
   Stewart RM, 2000, J TRAUMA, V48, P206
   Sukkar SM, 2001, AM J SURG, V181, P115, DOI 10.1016/S0002-9610(00)00566-3
   Testa G, 2004, ANN SURG, V240, P779, DOI 10.1097/01.sla.0000143266.59408.d7
   Testa G, 2005, TRANSPLANTATION, V79, P1401, DOI 10.1097/01.TP.0000157280.75015.14
   VASSILIOU M, 2005, PLAST RECONSTR SUR S, V116, P123, DOI 10.1097/00006534-200509011-00102
   DATA UNITED NETWORK
NR 21
TC 16
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2009
VL 13
IS 2
BP 177
EP 181
DI 10.1111/j.1399-3046.2008.00966.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 402YA
UT WOS:000263047800008
PM 18537902
ER

PT J
AU Saito, T
   Mizuta, K
   Hishikawa, S
   Kawano, Y
   Sanada, Y
   Fujiwara, T
   Yasuda, Y
   Sugimoto, K
   Sakamoto, K
   Kawarasaki, H
AF Saito, Takeshi
   Mizuta, Koichi
   Hishikawa, Shuji
   Kawano, Youichi
   Sanada, Yukihiro
   Fujiwara, Takehito
   Yasuda, Yoshikazu
   Sugimoto, Koichi
   Sakamoto, Koichi
   Kawarasaki, Hideo
TI Lymphocytotoxic crossmatch in pediatric living donor liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; living donor liver transplantation;
   acute rejection; graft survival; lymphocytotoxic crossmatch; humoral
   theory
ID FLOW-CYTOMETRY; ACUTE REJECTION; RECIPIENTS; SURVIVAL; IMPACT; RISK
AB To investigate the relationship between the pretransplant LCT results and the outcome after pediatric LDLT in a single center. The clinical data of 76 children undergoing 79 LDLTs including three retransplantations from May 2001 to January 2006 were retrospectively analyzed. All of the children had end-stage liver disease, and their median age was 1.4 yr (range, six months to 16.5 yr). Immunosuppressive therapy consisted of cyclosporine- or FK-based regimens with steroids. The children were classified into two groups (positive or negative) according to the pretransplant LCT results. The incidences of post-transplant surgical complications and of rejection episodes were compared. The relationship between the pretransplant LCT results and patient and graft survival rates was also analyzed. Seventy-nine pretransplant crossmatch tests were done; 13 (16.5%) were positive, and 66 (83.5%) were negative. No significant difference was found in the pretransplant clinical factors between two crossmatch groups. There was no significant difference between the groups in the incidence of vascular and biliary tract complications, in the rate of early or steroid-resistant cellular rejections, or in one- and three-yr patient (91.7%, 91.7%, respectively, in the positive group, 93.5%, 93.5%, respectively, in the negative group, p = 0.80) and graft (92.3%, 92.3%, respectively, in the positive group, 88.8%, 86.4%, respectively, in the negative group, p = 0.63) survival. The present study demonstrates that there is no reason to do pretransplant LCT to select the living donor for pediatric LDLT.
C1 [Saito, Takeshi; Mizuta, Koichi; Hishikawa, Shuji; Kawano, Youichi; Sanada, Yukihiro; Kawarasaki, Hideo] Jichi Med Univ, Div Transplant Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Fujiwara, Takehito; Yasuda, Yoshikazu] Jichi Med Univ, Div Surg, Shimotsuke, Tochigi 3290498, Japan.
   [Sugimoto, Koichi] Jichi Med Univ, Div Clin Pharmacol, Shimotsuke, Tochigi 3290498, Japan.
   [Sakamoto, Koichi] Jichi Med Univ, Div Pharmacol, Shimotsuke, Tochigi 3290498, Japan.
   [Saito, Takeshi] Chiba Univ, Grad Sch Med, Dept Pediat Surg E6, Chiba, Japan.
RP Saito, T (reprint author), Jichi Med Univ, Div Transplant Surg, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM takk@faculty.chiba-u.jp
CR Bathgate AJ, 1998, LIVER TRANSPLANT SUR, V4, P280
   Dagher L, 1999, TRANSPLANT P, V31, P2363, DOI 10.1016/S0041-1345(99)00379-6
   DONALDSON PT, 1995, TRANSPLANTATION, V60, P1016, DOI 10.1097/00007890-199511150-00024
   Doran TJ, 2000, TRANSPLANTATION, V69, P1491, DOI 10.1097/00007890-200004150-00047
   Doyle HR, 1996, ANN SURG, V224, P168, DOI 10.1097/00000658-199608000-00009
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Goggins WC, 1996, TRANSPLANTATION, V62, P1794, DOI 10.1097/00007890-199612270-00019
   Gugenheim J, 1999, TRANSPLANT P, V31, P552, DOI 10.1016/S0041-1345(98)01551-6
   Hathaway M, 1997, TRANSPLANTATION, V64, P54, DOI 10.1097/00007890-199707150-00011
   Kasahara M, 1999, TRANSPLANTATION, V67, P568, DOI 10.1097/00007890-199902270-00014
   KATZ SM, 1994, TRANSPLANTATION, V57, P616
   MANUEL M, 2005, TRANSPL IMMUNOL, V14, P91
   Neumann UP, 2001, TRANSPLANTATION, V71, P1163, DOI 10.1097/00007890-200104270-00025
   Suehiro T, 2005, LIVER INT, V25, P1182, DOI 10.1111/j.1478-3231.2005.01160.x
   Sugawara Y, 2003, CLIN TRANSPLANT, V17, P347, DOI 10.1034/j.1399-0012.2003.00057.x
   Takakura K, 2001, CLIN TRANSPLANT, V15, P309, DOI 10.1034/j.1399-0012.2001.150502.x
   Terasaki PI, 2003, AM J TRANSPLANT, V3, P665, DOI 10.1034/j.1600-6143.2003.00135.x
   Terasaki PI, 2004, AM J TRANSPLANT, V4, P438, DOI 10.1111/j.1600-6143.2004.00360.x
NR 18
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2009
VL 13
IS 2
BP 194
EP 199
DI 10.1111/j.1399-3046.2008.00982.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 402YA
UT WOS:000263047800011
PM 18503481
ER

PT J
AU Schubert, S
   Abdul-Khaliq, H
   Lehmkuhl, HB
   Yegitbasi, M
   Reinke, P
   Kebelmann-Betzig, C
   Hauptmann, K
   Gross-Wieltsch, U
   Hetzer, R
   Berger, F
AF Schubert, S.
   Abdul-Khaliq, H.
   Lehmkuhl, H. B.
   Yegitbasi, M.
   Reinke, P.
   Kebelmann-Betzig, C.
   Hauptmann, K.
   Gross-Wieltsch, U.
   Hetzer, R.
   Berger, F.
TI Diagnosis and treatment of post-transplantation lymphoproliferative
   disorder in pediatric heart transplant patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplant lymphoproliferative disease; Epstein-Barr virus;
   pediatric heart transplant; PCR; maintenance immunosuppression; T
   lymphocytes
ID EPSTEIN-BARR-VIRUS; SINGLE-CENTER EXPERIENCE; KIDNEY-TRANSPLANTATION;
   LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; ORGAN-TRANSPLANTATION;
   RISK-FACTORS; DISEASE; RECIPIENTS; PTLD
AB PTLD is a severe complication in transplant recipients. Detection of increased EBV load in the peripheral blood acts as a surrogate marker for increased risk of PTLD development. We analyzed the time course of the disease, its severitiy, the organs involved, and mortality rates in our institutional experience of pediatric heart transplantation. This paper identifies risk factors for PTLD and describes the different ways of diagnosing and treating the disease. PTLD was screened for in 146 pediatric heart transplant patients using a retrospective analysis in patients who received transplantation before 1998. Prospective determination was performed in 72/146 patients transplanted after 1998 within the post-transplant follow-up. The occurrence of PTLD with all interventions, including tapering of immunosuppression, surgery, viral monitoring, and antiviral interventions, was recorded. PTLD was diagnosed in 12/147 (8.2%) children at a mean age of 7.2 +/- 3.3 yr after a mean post-transplant period of 3.2 +/- 2.2 yr. PTLD manifested in: lymph nodes (n = 4), intestine (n = 3), tonsils and adenoids (n = 2), eye (n = 2), and lung (n = 1). It was diagnosed in 7/12 as a monomorphic B-cell lymphoma and in four patients as a monomorphic Burkitt lymphoma, a polymorphic B-cell lymphoma, a T-cell rich or angiocentric lymphoma (Liebow) and as reactive plasmacytic hyperplasia (early lesion), respectively. Histology was not possible in one patient with ocular manifestation. EBV association was 83%. Risk factors in the comparison with patients without PTLD were age at time of Tx, primary EBV infection after Tx, use of Azathioprine and >= 3 doses of ATG. CMV mismatch and CMV infection, rejection episodes and steroids were not risk factors. Despite reduction of immunosuppression, treatment consisted of surgical procedures to remove tumor masses (n = 6), Rituximab (n = 5), polychemotherapy (n = 3), antiviral (n = 1) and autologous T-cell therapy (n = 1). All patients demonstrated full remission without death related to PTLD or treatment at 3.9 (1.3-6.2) yr median follow-up time. The manifestation of PTLD in pediatric heart transplant recipients is associated with EBV infection and is predominantly in the form of a B-cell lymphoma. A tight and specific follow-up including early assessment of immunity status and specific therapeutic intervention to improve cellular immunity is warranted and may contribute to a significant reduction of PTLD-related morbidity and mortality.
C1 [Schubert, S.; Yegitbasi, M.; Berger, F.] Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects Pediat Cardiol, D-13353 Berlin, Germany.
   [Abdul-Khaliq, H.] Saarland Univ Hosp, Dept Pediat Cardiol, Homburg, Germany.
   [Lehmkuhl, H. B.] Deutsch Herzzentrum Berlin, Dept Internal Med Cardiol, D-13353 Berlin, Germany.
   [Reinke, P.] Charite Univ Med Berlin, Dept Nephrol & Intens Care, D-13353 Berlin, Germany.
   [Kebelmann-Betzig, C.] Charite Univ Med Berlin, Dept Pediat Hematol & Oncol, D-13353 Berlin, Germany.
   [Hauptmann, K.] Charite Univ Med Berlin, Dept Pathol, D-13353 Berlin, Germany.
   [Gross-Wieltsch, U.] Olga Hosp, Dept Pediat Hematol & Oncol, Stuttgart, Germany.
   [Hetzer, R.] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, D-13353 Berlin, Germany.
RP Schubert, S (reprint author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM sschubert@dhzb.de
CR Aalto SM, 1998, J MED VIROL, V56, P186, DOI 10.1002/(SICI)1096-9071(199811)56:3<186::AID-JMV2>3.0.CO;2-3
   Allen UD, 2005, PEDIATR TRANSPLANT, V9, P450, DOI 10.1111/j.1399-3046.2005.00318.x
   Aull MJ, 2004, TRANSPLANTATION, V78, P1676, DOI 10.1097/01.TP.0000144333.19106.58
   Bakker NA, 2005, CLIN TRANSPLANT, V19, P327, DOI 10.1111/j.1399-0012.2005.00342.x
   Birkeland SA, 2003, TRANSPLANTATION, V76, P984, DOI 10.1097/01.TP.0000085602.22498.CF
   Caillard S, 2005, TRANSPLANTATION, V80, P1233, DOI 10.1097/01.tp.0000179639.98338.39
   Caillard S, 2006, AM J TRANSPLANT, V6, P2735, DOI 10.1111/j.1600-6143.2006.01540.x
   Cao S, 1998, TRANSPLANTATION, V66, P851, DOI 10.1097/00007890-199810150-00007
   Cohen AH, 2000, AM J RESP CRIT CARE, V161, P1252
   Comoli P, 2002, BLOOD, V99, P2592, DOI 10.1182/blood.V99.7.2592
   Dharnidharka V, 2003, PEDIATR TRANSPLANT, V7, P337, DOI 10.1034/j.1399-3046.2003.00031.x
   Dharnidharka VR, 2001, TRANSPLANTATION, V71, P1065, DOI 10.1097/00007890-200104270-00010
   Dharnidharka VR, 2005, PEDIATR TRANSPLANT, V9, P622, DOI 10.1111/j.1399-3046.2005.00361.x
   Dror Y, 1999, TRANSPLANTATION, V67, P990, DOI 10.1097/00007890-199904150-00010
   El-Salem M, 2007, LAB INVEST, V87, P29, DOI 10.1038/labinvest.3700494
   Elstrom RL, 2006, AM J TRANSPLANT, V6, P569, DOI 10.1111/j.1600-6143.2005.01211.x
   Frey NV, 2007, MED ONCOL, V24, P125, DOI 10.1007/BF02698031
   Gao SZ, 2003, J HEART LUNG TRANSPL, V22, P505, DOI 10.1016/S1053-2498(02)01229-9
   GRAMBSCH P, 1994, STAT MED, V13, P1619, DOI 10.1002/sim.4780131603
   Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8
   Hymes LC, 2005, PEDIATR TRANSPLANT, V9, P520, DOI 10.1111/j.1399-3046.2005.00324.x
   LAMY ME, 1990, MED MICROBIOL IMMUN, V179, P137
   Leblond V, 1998, J CLIN ONCOL, V16, P2052
   Lee JJ, 2007, ANN PHARMACOTHER, V41, P1648, DOI 10.1345/aph.1K175
   Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19
   Manez R, 1997, J INFECT DIS, V176, P1462
   Mendoza F, 2006, PEDIATR TRANSPLANT, V10, P60, DOI 10.1111/j.1399-3046.2005.00401.x
   Merlino C, 2001, New Microbiol, V24, P223
   Nalesnik M A, 1997, Ann Transplant, V2, P33
   Nalesnik M A, 2001, Transpl Infect Dis, V3, P88, DOI 10.1034/j.1399-3062.2001.003002088.x
   Nalesnik M A, 1996, Semin Thorac Cardiovasc Surg, V8, P139
   Nalesnik Michael A, 2002, Recent Results Cancer Res, V159, P9
   Raj R, 2005, J HEART LUNG TRANSPL, V24, P671, DOI 10.1016/j.healun.2004.04.011
   Riebel T, 2007, ULTRASCHALL MED, V28, P201, DOI 10.1055/s-2006-926690
   Ross M, 2006, J HEART LUNG TRANSPL, V25, P261, DOI 10.1016/j.healun.2005.09.011
   SALAMAN J, 1988, TRANSPLANT P, V20, P117
   Savoldo B, 2005, AM J TRANSPLANT, V5, P566, DOI 10.1111/j.1600-6143.2004.00693.x
   Savoldo B, 2006, BLOOD, V108, P2942, DOI 10.1182/blood-2006-05-021782
   Schubert S, 2008, J HEART LUNG TRANSPL, V27, P100, DOI 10.1016/j.healun.2007.09.027
   Sherritt MA, 2003, TRANSPLANTATION, V75, P1556, DOI 10.1097/01.TP.0000058745.02123.6F
   Shroff R, 2004, PEDIATR NEPHROL, V19, P369, DOI 10.1007/s00467-003-1392-x
   Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165
   Verschuuren EAM, 2002, TRANSPLANTATION, V73, P100, DOI 10.1097/00007890-200201150-00019
   Wasson S, 2006, J CARDIOVASC PHARM T, V11, P77, DOI 10.1177/107424840601100107
   Zangwill SD, 1998, J HEART LUNG TRANSPL, V17, P1161
NR 45
TC 33
Z9 33
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2009
VL 13
IS 1
BP 54
EP 62
DI 10.1111/j.1399-3046.2008.00969.x
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 392EJ
UT WOS:000262285400010
PM 18518912
ER

PT J
AU Oya, H
   Sato, Y
   Yamamoto, S
   Kobayashi, T
   Watanabe, T
   Kokai, H
   Hatakeyama, K
AF Oya, H.
   Sato, Y.
   Yamamoto, S.
   Kobayashi, T.
   Watanabe, T.
   Kokai, H.
   Hatakeyama, K.
TI De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation in
   a 25-Day-Old Newborn Baby: A Case Report
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 22nd International Congress of the Transplantation-Society
CY AUG 10-14, 2008
CL Local Org Comm, Sydney, AUSTRALIA
SP Transplantat Soc, Transplantat Soc Australia & New Zealand
HO Local Org Comm
ID CIRRHOSIS
AB De novo autoimmune hepatitis (AIH) has been described recently as a new type of graft dysfunction in pediatric patients receiving liver transplantation. Herein we have reported the case of a boy, diagnosed as neonatal hemochromatosis, who received a reduced left lateral graft 25 days after birth. Pretransplantation autoantibodies and serological tests were negative. The postoperative course was smooth. No episode of vascular or biliary complication or acute cellular rejection was observed. The maintenance immunosuppressant was tacrolimus only. Liver dysfunction occurred 13 months after living donor liver transplantation. Liver biopsies showed no acute cellular rejection, but severe apoptosis and regeneration of liver cells at the centrolobular area. At that time, various autoantibodies including anti-nuclear, anti-double-stranded DNA, and anti-smooth muscle antibodies were positive. In addition, serum immunoglobulin G (IgG) was elevated. Based on these findings, he was diagnosed as de novo AIR. The treatment consisted of reducing the tacrolimus dose and reintroduction of steroids. After 12 months of treatment, liver dysfunction improved, serum autoantibodies became negative, and serum IgG level normalized. Currently his immunosuppressive therapy consists of low-dose tacrolimus and prednisolone. In conclusion, the present case demonstrated that de novo AIH can appear in living donor liver transplant patients despite appropriate immunosuppression. Reducing the tacrolimus dose and reintroduction of prednisolone sustained the graft and prevented retransplantation.
C1 [Oya, H.; Sato, Y.; Yamamoto, S.; Kobayashi, T.; Watanabe, T.; Kokai, H.; Hatakeyama, K.] Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, Niigata 9518510, Japan.
RP Oya, H (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, 1-757 Asahimachi Dori, Niigata 9518510, Japan.
CR Gibelli NE, 2006, PEDIATR TRANSPLANT, V10, P371, DOI 10.1111/j.1399-3046.2005.00470.x
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Miyagawa-Hayashino A, 2004, TRANSPLANTATION, V78, P128, DOI 10.1097/01.TP.0000132328.33460.43
   Salcedo M, 2002, HEPATOLOGY, V35, P349, DOI 10.1053/jhep.2002.31167
   Yoshizawa K, 2008, CLIN TRANSPLANT, V22, P385, DOI 10.1111/j.1399-0012.2007.00787.x
NR 5
TC 5
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2009
VL 41
IS 1
BP 433
EP 434
DI 10.1016/j.transproceed.2008.10.031
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 412UG
UT WOS:000263749100113
PM 19249573
ER

PT J
AU Bucuvalas, JC
   Alonso, E
   Magee, JC
   Talwalkar, J
   Hanto, D
   Doo, E
AF Bucuvalas, J. C.
   Alonso, E.
   Magee, J. C.
   Talwalkar, J.
   Hanto, D.
   Doo, E.
TI Improving Long-Term Outcomes After Liver Transplantation in Children
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Children; liver transplantation; outcomes
ID CARDIOVASCULAR RISK-FACTORS; REGULATORY T-CELLS; EPSTEIN-BARR-VIRUS;
   POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDERS; HEALTH-INSURANCE
   CONSIDERATIONS; DONOR-SPECIFIC ALLOREACTIVITY; CHRONIC RENAL
   DYSFUNCTION; QUALITY-OF-LIFE; CALCINEURIN INHIBITORS; HISTONE
   ACETYLATION
AB The objective was to review the current state of knowledge and recommend future research directions related to long-term outcomes for pediatric liver transplant recipients. A 1-day Clinical Research Workshop on Improving Long-Term Outcomes for Pediatric Liver Transplant Recipients was held on February 12, 2007, in Washington, DC. The speaker topics were germane to research priorities delineated in the chapters on Pediatric Liver Diseases and on Liver Transplantation in the Trans-NIH Action Plan for Liver Disease Research. Issues that compromise long-term well-being and survival but are amenable to existing and new research efforts were presented and discussed. Areas of research that further enhanced the research priorities in the Action Plan for Liver Disease Research included collection of longitudinal data to define emerging trends of clinical challenges; identification of risk factors associated with long-term immunosuppression complications; development of tolerance-inducing regimens; definition of biomarkers that reflect the level of clinical immunosuppression; development of instruments for the measurement of health wellness; identification of risk factors that impede growth and intellectual development before and after liver transplantation and identification of barriers and facilitators that impact nonadherence and transition of care for adolescents.
C1 [Bucuvalas, J. C.] Cincinnati Childrens Hosp, Pediat Liver Care Ctr, Cincinnati, OH USA.
   [Alonso, E.] Childrens Mem Hosp, Siragusa Transplant Ctr, Chicago, IL 60614 USA.
   [Alonso, E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Magee, J. C.] Univ Michigan Hlth Syst, Sect Gen Surg, Div Transplantat, Ann Arbor, MI USA.
   [Talwalkar, J.] Mayo Clin, Transplant Ctr, Rochester, MN USA.
   [Hanto, D.] Beth Israel Deaconess Med Ctr, Div Transplantat, Boston, MA 02215 USA.
   [Doo, E.] NIDDK, Liver Dis Res Branch, Natl Inst Hlth, Bethesda, MD USA.
RP Bucuvalas, JC (reprint author), Cincinnati Childrens Hosp, Pediat Liver Care Ctr, Cincinnati, OH USA.
EM john.bucuvalas@cchmc.org
FU Liver Diseases Research Branch; Division of Digestive Diseases and
   Nutrition; National Institute of Diabetes; Digestive and Kidney
   Diseases; National Institutes of Health
FX The workshop was sponsored by the Liver Diseases Research Branch,
   Division of Digestive Diseases and Nutrition, National Institute of
   Diabetes and Digestive and Kidney Diseases (NIDDK) in collaboration with
   the Office of Rare Diseases (ORD), National Institutes of Health.
CR Adeback P, 2003, PEDIATR TRANSPLANT, V7, P385, DOI 10.1034/j.1399-3046.2003.00081.x
   Alonso EM, 2003, J PEDIATR GASTR NUTR, V37, P155, DOI 10.1097/00005176-200308000-00014
   Alonso EM, 2008, LIVER TRANSPLANT, V14, P460, DOI 10.1002/lt.21352
   Barkmann A, 2000, TRANSPLANTATION, V69, P1886, DOI 10.1097/00007890-200005150-00025
   Barozzi P, 2003, NAT MED, V9, P554, DOI 10.1038/nm862
   Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302
   BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F
   Birkeland SA, 2002, TRANSPLANTATION, V74, P1409, DOI 10.1097/01.TP.0000034717.19606.B5
   Bucuvalas JC, 2003, LIVER TRANSPLANT, V9, P62, DOI 10.1053/jlts.2002.50012
   Bucuvalas JC, 2003, PEDIATR TRANSPLANT, V7, P265, DOI 10.1034/j.1399-3046.2003.02054.x
   Bucuvalas JC, 2006, J PEDIATR GASTR NUTR, V43, pS41, DOI 10.1097/01.mpg.0000226389.64236.dc
   Butler JA, 2004, TRANSPLANTATION, V77, P769, DOI 10.1097/01.TP.0000110408.83054.88
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200
   Choquet S, 2006, BLOOD, V107, P3053, DOI 10.1182/blood-2005-01-0377
   CODONERFRANCH P, 1994, J PEDIATR-US, V124, P368, DOI 10.1016/S0022-3476(94)70357-4
   Cohen AJ, 2002, LIVER TRANSPLANT, V8, P916, DOI 10.1053/jlts.2002.35668
   Davis PH, 2001, CIRCULATION, V104, P2815, DOI 10.1161/hc4601.099486
   Evans HM, 2005, TRANSPLANTATION, V79, P1575, DOI 10.1097/01.TP.0000163504.29054.3F
   Evans HM, 2006, HEPATOLOGY, V43, P1109, DOI 10.1002/hep.21152
   Everhart JE, 1998, LIVER TRANSPLANT SUR, V4, P285
   Fisher NC, 1998, TRANSPLANTATION, V66, P59, DOI 10.1097/00007890-199807150-00010
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Fredericks EM, 2007, AM J TRANSPLANT, V7, P1974, DOI 10.1111/j.1600-6143.2007.01878.x
   Geenen SJ, 2003, J ADOLESCENT HEALTH, V32, P225, DOI 10.1016/S1054-139X(02)00396-8
   Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010
   Gross TG, 2005, J CLIN ONCOL, V23, P6481, DOI 10.1200/JCO.2005.08.074
   Horslen S, 2007, AM J TRANSPLANT, V7, P1339, DOI 10.1111/j.1600-6143.2007.01780.x
   Kaller T, 2005, TRANSPLANTATION, V79, P1252, DOI 10.1097/01.TP.0000161251.20520.42
   Kennard BD, 1999, J DEV BEHAV PEDIATR, V20, P17, DOI 10.1097/00004703-199902000-00003
   Khera N, 2007, FRONT BIOSCI, V12, P660, DOI 10.2741/2090
   Lam AL, 2005, CHROMOSOMA, V114, P242, DOI 10.1007/s00412-005-0001-0
   Leblond V, 2001, J CLIN ONCOL, V19, P772
   Leblond V, 1998, J CLIN ONCOL, V16, P2052
   Lee TC, 2005, AM J TRANSPLANT, V5, P2222, DOI 10.1111/j.1600-6143.2005.01002.x
   Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104
   Lotstein DS, 2005, PEDIATRICS, V115, P1562, DOI 10.1542/peds.2004-1262
   Manzanares C, 2002, THERAPIE, V57, P133
   Mathis AS, 2001, TRANSPLANTATION, V71, P1069, DOI 10.1097/00007890-200104270-00011
   Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102
   Mazariegos GV, 1997, TRANSPLANTATION, V63, P243, DOI 10.1097/00007890-199701270-00012
   McDiarmid SV, 1999, TRANSPLANTATION, V67, P404, DOI 10.1097/00007890-199902150-00011
   McDonagh JE, 2005, PEDIATR TRANSPLANT, V9, P364, DOI 10.1111/j.1399-3046.2004.00287.x
   McKinsey TA, 2004, TRENDS GENET, V20, P206, DOI 10.1016/j.tig.2004.02.002
   Meyer AA, 2006, PEDIATRICS, V117, P1560, DOI 10.1542/peds.2005-2140
   Nair S, 2003, LIVER TRANSPLANT, V9, P126, DOI 10.1053/jlts.2003.50026
   Nair S, 2002, HEPATOLOGY, V35, P105, DOI 10.1053/jhep.2002.30318
   Oike F, 2002, TRANSPLANT P, V34, P1521, DOI 10.1016/S0041-1345(02)02980-9
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Otte JB, 2004, PEDIATR BLOOD CANCER, V42, P74, DOI 10.1002/pbc.10376
   Parasrampuria DA, 2002, J CLIN PHARMACOL, V42, P304, DOI 10.1177/00912700222011337
   Pawarode A, 2003, LIVER TRANSPLANT, V9, P741, DOI 10.1053/jlts.2003.50113
   Penn I, 1996, TRANSPLANTATION, V61, P274, DOI 10.1097/00007890-199601270-00019
   PENN I, 1990, NEW ENGL J MED, V323, P1767, DOI 10.1056/NEJM199012203232510
   Penn I, 2000, DRUG SAFETY, V23, P101, DOI 10.2165/00002018-200023020-00002
   RAMOS HC, 1995, TRANSPLANTATION, V59, P212, DOI 10.1097/00007890-199501270-00010
   Reiss JG, 2005, PEDIATRICS, V115, P112, DOI 10.1542/peds.2004-1321
   Rianthavorn P, 2005, PEDIATR TRANSPLANT, V9, P398, DOI 10.1111/j.1399-3046.2005.00358.x
   Scal P, 1999, J ADOLESCENT HEALTH, V24, P259, DOI 10.1016/S1054-139X(98)00127-X
   Schmidt-Lucke C, 2007, AM J PHYSIOL-HEART C, V292, pH2425, DOI 10.1152/ajpheart.01197.2006
   Shalev A, 2005, PEDIATR TRANSPLANT, V9, P718, DOI 10.1111/j.1399-3046.2005.00365.x
   Shemesh E, 2004, PEDIATRICS, V113, P825, DOI 10.1542/peds.113.4.825
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Sindhi R, 2005, AM J TRANSPLANT, V5, P96, DOI 10.1111/j.1600-6143.2004.00639.x
   Soltys KA, 2007, AM J TRANSPLANT, V7, P2165, DOI 10.1111/j.1600-6143.2007.01893.x
   Stuber ML, 2006, CHILD ADOL PSYCH CL, V15, P597, DOI 10.1016/j.chc.2006.02.006
   Takatsuki M, 2001, TRANSPLANTATION, V72, P449, DOI 10.1097/00007890-200108150-00016
   Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652
   Textor SC, 2000, LIVER TRANSPLANT, V6, P521, DOI 10.1053/jlts.2000.9737
   Tian L, 2005, GENETICS, V169, P337, DOI 10.1534/genetics.104.033142
   Tiao GM, 2005, J PEDIATR-US, V146, P204, DOI 10.1016/j.jpeds.2004.09.011
   Varo E, 2002, TRANSPLANT P, V34, P1553, DOI 10.1016/S0041-1345(02)03018-X
   Velthuis JHL, 2006, AM J TRANSPLANT, V6, P2955, DOI 10.1111/j.1600-6143.2006.01566.x
   Venkat VL, 2008, PEDIATR TRANSPLANT, V12, P67, DOI 10.1111/j.1399-3046.2007.00794.x
   White PH, 2002, PEDIATRICS, V110, P1328
   Willoughby LM, 2007, PEDIATR TRANSPLANT, V11, P127, DOI 10.1111/j.1399-3046.2006.00639.x
   Yang J, 2000, BLOOD, V96, P4055
   Ziolkowski J, 2003, TRANSPLANT P, V35, P2307, DOI 10.1016/S0041-1345(03)00786-3
NR 79
TC 28
Z9 28
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD DEC
PY 2008
VL 8
IS 12
BP 2506
EP 2513
DI 10.1111/j.1600-6143.2008.02432.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 374OM
UT WOS:000261053600010
PM 18853949
ER

PT J
AU Zarkhin, V
   Li, L
   Kambham, N
   Sigdel, T
   Salvatierra, O
   Sarwal, MM
AF Zarkhin, V.
   Li, L.
   Kambham, N.
   Sigdel, T.
   Salvatierra, O.
   Sarwal, M. M.
TI A Randomized, Prospective Trial of Rituximab for Acute Rejection in
   Pediatric Renal Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE B cells; pediatric; Rituximab; transplant rejection
ID ANTI-CD20 MONOCLONAL-ANTIBODY; CHRONIC ALLOGRAFT NEPHROPATHY; B-CELL
   DEPLETION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; INCOMPATIBLE
   KIDNEY-TRANSPLANTATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; DONOR
   LIVER-TRANSPLANTATION; RHEUMATOID-ARTHRITIS; MEDIATED REJECTION; HUMORAL
   REJECTION
AB We report 1-year outcomes of a randomized study of Rituximab versus standard-of-care immunosuppression (Thymoglobulin and/or pulse steroids) for treatment of biopsy confirmed, acute transplant rejection with B-cell infiltrates, in 20 consecutive recipients (2-23 years). Graft biopsies, with Banff and CADI scores, CD20 and C4d stains, were performed at rejection and 1 and 6 months later. Peripheral blood CMV, EBV and BK viral loads, graft function, DSA, immunoglobulins, serum humanized antichimeric antibody (HACA) and Rituximab, and lymphocyte counts were monitored until 1 year posttreatment. Rituximab infusions were given with a high index of safety without HACA development and increased infections complications. Rituximab therapy resulted in complete tissue B-cell depletion and rapid peripheral B-cell depletion. Peripheral CD19 cells recovered at a mean time of similar to 12 months. There were some benefits for the recovery of graft function (p = 0.026) and improvement of biopsy rejection scores at both the 1- (p = 0.0003) and 6-month (p < 0.0001) follow-up biopsies. Reappearance of C4d deposition was not seen on follow-up biopsies after Rituximab therapy, but was seen in 30% of control patients. There was no change in DSA in either group, independent of rejection resolution. This study reports safety and suggests further investigation of Rituximab as an adjunctive treatment for B-cell-mediated graft rejection.
C1 [Zarkhin, V.; Li, L.; Sigdel, T.; Salvatierra, O.; Sarwal, M. M.] Stanford Univ, Ctr Med, Dept Pediat, Stanford, CA 94305 USA.
   [Kambham, N.] Stanford Univ, Ctr Med, Dept Pathol, Stanford, CA 94305 USA.
RP Sarwal, MM (reprint author), Stanford Univ, Ctr Med, Dept Pediat, Stanford, CA 94305 USA.
EM msarwal@stanford.edu
FU Genentech Inc.; BIOGEN-IDEC Pharmaceuticals, San Francisco, CA
FX Rituximab study drug and support for mechanistic studies funding was
   provided by Genentech Inc. and BIOGEN-IDEC Pharmaceuticals, San
   Francisco, CA.
CR Agarwal A, 2004, AM J TRANSPLANT, V4, P1357, DOI 10.1111/j.1600-6143.2004.00502.x
   AGARWAL A, 2005, AM J TRANSPLANT S11, V5, P1239
   Ahlenstiel T, 2006, XENOTRANSPLANTATION, V13, P141, DOI 10.1111/j.1399-3089.2006.00279.x
   Alausa M, 2005, CLIN TRANSPLANT, V19, P137, DOI 10.1111/j.1399-0012.2004.00292.x
   Anolik JH, 2007, ARTHRITIS RHEUM, V56, P3044, DOI 10.1002/art.22810
   Anolik JH, 2007, CLIN IMMUNOL, V122, P139, DOI 10.1016/j.clim.2006.08.009
   Aranda JM, 2002, TRANSPLANTATION, V73, P907, DOI 10.1097/00007890-200203270-00013
   Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025
   Balfour IC, 2005, J HEART LUNG TRANSPL, V24, P628, DOI 10.1016/j.healun.2004.01.006
   Baran DA, 2004, TRANSPLANT P, V36, P3164, DOI 10.1016/j.transproceed.2004.10.087
   Bearden CM, 2005, AM J TRANSPLANT, V5, P50, DOI 10.1111/j.1600-6143.2003.00646.x
   Becker YT, 2004, AM J TRANSPLANT, V4, P996, DOI 10.1111/j.1600-6143.2004.00454.x
   Berney T, 2002, TRANSPLANTATION, V74, P1000, DOI 10.1097/01.TP.0000031931.31954.53
   Beum PV, 2006, J IMMUNOL, V176, P2600
   Bueno J, 2003, PEDIATR TRANSPLANT, V7, P153, DOI 10.1034/j.1399-3046.2003.00024.x
   Culic S, 2003, PEDIATR HEMAT ONCOL, V20, P339, DOI 10.1080/08880010390203125
   Edwards JCW, 2004, RHEUM DIS CLIN N AM, V30, P393, DOI 10.1016/j.rdc.2004.01.006
   Egawa H, 2008, HEPATOLOGY, V47, P143, DOI 10.1002/hep.21928
   Faguer S, 2007, TRANSPLANTATION, V83, P1277, DOI 10.1097/01.tp.0000261113.30757.d1
   Garrett HE, 2005, J HEART LUNG TRANSPL, V24, P1337, DOI 10.1016/j.healun.2004.09.003
   Garrett HE, 2002, ANN THORAC SURG, V74, P1240, DOI 10.1016/S0003-4975(02)03824-9
   Genberg H, 2005, AM J TRANSPLANT, V5, P397
   Genberg H, 2006, AM J TRANSPLANT, V6, P2418, DOI 10.1111/j.1600-6143.2006.01497.x
   Genberg H, 2007, TRANSPLANTATION, V84, pS33, DOI 10.1097/01.tp.0000296122.19026.0f
   Ghielmini A, 2005, ANN ONCOL, V16, P1675, DOI 10.1093/annonc/mdi320
   Gong Q, 2005, J IMMUNOL, V174, P817
   Grim SA, 2007, CLIN TRANSPLANT, V21, P628, DOI 10.1111/j.1399-0012.2007.00700.x
   Gross TG, 2007, PEDIATR TRANSPLANT, V11, P575, DOI 10.1111/j.1399-3046.2007.00748.x
   Hayashida M, 2007, PEDIATR TRANSPLANT, V11, P671, DOI 10.1111/j.1399-3046.2007.00714.x
   Herman J, 2002, J HEART LUNG TRANSPL, V21, P1304, DOI 10.1016/S1053-2498(02)00439-4
   Hippen BE, 2005, AM J TRANSPLANT, V5, P2248, DOI 10.1111/j.1600-6143.2005.01009.x
   ISONIEMI H, 1994, TRANSPLANTATION, V58, P1195, DOI 10.1097/00007890-199412150-00010
   ISONIEMI HM, 1992, KIDNEY INT, V41, P155, DOI 10.1038/ki.1992.21
   Jezior D, 2003, TRANSPLANT P, V35, P2182, DOI 10.1016/S0041-1345(03)00776-0
   Kaczmarek I, 2007, J HEART LUNG TRANSPL, V26, P511, DOI 10.1016/j.healun.2007.01.027
   Kerjaschki D, 2004, J AM SOC NEPHROL, V15, P603, DOI 10.1097/01.ASN.0000113316.52371.2E
   Kirk AD, 2003, TRANSPLANTATION, V76, P120, DOI 10.1097/01.TP.0000071362.99021.D9
   Kitchens WH, 2006, TRANSPLANTATION, V81, P811, DOI 10.1097/01.tp.0000202844.33794.0e
   Krukemeyer MG, 2004, TRANSPLANTATION, V78, P65, DOI 10.1097/01.TP.0000132324.14207.8B
   Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617
   Lehnhardt A, 2006, AM J TRANSPLANT, V6, P847, DOI 10.1111/j.1600-6143.2006.01246.x
   Luke PPW, 2001, TRANSPLANTATION, V72, P419, DOI 10.1097/00007890-200108150-00010
   MALONEY DG, 1994, BLOOD, V84, P2457
   Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7
   Martin F, 2004, IMMUNITY, V20, P517, DOI 10.1016/S1074-7613(04)00112-8
   Martin F, 2006, ANNU REV IMMUNOL, V24, P467, DOI 10.1146/annurev.immunol.24.021605.090517
   Martins HL, 2007, TRANSPL P, V39, P432, DOI 10.1016/j.transproceed.2007.01.042
   McGregor CGA, 2005, J THORAC CARDIOV SUR, V130, P844, DOI 10.1016/j.jtcvs.2005.04.017
   McLaughlin P, 1998, J CLIN ONCOL, V16, P2825
   Melcher ML, 2006, AM J TRANSPLANT, V6, P423, DOI 10.1111/j.1600-6143.2005.01185.x
   MUORAH MR, 2008, PEDIAT TRANSPLANT
   Nozu K, 2005, PEDIATR NEPHROL, V20, P1660, DOI 10.1007/s00467-005-2013-7
   Pescovitz MD, 2004, PEDIATR TRANSPLANT, V8, P9, DOI 10.1046/j.1397-3142.2003.00135.x
   Peter HH, 2005, EXPERT OPIN BIOL TH, V5, pS61, DOI 10.1517/14712598.5.1.S61
   Pollock-BarZiv SM, 2007, CIRCULATION S, V116, pI
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   Racusen LC, 2003, AM J TRANSPLANT, V3, P708, DOI 10.1034/j.1600-6143.2003.00072.x
   Roll P, 2006, ARTHRITIS RHEUM, V54, P2377, DOI 10.1002/art.22019
   Sarwal M, 2003, NEW ENGL J MED, V349, P125, DOI 10.1056/NEJMoa035588
   Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
   Schwarz A, 2005, KIDNEY INT, V67, P341, DOI 10.1111/j.1523-1755.2005.00087.x
   Scolari MP, 2005, TRANSPLANT P, V37, P2482, DOI 10.1016/j.transproceed.2005.06.092
   Serinet MO, 2002, J PEDIATR GASTR NUTR, V34, P389, DOI 10.1097/00005176-200204000-00014
   Shishido S, 2003, J AM SOC NEPHROL, V14, P1046, DOI 10.1097/01.ASN.0000056189.02819.32
   Sidner Richard A, 2004, Hum Antibodies, V13, P55
   Solez K, 2007, AM J TRANSPLANT, V7, P518, DOI 10.1111/j.1600-6143.2006.01688.x
   Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x
   Suzan F, 2001, NEW ENGL J MED, V345, P1000, DOI 10.1056/NEJM200109273451315
   Tanabe K, 1998, TRANSPLANTATION, V65, P224
   Terasaki PI, 2003, AM J TRANSPLANT, V3, P665, DOI 10.1034/j.1600-6143.2003.00135.x
   Tsai EW, 2006, TRANSPLANTATION, V82, P1769, DOI 10.1097/01.tp.0000250572.46679.45
   Tsutsumi Yutaka, 2005, Expert Opin Drug Saf, V4, P599, DOI 10.1517/14740338.4.3.599
   Tyden G, 2005, TRANSPL P, V37, P3286, DOI 10.1016/j.transproceed.2005.09.002
   Usuda M, 2005, TRANSPLANTATION, V79, P12, DOI 10.1097/01.TP.0000149337.40911.E4
   Vallerskog T, 2007, CLIN IMMUNOL, V122, P62, DOI 10.1016/j.clim.2006.08.016
   Verschuuren EAM, 2002, TRANSPLANTATION, V73, P100, DOI 10.1097/00007890-200201150-00019
   Vieira CA, 2004, TRANSPLANTATION, V77, P542, DOI 10.1097/01.TP.0000112934.12622.2B
   Watson R, 2006, AM J TRANSPLANT, V6, P3022, DOI 10.1111/j.1600-6143.2006.01554.x
   WEBBER SA, 2001, AM J TRANSPLANT S1, V1, P469
   Williams ME, 2006, J IMMUNOL, V177, P7435
   Yilmaz S, 2003, J AM SOC NEPHROL, V14, P773, DOI 10.1097/01.ASN.000054496.68498.13
   Yilmaz S, 2000, TRANSPLANT P, V32, p12S
   Zand MS, 2006, TRANSPLANTATION, V82, P1387, DOI 10.1097/01.tp.0000244063.05338.27
   ZARKHIN V, 2008, KIDNEY INT, V85, P1705
NR 85
TC 59
Z9 62
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD DEC
PY 2008
VL 8
IS 12
BP 2607
EP 2617
DI 10.1111/j.1600-6143.2008.02411.x
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 374OM
UT WOS:000261053600021
PM 18808404
ER

PT J
AU Shirouzu, Y
   Okajima, H
   Ogata, S
   Ohya, Y
   Tsukamoto, Y
   Yamamoto, H
   Takeichi, T
   Kwang-Jong, L
   Asonuma, K
   Inomata, Y
AF Shirouzu, Yasumasa
   Okajima, Hideaki
   Ogata, Satsuki
   Ohya, Yuki
   Tsukamoto, Yukika
   Yamamoto, Hidekazu
   Takeichi, Takayuki
   Kwang-Jong, Lee
   Asonuma, Katsuhiro
   Inomata, Yukihiro
TI Biliary Reconstruction for Infantile Living Donor Liver Transplantation:
   Roux-en-Y Hepaticojejunostomy or Duct-to-Duct Choledochocholedochostomy?
SO LIVER TRANSPLANTATION
LA English
DT Article
ID RECURRENT CHOLANGITIS; RIGHT LOBE; COMPLICATIONS; FEASIBILITY; TRACT
AB Hepaticojejunostomy is a standard biliary reconstruction method for infantile living donor liver transplantation (LDLT), but choledochocholedochostomy for infants is not generally accepted yet. Ten pediatric recipients weighing no more than 10 kg underwent duct-to-duct choledochocholedochostomy (DD) for biliary reconstruction for LDLT. Patients were followed up for a median period of 26.8 months (range: 4.0-79.0 months). The incidence of posttransplant biliary complications for DD was compared with that for Roux-en-Y hepaticojejunostomy (RY). No DD patients and 1 RY patient (5%) developed biliary leakage (P > 0.05), and biliary stricture occurred in 1 DD patient (10%) and none of the RY patients (P > 0.05); none of the DD patients and 5 RY patients (25%) suffered from uncomplicated cholangitis after LDLT (P > 0.05), and 1 DD patient (10%) and 2 RY patients (10%) died of causes unrelated to biliary complications. In conclusion, both hepaticojejunostomy and choledochocholedochostomy resulted in satisfactory outcome in terms of biliary complications, including leakage and stricture, for recipients weighing no more than 10 kg. Liver Transpl 14:1761-1765, 2008. (C) 2008 AASLD.
C1 [Shirouzu, Yasumasa; Okajima, Hideaki; Ogata, Satsuki; Ohya, Yuki; Tsukamoto, Yukika; Yamamoto, Hidekazu; Takeichi, Takayuki; Kwang-Jong, Lee; Asonuma, Katsuhiro; Inomata, Yukihiro] Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat & Pediat Surg, Kumamoto 8608556, Japan.
RP Shirouzu, Y (reprint author), Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat & Pediat Surg, 1-1-1 Honjyo, Kumamoto 8608556, Japan.
EM shirouzu@fc.kuh.kumamoto-u.ac.jp
CR Chuang JH, 2001, WORLD J SURG, V25, P1512
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Egawa H, 2001, WORLD J SURG, V25, P1300
   FERREIRA CT, 2000, J PEDIAT RIO J, V76, pS198
   Haberal M, 2007, TRANSPL P, V39, P1161, DOI 10.1016/j.transproceed.2007.02.046
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Kimura T, 2006, PEDIATR TRANSPLANT, V10, P248, DOI 10.1111/j.1399-3046.2005.00430.x
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   LETOURNEAU JG, 1989, RADIOLOGY, V170, P1095
   Lin CH, 2007, TRANSPL P, V39, P3251, DOI 10.1016/j.transproceed.2007.06.079
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   Marcos A, 2000, ANN SURG, V231, P824, DOI 10.1097/00000658-200006000-00006
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Orlando G, 2004, TRANSPLANTATION, V77, P1307
   SANCHEZURDAZPAL L, 1993, ANN SURG, V218, P152, DOI 10.1097/00000658-199308000-00006
   Soejima Y, 2003, TRANSPLANTATION, V75, P557, DOI 10.1097/01.TP.0000048220.90971.5A
   Stapleton GN, 1998, BRIT J SURG, V85, P202
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   SUNG JY, 1992, DIGEST DIS SCI, V37, P689, DOI 10.1007/BF01296423
   Vrochides D, 2007, TRANSPL INFECT DIS, V9, P327, DOI 10.1111/j.1399-3062.2007.00221.x
NR 21
TC 12
Z9 12
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD DEC
PY 2008
VL 14
IS 12
BP 1761
EP 1765
DI 10.1002/lt.21599
PG 5
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 382KL
UT WOS:000261604600010
PM 19025922
ER

PT J
AU Miraglia, R
   Maruzzelli, L
   Caruso, S
   Spada, M
   Luca, A
   Gridelli, B
AF Miraglia, Roberto
   Maruzzelli, Luigi
   Caruso, Settimo
   Spada, Marco
   Luca, Angelo
   Gridelli, Bruno
TI Percutaneous retrograde colangiography of segment III bile duct, through
   the previously catheterized segment II bile duct, in 15-month-old
   patient after partial liver transplantation with two separate
   bilio-enteric anastomoses
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; complication of liver transplantation;
   biliary; interventional radiology
ID BALLOON DILATATION; COMPLICATIONS; STRICTURES; CHILDREN
AB We report one case of percutaneous retrograde colangiography of segment III bile duct, through the previously catheterized segment II bile duct, in 15-month-old patient after partial liver transplantation and two separate biliary anastomoses. The retrograde diagnostic cholangiogram confirmed the suspicion of anastomotic stricture and distended the bile ducts, which were easily punctured with percutaneous approach with a 20 Ga Chiba needle.
C1 [Miraglia, Roberto; Maruzzelli, Luigi; Caruso, Settimo; Spada, Marco; Luca, Angelo; Gridelli, Bruno] Univ Pittsburgh, Med Ctr, IsMeTT, Ist Mediterraneo Trapianti & Terapie Alta Special, Palermo, Italy.
RP Miraglia, R (reprint author), IsMeTT, Dept Radiol, Via Via Tricomi 1,CAP, I-90127 Palermo, Italy.
EM rmiraglia@ismett.edu
RI miraglia, roberto/B-2051-2016
CR Belenky A, 2004, CARDIOVASC INTER RAD, V27, P491, DOI 10.1007/s00270-003-2675-0
   HEFFRON TG, 1992, TRANSPLANTATION, V53, P391, DOI 10.1097/00007890-199202010-00024
   LALLIER M, 1993, J PEDIATR SURG, V28, P1102, DOI 10.1016/0022-3468(93)90139-C
   Lorenz JM, 2005, AM J ROENTGENOL, V184, P151
   Schwarzenberg SJ, 2002, PEDIATR TRANSPLANT, V6, P132, DOI 10.1034/j.1399-3046.2002.01053.x
   Sieders E, 2001, TRANSPLANTATION, V71, P90, DOI 10.1097/00007890-200101150-00015
   Sunku Bhanu, 2006, Liver Transpl, V12, P821, DOI 10.1002/lt.20712
NR 7
TC 1
Z9 1
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2008
VL 12
IS 7
BP 813
EP 815
DI 10.1111/j.1399-3046.2008.00939.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 364NC
UT WOS:000260341400016
PM 18397215
ER

PT J
AU Marques, E
   Jimenez, C
   Manrique, A
   Vallejo, GH
   Clemares, M
   Ortega, P
   Moreno, E
AF Marques, E.
   Jimenez, C.
   Manrique, A.
   Vallejo, G. H.
   Clemares, M.
   Ortega, P.
   Moreno, E.
TI Development of Lymphoproliferative Disease After Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 5th Congress of the
   Andalusian-Society-of-Organ-and-Tissue-Transplantation
CY MAR 05-07, 2008
CL Malaga, SPAIN
SP Andalusian Soc Organ & Tissue Transplantat, ASTELLAS, NOVARTIS, ROCHE
ID RISK-FACTORS; DISORDERS; TUMORS
AB Introduction. Malignancies are a serious long-term complication among liver transplant recipients, with an overall incidence of 4.5%-15%. Posttransplantation lymphoproliferative disease (PTLD) is one of the leading causes of late death. Its development is related to complex interactions between immunosuppressive drugs and environmental agents. The aim of this study was to analyze risk factors for PTLD and survival after orthotopic liver transplantation (OLT) compared with solid tumors.
   Patients and Methods. We undertook a retrospective review of the clinical histories of adult patients who underwent OLT between July 1986 and February 2001, and who had been followed until 2005. This study comprised 528 adult recipients who survived more than 2 months after OLT. We excluded pediatric, partial-organ, and multiorgan recipients.
   Results. No differences were observed concerning gender, viral etiology of hepatitis, calcineurin inhibitor regimen, or steroid maintenance period. Treated acute rejection episodes accounted for 53.3% of patients who developed PTLD compared with 47.3% in the control group (P =.787). Patients with solid tumors were older at the time of diagnosis than those with PTLD (57.5 +/- 8.13 years vs 48.8 +/- 13.9; P =.002). The overall mortality rate for PTLD was 55.5%, which did not differ significantly from solid tumors.
   Conclusions. PTLD develops in younger patients after OLT. Various immunosuppressive regimens do not seem to influence the incidence of PTLD or other solid tumors.
C1 [Marques, E.; Jimenez, C.; Manrique, A.; Vallejo, G. H.; Clemares, M.; Ortega, P.; Moreno, E.] Hosp Doce Octubre, Serv Cirugia Gen, Madrid 28041, Spain.
RP Marques, E (reprint author), Hosp Doce Octubre, Serv Cirugia Gen, Ctra Andalucia Km 5,4, Madrid 28041, Spain.
EM emarquesmedina@hotmail.com
CR Duvoux C, 2002, TRANSPLANTATION, V74, P1103, DOI 10.1097/01.TP.000031543.16208.1C
   Jimenez-Romero C, 2006, TRANSPLANT P, V38, P2505, DOI 10.1016/j.transproceed.2006.08.065
   Kelly DM, 1998, CANCER-AM CANCER SOC, V83, P1237, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1237::AID-CNCR25>3.3.CO;2-K
   REYES J, 1991, TRANSPLANT P, V23, P3044
   Xiol X, 2001, LIVER TRANSPLANT, V7, P971, DOI 10.1053/jlts.2001.28744
NR 5
TC 4
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2008
VL 40
IS 9
BP 2988
EP 2989
DI 10.1016/j.transproceed.2008.09.008
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 375QQ
UT WOS:000261128800041
PM 19010169
ER

PT J
AU Cano, JR
   Cerezo, F
   Algar, FJ
   Alvarez, A
   Espinosa, D
   Moreno, P
   Baamonde, C
   Salvatierra, A
AF Cano, J. R.
   Cerezo, F.
   Algar, F. J.
   Alvarez, A.
   Espinosa, D.
   Moreno, P.
   Baamonde, C.
   Salvatierra, A.
TI Prognostic Factors Influencing Survival Rates in Children Following Lung
   Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 5th Congress of the
   Andalusian-Society-of-Organ-and-Tissue-Transplantation
CY MAR 05-07, 2008
CL Malaga, SPAIN
SP Andalusian Soc Organ & Tissue Transplantat, ASTELLAS, NOVARTIS, ROCHE
AB Objectives. To assess the results of lung transplantation (LT) in children under 17 years of age and identify factors affecting long-term survival.
   Methods. A retrospective review was performed of 37 patients (<17 years) who had received a lung transplant between 1996 and 2007. Morbidity, mortality, and survival were analyzed by the Kaplan-Meier method and the log-rank test.
   Results. There were 37 LTs: 30 bilateral, four lobar, two liver-lung, one unilateral. Indications for transplantation were: cystic fibrosis (n = 30), pulmonary fibrosis (n = 1), bronchiectasis (n = 1), Kartagener's syndrome (n = 1), bronchiolitis obliterans (n = 3), and pulmonary fibrosis due to radiotherapy-chemotherapy (n = 1). The intubation time and oxygenation index of donors were 49 +/- 36 hours and 455 +/- 83.5 mm Hg, respectively. Seventeen patients needed extracorporeal circulation (ECC) and 13 were coded as priorities. High blood pressure and renal failure were the most frequent complications. Overall survival rates were 65.7%, 59.4%, 56.1%, 44.5%, and 39.6% at 1, 2, 3, 5, and 10 years, respectively. Need for ECC (P = .001), surgical complications (P = .037), oxygenation index 450 mm Hg (P = .005), OLT in priority code (P = .04), and age of donor >16 years (P = .005) were associated with poor survival.
   Conclusions. LT is an appropriate procedure for certain types of end-stage pediatric pulmonary pathologies, achieving acceptable long-term survival rates. When the procedure is carried out under a surgical priority code, it is associated with a high rate of perioperative morbidity and mortality and poorer long-term survival. Other factors that have a negative influence on survival include the need for ECC, surgical complications, an oxygenation index <450 mm Hg, and donor age >16 years.
C1 [Cano, J. R.; Cerezo, F.; Algar, F. J.; Alvarez, A.; Espinosa, D.; Moreno, P.; Baamonde, C.; Salvatierra, A.] Univ Cordoba, Reina Sofia Univ Hosp, Thorac Surg & Lung Transplantat Serv, Dept Med Surg Special, Cordoba, Spain.
RP Cano, JR (reprint author), Hosp Univ Reina Sofia, Serv Cirugia Torac, Avda Menendez Pidal, Cordoba 14004, Spain.
EM joseravich@hotmail.com
CR Bowdish Michael E, 2004, Respir Care Clin N Am, V10, P563, DOI 10.1016/j.rcc.2004.06.004
   DATE H, 2008, FRONT BIOSCI, V1, P1433
   Faro A, 2007, AM J TRANSPLANT, V7, P285, DOI 10.1111/j.1600-6143.2006.01612.x
   Jerkic P, 2007, PEDIATR TRANSPLANT, V11, P14, DOI 10.1111/j.1399-3046.2006.00613.x
   Mallory GB, 2004, EUR RESPIR J, V24, P839, DOI 10.1183/09031936.04.00064804
   Wells A, 2006, SEM RESP CRIT CARE M, V27, P552, DOI 10.1055/s-2006-954614
   Woo Marlyn S, 2004, Paediatr Respir Rev, V5, P249, DOI 10.1016/j.prrv.2004.04.005
NR 7
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2008
VL 40
IS 9
BP 3070
EP 3072
DI 10.1016/j.transproceed.2008.09.024
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 375QQ
UT WOS:000261128800069
PM 19010197
ER

PT J
AU Uribe, M
   Gonzalez, G
   Alba, A
   Godoy, J
   Ferrario, M
   Hunter, B
   Iniguez, R
   Cavallieri, S
   Diaz, V
   Macho, L
   Ferron, S
   Buckel, E
AF Uribe, M.
   Gonzalez, G.
   Alba, A.
   Godoy, J.
   Ferrario, M.
   Hunter, B.
   Iniguez, R.
   Cavallieri, S.
   Diaz, V.
   Macho, L.
   Ferron, S.
   Buckel, E.
TI Living Donor Liver Transplantation in Pediatric Patients With Acute
   Liver Failure: Safe and Effective Alternative
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 5th Congress of the
   Andalusian-Society-of-Organ-and-Tissue-Transplantation
CY MAR 05-07, 2008
CL Malaga, SPAIN
SP Andalusian Soc Organ & Tissue Transplantat, ASTELLAS, NOVARTIS, ROCHE
ID FULMINANT HEPATIC-FAILURE; CHILDREN; PROGRAM; CHILE
AB Living donor liver transplantation (LDLT) for patients with acute liver failure (ALF) is still controversial. To be considered a feasible alternative, this therapeutic option should offer similar results to transplants performed with cadaveric grafts, without significant risks for donors. The aim of this study was to compare the outcomes of pediatric patients with ALF who were transplanted with either cadaveric or living donor grafts.
   Patients and Methods. Between March 1994 and February 2007, 149 patients under 18 years were transplanted, including 43 (28.8%) with ALF. We reviewed the demography, etiology, surgical technique, complications, and long-term results in this group. Patient actuarial survival was determined by Kaplan-Meier analysis.
   Results. The median age of the recipients was 4.8 years (range 1.2 to 18) including 26 boys and 17 girls. Sixteen (37.2%) underwent LDLT. Three patients in the living donor group needed a second graft (18.7%) versus 7 (26%) among the cadaveric group. No mortality or serious morbidity was observed in living donors. Fifteen patients died. Septic and neurologic complications, and primary graft non-function were the most frequent causes of death. All patients died during the first year after liver transplant. Actuarial land 5-year survivals were 65% without a significant difference between the groups.
   Conclusion. Considering that patients with ALF have no chance of survival without transplantation and that cadaveric grafts, remain a limited resource, especially in our country, these results showed that LDLT was a valid option for these patients, as well as a secure procedure for the donors.
C1 [Uribe, M.] Hosp Ninos Luis Calvo Mackenna, Unidad Trasplante, Clin Las Condes, Liver Transplant Program, Santiago, Chile.
RP Uribe, M (reprint author), Hosp Ninos Luis Calvo Mackenna, Unidad Trasplante, Clin Las Condes, Liver Transplant Program, Fontecilla 441, Santiago, Chile.
EM muribemd@hotmail.com
CR Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Bucuvalas John, 2006, Clin Liver Dis, V10, P149, DOI 10.1016/j.cld.2005.10.006
   Emre S, 1999, LIVER TRANSPLANT SUR, V5, P161, DOI 10.1002/lt.500050315
   Hattori H, 1998, TRANSPLANTATION, V65, P686, DOI 10.1097/00007890-199803150-00015
   Karakayali H, 2007, TRANSPL P, V39, P1157, DOI 10.1016/j.transproceed.2007.02.053
   Kilic M, 2007, TRANSPLANTATION, V84, P475, DOI 10.1097/01.tp.0000276987.55382.e2
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   Miwa S, 1999, HEPATOLOGY, V30, P1521, DOI 10.1002/hep.510300621
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Uemoto S, 2000, TRANSPLANTATION, V70, P152
   Uribe M, 2005, TRANSPL P, V37, P3378, DOI 10.1016/j.transproceed.2005.09.097
   Uribe M, 2005, TRANSPL P, V37, P3375, DOI 10.1016/j.transproceed.2005.09.096
NR 14
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD NOV
PY 2008
VL 40
IS 9
BP 3253
EP 3255
DI 10.1016/j.transproceed.2008.03.128
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 375QQ
UT WOS:000261128800118
PM 19010246
ER

PT J
AU Harambat, J
   Ranchin, B
   Dubourg, L
   Liutkus, A
   Hadj-Haissa, A
   Rivet, C
   Boillot, O
   Lachaux, A
   Cochat, P
AF Harambat, Jerome
   Ranchin, Bruno
   Dubourg, Laurence
   Liutkus, Aurelia
   Hadj-Haissa, Aoumeur
   Rivet, Christine
   Boillot, Olivier
   Lachaux, Alain
   Cochat, Pierre
TI Renal Function in Pediatric Liver Transplantation: A Long-Term Follow-Up
   Study
SO TRANSPLANTATION
LA English
DT Article
DE Liver transplantation; Child; Glomerular filtration rate; Chronic renal
   insufficiency; Nephrotoxicity; Calcineurin inhibitor
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; CYCLOSPORINE-A;
   CHILDREN; RECIPIENTS; DYSFUNCTION; SURVIVORS; OUTCOMES; FAILURE; VOLUME
AB Background. Renal impairment is a frequent complication after orthotopic liver transplantation (OLT). However, most studies in children use inaccurate renal assessment based on serum creatinine, and long-term follow-up data are lacking. The purpose of this study was to determine incidence, determinants, and progression of long-term chronic renal insufficiency (CRI) in a single-center series of pediatric liver transplant recipients.
   Methods. The true glomerular filtration rate was measured by inulin clearance before and serially after OLT in 69 consecutive patients followed more than 2 years after transplantation. Cumulative incidence of CRI (glomerular filtration rate < 60 mL/min/1.73 m(2)) was determined using a Kaplan-Meier method. A Cox proportional hazard model was performed to identify predictors of CRI.
   Results. The median age at OLT was 3.2 years. The median follow-up time after OLT was 9.3 years (interquartile range 6.3-11.9). At 10 years Post-OLT, the cumulative incidence of CRI was 25%. In a multivariate Cox regression model, arterial hypertension during follow-up as time dependant variable (P=0.03), cyclosporine as primary immunosuppression (P=0.048), and liver diseases with potential renal involvement including inborn errors of metabolism, Alagille syndrome, and hepatic fibrosis (P=0.003) were associated with CRI.
   Conclusions. Renal function is a major concern long after OLT in children. Renal dysfunction post-OLT may be reduced by optimal control of arterial hypertension, immunosuppression protocols adapted to primary liver disease, and calcineurin inhibitor sparing regimen.
C1 [Harambat, Jerome; Ranchin, Bruno; Dubourg, Laurence; Liutkus, Aurelia; Hadj-Haissa, Aoumeur; Rivet, Christine; Boillot, Olivier; Lachaux, Alain; Cochat, Pierre] Univ Lyon 1, F-69365 Lyon, France.
   [Harambat, Jerome; Ranchin, Bruno; Liutkus, Aurelia; Rivet, Christine; Lachaux, Alain; Cochat, Pierre] Hosp Civils Lyon, Serv Pediat, Lyon, France.
   [Harambat, Jerome; Ranchin, Bruno; Liutkus, Aurelia; Rivet, Christine; Lachaux, Alain; Cochat, Pierre] Hosp Civils Lyon, Ctr Reference Malad Renales Rares, Lyon, France.
   [Dubourg, Laurence; Hadj-Haissa, Aoumeur] Hosp Civils Lyon, Serv Explorat Fonct Renale & Metab, Lyon, France.
   [Dubourg, Laurence; Hadj-Haissa, Aoumeur; Boillot, Olivier; Cochat, Pierre] Hosp Civils Lyon, INSERM, U820, Lyon, France.
   [Boillot, Olivier] Hosp Civils Lyon, Unite Transplantat Hepat, Lyon, France.
RP Cochat, P (reprint author), Hop Femme Mere Enfant, Serv Pediat, Blvd Pinel, F-69677 Bron, France.
EM pierre.cochat@chu-lyon.fr
RI dubourg, laurence/F-8299-2016
CR ANDREWS WS, 1991, TRANSPLANT P, V23, P1452
   Arora-Gupta N, 2004, PEDIATR TRANSPLANT, V8, P145, DOI 10.1046/j.1399-3046.2003.00132.x
   Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
   Bartosh SM, 1997, CLIN TRANSPLANT, V11, P354
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   BILIK R, 1993, TRANSPLANT P, V25, P2578
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Casas-Melley AT, 2004, PEDIATR TRANSPLANT, V8, P362, DOI 10.1111/j.1399-3046.2004.00193.x
   Cheng CH, 2005, AM J KIDNEY DIS, V46, P830, DOI 10.1053/j.ajkd.2005.07.033
   COCHAT P, 1989, LANCET, V1, P1142
   Evans HM, 2005, TRANSPLANTATION, V79, P1575, DOI 10.1097/01.TP.0000163504.29054.3F
   Fisher NC, 1998, TRANSPLANTATION, V66, P59, DOI 10.1097/00007890-199807150-00010
   GIBB DM, 1989, PEDIATR NEPHROL, V3, P414
   Gonwa TA, 2001, TRANSPLANTATION, V72, P1934, DOI 10.1097/00007890-200112270-00012
   Herzog D, 2006, TRANSPLANTATION, V81, P672, DOI 10.1097/01.tp.0000185194.62108.a7
   Hogg RJ, 2003, PEDIATRICS, V111, P1416, DOI 10.1542/peds.111.6.1416
   KUEHNLE HF, 1992, NEPHRON, V62, P104
   LAINE J, 1994, J PEDIATR-US, V125, P863, DOI 10.1016/S0022-3476(05)82000-1
   LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159
   Mattman A, 2006, J AM SOC NEPHROL, V17, P487, DOI 10.1681/ASN.2005010034
   MCDIARMID SV, 1989, TRANSPLANTATION, V47, P314, DOI 10.1097/00007890-198902000-00025
   MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018
   McLin VA, 2005, PEDIATR TRANSPLANT, V9, P512, DOI 10.1111/j.1399-3046.2005.00320.x
   Mention K, 2005, PEDIATR TRANSPLANT, V9, P201, DOI 10.1111/j.1399-3046.2005.00289.x
   National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004, PEDIATRICS, V114, P555, DOI DOI 10.1542/PEDS.114.2.S2.555
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Scheenstra R, 2006, LIVER TRANSPLANT, V12, P240, DOI 10.1002/lt.20591
   Schell M, 2001, PEDIATR TRANSPLANT, V5, P51, DOI 10.1034/j.1399-3046.2001.00034.x
   SOMMERAUER JF, 1991, TRANSPLANT P, V23, P1466
   Wiesmayr S, 2005, PEDIATR TRANSPLANT, V9, P604, DOI 10.1111/j.1399-3046.2005.00348.x
   [Anonymous], 2002, AM J KIDNEY DIS, V39, pS1
NR 31
TC 30
Z9 31
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD OCT 27
PY 2008
VL 86
IS 8
BP 1028
EP 1034
DI 10.1097/TP.0b013e318187748f
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 367LY
UT WOS:000260554700004
PM 18946339
ER

PT J
AU Grabhorn, E
   Richter, A
   Fischer, L
   Ganschow, R
AF Grabhorn, Enke
   Richter, Andrea
   Fischer, Lutz
   Ganschow, Rainer
TI Emergency Liver Transplantation in Neonates With Acute Liver Failure:
   Long-Term Follow-Up
SO TRANSPLANTATION
LA English
DT Article
DE Infants; Neonatal hemochromatosis; Survival; Long-term outcome
ID INFANTILE HEPATIC HEMANGIOENDOTHELIOMA; EXPERIENCE; HEMOCHROMATOSIS;
   MONOSEGMENTS; CHILDREN; KILOGRAMS
AB Background. Acute neonatal liver failure is a rare condition that is often fatal. Liver transplantation (LTx) in affected neonates may be life saving, but there are only few data on the long-term outcome of neonatal LTx.
   Patients and Methods. We conducted a retrospective study of 11 LTx performed in 10 pediatric patients with acute liver failure in the first month of life. Median age at LTx was 15 days (range: 7-31 days) and median weight was 3.25 kg (range: 2-4 kg). The reasons for liver failure were neonatal hemochromatosis (n=5), hemangioendothelioma (n=2), infection caused by echovirus type 11 (n=1), mitochondrial disorder (n=1), unknown (n=1), and primary nonfunction after LTx (n=1). In 10 patients, LTx organs of deceased donors were used (reduced size n=5, split n=5), and living donor LTx was performed in one neonate. The patients were evaluated with respect to survival, graft function, perioperative complications, and neurodevelopmental outcome.
   Results. After a median follow-up time of 5 years (range: 1-14 years), 8 of 10 patients (80%) were alive. Seven of them were in good clinical condition and had normal liver function tests. One patient had to undergo retransplantation because of primary nonfunction and another is currently listed for retransplantation because of chronic graft dysfunction. Neurodevelopment was normal in 75% of the surviving patients.
   Conclusions. Liver transplantation provides good short- and medium-term results in neonatal acute liver failure.
C1 [Grabhorn, Enke; Richter, Andrea; Ganschow, Rainer] Univ Med Ctr Hamburg Eppendorf, Dept Pediat, D-20246 Hamburg, Germany.
   [Fischer, Lutz] Univ Med Ctr Hamburg Eppendorf, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Grabhorn, E (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.
EM e.grabhorn@uke.uni-hamburg.de
RI Grabhorn, Enke/F-9785-2011
CR Baliga P, 2004, LIVER TRANSPLANT, V10, P1364, DOI 10.1002/lt.20252
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Dhawan A, 2005, EARLY HUM DEV, V81, P1005, DOI 10.1016/j.earlhumdev.2005.10.003
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   Flynn DM, 2003, ARCH DIS CHILD, V88, pF124, DOI 10.1136/fn.88.2.F124
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   Grabhorn E, 2006, PEDIATRICS, V118, P2060, DOI 10.1542/peds.2006-0908
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, J PEDIATR SURG, V38, P1108, DOI 10.1016/S0022-3468(03)00206-9
   Lee WS, 2002, J PEDIATR GASTR NUTR, V35, P220, DOI 10.1097/01.MPG.0000018757.78665.6C
   Lee WS, 2005, J PEDIATR GASTR NUTR, V40, P575, DOI 10.1097/01.MPG.0000158524.30294.E2
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   Murray KF, 2001, PEDIATRICS, V108, P960, DOI 10.1542/peds.108.4.960
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Rodrigues F, 2005, LIVER TRANSPLANT, V11, P1417, DOI 10.1002/lt.20497
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   Sundaram SS, 2003, LIVER TRANSPLANT, V9, P783, DOI 10.1053/jlts.2003.50104
   Verma A, 2006, J PEDIATR GASTR NUTR, V42, P282, DOI 10.1097/01.mpg.0000214156.58659.4c
   Walsh R, 2004, J PEDIAT HEMATOL ONC, V26, P121, DOI 10.1097/00043426-200402000-00014
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 28
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD OCT 15
PY 2008
VL 86
IS 7
BP 932
EP 936
DI 10.1097/TP.0b013e318186d64a
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 362HL
UT WOS:000260188700010
PM 18852658
ER

PT J
AU Ueda, M
   Oike, F
   Kasahara, M
   Ogura, Y
   Ogawa, K
   Haga, H
   Takada, Y
   Egawa, H
   Tanaka, K
   Uemoto, S
AF Ueda, M.
   Oike, F.
   Kasahara, M.
   Ogura, Y.
   Ogawa, K.
   Haga, H.
   Takada, Y.
   Egawa, H.
   Tanaka, K.
   Uemoto, S.
TI Portal vein complications in pediatric living donor liver
   transplantation using left-side grafts
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE pediatric living donor liver transplantation
ID VASCULAR COMPLICATIONS; VENOUS STENOSIS; RECONSTRUCTION
AB The aim of this report is to assess the rate of portal vein complications (PVCs), the success rate of treatment for PVCs and the prognosis of patients with PVCs for pediatric living donor liver transplantation (LDLT). Pre- and postoperative records of 521 pediatric LDLTs, using left-side grafts were retrospectively reviewed. The overall rate of PVC was 9%, with early PVC occurring in nine patients (1.7%) with a mortality rate of 67% and late PVC in 38 patients (7.3%). Fifteen of these patients with late PVC showed complete portal vein occlusion despite various treatments, and in six of them the graft was lost. Histological examination revealed fibrosis in portal areas in 13 patients, around the central veins associated with cholestasis in the parenchyma in 10, and hepatocyte ballooning in 12.
   Correction of portal vein flow or retransplantation is necessary for the rescue of patients with early PVCs. Graft loss in the long term may be high with the occurrence of liver failure or portal hypertension related causes, such as hepatopulmonary syndrome and gastrointestinal bleeding in patients with late PVCs. For the rescue of these patients, especially for patients with body weight < 6 kg, regular monitoring of portal vein flow is essential.
C1 [Ueda, M.; Oike, F.; Kasahara, M.; Ogura, Y.; Ogawa, K.; Takada, Y.; Egawa, H.; Tanaka, K.; Uemoto, S.] Kyoto Univ, Dept Surg, Grad Sch Med, Kyoto, Japan.
   [Haga, H.] Kyoto Univ Hosp, Lab Diagnost Pathol, Kyoto 606, Japan.
   [Tanaka, K.] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan.
RP Ueda, M (reprint author), Kyoto Univ, Dept Surg, Grad Sch Med, Kyoto, Japan.
EM mikiko@kuhp.kyoto-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This work was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology of Japan.
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   Funaki B, 2000, RADIOLOGY, V215, P147
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   LERUT J, 1987, ANN SURG, V205, P404, DOI 10.1097/00000658-198704000-00011
   Marwan IK, 1999, SURGERY, V125, P265, DOI 10.1067/msy.1999.95114
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   OZAWA K, 1992, ANN SURG, V216, P547, DOI 10.1097/00000658-199211000-00004
   SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O
   Shibata T, 2005, RADIOLOGY, V235, P1078, DOI 10.1148/radiol.2353040489
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Superina R, 2006, PEDIATR TRANSPLANT, V10, P908, DOI 10.1111/j.1399-3046.2006.00598.x
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
NR 17
TC 47
Z9 48
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD OCT
PY 2008
VL 8
IS 10
BP 2097
EP 2105
DI 10.1111/j.1600-6143.2008.02360.x
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 349GS
UT WOS:000259269900018
PM 18727696
ER

PT J
AU Tam, NL
   Concejero, AM
   Liang, CD
AF Tam, N. -L.
   Concejero, A. M.
   Liang, C. -D.
TI Fate of Atrial Septal Defect in Children With End-Stage Liver Disease
   Undergoing Living Donor Liver Transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID BILIARY ATRESIA
AB Background and Objective. The course of atrial septal defects (ASD) in children undergoing liver transplantation is poorly described. Our objective was to present our experience in living donor liver transplantation (LDLT) in children with type II ASD.
   Patients and Methods. Between June 1994 and December 2006, 18/140 (12.8%) pediatric LDLT were diagnosed to have both type II ASD and end-stage liver disease. We reviewed the records of these patients. The median follow-up was 48.7 months. Data were analyzed using descriptive statistics.
   Results. There were 8 male and 10 female patients whose overall mean age was 12 months. There were 15 biliary atresia and 3 neonatal hepatitis patients. The median Child score was 9. The mean Pediatric Model End-stage Liver Disease score was 14. There were 13 with small (<= 4 mm), 4 with medium (5 to 9 mm), and 1 large (> 10 mm) ASD. Six small ASD closed spontaneously pretransplant. Seven small ASD closed post transplant. The medium and large ASD persisted or increased in size posttransplant. Only one patient showed hemodynamically significant ASD based on cardiac echocardiography and catheterization. This patient underwent Amplatzer closure of the ASD at 10 months posttransplant. All patients are Surviving with their original grafts to date. There were no perioperative cardiac or neurologic complications.
   Conclusion. This series demonstrated that LDLT can be safely performed in hemodynamically stable patients with small- to large-sized ASD. Small ASD may close pre- or posttransplant.
C1 [Concejero, A. M.] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Liver Transplant Program, Dept Surg, Kaohsiung 83305, Taiwan.
   [Liang, C. -D.] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Pediat Cardiol, Kaohsiung 83305, Taiwan.
   [Tam, N. -L.] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplantat Ctr, Guangzhou 510275, Guangdong, Peoples R China.
   Chang Gung Univ, Coll Med, Tao Yuan, Taiwan.
RP Concejero, AM (reprint author), Chang Gung Mem Hosp, Kaohsiung Med Ctr, Liver Transplant Program, Dept Surg, 123 Ta Pei Rd, Kaohsiung 83305, Taiwan.
EM allanc_md@yahoo.com
CR BEHRENDT DM, 1994, PEDIAT CARDIAC SURG, P195
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Chen CL, 2000, TRANSPLANTATION, V69, P2580, DOI 10.1097/00007890-200006270-00018
   de Villa VH, 2000, TRANSPLANTATION, V70, P1604, DOI 10.1097/00007890-200012150-00011
   Jawan B, 2004, TRANSPLANTATION, V77, P1394, DOI 10.1097/01.TP.0000122419.66639.19
   Jawan B, 2005, J SURG RES, V126, P82, DOI 10.1016/j.jss.2005.01.004
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD OCT
PY 2008
VL 40
IS 8
BP 2510
EP 2511
DI 10.1016/j.transproceed.2008.07.015
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 361NL
UT WOS:000260134300016
PM 18929782
ER

PT J
AU Chen, HL
   Concejero, AM
   Huang, TL
   Chen, TY
   Tsang, LLC
   Wang, CC
   Wang, SH
   Chen, CL
   Cheng, YF
AF Chen, H. -L.
   Concejero, A. M.
   Huang, T. -L.
   Chen, T. -Y.
   Tsang, L. L. -C.
   Wang, C. -C.
   Wang, S. -H.
   Chen, C. -L.
   Cheng, Yu-Fan
TI Diagnosis and Interventional Radiological Treatment of Vascular and
   Biliary Complications After Liver Transplantation in Children With
   Biliary Atresia
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID THROMBOSIS
AB Objective. Early diagnosis and appropriate management of vascular and biliary complications after living donor liver transplantation (LDLT) result in longer survival. We report our institutional experience regarding radiological management of these complications among patients with biliary atresia (BA) who underwent LDLT.
   Methods. We analyzed the records of 116 children. All patients underwent Doppler ultrasound (US) at operation, daily for the first 2 postoperative weeks, and when necessary thereafter. After primary evaluation using US, the definite diagnosis of postoperative complication was confirmed using computed tomography, magnetic resonance imaging, and/or operation.
   Results. There were 61 boys and 55 girls. The overall mean age was 2.69 years. The overall mean preoperative weight and height were 13.06 kg and 83.79 cm, respectively. There were 28 (24.13%) biliary and vascular complications. These were cases of biliary stricture (n = 5), bile leakage (n = 3), hepatic artery stenosis (n = 6), hepatic vein stenosis (n = 4), and portal vein thrombosis (n = 17). The diagnostic accuracy of US in detecting biliary complication, hepatic artery stenosis, hepatic venous stenosis, and portal vein thrombosis was 95.69%, 97.41%, 100%, and 100%, respectively. US in combination with multiple imaging modalities and clinical suspicion resulted in 100% diagnostic accuracy. Percutaneous transhepatic cholangiography, thrombolysis, balloon angioplasty, and stent placement were performed for the complications noted. There was an early mortality due to multiple-organ failure after failed radiological invention and subsequent surgical management.
   Conclusions. Doppler US is accurate in detecting postoperative complications after pediatric LDLT for BA. Radiological interventions for vascular and biliary complications are effective and safe alternatives to reconstructive surgery.
C1 [Chen, H. -L.; Huang, T. -L.; Chen, T. -Y.; Tsang, L. L. -C.; Cheng, Yu-Fan] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Diagnost Radiol, Kaohsiung 83305, Taiwan.
   [Concejero, A. M.; Wang, C. -C.; Wang, S. -H.; Chen, C. -L.] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Kaohsiung 83305, Taiwan.
RP Cheng, YF (reprint author), Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Diagnost Radiol, 123 Ta Pei Rd, Kaohsiung 83305, Taiwan.
EM cheng.yufan@msa.hinet.net
FU National Health Research Institutes [NHR1-EX 93-9228SP]; National
   Science Council, Taiwan [NSC 95-2314-B-182A-132]
FX This work was partly supported by project grant NHR1-EX 93-9228SP from
   the National Health Research Institutes and Grant NSC 95-2314-B-182A-132
   from the National Science Council, Taiwan.
CR DODD GD, 1994, RADIOLOGY, V192, P657
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   OSORIO RW, 1993, TRANSPLANTATION, V55, P1074, DOI 10.1097/00007890-199305000-00026
   PARIENTE D, 1991, PEDIATR RADIOL, V21, P175, DOI 10.1007/BF02011040
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Yoon PW, 1997, PEDIATRICS, V99, P376, DOI 10.1542/peds.99.3.376
NR 6
TC 11
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD OCT
PY 2008
VL 40
IS 8
BP 2534
EP 2536
DI 10.1016/j.transproceed.2008.07.057
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 361NL
UT WOS:000260134300026
PM 18929792
ER

PT J
AU Seda-Neto, J
   Godoy, AL
   Carone, E
   Pugliese, V
   Fonseca, EA
   Porta, G
   Pugliese, R
   Miura, IK
   Baggio, V
   Kondo, M
   Chapchap, P
AF Seda-Neto, Joao
   Godoy, Andre L.
   Carone, Eduardo
   Pugliese, Vincenzo
   Fonseca, Eduardo A.
   Porta, Gilda
   Pugliese, Renata
   Miura, Irene K.
   Baggio, Vera
   Kondo, Mario
   Chapchap, Paulo
TI Left lateral segmentectomy for pediatric live-donor liver
   transplantation: Special attention to segment IV complications
SO TRANSPLANTATION
LA English
DT Article
DE liver transplantation; postoperative complications; outcomes; live
   donation; liver segments
ID HEALTH ASSESSMENT; PRINGLE MANEUVER; LIVING DONORS; MORBIDITY;
   CLASSIFICATION; OUTCOMES; ETHICS
AB Background. During left lateral segmentectomy for live-donor liver transplant, the vascular inflow to segment IV can be compromised. An area of ischemia can be seen intraoperatively and further segment IV resection may be needed to prevent necrosis and abscess formation.
   Methods. From July 1995 to February 2007, 324 consecutive living donor liver transplantations were performed at Hospital A. C. Camargo and Hospital Sirio-Libanes, Sao Paulo, Brazil. Two hundred eleven left lateral segments were transplanted in this period. Data on 204 left lateral segments donors were available for this analysis.
   Results. There were 108 female and 96 male donors. Median age was 29 years (range, 16-48 years). Median follow-up time was 2.2 years (range, 2 months-11.8 years). Median intensive care unit stay was 1 day (range, 1-3 days), and median hospital stay was 5 days (range, 4-47 days). Postoperative complications were encountered in 39 donors (19.1%). Partial segment IV resection on the course of the primary surgery due to parenchyma discoloration was required in 107 cases (52.5%). Ten patients (4.9%) developed segment IV necrosis or abscesses, although four of them had had segment IVB resection intraoperatively. Segment IV necrosis or abscess significantly increased hospital stay and the number of readmissions, from 5.5 +/- 3.5 days to 8.4 +/- 3.7 days (P=0.012) and from 6 of 194 (3%) to 5 of 10 (50%) (P=0.001), respectively.
   Conclusions. Middle hepatic segment abscess or necrosis was the most frequent complication after left lateral segmentectomy (4.9%). Objective intraoperative strategies need to be developed to evaluate middle hepatic segment ischemia to identify and treat patients at higher risk.
C1 [Chapchap, Paulo] Hosp Sirio Libanes, Hosp AC Camargo, Dept Hepatol, BR-01308000 Sao Paulo, Brazil.
   Hosp Sirio Libanes, Hosp AC Camargo, Dept Liver Transplantat, BR-01308000 Sao Paulo, Brazil.
RP Chapchap, P (reprint author), Hosp Sirio Libanes, Hosp AC Camargo, Dept Hepatol, Rua Barata Ribeiro 414,Cj 65, BR-01308000 Sao Paulo, Brazil.
EM paulo.chapchap@gmail.com
CR Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443
   BOILLOT O, 1995, TRANSPLANT P, V27, P1179
   Broering DC, 2004, ANN SURG, V240, P1013, DOI 10.1097/01.sla.0000146146.97485.6c
   Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345
   Cheng YF, 1998, CLIN TRANSPLANT, V12, P476
   CLAVIEN PA, 1994, ANN SURG, V220, P109, DOI 10.1097/00000658-199408000-00002
   COUINAUD C, 1993, J CHIR-PARIS, V130, P443
   Diaz GC, 2002, ANN SURG, V236, P120, DOI 10.1097/01.SLA.0000018662.29095.4F
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Fujita S, 2000, TRANSPLANT INT, V13, P333, DOI 10.1111/j.1432-2277.2000.tb01006.x
   Ghobrial RM, 2002, ANN SURG, V236, P315, DOI 10.1097/01.SLA.0000026684.68004.1E
   Grewal HP, 1998, ANN SURG, V228, P214, DOI 10.1097/00000658-199808000-00011
   Hwang S, 2006, HEPATO-GASTROENTEROL, V53, P773
   KIM YI, 1995, HEPATO-GASTROENTEROL, V42, P169
   Kimura F, 2002, HEPATO-GASTROENTEROL, V49, P225
   RAIA S, 1989, LANCET, V2, P497
   SHIMAHARA Y, 1992, TRANSPLANTATION, V54, P983, DOI 10.1097/00007890-199212000-00008
   SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919
   SINGER PA, 1988, CLIN RES, V36, P539
   SINGER PA, 1990, THEOR MED, V11, P87, DOI 10.1007/BF00489452
   Sugawara Y, 2002, LIVER TRANSPLANT, V8, P58, DOI 10.1053/jlts.2002.29761
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tojimbara T, 1998, TRANSPLANTATION, V66, P1035, DOI 10.1097/00007890-199810270-00012
   Trotter JF, 2006, LIVER TRANSPLANT, V12, P1485, DOI 10.1002/lt.20875
   Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4
NR 26
TC 17
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD SEP 15
PY 2008
VL 86
IS 5
BP 697
EP 701
DI 10.1097/TP.0b013e318183ed22
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 350OI
UT WOS:000259361700013
PM 18791451
ER

PT J
AU Sakamoto, S
   Egawa, H
   Ogawa, K
   Ogura, Y
   Oike, F
   Ueda, M
   Yazumi, S
   Shibata, T
   Takada, Y
   Uemoto, S
AF Sakamoto, Seisuke
   Egawa, Hiroto
   Ogawa, Kohei
   Ogura, Yasuhiro
   Oike, Fumitaka
   Ueda, Mikiko
   Yazumi, Shujiro
   Shibata, Toshiya
   Takada, Yasutsugu
   Uemoto, Shinji
TI The technical pitfalls of duct-to-duct biliary reconstruction in
   pediatric living-donor left-lobe liver transplantation: The impact of
   stent placement
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary reconstruction; duct-to-duct anastomosis; living donor liver
   transplantation; pediatric liver transplantation; surgical complication
ID COMPLICATIONS; FEASIBILITY
AB The feasibility of D-D biliary reconstruction in pediatric LDLT using a left-lobe graft is still controversial. The medical records of 19 pediatric patients (age: four months to 16 yr) were reviewed. The biliary reconstruction was performed in an end-to-end fashion using absorbable sutures. An external biliary tube was placed into the bile duct through the anastomotic site (n = 10) and not through the anastomotic site (n = 4). An external tube was not used in five patients. The median follow-up was 4.7 yr. Nine patients had 11 biliary complications (leakage, n = 2; stricture, n = 7; stricture with leakage, n = 2). Due to biliary complications, conversion to an R-Y was required in five patients, and four patients required radiological or endoscopic management. The patients younger than one yr of age required conversion to R-Y within one wk after LDLT. The analysis of factors related to biliary complications revealed that the use of a trans-anastomotic biliary tube was the only significant factor to avoid biliary complications. In conclusion, D-D biliary reconstruction in LDLT using a left-lobe graft is feasible in selected cases, though it remains challenging. The use of a trans-anastomotic biliary tube is important to avoid biliary complications.
C1 [Sakamoto, Seisuke; Egawa, Hiroto; Ogawa, Kohei; Ogura, Yasuhiro; Oike, Fumitaka; Ueda, Mikiko; Takada, Yasutsugu; Uemoto, Shinji] Kyoto Univ, Fac Med, Dept Hepatobiliary Pancreat Surg & Transplantat, Kyoto, Japan.
RP Sakamoto, S (reprint author), 54 Kawara Cho, Kyoto 6068507, Japan.
EM sseisuke@kuhp.kyoto-u.ac.jp
CR Azoulay D, 2001, ARCH SURG-CHICAGO, V136, P1197, DOI 10.1001/archsurg.136.10.1197
   Dulundu E, 2004, TRANSPLANTATION, V78, P574, DOI 10.1097/01.TP.0000128912.09581.46
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   HEFFRON TG, 1992, TRANSPLANTATION, V53, P391, DOI 10.1097/00007890-199202010-00024
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Kasahara M, 2005, AM J TRANSPLANT, V5, P2229, DOI 10.1111/j.1600-6143.2005.01003.x
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kimura T, 2006, PEDIATR TRANSPLANT, V10, P248, DOI 10.1111/j.1399-3046.2005.00430.x
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Soejima Y, 2003, TRANSPLANTATION, V75, P557, DOI 10.1097/01.TP.0000048220.90971.5A
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   Tada S, 2007, AM J GASTROENTEROL, V102, P1331, DOI 10.1111/j.1572-0241.2007.01177.x
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   YAMAOKA Y, 1995, TRANSPLANTATION, V59, P224, DOI 10.1097/00007890-199501270-00012
NR 14
TC 9
Z9 11
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2008
VL 12
IS 6
BP 661
EP 665
DI 10.1111/j.1399-3046.2007.00870.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 335JW
UT WOS:000258287900010
PM 18093087
ER

PT J
AU Calvo-Garcia, MA
   Campbell, KM
   O'Hara, SM
   Khoury, P
   Mitsnefes, MM
   Strife, CF
AF Calvo-Garcia, M. A.
   Campbell, K. M.
   O'Hara, S. M.
   Khoury, P.
   Mitsnefes, M. M.
   Strife, C. F.
TI Acquired renal cysts after pediatric liver transplantation: Association
   with cyclosporine and renal dysfunction
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; cysts; calcineurin inhibitors; ultrasound
ID EPITHELIAL-MESENCHYMAL TRANSITION; GLOMERULAR-FILTRATION-RATE;
   KIDNEY-DISEASE; CHILDREN; LONG; RECIPIENTS; FIBROSIS; PREVALENCE;
   TACROLIMUS; EXPRESSION
AB ACKD has been observed in children on dialysis and with chronic renal insufficiency. In one report, ACKD was observed in 30% of pediatric liver transplant recipients after 10 yr. We retrospectively reviewed all renal imaging and measurements of GFR of 235 childhood liver transplant recipients with no known risk for renal cyst formation, no evidence of renal cyst(s) at the time of transplantation and renal imaging at least one yr post-transplant. Twenty-six patients (11%) developed one or more cyst(s). Mean GFR was significantly lower in patients with renal cyst(s). Two (1.4%) of the 146 patients treated with tacrolimus and 24 (27%) of the 89 patients treated with CsA acquired renal cyst(s) (p < 0.001). CsA-treated patients had significantly lower GFR. Multivariate analysis identified CsA as the only independent variable associated with ACKD. These results confirm that ACKD can be a late complication of pediatric liver transplantation. Those at most risk are at least 10-yr post-liver transplantation, have been treated with CsA and have impaired renal function. We speculate that ACKD in these patients is the result of calcineurin inhibitor nephrotoxicity. Whether patients with ACKD will be prone to develop solid renal tumors is unknown.
C1 [Mitsnefes, M. M.; Strife, C. F.] Cincinnati Childrens Hosp, Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA.
   [Calvo-Garcia, M. A.; O'Hara, S. M.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.
   [Campbell, K. M.] Cincinnati Childrens Hosp, Med Ctr, Pediat Liver Care Ctr, Cincinnati, OH 45229 USA.
   [Khoury, P.] Cincinnati Childrens Hosp, Med Ctr, Div Cardiol, Cincinnati, OH 45229 USA.
   [Calvo-Garcia, M. A.; O'Hara, S. M.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat Radiol, Cincinnati, OH 45229 USA.
RP Strife, CF (reprint author), Cincinnati Childrens Hosp, Med Ctr, Div Nephrol & Hypertens, MLC 7022,3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM frederic.strife@cchmc.org
CR Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Bicknell GR, 2000, BRIT J SURG, V87, P1569, DOI 10.1046/j.1365-2168.2000.01577.x
   BROCHNER.J, 1972, SCAND J CLIN LAB INV, V30, P271, DOI 10.3109/00365517209084290
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   DUNNILL MS, 1977, J CLIN PATHOL, V30, P868, DOI 10.1136/jcp.30.9.868
   Esposito C, 2004, TRANSPLANT P, V36, P695, DOI 10.1016/j.transproceed.2004.03.013
   Fine RN, 2005, PEDIATR TRANSPLANT, V9, P680, DOI 10.1111/j.1399-3046.2005.00381.x
   Franchi-Abella S, 2007, TRANSPL P, V39, P2601, DOI 10.1016/j.transproceed.2007.08.019
   Gulanikar AC, 1998, TRANSPLANTATION, V66, P1669, DOI 10.1097/00007890-199812270-00017
   HOGG RJ, 1992, PEDIATR NEPHROL, V6, P176
   Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887
   Kidney Disease Outcomes Quality Initiative (K/DOQI), 2002, AM J KIDNEY DIS, V39, pS1
   Kelly DM, 1998, CANCER-AM CANCER SOC, V83, P1237, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1237::AID-CNCR25>3.3.CO;2-K
   KOPP JB, 1990, J AM SOC NEPHROL, V1, P162
   LEICHTER HE, 1988, PEDIATR NEPHROL, V2, P8
   LIEN YHH, 1993, KIDNEY INT, V44, P613, DOI 10.1038/ki.1993.288
   Liptak P, 2006, NAT CLIN PRACT NEPHR, V2, P398, DOI 10.1038/ncpneph0225
   MARIAN C, 2006, J AM SOC NEPHROL, V17, P881
   MATOO TK, 1997, PEDIATR NEPHROL, V11, P447
   MATSON MA, 1990, MEDICINE, V69, P217
   MCDIARMID SV, 1989, TRANSPLANTATION, V47, P314, DOI 10.1097/00007890-198902000-00025
   McMorrow T, 2005, NEPHROL DIAL TRANSPL, V20, P2215, DOI 10.1093/ndt/gfh967
   Mention K, 2005, PEDIATR TRANSPLANT, V9, P201, DOI 10.1111/j.1399-3046.2005.00289.x
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Pirsch JD, 1997, TRANSPLANTATION, V63, P977, DOI 10.1097/00007890-199704150-00013
   QUERFELD U, 1992, J PEDIATR-US, V121, P61, DOI 10.1016/S0022-3476(05)82542-9
   SIENIAWSKA M, 1991, CHILD NEPHROL UROL, V11, P20
   Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039
   Strutz F, 2000, NEPHROL DIAL TRANSPL, V15, P1729, DOI 10.1093/ndt/15.11.1729
   WILSON SR, 2005, DIAGNOSTIC ULTRASOUN, P367
   Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3
NR 31
TC 11
Z9 11
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2008
VL 12
IS 6
BP 666
EP 671
DI 10.1111/j.1399-3046.2007.00872.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 335JW
UT WOS:000258287900011
PM 18331544
ER

PT J
AU Kilic, M
   Aydinli, B
   Aydin, U
   Alper, M
   Zeytunlu, M
AF Kilic, Murat
   Aydinli, Bulent
   Aydin, Unal
   Alper, Mehmet
   Zeytunlu, Murat
TI A new surgical technique for hepatic vein reconstruction in pediatric
   live donor liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric live donor liver transplantation; hepatic venous
   reconstruction; surgical technique
ID LIVING-RELATED DONORS; VENOUS RECONSTRUCTION; SINGLE-CENTER;
   COMPLICATIONS; EXPERIENCE; RECIPIENTS; OUTCOMES; GRAFT; SIZE
AB The hepatic venous reconstruction is one of the corner stones of pediatric LDLT. However, problems associated with hepatic venous outflow still remain to be an issue. In this study, we aimed at comparing two methods used in hepatic venous reconstruction. Between November 1999 and December 2006, 61 consecutive left lateral segment pediatric LDLT were performed at Ege University Organ Transplant Center, and two methods were used for hepatic venous reconstruction. In the former group (group 1: 32 patients) continuous anastomosis was performed between the donor LHV and common orifice of the recipient HV. In the later group (group 2: 29 patients), the posterior wall of the anastomosis was sutured continuously while the anterior wall was sutured with interrupted sutures. HV thrombosis was detected in one patient and stenosis was detected in four patients in group 1. No hepatic venous outflow obstruction was detected in group 2 (p < 0.05). In both groups, mortality was not associated with hepatic venous outflow obstruction. As our results indicate, the novel technique used in this study is a simple and safe anastomosis procedure that has contributed into overcoming hepatic venous outflow problems in pediatric LDLT.
C1 [Kilic, Murat; Aydin, Unal; Alper, Mehmet; Zeytunlu, Murat] Ege Univ Hosp, Dept Surg, TR-35100 Izmir, Turkey.
   [Aydinli, Bulent] Ataturk Univ, Dept Surg, Erzurum, Turkey.
RP Kilic, M (reprint author), Ege Univ Hosp, Dept Surg, TR-35100 Izmir, Turkey.
EM murat.kilic@ege.edu.tr
CR Aydogdu S, 2006, TRANSPLANT P, V38, P1459, DOI 10.1016/j.transproceed.2006.02.087
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   CLAVIEN PA, 1994, ANN SURG, V220, P109, DOI 10.1097/00000658-199408000-00002
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   de Villa VH, 2000, TRANSPLANTATION, V70, P1604, DOI 10.1097/00007890-200012150-00011
   Egawa H, 1997, SURGERY, V121, P250, DOI 10.1016/S0039-6060(97)90353-6
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Kubo T, 2006, RADIOLOGY, V239, P285, DOI 10.1148/radiol.2391050387
   Kubota K, 2000, SURGERY, V128, P48, DOI 10.1067/msy.2000.106783
   Lin CC, 2004, TRANSPLANT P, V36, P2338, DOI 10.1016/j.transproceed.2004.07.044
   MATSUNAMI H, 1995, TRANSPLANTATION, V59, P917, DOI 10.1097/00007890-199503270-00024
   Miraglia R, 2007, PEDIATR TRANSPLANT, V11, P222, DOI 10.1111/j.1399-3046.2006.00625.x
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   Takemura N, 2005, LIVER TRANSPLANT, V11, P356, DOI 10.1002/lt.20374
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   YAMAGUCHI T, 1993, SURGERY, V114, P976
   YAMAOKA Y, 1995, TRANSPLANTATION, V59, P224, DOI 10.1097/00007890-199501270-00012
NR 20
TC 7
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2008
VL 12
IS 6
BP 677
EP 681
DI 10.1111/j.1399-3046.2007.00877.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 335JW
UT WOS:000258287900013
PM 18208439
ER

PT J
AU Attia, MS
   Stringer, MD
   McClean, P
   Prasad, KR
AF Attia, M. S.
   Stringer, M. D.
   McClean, P.
   Prasad, K. R.
TI The reduced left lateral segment in pediatric liver transplantation: An
   alternative to the monosegment graft
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE paediatric liver transplantation; monosegent; left lateral segment
ID LIVING-DONOR; INFANTS; KILOGRAMS
AB Tailoring graft size to small paediatric recipients is a challenge. We have developed a reduced left lateral segment as an alternative to monosegment transplantation for small size recipients. Since November 2000, 89 children have been transplanted with 100 deceased donor liver grafts in our unit. Our median patient and graft survival is 89% and 88% respectively. Four of these cases were performed using a new technique of creating a small donor graft by reducing the left lateral segment. The median weight of the reduced liver graft was 264 g (range: 165-390 g). The median blood transfusion requirement was 101 mL/kg body weight (range 69-167 mL/kg). The median values of peak ALT were 1473 IU/L, INR 2.2 and bilirubin 293 mu mol/L in the first two wk following surgery. One neonatal recipient died five days after transplantation from a massive intracranial haemorrhage despite satisfactory graft function. Another recipient with excellent graft function died 10 months later from primary pulmonary hypertension and secondary cardiac failure. Hepatic artery thrombosis occurred in one patient with successful revascularization but he was retransplanted three months later for chronic rejection. No biliary or venous outflow complications occurred in this group. This technique of reduced left lateral segment liver transplantation is an alternative to the monosegment graft and allows small recipients to be successfully transplanted with few technical complications related to graft preparation.
C1 [Attia, M. S.; Stringer, M. D.; McClean, P.; Prasad, K. R.] St James Univ Hosp, Dept Transplantat & Heptobiliary Surg, Leeds LS1 9NN, W Yorkshire, England.
RP Prasad, KR (reprint author), St James Univ Hosp, Dept Transplantat & Heptobiliary Surg, Leeds LS1 9NN, W Yorkshire, England.
EM krprasad1@aol.com
CR de Santibanes E, 2000, LIVER TRANSPLANT, V6, P108, DOI 10.1002/lt.500060104
   Enne M, 2004, PEDIATR TRANSPLANT, V8, P189, DOI 10.1046/j.1399-3046.2003.00140.x
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   HOUSSIN D, 1992, SURGERY, V111, P532
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kasahara M, 2003, J PEDIATR SURG, V38, P1108, DOI 10.1016/S0022-3468(03)00206-9
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Mentha G, 1996, TRANSPLANTATION, V62, P1176, DOI 10.1097/00007890-199610270-00026
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Shirouzu Y, 2006, LIVER TRANSPLANT, V12, P1224, DOI 10.1002/lt.20800
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   STRONG R, 1995, SURGERY, V118, P904, DOI 10.1016/S0039-6060(05)80283-1
NR 14
TC 7
Z9 10
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2008
VL 12
IS 6
BP 696
EP 700
DI 10.1111/j.1399-3046.2007.00882.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 335JW
UT WOS:000258287900016
PM 18786070
ER

PT J
AU Lopez-Benitez, R
   Schlieter, M
   Hallscheidt, PJ
   Radeleff, BA
   Kauffmann, G
   Richter, GM
   Schmidt, J
   Engelmann, G
AF Lopez-Benitez, R.
   Schlieter, M.
   Hallscheidt, P. J.
   Radeleff, B. A.
   Kauffmann, G.
   Richter, G. M.
   Schmidt, J.
   Engelmann, G.
TI Successful arterial thrombolysis and percutaneous transluminal
   angioplasty for early hepatic artery thrombosis after split liver
   transplantation in a four-month-old baby
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric transplantation; pediatric liver transplantation; liver
   transplantation
ID VASCULAR COMPLICATIONS; STENOSIS; EXPERIENCE; CHILDREN
AB Early HAT is the most frequent and severe vascular complication following liver transplantation. It is one of the major causes of graft failure and mortality. Endovascular thrombolytic treatment in patients with thrombotic complications after liver transplantation is an attractive alternative to open surgery as lower morbidity and mortality rates are reported for it. PTA following transcatheter thrombolysis has been successfully used to treat HAT in adults. To the best of our knowledge, there have not been any reports of a successful transcatheter thrombolysis using interventional radiological techniques in a patient only four months old. The present report describes the successful endovascular emergency treatment of a HAT three days after DD split liver transplantation.
C1 [Lopez-Benitez, R.; Schlieter, M.; Hallscheidt, P. J.; Radeleff, B. A.; Kauffmann, G.; Richter, G. M.] Univ Heidelberg, Dept Diagnost Radiol, D-69120 Heidelberg, Germany.
   [Schmidt, J.] Univ Heidelberg, Dept Surg, D-69120 Heidelberg, Germany.
   [Engelmann, G.] Univ Heidelberg, Dept Pediat, D-69120 Heidelberg, Germany.
RP Lopez-Benitez, R (reprint author), Univ Heidelberg, Dept Diagnost Radiol, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
EM ruben_lopez@med.uni-heidelberg.de
RI Hallscheidt, Peter/H-4760-2011
CR Abbasoglu O, 1997, TRANSPLANTATION, V63, P250, DOI 10.1097/00007890-199701270-00013
   Belenky A, 2004, CARDIOVASC INTER RAD, V27, P491, DOI 10.1007/s00270-003-2675-0
   Cheng YF, 1998, CLIN TRANSPLANT, V12, P292
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   Hasegawa T, 2002, PEDIATR TRANSPLANT, V6, P244, DOI 10.1034/j.1399-3046.2002.01081.x
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   HIDALGO EG, 1989, HEPATO-GASTROENTEROL, V36, P529
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   Kim BW, 2006, TRANSPLANT P, V38, P3128, DOI 10.1016/j.transproceed.2006.08.164
   Kodama Y, 2006, LIVER TRANSPLANT, V12, P465, DOI 10.1002/lt.20724
   LALLIER M, 1995, J PEDIATR SURG, V30, P1122, DOI 10.1016/0022-3468(95)90002-0
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   MONDRAGON RS, 1994, TRANSPLANTATION, V57, P228, DOI 10.1097/00007890-199401001-00013
   ORONS PD, 1995, J VASC INTERV RADIOL, V6, P523, DOI 10.1016/S1051-0443(95)71128-9
   Pawlak J, 2003, TRANSPLANT P, V35, P2313, DOI 10.1016/S0041-1345(03)00836-4
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   Saad Wael E A, 2007, Vasc Endovascular Surg, V41, P19, DOI 10.1177/1538574406296210
   Saad WEA, 2005, J VASC INTERV RADIOL, V16, P795, DOI 10.1097/01.RVI.0000156441.12330.13
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
   Yilmaz A, 2007, PEDIATR TRANSPLANT, V11, P160, DOI 10.1111/j.1399-3046.2006.00601.x
NR 21
TC 11
Z9 13
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2008
VL 12
IS 5
BP 606
EP 610
DI 10.1111/j.1399-3046.2008.00925.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 327AK
UT WOS:000257700900024
PM 18652621
ER

PT J
AU Herlenius, G
   Fagerlind, M
   Krantz, M
   Molne, J
   Olausson, M
   Gabel, M
   Friman, V
   Oltean, M
   Friman, S
AF Herlenius, Gustaf
   Fagerlind, Mattias
   Krantz, Marie
   Molne, Johan
   Olausson, Michael
   Gabel, Markus
   Friman, Vanda
   Oltean, Mihai
   Friman, Styrbjorn
TI Chronic kidney disease - A common and serious complication after
   intestinal transplantation
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 10th International Symposium on Small Bowel Transplantation
CY SEP 06-08, 2007
CL Los Angeles, CA
DE intestinal transplantation; renal toxicity; chronic kidney disease;
   glomerular filtration rate; calcineurin inhibitors
ID GLOMERULAR-FILTRATION-RATE; RENAL-FUNCTION; LIVER-TRANSPLANTATION;
   RECIPIENTS; SIROLIMUS; CHILDREN; ORGAN
AB Background. Chronic kidney disease after organ transplantation is a serious complication that negatively impacts on long-term patient survival. We describe long-term renal function after intestinal transplantation by serial measurements of glomerular filtration rates (GFR) with "Chromium EDTA clearance.
   Materials and Methods. Ten patients with at least 6 months survival form the basis of this report. Glomerular filtration rate measurements were performed at baseline, 3 months posttransplantation, and yearly thereafter. Median follow-up time for the cohort was 1.5 years (0.5-7.8 years). Tacrolimus (Prograf) was discontinued in four patients because of impaired renal function. These four patients were switched to sirolimus; (Rapamune) at 11, 18, 24, and 40 months posttransplantation.
   Results. Median baseline GFR was 67 (22-114) mL/min/1.73 m(2). In the adult patients, GFR 3 months posttransplantation had decreased to 50% of the baseline. At 1 year, median GFR in the adult patients was reduced by 72% (n=5). Two patients developed renal failure within the first year and required hemodialysis. One of the pediatric patients fully recovered her renal function, the second pediatric patient lost 20% of her baseline GFR at 6 months posttransplantation. Glomerular filtration rate calculated with the modified diet in renal disease formula consistently overestimated GFR by approximately 30% compared with measured GFR.
   Conclusion. Chronic kidney disease and renal failure are common after intestinal transplantation. These two factors significantly contribute to poor long-term survival rates. Measurements of GFR may help to identify those individuals at risk for developing chronic kidney disease to implement renal sparing strategies.
C1 [Herlenius, Gustaf; Fagerlind, Mattias; Olausson, Michael; Gabel, Markus; Oltean, Mihai; Friman, Styrbjorn] Sahlgrens Univ Hosp, Dept Transplantat & Liver Surg, S-41345 Gothenburg, Sweden.
   [Krantz, Marie] HRH Queen Silvia Childrens Hosp, Dept Pediat, Gothenburg, Sweden.
   [Molne, Johan] Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   [Friman, Vanda] Sahlgrens Univ Hosp, Dept Infect Dis, S-41345 Gothenburg, Sweden.
RP Herlenius, G (reprint author), Sahlgrens Univ Hosp, Dept Transplantat & Liver Surg, S-41345 Gothenburg, Sweden.
EM Gustaf.herlenius@gmail.com
RI Olausson, Michael/E-5822-2012; 
OI Olausson, Michael/0000-0002-3949-9430; Molne, Johan/0000-0001-6241-7117
CR Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Borrows R, 2007, TRANSPLANTATION, V83, P529, DOI 10.1097/01.tp.0000255566.42513.00
   Delanaye P, 2007, TRANSPLANTATION, V83, P641, DOI 10.1097/01.tp.0000253746.30273.cd
   Fairbanks KD, 2003, LIVER TRANSPLANT, V9, P1079, DOI 10.1053/jlts.2003-50183
   Fine RN, 2005, PEDIATR TRANSPLANT, V9, P680, DOI 10.1111/j.1399-3046.2005.00381.x
   Gonwa T, 2004, LIVER TRANSPLANT, V10, P301, DOI 10.1002/lt.20017
   GRANERUS G, 1981, SCAND J CLIN LAB INV, V41, P611, DOI 10.3109/00365518109090505
   Kniepeiss D, 2003, TRANSPLANT INT, V16, P504, DOI 10.1007/s00147-003-0579-1
   National Kidney Foundation, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   PAPADAKIS MA, 1987, AM J MED, V82, P945, DOI 10.1016/0002-9343(87)90156-2
   RANDHAWA PS, 1993, AM J SURG PATHOL, V17, P60, DOI 10.1097/00000478-199301000-00007
   Reyes J, 2005, AM J TRANSPLANT, V5, P1430, DOI 10.1111/j.1600-6143.2005.00874.x
   Sanchez EQ, 2005, TRANSPLANT P, V37, P4416, DOI 10.1016/j.transproceed.2005.10.019
   Selvaggi G, 2006, CURR OPIN ORGAN TRAN, V11, P263, DOI 10.1097/01.mot.0000227843.37076.54
   Tzakis AG, 2005, ANN SURG, V242, P480, DOI 10.1097/01.sla..0000183347.61361.7a
   Ueno T, 2006, TRANSPLANT P, V38, P1759, DOI 10.1016/j.transproceed.2006.05.026
   Ueno T, 2006, TRANSPLANT P, V38, P1762, DOI 10.1016/j.transproceed.2006.05.066
NR 18
TC 11
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD JUL 15
PY 2008
VL 86
IS 1
BP 108
EP 113
DI 10.1097/TP.0b013e31817613f8
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 328IA
UT WOS:000257790400019
PM 18622286
ER

PT J
AU Te, HS
   Anderson, AS
   Millis, JM
   Jeevanandam, V
   Jensen, DM
AF Te, Helen S.
   Anderson, Allen S.
   Millis, J. Michael
   Jeevanandam, Valluvan
   Jensen, Donald M.
TI Current state of combined heart-liver transplantation in the United
   States
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
ID HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HEREDITARY TRANSTHYRETIN
   AMYLOIDOSIS; OF-THE-LITERATURE; KIDNEY-TRANSPLANTATION; GENETIC
   HEMOCHROMATOSIS; AUXILIARY LIVER; PATIENT; POLYNEUROPATHY; SURVIVAL;
   EXPRESSION
AB Background: Combined heart-liver transplantation (CHLT) has been increasingly performed in the USA, but published data on overall patient and graft outcomes have been limited.
   Methods: This study aimed to review the indications, immunosuppression, complications and outcomes of CHLT in the USA. From October 1987 to December 2005, a total of 47 cases of combined heart-liver (n = 4 1) and heart-liver-kidney transplantation (n = 6) were reported to the United Network for Sharing (UNOS) database. One pediatric case was excluded from the analysis. The mean age of recipients was 46 years (range, 22 to 65 years) and included 31 (67%) men and 16 (33%) women.
   Results: The most common indication for both heart and liver transplantation was amyloidosis (30%). Patients were followed for a mean duration of 1,362 days or 3.7 years (range, I to 4,598 days or 0 to 12.6 years). Patient, heart and liver graft survival rates were 84.8%, 84.8% and 82.4% at I year, and 75.6%, 75.6% and 73.5% at 5 years, respectively. At the latest follow-tip of patients who survived at least 6 months after transplantation (n 39), 28.2% of patients were on a single immunosuppressive agent.
   Conclusions: Combined heart-liver transplantation is a viable option for candidates who require the combined transplantation, with outcomes comparable to those of single-organ recipients.
C1 [Te, Helen S.; Jensen, Donald M.] Univ Chicago, Med Ctr, Ctr Liver Dis, Dept Med, Chicago, IL 60637 USA.
   [Anderson, Allen S.] Univ Chicago, Med Ctr, Cardiol Sect, Dept Med, Chicago, IL 60637 USA.
   [Millis, J. Michael] Univ Chicago, Med Ctr, Sect Transplant Surg, Dept Surg, Chicago, IL 60637 USA.
   [Jeevanandam, Valluvan] Univ Chicago, Med Ctr, Sect Cardiac & Thorac Surg, Dept Surg, Chicago, IL 60637 USA.
RP Te, HS (reprint author), Univ Chicago, Med Ctr, Ctr Liver Dis, Dept Med, 5841 S Maryland Ave,MC 7120, Chicago, IL 60637 USA.
EM hte@medicine.bsd.uchicago.edu
CR Adams PC, 1997, HEPATOLOGY, V25, P162, DOI 10.1002/hep.510250130
   Alexander Jacob, 2005, Ann Hepatol, V4, P240
   Alkofer BJ, 2005, TRANSPLANT P, V37, P2250, DOI 10.1016/j.transproceed.2005.03.037
   Bacon BR, 1999, ANN INTERN MED, V130, P953
   Bahnson H T, 1990, Cardiovasc Clin, V20, P237
   BARBIR M, 1992, Q J MED, V85, P807
   Befeler AS, 1999, TRANSPLANTATION, V68, P1423, DOI 10.1097/00007890-199911150-00034
   Benson MD, 2002, CLIN CHEM LAB MED, V40, P1262, DOI 10.1515/CCLM.2002.218
   Beutler E, 2006, ANNU REV MED, V57, P331, DOI 10.1146/annurev.med.57.121304.131310
   Calne RY, 2000, IMMUNOL REV, V174, P280, DOI 10.1034/j.1600-0528.2002.017419.x
   COHEN AS, 1967, NEW ENGL J MED, V277, P522, DOI 10.1056/NEJM196709072771006
   Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8
   Creput C, 2003, AM J TRANSPLANT, V3, P348, DOI 10.1034/j.1600-6143.2003.00050.x
   Detry O, 1997, TRANSPLANT INT, V10, P150, DOI 10.1111/j.1432-2277.1997.tb00559.x
   FARRELL FJ, 1994, HEPATOLOGY, V20, P404, DOI 10.1016/0270-9139(94)90193-7
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Gillmore Julian D., 1999, Journal of Hepatology, V30, P17
   Grazi GL, 2003, LIVER TRANSPLANT, V9, P986, DOI 10.1053/jlts.2003.50173
   Gutierrez A, 2003, TRANSPLANT P, V35, P1861, DOI 10.1016/S0041-1345(03)00621-3
   Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3
   HOLMGREN G, 1993, LANCET, V341, P1113
   Jiang M, 2004, TRANSPLANT P, V36, P1607, DOI 10.1016/j.transproceed.2004.04.073
   Kowdley K V, 1995, Liver Transpl Surg, V1, P237, DOI 10.1002/lt.500010408
   Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000
   Offstad J, 2001, CLIN TRANSPLANT, V15, P432, DOI 10.1034/j.1399-0012.2001.150612.x
   Olausson M, 2007, AM J TRANSPLANT, V7, P130, DOI 10.1111/j.1600-6143.2006.01592.x
   OLIVIERI NF, 1994, NEW ENGL J MED, V330, P1125, DOI 10.1056/NEJM199404213301605
   Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002
   Pinderski LJ, 2005, J HEART LUNG TRANSPL, V24, P1828, DOI 10.1016/j.healun.2005.03.015
   Porrett PM, 2004, LIVER TRANSPLANT, V10, P1539, DOI 10.1002/lt.20279
   RELA M, 1995, TRANSPLANT INT, V8, P41, DOI 10.1111/j.1432-2277.1995.tb01704.x
   REVELL SP, 1995, ARCH DIS CHILD, V73, P456
   Rydh A, 1998, EUR J NUCL MED, V25, P709
   SALLIE RW, 1991, GUT, V32, P207, DOI 10.1136/gut.32.2.207
   Shah KB, 2006, ARCH INTERN MED, V166, P1805, DOI 10.1001/archinte.166.17.1805
   Stangou AJ, 1998, TRANSPLANTATION, V66, P229, DOI 10.1097/00007890-199807270-00016
   STARZL TE, 1984, LANCET, V1, P1382
   Suhr OB, 2000, LIVER TRANSPLANT, V6, P263, DOI 10.1053/lv.2000.6145
   VALDIVIELSO P, 1988, ANN INTERN MED, V108, P204
   Yazaki M, 2000, BIOCHEM BIOPH RES CO, V274, P702, DOI 10.1006/bbrc.2000.3203
   Yu L, 2007, GASTROENTEROLOGY, V133, P489, DOI 10.1053/j.gastro.2007.05.054
NR 41
TC 37
Z9 37
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JUL
PY 2008
VL 27
IS 7
BP 753
EP 759
DI 10.1016/j.healun.2008.04.004
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA 320TD
UT WOS:000257257000009
PM 18582805
ER

PT J
AU Novelli, G
   Rossi, M
   Morabito, V
   Pugliese, F
   Ruberto, F
   Perrella, SM
   Novelli, S
   Spoletini, G
   Ferretti, G
   Mennini, G
   Berloco, PB
AF Novelli, G.
   Rossi, M.
   Morabito, V.
   Pugliese, F.
   Ruberto, F.
   Perrella, S. M.
   Novelli, S.
   Spoletini, G.
   Ferretti, G.
   Mennini, G.
   Berloco, P. B.
TI Pediatric acute liver failure with molecular adsorbent recirculating
   system treatment
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 31st Congress of the Italian-Transplantation-Society
CY NOV 28-30, 2007
CL Modena, ITALY
SP Italian Transplantat Soc
ID FULMINANT HEPATIC-FAILURE; TRANSPLANTATION; CHILDREN; EXPERIENCE;
   INFANTS
AB Background. The prognosis of pediatric acute liver failure (PALF) has been significantly improved by emergency orthotopic liver transplantation (OLT). Since 2004, the molecular adsorbent recirculating system (MARS) has been proposed as a bridging procedure. The aim of our study was to assess its efficacy in children with PALF.
   Patients and Methods. Since 1999 we performed treatment of 39 fulminant hepatic failure (FHF) cases with MARS. Since September 2004 we treated 6 pediatric patients with FHF who were of mean age 1.0.6 years (range, 3-15 years) including 4 females and 2 males. In 3 cases the cause of FHF was unknown; in 2 cases, it was induced by paracetamol overdose; and in 1, by acute hepatitis B virus. Inclusion criteria were: bilirubin > 15 mg/dL; creatinine 2 mg/dL; encephalopathy grade >II; and International normalized ratio (INR) >2.5. Other estimated parameters were: AST and ALT serum levels, lactate, and urine volume. Neurological status was monitored using the Glasgow Coma Scale (GCS). Continuous MARS treatment was performed in all patients with a kit change every 8 hours. Intensive care unit (ICU) treatment was applied to optimize regeneration and to prevent cardiovascular complications.
   Results. We observed a significant improvement among levels of bilirubin (P < .009), ammonia (P < .005), creatinine (P < .02), GCS (P < .002), and predictive criteria and as Sequential Organ Failure Assessment (SOFA) and Pediatric End-Stage Liver Disease (PELD). Three children underwent OLT: I died after 5 days due to primary nonfunction and 2 children are alive after a median follow-up of 14 months. In 2 children the MARS treatment led to resolution of clinical status without liver transplantation. One child died before OLT due to sepsis and multiorgan failure.
   Conclusions. We concluded that application of the MARS liver support device in combination with experienced ICU management contributed to improve the clinical status in children with PALF awaiting liver transplantation.
C1 [Novelli, G.; Rossi, M.; Morabito, V.; Spoletini, G.; Mennini, G.; Berloco, P. B.] Univ Roma La Sapienza, Dipartimento Paride Stefanini, Unita Chirurg Gen & Trapianti Organo, I-00144 Rome, Italy.
   [Ferretti, G.] Univ Roma La Sapienza, Dipartimento Malattie Infett & Trop, I-00144 Rome, Italy.
RP Novelli, G (reprint author), Univ Roma La Sapienza, Dipartimento Paride Stefanini, Unita Chirurg Gen & Trapianti Organo, Viale Policlin 188, I-00144 Rome, Italy.
EM novelligilnardo@virgilio.it
RI rossi, massimo/C-8411-2012
CR Auth MKH, 2005, J PEDIATR GASTR NUTR, V40, P54, DOI 10.1097/00005176-200501000-00010
   Balistreri WF, 1998, LIVER TRANSPLANT SUR, V4, pS18
   Brandsaeter B, 2002, LIVER TRANSPLANT, V8, P1055, DOI 10.1053/jlts.2002.35556
   DEVICTOR D, 1992, HEPATOLOGY, V16, P1156, DOI 10.1016/0270-9139(92)90008-W
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Ellis A, 1996, SEMIN LIVER DIS, V16, P379, DOI 10.1055/s-2007-1007251
   Liu CL, 2003, TRANSPLANTATION, V75, pS33, DOI 10.1097/01.TP.0000047031.65448.47
   MONDRAGON R, 1992, TRANSPLANT INT, V5, pS206
   Nachulewicz P, 2006, TRANSPLANT P, V38, P253, DOI 10.1016/j.transproceed.2005.12.043
   OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439
   Rolando N, 2000, HEPATOLOGY, V32, P734, DOI 10.1053/jhep.2000.17687
   TAN KC, 1992, BRIT J SURG, V79, P1192, DOI 10.1002/bjs.1800791130
   Tanaka Koichi, 2002, J Hepatobiliary Pancreat Surg, V9, P218, DOI 10.1007/s005340200022
   Tanaka Y., 1994, J JAPANESE SOC COMPU, V7, P1
   Tissieres P, 2003, PEDIATR TRANSPLANT, V7, P64, DOI 10.1034/j.1399-3046.2003.00020.x
   Tissieres Pierre, 2005, Pediatr Crit Care Med, V6, P585, DOI 10.1097/01.PCC.0000170624.29667.7B
NR 16
TC 9
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2008
VL 40
IS 6
BP 1921
EP 1924
DI 10.1016/j.transproceed.2008.05.075
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 340FG
UT WOS:000258630900036
PM 18675090
ER

PT J
AU Audet, M
   Cag, M
   Piardi, T
   Ghislotti, E
   Saouli, AC
   Panaro, F
   Jaeck, D
   Wolf, P
AF Audet, M.
   Cag, M.
   Piardi, T.
   Ghislotti, E.
   Saouli, A. C.
   Panaro, F.
   Jaeck, D.
   Wolf, P.
TI Twenty seven years of experience in pediatric liver transplantation in
   Strasbourg: Focus on the ex situ split techniques
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 31st Congress of the Italian-Transplantation-Society
CY NOV 28-30, 2007
CL Modena, ITALY
SP Italian Transplantat Soc
ID SINGLE-CENTER EXPERIENCE
AB Introduction. Despite the well-known controversies about split-liver procedures, since 1979 we have utilized an ex situ instead of an in situ technique because of its feasibility. However, we sought to prove the equality of the results of these two procedures. Herein, we have presented our experience after 27 years' follow-up.
   Materials and methods. Between March 1979 and June 2006, we transplanted 84 livers in 67 pediatric recipients including 37 ex situ split livers implanted into 28 patients.
   Results. We recorded demographic characteristics, transplantation, and retransplantation indications, age difference between donors and recipients, comorbidities, cold ischemia times, surgical times and complications, graft/recipient body weight ratios, organ recovery times, and overall survivals after 1, 5, and 15 years follow-up. We have herein reported 1, 5, and 15 years of patient versus organ survivals of 88.9.1%, 84.5%, 62.1% versus 78.6%, 74.2%, 57.4%, respectively.
   Conclusion. We have concluded that an ex situ split liver may be a valid alternative to in situ techniques to achieve good grafts for pediatric transplantation.
C1 [Audet, M.; Cag, M.; Piardi, T.; Ghislotti, E.; Saouli, A. C.; Panaro, F.; Jaeck, D.; Wolf, P.] Hosp Univ Hautepierre, Strasbourg, France.
RP Cag, M (reprint author), Hosp Univ Hautepierre, Strasbourg, France.
EM murat.cag@chru-strasbourg.fr
CR Baccarani U, 2005, TRANSPLANT P, V37, P2592, DOI 10.1016/j.transproceed.2005.06.026
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Cescon M, 2006, ANN SURG, V244, P805, DOI 10.1097/01.sla.0000218076.85213.60
   Cintorino D, 2006, TRANSPLANT P, V38, P1096, DOI 10.1016/j.transproceed.2006.02.146
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   Farmer DG, 2007, J AM COLL SURGEONS, V204, P904, DOI 10.1016/j.jamcollsurg.2007.01.061
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Oikawa K, 1998, TRANSPLANT P, V30, P3209, DOI 10.1016/S0041-1345(98)00998-1
   Reyes J, 2000, J PEDIATR SURG, V35, P283, DOI 10.1016/S0022-3468(00)90026-5
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
NR 11
TC 5
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2008
VL 40
IS 6
BP 1932
EP 1936
DI 10.1016/j.transproceed.2008.05.031
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 340FG
UT WOS:000258630900039
PM 18675093
ER

PT J
AU Anderson, CD
   Turmelle, YP
   Lowell, JA
   Nadler, M
   Millis, M
   Anand, R
   Martz, K
   Shepherd, RW
AF Anderson, C. D.
   Turmelle, Y. P.
   Lowell, J. A.
   Nadler, M.
   Millis, M.
   Anand, R.
   Martz, K.
   Shepherd, R. W.
CA SPLIT Res Grp
TI The effect of recipient-specific surgical issues on outcome of liver
   transplantation in biliary atresia
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE biliary atresia; biliary complication; pediatric hepatology/liver
   transplant; pediatric liver transplant; pediatric liver transplantation;
   liver transplantation; vascular complications of liver transplantation
ID INFERIOR VENA-CAVA; EXPERIENCE
AB Biliary atresia (BA), the most common reason for orthotopic liver transplantation (OLT) in children, is often accompanied by unique and challenging anatomical variations. This study examines the effect of surgical-specific issues related to the presence of complex vascular anatomic variants on the outcome of OLT for BA. The study group comprised 944 patients who were enrolled in the Studies of Pediatric Liver Transplantation (SPLIT) registry and underwent OLT for BA over an 11-year period. 63 (6.7%) patients met the study definition of complex vascular anomalies (CVA). Patient survival, but not graft survival, was significantly lower in the CVA group, (83 vs. 93 % at 1-year post-OLT). The CVA group had a significantly higher incidence of all reoperations, total biliary tract complications, biliary leaks and bowel perforation. The most frequent cause of death was infection, and death from bacterial infection was more common in the CVA group. Pretransplant portal vein thrombosis and a preduodenal portal vein were significant predictors of patient survival but not graft survival. This study demonstrates that surgical and technical factors have an effect on the outcome of BA patients undergoing OLT. However, OLT in these complex patients is technically achievable with an acceptable patient and graft survival.
C1 [Turmelle, Y. P.; Lowell, J. A.; Shepherd, R. W.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
   [Anderson, C. D.; Lowell, J. A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Turmelle, Y. P.; Lowell, J. A.; Nadler, M.; Shepherd, R. W.] St Louis Childrens Hosp, Childrens Liver Care Ctr, St Louis, MO 63178 USA.
   [Millis, M.] Univ Chicago, Chicago, IL 60637 USA.
   [Martz, K.; Shepherd, R. W.] EMMES Corp, Rockville, MD USA.
RP Shepherd, RW (reprint author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
EM shepherd_r@kids.wustl.edu
RI Shepherd, Ross/M-9713-2014
OI Shepherd, Ross/0000-0002-5348-5107
CR Barshes NR, 2005, LIVER TRANSPLANT, V11, P1193, DOI 10.1002/lt.20509
   Chardot C, 2006, J PEDIATR-US, V148, P432, DOI 10.1016/j.jpeds.2006.01.049
   Chen TY, 2001, TRANSPLANT P, V33, P3470, DOI 10.1016/S0041-1345(01)02495-2
   CUERVASMONS V, 1986, GASTROENTEROLOGY, V90, P853
   Dulundu E, 2007, CLIN TRANSPLANT, V21, P13, DOI 10.1111/j.1399-0012.2006.00559.x
   Goss JA, 1996, ANN SURG, V224, P276, DOI 10.1097/00000658-199609000-00004
   Karrer FM, 1996, ARCH SURG-CHICAGO, V131, P493
   Kawamoto S, 1995, Liver Transpl Surg, V1, P23, DOI 10.1002/lt.500010106
   Maggard MA, 1999, TRANSPLANTATION, V68, P1206, DOI 10.1097/00007890-199910270-00025
   Ohi R, 1998, SURG TODAY, V28, P1229
   Perlmutter DH, 2002, HEPATOLOGY, V35, P1297, DOI 10.1053/jhep.2002.34170
   Sandler AD, 1997, J PEDIATR SURG, V32, P416, DOI 10.1016/S0022-3468(97)90594-7
   Shneider BL, 2006, J PEDIATR-US, V148, P467, DOI 10.1016/j.jpeds.2005
   Sokol RJ, 2003, J PEDIATR GASTR NUTR, V37, P4, DOI 10.1097/00005176-200307000-00003
   Srinivasan P, 2001, LIVER TRANSPLANT, V7, P376, DOI 10.1053/jlts.2001.22760
   Utterson EC, 2005, J PEDIATR-US, V147, P180, DOI 10.1016/j.jpeds.2005.04.073
NR 16
TC 8
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2008
VL 8
IS 6
BP 1197
EP 1204
DI 10.1111/j.1600-6143.2008.02223.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 307VP
UT WOS:000256347100014
PM 18444930
ER

PT J
AU Israeli, M
   Klein, T
   Sredni, B
   Avitzur, Y
   Mor, E
   Bar-Nathen, N
   Steinberg, R
   Dinari, G
   Shapiro, R
AF Israeli, Moshe
   Klein, Tirza
   Sredni, Benjamin
   Avitzur, Yaron
   Mor, Eitan
   Bar-Nathen, Nathan
   Steinberg, Ran
   Dinari, Gabriel
   Shapiro, Rivka
TI ImmuKnow: A new parameter in immune monitoring of pediatric liver
   transplantation recipients
SO LIVER TRANSPLANTATION
LA English
DT Article
ID FUNCTION ASSAY; REJECTION
AB Lifelong immunosuppression is mandatory for optimal graft and patient survival following liver transplantation. Nevertheless, graft rejection or numerous adverse events associated with overimmunosuppression or underimmunosuppression cannot be completely avoided. The ImmuKnow assay measures cell-mediated immunity and is able to discern between conditions of overimmunosuppression and underimmunosuppression. The aim of this study was to evaluate the ImmuKnow assay in the evaluation of the immune function in pediatric liver transplant recipients and to assess its correlation with the patients' clinical and biochemical status. Eighty-nine whole blood samples were collected from 23 liver transplant recipients that were 1 to 18 years old. The net state of immune function was determined by the quantitative measurement of the intracellular adenosine 5-triphosphate level in CD4(+) lymphocytes after phytohemagglutinin stimulation. Comprehensive clinical data were correlated with the ImmuKnow assay results. In 23 of the 28 samples collected during clinical quiescence, ImmuKnow results were correlated with the clinical status, expressing the patient's moderate immune function. However, a correlation between measured therapeutic drug levels and clinical quiescence was found in only 18 of the 28 samples. In 6 patients who suffered from clinical complications, ImmuKnow measurements showed a wide range of deviations, expressing the unstable immunological status of these patients. In conclusion, the ImmuKnow assay correlates with the clinical status of liver-transplanted children. It serves as a reliable and unique parameter of the cellular immune function. We conclude that the ImmuKnow assay, together with existing clinical tools, may allow for the immune monitoring of pediatric liver recipients.
C1 [Israeli, Moshe; Klein, Tirza] Rabin Med Ctr, Tissue Typing Lab, IL-49100 Petah Tiqwa, Israel.
   [Mor, Eitan; Bar-Nathen, Nathan] Rabin Med Ctr, Dept Organ Transplantat, IL-49100 Petah Tiqwa, Israel.
   [Israeli, Moshe; Sredni, Benjamin] Bar Ilan Univ, Goodman Fac Life Sci, Canc AIDS & Immunol Res Inst, Ramat Gan, Israel.
   [Avitzur, Yaron; Steinberg, Ran; Dinari, Gabriel; Shapiro, Rivka] Schneider Childrens Med Ctr Israel, Inst Gastroenterol Hepatol & Nutr, Petah Tiqwa, Israel.
   [Klein, Tirza; Avitzur, Yaron; Steinberg, Ran; Dinari, Gabriel; Shapiro, Rivka] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
RP Israeli, M (reprint author), Rabin Med Ctr, Tissue Typing Lab, Beilinson Campus,Zabotinski Rd, IL-49100 Petah Tiqwa, Israel.
EM israelimoshe@yahoo.com
OI Israeli, Moshe/0000-0002-3776-8692
CR ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2
   Danovitch G, 2005, HDB KIDNEY TRANSPLAN
   Dharnidharka VR, 2004, AM J TRANSPLANT, V4, P384, DOI 10.1111/j.1600-6143.2004.00350.x
   Gautam A, 2006, PEDIATR TRANSPLANT, V10, P613, DOI 10.1111/j.1399-3046.2006.00510.x
   Hooper E, 2005, CLIN TRANSPLANT, V19, P834, DOI 10.1111/j.1399-0012.2005.00429.x
   Israeli M, 2007, TRANSPL IMMUNOL, V18, P7, DOI 10.1016/j.trim.2007.03.005
   Khera N, 2007, FRONT BIOSCI, V12, P660, DOI 10.2741/2090
   Kowalski R, 2003, CLIN TRANSPLANT, V17, P77, DOI 10.1034/j.1399-0012.2003.00013.x
   Kowalski RJ, 2006, TRANSPLANTATION, V82, P663, DOI 10.1097/01.tp.0000234837.02126.70
NR 9
TC 32
Z9 48
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2008
VL 14
IS 6
BP 893
EP 898
DI 10.1002/lt.21426
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 309VK
UT WOS:000256488100020
PM 18508374
ER

PT J
AU Haberal, M
   Sevmis, S
   Karakayali, H
   Moray, G
   Ozcay, F
   Torgay, A
   Arslan, G
AF Haberal, Mehmet
   Sevmis, Sinasi
   Karakayali, Hamdi
   Moray, Gokhan
   Ozcay, Figen
   Torgay, Adnan
   Arslan, Gulnaz
TI Outcome of pediatric liver transplant in grafts with multiple arteries
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; outcome; graft with multiple hepatic
   arteries
ID HEPATIC-ARTERY; LIVING DONORS; RECONSTRUCTION; ARTERIALIZATION
AB Young age, small diameter of the hepatic artery, presence of multiple arteries, and the selected technique are risk factors for hepatic arterial complications. We report the outcomes of pediatric liver transplant (LT) patients who had received a liver graft with multiple arteries. Since April 2001, 89 pediatric LTs have been performed at our center. Twenty-six liver grafts (29.2%) that had multiple hepatic arteries were analyzed retrospectively. Twenty-five grafts had 2, and 1 graft had 3, hepatic arteries. In 17 grafts with double arteries, and in 1 graft with 3 arteries, the adjacent edges of the hepatic arteries were sutured together at the back table to create a single opening, and the recipient's common hepatic artery was then anastomosed to that orifice. In 8 grafts with double arteries, 2 separate anastomoses were performed between the graft hepatic arteries and the recipient's hepatic artery branches. The mean age of the recipients was 7.9 +/- 5.4 years (range, 0.6-17 years). During the early postoperative period, hepatic arterial thromboses occurred in 3 recipients. Two of these 3 recipients were treated with transcatheter arterial thrombolysis using streptokinase or recombinant plasminogen and intraluminal stent placement, and the remaining recipient was treated with a re-anastomosis using a polytetrafluoroethylene graft. Three recipients died during follow-up, which ranged from 1 to 71 months. In conclusion, multiple graft arteries did not increase the incidence of hepatic arterial complications in our series.
C1 [Haberal, Mehmet; Sevmis, Sinasi; Karakayali, Hamdi; Moray, Gokhan] Baskent Univ, Dept Gen Surg & Transplantat, TR-06490 Ankara, Turkey.
   [Ozcay, Figen] Baskent Univ, Dept Pediat Gastroenterol, TR-06490 Ankara, Turkey.
   [Torgay, Adnan; Arslan, Gulnaz] Baskent Univ, Dept Anesthesiol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Dept Gen Surg & Transplantat, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Alper M, 2005, MICROSURG, V25, P378, DOI 10.1002/micr.20145
   Broelsch CE, 1991, ANN SURG, V214, P437
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Chen YS, 2003, TRANSPLANTATION, V75, pS16, DOI 10.1097/01.TP.0000046535.49186.EB
   Douard R, 2002, TRANSPLANTATION, V73, P993, DOI 10.1097/00007890-200203270-00029
   HABERAL M, 1993, TRANSPLANT P, V25, P2216
   HABERAL M, 1993, TRANSPLANT P, V25, P1899
   Haberal M, 2002, TRANSPLANT P, V34, P2145, DOI 10.1016/S0041-1345(02)02884-1
   Haberal M, 2007, EXP CLIN TRANSPLANT, V5, P585
   Ikegami T, 1996, SURGERY, V119, P431, DOI 10.1016/S0039-6060(96)80144-9
   INOMOTO T, 1996, SURGERY, V119, P263
   KALAYOGLU M, 1987, Surgery Gynecology and Obstetrics, V164, P564
   Kishi Y, 2004, LIVER TRANSPLANT, V10, P129, DOI 10.1002/lt.20010
   Kostelic JK, 1996, AM J ROENTGENOL, V166, P1103
   Marcos A, 2003, LIVER TRANSPLANT, V9, P570, DOI 10.1053/jlts.2003.50093
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Sakamoto Y, 2002, TRANSPLANTATION, V74, P518, DOI 10.1097/00007890-200208270-00014
   SHAW BW, 1984, SURG GYNECOL OBSTET, V159, P490
   Takatsuki M, 2006, SURGERY, V140, P824, DOI 10.1016/j.surg.2006.02.021
NR 19
TC 4
Z9 5
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2008
VL 12
IS 4
BP 407
EP 411
DI 10.1111/j.1399-3046.2008.00888.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 296MY
UT WOS:000255551700007
PM 18266797
ER

PT J
AU Wildhaber, BE
   Rubbia-Brandt, L
   Majno, P
   Mentha, G
   Schappi, MG
   Anooshiravani, M
   Belli, D
   Chardot, C
AF Wildhaber, Barbara E.
   Rubbia-Brandt, Laura
   Majno, Pietro
   Mentha, Gilles
   Schaeppi, Michela G.
   Anooshiravani, Mehrak
   Belli, Dominique
   Chardot, Christophe
TI Focal ischemic necrosis in advanced biliary atresia cirrhosis
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary atresia; cirrhosis; ischemic necrosis; hepatic artery resistance
   index; hepatic failure; chronic liver disease; complications; pediatric
   liver transplantation
ID CLINICAL-FEATURES; BLOOD-FLOW; HEPATITIS; DIAGNOSIS
AB This report correlates the clinical and biological findings, liver hemodynamics and histological features of focal INL in an infant with BA cirrhosis. An eight month old boy with BA, with previous successful porto-enterostomy, was admitted with signs of cholangitis and ascites. He was treated with antibiotics and diuretics with subsequent clinical improvement. Eight days later, while being fed with hyper-osmolar milk, he became febrile again: ASAT/ALAT climbed (9000/2300 IU/L), liver function deteriorated. Infectious work-up was negative. Liver-ultrasound showed reversed portal flow and a negative arterial diastolic flow. The patient recovered within five days under supportive treatment. A similar event recurred five days later. INL was suspected and semi-urgent living-related liver transplantation was performed, with uneventful post-operative course. Histology of the explanted liver showed extensive foci of INL of different ages. This report illustrates how the association of reversed portal and arterial diastolic flows, with subsequent liver hypoperfusion, may repeatedly cause foci of INL in BA cirrhosis, and lead to rapid progression to liver failure. Because of precarious hepatic blood supply in such patients, close monitoring of portal and diastolic arterial flows is recommended.
C1 [Wildhaber, Barbara E.; Chardot, Christophe] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.
   [Rubbia-Brandt, Laura] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland.
   [Majno, Pietro; Mentha, Gilles] Univ Hosp Geneva, Dept Surg, Geneva, Switzerland.
   [Schaeppi, Michela G.; Anooshiravani, Mehrak; Belli, Dominique] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.
RP Wildhaber, BE (reprint author), Hop Enfants, Rue Willy Donze 6, CH-1211 Geneva, Switzerland.
EM barbara.wildhaber@hcuge.ch
RI Schappi Tempia-Caliera, Michela/A-7619-2012; Schappi,
   Michela/D-5363-2012
OI Schappi Tempia-Caliera, Michela/0000-0002-9860-7294; 
CR Broide E, 1997, Liver Transpl Surg, V3, P604, DOI 10.1002/lt.500030609
   BURRIN DG, 1989, BRIT J NUTR, V62, P23, DOI 10.1079/BJN19890005
   Calvani Mario, 1994, Recenti Progressi in Medicina, V85, P204
   CHARDOT C, 2006, J RARE DIS, V1, P28
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Colivicchi F, 1995, Minerva Med, V86, P379
   CORBALLY MT, 1994, ARCH DIS CHILD, V70, P147
   de Aguilar-Nascimento JE, 2005, CURR OPIN CLIN NUTR, V8, P552, DOI 10.1097/01.mco.0000170755.32996.1d
   Fuchs S, 1998, J CLIN GASTROENTEROL, V26, P183, DOI 10.1097/00004836-199804000-00007
   GARLAND JS, 1988, CRIT CARE MED, V16, P1209, DOI 10.1097/00003246-198812000-00006
   GIBSON PR, 1984, AUST NZ J MED, V14, P822, DOI 10.1111/j.1445-5994.1984.tb03780.x
   Henrion J, 1996, J CLIN GASTROENTEROL, V23, P305, DOI 10.1097/00004836-199612000-00016
   HENRION J, 1993, J CLIN GASTROENTEROL, V16, P35, DOI 10.1097/00004836-199301000-00010
   Henrion J, 2003, MEDICINE, V82, P392, DOI 10.1097/01.md.0000101573.54295.bd
   Kahn JA, 2000, J COMPUT ASSIST TOMO, V24, P887, DOI 10.1097/00004728-200011000-00012
   Kamiyama T, 1996, J CLIN GASTROENTEROL, V22, P126, DOI 10.1097/00004836-199603000-00011
   LAURENT J, 1993, J PEDIAT GASTROENTER, V17, P468, DOI 10.1097/00005176-199311000-00082
   Seeto RK, 2000, AM J MED, V109, P109, DOI 10.1016/S0002-9343(00)00461-7
   Zaza Stephane, 2005, Nephrol Ther, V1, P174, DOI 10.1016/j.nephro.2005.03.002
NR 19
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2008
VL 12
IS 4
BP 487
EP 491
DI 10.1111/j.1399-3046.2008.00913.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 296MY
UT WOS:000255551700021
PM 18331537
ER

PT J
AU Xu, MQ
   Yan, LN
   Li, B
   Zeng, Y
   Wen, TF
   Zhao, JC
   Wang, WT
   Yang, JY
   Ma, YK
   Cheng, ZY
AF Xu, M. -Q.
   Yan, L. -N.
   Li, B.
   Zeng, Y.
   Wen, T. -F.
   Zhao, J. -C.
   Wang, W. -T.
   Yang, J. -Y.
   Ma, Y. -K.
   Cheng, Z. -Y.
TI Surgical procedures for management of right portal venous branching in
   right lobe living donor liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID ANATOMICAL VARIATIONS; RECONSTRUCTION; VEIN; GRAFT
AB Objective. This study sought to describe the surgical management of right portal venous (PV) branches encountered among 104 cases of right lobe living donor liver transplantation (LDLT).
   Methods. From January 2002 to September 2007, we performed 104 cases of right-lobe LDLT including 11-donors who had anomalous right portal venous branches (APVB). One recipient had PV sponginess hemangioma. The donor right PV branches were type I in 93 cases, type II (trifurcation) in nine cases, and type III in two cases. Except one narrow bridge of tissue excision, the PV branches were transected on the principal of donor priority: PV branches were excised approximately 2 to 3 mm from the confluence while leaving the donor's main portal vein and confluence intact. In type II APVB, donor PV branches were obtained with two separate openings in six cases; with two separate openings joined as a common orifice at the back table in two cases, with one common opening with a narrow bridge of tissue in one case. In type III APVB, the donor right anterior and posterior PV branches were obtained with separate openings. The donor right PV branches with one common opening in 92 cases of type I PV branches and a joined common orifice in three cases of type II APVB were anastomosed to the recipient's main portal vein or to right branching. As the unavailable recipient PV for sponginess hemangioma, one case of type I right PV branches was end-to-end anastomosed to one of the variceal lateral veins of about 1 cm diameter in a pediatric patient. The PV were reconstructed as double anastomoses in six type II APVB and in one type III APVB obtained with two separate PV openings. In the another type III APVB reconstruction, we successfully utilized a novel U-shaped vein graft interposition.
   Results. The type II APVB donor receiving a narrow bridge of portal vein tissue excision developed portal vein thrombosis on the third postoperative day and underwent reexploration for thrombectomy. There were no vascular complications, such as portal vein thrombosis or stricture among other donors or all recipients. The velocity of blood flow in the U-graft was normal. The anastomosis between the type I donor right portal vein and recipient variceal lateral vein was unobstructed.
   Conclusion. Right PV branches should be excised on the principal of donor priority while leaving the donor's main portal vein and confluence intact. Single anastomoses was the fundamental procedure of right branch reconstruction. Double anastomoses could be used as the main management for type II and type III APVB reconstruction. U-graft interposition may be a potential procedure for type III APVB reconstruction. Single anastomoses between the donor right portal vein and the recipient variceal lateral vein may be performed when recipient portal vein is unavailable. These innovations for excision and reconstruction of right PV branches were feasible, safe, and had good outcomes.
C1 [Yan, L. -N.] Sichuan Univ, Liver Transplantat Ctr, W China Hosp, Liver Transplantat Div, Chengdu 610041, Peoples R China.
RP Yan, LN (reprint author), Sichuan Univ, Liver Transplantat Ctr, W China Hosp, Liver Transplantat Div, Chengdu 610041, Peoples R China.
EM xumingqing0018@163.com
CR Cheng YF, 1996, TRANSPLANT P, V28, P1667
   Covey AM, 2004, AM J ROENTGENOL, V183, P1055
   Lee SG, 2003, TRANSPLANTATION, V75, pS28, DOI 10.1097/01.TP.0000047028.97031.66
   Marcos A, 2001, LIVER TRANSPLANT, V7, P673, DOI 10.1053/jlts.2001.26568
   Marcos A, 2000, ANN SURG, V231, P824, DOI 10.1097/00000658-200006000-00006
   Nakamura T, 2002, TRANSPLANTATION, V73, P1896, DOI 10.1097/00007890-200206270-00008
   Thayer WP, 2002, J AM COLL SURGEONS, V194, P96, DOI 10.1016/S1072-7515(01)01085-7
   Varotti G, 2004, J AM COLL SURGEONS, V198, P577, DOI 10.1016/j.jamcollsurg.2003.11.014
   Xu MQ, 2007, LIVER TRANSPLANT, V13, P1062, DOI 10.1002/lt.21115
   Yan LN, 2006, LIVER TRANSPLANT, V12, P1017, DOI 10.1002/lt.20773
   Yan Lu-Nan, 2006, Hepatobiliary Pancreat Dis Int, V5, P173
NR 11
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2008
VL 40
IS 5
BP 1529
EP 1533
DI 10.1016/j.transproceed.2008.02.085
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 326YJ
UT WOS:000257695300065
PM 18589144
ER

PT J
AU Aydin, U
   Yazici, P
   Yuksekkaya, H
   Arikan, C
   Aydogdu, S
   Zeytunlu, M
   Kilic, M
AF Aydin, Unal
   Yazici, Pinar
   Yuksekkaya, Hasan
   Arikan, Cigdem
   Aydogdu, Sema
   Zeytunlu, Murat
   Kilic, Murat
TI Timing of Roux-en-Y limb reconstruction for pediatric live donor liver
   transplantation
SO TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; pre-clampage Roux limb; postoperative
   gastrointestinal bleeding
ID BILIARY-TRACT COMPLICATIONS; SURGICAL COMPLICATIONS; MANAGEMENT
AB Background. Roux-en-Y (R-Y) hepaticojejunostomy is usually accepted as the standard method of choice for biliary reconstruction in pediatric cases though the potential risks for gastrointestinal complications are higher: In this study, we examined gastrointestinal complications in pediatric patients by comparing two different strategies of R-Y reconstruction with respect to the portal clampage time.
   Methods. Forty-three pediatric recipients who underwent Live Donor Liver Transplantation with R-Y for biliary reconstruction between March 2001 and December 2006 in our transplantation center were divided into two groups regarding the time of dissection and creation of the roux limb. R-Y limb reconstruction was performed before clampage of the portal vein in group A-preclampage group. In group B, because of prolonged catheterization period, R-Y limb was reconstructed after implantation of the graft (Group B-postclampage group).
   Results. Overall, seven patients (16%) had gastrointestinal bleeding in the postoperative period, all in group B (0/20 vs. 7/23, P<0.01). One of those three cases who were diagnosed after endoscopy and one another were performed surgical treatment. Although remaining three cases had multiple bleeding episodes but no diagnostic findings by endoscopic/colonoscopic interventions, conservative treatment was successful and therefore, plausible R-Y limb bleeding was considered for these cases. The timing of removal of nasogastric tube and postoperative oral intake were also significantly earlier (P<0.01) in Group A than in Group B.
   Conclusion. In Live Donor Liver Transplantation, if recipient team may have enough time until the donor team got ready for the recovery of the graft, dissection and preparation of the R-Y limb should be performed. This approach can be helpful to avoid gastrointestinal complications due to the reconstruction of the R-Y limb.
C1 [Aydin, Unal; Yazici, Pinar; Yuksekkaya, Hasan; Arikan, Cigdem; Aydogdu, Sema; Zeytunlu, Murat; Kilic, Murat] Ege Univ, Sch Med, Organ Transplantat & Res Ctr, TR-35100 Izmir, Turkey.
RP Aydin, U (reprint author), Ege Univ, Sch Med, Organ Transplantat & Res Ctr, TR-35100 Izmir, Turkey.
EM drunalaydin@gmail.com
CR Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   GREIF F, 1994, ANN SURG, V219, P40, DOI 10.1097/00000658-199401000-00007
   Heffron TG, 2003, TRANSPLANT P, V35, P1461, DOI 10.1016/S0041-1345(03)00463-9
   Icoz G, 2003, TRANSPLANT P, V35, P1463, DOI 10.1016/S0041-1345(03)00484-6
   Karakayali H, 2005, TRANSPLANT P, V37, P3174, DOI 10.1016/j.transproceed.2005.07.023
   KONERU B, 1988, GASTROENTEROL CLIN N, V17, P71
   LEBEAU G, 1990, SURG GYNECOL OBSTET, V170, P317
   MANZARBEITIA C, 1993, TRANSPLANTATION, V56, P1545
   Nyckowski P, 2000, TRANSPLANT P, V32, P1432, DOI 10.1016/S0041-1345(00)01283-5
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   ROLLES K, 1994, TRANSPLANTATION, V57, P402, DOI 10.1097/00007890-199402150-00015
   STRATTA RJ, 1989, SURGERY, V106, P675
   TabascoMinguillan J, 1997, TRANSPLANTATION, V63, P60, DOI 10.1097/00007890-199701150-00012
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   WOOD RP, 1985, SEMIN LIVER DIS, V5, P377, DOI 10.1055/s-2008-1040636
NR 15
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 27
PY 2008
VL 85
IS 10
BP 1431
EP 1435
DI 10.1097/TP.0b013e31816f1b17
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 305LS
UT WOS:000256180500013
PM 18497683
ER

PT J
AU Margreiter, C
   Aigner, F
   Orozco, H
   Wechselberger, G
   Ollinger, R
   Bosmuller, C
   Sucher, R
   Mark, W
   Margreiter, R
AF Margreiter, Christian
   Aigner, Felix
   Orozco, Hector
   Wechselberger, Gottfried
   Oellinger, Robert
   Boesmueller, Claudia
   Sucher, Robert
   Mark, Walter
   Margreiter, Raimund
TI Hepatic artery reconstruction with inferior mesenteric vein graft in
   pediatric living donor liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; arterial variation; interposition
   graft
ID VASCULAR COMPLICATIONS; SURGICAL TECHNIQUES
AB We report a transplant of the left lateral liver segments with two arteries for a pediatric recipient from a live donor. A six-month-old female patient was diagnosed with liver cirrhosis secondary to biliary atresia and scheduled for LDLT (father as donor). Left lateral hepatectomy was performed at the donor site. The dissection of the left HA, which divided immediately after its origin, showed two branches for segments II and III. The artery for segment III was anastomosed to recipient HA. The artery for segment II was too short for direct anastomosis with the gastroducidenal artery. After an unsuccessful attempt to use of the recipient's saphenous vein, the recipient's IMV was used an interposition graft. No post-operative complications were observed. The outcome of this case demonstrates that left lateral segments with two arteries can be successfully used if proper surgical techniques are applied. From this experience we can recommend the IMV as an alternative to the saphenous vein for an interposition graft.
C1 [Margreiter, Christian; Aigner, Felix; Oellinger, Robert; Boesmueller, Claudia; Sucher, Robert; Mark, Walter; Margreiter, Raimund] Innsbruck Med Univ, Dept Gen & Transplant Surg, A-6020 Innsbruck, Austria.
   [Wechselberger, Gottfried] Innsbruck Med Univ, Dept Plast & Reconstruct Surg, A-6020 Innsbruck, Austria.
   [Orozco, Hector] Univ Guadalajara, Hosp Civil Guadalajara, Dept Gen Surg, Jalisco, Mexico.
RP Margreiter, C (reprint author), Innsbruck Med Univ, Dept Gen & Transplant Surg, Anichstr 35, A-6020 Innsbruck, Austria.
EM raimund.margreiter@i-med.ac.at
RI Ollinger, Robert/D-1538-2009; Aigner, Felix/E-1501-2012
CR BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Del Gaudio M, 2005, CLIN TRANSPLANT, V19, P399, DOI 10.1111/j.1399-0012.2005.00363.x
   Douard R, 2002, TRANSPLANTATION, V73, P993, DOI 10.1097/00007890-200203270-00029
   GOLLING M, 1995, ZBL CHIR, V120, P445
   Guarrera JV, 2004, TRANSPLANT INT, V17, P585, DOI 10.1007/s00147-004-0782-8
   HELVELKE P, 2003, TRANSPL P, V35, P2253
   HIATT JR, 1994, ANN SURG, V220, P50, DOI 10.1097/00000658-199407000-00008
   HODSON EM, 2007, COCHRANE DB SYST REV, V18, P5129
   Itabashi Y, 2000, HEPATO-GASTROENTEROL, V47, P512
   Kim BS, 2003, AM J ROENTGENOL, V181, P467
   Koops A, 2004, SURG RADIOL ANAT, V26, P239, DOI 10.1007/s00276-004-0229-z
   Kuang AA, 1996, TRANSPLANTATION, V62, P742, DOI 10.1097/00007890-199609270-00007
   MIZUNO S, 2005, TRANSPLANT INT, V18, P409
   Mlakar Bostjan, 2002, European Journal of Morphology, V40, P115
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Proposito D, 2001, Ann Ital Chir, V72, P303
   Puttemans T, 1999, Eur J Ultrasound, V9, P155, DOI 10.1016/S0929-8266(99)00024-5
   Settmacher U, 2003, TRANSPLANT INT, V16, P742, DOI 10.1007/s00147-003-0633-z
   Takatsuki M, 2006, SURGERY, V140, P824, DOI 10.1016/j.surg.2006.02.021
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   UCHIYAMA H, 2002, SURGERY, V131, P200
   Wei WI, 2004, ARCH SURG-CHICAGO, V139, P304, DOI 10.1001/archsurg.139.3.304
NR 22
TC 1
Z9 2
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2008
VL 12
IS 3
BP 324
EP 328
DI 10.1111/j.1399-3046.2007.00868.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 296BC
UT WOS:000255517500012
PM 18363615
ER

PT J
AU Tumgor, G
   Arikan, C
   Yuksekkaya, HA
   Cakir, M
   Levent, E
   Yagci, RV
   Kilic, M
   Aydogdu, S
AF Tumgor, Gokhan
   Arikan, Cigdern
   Yuksekkaya, Hasan Ali
   Cakir, Murat
   Levent, Erturk
   Yagci, Rasit Vural
   Kilic, Murat
   Aydogdu, Sema
TI Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatopulmonary syndrome; liver transplantation; children
ID NITRIC-OXIDE SYNTHASE; PORTOPULMONARY HYPERTENSION; PORTAL-HYPERTENSION;
   PULSE OXIMETRY; RAT MODEL; OXYGENATION; CANDIDATES; HYPOXEMIA; SEVERITY;
   DISEASE
AB Objectives: The hepatopulmonary syndrome (HPS) is characterized as a triad: liver disease, intrapulmonary vascular dilatatiton, and arterial hypoxemia. The aim of this study is to analyze outcome of children with HPS in liver transplant era. Methods: Between September 1996 and November 2006, 172 cirrhotic patients (median age 5 years; range 0.2-22 years, M/F; 97/75) were followed at Ege University Pediatric Gastroenterology, Hepatology and Nutrition Unit. All patients were evaluated by chest radiography, arterial blood gas analysis, and alveolar-arterial oxygen tension difference, contrast echo-cardiography (CEE) after and before the liver transplantation. Results: HPS was diagnosed in 33 patients (19%) by CEE. None of them had pulmonary hypertension. HPS was not found related to etiology of the liver disease. Portal hypertension was found related to the development of HPS (75.7% in patients with HPS and 54.6% in others, p = 0.02). 17 of 33 patients with HPS underwent liver transplantation. Preoperative and postoperative period of these patients was uneventful. Patients were extubated in the operating room except for two. Median follow up of transplanted children was 1.9 year (range; 0.75-10 years). Arterial blood gas analysis and CEE positivity regressed in all of them by postoperative 6th month. Conclusions: HPS is a serious and important complication of cirrhotic children that leads to tissue hypoxia and central cyanosis. HPS seems reversible after liver transplantation in all patients.
C1 [Tumgor, Gokhan; Arikan, Cigdern; Yuksekkaya, Hasan Ali; Cakir, Murat; Yagci, Rasit Vural; Aydogdu, Sema] Ege Univ, Sch Med, Organ Transplantat & Res Ctr, Div Gastroenterol Hepatol & Nutr,Dept Pediat, TR-35040 Izmir, Turkey.
   [Levent, Erturk] Ege Univ, Sch Med, Organ Transplantat & Res Ctr, Dept Pediat,Div Cardiol, TR-35040 Izmir, Turkey.
   [Kilic, Murat] Ege Univ, Sch Med, Organ Transplantat & Res Ctr, TR-35040 Izmir, Turkey.
RP Tumgor, G (reprint author), Ege Univ, Sch Med, Organ Transplantat & Res Ctr, Div Gastroenterol Hepatol & Nutr,Dept Pediat, 250 Sok 6 D-1, TR-35040 Izmir, Turkey.
EM gtumgor74@yahoo.com
CR Abrams GA, 2002, LIVER TRANSPLANT, V8, P391, DOI 10.1053/jlts.2002.32252
   Arguedas MR, 2007, CLIN GASTROENTEROL H, V5, P749, DOI 10.1016/j.cgh.2006.12.003
   Avendano CE, 2001, LIVER TRANSPLANT, V7, P1081, DOI 10.1053/jlts.2001.29416
   Carter EP, 2002, AM J PHYSIOL-LUNG C, V283, pL346, DOI [10.1152/ajplung.00385.2001, DOI 10.1152/AJPLUNG.00385.2001]
   Cheng TO, 2002, CIRCULATION, V105, P47
   Fallon MB, 1997, GASTROENTEROLOGY, V113, P606, DOI 10.1053/gast.1997.v113.pm9247483
   Gomez FP, 2004, HEPATOLOGY, V40, P660, DOI 10.1002/hep.20358
   Kim HY, 2004, TRANSPLANT P, V36, P2762, DOI 10.1016/j.transproceed.2004.10.002
   Koksal D, 2006, J CLIN GASTROENTEROL, V40, P77
   Krowka MJ, 2004, LIVER TRANSPLANT, V10, P174, DOI 10.1002/lt.20016
   Krowka MJ, 1997, HEPATOLOGY, V25, P1282, DOI 10.1002/hep.510250540
   Krowka MJ, 2000, GUT, V46, P1, DOI 10.1136/gut.46.1.1
   Krowka MJ, 2000, CHEST, V118, P615, DOI 10.1378/chest.118.3.615
   KROWKA MJ, 1993, CHEST, V104, P515, DOI 10.1378/chest.104.2.515
   LANGE PA, 1995, ANN INTERN MED, V122, P521
   Lasch HM, 2001, LIVER TRANSPLANT, V7, P147, DOI 10.1053/jlts.2001.21287
   Liu LC, 2001, HEPATOLOGY, V33, P722, DOI 10.1053/jhep.2001.22701
   Martinez G, 1999, J HEPATOL, V30, P882, DOI 10.1016/S0168-8278(99)80143-3
   MAZARIEGOS GV, 2002, AM J TRANSPLANT, V2, P251
   Naeije R, 2003, SWISS MED WKLY, V133, P163
   Nunes H, 2001, AM J RESP CRIT CARE, V164, P879
   Paramesh AS, 2003, PEDIATR TRANSPLANT, V7, P157, DOI 10.1034/j.1399-3046.2003.00033.x
   Rabiller A, 2002, AM J RESP CRIT CARE, V166, P514, DOI 10.1164/rccm.200201-0270C
   Regev A, 2001, J VIRAL HEPATITIS, V8, P83, DOI 10.1046/j.1365-2893.2001.00270.x
   ROBALINO BD, 1991, J AM COLL CARDIOL, V17, P492
   Rodriguez-Roisin R, 2004, EUR RESPIR J, V24, P861, DOI 10.1183/09031936.04.00010904
   Rolla G, 1998, ANN INTERN MED, V129, P375
   Schenk P, 2000, ANN INTERN MED, V133, P701
   Schenk P, 2002, GUT, V51, P853, DOI 10.1136/gut.51.6.853
   Schroeder RA, 2000, DIGEST DIS SCI, V45, P2405, DOI 10.1023/A:1005651327654
   SHNEIDER BJ, 2001, LIVER DIS CHILDREN, V1, P129
   Strassburg CP, 2003, BEST PRACT RES CL GA, V17, P369, DOI 10.1053/ybega.2003.383
   Teuber G, 2002, EUR J INTERN MED, V13, P311, DOI 10.1016/S0953-6205(02)00066-3
   Torregrosa M, 2001, TRANSPLANTATION, V71, P572, DOI 10.1097/00007890-200102270-00015
   Vachiery F, 1997, J HEPATOL, V27, P492, DOI 10.1016/S0168-8278(97)80353-4
   VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7
   Whyte MKB, 1998, J HEPATOL, V29, P85, DOI 10.1016/S0168-8278(98)80182-7
NR 37
TC 13
Z9 13
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2008
VL 12
IS 3
BP 353
EP 357
DI 10.1111/j.1399-3046.2007.00807.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 296BC
UT WOS:000255517500017
PM 18435611
ER

PT J
AU Gras, JM
   Gerkens, S
   Beguin, C
   Janssen, M
   Smets, F
   Otte, JB
   Sokal, E
   Reding, R
AF Gras, Jeremie M.
   Gerkens, Sophie
   Beguin, Claire
   Janssen, Magdalena
   Smets, Francoise
   Otte, Jean-Bernard
   Sokal, Etienne
   Reding, Raymond
TI Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric
   liver transplantation: Clinical and pharmacoeconomic study in 50
   children
SO LIVER TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT World Transplant Congress
CY JUL 22-27, 2006
CL Boston, MA
ID ALLOGRAFT RECIPIENTS; FOLLOW-UP; TOLERANCE; ACCEPTANCE; ANTIBODIES;
   WITHDRAWAL; REJECTION; SAFETY; TRIAL
AB Corticosteroid-free immunosuppression (IS) may be potentially beneficial for transplanted patients, particularly children. The purpose of this study was to evaluate the efficacy and cost of such strategy in primary pediatric liver transplantation (LT). Fifty pediatric LT recipients were prospectively treated with a steroid-free, tacrolimus-basiliximab-based IS (group TB). A group of 34 children transplanted under a conventional tacrolimus-steroids regimen served as control series (group TS). Groups TB and TS were compared regarding patient and graft survival, rejection incidence, infectious complications, and growth, as well as cost of the transplant procedure. Patient and graft survivals at 3 years were 96% and 94% in group TB, versus 91% and 88% in group TS (P = 0.380 and P = 0.370, respectively). Rejection-free graft survival at 3 years was 72% in group TB, versus 41% in group TS (P = 0.007). Patients in group TB had significantly less viral infections than patients in group TS (P = 0.045). Height standard deviation score was significantly enhanced in children from group TB, when compared to group TS. Medical care costs were similar in both groups. Steroid avoidance together with basiliximab immunoprophylaxis was not harmful in terms of allograft acceptance, and even seemed to be beneficial in the long term.
C1 [Gras, Jeremie M.; Janssen, Magdalena; Smets, Francoise; Otte, Jean-Bernard; Sokal, Etienne; Reding, Raymond] Univ Catholique Louvain, Clin Univ St Luc, Pediat Liver Transplant Program, B-1200 Brussels, Belgium.
   [Gras, Jeremie M.] Univ Catholique Louvain, Clin Univ St Luc, Dept Biol Clin, B-1200 Brussels, Belgium.
   [Gerkens, Sophie; Beguin, Claire] Univ Catholique Louvain, Clin Univ St Luc, Financial Dept, B-1200 Brussels, Belgium.
RP Gras, JM (reprint author), Univ Catholique Louvain, Clin Univ St Luc, Pediat Liver Transplant Program, 10 Ave Hippocrate, B-1200 Brussels, Belgium.
EM jeremie.gras@gmail.com
CR Bishop GA, 1996, J IMMUNOL, V156, P4925
   Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4
   DALLMAN MJ, 1991, J EXP MED, V173, P79, DOI 10.1084/jem.173.1.79
   Delriviere L, 1997, TRANSPLANTATION, V63, P1698, DOI 10.1097/00007890-199706150-00029
   Diem HVT, 2003, TRANSPLANTATION, V75, P1664, DOI 10.1097/01.TP.0000063938.49112.C2
   DISTEFANO R, 1988, J EXP MED, V167, P1981, DOI 10.1084/jem.167.6.1981
   Gras J, 2007, LIVER TRANSPLANT, V13, P426, DOI 10.1002/lt.21084
   Kelly D, 2004, LANCET, V364, P1054, DOI 10.1016/S0140-6736(04)17060-8
   Kelly DA, 2001, PEDIATR TRANSPLANT, V5, P386, DOI 10.1034/j.1399-3046.2001.00038.x
   Koshiba T, 2001, TRANSPLANT P, V33, P375, DOI 10.1016/S0041-1345(00)02054-6
   Kovarik JM, 2002, PEDIATR TRANSPLANT, V6, P224, DOI 10.1034/j.1399-3046.2002.01086.x
   MARCHIORO TL, 1964, SURGERY, V55, P412
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Reding R, 1999, ACTA GASTRO-ENT BELG, V62, P285
   Reding R, 2000, TRANSPLANTATION, V70, P405, DOI 10.1097/00007890-200008150-00001
   Reding R, 1996, TRANSPLANTATION, V61, P1406, DOI 10.1097/00007890-199605150-00022
   Reding R, 2003, LANCET, V362, P2068, DOI 10.1016/S0140-6736(03)15104-5
   Ringe B, 2001, TRANSPLANTATION, V71, P508, DOI 10.1097/00007890-200102270-00005
   RODECK B, 1994, TRANSPLANT P, V26, P165
   Shroff R, 2004, PEDIATR NEPHROL, V19, P369, DOI 10.1007/s00467-003-1392-x
   Spada M, 2006, AM J TRANSPLANT, V6, P1913, DOI 10.1111/j.1600-6143.2006.01406.x
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385
   Tisone G, 1999, TRANSPLANTATION, V67, P1308, DOI 10.1097/00007890-199905270-00003
   VINTERMYR OK, 1989, J CELL PHYSIOL, V138, P29, DOI 10.1002/jcp.1041380106
   WHITEHEAD B, 1991, ARCH DIS CHILD, V66, P1022
NR 25
TC 27
Z9 29
U1 1
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD APR
PY 2008
VL 14
IS 4
BP 469
EP 477
DI 10.1002/lt.21397
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 284RS
UT WOS:000254724100012
PM 18383091
ER

PT J
AU de Faria, EP
   Llanos, JC
   Neto, AB
   Silva, APC
   Winckler, CC
   Mutti, A
   Saad-Hossne, R
   Silva, GF
   Gomes, MRB
   de Paula, RCC
   Biagioni, DS
   Almeida, RAMB
   Rosa, RAG
   Guaclagnucci, JC
AF de Faria, E. Petribu
   Llanos, J. C.
   Neto, A. B.
   Silva, A. P. C.
   Winckler, C. C.
   Mutti, A.
   Saad-Hossne, R.
   Silva, G. F.
   Gomes, M. R. B.
   de Paula, R. C. Callile
   Biagioni, D. S.
   Almeida, R. A. M. B.
   Rosa, R. A. G.
   Guaclagnucci, J. C.
TI Opinion of hepatic transplant waiting list patients regarding split
   liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Joint Congress of the 10th Transplantation-Society-of-Brazil/19th
   Latin-American-and-Caribbean-Transplantation-Society/6th
   Luso-Brazilian-Transplantation-Society
CY SEP 02-05, 2007
CL Florianopolis, BRAZIL
SP Transplantat Soc Brazil, Latin Amer & Caribbean Transplantat Soc, Luso Brazilian Transplantat Soc
AB Background. Split liver transplantation (SLT) increases organ supply for hepatic transplantation. Long-term patient survival and complication rates seem to be equivalent between orthotopic liver transplantation (OLT) and SLT. There are controversies among transplant physicians due to an ethical dilemma between benefiting individual needs or those of society. Barshes and Goss (Am J Transplant 5:2047, 2005) demonstrated that the majority of adult liver transplant candidates are favorable to SLT. The aim of our study was to evaluate the opinions of patients at a Brazilian university hospital regarding SLT.
   Materials and Methods. A questionnaire with 14 questions was applied to 50 patients included in a hepatic transplant waiting list regarding SLT.
   Results. The overall attitudes of 66% of the participants were classified as utilitarian, 31% were classified as self-preserving, and 3% were undecided. Ninety-one percent of patients would be willing to share even if their expected survival after SLT was shorter than that with OLT. For 77% of patients, children must have priority over adults. However, 83% were unaware of the donors for pediatric transplantations.
   Conclusions. SLT is a consistent solution for organ demand despite controversies among transplant physicians. The present study demonstrated that most patients were favorable to SLT. In conclusion, attitudes toward graft sharing are not barriers to SLT.
C1 [de Faria, E. Petribu; Llanos, J. C.; Neto, A. B.; Silva, A. P. C.; Winckler, C. C.; Mutti, A.; Saad-Hossne, R.; Silva, G. F.; Gomes, M. R. B.; de Paula, R. C. Callile; Biagioni, D. S.; Almeida, R. A. M. B.; Rosa, R. A. G.; Guaclagnucci, J. C.] UNESP, Botucatu Sch Med, Div Liver & Gastrointestinal Transplantat, Botucatu, SP, Brazil.
RP Llanos, JC (reprint author), Rua Jose Dal Ferra 870, BR-18603555 Botucatu, SP, Brazil.
EM juan@fmb.unesp.br
RI LLANOS, JUAN/F-4711-2012
CR Barshes NR, 2005, AM J TRANSPLANT, V5, P2047, DOI 10.1111/j.1600-6143.2005.00946.x
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   *UNOS, 2004, SPLIT WHOL LIV TRANS
   Vulchev A, 2004, AM J TRANSPLANT, V4, P1737, DOI 10.1111/j.1600-6143.2004.00630.x
   Wilms C, 2006, ANN SURG, V244, P865, DOI 10.1097/01.sla.0000247254.76747.f3
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2008
VL 40
IS 3
BP 780
EP 781
DI 10.1016/j.transproceed.2008.02.060
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 296EZ
UT WOS:000255527600038
ER

PT J
AU Polak, WG
   Peeters, PMJG
   Miyamoto, S
   Sieders, E
   de Jong, KP
   Porte, RJ
   Bijleveld, CMA
   Hendriks, HG
   TenVergert, EM
   Slooff, MJH
AF Polak, Wojciech G.
   Peeters, Paul M. J. G.
   Miyamoto, Shungo
   Sieders, Egbert
   de Jong, Koert P.
   Porte, Robert J.
   Bijleveld, Charles M. A.
   Hendriks, Herman G.
   TenVergert, Elisabeth M.
   Slooff, Maarten J. H.
TI The outcome of primary liver transplantation from deceased donors in
   children with body weight <= 10 kg
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE children; donor/recipient weight ratio; liver transplantation; low body
   weight; outcome; retransplantation
ID THAN 10 KILOGRAMS; PEDIATRIC-PATIENTS; BILIARY ATRESIA; SMALL INFANTS;
   LESS; AGE; MONOSEGMENTS; GRAFTS; COMPLICATIONS; SURVIVAL
AB Between November 1982 and March 2006, 67 children with body weight <= 10 kg had a primary liver transplantation from deceased donors in our unit. The aim of this study was to analyze the outcome in terms of patient and graft survival and to search for factors affecting this outcome. Overall, one-, three-, five-, and 10-yr primary patient and graft survival rates were 73%, 71%, 66%, 63% and 59%, 56%, 53%, 48%, respectively. Twenty-four of 67 (36%) children died and in the remaining 22 (33%), the first grafts failed and they were retransplanted. Cox regression analysis revealed that a need for retransplantation and urgent transplantation were important predictors for patient survival (p = 0.04 and p = 0.001, respectively). To assess whether the need for retransplantation can be influenced, all study variables were compared between surviving grafts and failed grafts. Cox regression analysis showed that only donor/recipient (D/R) weight ratio proved to be independent predictor for graft survival (p = 0.004). After comparison of graft survival with the long rank test according to different D/R weight ratios (3.0-7.0), the cut-off point for significantly different graft survival approached 4.0. The one-, three-, five-, and 10-yr graft survival for technical variant grafts with a D/R weight ratio < 4.0 was 85%, 68%, 68%, and 68% compared with a D/R weight ratio > 4.0 was 44%, 38%, 38%, and 30%, respectively (p = 0.02). In summary, patient survival in children with body weight <= 10 kg is determined by urgent transplantation and the need for retransplantation. Graft loss and retransplantation in small children can be prevented by adequate size matching of donor and recipient whereby a D/R weight ratio < 4.0 seems to offer the favorable outcome.
C1 [Polak, Wojciech G.; Peeters, Paul M. J. G.; Miyamoto, Shungo; Sieders, Egbert; de Jong, Koert P.; Porte, Robert J.; Slooff, Maarten J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Div Hepatobiliary Surg & Liver Transplantat, NL-9713 GZ Groningen, Netherlands.
   [Bijleveld, Charles M. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, NL-9713 GZ Groningen, Netherlands.
   [Hendriks, Herman G.] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, NL-9713 GZ Groningen, Netherlands.
   [TenVergert, Elisabeth M.] Univ Groningen, Univ Med Ctr Groningen, Off Med Technol Assessment, NL-9713 GZ Groningen, Netherlands.
RP Slooff, MJH (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Div Hepatobiliary Surg & Liver Transplantat, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM m.j.h.slooff@chir.azg.nl
CR BEATH SV, 1993, BRIT MED J, V307, P825
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Bouchut JC, 2001, PAEDIATR ANAESTH, V11, P93, DOI 10.1046/j.1460-9592.2001.00574.x
   BROELSCH CE, 1988, TRANSPLANTATION, V45, P519, DOI 10.1097/00007890-198803000-00003
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   COX K, 1991, TRANSPLANT P, V23, P1579
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   DUNN SP, 1993, J PEDIATR SURG, V28, P1048, DOI 10.1016/0022-3468(93)90516-N
   Enne M, 2005, LIVER TRANSPLANT, V11, P564, DOI 10.1002/lt.20421
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   *EUR LIV TRANSP RE, 2004, DAT AN BOOKL
   Farmer DG, 2001, TRANSPLANTATION, V72, P1795, DOI 10.1097/00007890-200112150-00015
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   Haberal M, 2006, TRANSPL P, V38, P3585, DOI 10.1016/j.transproceed.2006.10.016
   Iglesias J, 2004, PEDIATR TRANSPLANT, V8, P228, DOI 10.1111/j.1399-3046.2004.00128.x
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   Lucianetti A, 2005, TRANSPLANT P, V37, P1143, DOI 10.1016/j.transproceed.2004.12.307
   LYNCH SV, 1992, TRANSPLANT P, V24, P186
   Mekeel KL, 2007, PEDIATR TRANSPLANT, V11, P66, DOI 10.1111/j.1399-3046.2006.00610.x
   MOUKARZEL AA, 1990, TRANSPLANT P, V22, P1560
   Neto JS, 2007, LIVER TRANSPLANT, V13, P1153, DOI 10.1002/lt.21206
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Ogawa K, 2007, TRANSPLANTATION, V83, P1337, DOI 10.1097/01.tp.0000263340.82489.18
   Oswari H, 2005, J GASTROEN HEPATOL, V20, P1850, DOI 10.1111/j.1440-1746.2005.03926.x
   OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006
   PAYEN DM, 1990, SURGERY, V107, P417
   PEETERS PMJG, 1995, PEDIATR SURG INT, V10, P120
   RINGE B, 1988, TRANSPLANT INT, V1, P30
   Rodeck B, 1996, TRANSPLANTATION, V62, P1071, DOI 10.1097/00007890-199610270-00008
   ROSMAN C, 1990, TRANSPLANT P, V22, P1554
   Saing H, 1999, J PEDIATR SURG, V34, P1721, DOI 10.1016/S0022-3468(99)90653-X
   SHEPHERD RW, 1991, J PAEDIATR CHILD H, V27, P295, DOI 10.1111/j.1440-1754.1991.tb02541.x
   SHUN A, 1992, CLIN TRANSPLANT, V6, P315
   Sieders E, 2001, TRANSPLANTATION, V71, P90, DOI 10.1097/00007890-200101150-00015
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343
   STARZL TE, 1984, SURG GYNECOL OBSTET, V158, P223
   STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009
   Tanaka A, 1996, TRANSPLANT INT, V9, P15, DOI 10.1111/j.1432-2277.1996.tb00847.x
   *US ORG PROC TRANS, 1996, 2006 ANN REP US ORG
   Van der Werf WJ, 1998, J PEDIATR SURG, V33, P20, DOI 10.1016/S0022-3468(98)90353-0
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 50
TC 4
Z9 5
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD MAR-APR
PY 2008
VL 22
IS 2
BP 171
EP 179
DI 10.1111/j.1399-0012.2007.00762.x
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 274DM
UT WOS:000253982000007
PM 18339136
ER

PT J
AU Haberal, M
   Semis, S
   Karakayali, H
   Ozcay, F
   Moray, G
   Yilmaz, U
   Torgay, A
   Demirhan, B
   Arslan, G
AF Haberal, Mehmet
   Semis, Sinasi
   Karakayali, Hamdi
   Ozcay, Figen
   Moray, Gokhan
   Yilmaz, Ugur
   Torgay, Adnan
   Demirhan, Beyhan
   Arslan, Gunaz
TI Pediatric liver transplant: Results of a single center
SO EXPERIMENTAL AND CLINICAL TRANSPLANTATION
LA English
DT Article
DE liver transplantation; complications; treatment; outcome; children
ID HEPATIC-ARTERY THROMBOSIS; DONOR LIVER; VASCULAR COMPLICATIONS; VENOUS
   COMPLICATIONS; CHILDREN; SIZE; RECONSTRUCTION; EXPERIENCE; SAFE
AB Objectives: Liver transplant in the pediatric population has become an accepted treatment modality for children with end-stage liver disease. In this study, we analyze our experiences with pediatric liver transplant at our center.
   Materials and Methods: Since September 2001, 8 deceased-donor and 96 living-donor liver transplants have been done in 101 children (mean age, 6.7 +/- 5.5 years; range, 2 months to 17 years). The children's charts were reviewed retrospectively.
   Results: indications for liver transplant were cholestatic liver disease (n=17), biliary atresia (n=24), Wilson's disease (n=16),fulminant liver failure (n=18), hepatic tumor (n=13), and other (n=13). The median pediatric end-stage liver disease score was 23.1 +/- 11.1 (range, -8 to 48). The median follow-up was 24.2 +/- 19.4 months (range, 1-77 months). Three children underwent retransplant. The main complications were infections (25.9%) and surgical complications (39.5%) (including biliary complications and vascular problems). The incidence of acute cellular rejection was 42.3%. Sixteen children died during follow-up, and, at the time of this writing, the remaining 85 children (85%) were alive with good graft functioning, showing patient survival rates of 90%, 85%, and 83% at 6,12, and 36 months, respectively.
   Conclusions: in conclusion, the overall outcomes of pediatric liver transplantation at our center are quite promising.
C1 [Haberal, Mehmet; Semis, Sinasi; Karakayali, Hamdi; Moray, Gokhan] Baskent Univ, Fac Med, Dept Gen Surg & Transplantat, TR-06490 Ankara, Turkey.
   [Ozcay, Figen] Baskent Univ, Fac Med, Dept Pediat Gastroenterol, TR-06490 Ankara, Turkey.
   [Yilmaz, Ugur] Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
   [Torgay, Adnan; Arslan, Gunaz] Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey.
   [Demirhan, Beyhan] Baskent Univ, Fac Med, Dept Pathol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg & Transplantat, 1 Cadde,77, TR-06490 Ankara, Turkey.
EM rektorluk@baskeni-ank.edu.tr
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   EMOND JC, 1993, TRANSPLANTATION, V55, P835, DOI 10.1097/00007890-199304000-00029
   HABERAL M, 1993, TRANSPLANT P, V25, P1899
   Haberal M, 2002, TRANSPLANT P, V34, P2145, DOI 10.1016/S0041-1345(02)02884-1
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   Haberal M, 2007, EXP CLIN TRANSPLANT, V5, P585
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011
   KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7
   KALAYOGLU M, 1993, SURGERY, V114, P711
   KALAYOGLU M, 1990, SURG GYNECOL OBSTET, V171, P139
   KALAYOGLU M, 1993, SURGERY, V114, P717
   Karakayali H, 2007, TRANSPL P, V39, P1153, DOI 10.1016/j.transproceed.2007.02.054
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   STRATTA RJ, 1989, SURGERY, V106, P675
   Stratta RJ, 1989, SURGERY, V106, P683
   Vallera R A, 1995, Liver Transpl Surg, V1, P143, DOI 10.1002/lt.500010302
   WHITINGTON PF, 1991, J PEDIATR-US, V118, P169, DOI 10.1016/S0022-3476(05)80478-0
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
NR 26
TC 12
Z9 12
U1 0
U2 0
PU BASKENT UNIV
PI ANKARA
PA TASKENT CADDESI NO 77, KAT 4, BAHCELIEVLER, ANKARA, 06490, TURKEY
SN 1304-0855
J9 EXP CLIN TRANSPLANT
JI Exp. Clin. Transplant.
PD MAR
PY 2008
VL 6
IS 1
BP 7
EP 13
PG 7
WC Transplantation
SC Transplantation
GA 294LZ
UT WOS:000255408800002
PM 18405239
ER

PT J
AU Davis, MK
   Weinstein, DA
AF Davis, Michael K.
   Weinstein, David A.
TI Liver transplantation in children with glycogen storage disease:
   Controversies and evaluation of the risk/benefit of this procedure
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE glycogen storage disease; pediatric liver transplantation; treatment
ID I ESGSD-I; HEPATOCELLULAR-CARCINOMA; LONG-TERM; HEPATIC ADENOMAS;
   GLUCOSE-6-PHOSPHATASE GENE; KIDNEY-TRANSPLANTATION; ENZYME DEFICIENCY;
   CLINICAL-COURSE; RENAL-FAILURE; THERAPY
AB GSD-I, III, and IV are congenital disorders of glycogen metabolism that are commonly associated with severe liver disease. Liver transplantation has been proposed as a therapy for these disorders. While liver transplantation corrects the primary hepatic enzyme defect, the extrahepatic manifestations of GSD often complicate post-transplantation management. Upon review of the English-language literature, 42 children < 19 yr of age were discovered to have undergone liver transplantation for complications associated with GSD (18 patients with GSD-Ia, six with GSD-Ib, one with GSD-III, 17 with GSD-IV). An additional two children followed at our institution have undergone liver transplantation for GSD complications (one with GSD-Ia and one with GSD-III) and are included in this review. The risks and benefits of liver transplantation should be considered prior to performing liver transplantation in these metabolic disorders, particularly in GSD-Ia. As liver pathology is not the major source of morbidity in GSD-Ib and GSD-IIIa, liver transplantation should only be performed when there is high risk for HCC or evidence of substantial cirrhosis or liver dysfunction. Liver transplantation remains the best option for treatment of GSD-IV.
C1 [Davis, Michael K.] Univ Florida, Coll Med, Div Pediat Gastroenterol, Gainesville, FL 32610 USA.
   [Weinstein, David A.] Univ Florida, Coll Med, Dept Pediat, Div Pediat Endocrinol, Gainesville, FL USA.
RP Davis, MK (reprint author), Univ Florida, Coll Med, Div Pediat Gastroenterol, POB 100296, Gainesville, FL 32610 USA.
EM davismk@peds.ufl.edu
CR Adachi M, 2004, EUR J PEDIATR, V163, P202, DOI 10.1007/s00431-004-1405-1
   ALSHAK NS, 1994, ARCH PATHOL LAB MED, V118, P88
   Arikan C, 2006, PEDIATR TRANSPLANT, V10, P42, DOI 10.1111/j.1399-3046.2005.00395.x
   Belingheri M, 2007, LIVER TRANSPLANT, V13, P762, DOI 10.1002/lt.21147
   Bhattacharya K, 2004, J INHERIT METAB DIS, V27, P539, DOI 10.1023/B:BOLI.0000037400.49488.20
   BIANCHI L, 1993, EUR J PEDIATR, V152, pS63
   Bruno C, 2004, NEUROLOGY, V63, P1053
   Chen Y-T, 2001, METABOLIC MOL BASES, P1521
   Choi BY, 2005, J CLIN GASTROENTEROL, V39, P401, DOI 10.1097/01.mcg.0000159226.63037.a2
   Cochrane AB, 2007, TRANSPLANT P, V39, P308, DOI 10.1016/j.transproceed.2006.10.018
   COIRE CI, 1987, ARCH PATHOL LAB MED, V111, P166
   COLEMAN RA, 1992, J INHERIT METAB DIS, V15, P869, DOI 10.1007/BF01800225
   Czauderna P, 2002, MED PEDIATR ONCOL, V39, P519, DOI 10.1002/mpo.10178
   DELABLANCHARDIERE A, 1994, PRESSE MED, V23, P1124
   Demo E, 2007, J HEPATOL, V46, P492, DOI 10.1016/j.jhep.2006.09.022
   DHAWAN A, 1994, ARCH DIS CHILD, V71, P450
   Endoh A, 2001, J PEDIATR GASTR NUTR, V33, P333, DOI 10.1097/00005176-200109000-00020
   Ewert R, 1999, Z KARDIOL, V88, P850, DOI 10.1007/s003920050361
   Faivre L, 1999, J INHERIT METAB DIS, V22, P723, DOI 10.1023/A:1005544117285
   Franco LM, 2005, J INHERIT METAB DIS, V28, P153, DOI 10.1007/s10545-005-7500-2
   Ghosh A, 2006, GENE THER, V13, P321, DOI 10.1038/sj.gt.3302650
   GITZELMANN R, 1993, EUR J PEDIATR, V152, pS33
   Grazioli L, 2001, RADIOGRAPHICS, V21, P877
   Haagsma EB, 1997, HEPATOLOGY, V25, P537, DOI 10.1002/hep.510250307
   Koestinger A, 2000, TRANSPLANTATION, V69, P2205, DOI 10.1097/00007890-200005270-00045
   Kudo M, 2001, J GASTROENTEROL, V36, P65, DOI 10.1007/s005350170157
   Labrune P, 1997, J PEDIATR GASTR NUTR, V24, P276, DOI 10.1097/00005176-199703000-00008
   Labrune P, 2002, EUR J PEDIATR, V161, pS53, DOI 10.1007/s00431-002-1004-y
   LACHAUX A, 1993, J PEDIATR-US, V123, P1005, DOI 10.1016/S0022-3476(05)80403-2
   Lee PJ, 2002, EUR J PEDIATR, V161, pS46
   Lee PJ, 2004, J INHERIT METAB DIS, V27, P537, DOI 10.1023/B:BOLI.0000037397.39725.57
   LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187
   LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645
   Lerut JP, 2003, TRANSPLANT INT, V16, P879, DOI 10.1007/s00147-003-0613-3
   LIMMER J, 1988, HEPATOLOGY, V8, P531, DOI 10.1002/hep.1840080317
   Liu PP, 2003, TRANSPLANT P, V35, P366, DOI 10.1016/S0041-1345(02)03951-9
   MALATACK JJ, 1983, LANCET, V1, P1073
   Martin AP, 2006, TRANSPLANT P, V38, P3615, DOI 10.1016/j.transproceed.2006.10.160
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   Martinez Ibanez V, 1987, Transplant Proc, V19, P3803
   Matern D, 1999, EUR J PEDIATR, V158, pS43, DOI 10.1007/PL00014320
   Morioka D, 2005, AM J TRANSPLANT, V5, P2754, DOI 10.1111/j.1600-6143.2005.01084.x
   Moses Shimon W., 2002, Current Molecular Medicine (Hilversum), V2, P177, DOI 10.2174/1566524024605815
   Muraca M, 2005, ACTA GASTRO-ENT BELG, V68, P469
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   PARKER P, 1981, GASTROENTEROLOGY, V81, P534
   POE R, 1988, AM J SURG PATHOL, V12, P477, DOI 10.1097/00000478-198806000-00008
   Rake JP, 2002, EUR J PEDIATR, V161, pS112, DOI 10.1007/s00431-002-1016-7
   Rake JP, 2002, EUR J PEDIATR, V161, pS20, DOI 10.1007/s00431-002-0999-4
   Reid CJD, 1996, TRANSPLANT P, V28, P3629
   SELBY R, 1993, EUR J PEDIATR, V152, pS71
   Shirasawa Y, 2004, INTERNAL MED, V43, P802, DOI 10.2169/internalmedicine.43.802
   SOKAL EM, 1993, J PEDIATR GASTR NUTR, V16, P465, DOI 10.1097/00005176-199305000-00021
   SOKAL EM, 1992, EUR J PEDIATR, V151, P200, DOI 10.1007/BF01954384
   STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101
   SUPERINA RA, 1989, J PEDIATR SURG, V24, P1013, DOI 10.1016/S0022-3468(89)80205-2
   Takeshita K, 2002, J COMPUT ASSIST TOMO, V26, P451, DOI 10.1097/01.RCT.0000018204.77798.7F
   Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260
   Wolfsdorf JI, 1999, ENDOCRIN METAB CLIN, V28, P801, DOI 10.1016/S0889-8529(05)70103-1
   Wolfsdorf JI, 2003, REV ENDOCR METAB DIS, V4, P95, DOI 10.1023/A:1021831621210
   Wolfsdorf JI, 1999, J PEDIATR GASTR NUTR, V29, P136, DOI 10.1097/00005176-199908000-00008
   Wolfsdorf JI, 1997, AM J CLIN NUTR, V65, P1507
   Yiu WH, 2007, GENE THER, V14, P219, DOI 10.1038/sj.gt.3302869
   Yoshikawa M, 2001, J GASTROENTEROL, V36, P52, DOI 10.1007/s005350170155
NR 64
TC 30
Z9 32
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2008
VL 12
IS 2
BP 137
EP 145
DI 10.1111/j.1399-3046.2007.00803.x
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 269GL
UT WOS:000253637400005
PM 18307661
ER

PT J
AU Dehghani, SM
   Nikeghbalian, S
   Kazemi, K
   Dehghani, M
   Gholami, S
   Bahador, A
   Salahi, H
   Malek-Hosseini, SA
AF Dehghani, Seyed Mohsen
   Nikeghbalian, Saman
   Kazemi, Koorosh
   Dehghani, Masood
   Gholami, Siavash
   Bahador, Ali
   Salahi, Heshmatollah
   Malek-Hosseini, Seyed Ali
TI Outcome of bowel perforation after pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; liver transplantation; bowel perforation; risk factors;
   outcome
ID GASTROINTESTINAL PERFORATION; DIAGNOSIS; CHILDREN; TRACT
AB Bowel perforation is one of the causes of mortality after pediatric liver transplantation. The aim of this study was to evaluate the incidence, risk factors, clinical presentations, and outcomes of bowel perforation in pediatric liver recipients. This is a retrospective analysis of all pediatric patients who underwent liver transplantation at a single liver transplant center in Iran between 1999 and 2006. During this period 72 liver transplantations were performed in children < 18 yr. Twenty-two children underwent 33 re-explorations after liver transplantation. Five bowel perforations occurred in four children (incidence, 6.9%). One patient required two re-explorations. The median time between liver transplantation and the diagnosis of the bowel perforation was seven days. All patients had abdominal distention before re-exploration. The sites of perforation were jejunum (n = 3) and ileum (n = 2), and simple repair was performed in all cases. Three children had a history of prior Kasai operation. One of them received high dose of methylprednisolone before bowel perforation. Two children expired after bowel perforation (mortality rate, 50%). Bowel perforation is relatively frequent after pediatric liver transplantation. Among risk factors, prior Kasai operation may have a role. We observed that abdominal distention is a sign of bowel perforation and a high index of suspicion is required for rapidly diagnosis of this complication. The outcome of bowel perforation is poor and its mortality is high. Further studies are needed to establish real risk factors for this complication.
C1 [Dehghani, Seyed Mohsen; Nikeghbalian, Saman; Kazemi, Koorosh; Dehghani, Masood; Gholami, Siavash; Bahador, Ali; Salahi, Heshmatollah; Malek-Hosseini, Seyed Ali] Shiraz Univ Med Sci, Organ Transplantat Ctr, Nemazee Hosp, Shiraz, Iran.
   [Dehghani, Seyed Mohsen] Shiraz Univ Med Sci, Gastroenterohepatol Res Unit, Nemazee Hosp, Shiraz, Iran.
RP Dehghani, SM (reprint author), Shiraz Univ Med Sci, Organ Transplantat Ctr, Nemazee Hosp, Shiraz, Iran.
EM dehghanism@sums.ac.ir
CR BEATH S, 1993, J PEDIATR SURG, V28, P1044
   Beierle EA, 1998, J PEDIATR SURG, V33, P240, DOI 10.1016/S0022-3468(98)90439-0
   BILIK R, 1992, J PEDIATR SURG, V27, P1371, DOI 10.1016/0022-3468(92)90179-B
   DAYTON MT, 1987, ARCH SURG-CHICAGO, V122, P376
   HINNANT KL, 1986, AM J GASTROENTEROL, V81, P944
   MARUJO WC, 1991, AM J SURG, V162, P594, DOI 10.1016/0002-9610(91)90116-U
   MAYORAL JL, 1991, ARCH SURG-CHICAGO, V126, P202
   Melendez HV, 1998, TRANSPLANT INT, V11, P301, DOI 10.1111/j.1432-2277.1998.tb00975.x
   MUTESAN P, 2007, J HEPATOL, V46, P340
   Pirenne J, 1997, CLIN TRANSPLANT, V11, P88
   REMINE SG, 1980, ANN SURG, V192, P581, DOI 10.1097/00000658-198010000-00016
   SHAKED A, 1993, ARCH SURG-CHICAGO, V128, P994
   Soubrane O, 1995, Liver Transpl Surg, V1, P2, DOI 10.1002/lt.500010103
   YAMANAKA J, 1994, J PEDIATR SURG, V29, P635, DOI 10.1016/0022-3468(94)90729-3
NR 14
TC 10
Z9 12
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2008
VL 12
IS 2
BP 146
EP 149
DI 10.1111/j.1399-3046.2007.00829.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 269GL
UT WOS:000253637400006
PM 18307662
ER

PT J
AU Wang, SH
   Concejero, AM
   Chen, CL
   Wang, CC
   Lin, CC
   Liu, YW
   Yang, CH
   Yong, CC
AF Wang, Shih-Ho
   Concejero, Allan M.
   Chen, Chao-Long
   Wang, Chih-Chi
   Lin, Chih-Che
   Liu, Yeuh-Wei
   Yang, Chin-Hsiang
   Yong, Chee-Chien
TI A simple and inexpensive technique of upper abdominal wall retraction in
   pediatric liver surgery and transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE abdominal wall retractor; incision; liver transplantation; pediatric
   surgery
ID SELF-RETAINING RETRACTOR
AB In majority of centers, pediatric liver surgery and transplantation involves a team of four at any given time: the surgeon, the first and second assistants, and the instrument nurse. This creates considerable crowding around both operative field and operating table. Mechanical devices have been occasionally employed to solve this problem, but most table-mounted devices are designed for adult patients. Based on our experience with pediatric living donor liver transplantation, we developed a simple, safe, and inexpensive method of upper abdominal wall retraction to facilitate surgical exposure and avoid over-crowding in the sterile field. The key points of this technique are the use of the Mercedes incision for liver transplantation or right subcostal incision with upper abdominal midline extension for hepatic resection and an adult-designed Kent retractor. A pediatric-designed Kent retractor is expensive, unnecessary, and may even cause complications as rib fractures and nerve paralysis. We used this technique in 142 consecutive pediatric living donor liver transplants and 16 major hepatectomies in children without any complication resulting from the exposure. The presented technique is simple, safe, reliable, and inexpensive. It can be used in pediatric liver surgery, as well as general pediatric upper abdominal operations.
C1 [Chen, Chao-Long] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Liver Transplantat Program, Kaohsiung 83305, Taiwan.
   Chang Gung Univ Coll Med, Kaohsiung, Taiwan.
RP Chen, CL (reprint author), Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Liver Transplantat Program, 123 Tapei Rd, Kaohsiung 83305, Taiwan.
EM clchen@adm.cgmh.org.tw
CR Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Lee HC, 2003, YONSEI MED J, V44, P1106
   LIN CC, 2006, WORLD J SURG, V30, P115
   Noldus J, 2002, UROLOGY, V60, P964, DOI 10.1016/S0090-4295(02)01946-5
   PINSON CW, 1995, AM SURGEON, V61, P178
   STEBER AC, 1990, AM J SURG, V160, P300
   THOMPSON RC, 1962, AM J SURG, V103, P597, DOI 10.1016/0002-9610(62)90527-5
NR 7
TC 0
Z9 1
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2008
VL 12
IS 2
BP 150
EP 152
DI 10.1111/j.1399-3046.2007.00818.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 269GL
UT WOS:000253637400007
PM 18307663
ER

PT J
AU Ammori, JB
   Pelletier, SJ
   Mathur, A
   Cohn, J
   Ads, Y
   Campbell, DA
   Magee, JC
   Englesbe, MJ
AF Ammori, John B.
   Pelletier, Shawn J.
   Mathur, Amit
   Cohn, Joshua
   Ads, Yasser
   Campbell, Darrell A.
   Magee, John C.
   Englesbe, Michael J.
TI Financial implications of surgical complications in pediatric liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE quality improvement; transplant finances; complications
ID QUALITY IMPROVEMENT PROGRAM; COST; CHILDREN; UPDATE
AB Surgical complications following pediatric liver transplantation are common and expensive. We examined the incremental costs of surgical complications and determined who pays for these complications (center or payer). We reviewed the records of 36 pediatric liver transplant patients aged <= 12 yr transplanted between July 1, 2002 and December 31, 2005. The association of recipient and financial data points was assessed. On univariate analysis, total hospital costs were significantly increased in patients with ACR, PNF, HAT, biliary complications, and ARF. Reimbursement by the payer was significantly increased in patients with PNF, HAT, biliary complications, and ARF. Hospital profits were significantly decreased in recipients with ACR and pneumonia. Multiple linear regression models (controlling for recipient factors) revealed that ARF and HAT were independently associated with a significant increase in median hospital costs (incremental costs of $238 990 and $125 650, respectively). ARF and HAT were also independently associated with a significant increase in median reimbursements (incremental costs of $231 611 and $125 287, respectively). No complications were independently associated with hospital margins. All parties (patient and families, physician, payer, and medical center) should benefit from quality improvement efforts, with payers having the largest financial interest.
C1 [Ammori, John B.; Pelletier, Shawn J.; Mathur, Amit; Cohn, Joshua; Ads, Yasser; Campbell, Darrell A.; Magee, John C.; Englesbe, Michael J.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
RP Englesbe, MJ (reprint author), Univ Michigan, Dept Surg, 1500 E Med Ctr Dr,2926 Taubman Ctr, Ann Arbor, MI 48109 USA.
EM englesbe@med.umich.edu
OI Englesbe, Michael/0000-0001-8691-9111; Cohn, Joshua/0000-0002-4953-3321
CR Arozullah AM, 2001, ANN INTERN MED, V135, P847
   Arozullah AM, 2003, MED CARE, V41, P979, DOI 10.1097/00005650-200308000-00011
   Bucuvalas JC, 2002, PEDIATR TRANSPLANT, V6, P30, DOI 10.1034/j.1399-3046.2002.1r058.x
   Bucuvalas JC, 2001, J PEDIATR-US, V139, P66, DOI 10.1067/mpd.2001.115068
   Cole CR, 2004, J PEDIATR-US, V144, P729, DOI 10.1016/j.jpeds.2004.03.032
   Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276
   Englesbe MJ, 2006, AM J TRANSPLANT, V6, P2978, DOI 10.1111/j.1600-6143.2006.01575.x
   Englesbe MJ, 2006, AM J TRANSPLANT, V6, P666, DOI 10.1111/j.1600-6143.2006.01267.x
   Fink AS, 2002, ANN SURG, V236, P344, DOI 10.1097/01.SLA.0000027082.79556.55
   Hollenbeak C S, 2003, Transpl Infect Dis, V5, P72, DOI 10.1034/j.1399-3062.2003.00013.x
   HOLSEN S, 2007, AM J TRANSPLANT, V7, P1656
   Khuri SF, 2002, ARCH SURG-CHICAGO, V137, P20, DOI 10.1001/archsurg.137.1.20
   Khuri SF, 2005, ANN SURG, V242, P326, DOI 10.1097/01.sla.0000179621.33268.83
   McDiarmid S V, 2003, Clin Transpl, P119
   McDiarmid SV, 2001, TRANSPLANT P, V33, P3604, DOI 10.1016/S0041-1345(01)02550-7
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   Pronovost P, 2000, CRIT CARE MED, V28, P581, DOI 10.1097/00003246-200002000-00055
   *UN FOR ORG SHAR A, 1999, ANN REP
NR 18
TC 7
Z9 7
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2008
VL 12
IS 2
BP 174
EP 179
DI 10.1111/j.1399-3046.2007.00783.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 269GL
UT WOS:000253637400010
PM 18307665
ER

PT J
AU Ng, V
   Anand, R
   Martz, K
   Fecteau, A
AF Ng, V.
   Anand, R.
   Martz, K.
   Fecteau, A.
TI Liver retransplantation in children: A SPLIT database analysis of
   outcome and predictive factors for survival
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE outcomes; pediatric; pediatric hepatology/liver transplant; registry;
   retransplantation
ID HEPATIC RETRANSPLANTATION; TRANSPLANTATION; EXPERIENCE; IMPACT; GRAFT;
   REJECTION; FAILURE; MODEL
AB To examine outcomes and identify prognostic factors affecting survival after pediatric liver transplantation, data from 246 children who underwent a second liver transplantation (rLT) between 1996 and 2004 were analyzed from the SPLIT registry, a multi-center database currently comprised of 45 North American pediatric liver transplant programs. The main causes for loss of primary graft necessitating rLT were primary nonfunction, vascular complications, chronic rejection and biliary complications. Three-month, 1- and 2-year patient survival rates were inferior after rLT (74%, 67% and 65%) compared with primary LT (92%, 88% and 85%, respectively). Multivariate analysis of pretransplant variables revealed donor age less than 1 year, use of a technical variant allograft and INR at time of rLT as independent predictive factors for survival after rLT. Survival of patients who underwent early rLT (ErLT, <30 days after LT) was poorer than those who received rLT>30 days after LT (late rLT, LrLT): 3-month, 1- and 2-year patient survival rates 66%, 59%, and 56% versus 80%, 74% and 61%, respectively, log-rank p = 0.0141. Liver retransplantation in children is associated with decreased survival compared with primary LT, particularly, in the clinical settings of those patients requiring ErLT.
C1 [Ng, V.; Anand, R.; Martz, K.; Fecteau, A.] Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada.
RP Ng, V (reprint author), Hosp Sick Children, Div Gastroenterol Hepatol & Nutr, 555 Univ Ave Room 8262, Toronto, ON M5G 1X8, Canada.
EM vicky.ng@sickkids.ca
CR Achilleos OA, 1999, LIVER TRANSPLANT SUR, V5, P401, DOI 10.1002/lt.500050505
   Azoulay D, 2002, ANN SURG, V236, P713, DOI 10.1097/01.SLA.0000036264.66247.65
   Biggins SW, 2002, LIVER TRANSPLANT, V8, P313, DOI 10.1053/jlts.2002.31746
   DALESSANDRO AM, 1993, TRANSPLANTATION, V55, P1083, DOI 10.1097/00007890-199305000-00028
   Deshpande PR, 2002, TRANSPLANTATION, V74, P1124, DOI 10.1097/01.TP.0000030640.11006.CE
   Diamond IR, 2007, ANN SURG, V246, P301, DOI 10.1097/SLA.0b013e3180caa415
   DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1016/0270-9139(93)90115-4
   HAMADA H, 1995, J PEDIATR SURG, V30, P705, DOI 10.1016/0022-3468(95)90696-7
   Jain A, 2001, PEDIATR TRANSPLANT, V5, P93, DOI 10.1034/j.1399-3046.2001.005002093.x
   KAMATH GS, 1991, TRANSPLANT P, V23, P1954
   Kim WR, 1999, HEPATOLOGY, V30, P395, DOI 10.1002/hep.510300210
   Kumar N, 1999, TRANSPLANT P, V31, P541, DOI 10.1016/S0041-1345(98)01546-2
   LANGNAS AN, 1993, TRANSPLANT P, V25, P1921
   Marino IR, 1995, HEPATOLOGY, V22, P1754, DOI 10.1016/0270-9139(95)90202-3
   Markmann JF, 1997, ANN SURG, V226, P408, DOI 10.1097/00000658-199710000-00002
   Molmenti E, 1999, TRANSPLANT P, V31, P408, DOI 10.1016/S0041-1345(98)01682-0
   MORA NP, 1991, TRANSPLANT INT, V4, P231, DOI 10.1111/j.1432-2277.1991.tb01986.x
   Newell KA, 1998, TRANSPLANTATION, V65, P1172, DOI 10.1097/00007890-199805150-00005
   POWELSON JA, 1993, TRANSPLANTATION, V55, P802, DOI 10.1097/00007890-199304000-00023
   Rosen H R, 2000, Clin Liver Dis, V4, P675, DOI 10.1016/S1089-3261(05)70132-X
   Rosen HR, 1999, HEPATOLOGY, V29, P365, DOI 10.1002/hep.510290221
   SAITO S, 1992, CLIN TRANSPLANT, V6, P430
   Sanchez-Bueno F, 2000, TRANSPLANT P, V32, P2671, DOI 10.1016/S0041-1345(00)01836-4
   Sieders E, 2001, TRANSPLANTATION, V71, P90, DOI 10.1097/00007890-200101150-00015
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   UBEL PA, 1993, JAMA-J AM MED ASSOC, V270, P2469, DOI 10.1001/jama.270.20.2469
   Wiesner RH, 1998, HEPATOLOGY, V28, P638, DOI 10.1002/hep.510280306
   Wong T, 1997, TRANSPLANTATION, V64, P878, DOI 10.1097/00007890-199709270-00015
   Yoong K F, 1998, Transpl Int, V11 Suppl 1, pS221
NR 29
TC 26
Z9 26
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD FEB
PY 2008
VL 8
IS 2
BP 386
EP 395
DI 10.1111/j.1600-6143.2007.02056.x
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 252DD
UT WOS:000252424300017
PM 18211508
ER

PT J
AU Kyoden, Y
   Tamura, S
   Sugawara, Y
   Yamashiki, N
   Matsui, Y
   Togashi, J
   Kaneko, J
   Kokudo, N
   Makuuchi, M
AF Kyoden, Yusuke
   Tamura, Sumihito
   Sugawara, Yasuhiko
   Yamashiki, Noriyo
   Matsui, Yuichi
   Togashi, Junichi
   Kaneko, Junichi
   Kokudo, Norihiro
   Makuuchi, Masatoshi
TI Outcome of living donor liver transplantation for post-kasai biliary
   atresia in adults
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SINGLE-CENTER EXPERIENCE; EN-Y HEPATICOJEJUNOSTOMY;
   HEPATOCELLULAR-CARCINOMA; HEPATIC VEIN; COMPLICATIONS; LOBE;
   RECONSTRUCTION; GRAFTS; RECIPIENTS; HEPATECTOMY
AB Previous reports described the effectiveness of living donor liver transplantation (LDLT) for post-Kasai biliary atresia (BA) in the pediatric population. Information on the outcome of LDLT in patients that have reached adulthood after the Kasai procedure, however, is limited. A recent report postulated a poorer long-term outcome of LDLT in these adults. We reviewed our experience to evaluate the validity of this hypothesis. Between January 1996 and October 2006, 385 LDLTs were performed at our institution. There were 80 post-Kasai BA cases in the series; 60 (75%) were pediatric, and 20 (25%) were adults. There were no ABO blood type-incompatible cases. None were complicated with severe hepatopulmonary syndrome, portopulmonary hypertension, or hepatocellular carcinoma. The 5-year overall survival rates were 90% for the adults and 90% for the children (P > 0.99). The median follow-up period was 7 years in the adults and 11 years in the children. There was no donor mortality. The outcome of LDLT in adult post-Kasai BA patients in the present series was satisfactory; that is, adult and pediatric patient survival rates were not different. This finding suggests that for post-Kasai BA patients without serious comorbidity at the time of transplantation, LDLT can be performed safely in all age groups.
C1 [Kyoden, Yusuke; Tamura, Sumihito; Sugawara, Yasuhiko; Yamashiki, Noriyo; Matsui, Yuichi; Togashi, Junichi; Kaneko, Junichi; Kokudo, Norihiro; Makuuchi, Masatoshi] Univ Tokyo, Grad Sch Med, Dept Surg & Organ Transplantat Serv, Artificial Organ & Transplantat Div, Tokyo 113, Japan.
RP Sugawara, Y (reprint author), Univ Tokyo, Grad Sch Med, Dept Surg, Artificial Organ & Transplantat Div,Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.
EM yasusugatky@yahoo.co.jp
RI 幕内, 雅敏/A-2140-2012
CR Balistreri WF, 1996, HEPATOLOGY, V23, P1682, DOI 10.1002/hep.510230652
   Barshes NR, 2005, TRANSPLANTATION, V80, P1161, DOI 10.1097/01.tp.0000165717.23652.09
   Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Colledan M, 2005, TRANSPLANT P, V37, P1153, DOI 10.1016/j.transproceed.2004.11.031
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Dulundu E, 2004, TRANSPLANTATION, V78, P574, DOI 10.1097/01.TP.0000128912.09581.46
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Fan ST, 2002, ANN SURG, V236, P676, DOI 10.1097/01.SLA.0000033323.01380.AC
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Gondolesi GE, 2004, ANN SURG, V239, P142, DOI 10.1097/01.sla.0000109022.32391.eb
   Gondolesi GE, 2004, TRANSPLANTATION, V77, P1842, DOI 10.1097/01.tp.0000123077.78702.0c
   Goss JA, 1996, ANN SURG, V224, P276, DOI 10.1097/00000658-199609000-00004
   Hashimoto T, 2005, TRANSPLANTATION, V79, P920, DOI 10.1097/01.TP.0000155306.76466.FD
   Hays D M, 1981, Curr Probl Surg, V18, P541, DOI 10.1016/S0011-3840(81)80016-0
   Imamura H, 2004, LIVER TRANSPLANT, V10, P771, DOI 10.1002/lt.20158
   Kaneko J, 2005, CLIN TRANSPLANT, V19, P804, DOI 10.1111/j.1399-0012.2005.00425.x
   Kasahara M, 2006, ANN SURG, V243, P559, DOI 10.1097/01.sla.0000206419.65678.2e
   Kasai M, 1968, J PEDIATR SURG, V3, P655
   KASAI M, 1989, J PEDIATR SURG, V24, P851, DOI 10.1016/S0022-3468(89)80580-9
   Kawachi S, 2002, SURGERY, V132, P48, DOI 10.1067/msy.2002.125314
   KAWASAKI S, 1993, HEPATOLOGY, V18, P1115
   Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2
   Kishi Y, 2005, LIVER TRANSPLANT, V11, P101, DOI 10.1012/lt.20306
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Kobayashi Hiroyuki, 2003, Semin Neonatol, V8, P383, DOI 10.1016/S1084-2756(03)00065-4
   Kokudo N, 2003, TRANSPLANTATION, V76, P803, DOI 10.1097/01.TP.0000080982.03297.A7
   Kokudo N, 2005, AM J TRANSPLANT, V5, P1694, DOI 10.1111/j.1600-6143.2005.00917.x
   LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793
   Liu CL, 2005, J HEPATOL, V43, P17, DOI 10.1016/j.jhep.2005.05.003
   Lo CM, 1997, ANN SURG, V226, P261, DOI 10.1097/00000658-199709000-00005
   Lykavieris P, 2005, HEPATOLOGY, V41, P366, DOI 10.1002/hep.20547
   MAKUUCHI M, 1993, SURGERY, V113, P395
   [Anonymous], 1984, HEPATOLOGY, V4, p107S
   Nio M, 2003, J PEDIATR SURG, V38, P997, DOI 10.1016/S0022-3468(03)00178-7
   OTTE JB, 1994, HEPATOLOGY, V20, P415
   RAIA S, 1989, LANCET, V2, P497
   RYCKMAN F, 1993, J PEDIATR SURG, V28, P382
   Schiffer E, 2006, AM J TRANSPLANT, V6, P1430, DOI 10.1111/j.1600-6143.2006.01334.x
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Sugawara Y, 2002, CLIN TRANSPLANT, V16, P102, DOI 10.1034/j.1399-0012.2002.1o106.x
   Sugawara Y, 2002, TRANSPLANTATION, V73, P111, DOI 10.1097/00007890-200201150-00021
   Sugawara Y, 2003, LIVER TRANSPLANT, V9, P306, DOI 10.1053/jlts.2003.50021
   Sugawara Y, 2004, LIVER TRANSPLANT, V10, P541, DOI 10.1002/lt.20129
   Takada Y, 2006, LIVER TRANSPLANT, V12, P912, DOI 10.1002/lt.20642
   Takayama T, 2000, J AM COLL SURGEONS, V190, P635, DOI 10.1016/S1072-7515(00)00255-6
   Takemura N, 2005, LIVER TRANSPLANT, V11, P356, DOI 10.1002/lt.20374
   Tamura S, 2004, TRANSPLANT P, V36, P3242, DOI 10.1016/j.transproceed.2004.11.096
   Tamura S, 2006, TRANSPLANT INT, V19, P982, DOI 10.1111/j.1432-2277.2006.00375.x
   Tanaka Koichi, 2002, J Hepatobiliary Pancreat Surg, V9, P218, DOI 10.1007/s005340200022
   Testa G, 2000, LIVER TRANSPLANT, V6, P710, DOI 10.1053/jlts.2000.18706
   Todo S, 2004, ANN SURG, V240, P451, DOI 10.1097/01.sla.0000137129.98894.42
   Todo S, 2005, J HEPATOL, V43, P22, DOI 10.1016/j.jhep.2005.05.004
   Trotter JF, 2006, LIVER TRANSPLANT, V12, P1485, DOI 10.1002/lt.20875
   Trotter JF, 2002, NEW ENGL J MED, V346, P1074, DOI 10.1056/NEJMra011629
   Uchida Y, 2006, AM J TRANSPLANT, V6, P2443, DOI 10.1111/j.1600-6143.2006.01487.x
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5
   Yamashiki N, 2006, LIVER TRANSPLANT, V12, P1077, DOI 10.1002/lt.20759
NR 61
TC 8
Z9 11
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2008
VL 14
IS 2
BP 186
EP 192
DI 10.1002/lt.21344
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 260WA
UT WOS:000253039900012
PM 18236393
ER

PT J
AU Venkat, VL
   Nick, TG
   Bucuvalas, JC
   Wang, Y
AF Venkat, Veena L.
   Nick, Todd G.
   Bucuvalas, John C.
   Wang, Yu
TI An objective measure to identify pediatric liver transplant recipients
   at risk for late allograft rejection related to non-adherence
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; rejection; complications of liver
   transplantation
ID MEDICATION; TACROLIMUS; ADHERENCE; PHARMACOKINETICS; NONCOMPLIANCE;
   THERAPY
AB Non-adherence to a prescribed immunosuppressive regimen increases risk for late allograft rejection (LAR). We implemented a protocol for immunosuppression management which decreased variation in calcineurin inhibitor blood levels in pediatric liver transplant recipients by controlling for confounders such as physician practice variability. We hypothesized that patients with increased variation in tacrolimus blood levels despite implementation of the immunosuppression management protocol were at increased risk for LAR. We conducted a single center retrospective cohort study of 101 pediatric liver transplant recipients who were at least one year post liver transplantation and receiving tacrolimus for immunosuppression. The primary outcome variable was biopsy proven allograft rejection. Primary candidate predictor variables were the standard deviation (SD) of tacrolimus blood levels (a marker of drug level variability), mean tacrolimus blood level, age, and insurance type. SD of tacrolimus blood levels was determined for each patient from a minimum of four outpatient levels during the study period. Unadjusted and adjusted logistic regression models were used to determine the prognostic value of candidate predictors. The median and interquartile range of the SD of tacrolimus blood levels was 1.6 (1.1, 2.1). Eleven episodes of LAR occurred during the study period. Ten of the 11 episodes occurred in patients with tacrolimus blood level SD > 2. Insurance type, mean tacrolimus blood level and SD of tacrolimus blood levels were significantly related to LAR in the unadjusted analyses (p < 0.05). A multivariable model including age, insurance type, mean and SD of tacrolimus blood levels was significantly associated with LAR (validated C-statistic = 0.88, p = 0.012). The adjusted odds of rejection for a one unit increase in the SD of tacrolimus blood level was 3.49 (95% CI 1.31 to 9.29). Effects of age and insurance status on LAR did not provide independent prognostic value after controlling for SD. Variation in tacrolimus blood levels is associated with an increased risk of LAR in pediatric liver transplant recipients. Despite standardized management of tacrolimus levels to control for confounders, some patients were found to have significant variability of tacrolimus blood levels. This may be due to non-adherence and amenable to targeted psychosocial and behavioral interventions to prevent LAR.
C1 [Venkat, Veena L.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Dept Pediat,Div Pediat Gastroenterol, Pittsburgh, PA USA.
   [Nick, Todd G.] Univ Cincinnati, Coll Med,Cincinnati Childrens Hosp, Med Ctr,Dept Pediat, Ctr Biostat & Epidemiol, Cincinnati, OH 45221 USA.
   [Wang, Yu] Cincinnati Childrens Hosp Med Ctr, Pediat Liver Care Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA.
RP Venkat, VL (reprint author), Childrens Hosp Pittsburgh, Div Gastroenterol, 3705 5th Ave, Pittsburgh, PA 15213 USA.
EM veenasvenkat@hotmail.com
CR ANAND AC, 1995, TRANSPLANTATION, V60, P1098, DOI 10.1097/00007890-199511270-00007
   Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9
   Bucuvalas JC, 2005, J PEDIATR-US, V146, P744, DOI 10.1016/j.jpeds.2005.01.036
   Chisholm MA, 2002, CLIN TRANSPLANT, V16, P30, DOI 10.1034/j.1399-0012.2002.00104.x
   D'Antiga L, 2002, TRANSPLANTATION, V73, P80, DOI 10.1097/00007890-200201150-00015
   Falkenstein K, 2004, PEDIATR TRANSPLANT, V8, P233, DOI 10.1111/j.1399-3046.2004.00136.x
   Mittal N, 2001, PEDIATR TRANSPLANT, V5, P75, DOI 10.1034/j.1399-3046.2001.005002075.x
   Molmenti E, 1999, TRANSPLANT P, V31, P408, DOI 10.1016/S0041-1345(98)01682-0
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Ramji A, 2002, LIVER TRANSPLANT, V8, P945, DOI 10.1053/jlts.2002.34969
   Sabate E, 2003, ADHERENCE LONG TERM
   Sellers M, 1997, TRANSPLANT P, V29, P428, DOI 10.1016/S0041-1345(96)00165-0
   Shemesh E, 2004, PEDIATRICS, V113, P825, DOI 10.1542/peds.113.4.825
   Staatz CE, 2004, CLIN PHARMACOKINET, V43, P623, DOI 10.2165/00003088-200443100-00001
   Sudan DL, 1998, ANN SURG, V227, P289, DOI 10.1097/00000658-199802000-00020
   Utecht KN, 2006, AM J HEALTH-SYST PH, V63, P2340, DOI 10.2146/ajhp060080
   van Gelder T, 2002, DRUG SAFETY, V25, P707, DOI 10.2165/00002018-200225100-00003
   Wiesner RH, 2006, AM J TRANSPLANT, V6, P1609, DOI 10.1111/j.1600-6143.2006.01382.x
NR 18
TC 32
Z9 33
U1 0
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2008
VL 12
IS 1
BP 67
EP 72
DI 10.1111/j.1399-3046.2007.00794.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 247ZX
UT WOS:000252122200012
PM 18186891
ER

PT J
AU Maksoud-Filho, JG
   Tannuri, U
   Gibelli, NEM
   de Pinho-Appezzato, ML
   da Silva, MM
   Ayoub, AAR
   Santos, MM
   Velhote, MCP
   de Mello, ES
   Maksoud, JG
AF Maksoud-Filho, Joao Gilberto
   Tannuri, Uenis
   Gibelli, Nelson Elias Mendes
   de Pinho-Appezzato, Maria Lucia
   da Silva, Marcos Marques
   Ayoub, Ali Abdoul Rahman
   Santos, Maria Merces
   Velhote, Manoel Carlos Prieto
   de Mello, Eduardo Sobrosa
   Maksoud, Joao Gilberto
TI Intimal dissection of the hepatic artery after thrombectomy as a cause
   of graft loss in pediatric living-related liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pediatrics; living donor; hepatic artery
   thrombosis; revascularization; thrombectomy; intimal dissection
ID BALLOON-CATHETER; THROMBOSIS; RECONSTRUCTION; REVASCULARIZATION;
   COMPLICATION; EMBOLECTOMY; OCCLUSION; DONORS
AB HAT is the main cause of graft loss in pediatric living-related LTx. Revascularization of the graft by thrombectomy and re-anastomosis has been reported to be effective for graft salvage in cases of HAT and should be attempted when potential donors are not available for emergency re-transplantation. Immediate complications secondary to revascularization attempts in cases of HAT are not described. Late complications are mainly related to biliary tree ischemia. We report a case of child who experienced intimal hepatic artery dissection, which extended into intra-hepatic branches of the artery after a thrombectomy with a Fogarty balloon catheter in an attempt to restore arterial flow after HAT. This complication led to acute deterioration of the graft and the need for emergency re-transplantation.
C1 [Maksoud-Filho, Joao Gilberto; Tannuri, Uenis; Gibelli, Nelson Elias Mendes; de Pinho-Appezzato, Maria Lucia; da Silva, Marcos Marques; Ayoub, Ali Abdoul Rahman; Santos, Maria Merces; Velhote, Manoel Carlos Prieto; de Mello, Eduardo Sobrosa; Maksoud, Joao Gilberto] Univ Sao Paulo, Sch Med, Inst Crianca, Pediat Liver Transplantat Serv, Sao Paulo, Brazil.
RP Maksoud-Filho, JG (reprint author), Av Dr Arnaldo 455,Rm 4109, BR-01246903 Sao Paulo, Brazil.
EM maksoudf@icr.hcnet.usp.br
RI Tannuri, Uenis/D-3876-2012
CR [Anonymous], 1988, J VASC SURG
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   FIGUERAS J, 1995, TRANSPLANTATION, V59, P1356
   FUGIMOTO M, 1997, CLIN TRANSPLANT, V11, P380
   GARCIAVALDECASAS JC, 1990, TRANSPLANT P, V22, P2376
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   HIDALGO EG, 1989, HEPATO-GASTROENTEROL, V36, P529
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   INOMOTO T, 1995, TRANSPLANTATION, V60, P881, DOI 10.1097/00007890-199510270-00022
   JORGENSEN RA, 1983, SURGERY, V93, P798
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   KATZ E, 1992, TRANSPLANTATION, V53, P1373
   KLINTMALM GB, 1988, TRANSPLANT P, V20, P610
   LAGANS AN, 1991, TRANSPLANTATION, V51, P86
   MASUAOKAS S, 1980, J CARDIOVASC SURG, V210, P67
   MCGURRIN MA, 1991, ARCH SURG-CHICAGO, V126, P786
   MILLER DL, 1984, CARDIOVASC INTER RAD, V7, P214, DOI 10.1007/BF02553136
   Nakatsuka T, 1999, TRANSPLANTATION, V67, P1490, DOI 10.1097/00007890-199906150-00019
   NEVELSTEEN A, 1987, ACTA CHIR BELG, V87, P300
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   Sakamoto Y, 1999, BRIT J SURG, V86, P886, DOI 10.1046/j.1365-2168.1999.01166.x
   SCHWEITZER D L, 1976, Vascular Surgery, V10, P144, DOI 10.1177/153857447601000305
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   Taniai N, 2002, HEPATO-GASTROENTEROL, V49, P1420
   Tannuri U, 2006, PEDIATR TRANSPLANT, V10, P101, DOI 10.1111/j.1399-3046.2005.00392.x
   TSAKIS AG, 1995, TRANSPLANTATION, V40, P667
   UCHIYAMA H, 2002, SURGERY, V131, pS300
   Yoong K F, 1998, Transpl Int, V11 Suppl 1, pS221
NR 29
TC 2
Z9 2
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2008
VL 12
IS 1
BP 91
EP 94
DI 10.1111/j.1399-3046.2006.00656.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 247ZX
UT WOS:000252122200016
PM 18186894
ER

PT J
AU Valta, H
   Jalanko, H
   Holmberg, C
   Helenius, I
   Makitie, O
AF Valta, H.
   Jalanko, H.
   Holmberg, C.
   Helenius, I.
   Makitie, O.
TI Impaired bone health in adolescents after liver transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE adolescence; bone mineral density; corticosteroids; osteoporosis;
   pediatric liver transplantation
ID SOLID-ORGAN TRANSPLANTATION; LONG-TERM SURVIVORS; MINERAL DENSITY;
   LUMBAR SPINE; CHILDREN; FRACTURES; OSTEOPOROSIS; RECIPIENTS; DISEASE;
   GROWTH
AB Long-term complications related to immunosuppressive medication are an important problem after liver transplantation (OLT). This study was carried out to evaluate the bone health and risk factors for osteoporosis and fractures in 40 pediatric liver transplant recipients. The results of 208 longitudinal bone mineral density (BMD) measurements were analyzed retrospectively. In addition, a dual-energy X-ray absorptiometry was performed to assess the bone mineral content more precisely and to detect subclinical vertebral fractures (VF). The median age of the patients was 14 years and mean postoperative follow-up 7.0 years. The results showed that over half (58%) had lumbar spine (LS) Z-score <=-1.0 and one-fifth (18%) had asymptomatic VF. LS Z-score tended to increase from the first year after OLT, but during puberty the bone mass gain was suboptimal and Z-scores decreased in some subjects. Patients with VF were older at the time of OLT (p = 0.002) and their LS Z-score was lower (p = 0.001). Children transplanted before 10 years of age had less VF (p = 0.004) and higher LS Z-score (p = 0.005) than older patients. In conclusion, adolescent liver recipients are prone to osteoporosis and prevention should be targeted especially to this age group.
C1 [Makitie, O.] Univ Helsinki, Hosp Children & Adolescents, Metab Bone Clin, FIN-00014 Helsinki, Finland.
   [Valta, H.; Jalanko, H.; Holmberg, C.] Univ Helsinki, Hosp Children & Adolescents, Dept Pediat Nephrol & Transplantat, FIN-00014 Helsinki, Finland.
   [Helenius, I.] Univ Helsinki, Hosp Children & Adolescents, Dept Pediat Surg, FIN-00014 Helsinki, Finland.
RP Makitie, O (reprint author), Univ Helsinki, Hosp Children & Adolescents, Metab Bone Clin, FIN-00014 Helsinki, Finland.
EM outi.makitie@helsinki.fi
OI Makitie, Outi/0000-0002-4547-001X
CR Adeback P, 2003, PEDIATR TRANSPLANT, V7, P385, DOI 10.1034/j.1399-3046.2003.00081.x
   ARGAO EA, 1994, HEPATOLOGY, V20, P598, DOI 10.1016/0270-9139(94)90093-0
   Bailey DA, 1999, J BONE MINER RES, V14, P1672, DOI 10.1359/jbmr.1999.14.10.1672
   Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Bjoro K, 2003, SCAND J GASTROENTERO, V38, P320, DOI 10.1080/00365520310000681
   BRYER HP, 1995, J BONE MINER RES, V10, P132
   Campbell KM, 2006, J PEDIATR-US, V148, P475, DOI 10.1016/j.jpeds.200S
   Canalis E, 2001, J CLIN ENDOCR METAB, V86, P5681, DOI 10.1210/jc.86.12.5681
   Crosbie OM, 1999, GUT, V44, P430
   D'Antiga L, 2004, TRANSPLANTATION, V78, P899, DOI 10.1097/01.TP.0000136987.38729.C0
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Dissanayake IR, 1998, TRANSPLANTATION, V65, P275
   Epstein S, 1996, J BONE MINER RES, V11, P1
   Goulding A, 2000, J BONE MINER RES, V15, P2011, DOI 10.1359/jbmr.2000.15.10.2011
   Greulich WW, 1959, RADIOGRAPHIC ATLAS S
   GUICHELAAR, 2006, LIVER TRANSPL, V12, P1390
   GUICHELAAR MM, 2004, LIVER TRANSPLANT, V40, P638
   Guthery SL, 2003, LIVER TRANSPLANT, V9, P365, DOI 10.1053/jlts.2003.50071
   Hamburg SM, 2000, OSTEOPOROSIS INT, V11, P600, DOI 10.1007/s001980070081
   Hardinger KL, 2003, LIVER TRANSPLANT, V9, P857, DOI 10.1053/jlts.2003.50135
   Helenius I, 2006, AM J TRANSPLANT, V6, P324, DOI 10.1111/j.1600-6143.2005.01135.x
   Helenius I, 2006, J BONE MINER RES, V21, P380, DOI 10.1359/JBMR.051107
   Helenius I, 2006, SPINE, V31, P2130, DOI 10.1097/01.brs.0000231717.63974.f3
   Hill SA, 1995, PEDIATR RADIOL, V25, pS112
   Hogler W, 2003, J PEDIATR-US, V143, P81, DOI 10.1016/S0022-3476(03)00187-2
   KARLSSON KM, 2003, SPINE, V28, P2087
   Kayler LK, 2002, PEDIATR TRANSPLANT, V6, P295, DOI 10.1034/j.1399-3046.2002.02009.x
   Kuczmarski RJ, 2000, ADV DATA, V1, P27
   Leidig-Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140-6736(00)03641-2
   Makitie O, 2005, J PEDIATR-US, V146, P395, DOI 10.1016/j.jpeds.2004.10.052
   MEYS E, 1994, AM J MED, V97, P445, DOI 10.1016/0002-9343(94)90324-7
   Ninkovic M, 2000, EUR J GASTROEN HEPAT, V12, P931, DOI 10.1097/00042737-200012080-00013
   Okajima H, 2003, LIVER TRANSPLANT, V9, P360, DOI 10.1005/jlts.2001.50038
   Pere A, 2000, ANN HUM BIOL, V27, P35, DOI 10.1080/030144600282361
   Qvist E, 2003, PEDIATR CLIN N AM, V50, P1505, DOI 10.1016/S0031-3955(03)00128-7
   Ramsey-Goldman R, 1999, J BONE MINER RES, V14, P456, DOI 10.1359/jbmr.1999.14.3.456
   Renz JF, 2001, LIVER TRANSPLANT, V7, P1040, DOI 10.1053/jlts.2001.29413
   ROMERO DF, 1995, J BONE MINER RES, V10, P760
   Sochett EB, 2005, ANN MED, V37, P286, DOI 10.1080/07583890510007250
   SORVA R, 1990, ACTA PAEDIATR SCAND, V79, P498, DOI 10.1111/j.1651-2227.1990.tb11503.x
   Tanner JM, 1962, GROWTH ADOLESCENCE, P32
   THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060
NR 42
TC 25
Z9 25
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JAN
PY 2008
VL 8
IS 1
BP 150
EP 157
DI 10.1111/j.1600-6143.2007.02015.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 244IK
UT WOS:000251859400023
PM 17973968
ER

PT J
AU Schubert, S
   Renner, C
   Hammer, M
   Abdul-Khatiq, H
   Lehmkuhl, HB
   Berger, F
   Hetzer, R
   Reinke, P
AF Schubert, Stephan
   Renner, Christiane
   Hammer, Markus
   Abdul-Khatiq, Hashim
   Lehmkuhl, Hans Brendan
   Berger, Felix
   Hetzer, Roland
   Reinke, Petra
TI Relationship of immunosuppression to Epstein-Barr viral load and
   lymphoproliferative disease in pediatric heart transplant patients
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
ID STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; VIRUS INFECTION;
   LIVER-TRANSPLANTATION; DISORDER PTLD; RECIPIENTS; EXPERIENCE; RISK;
   CHILDREN; BLOOD
AB Background: Post-transplant lymphoproliferative disease (PTLD) is a severe complication in transplant recipients. Detection of increased Epstein-Barr viral (EBV) load in the peripheral blood acts as a surrogate marker for increased risk,of PTLD development. We prospectively monitored EBV load, immunosuppression and PTLD in pediatric heart transplant (HTx) patients to determine risk factors for an increased EBV load and risk of PTLD.
   Methods: Forty-one pediatric heart transplant recipients were included and under-went prospective monitoring of their immunosuppression and ethylene-diamine tetraacetic acid (EDTA) blood sampling for EBV load (copies/mu g DNA) measurement using quantitative real-time polymerase chain reaction (PCR; TaqMan) during January 2001 to December 2006.
   Results: EBV load was measurable in 70% and was significantly increased (>2,000 copies/mu g DNA) in 35% of the patients, with a median EBV load of 5,100 (range 0 to 50,665 copies/mu g DNA). Increased EBV load was detected in patients receiving CsA-azathioprine or more than two doses of anti-thymocyte globutin (ATG) and in those <10 years of age, without any significant differences in CsA blood levels. Lowest or negative EBV load was measured in patients receiving CsA-mycophenolate mofetil (MMF) or CsA only. CsA blood levels were not predictable for increased EBV load or PTLD. Six patients developed a EBV-associated B-cell lymphoma (PTLD), among whom 4 (67%) were receiving CsA-azathioprine.
   Conclusions: Frequent EBV load monitoring identifies patients at high risk for PTLD development. Azathioprine and ATG are major risk factors for increased EBV load and PTLD and patients may benefit from a change of immunosuppression in addition to pre-emptive anti-viral or anti-tumor strategies.
C1 [Schubert, Stephan; Renner, Christiane; Abdul-Khatiq, Hashim; Berger, Felix] Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects Pediat Cardiol, D-13353 Berlin, Germany.
   [Hammer, Markus; Reinke, Petra] Charite Univ Med Berlin, Dept Nephrol & Intens Care, Berlin, Germany.
   [Lehmkuhl, Hans Brendan] Deutsch Herzzentrum Berlin, Dept Internal Med Cardiol, D-13353 Berlin, Germany.
   [Hetzer, Roland] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, D-13353 Berlin, Germany.
RP Schubert, S (reprint author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Defects Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM sschubert@dhzb.de
CR Aalto SM, 1998, J MED VIROL, V56, P186, DOI 10.1002/(SICI)1096-9071(199811)56:3<186::AID-JMV2>3.0.CO;2-3
   Ault BH, 2002, PEDIATR NEPHROL, V17, P815, DOI 10.1007/s00467-002-0942-y
   Benden C, 2005, J HEART LUNG TRANSPL, V24, P2103, DOI 10.1016/j.healun.2005.06.014
   Cao S, 1998, TRANSPLANTATION, V66, P851, DOI 10.1097/00007890-199810150-00007
   Cohen AH, 2000, AM J RESP CRIT CARE, V161, P1252
   Dharnidharka VR, 2001, TRANSPLANTATION, V71, P1065, DOI 10.1097/00007890-200104270-00010
   Dror Y, 1999, TRANSPLANTATION, V67, P990, DOI 10.1097/00007890-199904150-00010
   Ganschow R, 2004, J PEDIATR GASTR NUTR, V38, P198, DOI 10.1097/00005176-200402000-00018
   Halkos ME, 2004, CHEST, V126, P2013, DOI 10.1378/chest.126.6.2013
   Juvonen E, 2003, BONE MARROW TRANSPL, V32, P97, DOI 10.1038/sj.bmt.1704089
   Kogan-Liberman D, 2001, J PEDIATR GASTR NUTR, V33, P445, DOI 10.1097/00005176-200110000-00005
   Krieger NR, 2000, LIVER TRANSPLANT, V6, P62, DOI 10.1002/lt.500060102
   LAMY ME, 1990, MED MICROBIOL IMMUN, V179, P137
   Leblond V, 1998, J CLIN ONCOL, V16, P2052
   Lucas KG, 1998, BLOOD, V91, P3654
   Malouf MA, 2002, J HEART LUNG TRANSPL, V21, P547, DOI 10.1016/S1053-2498(01)00407-7
   Merlino C, 2001, New Microbiol, V24, P223
   Micallef INM, 1998, BONE MARROW TRANSPL, V22, P981, DOI 10.1038/sj.bmt.1701468
   Nalesnik M A, 1997, Ann Transplant, V2, P33
   Nalesnik M A, 2001, Transpl Infect Dis, V3, P88, DOI 10.1034/j.1399-3062.2001.003002088.x
   Nalesnik M A, 1996, Semin Thorac Cardiovasc Surg, V8, P139
   Nalesnik Michael A, 2002, Recent Results Cancer Res, V159, P9
   Newell KA, 1996, TRANSPLANTATION, V62, P370, DOI 10.1097/00007890-199608150-00012
   Orentas RJ, 2003, PEDIATR TRANSPLANT, V7, P305, DOI 10.1034/j.1399-3046.2003.00090.x
   Raj R, 2005, J HEART LUNG TRANSPL, V24, P671, DOI 10.1016/j.healun.2004.04.011
   Ross M, 2006, J HEART LUNG TRANSPL, V25, P261, DOI 10.1016/j.healun.2005.09.011
   Savoldo B, 2005, AM J TRANSPLANT, V5, P566, DOI 10.1111/j.1600-6143.2004.00693.x
   Scheenstra R, 2004, Transpl Infect Dis, V6, P15, DOI 10.1111/j.1399-3062.2004.00044.x
   Seidel MG, 2005, J PEDIAT HEMATOL ONC, V27, P532, DOI 10.1097/01.mph.0000184575.00717.25
   Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165
   Trofe J, 2005, AM J TRANSPLANT, V5, P775, DOI 10.1111/j.1600-6143.2005.00776.x
   Zangwill SD, 1998, J HEART LUNG TRANSPL, V17, P1161
NR 32
TC 47
Z9 49
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JAN
PY 2008
VL 27
IS 1
BP 100
EP 105
DI 10.1016/j.healun.2007.09.027
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA 253IW
UT WOS:000252512900016
PM 18187094
ER

PT J
AU Manzoni, D
   D'Ercole, C
   Spotti, A
   Carrara, B
   Sonzogni, V
AF Manzoni, Diego
   D'Ercole, Carlo
   Spotti, Angelica
   Carrara, Bruno
   Sonzogni, Valter
TI Congenital heart disease and pediatric liver transplantation:
   Complications and outcome
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE congenital heart disease; pediatric liver transplantation;
   complications; outcome
ID HEPATIC-ARTERY THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;
   ALAGILLE-SYNDROME; BILIARY ATRESIA; HEMATOCRIT; CHILDREN; PATIENT
AB Mild and moderate CHD in infants do not always need surgical correction but possibly augment the operative risk of patients with ESLD undergoing OLT. The aim of this study is to assess the intraoperative and post-operative complications and evaluate the outcome of these patients. The records of 196 patients were reviewed retrospectively in a cohort study, 50 CHD were found in 36 patients undergoing 41 OLT procedures. The prevalence of CHD during pediatric OLT was 18%. Our data identified no significant differences between the two groups of patients, regarding hypotension, desaturation, acidosis, and bleeding during the procedure. Post-operatively, no differences were observed in the hemodynamic, respiratory, and renal systems as no differences were detected for graft failure, surgical complications, infection, and rejection rates. Mortality is comparable in the two groups as are re-transplantation and recovery rates. The above mentioned results indicate that minor cardiac defects do not significantly influence the operative risk of these patients.
C1 Osped Riuniti Bergamo, Dept Anaesthesia & Intens Care 1, I-24100 Bergamo, Italy.
RP Manzoni, D (reprint author), Osped Riuniti Bergamo, Dept Anaesthesia & Intens Care 1, Largo Barozzi 1, I-24100 Bergamo, Italy.
EM diegomanzoni@libero.it
CR Adachi T, 1999, BRIT J ANAESTH, V83, P488
   AGGARWAL S, 1987, TRANSPLANT P, V19, P54
   BUCKELS JAC, 1989, TRANSPLANT P, V21, P2460
   De Wolfe A, 1999, LIVER TRANSPLANT SUR, V5, P339, DOI 10.1002/lt.500050408
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Englert C, 2006, PEDIATR TRANSPLANT, V10, P154, DOI 10.1111/j.1399-3046.2005.00432.x
   Feierman DE, 2006, PEDIATR ANESTH, V16, P669, DOI 10.1111/j.1460-9592.2005.01823.x
   Fischler B, 2002, J PEDIATR-US, V141, P217, DOI 10.1067/mpd.2002.126001
   FUKUZAWA K, 1994, J AM COLL SURGEONS, V178, P541
   Heffron TG, 2003, TRANSPLANT P, V35, P1447, DOI 10.1016/S0041-1345(03)00459-7
   HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907
   MARINO IR, 1992, TRANSPLANT INT, V5, P61
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Peeters PMJG, 2001, EUR J PEDIATR SURG, V11, P28, DOI 10.1055/s-2001-12188
   Suriani RJ, 1996, J CARDIOTHOR VASC AN, V10, P699, DOI 10.1016/S1053-0770(96)80193-5
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
   TISONE G, 1988, TRANSPLANTATION, V46, P162, DOI 10.1097/00007890-198807000-00032
NR 18
TC 5
Z9 5
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2007
VL 11
IS 8
BP 876
EP 881
DI 10.1111/j.1399-3046.2007.00755.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 225LT
UT WOS:000250520100007
PM 17976122
ER

PT J
AU Stelzmueller, I
   Wiesmayr, S
   Swenson, BR
   Biebl, M
   Goegele, H
   Margreiter, R
   Bonatti, H
AF Stelzmueller, I.
   Wiesmayr, S.
   Swenson, B. R.
   Biebl, M.
   Goegele, H.
   Margreiter, R.
   Bonatti, H.
TI Rotavirus enteritis in solid organ transplant recipients: an
   underestimated problem?
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE diarrhea; rotavirus; solid organ transplantation; liver recipients
ID GASTROINTESTINAL INFECTIONS; PROPHYLAXIS; PREVENTION; CHILDREN; ILLNESS;
   DISEASE
AB Background. Diarrhea in solid organ transplantation can be a complication with a high morbidity and mortality. Rotavirus (RV) infection normally occurs in children up to 3 years of age and often presents with severe diarrhea; however, it can also affect adults. We investigated the prevalence and outcome of RV infections in both adult and pediatric patients after solid organ transplantation.
   Patients and methods. Retrospective analysis of RV-related enteritis in solid organ transplant recipients with a minimum of a 1-year follow-up from a single center between 2000 and 2004.
   Results. Within our cohort of 1303 solid organ transplants, RV infection was observed in 19 patients (1.5%); 14 of these were liver recipients. Infection was most prevalent among pediatric liver recipients, with 52% (11/21) of the children affected. Five adults acquired the infection during their initial hospitalization. Two adult patients had to be readmitted following late-onset RV infection. In all cases, infection was self-limiting, but led to prolonged hospitalization because of significant loss of fluids and electrolytes.
   Conclusions. RV enteritis is a common infection in pediatric solid organ recipients but may also affect adult patients.
C1 Univ Virginia Hlth Syst, Dept Surg, Div Transplant Surg, Charlottesville, VA 22908 USA.
   Univ Innsbruck Hosp, Dept Gen & Transplant Surg, A-6020 Innsbruck, Austria.
   Univ Innsbruck Hosp, Dept Pediat, A-6020 Innsbruck, Austria.
RP Bonatti, H (reprint author), Univ Virginia Hlth Syst, Dept Surg, Div Transplant Surg, 1215 Lee St, Charlottesville, VA 22908 USA.
EM hugo.bonatti@dr.com
CR Baden LR, 2001, INFECT DIS CLIN N AM, V15, P639, DOI 10.1016/S0891-5520(05)70163-X
   Bresee JS, 2005, PEDIATR INFECT DIS J, V24, P947, DOI 10.1097/01.inf.0000186295.18969.e6
   Cocchi S, 2006, DIGEST LIVER DIS, V38, P429, DOI 10.1016/j.dld.2005.07.005
   Farthing MJG, 2001, NOVART FDN SYMP, V238, P289
   Forrest G, 2004, CURR OPIN GASTROEN, V20, P16, DOI 10.1097/00001574-200401000-00005
   GINSBURG PM, 2006, LIVER TRANSPLANT, V12, P163
   HABER P, 2004, PEDIATRICS, V113, P353
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   Liakopoulou E, 2005, BONE MARROW TRANSPL, V36, P691, DOI 10.1038/sj.bmt.1705127
   Marty FM, 2006, TRANSPLANT INT, V19, P2, DOI 10.1111/j.1432-2277.2005.00218.x
   Parashar UD, 2003, EMERG INFECT DIS, V9, P565
   Parashar UD, 2006, EMERG INFECT DIS, V12, P304
   Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1
   PEIGUELAFEUILLE H, 1991, J HOSP INFECT, V18, P67, DOI 10.1016/0195-6701(91)90095-P
   Soave R, 2001, CLIN INFECT DIS, V33, pS26, DOI 10.1086/320901
   Soriano-Gabarro M, 2006, PEDIATR INFECT DIS J, V25, pS7, DOI 10.1097/01.inf.000197622.98559.01
   Stelzmueller I, 2005, TRANSPLANT INT, V18, P470, DOI 10.1111/j.1432-2277.2004.00073.x
   STELZMUELLER I, 2006, LIVER TRANSPLANT, V2, P163
   Villacian J S, 1999, Transpl Infect Dis, V1, P50, DOI 10.1034/j.1399-3062.1999.10106.x
NR 19
TC 21
Z9 23
U1 1
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD DEC
PY 2007
VL 9
IS 4
BP 281
EP 285
DI 10.1111/j.1399-3062.2007.00251.x
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 227IF
UT WOS:000250649700005
PM 17605739
ER

PT J
AU Fang, BJ
   Song, YP
   Lin, QD
   Zhang, YL
   Cao, Y
   Zhao, RCH
   Ma, YF
AF Fang, Baijun
   Song, Yongping
   Lin, Quande
   Zhang, Yanli
   Cao, Ying
   Zhao, Robert Chunhua
   Ma, Yuanfang
TI Human adipose tissue-derived mesenchymal stromal cells as salvage
   therapy for treatment of severe refractory acute graft-vs.-host disease
   in two children
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hematopoietic stem cell transplantation; graft-vs.-host disease;
   mesenchymal stromal cell; adipose tissue
ID ANTI-THYMOCYTE GLOBULIN; STEM-CELLS; RESISTANT ACUTE; IN-VITRO; BONE;
   VIVO; TRANSPLANTATION; DACLIZUMAB; INFUSION
AB Severe GVHD is a lethal complication to ASCT, and a number of approaches are therefore being evaluated. Recently, Le Blanc et al. reported a case of grade IV therapy-resistant acute GVHD of the gut and liver that showed rapid improvement after infusion of mesenchymal stem cells. Here we describe two pediatric patients who developed severe refractory acute GVHD following ASCT and were successfully treated with AMSC from HLA-mismatched unrelated donors.
C1 Henan Tumor Hosp, Inst Haematol, Zhengzhou 450008, Peoples R China.
   Chinese Acad Med Sci, Inst Basic Med Sci, Ctr Excellence Tissue Engn, Beijing 100730, Peoples R China.
   Chinese Acad Med Sci, Sch Basic Med, Beijing 100730, Peoples R China.
   Peking Union Med Coll, Beijing, Peoples R China.
   Henan Univ, Inst Immunol, Cellular & Mol Immunol Lab, Kaifeng, Peoples R China.
RP Song, YP (reprint author), Henan Tumor Hosp, Inst Haematol, 127 Dongming Rd, Zhengzhou 450008, Peoples R China.
EM fdation@126.com
CR Abhyankar S, 1998, BLOOD, V92, p340B
   BACIGALUPO A, 1983, BLUT, V46, P125, DOI 10.1007/BF00320270
   Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X
   Benito AI, 2001, TRANSPLANTATION, V72, P1924, DOI 10.1097/00007890-200112270-00010
   Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121
   Cao Y, 2005, BIOCHEM BIOPH RES CO, V332, P370, DOI 10.1016/j.bbrc.2005.04.135
   Chen X, 2006, IMMUNOL CELL BIOL, V84, P413, DOI 10.1111/j.1440-1711.2006.01458.x
   Deng WM, 2004, EXP HEMATOL, V32, P861, DOI 10.1016/j.exphem.2004.06.009
   Fang B, 2006, BONE MARROW TRANSPL, V38, P389, DOI 10.1038/sj.bmt.1705457
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Khoury H, 2001, BONE MARROW TRANSPL, V27, P1059, DOI 10.1038/sj.bmt.1703032
   Koc ON, 2000, J CLIN ONCOL, V18, P307
   Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Le Blanc K, 2005, BIOL BLOOD MARROW TR, V11, P321, DOI 10.1016/j.bbmt.2005.01.005
   MARTIN PJ, 1991, BLOOD, V77, P1821
   McCaul KG, 2000, J HEMATOTH STEM CELL, V9, P367, DOI 10.1089/15258160050079470
   Przepiorka D, 2000, BLOOD, V95, P83
   Ratanatharathorn V, 2003, BIOL BLOOD MARROW TR, V9, P505, DOI 10.1016/S1083-8791(03)00216-7
   Remberger M, 2001, CLIN TRANSPLANT, V15, P147, DOI 10.1034/j.1399-0012.2001.150301.x
   Ringden O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   WEISDORF D, 1990, BLOOD, V75, P1024
   Wolff D, 2005, BONE MARROW TRANSPL, V35, P1003, DOI 10.1038/sj.bmt.1704929
NR 24
TC 62
Z9 75
U1 0
U2 7
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD NOV
PY 2007
VL 11
IS 7
BP 814
EP 817
DI 10.1111/j.1399-3046.2007.00780.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 217CC
UT WOS:000249925000022
PM 17910665
ER

PT J
AU Pirenne, J
   Aerts, R
   Monbaliu, D
   Coosemans, W
   Vlasselaers, D
   Desmet, L
   Herman, J
   Hoffman, I
   Lombaerts, R
AF Pirenne, J.
   Aerts, R.
   Monbaliu, D.
   Coosemans, W.
   Vlasselaers, D.
   Desmet, L.
   Herman, J.
   Hoffman, I.
   Lombaerts, R.
TI Results of pediatric liver transplantation in an originally adult liver
   transplant program
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 14th Annual Meeting of the Belgian-Transplantation-Society
CY MAR   27, 2006
CL Brussels, BELGIUM
SP Belgian Transplantat Soc
AB Background. It is controversial whether pediatric liver transplantation (OLT) should only be performed in a high-volume pediatric or in mixed adult/pediatric centers. We reviewed pediatric OLT results in an originally adult OLT center.
   Methods/results. Our adult OLT program was initiated in 1989, currently transplanting approximately 55 livers/year. A pediatric OLT program was launched in 1999. Pre- and posttransplant follow-up is multidisciplinary. In the study period, 26 OLT were performed in 25 patients (6% of all OLT; n = 430). The mean age was 8 years (range: I month to 18 years). Mean weight was 22 kg (4 to 80 kg). The indications were: acute liver failure in one (4%); chronic liver failure in 25 (96%)-10 metabolic, six biliary atresia, five polycystic/liver fibrosis, four other, and one retransplant. Nine (35%) received partial graft; 5 (19%) multivisceral grafts (liver-kidney, liver-bowel) and 12 (46%), conventional OLT. In all small-weight children, microsurgery was used. Immunosuppression included calcineurin inhibitors (cyclosporine/tacrolimus), azathioprine/mycophenolate mofetil, low-dose steroid, and anti-interleukin-2 receptor in 14. Early hepatic artery thrombosis (HAT), portal vein thrombosis, and primary nonfunction were not encountered. One retransplantation (4%) was done at 4 years posttransplantation for late HAT. Three biliary complications (11%) were encountered at 2 weeks, 4 months, and 2 years. Percentage of early acute and chronic rejections were 7.7% and 0%. Three deaths occurred due to mycotic aneurysm at 2 weeks; Cytomegalovirus at 4 months; pulmonary infection at 2 years. Twenty-two of 25 patients (88%) are well at last follow-up (up to 8 years).
   Conclusion. Despite representing a small percentage of overall OLT activity pediatric OLT were performed with excellent results in a center with sufficient OLT volume and ad hoc surgical, pediatric, and intensive care team expertise.
C1 Univ Hosp Leuven, Abdominal Transplant Surg Dept, B-3000 Louvain, Belgium.
   Univ Hosp Leuven, Pediat Intens Care Unit, Louvain, Belgium.
RP Pirenne, J (reprint author), Univ Hosp Leuven, Abdominal Transplant Surg Dept, Herestr 49, B-3000 Louvain, Belgium.
EM Jacques.Pirenne@uz.kuleuven.ac.be
CR Bourdeaux C, 2007, AM J TRANSPLANT, V7, P440, DOI 10.1111/j.1600-6143.2006.01626.x
   Burroughs AK, 2006, LANCET, V367, P225, DOI 10.1016/S0140-6736(06)68033-1
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   Pirenne J, 2004, AM J TRANSPLANT, V4, P1921, DOI 10.1111/j.1600-6143.2004.00588.x
   Pirenne J, 2001, PEDIATR TRANSPLANT, V5, P452, DOI 10.1034/j.1399-3046.2001.t01-2-00025.x
   Van Damme-Lombaerts R, 2001, PEDIATR TRANSPLANT, V5, P447, DOI 10.1034/j.1399-3046.2001.t01-1-00008.x
   [Anonymous], 2006, SCAND J GASTROENTE S, DOI DOI 10.1080/00365520600664375
NR 7
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD OCT
PY 2007
VL 39
IS 8
BP 2672
EP 2674
DI 10.1016/j.transproceed.2007.08.005
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 227EJ
UT WOS:000250639700056
PM 17954204
ER

PT J
AU Soltys, KA
   Mazariegos, GV
   Squires, RH
   Sindhi, RK
   Anand, R
AF Soltys, K. A.
   Mazariegos, G. V.
   Squires, R. H.
   Sindhi, R. K.
   Anand, R.
CA SPLIT RES Grp
TI Late graft loss or death in pediatric liver transplantation: An analysis
   of the SPLIT database
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE immunosuppression; infection; long-term outcomes; malignancy; patient
   and graft survival; pediatric liver transplantation
ID LONG-TERM SURVIVAL; SINGLE-CENTER EXPERIENCE; CHRONIC REJECTION;
   RECIPIENTS; TACROLIMUS; MORTALITY; CHILDREN; THERAPY; FAILURE; PATIENT
AB Late graft loss (LGL) and late mortality (LM) following liver transplantation (LT) in children were analyzed from the studies of pediatric liver transplantation (SPLIT) database. Univariate and multivariate associations between pre- and postoperative factors and LGL and LM in 872 patients alive with their primary allografts 1 year after LT were reviewed. Thirty-four patients subsequently died (LM) and 35 patients underwent re-LT (LGL). Patients who survive the first posttransplant year had 5-year patient and graft survival rates of 94.2% and 89.2%, respectively. Graft loss after the first year was caused by rejection in 49% of the cases with sequelae of technical complications accounting for an additional 20% of LGL. LT for tumor, steroid resistant rejection, reoperation in the first 30 days and > 5 admissions during the first posttransplant year were independently associated with LGL in multivariate analysis. Malignancy, infection, multiple system organ failure and posttransplant lymphoproliferative disease accounted for 61.8% of all late deaths after LT. LT performed for FHF and tumor were associated with LM. Patients who are at or below the mean for weight at the time of transplant were also at an increased risk of dying. Frequent readmission was also found to be associated with LM.
C1 Univ Pittsburgh, Med Ctr, Hillman Ctr Pediat Transplant, Pittsburgh, PA 15260 USA.
   Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA 15260 USA.
   Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplant Inst, Pittsburgh, PA 15260 USA.
RP Mazariegos, GV (reprint author), Univ Pittsburgh, Med Ctr, Hillman Ctr Pediat Transplant, Pittsburgh, PA 15260 USA.
EM george.mazariegos@chp.edu
OI Mazariegos, George/0000-0002-2624-8632
CR Abbasoglu O, 1997, TRANSPLANTATION, V64, P1801, DOI 10.1097/00007890-199712270-00030
   BALAGIA P, 2004, LIVER TRANSPLANT, V10, P1364
   Cacclarelli TV, 1999, TRANSPLANTATION, V68, P650, DOI 10.1097/00007890-199909150-00010
   Cao S, 1999, Pediatr Transplant, V3, P22, DOI 10.1034/j.1399-3046.1999.00002.x
   Fridell JA, 2002, TRANSPLANTATION, V74, P1721, DOI 10.1097/01.TP.0000039334.85487.AB
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Goss JA, 1998, ARCH SURG-CHICAGO, V133, P839, DOI 10.1001/archsurg.133.8.839
   Gupta P, 2001, TRANSPLANTATION, V72, P1098, DOI 10.1097/00007890-200109270-00020
   Jain A, 2000, ANN SURG, V232, P490, DOI 10.1097/00000658-200010000-00004
   Jain A, 2003, TRANSPLANTATION, V75, P1020, DOI 10.1097/01.TP.0000056168.79903.20
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   McDiarmid SV, 1998, TRANSPLANTATION, V66, P1604, DOI 10.1097/00007890-199812270-00006
   Rowe D T, 2001, Transpl Infect Dis, V3, P79, DOI 10.1034/j.1399-3062.2001.003002079.x
   Ryckman FC, 1999, J PEDIATR SURG, V34, P845, DOI 10.1016/S0022-3468(99)90385-8
   SHEPHERD RW, 1991, J PAEDIATR CHILD H, V27, P295, DOI 10.1111/j.1440-1754.1991.tb02541.x
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   *SPLIT RES GROUP, 2000, TRANSPLANTATION, V72, P463
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
   Sudan DL, 1998, ANN SURG, V227, P289, DOI 10.1097/00000658-199802000-00020
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
NR 21
TC 61
Z9 64
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD SEP
PY 2007
VL 7
IS 9
BP 2165
EP 2171
DI 10.1111/j.1600-6143.2007.01893.x
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 199AE
UT WOS:000248667800016
PM 17608834
ER

PT J
AU Engelmann, G
   Schmidt, J
   Oh, J
   Lenhartz, H
   Wenning, D
   Teufel, U
   Buchler, MW
   Hoffmann, GF
   Meyburg, J
AF Engelmann, G.
   Schmidt, J.
   Oh, J.
   Lenhartz, H.
   Wenning, D.
   Teufel, U.
   Buechler, M. W.
   Hoffmann, G. F.
   Meyburg, J.
TI Indications for pediatric liver transplantation. Data from the
   Heidelberg pediatric liver transplantation program
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT Annual Multidisciplinary Heidelberg Transplant Sympsoum
CY OCT, 2006
CL Heidelberg, GERMANY
ID FAMILIAL INTRAHEPATIC CHOLESTASIS; CYSTIC-FIBROSIS; HEPATIC-FAILURE;
   BILIARY ATRESIA; CYCLOSPORIN-A; CHILDREN; DISEASE; MANAGEMENT; REGISTRY
AB Nowadays liver transplantation is an established treatment for children with end-stage liver disease with very good 1- and 5-year survival. This has been achieved through constant improvement of surgical techniques, new immunosuppressive drugs and clinical management. Indications for liver transplantation in infants and children include acute liver failure (ALF), chronic liver failure with pruritus, complications of cholestasis and failure to thrive. In young children, the most common liver disease leading to transplantation is biliary atresia. Biliary atresia accounts for at least 50 percent of all liver transplants in children and is characterized by the failure of the bile ducts to develop normally and drain bile from the liver.
   Several models to assess prognosis of liver disease have been developed. In acute liver failure leukocyte count, bilirubin, International Normalized Ratio (INR) and age have a strong correlation with outcome. In chronic liver failure, PELD (Pediatric end-stage liver disease) Score and the occurrence of complications of liver disease are important prognostic tools. Since the start of our own paediatric liver transplantation program at the University of Heidelberg in 2003, already 15 Children between 5 months and 14 years have been transplanted. Indications and outcome of these patients are reviewed in this paper.
C1 Univ Heidelberg, Dept Paediat, D-69120 Heidelberg, Germany.
   Univ Heidelberg, Dept Gen Visceral & Transplant Surg, D-69120 Heidelberg, Germany.
RP Engelmann, G (reprint author), Univ Heidelberg, Dept Paediat, Im Neuenheimer Feld 150, D-69120 Heidelberg, Germany.
EM guido_engelmann@med.uni-heidelberg.de
CR ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2
   Belghiti J, 1992, Surg Gynecol Obstet, V175, P270
   BELGHITI J, 1992, PRESSE MED, V21, P569
   BISMUTH H, 1987, LANCET, V2, P674
   BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261
   CALNE RY, 1981, BRIT MED J, V282, P934
   Chardot C, 2001, J PEDIATR-US, V138, P224, DOI 10.1067/mpd.2001.111276
   Chardot C, 1999, HEPATOLOGY, V30, P606, DOI 10.1002/hep.510300330
   CLAYTON RJ, 1969, AM J DIS CHILD, V117, P112
   Colombo C, 2006, J PEDIATR GASTR NUTR, V43, pS49, DOI 10.1097/01.mpg.0000226390.02355.52
   De Kerckhove L, 2006, TRANSPLANT INT, V19, P381, DOI 10.1111/j.1432-2277.2006.00292.x
   Debray Dominique, 2006, Paediatr Drugs, V8, P1, DOI 10.2165/00148581-200608010-00001
   Delarue A, 2000, Pediatr Transplant, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   Dhawan A, 2004, PEDIATR TRANSPLANT, V8, P584, DOI 10.1111/j.1399-3046.2004.00292.x
   Engelmann G, 2006, CLIN TRANSPLANT, V20, P124, DOI 10.1111/j.1399-0012.2006.00611.x
   Ganschow R, 2000, Pediatr Transplant, V4, P273, DOI 10.1034/j.1399-3046.2000.00127.x
   Kayihan N, 2000, Pediatr Transplant, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Keitel V, 2005, HEPATOLOGY, V41, P1160, DOI 10.1002/hep.20682
   Kelly D, 2004, LANCET, V364, P1054, DOI 10.1016/S0140-6736(04)17060-8
   Lee WS, 2005, J PEDIATR GASTR NUTR, V40, P575, DOI 10.1097/01.MPG.0000158524.30294.E2
   Leumann E, 2000, Pediatr Transplant, V4, P161, DOI 10.1034/j.1399-3046.2000.00119.x
   Melzi ML, 2006, TRANSPLANT INT, V19, P726, DOI 10.1111/j.1432-2277.2006.00344.x
   Meyburg J, 2005, TRANSPLANTATION, V80, pS135, DOI 10.1097/01.tp.0000186905.10088.e5
   Molmenti EP, 2003, PEDIATR TRANSPLANT, V7, P93, DOI 10.1034/j.1399-3046.2003.00021.x
   PAUWELS A, 1993, J HEPATOL, V17, P124, DOI 10.1016/S0168-8278(05)80532-X
   Price MR, 1996, J PEDIATR SURG, V31, P1056, DOI 10.1016/S0022-3468(96)90086-X
   Saliba F, 2006, CRIT CARE, V10, DOI 10.1186/cc4825
   Squires RH, 2006, J PEDIATR-US, V148, P652, DOI 10.1016/j.jpeds.2005.12.051
NR 28
TC 2
Z9 3
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD SEP
PY 2007
VL 22
SU 8
BP 23
EP 28
DI 10.1093/ndt/gfm649
PG 6
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 235MK
UT WOS:000251238200006
ER

PT J
AU D'Alessandro, AM
   Knechtle, J
   Chin, LT
   Fernandez, LA
   Yagci, G
   Leverson, G
   Kalayoglu, M
AF D'Alessandro, A. M.
   Knechtle, J.
   Chin, L. Thomas
   Fernandez, L. A.
   Yagci, G.
   Leverson, G.
   Kalayoglu, M.
TI Liver transplantation in pediatric patients: Twenty years of experience
   at the University of Wisconsin
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; liver transplantation; reduced; split; complications
ID HEPATIC-ARTERY THROMBOSIS; SINGLE-CENTER EXPERIENCE; CHILDREN;
   RECIPIENTS; SPLIT; COMPLICATIONS; DISEASE; MICROSCOPE; INFANTS; GRAFTS
AB Developments in surgical technique, immunosuppression, organ procurement and preservation, and patient selection criteria have resulted in improved long-term patient and graft survival after pediatric liver transplantation. In this study, we examined the results of 196 liver transplants performed in 155 pediatric patients at University of Wisconsin Children's Hospital. Patients were divided into two groups according to age at the time of liver transplant. Infants under 12 months of age comprised Group 1 (n = 74) and children from one to 18 yr comprised Group 2 (n = 122). Outcomes for whole, reduced-size, and split liver transplantation were compared in infants and children. Biliary atresia was the most common indication in both groups. Patients underwent 128 whole size, 50 reduced size, and IS split liver transplants. Forty-one retransplantations were performed in 14 infants (18.9%) and in 27 children (22.1 %). One hundred eleven patients (56.6%) had one or more rejection episode [37 infants (50.0%) and 74 children (60.6%)]. Thirty-nine patients (19.8%) developed CMV infections, 42 (21.4%) developed EBV infections, and 14 developed PTLD (six infants and eight children). Thirty-six patients (18.3%) developed HAT. Seven patients (4.5%) developed malignancy (one infant and six children). Out of 155 patients, 33 (21.3%) died during the study period. The most common etiology of mortality included central nervous system pathology (n = 7 ; 4.5%), sepsis (n = 6; 3.8%), and cardiac causes (n = 6; 3.8%). One-, five-, and 10-yr actuarial patient survival was 86, 79, and 74% in infants and 90, 83 and 80% in children. Graft survival at one, five, and 10 yr was 77, 73 and 71 % in infants and 88, 81 and 78% in children, respectively. Despite its technical challenges, the outcomes of liver transplantation in pediatric patients with end-stage liver disease are excellent and result in significant long-term patient and graft survival.
C1 Univ Wisconsin, Dept Surg, Madison, WI 53792 USA.
   Gulhane Mil Med Acad, Ankara, Turkey.
RP Kalayoglu, M (reprint author), Univ Wisconsin, Dept Surg, H4-780 CSC,600 Highland Ave, Madison, WI 53792 USA.
EM munci@surgery.wisc.edu
CR Aydogdu S, 2005, PEDIATR TRANSPLANT, V9, P723, DOI 10.1111/j.1399-3046.2005.00366.x
   Barshes NR, 2006, LIVER TRANSPLANT, V12, P475, DOI 10.1002/lt.20703
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   CALNE RY, 1979, LANCET, V2, P1033
   CALNE RY, 1977, BRIT MED J, V1, P471
   DALESSANDRO AM, 1991, TRANSPLANT P, V23, P2309
   DALESSANDRO AM, 1993, TRANSPLANTATION, V55, P1083, DOI 10.1097/00007890-199305000-00028
   Dalgic A, 2005, TRANSPLANT P, V37, P3133, DOI 10.1016/j.transproceed.2005.07.004
   EMOND JC, 1993, TRANSPLANTATION, V55, P835, DOI 10.1097/00007890-199304000-00029
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Green M, 2006, AM J TRANSPLANT, V6, P1906, DOI 10.1111/j.1600-6143.2006.01394.x
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Guarrera JV, 2004, TRANSPLANT INT, V17, P585, DOI 10.1007/s00147-004-0782-8
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Jain A, 2006, TRANSPLANT INT, V19, P27, DOI 10.1111/j.1432-2277.2005.00224.x
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7
   Kalayoglu M, 1996, J AM COLL SURGEONS, V182, P381
   KALAYOGLU M, 1993, SURGERY, V114, P711
   KALAYOGLU M, 1990, SURG GYNECOL OBSTET, V171, P139
   KALAYOGLU M, 1989, TRANSPLANT P, V21, P3487
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   MCDIARMID SV, 1995, TRANSPLANTATION, V59, P530
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   STARZL TE, 1982, HEPATOLOGY, V2, P614
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   STOCK PG, 1987, TRANSPLANT P, V19, P3303
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Van der Werf WJ, 1998, J PEDIATR SURG, V33, P20, DOI 10.1016/S0022-3468(98)90353-0
   WHITINGTON PF, 1991, J PEDIATR-US, V118, P169, DOI 10.1016/S0022-3476(05)80478-0
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
NR 37
TC 29
Z9 30
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2007
VL 11
IS 6
BP 661
EP 670
DI 10.1111/j.1399-3046.2007.00737.x
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 203WF
UT WOS:000249004000016
PM 17663691
ER

PT J
AU Hayashida, M
   Ogita, K
   Matsuura, T
   Takahashi, Y
   Nishimotol, Y
   Ohga, S
   Hara, T
   Soejima, Y
   Taketorni, A
   Maehara, Y
   Kohash, K
   Tsuneyosh, M
   Taguchi, T
AF Hayashida, Makoto
   Ogita, Keiko
   Matsuura, Toshiharu
   Takahashi, Yukiko
   Nishimotol, Yuko
   Ohga, Shouichi
   Hara, Toshiro
   Soejima, Yuji
   Taketorni, Akinobu
   Maehara, Yoshihiko
   Kohash, Kenichi
   Tsuneyosh, Masazumi
   Taguchi, Tornoaki
TI Successful prolonged rituximab treatment for post-transplant
   lymphoproliferative disorder following living donor liver
   transplantation in a child
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
ID THERAPY; DISEASE; IMMUNOSUPPRESSION; MANAGEMENT; RECIPIENTS; LYMPHOMA;
   PET/CT; ADULT
AB PTLD is a serious complication of immunosuppression in solid organ transplant recipients. The incidence of PTLD is significantly higher in pediatric recipients than in adult because children are often EBV-seronegative and they may develop primary EBV infection after transplantation. We herein describe a case of GI-PTLD who achieved a complete remission by prolonged rituximab, a chimeric monoclonal antibody against CD20, mono-therapy. A one-yr-old female underwent a LDLT for liver failure after having previously undergone the Kasai procedure for billary atresia. At sixty days following the transplantation. GI-PTLD developed. Withdrawal of immunosuppression and a Surgical resection were thus performed. A histopathological examination of tumor revealed atypical medium to large cell lymphoid proliferation with strong CD20 immunopositivity indicating their B-cell origin. Polymorphic PTLD was diagnosed. Rituximab was administered at a dose of 375 mg/m(2) once a week, and the monotherapy resulted in a complete remission after 34 administrations. Based on this case, rituximab appears to be beneficial as a first-line therapy for PTLD.
C1 Kyushu Univ, Grad Sch Med Sci, Dept Pediat Surg Reprod & Dev Med, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, Fukuoka 8128582, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan.
RP Hayashida, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Pediat Surg, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM makoto-h@pedsurg.med.kyushu-u.ac.jp
RI Maehara, Yoshihiko/A-4867-2010
CR Berney T, 2002, TRANSPLANTATION, V74, P1000, DOI 10.1097/01.TP.0000031931.31954.53
   Boyle GJ, 1997, J PEDIATR-US, V131, P309, DOI 10.1016/S0022-3476(97)70173-2
   Buell JF, 2005, TRANSPLANT P, V37, P956, DOI 10.1016/j.transproceed.2004.12.124
   Campbell P, 2003, BLOOD REV, V17, P143, DOI 10.1016/S0268-960X(03)00005-5
   COX KL, 1995, TRANSPLANTATION, V59, P524
   Dror Y, 1999, TRANSPLANTATION, V67, P990, DOI 10.1097/00007890-199904150-00010
   Hachem RR, 2004, TRANSPLANTATION, V77, P431, DOI 10.1097/01.TP.0000112938.88948.F5
   HANTO DW, 1982, NEW ENGL J MED, V306, P913, DOI 10.1056/NEJM198204153061506
   Hustinx R, 1999, EUR J NUCL MED, V26, P1345, DOI 10.1007/s002590050593
   Kostakoglu Lale, 2004, Clin Adv Hematol Oncol, V2, P115
   McCormack L, 2006, AM J TRANSPLANT, V6, P1731, DOI 10.1111/j.1600-6143.2006.01358.x
   Messa C, 2004, Q J NUCL MED MOL IM, V48, P66
   Oertel SHK, 2005, AM J TRANSPLANT, V5, P2901, DOI 10.1111/j.1600-6143.2005.01098.x
   Pickhardt PJ, 2000, RADIOLOGY, V217, P16
   Pickhardt PJ, 1999, RADIOLOGY, V213, P73
   Shapiro R, 1999, TRANSPLANTATION, V68, P1851, DOI 10.1097/00007890-199912270-00006
   SHAPIRO RS, 1988, BLOOD, V71, P1234
   Smets F, 2002, PEDIATR TRANSPLANT, V6, P280, DOI 10.1034/j.1399-3046.2002.02029.x
   STARZL TE, 1984, LANCET, V1, P583
   Tsai DE, 2001, TRANSPLANTATION, V71, P1076, DOI 10.1097/00007890-200104270-00012
   Younes BS, 1999, J PEDIATR GASTR NUTR, V28, P380, DOI 10.1097/00005176-199904000-00007
NR 21
TC 7
Z9 10
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2007
VL 11
IS 6
BP 671
EP 675
DI 10.1111/j.1399-3046.2007.00714.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 203WF
UT WOS:000249004000017
PM 17663692
ER

PT J
AU Falkenstein, K
   Flynn, L
   Dunn, S
   Baldridge, A
AF Falkenstein, Kathleen
   Flynn, Louise
   Dunn, Stephen
   Baldridge, Alan
TI Arterial-venous fistulas following pediatric liver transplant case
   studies
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplant; liver biopsy; arterialvenous; fistula; ascites;
   percutaneous transhelpatic cholangiogram; Epstein Barr virus
ID HEPATIC ARTERIOVENOUS-FISTULA; PORTAL-HYPERTENSION; DIAGNOSIS; BIOPSY
AB AV fistula is a rare but serious complication following pediatric liver transplant and may lead to graft loss. Our aim was to describe two pediatric centers' experience with the diagnosis, treatment and outcomes of children who presented with AV fistulas post-liver transplantation We report five cases of late arterio-portal fistula following liver transplantation. Four children were successfully treated with coil embolization. All of the children in this series had liver biopsies within 2-6 months of their AV fistula diagnosis. All biopsies were performed using a Bard Monopty 18 gauge needle with no ultrasound guidance and only one pass per biopsy. Two children also had PTC 4-8 months prior to their diagnosis of AV fistula. Three of the five children in this series had GI bleeds requiring banding or sclerotherapy. The other two had varices found on CT scan. All five cases in this series had ascites on their initial presentation. Four out of the five children had a history of non-compliance and the other child had a history of malabsorption and chronic diarrhea.
C1 Drexel Univ, PNP, Philadelphia, PA 19104 USA.
   DuPont Hosp Children, Wilmington, DE 19803 USA.
   St Christophers Hosp Children, Philadelphia, PA 19134 USA.
RP Falkenstein, K (reprint author), Drexel Univ, PNP, 3141 Chestnut St, Philadelphia, PA 19104 USA.
EM kf33@drexel.edu
CR BAER J, 1977, GASTROINTEST RADIOL, V2, P299
   Chavan A, 1993, Bildgebung, V60, P215
   Gupta TK, 1997, BAILLIERE CLIN GASTR, V11, P203, DOI 10.1016/S0950-3528(97)90036-1
   JABBOUR N, 1995, DIGEST DIS SCI, V40, P104
   LUMSDEN AB, 1993, AM SURGEON, V59, P722
   Mieles LA, 2002, PEDIATR TRANSPLANT, V6, P419, DOI 10.1034/j.1399-3046.2002.t01-2-00002.x
   NORTON S, 2006, J PEDIAT GASTROENTER, V3, P248
   OCTBE Y, 1995, SURG TODAY, V25, P916
   OKUDA K, 1978, GASTROENTEROLOGY, V74, P1204
   PREGER L, 1967, AMER J ROENTGENOL RA, V101, P619
   Quiroga S, 2001, RADIOGRAPHICS, V21, P65
   Raghuram L, 2001, ABDOM IMAGING, V26, P194, DOI 10.1007/s002610000116
   Shneider B, 2006, PEDIATR TRANSPLANT, V10, P893, DOI 10.1111/j.1399-3046.2006.00597.x
   WALTER JF, 1976, AM J ROENTGENOL, V127, P847
NR 14
TC 3
Z9 6
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2007
VL 11
IS 6
BP 683
EP 688
DI 10.1111/j.1399-3046.2007.00742.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 203WF
UT WOS:000249004000020
PM 17663695
ER

PT J
AU Concejero, A
   Chen, CL
   Liang, CD
   Wang, CC
   Wang, SH
   Lin, CC
   Liu, YW
   Yong, CC
   Yang, CH
   Lin, TS
   Jawan, B
   Huang, TL
   Cheng, YF
   Eng, HL
AF Concejero, Allan
   Chen, Chao-Long
   Liang, Chi-Di
   Wang, Chih-Chi
   Wang, Shih-Ho
   Lin, Chih-Che
   Liu, Yeuh-Wei
   Yong, Chee-Chien
   Yang, Chin-Hsiang
   Lin, Tsan-Shiun
   Jawan, Bruno
   Huang, Tung-Liang
   Cheng, Yu-Fan
   Eng, Hock-Liew
TI Living donor liver transplantation in children with congenital heart
   disease
SO TRANSPLANTATION
LA English
DT Article
DE biliary dysgenesis; congenital cardiovascular malformation; congenital
   heart disease; liver disease; liver transplantation
ID ATRIAL SEPTAL-DEFECTS; BILIARY ATRESIA; HEPATOPULMONARY SYNDROME;
   SPONTANEOUS CLOSURE; MANAGEMENT
AB Background. The occurrence of congenital heart disease (CHD) with congenital biliary disease is uncommon. Our aim is to present our experience in living donor liver transplantation (LDLT) as treatment for end-stage liver disease (ESLD) in children with CHD.
   Methods. A review of transplant records from June 1994 to December 2004 was performed. Twenty-three LDLT (13 males, 10 females) recipients were diagnosed to have both CHD and ESLD.
   Results. CHD diagnoses were made preoperatively using transthoracic two-dimensional color flow Doppler echocardiography. The mean age was 22.3 months. There were 20 (87%) biliary atresia, two (9%) neonatal hepatitis, and one (4%) glycogen storage disease patients. Isolated CHD associated with ESLD included atrial septal defect (11, 48%), pulmonary stenosis (including 2 Alagille syndrome; 4, 17%), patent foramen ovale (4, 17%), ventricular septal defect (1, 4%), and mitral valve prolapse (1, 4%). Complex CHD included atrial septal defect + patent ductus arteriosus + patent foramen ovale (1, 4%), and atrial septal defect + pulmonary stenosis (1, 4%). The median Child's and Pediatric End-stage Liver Disease scores were 9, and 17, respectively. In all, 70% presented with varying degrees of pulmonary congestion pretransplant. There were no perioperative cardiac complications. Posttransplant, the patent foramen ovale in four recipients and atrial septal defect in four recipients closed spontaneously; and two recipients with pulmonary stenosis had their stenoses resolved spontaneously. The overall rejection rate was 17%. There was no mortality. The overall recipient and graft survivals at 1 and 5 years were both 100%.
   Conclusion. LDLT is a safe procedure in a select group of ESLD patients with CHD.
C1 Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Liver Transplantat Program, Kaohsiung 833, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Pediat Cardiol, Kaohsiung, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Anesthesiol, Kaohsiung, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Pathol, Kaohsiung 83305, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Diagnost Radiol, Kaohsiung, Taiwan.
RP Chen, CL (reprint author), Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Liver Transplantat Program, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.
EM clchen@adm.cgmh.org.tw
CR BEHRENDT DM, 1994, PEDIAT CARDIAC SURG, P195
   Brassard M, 1999, AM J CARDIOL, V83, P1552, DOI 10.1016/S0002-9149(99)00146-0
   Chen CL, 2006, AM J TRANSPLANT, V6, P2672, DOI 10.1111/j.1600-6143.2006.01528.x
   Chen CL, 2000, TRANSPLANTATION, V69, P2580, DOI 10.1097/00007890-200006270-00018
   Cheng Kwok-Wai, 2004, Chang Gung Med J, V27, P449
   CZEIZEL A, 1987, Acta Paediatrica Hungarica, V28, P63
   de Villa VH, 2000, TRANSPLANTATION, V70, P1604, DOI 10.1097/00007890-200012150-00011
   GREENWOOD RD, 1976, PEDIATRICS, V58, P243
   Helgason H, 1999, PEDIATR CARDIOL, V20, P195, DOI 10.1007/s002469900439
   Jawan B, 2005, J SURG RES, V126, P82, DOI 10.1016/j.jss.2005.01.004
   Liang CD, 2001, J FORMOS MED ASSOC, V100, P403
   McMahon CJ, 2002, HEART, V87, P256, DOI 10.1136/heart.87.3.256
   Mohart D, 2002, PAEDIATR ANAESTH, V12, P649, DOI 10.1046/j.1460-9592.2002.00942.x
   Orii I, 1998, TRANSPLANT P, V30, P3254
   Ovaert C, 2001, TRANSPLANTATION, V72, P345, DOI 10.1097/00007890-200107270-00034
   Png K, 1999, ANESTH ANALG, V89, P1137
   Popescu Irinel, 2004, Rom J Gastroenterol, V13, P125
   Riggs T, 2000, PEDIATR CARDIOL, V21, P129, DOI 10.1007/s002469910020
   SHIMOTAKE T, 1992, EUR J PEDIATR SURG, V2, P110, DOI 10.1055/s-2008-1063416
   SHUB C, 1976, MAYO CLIN PROC, V51, P81
   SILVEIRA TR, 1991, ACTA PAEDIATR SCAND, V80, P1192, DOI 10.1111/j.1651-2227.1991.tb11808.x
   Tanano H, 1999, J PEDIATR SURG, V34, P1687, DOI 10.1016/S0022-3468(99)90645-0
   Wang CC, 2006, CLIN TRANSPLANT, V20, P81, DOI 10.1111/j.1399-0012.2005.00431.x
   ZUKIN DD, 1981, CLIN PEDIATR, V20, P64, DOI 10.1177/000992288102000110
NR 24
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 27
PY 2007
VL 84
IS 4
BP 484
EP 489
DI 10.1097/01.tp.0000277599.25079.94
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 204VJ
UT WOS:000249071800008
PM 17713432
ER

PT J
AU Chahal, P
   Baron, TH
   Poterucha, JJ
   Rosen, CB
AF Chahal, Prabhleen
   Baron, Todd H.
   Poterucha, John J.
   Rosen, Charles B.
TI Endoscopic retrograde cholangiography in post-orthotopic liver
   transplant population with Roux-en-Y biliary reconstruction
SO LIVER TRANSPLANTATION
LA English
DT Article
ID PRIMARY SCLEROSING CHOLANGITIS; TRACT COMPLICATIONS; MANAGEMENT; ERCP;
   CHOLANGIOPANCREATOGRAPHY; DIAGNOSIS; STRICTURES
AB Endoscopic retrograde cholangiography (ERC) is a well-established modality for diagnostic and therapeutic maneuvers in pancreaticobiliary disorders. However, it is technically more challenging in patients with postsurgical anatomy like Roux-en-Y anastomoses. Its effectiveness in post-orthotopic liver transplantation (OLT) patients with Roux-en-Y biliary reconstruction has not been reported. We sought to assess the efficacy and safety of ERC in this patient population. A total of 132 OLTs with Roux-en-Y biliary reconstruction were performed at our institution from June 1998 to August 2005. Data from consenting patients who underwent ERC were reviewed once they were identified through computerized medical index system. Of 132 OLT patients with Roux-en-Y biliary reconstruction, 31 patients (9 female and 22 male subjects ranging in age from 11 months to 70 years) underwent ERC. The indication for liver transplant was end-stage liver disease or occurrence of cholangiocarcinoma from primary sclerosing cholangitis in 28 patients and a case each of chronic hepatitis C, alcoholic liver disease, and metastatic islet cell carcinoma. A variable-stiffness pediatric colonoscope was used in most cases. ERC indications were both diagnostic and therapeutic and included the following: evaluation of increased liver biochemistries and fever in 12 patients, dilation of anastomotic biliary strictures in 10 patients, removal of fractured biliary tube or retained biliary stent in 6 patients, and in 1 patient each, biliary stone removal, management of bile leak, and jejunal tube extension placement for nutritional purpose. ERC was successful in 22 patients (71%). There were no postprocedural complications. Although ERC is technically more difficult and time-consuming in OLT patients with Roux-en-Y anastomoses, these data suggest that ERC is an effective and safe diagnostic and therapeutic modality with few or no complications when performed by experienced endoscopists. ERC was successful in most patients and allowed therapeutic interventions that obviated the need for percutaneous radiological intervention or surgery.
C1 Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN USA.
   Mayo Clin, Coll Med, Div Transplant Surg, Rochester, MN USA.
RP Baron, TH (reprint author), 200 1st ST SW, Rochester, MN 55901 USA.
EM baron.todd@mayo.edu
CR Akahoshi K, 2006, WORLD J GASTROENTERO, V12, P7654
   Baccarani U, 2002, DIGEST LIVER DIS, V34, P582, DOI 10.1016/S1590-8658(02)80092-5
   COLONNA JO, 1992, ANN SURG, V216, P344
   COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2
   Distante V, 1996, TRANSPLANT INT, V9, P126, DOI 10.1111/j.1432-2277.1996.tb00866.x
   Feith MP, 1997, TRANSPLANT P, V29, P560, DOI 10.1016/S0041-1345(96)00706-3
   Feitoza AB, 2002, GASTROINTEST ENDOSC, V55, P75, DOI 10.1067/mge.2002.120385
   Gholson CF, 1996, DIGEST DIS SCI, V41, P1045, DOI 10.1007/BF02088217
   Gomez R, 2001, WORLD J SURG, V25, P1308
   Grief F, 1994, ANN SURG, V219, P40
   Guichelaar MMJ, 2003, AM J TRANSPLANT, V3, P885, DOI 10.1034/j.1600-6143.2003.00165.x
   Hintze RE, 1997, ENDOSCOPY, V29, P69, DOI 10.1055/s-2007-1004077
   Hintze RE, 1997, ENDOSCOPY, V29, P182, DOI 10.1055/s-2007-1004160
   Jagannath S, 2002, CURR TREAT OPTIONS G, V5, P101, DOI 10.1007/s11938-002-0057-3
   KUO PC, 1994, J AM COLL SURGEONS, V179, P177
   LOPEZ RR, 1992, AM J SURG, V163, P519, DOI 10.1016/0002-9610(92)90401-C
   MALCOLM S, 1997, MED CARE LIVER TRANS, P193
   Mata A, 2004, HEPATO-GASTROENTEROL, V51, P1801
   Moser MA, 2001, LIVER TRANSPL S1, V7, P46
   Park JS, 2003, GASTROINTEST ENDOSC, V57, P78, DOI 10.1067/mge.2003.11
   Pfau PR, 2000, GASTROINTEST ENDOSC, V52, P55, DOI 10.1067/mge.2000.106687
   QIAN YB, 2004, ARCH SURG-CHICAGO, V139, P110
   RASKMADSEN C, 1994, TRANSPLANT P, V26, P1796
   Rerknimitr R, 2002, GASTROINTEST ENDOSC, V55, P224, DOI 10.1067/mge.2002.120813
   Rizk RS, 1998, GASTROINTEST ENDOSC, V47, P128, DOI 10.1016/S0016-5107(98)70344-X
   SAWYER RG, 1998, TRANSPLANTATION, V66, P120
   Shah JN, 2004, AM J GASTROENTEROL, V99, P1291, DOI 10.1111/j.1572-0241.2004.30775.x
   STRATTA RJ, 1989, SURGERY, V106, P675
   Suissa A, 2005, HEPATO-GASTROENTEROL, V52, P352
   Thethy S, 2004, CLIN TRANSPLANT, V18, P647, DOI 10.1111/j.1399-0012.2004.00254.x
   Thuluvath PJ, 2003, LIVER INT, V23, P156, DOI 10.1034/j.1600-0676.2003.00823.x
   Turrion VS, 1999, TRANSPLANT P, V31, P2392, DOI 10.1016/S0041-1345(99)00396-6
   Welsh FKS, 2004, TRANSPLANTATION, V77, P602, DOI 10.1097/1.TP.0000113807.74942.D2
   WOOD EM, 1990, RADIOLOGY, V177, P259
NR 34
TC 36
Z9 37
U1 1
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2007
VL 13
IS 8
BP 1168
EP 1173
DI 10.1002/lt.21198
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 198BM
UT WOS:000248602000015
PM 17663414
ER

PT J
AU Brunner, B
   Kropshofer, G
   Ellemunter, H
   Brunner, A
   Mueller, T
   Margreiter, R
   Tzankov, A
AF Brunner, Barbara
   Kropshofer, Gabriele
   Ellemunter, Helmut
   Brunner, Andrea
   Mueller, Thomas
   Margreiter, Raimund
   Tzankov, Alexandar
TI Severe cold agglutinin disease caused by recurrent monomorphic
   Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative
   disorder (PTLD), clonally related to an EBV-negative plasmacytic
   hyperplasia in a pediatric multivisceral organ transplant recipient
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplant lymphoproliferative disorder; cold agglutinin disease;
   pediatric multivisceral organ transplantation
ID CHEMOTHERAPY; CHILDREN
AB PTLD represent major post-transplant complications. The major etiologic factor is EBV. Association with cold agglutinin disease has not been described so far. We report a three-yr-old girl who developed oligoclonal EBV-negative plasmacytic hyperplasia as well as Coombs test-positive anemia one yr after multivisceral organ transplantation, performed after subtotal bowel resection for colointestinal aganglionosis and liver cirrhosis resulting from long-term parenteral nutrition. The patient was treated for plasmacytic hyperplasia with cyclophosphamide and prednisolone and achieved clinical remission. One yr later PTLD progressed possibly driven by EBV to DLBCL. The migration patterns of the amplified Ig heavy chain genes demonstrated a probable clonal relationship of the DLBCL to a clone almost present in the plasmacytic hyperplasia. This progression was accompanied by a rapid rise of cold agglutinin titers with symptoms of severe cold agglutinin disease, leading to right femoral and extern iliac vein thromboses requiring partial leg amputation. After four cycles of rituximab, cyclophosphamide, and prednisolone, the patient achieved complete PTLD remission and the cold agglutinins disappeared. Summarizing, PTLD may be accompanied by cold agglutinin disease, and both may be successfully treated by immuno-chemotherapy. The appearance of cold agglutinins in transplant patients may indicate PTLD development.
C1 Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria.
   Med Univ Innsbruck, Dept Pediat 3, Innsbruck, Austria.
   Med Univ Innsbruck, Inst Pathol, Innsbruck, Austria.
   Med Univ Innsbruck, Dept Gen & Transplant Surg, Innsbruck, Austria.
   Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland.
RP Brunner, B (reprint author), Med Univ Innsbruck, Dept Pediat 2, Anichstr 35, A-6020 Innsbruck, Austria.
EM barbara.brunner@i-med.ac.at
RI Tzankov, Alexandar/A-9155-2008
CR Aberle S.W., 2002, J CLIN VIROL S1, V25, P79, DOI DOI 10.1016/S1386-6532(02)00037-9
   Allen UD, 2005, PEDIATR TRANSPLANT, V9, P450, DOI 10.1111/j.1399-3046.2005.00318.x
   Axelrod DA, 2003, PEDIATR TRANSPLANT, V7, P223, DOI 10.1034/j.1399-3046.2003.00080.x
   Berentsen S, 2004, BLOOD, V103, P2925, DOI 10.1182/blood-2003-10-3597
   Buell JF, 2005, TRANSPLANT P, V37, P956, DOI 10.1016/j.transproceed.2004.12.124
   Fong D, 2005, BRIT J HAEMATOL, V129, P199, DOI 10.1111/j.1365-2141.2005.05426.x
   Green M, 1999, Pediatr Transplant, V3, P271, DOI 10.1034/j.1399-3046.1999.00066.x
   Gross TG, 2005, J CLIN ONCOL, V23, P6481, DOI 10.1200/JCO.2005.08.074
   Harris NL, 2001, TUMOURS HAEMATOPOIET, P264
   Kitamura T, 2003, TRANSPLANT P, V35, P399, DOI 10.1016/S0041-1345(02)03816-2
   Leblond V, 1998, J CLIN ONCOL, V16, P2052
   Nalesnik M A, 2001, Transpl Infect Dis, V3, P88, DOI 10.1034/j.1399-3062.2001.003002088.x
   ORJUELA M, 2003, CLIN CANC RES 2, V9, P3945
   Sevilla J, 2004, J PEDIAT HEMATOL ONC, V26, P831
   Smets F, 2002, PEDIATR TRANSPLANT, V6, P280, DOI 10.1034/j.1399-3046.2002.02029.x
   Young LS, 2000, J CLIN PATHOL-MOL PA, V53, P238
NR 16
TC 13
Z9 13
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2007
VL 11
IS 5
BP 547
EP 551
DI 10.1111/j.1399-3046.2007.00711.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 192CC
UT WOS:000248177400017
PM 17631026
ER

PT J
AU Brolese, A
   Vitale, A
   Zanus, G
   Boccagni, P
   Neri, D
   Gringeri, E
   D'Amico, F
   Valmasoni, M
   Ciarleglio, FA
   Carraro, A
   Zancan, L
   Guariso, G
   D'Antiga, L
   D'Amico, DF
   Cillo, U
AF Brolese, A.
   Vitale, A.
   Zanus, G.
   Boccagni, P.
   Neri, D.
   Gringeri, E.
   D'Amico, F.
   Valmasoni, M.
   Ciarleglio, F. A.
   Carraro, A.
   Zancan, L.
   Guariso, G.
   D'Antiga, L.
   D'Amico, D. F.
   Cillo, U.
TI Pediatric liver transplantation: The University of Padua experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 30th Congress of the Italian-Society-of-Organ-Transplantation
CY NOV 30-DEC 02, 2006
CL Padova, ITALY
SP Soc Organ Transplantat
ID SPLIT; CHILDREN; FAILURE
AB Objective. The objective of this study was to analyze experience on pediatric liver transplantation (LT) between June 1993 and September 2006, including split liver transplantation (SLT), living donor liver transplantation (LDLT), and auxiliary partial orthotopic liver transplantation (APOLT). Furthermore, hepatocyte transplantation (HT) had a role in one patient with metabolic disease.
   Methods. From November 1990 to September 2006, 657 LTs were performed including 63 pediatric LTs (9.6%) in 57 patients (32 boys and 25 girls). Six were retransplantations (9.5%). Thirty-two patients (57%) were younger than 5 years. The types of graft included the following: 26 whole organs (41%), 32 in situ split organs (51%), 4 reduced-size organs (6%), and I graft from a living donor (2%). Two patients received an APOLT, 4 patients received a combined kidney-liver transplantation (CKLT), and 1 patient received HT. Of the 63 pediatric LTs, 16 were behaved to be highly urgent (25%).
   Results. Overall 1-, 3-, 5-, and 10-year patient survival rates were 82%, 82%, 78%, and 78%, respectively. Overall 1-, 3-, 5-, and 10-year graft survival rates were 76%, 76%, 72%, and 72%, respectively. In patients younger than I year, the 5-year survival rate was 100%. Perioperative mortality was 8.8%. Vascular complications occurred in 4 patients (6.3%). Six children required retransplantation due to primary nonfunction (PNF) in 4 cases (7%) and vascular thrombosis in 2 cases (3.5%).
   Conclusions. Cholestatic liver disease and age younger than I year were the best prognostic factors for excellent survival.
C1 IOV IRCCS, Hepato Biliary & Liver Transplantat Unit, Padua, Italy.
   IOV IRCCS, Dept Surg & Gastroenterol Sci, Oncol Inst Veneto, Padua, Italy.
   Univ Padua, Dept Pediat, Padua, Italy.
RP Brolese, A (reprint author), Via Giustiniani 2, I-35128 Padua, Italy.
EM brolese@unipd.it
RI Valmasoni, Michele/C-7574-2014
OI Guariso, Graziella/0000-0002-3120-5063; D'Amico,
   Francesco/0000-0001-6915-9755; Vitale, Alessandro/0000-0002-4548-8308;
   Cillo, Umberto/0000-0002-2310-0245; Valmasoni,
   Michele/0000-0002-1462-8275
CR Baccarani U, 2005, TRANSPLANT P, V37, P2702, DOI 10.1016/j.transproceed.2005.06.027
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   Cardillo M, 2006, LIVER TRANSPLANT, V12, P402, DOI 10.1002/lt.20720
   Cescon M, 2006, ANN SURG, V244, P805, DOI 10.1097/01.sla.0000218076.85213.60
   Cillo U, 2004, TRANSPLANT INT, V17, P713, DOI 10.1007/s00147-004-0798-0
   Cillo U, 2003, TRANSPLANT P, V35, P2983, DOI 10.1016/j.trnasproceed.2003.10.072
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Kane R, 2001, TRANSPLANTATION, V72, P463
   PALETTO AE, 2004, NUOVO TRATTATO TECNI
   Tiao GM, 2005, J PEDIATR SURG, V40, P268, DOI 10.1016/j.jpedsurg.2004.09.021
NR 10
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUL-AUG
PY 2007
VL 39
IS 6
BP 1939
EP 1941
DI 10.1016/j.transproceed.2007.05.041
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 201EF
UT WOS:000248813600061
PM 17692659
ER

PT J
AU Diamanti, A
   Basso, MS
   Castro, M
   Calce, A
   Pietrobattista, A
   Gambarara, M
AF Diamanti, A.
   Basso, M. S.
   Castro, M.
   Calce, A.
   Pietrobattista, A.
   Gambarara, M.
TI Prevalence of life-threatening complications in pediatric patients
   affected by intestinal failure
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
AB Intestinal failure (IF) is defined as the reduction of functional gut mass necessary to maintain health and growth in children. Causes of IF include short bowel syndrome (SBS), neuromuscular intestinal disorders (NID), and severe protracted diarrhea (SPD). If patients require long-term parenteral nutrition (PN); they can now be discharged on home PN (HPN), thus improving their quality of life. Children requiring long-term PN are at high risk of developing life-threatening IF complications that hinder HPN, namely, IF associated liver disease (IFALD), catheter-related infections (CRI), and thrombosis. The goal of our study was to retrospectively evaluate the prevalence of life-threatening complications among IF patients according to the HPN indication. From January 1989 to May 2006, 60 IF patients (41 boys and 19 girls) underwent prolonged HPN. Total program duration was 46,391 days (127 total years, mean 2.1 years per patient). Indications for HPN were SBS in 36 cases, SPD in 19 cases, or NID in 5 cases. In our experience patients affected by SBS displayed a significantly higher prevalence of life-threatening complications than patients with other IF causes. Sixteen (27%) among 60 patients developed IFALD. CRI and thrombosis prevalence were 1.4/1000 central venous catheter (CVC) days and 0.2/1000 CVC days respectively. SBS seemed to lead to life-threatening complications more often than other HPN indications. SBS patients on long-term PN therefore require careful management to identify complications early, and they seem to be the candidates for early referral to small bowel transplantation centers.
C1 Bambino Gesu Children Hosp, Home Artif Nutr Ctr, I-00165 Rome, Italy.
   Bambino Gesu Children Hosp, Gastroenterol & Nutr Unit, Rome, Italy.
RP Diamanti, A (reprint author), Bambino Gesu Children Hosp, Home Artif Nutr Ctr, Piazza S Onofrio 4, I-00165 Rome, Italy.
EM diamanti@opbg.net
CR Cavicchi M, 2000, ANN INTERN MED, V132, P525
   de Jonge Rogier C J, 2005, Pediatr Crit Care Med, V6, P329, DOI 10.1097/01.PCC.0000161074.94315.0A
   Goulet O, 2004, J PEDIATR GASTR NUTR, V38, P250, DOI 10.1097/00005176-200403000-00006
   Gupte GL, 2006, ARCH DIS CHILD, V91, P259, DOI 10.1136/adc.2004.068684
   Ingham Clark C L, 1992, Br J Surg, V79, P676
   Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x
   KELLY DA, 1998, NUTRITION, V20, P17
   Koletzko Berthold, 2005, J Pediatr Gastroenterol Nutr, V41 Suppl 2, pS1, DOI 10.1097/01.mpg.0000181841.07090.f4
NR 8
TC 31
Z9 31
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JUN
PY 2007
VL 39
IS 5
BP 1632
EP 1633
DI 10.1016/j.transproceed.2007.02.083
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 185LJ
UT WOS:000247712200080
PM 17580205
ER

PT J
AU Dehghani, SM
   Bahador, A
   Gholami, S
   Nikeghbalian, S
   Salahi, H
   Imanieh, MH
   Haghighat, M
   Davari, HR
   Serati, Z
   Mehrabani, D
   Malek-Hosseini, SA
AF Dehghani, Seyed Mohsen
   Bahador, Ali
   Gholami, Siavash
   Nikeghbalian, Saman
   Salahi, Heshmatollah
   Imanieh, Mohammad Hadi
   Haghighat, Mahmood
   Davari, Hamid Reza
   Serati, Zahra
   Mehrabani, Davood
   Malek-Hosseini, Seyed Ali
TI Pediatric liver transplantation in Iran: Evaluation of the first 50
   cases
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; indications; complications; survival;
   mortality
ID RISK-FACTORS; RECIPIENTS; CHILDREN
AB LT is nowadays accepted as the definitive therapy for end-stage liver disease. We report our experiences with pediatric LT using grafts from living related and DD. From April 1999 to March 2006, 50 infants and children who underwent LT were studied for pretransplantation status, medical and surgical complications and survival rate. There were 33 (66%) boys and 17 (34%) girls. The mean age of patients was 9.9 +/- 4.8 yr (range: 0.9-17.7) with a mean weight of 33.4 +/- 18.4 kg (range: 7.5-80). The main indications were cryptogenic cirrhosis (30%), autoimmune cirrhosis (24%), followed by biliary atresia (22%), Wilson disease (14%), progressive familial intrahepatic cholestasis (4%), fulminant hepatitis (4%) and tyrosinemia (2%). We used living-related donor in 14 (28%) and split liver in 5 (10%) cases and other patients received whole liver from DD. The mean follow-up of patients was 24.7 +/- 22.6 months (range: 1-72). The main postoperative complications were acute cellular rejection (44%) and infections (30%), whereas chronic rejection was seen in 26% of cases. The mortality rate was 24%. Overall mean survival (76% alive) was 63.5 +/- 5.7, 95% CI: 52.3-74.6. Our results demonstrate that pediatric LT is a feasible undertaking in Iran. Organ shortage in our area led to liberal use of living related and split liver techniques. The overall results of the pediatric LT in Iran are encouraging.
C1 Shiraz Univ Med Sci, Nemazee Hosp, Organ Transplantat Ctr, Shiraz, Iran.
   Shiraz Univ Med Sci, Nemazee Hosp, Dept Pediat Gastroenterol, Shiraz, Iran.
   Shiraz Univ Med Sci, Nemazee Hosp, Gastroenterohepatol Res Ctr, Shiraz, Iran.
RP Dehghani, SM (reprint author), Shiraz Univ Med Sci, Organ Transplantat Ctr, Shiraz, Iran.
EM dehghanism@sums.ac.ir
RI Mehrabani, Davood/K-7509-2013
OI Mehrabani, Davood/0000-0002-5738-1719
CR ARIKAN C, 2002, TRANSPLANTATION S, V74, P3526
   Aydogdu S, 2005, PEDIATR TRANSPLANT, V9, P723, DOI 10.1111/j.1399-3046.2005.00366.x
   Balistreri WF, 1998, LIVER TRANSPLANT SUR, V4, pS18
   Emre S, 2002, PEDIATR TRANSPLANT, V6, P43, DOI 10.1034/j.1399-3046.2002.1r072.x
   Ganschow R, 2000, Pediatr Transplant, V4, P273, DOI 10.1034/j.1399-3046.2000.00127.x
   Garcia S, 1998, CLIN TRANSPLANT, V12, P190
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   MCDIARMID SV, 2003, PEDIATR CLIN N AM, V6, P1335
   Murphy MS, 1996, ARCH DIS CHILD, V75, P502
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   ROGIERS MX, 1994, TRANSPL P, V6, P3620
   TANAKA K, 1994, AM J SURG, V168, P41, DOI 10.1016/S0002-9610(05)80069-8
   Williams HJ, 1998, PERFUSION-UK, V13, P322, DOI 10.1177/026765919801300507
NR 14
TC 2
Z9 2
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2007
VL 11
IS 3
BP 256
EP 260
DI 10.1111/j.1399-3046.2006.00665.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 153EU
UT WOS:000245415600005
PM 17430479
ER

PT J
AU Turska-Kmiec, A
   Jankowska, I
   Pawlowska, J
   Kalicinski, P
   Kawalec, W
   Tomyn, M
   Markiewicz, M
   Teisseyre, J
   Czubkowski, P
   Rekawek, J
   Socha, J
AF Turska-Kmiec, Anna
   Jankowska, Irena
   Pawlowska, Joanna
   Kalicinski, Piotr
   Kawalec, Wanda
   Tomyn, Malgorzata
   Markiewicz, Malgorzata
   Teisseyre, Joanna
   Czubkowski, Piotr
   Rekawek, Joanna
   Socha, Jerzy
TI Reversal of tacrolimus-related hypertrophic cardiomyopathy after
   conversion to rapamycin in a pediatric liver transplant recipient
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hypertrophic cardiomyopathy; tacrolimus; rapamycin; pediatric liver
   transplantation
ID ECHOCARDIOGRAPHIC FINDINGS; CHILDREN; CYCLOSPORINE; IMMUNOSUPPRESSION;
   FK506; CA2+
AB Tacrolimus (Tac)-related hypertrophic cardiomyopathy (HCM) has been reported to be an unusual but serious complication affecting pediatric patients after solid organ transplantation. Herein, we present a case of young liver transplant recipient with Tac-induced HCM, treated by discontinuation of Tac followed by conversion to rapamycin (Rap). Our case report points out the potential but rather low risk of HCM during Tac immunosuppression in pediatric liver transplants and demonstrates that replacement of calcineurin inhibitors with mammalian target of Rap (mTOR) inhibitors may be an efficacious therapeutic tool to effect regression of established cardiac hypertrophy.
C1 Childrens Mem Hlth Inst, Dept Cardiol, PL-04730 Warsaw, Poland.
   Childrens Mem Hlth Inst, Dept Gastroenterol Hepatol & Immunol, PL-04730 Warsaw, Poland.
   Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, PL-04730 Warsaw, Poland.
RP Turska-Kmiec, A (reprint author), Childrens Mem Hlth Inst, Dept Cardiol, Aleja Dzieci Polskich 20, PL-04730 Warsaw, Poland.
EM turskakmiec@op.pl
CR ATKISON P, 1995, LANCET, V345, P894, DOI 10.1016/S0140-6736(95)90011-X
   Atkison PR, 1997, TRANSPLANTATION, V64, P773, DOI 10.1097/00007890-199709150-00020
   BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2
   Chang RKR, 1998, AM J CARDIOL, V81, P1277, DOI 10.1016/S0002-9149(98)00126-X
   Chang RKR, 2001, PEDIATR TRANSPLANT, V5, P187, DOI 10.1034/j.1399-3046.2001.00052.x
   Coley KC, 2001, ANN PHARMACOTHER, V35, P985
   Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1
   Dedmon Mark, 2005, JAAPA, V18, P41
   Emre S, 2000, TRANSPLANT INT, V13, P73, DOI 10.1111/j.1432-2277.2000.tb01040.x
   Glass DJ, 2003, TRENDS MOL MED, V9, P344, DOI 10.1016/S1471-4914(03)00138-2
   Jardine AG, 2001, HEART, V86, P459, DOI 10.1136/heart.86.4.459
   Jarzembowski TM, 2005, PEDIATR TRANSPLANT, V9, P117, DOI 10.1111/j.1399-3046.2005.00260.x
   Kampmann C, 2000, HEART, V83, P667, DOI 10.1136/heart.83.6.667
   KOGEL M, 1992, AM J CARDIOL, V69, P941
   MARTINEZ YL, 2005, CARDIOL YOUNG, V15, P106
   Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131
   Nakata Y, 2000, TRANSPLANTATION, V69, P1960, DOI 10.1097/00007890-200005150-00039
   Ozcay F, 2002, TRANSPLANT P, V34, P2150, DOI 10.1016/S0041-1345(02)02886-5
   Pappas P A, 2000, Pediatr Transplant, V4, P45, DOI 10.1034/j.1399-3046.2000.00083.x
   PARK SC, 1985, AM J CARDIOL, V55, P1373, DOI 10.1016/0002-9149(85)90507-7
   PAUL A, 1995, LANCET, V343, P894
   Roberts CA, 2002, TRANSPLANTATION, V74, P817, DOI 10.1097/01.TP.0000029026.03278.46
   Sindhi R, 2001, TRANSPLANTATION, V72, P851, DOI 10.1097/00007890-200109150-00019
   Therapondos G, 2002, LIVER TRANSPLANT, V8, P690, DOI 10.1053/jlts.2002.34381
   *US MULT FK506 LIV, 1994, NEW ENGL J MED, V331, P1110
   WATSON CJE, 2001, TRANSPLANT REV, V15, P165, DOI 10.1016/S0955-470X(01)80016-1
NR 26
TC 11
Z9 13
U1 0
U2 4
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2007
VL 11
IS 3
BP 319
EP 323
DI 10.1111/j.1399-3046.2006.00633.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 153EU
UT WOS:000245415600016
PM 17430490
ER

PT J
AU Okajima, H
   Hayashida, S
   Iwasaki, H
   Suda, H
   Takeichi, T
   Ueno, M
   Asonuma, K
   Inomata, Y
AF Okajima, Hideaki
   Hayashida, Shintaro
   Iwasaki, Hironori
   Suda, Hiroko
   Takeichi, Takayuki
   Ueno, Mikako
   Asonuma, Katsuhiro
   Inomata, Yukihiro
TI Bowel obstruction due to diaphragmatic hernia in an elder child after
   pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; diaphragmatic hernia; complication;
   bowel obstruction
ID INTERNAL HERNIA
AB A 10-yr-old boy with end-stage liver cirrhosis due to Wilson's disease received a living donor liver transplantation (LDLT) at our institution. The donor was his father and the graft was a left lateral segment. The liver transplantation procedure and the postoperative course were uneventful. Two months after the procedure, he developed a first episode of bowel obstruction that was treated with conservative therapy. During a second episode of bowel obstruction, he also presented respiratory distress. A plain chest X-ray revealed the presence of small intestine loops in the right thoracic cavity and bowel obstruction due to diaphragmatic hernia was diagnosed. Repair of the diaphragmatic hernia was performed and the patient has been doing well after the surgery. Diaphragmatic hernia after LDLT is rare but should be recognized as a possible complication when a left lobe or a left lateral segment graft is used.
C1 Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat Pediat Surg, Kumamoto, Japan.
RP Okajima, H (reprint author), Kumamoto Univ Hosp, Dept Transplantat Pediat Surg, 860-8556,1-1-1 Honjo Kumamoto, Kumamoto, Japan.
EM hokajima@fc.kuh.kumamoto-u.ac.jp
CR Blachar A, 2001, RADIOLOGY, V218, P384
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Englert C, 2006, TRANSPLANTATION, V82, P574, DOI 10.1097/01.tp.0000231709.63721.5c
   Hawxby Alan M, 2006, Hepatobiliary Pancreat Dis Int, V5, P459
   Mack C L, 2000, Pediatr Transplant, V4, P39, DOI 10.1034/j.1399-3046.2000.00080.x
   Manczur TI, 2002, TRANSPLANTATION, V73, P228, DOI 10.1097/00007890-200201270-00013
   McCabe AJ, 2005, J PEDIATR SURG, V40, P1181, DOI 10.1016/j.jpedsurg.2005.03.063
   Nishida S, 2002, CLIN TRANSPLANT, V16, P334, DOI 10.1034/j.1399-0012.2002.01149.x
   Sandler AD, 1997, J PEDIATR SURG, V32, P416, DOI 10.1016/S0022-3468(97)90594-7
   Smyrniotis V, 1998, TRANSPLANT INT, V11, P281, DOI 10.1111/j.1432-2277.1998.tb00971.x
NR 10
TC 11
Z9 11
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2007
VL 11
IS 3
BP 324
EP 326
DI 10.1111/j.1399-3046.2006.00658.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 153EU
UT WOS:000245415600017
PM 17430491
ER

PT J
AU Emiroglu, R
   Sevmis, S
   Moray, G
   Savas, N
   Haberal, M
AF Emiroglu, R.
   Sevmis, S.
   Moray, G.
   Savas, N.
   Haberal, M.
TI Living-donor liver transplantation: Results of a single center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Middle-East-Society-for-Organ-Transplantation
CY NOV 26-29, 2006
CL Kuwait City, KUWAIT
SP Middle E Soc Organ Transplantat
ID PEDIATRIC-PATIENTS; COMPLICATIONS; EXPERIENCE
AB In the absence of cadaveric donor liver transplantation, living-donor liver transplantation (LDLT) is an alternative option for patients with end-stage liver disease. The objective of this study was to evaluate the outcome of LDLT at a single medical center in Turkey. We retrospectively analyzed the results of 101 LDLTs in 99 recipients with end-stage liver disease. We transplanted 49 right liver lobes, 16 left lobes, and 36 hepatic segments II and III. Most donors (46%) were parents of the recipients. Seventeen recipients had concomitant hepatocellular carcinoma and cirrhosis. Retransplantation was performed in two recipients. Ten hepatic arterial thromboses, 1 hepatic arterial bleeding, and 12 biliary leaks occurred in the early postoperative period. Most complications were treated with interventional techniques. Three hepatic vein stenoses, three portal vein stenoses, one hepatic arterial stenosis, and six biliary stenoses developed during the late postoperative period. Recipients with those complications were treated with interventional techniques. Mean follow-up was 14.2 +/- 10.9 months. During that time, no tumor recurrence was detected in any recipient with hepatocellular carcinoma. Twenty-two recipients died during the follow-up. At this time, the remaining 77 recipients (77%) are alive, exhibiting good graft function. In general, complication rates are slightly higher after LDLT than after cadaveric liver transplantation. However, most complications can be treated with interventional techniques. LDLT continues to be a life-saving option in countries without satisfactory cadaveric donation rates.
C1 Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Dalgic A, 2005, TRANSPLANT P, V37, P3133, DOI 10.1016/j.transproceed.2005.07.004
   Dazzi A, 2005, TRANSPLANT P, V37, P2595, DOI 10.1016/j.transproceed.2005.06.061
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   HABERAL M, 1993, TRANSPLANT P, V25, P1899
   Haberal M, 2002, TRANSPLANT P, V34, P2145, DOI 10.1016/S0041-1345(02)02884-1
   Haberal M, 2006, TRANSPLANT P, V38, P584, DOI 10.1016/j.transproceed.2006.01.023
   HARPER AM, 1999, CLIN TRANSPLANTS 199, P73
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Kiuchi T, 1998, TRANSPLANT P, V30, P687, DOI 10.1016/S0041-1345(98)00009-8
   Kiuchi T, 2001, Clin Transpl, P195
   Lee RKK, 2002, INT J ANDROL, V25, P277, DOI 10.1046/j.1365-2605.2002.00355.x
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   RAIA S, 1989, LANCET, V2, P497
   Testa G, 2001, WORLD J SURG, V25, P1296
   Williams RS, 2003, EUR J GASTROEN HEPAT, V15, P7, DOI 10.1097/00042737-200301000-00003
NR 16
TC 5
Z9 6
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2007
VL 39
IS 4
BP 1149
EP 1152
DI 10.1016/j.transproceed.2007.02.052
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 174MW
UT WOS:000246947400108
PM 17524917
ER

PT J
AU Karakayali, H
   Ozcay, F
   Sevmis, S
   Savas, N
   Haberal, M
AF Karakayali, H.
   Ozcay, F.
   Sevmis, S.
   Savas, N.
   Haberal, M.
TI Liver transplantation for small babies
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Middle-East-Society-for-Organ-Transplantation
CY NOV 26-29, 2006
CL Kuwait City, KUWAIT
SP Middle E Soc Organ Transplantat
ID CHILDREN; GRAFT; COMPLICATIONS; INFANTS; DONORS; SPLIT; LESS; AGE
AB Orthotopic liver transplantation remains a major medical and surgical challenge in small pediatric patients. From April 2003 to June 2006, 21 small babies (each of whom weighed less than 10 kg or was younger than I year of age) underwent orthotopic liver transplantation. Five were girls and 16 were boys with a mean age of 15.7 +/- 9.3 months (range, 2-24 months); their mean weight at the time of transplantation was 9.8 +/- 3.6 kg (range, 6-16 kg). All transplants were obtained from a living-related donor. Left lateral segment was used for all transplantations. The median graft-to-recipient weight ratio was 3.5% +/- 1.2% (range, 1.5%-6.1%). During the early postoperative period, hepatic arterial thrombosis was identified in 4 patients, and a biliary leak was detected in 2 patients. In 2 patients, portal vein stenosis was identified during the late postoperative period. At the time of this writing, the 17 alive patients (81%) exhibited good graft function at median follow-up of 14.8 +/- 10.9 months (range, 1-39 months). Four patients died during the follow-up. Histological examination revealed hepatocellular carcinoma in 2 patients, and Burkitt's lymphoma in I patient. In conclusion, our data confirmed that living-related donors, especially in this age group, provide a reliable source for the organ pool. Satisfactory results can be achieved despite the anatomic handicaps of this age group.
C1 Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR BEATH SV, 1993, BRIT MED J, V307, P825
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   DUNN SP, 1993, J PEDIATR SURG, V28, P1048, DOI 10.1016/0022-3468(93)90516-N
   Glanemann M, 2001, TRANSPLANT INT, V14, P48, DOI 10.1007/s001470050742
   HABERAL M, 2006, TRANSPL P, V38, P3576
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   Haberal M, 2006, TRANSPLANT P, V38, P584, DOI 10.1016/j.transproceed.2006.01.023
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   McDiarmid S V, 2000, Clin Liver Dis, V4, P879, DOI 10.1016/S1089-3261(05)70146-X
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   OTTE JB, 1994, HEPATOLOGY, V20, pS41, DOI 10.1002/hep.1840200711
   Saing H, 1997, J PEDIATR SURG, V32, P80, DOI 10.1016/S0022-3468(97)90100-7
   Saing H, 1999, J PEDIATR SURG, V34, P1721, DOI 10.1016/S0022-3468(99)90653-X
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
NR 21
TC 6
Z9 6
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2007
VL 39
IS 4
BP 1153
EP 1156
DI 10.1016/j.transproceed.2007.02.054
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 174MW
UT WOS:000246947400109
PM 17524918
ER

PT J
AU Haberal, M
   Sevmis, S
   Emiroglu, R
   Karakayali, H
   Arslan, G
AF Haberal, M.
   Sevmis, S.
   Emiroglu, R.
   Karakayali, H.
   Arslan, G.
TI Duct-to-duct biliary reconstruction in pediatric liver transplantation:
   One center's results
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th Congress of the Middle-East-Society-for-Organ-Transplantation
CY NOV 26-29, 2006
CL Kuwait City, KUWAIT
SP Middle E Soc Organ Transplantat
ID FEASIBILITY; ANASTOMOSIS
AB In pediatric liver transplantation, both for cadaveric and living-related patients, the Roux-en-Y hepaticojejunostomy is often preferable to biliary reconstruction. Duct-to-duct biliary reconstruction in pediatric patients has been utilized only in a limited numbers of studies. Here, we retrospectively review our experience with duct-to-duct biliary reconstruction in pediatric liver transplantation patients. Since September 2001, 46 liver transplantations have been performed in 44 patients (29 boys and 15 girls of mean age, 8.4 +/- 5.5 years). For the anastomoses, a corner-saving suture technique was used with 6-0 or 7-0 polypropylene monofilament nonabsorbable suture. A T tube was used in three patients, and in 11 patients, a straight feeding tube was inserted from the recipient common bile duct to the anastomotic site. A transhepatic biliary catheter insertion technique was used in 28 patients for external bile drainage; the remaining four patients had no tubes or stents. Four patients developed bile leakage in the early postoperative period. Three of these patients were treated with percutaneous drainage with excellent outcomes; the remaining patient required reoperation with a Roux-en-Y hepaticojejunostomy for bile leakage. Four biliary stenoses occurred in the late postoperative period. All biliary stenoses were successfully treated with balloon dilatation. There was no mortality or graft loss due to biliary complications. Of the 44 original patients, 36 (82%) are well at this time, with optimal liver function during follow-up (2-34 months). The remaining eight (18%) died during the study from acute respiratory distress syndrome (n = 2), sepsis with multiorgan failure (n = 5), and intracranial bleeding (n = 1). Our results showed that duct-to-duct biliary reconstruction is a safe and easy technique for pediatric patients.
C1 Baskent Univ, Dept Gen Surg, Fac Med, TR-06490 Ankara, Turkey.
   Baskent Univ, Dept Anesthesiol, Fac Med, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Dept Gen Surg, Fac Med, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Azoulay D, 2001, ARCH SURG-CHICAGO, V136, P1197, DOI 10.1001/archsurg.136.10.1197
   Dalgic A, 2005, TRANSPLANT P, V37, P3137, DOI 10.1016/j.transproceed.2005.08.046
   HABERAL M, 1992, TRANSPLANT P, V24, P1967
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   Haberal M, 2006, TRANSPLANT P, V38, P584, DOI 10.1016/j.transproceed.2006.01.023
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Kimura T, 2006, PEDIATR TRANSPLANT, V10, P248, DOI 10.1111/j.1399-3046.2005.00430.x
   Liu CL, 2004, TRANSPLANTATION, V77, P726, DOI 10.1097/01.TP.0000116604.89083.2F
   Okajima H, 2005, PEDIATR TRANSPLANT, V9, P531, DOI 10.1111/j.1399-3046.2005.00336.x
   Soejima Y, 2003, TRANSPLANTATION, V75, P557, DOI 10.1097/01.TP.0000048220.90971.5A
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5
NR 13
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2007
VL 39
IS 4
BP 1161
EP 1163
DI 10.1016/j.transproceed.2007.02.046
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 174MW
UT WOS:000246947400111
PM 17524920
ER

PT J
AU Venick, RS
   McDiarmid, SV
   Farmer, DG
   Gornbein, J
   Martin, MG
   Vargas, H
   Ament, ME
   Busuttil, RW
AF Venick, R. S.
   McDiarmid, S. V.
   Farmer, D. G.
   Gornbein, J.
   Martin, M. G.
   Vargas, H.
   Ament, M. E.
   Busuttil, R. W.
TI Rejection and steroid dependence: Unique risk factors in the development
   of pediatric posttransplant de novo autoimmune hepatitis
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE de novo autoimmune hepatitis; liver transplantation; pediatric;
   rejection
ID LATE GRAFT DYSFUNCTION; LIVER-TRANSPLANT RECIPIENTS; IMMUNE HEPATITIS;
   CYCLOSPORINE-A; ANTIBODIES; CHILDREN; DISEASE; EXPERIENCE; THERAPY; MICE
AB Posttransplant de novo autoimmune hepatitis (d-AIH) is increasingly described as a long-term complication after pediatric liver transplantation (LT). d-AIH is characterized by graft dysfunction, the development of autoimmune antibodies and histologic evidence of hepatitis in liver transplant recipients without previous history of autoimmune liver disease. This study is a matched case-control, univariate analysis aimed at identifying risk factors for the development of d-AIH and evaluating response to treatment. From 1984 to 2003, 619 children received 788 LTs at a single center. Forty-one patients developed d-AIH and were matched with controls for year of LT, age at time of LT and diagnosis. The following variables were insignificant in the development of d-AIH: age, gender, race, initial diagnosis, ischemia time, graft type, Epstein-Barr virus and cytomegalovirus status, HLA typing and primary immunosuppression. Compared to controls, d-AIH patients were less likely to be on monotherapy immunosuppression or weaned off prednisone at the time of diagnosis. The d-AIH group relative to the controls had statistically significant greater numbers of rejection episodes. d-AIH was treated with prednisone and/or MMF in 39 of 41 patients and lead to significant improvements in liver function tests. Thirty-nine patients are alive at a mean of 4.0 years follow-up after diagnosis. Three have required retransplantation.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90024 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat & Surg, Los Angeles, CA USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA USA.
   Dumont UCLA Transplant Ctr, Dept Surg, Dept Biomath, Los Angeles, CA USA.
RP Venick, RS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90024 USA.
EM Rvenick@mednet.ucla.edu
CR Aguilera I, 2001, CLIN EXP IMMUNOL, V126, P535, DOI 10.1046/j.1365-2249.2001.01682.x
   Aguilera I, 2004, LIVER TRANSPLANT, V10, P1166, DOI 10.1002/lt.20209
   Alvarez F., 1999, Journal of Hepatology, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   Andries S, 2001, TRANSPLANTATION, V72, P267, DOI 10.1097/00007890-200107270-00018
   Bogdanos DP, 2001, LIVER, V21, P225, DOI 10.1034/j.1600-0676.2001.021004225.x
   BUCY RP, 1993, J IMMUNOL, V151, P1039
   Chinnakotla S, 2005, TRANSPLANTATION LIVE, P1213, DOI 10.1016/B978-0-7216-0118-2.50080-X
   Clemente MG, 2001, J HEPATOL, V34, P45, DOI 10.1016/S0168-8278(01)81023-0
   Conti F., 1997, Journal of Hepatology, V26, P150
   Czaja AJ, 2002, LIVER TRANSPLANT, V8, P505, DOI 10.1053/jlts.2002.3348
   Czaja AJ, 1999, DRUGS, V57, P49, DOI 10.2165/00003495-199957010-00005
   Doron S, 2006, TRANSPLANTATION, V81, P697, DOI 10.1097/01.tp.0000180531.66518.9e
   Dubel L, 1998, TRANSPLANTATION, V65, P1072, DOI 10.1097/00007890-199804270-00011
   Fedoseyeva EV, 1999, J IMMUNOL, V162, P6836
   Fedoseyeva EV, 1996, TRANSPLANTATION, V61, P679, DOI 10.1097/00007890-199603150-00001
   GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0
   Gregorio GV, 1997, HEPATOLOGY, V25, P541, DOI 10.1002/hep.510250308
   Gupta P, 2001, TRANSPLANTATION, V71, P664, DOI 10.1097/00007890-200103150-00016
   Hadzic N, 2003, HEPATOLOGY, V38, p202A
   Heneghan MA, 2001, HEPATOLOGY, V34, P464, DOI 10.1053/jhep.2001.26756
   Hernandez Albujar A., 1997, Journal of Hepatology, V26, P152
   Hernandez HM, 2001, J PEDIATR GASTR NUTR, V32, P131, DOI 10.1097/00005176-200102000-00007
   HUSBY G, 1977, SCAND J GASTROENTERO, V12, P297
   Jankowska I, 2004, TRANSPLANT P, V36, P3077, DOI 10.1016/j.transproceed.2004.11.103
   JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237
   Jones DEJ, 1999, HEPATOLOGY, V30, P53, DOI 10.1002/hep.510300103
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   McDiarmid SV, 1995, TRANSPLANTATION, V60, P1443, DOI 10.1097/00007890-199560120-00013
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   Mieli-Vergani G, 2004, J HEPATOL, V40, P3, DOI 10.1016/j.jhep.2003.10.022
   Mieli-Vergani Giorgina, 2002, Clin Liver Dis, V6, P623, DOI 10.1016/S1089-3261(02)00020-X
   Miyagawa-Hayashino A, 2004, TRANSPLANTATION, V78, P128, DOI 10.1097/01.TP.0000132328.33460.43
   Miyagawa-Hayashino Aya, 2003, Transplantation, V76, P271, DOI 10.1097/01.TP.0000072338.88465.59
   Petz W, 2002, TRANSPLANT P, V34, P1958, DOI 10.1016/S0041-1345(02)03137-8
   RONG PB, 1984, CLIN EXP IMMUNOL, V55, P546
   Salcedo M, 2002, HEPATOLOGY, V35, P349, DOI 10.1053/jhep.2002.31167
   Salcedo M, 2001, J HEPATOL, V34, P47
   Salcedo M, 2001, J HEPATOL, V34, P49, DOI 10.1016/S0168-8278(01)81036-9
   SAXENA R, 2001, HEPATOLOGY, V34, P292
   Spada M, 2001, TRANSPLANT P, V33, P1747, DOI 10.1016/S0041-1345(00)02826-8
   Vergani D, 2004, PEDIATR TRANSPLANT, V8, P589, DOI 10.1111/j.1399-3046.2004.00288.x
   VERGANI D, 2003, LIVER IMMUNOLOGY, P469
NR 42
TC 43
Z9 43
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2007
VL 7
IS 4
BP 955
EP 963
DI 10.1111/j.1600-6143.2006.01717.x
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 149MR
UT WOS:000245151500029
PM 17391135
ER

PT J
AU Mekeel, KL
   Langham, MR
   Gonzalez-Peralta, R
   Fujita, S
   Hemming, AW
AF Mekeel, Kristin L.
   Langham, Max R., Jr.
   Gonzalez-Peralta, Regino
   Fujita, Shiro
   Hemming, Alan W.
TI Liver transplantation in children with sickle-cell disease
SO LIVER TRANSPLANTATION
LA English
DT Article
ID INTRAHEPATIC CHOLESTASIS; HEPATITIS-C; ANEMIA; PATIENT; TRANSFUSION;
   HEPATOPATHY
AB Severe liver disease is an unusual but potentially fatal complication of sickle-cell disease (SCD). Liver transplantation has been complicated by ongoing SCD and thrombosis. We reviewed 214 pediatric transplants done at our institution from 1990 to 2005. Three patients were transplanted for complications of SCD, including intrahepatic cholestasis and viral hepatitis. Overall patient and graft survival was 66%. One patient died after 6 years from a subdural hematoma. There were not any incidences of graft loss, primary nonfunction, or thrombosis. All 3 patients required between 1 and 4 postoperative transfusions to keep hemoglobin (Hgb) >9 g/dL with an S fraction of less than 25%. One patient required a preoperative transfusion for a hemoglobin S (HbS) fraction of 30%. Mean follow-up has been 4.2 years (range, 2.6-5.4 years). All 3 children continued to suffer sequelae from their SCD. One child suffered from recurrent sickle-cell hepatopathy and chronic graft failure. In conclusion, children with SCD can in rare instances develop acute and chronic liver failure. These children can be successfully transplanted with good outcomes. Careful attention must be paid to HbS fraction and hemoglobin level to prevent sickling and vascular thrombosis. Unfortunately, liver transplant cannot alter the natural course of the disease.
C1 Univ Florida, Ctr Hepatobiliary Dis, Dept Surg, Div Transplantat, Gainesville, FL 32610 USA.
   Univ Tennessee, Ctr Hlth Sci, Div Pediat Surg, Memphis, TN 38163 USA.
   Univ Florida, Dept Pediat, Div Gastroenterol, Gainesville, FL USA.
RP Hemming, AW (reprint author), Univ Florida, Ctr Hepatobiliary Dis, Dept Surg, Div Transplantat, POB 100286, Gainesville, FL 32610 USA.
EM hemming@surgery.ufl.edu
CR Ahn H, 2005, PEDIATR BLOOD CANCER, V45, P184, DOI 10.1002/pbc.20317
   Baichi MM, 2005, TRANSPLANTATION, V80, P1630, DOI 10.1097/01.tp.0000184446.52454.69
   Banerjee S, 2001, HEPATOLOGY, V33, P1021, DOI 10.1053/jhep.2001.24114
   CASTRO OL, 1987, PUBLIC HEALTH REP, V102, P232
   DEVAULT KR, 1994, J CLIN GASTROENTEROL, V18, P206, DOI 10.1097/00004836-199404000-00006
   Emre S, 2000, TRANSPLANTATION, V69, P675, DOI 10.1097/00007890-200002270-00036
   Gilli SCO, 2002, TRANSPLANTATION, V74, P896, DOI 10.1097/01.TP.0000028445.23375.FA
   Haberkern CM, 1997, BLOOD, V89, P1533
   Harmatz P, 2000, BLOOD, V96, P76
   Hasan MF, 1996, AM J GASTROENTEROL, V91, P1204
   KINDSCHER JD, 1995, TRANSPLANTATION, V60, P762, DOI 10.1097/00007890-199510150-00026
   LANG T, 1995, TRANSPLANTATION, V59, P1490, DOI 10.1097/00007890-199505270-00025
   Lerut JP, 1999, TRANSPLANTATION, V67, P65, DOI 10.1097/00007890-199901150-00010
   Miller ST, 2001, J PEDIATR-US, V139, P785, DOI 10.1067/mpd.2001.119593
   Ross AS, 2002, TRANSPLANTATION, V73, P605, DOI 10.1097/00007890-200202270-00022
   SHAO SH, 1995, AM J GASTROENTEROL, V90, P2048
   van den Hazel SJ, 2003, TRANSPLANT INT, V16, P434, DOI 10.1007/s00147-003-0567-5
   VICHINSKY EP, 1995, NEW ENGL J MED, V333, P206, DOI 10.1056/NEJM199507273330402
NR 18
TC 12
Z9 12
U1 1
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD APR
PY 2007
VL 13
IS 4
BP 505
EP 508
DI 10.1002/lt.20999
PG 4
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 155RT
UT WOS:000245596400007
PM 17394147
ER

PT J
AU Uribe, M
   Buckel, E
   Ferrario, M
   Hunter, B
   Godoy, J
   Gonzalez, G
   Cavallieri, S
   Iniguez, R
   Calabran, L
   Herzog, C
AF Uribe, M.
   Buckel, E.
   Ferrario, M.
   Hunter, B.
   Godoy, J.
   Gonzalez, G.
   Cavallieri, S.
   Iniguez, R.
   Calabran, L.
   Herzog, C.
TI Pediatric liver retransplantation: Indications and outcome
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 1st Congress of the Chilean-Transplantation-Society
CY MAY 10-13, 2006
CL Vina del Mar, CHILE
SP Chilean Transplantat Soc
ID TRANSPLANTATION; CHILDREN; EXPERIENCE; CHILE
AB Introduction. Liver transplantation is the only treatment for end-stage liver disease. Not all patients have a favorable outcome. Graft failure secondary to primary nonfunction, vascular complications, or chronic rejection among other problems may lead to retransplantation. Retransplantation represents 8% to 29% of liver transplantations in the pediatric population. The aim of this study was to present our experience with retransplanted children by analyzing the indications and the results.
   Methods. All patients were prospectively included in our database, including 125 children. We included the indications for retransplantation, complications, and mortality. Kaplan-Meier curves were used for survival analysis.
   Results. Since 1994, 125 patients were transplanted and 25 were retransplanted (20%), including 5 who received a third graft. Primary nonfunction represented 30% of the indications for retransplantation and hepatic artery thrombosis, 20%. Six of 25 patients who received a first retransplantation and 2 of 5 who received a second retransplantation died. The most frequent cause of death was multiorgans failure. The survivals at I and 5 years were 82% and 76% for children receiving a first retransplantation, and 60% at 1 and 5 years for those who received a second retransplantation.
   Conclusions. Organ failure after liver transplantation was a common event in pediatric transplantation. Survival was similar between patients transplanted once and those who received one retransplantation. Survival decreased among patients who received a third graft but was maintained at 60%, which is better than most published results for first retransplanted patients. Retransplantation is a valid option with good results for selected pediatric cases.
C1 Hosp Ninos Luis Calvo Mackenna, Clin Las Condes, Liver Transplant Program, Santiago, Chile.
RP Uribe, M (reprint author), Lo Fontecilla 441,Las Condes, Santiago, Chile.
EM muribe@manquehue.net
CR Achilleos OA, 1999, LIVER TRANSPLANT SUR, V5, P401, DOI 10.1002/lt.500050505
   Azoulay D, 2002, ANN SURG, V236, P713, DOI 10.1097/01.SLA.0000036264.66247.65
   Deshpande PR, 2002, TRANSPLANTATION, V74, P1124, DOI 10.1097/01.TP.0000030640.11006.CE
   Feng S, 2006, LIVER TRANSPLANT, V12, P578, DOI 10.1002/lt.20650
   Newell KA, 1998, TRANSPLANTATION, V65, P1172, DOI 10.1097/00007890-199805150-00005
   Ogura Y, 2003, TRANSPLANTATION, V76, P943, DOI 10.1097/01.TP.0000080068.22576.3B
   Rand EB, 2003, GASTROENTEROL CLIN N, V32, P913, DOI 10.1016/S0889-8553(03)00048-7
   Sieders E, 2001, TRANSPLANTATION, V71, P90, DOI 10.1097/00007890-200101150-00015
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Uribe M, 2005, TRANSPLANT P, V37, P1567, DOI 10.1016/j.transproceed.2004.09.010
   Uribe M, 2005, TRANSPL P, V37, P3375, DOI 10.1016/j.transproceed.2005.09.096
NR 11
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2007
VL 39
IS 3
BP 609
EP 611
DI 10.1016/j.transproceed.2006.12.031
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 161XK
UT WOS:000246050100007
PM 17445556
ER

PT J
AU Erol, I
   Alehan, F
   Ozcay, F
   Canan, O
   Haberal, M
AF Erol, Ilknur
   Alehan, Fuesun
   Ozcay, Figen
   Canan, Oguz
   Haberal, Mehmet
TI Neurological complications of liver transplantation in pediatric
   patients: A single center experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; pediatric patients; neurologic complication;
   acute dystonic reaction; tacrolimus; posterior leukoencephalopathy
   syndrome
ID RECIPIENTS; LEUKOENCEPHALOPATHY; MANAGEMENT
AB Neurologic complications (NCs) are a significant cause of morbidity and mortality in patients who undergo liver transplantation (LT). The aim of this study was to evaluate the incidence and type of NCs and associated factors in pediatric LT patients. We retrospectively reviewed NCs in the medical records of 40 consecutive infants, children, and adolescents who underwent LT at our institution. The subjects consisted of 23 boys and 17 girls (median age, 8.5 +/- 0.85 yr; range, 11 months to 17 yr). The indications for LT were Wilson's disease in 10 patients, fulminant hepatic failure (FHF) in nine, and other types of chronic liver disease in 21. NCs were found in 14 patients (35%). Those 14 individuals experienced a total of 16 episodes of NCs (two separate episodes in two of the patients). The most common NCs were seizure (seven episodes in six patients) and posterior leukoencephalopathy syndrome (PLES; five episodes in four patients). Seizure was the presenting symptom in three episodes of PLES. Two episodes of diffuse encephalopathy were observed in two patients, and two episodes of psychiatric symptoms occurred in two patients. We also noted one episode of tremor in one patient, one episode of acute dystonic reaction in one patient, and one episode of headache in one patient. Patients with Wilson's disease had a higher incidence of NCs (60%) than did patients without Wilson's disease (26.7%); however, this difference was not significant. The incidence of NCs was 44% in patients with FHF and 35% in those without FHF. That difference also was not significant. Immunosuppressive agents were the primary cause of 13 of the 16 episodes of NC. Uremia with hypertension, hypoxia, and hypomagnesemia caused one neurologic episode each. NCs, which are frequent in the first 30 days after pediatric LT, did not affect survival in this group. NCs were reversed by the discontinuation or reduction of immunosuppressive agents in 12 episodes, correction of hypomagnesemia and the reduction of immunosuppressive agents in one episode, and the correction of uremia and hypertension in one episode. Refractory epilepsy developed in one patient, and death unrelated to NCs occurred in one. The mortality rate was 7.1% (n = 1) in patients with NCs and 15.4% (n = 4) in those without NCs (p = 0.64). NCs are an important complication after LT. It is essential that each transplantation team collaborate with pediatric neurologists to ensure the rapid and accurate diagnosis of NCs in infants, children, and adolescents after LT and to prevent the delay of appropriate treatment.
C1 Baskent Univ, Fac Med, Div Pediat Neurol, Dept Pediat, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Div Pediat Gastroenterol & Hepatol, Dept Pediat, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Gen Surg & Transplantat, TR-06490 Ankara, Turkey.
RP Erol, I (reprint author), Baskent Univ, Fac Med, Div Pediat Neurol, Dept Pediat, 6 Cadde 72-3 Bahcelievler, TR-06490 Ankara, Turkey.
EM ilknur_erol@yahoo.com
CR ALEHAN F, IN PRESS J CHILD NEU
   Araz C, 2004, TRANSPLANT P, V36, P214, DOI 10.1016/j.transproceed.2003.11.029
   Bechstein WO, 2000, TRANSPLANT INT, V13, P313, DOI 10.1111/j.1432-2277.2000.tb01004.x
   BELTRAN J, 1993, TRANSPLANT P, V25, P1749
   Boin IFSF, 2001, TRANSPLANT P, V33, P3695, DOI 10.1016/S0041-1345(01)02507-6
   Bonham CA, 1998, TRANSPLANTATION, V66, P1596, DOI 10.1097/00007890-199812270-00005
   Bronster DJ, 2000, CLIN TRANSPLANT, V14, P1, DOI 10.1034/j.1399-0012.2000.140101.x
   Emre S, 2001, TRANSPLANTATION, V72, P1232, DOI 10.1097/00007890-200110150-00008
   GARG BP, 1993, PEDIATR NEUROL, V9, P444, DOI 10.1016/0887-8994(93)90023-6
   Ghaus N, 2001, J NEUROL, V248, P1042, DOI 10.1007/s004150170023
   GRIDELLI B, 1994, TRANSPLANT P, V26, P193
   Hattori H, 1998, TRANSPLANTATION, V65, P686, DOI 10.1097/00007890-199803150-00015
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Kemper MJ, 2003, CLIN TRANSPLANT, V17, P130, DOI 10.1034/j.1399-0012.2003.00028.x
   Lewis MB, 2003, NEUROLOGY, V61, P1174
   MARSDEN CD, 1980, PSYCHOL MED, V10, P55
   MENEGAUX F, 1994, TRANSPLANTATION, V58, P447, DOI 10.1097/00007890-199408270-00010
   MORENO E, 1993, ACTA NEUROL SCAND, V87, P25
   PUJOL A, 1994, NEUROLOGY, V44, P1226
   Rand EB, 2003, GASTROENTEROL CLIN N, V32, P913, DOI 10.1016/S0889-8553(03)00048-7
   Shibolet O, 2001, TRANSPLANT P, V33, P2959, DOI 10.1016/S0041-1345(01)02271-0
   Singh N, 2000, TRANSPLANTATION, V69, P467, DOI 10.1097/00007890-200002270-00001
   STEIN DP, 1992, ANN NEUROL, V31, P644, DOI 10.1002/ana.410310612
   Vecino MC, 1999, TRANSPLANT P, V31, P3048, DOI 10.1016/S0041-1345(99)00665-X
   VOGT DP, 1988, TRANSPLANTATION, V45, P1057, DOI 10.1097/00007890-198806000-00011
   WIJDICKS EFM, 1999, NEUROLOGIC COMPLICAT, P127
   Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7
NR 27
TC 26
Z9 30
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2007
VL 11
IS 2
BP 152
EP 159
DI 10.1111/j.1399-3046.2006.00620.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 130ID
UT WOS:000243792400008
PM 17300494
ER

PT J
AU Yilmaz, A
   Arikan, C
   Tumgor, G
   Kilic, M
   Aydogdu, S
AF Yilmaz, Aygen
   Arikan, Cigdem
   Tumgor, Gokhan
   Kilic, Murat
   Aydogdu, Sema
TI Vascular complications in living-related and deceased donation pediatric
   liver transplantation: Single center's experience from Turkey
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE vascular complication; liver transplantation; children
ID HEPATIC-ARTERY THROMBOSIS; STENOSIS; VEIN; CHILDREN
AB The aim of the study was to assess early and long-term incidence of venous complications, in both deceased donation (DD) and living-related (LR) liver transplantation (LT) in a pediatric population. Seventy-five liver transplants performed in 69 (39 boys, 30 girls) children at Ege University Hospital between 1997 and 2004 were prospectively monitored and reviewed. Age, sex, primary diagnosis, graft type, vascular complications and their management were evaluated. All patients received Doppler ultrasonographic examination both during operation and daily for the first three postoperative days and when necessary thereafter. The complications were classified as early and late presented. Thirty-three grafts (47.8%) were from DD and 36 (52.2%) were from LR donors. Recipients of DD were older than LR donors (mean age 10.5 +/- 5.1 and 5.0 +/- 0.7, respectively) (p < 0.05). Vascular complication occurrence was not statistically different between DDLT and LRLT recipients (p = 0.2), and between infants and children (p = 0.9). Overall, stenosis was more common than thrombosis. We observed hepatic artery (HA) thrombosis, in five of 75 (6.7%) transplants within 30 days post-transplant. Portal vein (PV) thrombosis and hepatic vein (HV) thrombosis were detected in six and one patients (8.7% and 1.3%), respectively. Six PV stenosis were identified (8.7%), while HA and HV-VC (vena cava) stenosis occurred in one and six patients (1.4% and 8.7%), respectively. All PV stenosis (6/33, 18.2%) and one PV aneurysm occurred in DDLT recipients while HV-VC stenosis were detected almost equally in LRLT and DDLT recipients (4/36 vs. 2/33). Except one, all PV stenosis were detected as a late complication and no intervention were needed. Stenosis of HV-VC was more common in girls (5/30 vs. 1/39) (p < 0.05) and the incidence was not different in DDLT and LRLT recipients (p = 0.8). In conclusion, overall incidences of thrombosis and stenosis formation after orthotopic liver transplantation (OLT) were 17.4% and 18.8%, respectively in our center. We suggest that in the cases with HA thrombosis manifested intra-operatively or within the early postoperative period, graft salvage was successful. Thrombosis of HA causes significant mortality. Thrombosis of PV was among the causes of mortality and morbidity. Stenosis of HV-VC could be managed by angioplasty and endovascular stenting with no significant effect to mortality.
C1 Akdeniz Univ, Liver Transplant Grp, Dept Pediat Gastroenterol, Solid Organ Transplant Ctr, Antalya, Turkey.
   Ege Univ, Dept Pediat Gastroenterol, Solid Organ Transplant Ctr, Izmir, Turkey.
   Ege Univ, Liver Transplant Grp, Solid Organ Transplant Ctr, Dept Gen Surg, Izmir, Turkey.
RP Yilmaz, A (reprint author), Akdeniz Univ, Pediat Anabilim Dali, TR-07059 Antalya, Turkey.
EM aygen@akdeniz.edu.tr
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   Carnevale FC, 2004, PEDIATR TRANSPLANT, V8, P576, DOI 10.1111/j.1399-3046.2004.00213.x
   Cheng YF, 2004, LIVER TRANSPLANT, V10, P248, DOI 10.1002/lt.20055
   Cronin DC, 2002, TRANSPLANTATION, V74, P887, DOI 10.1097/01.TP.0000027976.23051.4A
   Dalgic A, 2003, PEDIATR TRANSPLANT, V7, P149, DOI 10.1034/j.1399-3046.2003.00017.x
   Eid A, 1999, TRANSPLANT P, V31, P1903, DOI 10.1016/S0041-1345(99)00148-7
   Funaki B, 2000, RADIOLOGY, V215, P147
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Harihara Y, 1998, TRANSPLANT P, V30, P3188, DOI 10.1016/S0041-1345(98)00988-9
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Heffron TG, 2003, TRANSPLANT P, V35, P1447, DOI 10.1016/S0041-1345(03)00459-7
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Ueda M, 2005, TRANSPLANT P, V37, P1138, DOI 10.1016/j.transproceed.2005.01.044
NR 17
TC 24
Z9 29
U1 1
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2007
VL 11
IS 2
BP 160
EP 164
DI 10.1111/j.1399-3046.2006.00601.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 130ID
UT WOS:000243792400009
PM 17300495
ER

PT J
AU Miraglia, R
   Luca, A
   Marrone, G
   Caruso, S
   Cintorino, D
   Spada, M
   Gridelli, B
AF Miraglia, Roberto
   Luca, Angelo
   Marrone, Gianluca
   Caruso, Settimo
   Cintorino, Davide
   Spada, Marco
   Gridelli, Bruno
TI Percutaneous transhepatic venous angioplasty in a two-yr-old patient
   with hepatic vein stenosis after partial liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatic venous obstruction; pediatric liver transplantation;
   interventional radiology
ID COMPLICATIONS; OBSTRUCTION; OUTFLOW
AB We report one case of severe hepatic vein stenosis, in a two-yr-old pediatric patient with a left lateral split liver transplantation (S2-S3) and severe ascites, in whom color Doppler ultrasound failed to make the diagnosis and transhepatic balloon angioplasty was successfully performed.
C1 Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
RP Miraglia, R (reprint author), Ist Mediterraneo Trapianti & Terapie Alta Special, Dept Radiol, Via Tricomi 1, I-90127 Palermo, Italy.
EM rmiraglia@ismett.edu
RI miraglia, roberto/B-2051-2016
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 2005, TRANSPLANT INT, V18, P556, DOI 10.1111/j.1432-2277.2005.00088.x
   Ducerf C, 1996, SURGERY, V120, P484, DOI 10.1016/S0039-6060(96)80067-5
   Huang TL, 2004, TRANSPLANT P, V36, P2342, DOI 10.1016/j.transproceed.2004.07.067
   Ko EY, 2003, RADIOLOGY, V229, P806, DOI 10.1148/radiol.2293020700
   Ko GY, 2002, J VASC INTERV RADIOL, V13, P591, DOI 10.1016/S1051-0443(07)61652-2
   KUBO T, 2006, RADIOLOGY, V339, P285
   Stafford-Johnson DB, 1998, RADIOLOGY, V207, P153
   ZAJKO AB, 1989, RADIOLOGY, V170, P763
NR 9
TC 6
Z9 6
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2007
VL 11
IS 2
BP 222
EP 224
DI 10.1111/j.1399-3046.2006.00625.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 130ID
UT WOS:000243792400020
PM 17300506
ER

PT J
AU Bourdeaux, C
   Darwish, A
   Jamart, J
   Tri, TT
   Janssen, M
   Lerut, J
   Otte, JB
   Sokal, E
   de Ville de Goyet, J
   Reding, R
AF Bourdeaux, C.
   Darwish, A.
   Jamart, J.
   Tri, T. T.
   Janssen, M.
   Lerut, J.
   Otte, J. -B.
   Sokal, E.
   de Ville de Goyet, J.
   Reding, R.
TI Living-related versus deceased donor pediatric liver transplantation: A
   multivariate analysis of technical and immunological complications in
   235 recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE children; living donors; outcome; pediatric liver transplantation
ID HLA COMPATIBILITY; PRIMARY GRAFTS; CHILDREN; REVASCULARIZATION;
   EXPERIENCE; THROMBOSIS; REJECTION; ALLOGRAFT; IMPACT; SPLIT
AB Timely access to a living donor (LD) reduced pretransplant mortality in pediatric liver transplantation (LT). We hypothesized that this strategy may provide better posttransplant outcome. Between July 1993 and April 2002, 235 children received a primary LT from a LD (n = 100) or a deceased donor (DD) (n = 135). Demographic, surgical and immunological variables were compared, and respective impact on posttransplant complications was studied using a multivariate analysis. Five-year patient survival rates were 92% and 85% for groups LD and DD, respectively (p = 0.181), the corresponding graft survival rates being 89% and 77% (p = 0.033). At multivariate analysis: (1) type of donor (DD) was correlated with higher rate of artery thrombosis (p < 0.012); (2) biliary complication rate at 5 years was 29% and 23% for groups LD and DD, respectively (p = 0.451); (3) lower acute rejection incidence could be correlated with type of donor (DD) (p = 0.001), and immunosuppressive therapy (tacrolimus) (p < 0.001). We conclude that (1) according to the multivariate analysis, LT with LD provided similar patient and graft outcome, when compared to DD; (2) a higher rate of artery thrombosis and a lower rate of rejection were observed in group DD; (3) this study comfirms the efficacy of tacrolimus for immunoprophylaxis, whatever the type of organ donor is.
C1 Univ Catholique Louvain, Clin Univ St Luc, Pediat Liver Transplant Program, B-1200 Brussels, Belgium.
RP Reding, R (reprint author), Univ Catholique Louvain, Clin Univ St Luc, Pediat Liver Transplant Program, B-1200 Brussels, Belgium.
EM reding@chex.ucl.ac.be
RI Lerut, Jan/B-9571-2016
OI Lerut, Jan/0000-0002-4718-9950
CR Austin MT, 2005, ARCH SURG-CHICAGO, V140, P465, DOI 10.1001/archsurg.140.5.465
   Bourdeaux C, 2005, TRANSPLANTATION, V79, P1273, DOI 10.1097/00007890-200505150-00060
   Darwish AA, 2006, PEDIATR TRANSPLANT, V10, P345, DOI 10.1111/j.1399-3046.2005.00477.x
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   deGoyet JD, 1996, TRANSPLANTATION, V62, P71, DOI 10.1097/00007890-199607150-00015
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Francavilla R, 1998, TRANSPLANTATION, V66, P53, DOI 10.1097/00007890-199807150-00009
   HUBSCHER SG, 1985, J CLIN PATHOL, V38, P1366, DOI 10.1136/jcp.38.12.1366
   Kasahara M, 2002, TRANSPLANTATION, V74, P1175, DOI 10.1097/01.TP.0000030636.35519.EA
   Kelly D, 2004, LANCET, V364, P1054, DOI 10.1016/S0140-6736(04)17060-8
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Martinez JA, 1999, TRANSPLANTATION, V68, P672, DOI 10.1097/00007890-199909150-00013
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   MCENERY PT, 1992, NEW ENGL J MED, V326, P1727, DOI 10.1056/NEJM199206253262602
   MOR E, 1993, TRANSPLANTATION, V56, P1399, DOI 10.1097/00007890-199312000-00024
   Oswari H, 2005, J GASTROEN HEPATOL, V20, P1850, DOI 10.1111/j.1440-1746.2005.03926.x
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Otte JB, 2004, PEDIATR TRANSPLANT, V8, P317, DOI 10.1111/j.1399-3046.2004.00205.x
   RAIA S, 1989, LANCET, V2, P497
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Reding R, 1998, TRANSPLANTATION, V65, P681, DOI 10.1097/00007890-199803150-00014
   Reding R, 2004, ACTA GASTRO-ENT BELG, V67, P176
   Reding R, 2005, AM J TRANSPLANT, V5, P1587, DOI 10.1111/j.1600-6143.2005.00915.x
   Reding R, 2003, LANCET, V362, P2068, DOI 10.1016/S0140-6736(03)15104-5
   STIEHL A, 1984, HEPATOLOGY, V4, P107, DOI 10.1002/hep.1840040119
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   Sweet SC, 2006, AM J TRANSPLANT, V6, P1132, DOI 10.1111/j.1600-6143.2006.02171.x
   Toyoki Y, 2002, PEDIATR TRANSPLANT, V6, P301, DOI 10.1034/j.1399-3046.2002.02013.x
NR 29
TC 57
Z9 59
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD FEB
PY 2007
VL 7
IS 2
BP 440
EP 447
DI 10.1111/j.1600-6143.2006.01626.x
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 125KF
UT WOS:000243440100022
PM 17173657
ER

PT J
AU Katz, BZ
   Pahl, E
   Crawford, SE
   Kostyk, MC
   Rodgers, S
   Seshadri, R
   Proytcheva, M
   Pophal, S
AF Katz, B. Z.
   Pahl, E.
   Crawford, S. E.
   Kostyk, M. C.
   Rodgers, S.
   Seshadri, R.
   Proytcheva, M.
   Pophal, S.
TI Case-control study of risk factors for the development of
   post-transplant lymphoproliferative disease in a pediatric heart
   transplant cohort
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplant lymphoproliferative disease; pediatrics; heart
   transplant; case-control study
ID EPSTEIN-BARR-VIRUS; THORACIC ORGAN RECIPIENTS; CARDIAC TRANSPLANTATION;
   LIVER-TRANSPLANT; DISORDERS; IMMUNOSUPPRESSION; LOAD; EXPERIENCE;
   MANAGEMENT; INFECTION
AB PTLD is an important complication following heart transplantation. To better define the risk factors of PTLD in children, we performed a case-control study. All pediatric cardiac transplant recipients who developed their first episode of PTLD were matched by age (+/- 1 yr) and time since transplant ( I yr) with those who did not. PTLD occurred in nine of 95 cardiac transplant recipients (9%), 0.3-7.8 yr following cardiac transplantation (median = 2.5 yr). Patients were 0.1-16.4 yr (median = 3.7) at transplantation. Biopsies revealed polymorphic B cell hyperplasia (three), polymorphic B cell lymphoma (one), monomorphic diffuse large cell B cell lymphoma (three) and monomorphic Burkitt's-like lymphoma (two). Patients who developed PTLD were at no greater risk of death (p = 0.31). Recipient EBV seronegativity at time of transplant (p = 0.08), EBV seroconversion (p = 0.013) and recipient CMV seronegativity (p = 0.015) were associated with the development of PTLD by conditional logistic regression; sex, race, donor age, recipient diagnosis, donor CMV seropositivity, recipient treatment for CMV infection, EBV seropositivity at the time of PTLD diagnosis, and number of rejection episodes, treated rejection episodes, and lympholytics used were not. There was no significant association between PTLD and death in our recipients. EBV seroconversion and recipient CMV seronegativity were associated with the development of PTLD.
C1 Childrens Mem Hosp, Div Infect Dis, Dept Pediat, Chicago, IL 60614 USA.
   Childrens Mem Hosp, Dept Pathol, Chicago, IL 60614 USA.
   Northwestern Univ, Feinberg Sch Med, Mary Ann & J milburn Smith Child Hlth Res Core Pr, Chicago, IL 60611 USA.
RP Katz, BZ (reprint author), Childrens Mem Hosp, Div Infect Dis, Dept Pediat, 2300 Childrens Plaza,Box 20, Chicago, IL 60614 USA.
EM bkatz@northwestern.edu
CR Allen UD, 2005, PEDIATR TRANSPLANT, V9, P450, DOI 10.1111/j.1399-3046.2005.00318.x
   ANDERSON JL, 1978, LANCET, V2, P1174
   Annels NE, 2006, CLIN INFECT DIS, V42, P1743, DOI 10.1086/503838
   ARMITAGE JM, 1991, J HEART LUNG TRANSPL, V10, P877
   Aull MJ, 2004, TRANSPLANTATION, V78, P1676, DOI 10.1097/01.TP.0000144333.19106.58
   Benden C, 2005, J HEART LUNG TRANSPL, V24, P2103, DOI 10.1016/j.healun.2005.06.014
   BERNSTEIN D, 1993, CIRCULATION, V88, P230
   Boucek MM, 2005, J HEART LUNG TRANSPL, V24, P968, DOI 10.1016/j.healun.2005.05.020
   Boyle GJ, 1997, J PEDIATR-US, V131, P309, DOI 10.1016/S0022-3476(97)70173-2
   Brumbaugh J., 1985, HEART TRANSPLANT, V4, P307
   CESARO S, 2004, BRIT J HAEMATOL, V128, P224
   CHEN JM, 1993, ANN THORAC SURG, V56, P527
   COSTANZONORDIN MR, 1992, J HEART LUNG TRANSPL, V11, P837
   Dotti G, 2000, TRANSPLANTATION, V69, P827
   Fatio R, 1998, TRANSPLANT P, V30, P1118, DOI 10.1016/S0041-1345(98)00175-4
   Gao SZ, 2003, J HEART LUNG TRANSPL, V22, P505, DOI 10.1016/S1053-2498(02)01229-9
   GRATTAN MT, 1990, J THORAC CARDIOV SUR, V99, P500
   Green M, 2006, AM J TRANSPLANT, V6, P1906, DOI 10.1111/j.1600-6143.2006.01394.x
   Harwood J S, 1999, Pediatr Transplant, V3, P100, DOI 10.1034/j.1399-3046.1999.00019.x
   Higgins CD, 2003, TRANSPLANTATION, V75, P1698, DOI 10.1097/01.TP.0000062571.56977.26
   KATZ BZ, IN PRESS PRINCIPLES
   Leblond V, 1998, J CLIN ONCOL, V16, P2052
   Lim GY, 2002, RADIOLOGY, V222, P699, DOI 10.1148/radiol.2223010456
   Manez R, 1997, J INFECT DIS, V176, P1462
   Mihalov ML, 1996, CLIN TRANSPLANT, V10, P248
   Nalesnik M A, 2001, Transpl Infect Dis, V3, P88, DOI 10.1034/j.1399-3062.2001.003002088.x
   Pahl E, 2001, J HEART LUNG TRANSPL, V20, P279, DOI 10.1016/S1053-2498(00)00228-X
   Pahl E, 2000, AM J CARDIOL, V85, P735, DOI 10.1016/S0002-9149(99)00850-4
   Peraira JR, 2003, TRANSPLANT P, V35, P2009, DOI 10.1016/S0041-1345(03)00659-6
   PREIKSAITIS JK, 1992, J INFECT DIS, V166, P986
   RANDHAWA PS, 1989, AM J CLIN PATHOL, V92, P177
   RINDEHOFFMAN D, 1991, AM J CARDIOL, V68, P1724, DOI 10.1016/0002-9149(91)90340-Q
   Rowe DT, 1997, J CLIN MICROBIOL, V35, P1612
   SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502
   Ward K. M., 2004, Journal of Heart and Lung Transplantation, V23, pS77, DOI 10.1016/j.healun.2003.11.104
   Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6
   WEINTRAUB J, 1982, TRANSPLANTATION, V33, P347, DOI 10.1097/00007890-198204000-00002
   YOUSEM SA, 1989, HUM PATHOL, V20, P361, DOI 10.1016/0046-8177(89)90046-4
   ZALES VR, 1994, J AM COLL CARDIOL, V23, P766
   Zangwill SD, 1998, J HEART LUNG TRANSPL, V17, P1161
NR 40
TC 35
Z9 35
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2007
VL 11
IS 1
BP 58
EP 65
DI 10.1111/j.1399-3046.2006.00609.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 135IO
UT WOS:000244147500011
PM 17239124
ER

PT J
AU Mekeel, KL
   Langham, MR
   Gonzalez-Peralta, RP
   Hemming, AW
AF Mekeel, Kristin L.
   Langham, Max R., Jr.
   Gonzalez-Peralta, Regino P.
   Hemming, Alan W.
TI Liver transplantation in very small infants
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; long-term results; infant
ID HEPATIC-ARTERY THROMBOSIS; REDUCED-SIZE GRAFTS; PEDIATRIC-PATIENTS;
   CHILDREN; AGE; EXPERIENCE; ADENOVIRUS; COMPLICATIONS; RECIPIENTS;
   INFECTION
AB Background: This study examines the results of liver transplantation (LT) in children 5 kg or less. Reports suggest an increased morbidity and mortality in children weighing 5 kg or less as compared to larger children. However, over half of all children needing LT are <1 year old. Improving outcomes in very small children is a major goal of liver transplantation. Methods: All children under 21 years of age transplanted from January 1990 to June 2005 were included in this study. One hundred sixty-eight primary liver transplants were done: 61 in children less than one year of age and 20 in infants weighing 5 kg or less at LT (2 to 5 kg). These 20 infants underwent 23 transplants. Whole organs were used in 39% of transplants, and reduced or split grafts were used in 61%. Arterial reconstruction using aortic conduits was done in 22%. Analysis included Fischer's exact or Chi square test for non-parametric analysis while patient survival was calculated using the Kaplan-Meier method test with differences in survival assessed using the log rank test. Results: Five-year survival for infants 5 kg or less was 74%, and graft survival was 60%, which was not different from patients transplanted that were >5 kg. There were three perioperative deaths, one from primary graft non-function, and two from portal vein thrombosis. There were no bile leaks or hepatic artery thromboses. Bacterial, fungal, and viral infections made up the vast majority of the postoperative complications (65%), with viral infections resulting in two graft losses requiring re-transplantation. Rejection occurred in 25% of patients, of which one required OKT3. Five of the 23 liver transplants in infants less than 5 kg were done prior to 1996, with a five-year graft survival of only 20%. Improvements in technique and postoperative care after 1996 led to improved graft and patient survival of 77% and 86% respectively. Conclusions: Liver transplantation for infants weighing less than 5 kilograms can be technically challenging but can have equivalent graft and patient survival when compared to larger children requiring liver transplantation. Infants should not be denied liver transplantation based on weight alone.
C1 Univ Florida, Div Transplantat & Hepatobiliary Surg, Gainesville, FL 32410 USA.
   Univ Tennessee, Div Pediat Surg, Memphis, TN USA.
   Univ Florida, Dept Pediat, Gainesville, FL 32410 USA.
RP Hemming, AW (reprint author), Univ Florida, Div Transplantat & Hepatobiliary Surg, POB 100286, Gainesville, FL 32410 USA.
EM hemming@surgery.ufl.edu
CR Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   CAMES B, 1992, J PEDIATR-US, V120, P33, DOI 10.1016/S0022-3476(05)80593-1
   Carter BA, 2002, TRANSPLANTATION, V74, P1050, DOI 10.1097/00007890-200210150-00027
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Cox KL, 1999, J GASTROEN HEPATOL, V14, pS61
   DEGOYET JD, 1993, TRANSPLANTATION, V56, P1130
   DUNN SP, 1993, J PEDIATR SURG, V28, P1048, DOI 10.1016/0022-3468(93)90516-N
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   Farmer DG, 2001, TRANSPLANTATION, V72, P1795, DOI 10.1097/00007890-200112150-00015
   GEORGE DL, 1992, AM J DIS CHILD, V146, P924
   Goss JA, 1998, ARCH SURG-CHICAGO, V133, P839, DOI 10.1001/archsurg.133.8.839
   Jain A, 2002, TRANSPLANT P, V34, P1955, DOI 10.1016/S0041-1345(02)03136-6
   JURIM O, 1995, J PEDIATR SURG, V30, P53, DOI 10.1016/0022-3468(95)90609-6
   Langham MR, 2001, J PEDIATR SURG, V36, P1205, DOI 10.1053/jpsu.2001.25763
   LUND DP, 1993, TRANSPLANT P, V25, P1068
   MAZZAFERRO V, 1989, TRANSPLANT P, V21, P2466
   MICHAELS MG, 1992, J INFECT DIS, V165, P170
   Murcia J, 2001, Cir Pediatr, V14, P121
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   OTTE JB, 1991, J HEPATOL, V12, P386, DOI 10.1016/0168-8278(91)90845-3
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   SAINTVIL D, 1991, J PEDIATR SURG, V26, P908, DOI 10.1016/0022-3468(91)90835-H
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   STARZL TE, 1979, PEDIATRICS, V63, P825
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Sundaram SS, 2003, LIVER TRANSPLANT, V9, P783, DOI 10.1053/jlts.2003.50104
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   Tiao GM, 2005, J PEDIATR SURG, V40, P268, DOI 10.1016/j.jpedsurg.2004.09.021
   Van der Werf WJ, 1998, J PEDIATR SURG, V33, P20, DOI 10.1016/S0022-3468(98)90353-0
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 32
TC 25
Z9 28
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2007
VL 11
IS 1
BP 66
EP 72
DI 10.1111/j.1399-3046.2006.00610.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 135IO
UT WOS:000244147500012
PM 17239125
ER

PT J
AU Koshiba, T
   Li, Y
   Takemura, M
   Wu, YL
   Sakaguchi, S
   Minato, N
   Wood, KJ
   Haga, H
   Ueda, M
   Uemoto, S
AF Koshiba, Takaaki
   Li, Ying
   Takemura, Mami
   Wu, Yanling
   Sakaguchi, Shimon
   Minato, Nagahiro
   Wood, Kathryn J.
   Haga, Hironori
   Ueda, Mikiko
   Uemoto, Shinji
TI Clinical, immunological, and pathological aspects of operational
   tolerance after pediatric living-donor liver transplantation
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article; Proceedings Paper
CT World Transplant Congress
CY JUL 22-27, 2006
CL Boston, MA
DE operational tolerance; liver transplantation; regulatory T cells;
   protocol biopsy; gamma delta T cells
ID REGULATORY T-CELLS; PREGNANCY; BLOOD
AB In the setting of our pediatric living-donor liver transplantation (LDLT), 87 patients (15.0% of all the patients: significantly higher proportion, compared with those of other transplant centers) achieved complete withdrawal of immunosuppression, which is referred to as "operational tolerance". Immunosuppressants were completely discontinued for 54 patients as scheduled, and for 33 because of EBV infection or other complications.
   Immunological analyses of the peripheral blood derived from operationally tolerant patients demonstrated that non-deletional tolerance takes place in which potentially reactive T cells to donor-antigens remain physically in the immune repertoire, but specifically suppressed by certain mechanisms. Not only CD4(+)CD25(high+) T cells were increased in the proportion in the tolerant patients' peripheral lymphocytes and suppressed MLR specifically to the donor antigen, but also FOXP3 expressing cells were present within the tolerant liver. Thus, among several mechanisms accounting for non-deletional tolerance, Tregs are likely to involve at least in part in our tolerant patients. V delta 1 gamma delta T cells, a subset of gamma delta T cells, which otherwise reside mainly in the intestine, emerge into the peripheral blood during successful pregnancy but not abortive pregnancy. Since V delta 1 gamma delta T cells produce massive IL-10, it is proposed that V delta 1 gamma delta T cells induce fetomatemal tolerance by promoting Th2 immune deviation. Consistent with pregnancy, IL-10 producing V delta 1 gamma delta T cells emerge into the blood of our tolerant patients. This may reflect a common feature between fetomatemal tolerance and transplant tolerance.
   We began protocol biopsy in post-LDLT patients who exhibit normal liver function from January 2003. Operationally tolerant patients, albeit showing normal liver function, exhibited decrease in size and increase in number of the bile duct and the fibrosis to a greater extent, compared with patients on maintenance immunosuppression. This warrants serial protocol biopsy before and after complete cessation of immunosuppression even in the presence of normal liver function. (c) 2006 Elsevier B.V. All rights reserved.
C1 Kyoto Univ, Fac Med, Horizontal Med Res Org, Dept Transplantat & Immunol,Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ Hosp, Div Hepatobiliary Pancreat Surg & Transplantat, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ, Inst Frontier Med Sci, Dept Expt Pathol, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ, Fac Med, Dept Immunol & Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England.
   Kyoto Univ Hosp, Dept Diagnost Pathol, Sakyo Ku, Kyoto 6068507, Japan.
RP Koshiba, T (reprint author), Kyoto Univ, Fac Med, Horizontal Med Res Org, Dept Transplantat & Immunol,Sakyo Ku, 54 Kawaramachi Shogoin, Kyoto 6068507, Japan.
EM tkoshiba@kuhp.kyoto-u.ac.jp
RI Sakaguchi, Shimon/C-9535-2009
CR Barakonyi A, 2002, J IMMUNOL, V168, P2683
   LI Y, 2006, AM J TRANSPLANT, V6, P1056
   Li Y, 2004, AM J TRANSPLANT, V4, P2118, DOI 10.1111/j.1600-6143.2004.00611.x
   LOUIS S, 2003, AM J TRANSPLANT, V3, P328
   Nagaeva O, 2002, AM J REPROD IMMUNOL, V48, P9, DOI 10.1034/j.1600-0897.2002.01131.x
   PARKER CM, 1990, J EXP MED, V171, P1597, DOI 10.1084/jem.171.5.1597
   Salama AD, 2003, J AM SOC NEPHROL, V14, P1643, DOI 10.1097/01.ASN.0000057540.98231.C1
   Takatsuki M, 2001, TRANSPLANTATION, V72, P449, DOI 10.1097/00007890-200108150-00016
   Ueda M, 2006, LIVER TRANSPLANT, V12, P1326, DOI 10.1002/lt.20826
   Waldmann H, 2004, SEMIN IMMUNOL, V16, P119, DOI 10.1016/j.smim.2003.12.007
   Wing K, 2002, IMMUNOLOGY, V106, P190, DOI 10.1046/j.1365-2567.2002.01412.x
   Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027
   YOSHITOMI M, 2006, AM J TRANSPLANT, V6, P173
   Yoshizawa A, 2005, TRANSPLANT P, V37, P37, DOI 10.1016/j.transproceed.2004.12.259
NR 14
TC 102
Z9 111
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD FEB
PY 2007
VL 17
IS 2
BP 94
EP 97
DI 10.1016/j.trim.2006.10.004
PG 4
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 152EM
UT WOS:000245343800003
PM 17306739
ER

PT J
AU Haberal, M
   Karakayali, H
   Arslan, G
   Ozcay, F
   Boyvat, F
   Sevmis, S
   Demirhan, B
AF Haberal, M.
   Karakayali, H.
   Arslan, G.
   Ozcay, F.
   Boyvat, F.
   Sevmis, S.
   Demirhan, B.
TI Liver transplantation in children weighing less than 10 kilograms
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT World Transplant Congress
CY JUL 22-27, 2006
CL Boston, MA
ID BABIES; COMPLICATIONS
AB Orthotopic liver transplantation (OLT) remains a major medical and surgical challenge in small pediatric patients. From April 2003 through October 2005, 17 infants (each of whom weighed less than 10 kg) underwent the procedure. Four were girls and 13 were boys (mean age, 15.7 +/- 9.3 months [range, 2-36 months]; mean weight at the time of transplantation, 7.4 +/- 2.6 kg [range, 6-10 kg]). All transplants were obtained from living-related donors. Sixteen left lateral segments and 1 left lobe were transplanted. The median graft-to-recipient weight ratio was 3.5% +/- 1.2% (range, 1.5%-6.1%). During the early postoperative period, hepatic arterial thrombosis was identified in 2 infants, and a biliary leak in 1. Hepatic arterial thrombosis was treated by reanastomosis with polytetrafluoroethylene grafting in the first patient and by surgical embolectomy in the second. The biliary leak was treated with percutaneous drainage. In 1 infant, portal vein stenosis, which was identified during the late postoperative period, was treated by percutaneous balloon dilatation. At this time, 14 (82.3%) infants were alive, exhibiting good graft function at a median follow-up of 11 months (range, 2-36 months). Three infants died: 1 on postoperative day 47 from adult respiratory distress syndrome, 1 on postoperative day 12 from sepsis, and 1 on postoperative day 65 from sepsis associated with EBV infection. Episodes of acute rejection, which occurred in 5 patients, were treated with pulse steroid therapy. On follow-up, histologic examination revealed hepatocellular carcinoma in 2 infants and Burkitt's lymphoma in 1 infant. Our data confirm that extensive use of living-related donors in liver transplantation can result in an excellent outcome for small pediatric patients.
C1 Baskent Univ, Dept Gen Surg, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Dept Gen Surg, 1 Cadde 77-4, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR BEATH S, 1994, TRANSPLANT P, V26, P180
   BEATH SV, 1993, BRIT MED J, V307, P825
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   Haberal M, 2006, TRANSPLANT P, V38, P584, DOI 10.1016/j.transproceed.2006.01.023
   Karakayali H, 2006, TRANSPLANT P, V38, P604, DOI 10.1016/j.transproceed.2006.01.011
   Langham MR, 2001, J PEDIATR SURG, V36, P1205, DOI 10.1053/jpsu.2001.25763
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   OTTE JB, 1994, HEPATOLOGY, V20, pS41, DOI 10.1002/hep.1840200711
   Saing H, 1997, J PEDIATR SURG, V32, P80, DOI 10.1016/S0022-3468(97)90100-7
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
NR 13
TC 3
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD DEC
PY 2006
VL 38
IS 10
SI SI
BP 3585
EP 3587
DI 10.1016/j.transproceed.2006.10.016
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 120PY
UT WOS:000243098400126
PM 17175338
ER

PT J
AU Uchida, Y
   Kasahara, M
   Egawa, H
   Takada, Y
   Ogawa, K
   Ogura, Y
   Uryuhara, K
   Morioka, D
   Sakamoto, S
   Inomata, Y
   Kamiyama, Y
   Tanaka, K
AF Uchida, Y.
   Kasahara, M.
   Egawa, H.
   Takada, Y.
   Ogawa, K.
   Ogura, Y.
   Uryuhara, K.
   Morioka, D.
   Sakamoto, S.
   Inomata, Y.
   Kamiyama, Y.
   Tanaka, K.
TI Long-term outcome of adult-to-adult living donor liver transplantation
   for post-Kasai biliary atresia
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE adult; biliary atresia; liver transplantation; living donor
ID FOLLOW-UP; SURGERY; GRAFTS; IMPACT; RECIPIENTS; HYPOXEMIA; PROGNOSIS;
   SURVIVORS; JAPAN
AB Our objective was to analyze problems in the perioperative management and long-term outcome of living donor liver transplantation (LDLT) for biliary atresia (BA). Many reports have described the effectiveness of liver transplantation (LT) for BA, particularly in pediatric cases, but little information is available regarding LT in adults (>= 16 years old). Between June 1990 and December 2004, 464 patients with BA underwent LDLT at Kyoto University Hospital, of whom 47 (10.1%) were older than 16 years. In this study, we compared the outcomes between adult (>= 16 years old) and pediatric (< 16 years old) patients. The incidence of post-transplant intestinal perforation, intra-abdominal bleeding necessitating repeat laparotomy and biliary leakage was significantly higher (p < 0.0001, < 0.001 and < 0.001, respectively) in adults. Overall cumulative 1-, 5- and 10-year survival rates in pediatric patients were significantly higher (p < 0.005) than in adults. Two independent prognostic determinants of survival were identified: a MELD score over 20 and post-transplant complications requiring repeat laparotomy. Outcome of LDLT in adult BA patients was poorer than in pediatric patients. It seems likely that LT will be the radical treatment of choice for BA and that LDLT should be considered proactively at the earliest possible stage.
C1 Kyoto Univ, Fac Med, Dept Transplantat & Immunol, Kyoto, Japan.
   Kyoto Univ Hosp, Dept Transplantat Surg, Organ Transplant Unit, Kyoto 606, Japan.
   Kansai Med Univ, Dept Surg, Osaka, Japan.
   Kumamoto Univ Hosp, Dept Pediat & Transplant Surg, Kumamoto, Japan.
RP Uchida, Y (reprint author), Kyoto Univ, Fac Med, Dept Transplantat & Immunol, Kyoto, Japan.
EM uchiday@kuhp.kyoto-u.ac.jp
CR Altman RP, 1997, ANN SURG, V226, P348, DOI 10.1097/00000658-199709000-00014
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Chardot C, 1999, HEPATOLOGY, V30, P606, DOI 10.1002/hep.510300330
   Chittmittrapap Soottiporn, 2005, Journal of the Medical Association of Thailand, V88, P1077
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Fouquet V, 2005, LIVER TRANSPLANT, V11, P152, DOI 10.1002/lt.20358
   Howard ER, 2001, J PEDIATR SURG, V36, P892, DOI 10.1053/jpsu.2001.23965
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   Inomata Y, 1999, TRANSPLANTATION, V67, P1314, DOI 10.1097/00007890-199905270-00004
   Kasai M, 1968, J PEDIATR SURG, V3, P655
   KAWAGISHI N, 2001, JPN J PEDIAT SURG, V33, P366
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Kobayashi Hiroyuki, 2003, Semin Neonatol, V8, P383, DOI 10.1016/S1084-2756(03)00065-4
   Krowka MJ, 1997, MAYO CLIN PROC, V72, P44
   Lykavieris P, 2005, HEPATOLOGY, V41, P366, DOI 10.1002/hep.20547
   Melendez HV, 1998, TRANSPLANT INT, V11, P301, DOI 10.1111/j.1432-2277.1998.tb00975.x
   MURAJI T, 2002, J PEDIATR SURG, V38, P855
   Nio M, 2004, J PEDIATR SURG, V39, P1797, DOI 10.1016/j.jpedsurg.2004.08.021
   NIO M, 2002, JPN J PEDIAT SURG, V34, P960
   Ohhama Y, 2000, J PEDIATR SURG, V35, P1031, DOI 10.1053/jpsu.2000.7765
   OHI R, 1990, J PEDIATR SURG, V25, P442, DOI 10.1016/0022-3468(90)90390-U
   OHI R, 1986, BILIARY ATRESIA, P125
   Ohi R, 2001, LIVER, V21, P175, DOI 10.1034/j.1600-0676.2001.021003175.x
   Soubrane O, 1995, Liver Transpl Surg, V1, P2, DOI 10.1002/lt.500010103
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Uemoto S, 1997, TRANSPLANTATION, V63, P407, DOI 10.1097/00007890-199702150-00014
   Umeshita K, 2003, LANCET, V362, P687, DOI 10.1016/S0140-6736(03)14230-4
   Wiesner R, 2003, GASTROENTEROLOGY, V124, P91, DOI 10.1053/gast.2003.60016
NR 30
TC 24
Z9 26
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD OCT
PY 2006
VL 6
IS 10
BP 2443
EP 2448
DI 10.1111/j.1600-6143.2006.01487.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 082DD
UT WOS:000240366000028
PM 16889600
ER

PT J
AU Nalli, N
   Stewart-Teixeira, L
   Dipchand, AI
AF Nalli, Nadya
   Stewart-Teixeira, Lilian
   Dipchand, Anne I.
TI Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart
   transplant patient
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE heart transplant; drug interaction; amiodarone; sirolimus; tacrolimus
ID DRUG-INTERACTIONS; CYCLOSPORINE INTERACTION; SIROLIMUS;
   PHARMACOKINETICS; RECIPIENTS
AB A two year-old female who had underwent ABO-incompatible heart transplantation at four months of age was admitted with unexplained anemia and renal dysfunction. The patient also had evidence of moderate liver dysfunction. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil and prednisolone. Tacrolimus was held on day 2 for five days because of an elevated trough blood concentration. The patient required one fourth of her maintenance dose to keep trough concentrations within the target range. Nadolol and amiodarone were prescribed on day 7 to control ventricular arrhythmias. Sirolimus was prescribed on day 11. A precautionary (non-steady-state) sirolimus trough concentration was grossly elevated. Sirolimus was held and tacrolimus was discontinued. Sirolimus blood concentrations remained above the target range for fourteen days despite successive dose manipulations. The patient succumbed from complications of ECMO on day 42. Amiodarone and cyclosporine interactions in the solid organ transplant population have been previously described. To our knowledge, there are no cases of amiodarone and sirolimus or tacrolimus interactions reported in English literature. Both tacrolimus and sirolimus are metabolized through the same enzyme system as cyclosporine, and the chance of a similar interaction occurring is high. Sirolimus is also a substrate of p-glycoprotein and thus may be significantly affected by amiodarone. We have described a potential interaction with sirolimus, tacrolimus and amiodarone. If amiodarone is deemed the most appropriate choice for the patient, clinicians should consider prospectively decreasing sirolimus and tacrolimus doses. Blood concentrations should also be monitored more frequently in order to minimize prolonged periods of supratherapeutic concentrations and related toxicities.
C1 Hosp Sick Children, Dept Pharm, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada.
   Hosp Sick Children, Div Cardiol, Toronto, ON M5G 1X8, Canada.
RP Nalli, N (reprint author), Hosp Sick Children, Dept Pharm, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM nadya.nalli@sickkids.ca
CR Boucek MM, 2004, J HEART LUNG TRANSPL, V23, P933, DOI 10.1016/j.healun.2004.06.011
   Brattstrom C, 1997, THER DRUG MONIT, V19, P397, DOI 10.1097/00007691-199708000-00007
   CHITWOOD KK, 1993, ANN PHARMACOTHER, V27, P569
   Doherty MM, 2002, CLIN PHARMACOKINET, V41, P235, DOI 10.2165/00003088-200241040-00001
   Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003
   *FUJISAWA, 2002, PROGR TACR PROD MON
   LESKO LJ, 1989, CLIN PHARMACOKINET, V17, P130, DOI 10.2165/00003088-198917020-00005
   MAMPRIN F, 1992, AM HEART J, V123, P1725, DOI 10.1016/0002-8703(92)90848-P
   MCDIARMID SV, 1993, TRANSPLANTATION, V55, P1328, DOI 10.1097/00007890-199306000-00022
   Michalets EL, 1998, PHARMACOTHERAPY, V18, P84
   NICOLAU DP, 1992, J HEART LUNG TRANSPL, V11, P564
   *NOVARTIS PHARM, 2003, NEOR CYCL PROD MON
   Russo LM, 2004, CURR OPIN CARDIOL, V19, P104, DOI 10.1097/00001573-200403000-00006
   Schachter AD, 2004, PEDIATR TRANSPLANT, V8, P171, DOI 10.1046/j.1399-3046.2003.00148.x
   Schubert M, 2004, AM J TRANSPLANT, V4, P767, DOI 10.1111/j.1600-6143.2004.00411.x
   Tejani A, 2004, PEDIATR TRANSPLANT, V8, P151, DOI 10.1046/j.1399-3046.2003.00137.x
   West LJ, 2001, NEW ENGL J MED, V344, P793, DOI 10.1056/NEJM200103153441102
   *WYETH, 2004, RAP SIR PROD MON
   Yamreudeewong W, 2003, DRUG SAFETY, V26, P421, DOI 10.2165/00002018-200326060-00004
NR 19
TC 10
Z9 10
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD SEP
PY 2006
VL 10
IS 6
BP 736
EP 739
DI 10.1111/j.1399-3046.2006.00561.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 070GR
UT WOS:000239509300016
PM 16911499
ER

PT J
AU Haberal, M
AF Haberal, M.
TI Liver transplantation: Experience at our center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Asian-Society-of-Transplantation
CY NOV 29-DEC 02, 2005
CL Karachi, PAKISTAN
SP Asian Soc Transplantat
ID HEPATOCELLULAR-CARCINOMA; KIDNEY-TRANSPLANTATION; BILIARY COMPLICATIONS;
   DONOR; CRITERIA; FAILURE; LOBE; ANASTOMOSIS; SURVIVAL; CHILDREN
AB Liver transplantation was pioneered by Starzl and his team in 1967. Since then, many difficulties have been overcome and this treatment modality has gained worldwide acceptance as the definitive treatment for end-stage liver disease. However, the current numbers of liver transplantations are still far below what is needed, the rising numbers on waiting lists have pushed transplant surgeons to search for new alternatives, and living related donors are considered one solution. At our center, the only living liver donors we accept are relatives and spouses of recipients. We have held the same policy for our kidney program from the beginning. In the past 3 years, we have increased the annual numbers of liver transplantations; our graft and patient survival rates for this period exceed 90%. Liver grafts donated by living related donors offer an extremely important, lifesaving alternative in urgent situations, such as acute liver failure, where there is limited time to wait for a deceased donor. Hepatocellular carcinoma is another important indication for living related liver transplantation. Availability of living donors allows us to perform transplantations even in recipients with advanced tumors who would not be accepted as appropriate transplant candidates according to widely used selection criteria. Liver transplantation is a lifesaving procedure that presents many challenges, and our experience has led us to develop an innovative technique for biliary reconstruction. We have used a method of "back-table guide-wire placement and intraoperative transhepatic biliary catheter insertion" in 44 patients since December 2004 to significantly decrease biliary complications and perform duct-to-duct anastomosis even in small pediatric recipients.
C1 Baskent Univ, Fac Med, Dept Gen Surg, Transplantat & Burn Inst, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ Rektorluk, 1 Cad 77 Kat 4 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Bismuth H, 1996, SEMIN LIVER DIS, V16, P415, DOI 10.1055/s-2007-1007254
   Broelsch CE, 2005, J HEPATOL, V43, P569, DOI 10.1016/j.jhep.2005.07.016
   Busuttil RW, 2005, ANN SURG, V241, P905, DOI 10.1097/01.sla.0000164077.77912.98
   Chang JM, 2005, CARDIOVASC INTER RAD, V28, P756, DOI 10.1016/s00270-004-0262-7
   Dalgic A, 2005, TRANSPLANT P, V37, P3154, DOI 10.1016/j.transproceed.2005.06.096
   Dalgic A, 2005, TRANSPLANT P, V37, P3137, DOI 10.1016/j.transproceed.2005.08.046
   Emiroglu R, 2003, TRANSPLANT P, V35, P2765, DOI 10.1016/j.transproceed.2003.08.033
   Grief F, 1994, ANN SURG, V219, P40
   HABERAL M, 1988, TRANSPLANT P, V20, P353
   Haberal M, 1972, HACETTEPE TIP CERRAH, V5, P462
   Haberal M, 1999, TRANSPLANT P, V31, P2899, DOI 10.1016/S0041-1345(99)00767-8
   HABERAL M, 1992, TRANSPLANT P, V24, P2687
   HABERAL M, 1992, TRANSPLANT P, V24, P1967
   HABERAL M, 1993, TRANSPLANT P, V25, P2211
   Hiatt JR, 2005, J HEPATOL, V43, P573, DOI 10.1016/j.jhep.2005.07.017
   Karakayali H, 2005, TRANSPLANT P, V37, P2905, DOI 10.1016/j.transproceed.2005.07.025
   Karakayali H, 2005, TRANSPLANT P, V37, P3174, DOI 10.1016/j.transproceed.2005.07.023
   Leong Trishe Y-M, 2005, HPB (Oxford), V7, P5, DOI 10.1080/13651820410024021
   LERUT J, 1987, TRANSPLANTATION, V43, P47, DOI 10.1097/00007890-198701000-00011
   Liu CL, 2004, TRANSPLANTATION, V77, P726, DOI 10.1097/01.TP.0000116604.89083.2F
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   Liu CL, 2002, BRIT J SURG, V89, P317, DOI 10.1046/j.0007-1323.2001.02035.x
   MCBRIDE MA, 2003, CLIN TRANSPL, V53
   MCDIARMID SV, 2001, PRIMER TRANSPLANTATI, P521
   PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205
   Pichlmayr R, 1998, EUR J SURG ONCOL, V24, P60, DOI 10.1016/S0748-7983(98)80130-3
   STARZL TE, 1968, SURGERY, V63, P549
   Testa G, 2000, LIVER TRANSPLANT, V6, P710, DOI 10.1053/jlts.2000.18706
NR 28
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2006
VL 38
IS 7
BP 2111
EP 2116
DI 10.1016/j.transproceed.2006.06.035
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 089NW
UT WOS:000240888400050
PM 16980016
ER

PT J
AU Longworth, L
   Young, T
   Beath, SV
   Kelly, DA
   Mistry, H
   Protheroe, SM
   Ratcliffe, J
   Buxton, MJ
AF Longworth, Louise
   Young, Tracey
   Beath, Sue V.
   Kelly, Deirdre A.
   Mistry, Hema
   Protheroe, Sue M.
   Ratcliffe, Julie
   Buxton, Martin J.
TI An economic evaluation of pediatric small bowel transplantation in the
   United Kingdom
SO TRANSPLANTATION
LA English
DT Article
DE economics; intestine; parenteral nutrition; pediatrics; transplantation
ID HOME PARENTERAL-NUTRITION; PRIMARY BILIARY-CIRRHOSIS; COST-UTILITY
   ANALYSIS; SHORT-TERM SURVIVAL; QUALITY-OF-LIFE; INTESTINAL
   TRANSPLANTATION; LIVER-TRANSPLANTATION; PROGRAM; PREDICTION
AB Background. Small bowel transplantation (SBTx) offers an alternative to parenteral nutrition (PN) for the treatment of chronic intestinal failure in children: this study estimated its cost-effectiveness in the early phase of a U.K. program.
   Methods. Children assessed for SBTx were categorized as: 1) requiring SBTx following PN-related complications (n=23), 2) stable at home not requiring SBTx (n=24), and 3) terminally ill and unsuitable for SBTx (n=6). Costs were estimated from detailed resource-use data. Two comparisons were used for effectiveness: actual survival following transplantation (n=14) compared to: 1) estimated survival without transplantation using a prognostic model, and 2) the waiting list experiences of all patients listed for SBTx (n=23).
   Results. Mean costs up to 30 months were 207,000 pound for those transplanted or on the waiting list, 159,000 pound for those stable on home PN, and 56,000 pound for those terminally ill. The prognostic model estimated a mean survival gain from transplantation of 0.12 years over 30 months, and suggested that transplantation was cost-saving. The second approach suggested that transplantation reduced survival by 0.24 years at an additional cost of 131,000 pound.
   Conclusions. Firm conclusions on cost-effectiveness of SBTx are not possible given the two different estimates. The prognostic model approach (suggesting that pediatric SBTx may provide a small survival benefit at a small reduction in costs) should be less subject to bias, but the model requires external validation. Meanwhile, children at risk of fatal PN-complications should be given the opportunity to receive a SBTx only within a continuing formal assessment of the technology.
C1 Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England.
   Birmingham Childrens Hosp, Liver Unit, Birmingham, W Midlands, England.
   Birmingham Childrens Hosp, Dept Gastroenterol & Nutr, Birmingham, W Midlands, England.
RP Buxton, MJ (reprint author), Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England.
EM martin.buxton@brunel.ac.uk
RI Young, Tracey/A-4543-2010; 
OI Young, Tracey/0000-0001-8467-0471; Longworth, Louise/0000-0003-2512-4862
CR Abu-Elmagd KM, 1999, TRANSPLANT P, V31, P582, DOI 10.1016/S0041-1345(98)01565-6
   Beath SV, 1997, J PEDIATR SURG, V32, P459, DOI 10.1016/S0022-3468(97)90606-0
   BEATH SV, 1995, ARCH DIS CHILD, V73, P348
   BONSEL GJ, 1990, TRANSPLANT P, V22, P1481
   *BRIT MED ASS ROYA, 1999, BRIT NAT FORM 37
   Bueno J, 2001, J PEDIATR SURG, V36, P178, DOI 10.1053/jpsu.2001.20047
   BUXTON MJ, 1985, 12 DEP HLTH SOC SEC
   CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1895
   de Goyet Jean de Ville de, 2000, Transplantation (Baltimore), V69, P555, DOI 10.1097/00007890-200002270-00016
   DETSKY AS, 1986, JPEN-PARENTER ENTER, V10, P49, DOI 10.1177/014860718601000149
   ELIA M, 2000, TRENDS ARTIFICIAL NU
   Freeman RB, 2004, AM J TRANSPLANT, V4, P114, DOI 10.1111/j.1600-6135.2004.00403.x
   HM Treasury, 2003, GREEN BOOK APPR EV C
   HUGHES MD, 1992, STAT MED, V11, P1731, DOI 10.1002/sim.4780111307
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x
   Langnas A, 2002, TRANSPLANT P, V34, P958, DOI 10.1016/S0041-1345(02)02716-1
   Lin DY, 1997, BIOMETRICS, V53, P419, DOI 10.2307/2533947
   Longworth L, 2003, LIVER TRANSPLANT, V9, P1295, DOI 10.1016/j.lts.2003.09.012
   MALATACK JJ, 1987, J PEDIATR-US, V111, P479, DOI 10.1016/S0022-3476(87)80105-1
   MANLY BFJ, 1997, RANDOMISATION BOOSTR
   *MICR CORP, 2000, EXC 2000
   MURTAUGH PA, 1994, HEPATOLOGY, V20, P126, DOI 10.1016/0270-9139(94)90144-9
   *NICE COMPL TECHN, 2001, ANN GEN M JUL NAT I
   Peters M, 2000, ARCH DIS CHILD, V83, P163, DOI 10.1136/adc.83.2.163
   Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300
   Richards DM, 1996, BRIT J SURG, V83, P1226, DOI 10.1046/j.1365-2168.1996.02308.x
   Rovera GM, 1998, TRANSPLANT P, V30, P2513, DOI 10.1016/S0041-1345(98)00704-0
   *STAT CORP COLL ST, 2001, STAT CORP STAT STAT
   Sudan DL, 2000, TRANSPLANT P, V32, P1211, DOI 10.1016/S0041-1345(00)01190-8
   TURNBULL BW, 1974, J AM STAT ASSOC, V69, P74, DOI 10.2307/2285502
   VanEnckevort PJ, 1997, HEALTH ECON, V6, P479, DOI 10.1002/(SICI)1099-1050(199709)6:5<479::AID-HEC287>3.0.CO;2-V
   VANHOUT B, 1993, J HEALTH ECON, V12, P73, DOI 10.1016/0167-6296(93)90041-C
NR 33
TC 8
Z9 8
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 27
PY 2006
VL 82
IS 4
BP 508
EP 515
DI 10.1097/01.tp.0000229438.14914.82
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 078TD
UT WOS:000240125600011
PM 16926595
ER

PT J
AU Englert, C
   Helmke, K
   Richter, A
   Beckmann, M
   Rogiers, X
   Burdelski, M
   Ganschow, R
AF Englert, Cornelia
   Helmke, Knut
   Richter, Andrea
   Beckmann, Matthias
   Rogiers, Xavier
   Burdelski, Martin
   Ganschow, Rainer
TI Diaphragmatic hernia resulting in enterothorax following pediatric liver
   transplantation: A rare complication
SO TRANSPLANTATION
LA English
DT Article
DE children; diaphragmatic hernia; enterothorax; liver transplantation
ID INFANTS; FUTURE
AB Diaphragmatic hernia is a rare complication following solid organ transplantation. We here report three pediatric patients suffering from posttransplant enterothorax. One patient with biliary atresia presented with clinical signs of peritonitis without showing pulmonary symptoms four weeks following liver transplantation. The second patient was admitted with suspected pneumonia, whereas the third patient presented with recurrent abdominal pain over weeks and physical examination revealed the unexpected diagnosis of enterothorax. All patients received split liver transplants. Unspecific clinical signs mislead to suspected infectious complication under immunosuppression. No apparent risk factors for diaphragmatic hernia could be identified. Diaphragmatic hernia can present with a variety of atypical clinical symptoms. Severe or prolonged abdominal complains should lead to x-ray examination. We speculate that the split liver technique used in our center could lead to this rare complication due to the different anatomic position of the liver transplant in the abdomen.
C1 Univ Hamburg, Med Ctr, Dept Pediat, D-20246 Hamburg, Germany.
   Univ Hamburg, Med Ctr, Dept Pediat Radiol, D-20246 Hamburg, Germany.
   Univ Hamburg, Med Ctr, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Englert, C (reprint author), Univ Hamburg, Med Ctr, Dept Pediat, Martinistr 52, D-20246 Hamburg, Germany.
EM cenglert@uke.uni-hamburg.de
CR Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   FASOLINI F, 1994, HELV CHIR ACTA, V60, P907
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   Kim JS, 2004, PEDIATR TRANSPLANT, V8, P644, DOI 10.1111/j.1399.3046.00264.x
   Kitano Y, 2005, J PEDIATR SURG, V40, P1839, DOI 10.1016/j.jpedsurg.2005.08.023
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   McCabe AJ, 2005, J PEDIATR SURG, V40, P1181, DOI 10.1016/j.jpedsurg.2005.03.063
   Stokes K B, 1991, Prog Pediatr Surg, V27, P127
   Whitington Peter F., 2002, JPGN Journal of Pediatric Gastroenterology and Nutrition, V35, pS44, DOI 10.1097/00005176-200207001-00011
NR 11
TC 15
Z9 15
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 27
PY 2006
VL 82
IS 4
BP 574
EP 576
DI 10.1097/01.tp.0000231709.63721.5c
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 078TD
UT WOS:000240125600020
PM 16926604
ER

PT J
AU Spada, M
   Petz, W
   Bertani, A
   Riva, S
   Sonzogni, A
   Giovannelli, M
   Torri, E
   Torre, G
   Colledan, M
   Gridelli, B
AF Spada, M.
   Petz, W.
   Bertani, A.
   Riva, S.
   Sonzogni, A.
   Giovannelli, M.
   Torri, E.
   Torre, G.
   Colledan, M.
   Gridelli, B.
TI Randomized trial of basiliximab induction versus steroid therapy in
   pediatric liver allograft recipients under tacrolimus immunosuppression
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE glucocorticoids; liver transplantation; pediatric; rejection; simulect;
   tacrolimus
ID TRANSPLANT RECIPIENTS; RENAL-TRANSPLANTATION; DACLIZUMAB INDUCTION;
   REJECTION; GROWTH; MONOTHERAPY; EXPERIENCE; INFECTION; CHILDREN; DNA
AB Avoidance of corticosteroids could be beneficial after pediatric liver transplantation (LTx). To test this hypothesis, we performed a randomized prospective study to compare immunosuppression with tacrolimus (TAC) and steroids versus TAC and basiliximab (BAS) after pediatric LTx. Seventy-two patients were recruited, 36 receiving TAC and steroids and 36 TAC and BAS. The primary endpoint was the occurrence of the first rejection episode. Secondary endpoints were the cumulative incidence and severity of rejection, patient and graft survival, and incidence of adverse events. Overall 1-year patient and graft survival rates were 91.4% and 85.5% in the steroid group, and 88.6% and 80% in the BAS group (p = NS). Patients free from rejection were 87.7% in the BAS group and 67.7% in the steroid group (p = 0.036). The use of BAS was associated with a 63.6% reduction in incidence of acute rejection episodes. Overall incidence of infection was 72.3% in the steroid group and 50% in the BAS group (p = 0.035). We conclude that the combination of TAC with BAS is an alternative to TAC and steroid immunosuppression in pediatric LTx, which allows for a significant reduction in the incidence of acute rejection and infectious complications.
C1 Univ Pittsburgh, Med Ctr, IsMeTT, Ist Mediterraneo Trapianti & Terapie Specializz, Pittsburgh, PA 15260 USA.
   Osped Riuniti Bergamo, Liver & Lung Transplantat Unit, I-24100 Bergamo, Italy.
   Osped Riuniti Bergamo, Pathol Univ, I-24100 Bergamo, Italy.
   Osped Riuniti Bergamo, Pediat Unit, I-24100 Bergamo, Italy.
RP Spada, M (reprint author), Univ Pittsburgh, Med Ctr, IsMeTT, Ist Mediterraneo Trapianti & Terapie Specializz, Pittsburgh, PA 15260 USA.
EM mspada@ismett.edu
CR Asensio M, 2002, TRANSPLANT P, V34, P1970, DOI 10.1016/S0041-1345(02)03144-5
   Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   BILLINGHAM R E, 1951, Br Med J, V1, P1157
   Bishop GA, 1996, J IMMUNOL, V156, P4925
   Demetris A, 2000, Hepatology, V31, P792
   Di Filippo S, 2005, PEDIATR TRANSPLANT, V9, P373, DOI 10.1111/j.1399-3046.2005.00303.x
   FRYER JP, 1994, CLIN TRANSPLANT, V8, P224
   Ganschow R, 2001, PEDIATR TRANSPLANT, V5, P353, DOI 10.1034/j.1399-3046.2001.00020.x
   Ganschow R, 2005, PEDIATR TRANSPLANT, V9, P741, DOI 10.1111/j.1399-3046.2005.00371.x
   Gras J, 2005, PEDIATR TRANSPLANT, V9, P71
   Gupta P, 2001, TRANSPLANTATION, V72, P1098, DOI 10.1097/00007890-200109270-00020
   HEELEY PJ, 2002, LIVER TRANSPLANT, V6, pC14
   Heffron TG, 2003, TRANSPLANTATION, V75, P2040, DOI 10.1097/01.TP.0000065740.69296.DA
   Hendrickson RJ, 2004, CURR OPIN PEDIATR, V16, P309, DOI 10.1097/01.mop.0000127160.82531.77
   HYAMS JS, 1988, J PEDIATR-US, V113, P249, DOI 10.1016/S0022-3476(88)80260-9
   Kelly DA, 2001, PEDIATR TRANSPLANT, V5, P386, DOI 10.1034/j.1399-3046.2001.00038.x
   Kovarik JM, 2002, PEDIATR TRANSPLANT, V6, P224, DOI 10.1034/j.1399-3046.2002.01086.x
   Leonard H, 2003, PEDIATR TRANSPLANT, V7, P59, DOI 10.1034/j.1399-3046.2003.00014.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   MAZARIEGOS GV, 2003, AM J TRANSPLANT, V3, P453
   Newell KA, 1996, TRANSPLANTATION, V62, P370, DOI 10.1097/00007890-199608150-00012
   Reding R, 2000, TRANSPLANTATION, V70, P405, DOI 10.1097/00007890-200008150-00001
   Reding R, 2003, LANCET, V362, P2068, DOI 10.1016/S0140-6736(03)15104-5
   Reyes J, 2005, AM J TRANSPLANT, V5, P1430, DOI 10.1111/j.1600-6143.2005.00874.x
   Sarwal MM, 2003, TRANSPLANTATION, V76, P1331, DOI 10.1097/01.TP.0000092950.54184.67
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   Shapiro R, 2005, AM J TRANSPLANT, V5, P874, DOI 10.1111/j.1600-6135.2005.00833.x
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Spada M, 2001, TRANSPLANT P, V33, P1835, DOI 10.1016/S0041-1345(00)02828-1
   Veenstra DL, 1999, AM J KIDNEY DIS, V33, P829, DOI 10.1016/S0272-6386(99)70414-2
   Viner RM, 1999, ARCH DIS CHILD, V80, P235
   VINTERMYR OK, 1989, J CELL PHYSIOL, V138, P29, DOI 10.1002/jcp.1041380106
   1990, GOOD CLIN PRACT EUR
NR 33
TC 28
Z9 30
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD AUG
PY 2006
VL 6
IS 8
BP 1913
EP 1921
DI 10.1111/j.1600-6143.2006.01406.x
PG 9
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 061NQ
UT WOS:000238879700023
PM 16771811
ER

PT J
AU Ueno, T
   Kato, T
   Revas, K
   Gaynor, J
   Velasco, M
   Selvaggi, G
   McLaughlin, G
   Hernandez, E
   Krame, R
   Thompson, J
   Tzakis, A
AF Ueno, T.
   Kato, T.
   Revas, K.
   Gaynor, J.
   Velasco, M.
   Selvaggi, G.
   McLaughlin, G.
   Hernandez, E.
   Krame, R.
   Thompson, J.
   Tzakis, A.
TI Growth after intestinal transplant in children
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 10th International Symposium on Small Bowel Transplantation
CY JUN 30-JUL 02, 2005
CL Brussels, BELGIUM
ID PEDIATRIC LIVER-TRANSPLANTATION
AB Intestinal transplantation has been more frequent in children with intestinal failure. However, the growth after intestinal transplantation has not been well documented. The demographics, transplant information, postoperative complications, heights, and weights were obtained retrospectively from medical records on 23 children who underwent intestinal transplantation. Z-scores were calculated from the STAT Growth-BP, based on Centers for Disease Control and Prevention growth chart (2000). Transplantations were performed between 1999 and 2004. Patient median age was 1.1 years (range 0.5 to 6.9 years). Twelve were boys and 11 girls. Seventeen children received multivisceral transplantations, one modified multivisceral transplantation, and five isolated intestinal transplantations. Baseline immunosuppression consisted of tacrolimus and corticosteroids. Daclizurnab was used as induction agent in 18 patients; alemtuzumab, in five patients. Median pretransplant Z-scores were median -1.67 (n = 23) in weight, and median -3.36 (n = 21) in height. Pretransplant growth was significantly retarded. We analyzed significantly retarded patients with Z-score <-2.0. The change of weight Z-score from pretransplant was: 1.25 at 6 months (n = 11), 1.46 at 12 months (n = 10), and 2.21 at 24 months (n = 7). The change of height Z-score: 1.9 at 6 months (n = 16), 1.42 at 12 months (n = 13), and 1.51 at 24 months (n = 10). Z-score significantly improved (P < .002, ANOVA). Among the analyzed factors sex, age at transplant, length of stay, and rejection within 6 months, were not associated with catch-up growth. Children with retarded growth showed significant catch-up after successful intestinal transplantation.
C1 Univ Miami, Dept Surg, Miami, FL 33136 USA.
RP Kato, T (reprint author), Univ Miami, Dept Surg, 1801 NW 9th Ave, Miami, FL 33136 USA.
EM Tkato@med.miami.edu
CR Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Falkenstein K, 1998, TRANSPLANT P, V30, P1969, DOI 10.1016/S0041-1345(98)00499-0
   Kato T, 2005, J GASTROINTEST SURG, V9, P75, DOI 10.1016/j.gassur.2004.10.012
   McDiarmid SV, 1999, TRANSPLANTATION, V67, P404, DOI 10.1097/00007890-199902150-00011
   Pasqualini T, 2000, TRANSPLANTATION, V70, P472, DOI 10.1097/00007890-200008150-00013
NR 5
TC 15
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JUL-AUG
PY 2006
VL 38
IS 6
BP 1702
EP 1704
DI 10.1016/j.transproceed.2006.05.025
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 077SY
UT WOS:000240051700017
PM 16908254
ER

PT J
AU Hwang, S
   Lee, SG
   Lee, YD
   Sung, KB
   Park, KM
   Kim, KH
   Ahn, CS
   Moon, DB
   Hwang, GS
   Kim, KM
   Ha, TY
   Kim, DS
   Jung, JP
   Song, GW
AF Hwang, S
   Lee, SG
   Lee, YD
   Sung, KB
   Park, KM
   Kim, KH
   Ahn, CS
   Moon, DB
   Hwang, GS
   Kim, KM
   Ha, TY
   Kim, DS
   Jung, JP
   Song, GW
TI Lessons learned from 1,000 living donor liver transplantations in a
   single center: How to make living donations safe
SO LIVER TRANSPLANTATION
LA English
DT Article
ID HEPATIC VENOUS CONGESTION; ANTIBODY-POSITIVE DONORS; RIGHT-LOBE;
   HEPATOCELLULAR-CARCINOMA; GRAFT; VEIN; COMPLICATIONS; RECONSTRUCTION;
   HEPATECTOMY; EXPERIENCE
AB Serious complications have occurred in a considerable proportion of living donors of liver transplants, but data from a single high-volume center has rarely been available. We analyzed the medical records of donors and recipients of the first 1,000 living donor liver transplants, performed at Asan Medical Center from December 1994 to June 2005, with a focus on donor safety. There were 107 pediatric and 893 adult transplants. The most common diagnoses were biliary atresia in pediatric recipients (63%) and hepatitis B-associated liver cirrhosis (80%) in adult recipients. Right lobe donors were strictly selected based on liver resection rate and steatosis. From 1,162 living donors, 588 right lobes, 6 extended right lobes, 7 right posterior segments, 464 left lobes, and 107 left lateral segments were obtained. Of these, 837 grafts were implanted singly, whereas 325, along with 1 cadaveric split graft, were implanted as dual grafts into 163 recipients. The 5-yr survival rates were 84.8% in pediatric recipients and 83.2% in adult recipients. There was no donor mortality, but 3.2% of donors experienced major complications. Until the end of 2001, the major donor complication rate was 6.7%, with most occurring in right liver donors. Since 2002, liver resection exceeding 65% of whole liver volume were avoided except for young donors with no hepatic steatosis, and the donor complication rate has been reduced to 1.3%. In conclusion, a majority of major living donor complications appear to be avoidable through the strict selection of living donor and graft type, intensive postoperative surveillance, and timely feedback of surgical techniques. Selection of right lobe graft should be very prudently considered if the donor right liver appears to be larger than 65% of the whole liver volume.
C1 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg,Div Hepatobiliary Surg & Liver Transpla, Seoul 138736, South Korea.
   Univ Ulsan, Coll Med, Asan Med Ctr, Dept Diagnost Radiol, Seoul 138736, South Korea.
   Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol, Seoul 138736, South Korea.
   Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat, Seoul 138736, South Korea.
RP Lee, SG (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg,Div Hepatobiliary Surg & Liver Transpla, 388-1 Poongnap Dong, Seoul 138736, South Korea.
EM sglee2@amc.seoul.kr
OI Kim, Kyung Mo/0000-0001-7896-6751
CR Akabayashi A, 2004, TRANSPLANTATION, V77, P634, DOI 10.1097/01.TP.0000115342.98226.7C
   Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345
   Chan SC, 2003, ARCH SURG-CHICAGO, V138, P265, DOI 10.1001/archsurg.138.3.265
   Chen CH, 2004, TRANSPLANT P, V36, P1920, DOI 10.1016/j.transproceed.2004.08.016
   Cywinski JB, 2004, ANESTH ANALG, V99, P1747, DOI 10.1213/01.ANE.0000136423.17446.5D
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Egawa H, 2002, TRANSPLANT P, V34, P235, DOI 10.1016/S0041-1345(01)02739-7
   Ghobrial RM, 2002, LIVER TRANSPLANT, V8, P901, DOI 10.1053/jlts.2002.35548
   Hwang S, 2004, TRANSPLANT P, V36, P1462, DOI 10.1016/j.transproceed.2004.05.018
   Hwang S, 2005, LIVER TRANSPLANT, V11, P644, DOI 10.1002/lt.20430
   Hwang S, 2004, LIVER TRANSPLANT, V10, P1150, DOI 10.1002/lt.20225
   Hwang S, 2005, LIVER TRANSPLANT, V11, P449, DOI 10.1002/lt.20387
   Hwang S, 2004, LIVER TRANSPLANT, V10, P1398, DOI 10.1002/lt.20241
   Hwang S, 2003, TRANSPLANTATION, V75, pS45, DOI 10.1097/01.TP.0000047030.38665.0D
   Hwang S, 2005, LIVER TRANSPLANT, V11, P104, DOI 10.1002/lt.20314
   Hwang S, 2005, TRANSPLANT P, V37, P4347, DOI 10.1016/j.transproceed.2005.11.051
   Hwang S, 2004, LIVER TRANSPLANT, V10, P721, DOI 10.1002/lt.20172
   Hwang S, 2005, LIVER TRANSPLANT, V11, P1265, DOI 10.1002/lt.20549
   Hwang S, 2004, LIVER TRANSPLANT, V10, P763, DOI 10.1002/lt.20178
   Ko GY, 2002, J VASC INTERV RADIOL, V13, P591, DOI 10.1016/S1051-0443(07)61652-2
   Lee RKK, 2002, INT J ANDROL, V25, P277, DOI 10.1046/j.1365-2605.2002.00355.x
   Lee SG, 2001, TRANSPLANT P, V33, P3461, DOI 10.1016/S0041-1345(01)02491-5
   Lee SG, 2002, TRANSPLANTATION, V74, P54
   Lee SG, 2003, TRANSPLANTATION, V75, pS28, DOI 10.1097/01.TP.0000047028.97031.66
   Lee SH, 2005, TRANSPLANT P, V37, P1081, DOI 10.1016/j.transproceed.2005.01.032
   Lee SS, 2003, RADIOLOGY, V227, P391, DOI 10.1148/radiol.2272012033
   Lee SG, 2005, J HEPATO-BILIARY-PAN, V12, P38, DOI 10.1007/s00534-004-0949-9
   Lee SY, 2004, RADIOLOGY, V230, P443, DOI 10.1148/radiol.2302021318
   Lo CM, 2003, TRANSPLANTATION, V75, pS12, DOI 10.1097/01.TP.0000046534.45645.47
   Lo CM, 2003, LIVER TRANSPLANT, V9, P827, DOI 10.1053/jlts.2003.50115
   Marcos A, 2001, LIVER TRANSPLANT, V7, P673, DOI 10.1053/jlts.2001.26568
   Matot I, 2002, ANESTH ANALG, V95, P1179, DOI 10.1213/01.ANE.0000019057.79800.88
   Miller C, 2004, LIVER TRANSPLANT, V10, P1315, DOI 10.1002/lt.20227
   Park JS, 2003, GASTROINTEST ENDOSC, V57, P78, DOI 10.1067/mge.2003.11
   Park K, 2004, TRANSPLANT P, V36, P2949, DOI 10.1016/j.transproceed.2004.12.013
   Settmacher U, 2004, NEPHROL DIAL TRANSPL, V19, P16, DOI 10.1093/ndt/gfh1036
   Sugawara Y, 2004, LIVER TRANSPLANT, V10, P715, DOI 10.1002/lt.20179
   Tanaka K, 2005, J HEPATOL, V42, P25, DOI 10.1016/j.jhep.2004.11.004
   Wakeno-Takahashi M, 2005, J CLIN ANESTH, V17, P218, DOI 10.1016/j.jclinane.2004.06.011
   Wiederkehr JC, 2005, TRANSPLANT P, V37, P1079, DOI 10.1016/j.transproceed.2004.12.221
   Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023
NR 41
TC 171
Z9 184
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2006
VL 12
IS 6
BP 920
EP 927
DI 10.1002/lt.20734
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 052AI
UT WOS:000238202400006
PM 16721780
ER

PT J
AU Heffron, T
   Welch, D
   Pillen, T
   Asolati, M
   Smallwood, G
   Hagedorn, P
   Nam, C
   Duncan, A
   Guy, M
   Martinez, E
   Spivey, J
   Douglas, P
   Fasola, C
   De Paolo, J
   Rodriguez, J
   Romero, R
AF Heffron, T
   Welch, D
   Pillen, T
   Asolati, M
   Smallwood, G
   Hagedorn, P
   Nam, C
   Duncan, A
   Guy, M
   Martinez, E
   Spivey, J
   Douglas, P
   Fasola, C
   De Paolo, J
   Rodriguez, J
   Romero, R
TI Successful ABO-incompatible pediatric liver transplantation utilizing
   standard immunosuppression with selective postoperative plasmapheresis
SO LIVER TRANSPLANTATION
LA English
DT Article
ID BLOOD-GROUPS; HEMOLYTIC-ANEMIA; RECIPIENT; DONOR; SPLENECTOMY;
   MICROSCOPE; IMPACT
AB Transplanting blood group A, B, or O (ABO)-incompatible (ABO-I) liver grafts has resulted in lower patient and graft survival with an increased incidence of vascular and biliary complications and rejection. We report that, without modification of our standard immunosuppression protocol, crossing blood groups is an acceptable option for children requiring liver transplantation. In our study, ABO-I liver grafts-regardless of recipient age-have comparable long-term survival (mean follow-up of 3.25 yr) with ABO-compatible grafts without any difference in rejection, vascular or biliary complications. From January 1, 1999 to October 1, 2005, we studied 138 liver transplants in 121 children: 16 (13.2%) received an ABO incompatible liver allograft. One-year actuarial patient survival for ABO-matched grafts vs. ABO-I grafts was 93.0%a and 100%, respectively, whereas graft survival was 83.4% and 92.3%. Additionally, 6 of 16 (37.5%) ABO-I transplanted children had 8 rejection episodes, whereas 47 patients (44.8%) had 121 rejection episodes in the ABO-compatible group. There were no vascular complications and 2 biliary strictures in the ABO-I group. Plasmapheresis was not used for pretransplantation desensitization and was only required in 1 posttransplantation recipient. No child was splenectomized. Six of the 16 children were older than 13 yr of age, suggesting the possibility of successfully expanding this technique to an older population. In conclusion, our outcomes may support the concept of using ABO-I grafts in a more elective setting associated with split and living donor liver transplants.
C1 Emory Univ, Dept Surg, Sch Med, Atlanta, GA 30322 USA.
   Childrens Healthcare Atlanta Egleston, Atlanta, GA USA.
   Emory Univ Hosp, Dept Pharm, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   Dallas VA Med Ctr, Dallas, TX USA.
   Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA.
RP Heffron, T (reprint author), 1405 Clifton Rd, Atlanta, GA 30322 USA.
EM thomas.heffron@choa.org
RI Hagedorn, Philip/H-5688-2013
OI Hagedorn, Philip/0000-0003-1650-6359
CR Bjoro K, 2003, TRANSPLANTATION, V75, P347, DOI 10.1097/01.TP.0000044359.72379.E5
   Egawa H, 2004, TRANSPLANTATION, V77, P403, DOI 10.1097/01.TP.0000110295.88926.5C
   Fang WC, 2000, LIVER TRANSPLANT, V6, P497, DOI 10.1053/jlts.2000.6448
   FARGES O, 1995, TRANSPLANTATION, V59, P1124, DOI 10.1097/00007890-199504270-00009
   FARGES O, 1995, TRANSPLANT P, V27, P1701
   GORDON RD, 1986, SURGERY, V100, P342
   GREGOIRE JR, 1993, J AM SOC NEPHROL, V4, P1122
   Guarrera JV, 2004, TRANSPLANT INT, V17, P585, DOI 10.1007/s00147-004-0782-8
   GUGENHEIM J, 1990, LANCET, V336, P519, DOI 10.1016/0140-6736(90)92082-S
   Hanto DW, 2003, LIVER TRANSPLANT, V9, P22, DOI 10.1053/jlts.2002.50011
   Hareuveni M, 2002, TRANSFUSION, V42, P363, DOI 10.1046/j.1537-2995.2002.00075.x
   Heffron TG, 2005, PEDIATR TRANSPLANT, V9, P486, DOI 10.1111/j.1399-3046.2005.00327.x
   Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2
   Monteiro I, 2003, TRANSPLANTATION, V76, P1648, DOI 10.1097/01.TP.0000082723.02477.87
   Panaro F, 2004, CLIN TRANSPLANT, V18, P332, DOI 10.1111/j.1399-0012.2004.00158.x
   Rydberg L, 2001, TRANSFUSION MED, V11, P325, DOI 10.1046/j.1365-3148.2001.00313.x
   Stegall M, 2003, LIVER TRANSPLANT, V9, P31, DOI 10.1053/jlts.2003.00000
   Szymczak M, 2003, TRANSPLANT P, V35, P2273, DOI 10.1016/S0041-1345(03)00846-7
   Takayama J, 1998, TRANSPLANT P, V30, P3504, DOI 10.1016/S0041-1345(98)01115-4
   TANAKA A, 1994, TRANSPLANTATION, V58, P548, DOI 10.1097/00007890-199409150-00004
   Varela-Fascinetto G, 1999, TRANSPLANT P, V31, P467, DOI 10.1016/S0041-1345(98)01711-4
NR 21
TC 29
Z9 32
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2006
VL 12
IS 6
BP 972
EP 978
DI 10.1002/lt.20760
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 052AI
UT WOS:000238202400013
PM 16721774
ER

PT J
AU Soejima, Y
   Taketomi, A
   Yoshizumi, T
   Uchiyama, H
   Harada, N
   Ijichi, H
   Yonemura, Y
   Ikeda, T
   Shimada, M
   Maehara, Y
AF Soejima, Y
   Taketomi, A
   Yoshizumi, T
   Uchiyama, H
   Harada, N
   Ijichi, H
   Yonemura, Y
   Ikeda, T
   Shimada, M
   Maehara, Y
TI Biliary strictures in living donor liver transplantation: Incidence,
   management, and technical evolution
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SINGLE-CENTER EXPERIENCE/; RIGHT-LOBE; TRACT COMPLICATIONS;
   RECONSTRUCTION; ANASTOMOSIS; RECIPIENTS; GRAFT
AB Biliary complications, biliary strictures (BS) in particular, continue to be a significant cause of morbidity after LDLT despite technical refinement. In this study, we assessed the incidence of BS and their management in living donor liver transplantation (LDLT) with special reference to the type of biliary reconstruction. A total of 182 LDLTs performed at our institution for either adult (n = 157) or pediatric (n = 25) patients were included in the study. The duct-to-duct (DD) biliary reconstruction was performed for 106 cases, while the conventional Roux-en-Y hepaticojejunostomy (HJ) was utilized for the remaining 76 cases. Overall, BS developed in 46/182 (25.3%) of the cases (DD, 26.4%; HJ, 25.0%). The 1- and 3-year cumulative incidences of BS were 22.9% and 31.9%, respectively, in the DD group, and 15.2% and 29.1%, respectively, in the HJ group (P = not significant). The left-lobe LDLT was more prone to develop BS. Continuous anastomosis tended to be associated with the high incidence of BS in the DD group. The incidence of anastomotic leak was significantly lower in the DD group. Intervention via either precutaneous or endoscopic approach was successful in the majority of cases, although recurrence could occur in some patients. In conclusion, BS was not associated with the type of reconstruction in LDLT. The primary radiological or endoscopic interventions were satisfactory treatments of choice. Technical refinement is an important factor to reduce the incidence of BS.
C1 Univ Tokushima, Sch Med, Dept Digest & Pediat Surg, Tokushima 770, Japan.
   Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan.
   Ohita Prefectural Hosp, Dept Surg, Ohita, Japan.
RP Soejima, Y (reprint author), Univ Tokushima, Sch Med, Dept Digest & Pediat Surg, Tokushima 770, Japan.
EM ysoejima@clin.med.tokushima-u.ac.jp
RI Maehara, Yoshihiko/A-4867-2010
CR Azoulay D, 2001, ARCH SURG-CHICAGO, V136, P1197, DOI 10.1001/archsurg.136.10.1197
   Bak T, 2001, LIVER TRANSPLANT, V7, P680, DOI 10.1053/jlts.2001.26509
   COLONNA JO, 1992, ANN SURG, V216, P344
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Fan ST, 2002, ANN SURG, V236, P676, DOI 10.1097/01.SLA.0000033323.01380.AC
   Gondolesi GE, 2004, TRANSPLANTATION, V77, P1842, DOI 10.1097/01.tp.0000123077.78702.0c
   GREIF F, 1994, ANN SURG, V219, P40, DOI 10.1097/00000658-199401000-00007
   Grewal HP, 2001, ANN SURG, V233, P502, DOI 10.1097/00000658-200104000-00004
   Hisatsune H, 2003, TRANSPLANTATION, V76, P810, DOI 10.1097/01.TP.0000083224.00756.8F
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Kawachi S, 2002, SURGERY, V132, P48, DOI 10.1067/msy.2002.125314
   Lee SG, 2002, TRANSPLANTATION, V74, P54
   LERUT J, 1987, TRANSPLANTATION, V43, P47, DOI 10.1097/00007890-198701000-00011
   Liu CL, 2004, TRANSPLANTATION, V77, P726, DOI 10.1097/01.TP.0000116604.89083.2F
   Marcos A, 2000, ANN SURG, V231, P824, DOI 10.1097/00000658-200006000-00006
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   NISHIZAKI T, 2001, ANN SURG, V233, P577
   Park JS, 2003, GASTROINTEST ENDOSC, V57, P78, DOI 10.1067/mge.2003.11
   Schindel D, 2000, J PEDIATR SURG, V35, P940, DOI 10.1053/jpsu.2000.6932
   Soejima Y, 2003, TRANSPLANTATION, V75, P557, DOI 10.1097/01.TP.0000048220.90971.5A
   Sung RS, 2004, TRANSPLANTATION, V77, P110, DOI 10.1097/01.TP.0000101518.19849.C8
   Testa G, 2000, LIVER TRANSPLANT, V6, P710, DOI 10.1053/jlts.2000.18706
NR 24
TC 62
Z9 67
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2006
VL 12
IS 6
BP 979
EP 986
DI 10.1002/lt.20740
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 052AI
UT WOS:000238202400014
PM 16721777
ER

PT J
AU Traum, AZ
   Rodig, NM
   Pilichowska, ME
   Somers, MJG
AF Traum, AZ
   Rodig, NM
   Pilichowska, ME
   Somers, MJG
TI Central nervous system lymphoproliferative disorder in pediatric kidney
   transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplant lymphoproliferative disorder; central nervous system;
   ocular; rituximab
ID EPSTEIN-BARR-VIRUS; ANTI-CD20 ANTIBODY RITUXIMAB; PRIMARY CNS LYMPHOMA;
   B-CELL LYMPHOMA; LIVER-TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENT;
   DISEASE; IRIS; CHILD; CYCLOSPORINE
AB Post-transplant lymphoproliferative disorder (PTLD) is a complication of transplantation resulting from impaired immune surveillance because of pharmacologic immunosuppression. We present two cases of central nervous system (CNS) PTLD in children on calcineurin-inhibitor free immunosuppression with dramatically different presentations and outcomes. One patient had brain and spinal cord lymphoma with a rapid and fatal course. The other patient had brain and ocular PTLD that responded to multimodal therapy with reduction of immunosuppression, high-dose steroids, and rituximab given in a dose-escalation protocol. This protocol may have enhanced the penetration of rituximab into the CNS. We review the literature on CNS and ocular PTLD and elaborate on the treatments available for both diseases.
C1 Childrens Hosp, Div Nephrol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Traum, AZ (reprint author), Childrens Hosp, Div Nephrol, 300 Longwood Ave, Boston, MA 02115 USA.
EM avram.traum@childrens.harvard.edu
CR Al-Attar L, 2004, AM J OPHTHALMOL, V137, P569, DOI 10.1016/j.ajo.2003.08.013
   Berney T, 2002, TRANSPLANTATION, V74, P1000, DOI 10.1097/01.TP.0000031931.31954.53
   BRODSKY MC, 1991, SURV OPHTHALMOL, V36, P217, DOI 10.1016/0039-6257(91)90004-Y
   Buell JF, 2005, TRANSPLANT P, V37, P954, DOI 10.1016/j.transproceed.2004.12.130
   Bueno J, 2003, PEDIATR TRANSPLANT, V7, P153, DOI 10.1034/j.1399-3046.2003.00024.x
   Castellano-Sanchez AA, 2004, AM J CLIN PATHOL, V121, P246, DOI 10.1309/N82CTQ1J0XEVEFQ8
   Chan SM, 2000, OPHTHALMOLOGY, V107, P1479, DOI 10.1016/S0161-6420(00)00172-X
   Cho AS, 2001, ARCH OPHTHALMOL-CHIC, V119, P183
   Ciancio G, 1997, CLIN TRANSPLANT, V11, P243
   Clark WL, 1998, ARCH OPHTHALMOL-CHIC, V116, P1667
   COHEN DJ, 1984, ANN INTERN MED, V101, P667
   Cook T, 2001, ARCH OPHTHALMOL-CHIC, V119, P768
   COX KL, 1995, TRANSPLANTATION, V59, P524
   Demols PF, 2001, BRIT J OPHTHALMOL, V85, P93, DOI 10.1136/bjo.85.1.93
   Dharnidharka VR, 2001, TRANSPLANTATION, V71, P1065, DOI 10.1097/00007890-200104270-00010
   Dharnidharka VR, 2002, PEDIATR TRANSPLANT, V6, P396, DOI 10.1034/j.1399-3046.2002.00021.x
   Dotti G, 2001, HAEMATOLOGICA, V86, P618
   FLECHNER SM, 1983, UROL CLIN N AM, V10, P263
   GOLDMAN MH, 1985, SURG CLIN N AM, V65, P637
   Green M, 2003, PEDIATR CLIN N AM, V50, P1471, DOI 10.1016/S0031-3955(03)00127-5
   Harjunpaa A, 2001, LEUKEMIA LYMPHOMA, V42, P731, DOI 10.3109/10428190109099335
   JOHNSON BL, 1992, OPHTHALMOLOGY, V99, P987
   KHETERPAL S, 1993, AM J OPHTHALMOL, V116, P507
   Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19
   Majewski M, 2000, P NATL ACAD SCI USA, V97, P4285, DOI 10.1073/pnas.080068597
   MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010
   Nepomuceno RR, 2003, CANCER RES, V63, P4472
   O'Brien SM, 2001, J CLIN ONCOL, V19, P2165
   O'Connor JA, 2001, J PEDIATR GASTR NUTR, V32, P89, DOI 10.1097/00005176-200101000-00023
   O'Hara M, 2001, J AAPOS, V5, P62, DOI 10.1067/mpa.2001.112444
   Pels H, 2002, J NEURO-ONCOL, V59, P213, DOI 10.1023/A:1019999830455
   Pels H, 2003, ONKOLOGIE, V26, P351, DOI 10.1159/000072095
   PENN I, 1995, TRANSPLANTATION, V59, P240, DOI 10.1097/00007890-199501270-00016
   Phan TG, 2000, NEURO-ONCOLOGY, V2, P229, DOI 10.1215/15228517-2-4-229
   Pomeranz HD, 1996, ARCH OPHTHALMOL-CHIC, V114, P1422
   ROBINSON R, 1995, J PEDIATR OPHTHALMOL, V32, P393
   Rohrbach JM, 2004, GRAEF ARCH CLIN EXP, V242, P44, DOI 10.1007/s00417-003-0751-4
   Rowe D T, 2001, Transpl Infect Dis, V3, P79, DOI 10.1034/j.1399-3062.2001.003002079.x
   Rubenstein JL, 2003, BLOOD, V101, P466, DOI 10.1182/blood-2002-06-1636
   Ruhstaller TW, 2000, ANN ONCOL, V11, P374, DOI 10.1023/A:1008371602708
   Schulz H, 2004, HAEMATOLOGICA, V89, P753
   Serinet MO, 2002, J PEDIATR GASTR NUTR, V34, P389, DOI 10.1097/00005176-200204000-00014
   Shroff R, 2004, PEDIATR NEPHROL, V19, P369, DOI 10.1007/s00467-003-1392-x
   Snanoudj R, 2003, TRANSPLANTATION, V76, P930, DOI 10.1097/01.TP.0000079253.06061.52
   WALKER RC, 1995, CLIN INFECT DIS, V20, P1346
NR 45
TC 19
Z9 21
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2006
VL 10
IS 4
BP 505
EP 512
DI 10.1111/j.1399-3046.2006.00497.x
PG 8
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 043XD
UT WOS:000237635300019
PM 16712612
ER

PT J
AU Broniszczak, D
   Szymczak, M
   Kaminski, A
   Chyzynska, A
   Ismail, H
   Drewniak, T
   Nachulewicz, P
   Markiewicz, M
   Teisseyre, J
   Dzik, E
   Lembas, A
   Kalicinski, P
AF Broniszczak, D
   Szymczak, M
   Kaminski, A
   Chyzynska, A
   Ismail, H
   Drewniak, T
   Nachulewicz, P
   Markiewicz, M
   Teisseyre, J
   Dzik, E
   Lembas, A
   Kalicinski, P
TI Vascular complications after pediatric liver transplantation from the
   living donors
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID HEPATIC-ARTERY THROMBOSIS; CHILDREN; INFANTS; GRAFTS
AB Early arterial or portal vein thrombosis is a complications that can lead to graft loss and patient death or need of immediate retransplantation. The aim of the study was to assess the incidence, causes, treatment, and outcome of vascular thrombosis after living related donor liver transplantation (LRdLTx). Between 1999 and 2004 71 LRdLTx were performed in children aged from 6 months to 10 years. Vascular thrombosis was found in 12 recipients. Hepatic artery thrombosis (HAT) occurred in 4 (5.6%), portal vein thrombosis (PVT) in 8 (11.2%) cases. FIAT occurred 5 to 8 days, PVT 1 to 22 days after LTx. Diagnosis of vascular thrombosis was confirmed by routine Doppler ultrasound examination. Thrombectomy was successful in one patient with HAT and in three patients with PVT. Venous conduit was performed in one patient with PVT after second thrombosis. Two children developed biliary strictures as a late complication of HAT and required additional surgical interventions. Two children with PVT developed portal hypertension with esophageal bleeding, which required surgical intervention; one another underwent endoscopic variceal ligation for grade III varices. Follow-up ranged from 7 to 60 months. One patient died as a result of HAT after retransplantation due to multiple intrahepatic abscesses 2 months after first transplant. Any risk factors of vascular thrombosis that can be controlled should be avoided after transplantation. Routine posttransplant Doppler examination should be performed at least twice a day within 7 to 14 posttransplant days. Immediate thrombectomy should be always carried out to avoid late complications and even mortality.
C1 Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, Warsaw, Poland.
RP Broniszczak, D (reprint author), Childrens Mem Hlth Inst, Dept Pediat Surg & Organ Transplantat, Dzieci Polskich 20, Warsaw, Poland.
CR BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Cheng YF, 2004, CLIN TRANSPLANT, V18, P390, DOI 10.1111/j.1399-0012.2004.00178.x
   Colombani PM, 2000, J PEDIATR SURG, V35, P9, DOI 10.1016/S0022-3468(00)80067-6
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   JURIM O, 1995, AM J SURG, V169, P529, DOI 10.1016/S0002-9610(99)80211-6
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Lin CC, 2004, TRANSPLANT P, V36, P2338, DOI 10.1016/j.transproceed.2004.07.044
   MAZZAFERRO V, 1989, TRANSPLANT P, V21, P2466
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Sakamoto Y, 1999, BRIT J SURG, V86, P886, DOI 10.1046/j.1365-2168.1999.01166.x
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   Wagner C, 2000, J CLIN ANESTH, V12, P454, DOI 10.1016/S0952-8180(00)00192-6
NR 15
TC 29
Z9 35
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JUN
PY 2006
VL 38
IS 5
BP 1456
EP 1458
DI 10.1016/j.transproceed.2006.02.094
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 058YM
UT WOS:000238700500066
PM 16797331
ER

PT J
AU Muiesan, P
   Jassem, W
   Girlanda, R
   Steinberg, R
   Vilca-Melendez, H
   Mieli-Vergani, G
   Dhawan, A
   Rela, M
   Heaton, N
AF Muiesan, P
   Jassem, W
   Girlanda, R
   Steinberg, R
   Vilca-Melendez, H
   Mieli-Vergani, G
   Dhawan, A
   Rela, M
   Heaton, N
TI Segmental liver transplantation from non-heart beating donors - An early
   experience with implications for the future
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE donation after cardiac death; liver transplantation; non-heart beating
   donors; pediatric transplantation; segmental grafts; split liver
AB We report our experience of pediatric liver transplantation with partial grafts from non-heart beating donors (NHBD). Controlled donors less than 40 years of age with a warm ischemia time (WI) of less than 30 min were considered for pediatric recipients. Death was declared 5 min after asystole. A super-rapid recovery technique with aortic and portal perfusion was utilized. Mean donor age was 29 years and WI 14.6 min (range 11-18). Seven children, mean age 4.9 years (0.7-11), median weight 20 kg (8.4-53) received NHBD segmental liver grafts. Diagnoses included seronegative hepatitis, neonatal sclerosing cholangitis, familial intrahepatic cholestasis, hepatoblastoma, primary hyperoxaluria and factor VII deficiency (n = 2). The grafts included four reduced and one split left lateral segments, one left lobe and one right auxiliary graft. Mean cold ischemia was 7.3 h (6.2-8.8). Complications included one pleural effusion and one biliary collection drained percutaneously. At 20 months (10-36) follow-up all children are alive and well with functioning grafts.
C1 Kings Coll Hosp, Inst Liver Studies, Liver Transplant Surg Serv, London, England.
RP Muiesan, P (reprint author), Kings Coll Hosp, Inst Liver Studies, Liver Transplant Surg Serv, London, England.
EM paolo.muiesan@kingsch.nhs.uk
RI Dhawan, Anil/B-6730-2009; 
OI Muiesan, Paolo/0000-0002-7389-6691
CR Abt P, 2003, TRANSPLANTATION, V75, P1659, DOI 10.1097/01.TP.0000062574.18648.7C
   Abt PL, 2004, ANN SURG, V239, P87, DOI 10.1097/01.sla.0000103063.82181.2c
   CASAVILLA A, 1995, TRANSPLANTATION, V59, P197, DOI 10.1097/00007890-199501270-00008
   D'Alessandro AM, 2000, SURGERY, V128, P579, DOI 10.1067/msy.2000.108421
   Garcia-Valdecasas JC, 1999, EUR SURG RES, V31, P447, DOI 10.1159/000008724
   Hutchinson C, 2003, PEDIATR TRANSPLANT, V7, P441, DOI 10.1046/j.1399-3046.2003.00073.x
   Manzarbeitia CY, 2004, TRANSPLANTATION, V78, P211, DOI 10.1097/01.tp.0000128327.95311.e3
   Muiesan P, 2003, TRANSPLANTATION, V75, P1627, DOI 10.1097/01.TP.0000071487.73903.90
   Muiesan P, 2003, TRANSPLANTATION, V75, P1443, DOI 10.1097/01.TP.0000069024.86527.0B
   Saito K, 2001, TRANSPLANT P, V33, P3781, DOI 10.1016/S0041-1345(01)02599-4
NR 10
TC 26
Z9 26
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2006
VL 6
IS 5
BP 1012
EP 1016
DI 10.1111/j.1600-6143.2006.01293.x
PN 1
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 033PH
UT WOS:000236860700019
PM 16611338
ER

PT J
AU Sweet, SC
   Wong, HH
   Webber, SA
   Horslen, S
   Guidinger, MK
   Fine, RN
   Magee, JC
AF Sweet, SC
   Wong, HH
   Webber, SA
   Horslen, S
   Guidinger, MK
   Fine, RN
   Magee, JC
TI Pediatric transplantation in the United States, 1995-2004
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE deceased donors; graft survival; immunosuppression; living donors; organ
   donation; OPTN; patient survival; pediatric transplantation; SRTR;
   waiting list
ID LOBAR LUNG TRANSPLANTATION; INTESTINAL TRANSPLANTATION;
   LIVER-TRANSPLANTATION; HEART-TRANSPLANTATION; INTERNATIONAL-SOCIETY;
   SINGLE-CENTER; 1ST YEAR; RECIPIENTS; REGISTRY; CHILDREN
AB This article reviews trends in pediatric solid organ transplantation over the last decade, as reflected in OPTN/SRTR data. In 2004, children younger than 18 years made up nearly 3% of the 86378 candidates for organ transplantation and nearly 7% of the 27 031 organ transplant recipients. Children accounted for nearly 14% of the 7152 deceased organ donors. The transplant community recognizes important differences between pediatric and adult organ transplant recipients, including different etiologies of organ failure, surgical procedures that are more complex or technically challenging, effects of development on the pharmacokinetic properties of common immunosuppressants, unique immunological aspects of transplant in the developing immune system and increased susceptibility to posttransplant complications, particularly infectious diseases. For these reasons, and be-cause of the impact of end-stage organ failure on growth and development, the transplant community has generally provided pediatric candidates with special consideration in the allocation of deceased donor organs. Outcomes following kidney, liver and heart transplantation in children often rank among the best. This article emphasizes that the prospects for solid organ transplantation in children, especially those aged 1-10 years are excellent. It also identifies themes warranting further consideration, including organ availability, adolescent survival and challenges facing pediatric transplant clinical research.
C1 Washington Univ, Sch Med, St Louis, MO 63130 USA.
   US Hlth Resources & Serv Adm, Dept Hlth & Human Serv, Healthcare Syst Bur, Div Transplantat, Rockville, MD 20857 USA.
   Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.
   Childrens Hosp, Seattle, WA USA.
   Reg Med Ctr, Seattle, WA USA.
   Univ Renal Res & Educ Assoc, Sci Registry Transplant Recipients, Ann Arbor, MI USA.
   SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA.
   Univ Michigan, Sci Registry Transplant Recipients, Ann Arbor, MI 48109 USA.
RP Sweet, SC (reprint author), Washington Univ, Sch Med, St Louis, MO 63130 USA.
EM sweet@kids.wustl.edu
CR Addonizio LJ, 2005, J HEART LUNG TRANSPL, V24, pS64, DOI 10.1016/j.healun.2004.11.092
   BLUME ED, 2005, J HEART LUNG TRAN S2, V24, pS75, DOI 10.1016/j.healun.2004.11.122
   Boucek MM, 2004, J HEART LUNG TRANSPL, V23, P933, DOI 10.1016/j.healun.2004.06.011
   Chrisant MRK, 2005, J HEART LUNG TRANSPL, V24, P576, DOI 10.1016/j.healun.2004.01.019
   Dahlke MH, 2005, PSYCHOSOMATICS, V46, P58, DOI 10.1176/appi.psy.46.1.58
   Danziger-Isakov LA, 2003, PEDIATR TRANSPLANT, V7, P469, DOI 10.1046/j.1397-3142.2003.00102.x
   Date H, 2004, J THORAC CARDIOV SUR, V128, P933, DOI 10.1016/j.jtcvs.2004.07.032
   Dobbels F, 2004, J HEART LUNG TRANSPL, V23, P1245, DOI 10.1016/j.healun.2003.09.016
   Dobbels F, 2005, PEDIATR TRANSPLANT, V9, P381, DOI 10.1111/j.1399-3046.2005.00356.x
   Egan TM, 2006, AM J TRANSPLANT, V6, P1212, DOI 10.1111/j.1600-6143.2006.01276.x
   English RF, 2002, AM J TRANSPLANT, V2, P769, DOI 10.1034/j.1600-6143.2002.20811.x
   Fan LL, 2002, AM J RESP CRIT CARE, V165, P1466, DOI 10.1164/rccm.2204012
   Freeman RB, 2004, LIVER TRANSPLANT, V10, P7, DOI 10.1002/lt.20024
   Grant D, 1999, TRANSPLANTATION, V67, P1061, DOI 10.1097/00007890-199904150-00021
   Grant D, 2005, ANN SURG, V241, P607, DOI 10.1097/01.sla.0000157265.85388.a1
   Hamvas A, 1997, J PEDIATR-US, V130, P231, DOI 10.1016/S0022-3476(97)70348-2
   HARMON WE, 1991, TRANSPLANTATION, V51, P406, DOI 10.1097/00007890-199102000-00026
   Harmon WE, 2005, AM J TRANSPLANT, V5, P887, DOI 10.1111/j.1600-6135.2005.00834.x
   Horslen S, 2004, LIVER TRANSPLANT, V10, pS86, DOI 10.1002/lt.20257
   Ibrahim JE, 2002, J HEART LUNG TRANSPL, V21, P311, DOI 10.1016/S1053-2498(01)00395-3
   Kato T, 2005, J GASTROINTEST SURG, V9, P75, DOI 10.1016/j.gassur.2004.10.012
   LEE CK, 2005, AM J TRANSPLANT S11, V5, P406
   Levine GN, 2006, AM J TRANSPLANT, V6, P1228, DOI 10.1111/j.1600-6143.2006.01277.x
   Lipshultz SE, 2003, NEW ENGL J MED, V348, P1647, DOI 10.1056/NEJMoa021715
   Magee JC, 2005, AM J TRANSPLANT, V5, P1785, DOI 10.1111/j.1600-6143.2005.00990.x
   Magee JC, 2004, AM J TRANSPLANT, V4, P54, DOI 10.1111/j.1600-6143.2004.00398.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   McDiarmid SV, 2004, LIVER TRANSPLANT, V10, pS23, DOI 10.1002/lt.20272
   McDonald RA, 2005, AM J TRANSPLANT, V5, P418
   McGiffin DC, 1997, J HEART LUNG TRANSPL, V16, P713
   Merion RM, 2005, AM J TRANSPLANT, V5, P307, DOI 10.1111/j.1600-6143.2004.00703.x
   *NAPRTCS, 2005, N AM PED REN TRANSPL
   Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805
   Pahl E, 2005, J HEART LUNG TRANSPL, V24, P645, DOI 10.1016/j.healun.2004.03.021
   Reyes J, 2005, AM J TRANSPLANT, V5, P1430, DOI 10.1111/j.1600-6143.2005.00874.x
   Rianthavorn P, 2004, TRANSPLANTATION, V77, P778, DOI 10.1091/01.TP.0000110410.11524.7B
   Ruff T, 2002, AM SURGEON, V68, P857
   Russo LM, 2004, CURR OPIN CARDIOL, V19, P104, DOI 10.1097/00001573-200403000-00006
   Salvalaggio PR, 2005, AM J TRANSPLANT, V5, P1868, DOI 10.1111/j.1600-6143.2005.00962.x
   Seikaly M, 2001, PEDIATR TRANSPLANT, V5, P215, DOI 10.1046/j.1397-3142.2001.00001.x
   Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178
   Starnes VA, 2004, J THORAC CARDIOV SUR, V127, P114, DOI 10.1016/j.jtcvs.2003.07.042
   Starzl TE, 2003, LANCET, V361, P1502, DOI 10.1016/S0140-6736(03)13175-3
   Trulock EP, 2004, J HEART LUNG TRANSPL, V23, P804, DOI 10.1016/j.healun.2003.05.013
NR 45
TC 44
Z9 44
U1 1
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD MAY
PY 2006
VL 6
IS 5
BP 1132
EP 1152
DI 10.1111/j.1600-6143.2006.02171.x
PN 2
PG 21
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 033PL
UT WOS:000236861100006
PM 16613592
ER

PT J
AU Sunku, H
   Salvalaggio, PRO
   Donaldson, JS
   Rigsby, CK
   Neighbors, K
   Superina, RA
   Alonso, EM
AF Sunku, H
   Salvalaggio, PRO
   Donaldson, JS
   Rigsby, CK
   Neighbors, K
   Superina, RA
   Alonso, EM
TI Outcomes and risk factors for failure of radiologic treatment of biliary
   strictures in pediatric liver transplantation recipients
SO LIVER TRANSPLANTATION
LA English
DT Article
ID REDUCED-SIZE; BALLOON DILATATION; COMPLICATIONS; MANAGEMENT; DRAINAGE;
   CHILDREN; STENTS; DONOR
AB Postiransplantation biliary strictures occur in 5-34% of the pediatric liver transplant patients and are conventionally managed by interventional radiological techniques. The aim of this manuscript is to assess the outcomes of patients with biliary strictures treated by percutaneous dilatation at our institution. Included in the study were 35 children with posttransplant biliary strictures that were treated with percutaneous dilatation and stenting. Initial dilation and biliary stent placement was accomplished in all patients without complications requiring surgical intervention. Recurrent strictures developed in 23 (66%) of 35 patients. The recurrence rate was 45% for anastomotic strictures, 90% for intrahepatic strictures, and 100% for those with both an anastomotic and intrahepatic component. Seven patients required revision of the choledochojejunostomy, 5 of them with a successful outcome and 2 requiring retransplant. Five patients were treated with retransplantation without surgical revision. Patients with an intrahepatic or a "combined" stricture were less likely to have a successful outcome after radiologic treatment. In conclusion, the radiological treatment of biliary strictures with balloon dilation and stenting can be performed successfully with minimal complications avoiding the need for surgical correction in many cases.
C1 Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA.
   Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Surg, Chicago, IL 60614 USA.
   Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Radiol, Chicago, IL 60614 USA.
RP Alonso, EM (reprint author), Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Pediat, 2300 Childrens Plaza Box 57, Chicago, IL 60614 USA.
EM ealonso@childrensmemorial.org
CR Alonso EM, 1996, HEPATOLOGY, V23, P40, DOI 10.1002/hep.510230106
   Belenky A, 2004, CARDIOVASC INTER RAD, V27, P491, DOI 10.1007/s00270-003-2675-0
   BROELSCH CE, 1988, ANN SURG, V208, P410, DOI 10.1097/00000658-198810000-00003
   BROELSCH CE, 1988, TRANSPLANTATION, V45, P519, DOI 10.1097/00007890-198803000-00003
   CALNE RY, 1976, ANN SURG, V184, P605, DOI 10.1097/00000658-197611000-00012
   Chahin NJ, 2001, TRANSPLANT P, V33, P2738, DOI 10.1016/S0041-1345(01)02174-1
   Culp WC, 1996, RADIOLOGY, V199, P339
   Diamond NG, 1995, J VASC INTERV RADIOL, V6, P755, DOI 10.1016/S1051-0443(95)71181-2
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   HEFFRON TG, 1992, TRANSPLANTATION, V53, P391, DOI 10.1097/00007890-199202010-00024
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   Lorenz JM, 2005, AM J ROENTGENOL, V184, P151
   Lorenz JM, 2001, AM J ROENTGENOL, V176, P761
   Moser MAJ, 2001, LIVER TRANSPLANT, V7, pS46, DOI 10.1053/jlts.2001.28518
   PECLET MH, 1994, J PEDIATR SURG, V29, P214, DOI 10.1016/0022-3468(94)90321-2
   Righi D, 2002, CARDIOVASC INTER RAD, V25, P30, DOI 10.1007/s00270-001-0078-7
   Salvalaggio PRO, 2004, PEDIATR TRANSPLANT, V8, P513, DOI 10.1111/j.1399-3046.2004.00212.x
   Sawyer RG, 1998, TRANSPLANTATION, V66, P1201, DOI 10.1097/00007890-199811150-00015
   SCHWEIZER WP, 1991, BRIT J SURG, V78, P559, DOI 10.1002/bjs.1800780514
   STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009
   STRATTA RJ, 1989, SURGERY, V106, P675
   Sung RS, 2004, TRANSPLANTATION, V77, P110, DOI 10.1097/01.TP.0000101518.19849.C8
   ZAJKO AB, 1995, J VASC INTERV RADIOL, V6, P79, DOI 10.1016/S1051-0443(95)71063-6
NR 23
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAY
PY 2006
VL 12
IS 5
BP 821
EP 826
DI 10.1002/lt.20712
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 035YG
UT WOS:000237037100020
ER

PT J
AU Shirouzu, Y
   Kasahara, M
   Takada, Y
   Taira, K
   Sakamoto, S
   Uryuhara, K
   Ogawa, K
   Doi, H
   Egawa, H
   Tanaka, K
AF Shirouzu, Y
   Kasahara, M
   Takada, Y
   Taira, K
   Sakamoto, S
   Uryuhara, K
   Ogawa, K
   Doi, H
   Egawa, H
   Tanaka, K
TI Development of pulmonary hypertension in 5 patients after pediatric
   living-donor liver transplantation: De novo or secondary?
SO LIVER TRANSPLANTATION
LA English
DT Article
ID PORTOPULMONARY HYPERTENSION; HEPATOPULMONARY SYNDROME;
   PORTAL-HYPERTENSION; HEMODYNAMICS; COMPLICATIONS; CIRRHOSIS; DISEASE;
   SHUNT
AB The development of portopulmonary hypertension (PH) in a patient with end-stage liver disease is related to high cardiac output and hyperdynamic circulation. However, PH following liver transplantation is not fully understood. Of 617 pediatric patients receiving transplants between June 1990 and March 2004, 5 (median age 12 yr, median weight 24.5 kg) were revealed to have portopulmonary hypertension (PH) after living-donor liver transplantation (LDLT), as confirmed by echocardiography and/or right heart catheterization. All children underwent LDLT for post-Kasai biliary atresia. In 2 patients with refractory biliary complications, PH developed following portal thrombosis; 2 with stable graft function, who had had intrapulmonary shunting (IPS) before LDLT, were found to have PH in spite of overcoming liver dysfunction due to hepatitis. PH developed shortly after distal splenorenal shunting in 1 patient, who suffered liver cirrhosis due to an intractable outflow blockage. The onset of PH ranged from 2.8 to 11 yr after LDLT, and mean pulmonary artery pressure (mPAP) estimated by echocardiography at the time of presentation ranged from 43 to 120 mmHg. Three of the 5 patients are alive under prostaglandin 12 (PG12) treatment. Of these, 1 is prepared for retransplantation for an intractable complications of liver allograft, while the other 2 with satisfactory grafts are being considered for lung transplantation. Even after LDLT, PH can develop with portal hypertension. Periodic echocardiography is essential for early detection and treatment of PH especially in the recipients with portal hypertension not only preoperatively but also postoperatively.
C1 Kyoto Univ Hosp, Dept Transplant Surg, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ Hosp, Dept Pediat, Kyoto 606, Japan.
RP Shirouzu, Y (reprint author), Kyoto Univ Hosp, Dept Transplant Surg, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.
EM yasumasa@indigo.plala.or.jp
CR Budhiraja R, 2003, CHEST, V123, P562, DOI 10.1378/chest.123.2.562
   DABESTANI A, 1987, AM J CARDIOL, V59, P662, DOI 10.1016/0002-9149(87)91189-1
   Egawa H, 1999, TRANSPLANTATION, V67, P712, DOI 10.1097/00007890-199903150-00012
   Fallon MB, 2005, J CLIN GASTROENTEROL, V39, pS138, DOI 10.1097/01.mcg.0000155570.19340.61
   Fallon MB, 2003, HEPATOLOGY, V37, P253, DOI 10.1053/jhep.2003.50090
   FUJIMOTO M, 1995, TRANSPLANTATION, V60, P41, DOI 10.1097/00007890-199507150-00008
   HADENGUE A, 1991, GASTROENTEROLOGY, V100, P520
   HADENGUE A, 1993, HEPATOLOGY, V17, P175, DOI 10.1016/0270-9139(93)90072-U
   HENDERSON JM, 1992, HEPATOLOGY, V15, P258, DOI 10.1002/hep.1840150214
   Hoeper MM, 2004, LANCET, V363, P1461, DOI 10.1016/S0140-6736(04)16107-2
   Inomata Y, 1996, TRANSPLANTATION, V61, P247, DOI 10.1097/00007890-199601270-00015
   JAMES WC, 2002, CHEST, V122, P1668
   Koneru B, 2002, AM J TRANSPLANT, V2, P883, DOI 10.1034/j.1600-6143.2002.20913.x
   Krowka MJ, 2000, LIVER TRANSPLANT, V6, P443, DOI 10.1053/jlts.2000.6356
   Kuo PC, 1999, TRANSPLANTATION, V67, P1087, DOI 10.1097/00007890-199904270-00001
   Mal H, 1999, J HEPATOL, V31, P360, DOI 10.1016/S0168-8278(99)80236-0
   MANDELL MS, 1995, TRANSPLANTATION, V59, P1488, DOI 10.1097/00007890-199505270-00024
   MANTZ FA, 1951, AMA ARCH PATHOL, V52, P91
   Rafanan Albert Lim, 2000, Chest, V118, P1497, DOI 10.1378/chest.118.5.1497
   Takada Y, 2004, LIVER TRANSPLANT, V10, P807, DOI 10.1002/lt.20164
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   VanderLinden P, 1996, HEPATOLOGY, V23, P982
   Whyte MKB, 1998, J HEPATOL, V29, P85, DOI 10.1016/S0168-8278(98)80182-7
   YOSHIDA EM, 1994, GUT, V35, P280, DOI 10.1136/gut.35.2.280
   1994, CHEST, V105, pS37
NR 25
TC 9
Z9 10
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAY
PY 2006
VL 12
IS 5
BP 870
EP 875
DI 10.1002/lt.20758
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 035YG
UT WOS:000237037100027
PM 16628693
ER

PT J
AU Darwish, AA
   Bourdeaux, C
   Kader, HA
   Janssen, M
   Sokal, E
   Lerut, J
   Ciccarelli, O
   Veyckemans, F
   Otte, JB
   de Goyet, JD
   Reding, R
AF Darwish, AA
   Bourdeaux, C
   Kader, HA
   Janssen, M
   Sokal, E
   Lerut, J
   Ciccarelli, O
   Veyckemans, F
   Otte, JB
   de Goyet, JD
   Reding, R
TI Pediatric liver transplantation using left hepatic segments from living
   related donors: Surgical experience in 100 recipients at Saint-Luc
   University Clinics
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric liver transplantation; living donation; surgical technique;
   complications
ID PORTAL-VEIN RECONSTRUCTION; PRIMARY GRAFTS; BILIARY COMPLICATIONS;
   REVASCULARIZATION; THROMBOSIS; CHILDREN
AB Living-related liver transplantation was developed in the context of deceased donor organ shortage, which is particularly acute for pediatric recipients. This retrospective study analyzes the surgical technique and complications in the first 100 pediatric liver transplantation using left segmental liver grafts from living donors, performed at Saint-Luc University Clinics between July 1993 and April 2002. Pre-operative evaluation in donors and recipients, analysis of the surgical technique, and postoperative complications were reviewed. After a median follow-up period of 2526 days, no donor mortality was encountered, with a minimal morbidity and no long-term sequelae. At one and five yr post-transplantation, the actuarial patient survival rates were 94% and 92%, the corresponding figures being 92% and 89% for graft survival. The incidences of portal vein and hepatic artery thromboses, and of biliary complications were 14%, 1%, and 27%, respectively. Living-related liver transplantation in children constitutes an efficient therapy for liver failure to face the increased demand for liver grafts. Donor morbidity was kept to acceptable incidence, and surgical technique in the recipient needs to be tailored to minimize postoperative complications.
C1 Catholic Univ Louvain, Pediat Surg Unit, Clin Univ St Luc, Pediat Liver Transplantat Program, B-1200 Brussels, Belgium.
RP Reding, R (reprint author), Catholic Univ Louvain, Pediat Surg Unit, Clin Univ St Luc, Pediat Liver Transplantat Program, 10 Hippocrate Ave, B-1200 Brussels, Belgium.
EM reding@chex.ucl.ac.be
RI Lerut, Jan/B-9571-2016
OI Lerut, Jan/0000-0002-4718-9950
CR BHATNAGAR V, 1995, TRANSPLANT INT, V8, P388
   Chardot C, 2002, TRANSPLANTATION, V73, P90, DOI 10.1097/00007890-200201150-00017
   de Goyet JD, 1998, TRANSPLANT INT, V11, P117
   deGoyet JD, 1996, TRANSPLANTATION, V62, P71, DOI 10.1097/00007890-199607150-00015
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Egawa H, 1997, SURGERY, V121, P250, DOI 10.1016/S0039-6060(97)90353-6
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Fujimoto M, 1997, CLIN TRANSPLANT, V11, P380
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Lee KW, 2004, TRANSPLANT P, V36, P2261, DOI 10.1016/j.transproceed.2004.08.079
   Martinez JA, 1999, TRANSPLANTATION, V68, P672, DOI 10.1097/00007890-199909150-00013
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Mitchell A, 2002, TRANSPLANTATION, V73, P1244, DOI 10.1097/00007890-200204270-00009
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   PECLET MH, 1994, J PEDIATR SURG, V29, P214, DOI 10.1016/0022-3468(94)90321-2
   RAIA S, 1989, LANCET, V2, P497
   REDING R, 2003, AM J TRANSPLANT S5, V3, P306
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7
   Saad S, 1998, ANN SURG, V227, P275, DOI 10.1097/00000658-199802000-00018
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Troisi R, 2003, LIVER TRANSPLANT, V9, pS36, DOI 10.1053/jlts.2003.50200
NR 25
TC 37
Z9 38
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2006
VL 10
IS 3
BP 345
EP 353
DI 10.1111/j.1399-3046.2005.00477.x
PG 9
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 036SW
UT WOS:000237096700013
PM 16677359
ER

PT J
AU Gibelli, NE
   Tannuri, U
   Mello, ES
   Cancado, ER
   Santos, MM
   Ayoub, AA
   Maksoud, JG
   Velhote, MCP
   Silva, MM
   Pinho-Apezzato, ML
   Maksoud, JG
AF Gibelli, NE
   Tannuri, U
   Mello, ES
   Cancado, ER
   Santos, MM
   Ayoub, AA
   Maksoud, JG
   Velhote, MCP
   Silva, MM
   Pinho-Apezzato, ML
   Maksoud, JG
TI Successful treatment of de novo autoimmune hepatitis and cirrhosis after
   pediatric liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; autoimmune hepatitis; immunosuppression
ID LATE GRAFT DYSFUNCTION; EXPERIENCE; CHILDREN; DISEASE
AB Over a 15-yr period of observation, among the 205 children who underwent liver transplantations, one of them developed a particular type of late graft dysfunction with clinical and histological similarity to autoimmune hepatitis. The patient had alpha 1-antitrypsin deficiency and did not previously have autoimmune hepatitis or any other autoimmune disease before transplantation. Infectious and surgical complications were excluded. After repeated episodes of unexplained fluctuations of liver function tests and liver biopsies demonstrating reactive or a biliary pattern, without any corresponding alteration of percutaneous cholangiography, a liver-biopsy sample taken 4 yr after the transplant showed active chronic hepatitis progressing to cirrhosis, portal lymphocyte aggregates, and a large number of plasma cells. At that time, autoantibodies (gastric parietal cell antibody, liver-kidney microsomal antibody, and anti-hepatic cytosol) were positive and serum IgG levels were high. Based on these findings of autoimmune disease, a diagnosis of 'de novo autoimmune hepatitis' was made. The treatment consisted of reducing the dose of cyclosporine, reintroduction of corticosteroids, and addition of mycophenolate mofetil. After 19 months of treatment, a new liver-biopsy sample showed marked reduction of portal and lobular inflammatory infiltrate, with regression of fibrosis and of the architectural disruption. At that time, serum autoantibodies became negative. The last liver-biopsy sample showed inactive cirrhosis and disappearance of interface hepatitis and of plasma cell infiltrate. Presently, 9 yr after the transplantation, the patient is doing well, with normal liver function tests and no evidence of cirrhosis. Her immunosuppressive therapy consists of tacrolimus, mycophenolate mofetil, and prednisolone. In conclusion, the present case demonstrates that de novo autoimmune hepatitis can appear in liver-transplant patients despite appropriate anti-rejection immunosuppression, and triple therapy with tacrolimus, mycophenolate mofetil, and prednisolone could sustain the graft and prevent retransplantation.
C1 Univ Sao Paulo, Hosp Clin, Children Inst, Liver Transplantat Unit, Sao Paulo, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455,4o Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM uenist@usp.br
RI Tannuri, Uenis/D-3876-2012; Gibelli, Nelson Elias Mendes/I-7176-2016;
   Cancado, Eduardo/K-1861-2016
OI Cancado, Eduardo/0000-0002-9309-1524
CR Alvarez F., 1999, Journal of Hepatology, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
   GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0
   GHOBRIAL RM, 2001, TRANSPLANTATION LIVE, P79
   Gupta P, 2001, TRANSPLANTATION, V71, P664, DOI 10.1097/00007890-200103150-00016
   HANEGAN MA, 2001, HEPATOLOGY, V36, P464
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Mieli-Vergani G, 1998, SEMIN LIVER DIS, V18, P271, DOI 10.1055/s-2007-1007163
   Mieli-Vergani G, 2004, J HEPATOL, V40, P3, DOI 10.1016/j.jhep.2003.10.022
   MIELIVERGANI G, 2004, MINERVA GASTROENTERO, V50, P113
   Miyagawa-Hayashino A, 2004, TRANSPLANTATION, V78, P128, DOI 10.1097/01.TP.0000132328.33460.43
   PAPPO O, 1995, AM J SURG PATHOL, V19, P192, DOI 10.1097/00000478-199502000-00008
   Petz W, 2002, TRANSPLANT P, V34, P1958, DOI 10.1016/S0041-1345(02)03137-8
   Ryckman FC, 1999, J PEDIATR SURG, V34, P845, DOI 10.1016/S0022-3468(99)90385-8
   Salcedo M, 2002, HEPATOLOGY, V35, P349, DOI 10.1053/jhep.2002.31167
   Slapak GI, 1997, HEPATOLOGY, V25, P195, DOI 10.1002/hep.510250136
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   Wu DY, 1999, J IMMUNOL, V162, P6926
NR 18
TC 14
Z9 14
U1 1
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2006
VL 10
IS 3
BP 371
EP 376
DI 10.1111/j.1399-3046.2005.00470.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 036SW
UT WOS:000237096700018
PM 16677364
ER

PT J
AU Lai, YC
   Ni, YH
   Jou, ST
   Ho, MC
   Wu, JF
   Chen, HL
   Hu, RH
   Jeng, YM
   Chang, MH
   Lee, PH
AF Lai, YC
   Ni, YH
   Jou, ST
   Ho, MC
   Wu, JF
   Chen, HL
   Hu, RH
   Jeng, YM
   Chang, MH
   Lee, PH
TI Post-transplantation lymphoproliferative disorders localizing to the
   gastrointestinal tract after liver transplantation: Report of five
   pediatric cases
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE post-transplantation lymphoproliferative disorder; pediatric liver
   transplantation; Epstein-Barr virus
ID EPSTEIN-BARR-VIRUS; THORACIC ORGAN RECIPIENTS; DISEASE; CHILDREN;
   CHEMOTHERAPY; LOAD; DNA; PREDNISONE; INFECTION; BLOOD
AB Post-transplantation lymphoproliferative disorder (PTLD) is a life-threatening complication of organ transplantation. PTLD can occur in every kind of organ transplantation. From July 1992 to July 2004, five patients were diagnosed at our transplantation center with PTLD after pediatric liver transplantation. During this period, there were 52 pediatric patients (< 18 yr) receiving an orthotopic liver transplantation (OLT) at our center. All five patients had transmural gastrointestinal (GI) PTLD, which occurred mostly in the stomach and duodenum. Epstein-Barr virus (EBV) in situ was demonstrated in each case. EBV viral load was noted to be an important risk factor. Treatment included dose reduction of immunosuppressants and anti-CD20 antibody infusion. Chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisolone, was given to three patients. Four patients have survived more than 10 months until now after treatment. The one who was unresponsive to chemotherapy and anti-CD20 antibody had diffuse metastasis and died of systemic candidiasis. In our series, each PTLD involved the GI tract. The mechanism of this phenomenon is unclear, but these five cases indicate the high incidence of PTLD in pediatric solid organ transplantation.
C1 Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.
   Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan.
   Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan.
RP Lee, PH (reprint author), Natl Taiwan Univ Hosp, Dept Surg, 7 Chung Shan S Rd, Taipei 100, Taiwan.
EM pohuang@ha.mc.ntu.edu.tw
OI Chang, Mei Hwei/0000-0002-3648-9261; LEE, PO-HUANG/0000-0001-5831-035X;
   Ho, Ming-Chih/0000-0003-3660-1062; WU, JIA-FENG/0000-0001-6343-1658; HU,
   REY-HENG/0000-0001-6709-031X; Ni, Yen-Hsuan/0000-0002-1158-5249; JOU,
   SHIANN-TARNG/0000-0003-1483-0403
CR ALFREY EJ, 1992, TRANSPLANTATION, V54, P250, DOI 10.1097/00007890-199208000-00012
   Balfour IC, 1999, J HEART LUNG TRANSPL, V18, P492
   BERG LC, 1992, HUM PATHOL, V23, P159, DOI 10.1016/0046-8177(92)90237-W
   Berney T, 2002, TRANSPLANTATION, V74, P1000, DOI 10.1097/01.TP.0000031931.31954.53
   Boyle GJ, 1997, J PEDIATR-US, V131, P309, DOI 10.1016/S0022-3476(97)70173-2
   Donnelly LF, 1998, AM J ROENTGENOL, V171, P725
   Dotti G, 2000, TRANSPLANTATION, V69, P827
   Finn L, 1998, AM J SURG PATHOL, V22, P299, DOI 10.1097/00000478-199803000-00004
   GARRETT TJ, 1993, CANCER, V72, P2782, DOI 10.1002/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H
   GARTNER LP, 1997, COLOR TXB HISTOLOGY, P330
   Green M, 1998, TRANSPLANTATION, V66, P1641, DOI 10.1097/00007890-199812270-00012
   Gross TG, 1998, ANN ONCOL, V9, P339, DOI 10.1023/A:1008263226895
   Gross TG, 2001, J PEDIAT HEMATOL ONC, V23, P7, DOI 10.1097/00043426-200101000-00003
   Heo JS, 2004, TRANSPLANT P, V36, P2307, DOI 10.1016/j.transproceed.2004.08.138
   Holmes RD, 2002, TRANSPLANTATION, V74, P367, DOI 10.1097/00007890-200208150-00013
   Jain A, 2002, ANN SURG, V236, P429, DOI 10.1097/01.SLA.0000033429.89429.89424.F8
   Kimura H, 1999, J CLIN MICROBIOL, V37, P132
   Kogan DL, 1999, TRANSPLANTATION, V67, P1068, DOI 10.1097/00007890-199904150-00023
   Leblond V, 2001, J CLIN ONCOL, V19, P772
   Lim GY, 2002, RADIOLOGY, V222, P699, DOI 10.1148/radiol.2223010456
   MURPHY SB, 1980, SEMIN ONCOL, V7, P332
   ORJUELA M, 2003, CLIN CANC RES 2, V9, P3945
   RAYMOND E, 1995, CANCER, V76, P1344, DOI 10.1002/1097-0142(19951015)76:8<1344::AID-CNCR2820760808>3.0.CO;2-K
   Scheenstra R, 2004, Transpl Infect Dis, V6, P15, DOI 10.1111/j.1399-3062.2004.00044.x
   Smets F, 2002, J PEDIATR GASTR NUTR, V34, P499, DOI 10.1097/00005176-200205000-00004
   Smets F, 2000, TRANSPLANTATION, V69, P982
   Smets F, 2000, J HEPATOL, V32, P100, DOI 10.1016/S0168-8278(00)80195-6
   Spada M, 2001, TRANSPLANT P, V33, P1835, DOI 10.1016/S0041-1345(00)02828-1
   Stevens SJC, 2001, BLOOD, V97, P1165, DOI 10.1182/blood.V97.5.1165
NR 29
TC 10
Z9 10
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAY
PY 2006
VL 10
IS 3
BP 390
EP 394
DI 10.1111/j.1399-3046.2005.00457.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 036SW
UT WOS:000237096700022
PM 16677368
ER

PT J
AU Cintorino, D
   Spada, M
   Gruttadauria, S
   Riva, S
   Luca, A
   Volpes, R
   Vizzini, G
   Arcadipane, A
   Henderson, K
   Verzaro, R
   Foglieni, CS
   Gridelli, B
AF Cintorino, D
   Spada, M
   Gruttadauria, S
   Riva, S
   Luca, A
   Volpes, R
   Vizzini, G
   Arcadipane, A
   Henderson, K
   Verzaro, R
   Foglieni, CS
   Gridelli, B
TI In situ split liver transplantation for adult and pediatric recipients:
   An answer to organ shortage
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 29th Congress of the Italian-Society-of-Organ-Transplantation
CY NOV 03-05, 2005
CL Palermo, ITALY
SP Italian Soc Organ Transplantat
AB Background. We report our initial experience with in situ split liver transplantation (SLT) for adult and pediatric patients.
   Patients and Methods. From June 2003 to August 2005, 177 liver transplantations in 165 patients, 133 adults (81%) and 32 children (19%), were performed at our institution. Over this period, 45 liver transplantations (25%) were performed with an in situ split liver technique in 44 patients: 17 (39%) were adults and 27 (61%) children. All of the adult split liver recipients were transplanted with an extended right graft (ERG; segments I + IV-VIII), while pediatric recipients received in 23 cases a left lateral segment (LLS; segments II-III) and in 4 cases an ERG from a pediatric donor. The 45 split liver grafts (21 ERGs and 24 LLSs) were generated from 35 donors. In 10 cases we used both grafts generated with an in situ split procedure to transplant our patients, while in 25 cases the procurement procedure was performed in collaboration with other transplant centers.
   Results. After a median follow-up of 9 months (range, 1-27 months), the overall patient survival rate was 88% for adult patients and 82% for pediatric patients. Graft survivals were 88% and 79%, respectively. Two adult patients (12%) died from sepsis in the early postoperative period. Five children (18%) died after their transplantations. Only one pediatric recipient (2%) of primary SLT underwent retransplantation. Vascular complications were absent in adult recipients, whereas 4 arterial (14%) and 4 venous (14%) complications developed in the pediatric population. The incidence of biliary complications was 23% in adult and 18% in pediatric recipients.
   Conclusions. The use of in situ SLT for adult and pediatric populations allowed us to expand the cadaveric donor pool, significantly eliminating pediatric waiting list mortality without penalizing the adult population.
C1 UPMC Italy, Ist Mediterraneo Trapianti & Terapie Alta Special, I-90127 Palermo, Italy.
RP Spada, M (reprint author), UPMC Italy, Ist Mediterraneo Trapianti & Terapie Alta Special, Via E Tricomi 1, I-90127 Palermo, Italy.
EM mspada@ismett.edu
RI Foglieni, Chiara/O-2339-2015
OI Foglieni, Chiara/0000-0002-5155-6426
CR ROGIERS X, 1995, TRANSPLANTATION, V59, P1081, DOI 10.1097/00007890-199504270-00001
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5
NR 3
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAY
PY 2006
VL 38
IS 4
BP 1096
EP 1098
DI 10.1016/j.transproceed.2006.02.146
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 054AI
UT WOS:000238347300039
PM 16757275
ER

PT J
AU Cintorino, D
   Riva, S
   Spada, M
   Minervini, M
   Sonzogni, A
   Foglieni, CS
   Gruttadauria, S
   Verzaro, R
   Henderson, K
   Arico, M
   Gridelli, B
AF Cintorino, D
   Riva, S
   Spada, M
   Minervini, M
   Sonzogni, A
   Foglieni, CS
   Gruttadauria, S
   Verzaro, R
   Henderson, K
   Arico, M
   Gridelli, B
TI Corticosteroid-free immunosuppression in pediatric liver
   transplantation: Safety and efficacy after a short-term follow-up
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 29th Congress of the Italian-Society-of-Organ-Transplantation
CY NOV 03-05, 2005
CL Palermo, ITALY
SP Italian Soc Organ Transplantat
AB Background. We report our results with the use of corticosteroid-free immunosuppression after pediatric liver transplantation, evaluating the efficiency and safety of this protocol in the early posttransplantation period.
   Patients and Methods. From July 2003 to October 2005, 34 liver transplantations were performed in 32 pediatric patients (19 boys, 13 girls) at our institution. Recipient median age was 5 years (range, 0.2-14 years), and median body weight was 10 kg (range, 4-49 kg). Twenty-seven patients received a graft from in situ split liver transplantation, 5 a whole graft. Twenty-nine children (90%) received an immunosuppressive therapy based on methylprednisolone IV bolus at reperfusion (10 mg/kg) plus tacrolimus given at an initial dose of 0.08 mg/kg/d and then adjusted to obtain whole blood trough levels of 10 to 15 ng/mL during the first 3 months and 5 to 10 ng/mL after the 3rd month; basiliximab was given on postoperative days 0 and 4. Biopsy-proven acute rejection episodes were treated by methylprednisone IV boluses.
   Results. After a median follow-up of 9 months (range, 1-27 months), the overall patient survival rate was 84% and graft survival rate was 79%. Three children (9%) died after their transplantations. Three (9%) experienced episodes of biopsy-proven acute rejection, always treated with IV steroid boluses. Mean RAI score was 4. One patient experienced PTLD that resolved with temporary reduction of immunosuppression. Cytomegalovirus infection rate was 14%. Sepsis occurred in 2 cases (6%).
   Conclusions. Initial results with a steroid-free immunosuppressive protocol are encouraging, with low rates of acute rejection and infectious complications as in steroid-based protocols.
C1 UPMC, Ist Mediterraneo Trapianti & Terapie Alta Special, Liver Tranplantat Unit, I-90127 Palermo, Italy.
   Osped Riuniti Bergamo, Pathol Dept, Bergamo, Italy.
   Osped Civico, Pediat Oncol Dept, Bergamo, Italy.
RP Spada, M (reprint author), UPMC, Ist Mediterraneo Trapianti & Terapie Alta Special, Liver Tranplantat Unit, Via E Tricomi 1, I-90127 Palermo, Italy.
EM mspada@ismett.edu
RI Foglieni, Chiara/O-2339-2015
OI Foglieni, Chiara/0000-0002-5155-6426
CR Reding R, 2000, TRANSPLANTATION, V70, P405, DOI 10.1097/00007890-200008150-00001
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
NR 2
TC 6
Z9 7
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAY
PY 2006
VL 38
IS 4
BP 1099
EP 1100
DI 10.1016/j.transproceed.2006.02.147
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 054AI
UT WOS:000238347300040
PM 16757276
ER

PT J
AU Englert, C
   Grabhorn, E
   Burdelski, M
   Ganschow, R
AF Englert, C
   Grabhorn, E
   Burdelski, M
   Ganschow, R
TI Liver transplantation in children with Alagille syndrome: Indications
   and outcome
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE Alagille syndrome; pediatric liver transplantation; indications;
   hypercholesterolemia; outcome
AB An AGS is a dominant inherited multisystem disorder caused by mutations in the Notch signaling pathway (JAG1). In our center, 5.3% of liver transplantations (OLT) are performed in children with AGS. Some of the affected children fulfilled criteria for OLT, despite the absence of liver cirrhosis. The aim of our present study was to evaluate the indications and outcome for OLT in children with this complex disorder as clear criteria are difficult to establish in clinical practice. A total of 37 patients were included in a retrospective analysis. Twenty-four children underwent OLT for chronic end-stage liver failure (n = 8) or symptomatic liver disease (n = 16). Patient survival post-OLT was 91.7% after 1 yr, that of graft survival was 87.5%, respectively. Significant post-transplant vascular complications included a mid-aortic syndrome (n = 1) and severe lethal bleeding due to suspected vascular malformation (n = 1). Severe hypercholesterolemia (> 800 mg/dL) and xanthomata resolved completely in affected patients. We conclude from our data that indications for OLT in AGS should be extended to patients with severe symptomatic liver disease, even in the absence of liver cirrhosis because of the significantly improved outcome after pediatric OLT in the last decade. Future studies must identify underlying mechanisms of hypercholesterolemia and vascular malformation.
C1 Univ Med Ctr Hamburg Eppendorf, Dept Pediat, Hamburg, Germany.
RP Ganschow, R (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat Pediat Gastroenterol & Hepatol, Martinistr 52, D-20246 Hamburg, Germany.
EM ganschow@uke.uni-hamburg.de
RI Grabhorn, Enke/F-9785-2011
CR ALAGILLE D, 1975, J PEDIATR-US, V86, P63, DOI 10.1016/S0022-3476(75)80706-2
   Alagille D, 1996, CLIN INVEST MED, V19, P325
   Broering DC, 2004, ANN SURG, V240, P1002, DOI 10.1097/01.sla.0000146148.01586.72
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Ganschow R, 2000, Pediatr Transplant, V4, P273, DOI 10.1034/j.1399-3046.2000.00127.x
   Ganschow R, 2001, TRANSPLANT P, V33, P3608, DOI 10.1016/S0041-1345(01)02553-2
   Garcia MA, 2005, PEDIATR DERMATOL, V22, P11, DOI 10.1111/j.1525-1470.2005.22102.x
   Hia C P P, 2004, Heart, V90, P1150, DOI 10.1136/hrt.2003.032821
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   Lykavieris P, 2001, GUT, V49, P431, DOI 10.1136/gut.49.3.431
   ODA T, 1997, NAT GENET, V16, P212
   POMBO F, 1995, PEDIATR RADIOL, V25, P314, DOI 10.1007/BF02011114
   Quiros-Tejeira RE, 2000, LIVER TRANSPLANT, V6, P582, DOI 10.1053/jlts.2000.9739
   Quiros-Tejeira RE, 1999, J PEDIATR GASTR NUTR, V29, P431, DOI 10.1097/00005176-199910000-00011
   Rovner AJ, 2002, J PEDIATR GASTR NUTR, V35, P495, DOI 10.1097/00005176-200210000-00007
   TZAKIS AG, 1993, ARCH SURG-CHICAGO, V128, P337
NR 16
TC 19
Z9 20
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2006
VL 10
IS 2
BP 154
EP 158
DI 10.1111/j.1399-3046.2005.00432.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 022AG
UT WOS:000236026400007
PM 16573599
ER

PT J
AU Ganschow, R
   Albani, J
   Grabhorn, E
   Richter, A
   Burdelski, M
AF Ganschow, R
   Albani, J
   Grabhorn, E
   Richter, A
   Burdelski, M
TI Tacrolimus-induced cholestatic syndrome following pediatric liver
   transplantation and steroid-resistant graft rejection
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE basiliximab; liver transplantation; children; tacrolimus; cholestasis
ID FK506; RAT
AB Several factors may contribute to post-transplant cholestatic complications after liver transplantation. These include ischemic reperfusion injury, hypoperfusion, bile duct strictures, and hepatotoxic drugs. Up to now, there have been no publications on tacrolimus cholestatic toxicity in clinical transplantation when the drug was used in therapeutic doses. We describe six pediatric liver graft recipients in whom cholestatic complications developed under a tacrolimus-based immunosuppression following liver transplantation and all of them suffered from previous steroid-resistant graft rejection. The overall incidence of cholestatic syndrome was 5.4% in children receiving tacrolimus. The immunosuppression was switched back to cyclosporine and prednisolone in all six patients resulting in completely resolved clinical signs and laboratory findings. We conclude from our observations that a cholestatic syndrome following pediatric liver transplantation may be caused by tacrolimus therapy following steroid-resistant graft rejection, even if given in therapeutic doses.
C1 Univ Med Ctr Hamburg Eppendorf, Dept Pediat, D-20246 Hamburg, Germany.
   Univ Med Ctr Hamburg Eppendorf, Dept Pediat Gastroenterol & Hepatol, D-20246 Hamburg, Germany.
RP Ganschow, R (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pediat, Martinistr 52, D-20246 Hamburg, Germany.
EM ganschow@uke.uni-hamburg.de
RI Grabhorn, Enke/F-9785-2011
CR Abbasoglu O, 1997, TRANSPLANTATION, V63, P250, DOI 10.1097/00007890-199701270-00013
   COLINA F, 1995, HEPATO-GASTROENTEROL, V42, P212
   CURTIN JC, 1996, HEPATOLOGY, V24, P1053
   DESMET VJ, 1995, VERH DTSCH GES PATHO, V79, P326
   FISHER A, 1995, TRANSPLANTATION, V59, P1631
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Koopen NR, 1998, BBA-MOL BASIS DIS, V1408, P1, DOI 10.1016/S0925-4439(98)00053-2
   Nakache R, 1999, TRANSPLANTATION, V68, P1651, DOI 10.1097/00007890-199912150-00008
   Sanchez-Campos S, 1998, TRANSPLANTATION, V66, P84, DOI 10.1097/00007890-199807150-00013
   WIESNER RH, 1991, HEPATOLOGY, V14, P721, DOI 10.1016/0270-9139(91)90064-3
   YERSIZ H, 1995, TRANSPLANTATION, V60, P790, DOI 10.1097/00007890-199510270-00005
NR 11
TC 16
Z9 18
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2006
VL 10
IS 2
BP 220
EP 224
DI 10.1111/j.1399-3046.2005.00413.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 022AG
UT WOS:000236026400019
PM 16573611
ER

PT J
AU Kimura, T
   Hasegawa, T
   Ihara, Y
   Nara, K
   Sasaki, T
   Dono, K
   Mushiake, S
   Fukuzawa, M
AF Kimura, T
   Hasegawa, T
   Ihara, Y
   Nara, K
   Sasaki, T
   Dono, K
   Mushiake, S
   Fukuzawa, M
TI Feasibility of duct-to-duct biliary reconstruction in pediatric living
   related liver transplantation: Report of three cases
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 3rd Annual Congress of the
   International-Pediatric-Transplant-Association
CY AUG 06-09, 2005
CL Innsbruck, AUSTRIA
SP Int Pediatr Transplant Assoc
DE duct-to-duct biliary reconstruction; pediatric; living-related liver
   transplantation; choledochography
ID COMPLICATIONS
AB Feasibility of duct-to-duct biliary reconstruction in adult living related liver transplantation (LRLTx) has been recently reported; however, little has been known of its surgical outcome in children. To assess the feasibility and safety of duct-to-duct biliary reconstruction in children, the surgical outcomes of duct-to-duct biliary reconstruction were retrospectively analyzed. The subjects were three children who underwent LRLTx in our hospital each utilizing allografts with a right lobe, a left robe and a lateral segment, respectively. The cause of end-stage liver disease in each of them was fulminant Wilson's disease, fulminant hepatic failure and unresectable hepatoblastoma. Duct-to-duct anastomosis was performed in younger patients and adolescents with interrupted and continuous sutures, respectively. The diameter of bile duct in allografts was from 4 to 6 mm and 12 or 13 stitches were required for anastomosis. Post-operative choledochography from the external tube showed neither stenosis nor leakage and the tube was evacuated within 3 months after LRLTx. No biliary complications were observed with the median follow-up of 28 months. In conclusion, our results show that duct-to-duct biliary reconstructions in pediatric LRLTx seemed to be feasible and safe. Further studies are required to elucidate its real impact on pediatric LRLTx.
C1 Osaka Univ, Grad Sch Med, Div Pediat Surg, Dept Surg, Suita, Osaka 5650871, Japan.
   Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan.
RP Kimura, T (reprint author), Osaka Univ, Grad Sch Med, Div Pediat Surg, Dept Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM kimutaku@pedsurg.med.osaka-u.ac.jp
CR CHAIB E, 1994, TRANSPLANT INT, V7, P39, DOI 10.1111/j.1432-2277.1994.tb01276.x
   Dulundu E, 2004, TRANSPLANTATION, V78, P574, DOI 10.1097/01.TP.0000128912.09581.46
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Grewal HP, 2001, ANN SURG, V233, P502, DOI 10.1097/00000658-200104000-00004
   HEFFRON TG, 1992, TRANSPLANTATION, V53, P391, DOI 10.1097/00007890-199202010-00024
   Hisatsune H, 2003, TRANSPLANTATION, V76, P810, DOI 10.1097/01.TP.0000083224.00756.8F
   Ishiko T, 2002, ANN SURG, V236, P235, DOI 10.1097/01.SLA.0000022026.90761.FC
   Otte JB, 1999, ACTA GASTRO-ENT BELG, V62, P355
   Schlitt HJ, 1999, ANN SURG, V229, P137, DOI 10.1097/00000658-199901000-00018
   Sugawara Y, 2002, TRANSPLANTATION, V73, P1348, DOI 10.1097/00007890-200204270-00029
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
NR 11
TC 11
Z9 11
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD MAR
PY 2006
VL 10
IS 2
BP 248
EP 251
DI 10.1111/j.1399-3046.2005.00430.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 022AG
UT WOS:000236026400024
PM 16573616
ER

PT J
AU Karakayali, H
   Boyvat, F
   Coskun, M
   Isiklar, I
   Sozen, H
   Filik, L
   Yilmaz, U
   Gur, G
   Haberal, M
AF Karakayali, H
   Boyvat, F
   Coskun, M
   Isiklar, I
   Sozen, H
   Filik, L
   Yilmaz, U
   Gur, G
   Haberal, M
TI Venous complications after orthotopic liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Meeting of the Turkish-Transplantation-Society
CY JUN 22-24, 2005
CL Ankara, TURKEY
SP Turkish Transplantat Soc
AB We report venous complications, including portal vein and hepatic vein stenoses, that required interventional radiological treatment in three pediatric and two adult living related liver transplant recipients. Between April 2001 and April 2005, 81 liver transplantations were performed at our hospital. Sixty-two grafts were from living donors. During follow-up, three portal vein stenoses were identified in three pediatric recipients, and two hepatic vein stenoses in two adult patients. In the children, two had received left lateral segment grafts, and one had received a right lobe graft from two mothers and one father, respectively. The etiologies of liver failure were Alagille syndrome, biliary atresia, and fulminant Wilson's disease. Portal vein stenoses were identified at 8, 11, and 12 months after transplantation; all three patients underwent percutaneous transhepatic portal venous angioplasty with a success rate of 100%. The mean follow-up was 102 days; no recurrence has occurred. In contrast, hepatic venous stenoses were diagnosed in two adult recipients. One of them was a 24-year-old woman with autoimmune hepatitis and the other a 43-year-old man with cryptogenic cirrhosis. Hepatic vein stenoses were diagnosed at 3 and 4 months after transplantation. Both hepatic vein stenoses were dilated with balloon angioplasties via the transjugular route. Venous complications identified by Doppler ultrasonography were confirmed by computerized tomographic angiography. Angioplasty represents an effective and safe alternative to reconstructive surgery in the treatment of venous complications after liver transplantation.
C1 Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Radiol, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Gastroenterol, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cad 77, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR BISMUTH H, 1988, TRANSPLANT P, V20, P486
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Caine RY, 1979, LANCET, V2, P1033
   CHERQUI D, 1993, WORLD J SURG, V17, P669
   Glanemann M, 2001, TRANSPLANT INT, V14, P48, DOI 10.1007/s001470050742
   Haberal M, 1998, TRANSPLANT P, V30, P706, DOI 10.1016/S0041-1345(98)00016-5
   Inomata Y, 2000, TRANSPLANTATION, V69, P258, DOI 10.1097/00007890-200001270-00011
   Kuang AA, 1996, TRANSPLANTATION, V62, P742, DOI 10.1097/00007890-199609270-00007
   PICHLMAYR R, 1984, HEPATOLOGY, V4, pS56, DOI 10.1002/hep.1840040716
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   STARZL TE, 1982, HEPATOLOGY, V2, P614
NR 11
TC 25
Z9 33
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2006
VL 38
IS 2
BP 604
EP 606
DI 10.1016/j.transproceed.2006.01.011
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 027UC
UT WOS:000236440100071
PM 16549187
ER

PT J
AU Tutar, N
   Coskun, M
   Cevik, B
   Tarhan, NC
   Harman, A
   Karakayali, H
   Haberal, M
AF Tutar, N
   Coskun, M
   Cevik, B
   Tarhan, NC
   Harman, A
   Karakayali, H
   Haberal, M
TI Nonvascular complications in pediatric liver recipients: Multidetector
   computed tomography evaluation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Meeting of the Turkish-Transplantation-Society
CY JUN 22-24, 2005
CL Ankara, TURKEY
SP Turkish Transplantat Soc
ID BILIARY COMPLICATIONS; TRANSPLANTATION; CT; EXPERIENCE; SPECTRUM;
   CHILDREN
AB In pediatric liver transplantation postoperative diagnosis of complications is crucial for graft salvage. Multidetector computed tomography (MDCT) is a technique to evaluate complications. In this study we present nonvascular abdominal complications encountered in pediatric recipients after liver transplantation. We retrospectively examined 113 MDCT examinations in 43 pediatric patients who underwent liver transplantation between 1997 and 2005. Computed tomography (CT) examinations were made by a 16-detector multislice CT scanner. The pathological findings on CT images were: intraperitoneal free fluid, intrahepatic bile duct dilatation, graft liver infarction, perihepatic and intraperitoneal fluid collections (six biloma), colonic and/or intestinal dilatation, splenic infarction, perihepatic hematoma, right adrenal hemorrhage, perihepatic abscess, incisional hernia, intrahepatic biloma and periportal collar. In one patient intestinal hemorrhage was suspected. Intestinal perforation was suspected in three patients. Among these three patients, one patient died before any surgical intervention. In two patients the diagnosis was confirmed at surgery. In pediatric patients, the short examination time, brief sedation duration, and high-resolution images make MDCT an effective radiological method to evaluate nonvascular transplant complications.
C1 Baskent Univ, Fac Med, Dept Radiol, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Gen Surg, Transplantat Unit, TR-06490 Ankara, Turkey.
RP Tutar, N (reprint author), Baskent Univ, Fac Med, Dept Radiol, Fevzi Cakmak Cad 10 Sok 45, TR-06490 Ankara, Turkey.
EM nihalt@baskent-ank.edu.tr
CR Ametani F, 2001, RADIOGRAPHICS, V21, P53
   BORASCHI P, 2004, ABDOM IMAGING, V2, P189
   Borenstein S, 2003, J PEDIATR SURG, V38, P668, DOI 10.1010/s0022-3468(03)00023-X
   Choi SH, 2004, KOREAN J RADIOL, V5, P199
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Kling K, 2004, PEDIATR TRANSPLANT, V8, P178, DOI 10.1046/j.1399-3046.2003.00127.x
   Quiroga S, 2001, RADIOGRAPHICS, V21, P1085
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
NR 9
TC 3
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2006
VL 38
IS 2
BP 607
EP 610
DI 10.1016/j.transproceed.2005.12.053
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 027UC
UT WOS:000236440100072
PM 16549188
ER

PT J
AU Emiroglu, R
   Ayvaz, I
   Moray, G
   Karakayali, H
   Haberal, M
AF Emiroglu, R
   Ayvaz, I
   Moray, G
   Karakayali, H
   Haberal, M
TI Tacrolimus-related neurologic and renal complications in liver
   transplantation: A single-center experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Meeting of the Turkish-Transplantation-Society
CY JUN 22-24, 2005
CL Ankara, TURKEY
SP Turkish Transplantat Soc
ID RECIPIENTS
AB Among 71 patients, 19 (26.7%) experienced tacrolimus-related complications including 15 neurologic reactions and four problems with nephrotoxicity. Seven of these patients received grafts from cadaveric donors and 12 from living donors. Nine patients were children. The cohort included 5 female and 14 male subjects of mean age 26 +/- 20 (min 6, max 65) years. The common indications for the liver transplantation were cholestatic and metabolic diseases in pediatric patients, and viral hepatitis in adult patients. Blood tacrolimus levels were within the normal range. All patients with neurologic complications received antiepileptic therapy and drug conversion to rapamycin in 4 cases and to cyclosporine (CsA) in 11 cases. Six cases with Wilson disease and all cases with tyrosinemia experienced neurologic complications, which reversed in all but one case. In four cases with nephrotoxicity, we switched to rapamycin. Renal function improved in all cases. Patients with Wilson disease and tyrosinemia were more susceptible to the neurologic side effects of tacrolimus. In these cases we recommend the use of drugs with fewer neurologic side effects. Tacrolimus also has nephrotoxic effects, which can be reversed by converting to rapamycin.
C1 Baskent Univ, Fac Med, Dept Gen Surg & Transplantat, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg & Transplantat, 1 Cadde 77 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Bottiger Y, 2002, TRANSPLANT P, V34, P1544, DOI 10.1016/S0041-1345(02)03013-0
   BUSUTTIL RW, 2004, TRANSPLANTATION S, V77, P44
   Hagemann G, 2004, J HUM HYPERTENS, V18, P287, DOI 10.1038/sj.jhh.1001664
   McKee M, 1997, J PEDIATR SURG, V32, P973, DOI 10.1016/S0022-3468(97)90380-8
   Pizzolato GP, 1998, NEUROLOGY, V50, P1154
   Singh N, 2000, TRANSPLANTATION, V69, P467, DOI 10.1097/00007890-200002270-00001
   Takatsuki M, 2001, TRANSPLANTATION, V72, P449, DOI 10.1097/00007890-200108150-00016
   Wijdicks EFM, 2001, LIVER TRANSPLANT, V7, P937, DOI 10.1053/jlts.2001.27475
NR 8
TC 13
Z9 19
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2006
VL 38
IS 2
BP 619
EP 621
DI 10.1016/j.transproceed.2005.12.114
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 027UC
UT WOS:000236440100074
PM 16549190
ER

PT J
AU Khan, S
   Erlichman, J
   Rand, EB
AF Khan, S
   Erlichman, J
   Rand, EB
TI Live virus immunization after orthotopic liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE transplantation; immunization; measles; varicella
ID PEDIATRIC LIVER; VARICELLA VACCINE; MEASLES; RECIPIENTS; EFFICACY;
   CHILDREN; RUBELLA; SAFETY; MUMPS
AB Viral infection is a recognized and potentially serious complication in children following solid organ transplantation. The risks of viral infection are particularly important for infants who may not have completed standard childhood immunizations at the time of transplantation and are therefore at risk for otherwise preventable infections. The general practice of withholding live virus immunization from transplant recipients has been questioned and several small studies have looked at MMR and/or Varivax administration in children following transplantation. This retrospective study analyzes the response to primary MMR and varicella immunization in selected pediatric liver transplant recipients in the largest such study to date. Nineteen of 26 children (73%) developed serologic immunity for measles following MMR (although 18 required multiple doses). Similarly, varicella immunization resulted in seroconversion in 20 of 31 children (64.5%; seven required multiple doses). Only minor adverse effects reported in the general population were observed. Live virus immunization with MMR and Varivax was safe and immunogenic in this selected population of liver transplant recipients.
C1 Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Fred & Suzanne Biesecker Liver Ctr, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Div GI & Nutr, Philadelphia, PA 19104 USA.
RP Rand, EB (reprint author), Childrens Hosp Philadelphia, Liver Transplant Program, 324 S 34th St, Philadelphia, PA 19104 USA.
EM rand@email.chop.edu
CR Chaves TDS, 2005, PEDIATR TRANSPLANT, V9, P192, DOI 10.1111/j.1399-3046.2005.00279.x
   Donati M, 2000, TRANSPLANTATION, V70, P1401, DOI 10.1097/00007890-200011150-00023
   Furth SL, 2002, PEDIATR TRANSPLANT, V6, P97, DOI 10.1034/j.1399-3046.2002.01059.x
   Kano H, 2002, TRANSPLANTATION, V74, P543, DOI 10.1097/00007890-200208270-00020
   KAPLAN LJ, 1992, JAMA-J AM MED ASSOC, V267, P1237, DOI 10.1001/jama.267.9.1237
   KITAI IC, 1993, CLIN INFECT DIS, V17, P441
   LJUNGMAN P, 1989, J INFECT DIS, V159, P610
   Lopez MJ, 2003, PEDIATR CLIN N AM, V50, P1435, DOI 10.1016/S0031-3955(03)00125-1
   Pacini-Edelstein SJ, 2003, J PEDIATR GASTR NUTR, V37, P183, DOI 10.1097/00005176-200308000-00018
   Pandya A, 2001, PEDIATR TRANSPLANT, V5, P153, DOI 10.1034/j.1399-3046.2001.00048.x
   Perry RT, 2004, J INFECT DIS, V189, pS4, DOI 10.1086/377712
   Pickering LK, 2000, 2000 RED BOOK REPORT
   RAND EB, 1993, J PEDIATR-US, V123, P87, DOI 10.1016/S0022-3476(05)81545-8
   Scanlon-Kohlroser CA, 2002, AM J KIDNEY DIS, V39, P1310, DOI 10.1053/ajkd.2002.33410
   Wellington K, 2003, DRUGS, V63, P2107, DOI 10.2165/00003495-200363190-00012
NR 15
TC 57
Z9 58
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2006
VL 10
IS 1
BP 78
EP 82
DI 10.1111/j.1399-3046.2005.00403.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 012WK
UT WOS:000235371400014
PM 16499592
ER

PT J
AU Gondolesi, GE
   Rodriguez-Davalos, M
   Soltys, K
   Florman, S
   Kaufman, S
   Fishbein, T
AF Gondolesi, GE
   Rodriguez-Davalos, M
   Soltys, K
   Florman, S
   Kaufman, S
   Fishbein, T
TI End-to-end portocaval shunt for venous drainage of the native foregut in
   combined liver-intestinal transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE intestine; liver; porto-caval shunt; transplantation; venous drainage
ID BOWEL TRANSPLANTATION; PRESERVATION
AB An end-to-side portocaval shunt has been classically described as the standard procedure that needs to be performed to obtain adequate venous drainage of the foregut in combined liver-intestinal transplant. The transplanted organs are placed en bloc in a piggyback fashion on the recipient's vena cava, and graft's porto-mesenteric venous circulation is left intact. Recurrent portal hypertension with hemorrhage has been reported as a complication after such a procedure. In an effort to improve the technical aspects of this complex operation, we began to perform an end-to-end shunt from the recipient portal vein to the infrahepatic donor cava. Here, we describe this new surgical technique and discuss its potential advantages. The new technique is described in detail. Of the 70 intestinal transplants performed in 67 patients at The Mount Sinai Hospital from 1998 to December 2004, three were multivisceral transplants (MVTx) and 28 were combined liver intestine transplants (LITx), post-surgical outcome including recurrent portal hypertension and the presence of splenomegaly and significant thrombocytopenia was retrospectively review between the group that received the classic end-side vs. the new end-end portocaval shunt. Of the 28 LITx, 23 were done with the classic end-side portocaval shunt and in five (one adult, four pediatric) the end-to-end portocaval shunt described in the present study. One patient in this group died on post-operative day 31 (adult); after a mean follow up of 19.5 months there is a 100% patient and graft survival for the pediatric population. Post-operatively there have been no complications related to this technique. Few modifications have been made to the original description of MVTx. This is the first description of this technique that is relatively simple to perform, creating a large vascular conduit with high flow rates and theoretically less turbulence compared with the end-to-side shunt.
C1 CUNY Mt Sinai Sch Med, Recanati Miller Transplantat Inst, New York, NY USA.
   Tulane Univ, New Orleans, LA 70118 USA.
   Georgetown Univ, Washington, DC USA.
RP Gondolesi, GE (reprint author), CUNY, Mt Sinai Med Ctr, Recanati Miller Transplantat Inst, 1 Gustave L Levy Pl,Box 1104, New York, NY 10029 USA.
EM gabriel.gondolesi@msnyuhealth.org
CR Abu-Elmagd K, 2001, ANN SURG, V234, P404, DOI 10.1097/00000658-200109000-00014
   Bueno J, 2000, J PEDIATR SURG, V35, P291, DOI 10.1016/S0022-3468(00)90027-7
   Fishbein TM, 2002, LIVER TRANSPLANT, V8, P639, DOI 10.1053/jlts.2002.33455
   GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A
   KOYANAGI N, 1988, AM J SURG, V156, P29, DOI 10.1016/S0002-9610(88)80164-8
   LANGNAS A, 1996, PEDIATRICS, V87, P443
   SHAFFER D, 1988, TRANSPLANTATION, V45, P262, DOI 10.1097/00007890-198802000-00002
   STARZL TE, 1989, JAMA-J AM MED ASSOC, V261, P1449, DOI 10.1001/jama.261.10.1449
   STARZL TE, 1991, SURG GYNECOL OBSTET, V172, P335
   Sudan DL, 2001, TRANSPLANTATION, V72, P1846, DOI 10.1097/00007890-200112150-00025
   TZAKIS A, 1989, ANN SURG, V210, P649, DOI 10.1097/00000658-198911000-00013
NR 11
TC 5
Z9 5
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2006
VL 10
IS 1
BP 98
EP 100
DI 10.1111/j.1399-3046.2005.00410.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 012WK
UT WOS:000235371400017
PM 16499595
ER

PT J
AU Tannuri, U
   Maksoud, JG
   Silva, MM
   Suzuki, L
   Santos, MM
   Gibelli, NE
   Ayoub, AA
   Velhote, MCP
   Pinho-Apezzato, ML
   Maksoud, JG
AF Tannuri, U
   Maksoud, JG
   Silva, MM
   Suzuki, L
   Santos, MM
   Gibelli, NE
   Ayoub, AA
   Velhote, MCP
   Pinho-Apezzato, ML
   Maksoud, JG
TI An alternative method of arterial reconstruction in pediatric living
   donor liver transplantation with the recipient right gastroepiploic
   artery
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; right gastroepiploic artery; hepatic artery
   thrombosis; pediatric liver transplantation; complications of liver
   transplantation
ID HEPATIC-ARTERY; CORONARY-ARTERY; SPLENIC ARTERY; THROMBOSIS;
   REVASCULARIZATION; EXPERIENCE; GRAFT; COMPLICATIONS; CHILDREN
AB The classical method for arterial reconstruction in pediatric living donor liver transplantation using left lateral segment consists of end-to-end anastomosis between the donor left hepatic artery and the recipient right hepatic artery. In the present case, an intra-operative hepatic artery thrombosis occurred because of extensive intima wall dissection of the recipient hepatic artery. The patient was a 6-yr-old boy with fulminant hepatic failure, who underwent living donor partial liver transplantation with left lateral segment from his father. The graft was irrigated by a left hepatic artery and an accessory left hepatic artery from gastric artery, both arteries with diameter of < 2 mm. These arteries were anastomosed to the recipient right and left hepatic arteries, respectively. Before performing the bile duct reconstruction it was noted that these anastomoses were occluded by clots of blood. An extensive subintimal dissection of the recipient hepatic artery was the cause of this problem. The creation of a new anastomosis by using a more proximal part of this artery without subintimal dissection was judged impossible. Then, the right gastroepiploic artery was mobilized and an anastomosis was performed with the donor left hepatic artery in an end-to-end fashion. Arterial blood flow to the graft was established successfully and the patient's postoperative recovery was excellent. Fifteen days after the transplantation, an angiotomography demonstrated a good hepatic arterial blood flow. The patient is now alive and well, 4 months after the transplantation. In conclusion, the method of hepatic graft arterialization described here is an important option for patients who undergo living donor or split liver transplantation.
C1 Univ Sao Paulo, Fac Med, Liver Transplantat Unit, Children Inst,Hosp Clin, BR-01246903 Sao Paulo, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Fac Med, Liver Transplantat Unit, Children Inst,Hosp Clin, Avenida Dr Arnaldo 455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM uenist@usp.br
RI Tannuri, Uenis/D-3876-2012; Gibelli, Nelson Elias Mendes/I-7176-2016
CR Albertini A, 1998, CARDIOVASC SURG, V6, P419, DOI 10.1016/S0967-2109(98)00009-X
   Asonuma K, 2004, TRANSPLANT INT, V17, P639, DOI 10.1007/s00147-004-0763-y
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BUCKELS JAC, 1989, TRANSPLANT P, V21, P2460
   CHERQUI D, 1994, AM J SURG, V167, P327, DOI 10.1016/0002-9610(94)90210-0
   Clemente CD, 1985, GRAYS ANATOMY
   GARCIAVALDECASAS JC, 1990, TRANSPLANT P, V22, P2376
   GHOBRIAL RM, 2001, TRANSPLANTATION LIVE, P79
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Ikegami T, 2000, TRANSPLANTATION, V69, P1953, DOI 10.1097/00007890-200005150-00036
   INOMOTO T, 1995, TRANSPLANTATION, V60, P881, DOI 10.1097/00007890-199510270-00022
   Itabashi Y, 2000, HEPATO-GASTROENTEROL, V47, P512
   Kaneko J, 2004, ABDOM IMAGING, V29, P603, DOI 10.1007/s00261-003-0156-1
   KATZ E, 1992, TRANSPLANTATION, V53, P1373
   Kusano T, 1999, HEPATO-GASTROENTEROL, V46, P2278
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   LEHAR SC, 1990, J COMPUT ASSIST TOMO, V14, P362, DOI 10.1097/00004728-199005000-00007
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   Miyakawa S, 1996, HEPATO-GASTROENTEROL, V43, P225
   Pevni D, 2005, ANN THORAC SURG, V79, P564, DOI 10.1016/j.athoracsur.2004.07.031
   RADERMECKER MA, 1993, CLIN TRANSPLANT, V7, P33
   SHAW B W JR, 1984, Surgery Gynecology and Obstetrics, V159, P491
   Takahashi K, 2004, ANN THORAC SURG, V78, P2033, DOI 10.1016/j.athoracsur.2004.06.071
   TAN KC, 1988, J PEDIATR SURG, V23, P927, DOI 10.1016/S0022-3468(88)80387-7
   Taniai N, 2002, HEPATO-GASTROENTEROL, V49, P1420
   Tannuri U, 2004, TRANSPLANT P, V36, P941, DOI 10.1016/j.transproceed.2004.03.101
   Tannuri U, 2005, PEDIATR TRANSPLANT, V9, P293, DOI 10.1111/j.1399-3046.2005.00306.x
   TODO S, 1987, TRANSPLANT P, V19, P2406
   Wei WI, 2004, ARCH SURG-CHICAGO, V139, P304, DOI 10.1001/archsurg.139.3.304
NR 29
TC 8
Z9 11
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2006
VL 10
IS 1
BP 101
EP 104
DI 10.1111/j.1399-3046.2005.00392.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 012WK
UT WOS:000235371400018
PM 16499596
ER

PT J
AU Engelmann, G
   Meyburg, J
   Schmidt, J
   Lenhartz, H
AF Engelmann, Guido
   Meyburg, Jochen
   Schmidt, Jan
   Lenhartz, Henning
TI Pediatric liver transplantation. Introduction of a program for southern
   Germany in Heidelberg
SO CLINICAL TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT Annal Multidisciplinary Heidelberg Transplant Symposium
CY OCT, 2005
CL Heidelberg, GERMANY
DE Heidelberg; pediatric liver transplantation
ID HEPATIC-FAILURE; EXPERIENCE; COMPLICATIONS; FULMINANT
AB Pediatric liver transplantation in Germany is exclusively performed in four centers in the north of Germany. We report our experience with the implementation of a new pediatric liver transplantation program in Heidelberg for children living in the south of Germany. In a pilot phase, we have transplanted eight children with various transplantation techniques including reduced size, left lateral split (segments 2 and 3), and full left split (segments 1-4). All transplantations were successful. No vascular complications occurred. The immunosuppressive regimen we used was cyclosporine A and methylprednisolone. The rate of acute rejection was three of eight patients. No patient required a retransplantation. One patient died due to a severe fungal sepsis he had acquired prior to transplantation. We conclude that in a multidisciplinary approach with careful patient selection a new program for pediatric liver transplantation can be successfully established.
C1 Univ Childrens Hosp, Dept Pediat Gastroenterol & Hepatol, Heidelberg, Germany.
   Univ Hosp Heidelberg, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany.
RP Engelmann, G (reprint author), Univ Heidelberg, Dept Pediat Pediat Gastroenterol & Hepatol, INF 153, D-69120 Heidelberg, Germany.
EM guido_engelmann@med.uni-heidelberg.de
CR Auth MKH, 2005, J PEDIATR GASTR NUTR, V40, P54, DOI 10.1097/00005176-200501000-00010
   Barshes NR, 2005, LIVER TRANSPLANT, V11, P1193, DOI 10.1002/lt.20509
   BELGHITI J, 1995, BRIT J SURG, V82, P986, DOI 10.1002/bjs.1800820741
   Broering DC, 2005, ANN SURG, V242, P802, DOI 10.1097/01.sla.0000189120.62975.0d
   Burdelski M, 1987, Clin Transpl, P55
   Burdelski MM, 2005, J HEPATOL, V42, P28, DOI 10.1016/j.jhep.2004.11.005
   Cintorino D, 2005, TRANSPLANT P, V37, P2597, DOI 10.1016/j.transprocedd.2005.06.017
   Ganschow R, 2000, Pediatr Transplant, V4, P273, DOI 10.1034/j.1399-3046.2000.00127.x
   Hellinger A, 1996, LANGENBECK ARCH CHIR, V381, P182
   Kelly D A, 2000, Pediatr Transplant, V4, P170, DOI 10.1034/j.1399-3046.2000.00125.x
   Kim JS, 2005, TRANSPLANTATION, V79, P1206, DOI 10.1097/01.TP.0000160758.13505.D2
   Lee WS, 2005, J PEDIATR GASTR NUTR, V40, P575, DOI 10.1097/01.MPG.0000158524.30294.E2
   Moray G, 2005, TRANSPLANT P, V37, P3200, DOI 10.1016/j.transproceed.2005.08.045
   RINGE B, 1990, CLIN TRANSPL, V4, P135
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Sauer IM, 2001, TRANSPLANT P, V33, P1459, DOI 10.1016/S0041-1345(00)02551-3
   SAUVANET A, 1994, J AM COLL SURGEONS, V178, P79
   Schmied BM, 2005, TRANSPLANTATION, V80, pS147, DOI 10.1097/01.tp.0000186.58294.d1
   Vivarelli M, 2004, ARCH SURG-CHICAGO, V139, P1069, DOI 10.1001/archsurg.139.10.1069
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   Wigg AJ, 2005, LIVER TRANSPLANT, V11, P27, DOI 10.1002/lt.20289
NR 21
TC 2
Z9 2
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PY 2006
VL 20
SU 17
BP 124
EP 130
DI 10.1111/j.1399-0012.2006.00611.x
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 113MS
UT WOS:000242602600019
PM 17100712
ER

PT J
AU Sanko-Resmer, J
   Paczek, L
   Wyzgal, J
   Ziolkowski, J
   Ciszek, M
   Alsharabi, A
   Grzelak, I
   Paluszkiewicz, R
   Patkowski, W
   Krawczyk, M
AF Sanko-Resmer, J
   Paczek, L
   Wyzgal, J
   Ziolkowski, J
   Ciszek, M
   Alsharabi, A
   Grzelak, I
   Paluszkiewicz, R
   Patkowski, W
   Krawczyk, M
TI Biliary liver cirrhosis secondary to cystic fibrosis: A rare indication
   for liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th International Congress of the Polish-Transplantation-Society
CY MAY 12-14, 2005
CL Wisla, POLAND
SP Polish Transplantation Soc
ID PORTAL-HYPERTENSION; DISEASE
AB As more effective therapies prolong the lives of patients with cystic fibrosis, there are now more patients in this population diagnosed with liver diseases. Secondary biliary cirrhosis is not a rare complication of mucoviscidosis. It is diagnosed in 20% of patients with mucoviscidosis; in 2% it is accompanied by portal hypertension. On average patients with portal hypertension and its complications are 12 years old. Liver transplantation is an accepted method of treatment for children with cystic fibrosis and portal hypertension. It eliminates the cause of the portal hypertension, decreases life-threatening medical conditions, and improves their nutritional status and quality of life. Despite immunosuppressive treatment they do not seem to beat increased risk of upper respiratory tract infections. On the contrary improved respiratory function and status are generally observed. We present our first case of orthotopic liver transplantation performed in a 29-year-old man with cystic fibrosis. The donor was a 42-year-old woman who died of a ruptured cerebral aneurysm. The surgery was performed in September 2004. The patient received immunosuppression based on steroids, basiliximab, tacrolimus, and mycophenolic acid due to renal insufficiency. Antibiotic (meropenem) and antiviral prophylaxis (gancy-clovir) were used. A 6-month period of observation confirmed the clinical data from the pediatric population-a good prognosis with improved nutritional status, respiratory function, and quality of life.
C1 Warsaw Med Univ, Dept Immunol Transplantol & Internal Dis, Inst Transplantat, PL-02006 Warsaw, Poland.
   Warsaw Med Univ, Dept Gen Transplant & Liver Surg, Warsaw, Poland.
RP Sanko-Resmer, J (reprint author), Warsaw Med Univ, Dept Immunol Transplantol & Internal Dis, Inst Transplantat, Nowogrodzka 59, PL-02006 Warsaw, Poland.
EM joannaresmer@poczta.onet.pl
CR Colombo C, 2005, TRANSPLANT INT, V18, P246, DOI 10.1111/j.1432-2277.2004.00013.x
   Colombo C, 2002, HEPATOLOGY, V36, P1374, DOI 10.1053/jhep.2002.37136
   Debray D, 1999, J HEPATOL, V31, P77, DOI 10.1016/S0168-8278(99)80166-4
   Efrati O, 2003, EUR J GASTROEN HEPAT, V15, P1073, DOI 10.1097/01.meg.0000085471.12407.92
   Fridell JA, 2003, J PEDIATR SURG, V38, P1152, DOI 10.1016/S0022-3468(03)00260-4
   Genyk Y S, 2001, Curr Opin Pulm Med, V7, P441, DOI 10.1097/00063198-200111000-00014
   Lamireau T, 2004, J HEPATOL, V41, P920, DOI 10.1016/j.jhep.2004.08.006
   Milkiewicz P, 2002, J GASTROEN HEPATOL, V17, P208, DOI 10.1046/j.1440-1746.2002.02671.x
   NobleJamieson G, 1996, J ROY SOC MED, V89, P31
   Pfister ED, 2002, TRANSPLANT P, V34, P2281, DOI 10.1016/S0041-1345(02)03236-0
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JAN-FEB
PY 2006
VL 38
IS 1
BP 212
EP 214
DI 10.1016/j.transproceed.2005.12.002
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 021AH
UT WOS:000235954200056
PM 16504705
ER

PT J
AU Levitsky, J
   Kalil, AC
   Meza, JL
   Hurst, GE
   Freifeld, A
AF Levitsky, J
   Kalil, AC
   Meza, JL
   Hurst, GE
   Freifeld, A
TI Chicken pox after pediatric liver transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 6th American Transplant Congress
CY MAY 21-25, 2005
CL Seattle, WA
SP Amer Soc Transplant Surg, Amer Soc Transplantat
ID VARICELLA VACCINE; CHILDREN; RECIPIENTS; IMMUNIZATION; INFECTION;
   EFFICACY; VIRUS
AB Previous case series have reported serious complications of chicken pox (CP) after pediatric liver transplantation (PLT), mainly due to visceral dissemination. The goal of our study was to determine the incidence, risk factors, and outcomes of CP after PLT. A case-control study of all CP infections in pediatric transplant recipients followed at our center from September 1993 to April 2004 was performed. Data were collected before and after infection and at the same time points in age-, gender-, and transplant year-matched controls. Potential risk factors prior to CP and adverse outcomes after infection were compared between cases and controls. Twenty (6.2%) developed CP at a median of 1.8 yr (0.6-4.8) after PLT. All CP infections were cutaneous, with no evidence of organ involvement. Twelve were hospitalized: 9 only to receive intravenous acyclovir and 3 stayed >= 2 weeks for other complications. Risk factors were not statistically different among cases and controls. Of the outcomes analyzed, cases were significantly more likely to develop non-CP infections within one year of CP than controls (Hazard Ratio = 12.6, 95% confidence interval = 3.1-51.7; P < 0.001). These infections were often bacterial and occurred long after CP infection. In conclusion, CP is uncommon after PLT and has a low likelihood of organ dissemination. No risk factors were identified. Some cases required prolonged hospitalizations. Close monitoring for the development of late bacterial infections is warranted.
C1 Univ Nebraska, Sch Med, Dept Med, Div Infect Dis, Omaha, NE 68198 USA.
   Univ Nebraska, Sch Med, Dept Prevent & Societal Med, Biostat Sect, Omaha, NE 68198 USA.
   NW Mem Hosp, Feinberg Sch Med, Dept Med, Div Hepatol, Chicago, IL 60611 USA.
RP Freifeld, A (reprint author), Univ Nebraska, Med Ctr, Div Infect Dis, Dept Internal Med, 600 S 42nd St, Omaha, NE 68198 USA.
EM afreifeld@unmc.edu
CR Aebi C, 1996, CLIN INFECT DIS, V23, P698
   Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361
   Donati M, 2000, TRANSPLANTATION, V70, P1401, DOI 10.1097/00007890-200011150-00023
   FELDHOFF CM, 1981, J PEDIATR-US, V98, P25, DOI 10.1016/S0022-3476(81)80527-6
   GIACCHINO R, 1995, TRANSPLANTATION, V60, P1055
   Kano H, 2002, TRANSPLANTATION, V74, P543, DOI 10.1097/00007890-200208270-00020
   Kashtan CE, 1997, J PEDIATR-US, V131, P874, DOI 10.1016/S0022-3476(97)70036-2
   KITAI IC, 1993, CLIN INFECT DIS, V17, P441
   La Russa P, 2000, VARICELLA ZOSTER VIR, P206, DOI 10.1017/CBO9780511601194.013
   Levitsky J, 2002, AM J TRANSPLANT, V2, P880, DOI 10.1034/j.1600-6143.2002.20912.x
   Levitsky J, 2005, LIVER TRANSPLANT, V11, P320, DOI 10.1002/lt.20356
   MCGREGOR RS, 1989, PEDIATRICS, V83, P256
   MORGAN ER, 1983, AM J DIS CHILD, V137, P883
   Pacini-Edelstein SJ, 2003, J PEDIATR GASTR NUTR, V37, P183, DOI 10.1097/00005176-200308000-00018
   Patel RA, 2004, J PEDIATR-US, V144, P68, DOI 10.1016/j.jpeds.2003.10.025
   Vazquez M, 2001, NEW ENGL J MED, V344, P955, DOI 10.1056/NEJM200103293441302
   WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201
NR 17
TC 8
Z9 8
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD DEC
PY 2005
VL 11
IS 12
BP 1563
EP 1566
DI 10.1002/lt.20527
PG 4
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 991MB
UT WOS:000233817000016
PM 16315312
ER

PT J
AU Haruta, H
   Yamamoto, H
   Mizuta, K
   Kita, Y
   Uno, T
   Egami, S
   Hishikawa, S
   Sugano, K
   Kawarasaki, H
AF Haruta, H
   Yamamoto, H
   Mizuta, K
   Kita, Y
   Uno, T
   Egami, S
   Hishikawa, S
   Sugano, K
   Kawarasaki, H
TI A case of successful enteroscopic balloon dilation for late anastomotic
   stricture of choledochojejunostomy after living donor liver
   transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID BILIARY COMPLICATIONS; MANAGEMENT
AB Biliary complications remain a major concern after living donor liver transplantation. We describe a pediatric case who underwent a successful endoscopic balloon dilatation of biliary-enteric stricture following living donor liver transplantation using a newly developed method of enteroscopy. The 7-year-old boy with late biliary stricture of choledochojejunostomy was admitted 6 years after transplantation. Since percutaneous transhepatic cholangiography was technically difficult in this case, endoscopic retrograde cholangiography was performed using a double-balloon enteroscope under general anesthesia. The enteroscope was advanced retrograde through the duodenum, jejunum, and the leg of Roux-Y by the double-balloon method, and anastomotic stricture of choledochojejunostomy was clearly confirmed by endoscopic retrograde cholangiography and endoscopic direct vision. Balloon dilatation was performed and the anastomosis was expanded. Restenosis was not noted as of 2 years after the treatment. In conclusion, endoscopic balloon dilation of biliary-enteric anastomotic stricture using a new enteroscopic method can be regarded as an alternative choice to percutaneous transhepatic management and surgical re-anatomists.
C1 Jichi Med Sch, Dept Transplant Surg, Minamimaki, Tochigi 3290498, Japan.
   Jichi Med Sch, Dept Gastroenterol, Minamimaki, Tochigi 3290498, Japan.
RP Mizuta, K (reprint author), Jichi Med Sch, Dept Transplant Surg, Minamimaki, Tochigi 3290498, Japan.
EM koimizu@jichi.ac.jp
CR Egawa H, 2001, WORLD J SURG, V25, P1300
   Mata A, 2004, HEPATO-GASTROENTEROL, V51, P1801
   Park JS, 2003, GASTROINTEST ENDOSC, V57, P78, DOI 10.1067/mge.2003.11
   Roumilhac D, 2003, LIVER TRANSPLANT, V9, P394, DOI 10.1053/jlts.2003.50052
   Thethy S, 2004, CLIN TRANSPLANT, V18, P647, DOI 10.1111/j.1399-0012.2004.00254.x
   Thuluvath PJ, 2003, LIVER INT, V23, P156, DOI 10.1034/j.1600-0676.2003.00823.x
   Yamamoto H, 2001, GASTROINTEST ENDOSC, V53, P216, DOI 10.1067/mge.2001.112181
   Yamamoto H, 2003, CAN J GASTROENTEROL, V17, P273
   Yamamoto H, 2004, CLIN GASTROENTEROL H, V2, P1010, DOI 10.1053/S1542-3565(04)00453-7
NR 9
TC 76
Z9 81
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD DEC
PY 2005
VL 11
IS 12
BP 1608
EP 1610
DI 10.1002/lt.20623
PG 3
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 991MB
UT WOS:000233817000023
PM 16315301
ER

PT J
AU Aydogdu, S
   Arikan, C
   Kilic, M
   Ozgenc, F
   Akman, S
   Unal, F
   Yagci, RV
   Tokat, Y
AF Aydogdu, S
   Arikan, C
   Kilic, M
   Ozgenc, F
   Akman, S
   Unal, F
   Yagci, RV
   Tokat, Y
TI Outcome of pediatric liver transplant recipients in Turkey: Single
   center experience
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE chronic liver disease; pediatric liver transplantation; survival;
   surgical complication; pediatric end-stage liver disease score
ID CHRONIC REJECTION; TACROLIMUS; CHILDREN; RISK
AB To summarize the evolution of the pediatric liver transplant program in a developing country. Between April 1997, and September 2003, 32 cadaveric (CD) and 35 living donor (LD) liver transplantations were performed on 61 children (median age 3.8 yr, range 0.5-16) at Ege University Organ Transplantation and Research Center. The patient's charts were reviewed retrospectively. The outcome of patient and graft survival was analyzed and the incidence of graft loss, complications and rejections was calculated. Indications for liver transplantation were metabolic liver disease (n = 17), biliary atresia (n = 14), viral hepatitis (n = 4), autoimmune hepatitis (n = 6), cryptogenic cirrhosis (n = 11), fulminant liver failure (n = 5) and others (n = 5). Seven of 61 children with chronic liver disease had hepatocellular carcinoma concomitantly. Median pediatric end-stage liver disease score was 23 (range 1-54). Seven children (11.4%) were UNOS status I, 44 (72%) were UNOS status II and 10 (16.6%) were UNOS status III. The median follow-up of the study population was 3.6 yr (range 0.5-6). Actuarial patient survival rates at 1, 2, 3 and 4 yr were 86, 86, 71.3 and 65% in the CD group vs. 80, 76, 67 and 67% in the LR group, respectively (p = NS). Patients listed as UNOS status 1 had lower survival rates than patients listed as UNOS status 2 and 3 (p < 0.05). The mortality rate was 26.2%. Graft survival rates were 81, 81, 75 and 64% at 1, 2, 3 and 4-yr respectively. Six patients (9%) underwent retransplantation. The main complications were infections (64.7%) and surgical complications (43.2%) (including biliary complication, vascular problems, postoperative bleeding, small for size and large for size). The incidence of acute cellular rejection was 39.3%, whereas chronic rejection was 7.4%. The result of liver transplantation in Turkish children was slightly inferior to those reported for North American and European children. However, an important characteristic of these patients that distinguishes them from Europe and North America is that most were UNOS status IIa and UNOS status I (44%). Despite technical and medical progress, infectious and biliary problems have continued to be an important cause of mortality in these patients.
C1 Ege Univ Sch Med, Dept Pediat, Div Gastroenterol, Izmir, Turkey.
   Ege Univ Sch Med, Dept Pediat, Div Hepatol, Izmir, Turkey.
   Ege Univ Sch Med, Dept Pediat, Div Nutr, Izmir, Turkey.
   Ege Univ Sch Med, Dept Gen Surg, Izmir, Turkey.
RP Arikan, C (reprint author), 250 Sok 6 D-1, TR-35040 Izmir, Turkey.
EM arikan@med.ege.edu.tr
CR ARIKAN C, 2002, TRANSPLANTATION S, V74, P3526
   Emre S, 2002, PEDIATR TRANSPLANT, V6, P43, DOI 10.1034/j.1399-3046.2002.1r072.x
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   GREEN M, 2002, PRINCIPLES PRACTICE, P554
   Gupta P, 2001, TRANSPLANTATION, V72, P1098, DOI 10.1097/00007890-200109270-00020
   Jain A, 2002, TRANSPLANT P, V34, P1968, DOI 10.1016/S0041-1345(02)03143-3
   Jain A, 2001, LIVER TRANSPLANT, V7, P623, DOI 10.1053/jlts.2001.25364
   KAM I, 2002, LIVER TRANSPLANT, V18, P347
   MAZARIEGOS GV, 2002, AM J TRANSPLANT, V2, P251
   MCDIARMID SV, 1999, GRAFT S2, V2, pS86
   MCDIARMID SV, 2003, PEDIATR CLIN N AM, V6, P1335
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   ROGIERS MX, 1994, TRANSPL P, V6, P3620
   Testa G, 2002, LIVER TRANSPLANT, V8, P340, DOI 10.1053/jlts.2002.32941
   Ulukaya S, 2003, PEDIATR TRANSPLANT, V7, P381, DOI 10.1034/j.1399-3046.2003.00072.x
NR 17
TC 17
Z9 18
U1 1
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2005
VL 9
IS 6
BP 723
EP 728
DI 10.1111/j.1399-3046.2005.00366.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 980FG
UT WOS:000232999000006
PM 16269042
ER

PT J
AU Choi, SW
   Islam, S
   Greenson, J
   Levine, J
   Hutchinson, R
   Yanik, G
   Teitelbaum, DH
   Ferrara, JLM
   Cooke, KR
AF Choi, SW
   Islam, S
   Greenson, J
   Levine, J
   Hutchinson, R
   Yanik, G
   Teitelbaum, DH
   Ferrara, JLM
   Cooke, KR
TI The use of laparoscopic liver biopsies in pediatric patients with
   hepatic dysfunction following allogeneic hematopoietic stem cell
   transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE allogeneic HSCT; pediatric patients; hepatic dysfunction; laparoscopic
   liver biopsy; GVHD; VOD
ID BONE-MARROW TRANSPLANTATION; COMPLICATIONS; CHILDREN; NEEDLE;
   EXPERIENCE; DISEASE; RISK
AB Hepatic dysfunction following hematopoietic stem cell transplantation (HSCT) is common, but making the correct diagnosis can be challenging. Liver biopsies can serve as an important diagnostic tool when the etiology cannot be clearly determined by laboratory data, physical examination, and imaging studies. We reviewed 12 consecutive pediatric patients (seven males, five females, age 9 - 23 years) who received allogeneic HSCT and underwent a laparoscopic-guided liver biopsy for hepatic dysfunction of unknown etiology from 1998 to 2005. Biopsies were performed using a single-port technique with a 16 or 18 gauge, spring-loaded biopsy gun. The time from HSCT to biopsy ranged from 31 days to 821 days (median 92 days). No intra- or post- operative complications were observed. The initial clinical diagnosis was confirmed in seven patients, whereas the initial working diagnosis was inaccurate in the remaining five patients. Our results suggest that laparoscopic-guided liver biopsy is an informative and safe procedure in pediatric HSCT recipients; this approach helped delineate the true cause of hepatic dysfunction and changed our therapeutic approach in approximately 40% of the patients reviewed. While the safety record at our institution appears promising, a larger multi-institutional study would be necessary to more accurately describe the overall efficacy of this procedure in pediatric HSCT patients.
C1 Univ Michigan, Dept Pediat, Blood & Marrow Stem Cell Transplantat Program, Ann Arbor, MI 48109 USA.
   Univ Mississippi, Div Pediat Surg, Jackson, MS 39216 USA.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
RP Cooke, KR (reprint author), Univ Michigan, Ctr Canc, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM krcooke@umich.edu
CR Arai S, 2002, J HEMATOTH STEM CELL, V11, P215, DOI 10.1089/152581602753658420
   BABB RR, 1989, WESTERN J MED, V150, P39
   Bergey EA, 1998, J VASC INTERV RADIOL, V9, P829, DOI 10.1016/S1051-0443(98)70399-9
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   COHEN MB, 1992, GASTROENTEROLOGY, V102, P629
   CORR P, 1992, CLIN RADIOL, V45, P238, DOI 10.1016/S0009-9260(05)80004-2
   DOTTER CT, 1964, RADIOLOGY, V82, P312
   Esposito C, 1997, LIVER, V17, P288
   FARTHING MJG, 1982, GUT, V23, P465, DOI 10.1136/gut.23.6.465
   FURUYA KN, 1992, HEPATOLOGY, V15, P1036, DOI 10.1002/hep.1840150611
   GAMBLE P, 1985, RADIOLOGY, V157, P589
   Habdank K, 2003, AM J ROENTGENOL, V180, P1393
   Hoffer FA, 2000, PEDIATR RADIOL, V30, P481, DOI 10.1007/s002470000244
   Iqbal M, 1996, BONE MARROW TRANSPL, V17, P655
   LAZARUS HM, 1994, J AM COLL SURGEONS, V179, P433
   LEBREC D, 1982, GASTROENTEROLOGY, V83, P338
   LESKINEN R, 1989, TRANSPLANTATION, V48, P969, DOI 10.1097/00007890-198912000-00015
   LIU C, 2005, GRAFT VS HOST DIS, P257
   MCAFEE JH, 1992, HEPATOLOGY, V15, P726, DOI 10.1002/hep.1840150429
   MCDONALD GB, 1986, GASTROENTEROLOGY, V90, P770
   Papatheodoridis GV, 1999, ALIMENT PHARM THERAP, V13, P603
   PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7
   ROSCH J, 1973, NEW ENGL J MED, V289, P227, DOI 10.1056/NEJM197308022890501
   SHARMA P, 1982, J CLIN GASTROENTEROL, V4, P451, DOI 10.1097/00004836-198210000-00011
   Smith TP, 2003, AM J ROENTGENOL, V180, P167
   STEADMAN C, 1988, AUST NZ J MED, V18, P836, DOI 10.1111/j.1445-5994.1988.tb01640.x
   VELT PM, 1984, RADIOLOGY, V153, P91
NR 27
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD NOV
PY 2005
VL 36
IS 10
BP 891
EP 896
DI 10.1038/sj.bmt.1705158
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 980CL
UT WOS:000232991400009
PM 16184184
ER

PT J
AU Elola-Olaso, AM
   Gonzalez, EM
   Diaz, JCM
   Garcia, IG
   Segurola, CL
   Usera, MA
   Romero, CJ
   Perez-Saborido, B
   Suarez, YF
   Oliva, MC
AF Elola-Olaso, AM
   Gonzalez, EM
   Diaz, JCM
   Garcia, IG
   Segurola, CL
   Usera, MA
   Romero, CJ
   Perez-Saborido, B
   Suarez, YF
   Oliva, MC
TI Short- and long-term outcomes after living donor liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the Catalan-Transplantation-Society
CY FEB 06-09, 2005
CL Barcelona, SPAIN
SP Catalan Transplantat Soc
ID ADULT; MORBIDITY; LESSONS
AB Introduction. Living donor liver transplantation was first described as a way to alleviate the organ shortage. Extensive studies of both the prospective donor and the recipient are necessary to ensure successful outcome. In this paper we describe our results in 28 living donor liver transplantations from the perspective of the donor and the recipient.
   Methods. A prospective, longitudinal, observational, comparative study was conducted from April 1995 to October 2004, including 28 living donor liver transplantations.
   Results. After a mean follow-up time of 25.6 +/- 20.58 months, all donors are alive, showing normal liver function tests. All of them have been reincorporated into their normal lives. At the end of the study and after a mean follow-up time of 21.2 +/- 14.3 months, 86.3% of the adult recipients are alive. Actuarial recipient survivals at 6, 12, and 36 months were 86.36%. Actuarial mean survival time was 44 months (95% CI, 37 to 51). At the end of the study, 77.3% of the grafts are functioning. Actuarial graft survivals at 6, 12, and 36 months were 77.27%. Actuarial mean graft survival time was 32 months (95% CI, 25 to 39). The main complications were hepatic artery thrombosis (n = 2) and small for-size syndrome (n = 2). At a mean follow-up of 20.33 +/- 7.74 months, all pediatric recipients are alive. Actuarial recipient survivals at 12 and 36 months were 100% and actuarial graft survivals were 80%.
   Conclusions. Living donor liver transplantation may increase the liver graft pool, and therefore reduce waiting list mortality. Nevertheless caution must be deserved to avoid surgical morbidity and mortality in with the donor the recipient.
C1 Hosp 12 Octubre, Serv Cirugia Gen, Aparato Digest & Transplante Org Abdominales, E-28041 Madrid, Spain.
RP Elola-Olaso, AM (reprint author), Hosp 12 Octubre, Serv Cirugia Gen, Aparato Digest & Transplante Org Abdominales, Avda Cordoba,Km 5,400, E-28041 Madrid, Spain.
EM morenoalmudena@hotmail.com
CR Beavers KL, 2002, LIVER TRANSPLANT, V8, P110, DOI 10.1053/jlts.2002.31315
   Broelsch CE, 2003, LIVER TRANSPLANT, V9, pS50, DOI 10.1053/jlts.2003.50218
   FUIJTA S, 2000, TRANSPL INT, V13, P333
   Ito T, 2003, TRANSPLANTATION, V76, P158, DOI 10.1097/01.TP.0000072372.42396.47
   Lo CM, 2004, ANN SURG, V240, P151, DOI 10.1097/01.sla.000012940.05238.a0
   Marcos A, 2000, TRANSPLANTATION, V69, P2410, DOI 10.1097/00007890-200006150-00034
   Marcos A, 2000, LIVER TRANSPLANT, V6, P3, DOI 10.1002/lt.500060117
   Trotter JF, 2000, LIVER TRANSPLANT, V6, P52
   Wiederkehr JC, 2004, TRANSPLANT P, V36, P918, DOI 10.1016/j.transproceed.2004.03.102
NR 9
TC 3
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 2005
VL 37
IS 9
BP 3884
EP 3886
DI 10.1016/j.transproceed.2005.10.080
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 998KC
UT WOS:000234316400096
PM 16386572
ER

PT J
AU Oliveros, FH
   Santamaria, ML
   Gamez, MG
   Murcia, J
   Leal, N
   Frauca, E
   Hierro, L
   Camarena, C
   de la Vega, A
   Bortolo, G
   Diaz, MC
   Jara, P
AF Oliveros, FH
   Santamaria, ML
   Gamez, MG
   Murcia, J
   Leal, N
   Frauca, E
   Hierro, L
   Camarena, C
   de la Vega, A
   Bortolo, G
   Diaz, MC
   Jara, P
TI Comparative study between living and cadaveric donors in pediatric liver
   transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the Catalan-Transplantation-Society
CY FEB 06-09, 2005
CL Barcelona, SPAIN
SP Catalan Transplantat Soc
ID SPLIT; GRAFT
AB We examined whether the results in living-related hepatic transplantation (LRLT) are better than those from a cadaveric donor (CDLT).
   Material and methods. The last 27 consecutive LRLT, performed from 1998 to 2005, were compared with 27 CDLT matched for age, weight, date, and diagnosis. Grafts in LRLT group were left lateral segment (n = 22), left lobe (n = 3), and right lobe (n = 2). In the CDLT group, the grafts were split in situ (n = 10), hepatic reduction (n = 9) and whole liver (n = 8). We analyzed the actuarial survivals (grafts and children), retransplantation, primary nonfunction, initial graft malfunction (liver enzymes > 2000 U/L), surgical complications, rejection, and resource consumption.
   Results. Patient survivals at 6 months, 1 year, and 5 years were 100%, 96%, and 96% in LRLT and 100%, 100%, and 100% in CDLT (P = NS). Graft survivals were 93%, 89%, and 89% versus 96%, 96%, and 96%, respectively (P = NS). Complications were biliary complications (LRLT, 25% vs CDLT, 3%; P = .021); portal vein thrombosis (LRLT, 7% vs CDLT, 3%; NS), and hepatic artery thrombosis (LRLT, 0% vs CDLT, 3%; NS). The overall incidence of acute rejection was slightly higher (NS) in LRLT (LRLT, 18% vs CDLT, 11%; NS). Liver enzyme levels were higher in the CDLT group, but initial malfunction rate was not statistically different. Regarding resource consumption: blood product needs were higher in LRLT (P < .05) and hospital stay and ICU stay were longer, although not significantly, among LRLT.
   Conclusions. The results in LRLT among children are similar to those obtained in CDLT. We found a trend towards less initial graft malfunction in LRLT. Blood product needs were higher in LRLT. Hospital and ICU stay were longer, but not significantly different in LRLT. The benefits of LRLT are saving a scarce resource: a cadaveric donor liver graft.
C1 Univ Madrid, Hosp La Paz, Dept Pediat Surg, Madrid 28046, Spain.
   Univ Madrid, Hosp La Paz, Dept Hepatol, Madrid 28046, Spain.
RP Santamaria, ML (reprint author), Univ Madrid, Hosp La Paz, Dept Pediat Surg, Paseo Castellana 261, Madrid 28046, Spain.
EM mlopez.hulp@salud.madrid.org
CR DEVILLE, 1997, CHIRURGIE, V122, P83
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Lopez-Santamaria M, 2002, TRANSPLANT P, V34, P239, DOI 10.1016/S0041-1345(01)02741-5
   Lopez-Santamaria M, 2003, TRANSPLANT P, V35, P1808, DOI 10.1016/S0041-1345(03)00570-0
   *ONT, 2002, TRANSPL HEP ESP 2002
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Otte JB, 2004, PEDIATR TRANSPLANT, V8, P317, DOI 10.1111/j.1399-3046.2004.00205.x
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Testa G, 2001, PEDIATR TRANSPLANT, V5, P16, DOI 10.1034/j.1399-3046.2001.t01-1-00028.x
NR 10
TC 8
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 2005
VL 37
IS 9
BP 3936
EP 3938
DI 10.1016/j.transproceed.2005.10-072
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 998KC
UT WOS:000234316400114
PM 16386590
ER

PT J
AU Fine, RN
AF Fine, RN
TI Renal function following liver transplantation in children
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE glomerular filtration rate; liver transplantation; renal function
ID GLOMERULAR-FILTRATION RATE; C VIRUS-INFECTION; PEDIATRIC LIVER;
   CYCLOSPORINE; RECIPIENTS; LONG; NEPHROPATHY; ORGAN
AB The literature regarding the etiology and incidence of short and long-term renal functional impairment in pediatric liver allograft recipients was reviewed. Most of the reports include recipients receiving cyclosporine as the primary immunosuppressant. Using calculated glomerular filtration rate (cGFR), creatinine clearance or the serum creatinine level will lead to an overestimation of GFR. In contrast to data in adults, there are a limited number of pediatric recipients whose renal dysfunction has progressed to chronic kidney disease or end-state renal disease. Calcineurin inhibitors minimization has proven effective in reversing or preventing progressive deterioration of GFR; however, rejection episodes and complications have limited efficacy of this approach. Future multicenter studies using optimal GFR measurements are required to delineate the magnitude of renal dysfunction in pediatric recipients.
C1 SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA.
RP Fine, RN (reprint author), SUNY Stony Brook, Dept Pediat, HSC T-11,020, Stony Brook, NY 11794 USA.
EM richard.fine@stonybrook.edu
CR ALONSO EM, 2004, PEDIATR TRANSPLANT, V8, P1
   ANDREWS WS, 1991, TRANSPLANT P, V23, P1452
   Arora-Gupta N, 2004, PEDIATR TRANSPLANT, V8, P145, DOI 10.1046/j.1399-3046.2003.00132.x
   Aw MM, 2001, TRANSPLANTATION, V72, P746, DOI 10.1097/00007890-200108270-00034
   Bartosh SM, 1997, CLIN TRANSPLANT, V11, P354
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Casas-Melley AT, 2004, PEDIATR TRANSPLANT, V8, P362, DOI 10.1111/j.1399-3046.2004.00193.x
   Davis CL, 2002, LIVER TRANSPLANT, V8, P91, DOI 10.1053/jlts.2002.31516
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Gonwa TA, 2001, TRANSPLANTATION, V72, P1934, DOI 10.1097/00007890-200112270-00012
   JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703
   LAINE J, 1994, J PEDIATR-US, V125, P863, DOI 10.1016/S0022-3476(05)82000-1
   LAINE J, 1995, PEDIATR RES, V37, P640, DOI 10.1203/00006450-199505000-00015
   LEE WS, 2003, PEDIATR TRANSPLANT, V7, P1
   MCDIARMID SV, 1993, TRANSPLANTATION, V56, P847, DOI 10.1097/00007890-199310000-00014
   MCDIARMID SV, 1989, TRANSPLANTATION, V47, P314, DOI 10.1097/00007890-198902000-00025
   MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018
   Mention K, 2005, PEDIATR TRANSPLANT, V9, P201, DOI 10.1111/j.1399-3046.2005.00289.x
   MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103
   Nolkemper D, 2000, Pediatr Transplant, V4, P177, DOI 10.1034/j.1399-3046.2000.00107.x
   Ojo AO, 2003, NEW ENGL J MED, V349, P931, DOI 10.1056/NEJMoa021744
   Rogers J, 2001, TRANSPLANTATION, V72, P1666, DOI 10.1097/00007890-200111270-00016
   ROMAS E, 1994, PATHOLOGY, V26, P399
   Sayegh SE, 2004, PEDIATR TRANSPLANT, V8, P214, DOI 10.1111/j.1399-3046.2004.00190.x
   SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259
NR 25
TC 17
Z9 18
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD OCT
PY 2005
VL 9
IS 5
BP 680
EP 684
DI 10.1111/j.1399-3046.2005.00381.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 966GC
UT WOS:000232007100023
PM 16176430
ER

PT J
AU Uribe, M
   Buckel, E
   Ferrario, M
   Godoy, J
   Gonzalez, G
   Hunter, B
   Ceresa, S
   Cavallieri, S
   Berwart, F
   Herzog, C
   Santander, MT
   Calabran, L
AF Uribe, M
   Buckel, E
   Ferrario, M
   Godoy, J
   Gonzalez, G
   Hunter, B
   Ceresa, S
   Cavallieri, S
   Berwart, F
   Herzog, C
   Santander, MT
   Calabran, L
TI Pediatric liver transplantation: Ten years of experience in a
   multicentric program in Chile
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 22nd Congress of the Scandinavian-Transplantation-Society
CY JUN 02-04, 2004
CL Aarhus, DENMARK
SP Scandinavian Transplantat Soc
ID SINGLE-CENTER EXPERIENCE; FAILURE; MANAGEMENT; CHILDREN; ADULT
AB Liver transplantation is the only treatment for patients with terminal acute and chronic diseases. Liver transplantation was started in Chile in 1985; our pediatric program began in 1993. The aim of this paper work was to present our experience from 1993 through 2004. One hundred and thirty two orthotopic liver transplants (OLT) were performed in children of mean age 5 years and median age 4 years (8 months to 15 years). The most frequent indications were biliary atresia, (43.1%) and acute liver failure (ALF; 20.4%), whose frequent cause was unknown but viral hepatitis A was the second one. A complete liver was transplanted in 59 patients, reduced in 39, split in one, and as an auxiliary liver in another one. Living related liver transplantation was performed in 32 cases (24.2%), of which thirty included segments II and III, and two, a right liver. A terminal arterial anastomosis was performed in 1.02 (77.2%) recipients and a graft interposition in 32 patients (24.2%). In 16 cases, biliary reconstruction was performed through an enterobiliary anastomosis. Immunosuppression included cyclosporine (Neoral), steroids, and azathioprine with conversion to tacrolimus (Prograf) as indicated. Rejection episodes, which were always biopsy-proven, were treated either with methylprednisolone or with antibodies. Biliary complications were the most frequent (21.4%) and the second cause was vascular complications (13%). Sixty-six patients suffered an acute rejection episode. Actuarial graft survival was 81.3% at 1 year and 72% at 5 years, while actuarial graft Survival for ALF was 75.9% at 1 year and 67.8% at 5 years. Our results are comparable to those reported by most international groups.
C1 Hosp Ninos Luis Calvo Mackenna, Programa Transplante Hepat, Clin Las Condes, Santiago, Chile.
RP Uribe, M (reprint author), Fontecilla 441, Santiago, Chile.
EM muribemd@hotmail.com
CR Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   Andreu H, 2002, TRANSPLANTATION, V73, P1936, DOI 10.1097/00007890-200206270-00016
   Buckel E, 1996, REV MED CHILE, V124, P27
   Buckel E, 2003, TRANSPLANT P, V35, P2509, DOI 10.1016/j.transproceed.2003.09.024
   Dunn SP, 2003, PEDIATR TRANSPLANT, V7, P25, DOI 10.1034/j.1399-3046.2003.02040.x
   Gaspari R, 2003, ANN EMERG MED, V41, P104, DOI 10.1067/mem.2003.6
   Gridelli B, 2000, NEW ENGL J MED, V343, P404, DOI 10.1056/NEJM200008103430606
   Hepp J, 2002, REV MED CHILE, V130, P779, DOI 10.4067/S0034-98872002000700010
   Jaeck D, 2002, J GASTROENTEROL, V37, P88, DOI 10.1007/BF02990107
   Lamesch P, 2001, TRANSPLANT P, V33, P3480, DOI 10.1016/S0041-1345(01)02499-X
   Liu CL, 2003, LIVER TRANSPLANT, V9, P1185, DOI 10.1053/jlts.2003.50235
   MCDIARMID S, 1998, TRANSPLANATION, V12, P1604
   Moser MAJ, 2001, LIVER TRANSPLANT, V7, pS46, DOI 10.1053/jlts.2001.28518
   Sampathkumar P, 2000, LIVER TRANSPLANT, V6, P144, DOI 10.1002/lt.500060220
   Smets F, 2000, TRANSPLANTATION, V69, P982
   Testa G, 2001, WORLD J SURG, V25, P1296
   Uribe M, 2003, TRANSPLANT P, V35, P2511, DOI 10.1016/j.transproceed.2003.09.025
NR 17
TC 13
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD OCT
PY 2005
VL 37
IS 8
BP 3375
EP 3377
DI 10.1016/j.transproceed.2005.09.096
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 986KV
UT WOS:000233449400041
PM 16298599
ER

PT J
AU Uribe, M
   Buckel, E
   Ferrario, M
   Godoy, J
   Gonzalez, G
   Ceresa, S
   Hunter, B
   Cavallieri, S
   Berwart, F
   Blanco, A
   Smok, G
   Calabran, L
   Herzog, C
   Santander, MT
AF Uribe, M
   Buckel, E
   Ferrario, M
   Godoy, J
   Gonzalez, G
   Ceresa, S
   Hunter, B
   Cavallieri, S
   Berwart, F
   Blanco, A
   Smok, G
   Calabran, L
   Herzog, C
   Santander, MT
TI Living related liver transplantation. Why this option has been discarded
   in a pediatric liver transplant program in Chile
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 22nd Congress of the Scandinavian-Transplantation-Society
CY JUN 02-04, 2004
CL Aarhus, DENMARK
SP Scandinavian Transplantat Soc
ID CHILDREN; DONORS
AB Living related living transplantation (LRLT) has opened new possibilities for planning transplantation in better conditions for children with emergency situations and chronic liver diseases. Since we began the LRLT program in 1999, we have performed 57 pediatric liver transplants, 17 (29.8%) using living related donors (LRD). The aim of this study was to analyze the reasons why LRD were discarded as a therapeutic option. All pediatric patients were prospectively included in our Microsoft Excel database that was reviewed for obtaining information about causes why the LRLT could not be done. LRLT was proposed in 28 cases and performed in 17 (60.7%). The reasons for LRD rejection were: parent's fear of surgical complications in four cases; drug abuse in two; a mother without family support; medical reasons in two; and only one, due to anatomical reasons and in one case, cadaveric graft transplantation was performed while completing the father's evaluation. From these eleven cases, the indications for liver transplant were acute liver failure (ALF) in seven, biliary atresia in three, and Alagille syndrome in one. Nine were transplanted with cadaveric organs, but two patients with ALF died awaiting a liver. Efforts should be made to clarify the advantages and the disadvantages of LRD in each case, allowing parents to make a free, well-informed decision.
C1 Hosp Ninos Luis Calvo Mackenna, Programa Transplante Hepat, Clin Las Condes, Santiago, Chile.
RP Uribe, M (reprint author), Fontecilla 441, Santiago, Chile.
EM muribemd@hotmail.com
CR BAKER EA, 1999, BRIT J SURG, V86, P2005
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Broering DC, 2003, CHIRURG, V74, P951, DOI 10.1007/s00104-003-0693-8
   Chen YS, 2003, TRANSPLANTATION, V75, pS16, DOI 10.1097/01.TP.0000046535.49186.EB
   EMOND JC, 1993, TRANSPLANTATION, V55, P835, DOI 10.1097/00007890-199304000-00029
   Leni Davide, 2004, Radiol Med, V107, P58
   LIU CL, 2003, LIVER TRANSPLANT, V11, P1185
   McDiarmid SV, 2003, PEDIATR CLIN N AM, V50, P1335, DOI 10.1016/S0031-3955(03)00150-0
   Moreno Gonzalez E., 2003, Transplantation Proceedings, V35, P1787, DOI 10.1016/S0041-1345(03)00666-3
   TAN KC, 1992, BRIT J SURG, V79, P1192, DOI 10.1002/bjs.1800791130
NR 10
TC 3
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD OCT
PY 2005
VL 37
IS 8
BP 3378
EP 3379
DI 10.1016/j.transproceed.2005.09.097
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 986KV
UT WOS:000233449400042
PM 16298600
ER

PT J
AU Dalgic, A
   Ozcay, F
   Arslan, G
   Emiroglu, R
   Sozen, H
   Moray, G
   Karakayali, H
   Bilgin, N
   Haberal, M
AF Dalgic, A
   Ozcay, F
   Arslan, G
   Emiroglu, R
   Sozen, H
   Moray, G
   Karakayali, H
   Bilgin, N
   Haberal, M
TI Living-related liver transplantation in pediatric patients
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Middle-East-Society-for-Organ-Transplantation
CY DEC 06-10, 2004
CL Ankara, TURKEY
SP Middle E Soc Organ Transplantat
ID EXPERIENCE; CHILDREN; COMPLICATIONS; INFECTION; PATTERNS
AB Introduction. Many developments in surgical technique, immunosuppression, and patient selection criteria have led to improved long-term patient and graft survival in pediatric patients receiving liver transplants. In this study, we examined the early results of 26 pediatric recipients who underwent 26 liver transplantations between January 2003 and December 2004 at our institution.
   Materials and methods. The most common indications for liver transplantation were cholestasis in 10 patients (38.5%) and Wilson's disease in 8 (30.8%). Other indications were fulminant hepatic failure (4 patients, 15.4%), tyrosinemia (2 patients, 7.7%), Caroli disease (1 patient, 3.8%), and cryptogenic cirrhosis (1 patient, 3.8%). One recipient with Byler disease and two with tyrosinemia also had incidental hepatocellular carcinoma.
   Results. Of 26 patients, 24 (92.3%) underwent living-related liver transplantation and 2 (7.7%) underwent cadaveric transplantation. The medical records of all patients were retrospectively reviewed. Twenty-two of 26 survived with excellent graft function, showing 91.2%, 86.4%, and 81.6% at 3, 12, and 24 months graft and patient survival rates, respectively. Sixteen patients (61.5%) developed various morbidities with biliary and vascular complications being the most common. Four patients (15.3%) developed bile leaks. Four patients (15.3%) developed hepatic artery thromboses. Five patients (19.2%) developed life-threatening infections. Four patients (15.4%) died during the study period, three owing to infectious complications. The other patient died due to acute respiratory distress syndrome.
   Conclusion. Despite technical difficulties and a donor organ shortage, the results of liver transplantation in pediatric patients with end-stage liver disease have demonstrated promising results at our institution.
C1 Baskent Univ Hosp, Dept Gen Surg, TR-06490 Ankara, Turkey.
   Dept Pediat, Ankara, Turkey.
   Dept Anesthesiol, Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ Hosp, Dept Gen Surg, 5 Sok 48 Behcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR BARKHOLT L, 1993, TRANSPLANT INT, V6, P77, DOI 10.1111/j.1432-2277.1993.tb00755.x
   BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   DALESSANDRO AM, 1993, TRANSPLANTATION, V55, P1083, DOI 10.1097/00007890-199305000-00028
   DALGIC A, 2004, EXP CLIN TRANSPLAN S, V2, P21
   Dalgic A, 2003, PEDIATR TRANSPLANT, V7, P149, DOI 10.1034/j.1399-3046.2003.00017.x
   EMOND JC, 1993, TRANSPLANTATION, V55, P835, DOI 10.1097/00007890-199304000-00029
   GEORGE DL, 1992, AM J DIS CHILD, V146, P924
   HABERAL M, 2004, TRANSPLANT P       S, V36, P143
   HABERAL M, 1992, TRANSPLANT P, V24, P1967
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   HABERAL M, 1991, TRANSPLANT P, V23, P2563
   HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011
   KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7
   Kalayoglu M, 1996, J AM COLL SURGEONS, V182, P381
   KALAYOGLU M, 1993, SURGERY, V114, P711
   KALAYOGLU M, 1990, SURG GYNECOL OBSTET, V171, P139
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   MCDIARMID SV, 1995, TRANSPLANTATION, V59, P530
   STOCK PG, 1987, TRANSPLANT P, V19, P3303
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   *US DEP HHS, 1989, 1999 ANN REP US SCI
   WHITINGTON PF, 1991, J PEDIATR-US, V118, P169, DOI 10.1016/S0022-3476(05)80478-0
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
NR 23
TC 6
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2005
VL 37
IS 7
BP 3133
EP 3136
DI 10.1016/j.transproceed.2005.07.004
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 973UG
UT WOS:000232547500072
PM 16213328
ER

PT J
AU Dalgic, A
   Moray, G
   Emiroglu, R
   Sozen, H
   Karakayali, H
   Boyacioglu, S
   Bilgin, N
   Haberal, M
AF Dalgic, A
   Moray, G
   Emiroglu, R
   Sozen, H
   Karakayali, H
   Boyacioglu, S
   Bilgin, N
   Haberal, M
TI Duct-to-duct biliary anastomosis with a "corner-saving suture" technique
   in living-related liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Middle-East-Society-for-Organ-Transplantation
CY DEC 06-10, 2004
CL Ankara, TURKEY
SP Middle E Soc Organ Transplantat
ID DONOR LIVER
AB Objectives. Biliary complications after living-related liver transplantation (LRLT) remain a major source of morbidity for recipients. We describe our technique and early results with 32 recipients who underwent LRLT with duct-to-duct anastomoses during the last 2 years.
   Methods. Between January 2003 and December 2004, 50 patients underwent liver transplantation in our center with overall patient and graft survival rate of 86.4% and 86.4%. Of 50 patients, 41 (82.0%; 17 adult and 24 pediatric) underwent LRLT, 32 (78.0%) of whom had duct-to-duct biliary anastomoses with a "corner-saving suture" technique.
   Results. Of 32 patients in whom duct-to-duct biliary anastomoses were performed, 4 (12.5%) had an anastomotic leak with 2 eventually developing bile duct strictures within 3 months. One patient required reoperation for a bile leak. All other anastomotic leaks and strictures were treated with percutaneous drainage and balloon dilatation with excellent outcomes. There was no long-term morbidity and no graft loss owing to biliary complications. Seven patients died during follow-up (0.5 to 25 months); 43 are doing well with optimal liver function in the early posttransplantation period.
   Conclusion. According to our early results, we recommend duct-to-duct anastomosis in LRLT when calibration of the ducts show suitable results and when there is no tension on the anastomosis site. Otherwise, Roux-en-Y hepaticojejunostomy should be performed to decrease risk of biliary complications.
C1 Baskent Univ, Fac Med, Dept Gen Surg, Transplantat Unit, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, Transplantat Unit, 1 Cadde 77, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Broelsch CE, 2003, LIVER TRANSPLANT, V9, pS50, DOI 10.1053/jlts.2003.50218
   DALGIC A, 2004, EXP CLIN TRANSPLAN S, V2, P21
   HABERAL M, 2004, TRANSPLANT P       S, V36, P143
   HABERAL M, 1992, TRANSPLANT P, V24, P1967
   Haberal M, 2004, TRANSPLANT P, V36, P1219, DOI 10.1016/j.transproceed.2004.05.035
   Johnston TD, 2000, CLIN TRANSPLANT, V14, P365, DOI 10.1034/j.1399-0012.2000.14040102.x
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
NR 7
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2005
VL 37
IS 7
BP 3137
EP 3140
DI 10.1016/j.transproceed.2005.08.046
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 973UG
UT WOS:000232547500073
PM 16213329
ER

PT J
AU Basaran, O
   Ozcay, F
   Karakayali, H
   Turan, M
   Dalgic, A
   Haberal, M
AF Basaran, O
   Ozcay, F
   Karakayali, H
   Turan, M
   Dalgic, A
   Haberal, M
TI Influence of HLA compatibility on success with living-related pediatric
   liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Middle-East-Society-for-Organ-Transplantation
CY DEC 06-10, 2004
CL Ankara, TURKEY
SP Middle E Soc Organ Transplantat
ID CROSS-MATCH; REJECTION; HISTOCOMPATIBILITY
AB It is not clear how HLA compatibility influences acute rejection and postoperative complications in cadaveric liver transplantation. Even less is known about this factor in pediatric living-related liver transplantation (LRLT). This research assessed HLA compatibility relative to rejection rates and complications in pediatric LRLT. The study retrospectively investigated data from 14 pediatric LRLTs in which the donor and recipient HLA genotypes were determined preoperatively. Three recipients (21.4%) developed biliary complications (two biliary leakage, one bile duct stenosis). Three others (21.4%) developed vascular complications (two hepatic artery thrombosis, one hepatic artery stenosis). Eight recipients (57.1%) were diagnosed with acute rejection. The incidence of acute rejection was not correlated with the number of HLA mismatches (P >.05), or with the number of HLA class I mismatches (P >.05); however, it was negatively correlated with number of HLA class 11 mismatches (P =.02). Arterial and biliary complications were not correlated with any of these categories of HLA compatibility. in conclusion, the data from this small group of patients provided no evidence that closeness of donor-recipient HLA matching influences outcome in pediatric LRLT.
C1 Baskent Univ, Fac Med, Dept Gen Surg, Div Transplantat, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Pediat, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Biochem, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, Div Transplantat, 1 Cadde 77 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Alonso EM, 1996, HEPATOLOGY, V23, P40, DOI 10.1002/hep.510230106
   Bathgate AJ, 1999, LIVER TRANSPLANT SUR, V5, P475, DOI 10.1002/lt.500050608
   Bishara A, 2002, HUM IMMUNOL, V63, P742, DOI 10.1016/S0198-8859(02)00429-9
   CHEN M, 1994, TRANSPLANT P, V26, P2695
   Doyle HR, 1996, ANN SURG, V224, P168, DOI 10.1097/00000658-199608000-00009
   GUNSON BK, 1992, TRANSPLANT P, V24, P2434
   Hathaway M, 1997, TRANSPLANTATION, V64, P54, DOI 10.1097/00007890-199707150-00011
   KNECHTLE SJ, 1993, SURGERY, V114, P667
   MARKUS BH, 1988, TRANSPLANTATION, V46, P372
   Neumann UP, 2003, TRANSPLANTATION, V75, P132, DOI 10.1097/01.TP.0000042484.98341.71
NR 10
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2005
VL 37
IS 7
BP 3151
EP 3153
DI 10.1016/j.transproceed.2005.07.009
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 973UG
UT WOS:000232547500077
PM 16213333
ER

PT J
AU Torgay, A
   Pirat, A
   Akpek, E
   Zeyneloglu, P
   Arslan, G
   Haberal, M
AF Torgay, A
   Pirat, A
   Akpek, E
   Zeyneloglu, P
   Arslan, G
   Haberal, M
TI Pulse contour cardiac output system use in pediatric orthotopic liver
   transplantation: Preliminary report of nine patients
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Middle-East-Society-for-Organ-Transplantation
CY DEC 06-10, 2004
CL Ankara, TURKEY
SP Middle E Soc Organ Transplantat
ID PULMONARY-ARTERY CATHETER; THERMODILUTION TECHNIQUE; INDICATOR; PRELOAD
AB Anesthetic management of orthotopic liver transplantation (OLT) in pediatric patients is challenging in terms of intraoperative bleeding, fluid management, and hemodynamic monitoring. The pulse contour cardiac output (PiCCO) system, a relatively new device based on the single-indicator transaortic thermodilution technique, may be useful for intraoperative hemodynamic monitoring in pediatric patients. This is a preliminary report of PiCCO use in nine children (aged 9.8 +/- 4.7 years) undergoing OLT. Hemodynamic volumetric parameters monitored by the PiCCO system were mean arterial pressure (MAP), cardiac index (0), intrathoracic blood volume index (ITBVI), extravascular lung water index (EVLWI), systemic vascular resistance index (SVRI), and stroke volume variability (SVV). All parameters were recorded at anesthesia induction (T-0), at the end of the anhepatic phase (T-anhepatic), and at the end of operation (T-end). The PiCCO system revealed similar MAP, CI, EVLWI, SVV, and SVRI values at all measurement intervals. Despite similar central venous pressure measurements, ITBVI values indicated significantly lower values at T-anhepatic than at T-0 (627 +/- 160 mL/m(2) and 751 +/- 151 mL/m(2), respectively, P =.013). There were no PiCCO catheter-related complications in any patient. These findings demonstrate that the PiCCO system is a safe, continuous, multiparameter invasive monitoring device for use in pediatric patients undergoing OLT. This system may provide valuable data during pediatric OLT and appears to be a promising monitoring tool in these patients.
C1 Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
RP Pirat, A (reprint author), Baskent Univ Hosp, 10 Sok,45 Bahcelievler, TR-06490 Ankara, Turkey.
EM arashp@baskent-ank.edu.tr
CR Della Rocca G, 2002, EUR J ANAESTH, V19, P868, DOI 10.1017/S0265021502001394
   Della Rocca G, 2002, BRIT J ANAESTH, V88, P350, DOI 10.1093/bja/88.3.350
   Diaz S, 2003, CLIN TRANSPLANT, V17, P47, DOI 10.1034/j.1399-0012.2003.02072.x
   Pirat A, 2002, TRANSPLANT P, V34, P2153, DOI 10.1016/S0041-1345(02)02887-7
   Rhodes A, 2002, INTENS CARE MED, V28, P256, DOI 10.1007/s00134-002-1206-9
   Ruperez M, 2004, PEDIATR CARDIOL, V25, P119, DOI 10.1007/s00246-003-0450-2
   Schroeder RA, 2004, J CARDIOTHOR VASC AN, V18, P438, DOI 10.1053/j.jvca.2004.05.020
   Wiesenack C, 2001, J CARDIOTHOR VASC AN, V15, P584, DOI 10.1053/jcan.2001.26536
NR 8
TC 8
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2005
VL 37
IS 7
BP 3168
EP 3170
DI 10.1016/j.transproceed.2005.07.020
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 973UG
UT WOS:000232547500083
PM 16213339
ER

PT J
AU Karakayali, H
   Boyvat, F
   Sevmis, S
   Dalgic, A
   Moray, G
   Emiroglu, R
   Haberal, M
AF Karakayali, H
   Boyvat, F
   Sevmis, S
   Dalgic, A
   Moray, G
   Emiroglu, R
   Haberal, M
TI Biliary complications and their management in pediatric liver
   transplantations: One center's experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Middle-East-Society-for-Organ-Transplantation
CY DEC 06-10, 2004
CL Ankara, TURKEY
SP Middle E Soc Organ Transplantat
ID CHOLANGIOGRAPHY; TRACT
AB Following living-donor liver transplantation, biliary complications are more prevalent among pediatric patients (< 18 years old), with reported rates varying between 15% and 30%.
   In this study, we retrospectively analyzed biliary complications observed in 21 pediatric liver transplant patients (16 boys [76.2%], 5 girls [23.8%] of ages 1 to 18 years (mean, 8.3 +/- 5.05 years) between September 2001 and June 2004. Biliary reconstruction was accomplished via a duct-to-duct anastomosis in 12 (57.1%) and a Roux-en-Y hepaticojejunostomy in 9 (42.9%) patients.
   Postoperative biliary complications were encountered in six (28.5%) patients. Four of the biliary leaks were from a duct-to-duct anastomosis and two from an hepaticojejunostomy. One (4.7%) patient who experienced biliary leakage after a duct-to-duct anastomosis developed stenosis after the leak healed; five (23.8%) had the leakage treated successfully. One patient had biliary leakage from the duct-to-duct anastomosis subsequent to a hepatic artery thrombosis. All patients with biliary leakage were treated without surgery. Mean follow-up time was 10.2 +/- 9.6 months (range, I to 26 months). Three patients died during follow-up; however, these deaths were not related to the biliary complications.
   Interventional radiologic approaches are effective to biliary complications, even when the anastomoses are heavily disrupted. In cases of biliary complication, percutaneous combined with internal drainage may prevent biliary sepsis and provide long-term patency.
C1 Baskent Univ, Fac Med, Dept Gen Surg, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, 1 Cadde 77 Bahcekievler, TR-06490 Ankara, Turkey.
EM rektorluk@baskent-ank.edu.tr
CR Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   GREIF F, 1994, ANN SURG, V219, P40, DOI 10.1097/00000658-199401000-00007
   Hintze RE, 1997, HEPATO-GASTROENTEROL, V44, P258
   Kok T, 1996, J CLIN ULTRASOUND, V24, P103, DOI 10.1002/(SICI)1097-0096(199603)24:3<103::AID-JCU1>3.0.CO;2-L
   Lake J R, 1995, Liver Transpl Surg, V1, P45
   LETOURNEAU JG, 1989, RADIOLOGY, V170, P1095
   Lorenz JM, 2001, AM J ROENTGENOL, V176, P761
   Schindel D, 2000, J PEDIATR SURG, V35, P940, DOI 10.1053/jpsu.2000.6932
   *SPLIT RES GROUP, 1999, TRANSPLANT P, V31, P374
   Testa G, 2001, WORLD J SURG, V25, P1296
NR 10
TC 10
Z9 12
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2005
VL 37
IS 7
BP 3174
EP 3176
DI 10.1016/j.transproceed.2005.07.023
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 973UG
UT WOS:000232547500085
PM 16213341
ER

PT J
AU Moray, G
   Boyvat, F
   Sevmis, S
   Karakayali, F
   Ayvaz, I
   Dalgic, A
   Torgay, A
   Haberal, M
AF Moray, G
   Boyvat, F
   Sevmis, S
   Karakayali, F
   Ayvaz, I
   Dalgic, A
   Torgay, A
   Haberal, M
TI Vascular complications after liver transplantation in pediatric patients
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 9th Congress of the Middle-East-Society-for-Organ-Transplantation
CY DEC 06-10, 2004
CL Ankara, TURKEY
SP Middle E Soc Organ Transplantat
ID HEPATIC-ARTERY THROMBOSIS
AB Vascular complications are the major cause of morbidity and mortality after liver transplantation, particularly in pediatric patients, owing to their smaller vascular diameters. Between September 2001 and June 2004, among 21 (16 boys and 5 girls) pediatric liver transplantations of mean age 8.3 +/- 5.1 years, hepatic arterial thrombosis (HAT) was diagnosed in 2 (9.5%) patients, and hepatic arterial stenosis (HAS) in 4 (19.4%). Vascular patency was evaluated with Doppler ultrasonography every 12 hours in the first postoperative week and daily in the second postoperative week. When occlusion was suspected, conventional angiography was performed.
   Thrombectomy was performed in one patient, and thrombectomy and reanastomosis were performed in another patient with HAT. Two patients with HAS were treated with balloon angioplasty. A third patient was treated with balloon angioplasty and endoluminal stent placement at the same time. The last patient with HAS had an intimae dissection, which occurred 24 hours after balloon angioplasty, that was treated with subsequent endoluminal stent placement. Mean follow-up for the patients with vascular complications was 9.5 +/- 5.7 months (range, 4 to 18 months). The overall mortality rate was 14.1% (3/21); however, no deaths were caused by vascular complication. Routine Doppler ultrasonographic evaluation is an effective choice for diagnosing vascular complications seen after liver transplantation. Immediate surgical intervention is required for acute vascular complications, whereas late complications may be treated with balloon angioplasty and/or endoluminal stent placement.
C1 Baskent Univ, Fac Med, Dept Gen Surg, Div Transplantat, TR-06490 Ankara, Turkey.
RP Haberal, M (reprint author), Baskent Univ, Fac Med, Dept Gen Surg, Div Transplantat, 1 Cadde 77 Bahcelievler, TR-06490 Ankara, Turkey.
EM rektoriuk@baskent-ank.edu.tr
CR Bong SK, 2003, AJR, V181, P467
   DUNN SP, 1994, J PEDIATR SURG, V29, P1141, DOI 10.1016/0022-3468(94)90296-8
   Glockner JF, 1999, AM J ROENTGENOL, V173, P1055
   Heffron TG, 2003, TRANSPLANT P, V35, P1447, DOI 10.1016/S0041-1345(03)00459-7
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Jiang L, 2002, CHINESE MED J-PEKING, V115, P1679
   ORONS PD, 1995, RADIOL CLIN N AM, V33, P461
   Pastacaldi S, 2001, LIVER TRANSPLANT, V7, P75, DOI 10.1053/jlts.2001.22040
   Pinna AD, 1996, TRANSPLANTATION, V62, P1584, DOI 10.1097/00007890-199612150-00010
   RABY N, 1991, AM J ROENTGENOL, V157, P167
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
NR 11
TC 30
Z9 31
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD SEP
PY 2005
VL 37
IS 7
BP 3200
EP 3202
DI 10.1016/j.transproceed.2005.08.045
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 973UG
UT WOS:000232547500092
PM 16213348
ER

PT J
AU Renoult, E
   Buteau, C
   Lamarre, V
   Turgeon, N
   Tapiero, B
AF Renoult, E
   Buteau, C
   Lamarre, V
   Turgeon, N
   Tapiero, B
TI Infectious risk in pediatric organ transplant recipients: Is it
   increased with the new immunosuppressive agents?
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE infectious risk; immunosuppressive treatment; solid organ
   transplantation; children
ID EPSTEIN-BARR-VIRUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE;
   RENAL-ALLOGRAFT REJECTION; LIVER-TRANSPLANT; MYCOPHENOLATE-MOFETIL;
   KIDNEY-TRANSPLANTATION; ADENOVIRUS INFECTION; LUNG-TRANSPLANTATION;
   HUMAN HERPESVIRUS-6; SIROLIMUS THERAPY
AB The risk of infection in pediatric organ transplant recipients is determined by several factors, including age, the types of organ transplanted and the immunosuppressive treatment which has dramatically changed over the past 10 yr. Little information has been reported regarding the infectious complications related to the current immunosuppressive protocols used in these children. This paper reviews (i) the immunosuppressive agents, focusing on their mechanisms of action and on the new regimens, (ii) the infections related to excessive immunosuppression and also anti-infectious properties or infectious adverse reactions associated with specific immunosuppressive agents. With the new immunosuppressive protocols, the advances in immunologic monitoring, microbiological diagnosis, anti-infectious prophylactic and preemptive treatments, strategies to minimize the risk of infection related to the immunosuppressive therapy are proposed.
C1 Univ Montreal, Hop St Justine, Dept Pediat, Div Infect Dis, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Hop St Justine, Dept Microbiol & Immunol, Montreal, PQ H3T 1C5, Canada.
RP Renoult, E (reprint author), Univ Montreal, Hop St Justine, Dept Pediat, Div Infect Dis, 3175 Chemin Cote Sainte Catherine, Montreal, PQ H3T 1C5, Canada.
EM erenoult@msn.com
CR ALFIERI C, 1994, ANTIMICROB AGENTS CH, V38, P126
   ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x
   Avitzur Y, 2003, J PEDIATR GASTR NUTR, V37, P91, DOI 10.1097/00005176-200307000-00017
   BALATONI CE, 2003, AM J TRANSPLANT, V3, P327
   BEVERIDGE T, 1984, LANCET, V1, P788
   Boucek MM, 2003, J HEART LUNG TRANSPL, V22, P636, DOI 10.1016/S1053-2498(03)00184-0
   Bridges ND, 1998, J THORAC CARDIOV SUR, V116, P617, DOI 10.1016/S0022-5223(98)70168-0
   BROLIDEN K, 2003, PEDIATR TRANSPLANT, V5, P320
   BROYER M, 1993, TRANSPLANT P, V25, P570
   BUCHHEIDT D, 2003, 43 INT C ANT AG CHEM, pM2057
   Campe H, 2003, PEDIATR TRANSPLANT, V7, P46, DOI 10.1034/j.1399-3046.2003.02051.x
   Carpentier L, 2003, J INFECT DIS, V188, P1853, DOI 10.1086/379834
   Charlton Michael, 2003, Clin Liver Dis, V7, P585, DOI 10.1016/S1089-3261(03)00046-1
   Cherikh WS, 2003, TRANSPLANTATION, V76, P1289, DOI 10.1097/01.TP.00000100826.58738.2B
   Dean PG, 2004, TRANSPLANTATION, V77, P1555, DOI 10.1097/01.TP.0000123082.31092.53
   Debray Dominique, 2003, Paediatr Drugs, V5, P81, DOI 10.2165/00128072-200305020-00002
   Deresinski SC, 2003, CLIN INFECT DIS, V36, P1445, DOI 10.1086/375080
   DesJardin JA, 1998, J INFECT DIS, V178, P1783, DOI 10.1086/314510
   Dharnidharka VR, 2004, AM J TRANSPLANT, V4, P384, DOI 10.1111/j.1600-6143.2004.00350.x
   Dharnidharka VR, 2002, PEDIATR TRANSPLANT, V6, P396, DOI 10.1034/j.1399-3046.2002.00021.x
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Diem HVT, 2003, TRANSPLANTATION, V75, P1664, DOI 10.1097/01.TP.0000063938.49112.C2
   Dominguez J, 2000, TRANSPLANTATION, V70, P1244, DOI 10.1097/00007890-200010270-00021
   Dror Y, 1999, TRANSPLANTATION, V67, P990, DOI 10.1097/00007890-199904150-00010
   ETTENGER RB, 2001, AM J KIDNEY DIS, V4, pS22
   Filler G, 2002, PEDIATR TRANSPLANT, V6, P411, DOI 10.1034/j.1399-3046.2002.02039.x
   Flechner SM, 2002, TRANSPLANTATION, V74, P1070, DOI 10.1097/01.TP.0000037984.17605.B9
   Flynn JT, 2001, PEDIATR TRANSPLANT, V5, P439, DOI 10.1034/j.1399-3046.2001.t01-1-00042.x
   Fridell JA, 2002, TRANSPLANTATION, V74, P1721, DOI 10.1097/01.TP.0000039334.85487.AB
   Ganschow R, 2001, LANCET, V357, P388, DOI 10.1016/S0140-6736(00)03654-0
   Ginevri F, 2003, TRANSPLANTATION, V75, P1266, DOI 10.1097/01.TP.0000061767.32870.72
   Gjertson DW, 2001, PEDIATR TRANSPLANT, V5, P5, DOI 10.1034/j.1399-3046.2001.00137.x
   Groth CG, 1999, TRANSPLANTATION, V67, P1036, DOI 10.1097/00007890-199904150-00017
   Gupta M, 2003, AM J KIDNEY DIS, V41, P212, DOI 10.1053/ajkd.2003.50006
   HAMAD A, 2003, AM J TRANSPLANT S5, V3, P189
   Heeger PS, 2002, J AM SOC NEPHROL, V13, P288
   Heffron TG, 2003, TRANSPLANTATION, V75, P2040, DOI 10.1097/01.TP.0000065740.69296.DA
   Hengster P, 1999, TRANSPLANTATION, V68, P310, DOI 10.1097/00007890-199907270-00028
   HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013
   Holmes RD, 2002, TRANSPLANTATION, V74, P367, DOI 10.1097/00007890-200208150-00013
   Husain S, 2002, CLIN INFECT DIS, V35, P53, DOI 10.1086/340867
   *INT TRANSPL REG P, 2001, 7 INT SMALL BOW TRAN
   Jamil B, 1999, TRANSPLANTATION, V68, P1597, DOI 10.1097/00007890-199911270-00027
   Jimenez-Rivera C, 2004, PEDIATR TRANSPLANT, V8, P243, DOI 10.1111/j.1399-3046.2004.00156.x
   John GT, 2003, TRANSPLANTATION, V75, P1544, DOI 10.1097/01.TP.0000061610.34110.04
   Kahan BD, 2001, TRANSPLANTATION, V72, P1181, DOI 10.1097/00007890-200110150-00001
   Kahan BD, 1999, TRANSPLANTATION, V68, P1526, DOI 10.1097/00007890-199911270-00016
   Kaufman SS, 2002, TRANSPLANT P, V34, P943, DOI 10.1016/S0041-1345(02)02683-0
   Keown P, 1996, TRANSPLANTATION, V61, P1029
   Klein NC, 2001, INFECT DIS CLIN N AM, V15, P423, DOI 10.1016/S0891-5520(05)70154-9
   Li BG, 2001, NEW ENGL J MED, V344, P947, DOI 10.1056/NEJM200103293441301
   MacDonald AS, 2001, TRANSPLANTATION, V71, P271, DOI 10.1097/00007890-200101270-00019
   Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19
   Maluccio M, 2003, TRANSPLANTATION, V76, P597, DOI 10.1097/01.TP.0000081399.75231.3B
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   McDiarmid SV, 1998, TRANSPLANTATION, V66, P1604, DOI 10.1097/00007890-199812270-00006
   Mengel M, 2003, NEPHROL DIAL TRANSPL, V18, P1190, DOI 10.1093/ndt/gfg072
   MICHAELS MG, 1992, J INFECT DIS, V165, P170
   Morelon E, 2000, NEW ENGL J MED, V343, P225, DOI 10.1056/NEJM200007203430317
   Mylonakis E, 2001, TRANSPLANTATION, V72, P1587, DOI 10.1097/00007890-200111270-00001
   OHORI NP, 1995, HUM PATHOL, V26, P1073, DOI 10.1016/0046-8177(95)90268-6
   Oz HS, 2001, TRANSPLANTATION, V72, P1464, DOI 10.1097/00007890-200110270-00025
   Page RL, 2001, PHARMACOTHERAPY, V21, P1436, DOI 10.1592/phco.21.17.1436.34434
   Pescovitz MD, 2001, AM J KIDNEY DIS, V38, pS16, DOI 10.1053/ajkd.2001.27506
   Pinchoff RJ, 2003, TRANSPLANTATION, V76, P183, DOI 10.1097/01.TP.0000072808.93060.0F
   ROBSON RA, 2003, AM J TRANSPLANT S5, V3, P187
   Rogers J, 2000, TRANSPLANTATION, V69, P2566, DOI 10.1097/00007890-200006270-00016
   Romero AJ, 2002, CLIN PHARMACOL THER, V71, P226, DOI 10.1067/mcp.2002.121911
   Rossi C, 2001, TRANSPLANTATION, V71, P288, DOI 10.1097/00007890-200101270-00021
   Rubin RH, 2001, CLIN INFECT DIS, V33, pS1, DOI 10.1086/320896
   Sarwal MM, 2001, TRANSPLANTATION, V72, P13, DOI 10.1097/00007890-200107150-00006
   Schaffner A, 2001, CLIN INFECT DIS, V33, pS9, DOI 10.1086/320898
   Schuler W, 1997, TRANSPLANTATION, V64, P36, DOI 10.1097/00007890-199707150-00008
   Seikaly M, 2001, PEDIATR TRANSPLANT, V5, P215, DOI 10.1046/j.1397-3142.2001.00001.x
   Singer SJ, 2000, NEW ENGL J MED, V343, P1815
   Singh N, 2003, LANCET INFECT DIS, V3, P156, DOI 10.1016/S1473-3099(03)00546-2
   Snydman DR, 2001, CLIN INFECT DIS, V33, pS22, DOI 10.1086/320900
   Snydman DR, 2001, CLIN INFECT DIS, V33, pS5, DOI 10.1086/320897
   STABLEIN DM, 2003, AM J TRANSPLANT S5, V3, P285
   STARZL TE, 1984, LANCET, V1, P583
   Tanner J E, 2001, Transpl Infect Dis, V3, P60, DOI 10.1034/j.1399-3062.2001.003002060.x
   THISTLETHWAITE JR, 1988, AM J KIDNEY DIS, V11, P112
   Toungouz M, 2003, TRANSPLANTATION, V75, p58S, DOI 10.1097/01.TP.0000067955.60639.D5
   Turhal NS, 1999, J CHEMOTHERAPY, V11, P410
   TURKASPA R, 1988, VIROLOGY, V167, P630, DOI 10.1016/0042-6822(88)90127-4
   Van Damme-Lombaerts R, 2002, PEDIATR TRANSPLANT, V6, P147, DOI 10.1034/j.1399-3046.2002.01070.x
   van Gelder T, 2003, TRANSPLANTATION, V75, P788, DOI 10.1097/01.TP.0000056639.74982.F9
   Vester U, 2002, TRANSPLANT P, V34, P2209, DOI 10.1016/S0041-1345(02)03204-9
   Waldmann TA, 1998, CURR OPIN IMMUNOL, V10, P507, DOI 10.1016/S0952-7915(98)80215-X
   WALKER RC, 1995, CLIN INFECT DIS, V20, P1346
   YAKUPOGLU Y, 2003, AM J TRANSPLANT, V3, P186
   Yoshikawa T, 2003, PEDIATR TRANSPLANT, V7, P11, DOI 10.1034/j.1399-3046.2003.02094.x
   Younes BS, 2000, TRANSPLANTATION, V70, P94
NR 93
TC 5
Z9 6
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2005
VL 9
IS 4
BP 470
EP 479
DI 10.1111/j.1399-3046.2005.00325.x
PG 10
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 949VP
UT WOS:000230816500009
PM 16048599
ER

PT J
AU Heffron, TG
   Welch, D
   Pillen, T
   Fasola, C
   Redd, D
   Smallwood, GA
   Martinez, E
   Atkinson, G
   Guy, M
   Nam, C
   Henry, S
   Romero, R
AF Heffron, TG
   Welch, D
   Pillen, T
   Fasola, C
   Redd, D
   Smallwood, GA
   Martinez, E
   Atkinson, G
   Guy, M
   Nam, C
   Henry, S
   Romero, R
TI Low incidence of hepatic artery thrombosis after pediatric liver
   transplantation without the use of intraoperative microscope or
   parenteral anticoagulation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hepatic artery thrombosis; living donor; pediatric liver
   transplantation; surgical complications
ID LIVING-RELATED DONORS; VASCULAR COMPLICATIONS; MICROVASCULAR SURGERY;
   SURGICAL TECHNIQUES; FACTOR-V; RECONSTRUCTION; REVASCULARIZATION;
   MUTATION; CHILDREN; INFANTS
AB The risk of hepatic artery thrombosis (HAT) after pediatric liver transplantation (PLT) has been reported to range from 0 to 25%. We report our experience focusing on the interrelationships between risk factors, surgical technique and the incidence of HAT after liver transplantation in the pediatric age group. From February 18, 1997 to December 31, 2003, 150 consecutive liver transplants were performed in 132 pediatric patients. There were similar numbers of whole grafts when compared with partial grafts, 80 (53.3%) vs. 70 (46.7%), p = 0.30. Four grafts (2.7%) developed HAT. Of the grafts with HAT, three were successfully revascularized within the first 24 h. Only one graft (0.66%) was lost to HAT. A single surgeon utilizing 3.5-6.0 magnification loupes performed all but one hepatic arterial anastomoses. All patients were followed postoperatively by a daily ultrasound protocol and with anticoagulation of aspirin and alprostadil only. Living and deceased donor left lateral segment grafts had an increased rate of HAT when compared with whole liver grafts. HAT with subsequent graft loss may be minimized in PLT with the use of surgical loupes only, anticoagulation utilizing aspirin, alprostadil, and daily ultrasounds.
C1 Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA.
   Childrens Healthcare Atlanta Egleston, Atlanta, GA USA.
   Emory Univ Hosp Pharm, Atlanta, GA USA.
   Emory Univ, Sch Med, Dept Pediat Med, Atlanta, GA 30322 USA.
   Ulsam Univ Hosp, UUCM, Ulsam, South Korea.
RP Guy, M (reprint author), 1405 Cliffon Rd, Atlanta, GA 30322 USA.
EM mark.guy@choa.org
CR BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   FIGUERAS J, 1995, TRANSPLANTATION, V59, P1356
   Furuta S, 1997, Liver Transpl Surg, V3, P388, DOI 10.1002/lt.500030405
   HASHIKURA Y, 1995, TRANSPLANTATION, V60, P1109, DOI 10.1097/00007890-199511270-00009
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   LANGNAS AN, 1991, AM J SURG, V161, P76, DOI 10.1016/0002-9610(91)90364-J
   LANGNAS AN, 1991, TRANSPLANTATION, V51, P86, DOI 10.1097/00007890-199101000-00013
   Madalosso C, 1998, TRANSPLANTATION, V66, P294, DOI 10.1097/00007890-199808150-00003
   MAZZAFERRO V, 1989, TRANSPLANTATION, V47, P971, DOI 10.1097/00007890-198906000-00011
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   MORI K, 1993, TRANSPLANT P, V25, P1093
   NAKAZATO PZ, 1993, J PEDIATR SURG, V28, P923, DOI 10.1016/0022-3468(93)90698-K
   Oh CK, 2000, CLIN TRANSPLANT, V14, P386, DOI 10.1034/j.1399-0012.2000.14040502.x
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403
   Santamaria ML, 1996, J PEDIATR SURG, V31, P600, DOI 10.1016/S0022-3468(96)90506-0
   Shackleton CR, 1997, AM J SURG, V173, P431, DOI 10.1016/S0002-9610(97)00066-4
   Sieders E, 2000, LIVER TRANSPLANT, V6, P326, DOI 10.1053/lv.2000.6146
   STAHL RL, 1990, HEPATOLOGY, V12, P553, DOI 10.1002/hep.1840120317
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   TAN K, 1988, JJ PEDIAT SURG, V23, P27
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Tanyel FC, 2000, J PEDIATR SURG, V35, P607, DOI 10.1053/jpsu.2000.0350607
   YANAGA K, 1990, ARCH SURG-CHICAGO, V125, P628
NR 26
TC 22
Z9 22
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2005
VL 9
IS 4
BP 486
EP 490
DI 10.1111/j.1399-3046.2005.00327.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 949VP
UT WOS:000230816500011
PM 16048601
ER

PT J
AU Okajima, H
   Inomata, Y
   Asonuma, K
   Ueno, M
   Ishiko, T
   Takeichi, T
   Kodera, A
   Yoshimoto, K
   Ohya, Y
AF Okajima, H
   Inomata, Y
   Asonuma, K
   Ueno, M
   Ishiko, T
   Takeichi, T
   Kodera, A
   Yoshimoto, K
   Ohya, Y
TI Duct-to-duct biliary reconstruction in pediatric living donor liver
   transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; pediatric transplantation;
   duct-to-duct anastomosis; biliary reconstruction
ID ANASTOMOSIS
AB The results of duct-to-duct biliary reconstruction in six pediatric patients who received a living donor liver transplant aged from 2 months to 11 yr old are reported. The graft was either entire or a part of the left lateral segments. The orifice of the bile duct of the graft was anastomosed to the recipients' hepatic duct in an end-to-end fashion by interrupted suture using 6-0 absorbable material. A transanastomotic external stent tube (4 Fr) was passed through the stump of the recipients' cystic duct. Mean time for reconstruction was 24 min. All the recipients survived the operation and reinitiated oral intake on postoperative day 3. There were no early biliary complications. One 5-yr-old boy suffered from an anastomotic stenosis 9 months after transplantation. He underwent re-anastomosis by Roux-en Y (R-Y) procedure and recovered uneventfully. Duct-to-duct anastomosis in pediatric living donor liver transplantation has benefits while the complication rate is comparable to R-Y reconstruction.
C1 Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat Pediat Surg, Kumamoto 8608556, Japan.
   Kumamoto Univ, Postgrad Sch Med Sci, Dept Gastroenterol & Hepatobiliary Surg, Kumamoto 8608556, Japan.
RP Okajima, H (reprint author), Kumamoto Univ, Postgrad Sch Med Sci, Dept Transplantat Pediat Surg, 1-1-1 Honjo, Kumamoto 8608556, Japan.
EM hokajima@fc.kuh.kumamoto-u.ac.jp
CR Azoulay D, 2001, ARCH SURG-CHICAGO, V136, P1197, DOI 10.1001/archsurg.136.10.1197
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Grewal HP, 2001, ANN SURG, V233, P502, DOI 10.1097/00000658-200104000-00004
   Kiuchi T, 2001, TRANSPLANT P, V33, P1320, DOI 10.1016/S0041-1345(00)02490-8
   Malago M, 2002, LANGENBECK ARCH SURG, V387, P37, DOI 10.1007/s00423-002-0282-1
   SUGAWARA Y, 2001, TRANSPLANTATION, V73, P1348
NR 6
TC 14
Z9 16
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2005
VL 9
IS 4
BP 531
EP 533
DI 10.1111/j.1399-3046.2005.00336.x
PG 3
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 949VP
UT WOS:000230816500018
PM 16048608
ER

PT J
AU Lee, TC
   Barshes, NR
   Washburn, WK
   Halff, GA
   Carter, BA
   Karpen, SJ
   Bristow, LJ
   Scott, JD
   Goss, JA
AF Lee, TC
   Barshes, NR
   Washburn, WK
   Halff, GA
   Carter, BA
   Karpen, SJ
   Bristow, LJ
   Scott, JD
   Goss, JA
TI Split-liver transplantation using the left lateral segment: A
   collaborative sharing experience between two distant centers
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE left lateral segment; pediatric transplantation; split-liver
   transplantation
ID DONOR LIVER; UNITED-STATES; CHILDREN; RECIPIENTS; SURVIVAL; OUTCOMES;
   NEED
AB Split-liver transplantation (SLT) increases the pool of organs for pediatric orthotopic liver transplantation (pOLT). With increased collaboration and organ sharing, transplant centers can fully maximize the use of all split donor allografts. Herein, we report the collaborative results between two distant centers involved in a sharing alliance.
   The current study consists of a retrospective review of 56 pediatric LLS transplants performed at two collaborating centers between 9/1997 and 10/2003. Fifty-three patients (41% Status 1) were transplanted using 56 left lateral segment (LLS) grafts. Sixteen percent of LLS grafts were shared between the two institutions. Overall patient survival at both 1 and 3 years was 90% and 90%, respectively. Overall graft survival at both 1 and 3 years was 82% and 82%, respectively. Shared patient and graft survival was 89% and 89%, respectively. There was an 11% biliary complication and 18% vascular complication rate. Five patients required retransplantation. In conclusion, SLT increases the number of available allografts for pOLT. While SLT is technically demanding, with a significant learning curve, patient and graft survival rates compare favorably with United Network Organ Sharing (UNOS) averages. Sharing of grafts between centers is a safe and effective way to maximize organ usage and should be actively pursued through collaborative networks.
C1 Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
RP Goss, JA (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
EM jgoss@bcm.tmc.edu
CR Abt PL, 2004, LIVER TRANSPLANT, V10, P1287, DOI 10.1002/lt.20270
   Adam Rene, 2003, Liver Transpl, V9, P1231, DOI 10.1016/j.lts.2003.09.018
   Akabayashi A, 2004, TRANSPLANTATION, V77, P634, DOI 10.1097/01.TP.0000115342.98226.7C
   Broering DC, 2001, ANN SURG, V234, P713, DOI 10.1097/00000658-200112000-00002
   Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Gawad KA, 2000, TRANSPLANT P, V32, P59, DOI 10.1016/S0041-1345(99)00877-5
   Ghobrial RM, 2000, ANN SURG, V232, P312, DOI 10.1097/00000658-200009000-00003
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Lee SY, 2004, RADIOLOGY, V230, P443, DOI 10.1148/radiol.2302021318
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Rela M, 1998, ANN SURG, V227, P282, DOI 10.1097/00000658-199802000-00019
   Renz JF, 2004, ANN SURG, V239, P172, DOI 10.1097/01.sla.0000109150.89438.bd
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Sauer IM, 2001, TRANSPLANT P, V33, P1459, DOI 10.1016/S0041-1345(00)02551-3
   Vulchev A, 2004, AM J TRANSPLANT, V4, P1737, DOI 10.1111/j.1600-6143.2004.00630.x
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
NR 20
TC 18
Z9 19
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUL
PY 2005
VL 5
IS 7
BP 1646
EP 1651
DI 10.1111/j.1600-6132.2005.00911.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 933MV
UT WOS:000229635100010
PM 15943622
ER

PT J
AU Barker, CC
   Anderson, RA
   Sauve, RS
   Butzner, JD
AF Barker, CC
   Anderson, RA
   Sauve, RS
   Butzner, JD
TI GI complications in pediatric patients post-BMT
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE pediatric; gastrointestinal complications
ID BONE-MARROW-TRANSPLANTATION; HEPATIC VENOOCCLUSIVE DISEASE; STEM-CELL
   TRANSPLANTATION; VENO-OCCLUSIVE DISEASE; RISK-FACTORS;
   CLOSTRIDIUM-DIFFICILE; CYTOMEGALOVIRUS DISEASE; ACUTE-PANCREATITIS;
   CLINICAL-COURSE; WILMS-TUMOR
AB This retrospective study comprehensively examined hepatic and gastrointestinal complications post- bone marrow transplant ( BMT) in a heterogeneous group of 1 32 pediatric patients that underwent 142 transplants. Hyperbilirubinemia occurred in 28% of this population with clinically evident jaundice in 16%. Acute graft- versus- host disease ( GVHD) occurred in 46% of the population, with liver involvement in 39% and intestinal involvement in 60% of those with acute GVHD. Veno- occlusive disease ( VOD) occurred in 18% of the population. A greater increase in hepatic transaminases was noted in GVHD and VOD than nonspecific liver injury. Serum bilirubin may help to differentiate between VOD and hepatic GVHD. Biliary sludging occurred in 20% of patients and was associated with increased morbidity. Common post transplant gastrointestinal complications included mucositis in 90%, vomiting in 85% and abdominal pain in 71%. TPN support post transplant was required in 91%. Diarrhea occurred in 67% with the most common identified etiologies reported as GVHD ( 27%), viral ( 6%), Clostridium difficile ( 8%) infections and unknown ( 28%). Typhilitis developed in 3.5%. Melena or hematochezia occurred in 11 patients ( 8%). However, gastrointestinal bleeding was disproportionately represented in intensive care unit admissions ( 5/ 27) and 100 day mortality ( 5/ 21). Gastrointestinal and hepatic complications represent a major cause of morbidity and mortality in pediatric BMT recipients.
C1 Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada.
   Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada.
RP Barker, CC (reprint author), British Columbia Childrens Hosp, Rm K4-180,4480 Oak St, Vancouver, BC V6H 3V4, Canada.
EM cbarker@cw.bc.ca
CR Akpek G, 2001, BONE MARROW TRANSPL, V27, P163, DOI 10.1038/sj.bmt.1702769
   Al Otaibi A, 2002, J PEDIATR SURG, V37, P770, DOI 10.1053/jpsu.2002.32274
   Aljurf M, 1999, BONE MARROW TRANSPL, V24, P551, DOI 10.1038/sj.bmt.1701930
   Barker CC, 2003, BONE MARROW TRANSPL, V32, P79, DOI 10.1038/sj.bmt.1704069
   Bilgrami S, 1999, BONE MARROW TRANSPL, V23, P1039, DOI 10.1038/sj.bmt.1701773
   Bisogno G, 1997, MED PEDIATR ONCOL, V29, P245, DOI 10.1002/(SICI)1096-911X(199710)29:4<245::AID-MPO2>3.0.CO;2-M
   Boggio L., 2000, Bone Marrow Transplantation, V25, P321, DOI 10.1038/sj.bmt.1702134
   BRUGIERES L, 1988, BONE MARROW TRANSPL, V3, P53
   Carreras E, 1998, BLOOD, V92, P3599
   Chakrabarti S, 2000, BONE MARROW TRANSPL, V25, P277, DOI 10.1038/sj.bmt.1702164
   Claviez A, 2000, Pediatr Transplant, V4, P151, DOI 10.1034/j.1399-3046.2000.00108.x
   Essell JH, 1998, ANN INTERN MED, V128, P975
   Frisk P, 1998, ACTA PAEDIATR, V87, P579
   GUDNASON T, 1989, PEDIATR INFECT DIS J, V8, P436, DOI 10.1097/00006454-198907000-00006
   Holmberg LA, 1999, BLOOD, V94, P4029
   Kavan P, 1998, BONE MARROW TRANSPL, V21, P521, DOI 10.1038/sj.bmt.1701117
   Ko CW, 1997, BONE MARROW TRANSPL, V20, P1081, DOI 10.1038/sj.bmt.1701024
   Kottaridis PD, 2000, HAEMATOLOGICA, V85, P1116
   Kullendorff CM, 1996, EUR J PEDIATR SURG, V6, P338, DOI 10.1055/s-2008-1071010
   Locasciulli A, 1997, BLOOD, V90, P3799
   Lones MA, 2000, BONE MARROW TRANSPL, V26, P1021, DOI 10.1038/sj.bmt.1702593
   MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121
   MERESSE V, 1992, BONE MARROW TRANSPL, V10, P135
   Mirza N., 1995, Blood, V86, p218A
   Naik HR, 1996, BONE MARROW TRANSPL, V17, P285
   Nieto Y, 2000, BONE MARROW TRANSPL, V26, P109, DOI 10.1038/sj.bmt.1702471
   Ohashi K, 2000, AM J HEMATOL, V64, P32, DOI 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.3.CO;2-E
   OR R, 1992, BONE MARROW TRANSPL, V9, P383
   Ortega JA, 1997, CANCER-AM CANCER SOC, V79, P2435, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2435::AID-CNCR21>3.0.CO;2-R
   OZKAYNAK MF, 1991, BONE MARROW TRANSPL, V7, P467
   Papadopoulou A, 1996, ARCH DIS CHILD, V75, P208
   Perez-Ceballos E, 2001, EUR J HAEMATOL, V66, P130, DOI 10.1034/j.1600-0609.2001.00356.x
   PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825
   Reiss U, 2002, J PEDIAT HEMATOL ONC, V24, P746, DOI 10.1097/00043426-200212000-00013
   Roy V, 1995, BLOOD, V86, P861
   SCHULLER I, 1995, ARCH DIS CHILD, V72, P219
   SHAMBERGER RC, 1986, CANCER, V57, P603, DOI 10.1002/1097-0142(19860201)57:3<603::AID-CNCR2820570335>3.0.CO;2-K
   SHAW PJ, 1986, BONE MARROW TRANSPL, V1, P193
   SHIELDS AF, 1985, NEW ENGL J MED, V312, P529, DOI 10.1056/NEJM198502283120901
   Somervaille TCP, 1999, BONE MARROW TRANSPL, V24, P99, DOI 10.1038/sj.bmt.1701854
   WAGNER ML, 1970, AMER J ROENTGENOL RA, V109, P341
   WERLIN SL, 1992, BONE MARROW TRANSPL, V10, P65
   YOLKEN RH, 1982, NEW ENGL J MED, V306, P1009, DOI 10.1056/NEJM198204293061701
NR 43
TC 37
Z9 37
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2005
VL 36
IS 1
BP 51
EP 58
DI 10.1038/sj.bmt.1705004
PG 8
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 937ID
UT WOS:000229916900006
PM 15908980
ER

PT J
AU Shneider, BL
   Neimark, E
   Frankenberg, T
   Arnott, L
   Suchy, FJ
   Emre, S
AF Shneider, BL
   Neimark, E
   Frankenberg, T
   Arnott, L
   Suchy, FJ
   Emre, S
TI Critical analysis of the pediatric end-stage liver disease scoring
   system: A single center experience
SO LIVER TRANSPLANTATION
LA English
DT Article
ID TRANSPLANTATION; SURVIVAL
AB The Pediatric End-Stage Liver Disease (PELD) scoring system is a new nationally utilized formula developed to provide a continuous numerical assessment of the risk of death in order to allocate livers to children for transplantation. A retrospective review of the clinical course of children undergoing liver transplantation at the Mount Sinai Medical Center was performed in order to assess the effectiveness of this scoring system in the first 24 months of its utilization. Forty-eight patients underwent liver transplantation with overall patient and graft survival rates of 98% and 96%, respectively. In 23 cases the PELD scoring system determined waiting time for transplantation. Of these 23 patients, 7 moved to the intensive care unit (ICU). Only 2 of 23 patients underwent transplantation with their actual PELD score. The rest required petition for exception (17) or status I listing (4). Significant morbidity occurred while awaiting transplantation: failure to thrive (78%), ascites (73%), hemorrhage (49%), infectious complications (39%), encephalopathy (30%), peritonitis (17%), pathologic bone fractures (13%), and hepatopulmonary syndrome (9%). In patients with PELD scores granted by exception the average score that did not yield a liver offer was 38 with an average waiting time of 55 days. At the time of transplantation actual PELD score averaged 22, while the petitioned score was 40. Based upon our center's initial experience, the current PELD scoring system is not adequate. Actual PELD scores did not lead to timely allocation of livers to children. It appears that this scoring system underestimates the near-term risk of death. Urgent reassessment is required to prevent potential morbidity and mortality in children. In conclusion the United Network for Organ Sharing policy that permits granting of exceptions has circumvented these problems with the PELD scoring system.
C1 Mt Sinai Sch Med, Dept Pediat, New York, NY USA.
   Mt Sinai Sch Med, Dept Surg, New York, NY USA.
   Mt Sinai Sch Med, Recanati Miller Transplantat Inst, New York, NY USA.
RP Shneider, BL (reprint author), Mt Sinai Med Ctr, Box 1656,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM Benjamin.Shneider@mssm.edu
CR Busquets J, 2001, TRANSPLANTATION, V71, P1765, DOI 10.1097/00007890-200106270-00011
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   Kane R, 2001, TRANSPLANTATION, V72, P463
   McDiarmid SV, 2004, LIVER TRANSPLANT, V10, pS23, DOI 10.1002/lt.20272
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   OLTHOFF K, 2003, EVOLVING CONCEPTS LI
   Shinkai M, 2003, J PEDIATR SURG, V38, P1001, DOI 10.1016/S0022-3468(03)00179-9
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
NR 8
TC 23
Z9 23
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUL
PY 2005
VL 11
IS 7
BP 788
EP 795
DI 10.1002/lt.20401
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 940QH
UT WOS:000230158500010
PM 15973720
ER

PT J
AU Baccarani, U
   Adani, GL
   Risaliti, A
   Sainz-Barriga, M
   Lorenzin, D
   Chiarandini, P
   Montanaro, D
   Viale, P
   Della Rocca, G
   Bresadola, F
AF Baccarani, U
   Adani, GL
   Risaliti, A
   Sainz-Barriga, M
   Lorenzin, D
   Chiarandini, P
   Montanaro, D
   Viale, P
   Della Rocca, G
   Bresadola, F
TI Long-term results of in situ split-liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 28th National Congress of the Italian-Society-for-Organ-Transplantation
CY NOV 21-23, 2004
CL Rome, ITALY
SP Italian Soc Organ Transplantat
ID 2 ADULT RECIPIENTS; ONE DONOR LIVER; EXPERIENCE
AB Background. Split-liver transplantation (SLT) offers immediate expansion of the cadaver donor pool. The principal beneficiaries have been adult and pediatric recipients with excellent outcomes. This study analyzed a single-center experience of adult to adult in situ SLT in adult recipients.
   Patients and methods. Fourteen consecutive adult-to-adult in situ SLT have been performed at our institution since 1998. The extended right lobe comprising segment I was transplanted in to adult patients, the left lateral segment, for pediatric transplants. Results. Donors of SLT were significantly younger (P =.03) than those of whole liver transplants. Survival rates of patients receiving a split liver were 83%, 73%, and 73% at 1, 3, and 5 years after the transplant respectively and grafts of 73%, 73%, and 73% for SLT and 76%, 70%, and 66% for whole liver transplants (P =.44). The rate of biliary complication after SLT was 21%, which was comparable to that after whole organ transplantation (17%). The incidence of hepatic artery thrombosis and primary nonfunction was not significantly different between split liver and whole organ transplantation performed during the same time period (7% versus 4.6% P =.67 and 7% versus 2.6% P =.32, respectively).
   Conclusion. This limited single-center experience confirmed that both early and longterm results of SLT are comparable to those of traditional whole liver organ transplantation.
C1 Univ Hosp Udine, Dept Surg & Transplantat, Udine, Italy.
   Univ Hosp Udine, Inst Anesthesiol & Intens Care, Udine, Italy.
   Univ Hosp Udine, Inst Infect Dis, Udine, Italy.
RP Baccarani, U (reprint author), Dept Surg & Transplantat, Ple Santa Maria Misericordia Padiglione Petracco, I-33100 Udine, Italy.
EM umberto.baccarani@uniud.it
RI Sainz-Barriga, Mauricio/A-6456-2009; Sainz Barriga, Mauricio/I-2886-2012
OI Sainz-Barriga, Mauricio/0000-0002-9981-4340; Sainz Barriga,
   Mauricio/0000-0002-9981-4340
CR Andorno E, 2001, TRANSPLANT P, V33, P1420, DOI 10.1016/S0041-1345(00)02536-7
   Azoulay D, 2001, ANN SURG, V233, P565, DOI 10.1097/00000658-200104000-00013
   BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723
   BROERING D, 2001, TRANSPLANT 2001
   Colledan M, 2000, ACTA CHIR BELG, V100, P289
   DEGOYET DJ, 1995, TRANSPLANTATION, V59, P1371
   Gridelli B, 2000, NEW ENGL J MED, V343, P404, DOI 10.1056/NEJM200008103430606
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Gundlach M, 2000, LIVER TRANSPLANT, V6, P703, DOI 10.1053/jlts.2000.18503
   Humar A, 2001, AM J TRANSPLANT, V1, P366, DOI 10.1034/j.1600-6143.2001.10413.x
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   ROGIERS X, 1996, ANN SURG, V224, P31
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
NR 13
TC 6
Z9 7
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JUL-AUG
PY 2005
VL 37
IS 6
BP 2592
EP 2594
DI 10.1016/j.transproceed.2005.06.026
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 961VE
UT WOS:000231689100063
PM 16182754
ER

PT J
AU Tannuri, U
   Mello, ES
   Carnevale, FC
   Santos, MM
   Gibelli, NE
   Ayoub, AA
   Maksoud, JG
   Velhote, MCP
   Silva, MM
   Pinho, ML
   Miyatani, HT
   Maksoud, JG
AF Tannuri, U
   Mello, ES
   Carnevale, FC
   Santos, MM
   Gibelli, NE
   Ayoub, AA
   Maksoud, JG
   Velhote, MCP
   Silva, MM
   Pinho, ML
   Miyatani, HT
   Maksoud, JG
TI Hepatic venous reconstruction in pediatric living-related donor liver
   transplantation - Experience of a single center
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living donor liver transplantation; hepatic venous obstruction;
   pediatric liver transplantation; donor hepatectomy; complications of
   liver transplantation
ID VEIN RECONSTRUCTION; SURGICAL TECHNIQUES; CHILDREN; OUTFLOW;
   COMPLICATIONS; OBSTRUCTION; VENOPLASTY; SIZE
AB In pediatric patients submitted to living related liver transplantation, hepatic venous reconstruction is critical because of the diameter of the hepatic veins and the potential risk of twisting of the graft over the line of the anastomosis. The aim of the present study is to present our experience in hepatic venous reconstruction performed in pediatric living related donor liver transplantation. Fifty-four consecutive transplants were performed and two methods were utilized for the reconstruction of the hepatic vein: direct anastomosis of the orifice of the donor left or left and middle hepatic veins and the common orifice of the recipient left and middle hepatic veins (group 1-26 cases), and wide triangular anastomosis after creating a wide triangular orifice in the recipient inferior vena cava at the confluence of all the hepatic veins with an additional longitudinal incision in the inferior angle of the orifice (group 2-28 cases). In group 1, eight patients were excluded because of graft problems in the early postoperative period and five among the remaining 18 patients (27.7%) presented stricture at the site of the hepatic vein anastomosis. All these patients had to be submitted to two or three sessions of balloon dilatations of the anastomoses and in four of them a metal stent had to be placed. The liver histopathological changes were completely reversed by the placement of the stent. Among the 28 patients of the group 2, none of them presented hepatic vein stenosis (p = 0.01). The results of the present series lead to the conclusion that hepatic venous reconstruction in pediatric living donor liver transplantation must be preferentially performed by using a wide triangulation on the recipient inferior vena cava, including the orifices of the three hepatic veins. In cases of stenosis, the endovascular dilatation is the treatment of choice followed by stent placement in cases of recurrence.
C1 Univ Sao Paulo, Hosp Clin, Children Inst, Liver Transplantat Unit, Sao Paulo, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455,4 Andar,Sala 4106, Sao Paulo, Brazil.
EM uenist@usp.br
RI Tannuri, Uenis/D-3876-2012; Carnevale, Francisco /I-6135-2015; Gibelli,
   Nelson Elias Mendes/I-7176-2016; 
OI Carnevale, Francisco Cesar/0000-0003-2659-9624
CR Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   CARNEVALE FC, 2002, CARDIOVASC INTERVENT, V25, P244
   Chan KL, 1998, TRANSPLANT P, V30, P3200, DOI 10.1016/S0041-1345(98)00993-2
   Chan KL, 1998, CHINESE MED J-PEKING, V111, P610
   de Villa VH, 2000, TRANSPLANTATION, V70, P1604, DOI 10.1097/00007890-200012150-00011
   Egawa H, 1996, TRANSPLANT P, V28, P1661
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   FUNAKI B, 1995, AM J ROENTGENOL, V165, P161
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   JERUSALEM C, 1972, EUR SURG RES, V4, P189
   Kubota K, 2000, SURGERY, V128, P48, DOI 10.1067/msy.2000.106783
   Makuuchi M, 2003, TRANSPLANTATION, V75, pS23, DOI 10.1097/01.TP.0000046617.21019.17
   Mazariegos G V, 2000, Pediatr Transplant, V4, P322, DOI 10.1034/j.1399-3046.2000.00124.x
   Robles R, 1999, TRANSPLANT P, V31, P2390, DOI 10.1016/S0041-1345(99)00395-4
   Saing H, 2002, J PEDIATR SURG, V37, P1673, DOI 10.1053/jpsu.2002.36690
   Sato Y, 2003, TRANSPLANTATION, V76, P882, DOI 10.1097/01.TP.0000076492.10613.E6
   STARZL TE, 1960, SURG GYNECOL OBSTET, V111, P733
   Sugawara Y, 2002, LIVER TRANSPLANT, V8, P76, DOI 10.1053/jlts.2002.30159
   SUH KS, 2004, CURR OPIN ORGAN TRAN, V9, P90, DOI 10.1097/01.mot.0000127631.19060.51
   Sze DY, 1999, TRANSPLANTATION, V68, P446, DOI 10.1097/00007890-199908150-00018
   TANAKA K, 1994, AM J SURG, V168, P41, DOI 10.1016/S0002-9610(05)80069-8
   ZAJKO AB, 1989, RADIOLOGY, V170, P763
NR 24
TC 32
Z9 34
U1 0
U2 2
PU BLACKWELL MUNKSGAARD
PI FREDERIKSBERG C
PA 1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2005
VL 9
IS 3
BP 293
EP 298
DI 10.1111/j.1399-3046.2005.00306.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 927GP
UT WOS:000229180800005
PM 15910383
ER

PT J
AU Testa, G
   Holterman, M
   John, E
   Kecskes, S
   Abcarian, H
   Benedetti, E
AF Testa, G
   Holterman, M
   John, E
   Kecskes, S
   Abcarian, H
   Benedetti, E
TI Combined living donor liver/small bowel transplantation
SO TRANSPLANTATION
LA English
DT Article
DE pediatric transplant; small bowel transplant; living donor; liver/small
   bowel transplant; liver transplant
ID LIVER-TRANSPLANTATION; INTESTINAL TRANSPLANTATION;
   KIDNEY-TRANSPLANTATION; CHILDREN; DISEASE; GRAFTS
AB We are reporting the first known case of sequential combined living donor liver/small bowel transplantation (LDL/SBT). A 2-year-old boy born with gastroschisis and intestinal malrotation lost his entire small bowel and colon shortly after birth. He under-went a living donor small bowel transplant at 1 year of age that was lost 4 months after implantation for posttransplant lymphoproliferative disease (PTLD). He recovered from PTLD but developed total parenteral nutrition (TPN)-induced liver failure. He received a combined left lateral liver and terminal ileum transplant that we chose to perform sequentially due to the presence of preformed antibodies against his mother's tissues. The mother had no complications and a cumulative hospital stay of 7 days. At 9 months postsurgery, the patient is on full enteral nutrition and has suffered neither technical complications nor rejection. The technique described here is reproducible and makes combined living donor LDL/SBT an alternative to combined cadaveric liver-small bowel transplant.
C1 Univ Illinois, Dept Surg, Div Transplantat, Chicago, IL 60612 USA.
   Univ Illinois, Dept Surg, Div Pediat Surg, Chicago, IL 60612 USA.
   Univ Illinois, Dept Pediat, Chicago, IL 60612 USA.
RP Testa, G (reprint author), Univ Illinois, Dept Surg, Div Transplantat, MC 958,840 S Wood St,Ste 402, Chicago, IL 60612 USA.
EM gtesta@uic.edu
CR Abu-Elmagd K, 2000, ANN SURG, V232, P680, DOI 10.1097/00000658-200011000-00010
   ANDERSONSHAW L, IN PRESS J ETHICS
   Astarcioglu I, 2003, LIVER TRANSPLANT, V9, P433, DOI 10.1053/jlts.2003.50072
   BENEDETTI E, 2004, CLIN TRANSPL, V13, DOI UNSP INV134
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   de Goyet Jean de Ville de, 2000, Transplantation (Baltimore), V69, P555, DOI 10.1097/00007890-200002270-00016
   DLERIVIERE L, 2000, TRANSPLANTATION, V69, P1234
   Fishbein T, 2003, TRANSPLANTATION, V75, P564, DOI 10.1097/01.TP.0000045711.68765.84
   GRANT D, 1990, LANCET, V335, P181, DOI 10.1016/0140-6736(90)90275-A
   GRUESSNER RW, 1997, TRANSPLANTATION, V11, P271
   Gruessner RWG, 1997, ANN SURG, V226, P471, DOI 10.1097/00000658-199710000-00008
   Holterman MJ, 2003, J PEDIATR SURG, V38, P1763, DOI 10.1016/S0022-3468(03)00669-9
   Horslen SP, 2002, ANN SURG, V235, P435, DOI 10.1097/00000658-200203000-00016
   Langnas A, 2002, TRANSPLANT P, V34, P958, DOI 10.1016/S0041-1345(02)02716-1
   Marujo WC, 1999, LANCET, V353, P641, DOI 10.1016/S0140-6736(98)05658-X
   Muiesan P, 2000, TRANSPLANTATION, V69, P2323, DOI 10.1097/00007890-200006150-00017
   Nery JR, 1998, TRANSPLANT P, V30, P2640, DOI 10.1016/S0041-1345(98)00762-3
   OTTE JB, 2001, PEDIATR TRANSPLANT, V5, P16
   Panaro F, 2004, PEDIATR TRANSPLANT, V8, P65, DOI 10.1046/j.1397-3142.2003.00134.x
   RAINER WG, 2004, 2 INT C LIV DON ABD
   Reyes J, 1998, TRANSPLANTATION, V66, P489, DOI 10.1097/00007890-199808270-00013
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Sudan DL, 2001, TRANSPLANTATION, V72, P1846, DOI 10.1097/00007890-200112150-00025
   TESTA G, 2001, PEDIAT TRANSPL, V5, P1
   Testa G, 2004, ANN SURG, V240, P779, DOI 10.1097/01.sla.0000143266.59408.d7
   TZORACOLEFTHERAKIS, 2002, J TRAUMA, V53, P770
   Xenos ES, 1999, TRANSPLANT INT, V12, P63, DOI 10.1111/j.1432-2277.1999.tb00577.x
   Zielinski A, 2003, TRANSPLANTATION, V76, P547, DOI 10.1097/01.TP.0000076624.79720.14
NR 29
TC 20
Z9 22
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 27
PY 2005
VL 79
IS 10
BP 1401
EP 1404
DI 10.1097/01.TP.0000157280.75015.14
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 929WL
UT WOS:000229377200023
PM 15912110
ER

PT J
AU Cescon, M
   Spada, M
   Colledan, M
   Andorno, E
   Valente, U
   Rossi, G
   Reggiani, P
   Grazi, GL
   Tisone, G
   Majno, P
   Rogiers, X
   Santamaria, ML
   Baccarani, U
   Ettorre, GM
   Cillo, U
   Rossi, M
   Scalamogna, M
   Gridelli, B
AF Cescon, M
   Spada, M
   Colledan, M
   Andorno, E
   Valente, U
   Rossi, G
   Reggiani, P
   Grazi, GL
   Tisone, G
   Majno, P
   Rogiers, X
   Santamaria, ML
   Baccarani, U
   Ettorre, GM
   Cillo, U
   Rossi, M
   Scalamogna, M
   Gridelli, B
TI Split-liver transplantation with pediatric donors: A multicenter
   experience
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantation-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplantat Soc
DE liver transplantation; split; pediatric; donors
ID HEPATIC-ARTERY THROMBOSIS; SINGLE-CENTER EXPERIENCE; ADULT; CHILDREN;
   RECIPIENTS; RISK; NEED
AB Background. Outcomes of split-liver transplantation (SLT) with pediatric donors have never been specifically reported.
   Methods. A prospective multicenter study on SLT using donors younger than 15 years was conducted. Thirty-nine split-liver procedures generating a left lateral segment (LLS) and, an extended right graft (ERG) were performed. In three cases, no recipient was found for ERG. In all but one case, the celiac trunk was maintained with LLS. Data were available for 67 grafts (90% of the total): 38 LLSs and 9 ERGs transplanted into 46 children and 20 ERGs transplanted into 20 adults. Sixty-two (93%) grafts were used for primary transplants and five (7%) for retransplantation. SLT were performed with. 15 donors 10 years of age and less and with 24 between 11 and 15 years.
   Results. Median follow-up was 24 months. Two-year patient and graft survival were 87% and 82%. Patient and graft survivals were not significantly different between pediatric and adult recipients, between recipients from donors 10 years of age and less and those between I I and 15 years, and between recipients of LLS and ERG. Arterial complications occurred in 6% of cases (8% in the &LE; 10 year donors group, 5% in the 11-15 year donors group). The incidence of other complications was similar between groups.
   Conclusions. SLT with pediatric donors, even younger than 10 years, provided results comparable with those achievable using adult donors. The similar incidence of arterial complications among patients receiving LLS or ERG suggests that maintenance of the celiac trunk with LLS is not detrimental for right-sided grafts.
C1 Ist Mediterraneo Trapianti & Terapie Alta Special, I-90127 Palermo, Italy.
   Osped Riuniti Bergamo, Ctr Trapianti Fegato, I-24100 Bergamo, Italy.
   San Martino Univ Hosp, Genoa, Italy.
   IRCCS, Osped Maggiore, Ctr Trapianto Fegato & Polmone, Milan, Italy.
   Policlin S Orsola, Dept Surg & Transplantat, Bologna, Italy.
   Univ Roma Tor Vergata, S Eugenio Hosp, Transplantat Unit, Rome, Italy.
   Univ Hosp Geneva, Dept Surg, Transplantat Unit, Geneva, Switzerland.
   Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Hepatobiliare Chirurg & Viszerale, Hamburg, Germany.
   Hosp Univ La Paz, Dept Pediat Surg, Unit Liver Transplantat, Madrid, Spain.
   Univ Hosp Udine, Dept Surg, Udine, Italy.
   Univ Hosp Udine, Transplantat Unit, Udine, Italy.
   Regina Elena Inst Canc Res, Dept Digest Surg & Liver Transplantat, Rome, Italy.
   Univ Padua, Dipartimento Sci Chirurg & Gastroenterol, Sch Med, Padua, Italy.
   Univ Roma La Sapienza, Dept Transplant, Rome, Italy.
   Osped Maggiore Policlin, Ctr Interreg Trapianti, NITp, Ctr Transfus Immunol Trapianti, Milan, Italy.
RP Spada, M (reprint author), Ist Mediterraneo Trapianti & Terapie Alta Special, Via C Lazzaro 1, I-90127 Palermo, Italy.
EM mspada@ISMETT.edu
RI rossi, massimo/C-8411-2012; Rossi, Giorgio/M-3445-2015; 
OI Rossi, Giorgio/0000-0002-5588-1306; Cillo, Umberto/0000-0002-2310-0245;
   Ettorre, Giuseppe Maria/0000-0002-7501-5472
CR Broering DC, 2001, ANN SURG, V234, P713, DOI 10.1097/00000658-200112000-00002
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   Emond JC, 2002, LIVER TRANSPLANT, V8, P863, DOI 10.1053/jlts.2002.34639
   Emre S, 2001, LIVER TRANSPLANT, V7, P41, DOI 10.1053/jlts.2001.20940
   Ghobrial RM, 2000, ANN SURG, V232, P312, DOI 10.1097/00000658-200009000-00003
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Kilic M, 2002, TRANSPLANTATION, V73, P1252, DOI 10.1097/00007890-200204270-00011
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Le Foie C C., 1957, ETUDES ANATOMIQUES C
   Merion RM, 2004, AM J TRANSPLANT, V4, P1792, DOI 10.1111/j.1600-6143.2004.00594.x
   NASHAN B, 2001, LIVER TRANSPLANT, V7, pC94
   Noujaim HM, 2002, TRANSPLANTATION, V74, P1386, DOI 10.1097/01.TP.0000034628.29925.23
   Oh CK, 2001, TRANSPLANTATION, V71, P767, DOI 10.1097/00007890-200103270-00014
   Otte JB, 2002, SPLIT LIVER TRANSPLANTATION: THEORETICAL AND PRACTICAL ASPECTS, P3
   Pastacaldi S, 2001, LIVER TRANSPLANT, V7, P75, DOI 10.1053/jlts.2001.22040
   Rela M, 1998, ANN SURG, V227, P282, DOI 10.1097/00000658-199802000-00019
   Renz JF, 2003, AM J TRANSPLANT, V3, P1323, DOI 10.1046/j.1600-6135.2003.00254-x
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Sauer IM, 2001, TRANSPLANT P, V33, P1459, DOI 10.1016/S0041-1345(00)02551-3
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5
   Yasutomi M, 2001, LIVER TRANSPLANT, V7, P38, DOI 10.1053/jlts.2001.18482
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
NR 24
TC 4
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD MAY 15
PY 2005
VL 79
IS 9
BP 1148
EP 1153
DI 10.1097/01.TP.0000161719.44492.8B
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 925HT
UT WOS:000229044900034
PM 15880059
ER

PT J
AU Enne, M
   Pacheco-Moreira, L
   Balbi, E
   Cerqueira, A
   Santalucia, G
   Martinho, JM
AF Enne, M
   Pacheco-Moreira, L
   Balbi, E
   Cerqueira, A
   Santalucia, G
   Martinho, JM
TI Liver transplantation with monosegments. Technical aspects and outcome:
   A meta-analysis
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LIVING-DONOR; INFANTS; KILOGRAMS; GRAFT
AB The shortage of organ donors for low-weight liver transplant recipients, especially small children, has led to the development of new surgical techniques to increase the donor pool. Almost all of these techniques use the left lateral segment (Couinaud's segments II and III), but even this graft could be too large for children under 10 kg, and further reduction could be necessary. Few articles address the issue of monosegmental liver transplantation. Available articles are with small sample sizes or even case reports, which makes it difficult to draw conclusions about indication and outcome for monosegmental grafts. A search of the MEDLINE databases using the terms "Liver Transplantation" and "Monosegmental" or "Monosegments" limited to tide or abstract with publication in the English language was conducted. The data from each study were selected and analyzed, regarding donor status (living or cadaveric), donor weight, surgical techniques used in left lateral further reduction, recipient indication for liver transplantation, age and recipient weight, graft-to-recipient body weight ratio, segment utilized, type of abdominal closure, postoperative complications, and survival. Seven publications were identified from 1995 to 2004 and fulfilled the criteria. A total of 27 pediatric patients who received a monosegment transplant were identified, median age 211 days (range, 27 to 454 days) and median weight 4.6 kg (range, 2.45 to 7.4 kg). Segment III was utilized in 21 (78%) and segment II in 6 (22%). Patient survival was 85.2%. In conclusion, monosegment liver transplantation appears to be a satisfactory option for infants weighing less than 10 kg who require a liver transplant.
C1 Hosp Geral Bonsucesso, Minist Educ, Surg Serv, Liver Transplantat Program, BR-21041030 Rio De Janeiro, Brazil.
   Hosp Geral Bonsucesso, Minist Educ, Serv Hepatol, BR-21041030 Rio De Janeiro, Brazil.
   Hosp Geral Bonsucesso, Minist Educ, Serv Pediat, BR-21041030 Rio De Janeiro, Brazil.
RP Enne, M (reprint author), Hosp Geral Bonsucesso, Minist Educ, Surg Serv, Liver Transplantat Program, Av Londres 616, BR-21041030 Rio De Janeiro, Brazil.
EM marceloenne@ig.com.br
CR BISMUTH H, 1984, SURGERY, V104, P104
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Emre S, 2002, PEDIATR TRANSPLANT, V6, P43, DOI 10.1034/j.1399-3046.2002.1r072.x
   Enne M, 2004, PEDIATR TRANSPLANT, V8, P189, DOI 10.1046/j.1399-3046.2003.00140.x
   Grabhorn E, 2004, TRANSPLANTATION, V78, P235, DOI 10.1097/01.tp.0000128189.54868.18
   HOUSSIN D, 1992, SURGERY, V111, P532
   Iglesias J, 2004, PEDIATR TRANSPLANT, V8, P228, DOI 10.1111/j.1399-3046.2004.00128.x
   Kasahara M, 2003, TRANSPLANTATION, V76, P694, DOI 10.1097/01.TP.0000079446.94204.F9
   Kasahara M, 2003, TRANSPLANT P, V35, P1425, DOI 10.1016/S0041-1345(03)00445-7
   Kasahara M, 2003, J PEDIATR SURG, V38, P1108, DOI 10.1016/S0022-3468(03)00206-9
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Mentha G, 1996, TRANSPLANTATION, V62, P1176, DOI 10.1097/00007890-199610270-00026
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   RAIA S, 1989, LANCET, V2, P497
   Saing H, 1999, J PEDIATR SURG, V34, P1721, DOI 10.1016/S0022-3468(99)90653-X
   Santibanes E, 2000, LIVER TRANSPLANT, V6, P108
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   STRONG R, 1995, SURGERY, V118, P904, DOI 10.1016/S0039-6060(05)80283-1
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 20
TC 32
Z9 39
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAY
PY 2005
VL 11
IS 5
BP 564
EP 569
DI 10.1002/lt.20421
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 921AV
UT WOS:000228737500013
PM 15838874
ER

PT J
AU Vendryes, C
   McLaughlin, GE
   Romaguera, RL
   Sola, J
   Kato, T
AF Vendryes, C
   McLaughlin, GE
   Romaguera, RL
   Sola, J
   Kato, T
TI Open lung biopsy in pediatric patients with respiratory failure after
   abdominal transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biopsy; lung diseases; interstitial; liver transplantation; intestinal
   transplantation; respiratory insufficiency; adenovirus; respiratory
   syncytial virus; graft-vs.-host disease; Epstein-Barr virus infections
ID BONE-MARROW TRANSPLANTATION; PULMONARY COMPLICATIONS;
   LIVER-TRANSPLANTATION; VIRUS INFECTION; CHILDREN; DISEASE; RECIPIENTS;
   ADENOVIRUS; DIAGNOSIS; THERAPY
AB To understand the utility of open lung biopsy (OLB) in the evaluation of respiratory failure in pediatric abdominal organ transplant we reviewed the records of nine children in this patient population who underwent an OLB. Eight of nine patients had undergone a previous non-diagnostic bronchoalveolar lavage. Biopsies were performed at the bedside in the pediatric intensive care unit and tissue was processed by the Department of Pathology with special stains for infectious agents. There were no significant complications of OLB. A specific treatable etiology was identified in four patients (respiratory syncytial virus, adenovirus, graft-vs.-host disease and post-transplant lymphoproliferative disease), leading to a change in therapy and survival in two. Overall survival was 44%. Given the low morbidity, OLB as performed in this study appears appropriate in this patient population.
C1 Univ Miami, Sch Med, Dept Pediat, Miami, FL 33130 USA.
   Univ Miami, Sch Med, Dept Pathol, Miami, FL 33130 USA.
   Univ Miami, Sch Med, Dept Surg, Miami, FL 33130 USA.
RP McLaughlin, GE (reprint author), Univ Miami, Sch Med, Dept Pediat, POB 016960 R-131, Miami, FL 33130 USA.
EM gmclaugh@med.miami.edu
CR Carter BA, 2002, TRANSPLANTATION, V74, P1050, DOI 10.1097/00007890-200210150-00027
   Davies L, 1997, PEDIATRICS, V99, P660, DOI 10.1542/peds.99.5.660
   ETTINGER NA, 1991, AM REV RESPIR DIS, V143, P1386
   Fan LL, 1997, J PEDIATR-US, V131, P565, DOI 10.1016/S0022-3476(97)70063-5
   Hayes-Jordan A, 2002, J PEDIATR SURG, V37, P446, DOI 10.1053/jpsu.2002.30854
   Izraeli S, 1996, PEDIATR INFECT DIS J, V15, P112, DOI 10.1097/00006454-199602000-00005
   Jaklitsch MT, 2001, ANN THORAC SURG, V71, P1779, DOI 10.1016/S0003-4975(01)02516-4
   JENSEN WA, 1986, TRANSPLANTATION, V42, P484, DOI 10.1097/00007890-198611000-00008
   Kornecki A, 2001, CRIT CARE MED, V29, P1247, DOI 10.1097/00003246-200106000-00035
   KROWKA MJ, 1989, CLIN CHEST MED, V10, P593
   MCCUBBIN MM, 1992, PEDIATR PULM, V12, P43, DOI 10.1002/ppul.1950120110
   McLaughlin GE, 2003, AM J TRANSPLANT, V3, P224, DOI 10.1034/j.1600-6143.2003.00007.x
   Oommen A, 1999, J ROY SOC MED, V92, P81
   Patel SR, 2004, CHEST, V125, P197, DOI 10.1378/chest.125.1.197
   SNYDER CL, 1990, J PEDIATR SURG, V25, P871, DOI 10.1016/0022-3468(90)90194-E
   Spencer DA, 1996, PEDIATR PULM, V22, P111
   Stefanutti D, 2000, J PEDIATR-US, V137, P165, DOI 10.1067/mpd.2000.106228
   THOMPSON AB, 1988, TRANSPLANT P, V20, P646
   Vilchez RA, 2002, AM J TRANSPLANT, V2, P287, DOI 10.1034/j.1600-6143.2002.20315.x
NR 19
TC 2
Z9 2
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD APR
PY 2005
VL 9
IS 2
BP 197
EP 200
DI 10.1111/j.1399-3046.2004.00283.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 909CJ
UT WOS:000227836200014
PM 15787793
ER

PT J
AU Ganschow, R
   Englert, C
   Grabhorn, E
   Richter, A
   Hinrichs, B
   Broering, DC
   Rogiers, X
   Burdelski, M
AF Ganschow, R
   Englert, C
   Grabhorn, E
   Richter, A
   Hinrichs, B
   Broering, DC
   Rogiers, X
   Burdelski, M
TI Hypogammaglobulinemia in pediatric liver transplant recipients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE hypogammaglobulinemia; liver transplantation; children
ID EXPERIENCE; DISEASE
AB Hypogammaglobulinemia has been reported after solid organ transplantation in adults, however immunoglobulin replacement [intravenous immunoglobulins (IVIG)] is only necessary in a minority of affected patients. We here present three pediatric patients with severe post-transplant hypogammaglobulinemia following liver transplantation (LTx) receiving a cyclosporine-based standard immunosuppression. Patient 1 was transplanted at the age of 10 months for biliary atresia. Eight weeks post-Ltx the serum IgG was 1.7 g/L. Patient 2 was transplanted at the age of 12 yr for acute liver failure. Four weeks post-Ltx the IgG dropped to 2.6 g/L. Patient 3 was transplanted at the age of 4 months for biliary atresia. Ten weeks post-Ltx severe hypogammaglobulinemia (IgG < 1.48 g/L) was diagnosed during a severe infectious complication. Patients 1 and 3 received a steroid bolus therapy for acute graft rejection. All patients had normal IgG concentrations prior to Ltx and lymphocyte subsets were post-operatively in the normal range. There was no extensive loss of protein by ascites. IGIV were replaced in the three patients monthly without further complications. In two of the patients (1 and 3) IVIG therapy was discontinued 8 and 10 months after Ltx when the immunosuppression has been reduced and serum IgG concentrations were found in the normal range without further immunoglobulin replacement. Severe hypogammaglobulinemia is a rare phenomenon following pediatric LTx and seems to be mainly caused by immunosuppressive drugs, however, the exact underlying mechanisms are unclear. A screening for hypogammaglobulinemia is useful after pediatric LTx, especially in patients with an intensified immunosuppression. Moreover, further immunologic research in affected patients is necessary.
C1 Univ Hamburg, Dept Pediat, Div Pediat Immunol, D-20246 Hamburg, Germany.
   Univ Hamburg, Dept Hepatobiliary Surg, D-20246 Hamburg, Germany.
RP Ganschow, R (reprint author), Univ Hamburg, Dept Pediat, Div Pediat Immunol, Martinistr 52, D-20246 Hamburg, Germany.
EM ganschow@uke.uni-hamburg.de
RI Broering, Dieter/B-1890-2010; Grabhorn, Enke/F-9785-2011
CR Corales R, 2000, Transpl Infect Dis, V2, P133, DOI 10.1034/j.1399-3062.2000.020306.x
   de la Concha EG, 1999, CLIN EXP IMMUNOL, V116, P516
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   Ganschow R, 2001, PEDIATR TRANSPLANT, V5, P353, DOI 10.1034/j.1399-3046.2001.00020.x
   Ganschow R, 2001, PEDIATR TRANSPLANT, V5, P60, DOI 10.1034/j.1399-3046.2001.00026.x
   Goldfarb NS, 2001, TRANSPLANTATION, V71, P242, DOI 10.1097/00007890-200101270-00013
   Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x
   LEE WA, 1990, PHARMACEUT RES, V7, P161, DOI 10.1023/A:1015828802490
   POLLOCK CA, 1989, TRANSPLANTATION, V47, P952, DOI 10.1097/00007890-198906000-00007
   SMOLIN MR, 1988, AM J KIDNEY DIS, V11, P267
   Verschuuren EAM, 2002, TRANSPLANTATION, V73, P100, DOI 10.1097/00007890-200201150-00019
   Yamani MH, 2001, J HEART LUNG TRANSPL, V20, P425, DOI 10.1016/S1053-2498(00)00331-4
   YU DTY, 1974, J CLIN INVEST, V53, P565, DOI 10.1172/JCI107591
NR 13
TC 8
Z9 8
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD APR
PY 2005
VL 9
IS 2
BP 215
EP 219
DI 10.1111/j.1399-3046.2005.00291.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 909CJ
UT WOS:000227836200017
PM 15787796
ER

PT J
AU Stelzmueller, I
   Dunst, KM
   Hengster, P
   Wykypiel, H
   Steurer, W
   Wiesmayr, S
   Margreiter, R
   Bonatti, H
AF Stelzmueller, I
   Dunst, KM
   Hengster, P
   Wykypiel, H
   Steurer, W
   Wiesmayr, S
   Margreiter, R
   Bonatti, H
TI A cluster of rotavirus enteritis in adult transplant recipients
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE cyclosporin A; diarrhea; immunosuppression; rotavirus; tacrolimus;
   transplantation
ID TACROLIMUS; DIARRHEA; CHILDREN
AB Diarrhea following solid organ transplantation is a common side effect of some immunosuppressive agents but can also be caused by many pathogens. An outbreak of rotavirus (RV) enteritis presenting with severe diarrhea in four solid organ recipients was analyzed. The first case was diagnosed in a 6-month-old liver recipient who was prehospitalized on a pediatric ward. Within 1 month, three adult patients (two liver, one renal recipient) presented with enteritis. During diarrhea a significant rise in tacrolimus levels was observed. One patient developed toxic megacolon with ulcerative colitis. Infections were selflimiting but led to secondary infectious complications and prolonged hospitalization. This is the first reported outbreak of RV enteritis in a multiorgan transplant unit involving adult patients. Although no fingerprinting or subtyping of the virus was performed we assume the child was the primary source. In transplant recipients presenting with diarrhea RV infection should be considered.
C1 Univ Innsbruck Hosp, Dept Gen & Transplant Surg, A-6020 Innsbruck, Austria.
   Univ Innsbruck Hosp, Dept Cardiac Surg, A-6020 Innsbruck, Austria.
RP Bonatti, H (reprint author), Univ Innsbruck Hosp, Dept Gen & Transplant Surg, Anichstr 35, A-6020 Innsbruck, Austria.
EM hugo.bonatti@uklibk.ac.at
CR Berengue JI, 2003, CLIN TRANSPLANT, V17, P249, DOI 10.1034/j.1399-0012.2003.00043.x
   Farthing MJG, 2001, NOVART FDN SYMP, V238, P289
   Fruhwirth M, 2001, PEDIATR TRANSPLANT, V5, P88, DOI 10.1034/j.1399-3046.2001.005002088.x
   Hochleitner BW, 2001, TRANSPLANT INT, V14, P230, DOI 10.1007/s001470100331
   MAES BD, 2003, TRANSPLANTATION, V15, P665
   Midthun K, 1996, CLIN MICROBIOL REV, V9, P423
   Mittal N, 2001, PEDIATR TRANSPLANT, V5, P75, DOI 10.1034/j.1399-3046.2001.005002075.x
   Parashar UD, 1998, EMERG INFECT DIS, V4, P561
   PEIGUELAFEUILLE H, 1991, J HOSP INFECT, V18, P67, DOI 10.1016/0195-6701(91)90095-P
NR 9
TC 23
Z9 24
U1 1
U2 1
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0934-0874
J9 TRANSPLANT INT
JI Transpl. Int.
PD APR
PY 2005
VL 18
IS 4
BP 470
EP 474
DI 10.1111/j.1432-2277.2004.00073.x
PG 5
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 922XI
UT WOS:000228872800018
PM 15773970
ER

PT J
AU Samyn, M
   Cheeseman, P
   Bevis, L
   Taylor, R
   Samaroo, B
   Buxton-Thomas, M
   Heaton, N
   Rela, M
   Mieli-Vergani, G
   Dhawan, A
AF Samyn, M
   Cheeseman, P
   Bevis, L
   Taylor, R
   Samaroo, B
   Buxton-Thomas, M
   Heaton, N
   Rela, M
   Mieli-Vergani, G
   Dhawan, A
TI Cystatin C, an easy and reliable marker for assessment of renal
   dysfunction in children with liver disease and after liver
   transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; SERUM CONCENTRATION; BIOLOGICAL-FLUIDS;
   DIAGNOSTIC-VALUE; CREATININE; BETA(2)-MICROGLOBULIN; RECIPIENTS;
   INHIBITOR; CIRRHOSIS; FAILURE
AB Renal dysfunction of variable severity is being increasingly recognized as a major complication of calcineurin inhibitors (CI), in some patients even necessitating renal transplantation. Close and effective monitoring of the renal function is indicated. Current methods for this monitoring are calculation of the glomerular filtration rate (GFR) based on creatinine or exogenous substances like Cr-51-EDTA. The first method is unreliable in children and the second is expensive and cumbersome. Cystatin C has been shown to be an accurate marker of glomerular filtration but has not been evaluated in a large cohort of pediatric patients before and after liver transplantation (LT). We evaluated the accuracy of cystatin C in 62 children (30 Male) with LT, who had their Cr-51-EDTA measured on 40 occasions prior to LT and on 47 occasions after LT. The reciprocal of cystatin C correlated better with Cr-51-EDTA GFR (r = .78) than the reciprocal of creatinine (r = .40). Diagnostic accuracy in the identification of reduced GFR was assessed by ROC analysis. Cystatin C yielded the highest area under the ROC curve (AUC) in all groups assessed. From these data a cutoff level of cystatin C predicting Cr-51-EDTA GFR < 80 ml/min/1.73m(2) was calculated. A level of 1.06 mg/L was found to have a sensitivity of 91% and a specificity of 81%. Applying this cutoff level in our patient group would have avoided Cr-51-EDTA GFR estimation in 43 of the 87 estimations. In conclusion, the use of this simple test could be recommended as screening of renal dysfunction in children with liver disease and after LT.
C1 Kings Coll Hosp London, Dept Child Hlth, Paediat Liver Serv, London SE5 9RS, England.
   Kings Coll Hosp London, Dept Nucl Med, London SE5 9RS, England.
   Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England.
RP Dhawan, A (reprint author), Kings Coll Hosp London, Dept Child Hlth, Paediat Liver Serv, Denmark Hill, London SE5 9RS, England.
EM anil.dhawan@kcl.ac.uk
RI Dhawan, Anil/B-6730-2009
CR ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282
   Aw MM, 2001, TRANSPLANTATION, V72, P746, DOI 10.1097/00007890-200108270-00034
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Bokenkamp A, 2002, CLIN CHEM, V48, P1123
   Bokenkamp A, 1999, CLIN CHEM, V45, P1866
   Bokenkamp A, 1998, PEDIATRICS, V101, P875, DOI 10.1542/peds.101.5.875
   Cimerman N, 2000, CLIN CHIM ACTA, V300, P83, DOI 10.1016/S0009-8981(00)00298-9
   DONADIO C, 2001, J PHARM BIOMED ANAL, V24, P35
   Filler G, 1997, CLIN CHEM, V43, P1077
   Filler G, 2002, CLIN CHEM, V48, P729
   Finney H, 1997, CLIN CHEM, V43, P1016
   Finney H, 2000, ARCH DIS CHILD, V82, P71, DOI 10.1136/adc.82.1.71
   Gerbes AL, 2002, GUT, V50, P106, DOI 10.1136/gut.50.1.106
   GRUBB A, 1992, CLIN NEPHROL, V38, pS20
   GRUBB A, 1985, ACTA MED SCAND, V218, P499
   HARMOINEN A, 2000, PEDIATR NEPHROL, V15, P463
   Hermida J, 2002, CLIN CHIM ACTA, V316, P165, DOI 10.1016/S0009-8981(01)00728-8
   Holt R I, 1998, Pediatr Transplant, V2, P76
   Holt RIG, 1997, J HEPATOL, V27, P413, DOI 10.1016/S0168-8278(97)80190-0
   Holt RIG, 1997, AM J CLIN NUTR, V65, P534
   Krieser D, 2002, PEDIATR TRANSPLANT, V6, P392, DOI 10.1034/j.1399-3046.2002.02012.x
   Laterza OF, 2002, CLIN CHEM, V48, P699
   Leung N, 2002, LIVER TRANSPLANT, V8, P600, DOI 10.1053/jlts.2002.34152
   McDiarmid S V, 1996, Kidney Int Suppl, V53, pS77
   Neau-Cransac M, 2002, CLIN TRANSPLANT, V16, P368, DOI 10.1034/j.1399-0012.2002.02028.x
   Orlando R, 2002, CLIN CHEM, V48, P850
   Plebani M, 1998, RENAL FAILURE, V20, P303, DOI 10.3109/08860229809045115
   Randers E, 1999, CLIN CHEM, V45, P1856
   RIGDEN SPA, 1994, CLIN PAEDIAT NEPHROL, P266
   Schuck O, 2002, LIVER TRANSPLANT, V8, P594, DOI 10.1053/jlts.2002.33957
   SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571
   SIMONSEN O, 1985, SCAND J CLIN LAB INV, V45, P97, DOI 10.3109/00365518509160980
   WOITAS P, 2000, CLIN CHEM, V46, P712
NR 33
TC 39
Z9 42
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD MAR
PY 2005
VL 11
IS 3
BP 344
EP 349
DI 10.1012/lt.20330
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 901QR
UT WOS:000227297500014
PM 15719405
ER

PT J
AU Almyroudis, NG
   Fuller, A
   Jakubowski, A
   Sepkowitz, K
   Jaffe, D
   Small, TN
   Kiehn, TE
   Pamer, E
   Papanicolaou, GA
AF Almyroudis, NG
   Fuller, A
   Jakubowski, A
   Sepkowitz, K
   Jaffe, D
   Small, TN
   Kiehn, TE
   Pamer, E
   Papanicolaou, GA
TI Pre- and post-engraftment bloodstream infection rates and associated
   mortality in allogeneic hematopoietic stem cell transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE bloodstream infection; allogeneic hematopoietic; stem cell
   transplantation; rates; mortality
ID BONE-MARROW-TRANSPLANTATION; NEUTROPENIC CANCER-PATIENTS;
   PLACEBO-CONTROLLED TRIAL; VIRIDANS STREPTOCOCCI; FLUCONAZOLE
   PROPHYLAXIS; RISK-FACTORS; NOSOCOMIAL INFECTIONS; FUNGAL-INFECTIONS;
   BACTEREMIA; VANCOMYCIN
AB We report on bloodstream infection (BSI) rates, risk factors, and outcome in a cohort of 298 adult and pediatric hematopoietic stein cell transplantation (HSCT) recipients at Memorial Sloan-Kettering Hospital from September 1999 through June 2003. Methods. Prospective surveillance study. BSI rates are reported per 10,000 HSCT days. Date of engraftment is defined as the first of at least 3 consecutive dates of absolute neutrophil count > 500/mm(3) after stein cell infusion. BSI severity grades: severe (intravenous antibiotics), life threatening (sepsis), or fatal (caused or contributed to death). Results. The incidence of pre- and post-engraftment BSI was 22% and 19.5%, respectively Pre-engraftment highest rates were observed for viridans streptococci (58), Enterobacteriaceae (39) and Enterococcus faecium (34). Post-engraftment rates ranged from 0.2 to 2.9 without any predominant pathogen. In multivariate analyses, pre-engraftment BSI was associated with diagnosis of chronic myelogenous leukemia, age > 18 years and peripheral blood stem cell graft; post-engraftment BSI was associated with acute graft-versus-host disease, neutropenia, and liver or kidney dysfunction. Attributable mortality was 12.5% and 1.7% for pre- and post-engraftment BSI, respectively. BSI fatality rates were 24% for viridans streptococci, 8% for E faecium, 11% for Staplylococcus aureus, and 67% for Candida. Conclusions. Pre-engraftment BSI, especially by viridans streptococci and E faecium, was associated with substantial attributable mortality Post-engraftment BST was a marker of post-transplant complications and rarely the primary cause of death.
C1 Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Clin Labs, New York, NY 10021 USA.
RP Papanicolaou, GA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave,Box 9, New York, NY 10021 USA.
EM papanicg@mskcc.org
CR BOCHUD PY, 1994, AM J MED, V97, P256, DOI 10.1016/0002-9343(94)90009-4
   Boeckh M, 2002, CLIN APPROACH INFECT, P527, DOI 10.1007/0-306-47527-8_16
   BOSTROM B, 1984, LANCET, V1, P1120
   CARLISLE PS, 1993, INFECT CONT HOSP EP, V14, P320
   CARRATALA J, 1995, CLIN INFECT DIS, V20, P1169
   Collin BA, 2001, CLIN INFECT DIS, V33, P947, DOI 10.1086/322604
   Cometta A, 2003, CLIN INFECT DIS, V37, P382, DOI 10.1086/376637
   Eilers J, 1988, Oncol Nurs Forum, V15, P325
   ELTING LS, 1992, CLIN INFECT DIS, V14, P1201
   GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301
   Hughes WT, 2002, CLIN INFECT DIS, V34, P730, DOI 10.1086/339215
   Hughes WT, 1996, HOSP EPIDEMIOLOGY IN, P618
   The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, 1993, ANN INTERN MED, V119, P584
   Jaffe D, 2004, CLIN INFECT DIS, V39, P1625, DOI 10.1086/425612
   Kirkpatrick BD, 1999, CLIN INFECT DIS, V29, P1268, DOI 10.1086/313456
   Klausner JD, 1999, INFECT CONT HOSP EP, V20, P756, DOI 10.1086/501578
   Kolbe K, 1997, BONE MARROW TRANSPL, V19, P143, DOI 10.1038/sj.bmt.1700621
   Marena C, 2001, INFECT CONT HOSP EP, V22, P510, DOI 10.1086/501942
   Marr KA, 2000, BLOOD, V96, P2055
   Marr KA, 2000, J INFECT DIS, V181, P309, DOI 10.1086/315193
   MEIER E, 2003, 41 ANN M INF DIS SOC
   Mitchell AE, 2004, BONE MARROW TRANSPL, V33, P303, DOI 10.1038/sj.bmt.1704338
   Papadopoulos EB, 1998, BLOOD, V91, P1083
   PIERARD D, 1997, FEBRILE NEUTROPENIA, P8
   Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X
   RINGDEN O, 1984, LANCET, V1, P744
   ROLSTON KVI, 2003, HOLLANDFREI CANC MED, P2633
   Rotstein C, 1999, CLIN INFECT DIS, V28, P331, DOI 10.1086/515128
   Ruescher TJ, 1998, CANCER, V82, P2275, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2275::AID-CNCR25>3.3.CO;2-8
   SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604
   SLAVIN MA, 1995, J INFECT DIS, V171, P1545
   SMALL TN, 2002, 42 INT C ANT AG CHEM, P325
   Sparrelid E, 1998, BONE MARROW TRANSPL, V22, P795, DOI 10.1038/sj.bmt.1701404
   STEINER M, 1993, AM J HEMATOL, V42, P354, DOI 10.1002/ajh.2830420405
   VILLABLANCA JG, 1990, BONE MARROW TRANSPL, V5, P387
   VISCOLI C, 1990, EUR J CANCER, V26, P569
   Williamson ECM, 1999, BRIT J HAEMATOL, V104, P560, DOI 10.1046/j.1365-2141.1999.01229.x
   Wisplinghoff H, 2003, CLIN INFECT DIS, V36, P1103, DOI 10.1086/374339
   Yadegarynia D, 2003, CLIN INFECT DIS, V37, P1144, DOI 10.1086/378305
NR 39
TC 55
Z9 60
U1 0
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1398-2273
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD MAR
PY 2005
VL 7
IS 1
BP 11
EP 17
DI 10.1111/j.1399-3062.2005.00088.x
PG 7
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 030BR
UT WOS:000236608800003
PM 15984943
ER

PT J
AU Fortina, AB
   Piaserico, S
   Alaibac, M
   Caforio, ALP
   Brandolisio, L
   Zacchello, G
   Zanon, GF
   Zancan, L
   Peserico, A
AF Fortina, AB
   Piaserico, S
   Alaibac, M
   Caforio, ALP
   Brandolisio, L
   Zacchello, G
   Zanon, GF
   Zancan, L
   Peserico, A
TI Skin disorders in patients transplanted in childhood
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE cancer; immunosuppressive drugs; infection; organ transplantation;
   pediatric; skin
ID ORGAN-TRANSPLANTATION; RECIPIENTS; DISEASES; CHILDREN; THERAPY; LESIONS;
   CANCER
AB Only few data are available on skin disorders in pediatric organ transplant recipients. In order to describe the whole range of dermatological diseases in a population of pediatric organ transplant recipients, we studied a group of 217 consecutive organ transplant recipients (168 kidney, 29 heart, 19 liver, one lung) aged < 18 years at transplantation followed at a single center. A total of 193 patients showed at least one skin disorder; 149 had more than one skin disease. The most common skin infections were warts (24.4%), pityriasis versicolor (20.7%), folliculitis (12.9%), intertrigo (6.5%); the most common drug side effects were hypertrichosis (69.6%), steroid acne (39.6%), gingival hyperplasia (29%) and severe xerosis (20.7%). Two patients (0.9%) developed nonmelanoma skin cancer. Our study summarizes the main skin complications in patients transplanted in childhood and underlines the necessity of regular dermatologic surveillance of these patients.
C1 Univ Padua, Dept Pediat, Dermatol Unit, I-35128 Padua, Italy.
   Univ Padua, Dept Dermatol, I-35128 Padua, Italy.
   Univ Padua, Dept Cardiol, I-35128 Padua, Italy.
RP Fortina, AB (reprint author), Univ Padua, Dept Pediat, Dermatol Unit, Via Giustiniani 3, I-35128 Padua, Italy.
EM belloni@pediatria.unipd.it
CR Berg D, 2002, J AM ACAD DERMATOL, V47, P1, DOI 10.1067/mjd.2002.125579
   Caforio ALP, 2000, CIRCULATION, V102, P222
   Euvrard S, 2001, J AM ACAD DERMATOL, V44, P932, DOI 10.1067/mjd.2001.113465
   Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137
   HALPERT E, 1991, J PEDIATR-US, V119, P489, DOI 10.1016/S0022-3476(05)82071-2
   MENNI S, 1991, PEDIATR DERMATOL, V8, P194, DOI 10.1111/j.1525-1470.1991.tb00858.x
   PENN I, 1994, J PEDIATR SURG, V29, P221
   Stockfleth E, 2001, TRANSPLANT P, V33, P1848, DOI 10.1016/S0041-1345(00)02743-3
NR 8
TC 9
Z9 10
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0934-0874
J9 TRANSPLANT INT
JI Transpl. Int.
PD MAR
PY 2005
VL 18
IS 3
BP 360
EP 365
DI 10.1111/j.1432-2277.2004.00069.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 907KD
UT WOS:000227714800015
PM 15730499
ER

PT J
AU Atkison, PR
   Jardine, L
   Williams, S
   Barr, RM
   Quan, D
   Wall, W
AF Atkison, PR
   Jardine, L
   Williams, S
   Barr, RM
   Quan, D
   Wall, W
TI Use of recombinant factor VIIa in pediatric patients with liver failure
   and severe coagulopathy
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID FULMINANT HEPATIC-FAILURE
AB Background. Several reports have suggested a benefit for recombinant Factor VIIa (rFVIIa) in nonhematological conditions, including liver disease and transplantation. However, there are few reports of its use in children with liver failure. Recently, we used rFVIIa in four patients with liver failure and severe coagulopathy with bleeding who demonstrated significant laboratory and clinical improvement following its use with no side effects.
   Patients and Methods. All four patients were hospitalized with liver failure, coagulopathy, and bleeding that was controlled with fresh frozen plasma, platelets, and other therapies, as indicated. Their international normalization ratios (INR) ranged from 1.7 to 5.8 (normal 0.9-1.1). All four patients received rFVIIa for bleeding episodes that were not responding to their usual therapy, for procedures with a high risk of bleeding, or both. The dose of rFVIIa ranged from 0.067 to 0.3 mg/kg. The INR improved to normal or near normal in all four patients. In all cases, bleeding stopped within 10 minutes of receiving the rFVIIa, and there were no complications observed.
   Conclusions. rFVIIa provided significant benefit in these children with liver failure and severe coagulopathy, in terms of clinical and laboratory improvement in their bleeding and coagulation profiles. There were no obvious side effects from the rFVIIa. This drug may be an important tool in the treatment of children with liver failure and more study is needed to define the optimal dosing for children.
C1 Univ Western Ontario, Childrens Hosp, London, ON N6C 2V5, Canada.
   Univ Western Ontario, London Hlth Sci Ctr, London, ON N6C 2V5, Canada.
RP Atkison, PR (reprint author), Univ Western Ontario, Childrens Hosp, 800 Commissioners Rd E, London, ON N6C 2V5, Canada.
EM paul.atkison@lhsc.on.ca
CR Bernstein D, 2000, SEMIN THROMB HEMOST, V26, P437, DOI 10.1055/s-2000-8465
   Bernstein DE, 1997, GASTROENTEROLOGY, V113, P1930, DOI 10.1016/S0016-5085(97)70013-1
   Brown JB, 2003, J PEDIATR GASTR NUTR, V37, P268, DOI 10.1097/00005176-200309000-00013
   Hendriks HGD, 2001, TRANSPLANTATION, V71, P402, DOI 10.1097/00007890-200102150-00011
   MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395
   PARAMO JA, 1993, SEMIN THROMB HEMOST, V19, P184, DOI 10.1055/s-2007-994024
   RUTHERFORD CJ, 1999, SCHIFFS DIS LIVER, P583
   Shami VM, 2003, LIVER TRANSPLANT, V9, P138, DOI 10.1053/jlts.2003.50017
NR 8
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1091
EP 1093
DI 10.1016/j.transproceed.2004.11.067
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900184
PM 15848632
ER

PT J
AU Ueda, M
   Egawa, H
   Ogawa, K
   Uryuhara, K
   Fujimoto, Y
   Kasahara, M
   Ogura, Y
   Kozaki, K
   Takada, Y
   Tanaka, K
AF Ueda, M
   Egawa, H
   Ogawa, K
   Uryuhara, K
   Fujimoto, Y
   Kasahara, M
   Ogura, Y
   Kozaki, K
   Takada, Y
   Tanaka, K
TI Portal vein complications in the long-term course after pediatric living
   donor liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID SURGICAL TECHNIQUES
AB The frequency and the outcome of patients with portal vein (PV) complications in the long-term course after pediatric living donor liver transplantation (LDLT) have rarely been reported. Between June 1990 and September 2003, 527 pediatric patients underwent primary LDLT with left lobe grafts, among which 479 patients with functioning grafts at 3 months after LDLT were included in this analysis. The ages ranged from 29 days to 17 years, 3 months (median: 1 year, 9 months) and body weight from 3.1 kg to 62.4 kg (median: 9.6 kg). Biliary cirrhosis was the most common cause for LDLT (81%). The PV was anastomosed with or without a vein graft. Thirty-nine patients (8%) showed a PV complication (stenosis: 16; obstruction: 17; thrombus: 2; twist: 3). Their ages ranged from 4 months to 17 years, 3 months (median: 1 year) and their body weight from 3.8 kg to 44.8 kg (median: 8.5 kg) at operation. PV complications were detected between 4 and 116 months (median: 14 months) after the transplant. Splenomegaly and decreased platelet counts were observed in more than 90% of the patients with a PV complication. In 27 patients (71%), interventional venoplasty was successful. Eleven patients had obstruction of the PV (2.3%) including three who showed cirrhosis; one with severe pulmonary hypertension; one death after retransplantation; and one alive after retransplantation. Moderate fibrosis was found in two patients at 3 and 2 years after the procedure, one of whom had the complication of a moderate intrapulmonary shunt. Early detection of PV stenosis with these two markers can lead to successful angioplasty and avoid graft loss.
C1 Kyoto Univ, Fac Med, Dept Transplantat Immunol, Sakyo Ku, Kyoto 6068507, Japan.
RP Ueda, M (reprint author), Kyoto Univ, Fac Med, Dept Transplantat Immunol, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.
EM mikiko@kuhp.kyoto-u.ac.jp
RI FUJIMOTO, Yasuhiro/E-6565-2010
CR BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Marwan IK, 1999, SURGERY, V125, P265, DOI 10.1067/msy.1999.95114
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   TOKUNAGA Y, 1994, J AM COLL SURGEONS, V178, P297
NR 5
TC 40
Z9 44
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1138
EP 1140
DI 10.1016/j.transproceed.2005.01.044
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900200
PM 15848648
ER

PT J
AU Corno, V
   Torri, E
   Bertani, A
   Guizzetti, M
   Lucianetti, A
   Maldini, G
   Pinelli, D
   Zambelli, M
   Aluffi, A
   Alberti, D
   Spada, M
   Gridelli, B
   Torre, G
   Colledan, M
AF Corno, V
   Torri, E
   Bertani, A
   Guizzetti, M
   Lucianetti, A
   Maldini, G
   Pinelli, D
   Zambelli, M
   Aluffi, A
   Alberti, D
   Spada, M
   Gridelli, B
   Torre, G
   Colledan, M
TI Early portal vein thrombosis after pediatric split liver transplantation
   with left lateral segment graft
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID SIZE
AB Early portal vein thrombosis (PVT) represents a serious complication after liver transplantation (OLTx). From October 1997 through July 2004, 260 OLTx were performed in 231 children, including 189 of left lateral segments (LLS). We retrospectively analyzed the incidence and the outcome of early PVT in this group. A daily doppler US scan was performed during the first week after transplantation. Early PVT occurred in 14 patients (8%), 10 males and four females of median age 0.77 years. The main indication for primary transplantation was biliary atresia (10), followed by Byler's disease (2), acute liver failure on cryptogenetic cirrhosis (1), and Alagille syndrome (1). Four children underwent retransplantation; three cases of thrombectomy and revision of the anastomosis, two children were treated with beta blockers, one of whom had a later failed attempt at percutaneous revascularization and eventually a meso-caval shunt. Five patients were followed with observation and no treatment. Among the four patients who died, three were in the retransplantation group and one in the thrombectomy and revision of the anastomosis group; the overall mortality was 28%. With a median follow up of 399 days, 10 patients are alive with an actuarial survival at 1 and 5 years of 72%, and graft survival rates at 1 and 5 years of 64%. PVT represents a serious complication after pediatric OLTx with LLS grafts. Prompt detection and aggressive surgical treatment in selected cases are required to reduce the mortality and graft loss.
C1 Osped Riuniti Bergamo, Ctr Trapianto Fegato & Polmoni, I-24128 Bergamo, Italy.
   Univ Palermo, Ctr Med, ISMETT, Palermo, Italy.
RP Colledan, M (reprint author), Osped Riuniti Bergamo, Ctr Trapianto Fegato & Polmoni, Largo Barozzi,1, I-24128 Bergamo, Italy.
EM mcolledan@ospedaliriuniti.bergamo.it
CR Broering DC, 2001, ANN SURG, V234, P713, DOI 10.1097/00000658-200112000-00002
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   CORNO V, 1999, LIVER TRANSPLANT SUR, V5, P170
   DEGOYET JD, 1995, TRANSPLANTATION, V59, P1371
   EMOND JC, 1993, SURG GYNECOL OBSTET, V176, P11
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   HOUSSIN D, 1993, BRIT J SURG, V80, P75, DOI 10.1002/bjs.1800800126
   Kuang AA, 1996, ARCH SURG-CHICAGO, V131, P887
   Millis JM, 1996, TRANSPLANTATION, V62, P748, DOI 10.1097/00007890-199609270-00008
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
NR 11
TC 17
Z9 17
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1141
EP 1142
DI 10.1016/j.transproceed.2004.11.034
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900201
PM 15848649
ER

PT J
AU Lucianetti, A
   Guizzetti, M
   Bertani, A
   Corno, V
   Maldini, G
   Pinelli, D
   Aluffi, A
   Codazzi, D
   Spotti, A
   Spada, M
   Gridelli, B
   Torre, G
   Colledan, M
AF Lucianetti, A
   Guizzetti, M
   Bertani, A
   Corno, V
   Maldini, G
   Pinelli, D
   Aluffi, A
   Codazzi, D
   Spotti, A
   Spada, M
   Gridelli, B
   Torre, G
   Colledan, M
TI Liver transplantation in children weighting less than 6 kg: The Bergamo
   experience
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
AB Liver transpantation (OLT) remains a major medical and surgical challenge in small patients. From October 1997 through July 2004, 17 babies less than 6 kg underwent 18 OLTs. Median age and weight were 3 months (range = 1 to 9) and 4.7 kg (range = 2.2 to 5.8). Two whole, one reduced, and 15 split-liver grafts (left lateral segments) were obtained from donors of median age and weight of 11.6 years (range = 0.5 to 62) and 50 kg (range = 7 to 63). Donor-to-recipient median weight ratio (D/R) was 9.1 kg (range = 1.3 to 17.6) and median graft-to-recipient weight ratio (GRWR) was 5% (range = 3.1 to 10). The incidence of biliary complications was 23%. The only vascular complication was a portal vein thrombosis (6%). Fourteen patients (79%) are alive with good graft function at a median follow-up of 39 months (range = 0.5 to 74). Three patients (all status 1) died on postoperative day 285 (brain death), 17 (multiorgan failure), and 229 (cardiovascular failure during retransplantation). Actuarial patient survivals at 6 months and 6 years are 94% and 78% while graft survivals are 89% and 74%, respectively. Currently all the patients listed as UNOS status 2 and 3 (73%) at the time of transplant are alive. During the same period one premature neonate (1.8 kg) who presented with fulminant hepatic failure died on the waiting list after 12 days. Our data confirm that the extensive use of a split-liver technique from small adult or pediatric cadaveric donors can offer the benefits of liver transplantation to small pediatric candidates with excellent results.
C1 Osped Riuniti Bergamo, Ctr Trapianti Fegato & Polmoni, I-24128 Bergamo, Italy.
   Univ Palermo, Ctr Med, ISMETT, Palermo, Italy.
RP Lucianetti, A (reprint author), Osped Riuniti Bergamo, Ctr Trapianti Fegato & Polmoni, Largo Barozzi 1, I-24128 Bergamo, Italy.
EM alucianetti@ospedaliriuniti.bergamo.it
CR Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Sundaram SS, 2003, LIVER TRANSPLANT, V9, P783, DOI 10.1053/jlts.2003.50104
NR 5
TC 14
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1143
EP 1145
DI 10.1016/j.transproceed.2004.12.307
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900202
PM 15848650
ER

PT J
AU Colledan, M
   Torri, E
   Bertani, A
   Corno, V
   Guizzetti, M
   Lucianetti, A
   Maldini, G
   Pinelli, D
   Zambelli, M
   Giovanelli, M
   Carrara, B
   Riva, S
   Alberti, D
   Passoni, M
   Spada, M
   Gridelli, B
   Torre, G
AF Colledan, M
   Torri, E
   Bertani, A
   Corno, V
   Guizzetti, M
   Lucianetti, A
   Maldini, G
   Pinelli, D
   Zambelli, M
   Giovanelli, M
   Carrara, B
   Riva, S
   Alberti, D
   Passoni, M
   Spada, M
   Gridelli, B
   Torre, G
TI Orthotopic liver transplantation for biliary atresia
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID CHILDREN; GRAFTS
AB Biliary atresia (BA) represents the most frequent indication for liver transplantation (OLTX) in the pediatric population. The aim of this paper was to present a series collected over the last 7 years from October 1997 through July 2004, including 260 pediatric OLTX in 231 patients. BA was the indication in 137 patients. There were 69 boys and 68 girls of mean weight 10.68 kg and median age 0.9 years. As a primary transplant, 99 patients received a LLS graft; 27 a whole graft; four a I+ IV-VIII segment, and two a I-IV segment. Mean follow up was 1047 days (range, 1-2496 day). Infections were diagnosed in 45 patients, vascular complications in 27 patients. Surgical complications that required reintervention occurred in 25 patients. In 41 cases biliary complications occurred, 11 requiring reintervention. 16 patients were retransplanted. In two cases another re-OLTx was performed. Currently 126 patients are alive, showing an actuarial 1 year survival of 92% and 5 year 91%, with actuarial graft survivals of 85% at 1 year and 82% at 3 and 5 years. Our results confirm the effectiveness of OLTx for the treatment of children with BA and a failed Kasai procedure. Split liver grafts represent an excellent organ supply for these patients, achieving optimal results with no mortality on the waiting list.
C1 Osped Riuniti Bergamo, Ctr Trapianti Fegato & Polmoni, I-24128 Bergamo, Italy.
   Univ Palermo, Ctr Med, ISMETT, Palermo, Italy.
RP Torri, E (reprint author), Osped Riuniti Bergamo, Ctr Trapianti Fegato & Polmoni, I-24128 Bergamo, Italy.
EM elena.torri@tiscali.it
CR Alonso G, 2004, PEDIATR TRANSPLANT, V8, P255, DOI 10.1111/j.1399-3046.2004.00160.x
   Altman RP, 1997, ANN SURG, V226, P348, DOI 10.1097/00000658-199709000-00014
   Baerg J, 2004, J PEDIATR SURG, V39, P800, DOI 10.1016/j.jpedsurg.2004.02.020
   Bates MD, 1998, SEMIN LIVER DIS, V18, P281, DOI 10.1055/s-2007-1007164
   Colledan M, 1999, LANCET, V353, P1763, DOI 10.1016/S0140-6736(99)00661-3
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   KASAI M, 1983, JPN J SURG, V13, P265, DOI 10.1007/BF02469507
   Ohi R, 2000, Clin Liver Dis, V4, P779, DOI 10.1016/S1089-3261(05)70141-0
   Subramaniam R, 2000, J PEDIATR SURG, V35, P593, DOI 10.1053/jpsu.2000.0350593
NR 10
TC 1
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1153
EP 1154
DI 10.1016/j.transproceed.2004.11.031
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900206
PM 15848654
ER

PT J
AU Maggi, U
   Caccamo, L
   Melada, E
   Gatti, S
   Rossi, G
   Reggiani, P
   Paone, G
   Giussani, A
   Bertoli, P
   Fassati, LR
AF Maggi, U
   Caccamo, L
   Melada, E
   Gatti, S
   Rossi, G
   Reggiani, P
   Paone, G
   Giussani, A
   Bertoli, P
   Fassati, LR
TI Long-term outcome of right split in situ grafts in adults
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID SINGLE-CENTER EXPERIENCE; LIVER-TRANSPLANTATION; DONOR POOL
AB In situ split liver transplants represent a technical progression from ex situ split procedures conceived to retrieve grafts for pediatric recipients. The transection line runs along the falciform ligament, so the main artery to the right graft is the right proper artery, whereas the left graft retains the main arterial axis with the celiac trunk. Although the major advantages are for pediatric recipients, due to the expanded pool of grafts available, for adult recipients the results of right split in situ grafts must be compared with whole grafts. We considered two groups of consecutive grafts transplanted since 1993 as first grafts: 20 of the former and 261 of the latter. Groups were comparable for donor gender, recipient age and gender, perfusion solution, ischemia time, and follow-up time, but not for donor age and for the number of arterial anastomoses. Although there were more major surgical complications in the former compared with the latter group (40% vs 25%), the only statistically significant difference was found in retransplantation rate for arterial complications (15% vs 2.2%). No statistical difference was observed in graft or patient actuarial survival rates at 1, 3, or 6 years after transplantation; for right split grafts these were 85%, 69%, and 69% and 95%, 79%, and 79%, respectively.
C1 IRCCS, Osped Maggiore Policlin, Ctr Trapianto Fegato & Polmone, I-20121 Milan, Italy.
RP Maggi, U (reprint author), IRCCS, Osped Maggiore Policlin, Ctr Trapianto Fegato & Polmone, Via Francesco Sforza 35, I-20121 Milan, Italy.
EM u.maggi@tiscali.it
RI Caccamo, Lucio/J-4957-2015; Gatti, Stefano/M-1780-2015; Maggi,
   Umberto/M-3074-2015; Rossi, Giorgio/M-3445-2015
OI Caccamo, Lucio/0000-0002-5292-1376; Gatti, Stefano/0000-0003-2209-4338;
   Maggi, Umberto/0000-0002-5337-2866; Rossi, Giorgio/0000-0002-5588-1306
CR Azoulay D, 2001, ANN SURG, V233, P565, DOI 10.1097/00000658-200104000-00013
   Caccamo L, 2001, TRANSPLANT P, V33, P1474, DOI 10.1016/S0041-1345(00)02558-6
   Colledan M, 2001, TRANSPLANT P, V33, P1335, DOI 10.1016/S0041-1345(00)02498-2
   GRIDELLI B, 2003, TRANSPLANTATION, V7, P1197
   MAGGI U, 2001, LIVER TRANSPLANT, V7, pC62
   Nunez A, 2003, TRANSPLANTATION, V76, P1134, DOI 10.1097/01.TP.0000088665.04964.CC
   RENZ JF, 2004, ANN SURG, V229, P172
   Renz JF, 2003, AM J TRANSPLANT, V3, P1323, DOI 10.1046/j.1600-6135.2003.00254-x
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Toso C, 2002, TRANSPLANTATION, V74, P222, DOI 10.1097/00007890-200207270-00013
   Yersiz H, 2003, ANN SURG, V238, P496, DOI 10.1097/01.sla.0000089852.29654.72
NR 12
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1170
EP 1173
DI 10.1016/j.transproceed.2005.01.053
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900211
PM 15848659
ER

PT J
AU Maldini, G
   Torri, E
   Lucianetti, A
   Guizzetti, M
   Pinelli, D
   Bertani, A
   Corno, V
   Giovanelli, M
   Zambelli, M
   Stroppa, P
   Alberti, D
   Torre, G
   Spada, M
   Gridelli, B
   Colledan, M
AF Maldini, G
   Torri, E
   Lucianetti, A
   Guizzetti, M
   Pinelli, D
   Bertani, A
   Corno, V
   Giovanelli, M
   Zambelli, M
   Stroppa, P
   Alberti, D
   Torre, G
   Spada, M
   Gridelli, B
   Colledan, M
TI Orthotopic liver transplantation for Alagille syndrome
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID ARTERIOHEPATIC DYSPLASIA; HUMAN JAGGED1; MUTATIONS
AB Alagille syndrome (AS) is a dominantly inherited, multisystem disorder involving the liver, heart, eyes, face, and skeleton. From October 1997 through July 2004, 260 pediatric orthotopic liver transplantations (OLTx) were performed in 231 patients. This report describes 21 patients of median age 1.95 years (range, 0.7-16.7) who had alagille syndrome. We present the technical features of the OLTx, incidence and type of complications, medical conditions related to the syndrome, need for retransplantation, as well as patient and graft survival rates. A split liver technique was used in 16 patients (76%) who received a left lateral segment (LLS) graft whereas 7 patients (33%) received a whole liver. Only cadaveric donors were used. The major surgical complications requiring reintervention in 11 patients (52%) included biliary problems (19%) and vascular complications (17%). One case of hepatic artery thrombosis required retransplantation. Three recipients (14%) died. All other patients are alive with an actuarial survival rate of 90% at 1 year and 80% at 5 years. The actuarial graft survival rate is 85% at 1 year and 75% at 5 years. Patients with AS, despite the associated cardiovascular anomalies, can be treated successfully by a combined approach between cardiologist, radiologist, cardiothoracic, and liver transplant surgeons. With careful planning and operative management, the results are comparable with those obtained with other more common cholestatic diseases.
C1 Osped Riuniti Bergamo, Ctr Trapianti Fegato & Polmoni, I-24128 Bergamo, Italy.
   UPMC, ISMETT, Palermo, Italy.
RP Maldini, G (reprint author), Osped Riuniti Bergamo, Ctr Trapianti Fegato & Polmoni, Largo Barozzi 1, I-24128 Bergamo, Italy.
EM gmaldini@ospedaliriuniti.bergamo.it
CR ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1
   CARDONA J, 1995, TRANSPLANTATION, V60, P339, DOI 10.1097/00007890-199508270-00007
   Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331
   Kamath BM, 2004, CIRCULATION, V109, P1354, DOI 10.1161/01.CIR.0000121361.01862.A4
   Kasahara M, 2003, TRANSPLANTATION, V75, P2147, DOI 10.1097/01.TP.0000066804.33006.17
   Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243
   MARINO IR, 1992, TRANSPLANT INT, V5, P61
   Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235
   Ovaert C, 2001, TRANSPLANTATION, V72, P345, DOI 10.1097/00007890-200107270-00034
   Sugiyama H, 2004, CATHETER CARDIO INTE, V62, P71, DOI 10.1002/ccd.20030
   TZAKIS AG, 1993, ARCH SURG-CHICAGO, V128, P337
NR 11
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1174
EP 1176
DI 10.1016/j.transproceed.2004.12.245
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900212
PM 15848660
ER

PT J
AU Varela-Fascinetto, G
   Davila-Perez, R
   Nieto-Zermeno, J
   Bracho-Blanchet, E
   Fuentes-Garcia, V
   Castaneda-Martinez, P
   Abarca-Garcia, MA
   Olivar-Lopez, V
   Caltenco-Serrano, R
   Palafox-Vaquez, H
   Hernandez-Plata, JA
   Tovilla-Mercado, JM
   Lezama-del-Valle, P
   Valencia-Mayoral, P
AF Varela-Fascinetto, G
   Davila-Perez, R
   Nieto-Zermeno, J
   Bracho-Blanchet, E
   Fuentes-Garcia, V
   Castaneda-Martinez, P
   Abarca-Garcia, MA
   Olivar-Lopez, V
   Caltenco-Serrano, R
   Palafox-Vaquez, H
   Hernandez-Plata, JA
   Tovilla-Mercado, JM
   Lezama-del-Valle, P
   Valencia-Mayoral, P
TI Experience of a successful pediatric liver transplant program in Mexico
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
AB Orthotopic liver transplantation (OLT) has been very difficult to develop in Mexico and for many years its occurrence was anecdotal. This report presents the results of a pediatric liver transplant program, analyzing the variables that affect outcomes. Between June 1998 and March 2004, 35 OLT were performed in 34 recipients including 80% cadaveric whole-organ grafts and 20% segmental grafts, with 11% from cadaveric and 9% from living donors. Most of the recipients were infants or toddlers weighing less than 15 kg. There was only 1 case of arterial thrombosis (2.8%); the graft was saved with a Kasai procedure. Biliary complications were present in 22% of cases, all resolved with reoperations. Posttransplant cytomegalovirus infection or reactivation (28%), acute rejection (25%), or posttransplant lymphoproliferative disorders (5.7%) were not a cause of graft or patient loss. Overall, 1- and 5-year patient survival rates are 77.1% and 74.2%, respectively; however, when the 1998-2000 cohort was compared with the 2001-2004 cohort, there was a significant difference in survival (P = .004). The 1-year patient survival for the later group is 91.6%. We performed the first successful living donor liver transplantation and the first simultaneous liver-kidney transplantation in a child in our country. Our results demonstrate that pediatric liver transplantation is a feasible undertaking in Mexico, with survival rates comparable to those of foreign centers.
C1 Hosp Infantil Mexico Dr Federico Gomez, Dept Transplantat, Mexico City 06720, DF, Mexico.
RP Varela-Fascinetto, G (reprint author), Hosp Infantil Mexico Dr Federico Gomez, Dept Transplantat, Dr Marquez 162,Tercer Piso, Mexico City 06720, DF, Mexico.
EM varelafas@aol.com
CR *AS MED HEP, 1997, CIRUJANO GEN S2, V19, P7
   Diliz H, 1991, Rev Gastroenterol Mex, V56, P33
   DILIZPEREZ H, 1991, TRANSPLANT P, V23, P1797
   Podgaetz Eitan, 2003, Ann Hepatol, V2, P131
   Rodriguez-Montalvo C, 2002, TRANSPLANT P, V34, P314, DOI 10.1016/S0041-1345(01)02779-8
NR 5
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1201
EP 1202
DI 10.1016/j.transproceed.2005.01.010
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900220
PM 15848668
ER

PT J
AU Jain, A
   Marcos, A
   Reyes, J
   Mazariagos, G
   Kashyap, R
   Eghtesad, B
   Marsh, W
   Fontas, P
   De Vera, M
   Costa, G
   Patel, K
   Gadomski, M
   Starzi, T
   Fung, J
AF Jain, A
   Marcos, A
   Reyes, J
   Mazariagos, G
   Kashyap, R
   Eghtesad, B
   Marsh, W
   Fontas, P
   De Vera, M
   Costa, G
   Patel, K
   Gadomski, M
   Starzi, T
   Fung, J
TI Tacrolimus for primary liver transplantation: 12 to 15 years actual
   follow-up with safety profile
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 20th International Congress of the Transplantion-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplant Soc
ID SINGLE-CENTER EXPERIENCE; CHRONIC REJECTION; CYCLOSPORINE; FK-506;
   IMMUNOSUPPRESSION; CONVERSION; SURVIVAL; REASONS; KIDNEY; FK506
AB Background. Tacrolimus has been increasingly used for liver transplantation during the last decade. The drug has immunological advantages in short- to medium-term follow-up. However, data on longitudinal follow-up are lacking.
   Aim. The aim of the present report was to examine the impact of tacrolimus in primary adult and pediatric liver transplantation (LTx) patients.
   Material and method. One thousand consecutive primary LTx patients were performed under tacrolimus between August 1989 and December 1992 were followed up until August 2004. Mean follow-up was 13.4 +/- 0.92 (range, 11.7-15) years. There were 600 males and 400 females with a mean age of 42.6 +/- 20.2 years. There were 166 children (age 18 years or younger) and 834 adults, of whom 204 were older than 60 years (seniors).
   Results. Four hundred ninety-seven (49.7%) patients died in the follow-up period. The overall 15-year actuarial patient survival rate was 51.4%. The survival rate for children was significantly better (81.3%) compared with adults (47.5%) and seniors (36.4%) (P = .0001). One hundred fifty-one patients received a second LTx, 22 patients received a third LTx, and 4 patients. received a fourth LTx. Over all 15 years the actuarial graft survival rate was 46.1%. At last follow-up, 69.1% of patients were off steroids. The majority of late deaths were due to age-related complications, recurrence of disease, and De novo cancers.
   Conclusion. The data on longitudinal follow-up have shown actuarial survival for children to be significantly better than in adults and seniors. Graft loss from immunological causes are rare even with long-term follow-up.
C1 Univ Rochester, Strong Mem Hosp, Dept Surg, Transplant Div, Rochester, NY 14642 USA.
   Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15260 USA.
   Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.
RP Jain, A (reprint author), 601 Elmwood Ave,Box SURG, Rochester, NY 14642 USA.
EM Ashok_jain@urmc.Rochester.edu
RI Fung, John/A-2679-2012
CR FUNG JJ, 1991, TRANSPLANT P, V23, P14
   Jain A, 2001, PEDIATR TRANSPLANT, V5, P93, DOI 10.1034/j.1399-3046.2001.005002093.x
   Jain A, 2001, TRANSPLANTATION, V71, P1102, DOI 10.1097/00007890-200104270-00016
   Jain A, 2000, ANN SURG, V232, P490, DOI 10.1097/00000658-200010000-00004
   Jain A, 2000, TRANSPLANTATION, V70, P617, DOI 10.1097/00007890-200008270-00015
   Jain A, 2002, ANN SURG, V236, P429, DOI 10.1097/01.SLA.0000033429.89429.89424.F8
   Jain A, 1999, ANN SURG, V230, P441, DOI 10.1097/00000658-199909000-00016
   Jain A, 2001, LIVER TRANSPLANT, V7, P623, DOI 10.1053/jlts.2001.25364
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   JAIN AB, 1991, TRANSPLANT P, V23, P928
   Jain AB, 1998, TRANSPLANTATION, V66, P1193, DOI 10.1097/00007890-199811150-00014
   JAIN AB, 1995, TRANSPLANT P, V27, P1099
   NEUHAUS P, 1994, LANCET, V344, P423
   Reyes J, 2000, TRANSPLANTATION, V69, P2573, DOI 10.1097/00007890-200006270-00017
   STARZL TE, 1995, LANCET, V346, P1346, DOI 10.1016/S0140-6736(95)92349-7
   STARZL TE, 1989, LANCET, V2, P1000
   TODO S, 1994, ANN SURG, V220, P297, DOI 10.1097/00000658-199409000-00006
   TODO S, 1990, ANN SURG, V212, P295, DOI 10.1097/00000658-199009000-00008
   *US MULT FK506 LIV, 1994, NEW ENGL J MED, V344, P423
NR 19
TC 16
Z9 16
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 1207
EP 1210
DI 10.1016/j.transproceed.2004.12.077
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900223
PM 15848671
ER

PT J
AU Fouquet, V
   Alves, A
   Branchereau, S
   Grabar, S
   Debray, D
   Jacquemin, E
   Devictor, D
   Durand, P
   Baujard, C
   Fabre, M
   Pariente, D
   Chardot, C
   Dousset, B
   Massault, PP
   Bernard, D
   Houssin, D
   Bernard, O
   Gauthier, F
   Soubrane, O
AF Fouquet, V
   Alves, A
   Branchereau, S
   Grabar, S
   Debray, D
   Jacquemin, E
   Devictor, D
   Durand, P
   Baujard, C
   Fabre, M
   Pariente, D
   Chardot, C
   Dousset, B
   Massault, PP
   Bernard, D
   Houssin, D
   Bernard, O
   Gauthier, F
   Soubrane, O
TI Long-term outcome of pediatric liver transplantation for biliary
   atresia: A 10-year follow-up in a single center
SO LIVER TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 53rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Diseases
CY NOV 01-05, 2002
CL BOSTON, MA
SP Amer Assoc Study Liver Dis
ID QUALITY-OF-LIFE; CENTER EXPERIENCE; KASAI PORTOENTEROSTOMY; POLYSPLENIA
   SYNDROME; GRAFT LOSS; RECIPIENTS; CHILDREN; GROWTH; SURVIVAL;
   DYSFUNCTION
AB The aim of this study was to review our experience in orthotopic liver transplantation (OLT) for biliary atresia (BA) in children and analyze the survival and prognostic factors, and long-term outcome. We reviewed 332 OLTs performed in 280 children between the years 1986 and 2000. Univariate and multivariate analysis were performed on patient and graft survivals according to recipients' and donors' characteristics as well as intraoperative data. The long-term outcome among the 80 children living at 10 years after OLT was studied according to growth, immunosuppressive therapy, and liver and renal functions. Liver graft status was eventually documented by liver biopsy. Status of rehabilitation was assessed by reviewing school performance and employment. Overall patient survival rates at 1, 5, and 10 years were 85, 82, and 82%, respectively, and the corresponding overall graft survival rates were 77, 73, and 71%. In the multivariate analysis, we identified 4 independent prognostic factors: polysplenia syndrome (P = .03), United Network for Organ Sharing (UNOS) status (P = .05), donor's age (P = .01), and perioperative surgical complications (P = .03). At 10 years after transplant, 80 children were alive and had normal growth rates. Liver histology was abnormal in 73% of these long-term survivors, mainly due to chronic rejection and centrilobular fibrosis. A total of 63 of the 80 children attended normal school and in 55 children (69%).
C1 Hop Cochin, Dept Biostat, F-75674 Paris, France.
   Hop Cochin, Dept Surg, F-75674 Paris, France.
   Hop Cochin, Dept Anesthesiol, F-75674 Paris, France.
   Hop Bicetre, Dept Pediat Surg, Le Kremlin Bicetre, France.
   Hop Bicetre, Dept Pediat Hepatol, Le Kremlin Bicetre, France.
   Hop Bicetre, Dept Pediat Intens Care, Le Kremlin Bicetre, France.
   Hop Bicetre, Dept Anesthesiol, Le Kremlin Bicetre, France.
   Hop Bicetre, Dept Pathol, Le Kremlin Bicetre, France.
   Hop Bicetre, Dept Pediat Radiol, Le Kremlin Bicetre, France.
RP Soubrane, O (reprint author), Assistance Publ Hop Paris, Hop Cochin, Serv Chirurg, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
EM olivier.soubrane@cch.aphp.fr
CR Andrews W, 1996, J PEDIATR SURG, V31, P619, DOI 10.1016/S0022-3468(96)90660-0
   Balistreri WF, 1996, HEPATOLOGY, V23, P1682, DOI 10.1002/hep.510230652
   Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Bates MD, 1998, SEMIN LIVER DIS, V18, P281, DOI 10.1055/s-2007-1007164
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   BISMUTH H, 1984, SURGERY, V95, P36
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Bucuvalas JC, 2003, LIVER TRANSPLANT, V9, P62, DOI 10.1053/jlts.2002.50012
   Burdelski M, 1999, EUR J PEDIATR, V158, pS34, DOI 10.1007/PL00014322
   Chardot C, 1999, HEPATOLOGY, V30, P808
   CHERQUI D, 2002, LANCET, V329, P392
   CODONERFRANCH P, 1994, J PEDIATR-US, V124, P368, DOI 10.1016/S0022-3476(94)70357-4
   Deschenes M, 1998, TRANSPLANTATION, V66, P302, DOI 10.1097/00007890-199808150-00005
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Goss JA, 1996, ANN SURG, V224, P276, DOI 10.1097/00000658-199609000-00004
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Hathaway DK, 1998, CLIN TRANSPLANT, V12, P168
   HOUSSIN D, 1992, SURGERY, V111, P532
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   KALAYOGLU M, 1993, SURGERY, V114, P711
   KARRER FM, 1991, J PEDIATR SURG, V26, P524, DOI 10.1016/0022-3468(91)90697-R
   Kennard BD, 1999, J DEV BEHAV PEDIATR, V20, P17, DOI 10.1097/00004703-199902000-00003
   LEVY MF, 1995, TRANSPLANTATION, V59, P515
   Migliazza L, 2000, J PEDIATR SURG, V35, P5, DOI 10.1016/S0022-3468(00)80066-4
   OHI R, 1986, J PEDIATR SURG, V21, P271, DOI 10.1016/S0022-3468(86)80852-1
   Orii T, 2000, TRANSPLANT P, V32, P2210, DOI 10.1016/S0041-1345(00)01638-9
   OTTE JB, 1994, HEPATOLOGY, V20, pS41, DOI 10.1002/hep.1840200711
   PLOEG RJ, 1993, TRANSPLANTATION, V55, P807, DOI 10.1097/00007890-199304000-00024
   Ratcliffe J, 2002, LIVER TRANSPLANT, V8, P263, DOI 10.1053/jlts.2002.31345
   Renz JF, 2001, LIVER TRANSPLANT, V7, P1040, DOI 10.1053/jlts.2001.29413
   Sieders E, 2002, ANN SURG, V235, P125, DOI 10.1097/00000658-200201000-00016
   Sieders E, 2000, TRANSPLANTATION, V70, P1448, DOI 10.1097/00007890-200011270-00009
   SOUBRANE O, 1994, J AM COLL SURGEONS, V178, P139
   STEWART SM, 1987, PEDIATRICS, V79, P882
   Sugawara Y, 2004, HEPATO-GASTROENTEROL, V51, P192
   Tanaka Koichi, 2002, J Hepatobiliary Pancreat Surg, V9, P218, DOI 10.1007/s005340200022
   VACANTI JP, 1990, J PEDIATR SURG, V25, P149, DOI 10.1016/S0022-3468(05)80182-4
   Varela-Fascinetto G, 1998, ANN SURG, V227, P583, DOI 10.1097/00000658-199804000-00022
   VASQUEZ J, 1995, J PEDIATR SURG, V30, P485
   Visser BC, 2004, LIVER TRANSPLANT, V10, P1279, DOI 10.1002/lt.20234
   WALL WJ, 1990, TRANSPLANTATION, V49, P377, DOI 10.1097/00007890-199002000-00030
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   Wayman KI, 1997, J PEDIATR-US, V131, P894, DOI 10.1016/S0022-3476(97)70039-8
NR 43
TC 82
Z9 91
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2005
VL 11
IS 2
BP 152
EP 160
DI 10.1002/lt.20358
PG 9
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 891QF
UT WOS:000226594900005
PM 15666395
ER

PT J
AU Salvalaggio, PRO
   Whitington, PF
   Alonso, EM
   Superina, RA
AF Salvalaggio, PRO
   Whitington, PF
   Alonso, EM
   Superina, RA
TI Presence of multiple bile ducts in the liver graft increases the
   incidence of biliary complications in pediatric liver transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID LIVING-RELATED DONORS; REDUCED-SIZE; SURGICAL TECHNIQUES; CHILDREN;
   EXPERIENCE; RECIPIENTS; MORBIDITY; TRACT
AB We studied the impact of multiple bile duct anastomosis on the development of biliary complications after liver transplantation in children. A total of 101 patients received a primary liver transplant and were divided into 2 groups: those with a single bile duct (n = 77) and those with multiple bile ducts (n = 24). Mean follow-up was 39.8 +/- 20.8 months. A total of 27 patients presented with biliary complications (26.7%), 18 patients (18.7%) presented with early complications (12 leaks and 6 strictures), and 9 patients (8.9%) had late strictures. Hepatic artery thrombosis (HAT) and multiple bile ducts were significant risk factors for the development of biliary complications, and the presence of multiple bile ducts was an independent risk factor. Patients with multiple bile ducts had a significantly greater incidence of total biliary complications compared to those with single ducts. Patients with multiple ducts had a higher incidence of leaks when compared to those in the single duct group, but the incidence of strictures, both early and late, was similar in both groups. One-year patient and graft survivals were not statistically different in the 2 groups. In conclusion, the presence of more than one bile duct in the graft is an independent risk factor for the development of biliary complications after pediatric liver transplantation.
C1 Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Dept Surg, Chicago, IL 60611 USA.
   Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Dept Pediat, Chicago, IL 60611 USA.
RP Superina, RA (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Pediat Surg, 700 W Fullerton St,Suite N745, Chicago, IL 60614 USA.
EM RSuperin@childrensmemorial.org
CR BISMUTH H, 1984, SURGERY, V95, P367
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   BROELSCH CE, 1988, ANN SURG, V208, P410, DOI 10.1097/00000658-198810000-00003
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   CALNE RY, 1976, ANN SURG, V184, P605, DOI 10.1097/00000658-197611000-00012
   Chahin NJ, 2001, TRANSPLANT P, V33, P2738, DOI 10.1016/S0041-1345(01)02174-1
   CHARDOT C, 1995, TRANSPLANT INT, V8, P133, DOI 10.1111/j.1432-2277.1995.tb01488.x
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Cronin DC, 1997, TRANSPLANT P, V29, P419, DOI 10.1016/S0041-1345(96)00160-1
   Egawa H, 2001, WORLD J SURG, V25, P1300
   EMOND JC, 1990, ANN SURG, V212, P14
   Fujita S, 2000, TRANSPLANT INT, V13, P333, DOI 10.1111/j.1432-2277.2000.tb01006.x
   Gridelli B, 2003, TRANSPLANTATION, V75, P1197, DOI 10.1097/01.TP.0000061940.96949.A1
   Halme L, 2003, TRANSPLANTATION, V75, P1853, DOI 10.1097/01.TP.0000064620.08328.E5
   HEFFRON TG, 1992, TRANSPLANTATION, V53, P391, DOI 10.1097/00007890-199202010-00024
   Heffron TG, 2003, TRANSPLANT P, V35, P1461, DOI 10.1016/S0041-1345(03)00463-9
   LALLIER M, 1993, J PEDIATR SURG, V28, P1102, DOI 10.1016/0022-3468(93)90139-C
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   PECLET MH, 1994, J PEDIATR SURG, V29, P214, DOI 10.1016/0022-3468(94)90321-2
   PICHLMAYR R, 1988, LANGENBECK ARCH CHIR, V373, P127, DOI 10.1007/BF01262776
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Sieders E, 1999, TRANSPLANTATION, V68, P540, DOI 10.1097/00007890-199908270-00017
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Testa G, 2001, WORLD J SURG, V25, P1296
   Whittaker A, 2002, WOMEN HEALTH, V35, P1, DOI 10.1300/J013v35n04_01
NR 26
TC 24
Z9 24
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2005
VL 11
IS 2
BP 161
EP 166
DI 10.1002/lt.20288
PG 6
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 891QF
UT WOS:000226594900006
PM 15666393
ER

PT J
AU Chin, K
   Uemoto, S
   Takahashi, K
   Egawa, H
   Kasahara, M
   Fujimoto, Y
   Sumi, K
   Mishima, M
   Sullivan, CE
   Tanaka, K
AF Chin, K
   Uemoto, S
   Takahashi, K
   Egawa, H
   Kasahara, M
   Fujimoto, Y
   Sumi, K
   Mishima, M
   Sullivan, CE
   Tanaka, K
TI Noninvasive ventilation for pediatric patients including those under
   1-year-old undergoing liver transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID ACUTE RESPIRATORY-FAILURE; MUSCULAR-ATROPHY TYPE-1;
   ORGAN-TRANSPLANTATION; MANAGEMENT; INSUFFICIENCY; TRIAL; MASK
AB Pulmonary complications are an important cause of the mortality associated with liver transplantation. The efficacy of noninvasive ventilation (NIV) in pediatric patients following transplantation is unknown. The purpose of this retrospective study is to investigate the effects of NIV for pediatric patients undergoing liver transplantation. Of 102 pediatric patients who underwent liver transplantation, 15 patients (aged 73 months; range 2.5-179) were supported by NIV because of atelectasis, hypercapnia, hypoxemia, pneumonia, massive effusion, or postextubation ventilatory support. Of 15 patients, 5 were under the age of 1 year (range 2.5-12 months). Of the 15 patients, 7 had required multiple intubations before NIV treatment because of pulmonary complications. NIV treatment was administered to 6 patients because of hypercapnia. Partial pressure of arterial carbon dioxide (PaCO2) levels improved from 56.9 (95% confidence interval [CI]. 48.465.4) to 41.5 (95% Cl: 36.8-46.2) mmHg (P =.028) within 2 days. NIV treatment was very effective for patients with atelectasis with and without other pulmonary complications. Mean inspiratory positive pressure (IPAP) was 7.2 (95% CI: 6.0-8.3) cm H2O and expiratory positive pressure (EPAP) was 3.5 (95% CI: 3.2-3.9) cm of H2O. Mean duration of NIV was 18.5 (95% CI: 8.6-28.4) days. IPAP and EPAP levels were closely and significantly correlated with height (IPAP: r =.65, P =.016; EPAP: r =.77, P =.004). A total of 13 patients recovered and 2 patients died. However, no patient died of respiratory complications. In conclusion, NIV is effective in pediatric patients undergoing liver transplantation with subsequent pulmonary complications. The IPAP and EPAP levels may be predicted by the height of the patient.
C1 Kyoto Univ Hosp, Dept Phys Therapeut, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ, Kyoto Univ Hosp, Grad Sch Med, Dept Transplantat Surg, Kyoto, Japan.
   Kyoto Univ, Kyoto Univ Hosp, Grad Sch Med, Dept Resp Med, Kyoto, Japan.
   Mie Univ, Sch Med, Dept Surg 1, Tsu, Mie 514, Japan.
   Univ Sydney, Dept Med, David Read Lab, Sydney, NSW 2006, Australia.
RP Chin, K (reprint author), Kyoto Univ Hosp, Dept Phys Therapeut, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM chink@kuhp.kyoto-u.ac.jp
RI FUJIMOTO, Yasuhiro/E-6565-2010
CR Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235
   Bach JR, 2002, PEDIATR PULM, V34, P16, DOI 10.1002/ppul.10110
   Bach JR, 2000, CHEST, V117, P1100, DOI 10.1378/chest.117.4.1100
   Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352
   ESTES RJ, 1995, INTENS CARE MED, V21, P365, DOI 10.1007/BF01705418
   ETTINGER NA, 1991, AM REV RESPIR DIS, V143, P1386
   FORTENBERRY JD, 1995, CHEST, V108, P1059, DOI 10.1378/chest.108.4.1059
   Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703
   LIGHTOWLER JV, 2003, BRIT MED J, V325, P185
   Niranjan V, 1998, CRIT CARE MED, V26, P2061, DOI 10.1097/00003246-199812000-00042
   NORREGAARD O, 2001, EUROPEAN RESP SOC J, P147
   Norregaard O, 2002, EUR RESPIR J, V20, P1332, DOI 10.1183/09031936.02.00404802
   Padman R, 1998, CRIT CARE MED, V26, P169, DOI 10.1097/00003246-199801000-00034
   TEAGUE WG, 1997, RESP CARE, V42, P414
NR 14
TC 19
Z9 21
U1 1
U2 1
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2005
VL 11
IS 2
BP 188
EP 195
DI 10.1002/lt.20297
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 891QF
UT WOS:000226594900009
PM 15666379
ER

PT J
AU Tanaka, H
   Verran, D
   Shun, A
   Dorney, S
   Stormon, M
   Fisher, J
   McCaughan, G
AF Tanaka, H
   Verran, D
   Shun, A
   Dorney, S
   Stormon, M
   Fisher, J
   McCaughan, G
TI Liver transplantation utilizing pediatric cadaver donor livers
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; liver; transplantation; cadaver
ID ADULT RECIPIENTS; CHILDREN; SURVIVAL; SIZE; EXPERIENCE; GRAFTS
AB This is a review of a unit's experience with the use of pediatric (up to 15 yr of age), cadaver donor livers for orthotopic liver transplantation (OLTx). The records of 86 patients who underwent 90 OLTx with pediatric donor allografts from January 1986 to September 2002 were reviewed. A total of 69 of 90 (77%) allografts from pediatric donors were used for pediatric (P) recipients, and 21 of 90 (23%) for adult (A) recipients. Donor demographics were: mean donor age 8.5 (0-15) yr; donor sex 53 males/37 females; cause of death head injury 55/90 (61%), cerebral ischaemia 14 of 90 (15%), cerebrovascular 13 of 90 (15%), other eight of 90 (9%). Whole OLTx were performed in 44 of 69 (64%) P group and 20 of 21 (95%) A group. Reduced-size OLTx (13 left lateral lobe, 10 left lobe, one right lobe, one split left lateral lobe) were performed in 25 of 69 (36%) P group vs. in one of 21 (5%) A group, (right lobe split) (p < 0.005). The median follow up was 8.8 yr. The graft loss in the P recipients was 19 of 69 (27.5%) vs. eight of 21 (38.1%) in A recipients. Graft loss for reduced size P OLTx was nine of 25 (36%) vs. 10/44 (22.7%) for whole allograft P OLTx (p = NS). Underlying cause of P graft loss were: chronic rejection six (32%); patient mortality six (32%); vascular four (21%); other three (15%). Underlying cause of A graft loss were: patient mortality four (50%), acute rejection two (25%) and vascular two (25%). OLTx-utilizing pediatric cadaver donor allografts provides acceptable outcomes, including use of reduced-size grafts in pediatric recipients. Vascular complications and chronic rejection tend to be more common in pediatric recipients, whilst patient mortality and graft loss from acute rejection are more common in adult recipients.
C1 Royal Prince Alfred Hosp, Liver Transplantat Unit, Camperdown, NSW 2050, Australia.
   Childrens Hosp, Westmead, NSW, Australia.
RP Verran, D (reprint author), Royal Prince Alfred Hosp, Liver Transplant Unit, 9E, Camperdown, NSW 2050, Australia.
EM deborah@email.cs.nsw.gov.au
CR ADAM R, 1993, TRANSPLANT P, V25, P1105
   BISMUTH H, 1984, SURGERY, V95, P367
   BROELSCH CE, 1988, ANN SURG, V208, P410, DOI 10.1097/00000658-198810000-00003
   BUSUTTIL RW, 1991, ANN SURG, V213, P48, DOI 10.1097/00000658-199101000-00009
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   De Ville De Goyet Jean, 1993, Transplantation (Baltimore), V56, P1130, DOI 10.1097/00007890-199311000-00016
   Deshpande PR, 2002, TRANSPLANTATION, V74, P1124, DOI 10.1097/01.TP.0000030640.11006.CE
   DESHPANDE R, 2002, ANN SURG, V2, P248
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   Emre S, 2001, LIVER TRANSPLANT, V7, P41, DOI 10.1053/jlts.2001.20940
   Jain A, 2000, TRANSPLANTATION, V70, P617, DOI 10.1097/00007890-200008270-00015
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   McDiarmid SV, 2000, TRANSPLANTATION, V70, P1283, DOI 10.1097/00007890-200011150-00005
   OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006
   SHEIL AGR, 1992, MED J AUSTRALIA, V156, P9
   SHUN A, 1992, CLIN TRANSPLANT, V6, P315
   Sieders E, 1999, TRANSPLANTATION, V68, P540, DOI 10.1097/00007890-199908270-00017
   Yasutomi M, 2001, LIVER TRANSPLANT, V7, P38, DOI 10.1053/jlts.2001.18482
   YOKOYAMA I, 1992, TRANSPLANT INT, V5, P205
NR 19
TC 1
Z9 2
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2005
VL 9
IS 1
BP 47
EP 51
DI 10.1111/j.1399-3046.2005.00246.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 890LD
UT WOS:000226511800010
PM 15667611
ER

PT J
AU Herzog, D
   Martin, S
   Lallier, M
   Alvarez, F
AF Herzog, D
   Martin, S
   Lallier, M
   Alvarez, F
TI Ascites after orthotopic liver transplantation in children
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; portal hypertension; congenital liver disease; complications;
   albumin
ID ALBUMIN CONCENTRATION GRADIENT; PORTAL-HYPERTENSION; VENOUS-PRESSURE;
   DIAGNOSIS; CIRRHOSIS; SPLIT
AB Ascites is a poorly understood postoperative complication of orthotopic liver transplantation (OLT). It is associated with additional morbidity and can prolong hospitalization considerably. The incidence, the factors predictive of occurrence and the etiology of this complication are not known. The charts of 118 patients with 138 OLT were analyzed according to the following criteria: ascites lasting longer than the first 10 postoperative days, assessed by loss of ascitic fluid through drainage tubes, surgical wounds or paracentesis, with a peak volume of greater than or equal to10 mL/kg/day. Patients were divided into three groups: Group 1, no ascites; Group 2, ascites associated with postoperative complications, including chylus ascites; and Group 3, ascites not associated with postoperative complications. Postoperative ascites occurred in 43 of 138 OLT (31.2%). Patients with biliary atresia, preoperative portal hypertension, postoperative pleural effusion or at retransplantation had ascites significantly more often. In 32 of 138 (23.2%) OLT, ascites was associated with postoperative complications, including thrombosis, abdominal infections, intestinal perforation, biliary leak, pancreatitis, and chylus ascites. In 11 of 138 (7.9%) OLT, ascites was the only postoperative complication (group 3). Group three patients were significantly older, and had lower preoperative platelet counts and preoperative ascites more often than group 1 patients. The primary liver diseases were mainly cystic fibrosis of the pancreas, congenital hepatic fibrosis, and North American Indian childhood cirrhosis. The serum-ascites albumin gradient suggested a hepatic origin of ascites. Postoperative ascites is associated with the duration and degree of preoperative portal hypertension. We speculate that the mechanism involved includes a disproportion between venous blood volume and liver uptake capacity of the donor organ.
C1 Univ Montreal, Hop St Justine, Div Gastroenterol & Nutr, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Hop St Justine, Dept Surg, Montreal, PQ H3T 1C5, Canada.
   Univ Montreal, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada.
RP Herzog, D (reprint author), Univ Montreal, Hop St Justine, Div Gastroenterol & Nutr, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM denise.herzog@umontreal.ca
CR Adetiloye VA, 1998, PEDIATR RADIOL, V28, P539, DOI 10.1007/s002470050406
   Atkison PR, 2002, CAN MED ASSOC J, V166, P1663
   Bolognesi M, 2001, ULTRASOUND MED BIOL, V27, P901, DOI 10.1016/S0301-5629(01)00370-2
   Bolognesi M, 2002, HEPATOLOGY, V35, P601, DOI 10.1053/jhep.2002.31352
   Chardot C, 1997, Liver Transpl Surg, V3, P351, DOI 10.1002/lt.500030401
   Cirera I, 2000, LIVER TRANSPLANT, V6, P157, DOI 10.1002/lt.500060219
   Colle IO, 2003, HEPATOLOGY, V37, P401, DOI 10.1053/jhep.2003.50060
   Dittrich S, 2001, HEPATO-GASTROENTEROL, V48, P166
   Dousset B, 1994, Ann Radiol (Paris), V37, P386
   GANE E, 1995, GASTROENTEROLOGY, V109, P1631, DOI 10.1016/0016-5085(95)90653-3
   HAMMOND KB, 2001, CURRENT PEDIAT DIAGN, P1158
   HOEFS JC, 1983, J LAB CLIN MED, V102, P260
   Ito T, 2003, TRANSPLANTATION, V75, P1313, DOI 10.1097/01.TP.0000063707.90525.10
   Kane R, 2001, TRANSPLANTATION, V72, P463
   Leonardi LS, 2002, TRANSPLANT P, V34, P3336, DOI 10.1016/S0041-1345(02)03575-3
   McGilvray Ian D, 2002, Curr Opin Crit Care, V8, P178, DOI 10.1097/00075198-200204000-00015
   *NAT CTR HLTH STAT, 2000, CDC GROWTH CHARTS
   PARE P, 1983, GASTROENTEROLOGY, V85, P240
   Piscaglia F, 1999, HEPATOLOGY, V30, P58, DOI 10.1002/hep.510300112
   Schepke M, 2000, AM J GASTROENTEROL, V95, P2905, DOI 10.1016/S0002-9270(00)01995-X
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Torres E, 1998, AM J GASTROENTEROL, V93, P2172
NR 22
TC 5
Z9 5
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD FEB
PY 2005
VL 9
IS 1
BP 74
EP 79
DI 10.1111/j.1399-3046.2005.00259.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 890LD
UT WOS:000226511800015
PM 15667616
ER

PT J
AU Harmon, WE
   McDonald, RA
   Reyes, JD
   Bridges, ND
   Sweet, SC
   Sommers, CM
   Guidinger, MK
AF Harmon, WE
   McDonald, RA
   Reyes, JD
   Bridges, ND
   Sweet, SC
   Sommers, CM
   Guidinger, MK
TI Pediatric transplantation, 1994-2003
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE deceased donors; graft survival; immunosuppression; living donors; organ
   donation; patient survival; pediatric transplantation; SRTR; waiting
   list
ID INTERSTITIAL LUNG-DISEASE; UNITED-STATES; KIDNEY-TRANSPLANTATION;
   LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; INTERNATIONAL-SOCIETY;
   GRAFT-SURVIVAL; SINGLE-CENTER; RECIPIENTS; DONOR
AB This article uses OPTN/SRTR data to review trends in pediatric transplantation over the last decade. In 2003, children younger than 18 made up 3% of the 82,885 candidates for organ transplantation and 7% of the 25,469 organ transplant recipients. Children accounted for 14% of the 6,455 deceased organ donors. Pediatric organ transplant recipients differ from their adult counterparts in several important aspects, including the underlying etiology of organ failure, the complexity of the surgical procedures, the pharmacokinetic properties of common immunosuppressants, the immune response following transplantation, the number and degree of comorbid conditions, and the susceptibility to post-transplant complications, especially infectious diseases. Specialized pediatric organ transplant programs have been developed to address these special problems, The transplant community has responded to the particular needs of children and has provided them special consideration in the allocation of deceased donor organs. As a result of these programs and protocols, children are now frequently the most successful recipients of organ transplantation; their outcomes following kidney, liver, and heart transplantation rank among the best. This article demonstrates that substantial improvement is needed in several areas: adolescent outcomes, outcomes following intestine transplants, and waiting list mortality among pediatric heart and lung candidates.
C1 Childrens Hosp, Seattle, WA USA.
   Reg Med Ctr, Seattle, WA USA.
   Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
   NIAID, Bethesda, MD 20892 USA.
   Washington Univ, Sch Med, St Louis, MO USA.
   United Network Organ Sharing, Richmond, VA USA.
   Univ Renal Res & Educ Assoc, Sci Registry Transplant Recipients, Ann Arbor, MI USA.
RP Harmon, WE (reprint author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
EM william.harmon@TCH.Harvard.edu
CR Abecassis M, 2000, JAMA-J AM MED ASSOC, V284, P2919
   Barst RJ, 1999, PEDIATR CLIN N AM, V46, P331, DOI 10.1016/S0031-3955(05)70121-8
   Baum MA, 2002, PEDIATR TRANSPLANT, V6, P488, DOI 10.1034/j.1399-3046.2002.02036.x
   Benfield MR, 2003, PEDIATR TRANSPLANT, V7, P321, DOI 10.1034/j.1399-3046.2003.00029.x
   Boucek MM, 2003, J HEART LUNG TRANSPL, V22, P636, DOI 10.1016/S1053-2498(03)00184-0
   Boucek MM, 2004, J HEART LUNG TRANSPL, V23, P933, DOI 10.1016/j.healun.2004.06.011
   Chang RKR, 2002, PEDIATRICS, V110, P292, DOI 10.1542/peds.110.2.292
   *CYST FIBR FDN, PAT REG 2002 ANN REP
   Delmonico FL, 2002, AM J TRANSPLANT, V2, P333, DOI 10.1034/j.1600-6143.2002.20407.x
   Dickinson DM, 2005, AM J TRANSPLANT, V5, P850, DOI 10.1111/j.1600-6135.2005.00840.x
   EDWARDS LB, 2003, CLIN TRANSPLANTS 200, P29
   Fan LL, 2002, AM J RESP CRIT CARE, V165, P1466, DOI 10.1164/rccm.2204012
   Furth SL, 2003, AM J TRANSPLANT, V3, P28, DOI 10.1034/j.1600-6143.2003.30106.x
   Grant D, 1999, TRANSPLANTATION, V67, P1061, DOI 10.1097/00007890-199904150-00021
   Hamvas A, 1997, J PEDIATR-US, V130, P231, DOI 10.1016/S0022-3476(97)70348-2
   HARMON WE, 2003, AM J TRANSPLANT S5, V3, P285
   HARMON WE, 1991, TRANSPLANTATION, V51, P406, DOI 10.1097/00007890-199102000-00026
   HARMON WE, 1992, TRANSPLANTATION, V54, P232, DOI 10.1097/00007890-199208000-00008
   Hiramoto JS, 2002, AM J TRANSPLANT, V2, P337, DOI 10.1034/j.1600-6143.2002.20408.x
   Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7
   Magee JC, 2004, AM J TRANSPLANT, V4, P54, DOI 10.1111/j.1600-6143.2004.00398.x
   Martin SR, 2004, PEDIATR TRANSPLANT, V8, P273, DOI 10.1111/j.1399-3046.2004.00152.x
   McDiarmid SV, 2004, PEDIATR TRANSPLANT, V8, P284, DOI 10.1111/j.1399-3046.2004.00153.x
   McDonald RA, 2004, AM J TRANSPLANT, V4, P304
   Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805
   Ruff T, 2002, AM SURGEON, V68, P857
   Sarwal MM, 2000, TRANSPLANTATION, V70, P1728, DOI 10.1097/00007890-200012270-00012
   Schaubel DE, 2005, AM J TRANSPLANT, V5, P950, DOI 10.1111/j.1600-6135.2005.00837.x
   Seikaly M, 2001, PEDIATR TRANSPLANT, V5, P215, DOI 10.1046/j.1397-3142.2001.00001.x
   Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178
   Smith JM, 2002, PEDIATR TRANSPLANT, V6, P493, DOI 10.1034/j.1399-3046.2002.02042.x
   *U AL BIRM, 2002, PED HEART TRANSPL ST
NR 32
TC 52
Z9 52
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1600-6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PY 2005
VL 5
IS 4
BP 887
EP 903
DI 10.1111/j.1600-6135.2005.00834.x
PN 2
PG 17
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 904YQ
UT WOS:000227534900006
PM 15760416
ER

PT J
AU Takatsuki, M
   Chen, CL
   Chen, YS
   Wang, CC
   Lin, CC
   Yang, CH
   Yong, CC
   Liu, YW
AF Takatsuki, M
   Chen, CL
   Chen, YS
   Wang, CC
   Lin, CC
   Yang, CH
   Yong, CC
   Liu, YW
TI Impact of late conversion from C0 to C2 monitoring of microemulsified
   cyclosporine in pediatric living donor liver transplant recipients
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE C2; liver transplantation; living donor; Neoral
ID CELLULAR REJECTION; IMMUNOSUPPRESSION; TACROLIMUS; LONG; FORMULATION;
   THERAPY; C-2
AB The efficacy and feasibility of 2-h post-dose level (C2) monitoring of cyclosporine in long-term living donor liver transplantation (LDLT) is not clear. The aim of this study was to investigate the impact of late conversion from conventional trough-level (C0) monitoring to C2 monitoring of a microemulsion form of cyclosporine (Neoral) in pediatric LDLT recipients. From June 1994 to August 2002, we performed 116 LDLTs in 115 patients. Initially, we adapted conventional C0 monitoring of Neoral, which was converted to C2 monitoring starting in January 2002. The 60 patients who were enrolled in the study had the following characteristics: they were younger than or equal to 15 yr at transplantation, and they had survived LDLT, and they had received a Neoral-based immunosuppression regimen, and they underwent conversion to C2 more than 1 month after transplantation. We evaluated the impact of conversion on doses, blood levels, rejection, adverse effects, and patient/graft outcome. In the long-term patients, the mean C2 levels immediately after conversion were higher than the target levels at any time point selected after transplantation; thus, 34 patients (57%) finally required a dose reduction of Neoral. The current mean C2 level was significantly lower than that observed immediately after conversion (584.6 +/- 262.8 ng/ml vs. 893.1 +/- 260.2 ng/ml, mean +/- SD, p < 0.0001) with a mean follow-up period of 7.4 +/- 0.6 months (range: 5-8 months) after conversion. Only one patient encountered rejection after conversion (1.7%), and no de novo infection or adverse effects were observed. Traditional C0 monitoring of Neoral was safely replaced by C2 monitoring without an increase in the rejection rate or any adverse effects in pediatric LDLT patients. C2 monitoring contributed to the dose reduction of Neoral, which may lead to the avoidance of long-term complications due to immunosuppression.
C1 Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg,Liver Transplant Program, Kaohsiung 83301, Taiwan.
RP Chen, CL (reprint author), Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg,Liver Transplant Program, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan.
EM clchen@adm.cgmh.org.tw
CR Andreu H, 2002, TRANSPLANTATION, V73, P1936, DOI 10.1097/00007890-200206270-00016
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110
   CALNE RY, 1979, LANCET, V2, P1033
   Cantarovich M, 1998, TRANSPLANTATION, V66, P1621, DOI 10.1097/00007890-199812270-00009
   D'Antiga L, 2002, TRANSPLANTATION, V73, P80, DOI 10.1097/00007890-200201150-00015
   Grant D, 1999, TRANSPLANTATION, V67, P1133, DOI 10.1097/00007890-199904270-00008
   Jain A, 2000, TRANSPLANTATION, V70, P617, DOI 10.1097/00007890-200008270-00015
   Kasahara M, 2002, TRANSPLANTATION, V74, P1175, DOI 10.1097/01.TP.0000030636.35519.EA
   Levy G, 2002, TRANSPLANTATION, V73, P953, DOI 10.1097/00007890-200203270-00022
   Levy G A, 1997, Liver Transpl Surg, V3, P571, DOI 10.1002/lt.500030603
   Levy GA, 2001, BIODRUGS, V15, P279, DOI 10.2165/00063030-200115050-00001
   Mirza DF, 1997, LANCET, V349, P701, DOI 10.1016/S0140-6736(05)60138-9
   MUELLER EA, 1995, TRANSPLANTATION, V60, P515, DOI 10.1097/00007890-199509000-00021
   NEUHAUS P, 1994, LANCET, V344, P423
   Pruthi J, 2001, LIVER TRANSPLANT, V7, P811, DOI 10.1053/jlts.2001.27084
   Sheiner PA, 2000, TRANSPLANTATION, V69, P781
   Taber DJ, 2002, LIVER TRANSPLANT, V8, P219, DOI 10.1053/jlts.2002.30885
   Takatsuki M, 2001, TRANSPLANT P, V33, P3450, DOI 10.1016/S0041-1345(01)02487-3
   Trotter JF, 2002, LIVER TRANSPLANT, V8, P212, DOI 10.1053/jlts.2002.31346
   Wacke R, 2000, EUR J CLIN PHARMACOL, V56, P43, DOI 10.1007/s002280050718
   Wallot MA, 2002, LIVER TRANSPLANT, V8, P615, DOI 10.1053/jlts.2002.34149
   Winkler M, 1996, TRANSPLANTATION, V62, P1063, DOI 10.1097/00007890-199610270-00006
NR 23
TC 3
Z9 3
U1 1
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 0902-0063
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD DEC
PY 2004
VL 18
IS 6
BP 694
EP 699
DI 10.1111/j.1399-0012.2004.00279.x
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 866WK
UT WOS:000224803900013
PM 15516246
ER

PT J
AU Rumbo, C
   Shneider, BL
   Emre, SH
AF Rumbo, C
   Shneider, BL
   Emre, SH
TI Utility of azathioprine metabolite measurements in post-transplant
   recurrent autoimmune and immune-mediated hepatitis
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplant; 6-thioguanine; adherence; children
ID INFLAMMATORY-BOWEL-DISEASE; PEDIATRIC LIVER-TRANSPLANTATION; THERAPY;
   6-MERCAPTOPURINE; RECIPIENTS; MAINTENANCE; REMISSION; CHILDREN
AB Patients with post-transplant immune-mediated hepatitis (IMH) and recurrent autoimmune hepatitis (RAIH) have a poor outcome and a higher need for retransplantation. Azathioprine (AZA) is used as adjunctive immunosuppression after transplantation; optimizing its dose may be a key point in preserving graft function. Complications of high AZA dosing make dose escalation potentially problematic. Our aim was to correlate AZA metabolite levels with therapeutic effects, toxicity, and adherence to medication in children with IMH and RAIH. Charts of 14 patients were retrospectively reviewed. The post-transplant diagnosis was based on liver biopsy and autoimmune markers. AZA was prescribed after establishing the post-transplant diagnosis. AZA was started at 1.1 (1.0-1.8) mg/kg/day. Routine biochemical studies, tacrolimus levels, 6-thioguanine (6-TG) and 6-methylmercaptopurine levels were assessed every 8 wk. AZA dose was routinely adjusted to achieve 6-TG levels between 235 and 450 pmol per 8 x 10(8) RBC. A total of 92 samples from 14 patients were reviewed. Four patients were excluded because of non-adherence. AZA dose was increased by 245% resulting in eight of 10 patients in the target range; no hepatic or bone marrow toxicity was observed. ALT levels and steroid requirements were significantly reduced (p < 0.05). The AZA dose required to achieve target 6-TG levels was significantly greater in children <10 yr. AZA metabolite testing in children post-liver transplant is useful in assessing adherence to medication and it is potentially helpful in optimizing medication dosing. In younger children the AZA dose requirements were two to four times higher than previously reported standard doses.
C1 Mt Sinai Sch Med, Pediat Liver Liver Transplant Program, Recanati Miller Transplantat Inst, New York, NY 10029 USA.
   Mt Sinai Sch Med, Div Pediat Hepatol, New York, NY 10029 USA.
RP Rumbo, C (reprint author), Mt Sinai Sch Med, Pediat Liver Liver Transplant Program, Recanati Miller Transplantat Inst, 1 Gustave L Levy Pl,POB 1104, New York, NY 10029 USA.
EM Carolina.Rumbo@msnyuhealth.org
CR Andries S, 2001, TRANSPLANTATION, V72, P267, DOI 10.1097/00007890-200107270-00018
   Berkovitch M, 1996, MED PEDIATR ONCOL, V26, P85
   Bloomfeld RS, 2003, ALIMENT PHARM THERAP, V17, P69, DOI 10.1046/j.0269-2813.2003.01392.x
   Cuffari C, 2001, GUT, V48, P642, DOI 10.1136/gut.48.5.642
   Cuffari C, 1996, GUT, V39, P401, DOI 10.1136/gut.39.3.401
   Dubinsky MC, 2000, GASTROENTEROLOGY, V118, P705, DOI 10.1016/S0016-5085(00)70140-5
   Duclos-Vallee JC, 2003, GUT, V52, P893, DOI 10.1136/gut.52.6.893
   Elion G B, 1993, Ann N Y Acad Sci, V685, P400
   Gupta P, 2001, J PEDIATR GASTR NUTR, V33, P450, DOI 10.1097/00005176-200110000-00006
   Heffron TG, 2002, TRANSPLANT P, V34, P3311, DOI 10.1016/S0041-1345(02)03570-4
   Heffron TG, 2003, TRANSPLANT P, V35, P1435, DOI 10.1016/S0041-1345(03)00457-3
   Heneghan MA, 2002, HEPATOLOGY, V35, P7, DOI 10.1053/jhep.2002.30991
   JOHNSON PJ, 1995, NEW ENGL J MED, V333, P958, DOI 10.1056/NEJM199510123331502
   Kerkar N, 1998, LANCET, V351, P409, DOI 10.1016/S0140-6736(97)06478-7
   Laederach-Hofmann K, 2000, GEN HOSP PSYCHIAT, V22, P412, DOI 10.1016/S0163-8343(00)00098-0
   Langley PG, 2002, J HEPATOL, V37, P441, DOI 10.1016/S0168-8278(02)00214-3
   Lowry PW, 2001, GUT, V49, P665, DOI 10.1136/gut.49.5.665
   Maltzman JS, 2003, J CLIN INVEST, V111, P1122, DOI 10.1172/JCI200318384
   Manns MP, 2000, HEPATOLOGY, V32, P868, DOI 10.1053/jhep.2000.19149
   Medina J, 2003, ALIMENT PHARM THERAP, V17, P1, DOI 10.1046/j.0269-2813.2003.01389.x
   Molmenti EP, 2002, LIVER TRANSPLANT, V8, P519, DOI 10.1053/jlts.2002.32981
   Neuberger J, 2002, SEMIN LIVER DIS, V22, P379, DOI 10.1055/s-2002-35707
   Persley KM, 2001, EUR J GASTROEN HEPAT, V13, P1053, DOI 10.1097/00042737-200109000-00009
   Petz W, 2002, TRANSPLANT P, V34, P1958, DOI 10.1016/S0041-1345(02)03137-8
   REICH DJ, 2000, HEPATOLOGY, V32, P868
   Rumbo C, 2002, J PEDIATR GASTR NUTR, V35, P391, DOI 10.1097/00005176-200209000-00032
   Yachha SK, 2001, J GASTROEN HEPATOL, V16, P674, DOI 10.1046/j.1440-1746.2001.02492.x
NR 27
TC 9
Z9 9
U1 0
U2 2
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD DEC
PY 2004
VL 8
IS 6
BP 571
EP 575
DI 10.1111/j.1399-3046.2004.00230.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 878ZR
UT WOS:000225686700010
PM 15598326
ER

PT J
AU Narumi, S
   Hakamada, K
   Toyoki, Y
   Totsuka, E
   Niioka, T
   Umehara, Y
   Ono, H
   Nishimura, A
   Yoshihara, S
   Sasaki, M
AF Narumi, S
   Hakamada, K
   Toyoki, Y
   Totsuka, E
   Niioka, T
   Umehara, Y
   Ono, H
   Nishimura, A
   Yoshihara, S
   Sasaki, M
TI Hepatic clearance improves after angioplasty of the hepatic vein
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID PEDIATRIC LIVER-TRANSPLANTATION; VASCULAR COMPLICATIONS; VENOUS
   COMPLICATIONS; DOPPLER US; STENOSIS
AB Anastomotic stricture sometimes causes hepatic congestion leading to decreased hepatic clearance of drugs. We herein describe a correlation between trough levels of tacrolimus and an anastomotic stricture of the hepatic vein. A 13-year-old boy underwent living donor liver transplant with a left lobe graft from his mother. Outflow blockage due to an anastomotic stricture of the hepatic vein developed 3 months after transplant. His anastomotic site had been repeatedly treated with percutaneous transvenous angioplasty (PTA) by balloon dilation. About I year after transplant, his trough level of tacrolimus promptly decreased after balloon dilation (from 15.7 to 5.6 ng/dL). Liver function tests showed abnomalities, which were diagnosed as acute cellular rejection, and he was treated with pulse steroid therapy. The calculated half-life of tacrolimus (T1/2) showed marked improvement after PTA (from 35 to 22 hours). A 45-year-old woman underwent living donor transplantation due to alcoholic liver cirrhosis with a left lobe graft from her brother. An anastomotic stricture of the hepatic vein developed 4 months after transplant. She was treated with balloon dilation, which caused an abrupt decrease in the trough level of tacrolimus (12 to 4 ng/dL). Her alkaline phosphatase was elevated and she was diagnosed with rejection, which was treated with an increase of dosage of tacrolimus. In outflow block, the T1/2 of tacrolimus increases probably due to decreased hepatic clearance by stagnation or congestion of the liver. However, hepatic clearance of drugs quickly recovers after PTA. Close monitoring of immunosuppressive agents is fundamental at the time of angioplasty to avoid acute cellular rejection as developed in our two cases.
C1 Hirosaki Univ, Sch Med, Dept Surg, Hirosaki, Aomori 0368562, Japan.
   Hirosaki Univ Hosp, Dept Pharm, Hirosaki, Aomori 036, Japan.
RP Narumi, S (reprint author), Hirosaki Univ, Sch Med, Dept Surg, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.
CR Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 2001, TRANSPLANT INT, V14, P223, DOI 10.1007/s001470100324
   Cheng YF, 2004, LIVER TRANSPLANT, V10, P248, DOI 10.1002/lt.20055
   Mazariegos G V, 2000, Pediatr Transplant, V4, P322, DOI 10.1034/j.1399-3046.2000.00124.x
   ROSSI AR, 1993, RADIOLOGY, V187, P387
   Settmacher U, 2000, CLIN TRANSPLANT, V14, P235, DOI 10.1034/j.1399-0012.2000.140309.x
   SOMEDA H, 1995, J HEPATOL, V22, P623, DOI 10.1016/0168-8278(95)80218-5
   Sugimoto K, 2003, THER DRUG MONIT, V25, P294, DOI 10.1097/00007691-200306000-00007
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   ZAJKO AB, 1994, J VASC INTERV RADIOL, V5, P121, DOI 10.1016/S1051-0443(94)71467-6
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD DEC
PY 2004
VL 36
IS 10
BP 3091
EP 3092
DI 10.1016/j.transproceed.2004.10.040
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 894BV
UT WOS:000226765800052
PM 15686702
ER

PT J
AU Guarrera, JV
   Sinha, P
   Lobritto, SJ
   Brown, RS
   Kinkhabwala, M
   Emond, JC
AF Guarrera, JV
   Sinha, P
   Lobritto, SJ
   Brown, RS
   Kinkhabwala, M
   Emond, JC
TI Microvascular hepatic artery anastomosis in pediatric segmental liver
   transplantation: microscope vs loupe
SO TRANSPLANT INTERNATIONAL
LA English
DT Article; Proceedings Paper
CT Biennial Meeting of the
   International-Association-for-the-Study-of-the-Liver
CY APR 15-16, 2002
CL MADRID, SPAIN
SP Int Assoc Study Liver
DE pediatric transplant; liver transplantation; segmental graft; hepatic
   artery; microvascular anastomosis; technical complication
ID LIVING-DONOR; RECONSTRUCTION; CHILDREN; SURGERY
AB Use of operative microscopy (OM) has dramatically reduced the incidence of hepatic artery thrombosis (HAT) in children undergoing segmental liver transplantation. We used OM (12-16x) in our early experience. We changed to high power loupe magnification (6x) after 14 cases. We examined our experience with microvascular hepatic artery reconstruction in 28 consecutive children (<18 years) who underwent living donor (LDLT) or split liver transplantation (SLT). Reconstructions were done with interrupted, end-to-end anastomoses with 8-0 polypropylene using microvascular techniques. Group 1 consisted of 14 children who underwent LDLT employing OM for the hepatic artery anastomosis. Group 2 consisted of the subsequent 14 children (11 LDLT, 3 SLT) in whom 6x loupe optics were used for the arterial anastomosis. Grafts included 25 left lateral segments, 2 left lobes, and 1 right lobe. Recipients' median age was 1.0 years (range 3 months to 17 years). The mean follow-up time was 27.1 months. There were no cases of HAT. Variables of age, sex, graft type, number of Doppler ultrasound exams (DUS), and biliary complications were similar between groups. Microvascular hepatic artery reconstruction in children with 6x loupe magnification can yield results as good as operative microscopy.
C1 New York Presbyterian Hosp, Dept Surg, New York, NY 10032 USA.
   New York Presbyterian Hosp, Ctr Liver Dis & Transplantat, New York, NY USA.
   Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
RP Guarrera, JV (reprint author), New York Presbyterian Hosp, Dept Surg, 622 W 168th St,PH Box 411, New York, NY 10032 USA.
EM jjg46@columbia.edu
OI Sinha, Prashant/0000-0002-4017-553X
CR BROELSCH CE, 1988, ANN SURG, V208, P410, DOI 10.1097/00000658-198810000-00003
   Furuta S, 1997, Liver Transpl Surg, V3, P388, DOI 10.1002/lt.500030405
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   MORI K, 1993, TRANSPLANT P, V25, P1093
   Saing H, 1997, J PEDIATR SURG, V32, P80, DOI 10.1016/S0022-3468(97)90100-7
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Uchiyama H, 2002, SURGERY, V131, pS200, DOI 10.1067/msy.2002.119577
NR 9
TC 17
Z9 19
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0934-0874
J9 TRANSPLANT INT
JI Transpl. Int.
PD OCT
PY 2004
VL 17
IS 10
BP 585
EP 588
DI 10.1007/s00147-004-0782-8
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 877ZG
UT WOS:000225614100003
PM 15592715
ER

PT J
AU Visser, BC
   Suh, I
   Hirose, S
   Rosenthal, P
   Lee, H
   Roberts, JP
   Hirose, R
AF Visser, BC
   Suh, I
   Hirose, S
   Rosenthal, P
   Lee, H
   Roberts, JP
   Hirose, R
TI The influence of portoenterostomy on transplantation for biliary atresia
SO LIVER TRANSPLANTATION
LA English
DT Article
ID PEDIATRIC LIVER-TRANSPLANTATION; HEPATIC PORTOENTEROSTOMY; KASAI
   PROCEDURE; PRIMARY GRAFTS; RECIPIENTS; SURGERY; IMPACT; EXPERIENCE;
   DISSECTION; REGISTRY
AB After portoenterostomy (PE) for biliary atresia (BA), many patients suffer progressive deterioration of liver function and ultimately require liver transplantation. We retrospectively reviewed a single center's experience with pediatric liver transplantation for BA from 1988 to 2002. Sixty-six patients underwent 69 liver transplants for BA. Forty-two (63%) patients had previously undergone Kasai PE, 11 (17%) biliary appendicoduodenostomy (BAD), and 13 (20%) had no prior biliary drainage (NBD). The BAD procedure offered only short-term biliary drainage-the mean interval between PE and transplant was more than twice that for Kasai patients than for BAD patients (132 versus 49 weeks). The transplants included 11 cadaveric partial, 27 cadaveric whole, and 31 living related transplants. Three patients required retransplant. Prior PE did not increase the incidence of major perioperative complications or unplanned reexploration. After transplant, the 1-, 5-, and 10-year actuarial graft survival rates were 87%, 86%, and 80%, respectively. The 1-, 5-, and 10-year actuarial patient survival rates were 91%, 89%, and 83%. PE remains an important bridge to transplant. In conclusion, transplantation for BA offers excellent long-term graft and patient survival.
C1 Univ Calif San Francisco, Transplant Div, Dept Surg, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.
RP Hirose, R (reprint author), Univ Calif San Francisco, Transplant Div, Dept Surg, 505 Parnassus Ave,Room M-884, San Francisco, CA 94143 USA.
EM hiroser@surgery.ucsf.edu
CR Altman RP, 1997, ANN SURG, V226, P348, DOI 10.1097/00000658-199709000-00014
   Greenfeld J, 1997, ANN SURG, V226, P353
   Balistreri WF, 1996, HEPATOLOGY, V23, P1682, DOI 10.1002/hep.510230652
   BEATH S, 1993, J PEDIATR SURG, V28, P1044
   Carceller A, 2000, J PEDIATR SURG, V35, P717, DOI 10.1053/jpsu.2000.6034
   Chardot C, 1999, HEPATOLOGY, V30, P606, DOI 10.1002/hep.510300330
   CROMBLEHOLME TM, 1989, J PEDIATR SURG, V24, P665, DOI 10.1016/S0022-3468(89)80715-8
   Davenport M, 2004, LANCET, V363, P1354, DOI 10.1016/S0140-6736(04)16045-5
   Diem HVT, 2003, TRANSPLANTATION, V75, P1692, DOI 10.1097/01.TP.0000062570.83203.A3
   ENDO M, 1983, J PEDIATR SURG, V18, P784, DOI 10.1016/S0022-3468(83)80024-4
   Evrard V, 2004, ANN SURG, V239, P272, DOI 10.1097/01.sla.0000108681.24374.02
   Farmer DG, 2001, TRANSPLANTATION, V72, P1795, DOI 10.1097/00007890-200112150-00015
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   HAYS DM, 1963, SURGERY, V54, P373
   Howard ER, 1997, TOHOKU J EXP MED, V181, P75, DOI 10.1620/tjem.181.75
   Ibrahim M, 1997, TOHOKU J EXP MED, V181, P85, DOI 10.1620/tjem.181.85
   Inomata Y, 1997, J PEDIATR SURG, V32, P1201
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   KARRER FM, 1990, J PEDIATR SURG, V25, P1076, DOI 10.1016/0022-3468(90)90222-U
   Karrer FM, 1990, J PEDIATR SURG, V25, P1081
   KASAI M, 1989, J PEDIATR SURG, V24, P851, DOI 10.1016/S0022-3468(89)80580-9
   LAURENT J, 1990, GASTROENTEROLOGY, V99, P1793
   LILLY JR, 1987, J PEDIATR-US, V110, P561, DOI 10.1016/S0022-3476(87)80548-6
   Lopez-Santamaria M, 1998, PEDIATR SURG INT, V13, P327, DOI 10.1007/s003830050331
   McKiernan PJ, 2000, LANCET, V355, P25, DOI 10.1016/S0140-6736(99)03492-3
   MIELIVERGANI G, 1989, LANCET, V1, P421
   MIYANO T, 1993, WORLD J SURG, V17, P332
   NAKAJO T, 1990, J PEDIATR SURG, V25, P311, DOI 10.1016/0022-3468(90)90074-J
   Narkewicz MR, 2001, CURR OPIN PEDIATR, V13, P435, DOI 10.1097/00008480-200110000-00009
   National Institutes of Health Consensus, 1984, HEPATOLOGY, V4, p107S
   Ohi R, 1998, SURG TODAY, V28, P1229
   OHI R, 1985, WORLD J SURG, V9, P285
   Ohi R, 2001, LIVER, V21, P175, DOI 10.1034/j.1600-0676.2001.021003175.x
   OHYA T, 1995, J PEDIATR SURG, V30, P515, DOI 10.1016/0022-3468(95)90120-5
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Renz JF, 1997, ARCH SURG-CHICAGO, V132, P950
   Renz JF, 1997, ARCH SURG-CHICAGO, V132, P955
   Roberts JP, 2004, AM J TRANSPLANT, V4, P373, DOI 10.1111/j.1600-6143.2004.00359.x
   Sandler AD, 1997, J PEDIATR SURG, V32, P416, DOI 10.1016/S0022-3468(97)90594-7
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   SURUGA K, 1992, J PEDIATR SURG, V27, P707, DOI 10.1016/S0022-3468(05)80096-X
   Toyoki Y, 2002, PEDIATR TRANSPLANT, V6, P301, DOI 10.1034/j.1399-3046.2002.02013.x
   TOYOSAKA A, 1994, J PEDIATR SURG, V29, P896, DOI 10.1016/0022-3468(94)90011-6
   Tsao K, 2003, J PEDIATR SURG, V38, P1005, DOI 10.1016/S0022-3468(03)00180-5
   Valayer J, 1996, J PEDIATR SURG, V31, P1546, DOI 10.1016/S0022-3468(96)90174-8
   Volpert D, 2001, J PEDIATR GASTR NUTR, V32, P265, DOI 10.1097/00005176-200103000-00006
NR 46
TC 16
Z9 20
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2004
VL 10
IS 10
BP 1279
EP 1286
DI 10.1002/lt.20234
PG 8
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 857II
UT WOS:000224109300010
PM 15376306
ER

PT J
AU Lin, CC
   Chuang, FR
   Wang, CC
   Chen, YS
   Chen, CL
   Liu, YW
   Cheng, YF
   Lee, CH
   Jawan, B
AF Lin, CC
   Chuang, FR
   Wang, CC
   Chen, YS
   Chen, CL
   Liu, YW
   Cheng, YF
   Lee, CH
   Jawan, B
TI Early postoperative complications in recipients of living donor liver
   transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the Asian-Society-of-Transplantation
CY SEP 23-27, 2003
CL Kualu Lumpur, MALAYSIA
SP Asian Soc Transplantat
ID ACUTE-RENAL-FAILURE; MYCOPHENOLATE-MOFETIL; DYSFUNCTION; CHILDREN;
   THERAPY
AB Purpose. Complications are common in the early postoperative period after living donor liver transplantation (LDLT). The aims of this analysis were to describe and identify risk factors for early postoperative complications.
   Methods. Between June 1994 and June 2003, 140 consecutive LDLT patients were divided into 3 groups: group I was small infants < 9 kg (n = 30); group 11, pediatric patients (n = 63); and group III, adult patients (n = 47). The complications within 3 months after operation were analyzed.
   Results. The mortality rate was 1.4%. Surgical complications requiring relaparotomy occurred in 7.9% of patients. Intraoperative portal vein thrombosis requiring immediate thrombectomy, which occurred in 10 patients, was significantly more frequent in the small infant group (23.1% vs 3.2% vs 2.1%; P <.01). Acute hepatic artery thrombosis that occurred in 2 patients was remedied successfully using operative rearterilization. Hepatic outflow obstruction requiring radiological interventions developed in 5 subjects. Medical complications included the following: pulmonary (14.3%), renal (19.3%), bacteremia (10.7%), cytomegalovirus infection (9.3%), and drain-related infections (20.7%). The incidence of hospital-acquired renal insufficiency was significantly higher in adult patients (3.3% vs 14.3% vs 36.2%; P <.01). There was no significant difference in the incidence of acute cellular rejection between members of the 3 groups (10.0% vs 17.5% vs 17%; P.63).
   Conclusions. Sophisticated postoperative care with multiple disciplinary involvements may achieve a low early mortality rate in LDLT. Small infants weighing <9 kg may carry a greater risk of intraoperative portal vein thrombosis. Pulmonary complications and renal function impairments were the most troublesome in pediatric and adult recipients, respectively.
C1 Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Kaohsiung 83305, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Nephrol, Kaohsiung 83305, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Diagnost Radiol, Kaohsiung 83305, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Anesthesiol, Kaohsiung 83305, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Liver Transplant Program, Kaohsiung 83305, Taiwan.
RP Chen, CL (reprint author), Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, 123 Ta Pei Rd, Kaohsiung 83305, Taiwan.
EM clchen@adm.cgmh.org.tw
CR Barkmann A, 2000, TRANSPLANTATION, V69, P1886, DOI 10.1097/00007890-200005150-00025
   Bilbao I, 1998, CLIN TRANSPLANT, V12, P123
   Calmus Y, 2002, LIVER TRANSPLANT, V8, P123, DOI 10.1053/jlts.2002.30882
   Cantarovich M, 2003, TRANSPLANTATION, V76, P98, DOI 10.1097/01.TP.0000054367.57978.4C
   Chen CL, 2003, TRANSPLANTATION, V75, pS6, DOI 10.1097/01.TP.0000046533.93621.C7
   Cheng YF, 1998, CLIN TRANSPLANT, V12, P292
   Chuang FR, 2003, TRANSPLANT P, V35, P429, DOI 10.1016/S0041-1345(02)03861-7
   Drews D, 1997, TRANSPLANT P, V29, P421, DOI 10.1016/S0041-1345(96)00161-3
   Fisher NC, 1998, TRANSPLANTATION, V66, P59, DOI 10.1097/00007890-199807150-00010
   Gilbert JR, 1999, TRANSPLANTATION, V67, P246, DOI 10.1097/00007890-199901270-00010
   Heffron TG, 2003, TRANSPLANTATION, V75, P2040, DOI 10.1097/01.TP.0000065740.69296.DA
   Kadry Z, 2002, TRANSPLANTATION, V74, P696, DOI 10.1097/01.TP.0000024447.45019.C2
   LALLIER M, 1995, J PEDIATR SURG, V30, P1122, DOI 10.1016/0022-3468(95)90002-0
   Mack C L, 2000, Pediatr Transplant, V4, P39, DOI 10.1034/j.1399-3046.2000.00080.x
   Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766
   Wagner C, 2000, J CLIN ANESTH, V12, P454, DOI 10.1016/S0952-8180(00)00192-6
NR 16
TC 25
Z9 25
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD OCT
PY 2004
VL 36
IS 8
BP 2338
EP 2341
DI 10.1016/j.transproceed.2004.07.044
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 876DO
UT WOS:000225476300048
PM 15561242
ER

PT J
AU Avitzur, Y
   De Luca, E
   Cantos, M
   Jimenez-Rivera, C
   Jones, N
   Fecteau, A
   Grant, D
   Ng, VL
AF Avitzur, Y
   De Luca, E
   Cantos, M
   Jimenez-Rivera, C
   Jones, N
   Fecteau, A
   Grant, D
   Ng, VL
TI Health status ten years after pediatric liver transplantation - Looking
   beyond the graft
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Transplant-Congress
CY MAY 30-JUN 04, 2003
CL WASHINGTON, DC
SP Amer Transplant Congress
DE long-term outcome; renal failure; infection; anemia; quality of life
ID QUALITY-OF-LIFE; LONG; RECIPIENTS; VARICELLA; CHILDREN;
   IMMUNOSUPPRESSION; REJECTION; INFECTION; ZOSTER
AB Background. Little is known about long-term health after pediatric orthotopic liver transplantation (OLT). This study aimed to characterize the health status of recipients 10 years after OLT, with an emphasis on transplant-related morbidity and quality of life.
   Methods. We performed a retrospective database review of 32 children who underwent OLT before October 1992 at one center and were alive after 10 years. Outcome measures were assessed 10 years after OLT. Cantril's self-anchoring scale was used for global quality of life assessment.
   Results. Synthetic liver function at 10 years was preserved in all patients. The annual rate of episodes of acute rejection dropped markedly after the first year (1.4 at year 1 to 0.19 rejections/patient/year at year 10). Histologically confirmed chronic rejection developed in eight (25%) patients. At 10 years, long-term complications included mild to severe chronic renal failure (77%), mild chronic anemia (59%), and hypertension (25%). Significant growth retardation (z-score < -2), hyperlipidemia, and diabetes were uncommon. Infection requiring hospitalization occurred in 81% of the patients, with varicella zoster virus as the most common pathogen. Epstein-Barr virus-related malignancies affected 22% of patients. Ten-year survivors perceived quality of life as very good. Self-reporting of drug nonadherence by seven (22%) adolescents may have contributed to development of late onset rejection in this subgroup.
   Conclusions. Children who are 10-year survivors of OLT have excellent graft function and, despite chronic extrahepatic morbidities, a self-reported high quality of life.
C1 Hosp Sick Children, Div Gastroenterol & Nutr, Toronto, ON M5G 1X8, Canada.
RP Ng, VL (reprint author), Hosp Sick Children, Div Gastroenterol & Nutr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM vicky.ng@sickkids.ca
OI De Luca, Enza/0000-0001-6281-215X
CR ALONSO EM, 1990, TRANSPLANTATION, V49, P650
   Andrews W, 1996, J PEDIATR SURG, V31, P619, DOI 10.1016/S0022-3468(96)90660-0
   Atkison PR, 2002, CAN MED ASSOC J, V166, P1663
   Bartosh SM, 1997, CLIN TRANSPLANT, V11, P354
   BAUM M, 2002, RUDOLPHS PEDIAT
   Berg UB, 2001, TRANSPLANTATION, V72, P631, DOI 10.1097/00007890-200108270-00012
   Broyer M, 1997, PEDIATRICS, V99, P35, DOI 10.1542/peds.99.1.35
   Burdelski M, 1999, EUR J PEDIATR, V158, pS34, DOI 10.1007/PL00014322
   Cantrill H, 1965, PATTERN HUMAN CONCER
   Donati M, 2000, TRANSPLANTATION, V70, P1401, DOI 10.1097/00007890-200011150-00023
   Fishman JA, 1998, NEW ENGL J MED, V338, P1741, DOI 10.1056/NEJM199806113382407
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Jain A, 2001, PEDIATR TRANSPLANT, V5, P93, DOI 10.1034/j.1399-3046.2001.005002093.x
   Jain A, 2003, TRANSPLANTATION, V75, P1020, DOI 10.1097/01.TP.0000056168.79903.20
   KELLY DA, 1997, LIVER TRANSPLANT, V3, P32
   Kennard BD, 1999, J DEV BEHAV PEDIATR, V20, P17, DOI 10.1097/00004703-199902000-00003
   Krull K, 2003, PEDIATR TRANSPLANT, V7, P111, DOI 10.1034/j.1399-3046.2003.00026.x
   Levy GA, 2001, BIODRUGS, V15, P279, DOI 10.2165/00063030-200115050-00001
   Lurie S, 2000, Pediatr Transplant, V4, P200, DOI 10.1034/j.1399-3046.2000.00110.x
   Maes M, 1997, Pediatr Transplant, V1, P171
   MCGREGOR RS, 1989, PEDIATRICS, V83, P256
   Misra S, 2000, TRANSPLANTATION, V70, P1459, DOI 10.1097/00007890-200011270-00011
   Olyaei A J, 2001, Curr Opin Crit Care, V7, P384, DOI 10.1097/00075198-200112000-00003
   Otley A, 2002, J PEDIATR GASTR NUTR, V35, P557, DOI 10.1097/00005176-200210000-00018
   Pandya A, 2001, PEDIATR TRANSPLANT, V5, P153, DOI 10.1034/j.1399-3046.2001.00048.x
   Sheiner PA, 2000, TRANSPLANTATION, V69, P781
   Superina R A, 1998, Pediatr Transplant, V2, P70
   Tornqvist J, 1999, Pediatr Transplant, V3, P115, DOI 10.1034/j.1399-3046.1999.00026.x
   Wiesner RH, 1999, LIVER TRANSPLANT SUR, V5, P388, DOI 10.1002/lt.500050519
   [Anonymous], ORGAN PROCUREMENT TR
NR 30
TC 35
Z9 37
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 27
PY 2004
VL 78
IS 4
BP 566
EP 573
DI 10.1097/01.TP.0000131663.87106.1A
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 848SD
UT WOS:000223486500013
PM 15446316
ER

PT J
AU Bucuvalas, JC
   Zeng, L
   Anand, R
AF Bucuvalas, JC
   Zeng, L
   Anand, R
CA Studies Pediat Liver Trans Res Grp
TI Predictors of length of stay for pediatric liver transplant recipients
SO LIVER TRANSPLANTATION
LA English
DT Article
ID RESOURCE UTILIZATION; COST; COMPLICATIONS; CHILDREN; IMPACT; TRENDS
AB The resources that are directed towards the care of liver transplant recipients are substantial. Approximately 100 million dollars are spent on the hospitalization of the 400 - 500 children in the United States who undergo liver transplantation each year. Using length of stay as a surrogate marker for hospital resource use, we sought to identify factors that impact length of stay and assess the trends of hospitalization after liver transplantation for a representative population of pediatric liver transplant recipients. The study population was comprised of 956 patients who underwent primary liver transplantation between 1995 and 2003 and survived at least 90 days. Data were retrieved from the Studies of Pediatric Liver Transplantation data registry. The primary outcome was the length of initial hospitalization after liver transplantation. Independent variables were age, gender, race, pediatric endstage liver disease score (PELD), year of transplantation, organ type, primary disease, length of operation, and insurance status. The mean and standard deviation of length of stay after liver transplantation was 24.0 +/- 24.5 days. Multivariate analyses showed that increased hospital stay was associated with infants less than I year of age, fulminant liver failure, receiving a technical variant organ from a cadaveric donor, government insurance, and transplant era (before 1999 vs. 1999 or later). Decreasing height z-scores and increasing length of operation were also associated with increased hospital stay. In conclusion, these parameters accounted for only 11% of the total variance, suggesting that post-transplant complications and course account for much of the variability of resource use in the immediate post-transplant period. Supplementary material for this article can be found on the LIVER TRANSPLANTATION website (http://www.interscience.wiley. com/jpages/1527-6465/suppmat).
C1 EMMES Corp, Rockville, MD 20850 USA.
   Cincinnati Childrens Hosp, Pediat Liver Care Ctr, Cincinnati, OH USA.
RP Anand, R (reprint author), EMMES Corp, 401 N Washington St,Suite 700, Rockville, MD 20850 USA.
EM splitpub@emmes.com
CR Best JH, 2001, LIVER TRANSPLANT, V7, P858, DOI 10.1053/jlts.2001.27868
   Brown RS, 1998, LIVER TRANSPLANT SUR, V4, P170, DOI 10.1002/lt.500040211
   Brown RS, 1997, ARCH SURG-CHICAGO, V132, P1098
   Bucuvalas JC, 2001, J PEDIATR-US, V139, P66, DOI 10.1067/mpd.2001.115068
   Cole CR, 2002, HEPATOLOGY, V36, p192A
   Fisher L R, 1995, Liver Transpl Surg, V1, P10, DOI 10.1002/lt.500010104
   Gilbert JR, 1999, TRANSPLANTATION, V67, P246, DOI 10.1097/00007890-199901270-00010
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Kim WR, 1995, CLIN TRANSPL, V53, P315
   LAKE JR, 1995, TRANSPLANTATION, V60, P1089, DOI 10.1097/00007890-199511270-00005
   Luft HS, 1996, HEALTH AFFAIR, V15, P23, DOI 10.1377/hlthaff.15.1.23
   Magee JC, 2004, AM J TRANSPLANT, V4, P54, DOI 10.1111/j.1600-6143.2004.00398.x
   McDiarmid S V, 1996, Liver Transpl Surg, V2, P44
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   Pasha T, 1999, HEPATOLOGY, V29, P21, DOI 10.1002/hep.510290116
   Reichert PR, 1998, LIVER TRANSPLANT SUR, V4, P343, DOI 10.1002/lt.500040517
   Russo MW, 1998, LIVER TRANSPLANT SUR, V4, P370, DOI 10.1002/lt.500040510
   Showstack J, 1999, JAMA-J AM MED ASSOC, V281, P1381, DOI 10.1001/jama.281.15.1381
   Smits JMA, 2003, TRANSPLANTATION, V75, P90, DOI 10.1097/01.TP.0000049920.11506.06/
   Whiting JF, 1999, SURGERY, V125, P217, DOI 10.1016/S0039-6060(99)70268-0
NR 20
TC 12
Z9 12
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD AUG
PY 2004
VL 10
IS 8
BP 1011
EP 1017
DI 10.1002/lt.20203
PG 7
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 845VV
UT WOS:000223274300009
PM 15390327
ER

PT J
AU Saland, JM
AF Saland, JM
TI Osseous complications of pediatric transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT American Transplant Congress
CY MAY 30-JUN 04, 2003
CL WASHINGTON, DC
DE pediatric; organ transplantation; liver; kidney; heart; bone;
   osteopenia; osteoporosis; fracture; aseptic necrosis of bone;
   osteodystrophy; bisphosphonate; review
ID BONE-MINERAL DENSITY; ORTHOTOPIC LIVER-TRANSPLANTATION; GROWTH-HORMONE
   TREATMENT; RENAL TUBULAR-ACIDOSIS; TERM-FOLLOW-UP;
   GLUCOCORTICOID-INDUCED OSTEOPOROSIS; TACROLIMUS-BASED IMMUNOSUPPRESSION;
   CAPITAL FEMORAL EPIPHYSIS; PRIMARY BILIARY-CIRRHOSIS; CALCIUM-CHANNEL
   BLOCKERS
AB Adult stature and peak bone mass are achieved through childhood growth and development. Multiple factors impair this process in children undergoing solid organ transplantation, including chronic illness, pretransplant osteodystrophy, use of medications with negative impact on bone, and post-transplant renal dysfunction. While growth delay and short stature remain common, the most severe forms of transplant-related bone disease, fracture and avascular necrosis, appear to have become less common in the pediatric age group. Osteopenia is very prevalent in adult transplant recipients and probably also in pediatrics, but its occurrence and sequelae are difficult to study in these groups due to methodological shortfalls of planar densitometry related to short stature and altered patterns of growth and development. Although the effect on lifetime peak bone mass is not clear, data from adult populations suggest an elevated long-term risk of bone disease in children receiving transplants. Optimal management of pretransplantation osteodystrophy, attention to post-transplant renal insufficiency among both renal and non-renal transplant patients, reduction of steroid dose in select patients, and supplementation with calcium plus vitamin D during expected periods of maximal bone loss may improve bone health. Careful research is required to determine the role of bisphosphonate therapy in pediatric transplantation.
C1 CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
RP Saland, JM (reprint author), CUNY Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, Box 1664, New York, NY 10029 USA.
EM jeff.saland@mssm.edu
CR Abbott KC, 2001, ANN EPIDEMIOL, V11, P450, DOI 10.1016/S1047-2797(01)00226-5
   Ahsan N, 1999, TRANSPLANTATION, V68, P1865
   Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523-1755.2000.00178.x
   ALONZO E, 2003, PED S AM TRANSPL C W
   ANDRESEN J, 1981, ACTA ORTHOP SCAND, V52, P397, DOI 10.3109/17453678109050119
   APEL DM, 1989, J PEDIATR ORTHOPED, V9, P505
   ARGAO EA, 1994, HEPATOLOGY, V20, P598, DOI 10.1016/0270-9139(94)90093-0
   Aroldi A, 1997, TRANSPLANTATION, V63, P380, DOI 10.1097/00007890-199702150-00009
   AUBIA J, 1988, LANCET, V1, P1048
   Bachrach LK, 1999, J CLIN ENDOCR METAB, V84, P4702, DOI 10.1210/jc.84.12.4702
   Baecker N, 2003, J APPL PHYSIOL, V95, P977, DOI 10.1152/japplphysiol.00264.2003
   Ball AM, 2002, JAMA-J AM MED ASSOC, V288, P3014, DOI 10.1001/jama.288.23.3014
   Baran DA, 2001, J HEART LUNG TRANSPL, V20, P59, DOI 10.1016/S1053-2498(00)00237-0
   BARBOSA LM, 1995, TRANSPLANTATION, V59, P541
   Baron R., 1999, PRIMER METABOLIC BON, P3
   Baroncelli GI, 2003, PEDIATR RES, V54, P125, DOI 10.1203/01.PDR.00000369845.27657.EB
   Bartosh SM, 1999, J PEDIATR-US, V135, P624, DOI 10.1016/S0022-3476(99)70062-4
   Beals RK, 2002, PEDIATR TRANSPLANT, V6, P423, DOI 10.1034/j.1399-3046.2002.02024.x
   Behnke B, 1996, CLIN NEPHROL, V46, P24
   Bellorin-Font E, 2003, KIDNEY INT S, V85, P125
   Benfield M R, 1999, Pediatr Transplant, V3, P27, DOI 10.1034/j.1399-3046.1999.00001.x
   Bewick M, 1976, Clin Nephrol, V5, P66
   Bianchi ML, 2000, ARTHRITIS RHEUM, V43, P1960, DOI 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J
   Bianda T, 2000, CALCIFIED TISSUE INT, V67, P116, DOI 10.1007/s00223001126
   Blumsohn A, 1997, ANN CLIN BIOCHEM, V34, P449
   Bonarek H, 1999, KIDNEY INT, V56, P642, DOI 10.1046/j.1523-1755.1999.00589.x
   Bonnin MR, 1997, ANN CLIN BIOCHEM, V34, P651
   BOOT AM, 1995, ARCH DIS CHILD, V72, P502
   Boucek M M, 2000, Pediatr Transplant, V4, P173, DOI 10.1034/j.1399-3046.2000.00131.x
   Boucek MM, 2003, J HEART LUNG TRANSPL, V22, P636, DOI 10.1016/S1053-2498(03)00184-0
   BRADBURY G, 1994, J BONE JOINT SURG AM, V76A, P1385
   Braith RW, 1996, J AM COLL CARDIOL, V28, P1471, DOI 10.1016/S0735-1097(96)00347-6
   Braith RW, 2000, J HEART LUNG TRANSPL, V19, P840, DOI 10.1016/S1053-2498(00)00159-5
   BRIGGS WA, 1972, ANN SURG, V175, P282, DOI 10.1097/00000658-197202000-00022
   Bucci JR, 2002, AM J TRANSPLANT, V2, P999, DOI 10.1034/j.1600-6143.2002.21020.x
   Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73
   CANTER CE, 1994, J HEART LUNG TRANSPL, V13, P74
   CARTER DR, 1992, J BONE MINER RES, V7, P137
   Cayco AV, 2000, TRANSPLANTATION, V70, P1722, DOI 10.1097/00007890-200012270-00011
   CHESNEY RW, 1984, PEDIATRICS, V73, P459
   Cimaz R, 2002, J RHEUMATOL, V29, P1786
   Coco M, 2003, J AM SOC NEPHROL, V14, P2669, DOI 10.1097/01.ASN.0000087092.53894.80
   CODONERFRANCH P, 1994, J PEDIATR-US, V124, P368, DOI 10.1016/S0022-3476(94)70357-4
   Cohen A, 2003, OSTEOPOROSIS INT, V14, P617, DOI 10.1007/s00198-003-1426-z
   Compston JE, 2003, LIVER TRANSPLANT, V9, P321, DOI 10.1053/jlts.2003.50044
   Crosbie OM, 1999, GUT, V44, P430
   Cruz DN, 2002, AM J TRANSPLANT, V2, P62, DOI 10.1034/j.1600-6143.2002.020111.x
   Cueto-Manzano AM, 1999, KIDNEY INT, V55, P2021, DOI 10.1046/j.1523-1755.1999.00445.x
   D'Antiga L, 2002, TRANSPLANTATION, V73, P1788, DOI 10.1097/00007890-200206150-00015
   Daniels MW, 2003, TRANSPLANTATION, V76, P673, DOI 10.1097/01.TP.0000076627.70050.53
   de Broux E, 2000, J HEART LUNG TRANSPL, V19, P825, DOI 10.1016/S1053-2498(00)00172-8
   de Broux E, 2001, TRANSPLANT P, V33, P1735, DOI 10.1016/S0041-1345(00)02662-2
   De Sevaux RGL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016082.70875.36
   Diaz-Guerra GM, 2002, OSTEOPOROSIS INT, V13, P147
   Diem HVT, 2003, TRANSPLANTATION, V75, P1664, DOI 10.1097/01.TP.0000063938.49112.C2
   DIEMENSTEENVOOR.R, 1987, J PEDIATR, V110, P351
   Domrongkitchaiporn S, 2002, KIDNEY INT, V62, P2160, DOI 10.1046/j.1523-1755.2002.00656.x
   Domrongkitchaiporn S, 2001, KIDNEY INT, V59, P1086, DOI 10.1046/j.1523-1755.2001.0590031086.x
   DONALDSON C L, 1970, Metabolism Clinical and Experimental, V19, P1071, DOI 10.1016/0026-0495(70)90032-6
   Dumoulin G, 1997, AM J KIDNEY DIS, V29, P746, DOI 10.1016/S0272-6386(97)90129-3
   Durieux S, 2002, TRANSPLANTATION, V74, P496, DOI 10.1097/00007890-200208270-00011
   EASTELL R, 1991, HEPATOLOGY, V14, P296, DOI 10.1016/0270-9139(91)91418-Z
   Egan B, 1996, IRISH MED J, V89, P26
   El-Husseini AA, 2003, NEFROLOGIA, V23, P131
   Ellis E N, 2000, Pediatr Transplant, V4, P146, DOI 10.1034/j.1399-3046.2000.00106.x
   ELMSTEDT E, 1981, ACTA ORTHOP SCAND, V52, P279, DOI 10.3109/17453678109050104
   Englund MS, 2003, PEDIATR TRANSPLANT, V7, P192, DOI 10.1034/j.1399-3046.2003.00068.x
   Epstein S, 1996, J BONE MINER RES, V11, P1
   Fan SLS, 2003, KIDNEY INT, V63, P2275, DOI 10.1046/j.1523-1755.2003.00012.x
   Fan SLS, 2000, KIDNEY INT, V57, P684, DOI 10.1046/j.1523-1755.2000.00890.x
   Faulkner RA, 1996, CALCIFIED TISSUE INT, V59, P344, DOI 10.1007/s002239900138
   Feber J, 2000, PEDIATR NEPHROL, V14, P654
   FEBER J, 1994, J PEDIATR-US, V125, P870, DOI 10.1016/S0022-3476(05)82001-3
   Felkel TO, 2002, J HEART LUNG TRANSPL, V21, P530, DOI 10.1016/S1053-2498(01)00417-X
   FELSENFELD AJ, 1986, MINER ELECTROL METAB, V12, P333
   Fine RN, 2001, PEDIATR NEPHROL, V16, P951
   Fine RN, 2002, PEDIATR TRANSPLANT, V6, P47, DOI 10.1034/j.1399-3046.2002.1p067.x
   Fine RN, 2003, J PEDIATR-US, V142, P539, DOI 10.1067/mpd.2003.189
   Fine RN, 2002, KIDNEY INT, V62, P688, DOI 10.1046/j.1523-1755.2002.00489.x
   Gafni RI, 2002, FASEB J, V16, P736, DOI 10.1096/fj.01-0640fje
   GAUTHIER VJ, 1994, ANN INTERN MED, V121, P863
   Giannini S, 2000, OSTEOPOROSIS INT, V11, P417, DOI 10.1007/s001980070109
   Giannini S, 2002, J BONE MINER RES, V17, P1768, DOI 10.1359/jbmr.2002.17.10.1768
   Gilsanz V, 1998, J CLIN ENDOCR METAB, V83, P1420, DOI 10.1210/jc.83.5.1420
   GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Glendenning P, 1999, CLIN ENDOCRINOL, V50, P347, DOI 10.1046/j.1365-2265.1999.00657.x
   Gnudi S, 2000, OSTEOPOROSIS INT, V11, P518, DOI 10.1007/s001980070095
   Goffin E, 2003, CLIN NEPHROL, V59, P98
   Goh BL, 1998, TRANSPLANT P, V30, P3594, DOI 10.1016/S0041-1345(98)01151-8
   Goodman GR, 2001, J BONE MINER RES, V16, P72, DOI 10.1359/jbmr.2001.16.1.72
   Goodman W. G., 1999, PRIMER METABOLIC BON, P347
   Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134
   Gray H, 2000, ANATOMY HUMAN BODY
   Greig P, 2003, LIVER TRANSPLANT, V9, P587, DOI 10.1053/jlts.2003.50102
   Grissom LE, 2003, PEDIATR RADIOL, V33, P226, DOI 10.1007/s00247-003-0865-1
   Groothoff JW, 2003, KIDNEY INT, V63, P266, DOI 10.1046/j.1523-1755.2003.00727.x
   GROTZ W, 1994, TRANSPLANT P, V26, P2652
   GROTZ WH, 1995, NEPHROL DIAL TRANSPL, V10, P2096
   GROTZ WH, 1994, TRANSPLANTATION, V58, P912, DOI 10.1097/00007890-199410270-00009
   Grotz WH, 1998, TRANSPLANTATION, V66, P1004, DOI 10.1097/00007890-199810270-00007
   Guardiola J, 1999, ANN INTERN MED, V131, P752
   Guest G, 1998, PEDIATR NEPHROL, V12, P437
   Guthery SL, 2003, LIVER TRANSPLANT, V9, P365, DOI 10.1053/jlts.2003.50071
   Haas M, 2003, KIDNEY INT, V63, P1130, DOI 10.1046/j.1523-1755.2003.00816.x
   Haffner D, 2000, NEW ENGL J MED, V343, P923, DOI 10.1056/NEJM200009283431304
   Han D, 1998, TRANSPLANT P, V30, P3034, DOI 10.1016/S0041-1345(98)00918-X
   Hangartner TN, 1996, J BONE MINER RES, V11, P1518
   HAWKING KM, 1976, NEW ENGL J MED, V294, P397
   HAWKINS FG, 1994, HEPATO-GASTROENTEROL, V41, P158
   Heaf J, 2000, CLIN TRANSPLANT, V14, P457, DOI 10.1034/j.1399-0012.2000.140503.x
   Heering P, 1998, CLIN TRANSPLANT, V12, P465
   HEERING P, 1991, NEPHRON, V59, P66
   HEIDRICH FE, 1991, ANN INTERN MED, V115, P1
   Henderson K, 2001, J BONE MINER RES, V16, P565, DOI 10.1359/jbmr.2001.16.3.565
   HIJOSA MM, 1997, AN ESP PEDIATR, V47, P373
   Hill SA, 1995, PEDIAT RADIOL S1, V25, P112
   HOKKENKOELEGA ACS, 1993, J CLIN ENDOCR METAB, V77, P932, DOI 10.1210/jc.77.4.932
   Homik J, 2000, COCHRANE DB SYST REV
   Homik J, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001347
   Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801
   Hricik DE, 2003, TRANSPLANTATION, V76, P938, DOI 10.1097/01.TP.0000089440.47239.3F
   Hruska K, 2000, PEDIATR NEPHROL, V14, P636
   Ippoliti G, 2003, TRANSPLANTATION, V75, P330, DOI 10.1097/01.TP.0000044363.31492.E5
   Isiklar I, 1998, TRANSPLANT P, V30, P814
   Jabs K, 1996, TRANSPLANTATION, V61, P31, DOI 10.1097/00007890-199601150-00008
   Jensen S, 2003, PEDIATR TRANSPLANT, V7, P119, DOI 10.1034/j.1399-3046.2003.00027.x
   JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804
   Kane R, 2001, TRANSPLANTATION, V72, P463
   Karkoszka H, 1998, NEPHROL DIAL TRANSPL, V13, P2077, DOI 10.1093/ndt/13.8.2077
   Kart-Koseoglu H, 2003, RHEUMATOL INT, V23, P159, DOI 10.1007/s00296-002-0283-y
   Kasiske BL, 2000, J AM SOC NEPHROL, V11, P1910
   Keogh JB, 1999, NUTRITION, V15, P661, DOI 10.1016/S0899-9007(99)00121-5
   Kim H, 1998, TRANSPLANT P, V30, P3029, DOI 10.1016/S0041-1345(98)00916-6
   KLARE B, 1991, TRANSPLANT P, V23, P1013
   Klaus G, 1998, PEDIATR NEPHROL, V12, P343
   Klein GL, 2002, PEDIATR TRANSPLANT, V6, P136, DOI 10.1034/j.1399-3046.2002.01060.x
   Koc M, 2002, TRANSPLANT P, V34, P2111, DOI 10.1016/S0041-1345(02)02872-5
   Krieg MA, 2001, OSTEOPOROSIS INT, V12, P112, DOI 10.1007/s001980170142
   LEE AH, 1994, AM J MED, V96, P35, DOI 10.1016/0002-9343(94)90113-9
   Leidig-Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140-6736(00)03641-2
   Leonard H, 2003, PEDIATR TRANSPLANT, V7, P59, DOI 10.1034/j.1399-3046.2003.00014.x
   Leonard MB, 2001, AM J TRANSPLANT, V1, P193, DOI 10.1046/j.1600-6135.ajt10301.x
   Leonard MB, 2002, PEDIATR CLIN N AM, V49, P143, DOI 10.1016/S0031-3955(03)00113-5
   Leonard MB, 1999, J PEDIATR-US, V135, P182, DOI 10.1016/S0022-3476(99)70020-X
   Levi M, 2001, KIDNEY INT, V59, P2377
   Levitsky J, 2003, LIVER TRANSPLANT, V9, P373, DOI 10.1053/jlts.2003.50067
   LIM VS, 1987, AM J KIDNEY DIS, V9, P363
   Livi U, 1998, TRANSPLANT P, V30, P1975, DOI 10.1016/S0041-1345(98)00501-6
   Lockridge L, 2002, AM J KIDNEY DIS, V40, DOI 10.1053/ajkd.2002.33933
   Loder RT, 2001, J PEDIATR ORTHOPED, V21, P481, DOI 10.1097/00004694-200107000-00013
   Loder RT, 1997, J PEDIATR ORTHOPED, V17, P205, DOI 10.1097/00004694-199703000-00013
   Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093
   Lu PW, 1996, J CLIN ENDOCR METAB, V81, P1586, DOI 10.1210/jc.81.4.1586
   LUCAS VP, 1991, NEW ENGL J MED, V325, P1449
   LUKERT BP, 1999, PRIMER METABOLIC BON, P292
   Mahmud FH, 2003, J PEDIATR-US, V143, P279, DOI 10.1067/S0022-3476(03)00144-6
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164
   Maxwell H, 1998, ARCH DIS CHILD, V79, P481
   McClung MR, 2003, ENDOCRIN METAB CLIN, V32, P253, DOI 10.1016/S0889-8529(02)00079-8
   McDiarmid SV, 1999, TRANSPLANTATION, V67, P404, DOI 10.1097/00007890-199902150-00011
   MCDONALD JA, 1991, HEPATOLOGY, V14, P613, DOI 10.1016/0270-9139(91)90047-Y
   Mehls O, 2002, PEDIATR NEPHROL, V17, P984, DOI 10.1007/s00467-002-0962-7
   Mentser M, 1997, J PEDIATR-US, V131, pS20, DOI 10.1016/S0022-3476(97)70005-2
   Messa P, 1998, KIDNEY INT, V54, P1704, DOI 10.1046/j.1523-1755.1998.00142.x
   Mikuls TR, 2003, TRANSPLANTATION, V75, P49, DOI 10.1097/01.TP.0000040600.14084.3B
   Miller PD, 1996, SEMIN ARTHRITIS RHEU, V25, P361, DOI 10.1016/S0049-0172(96)80001-1
   Monegal A, 2001, OSTEOPOROSIS INT, V12, P484, DOI 10.1007/s001980170094
   Montpetit K, 2003, PEDIATRICS, V111, pE601, DOI 10.1542/peds.111.5.e601
   Mora S, 2003, ENDOCRIN METAB CLIN, V32, P39, DOI 10.1016/S0889-8529(02)00058-0
   Moreno A, 1999, TRANSPLANT P, V31, P2322, DOI 10.1016/S0041-1345(99)00360-7
   Mundy G. R., 1999, PRIMER METABOLIC BON, P30, DOI DOI 10.1080/10255840802136150
   NIELSEN HE, 1977, ACTA MED SCAND, V202, P27
   Nielsen SP, 1998, BRIT J RADIOL, V71, P934
   Ninkovic M, 2002, J HEPATOL, V37, P93, DOI 10.1016/S0168-8278(02)00100-9
   Noguera A, 2003, J PEDIATR ENDOCR MET, V16, P529
   Oertel P J, 1983, Kidney Int Suppl, V15, pS34
   OGORMAN MA, 1995, CLIN TRANSPLANT, V9, P312
   Okajima H, 2003, LIVER TRANSPLANT, V9, P360, DOI 10.1005/jlts.2001.50038
   PARFITT AM, 1987, J BONE MINER RES, V2, P595
   Park KM, 1996, TRANSPLANT P, V28, P1738
   Parker CR, 1999, J BONE MINER RES, V14, P1943, DOI 10.1359/jbmr.1999.14.11.1943
   Peeters PMJG, 1996, TRANSPL INT, V9, P581
   Pichette V, 1996, AM J KIDNEY DIS, V28, P105, DOI 10.1016/S0272-6386(96)90138-9
   PIETSCHMANN P, 1991, NEPHRON, V59, P533
   POTTER DE, 1991, KIDNEY INT, V40, P752, DOI 10.1038/ki.1991.271
   POTTER DE, 1978, AM J DIS CHILD, V132, P1125
   Powell DR, 1997, J PEDIATR-US, V131, pS13, DOI 10.1016/S0022-3476(97)70003-9
   Pradhan M, 2002, AM J TRANSPLANT, V2, P652, DOI 10.1034/j.1600-6143.2002.20711.x
   Ramsey-Goldman R, 1999, J BONE MINER RES, V14, P456, DOI 10.1359/jbmr.1999.14.3.456
   Reding R, 2000, TRANSPLANTATION, V70, P405, DOI 10.1097/00007890-200008150-00001
   REES L, 1988, ARCH DIS CHILD, V63, P1326
   Reinhardt W, 1998, NEPHROL DIAL TRANSPL, V13, P436
   Renz JF, 2001, LIVER TRANSPLANT, V7, P1040, DOI 10.1053/jlts.2001.29413
   Reusz GS, 2000, ARCH DIS CHILD, V83, P146, DOI 10.1136/adc.83.2.146
   RICH GM, 1992, J HEART LUNG TRANSPL, V11, P950
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Rodeck B, 2000, J PEDIATR GASTR NUTR, V31, P286, DOI 10.1097/00005176-200009000-00016
   Rojas E, 2003, KIDNEY INT, V63, P1915, DOI 10.1046/j.1523-1755.2003.00938.x
   RUDERMAN RJ, 1979, TRANSPLANT P, V11, P104
   Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889-8529(02)00064-6
   Saland JM, 2001, AM J TRANSPLANT, V1, P243, DOI 10.1034/j.1600-6143.2001.001003243.x
   SAMBROOK PN, 1994, J HEART LUNG TRANSPL, V13, P116
   Sanchez CP, 1998, KIDNEY INT, V53, P1358, DOI 10.1046/j.1523-1755.1998.00866.x
   Sanchez CP, 2002, PEDIATR NEPHROL, V17, P322
   Sanchez V, 2002, TRANSPLANT P, V34, P164, DOI 10.1016/S0041-1345(01)02712-9
   SARNA S, 1995, PEDIATR RES, V38, P366, DOI 10.1203/00006450-199509000-00016
   Sarna S, 1996, J CLIN ENDOCR METAB, V81, P1476, DOI 10.1210/jc.81.4.1476
   Schonau E, 1998, PEDIATR NEPHROL, V12, P420
   Schoofs MWCJ, 2003, ANN INTERN MED, V139, P476
   Seeman E, 1998, J CLIN ENDOCR METAB, V83, P1414, DOI 10.1210/jc.83.5.1414
   Segal E, 2003, CLIN TRANSPLANT, V17, P13, DOI 10.1034/j.1399-0012.2003.02065.x
   Sellers E, 1998, PEDIATR NEPHROL, V12, P778
   SHAEFER F, 1999, PEDIAT NEPHROLOGY, P1197
   SHANE E, 1993, AM J MED, V94, P257, DOI 10.1016/0002-9343(93)90057-V
   Shane E, 1996, J CLIN ENDOCR METAB, V81, P1740, DOI 10.1210/jc.81.5.1740
   Shane E, 1997, J CLIN ENDOCR METAB, V82, P1497, DOI 10.1210/jc.82.5.1497
   Shapiro R, 1999, TRANSPLANTATION, V67, P299, DOI 10.1097/00007890-199901270-00020
   Specker B, 2003, J BONE MINER RES, V18, P885, DOI 10.1359/jbmr.2003.18.5.885
   Springer JE, 2000, GASTROENTEROLOGY, V118, P145, DOI 10.1016/S0016-5085(00)70423-9
   Steelman J, 2003, J PEDIATR-US, V142, P417, DOI 10.1067/mpd.2003.137
   Stempfle HU, 1999, TRANSPLANTATION, V68, P523, DOI 10.1097/00007890-199908270-00014
   STERN PJ, 1979, J BONE JOINT SURG AM, V61, P851
   Stewart TL, 2000, J ENDOCRINOL, V166, P235, DOI 10.1677/joe.0.1660235
   Szulc P, 2000, OSTEOPOROSIS INT, V11, P281, DOI 10.1007/s001980070116
   TORREGROSA JV, 1995, NEPHROL DIAL TRANSPL, V10, P111
   Torres A, 1998, NEPHROL DIAL TRANSPL, V13, P94, DOI 10.1093/ndt/13.suppl_3.94
   Torres A, 1996, KIDNEY INT, V50, P1726, DOI 10.1038/ki.1996.492
   TROTTER M, 1974, ANAT REC, V179, P1, DOI 10.1002/ar.1091790102
   UITTENBOGAART CH, 1978, AM J DIS CHILD, V132, P765
   Ulivieri FM, 1999, TRANSPLANT P, V31, P2131, DOI 10.1016/S0041-1345(99)00285-7
   van den Bergh JPW, 2000, OSTEOPOROSIS INT, V11, P967, DOI 10.1007/s001980070036
   Van Rijn RR, 2000, INVEST RADIOL, V35, P548, DOI 10.1097/00004424-200009000-00005
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   VanCleemput J, 1996, TRANSPLANTATION, V61, P1495, DOI 10.1097/00007890-199605270-00015
   VANDAMMELOMBAERTS R, 1985, TRANSPLANT P, V17, P184
   Vedi S, 2002, TRANSPLANT INT, V15, P290, DOI 10.1007/s00147-002-0402-4
   Vedi S, 1999, J BONE MINER RES, V14, P281, DOI 10.1359/jbmr.1999.14.2.281
   Veillon S, 2002, TRANSPLANT P, V34, P2819, DOI 10.1016/S0041-1345(02)03527-3
   Vincenti F, 2003, AM J TRANSPLANT, V3, P306, DOI 10.1034/j.1600-6143.2003.00005.x
   Viner RM, 1999, ARCH DIS CHILD, V80, P235
   Wehrli FW, 2001, J BONE MINER RES, V16, P1520, DOI 10.1359/jbmr.2001.16.8.1520
   Westeel FP, 2000, KIDNEY INT, V58, P1788, DOI 10.1046/j.1523-1755.2000.00341.x
   WOLPAW T, 1994, TRANSPLANTATION, V58, P1186, DOI 10.1097/00007890-199412150-00008
   Zeitlin L, 2003, PEDIATRICS, V111, P1030, DOI 10.1542/peds.111.5.1030
   [Anonymous], 2002, AM J KIDNEY DIS S2, V39, pS1
NR 248
TC 10
Z9 10
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD AUG
PY 2004
VL 8
IS 4
BP 400
EP 415
DI 10.1111/j.1399-3046.2004.00167.x
PG 16
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 846JE
UT WOS:000223311000018
PM 15265169
ER

PT J
AU Iglesias, J
   Lopez, JA
   Ortega, J
   Roqueta, J
   Asensio, M
   Margarit, C
AF Iglesias, J
   Lopez, JA
   Ortega, J
   Roqueta, J
   Asensio, M
   Margarit, C
TI Liver transplantation in infants weighing under 7 kilograms: Management
   and outcome of PICU
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE liver transplantation; infants; management; outcome
ID BILIARY ATRESIA; CHILDREN; AGE; EXPERIENCE; BABIES; SURVIVAL; FAILURE;
   LESS
AB Liver transplantation (LT) is an established treatment for children with acute and chronic liver failure. Some reports suggest that infants under the age of 1 yr and children weighing under 13 kg are high-risk groups associated with less satisfactory results. This report describes our experience during the pediatric intensive care unit stay of 16 infants weighing <7 kg who received LT. We reviewed the records of 16 infants with median age 7.4 months and median weight 5.8 kg, who received 18 liver allografts, nine whole and nine reduced. We also reviewed the use of adrenergic agonist agents, anti-infectious agents, antihypertensive agents, diuretics, immunosuppression protocol, sedation-analgesia agents, others agents (prostaglandin E-1, heparin and dipyridamole), diagnosis and management of rejection episodes, follow-up examination, nutrition and outcome. Mean peri-operative blood transfusions were 204 mL/kg, 188 mL/kg of plasma and 36 mL/kg of platelets; mean operative time was 5 h. Primary abdominal wound closure was possible in nine patients. Median initial intensive care unit stay was 18 days. Reasons for an initial stay of more than 18 days were retransplantation (1), gastrointestinal bleeding (2), paralytic ileus and atelectasis (2), septic shock (2), diaphragmatic paralysis, renal impairment and acute respiratory distress syndrome (2). Mean requirement for artificial ventilation was 168 h. Mean use of dobutamine, prostaglandin E-1 and dopamine was 3.3, 7.5 and 8.8 days, respectively. Parenteral nutrition was started at a mean of 48 h and oral food intake was started at a mean of 72 h. The most frequent complications were infection, atelectasis, gastrointestinal bleeding, acute renal failure and hepatic artery thrombosis. Four children required six re-explorations and two received retransplantation. Mean overall survival rate was 82% and graft survival was 72%. Weight alone (under 7 kg) should not be considered as a contraindication for LT. The survival rate of children post-LT is excellent regardless of graft type.
C1 Hosp Gen Valle Hebron, Pediat ICU Serv, Barcelona 08035, Spain.
   Hosp Gen Valle Hebron, Pediat Surg & Liver Transplantat Grp, Barcelona 08035, Spain.
RP Iglesias, J (reprint author), Hosp Gen Valle Hebron, Pediat ICU Serv, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.
EM joiglesias@vhebron.net
CR BEATH S, 1993, J PEDIATR SURG, V28, P1044
   BEATH SV, 1993, BRIT MED J, V307, P825
   Bonatti H, 1997, J PEDIATR SURG, V32, P486, DOI 10.1016/S0022-3468(97)90612-6
   Bonatti H, 1997, TRANSPLANT P, V29, P434, DOI 10.1016/S0041-1345(97)82529-8
   Cacciarelli TV, 1997, TRANSPLANTATION, V64, P242, DOI 10.1097/00007890-199707270-00011
   DELTURCO M, 2002, YB INTENSIVE CARE EM
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   DUNN SP, 1993, J PEDIATR SURG, V28, P1048, DOI 10.1016/0022-3468(93)90516-N
   Durand P, 2001, J PEDIATR-US, V139, P871, DOI 10.1067/mpd.2001.119989
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   Langham MR, 2001, J PEDIATR SURG, V36, P1205, DOI 10.1053/jpsu.2001.25763
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   Noujaim HM, 2002, J PEDIATR SURG, V37, P159, DOI 10.1053/jpsu.2002.30242
   OTTE JB, 1994, HEPATOLOGY, V20, pS41, DOI 10.1002/hep.1840200711
   Saing H, 1997, J PEDIATR SURG, V32, P80, DOI 10.1016/S0022-3468(97)90100-7
   Saing H, 1999, J PEDIATR SURG, V34, P1721, DOI 10.1016/S0022-3468(99)90653-X
   SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1
   Srinivasan P, 1999, SURGERY, V126, P10, DOI 10.1067/msy.1999.98686
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 20
TC 20
Z9 24
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2004
VL 8
IS 3
BP 228
EP 232
DI 10.1111/j.1399-3046.2004.00128.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 824NL
UT WOS:000221693200007
PM 15176958
ER

PT J
AU Martin, SR
   Atkison, P
   Anand, R
   Lindblad, AS
AF Martin, SR
   Atkison, P
   Anand, R
   Lindblad, AS
CA SPLIT Res Grp
TI Studies of Pediatric Liver Transplantation 2002: Patient and graft
   survival and rejection in pediatric recipients of a first liver
   transplant in the United States and Canada
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE pediatric; liver; transplantation; graft survival; survival; rejection;
   risk factors
ID LONG-TERM SURVIVAL; SINGLE-CENTER; CHILDREN; EXPERIENCE; BABIES
AB Studies of Pediatric Liver Transplantation (SPLIT) is a cooperative research network comprising 38 pediatric liver transplant centers in North America. Data from the 1092 patients who have received a first liver transplant since 1995 were analyzed for factors influencing patient survival, graft survival and acute rejection. The 3, 12, 24 and 36 month Kaplan-Meier estimates of patient/graft survival were 90.9/85.5, 86.3/80.2, 84.3/76.0, and 83.8/75.3% respectively. Univariate analysis identified initial diagnosis, type of graft (whole vs. living and cadaveric technical variant), growth failure and continuous hospitalization or ICU admission prior to transplantation as significantly influencing patient and graft survival. Subsequent multivariate analysis identified as risk factors for death: fulminant liver failure (RR=3.05, p<0.05), cadaveric technical variant grafts (RR=1.95, p<0.05), continuous hospitalization pre-transplant (RR=1.79, p<0.05), height deficit >2 s.d. from mean (RR=3.22, p<0.05). Risk factors for graft loss included: fulminant liver failure (RR=2.27, p<0.05), cadaveric technical variant grafts, (RR=1.97, p<0.05). Eleven percent of the 1092 patients were re-transplanted; vascular complications, particularly hepatic artery thrombosis (8.3% overall; 36.3% of graft failures), were responsible for the majority of re-transplants. Infection was the single most important cause of death (40 of 141, 28.4%) and was a contributing cause in 55 (39%), particularly with bacterial or fungal organisms. The cumulative Kaplan-Meier estimates of first rejection at 3, 12, 24 and 36 months were 44.8, 52.9, 59.1, and 60.3%. Initial immunosuppression with tacrolimus reduced the probability of rejection (RR=0.62, p<0.05). Eleven percent of rejections were steroid-resistant; chronic rejection led to 7 of 121 (5.8%) re-transplants. The SPLIT registry, in compiling data from a large number of centers, reflects the current outcomes for pediatric liver transplants in North America.
C1 Univ Montreal, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada.
   Univ Western Ontario, Dept Pediat, Liver Transplant Serv, London, ON N6A 3K7, Canada.
   EMMES Corp, Rockville, MD USA.
RP Martin, SR (reprint author), Univ Montreal, Hop St Justine, Dept Pediat, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM steven.martin@umontreal.ca
CR Atkison PR, 2002, CAN MED ASSOC J, V166, P1663
   BEATH SV, 1993, BRIT MED J, V307, P825
   BURDELSKI M, 1999, EUR J PEDIATR, V158, P34
   Colombani PM, 1996, ANN SURG, V223, P658, DOI 10.1097/00000658-199606000-00004
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   Francavilla R, 1998, TRANSPLANTATION, V66, P602, DOI 10.1097/00007890-199809150-00009
   Ganschow R, 2001, TRANSPLANTATION, V72, P929, DOI 10.1097/00007890-200109150-00031
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Jain A, 2000, ANN SURG, V232, P490, DOI 10.1097/00000658-200010000-00004
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   McDiarmid SV, 2002, TRANSPLANTATION, V74, P173, DOI 10.1097/00007890-200207270-00006
   Migliazza L, 2000, J PEDIATR SURG, V35, P5, DOI 10.1016/S0022-3468(00)80066-4
   Murphy MS, 1996, ARCH DIS CHILD, V75, P502
   Nair S, 2002, LANCET, V359, P287, DOI 10.1016/S0140-6736(02)07494-9
   Nashan B, 2002, TRANSPLANTATION, V73, pS3, DOI 10.1097/00007890-200205151-00002
   Otte JB, 2002, PEDIATR TRANSPLANT, V6, P378, DOI 10.1034/j.1399-3046.2002.01082.x
   Reding R, 1999, J PEDIATR-US, V134, P280, DOI 10.1016/S0022-3476(99)70450-6
   Srinivasan P, 2002, TRANSPLANTATION, V74, P652, DOI 10.1097/00007890-200209150-00011
   Talbot D, 1997, J PEDIATR SURG, V32, P710, DOI 10.1016/S0022-3468(97)90011-7
   VAZQUEZ J, 1993, J PEDIATR SURG, V28, P1051, DOI 10.1016/0022-3468(93)90517-O
   Vogt DP, 2002, SURGERY, V132, P775, DOI 10.1067/mys.2002.128343
   WIESENHAANSTELL.GC, 2000, PEDIATR TRANSPLANT, V4, P124
   Woodle ES, 1998, TRANSPLANTATION, V66, P606, DOI 10.1097/00007890-199809150-00010
NR 23
TC 82
Z9 86
U1 0
U2 4
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2004
VL 8
IS 3
BP 273
EP 283
DI 10.1111/j.1399-3046.2004.00152.x
PG 11
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 824NL
UT WOS:000221693200015
PM 15176966
ER

PT J
AU Izaki, T
   Inomata, Y
   Asonuma, K
   Okajima, H
   Ohshiro, H
   Ueno, M
   Hamamoto, R
   Iyama, K
   Tanaka, K
AF Izaki, T
   Inomata, Y
   Asonuma, K
   Okajima, H
   Ohshiro, H
   Ueno, M
   Hamamoto, R
   Iyama, K
   Tanaka, K
TI Early graft failure due to a veno-occlusive disease after a pediatric
   living donor liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE veno-occlusive disease; complication; rejection; living donor liver
   transplantation
AB A 10-month-old boy with biliary atresia after Kasai procedure underwent a living donor liver transplantation (LDLT). Five days after the LDLT, high fever and increased ascites followed by poor bile drainage was accompanied by elevation of serum liver enzymes. Liver biopsy showed occlusion of the central veins by fibro-edematous endothelium and submassive necrosis of the parenchyma. Veno-occlusive disease (VOD) was suspected, and re-LDLT was urgently performed because of deterioration of hepatic failure. There are few cases of VOD after liver transplantation and this is the first one in an infant after LDLT.
C1 Kumamoto Univ Hosp, Dept Pediat Surg, Kumamoto, Japan.
   Kumamoto Univ Hosp, Dept Pathol, Kumamoto, Japan.
   Kyoto Univ, Dept Transplantat & Immunol, Kyoto, Japan.
RP Inomata, Y (reprint author), Kumamoto Univ, Dept Pediat Surg, Honjo 1-1-1, Kumamoto 8608556, Japan.
EM yino@fc.kuh.kumamoto-u.ac.jp
CR BRAS G, 1954, AMA ARCH PATHOL, V57, P285
   DHILLON AP, 1994, HEPATOLOGY, V19, P106
   Hasegawa S, 1998, BONE MARROW TRANSPL, V22, P1191, DOI 10.1038/sj.bmt.1701506
   Jeffries MA, 1998, DIGEST DIS SCI, V43, P229, DOI 10.1023/A:1018873415221
   Pegram AA, 2001, ANN PHARMACOTHER, V35, P935
   Sebagh M, 1999, HEPATOLOGY, V30, P1144, DOI 10.1002/hep.510300514
   TANAKA K, 1997, J HEP BIL PANCR SURG, V4, P51, DOI 10.1007/BF01211344
   Weigel G, 1999, THROMB RES, V94, P87, DOI 10.1016/S0049-3848(98)00199-6
NR 8
TC 8
Z9 11
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD JUN
PY 2004
VL 8
IS 3
BP 301
EP 304
DI 10.1111/j.1399-3046.2004.00171.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 824NL
UT WOS:000221693200018
PM 15176969
ER

PT J
AU Tsiatis, AC
   Manes, B
   Calder, C
   Billheimer, D
   Wilkerson, KS
   Frangoul, H
AF Tsiatis, AC
   Manes, B
   Calder, C
   Billheimer, D
   Wilkerson, KS
   Frangoul, H
TI Incidence and clinical complications of vancomycin-resistant
   enterococcus in pediatric stem cell transplant patients
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE vancomycin-resistant enterococcus; infection control; pediatric stem
   cell transplantation
ID NATURAL-HISTORY; ONCOLOGY UNIT; FAECIUM; COLONIZATION; LIVER; INFECTION;
   EPIDEMIOLOGY; RECIPIENTS; BACTEREMIA; MORTALITY
AB Vancomycin-resistant enterococcus (VRE) are increasingly important pathogens in stem cell transplant (SCT). In all, 61 pediatric SCT patients had surveillance stool cultures for VRE between July 1999 and November 2002. When VRE was identified, the patients were placed on strict contact isolation. VRE was detected in 15 patients (24.6%). The median age was 3.6 years ( range 0.6 - 18.5 years). Of the 15,13 (87%) received an allogeneic transplant ( six unrelated and seven related). Five of the 15 (33%) colonized patients developed VRE bacteremia. The bacteremia resolved in all five patients after therapy with quinupristin/dalfopristin; three patients required central line removal. Four patients died ( 38 - 153 days) post-SCT due to relapse or transplant complication not related to VRE. Of the 11 surviving patients, seven cleared the colonization at a median of 144 days ( range 61 - 198 days) postcolonization. Four patients remain colonized at 68 702 days after the first positive culture. Intestinal colonization with VRE occurred commonly in pediatric SCT patients. Although the morbidity from VRE was not substantial, trans plant patients were colonized for prolonged periods. Our results indicate that surveillance for VRE is an effective way to identify colonized patients and may lead to a decrease in transmission to other patients.
C1 Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Infect Control, Nashville, TN 37232 USA.
   Vanderbilt Childrens Hosp, Pediat Stem Cell Transplant Program, Nashville, TN USA.
RP Frangoul, H (reprint author), Vanderbilt Univ, Med Ctr, Dept Biostat, 397 PRB, Nashville, TN 37232 USA.
EM Haydar.Frangoul@Vanderbilt.edu
CR Bakir M, 2001, TRANSPLANTATION, V72, P1032, DOI 10.1097/00007890-200109270-00009
   Carretto E, 2000, HAEMATOLOGICA, V85, P1158
   Center for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P597
   Edmond MB, 1996, CLIN INFECT DIS, V23, P1234
   GREGORY JJ, 1999, P AN M AM SOC CLIN, V18, pA51
   HIERHOLZER WJ, 1995, AM J INFECT CONTROL, V23, P87
   Kapur D, 2000, BONE MARROW TRANSPL, V25, P147, DOI 10.1038/sj.bmt.1702123
   Kirkpatrick BD, 1999, CLIN INFECT DIS, V29, P1268, DOI 10.1086/313456
   Koc Y, 1998, BONE MARROW TRANSPL, V22, P207, DOI 10.1038/sj.bmt.1701303
   LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307
   Newell KA, 1998, TRANSPLANTATION, V65, P439, DOI 10.1097/00007890-199802150-00027
   NOSKIN GA, 1995, ARCH INTERN MED, V155, P1445, DOI 10.1001/archinte.155.13.1445
   Nourse C, 1998, EUR J PEDIATR, V157, P20, DOI 10.1007/s004310050760
   Orloff SL, 1999, AM J SURG, V177, P418, DOI 10.1016/S0002-9610(99)00083-5
   Patel R, 2001, LIVER TRANSPLANT, V7, P27, DOI 10.1053/jlts.2001.20784
   PEETERMANS WE, 1991, SCAND J INFECT DIS, V23, P105, DOI 10.3109/00365549109023382
   Pfundstein J, 1999, CLIN TRANSPLANT, V13, P245, DOI 10.1034/j.1399-0012.1999.130305.x
   Schuster F, 1998, KLIN PADIATR, V210, P261, DOI 10.1055/s-2008-1043889
   SHAY DK, 1995, J INFECT DIS, V172, P993
   Singh-Naz N, 1999, J CLIN MICROBIOL, V37, P413
   UTTLEY AHC, 1988, LANCET, V1, P57
   Weinstein MR, 1999, CLIN INFECT DIS, V29, P361, DOI 10.1086/520216
   Wong MT, 2001, CLIN INFECT DIS, V33, P1476, DOI 10.1086/322687
NR 23
TC 14
Z9 14
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD MAY
PY 2004
VL 33
IS 9
BP 937
EP 941
DI 10.1038/sj.bmt.1704462
PG 5
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 814CB
UT WOS:000220951700009
PM 15034540
ER

PT J
AU Wiederkehr, JC
   Schuller, S
   Camargo, CA
   Ekermann, M
   Avila, S
   Schultz, C
   Lemos, I
AF Wiederkehr, JC
   Schuller, S
   Camargo, CA
   Ekermann, M
   Avila, S
   Schultz, C
   Lemos, I
TI Results of 60 consecutive hepatectomies for pediatric living donor liver
   transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the Brazilian-Transplantion-Society
CY JUN 28-JUL 02, 2003
CL Forteleza, BRAZIL
SP Brazilian Transplant Soc
AB Several technical improvements have been made to increase donor pool for pediatric liver transplantation, including reduced-size grafts, split-liver, and recently living donors. The objective of the present study is to report our single-center experience with 60 hepatectomies for living donor liver transplantation in pediatric recipients between June 2000 and December 2002. Donor workup consisted. of a complete history and physical examination followed by laboratory test and liver function tests. Graft size was estimated using computed tomography scan or abdominal ultrasound. Liver biopsy was performed in all donors. Arteriogram was performed to evaluate hepatic arterial anatomy. All donors survived the procedure. Only seven patients experienced complications (10.2%) most of which were short term. We conclude that liver living donation for pediatric population is a safe procedure.
C1 PUCPR, Liver Transplant Div, Curitiba, Parana, Brazil.
   Hosp Pequeno, Curitiba, Parana, Brazil.
RP Wiederkehr, JC (reprint author), Pca Rui Barbosa,695, BR-80010030 Curitiba, Parana, Brazil.
EM wiederke@uol.com.br
CR BOX K, 1999, J GASTROEN HEPATOL, V14, pS61
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Rosendale JD, 1997, TRANSPLANT P, V29, P3408, DOI 10.1016/S0041-1345(97)00958-5
   RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7
   Sindhi R, 1999, J PEDIATR SURG, V34, P107, DOI 10.1016/S0022-3468(99)90238-5
NR 6
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAY
PY 2004
VL 36
IS 4
BP 918
EP 919
DI 10.1016/j.transproceed.2004.03.102
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 829QD
UT WOS:000222063800041
PM 15194316
ER

PT J
AU Tannuri, U
   Velhote, MCP
   Santos, MM
   Gibelli, NE
   Ayoub, AA
   Maksoud-Filho, JG
   Silva, MM
   Pinho, ML
   Miyatani, HT
   Maksoud, JG
AF Tannuri, U
   Velhote, MCP
   Santos, MM
   Gibelli, NE
   Ayoub, AA
   Maksoud-Filho, JG
   Silva, MM
   Pinho, ML
   Miyatani, HT
   Maksoud, JG
TI Pediatric liver transplantation: Fourteen years of experience at the
   Children Institute in Sao Paulo, Brazil
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the Brazilian-Transplantion-Society
CY JUN 28-JUL 02, 2003
CL Forteleza, BRAZIL
SP Brazilian Transplant Soc
AB This study reports the 14-year experience of a single center on 206 liver transplantations from living and cadaveric donors performed in 179 pediatric patients. Biliary atresia (57.2%) and fulminant hepatitis (9.8%) were the most frequent indications. The mean age of the recipients was 3 years, 7 months (9 months to 18 years) and mean weight was 14 kg (7 to 57 kg). The allografts were distributed as 82 (39.8%) whole cadaveric, 76 (36.9%) reduced-size cadaveric, 46 (22.3%) living donor liver transplants, and 2 (0.9%) ex situ split livers. The waiting periods were 25 days for living donors and 2.5 years for cadaveric donors (P < .001). Twenty-seven children were retransplanted with hepatic artery thrombosis the most frequent indication. The postoperative complications were: primary nonfunction (12.2%), biliary stenosis (28.8%), hepatic artery thrombosis (12.2%), portal vein stenosis (4.9%), hepatic vein stenosis (6.9%), and lymphoproliferative disorder (5.9%). The diagnosis of biliary stenosis was obtained by liver biopsy and transhepatic cholangiography and treated by balloon dilatation, although four children (3.9%) required a redo hepaticojejunostomy. The venous stenoses were percutaneously dilated with five-children (4.9%) requiring venous stents. The incidence of hepatic vein stenosis was 15.6% among living donor and 2.5% in cadaveric liver transplantation (P < .05). The overall 5-year patient and graft survivals were 70.2% and 65.1%. Liver transplantation provides excellent long-term survival. The use of grafts from living donors decreases the waiting periods but increases the incidence of hepatic vein stenosis.
C1 Univ Sao Paulo, Liver Transplantat Unit, Chlildren Inst, Hosp Clin, Sao Paulo, Brazil.
RP Tannuri, U (reprint author), Univ Sao Paulo, Disciplina Cirurgia Pediat, Unidade Transplante Hepat Pediat, Av Dr Arnaldo,455,4 Andar,Sala 4106, BR-01246903 Sao Paulo, Brazil.
EM uenist@usp.br
RI Tannuri, Uenis/D-3876-2012; Gibelli, Nelson Elias Mendes/I-7176-2016
CR BELZER FO, 1992, ANN SURG, V215, P579, DOI 10.1097/00000658-199206000-00004
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
NR 2
TC 27
Z9 30
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAY
PY 2004
VL 36
IS 4
BP 941
EP 942
DI 10.1016/j.transproceed.2004.03.101
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 829QD
UT WOS:000222063800050
PM 15194325
ER

PT J
AU Zanotelli, ML
   Vieira, S
   Alencastro, R
   Kieling, C
   Leipnitz, I
   Ferreira, C
   Silveira, TR
   Cantisani, GPC
AF Zanotelli, ML
   Vieira, S
   Alencastro, R
   Kieling, C
   Leipnitz, I
   Ferreira, C
   Silveira, TR
   Cantisani, GPC
TI Management of vascular complications after pediatric liver
   transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th Congress of the Brazilian-Transplantion-Society
CY JUN 28-JUL 02, 2003
CL Forteleza, BRAZIL
SP Brazilian Transplant Soc
ID PORTAL-VEIN THROMBOSIS; CHILDREN
AB Sixty-five children underwent liver transplantation (LTx) from March 1995 to December 2002. Cirrhosis due to biliary atresia was the main indication, and hepatic artery thrombosis (HAT) the most common vascular complication (n = 5). Other vascular problems were portal vein thrombosis and stenosis. Another patient developed hepatomegaly and ascites due to a late sterrosis of the left hepatic vein anastomosis. The two cases of venous stenosis were successfully treated by percutaneous angioplasty. One graft with HAT was saved, but four children died awaiting retransplant.
C1 Hosp Clin, Pediat Liver Transplant Grp, Porto Alegre, RS, Brazil.
RP Zanotelli, ML (reprint author), Hosp Clin, Serv Cirurgia Geral, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.
EM macluc@terra.com.br
RI Silveira, Themis/H-4286-2016
CR Funaki B, 1997, AM J ROENTGENOL, V169, P551
   GOLDSTEIN RM, 1990, SURGERY, V107, P540
   Ott R, 2003, TRANSPLANT INT, V16, P15, DOI 10.1007/s00147-002-0505-y
   Rela M, 1996, TRANSPLANTATION, V61, P1355, DOI 10.1097/00007890-199605150-00012
   ROUCH DA, 1988, SURG GYNECOL OBSTET, V166, P311
NR 5
TC 15
Z9 17
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAY
PY 2004
VL 36
IS 4
BP 945
EP 946
DI 10.1016/j.transproceed.2004.03.104
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 829QD
UT WOS:000222063800052
PM 15194327
ER

PT J
AU Kling, K
   Lau, H
   Colombani, P
AF Kling, K
   Lau, H
   Colombani, P
TI Biliary complications of living related pediatric liver transplant
   patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE biliary; pediatric liver transplantation; living related liver
   transplantation
ID MANAGEMENT
AB Patients who undergo living related left lateral segment liver transplants have been reported to have a high incidence of biliary complications and some studies suggest that most patients will ultimately need operative revision. We reviewed our experience with living related transplantation in pediatric recipients to examine the occurrence of biliary complications and the utility of percutaneous biliary procedures in their management. Over a 10-yr period, 48 living donor transplants were performed in 47 patients. Sixteen patients (33%) had biliary complications. Complications included 10 leaks (20%) and eight strictures (17%). Although leaks were treated predominantly with operation, other biliary complications were treated almost exclusively non-operatively. Self limited leaks that lead to biloma accumulation were most often treated via percutaneous catheter drainage and all strictures were treated using percutaneous transhepatic biliary cholangioplasty and stenting. Sixty-seven percent of biliary complications underwent non-operative biliary intervention. Most strictures were focal anastomotic strictures and were successfully treated with cholangioplasty although multiple interventions were necessary and patients required stenting for an average of 13 months. Three of eight strictures were diffuse in nature and these included the only patient who required retransplantation. Graft survival with respect to biliary complications was 94%; 1 yr, 5 yr and overall patient survival for those with biliary complications was 88, 88 and 81%, and for the entire living related group was 84, 81 and 77%, respectively. Although biliary complications are frequent in pediatric living related transplantation, they are not associated with decreased patient survival. Excepting significant bile leaks, the majority can be treated non-operatively via biliary cholangioplasty and stenting. Strictures are especially amenable to this technique which, in our experience, has been successful at decreasing or postponing the need for retransplantation.
C1 Johns Hopkins Childrens Ctr, Div Pediat Surg, Baltimore, MD 21205 USA.
RP Kling, K (reprint author), Johns Hopkins Childrens Ctr, Div Pediat Surg, 600 N Wolfe St,CMSC 7-113, Baltimore, MD 21205 USA.
EM kkling1@jhmi.edu
CR BHATNAGAR V, 1995, TRANSPLANT INT, V8, P388
   Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   Egawa H, 2001, WORLD J SURG, V25, P1300
   Jeffrey GP, 1999, AUST NZ J SURG, V69, P717, DOI 10.1046/j.1440-1622.1999.01671.x
   Kane R, 2001, TRANSPLANTATION, V72, P463
   LETOURNEAM JG, 1998, RADIOLOGY, V170, P1095
   Lorenz JM, 2001, AM J ROENTGENOL, V176, P761
   PECLET MH, 1994, J PEDIATR SURG, V29, P214, DOI 10.1016/0022-3468(94)90321-2
   Reichert PR, 1998, LIVER TRANSPLANT SUR, V4, P343, DOI 10.1002/lt.500040517
   Schindel D, 2000, J PEDIATR SURG, V35, P940, DOI 10.1053/jpsu.2000.6932
NR 10
TC 40
Z9 42
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD APR
PY 2004
VL 8
IS 2
BP 178
EP 184
DI 10.1046/j.1399-3046.2003.00127.x
PG 7
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 807EY
UT WOS:000220486000014
PM 15049799
ER

PT J
AU Seipelt, IM
   Crawford, SE
   Rodgers, S
   Backer, C
   Mavroudis, C
   Seipelt, RG
   Pahl, E
AF Seipelt, IM
   Crawford, SE
   Rodgers, S
   Backer, C
   Mavroudis, C
   Seipelt, RG
   Pahl, E
TI Hypercholesterolemia is common after pediatric heart transplantation:
   Initial experience with pravastatin
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; GRAFT VESSEL DISEASE; CARDIAC TRANSPLANTATION;
   ALLOGRAFT ARTERIOPATHY; REDUCTASE INHIBITORS; LIPOPROTEIN LEVELS;
   RISK-FACTORS; HYPERLIPIDEMIA; CYCLOSPORINE; RECIPIENTS
AB Background: Coronary allograft vasculopathy (CAV) is a progressive complication after cardiac transplantation and limits survival. Hyperlipidemia is a known risk factor for CAV, and pravastatin is effective in decreasing cholesterol levels in adults after transplantation. However, few data exist regarding lipid profiles and statin use after pediatric heart transplantation. We evaluated the prevalence of hyperlipidemia in pediatric heart transplant recipients and assessed the efficacy and safety of pravastatin therapy.
   Methods: We performed a retrospective chart review of lipid profiles greater than or equal to1 year after surgery in 50 pediatric cardiac transplant recipients to assess the incidence of hyperlipidemia. Twenty of these patients received pravastatin for hypercholesterolemia. Their primary immunosuppression therapy was cyclosporine/prednisone plus either azathioprine or mycophenolate mofetil. We reviewed serial lipid profiles, creatinine phosphokinase, and liver enzymes.
   Results: Overall, 36% of the patients (n = 50) had total cholesterol (TC) concentrations > 200 mg/dl and 52% had low-density lipoprotein (LDL) >110 mg/dL beyond 1 year after transplantation. Of the 20 treated with pravastatin, TC (236 51 vs 174 +/- 33 mg/dl) and LDL levels (151 32 vs 99 21 mg/dl) decreased significantly with therapy (p < .0001). We found no symptoms; however, 1 patient had increased creatinine phosphokinase. Liver enzyme concentrations remained normal in all.
   Conclusions: Hypercholesterolemia is prevalent in pediatric cardiac transplant recipients. Pravastatin therapy is effective in decreasing TC and LDL levels, seems to be safe, and is tolerated well. Further studies are necessary to determine whether pravastatin treatment is beneficial in decreasing CAV.
C1 Northwestern Univ, Childrens Mem Hosp, Sch Med, Dept Pediat Cardiol, Chicago, IL 60614 USA.
   Northwestern Univ, Childrens Mem Hosp, Sch Med, Dept Pathol, Chicago, IL 60614 USA.
   Northwestern Univ, Childrens Mem Hosp, Sch Med, Dept Cardiothorac Surg, Chicago, IL 60614 USA.
RP Pahl, E (reprint author), Northwestern Univ, Childrens Mem Hosp, Sch Med, Dept Pediat Cardiol, Box 21,2300 Childrens Plaza, Chicago, IL 60614 USA.
EM EPahl@northwestern.edu
CR ABOULJOUD MS, 1995, TRANSPLANT P, V27, P1121
   ARNADOTTIR M, 1991, AM J NEPHROL, V11, P391, DOI 10.1159/000168344
   Ballantyne CM, 1996, AM J CARDIOL, V78, P532, DOI 10.1016/S0002-9149(96)00358-X
   BALLANTYNE CM, 1992, J AM COLL CARDIOL, V19, P1315
   BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53
   BECKER DM, 1988, AM J MED, V85, P632
   Chin C, 2000, Pediatr Transplant, V4, P193, DOI 10.1034/j.1399-3046.2000.00112.x
   Christians U, 1998, PHARMACOL THERAPEUT, V80, P1, DOI 10.1016/S0163-7258(98)00016-3
   CORPIER CL, 1988, JAMA-J AM MED ASSOC, V260, P239, DOI 10.1001/jama.260.2.239
   Costanzo MR, 1998, J HEART LUNG TRANSPL, V17, P744
   EICH D, 1991, J HEART LUNG TRANSPL, V10, P45
   GADBUT AP, 1995, J MOL CELL CARDIOL, V27, P2397, DOI 10.1016/S0022-2828(95)92163-X
   HESS ML, 1983, CIRCULATION, V68, P94
   IBELS LS, 1978, AM J MED, V64, P634, DOI 10.1016/0002-9343(78)90584-3
   Jaeger BR, 1997, CIRCULATION, V96, P154
   Klish WJ, 1998, PEDIATRICS, V101, P141
   KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003
   LUKE DR, 1992, J PHARM SCI, V81, P208, DOI 10.1002/jps.2600810303
   MCMANUS BM, 1995, AM J PATHOL, V147, P293
   *NIH US DEP HHS, 1980, NAT I HLTH PUBL
   PAHL E, 1994, CIRCULATION, V90, P56
   Penson MG, 2001, J HEART LUNG TRANSPL, V20, P611, DOI 10.1016/S1053-2498(01)00251-0
   Rickenbacher PR, 1996, TRANSPLANTATION, V61, P46, DOI 10.1097/00007890-199601150-00011
   SCHORN TF, 1991, TRANSPLANT INT, V4, P92, DOI 10.1111/j.1432-2277.1991.tb01955.x
   URETSKY BF, 1987, CIRCULATION, V76, P827
   VALANTINE HA, 1995, J HEART LUNG TRANSPL, V14, P234
   Valantine Hannah A., 1995, Journal of Heart and Lung Transplantation, V14, pS58
   Valantine-von Kaeppler HA, 1998, CURR OPIN CARDIOL, V13, P111, DOI 10.1097/00001573-199803000-00007
   Wenke K, 1997, CIRCULATION, V96, P1398
   WINTERS GL, 1990, J HEART TRANSPLANT, V9, P364
NR 30
TC 28
Z9 29
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD MAR
PY 2004
VL 23
IS 3
BP 317
EP 322
DI 10.1016/S1053-2498(03)00193-1
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA 802HX
UT WOS:000220155700008
PM 15019641
ER

PT J
AU Loinaz, C
   Mittal, N
   Kato, T
   Miller, B
   Rodriguez, M
   Tzakis, A
AF Loinaz, C
   Mittal, N
   Kato, T
   Miller, B
   Rodriguez, M
   Tzakis, A
TI Multivisceral transplantation for pediatric intestinal
   pseudo-obstruction: Single center's experience of 16 cases
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 8th International Small Bowel Transplant Symposium
CY SEP 10-13, 2003
CL Miami, FL
SP Transplantat Soc
ID HYPOPERISTALSIS SYNDROME
AB Chronic intestinal pseudo-obstruction (CIPO) in children may be life-threatening due to the complications of parenteral nutrition (PN) or catheter-related sepsis. Multivisceral transplantation (MVTx) is a lifesaving option but limited experience is available. We report our experience with MVTx in pediatric CIPO patients. Sixteen children with CIPO underwent MVTx at median age of 4 years. Indications for MVTx were liver failure (n = 10), loss of venous access (n = 3), or sepsis (n = 3). Modified MVTx without the liver was performed in six patients. Induction immunosuppression included tacrolimus, steroid with adjunctive agent in period I (April 1996 to December 2000), namely, OKT3 (n = 1), mycophenolate mofetil (n = 4), or daclizumab (n = 2); and in period 11 (January 2001 to present), Campath 1H (n = 4) or daclizumab (n = 5). The grade of rejection was severe in 12.5% and mild to moderate in 87.5% of cases. Isolated rejection of the transplanted stomach or pancreas was not diagnosed during clinical course or on autopsy. Actuarial patient survival for 1 year/2 years for period, I and 11 were 57.1%/42.9% and 88.9%/77.8%. None of the long-term survivors is on PN and all tolerate enteral feedings. Pancreatic enzyme supplementation or insulin therapy is not needed in survivors. Gastric emptying was substantially affected in one case. Bladder function did not improve in those with urinary retention problems. MVTx for CIPO offers a lifesaving option with excellent function of the transplanted pancreas and stomach among survivors.
C1 Univ Miami, Jackson Mem Hosp, Liver GI Transplant Serv, Miami, FL 33136 USA.
   Univ Miami, Jackson Mem Hosp, Div Pediat Gastroenterol, Miami, FL 33136 USA.
RP Mittal, N (reprint author), Div Pediat GI, Locator Code D-820,1601 NW 12th Ave, Miami, FL 33136 USA.
EM nmittal@med.miami.edu
CR BERDON WE, 1976, AM J ROENTGENOL, V126, P957
   Di Lorenzo C, 1999, GASTROENTEROLOGY, V116, P980
   Faure C, 1999, DIGEST DIS SCI, V44, P953, DOI 10.1023/A:1026656513463
   Kato T, 2002, WORLD J SURG, V26, P226
   Masetti M, 1999, TRANSPLANTATION, V68, P228, DOI 10.1097/00007890-199907270-00011
NR 5
TC 15
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD MAR
PY 2004
VL 36
IS 2
BP 312
EP 313
DI 10.1016/j.transproceed.2004.01.084
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 805RZ
UT WOS:000220384700020
PM 15050142
ER

PT J
AU Cheng, YF
   Chen, CL
   Huang, TL
   Chen, TY
   Chen, YS
   Wang, CC
   Tsang, LLC
   Chiu, KW
   Jawan, B
   Eng, HL
AF Cheng, YF
   Chen, CL
   Huang, TL
   Chen, TY
   Chen, YS
   Wang, CC
   Tsang, LLC
   Chiu, KW
   Jawan, B
   Eng, HL
TI 3DCT angiography for detection of vascular complications in pediatric
   liver transplantation
SO LIVER TRANSPLANTATION
LA English
DT Article
ID HEPATIC-ARTERY THROMBOSIS; COMPUTED-TOMOGRAPHY; EXPERIENCE; STENOSIS; CT
AB Catheter angiography for early diagnosis of vascular complications in pediatric liver transplant yields excellent results but remains an extremely invasive examination for younger children, precluding its routine use. We assessed the efficacy of three-dimensional multislice computed tomographic angiography (3DCTA) as an alternative option in these patients. Methods Twenty children suspected of vascular complications on clinical grounds, laboratory findings, or Doppler ultrasound underwent 3DCTA between April 2000 and April 2003. Interventional procedures via conventional angiography were subsequently performed in 5 cases, thrombolytic therapy in 4 surgical in 1, and conservative treatment in 10. Results, Two hepatic artery stenosis, I hepatic artery thrombosis' 5 hepatic vein stenosis, 4 portal vein occlusion, I portal vein stenosis, and 7 non-vascular lesions were detected, all of which paralleled the findings of catheter angiography, Doppler ultrasound, and operations. The diagnostic accuracy for vascular complication was 90%. The sensitivity and specificity were 86.7% and 100%, respectively. The positive and negative predictive values were 100% and 71.4%, respectively. To date 19 patients arc alive, with a median follow-up period of 24.8 months. In conclusion, 3DCTA is accurate and efficient in the identification of pathological vascular insults and offers essential information for major decision on further management of the vascular complications in pediatric recipients of liver transplant.
C1 Chang Gung Univ, Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung Med Ctr, Kaohsiung 83305, Taiwan.
   Chang Gung Univ, Chang Gung Mem Hosp, Liver Transplant Program, Kaohsiung Med Ctr, Kaohsiung 83305, Taiwan.
   Chang Gung Univ, Chang Gung Mem Hosp, Dept Surg, Kaohsiung Med Ctr, Kaohsiung 83305, Taiwan.
   Chang Gung Univ, Chang Gung Mem Hosp, Dept Hepatogastroenterol, Kaohsiung Med Ctr, Kaohsiung 83305, Taiwan.
   Chang Gung Univ, Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung Med Ctr, Kaohsiung 83305, Taiwan.
   Chang Gung Univ, Chang Gung Mem Hosp, Dept Pathol, Kaohsiung Med Ctr, Kaohsiung 83305, Taiwan.
RP Cheng, YF (reprint author), Chang Gung Univ, Chang Gung Mem Hosp, Dept Diagnost Radiol, Kaohsiung Med Ctr, 123 Tai Pei Rd, Kaohsiung 83305, Taiwan.
EM cheng.yufan@msa.hinet.net
CR Brancatelli G, 2002, TRANSPLANTATION, V73, P237, DOI 10.1097/00007890-200201270-00015
   Buell JF, 2002, ANN SURG, V236, P658, DOI 10.1097/01.SLA.0000032944.15795.B8
   Cheng YF, 1998, CLIN TRANSPLANT, V12, P292
   Cheng YF, 2003, TRANSPLANTATION, V76, P353, DOI 10.1097/01.TP.0000074315.97151.AC
   Chiang YC, 1996, TRANSPLANT P, V28, P2417
   Dalgic A, 2003, PEDIATR TRANSPLANT, V7, P149, DOI 10.1034/j.1399-3046.2003.00017.x
   DODD GD, 1994, RADIOLOGY, V192, P657
   EGAWA H, 1993, CLIN TRANSPLANT, V7, P306
   FLINT EW, 1988, AM J ROENTGENOL, V151, P481
   Guckelberger O, 1999, TRANSPLANT INT, V12, P273
   Katyal S, 2000, AM J ROENTGENOL, V175, P1735
   LERUT J, 1987, ACTA CHIR BELG, V87, P193
   Quiroga S, 2001, RADIOGRAPHICS, V21, P1085
   TZAKIS AG, 1985, TRANSPLANTATION, V40, P667, DOI 10.1097/00007890-198512000-00019
   WOZNEY P, 1986, AM J ROENTGENOL, V147, P657
NR 15
TC 19
Z9 21
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD FEB
PY 2004
VL 10
IS 2
BP 248
EP 252
DI 10.1002/lt.20055
PG 5
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 805NX
UT WOS:000220374100013
PM 14762863
ER

PT J
AU Corbacioglu, S
   Greil, J
   Peters, C
   Wulffraat, N
   Laws, HJ
   Dilloo, D
   Strahm, B
   Gross-Wieltsch, U
   Sykora, KW
   Ridolfi-Luthy, A
   Basu, O
   Gruhn, B
   Gungor, T
   Mihatsch, W
   Schulz, A
AF Corbacioglu, S
   Greil, J
   Peters, C
   Wulffraat, N
   Laws, HJ
   Dilloo, D
   Strahm, B
   Gross-Wieltsch, U
   Sykora, KW
   Ridolfi-Luthy, A
   Basu, O
   Gruhn, B
   Gungor, T
   Mihatsch, W
   Schulz, A
TI Defibrotide in the treatment of children with veno-occlusive disease
   (VOD): a retrospective multicentre study demonstrates therapeutic
   efficacy upon early intervention
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE VOD; hepatic veno-occlusive disease; Defibrotide; child; treatment
   outcome; multiple-organ failure; restrospective studies
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION;
   TISSUE-PLASMINOGEN-ACTIVATOR; HEPATIC VENOCCLUSIVE DISEASE; MULTISYSTEM
   ORGAN FAILURE; MOLECULAR-WEIGHT HEPARIN; HIGH-RISK POPULATION;
   RANDOMIZED-TRIAL; URSODEOXYCHOLIC ACID; SIGNIFICANT TOXICITY
AB Veno-occlusive disease (VOD) of the liver is a complication observed particularly in patients undergoing hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is a polydeoxyribonucleotide with aptameric activity on endothelium. We evaluated in a retrospective analysis the efficacy of DF in pediatric patients developing hepatic VOD after HSCT.
   A total of 45 patients between 0.2 and 20 years ( median age: 8.2 years) with hepatic VOD were treated with DF: 22 patients (49%) met risk criteria for severe or progressive disease and 23 (51%) for moderately severe and mild disease. The median duration of DF treatment was 17 days. In all, 34 patients (76%) achieved complete response (CR) with a survival rate of 64% at day 100. CR rate in patients with severe disease was 50% with long-term survival of 36%. The average DF dose in the CR group was 45 mg/kg/day and in the no responder (NR) group 27 mg/kg/day. The use of additional drugs besides DF to treat VOD made no difference in the outcome compared to DF alone. The average interval from diagnosis to start of DF was 1 day in the CR and 5.5 days in NR group. In multivariate analysis, early intervention remained the only significant factor for a CR.
C1 Univ Ulm, Klin & Poliklin Kinder & Jugendmed, D-89069 Ulm, Germany.
RP Corbacioglu, S (reprint author), Prittwitzstr 43, D-89075 Ulm, Germany.
EM selim.corbacioglu@medizin.uni-ulm.de
CR ATTAL M, 1992, BLOOD, V79, P2834
   BAGLIN TP, 1990, BONE MARROW TRANSPL, V5, P439
   Bajwa RPS, 2003, BONE MARROW TRANSPL, V31, P591, DOI 10.1038/sj.bmt.1703881
   Bearman SI, 1997, BLOOD, V89, P1501
   BEARMAN SI, 1995, BLOOD, V85, P3005
   BRUGIERES L, 1988, BONE MARROW TRANSPL, V3, P53
   CARRERAS E, 1993, ANN HEMATOL, V66, P77, DOI 10.1007/BF01695888
   Carreras E, 2000, EUR J HAEMATOL, V64, P281, DOI 10.1034/j.1600-0609.2000.9r200.x
   Carreras E, 1998, BLOOD, V92, P3599
   Chopra R, 2000, BRIT J HAEMATOL, V111, P1122, DOI 10.1046/j.1365-2141.2000.02475.x
   Eissner G, 2002, BLOOD, V100, P334, DOI 10.1182/blood.V100.1.334
   Essell JH, 1998, ANN INTERN MED, V128, P975
   FALANGA A, 1999, BLOOD S, V94, pA148
   Falanga A, 2000, BLOOD, V96, p53A
   GLUCKMAN E, 1990, BRIT J HAEMATOL, V74, P277, DOI 10.1111/j.1365-2141.1990.tb02583.x
   Goldberg SL, 2002, BLOOD, V100, p415A
   Hasegawa S, 1998, BONE MARROW TRANSPL, V22, P1191, DOI 10.1038/sj.bmt.1701506
   Horn B, 2002, BONE MARROW TRANSPL, V29, P409, DOI 10.1038/sj/bmt/1703393
   JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011
   Kulkarni S, 1999, BONE MARROW TRANSPL, V23, P803, DOI 10.1038/sj.bmt.1701654
   Lucarelli G, 1996, BLOOD, V87, P2082
   LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701
   Martin T, 2001, BLOOD, V98, p191A
   MCDONALD GB, 1993, ANN INTERN MED, V118, P255
   MERESSE V, 1992, BONE MARROW TRANSPL, V10, P135
   Ohashi K, 2000, AM J HEMATOL, V64, P32, DOI 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.3.CO;2-E
   Or R, 1996, AM J HEMATOL, V53, P46, DOI 10.1002/(SICI)1096-8652(199609)53:1<46::AID-AJH11>3.0.CO;2-1
   PALMER KJ, 1993, DRUGS, V45, P259, DOI 10.2165/00003495-199345020-00007
   Park SH, 2002, BONE MARROW TRANSPL, V29, P137, DOI 10.1038/sj.bmt.1703342
   RADICH JP, 1993, J CLIN ONCOL, V11, P304
   Rajvanshi P, 2002, BLOOD, V99, P2310, DOI 10.1182/blood.V99.7.2310
   Reiss U, 2002, J PEDIAT HEMATOL ONC, V24, P746, DOI 10.1097/00043426-200212000-00013
   Richardson P, 1998, LEUKEMIA LYMPHOMA, V31, P267
   Richardson PG, 2002, BLOOD, V100, P4337, DOI 10.1182/blood-2002-04-1216
   Richardson PG, 1998, BLOOD, V92, P737
   Richardson PG, 2002, BLOOD, V100, p112A
   Rosenthal J, 1996, BONE MARROW TRANSPL, V18, P185
   Ruutu T, 2002, BLOOD, V100, P1977, DOI 10.1182/blood-2001-12-0159
   Schulz AS, 2002, BLOOD, V99, P3458, DOI 10.1182/blood.V99.9.3458
   SHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197
   Simon M, 2001, BONE MARROW TRANSPL, V27, P627, DOI 10.1038/sj.bmt.1702854
   Stadtmauer E, 2001, BLOOD, V98, p124A
   Strasser SI, 1999, HEPATOLOGY, V29, P1893, DOI 10.1002/hep.510290609
   Tack DK, 2001, BONE MARROW TRANSPL, V28, P895, DOI 10.1038/sj.bmt.1703242
   Vassal G, 1996, CANCER CHEMOTH PHARM, V37, P247
   Wadleigh M, 2003, BLOOD, V102, P1578, DOI 10.1182/blood-2003-01-0255
NR 46
TC 74
Z9 74
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JAN
PY 2004
VL 33
IS 2
BP 189
EP 195
DI 10.1038/sj.bmt.1704329
PG 7
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 762XT
UT WOS:000188010200008
PM 14661036
ER

PT J
AU Araz, C
   Pirat, A
   Torgay, A
   Zeyneloglu, P
   Arslan, G
AF Araz, C
   Pirat, A
   Torgay, A
   Zeyneloglu, P
   Arslan, G
TI Early postoperative complications of pediatric liver transplantation:
   Experience at one center
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT Joint Meeting of the Turkisn-Transplantation-Society and Eurotransplant
CY JUN 25-27, 2003
CL ANKARA, TURKEY
SP Turkish Transplantat Soc, Eurotransplant
AB To evaluate the postoperative complications within the first month among 20 pediatric liver transplant recipients between April 1990 and March 2003 we retrospectively studied their medical charts to gather demographic data; primary diagnosis; operative duration; perioperative transfusions; time to extubation; length of intensive care unit (ICU) stay; mortality; perioperative laboratory values; and postoperative complications including respiratory, infections, renal, neurological, cardiovascular, and gastrointestinal tract (GIT) complications.
   Ten male and ten female patients of mean age 8 +/- 4 years had a mean operative duration, time to extubation, and length of stay in the ICU of 12.1 +/- 2.3 hours, 11.1 +/- 15.0 hours, and 7.2 +/- 5.5 days, respectively. The most frequent postoperative complication was respiratory (n = 14, 70%), followed by infections (n = 13, 65%), renal (n = 8, 40%), neurological (n = 7, 35%), cardiovascular (n = 4, 20%), and GIT (n = 4, 20%) infections. The overall mortality rate was 25% (n = 5). Compared with patients who survived, those who died displayed significantly lower perioperative platelet counts (P < .05), as well as a significantly higher incidence of postoperative neurological disorders (P = .031), and cardiovascular complications (P = .032).
C1 Baskent Univ, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey.
RP Pirat, A (reprint author), Baskent Univ, Fac Med, Dept Anesthesiol, Hastanesi Anesteziyoloji Anabilim Dalt 10 Sok 45, TR-06490 Ankara, Turkey.
EM arashpirat@hotmail.com
CR BELLARY S, 1995, J HEPATOL, V23, P373, DOI 10.1016/0168-8278(95)80194-4
   CARLIER M, 1989, INTENS CARE MED S, V1, pS73
   Garcia S, 1999, TRANSPLANT P, V31, P1691, DOI 10.1016/S0041-1345(99)00066-4
   Goss JA, 1998, ANN SURG, V228, P411, DOI 10.1097/00000658-199809000-00014
   Hasegawa S, 1996, TRANSPLANTATION, V62, P943, DOI 10.1097/00007890-199610150-00012
   Jain A, 2002, TRANSPLANTATION, V73, P941, DOI 10.1097/00007890-200203270-00020
   OKAMOTO K, 1994, ANESTHESIOLOGY, V81, P256, DOI 10.1097/00000542-199407000-00033
   ROSENTHAL P, 1994, AM J GASTROENTEROL, V89, P480
NR 8
TC 12
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JAN-FEB
PY 2004
VL 36
IS 1
BP 214
EP 217
DI 10.1016/j.transproceed.2003.11.029
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 770YC
UT WOS:000188758100066
PM 15013350
ER

PT J
AU Diamanti, A
   Gambarara, M
   Knafelz, D
   Marcellini, M
   Boldrini, R
   Ferretti, F
   Papadatou, B
   Castro, M
AF Diamanti, A
   Gambarara, M
   Knafelz, D
   Marcellini, M
   Boldrini, R
   Ferretti, F
   Papadatou, B
   Castro, M
TI Prevalence of liver complications in pediatric patients on home
   parenteral nutrition: Indications for intestinal or combined
   liver-intestinal transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID DISEASE
AB Parenteral nutrition (PN) is the only treatment for patients affected by chronic intestinal failure (CIF). Home parenteral nutrition (HPN) programs are started when patients need prolonged PN. Unfortunately, many patients on prolonged PN develop liver disease (LD). The aim of our study was to assess the prevalence of LD in our series of patients on HPN. We reviewed our records of patients discharged from the hospital on HPN for CIF. HPN was started when one parent was fully trained in the use of this treatment and if the social and familial home environment was reliable. All patients received total PN by a central venous catheter. All patients with abnormal AST, ALT, ALK, gammaGT, and bilirubin values for more than 3 months were considered affected by PN-related LD. Thirty-six patients (23 of whom were boys and 13 girls) were discharged on HPN. During the study period, for CIF, 16 were affected by short bowel syndrome (SBS), of whom 6 had ultra-short bowel; 16 with functional intestinal failure, and 4 with chronic intestinal pseudobstruction (CIPO). Mean duration of HPN was 2.1 years/patient. Nine of 36 patients (25%) on HPN for CIF showed LD. Seven of the 16 patients (43%) with LD were affected by SBS and 2 (12.5%) patients by functional intestinal failure. No patients with CIPO developed LD. In patients affected by SBS, the onset of LD was very earlier than in patients with ID.
C1 Bambino Gesu Children Hosp, Gastroenterol Unit, I-00165 Rome, Italy.
   Bambino Gesu Children Hosp, Hepatol Unit, I-00165 Rome, Italy.
   Bambino Gesu Children Hosp, Serv Histol, I-00165 Rome, Italy.
RP Diamanti, A (reprint author), Bambino Gesu Children Hosp, Gastroenterol Unit, Piazza S Onofrio,4, I-00165 Rome, Italy.
CR *ASPEN BOARD DIR C, 2002, JPEN, V26, pS100
   Chan S, 1999, SURGERY, V126, P28, DOI 10.1067/msy.1999.98925
   DIAMANTI G, 2002, TRANSPLANT P, V34, P1
   GAMBARARA DC, 2002, TRANSPLANT P, V34, P3363
   Hasegawa T, 2002, PEDIATR TRANSPLANT, V6, P235, DOI 10.1034/j.1399-3046.2002.01074.x
   Kaufman SS, 2002, PEDIATR TRANSPLANT, V6, P37, DOI 10.1034/j.1399-3046.2002.1o061.x
   Kaufman SS, 2001, PEDIATR TRANSPLANT, V5, P80, DOI 10.1034/j.1399-3046.2001.005002080.x
   Luman W, 2002, CLIN NUTR, V21, P337, DOI 10.1054/clnu.2002.0554
NR 8
TC 5
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD DEC
PY 2003
VL 35
IS 8
BP 3047
EP 3049
DI 10.1016/j.transproceed.2003.10.037
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 757TE
UT WOS:000187576900058
PM 14697975
ER

PT J
AU Knafelz, D
   Gambarara, M
   Diamanti, A
   Papadatou, B
   Ferretti, F
   De Iacobis, IT
   Castro, M
AF Knafelz, D
   Gambarara, M
   Diamanti, A
   Papadatou, B
   Ferretti, F
   De Iacobis, IT
   Castro, M
TI Complications of home parenteral nutrition in a large pediatric series
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
ID CATHETER-RELATED INFECTIONS; CHILDREN; EXPERIENCE
AB When adequate nutrition cannot be provided by enteral route as a consequence of failure of intestinal functions, parenteral nutrition (PN) become the only way to maintain adequate nutrition; however, prolonged periods of PN can lead to severe complications. Furthermore, long hospital admissions for this form of nutrition can be detrimental for the child and the family. In the past 20 years, home parenteral nutrition (HPN) programs have been developed. The aim of our study was to retrospectively evaluate the kind and the frequency of complications in a HPN pediatric case series. We had 61 patients on HPN. Total duration of the program was 27,740 days (76 total years, mean 1.2 years per patient). We observed a total of 58 complications; mean 0.79 per patient per year with a prevalence of central venous cather-related complications (mechanical, 52%; infective, 26%). We had a very low incidence of metabolic complications (3%) and a low incidence of PN-related hepatic complications (19%). None of the complications described was the cause of death. Half of our patients have been able to stop the program.. We had a low incidence (0.20 per patient per year) of septic episodes, lower than we had in patients on hospital PN in the same period (0.38 per patient per year). We had to replace 20 catheters, 18 of them for mechanical problems. Our study show that HPN still can be a valid alternative to small intestinal transplantation in patients affected by intestinal failure and that only patients with PN-related liver disease must be considered early candidates for combined liver-small bowel transplant.
C1 Bambino Gesu Children Hosp, Gastroenterol Unit, I-00165 Rome, Italy.
RP Knafelz, D (reprint author), Bambino Gesu Children Hosp, Gastroenterol Unit, Piazza S Onofrio,4, I-00165 Rome, Italy.
CR BISSET WM, 1992, ARCH DIS CHILD, V67, P109
   BUCHMAN AL, 1994, JPEN-PARENTER ENTER, V18, P297, DOI 10.1177/0148607194018004297
   Colomb V, 2000, CLIN NUTR, V19, P355, DOI 10.1054/clnu.2000.0132
   Colomb V, 1998, Curr Opin Clin Nutr Metab Care, V1, P395, DOI 10.1097/00075197-199809000-00004
   Gambarara M, 2001, NUTRITION, V17, P970, DOI 10.1016/S0899-9007(01)00691-8
   KOWFMAN SS, 2001, PEDIATR TRANSPLANT, V5, P80
   RICOUR C, 1990, CLIN NUTR, V9, P65, DOI 10.1016/0261-5614(90)90055-W
NR 7
TC 20
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD DEC
PY 2003
VL 35
IS 8
BP 3050
EP 3051
DI 10.1016/j.transproceed.2003.10.040
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 757TE
UT WOS:000187576900059
PM 14697976
ER

PT J
AU Buckel, E
   Uribe, M
   Brahm, J
   Silva, G
   Ferrario, M
   Godoy, J
   Segovia, R
   Ceresa, S
   Hunter, B
   Alegria, S
   Berwart, F
   Smok, G
   Herzog, C
   Santander, T
   Calabran, L
AF Buckel, E
   Uribe, M
   Brahm, J
   Silva, G
   Ferrario, M
   Godoy, J
   Segovia, R
   Ceresa, S
   Hunter, B
   Alegria, S
   Berwart, F
   Smok, G
   Herzog, C
   Santander, T
   Calabran, L
TI Outcomes of orthotopic liver transplantation in Chile
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 18th Chilean Congress of Transplantation
CY OCT 02-05, 2002
CL PUCON, CHILE
ID SINGLE-CENTER; ADULT; RETRANSPLANTATION; EXPERIENCE; SURVIVAL
AB Our liver transplant program was started in 1993 in a private clinic and a public hospital. Thereafter, a rapid increase in adults and pediatric candidates for this therapeutic option lead to this analysis of results in 165 orthotopic liver transplants (OLT) in 143 patients between November 1993 and December 2002. Seventy-four OLT were performed in 66 adult patients and 91 in the pediatric group. Liver grafts came from cadaveric donors in 145 cases (74 adults and 71 children). The technique of living-related donor was utilized in 20 pediatric cases. Main indications for OLT in the adult group were HCV cirrhosis, primary biliary cirrhosis; biliary atresia and acute liver failure were the indications in pediatric patients. Retransplantation was needed for 23 patients, including 9 adults and 14 children. The most frequent causes of death were sepsis, graft primary nonfunction, and vascular complications. Actuarial survivals at 1 and 5 years were 80.7% and 72.6% for the adult group and 82% and 74.8% for the pediatric group, respectively. Our results are comparable to those published by large, experienced, international centers, with much better financial support.
C1 Clin Las Condes, Liver Transplant Program, Santiago, Chile.
   Hosp Ninos Luis Calvo Mackenna, Santiago, Chile.
RP Buckel, E (reprint author), Clin Las Condes, Liver Transplant Program, Santiago, Chile.
EM ebuckel@clinicalascondes.cl
CR Boillot O, 2001, CLIN TRANSPLANT, V15, P159, DOI 10.1034/j.1399-0012.2001.150303.x
   Borenstein S, 2003, J PEDIATR SURG, V38, P668, DOI 10.1010/s0022-3468(03)00023-X
   Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345
   Buckel E, 1996, REV MED CHILE, V124, P27
   Busuttil RW, 1996, TRANSPLANTATION LIVE
   Deshpande PR, 2002, TRANSPLANTATION, V74, P1124, DOI 10.1097/01.TP.0000030640.11006.CE
   Filipponi F, 2003, TRANSPLANTATION, V75, P1731, DOI 10.1097/01.TP.0000063828.20960
   Jain A, 2000, ANN SURG, V232, P490, DOI 10.1097/00000658-200010000-00004
   POWELSON JA, 1999, TRANSPLANTATION
   Rosen HR, 1996, TRANSPLANTATION, V62, P1773, DOI 10.1097/00007890-199612270-00015
   SEABERG EC, 1998, CLIN TRANS, P15
   Stange BJ, 2003, LIVER TRANSPLANT, V9, P612, DOI 10.1053/jlts.2003.50098
   STRATTA RJ, 1989, SURGERY, V106, P675
   WILSON BJ, 1989, AM J SURG, V158, P58
NR 14
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD NOV
PY 2003
VL 35
IS 7
BP 2509
EP 2510
DI 10.1016/j.transproceed.2003.09.024
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 741RU
UT WOS:000186473100034
PM 14611997
ER

PT J
AU Broelsch, CE
   Frilling, A
   Testa, G
   Cicinnati, V
   Nadalin, S
   Paul, A
   Malago, M
AF Broelsch, CE
   Frilling, A
   Testa, G
   Cicinnati, V
   Nadalin, S
   Paul, A
   Malago, M
TI Early and late complications in the recipient of an adult living donor
   liver
SO LIVER TRANSPLANTATION
LA English
DT Article
ID SINGLE-CENTER EXPERIENCE/; RIGHT-LOBE GRAFTS; TRANSPLANTATION; CHILDREN;
   RECONSTRUCTION; LESSONS
AB Key Points
   1. Adult-to-adult living donor liver transplantation has been established as a means of overcoming the cadaveric organ shortage.
   2. The anatomic situation of right-liver grafts and additional factors, i.e., underlying liver disease of the recipient, are responsible for different results in pediatric and adult recipients.
   3. In transplant recipients, small-for-size grafts, vascular problems, and biliary tract complications contribute to surgical morbidity.
   4. Management of biliary leakages needs additional attention to achieve better overall survival rates.
C1 Univ Hosp Essen, Dept Gen Surg & Transplantat, D-45122 Essen, Germany.
RP Broelsch, CE (reprint author), Univ Hosp Essen, Dept Gen Surg & Transplantat, Hufelandstr 55, D-45122 Essen, Germany.
CR Bak T, 2001, LIVER TRANSPLANT, V7, P680, DOI 10.1053/jlts.2001.26509
   BROELSCH CE, 1991, ANN SURG, V214, P428, DOI 10.1097/00000658-199110000-00007
   Fan ST, 2003, TRANSPLANTATION, V75, pS25, DOI 10.1097/01.TP.0000046618.44722.BE
   Fan ST, 2002, ANN SURG, V236, P676, DOI 10.1097/01.SLA.0000033323.01380.AC
   Fan ST, 2000, ANN SURG, V231, P126, DOI 10.1097/00000658-200001000-00018
   Ghobrial RM, 2001, LIVER TRANSPLANT, V7, P551, DOI 10.1053/jlts.2001.24910
   Goldstein MJ, 2003, WORLD J SURG, V27, P356, DOI 10.1007/s00268-002-6598-8
   Hatano E, 1997, TRANSPLANTATION, V64, P1443, DOI 10.1097/00007890-199711270-00012
   ITO T, 2003, TRANSPLANTATION, V8, P1313
   Kawasaki S, 1998, ANN SURG, V227, P269, DOI 10.1097/00000658-199802000-00017
   Kiuchi T, 1999, TRANSPLANTATION, V67, P321, DOI 10.1097/00007890-199901270-00024
   Lo CM, 1997, ANN SURG, V226, P261, DOI 10.1097/00000658-199709000-00005
   MALAGO M, IN PRESS ANN SURG
   Man K, 2003, ANN SURG, V237, P256, DOI 10.1097/00000658-200302000-00015
   Marcos A, 2000, LIVER TRANSPLANT, V6, P296, DOI 10.1053/lv.2000.6354
   Marcos A, 2000, TRANSPLANTATION, V70, P1697, DOI 10.1097/00007890-200012270-00006
   Marcos A, 2000, LIVER TRANSPLANT, V6, P3, DOI 10.1002/lt.500060117
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   Millis JM, 2000, ANN SURG, V232, P104, DOI 10.1097/00000658-200007000-00015
   Nakamura T, 2002, TRANSPLANTATION, V73, P1896, DOI 10.1097/00007890-200206270-00008
   Testa G, 2002, LIVER TRANSPLANT, V8, P340, DOI 10.1053/jlts.2002.32941
   Todo S, 2000, LIVER TRANSPLANT, V6, pS66, DOI 10.1053/jlts.2000.19009
   UCHIYAMA H, 2002, SURGERY, V131, P200
NR 23
TC 26
Z9 28
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 1527-6465
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD OCT
PY 2003
VL 9
IS 10
SU 2
BP S50
EP S53
DI 10.1053/jlts.2003.50218
PG 4
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA 731RQ
UT WOS:000185900600010
PM 14528429
ER

PT J
AU Davis, ID
   Ho, M
   Hupertz, V
   Avner, ED
AF Davis, ID
   Ho, M
   Hupertz, V
   Avner, ED
TI Survival of childhood polycystic kidney disease following renal
   transplantation: The impact of advanced hepatobiliary disease
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE polycystic kidney disease; pediatric renal transplantation; liver
   transplantation; congenital hepatic fibrosis
ID CONGENITAL HEPATIC-FIBROSIS; LONG-TERM; PEDIATRIC LIVER; CHILDREN;
   MORBIDITY
AB Childhood PKD encompasses the diagnoses of AR and ADPKD, glomerulocystic disease, and syndromes such as tuberous sclerosis or Jeune's syndrome. Given the fact that a majority of PKD children with ESRD carry the diagnosis of ARPKD, natural history studies assessing the long-term prognosis of PKD patients following renal transplantation must focus on morbidity and mortality issues related to complications from congenital hepatic fibrosis. Using the NAPRTCS registry, we analyzed the patient and graft survival rates of 203 PKD patients and 7044 non-PKD patients undergoing renal transplantation between 1987 and 2001. Deceased PKD patients, all with a diagnosis of ARPKD, were further identified and characterized using a special questionnaire submitted to the principal investigators. Overall graft and patient survival rates were not significantly different between PKD and non-PKD patients. No differences in rates of acute rejection or time to first rejection were noted between PKD and non-PKD patients. The relative risk of living longer than 3 yr in the PKD patients was not significantly different from non-PKD patients (RR = 0.70, p = 0.28). Sepsis was identified as a likely factor in the cause of death in nine (64%) ARPKD patients and was comfirmed with a positive blood culture in four patients. Despite similar graft and patient survival rates among PKD and non-PKD children following renal transplantation, our results suggest that ARPKD transplant recipients appear to be at increased risk for sepsis that may be related to hepatic fibrosis and ascending cholangitis. The utility of early liver transplantation in ARPKD patients with significant hepatobiliary disease is discussed.
C1 Rainbow Babies & Childrens Hosp, Rainbow Ctr Childhood PKD, Dept Pediat, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   EMMES Corp, Rockville, MD USA.
   Cleveland Clin Fdn, Dept Pediat, Cleveland, OH 44195 USA.
RP Davis, ID (reprint author), Rainbow Babies & Childrens Hosp, Rainbow Ctr Childhood PKD, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.
CR ALVAREZ F, 1981, J PEDIATR-US, V99, P370, DOI 10.1016/S0022-3476(81)80320-4
   BROYER M, 1993, PEDIATR NEPHROL, V7, P758
   COLE BR, 1987, J PEDIATR-US, V111, P693, DOI 10.1016/S0022-3476(87)80244-5
   DELL KM, 2001, GENECLINICS CLIN GEN
   DENNY RR, 2002, AM J TRANSPLANT, V2, pA195
   FITZPATRICK PM, 1990, AM J KIDNEY DIS, V15, P535
   Fonck C, 2001, NEPHROL DIAL TRANSPL, V16, P1648, DOI 10.1093/ndt/16.8.1648
   Fridell JA, 2002, TRANSPLANTATION, V74, P1721, DOI 10.1097/01.TP.0000039334.85487.AB
   Hanau LH, 2000, INFECT DIS CLIN N AM, V14, P521, DOI 10.1016/S0891-5520(05)70119-7
   Jamil B, 1999, NEPHROL DIAL TRANSPL, V14, P205, DOI 10.1093/ndt/14.1.205
   KAPLAN BS, 1989, PEDIATR NEPHROL, V3, P43
   Kashtan CE, 1995, PEDIATR NEPHROL, V9, P679
   Kashtan CE, 1999, PEDIATR NEPHROL, V13, P678
   Khan K, 2002, AM J TRANSPLANT, V2, P360, DOI 10.1034/j.1600-6143.2002.20412.x
   MCGONIGLE RJS, 1981, Q J MED, V50, P269
   Nakamura M, 2001, NEPHROL DIAL TRANSPL, V16, P166, DOI 10.1093/ndt/16.1.166
   PERISIC VN, 1995, ACTA PAEDIATR, V84, P695, DOI 10.1111/j.1651-2227.1995.tb13732.x
   Rogers J, 2001, TRANSPLANTATION, V72, P1666, DOI 10.1097/00007890-200111270-00016
   Roy S, 1997, PEDIATR NEPHROL, V11, P302
   Seikaly M, 2001, PEDIATR TRANSPLANT, V5, P215, DOI 10.1046/j.1397-3142.2001.00001.x
   Sharara AI, 2001, NEW ENGL J MED, V345, P669, DOI 10.1056/NEJMra003007
   Stiasny B, 2002, CLIN NEPHROL, V58, P16
   Tsimaratos M, 2000, PEDIATR NEPHROL, V14, P856
   Zerres K, 1996, ACTA PAEDIATR, V85, P437, DOI 10.1111/j.1651-2227.1996.tb14056.x
   Zerres K, 1996, Adv Nephrol Necker Hosp, V25, P147
NR 25
TC 35
Z9 38
U1 0
U2 3
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD OCT
PY 2003
VL 7
IS 5
BP 364
EP 369
DI 10.1034/j.1399-3046.2003.00094.x
PG 6
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 730RF
UT WOS:000185843200007
PM 14738296
ER

PT J
AU Ulukaya, S
   Arikan, C
   Aydogdu, S
   Ayanoglu, HO
   Tokat, Y
AF Ulukaya, S
   Arikan, C
   Aydogdu, S
   Ayanoglu, HO
   Tokat, Y
TI Immediate tracheal extubation of pediatric liver transplant recipients
   in the operating room
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE anesthesia; complication; early tracheal extubation; extubation; liver
   transplantation; pediatric liver transplantation; tracheal;
   transplantation
ID INTENSIVE-CARE; MECHANICAL VENTILATION
AB Keeping patients on mechanical ventilation after orthotopic liver transplantation (OLT) has been a standard anesthetic approach since the first utilization of liver transplantation. Advances in anesthetic management, surgical techniques and patient preparation, in addition to improved postoperative care and the reported advantages of early postoperative tracheal extubation of liver recipients, encouraged us to extubate most recipients at the end of the operation. The aim of the present study is to evaluate the pediatric liver recipients who were extubated immediately at the end of transplantation, in terms of respiratory complications and allograft function during their stay in the ICU. We retrospectively reviewed the records of 40 pediatric recipients who had undergone OLT at the Ege University Organ Transplantation Center between December 1997 and July 2002. Twelve out of 40 patients who had consecutively undergone OLT were extubated immediately at the end of the operation and were included this study. Mean Child-Pugh scores of the patients were 9 +/- 2.3 (range 6-12) and the mean PELD score was 23.1 +/- 12.3 (range 7-41). The mean age of the patients was 8.4 +/- 5.2 (range 0.8-16.8 yr). Five of the 12 extubated patients received a cadaveric and seven a living donor liver graft. The mean ICU stay of the patients was 49.1 +/- 24.2 h (6-120 h). No patients required reintubation or mechanical ventilation in the ICU. Respiratory complications diagnosed in the 12 extubated patients were hypercapnia without hypoxemia in three, atelectasis in one and pleural effusion in two. No primary non-function or delayed graft function was detected. The aspartate transaminase (AST), alanine transaminase (ALT) and protrombin time (PT) were normalized within a week. We believe that immediate tracheal extubation in the operating room is a safe procedure for selected cadaveric and living-related liver transplant recipients and will facilitate the patients' recovery and mobilization leading to reduction in complications and a reduced ICU stay.
C1 Ege Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-35100 Izmir, Turkey.
   Ege Univ, Sch Med, Dept Pediat, Div Gastroenterohepatol & Nutr, TR-35100 Izmir, Turkey.
   Ege Univ, Sch Med, Dept Gen Surg, Div Hepatobiliary & Organ Transplantat, TR-35100 Izmir, Turkey.
RP Ulukaya, S (reprint author), Ege Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-35100 Izmir, Turkey.
CR BORLAND LM, 1985, ANESTH ANALG, V64, P117
   de Carvalho EM, 1999, TRANSPLANT P, V31, P3053, DOI 10.1016/S0041-1345(99)00667-3
   DeWolf AM, 1996, BRIT J ANAESTH, V76, P624
   Ferraz-Neto BH, 1999, TRANSPLANT P, V31, P3067, DOI 10.1016/S0041-1345(99)00675-2
   Glanemann M, 2001, ACTA ANAESTH SCAND, V45, P333, DOI 10.1034/j.1399-6576.2001.045003333.x
   Glanemann M, 1998, TRANSPLANT P, V30, P1874, DOI 10.1016/S0041-1345(98)00466-7
   Harihara Y, 2000, TRANSPLANT P, V32, P2160, DOI 10.1016/S0041-1345(00)01615-8
   Hasegawa S, 1996, TRANSPLANTATION, V62, P943, DOI 10.1097/00007890-199610150-00012
   Park GR, 2000, EUR J ANAESTH, V17, P111, DOI 10.1046/j.1365-2346.2000.00618.x
   PLEVAK DJ, 1989, MAYO CLIN PROC, V64, P433
   SPAINER TB, 1995, CRIT CARE MED, V23, P466
   SUN CK, 1994, TRANSPLANT P, V26, P2246
   SUSAN MM, 1997, ANESTH ANALG, V84, P249
   Tallgren M, 1996, ACTA ANAESTH SCAND, V40, P760
   ULUKAYA S, 2001, CRIT CARE S1, V5, pS119
NR 15
TC 14
Z9 15
U1 0
U2 4
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD OCT
PY 2003
VL 7
IS 5
BP 381
EP 384
DI 10.1034/j.1399-3046.2003.00072.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 730RF
UT WOS:000185843200010
PM 14738299
ER

PT J
AU Ogura, Y
   Kaihara, S
   Haga, H
   Kozaki, K
   Ueda, M
   Oike, F
   Fujimoto, Y
   Ogawa, K
   Tanakal, K
AF Ogura, Y
   Kaihara, S
   Haga, H
   Kozaki, K
   Ueda, M
   Oike, F
   Fujimoto, Y
   Ogawa, K
   Tanakal, K
TI Outcomes for pediatric liver retransplantation from living donors
SO TRANSPLANTATION
LA English
DT Article
ID ETHICAL CONSIDERATIONS; TRANSPLANTATION; SURVIVAL; CHILDREN; MODEL
AB Background. The only therapeutic option for patients with a failing allograft is retransplantation. Living donor liver transplantation (LDLT) is a well-accepted therapeutic option for end-stage liver disease, but retransplantation from a living donor (Re-LDLT) has not previously been discussed.
   Methods. A total of 547 LDLTs were performed in 519 children (< 18 years old) at Kyoto University Hospital from June 1990 to October 2002. During the same study period, a total of 28 Re-LDLTs were performed in 27 recipients (Re-LDLT performed twice in 1 patient). Patient survival was analyzed with respect to various preoperative factors, such as functional status, pretransplantation apheresis, cause of primary graft failure, interval from primary to subsequent transplants, and laboratory values of total bilirubin and creatinine.
   Results. Kaplan-Meier survival rate from the date of Re-LDLT to 1 year was 47.6%. Functional status, pretransplantation apheresis, interval to Re-LDLT, and bilirubin and creatinine levels all exerted an adverse impact on survival after Re-LDLT. Pathologically proven major causes of primary graft failure were chronic rejection (n=10, 35.7%0), chronic cholangitis (n=6,21.4%), and vascular complications (n=7,25.0%). Among these causes, vascular complications displayed the strongest adverse impact on survival, compared with chronic cholangitis and chronic rejection (1-year survival was 35.7% in vascular complications; 66.7% in chronic cholangitis; and 60.0% in chronic rejection).
   Conclusions. Re-LDLT can save patients with a failing allograft. To achieve better results after Re-LDLT, further investigations are necessary to understand the factors leading to poor outcome after Re-LDLT.
C1 Kyoto Univ Hosp, Dept Transplantat & Immunol, Sakyo Ku, Kyoto 6068507, Japan.
   Kyoto Univ Hosp, Dept Pathol, Kyoto 606, Japan.
RP Ogura, Y (reprint author), Kyoto Univ Hosp, Dept Transplantat & Immunol, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.
RI FUJIMOTO, Yasuhiro/E-6565-2010
CR Achilleos OA, 1999, LIVER TRANSPLANT SUR, V5, P401, DOI 10.1002/lt.500050505
   Biggins SW, 2002, LIVER TRANSPLANT, V8, P313, DOI 10.1053/jlts.2002.31746
   Broelsch CE, 1990, ANN SURG, V212, P375, DOI 10.1016/ 0270- 9139( 91) 90202- 7]
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   BROLSCH CE, 1991, EUR J PEDIATR SURG, V1, P166, DOI 10.1055/s-2008-1042480
   DALESSANDRO AM, 1993, TRANSPLANTATION, V55, P1083, DOI 10.1097/00007890-199305000-00028
   Inomata Y, 2000, TRANSPLANTATION, V69, P258, DOI 10.1097/00007890-200001270-00011
   Kim WR, 1999, HEPATOLOGY, V30, P395, DOI 10.1002/hep.510300210
   Kiuchi T, 2000, ACTA CHIR BELG, V100, P279
   KIUCHI T, 2000, ACTA CHIR BELG, V10, P279
   LEMMENS HP, 1993, TRANSPLANT P, V25, P1923
   Malago M, 2001, LIVER TRANSPLANT, V7, P921, DOI 10.1053/jlts.2001.28301
   Markmann JF, 1997, ANN SURG, V226, P418
   Markmann JF, 1997, ANN SURG, V226, P408, DOI 10.1097/00000658-199710000-00002
   Markmann JF, 1999, TRANSPLANTATION, V67, P422, DOI 10.1097/00007890-199902150-00015
   MORA NP, 1990, TRANSPLANT P, V22, P1509
   Nakamura T, 2002, TRANSPLANTATION, V73, P1896, DOI 10.1097/00007890-200206270-00008
   OZAWA K, 1992, ANN SURG, V216, P547, DOI 10.1097/00000658-199211000-00004
   PIPER JB, 1992, PEDIAT LIVER TRANSPL, P179
   Rosen HR, 1999, HEPATOLOGY, V29, P365, DOI 10.1002/hep.510290221
   Shiffman ML, 2002, LIVER TRANSPLANT, V8, P174, DOI 10.1053/jlts.2002.30981
   STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505
   Strong RW, 1996, TRANSPLANT P, V28, P2366
   TANAKA K, 1992, TRANSPLANT P, V24, P2252
   Tanaka Koichi, 2002, J Hepatobiliary Pancreat Surg, V9, P218, DOI 10.1007/s005340200022
   Wong T, 1997, TRANSPLANTATION, V64, P878, DOI 10.1097/00007890-199709270-00015
   Yamaoka Y, 1993, Clin Transpl, P179
NR 27
TC 14
Z9 17
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD SEP 27
PY 2003
VL 76
IS 6
BP 943
EP 948
DI 10.1097/01.TP.0000080068.22576.3B
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 727CE
UT WOS:000185637900011
PM 14508358
ER

PT J
AU Lopez-Santamaria, M
   Vicente, EC
   Gamez, M
   Murcia, M
   Leal, N
   Hernandez, F
   Nuno, J
   Frauca, E
   Camarena, C
   Hierro, L
   de la Vega, A
   Bortolo, G
   Diaz, M
   Jara, P
   Tovar, J
AF Lopez-Santamaria, M
   Vicente, EC
   Gamez, M
   Murcia, M
   Leal, N
   Hernandez, F
   Nuno, J
   Frauca, E
   Camarena, C
   Hierro, L
   de la Vega, A
   Bortolo, G
   Diaz, M
   Jara, P
   Tovar, J
TI Pediatric living donor liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Congress of the Catalan-Transplantation-Society
CY FEB 02-05, 2003
CL BARCELONA, SPAIN
SP Fujisawa, Novartis, Roche, Wyeth, Fresenius, Imtix Sangstat
AB Aim. The aim of this study was to analyze the results of living donor in a pediatric liver transplantation program.
   Patients. Twenty-six living donor liver transplantations were performed in children from 0.5 to 14.8 years of age. The main indication was biliary atresia (72%) followed by tumors (2 hepatoblastomas and 1 hepatocarcinoma). Left lateral segments were used in 23 (1 transformed into a monosegment), 1 left lobe was used in 1, and right lobes were used in 2. Arterial reconstruction employed saphenous venous grafts in the first 3 cases and end-to-end anastomoses with a microsurgical technique in the following 22 cases.
   Results. There has been no major morbidity in the donors, with a median hospitalization of 6 days. Four grafts have been lost; 2 in the first 3 cases. In only I case, the graft loss was related to the procedure saphenous venous graft thrombosis). Early biliary complications were frequent (23%). Six month, I year, and 5 year graft and patient survival rates were 91%, 85%, and 85% and 100%, 96%, and 96%, respectively.
   Conclusions. Living donor liver transplantation is an excellent option for transplantation in children.
C1 La Paz Univ Hosp, Dept Pediat Surg, Unit Liver Transplantat, Madrid 28046, Spain.
   Hosp Univ Paz, Dept Pediat Hepatol, Madrid 28046, Spain.
   Hosp Ramon y Cajal, Dept Surg, Unit Liver Transplantat, Madrid, Spain.
RP Lopez-Santamaria, M (reprint author), La Paz Univ Hosp, Dept Pediat Surg, Unit Liver Transplantat, P La Castellana 261, Madrid 28046, Spain.
CR Lacaille F, 2001, J PEDIATR GASTR NUTR, V33, P431, DOI 10.1097/00005176-200110000-00002
   Otte JB, 2001, PEDIATR TRANSPLANT, V5, P1
   Testa G, 2001, PEDIATR TRANSPLANT, V5, P16, DOI 10.1034/j.1399-3046.2001.t01-1-00028.x
NR 3
TC 3
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD AUG
PY 2003
VL 35
IS 5
BP 1808
EP 1809
DI 10.1016/S0041-1345(03)00570-0
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 720MV
UT WOS:000185265300073
PM 12962803
ER

PT J
AU Margarit, C
   Asensio, M
   Iglesias, J
   Bilbao, I
   Ortega, J
   Lazaro, JL
   Escartin, A
   Segarra, A
   Murio, JE
AF Margarit, C
   Asensio, M
   Iglesias, J
   Bilbao, I
   Ortega, J
   Lazaro, JL
   Escartin, A
   Segarra, A
   Murio, JE
TI Outcome of 28 split liver grafts
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Congress of the Catalan-Transplantation-Society
CY FEB 02-05, 2003
CL BARCELONA, SPAIN
SP Fujisawa, Novartis, Roche, Wyeth, Fresenius, Imtix Sangstat
ID TRANSPLANTATION; VIVO
AB Our aim is to present our experience with split liver transplantation. From 1992-2002, 14 livers were split to obtain 28 grafts that were transplanted to 12 adults and 16 children. Ex situ splitting was performed in all cases. The left graft consisted of the left lateral segment (segments II-III) in 11 cases and the left lobe in three, depending on the size of the pediatric recipient. Pediatric recipients were of mean age 3, 4 years; mean weight 13 kg; six emergency cases for fulminant hepatic failure or urgent retransplantation and seven of 10 elective cases for biliary atresia. Postoperative mortality rate was 31% (five cases), including four of six emergency cases and one elective case (10%). The main cause was multiorgan failure. Technical complications were: one arterial thrombosis, one portal vein thrombosis, and four biliary complications. Eleven patients are alive and well. Adult recipients were of mean age 53 years. The indications were hepatocellular carcinoma in six cases, liver cirrhosis of various etiologies in five, and one recurrence of hepatitis C in a graft. Two patients died during the postoperative period from sepsis after retransplantation for primary nonfunction of the split graft and multiorgan failure with sepsis. One-year actuarial survival was 84%.
   Conclusions: The results of split liver transplantation in elective cases are similar to whole liver transplantation, whereas patient survival among emergency cases is low due to the critical condition of the patients.
C1 Hosp Gen Valle Hebron, Unidad Trasplante Hepat, Barcelona 08035, Spain.
RP Margarit, C (reprint author), Hosp Gen Valle Hebron, Unidad Trasplante Hepat, P Vall Hebron 119-129, Barcelona 08035, Spain.
RI ESCARTIN, ALFREDO/E-2823-2012; Bilbao, Itxarone/N-4358-2014
OI ESCARTIN, ALFREDO/0000-0002-5234-2366; Bilbao,
   Itxarone/0000-0002-7389-395X
CR BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   De Ville De Goyet Jean, 1995, Transplantation (Baltimore), V59, P1371, DOI 10.1097/00007890-199505270-00002
   Ghobrial RM, 2000, ANN SURG, V232, P312, DOI 10.1097/00000658-200009000-00003
   Rela M, 1998, ANN SURG, V227, P282, DOI 10.1097/00000658-199802000-00019
   Reyes J, 2000, J PEDIATR SURG, V35, P283, DOI 10.1016/S0022-3468(00)90026-5
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
NR 7
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD AUG
PY 2003
VL 35
IS 5
BP 1812
EP 1814
DI 10.1016/S0041-1345(03)00596-7
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 720MV
UT WOS:000185265300075
PM 12962805
ER

PT J
AU Shoji, M
   Ohkohchi, N
   Fujimori, K
   Koyamada, N
   Sekiguchi, S
   Kawagishi, N
   Tsukamoto, S
   Shirahata, Y
   Sato, K
   Satomi, S
AF Shoji, M
   Ohkohchi, N
   Fujimori, K
   Koyamada, N
   Sekiguchi, S
   Kawagishi, N
   Tsukamoto, S
   Shirahata, Y
   Sato, K
   Satomi, S
TI The safety of the donor operation in living-donor liver transplantation:
   an analysis of 45 donors
SO TRANSPLANT INTERNATIONAL
LA English
DT Article
DE living-donor liver transplantation; donor operation; lateral segment;
   left lobe
AB We retrospectively assessed the safety of the donor operation, based on parameters such as blood loss, blood transfusion, operation time, duration of hospitalization, and complications. Forty-five pediatric and adult recipients underwent living-donor liver transplantation (LDLTx) in Tohoku University Hospital from July 1991 to October 2000. Donor operations were classified into three groups. In the LS group, the graft was the lateral segment (n=20); in the LL group, the graft was the left lobe without the middle hepatic vein (n=16); and in the ELM group, the graft was the left lobe with the middle hepatic vein (n=9). No significant differences were observed among the three groups regarding postoperative liver function or duration of hospitalization. In the LS group, the operation time was shorter and the requirement of autologous blood transfusion was significantly lower than in the other two groups. Most complications following retrieval of the graft were minor. Safety is guaranteed when the left lobe or the left lateral segment is used for LDLTx, but meticulous management of the operation is required to prevent complications.
C1 Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Aoba Ku, Sendai, Miyagi 9808574, Japan.
   Tohoku Univ, Grad Sch Med, Div Surg Oncol, Sendai, Miyagi 9808574, Japan.
RP Shoji, M (reprint author), Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
CR GOLDMAN LS, 1993, PSYCHOSOMATICS, V34, P235
   KATOH H, 1994, TOHOKU J EXP MED, V175, P179
   Kawagishi N, 1998, TRANSPLANT P, V30, P3279, DOI 10.1016/S0041-1345(98)01028-8
   OHKOHCHI N, 1987, TOHOKU J EXP MED, V152, P375, DOI 10.1620/tjem.152.375
   Renz JF, 2000, LIVER TRANSPL S2, V6, P73
   SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919
   SINGER PA, 1990, THEOR MED, V11, P87, DOI 10.1007/BF00489452
NR 7
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0934-0874
J9 TRANSPLANT INT
JI Transpl. Int.
PD JUL
PY 2003
VL 16
IS 7
BP 461
EP 464
DI 10.1007/s00147-002-0480-3
PG 4
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 713JM
UT WOS:000184854200002
PM 12761611
ER

PT J
AU Heffron, TG
   Pillen, T
   Welch, D
   Smallwood, GA
   Redd, D
   Romero, R
AF Heffron, TG
   Pillen, T
   Welch, D
   Smallwood, GA
   Redd, D
   Romero, R
TI Hepatic artery thrombosis in pediatric liver transplantation
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
AB Purpose. Children have been reported to be at greater risk for hepatic artery thrombosis when compared to adults due to small arterial size, nonuse of intraoperative microscope, and postoperative hypercoagulable state.
   Methods. We evaluated arterial anastomosis type, intraoperative field magnification, and hepatic artery complications and how they were managed. All patients underwent ultrasound, anticoagulation consisted of 41 mg aspirin once a day, and 35 patients received alprostadil (PGE) for the first 7, days after transplantation. No patients were administered intravenous heparin following liver transplantation.
   Results. Of the 74 livers transplanted, 36 grafts (48.6%) were whole organ transplants and 38 grafts (51.4%) were partial livers. We observed HAT in 1 of 74 (1.35%) transplants in our pediatric liver transplant population. The only patient with HAT was a young girl with a history of biliary atresia. The occurrence of a hepatic artery thrombosis on day 7 was caused by the migration of an intimal plaque dissection within the artery graft. She was emergently taken back into the operating room for graft revision. This individual currently has a survival time of 426 days following her last transplant.
   Conclusion. Hepatic artery thrombosis may be minimized in pediatric liver transplantation without the use of microsurgery. Anticoagulation utilizing ASA and alprostadil is sufficient to avoid FIAT. Accurate use of ultrasound is crucial to avoid this complication. Graft and patient salvage is possible with expedient surgical treatment; microsurgery, anticoagulant therapy, site of arterial inflow, and recipient size and weight.
C1 Emory Univ Hosp, Sch Med, Dept Pharm, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA.
   Emory Univ Hosp, Dept Liver Transplantat, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA.
   Emory Univ Hosp, Dept Pharm, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA.
RP Smallwood, GA (reprint author), Emory Univ Hosp, Sch Med, Dept Pharm, 1364 Clifton Rd NE,Off EG 22, Atlanta, GA 30322 USA.
CR DUNN SP, 1994, J PEDIATR SURG, V29, P1141, DOI 10.1016/0022-3468(94)90296-8
   Eid A, 1999, TRANSPLANT P, V31, P1903, DOI 10.1016/S0041-1345(99)00148-7
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   Furuta S, 1997, Liver Transpl Surg, V3, P388, DOI 10.1002/lt.500030405
   Harihara Y, 1998, TRANSPLANT P, V30, P3188, DOI 10.1016/S0041-1345(98)00988-9
   Inomoto T, 1996, SURGERY, V119, P20, DOI 10.1016/S0039-6060(96)80208-X
NR 6
TC 26
Z9 33
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JUN
PY 2003
VL 35
IS 4
BP 1447
EP 1448
DI 10.1016/S0041-1345(03)00459-7
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 695WD
UT WOS:000183852600054
PM 12826187
ER

PT J
AU Heffron, TG
   Pillen, T
   Welch, D
   Smallwood, GA
   Redd, D
   Romero, R
AF Heffron, TG
   Pillen, T
   Welch, D
   Smallwood, GA
   Redd, D
   Romero, R
TI Biliary complications after pediatric liver transplantation revisited
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article
AB Background. Biliary complications in pediatric liver transplantation (PLT) are associated with increased morbidity and mortality.
   Methods. Prospectively, data was collected on 89 consecutive liver transplants performed in 82 children. Eighty-nine consecutive PLTs were tracked for transplant type (partial versus whole), recipient age/weight, duct anastomosis type, surgical technique, and biliary complications. Treatments of biliary complications (surgical versus interventional radiology) were also evaluated.
   Results. Forty-six children (51.7%) received partial transplants and 43 (48.3%) children received whole organs. The average age for whole liver transplanted children was 8.95 +/- 6.62 years and average weight was 36.2 +/- 28.7 kg; for those receiving partial livers, 3.19 +/- 3.52 years and 14.1 +/- 13.0 kg. Duct-to-duct anastomosis was performed for 26 grafts and Roux-en-Y choledochojejunostomy for 63 grafts. Biliary complications occurred in 10 of 89 (11.2%) grafts. Complications included anastomotic strictures in four (40%), bile leak in five (50%), intraparenchymal biloma in one (10%). The complication rate for whole organs was 1/43 (2.3%) and 9/46 (19.6%) for partial organ (P = .015). No difference in complication rates were seen in type of ductal anastomosis (7.7% vs 12.7%, P = NS). Reoperation for biliary complication was necessary in only 2/10 (20%) of grafts.
   Conclusion. Technical advances have reduced the incidence of biliary complications in PLT. Partial liver grafts have a statistically higher risk-of biliary complication than whole grafts. Most biliary complications can be managed with radiological intervention without surgical exploration. Pediatric biliary complications are not associated with graft loss.
C1 Emory Univ Hosp, Sch Med, Dept Pharm, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA.
   Childrens Healthcare Atlanta, Dept Liver Transplantat, Atlanta, GA USA.
   Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.
RP Smallwood, GA (reprint author), Emory Univ Hosp, Sch Med, Dept Pharm, 1364 Clifton Rd,NE Off EG 22, Atlanta, GA 30322 USA.
CR Egawa H, 1998, SURGERY, V124, P901, DOI 10.1016/S0039-6060(98)70015-7
   ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0
   Nishida S, 2002, ARCH SURG-CHICAGO, V137, P1279, DOI 10.1001/archsurg.137.11.1279
   OSORIO RW, 1993, TRANSPLANTATION, V55, P1074, DOI 10.1097/00007890-199305000-00026
NR 4
TC 24
Z9 26
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD JUN
PY 2003
VL 35
IS 4
BP 1461
EP 1462
DI 10.1016/S0041-1345(03)00463-9
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 695WD
UT WOS:000183852600059
PM 12826192
ER

PT J
AU Gridelli, B
   Spada, M
   Petz, W
   Bertani, A
   Lucianetti, A
   Colledan, M
   Altobelli, M
   Alberti, D
   Guizzetti, M
   Riva, S
   Melzi, ML
   Stroppa, P
   Torre, G
AF Gridelli, B
   Spada, M
   Petz, W
   Bertani, A
   Lucianetti, A
   Colledan, M
   Altobelli, M
   Alberti, D
   Guizzetti, M
   Riva, S
   Melzi, ML
   Stroppa, P
   Torre, G
TI Split-liver transplantation eliminates the need for living-donor liver
   transplantation in children with end-stage cholestatic liver disease
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 19th International Congress of the Transplantation-Society
CY AUG 25-30, 2002
CL MIAMI, FLORIDA
SP Transplantat Soc
ID SINGLE-CENTER EXPERIENCE; GRAFTS; RECIPIENTS
AB Background. End-stage cholestatic liver disease (ES-CLD) is the main indication for liver replacement in children. Pediatric cadaver-organ-donor shortage has prompted the most important evolutions in the technique of liver transplantation, in particular living-donor liver transplantation (LDLT) and split-liver transplantation (SLT).
   Methods. Between November 1997 and June 2001, 127 children with ESCLD were evaluated for liver transplantation, and 124 underwent 138 liver transplantations after a median time of 40 days. Causes of liver disease were congenital biliary atresia (n=96), Alagille's syndrome (n=12), Byler's disease (n=8), and other cholestatic diseases (n=8).
   Results. Ninety (73%) patients received a split-liver graft, 28 (23%) a whole liver, and 6 (4%) a reduced-size liver. Overall 2- and 4-year patient survival rates were 93% and 91%, respectively; the 2- and 4-year graft-survival rates were 84% and 80%, respectively. In split-liver recipients, 4-year patient and graft-survival rates were 91% and 83%, respectively; these were 93% and 78%, respectively, in whole-liver recipients and 67% and 63%, respectively, in reduced-size liver recipients. Retransplantation rate was 11%, whereas mortality rate was 81%. Overall incidence of vascular and biliary complication were 16% and 27%, respectively.
   Conclusions. SLT can provide liver grafts for children with ESCLD with an outcome similar to the one reported following LDLT, eliminating mortality while they are on a transplantation wait list. The need for pediatric LDLT should be reevaluated and programs of SLT strongly encouraged and supported at a national and international level.
C1 Osped Riuniti Bergamo, Dept Gen & Transplantat Surg, I-24100 Bergamo, Italy.
   Osped Riuniti Bergamo, Pediat Unit, I-24100 Bergamo, Italy.
   Osped Riuniti Bergamo, Pediat Surg Unit, I-24100 Bergamo, Italy.
RP Gridelli, B (reprint author), Osped Riuniti Bergamo, Dept Gen & Transplantat Surg, Largo Barozzi 1, I-24100 Bergamo, Italy.
CR Azoulay D, 1996, ANN SURG, V224, P737, DOI 10.1097/00000658-199612000-00009
   BISMUTH H, 1984, SURGERY, V95, P367
   BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015
   Busuttil RW, 1999, ANN SURG, V229, P313, DOI 10.1097/00000658-199903000-00003
   Colledan M, 1999, LANCET, V353, P1763, DOI 10.1016/S0140-6736(99)00661-3
   Colombani PM, 2000, J PEDIATR SURG, V35, P9, DOI 10.1016/S0022-3468(00)80067-6
   DEGOYET JD, 1995, TRANSPLANTATION, V59, P1371
   Deshpande RR, 2002, ANN SURG, V236, P248, DOI 10.1097/01.SLA.0000021846.08550.B2
   EMOND JC, 1989, HEPATOLOGY, V10, P867, DOI 10.1002/hep.1840100520
   Goss JA, 1997, TRANSPLANTATION, V64, P871, DOI 10.1097/00007890-199709270-00014
   Gridelli B, 2000, NEW ENGL J MED, V343, P404, DOI 10.1056/NEJM200008103430606
   GRIDELLI B, UNPUB LIVER TRANSPL
   HOUSSIN D, 1993, BRIT J SURG, V80, P75, DOI 10.1002/bjs.1800800126
   Kalayoglu M, 1996, J AM COLL SURGEONS, V182, P381
   McDiarmid S V, 2000, Clin Liver Dis, V4, P879, DOI 10.1016/S1089-3261(05)70146-X
   Miller CM, 2001, ANN SURG, V234, P301, DOI 10.1097/00000658-200109000-00004
   Mirza DF, 1998, BRIT J SURG, V85, P494
   OTTE JB, 1990, SURGERY, V107, P605
   Otte JB, 1998, PEDIATR SURG INT, V13, P308, DOI 10.1007/s003830050328
   Petz W, 2001, TRANSPLANT P, V33, P1361, DOI 10.1016/S0041-1345(00)02808-6
   Revillon Y, 1999, J PEDIATR SURG, V34, P851, DOI 10.1016/S0022-3468(99)90386-X
   Reyes J, 2000, J PEDIATR SURG, V35, P283, DOI 10.1016/S0022-3468(00)90026-5
   Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009
   Sindhi R, 1999, J PEDIATR SURG, V34, P107, DOI 10.1016/S0022-3468(99)90238-5
   SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919
   Spada M, 2000, LIVER TRANSPLANT, V6, P415, DOI 10.1053/jlts.2000.7570
   Spada M, 2001, TRANSPLANT P, V33, P1835, DOI 10.1016/S0041-1345(00)02828-1
   SPADA M, 2000, TRANSPL INT, V13, P341
   STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
NR 30
TC 63
Z9 67
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD APR 27
PY 2003
VL 75
IS 8
BP 1197
EP 1203
DI 10.1097/01.TP.0000061940.96949.A1
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 673GV
UT WOS:000182573100032
PM 12717203
ER

PT J
AU Krieger, NR
   Odorico, JS
   Heisey, DM
   D'Alessandro, AM
   Knechtle, SJ
   Pirsch, JD
   Sollinger, HW
AF Krieger, NR
   Odorico, JS
   Heisey, DM
   D'Alessandro, AM
   Knechtle, SJ
   Pirsch, JD
   Sollinger, HW
TI Underutilization of pancreas donors
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 19th International Congress of the Transplantation-Society
CY AUG 25-30, 2002
CL MIAMI, FLORIDA
SP Transplantat Soc
ID HEART-BEATING DONORS; KIDNEY-TRANSPLANTATION; RISK-FACTORS; MARGINAL
   DONORS; ALLOGRAFT FAILURE; UNIVARIATE; IMPACT; POOL; ERA
AB Background. Transplantation of the pancreas has become the treatment of choice for selected patients with type 1 diabetes mellitus. With the current shortage of cadaver donors and the increasing number of diabetic patients on the transplant waiting list, there is a critical need to optimally use all available pancreas grafts for transplantation. We have therefore explored the use of traditionally "less-than-ideal" pancreas donors, including pediatric (4-10 years), older (greater than or equal to45 years), obese (weight greater than or equal to200 lb), and non-heart-beating donors and donors with an elevated amylase (75% greater than normal values).
   Methods. A total of 620 primary simultaneous pancreas-kidney transplantations were performed at our center. We analyzed the ratio of livers to pancreata transplanted at our center and compared this to the United Network for Organ Sharing database. Using univariate and multivariate analyses, we then assessed the impact of these less-than-ideal donors on patient survival, graft survival, and postsurgical complications after simultaneous pancreas-kidney transplantation.
   Results. A substantial nationwide underutilization of pancreata from donor procurements is demonstrated in the United Network for Organ Sharing database. By using these less-than-ideal donors, the ratio of liver to pancreata procured can be reduced to 1.25:1. Graft survival was not significantly different in patients receiving transplants from obese, non-heart-beating, pediatric, or hyperamylasemic donors compared with grafts from ideal donors. However, grafts from donors 45 years of age or older had significantly lower 1- and 5-year graft survival rates (76% and 65% vs. 90% and 80%, P=0.006).
   Conclusions. This study demonstrates that utilization of pancreas grafts from selected, less-than-ideal donors results in good overall outcomes and could potentially expand the organ donor pool.
C1 Univ Wisconsin, Sch Med, Dept Surg, Div Organ Transplantat, Madison, WI USA.
RP Odorico, JS (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, H4-756 Clin Sci Ctr 7375,600 Highland Ave, Madison, WI 53792 USA.
CR Abouna GM, 1997, TRANSPLANT P, V29, P2759, DOI 10.1016/S0041-1345(97)00667-2
   Alexander JW, 1996, CLIN TRANSPLANT, V10, P1
   Becker BN, 2000, KIDNEY INT, V57, P2129, DOI 10.1046/j.1523-1755.2000.00064.x
   CECKA JM, 2001, CLIN TRANSPLANTS 200, P691
   D'Alessandro AM, 2000, CELL TRANSPLANT, V9, P889
   DALESSANDRO AM, 1995, TRANSPLANTATION, V59, P977
   Douzdjian V, 1996, CLIN TRANSPLANT, V10, P271
   DOUZDJIAN V, 1995, SURGERY, V118, P73, DOI 10.1016/S0039-6060(05)80012-1
   GABER AO, 1995, TRANSPLANTATION, V59, P1105, DOI 10.1097/00007890-199504270-00006
   Gruessner Angelika C, 2002, Clin Transpl, P41
   Humar A, 2000, ANN SURG, V231, P269, DOI 10.1097/00000658-200002000-00017
   Kapur S, 1999, TRANSPLANTATION, V67, P284, DOI 10.1097/00007890-199901270-00017
   Knight RJ, 2000, AM J SURG, V179, P99, DOI 10.1016/S0002-9610(00)00276-2
   Odorico JS, 1998, TRANSPLANT P, V30, P276, DOI 10.1016/S0041-1345(97)01263-3
   Tojimbara T, 1998, TRANSPLANT P, V30, P3793, DOI 10.1016/S0041-1345(98)01239-1
   Troppmann C, 1996, J AM COLL SURGEONS, V182, P285
   Troppmann C, 1998, ANN SURG, V227, P255, DOI 10.1097/00000658-199802000-00016
   Troppmann C, 1996, TRANSPLANTATION, V61, P1323, DOI 10.1097/00007890-199605150-00007
   Tullius SG, 2001, TRANSPLANTATION, V72, P1341, DOI 10.1097/00007890-200110270-00001
   Tyden G, 1999, TRANSPLANTATION, V67, P645
   *US DAT SYST ANN D, 2001, OPTN DAT REP ONL
   Van der Werf WJ, 1999, TRANSPLANT P, V31, P610, DOI 10.1016/S0041-1345(98)01578-4
NR 22
TC 65
Z9 67
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD APR 27
PY 2003
VL 75
IS 8
BP 1271
EP 1276
DI 10.1097/01.TP.0000061603.95572.BF
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 673GV
UT WOS:000182573100044
PM 12717215
ER

PT J
AU Molmenti, EP
   Squires, RH
   Nagata, D
   Roden, JS
   Molmenti, H
   Fasola, CG
   Prestidge, C
   D'Amico, L
   Casey, D
   Sanchez, EQ
   Goldstein, RM
   Levy, MF
   Benser, M
   McPhail, W
   Andrews, W
   Andersen, JA
   Klintmalm, GB
AF Molmenti, EP
   Squires, RH
   Nagata, D
   Roden, JS
   Molmenti, H
   Fasola, CG
   Prestidge, C
   D'Amico, L
   Casey, D
   Sanchez, EQ
   Goldstein, RM
   Levy, MF
   Benser, M
   McPhail, W
   Andrews, W
   Andersen, JA
   Klintmalm, GB
TI Liver transplantation for cholestasis associated with cystic fibrosis in
   the pediatric population
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE cholestatic liver disease; Aspergillus; chloride transport; pulmonary
   function; infection
ID HEPATIC CIRRHOSIS; CHILDREN; LUNG
AB The most common hepatic complications of cystic fibrosis (CF) are steatosis, fibrosis, biliary cirrhosis, atretic gallbladder, cholelithiasis, and sclerosing cholangitis. Cholestatic liver disease is a slow progressive disorder, but will stabilize for many patients. CF patients may suffer from the consequences of their liver disease and without liver transplantation, variceal hemorrhage, malnutrition, or end-stage liver disease can lead to death. Prospective data were collected and reviewed on 311 liver transplants performed in 283 patients at the Children's Medical Center of Dallas between October 1984 and November 2000. Ten children received an orthotopic liver transplant (OTLX) for end-stage liver disease associated with cystic fibrosis. Pulmonary function tests were obtained preoperatively in all cases. There were nine boys and one girl. Six are currently alive, and four are dead. Both patient and graft survival was 5.75 yr. Among those currently alive, mean patient and graft survival is 7.71 yr (range 0.10-12.62 yr). Mean patient and graft survival of those who died was 2.35 yr (range 0.78-5.33 yr). No survivor required re-transplantation and currently, all have normal serum aminotransferase values. Chronic sinusitis was not a significant pre- or post-transplant morbidity, although systematic radiographic evaluation of the sinuses did not occur. Pulmonary deaths occurred in three patients from pulmonary hemorrhage, pulmonary infection with Aspergillus and Candida glabrata , and acute bronchopneumonia associated with polymicrobial sepsis because of Pseudomonas , Klebsiella , and Candida albicans 1.44, 0.78, and 1.83 yr, respectively, after transplantation. The fourth death was associated with chronic rejection, and occurred 5.33 yr after transplantation. All non-survivors were below the 5th percentile for height and weight at the time of liver transplantation. Mean age at transplantation was 9.72 yr (range 1.23-19.09, median 9.61). Survivors were transplanted at a younger age than non-survivors (mean of 9.21 yr vs. 10.66 yr), and had shorter waiting times from diagnosis of end-stage liver disease to transplantation (6.87 months vs. 13.83 months). Eighty percentage (n = 8) of patients had pretransplant variceal bleeds (83% of survivors, 75% of non-survivors). While all non-survivors had a history of meconium ileus and preoperative need of pancreatic enzymes, only 67% of those alive experienced these complications. Preoperative forced vital capacity FVC was 103% for survivors and 95% for non-survivors. The corresponding numbers for forced expiratory flow (FEF) 25-75 were 74-84% respectively. Preoperative Aspergillus was identified in 30% of patients (n = 3). Two of these patients are alive. Cystic fibrosis constitutes an indication for 3.5% of pediatric liver transplants. Evaluation and transplantation for end-stage liver disease associated with cystic fibrosis should be undertaken at an early age. Most deaths were associated with pulmonary/septic events, and occurred less than 2 yr after OLTX. Those children who did not survive had poor growth and nutrition, prolonged waiting times prior to transplantation, were transplanted at an older age, and had a higher incidence of pancreatic insufficiency and meconium ileus. The presence of Aspergillus in the sputum does not constitute a contraindication for OLTX.
C1 Baylor Univ, Med Ctr, Dallas, TX 75246 USA.
   Childrens Med Ctr, Dallas, TX 75235 USA.
RP Klintmalm, GB (reprint author), Baylor Univ, Med Ctr, 3500 Gaston Ave, Dallas, TX 75246 USA.
EM gb.klintmalm@baylorhealth.edu
CR Berenguer M, 1996, Gastroenterol Hepatol, V19, P356
   BOND GJ, 1999, TRANSPLANTATION, V67, P5182
   Colombo C, 1996, EUR J GASTROEN HEPAT, V8, P748
   Couetil JPA, 1997, TRANSPLANT INT, V10, P33, DOI 10.1111/j.1432-2277.1997.tb00533.x
   COUETIL JPA, 1995, J THORAC CARDIOV SUR, V110, P1415, DOI 10.1016/S0022-5223(95)70064-1
   Debray D, 1999, J HEPATOL, V31, P77, DOI 10.1016/S0168-8278(99)80166-4
   Della Rocca G, 1998, EUR J PEDIATR SURG, V8, P278, DOI 10.1055/s-2008-1071214
   Dray-Charier N, 1999, HEPATOLOGY, V29, P1624, DOI 10.1002/hep.510290634
   FEIGELSON J, 1993, ARCH DIS CHILD, V68, P653
   Johnston TD, 1998, HEPATO-GASTROENTEROL, V45, P1387
   Kelly DA, 1998, J PEDIATR GASTR NUTR, V27, P214, DOI 10.1097/00005176-199808000-00017
   MACK DR, 1995, J PEDIATR-US, V127, P881, DOI 10.1016/S0022-3476(95)70022-6
   Milla PJ, 1998, DIGESTION, V59, P579, DOI 10.1159/000007533
   MOWAT AP, 1992, EUR J PEDIATR, V151, pS32, DOI 10.1007/BF02125800
   NOBLEJAMIESON G, 1994, ARCH DIS CHILD, V71, P349
   NobleJamieson G, 1996, J ROY SOC MED, V89, P31
   Perez-Aguilar F, 1999, Gastroenterol Hepatol, V22, P72
   STIEHL A, 1992, Z GASTROENTEROL, V30, P743
   Strandvik B, 1994, Scand J Gastroenterol Suppl, V204, P65
   Thevenot P, 1996, ARCH PEDIATRIE, V3, P1248, DOI 10.1016/S0929-693X(97)85936-2
   WILLIAMS SGJ, 1992, BRIT MED BULL, V48, P877
NR 21
TC 38
Z9 38
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD APR
PY 2003
VL 7
IS 2
BP 93
EP 97
DI 10.1034/j.1399-3046.2003.00021.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 658VV
UT WOS:000181742100003
PM 12654048
ER

PT J
AU Feldstein, AE
   Razonable, RR
   Boyce, TG
   Freese, DK
   El-Youssef, M
   Perrault, J
   Paya, CV
   Ishitani, MB
AF Feldstein, AE
   Razonable, RR
   Boyce, TG
   Freese, DK
   El-Youssef, M
   Perrault, J
   Paya, CV
   Ishitani, MB
TI Prevalence and clinical significance of human herpesviruses 6 and 7
   active infection in pediatric liver transplant patients
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE human herpesvirus-6; human herpesvirus-7; pediatrics; cytomegalovirus;
   rejection
ID POLYMERASE-CHAIN-REACTION; CYTOMEGALOVIRUS CMV DNA;
   RENAL-TRANSPLANTATION; EXANTHEM SUBITUM; CODING CONTENT; RECIPIENTS;
   DISEASE; SEQUENCE; COMPLICATIONS; REACTIVATION
AB Recent studies in adult liver transplant patients have suggested that both human herpesvirus (HHV)-6 and HHV-7 infection are important causes of morbidity following liver transplantation. However, the impact of HHV-6 and -7 infection in pediatric liver transplant patients remains largely unknown. The aims were to determine the prevalence of HHV-6 and -7 infection in pediatric liver transplant patients and to determine whether there is an association between HHV-6 and -7 infection with episodes of graft rejection and cytomegalovirus (CMV) infection. A total of 46 pediatric liver transplant patients transplanted at Mayo Clinic between January 1994 and January 2000 were evaluated. Quantitative polymerase chain reaction (PCR) assays for CMV, HHV-6 and HHV-7 were performed on stored sera obtained prior to transplant, weekly for 8 wk and at 4 months and 1 yr post-transplant. Pretransplant sera were tested for HHV-6 antibodies by indirect immunofluorescence assay. A total of 215 blood samples were tested (mean 6.5+/-3.1, range 3-18). CMV infection occurred in 11 of 33 (33.3%) patients, while CMV disease occurred in 4 of 33 (12%) patients. Infection with HHV-6 (variant B) was detected in three of 33 (9.1%) patients. HHV-7 infection was not detected. Case 1 and 2 were infants (10- and 11-month old, respectively). Both were seronegative for HHV-6 pretransplant. In both cases, HHV-6 infection was associated with concurrent episodes of moderate to severe acute graft rejection. Case 3 was a 16-yr-old girl who was seropositive for HHV-6 pretransplant. No clinical events were recorded and a liver biopsy performed per protocol showed no evidence of rejection. None of the three patients had concomitant CMV infection or disease. In this study, HHV-6 infection occurred in 9% of pediatric liver transplant patients while HHV-7 was not detected. A potential association between primary HHV-6 infection and allograft rejection warrants further investigation.
C1 Mayo Clin & Mayo Fdn, Div Pediat Gastroenterol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Div Hepatol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Div Transplant Surg, Rochester, MN 55905 USA.
RP Ishitani, MB (reprint author), Mayo Clin & Mayo Fdn, Div Pediat Gastroenterol, 200 1st St SW, Rochester, MN 55905 USA.
EM ishitani.michael@mayo.edu
CR Chan PKS, 1997, J MED VIROL, V53, P295, DOI 10.1002/(SICI)1096-9071(199711)53:3<295::AID-JMV20>3.0.CO;2-F
   CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302
   DesJardin JA, 1998, J INFECT DIS, V178, P1783, DOI 10.1086/314510
   Dockrell DH, 1997, J INFECT DIS, V176, P1135
   Dominguez G, 1999, J VIROL, V73, P8040
   DROBYSKI WR, 1993, J INFECT DIS, V167, P735
   FRENKEL N, 1990, P NATL ACAD SCI USA, V87, P748, DOI 10.1073/pnas.87.2.748
   GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228
   Griffiths PD, 1999, J MED VIROL, V59, P496, DOI 10.1002/(SICI)1096-9071(199912)59:4<496::AID-JMV12>3.0.CO;2-U
   HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703
   Herbein G, 1996, CLIN INFECT DIS, V22, P171
   Kidd IM, 2000, TRANSPLANTATION, V69, P2400, DOI 10.1097/00007890-200006150-00032
   Lautenschlager I, 1998, CLIN INFECT DIS, V26, P702, DOI 10.1086/514592
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Moschettini D, 1998, EUR J CLIN MICROBIOL, V17, P117, DOI 10.1007/BF01682168
   Nicholas J, 1996, J VIROL, V70, P5975
   OKUNO T, 1990, TRANSPLANTATION, V49, P519, DOI 10.1097/00007890-199003000-00009
   PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201
   Razonable RR, 2001, J CLIN MICROBIOL, V39, P4472, DOI 10.1128/JCM.39.12.4472-4476.2001
   Razonable RR, 2002, TRANSPLANTATION, V73, P968, DOI 10.1097/00007890-200203270-00025
   Rogers J, 2000, TRANSPLANTATION, V69, P2566, DOI 10.1097/00007890-200006270-00016
   SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520
   Schmidt CA, 1996, TRANSPLANTATION, V61, P662, DOI 10.1097/00007890-199602270-00027
   Singh N, 1996, ANN INTERN MED, V124, P1065
   YAMANISHI K, 1988, LANCET, V1, P1065
   YOSHIKAWA T, 1989, PEDIATRICS, V84, P675
NR 26
TC 28
Z9 29
U1 0
U2 0
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD APR
PY 2003
VL 7
IS 2
BP 125
EP 129
DI 10.1034/j.1399-3046.2003.00028.x
PG 5
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 658VV
UT WOS:000181742100008
PM 12654053
ER

PT J
AU Dalgic, A
   Dalgic, B
   Demirogullari, B
   Ozbay, F
   Latifoglu, O
   Ersoy, E
   Mahli, A
   Ilgit, E
   Ozdemir, H
   Arac, M
   Akyol, G
   Tatlicioglu, E
AF Dalgic, A
   Dalgic, B
   Demirogullari, B
   Ozbay, F
   Latifoglu, O
   Ersoy, E
   Mahli, A
   Ilgit, E
   Ozdemir, H
   Arac, M
   Akyol, G
   Tatlicioglu, E
TI Clinical approach to graft hepatic artery thrombosis following living
   related liver transplantation
SO PEDIATRIC TRANSPLANTATION
LA English
DT Article
DE living related liver transplantation; hepatic artery thrombosis; Doppler
   USG
ID RECONSTRUCTION; COMPLICATIONS; INFANTS
AB Hepatic artery thrombosis (HAT) has an occurrence rate of 1.7-26% following living donor liver transplantation (LDLT) and is one of the most common reasons for graft loss and mortality in this population. There is a higher incidence of HAT in pediatric recipients. The aim of this case report is to discuss clinical approaches for the treatment of HAT occurring in the early post-operative period after LDLT. An 11-month-old, 7.8-kg female with cirrhosis secondary to biliary atresia underwent LDLT at Gazi University Hospital in Ankara. The graft was a left lateral segment from her father with a left hepatic artery (HA) of 2 mm diameter and a graft weight/recipient body weight ratio of 2.0%. After an uneventful early post-operative period, HAT was diagnosed by Doppler ultrasonography (USG) on the fifth post-operative day. Following angiographic evaluation, immediate exploration and reanastomosis was performed using an operation microscope. Post-operatively, the HA was patented by Doppler USG and graft function returned to normal. Now, 42 months later, the patient continues to do well with normal graft function, using a regimen of tacrolimus monotherapy for immunosuppression. In countries which have very limited resources for urgent re-transplantation, given their serious donor shortage, graft salvage may be the only option for patient survival when HAT occurs. In these circumstances, early diagnosis and immediate revascularization may be the only method for graft salvage. A daily routine of Doppler USG examination in the early post-operative period may provide a method for the early diagnosis of HAT, before liver enzymes are elevated and hepatic necrosis has begun.
C1 Gazi Univ Hosp, Dept Surg, Ankara, Turkey.
   Gazi Univ Hosp, Dept Pediat Gastroenterol, Ankara, Turkey.
   Gazi Univ Hosp, Dept Pediat Surg, Ankara, Turkey.
   Gazi Univ Hosp, Dept Plast Surg, Ankara, Turkey.
   Gazi Univ Hosp, Dept Anesthesiol, Ankara, Turkey.
   Gazi Univ Hosp, Dept Radiol, Ankara, Turkey.
   Gazi Univ Hosp, Dept Pathol, Ankara, Turkey.
RP Dalgic, A (reprint author), Gazi Univ, Sch Med, Dept Transplantat Surg, TR-06510 Ankara, Turkey.
EM adalgic@yahoo.com
CR BALISTRERI WF, 2000, LIVER DIS CHILDREN, P252
   DALGIC A, 2001, TURKISH J GASTROENTE, V11, P46
   ETSURO H, 1997, TRANSPLANTATION, V10, P1443
   FIQUREAS J, 1995, TRANSPLANTATION, V59, P1356
   Garcia-Gallont R, 1999, Pediatr Transplant, V3, P74, DOI 10.1034/j.1399-3046.1999.00012.x
   Goss JA, 1996, ANN SURG, V224, P276, DOI 10.1097/00000658-199609000-00004
   Ikegami T, 2000, TRANSPLANTATION, V69, P1953, DOI 10.1097/00007890-200005150-00036
   INOMOTO T, 1995, TRANSPLANTATION, V60, P881, DOI 10.1097/00007890-199510270-00022
   KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7
   Lopez-Santamaria M, 1999, J PEDIATR SURG, V34, P316, DOI 10.1016/S0022-3468(99)90199-9
   MORI K, 1992, TRANSPLANTATION, V54, P263, DOI 10.1097/00007890-199208000-00014
   Nakatsuka T, 1999, TRANSPLANTATION, V67, P1490, DOI 10.1097/00007890-199906150-00019
   Sakamoto Y, 1999, BRIT J SURG, V86, P886, DOI 10.1046/j.1365-2168.1999.01166.x
   STEVENS LH, 1992, TRANSPLANTATION, V53, P396, DOI 10.1097/00007890-199202010-00025
   TANAKA K, 1993, ANN SURG, V217, P82, DOI 10.1097/00000658-199301000-00014
   Yamanaka J, 2000, HEPATO-GASTROENTEROL, V47, P1371
NR 16
TC 10
Z9 11
U1 0
U2 1
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1397-3142
J9 PEDIATR TRANSPLANT
JI Pediatr. Transplant.
PD APR
PY 2003
VL 7
IS 2
BP 149
EP 152
DI 10.1034/j.1399-3046.2003.00017.x
PG 4
WC Pediatrics; Transplantation
SC Pediatrics; Transplantation
GA 658VV
UT WOS:000181742100012
PM 12654057
ER

PT J
AU Eghtesad, B
   Reyes, JD
   Ashrafi, M
   Arzate, J
   Osorio, G
   Fung, JJ
   Mazariegos, GV
AF Eghtesad, B
   Reyes, JD
   Ashrafi, M
   Arzate, J
   Osorio, G
   Fung, JJ
   Mazariegos, GV
TI Pancreatitis after liver transplantation in children: A single-center
   experience
SO TRANSPLANTATION
LA English
DT Article
ID CONTRIBUTING FACTORS
AB Background and method. Posttransplantation acute pancreatitis (PTAP) is a rare but serious complication after pediatric liver transplantation (LTx). We performed a retrospective review in a large cohort of pediatric liver transplant recipients at a single institution to define the impact of this problem in children.
   Results. Between January 1986 and December 1999, 634 pediatric LTx were performed. Twenty-six patients developed serious acute pancreatitis. The mean age at transplantation was 7.7 years (9 months to 19 years), and the indications for transplantation were biliary atresia in seven, fulminant hepatic failure in six, chronic rejection in seven, and other etiologies in six patients. PTAP was more likely to occur early after LTx (61% within the first week), was associated with the presence of an infrarenal aortic graft in 14 (54%) of 26 patients, was more likely to occur after retransplantation (11/26 patients), and was associated with blood loss and prolonged surgery in four cases. Acute renal failure occurred in 15 (58% of 26 patients. Mortality was 42% (11/26); causes of death were sepsis or multiple organ failure in nine and hemorrhage in two patients. Management of PTAP included antibiotics, sphincterotomy, debridement with drainage, hepatic arterial revascularization, and arterial ligation. Of the 14 patients with complicated pancreatitis, 5 were treated conservatively and died. Nine patients had extensive operative interventions and four survived (45%).
   Conclusions. Several risk factors such as retransplantation, extensive dissection at the time of LTx, and use of infrarenal arterial graft contribute to development of PTAP in children. Early exploration and debridement in patients with complicated pancreatitis may result in a better outcome. Retransplantation in the presence of clinical pancreatitis has a high failure rate.
C1 Thomas E Strazl Transplantat Inst, Pittsburgh, PA 15213 USA.
   Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.
RP Eghtesad, B (reprint author), Thomas E Strazl Transplantat Inst, 3601 5th Ave, Pittsburgh, PA 15213 USA.
RI Fung, John/A-2679-2012; 
OI Mazariegos, George/0000-0002-2624-8632
CR ALEXANDER JA, 1988, TRANSPLANTATION, V45, P1062, DOI 10.1097/00007890-198806000-00012
   BADGER J, 1989, TRANSPLANTATION, V48, P526
   Camargo C A Jr, 1995, J Am Coll Surg, V181, P249
   CAVALLARI A, 1995, J HEPATOL, V22, P685, DOI 10.1016/0168-8278(95)80224-X
   Herline AJ, 1999, AM SURGEON, V65, P819
   KROKOS NV, 1995, TRANSPLANT INT, V8, P1
   Kuo PC, 1998, J AM COLL SURGEONS, V187, P522, DOI 10.1016/S1072-7515(98)00222-1
   Lupo L, 1997, TRANSPLANT P, V29, P473, DOI 10.1016/S0041-1345(96)00210-2
   Slakey DP, 1997, ANN SURG, V225, P217, DOI 10.1097/00000658-199702000-00010
   Starzl T.E., 1964, EXPERIENCE RENAL TRA, P111
   TILNEY NL, 1966, NEW ENGL J MED, V274, P1051, DOI 10.1056/NEJM196605122741903
   Tissieres P, 1998, J PEDIATR GASTR NUTR, V26, P315, DOI 10.1097/00005176-199803000-00014
NR 12
TC 3
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD JAN 27
PY 2003
VL 75
IS 2
BP 190
EP 193
DI 10.1097/01.TP.0000040865.61349.CA
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 644EV
UT WOS:000180905700005
PM 12548121
ER

EF